﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Midena, E
   Vujosevic, S
   Convento, E
   Manfre, A
   Cavarzeran, F
   Pilotto, E
AF Midena, Edoardo
   Vujosevic, Stela
   Convento, Enrica
   Manfre, Antonio
   Cavarzeran, Fabiano
   Pilotto, Elisabetta
TI Microperimetry and fundus autofluorescence in patients with early
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPE; OPTICAL COHERENCE TOMOGRAPHY;
   STARGARDTS-DISEASE; BRUCHS MEMBRANE; MACULOPATHY; DRUSEN; EYES;
   LIPOFUSCIN; PERIMETRY; SENSITIVITY
AB Background: Early age-related macular degeneration (AMD) has been correlated with different functional alterations, but the exact relationship between fundus lesions and overlying sensitivity is not well known. The aim of this study was to compare fundus-related sensitivity (microperimetry) and fundus autofluorescence (FAF) of the macular area with drusen and pigment abnormalities in early AMD.
   Methods: 13 consecutive patients with early AMD and visual acuity of 20/20 were studied by means of microperimetry, which automatically analyses macular light differential threshold and fixation patterns. Fundus colour photo and FAF of the macular area were recorded on the same day. Microperimetry was exactly (topographically) superimposed over FAF images.
   Results: Macular sensitivity significantly decreased over large drusen (11.2 +/- 5.6 dB, p < 0.0001) and over pigment abnormalities (13.1 +/- 3.6 dB, p < 0.0001). When both characteristics were present the reduction was greater if compared with its absence (9.6 +/- 4.3 versus 15.0 +/- 4.5 dB, p < 0.0001). Sensitivitity reduction was significant in areas with altered FAF when compared with areas with normal FAF ( p < 0.0001).
   Conclusions: Increased FAF in early AMD has a functional correlate exactly quantified by microperimetry. In retinal areas affected by early AMD retinal sensitivity deteriorates, despite good visual acuity. Microperimetry may allow the early detection of functional impairment caused by these lesions. Both microperimetry and FAF may be useful to monitor AMD progression.
C1 Univ Padua, Dept Ophthalmol, I-35128 Padua, Italy.
   IRCCS, Fdn GB Bietti Oftalmol, Rome, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Midena, E (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiani 2, I-35128 Padua, Italy.
EM edoardo.midena@unipd.it
RI Vujosevic, Stela/AAI-4874-2020; Midena, Edoardo/AAB-6010-2020
OI Vujosevic, Stela/0000-0001-6773-9967
CR ALTMAN D, 1991, PRACTICAL STAT MED R, P304
   BARTSCH DU, 1995, AM J OPHTHALMOL, V120, P642, DOI 10.1016/S0002-9394(14)72211-1
   Battaglia Parodi M, 2006, PERIMETRY FUNDUS INT, P53
   Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   Bindewald A, 2004, AM J OPHTHALMOL, V137, P556, DOI 10.1016/j.ajo.2003.08.004
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Pauleikhoff D, 2004, AGE-RELATED MACULAR DEGENERATION, P47
   PILOTTO E, 2006, INVEST OPHTHALMOL VI, V47
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Rohrschneider K, 1997, OPHTHALMOLOGE, V94, P624, DOI 10.1007/s003470050171
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   SJAARDA RN, 1993, OPHTHALMOLOGY, V100, P1513
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   Springer C, 2006, OPHTHALMOLOGE, V103, P791, DOI 10.1007/s00347-006-1396-6
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
NR 38
TC 186
Z9 191
U1 0
U2 11
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2007
VL 91
IS 11
BP 1499
EP 1503
DI 10.1136/bjo.2007.119685
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 221LN
UT WOS:000250229300024
PM 17504849
OA Green Submitted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Gomes, N
   Meireles, A
   Carneiro, A
   Silva, R
   Campos, A
   Duarte, L
   Flores, R
   Marques-Neves, C
AF Gomes, Nuno
   Meireles, Angelina
   Carneiro, Angela
   Silva, Rufino
   Campos, Antonio
   Duarte, Lilianne
   Flores, Rita
   Marques-Neves, Carlos
CA Portuguese RAMD Consensus Grp
TI A Delphi study on the clinical management of age-related macular
   degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Disease activity; Disease management;
   Retinal fluid; Treatment regimen; Consensus
ID VISUAL-ACUITY; THERAPY; TREAT; RANIBIZUMAB; REGIMEN; AFLIBERCEPT;
   PREDICTORS; MECHANISMS; MORPHOLOGY; ATROPHY
AB Purpose Age-related macular degeneration (AMD) is one of the main causes of blindness and visual impairment worldwide. As achieving a dry macula is one of the main objectives in AMD management, the purpose of this work was to reach a consensus on the relevance of retinal fluid in function, disease activity control and treatment patterns. Methods Forty-seven Portuguese ophthalmologists specialized in AMD participated in a DELPHI panel. Two rounds of presential meetings were conducted and a cut-off of 80% or more of votes was defined to consider answers consensual. Results Consensus was reached for 11 out of 18 questions. These questions focused on the impact of anatomical results on visual acuity, standards exams and parameters to assess disease activity, frequency and factors which influence disease activity assessment, criteria to use non-fixed treatment regimens, usefulness of individualized regimens and conditions for treatment interruption. No consensus was obtained for relevance of the different fluid types in AMD prognosis, frequency of fluid presence assessment, factors commonly associated with progression to geographic atrophy, ideal conditions for a fixed treatment regimen, date of first disease activity assessment and parameters to monitor disease activity. Conclusions Consensus was achieved for over half of the questions assessed through this Delphi study. The questions for which no consensus was reached concerned either subjects that need further investigation or monitoring times which are influenced by resource availability. Raising awareness for these issues will allow the improvement of AMD management and treatment.
C1 [Gomes, Nuno] Dept Retina Hosp Braga, Rua Comunidades Lusiadas 133, Braga, Portugal.
   [Meireles, Angelina] Ctr Hosp Univ Porto, Hosp Santo Antonio, Dept Ophthalmol, Porto, Portugal.
   [Carneiro, Angela] Ctr Hosp Univ Sao Joao, Dept Ophthalmol, Porto, Portugal.
   [Silva, Rufino] Ctr Hosp Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal.
   [Silva, Rufino] Univ Coimbra, Fac Med, Coimbra, Portugal.
   [Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Campos, Antonio] Ctr Hosp Leiria, Dept Ophthalmol, Leiria, Portugal.
   [Campos, Antonio] Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal.
   [Duarte, Lilianne] Ctr Hosp Entre O Douro & Vouga, Dept Ophthalmol, Santa Maria Feira, Portugal.
   [Flores, Rita] Ctr Hosp Lisboa Cent, Dept Ophthalmol, Lisbon, Portugal.
   [Marques-Neves, Carlos] Univ Lisbon, Univ Ophthalmol Clin, Fac Med, Lisbon, Portugal.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Universidade de Coimbra; Universidade
   de Coimbra; Centro Hospitalar de Lisboa Central, EPE; Universidade de
   Lisboa; Universidade de Lisboa
RP Gomes, N (通讯作者)，Dept Retina Hosp Braga, Rua Comunidades Lusiadas 133, Braga, Portugal.
EM nunolgomes@gmail.com
RI Flores, Rita/AAU-9934-2020; Duarte, Lilianne/AAA-5318-2021; Campos,
   Antonio/AEK-3054-2022; Carneiro, Angela/N-9680-2013; Farinha,
   Claudia/R-1392-2017
OI Flores, Rita/0000-0002-7523-2418; Duarte, Lilianne/0000-0003-3953-0730;
   Marques Neves, Carlos/0000-0002-3842-2466; Meireles,
   Angelina/0000-0001-9148-2786; Campos, Antonio/0000-0003-0490-5889;
   Silva, Rufino/0000-0001-8676-0833; Carneiro, Angela/0000-0002-3370-7243;
   Figueira, Joao P/0000-0002-3511-1515; Farinha,
   Claudia/0000-0003-4596-0913
FU Novartis Portugal
FX Support for editorial assistance was funded by Novartis Portugal.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Arrigo A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.48
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chakravarthy U, 2020, JAMA-J AM MED ASSOC, V324, P794, DOI 10.1001/jama.2020.5576
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Farinha C, 2020, RETINA-J RET VIT DIS, V40, P881, DOI 10.1097/IAE.0000000000002470
   Galvez MIL, 2020, ACTA OPHTHALMOL, V98, pE820, DOI 10.1111/aos.14399
   Garcia-Layana A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/412903
   German Soc Ophthalmology, 2021, OPHTHALMOLOGE, V118, P31, DOI 10.1007/s00347-020-01188-1
   Gonzalez-Buendia L, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0544-x
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hanemoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189035
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Kodjikian L, 2018, RETINA-J RET VIT DIS, V38, P1492, DOI 10.1097/IAE.0000000000001736
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lin TZ, 2020, BRIT J OPHTHALMOL, V104, P58, DOI 10.1136/bjophthalmol-2018-313447
   National Institute for Health and Care Excellence (NICE), 2018, NICE GUID NG 82 AG R
   Nguyen V, 2019, OPHTHALMOL RETINA, V3, P623, DOI 10.1016/j.oret.2019.05.013
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma A, 2020, EYE, V34, P1310, DOI 10.1038/s41433-020-0831-2
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Siedlecki J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64901-9
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Teixeira CC., 2018, REV SOCIEDADE PORTUG, DOI [10.48560/rspo.14162, DOI 10.48560/RSPO.14162]
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
   Wightman AJ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.3
NR 47
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD JUN
PY 2022
VL 42
IS 6
BP 1799
EP 1809
DI 10.1007/s10792-021-02177-2
EA FEB 2022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1S4GR
UT WOS:000754154600001
PM 35149923
DA 2022-11-30
ER

PT J
AU Ngwa, W
   Makrigiorgos, GM
   Berbeco, RI
AF Ngwa, Wilfred
   Makrigiorgos, G. Mike
   Berbeco, Ross I.
TI Gold nanoparticle enhancement of stereotactic radiosurgery for
   neovascular age-related macular degeneration
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID X-RAY-IRRADIATION; AMD 6-MONTH SAFETY; ANTI-VEGF AGENTS; PHOTODYNAMIC
   THERAPY; RANIBIZUMAB THERAPY; RADIATION-THERAPY; ENERGY; RADIOTHERAPY;
   VERTEPORFIN; BRACHYTHERAPY
AB Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries for people over the age of 50. In this work, the dosimetric feasibility of using gold nanoparticles (AuNP) as radiosensitizers to enhance kilovoltage stereotactic radiosurgery for neovascular AMD is investigated. Microdosimetry calculations at the sub-cellular level were carried out to estimate the radiation dose enhancement to individual nuclei in neovascular AMD endothelial cells (nDEF) due to photon-induced photo-/Auger electrons from x-ray-irradiated AuNP. The nDEF represents the ratio of radiation doses to the endothelial cell nuclei with and without AuNP. The calculations were carried out for a range of feasible AuNP local concentrations using the clinically applicable 100 kVp x-ray beam parameters employed by a commercially available x-ray therapy system. The results revealed nDEF values of 1.30-3.26 for the investigated concentration range of 1-7 mg g(-1), respectively. In comparison, for the same concentration range, nDEF values of 1.32-3.40, 1.31-3.33, 1.29-3.19, 1.28-3.12 were calculated for 80, 90, 110 and 120 kVp x-rays, respectively. Meanwhile, calculations as a function of distance from the AuNP showed that the dose enhancement, for 100 kVp, is markedly confined to the targeted neovascular AMD endothelial cells where AuNP are localized. These findings provide impetus for considering the application of AuNP to enhance therapeutic efficacy during stereotactic radiosurgery for neovascular AMD.
C1 [Ngwa, Wilfred] Brigham & Womens Hosp, Div Med Phys & Biophys, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
C3 Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer
   Institute; Harvard University; Harvard Medical School
RP Ngwa, W (通讯作者)，Brigham & Womens Hosp, Div Med Phys & Biophys, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
EM wngwa@lroc.harvard.edu
RI Makrigiorgos, Mike/AFC-4575-2022
CR AMD Alliance International, 2010, GLOB EC COST VIS IMP
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Bonnaud S, 2007, CANCER RES, V67, P1803, DOI 10.1158/0008-5472.CAN-06-2802
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Canton VM, 2011, OPHTHAL SURG LAS IM, V42, P468, DOI 10.3928/15428877-20110804-01
   COLE A, 1969, RADIAT RES, V38, P7, DOI 10.2307/3572707
   Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093
   Farjo KM, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-21
   Fine SL, 2001, ARCH OPHTHALMOL-CHIC, V119, P275
   Garnica-Garza HM, 2009, PHYS MED BIOL, V54, P5411, DOI 10.1088/0031-9155/54/18/004
   Gokeri G, 2010, PHYS MED BIOL, V55, P7469, DOI 10.1088/0031-9155/55/24/006
   Hanlon J, 2011, INVEST OPHTH VIS SCI, V52, P2334, DOI 10.1167/iovs.10-6421
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Iezzi R, 2012, BIOMATERIALS, V33, P979, DOI 10.1016/j.biomaterials.2011.10.010
   Jain S, 2012, BRIT J RADIOL, V85, P101, DOI 10.1259/bjr/59448833
   Kaiser PK, 2010, BRIT J OPHTHALMOL, V94, P143, DOI 10.1136/bjo.2009.159863
   Kang SJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P1043, DOI 10.1001/archophthalmol.2009.185
   Kim JH, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/50/505101
   Lasagna-Reeves C, 2010, BIOCHEM BIOPH RES CO, V393, P649, DOI 10.1016/j.bbrc.2010.02.046
   Lechtman E, 2011, PHYS MED BIOL, V56, P4631, DOI 10.1088/0031-9155/56/15/001
   McMahon SJ, 2011, SCI REP-UK, V1, DOI 10.1038/srep00018
   Canton VM, 2012, OPHTHAL SURG LAS IM, V43, P20, DOI 10.3928/15428877-20111129-01
   Moshfeghi AA, 2011, OPHTHAL SURG LAS IM, V42, P460, DOI 10.3928/15428877-20110804-03
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Mukherjee P, 2005, CLIN CANCER RES, V11, P3530, DOI 10.1158/1078-0432.CCR-04-2482
   Murphy MJ, 2007, MED PHYS, V34, P4041, DOI 10.1118/1.2775667
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Ngwa W, 2012, MED PHYS, V39, P392, DOI 10.1118/1.3671905
   Ngwa W, 2010, PHYS MED BIOL, V55, P6533, DOI 10.1088/0031-9155/55/21/013
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Poludniowski G, 2009, PHYS MED BIOL, V54, pN433, DOI 10.1088/0031-9155/54/19/N01
   Raju HB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017452
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salehi-Had H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018864
   Shukla R, 2005, LANGMUIR, V21, P10644, DOI 10.1021/la0513712
   Silva RA, 2011, SEMIN OPHTHALMOL, V26, P121, DOI 10.3109/08820538.2011.554486
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Taddei PJ, 2010, PHYS MED BIOL, V55, P7037, DOI 10.1088/0031-9155/55/23/S06
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Van den Heuvel F, 2010, PHYS MED BIOL, V55, P4509, DOI 10.1088/0031-9155/55/16/S06
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
NR 45
TC 26
Z9 27
U1 0
U2 36
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD OCT 21
PY 2012
VL 57
IS 20
BP 6371
EP 6380
DI 10.1088/0031-9155/57/20/6371
PG 10
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 016WD
UT WOS:000309549600005
PM 22995994
DA 2022-11-30
ER

PT J
AU Ladewig, MS
   Karl, SE
   Hamelmann, V
   Helb, HM
   Scholl, HPN
   Holz, FG
   Eter, N
AF Ladewig, Markus S.
   Karl, Stefanie E.
   Hamelmann, Victoria
   Helb, Hans-Martin
   Scholl, Hendrik P. N.
   Holz, Frank G.
   Eter, Nicole
TI Combined intravitreal bevacizumab and photodynamic therapy for
   neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE bevacizumab; photodynamic therapy; PDT; age-related macular
   degeneration; AMD; CNV; eye; vascular endothelial growth factor
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE;
   VERTEPORFIN THERAPY; INJECTION; RETINA; VEGF; SECONDARY; AVASTIN; TAP
AB Background Our aim was to evaluate the short-term safety and efficacy of combined photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in neovascular age-related macular degeneration (AMD).
   Methods A prospective non-randomized interventional case series of 30 eyes of 30 patients with choroidal neovascularization (CNV) caused by AMD was studied. All patients were treated with PDT followed by an intravitreal injection of bevacizumab (1.5 mg) on the same day. Ophthalmic evaluations included determination of best-corrected visual acuity by using ETDRS charts. CNV lesion characteristics were determined by fluorescein angiography, and retinal morphology by optical coherence tomography. Review examinations were performed 1, 4, and 12 weeks following treatment.
   Results The median ETDRS letter scores increased by 3 letters after 4 weeks and 4.3 letters after 12 weeks. Median central retinal thickness decreased from the baseline by 145 mu m (week 1), 205 mu m (week 4), and 171 mu m (week 12), respectively (P < 0.0001, for all comparisons). One patient experienced a transient moderate vision loss after 4 weeks post treatment. Leakage on fluorescein angiography was resolved in all patients at week 12. No significant ocular or systemic side-effects were observed.
   Conclusions Short-term results suggest that a single PDT in combination with intravitreal bevacizumab is safe and associated with stabilization of visual acuity and decrease of intraretinal and subretinal fluid accumulation in the macula. Further evaluation of this treatment strategy for neovascular AMD appears warranted.
C1 Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Frank.holz@ukb.uni-bonn.de
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Framme C, 2006, GRAEF ARCH CLIN EXP, V244, P773, DOI 10.1007/s00417-005-0221-2
   Hoffmann S, 2000, INVEST OPHTH VIS SCI, V41, P2389
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Jaissle GB, 2005, KLIN MONATSBL AUGENH, V222, P390, DOI 10.1055/s-2005-858231
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kent D, 2003, MOL VIS, V9, P747
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
NR 33
TC 33
Z9 33
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2008
VL 246
IS 1
BP 17
EP 25
DI 10.1007/s00417-007-0654-x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 233LQ
UT WOS:000251092800003
PM 17701197
DA 2022-11-30
ER

PT J
AU Smilnak, GJ
   Deans, JR
   Doraiswamy, PM
   Stinnett, S
   Whitson, HE
   Lad, EM
AF Smilnak, Gordon J.
   Deans, John R.
   Doraiswamy, P. Murali
   Stinnett, Sandra
   Whitson, Heather E.
   Lad, Eleonora M.
TI Comorbidity of age-related macular degeneration with Alzheimer's
   disease: A histopathologic case-control study
SO PLOS ONE
LA English
DT Article
ID COGNITIVE IMPAIRMENT; NEUROPATHOLOGIC ASSESSMENT; NATIONAL INSTITUTE;
   DIABETES-MELLITUS; BRAIN; GLAUCOMA; MACULOPATHY; VISION; RISK;
   EPIDEMIOLOGY
AB Introduction
   Previous studies evaluating the association between clinically diagnosed Alzheimer's disease (AD) and age-related macular degeneration (AMD) have generated conflicting results. This study is the first to assess whether AMD prevalence is higher in AD patients than non-AD controls by using histopathology to definitively diagnose AD.
   Methods
   This was a retrospective case-control study utilizing diagnostic information extracted from autopsy reports of patients age 75 and above, including 115 with a neuropathological diagnosis of AD and 57 age-matched normal controls.
   Results
   The rate of AMD was not significantly higher in AD cases (53.0%) than in controls (59.6%) (z = 0.820, p = 0.794). AMD severity as determined by Sarks score was similar between AD patients and controls (chi(2) = 2.96, p = 0.706). There was also no significant association between Braak stage of AD severity and AMD (chi(2) = 4.55, p = 0.602).
   Discussion
   No significant effect of AD diagnosis or pathologic severity on AMD comorbidity was found, suggesting that any shared mechanisms between AMD and AD may be nondeterministic.
C1 [Smilnak, Gordon J.; Deans, John R.; Stinnett, Sandra; Lad, Eleonora M.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Doraiswamy, P. Murali] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
   [Whitson, Heather E.] Duke Univ, Med Ctr, Dept Internal Med, Div Geriatr, Durham, NC 27710 USA.
   [Deans, John R.] Univ N Carolina, Dept Ophthalmol, Kittner Eye Ctr, Chapel Hill, NC 27515 USA.
C3 Duke University; Duke University; Duke University; University of North
   Carolina; University of North Carolina Chapel Hill
RP Lad, EM (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
EM nora.lad@duke.edu
OI Whitson, Heather/0000-0002-8417-4846; Stinnett,
   Sandra/0000-0001-7192-0195
FU National Institutes of Health [K23EY026988]; NATIONAL EYE INSTITUTE
   [K23EY026988] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health grant
   number K23EY026988 EML). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661
   Bayer AU, 2002, EUR NEUROL, V47, P165, DOI 10.1159/000047976
   Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b
   BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan KY, 2013, LANCET, V381, P2016, DOI 10.1016/S0140-6736(13)60221-4
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   GEN, 2019, GENETIC ENG BIOTECHN
   Gupta N, 2009, BRIT J OPHTHALMOL, V93, P56, DOI 10.1136/bjo.2008.138172
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Humpel C, 2011, TRENDS BIOTECHNOL, V29, P26, DOI 10.1016/j.tibtech.2010.09.007
   Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007
   Jindal V, 2015, MOL NEUROBIOL, V51, P878, DOI 10.1007/s12035-014-8732-7
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Marcus C, 2014, CLIN NUCL MED, V39, pE413, DOI 10.1097/RLU.0000000000000547
   MARGETA MA, 2018, OPHTHALMOLOGIE, V256, P2449, DOI DOI 10.1007/S00417-018-4081-Y
   MCGEER PL, 1994, TOHOKU J EXP MED, V174, P269, DOI 10.1620/tjem.174.269
   MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479
   Mott RT, 2005, NEUROIMAG CLIN N AM, V15, P755, DOI 10.1016/j.nic.2005.09.003
   Ong SS, 2019, J NEUROL, V266, P1566, DOI 10.1007/s00415-018-9028-z
   Ong SS, 2018, JAMA NEUROL, V75, P650, DOI 10.1001/jamaneurol.2018.0602
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Qiu Chengxuan, 2009, Dialogues Clin Neurosci, V11, P111
   Rogers MAM, 2010, AM J EPIDEMIOL, V171, P728, DOI 10.1093/aje/kwp453
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Servick K., 2019, SCI MAGAZINE
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Skoog I, 2006, NEUROL RES, V28, P605, DOI 10.1179/016164106X130506
   Tamura H, 2006, J NEUROL SCI, V246, P79, DOI 10.1016/j.jns.2006.02.009
   Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791
   Thorpe CT, 2012, J AM GERIATR SOC, V60, P644, DOI 10.1111/j.1532-5415.2012.03907.x
   Turunen M, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2009.08.010
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Walker J, 2019, WALL STREET J
   Whitson HE, 2011, AGING CLIN EXP RES, V23, P343, DOI 10.1007/BF03325233
   Williams MA, 2015, AM J GERIAT PSYCHIAT, V23, P1290, DOI 10.1016/j.jagp.2015.06.005
   Williams MA, 2014, J ALZHEIMERS DIS, V42, P909, DOI 10.3233/JAD-140243
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Yucel Y, 2008, PROG BRAIN RES, V173, P465, DOI 10.1016/S0079-6123(08)01132-1
NR 52
TC 2
Z9 2
U1 2
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 30
PY 2019
VL 14
IS 9
AR e0223199
DI 10.1371/journal.pone.0223199
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LM6MW
UT WOS:000532364900027
PM 31568508
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sturgill, GM
   Bala, E
   Yaniglos, SS
   Peachey, NS
   Hagstrom, SA
AF Sturgill, Gwen M.
   Bala, Elisa
   Yaniglos, Stacia S.
   Peachey, Neal S.
   Hagstrom, Stephanie A.
TI Mutation screen of beta-crystallin genes in 274 patients with
   age-related macular degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE age-related macular degeneration; crystallin; mutation; retinal
   degeneration
ID FACTOR-H POLYMORPHISM; ALPHA-A-CRYSTALLIN; EXTRALENTICULAR EXPRESSION;
   DELTA-CRYSTALLIN; CATARACT; PROTEIN; RETINA; RISK; LENS;
   BETA-B2-CRYSTALLIN
AB Purpose: The crystallin family of proteins comprise the main structural proteins of the vertebrate lens and have been classified into alpha-, beta-, and gamma-families. Several of the beta-crystallin proteins have been detected in the retina where they are each localized to different compartments of rod and cone photoreceptors. Functionally, beta-crystallins have been implicated in the protection of the retina from intense light exposure. Two members of the beta-crystallins, CRYBB1 and CRYBB2, have been identified in drusen preparations isolated from the retina of donor eyes of patients with age-related macular degeneration (AMD), the leading cause of blindness in the elderly population of developed countries. We therefore investigated CRYBB1 and CRYBB2 as candidate genes for AMD in 274 unrelated patients.
   Results: A mutation screen of the entire coding region of the CRYBB1gene uncovered eight sequence variations, including three missense changes, two intronic changes and three isocoding changes. A mutation screen of the entire coding region of the CRYBB2 gene uncovered three sequence variations, one isocoding change and two intronic changes.
   Conclusions: Although variant alleles of the CRYBB1 and CRYBB2 genes were found, none are considered pathogenic.
C1 [Peachey, Neal S.; Hagstrom, Stephanie A.] Cleveland Clin, Cole Eye Inst, Dept Ophthalm Res, Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Cleveland, OH 44195 USA.
   [Peachey, Neal S.; Hagstrom, Stephanie A.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Case Western Reserve University; Louis
   Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve
   University; Cleveland Clinic Foundation
RP Hagstrom, SA (通讯作者)，Cleveland Clin, Cole Eye Inst, Dept Ophthalm Res, Louis Stokes Cleveland Dept Vet Affairs Med Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM hagstrs@ccf.org
RI Peachey, Neal/G-5533-2010
OI Peachey, Neal/0000-0002-4419-7226
FU VA Medical Research Service, National Institutes of Health [EY015638,
   EY016072]; State of Ohio [BRTT 05-29]; Foundation Fighting Blindness
   Center; Karl Kirshgessner Foundation; Research to Prevent Blindness
   (RPB) Center; RPB Sybil B. Harrington Special Scholar Award; NATIONAL
   EYE INSTITUTE [R01EY016072, R24EY015638] Funding Source: NIH RePORTER
FX This work was supported in part by the VA Medical Research Service,
   National Institutes of Health (EY015638, EY016072), BRTT 05-29 from the
   State of Ohio, a Foundation Fighting Blindness Center Grant, Karl
   Kirshgessner Foundation, a Research to Prevent Blindness (RPB) Center
   Grant, and a RPB Sybil B. Harrington Special Scholar Award to SAH.
CR Andley UP, 2007, PROG RETIN EYE RES, V26, P78, DOI 10.1016/j.preteyeres.2006.10.003
   Brunekreef GA, 1997, INVEST OPHTH VIS SCI, V38, P2764
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   David LL, 1996, J BIOL CHEM, V271, P4273
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DERETIC D, 1994, J BIOL CHEM, V269, P16853
   Dirks RPH, 1998, EXP EYE RES, V66, P267, DOI 10.1006/exer.1997.0439
   Duncan G, 1999, EYE, V13, P480, DOI 10.1038/eye.1999.125
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Ferrer-Costa C, 2005, BIOINFORMATICS, V21, P3176, DOI 10.1093/bioinformatics/bti486
   Fischer D, 2008, MOL CELL NEUROSCI, V37, P471, DOI 10.1016/j.mcn.2007.11.002
   Fort PE, 2009, MOL CELL PROTEOMICS, V8, P767, DOI 10.1074/mcp.M800326-MCP200
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Graw J, 2009, EXP EYE RES, V88, P173, DOI 10.1016/j.exer.2008.10.011
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEAD MW, 1991, DIFFERENTIATION, V48, P147, DOI 10.1111/j.1432-0436.1991.tb00253.x
   HEAD MW, 1995, EXP EYE RES, V61, P423, DOI 10.1016/S0014-4835(05)80137-X
   HOLLMAN FW, 2003, METHODOLOGY ASSUMPTI, P1
   INANA G, 1983, NATURE, V302, P310, DOI 10.1038/302310a0
   Jones SE, 1999, INVEST OPHTH VIS SCI, V40, P3017
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LEIDTKE T, 2007, MOL CELLULAR PROTEOM, V6, P895
   Litt M, 1997, HUM MOL GENET, V6, P665, DOI 10.1093/hmg/6.5.665
   Mackay DS, 2002, AM J HUM GENET, V71, P1216, DOI 10.1086/344212
   Maeda A, 1999, INVEST OPHTH VIS SCI, V40, P2788
   Magabo KS, 2000, INVEST OPHTH VIS SCI, V41, P3056
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Rao NA, 2008, INVEST OPHTH VIS SCI, V49, P1161, DOI 10.1167/iovs.07-1259
   Sakaguchi H, 2003, EXP EYE RES, V76, P131, DOI 10.1016/S0014-4835(02)00249-X
   Santhiya ST, 2004, INVEST OPHTH VIS SCI, V45, P3599, DOI 10.1167/iovs.04-0207
   SHARMA Y, 1989, J BIOL CHEM, V264, P12794
   Sinha D, 1998, Mol Vis, V4, P8
   SMOLICH BD, 1994, MOL CELL BIOL, V14, P1355, DOI 10.1128/MCB.14.2.1355
   Stone EM, 2007, ANNU REV MED, V58, P477, DOI 10.1146/annurev.med.58.111405.133335
   Sturgill GM, 2006, OPHTHALMIC GENET, V27, P151, DOI 10.1080/13816810600976871
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Vanita, 2001, J MED GENET, V38, P392, DOI 10.1136/jmg.38.6.392
   Xi JH, 2003, MOL VIS, V9, P410
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 45
TC 2
Z9 3
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD SEP
PY 2010
VL 31
IS 3
BP 129
EP 134
DI 10.3109/13816810.2010.486774
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 655KE
UT WOS:000282248100005
PM 20565250
DA 2022-11-30
ER

PT J
AU Jelin, E
   Wisloff, T
   Moe, MC
   Heiberg, T
AF Jelin, Elma
   Wisloff, Torbjorn
   Moe, Morten C.
   Heiberg, Turid
TI Development and testing of a patient-derived questionnaire for treatment
   of neovascular age-related macular degeneration: dimensions of
   importance in treatment of neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; intravitreal injections;
   patient perspective; patient-derived questionnaire; patient-reported
   outcome measures
ID ANTI-VEGF TREATMENT; EYE; RANIBIZUMAB; EXPERIENCES; IMPACT; RISK
AB Purpose Studies reporting on patient perspectives during treatment of neovascular age-related macular degeneration (nAMD) are limited. Thus, the aim of this study was to develop and test psychometric performance of a patient-derived questionnaire to capture important experiences during intravitreal treatment. Methods Patients (n = 44) with at least 3-month experience of intravitreal injection treatment for nAMD identified the dimensions of priority and also performed a weighting procedure to develop a score for comparison. The questionnaire comprised two versions: one focusing on the relative importance' of the dimensions and one on the experience of the 'management' during treatment. The questionnaire was then tested for psychometric performance in a longitudinal design in newly diagnosed patients at baseline (n = 197), after three (n = 184) and six (n = 150) months of treatment. Results Of the 15 included dimensions, the following were most frequently reported: 'receive treatment to preserve vision', 'information', 'waiting time', 'trust' and 'accommodating staff. The psychometric testing showed moderate reliability (intraclass correlation coefficient: 0.65-0.67) for the two versions and high level of face validity (8.3). The dimensions, 'preserving vision', 'early access to treatment', 'pain relief', 'information about the treatment/diagnosis' and 'visual aids' were consistently reported higher in 'importance' than in 'management', at both 3 and 6 months, indicating a potential for improvement in clinical practice for these dimensions. Conclusion This study provides a brief patient-derived questionnaire, expressed with a score with good psychometric performance that can be used for monitoring during intravitreal injection treatment of nAMD patients.
C1 [Jelin, Elma; Moe, Morten C.] Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
   [Jelin, Elma; Moe, Morten C.] Univ Oslo, Inst Clin Med, Oslo, Norway.
   [Wisloff, Torbjorn] Norwegian Inst Publ Hlth, Oslo, Norway.
   [Wisloff, Torbjorn] Univ Oslo, Inst Hlth & Soc, Oslo, Norway.
   [Heiberg, Turid] Oslo Univ Hosp, Reg Res Support, Oslo, Norway.
   [Heiberg, Turid] Ostfold Univ Coll, Halden, Norway.
C3 University of Oslo; University of Oslo; Norwegian Institute of Public
   Health (NIPH); University of Oslo; University of Oslo; Ostfold
   University College
RP Heiberg, T (通讯作者)，Oslo Univ Hosp, Clin Trial Unit, Reg Res Support, Postbox 4950 Nydalen, N-0424 Oslo, Norway.
EM turid.heiberg@hiof.no
RI Wisløff, Torbjørn/AFM-8289-2022
OI Wisløff, Torbjørn/0000-0002-7539-082X
FU Norwegian Nurses Organisation; Division of Head, Neck and Reconstructive
   Surgery at Oslo University Hospital; Oslo University Hospital
FX We are grateful to Rowan Thomas Faber and Helene Elizabeth Simpson,
   Department Of Ophthalmology at Oslo University Hospital, for providing
   us with the translation of the questionnaire, as well as the two patient
   research partners who helped us throughout the entire process. In
   addition, we also want to thank for the research grant for PhD students
   from The Norwegian Nurses Organisation and the grant from Division of
   Head, Neck and Reconstructive Surgery at Oslo University Hospital. The
   assistance in data collection from Ana Carla Shippert, Britt Antonsen
   and Hanne Heiberg was helpful. Similarly, we appreciate the help we
   received from the administrative personnel and physicians at the medical
   retina unit who helped by identifying newly diagnosed patients. Finally,
   we thank the University of Oslo for hosting the PhD education and Oslo
   University Hospital for financial support.
CR Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chung SD, 2017, ACTA OPHTHALMOL, V95, pe800, DOI 10.1111/aos.13281
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Gossec L, 2009, ANN RHEUM DIS, V68, P1680, DOI 10.1136/ard.2008.100271
   Gossec L, 2014, ANN RHEUM DIS, V73, P1012, DOI 10.1136/annrheumdis-2014-205207
   GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N
   Heiberg T, 2008, ANN RHEUM DIS, V67, P967, DOI 10.1136/ard.2007.077503
   Heiberg T, 2013, SUPPORT CARE CANCER, V21, P1677, DOI 10.1007/s00520-012-1713-3
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jorstad OK, 2017, ACTA OPHTHALMOL, V95, P460, DOI 10.1111/aos.13480
   Kandula S, 2010, CLIN OPHTHALMOL, V4, P375
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Labori KJ, 2006, SUPPORT CARE CANCER, V14, P1126, DOI 10.1007/s00520-006-0067-0
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Revicki DA, 2007, QUAL LIFE RES, V16, P717, DOI 10.1007/s11136-006-9153-5
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Senthil MP, 2017, SURV OPHTHALMOL, V62, P546, DOI 10.1016/j.survophthal.2016.12.011
   Tailor R, 2011, CLIN OPHTHALMOL, V5, P1499, DOI 10.2147/OPTH.S24358
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Yamazaki H, 2009, BIOSCI TRENDS, V3, P202
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 34
TC 5
Z9 5
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2018
VL 96
IS 8
BP 804
EP 811
DI 10.1111/aos.13847
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA HC3IB
UT WOS:000451694500007
PM 30198182
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Holekamp, NM
   Bouck, N
   Volpert, O
AF Holekamp, NM
   Bouck, N
   Volpert, O
TI Pigment epithelium-derived factor is deficient in the vitreous of
   patients with choroidal neovascularization due to age-related macular
   degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; VEGF; PEDF; PHOTORECEPTORS; RETINOPATHY;
   PROTECTION; DAMAGE; CELLS
AB PURPOSE: Pigment epithelium-derived growth factor (PEDF) is a potent inhibitor of angiogenesis that is found in the normal eye. The purpose of this study is to report decreased levels of PEDF in the vitreous of eyes with choroidal neovascularization (CNV) due to age related macular degeneration (AMD).
   DESIGN: Prospective case,control study.
   METHODS: In a prospective case control study, undiluted vitreous was collected from nine eyes of nine patients with CNV due to AMD and from an age, matched control group of 12 eyes of 12 patients with retinal disorders not involving neovascularization. Vitreous PEDF and vascular endothelial growth factor (VEGF) concentrations were determined by Western blot analyses and enzyme-linked immunosorbent assay (ELISA), respectively. Angiogenic activities of the vitreous samples were assessed in vitro using an endothelial cell chemotaxis assay.
   RESULTS: In vitreous samples from nine eyes with CNV due to AMD the mean +/- SD PEDF level was 2.8 ng/mul +/- 1.3 ng/mul. In vitreous samples from 12 age. matched control eyes the mean +/- SD PEDF level was 16.4 ng/mul +/- 7.1 ng/mul. The difference between the two groups was statistically significant (P = .00003). No significant difference in vitreous VEGF concentration was seen between CNV/AMD samples and control samples (P = .23). All CNV/AMD vitreous samples induced endothelial cell migration in vitro. No sample from age matched non-age related macular degeneration con, trots could induce endothelial cell migration, and 11 of 12 were able to block VEGF-induced migration in vitro. This inhibitory activity required active PEDF.
   CONCLUSION: The vitreous of patients with CNV due to AMD contained lower levels of PEDF and lacked the antiangiogenic activity of vitreous from age-matched controls. This suggests that loss of PEDF creates a permissive environment for CNV patients with AMD. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Barnes Retina Inst, St Louis, MO 63141 USA.
   Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Microbiol Immunol, Chicago, IL USA.
   Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Urol, Chicago, IL USA.
C3 Washington University (WUSTL); Ann & Robert H. Lurie Children's Hospital
   of Chicago; Northwestern University; Robert H. Lurie Comprehensive
   Cancer Center; Ann & Robert H. Lurie Children's Hospital of Chicago;
   Northwestern University; Robert H. Lurie Comprehensive Cancer Center
RP Holekamp, NM (通讯作者)，Barnes Retina Inst, 1600 S Brentwood Blvd,8th Floor, St Louis, MO 63141 USA.
EM nholekamp@pol.net
OI Volpert, Olga/0000-0003-1381-5543
FU NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER;
   NCI NIH HHS [R01 CA64239] Funding Source: Medline
CR AIELLO JP, N ENGL J MED, V332, P1480
   Becerra SP, 1997, ADV EXP MED BIOL, V425, P223
   BREM S, 1977, American Journal of Ophthalmology, V84, P323
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chader GJ, 2001, P NATL ACAD SCI USA, V98, P2122, DOI 10.1073/pnas.061024098
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Ferris FL, 1999, NEW ENGL J MED, V341, P667, DOI 10.1056/NEJM199908263410907
   General Accounting Office, 1999, GEN MAN PROC PHAS 2B, P1
   GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Jablonski MM, 2000, J NEUROSCI, V20, P7149
   Karakousis PC, 2001, MOL VIS, V7, P154
   Keshet E, 2001, J CLIN INVEST, V107, P945, DOI 10.1172/JCI12704
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
NR 26
TC 180
Z9 203
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2002
VL 134
IS 2
BP 220
EP 227
AR PII S0002-9394(02)01549-0
DI 10.1016/S0002-9394(02)01549-0
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 579GB
UT WOS:000177169300010
PM 12140029
DA 2022-11-30
ER

PT J
AU Domalpally, A
   Clemons, TE
   Danis, RP
   Sadda, SR
   Cukras, CA
   Toth, CA
   Friberg, TR
   Chew, EY
AF Domalpally, Amitha
   Clemons, Traci E.
   Danis, Ronald P.
   Sadda, SriniVas R.
   Cukras, Catherine A.
   Toth, Cynthia A.
   Friberg, Thomas R.
   Chew, Emily Y.
CA OPTOS PEripheral RetinA study Anc
TI Peripheral Retinal Changes Associated with Age-Related Macular
   Degeneration in the Age-Related Eye Disease Study 2
SO OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT-EPITHELIUM; AUTOFLUORESCENCE; PREVALENCE
AB Purpose: To compare rates of peripheral retinal changes in Age-Related Eye Disease Study 2 (AREDS2) participants with at least intermediate age-related macular degeneration (AMD) with control subjects without intermediate age-related changes (large drusen).
   Design: Cross-sectional evaluation of clinic-based patients enrolled in AREDS2 and a prospective study. Participants:
   Participants from prospective studies.
   Methods: The 200 degrees pseudocolor and fundus autofluorescence (FAF) images were captured on the Optos 200 Tx Ultrawide-field device (Optos, Dunfermline, Scotland) by centering on the fovea and then steering superiorly and inferiorly. The montaged images were graded at a reading center with the images divided into 3 zones (zone 1 [posterior pole], zone 2 [midperiphery], and zone 3 [far periphery]) to document the presence of peripheral lesions.
   Main Outcome Measures: Peripheral retinal lesions: drusen, hypopigmentary/hyperpigmentary changes, reticular pseudodrusen, senile reticular pigmentary changes, cobblestone degeneration, and FAF abnormalities.
   Results: A total of 484 (951 eyes) AREDS2 participants with AMD (cases) and 89 (163 eyes) controls without AMD had gradable color and FAF images. In zones 2 and 3, neovascularization and geographic atrophy (GA) were present, ranging from 0.4% to 6% in eyes of cases, respectively, and GA was present in 1% of eyes of controls. Drusen were detected in 97%, 78%, and 64% of eyes of cases and 48%, 21%, and 9% of eyes of controls in zones 2 and 3 superior and 3 inferior, respectively (P < 0.001 for all). Peripheral reticular pseudodrusen were seen in 15%. Senile reticular pigmentary change was the predominant peripheral change seen in 48% of cases and 16% of controls in zone 2 (P < 0.001). Nonreticular pigment changes were less frequent in the periphery than in the posterior pole (46% vs. 76%) and negligible in controls.
   Conclusions: Peripheral retinal changes are more prevalent in eyes with AMD than in control eyes. Drusen are seen in a majority of eyes with AMD in both the mid and far periphery, whereas pigment changes and features of advanced AMD are less frequent. Age-related macular degeneration may be more than a "macular" condition but one that involves the entire retina. Future longitudinal studies of peripheral changes in AMD and their impact on visual function may contribute to understanding AMD pathogenesis.
C1 [Domalpally, Amitha; Danis, Ronald P.] Univ Wisconsin, Madison Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
   [Sadda, SriniVas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Cukras, Catherine A.; Chew, Emily Y.] NEI, Clin Trials Branch, NIH, Bethesda, MD 20892 USA.
   [Toth, Cynthia A.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Friberg, Thomas R.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
C3 University of Wisconsin System; University of Wisconsin Madison; Emmes
   Corporation; Doheny Eye Institute; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); Duke University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Chew, EY (通讯作者)，NIH, Bldg 10,CRC,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854
FU National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda Maryland [HHS-N-260-200500007-C,
   NO1-EY-5-0007]; National Institutes of Health: Office of Dietary
   Supplements, National Center for Complementary and Alternative Medicine;
   National Institute on Aging; National Heart, Lung, and Blood Institute;
   National Institute of Neurological Disorders and Stroke; Optos
   (Dunfermline, Scotland)
FX Supported by the intramural program funds and contracts from the
   National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda Maryland (Contract
   HHS-N-260-200500007-C; ADB Contract NO1-EY-5-0007). Funds were
   generously contributed to these contracts by the following National
   Institutes of Health: Office of Dietary Supplements, National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; and National Institute of
   Neurological Disorders and Stroke. The sponsor and funding organization
   participated in the design and conduct of the study; data collection,
   management, analysis and interpretation; and the preparation, review and
   approval of the manuscript. Optos (Dunfermline, Scotland) loaned devices
   to the clinical sites and provided funding for the acquisition of the
   images and for the centralized grading of the images conducted at the
   Wisconsin Fundus Photograph Reading Center but were not involved with
   the study design or manuscript preparation.
CR [Anonymous], 1992, Control Clin Trials, V13, P22
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Domalpally A, 2011, INVEST OPHTH VIS SCI, V52, P3070
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friberg TR, 2003, OPHTHAL SURG LAS IM, V34, P488
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   LEWIS H, 1985, OPHTHALMOLOGY, V92, P1485
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Witmer MT, 2012, ACTA OPHTHALMOL, V90, pe428, DOI 10.1111/j.1755-3768.2012.02434.x
NR 15
TC 34
Z9 34
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2017
VL 124
IS 4
BP 479
EP 487
DI 10.1016/j.ophtha.2016.12.004
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ1ST
UT WOS:000397850600029
OA Bronze
DA 2022-11-30
ER

PT J
AU Robman, L
   Mahdi, O
   McCarty, C
   Dimitrov, P
   Tikellis, G
   McNeil, J
   Byrne, G
   Taylor, H
   Guymer, R
AF Robman, L
   Mahdi, O
   McCarty, C
   Dimitrov, P
   Tikellis, G
   McNeil, J
   Byrne, G
   Taylor, H
   Guymer, R
TI Exposure to Chlamydia pneumoniae infection and progression of
   age-related macular degeneration
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Chlamydophila pneumoniae; disease progression; infection; macular
   degeneration
ID VISUAL IMPAIRMENT; MACULOPATHY; PREVALENCE; ATHEROSCLEROSIS; ANTIBODIES;
   RISK; SEROPOSITIVITY; DISEASE
AB Recent studies have found an association between exposure to Chlamydia pneumoniae infection and risk of age-related macular degeneration (AMD). To assess a potential risk of AMD progression posed by exposure to C. pneumoniae, the authors reexamined Australian residents in 2001-2002 who were aged 51-89 years with early AMD at baseline (1992-1995). Examination included macular photography and an enzyme-linked immunosorbent assay to determine antibody titers to the elementary bodies from C. pneumoniae AR39. AMD progression was assessed quantitatively, using both coarse and fine progression steps following an international classification for AMD grading, and also qualitatively, by side-by-side comparison of baseline and follow-up macular photographs. Serologic data were available for 246 of 254 (97%) subjects. AMD progression was associated with a higher antibody titer. After adjustment for age, smoking, family history of AMD, history of cardiovascular diseases, and source study, the subjects in the upper tertiles of antibody titers were 2.1 (95% confidence interval: 0.92, 4.69), 2.6 (95% confidence interval: 1.24, 5.41), and 3.0 (95% confidence interval: 1.46, 6.37) times more at risk of progression than those in the lowest tertile, using three definitions of progression, respectively. The fact that seroreactivity to C. pneumoniae was independently associated with the risk of AMD progression suggests that C. pneumoniae infection may be an additional risk factor for AMD progression.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA.
   Marshfield Clin Res Fdn, Marshfield, WI USA.
   Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Tennessee System; University of Tennessee Health Science Center;
   Monash University
RP Robman, L (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne 3002, Australia.
EM liubov@unimelb.edu.au
RI McNeil, John/L-6440-2019
OI McNeil, John/0000-0002-1049-5129; Guymer, Robyn/0000-0002-9441-4356;
   Taylor, Hugh/0000-0002-9437-784X; McCarty,
   Catherine/0000-0003-1089-0142; Mahdi, Olaimatu Sadia/0000-0003-1830-5411
FU NIAID NIH HHS [R01 AI042790] Funding Source: Medline; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASES [R01AI042790] Funding Source: NIH
   RePORTER
CR Anderson JL, 2004, TEX HEART I J, V31, P33
   BENYAAKOV M, 1994, J CLIN PATHOL, V47, P232, DOI 10.1136/jcp.47.3.232
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Camm AJ, 2000, EUR HEART J, V21, P1046, DOI 10.1053/euhj.1999.1950
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dimitrov PN, 2003, INVEST OPHTH VIS SCI, V44, P5075, DOI 10.1167/iovs.02-0457
   Fong IW, 2000, CAN MED ASSOC J, V163, P49
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   FREIDANK HM, 1993, J INFECTION, V27, P89, DOI 10.1016/0163-4453(93)94013-2
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   GRAYSTON JT, 1992, CLIN INFECT DIS, V15, P757, DOI 10.1093/clind/15.5.757
   Gupta S, 1999, ATHEROSCLEROSIS, V143, P1, DOI 10.1016/S0021-9150(98)00317-7
   Huhtinen M, 2001, INVEST OPHTH VIS SCI, V42, P1816
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Kalayoglu MV, 2004, INVEST OPHTH VIS SCI, V45, pU71
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Leinonen M, 2002, LANCET INFECT DIS, V2, P11, DOI 10.1016/S1473-3099(01)00168-2
   Livingston P M, 1994, Ophthalmic Epidemiol, V1, P139, DOI 10.3109/09286589409047222
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Quinn TC, 1999, AM HEART J, V138, pS507, DOI 10.1016/S0002-8703(99)70287-5
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Sander D, 2001, CIRCULATION, V103, P1390, DOI 10.1161/01.CIR.103.10.1390
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Shor A, 1999, JAMA-J AM MED ASSOC, V282, P2071, DOI 10.1001/jama.282.21.2071
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Streblow DN, 2001, J NUTR, V131, p2798S, DOI 10.1093/jn/131.10.2798S
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Taylor-Robinson D, 2000, J INFECT DIS, V181, pS437, DOI 10.1086/315614
   Tikellis G, 1999, Ophthalmic Epidemiol, V6, P181, DOI 10.1076/opep.6.3.181.1502
   Tikellis G, 2000, CLIN EXP OPHTHALMOL, V28, P367, DOI 10.1046/j.1442-9071.2000.00336.x
   Tutuncu NB, 2001, ENDOCR J, V48, P269, DOI 10.1507/endocrj.48.269
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Verkooyen RP, 1998, J CLIN MICROBIOL, V36, P2301, DOI 10.1128/JCM.36.8.2301-2307.1998
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WANG JH, 1993, SCAND J INFECT DIS, V25, P565, DOI 10.3109/00365549309008544
   Weger M, 2002, OPHTHALMOLOGY, V109, P749, DOI 10.1016/S0161-6420(01)01031-4
NR 41
TC 56
Z9 59
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 1
PY 2005
VL 161
IS 11
BP 1013
EP 1019
DI 10.1093/aje/kwi130
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 928PZ
UT WOS:000229285500003
PM 15901621
OA Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Krezel, AK
   Hogg, RE
   Azuara-Blanco, A
AF Krezel, Aniela K.
   Hogg, Ruth E.
   Azuara-Blanco, Augusto
TI Patient-reported outcomes in randomised controlled trials on age-related
   macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; CLINICAL-TRIALS; VISION
AB Background/aims The purpose of this systematic review was to identify the frequency and type of patient-reported outcome measures (PROMs) used in recent randomised controlled trials (RCTs) for age-related macular degeneration (AMD).
   Methods The authors conducted a systematic search between January 2010 and November 2013 in MEDLINE, EMBASE, Scopus, Cochrane Library (Central) and the clinical trials registries (http://www.controlledtrials.com and http://www.ClinicalTrials.gov) according to defined inclusion criteria (RCTs on AMD in English). Two independent reviewers evaluated studies for inclusion. One reviewer extracted data of included studies, and a second masked reviewer assessed 10% to confirm accuracy in data collection. Reference lists of included papers and appendices of relevant Cochrane systematic reviews were scanned to identify other relevant RCTs. Information collected on extracted outcomes was analysed using descriptive statistics.
   Results Literature and registry search yielded 3816 abstracts of journal articles and 493 records from trial registries. A total of 177 RCTs were deemed to have met inclusion criteria. Of the 858 outcomes reported, 38 outcomes were identified as PROMs (4.4%). Of the 177 RCTs examined, PROMs were used in 25 trials (14.1%). The National Eye Institute Visual Function Questionnaire-25 was the most frequently used PROM instrument (64% of RCTs with PROMs included).
   Conclusions This review highlights that a small proportion of AMD RCTs included PROMs as outcome measures and that there was a variety in the instruments used.
C1 [Krezel, Aniela K.; Hogg, Ruth E.; Azuara-Blanco, Augusto] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
C3 Queens University Belfast
RP Krezel, AK (通讯作者)，Royal Victoria Hosp, Ctr Med Expt, Inst Clin Sci, Block A,Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM akrezel01@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Azuara-Blanco,
   Augusto/0000-0002-4805-9322
CR AARONSON NK, 1992, EUR J CANCER, V28A, P1304, DOI 10.1016/0959-8049(92)90504-U
   AARONSON NK, 1989, CONTROL CLIN TRIALS, V10, pS195
   Aspinall A, 2007, BRIT J OPHTHALMOL, V91, P766, DOI 10.1136/bjo.2006.104679
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bradley C, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-78
   BYRNE M, 1992, BRIT MED J, V304, P1523, DOI 10.1136/bmj.304.6841.1523
   Carta A, 1998, CURR EYE RES, V17, P506, DOI 10.1076/ceyr.17.5.506.5191
   Covert D, 2007, SURV OPHTHALMOL, V52, pS20, DOI 10.1016/j.survophthal.2006.10.014
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Food and Drug Administration, 2009, PAT REP OUTC MEAS US
   GUYATT GH, 1989, CAN MED ASSOC J, V140, P1441
   Ismail R, 2014, BRIT J OPHTHALMOL, V98, P464, DOI 10.1136/bjophthalmol-2013-304323
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, P763, DOI 10.1097/OPX.0b013e3181339efd
   Moorfields Eye Hospital NHS Foundation Trust, 2011, EFFECT ECC FIX ENH C
   OSHAUGHNESSY JA, 1991, J CLIN ONCOL, V9, P2225, DOI 10.1200/JCO.1991.9.12.2225
   Owen Christopher G, 2006, BMC Ophthalmol, V6, P24, DOI 10.1186/1471-2415-6-24
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Vingolo EM, 2013, APPL PSYCHOPHYS BIOF, V38, P11, DOI 10.1007/s10484-012-9203-4
   Wiklund I, 2004, FUND CLIN PHARMACOL, V18, P351, DOI 10.1111/j.1472-8206.2004.00234.x
   Williamson P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000041
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 23
TC 14
Z9 14
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2015
VL 99
IS 11
BP 1560
EP 1564
DI 10.1136/bjophthalmol-2014-306544
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4BA
UT WOS:000363469800023
PM 25934846
DA 2022-11-30
ER

PT J
AU Aufartova, J
   Blaha, M
   Kasalova, E
   Honegrova, B
   Cervinkova, B
   Krcmova, LK
   Plisek, J
   Lanska, M
   Sobotka, L
   Solichova, D
AF Aufartova, Jana
   Blaha, Milan
   Kasalova, Eva
   Honegrova, Barbora
   Cervinkova, Barbora
   Krcmova, Lenka Kujovska
   Plisek, Jiri
   Lanska, Miriam
   Sobotka, Lubos
   Solichova, Dagmar
TI Blood levels of antioxidants during age-related macular degeneration
   treatment by rheohaemapheresis
SO BIOMEDICAL PAPERS-OLOMOUC
LA English
DT Article
DE rheohaemapheresis; age related macular degeneration; vitamin E; vitamin
   E/cholesterol ratio; antioxidants
ID OXIDATIVE STRESS; VITAMIN-E; LIQUID-CHROMATOGRAPHY; ALPHA-TOCOPHEROL;
   LDL-APHERESIS; VALIDATION; ZEAXANTHIN; PROTECTS; EPITOPES; LUTEIN
AB Aims. Rheohaemapheresis treatment influences rheological markers and most likely improves metabolism in affected retinal areas, resulting not only in absorption of soft drusen but also reduction or complete disappearance of drusenoid retinal pigment epithelium detachments. However, the character of the treatment process has raised suspicion that there is a decrease not only in cholesterol but also in antioxidants, such as vitamin E and vitamin A.
   Methods. Twenty-three patients with the progressive dry form of age-related macular degeneration were each treated with 8 procedures of rheohaemapheresis. We measured levels of vitamin E (a-tocopherol), the vitamin E/cholesterol ratio in serum and lipoproteins (VLDL, LDL, HDL). Vitamin E in erythrocyte membrane and serum vitamin A (retinol) were also measured. These parameters were determined before and after rheohaemapheresis. Erythrocyte superoxide dismutase, erythrocyte glutathione peroxidase and serum malondialdehyde were analysed as markers of antioxidant activity and lipid peroxidation, respectively.
   Results. In serum, the VLDL and LDL fraction ratios of vitamin E/cholesterol increased significantly. Additionally, the HDL fraction ratio showed an increase but this was not statistically significant. The patients showed no clinical signs of vitamin E deficiency, and their serum concentrations of vitamin E did not differ from normal values. The results show that rheohaemapheresis in addition to causing a significant reduction in atherogenic LDL cholesterol, may have favourable additive anti-atherogenic effects due to a relative increase in the content of vitamin E in the lipoprotein fractions.
C1 [Krcmova, Lenka Kujovska; Sobotka, Lubos; Solichova, Dagmar] Charles Univ Prague, Fac Med Hradec Kralove, Dept Internal Med Metab Care & Gerontol 3, Prague, Czech Republic.
   [Blaha, Milan; Krcmova, Lenka Kujovska; Lanska, Miriam; Sobotka, Lubos; Solichova, Dagmar] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic.
   [Blaha, Milan; Lanska, Miriam] Charles Univ Prague, Fac Med Hradec Kralove, Dept Internal Med Hematol 4, Prague, Czech Republic.
   [Aufartova, Jana; Kasalova, Eva; Honegrova, Barbora; Cervinkova, Barbora; Krcmova, Lenka Kujovska; Plisek, Jiri] Charles Univ Prague, Fac Med Hradec Kralove, Dept Analyt Chem, Prague, Czech Republic.
C3 Charles University Prague; Charles University Prague; Charles University
   Prague
RP Krcmova, LK (通讯作者)，Charles Univ Prague, Fac Med Hradec Kralove, Dept Internal Med Metab Care & Gerontol 3, Prague, Czech Republic.
EM LenkaKrcmova@seznam.cz
RI Sobotka, Lubos/V-2620-2017; Kujovska Krcmova, Lenka/S-7188-2017;
   Cervinkova, Barbora/G-9985-2018; Blaha, Milan/H-8955-2016
OI Sobotka, Lubos/0000-0002-0372-5790; Kujovska Krcmova,
   Lenka/0000-0003-3825-0294; Cervinkova, Barbora/0000-0002-0369-5499;
   Blaha, Milan/0000-0003-2330-5838
FU PRVOUK 37/12 programme; IGA [NT/14037-3/2013]; Project (Ministry of
   Health, Czech Republic) for Conceptual Development of Research
   Organisation MH-CZ-DRO (UHHK) [00179906]; European Social Fund; state
   budget of the Czech Republic [CZ.1.07/2.3.00/30.0061]
FX The authors gratefully acknowledge Hana Langrova, Eva Rencova for unique
   patient's group design, Marketa Drastikova, Iveta Svobodova and Martina
   Slanarova for their excellent technical assistance. The authors also
   would like to acknowledge the PRVOUK 37/12 programme, IGA grant
   NT/14037-3/2013 and the Project (Ministry of Health, Czech Republic) for
   Conceptual Development of Research Organisation MH-CZ-DRO (UHHK,
   00179906).; The publication is co-financed by the European Social Fund
   and the state budget of the Czech Republic. Project no.
   CZ.1.07/2.3.00/30.0061.
CR Bansal R, 2010, JIMSA, V23, P169
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIESALSKI HK, 1995, IMMUN INFEKT, V23, P166
   Blaha M, 2013, ATHEROSCLEROSIS SUPP, V14, P179, DOI 10.1016/j.atherosclerosissup.2012.10.023
   Blaha Milan, 2003, Acta Medica (Hradec Kralove), V46, P3
   Blaha V, 2002, ANAL CHIM ACTA, V467, P125, DOI 10.1016/S0003-2670(02)00306-9
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P41, DOI 10.1016/j.transci.2005.09.001
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P51, DOI 10.1016/j.transci.2005.11.001
   Borberg H, 2013, TRANSFUS APHER SCI, V48, P203, DOI 10.1016/j.transci.2013.02.003
   Brigelius-Flohe R, 2002, AM J CLIN NUTR, V76, P703, DOI 10.1093/ajcn/76.4.703
   Chou MY, 2009, J CLIN INVEST, V119, P1335, DOI 10.1172/JCI36800
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   Combs GF., 2008, VITAMINS
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ernest J, 2007, VEKEM PODMINENA MAKU
   FREI B, 1993, J LIPID RES, V34, P2135
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Naito HK, 1986, LIPOPROTEIN SEPARATI
   Prasad PS, 2010, MATURITAS, V66, P46, DOI 10.1016/j.maturitas.2010.02.006
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SIES H, 1992, ANN NY ACAD SCI, V669, P7
   Solichova D, 2003, ANAL BIOANAL CHEM, V376, P444, DOI 10.1007/s00216-003-1886-1
   Sun YY, 2012, NUTR RES, V32, P328, DOI 10.1016/j.nutres.2012.03.012
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Uchida T, 2012, LIPIDS, V47, P129, DOI 10.1007/s11745-011-3620-7
   Urbanek L, 2006, ANAL CHIM ACTA, V573, P267, DOI 10.1016/j.aca.2006.02.032
   Voet D, 1990, BIOCHEMISTRY
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
NR 40
TC 0
Z9 0
U1 0
U2 15
PU PALACKY UNIV, MEDICAL FAC
PI OLOMOUC
PA CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC
SN 1213-8118
EI 1804-7521
J9 BIOMED PAP
JI Biomed. Pap-Olomouc
PY 2015
VL 159
IS 3
BP 400
EP 406
DI 10.5507/bp.2015.028
PG 7
WC Engineering, Biomedical; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Research & Experimental Medicine
GA CW4FZ
UT WOS:000364948100011
PM 26077006
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Muftuoglu, IK
   Tsai, FF
   Gaber, R
   Alam, M
   Meshi, A
   Freeman, WR
AF Muftuoglu, Ilkay Kilic
   Tsai, Frank F.
   Gaber, Raouf
   Alam, Mostafa
   Meshi, Amit
   Freeman, William R.
TI High-frequency aflibercept injections in persistent neovascular
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Monthly aflibercept; Persistent AMD; As-needed treatment; Resistant wet
   AMD; Aflibercept; Wet AMD
ID INTRAVITREAL AFLIBERCEPT; VEGF TRAP; RANIBIZUMAB; OUTCOMES; BEVACIZUMAB;
   RESISTANT; RECURRENT; REGIMEN; TRIAL; FLUID
AB To report the 1-year outcomes of every-4-weeks (Q4W) as-needed aflibercept treatment in resistant neovascular age-related macular degeneration (nAMD) patients who had been treated and failed prior bevacizumab or ranibizumab injections, and who also responded poorly to every-8-weeks (Q8W) aflibercept treatment.
   Forty-three eyes of 39 patients with persistent nAMD despite monthly bevacizumab and/or ranibizumab injections and who were switched to Q8W 2-mg aflibercept injections, but showed persistence of fluid were included. Patients were treated with as-needed Q4W aflibercept injections with monthly monitoring. Maximum retinal thickness (MRT), central macular thickness (CMT), maximum pigment epithelial detachment height (PED) and best-corrected visual acuity (BCVA) were assessed and compared to baseline when high-frequency aflibercept was initiated.
   A mean of 8 (interquartile range, 4-11) Q4W injections were given during the follow-up. MRT and CMT significantly decreased at all follow-up visits (p < 0.05); however, there was no significant change in maximum PED height (p > 0.05) at any visit. Mean BCVA was 0.38 +/- 0.28 (logMAR) (ae20/63, Snellen) at baseline, and 0.4 +/- 0.34 (logMAR) (ae20/76, Snellen) at 1 year (p = 0.76). Seventy-two percent of eyes maintained a final BCVA of 20/63 or better. Twelve eyes (28 %) had some subretinal scar tissue formation and 5 eyes (11.6 %) had evidence of atrophy at 1 year.
   A stepwise algorithm with Q4W as-needed aflibercept treatment led to anatomic improvement in previously treated eyes which failed other therapies, including aflibercept every 8 weeks. Lack of visual improvement may be due to a ceiling effect as our eyes generally had good visual acuity.
C1 [Muftuoglu, Ilkay Kilic; Tsai, Frank F.; Gaber, Raouf; Alam, Mostafa; Meshi, Amit; Freeman, William R.] Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Inst, Jacobs Retina Ctr, La Jolla, CA 92093 USA.
   [Muftuoglu, Ilkay Kilic] Istanbul Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Tsai, Frank F.] Sharp Rees Stealy Med Grp, Div Ophthalmol, San Diego, CA USA.
   [Freeman, William R.] Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, 94093 Campus Point Dr, La Jolla, CA 92037 USA.
C3 University of California System; University of California San Diego;
   Istanbul Training & Research Hospital; University of California System;
   University of California San Diego
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Inst, Jacobs Retina Ctr, La Jolla, CA 92093 USA.; Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, 94093 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
RI Gaber, Raouf/GSN-8206-2022
FU Research to Prevent Blindness organization (NY, USA); Scientific and
   Technological Research Council of Turkey [2219/2015/2]; NATIONAL EYE
   INSTITUTE [P30EY022589] Funding Source: NIH RePORTER
FX This work was supported in part by an unrestricted grant from the
   Research to Prevent Blindness organization (NY, USA) to the Department
   of Ophthalmology, Jacobs Retina Center, University of California San
   Diego (WRF) and the Scientific and Technological Research Council of
   Turkey (IKM; 2219/2015/2). The funding organizations had no role in the
   design or conduct of this research.
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Chhablani JK, 2012, GRAEF ARCH CLIN EXP, V250, P1415, DOI 10.1007/s00417-012-1968-x
   Chin-Yee D, 2015, BR J OPHTHALMOL, DOI [10.1136/-306987, DOI 10.1136/-306987]
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muftuoglu IK, 2016, AM J OPHTHALMOL, V167, P1, DOI 10.1016/j.ajo.2016.03.038
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 21
TC 7
Z9 8
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2017
VL 255
IS 4
BP 709
EP 717
DI 10.1007/s00417-016-3547-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ER5DE
UT WOS:000398820800009
PM 27878592
DA 2022-11-30
ER

PT J
AU Haimovici, R
   Owens, SL
   Fitzke, FW
   Bird, AC
AF Haimovici, R
   Owens, SL
   Fitzke, FW
   Bird, AC
TI Dark adaptation in age-related macular degeneration: relationship to the
   fellow eye
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID BRUCHS MEMBRANE CHANGE; RETINAL-PIGMENT EPITHELIUM; FOVEAL FLICKER
   SENSITIVITY; SORSBYS-FUNDUS-DYSTROPHY; VISUAL FUNCTION;
   RETINITIS-PIGMENTOSA; GLARE RECOVERY; MACULOPATHY; ABNORMALITIES; DRUSEN
AB Background: Abnormalities of dark adaptation have been documented in patients with age-related macular degeneration (AMD), but the relationship with the various forms of this disorder has not been studied systematically. Methods: Dark-adapted retinal sensitivities and kinetics of dark adaptation were studied using a Humphrey visual field analyzer adapted for these purposes in patients over 64 years of age. One eye per patient was studied. Study eyes had a normal visual acuity and macular drusen only. The fellow eye was categorized as follows: group I, pigment epithelial detachments and tears of the retinal pigment epithelium (RPE); group II, choroidal neovascularization; and group III, drusen only. The results of psychophysical tests of the study eyes (group I and It and one eye of group III patients) were compared with one another and with older patients without evidence of AMD (group IV). Results: Retinal sensitivity was found to be most consistently abnormal nearest the fovea. The time course of dark adaptation was prolonged beyond 45 min in 10/11 patients (91%) in group I, 6/10 patients (60%) in group II, and 6/10 (60%) in group III and 1/11 (9%) in group IV. Conclusion: In a high proportion of patients with visual loss from AMD in one eye, the fellow eye shows abnormal dark adaptation. These changes appear to be most pronounced in patients with detachments of the RPE in the fellow eye.
C1 UCL, Inst Ophthalmol, London, England.
   Moorfields Eye Hosp, Dept Clin Ophthalmol, London EC1V 2PD, England.
   Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Boston University
RP Haimovici, R (通讯作者)，Gundersen Eye Ctr, DOB-10,720 Harrison Ave, Boston, MA 02118 USA.
EM Robert.Haimovici@bmc.org
RI Fitzke, Fred/C-3535-2008
CR ALEXANDER KR, 1984, BRIT J OPHTHALMOL, V68, P561, DOI 10.1136/bjo.68.8.561
   ALPERN M, 1981, INVEST OPHTH VIS SCI, V20, P183
   APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   BARONDES M, 1990, BRIT J OPHTHALMOL, V74, P180, DOI 10.1136/bjo.74.3.180
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AC, 1991, EYE, V5, P1
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   COLLINS M, 1989, CLIN VISION SCI, V4, P145
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   Collins MJ, 1986, CLIN EXP OPTOM, V69, P223, DOI DOI 10.1111/J.1444-0938.1986.TB04596.X
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   JACOBSON SG, 1986, OPHTHALMOLOGY, V93, P1604
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KEUNEN JEE, 1987, INVEST OPHTH VIS SCI, V28, P985
   KILBRIDE PE, 1986, VISION RES, V26, P321, DOI 10.1016/0042-6989(86)90029-5
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   LIEM ATA, 1992, AM J OPHTHALMOL, V114, P149, DOI 10.1016/S0002-9394(14)73978-9
   MASSOF RW, 1989, CLIN VISION SCI, V4, P221
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   OWSLEY C, 1990, HDB NEUROPSYCHOLOGY, V4, P229
   PandaJonas S, 1995, OPHTHALMOLOGY, V102, P1853, DOI 10.1016/S0161-6420(95)30784-1
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Pitts D., 1982, AGING HUMAN VISUAL F, P131
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STEINMETZ RL, 1992, INVEST OPHTH VIS SCI, V33, P1633
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
NR 62
TC 37
Z9 42
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2002
VL 240
IS 2
BP 90
EP 95
DI 10.1007/s00417-001-0417-z
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 534ZE
UT WOS:000174619000004
PM 11931085
DA 2022-11-30
ER

PT J
AU Lumi, X
   Sulak, M
AF Lumi, Xhevat
   Sulak, Marko
TI Treatment of Submacular Haemorrhage in Patients with Neovascular Age
   Related Macular Degeneration
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE submacular haemorrhage; age related macular degeneration; pneumatic
   displacement; tissue plasminogen activator; bevacizumab; visual acuity
ID TISSUE-PLASMINOGEN-ACTIVATOR; PNEUMATIC DISPLACEMENT; SUBRETINAL
   HEMORRHAGE; VITREOUS HEMORRHAGE; NATURAL-HISTORY; MANAGEMENT; INJECTION;
   GAS
AB To evaluate the efficacy of the pneumatic displacement of the submacular haemorrhage combined with the intravitreal injection of the tissue plasminogen activator. We present a retrospective clinical case series of nine eyes of nine patients that were treated with the intravitreal injection of the tissue plasminogen activator and expansile gas for the submacular haemorrhage due to the age related macular degeneration. We evaluated visual acuities and complications. Selected patients were additionally treated with the intravitreal bevacizumab injections after the procedure. Mean postoperative followup was 19 weeks. Four (419) eyes (44%) received additional treatment with the intravitreal bevacizumab during the postoperative period. Statistical analysis was performed using the Student's paired t-test. The mean visual acuity was 1.77 logMAR preoperatively and 1.06 logMAR postoperatively. After the surgery, 4 or more Snellen lines were gained in 719 eyes (78%). The improvement of the visual acuity postoperatively was statistically significant (p = 0.002). In 219 eyes (22%) the visual acuity did not get better after the procedure. We observed no complications during the follow up period. In our case series, pneumatic displacement of the submacular haemorrhage with the use of the intravitreal tissue plasminogen activator (with or without additional bevacizumab treatment in the selected cases) turned out to be an effective and safe method leading to the improvement of the visual acuity in the majority of cases. To maximise the treatment success, prompt referral to the retinal surgeon is imperative.
C1 [Lumi, Xhevat; Sulak, Marko] Univ Med Ctr Ljubljana, Hosp Eye, Ljubljana 1000, Slovenia.
C3 University Medical Centre Ljubljana
RP Lumi, X (通讯作者)，Univ Med Ctr Ljubljana, Hosp Eye, Ljubljana 1000, Slovenia.
EM xhlumi@hotmail.com
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Borrillo JL, 2001, CURR OPIN OPHTHALMOL, V12, P207, DOI 10.1097/00055735-200106000-00011
   Cakir M, 2010, EUR J OPHTHALMOL, V20, P565, DOI 10.1177/112067211002000305
   Chawla S, 2009, INDIAN J OPHTHALMOL, V57, P155, DOI 10.4103/0301-4738.45511
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Kokame GT, 2000, AM J OPHTHALMOL, V129, P546, DOI 10.1016/S0002-9394(99)00474-2
   Kung YH, 2010, J OCUL PHARMACOL TH, V26, P469, DOI 10.1089/jop.2010.0066
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Ratanasukon M, 2005, EYE, V19, P1328, DOI 10.1038/sj.eye.6701769
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shultz RW, 2011, SEMIN OPHTHALMOL, V26, P361, DOI 10.3109/08820538.2011.585368
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Tennant Matthew T S, 2002, Ophthalmol Clin North Am, V15, P445, DOI 10.1016/S0896-1549(02)00049-4
   VANDER JF, 1992, OPHTHALMIC SURG LAS, V23, P361
   Wu TT, 2011, RETINA-J RET VIT DIS, V31, P2071, DOI 10.1097/IAE.0b013e31822528c8
NR 25
TC 2
Z9 2
U1 0
U2 0
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD APR
PY 2013
VL 37
SU 1
BP 223
EP 226
PG 4
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 137SD
UT WOS:000318456800041
PM 23837248
DA 2022-11-30
ER

PT J
AU Sharp, DM
   Lai, S
   Markey, CM
AF Sharp, Dianne M.
   Lai, Susannah
   Markey, Caroline M.
TI Photodynamic therapy with verteporfin for choroidal neovascularization
   due to age-related macular degeneration and other causes: a New Zealand
   outcomes study
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   photodynamic therapy; verteporfin; visual acuity
ID ANGIOID STREAKS
AB Purpose: To assess the efficacy and safety of photodynamic therapy (PDT) for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and other conditions by analysing visual acuity changes.
   Methods: A retrospective review of patients treated with PDT was conducted. CNV was confirmed on fluorescein angiography. Visual acuity outcomes were recorded at 3-monthly intervals to a maximum of 48 months. The primary outcome measure was the proportion of patients avoiding moderate visual loss (losing less than three lines of visual acuity relative to baseline) at 12 months.
   Results: A total of 343 patients receiving PDT were followed up for a mean of 14.9 months. Two hundred and eighty-five (83%) patients presented with CNV due to AMD and 58 patients (17%) due to other causes. Seventy per cent of patients with CNV secondary to AMD avoided moderate visual loss at both 12 and 24 months. Secondary outcomes (including mean change in visual acuity, proportion of patients with stable or improved vision and proportion of patients with severe vision loss) also compared favourably with the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Investigation. Of patients with CNV secondary to causes other than AMD, 76% avoided moderate visual loss at both 12 and 24 months. The safety profile identified one severe adverse reaction, with development of a serous pigment epithelial detachment and subsequent rip.
   Conslusion: The results of this present retrospective, open-label, clinical practice study in New Zealand are consistent with the findings of multicentre randomized, placebo-controlled trials and confirm the treatment benefit of PDT in a clinical setting.
C1 Novartis Pharmaceut Australia Pty Ltd, N Ryde, NSW, Australia.
C3 Novartis
RP Sharp, DM (通讯作者)，POB 137070, Auckland 1001, New Zealand.
EM dianne@retinaspecialists.co.nz
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Barnes RM, 2004, EYE, V18, P809, DOI 10.1038/sj.eye.6701329
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Browning AC, 2005, OPHTHALMOLOGY, V112, P1227, DOI 10.1016/j.ophtha.2005.02.011
   Council NHMR, 2000, HDB SER PREP CLIN PR
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Krebs I, 2004, OPHTHALMOLOGICA, V218, P185, DOI 10.1159/000076843
   Menchini U, 2004, RETINA-J RET VIT DIS, V24, P763, DOI 10.1097/00006982-200410000-00013
   Sharma S, 2004, ARCH OPHTHALMOL-CHIC, V122, P853, DOI 10.1001/archopht.122.6.853
   Treatment Age Related Macular Dege, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
   *VIS MIN CLASS CHO, 2002, ARCH OPHTHALMOL-CHIC, V123, P448
   Wachtlin J, 2005, GRAEF ARCH CLIN EXP, V243, P438, DOI 10.1007/s00417-004-1071-z
   Wykrota Halina, 2002, Klin Oczna, V104, P239
NR 21
TC 9
Z9 11
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2007
VL 35
IS 1
BP 24
EP 31
DI 10.1111/j.1442-9071.2007.01394.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131KE
UT WOS:000243866900006
PM 17300567
DA 2022-11-30
ER

PT J
AU Hughes, AE
   Mullan, GM
   Bradley, DT
AF Hughes, Anne E.
   Mullan, Gemma M.
   Bradley, Declan T.
TI Complement factor B polymorphism 32W protects against age-related
   macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID FACTOR-H POLYMORPHISM; RISK; VARIANT; SYSTEM; CFHR1; AMD; C2
AB Purpose: The 32Q (rs641153; A) and 32W (rs12614; T) variants of complement factor B (CFB) cause less efficient complement activation in vitro than the common 32R variant. This is thought to be the reason that the 32Q variant is associated with decreased risk of age-related macular degeneration (AMD). We investigated whether the 32W variant was also associated with decreased risk of AMD.
   Methods: We genotyped 367 cases with neovascular AMD and 251 disease-free controls. Association with the disease phenotype was assessed by logistic regression for polymorphisms of CFB alone and in combination with smoking status and genetic risk markers of complement factor H (CFH) and HtrA serine peptidase 1 (HTRA1). We performed meta-analysis of all previously published reports of 32W allele frequency in AMD cases and controls.
   Results: The CFB variant 32W was associated with protection against neovascular AMD, compared to the common 32R variant (odds ratio 0.64, p<0.05, in logistic regression with CFB variants; odds ratio 0.53, p<0.05, in logistic regression with CFB variants, CFH haplotypes, HTRA1 rs10490924 genotype, and smoking status). Meta-analysis (n=1,795) including this study and two others of neovascular AMD showed a combined odds ratio of 0.75 (p<0.05) for 32W, compared to 32R. Meta-analysis (n=2,600) of all reported studies of all types of AMD showed a combined odds ratio of 0.79 (p<0.01).
   Conclusions: Our study shows that the 32W variant of CFB is associated with protection against AMD, in keeping with evidence of its functional effect on the complement system. The protective effect is less strong than that associated with 32Q.
C1 [Hughes, Anne E.; Mullan, Gemma M.; Bradley, Declan T.] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast
RP Hughes, AE (通讯作者)，Queens Univ Belfast, Royal Victoria Hosp, Ctr Publ Hlth, Inst Clin Sci, Block B,Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM a.hughes@qub.ac.uk
RI Hughes, Anne/A-1307-2012; Bradley, Declan T/AFO-1353-2022; Bradley,
   Declan/AFN-7904-2022
OI Bradley, Declan/0000-0003-1468-1823
FU Public Health Agency, Northern Ireland; Public Health Agency
   [EAT/3976/08] Funding Source: researchfish
FX We are grateful to the participants of the study for their involvement.
   We thank Usha Chakravarthy, Vivienne McConnell and Giuliana Silvestri
   for recruitment and provision of clinical data and blood samples, Ruth
   Hogg for validation of the AMD database, David McGibbon for extraction
   of DNA, Chris Patterson for statistical assistance and Gareth McKay for
   helpful discussions. D. T. B. is supported by a research and development
   doctoral fellowship from the Public Health Agency, Northern Ireland.
   Part of this work was presented at the annual meeting of the American
   Society of Human Genetics, November 2010.
CR Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Pinto MR, 2007, ADV EXP MED BIOL, V598, P372
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
NR 23
TC 12
Z9 14
U1 0
U2 6
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 20
PY 2011
VL 17
IS 109
BP 983
EP 988
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 755OV
UT WOS:000289943900001
PM 21541267
DA 2022-11-30
ER

PT J
AU Spencer, KL
   Hauser, MA
   Olson, LM
   Schmidt, S
   Scott, WK
   Gallins, P
   Agarwal, A
   Postel, EA
   Pericak-Vance, MA
   Haines, JL
AF Spencer, Kylee L.
   Hauser, Michael A.
   Olson, Lana M.
   Schmidt, Silke
   Scott, William K.
   Gallins, Paul
   Agarwal, Anita
   Postel, Eric A.
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID COMPLEMENT-FACTOR-H; JAPANESE POPULATION; NO ASSOCIATION; FACTOR-B;
   POLYMORPHISM; HAPLOTYPES; LOC387715; SMOKING; RISK
AB Age-related macular degeneration (AMD) impairs vision for similar to 7.5 million Americans. Both susceptibility variants and protective haplotypes in the complement factor H (CFH) gene modulate risk for AMD. Recently, deletion of the 'CFH-related' genes CFHR1 and CFHR3 was found to be segregating with a particular CFH haplotype, which reduced the risk of AMD. We tested the deletion for association in a Caucasian population of 780 cases and 265 controls and examined its effect in the context of known AMD risk factors. The deletion did not segregate perfectly with any one SNP, as previously suggested. CFH haplotype P2 was the most frequent haplotype in deletion homozygotes (47%), and the majority (14/16) of these individuals were homozygous for the non-risk allele of Y402H. Overall, deletion homozygosity was significantly more frequent in controls than cases (2.6% controls, 0.8% cases, P = 0.025, OR = 0.29, 95% CI = 0.10-0.86). After controlling for age, Y402H, smoking and LOC387715 A69S, the protective effect of the deletion was no longer statistically significant (P = 0.27). However, using a CFH haplotype that all deletion homozygotes share as a surrogate for the deletion, this marker remained modestly associated with AMD after adjustment for known risk factors (OR = 0.63, 95% CI 0.39-1.04, P = 0.07). Therefore, deletion of CFHR1 and CFHR3 may account for a small portion of the protection from AMD associated with particular haplotypes in CFH. The presence of protective haplotypes in CFH that do not carry the deletion, suggests that other protective variants in this region have yet to be discovered.
C1 [Spencer, Kylee L.; Olson, Lana M.; Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN 37232 USA.
   [Agarwal, Anita] Vanderbilt Univ, Med Ctr, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
   [Postel, Eric A.] Duke Univ, Med Ctr, Ctr Eye, Durham, NC 27710 USA.
   [Postel, Eric A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Scott, William K.; Gallins, Paul; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Miami Inst Human Genom, Miami, FL USA.
C3 Vanderbilt University; Vanderbilt University; Duke University; Duke
   University; University of Miami
RP Haines, JL (通讯作者)，Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, 519 Light Hall, Nashville, TN 37232 USA.
EM jonathan@chgr.mc.vanderbilt.edu
RI Scott, William/A-7593-2009; Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NCRR NIH HHS [M01 RR-00095] Funding Source: Medline; NEI NIH HHS
   [EY12118, EY015216] Funding Source: Medline; NATIONAL CENTER FOR
   RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [U10EY012118, R03EY015216, R01EY012118] Funding Source:
   NIH RePORTER
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Venables JP, 2006, PLOS MED, V3, P1957, DOI 10.1371/journal.pmed.0030431
   WANG JJ, IN PRESS OPHTHALMOLO
NR 25
TC 74
Z9 77
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD APR 1
PY 2008
VL 17
IS 7
BP 971
EP 977
DI 10.1093/hmg/ddm369
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 278NS
UT WOS:000254294200006
PM 18084039
OA Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Aggio, FB
   Farah, ME
   Silva, WC
   Melo, GB
AF Aggio, Fabio Bom
   Farah, Michel Eid
   Silva, Wagner Camilo
   Melo, Gustavo Barreto
TI Intravitreal bevacizumab for exudative age-related macular degeneration
   after multiple treatments
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE VEGF; intravitreal bevacizumab; age-related macular degeneration; laser;
   photodynamic therapy
ID GREEN-MEDIATED PHOTOTHROMBOSIS; CHOROIDAL NEOVASCULARIZATION;
   TRIAMCINOLONE ACETONIDE; PHOTODYNAMIC THERAPY; INJECTION
AB Photodynamic therapy with verteporfin (PDT) significantly reduces the risk of vision loss in patients with exudative age-related macular degeneration (AMD). Indocyanine green-mediated photothrombosis (IMP) and transpupillary thermotherapy (TTT) may also be beneficial for selective cases of exudative AMD. However, a substantial subset of patients responds poorly to these treatments. Intravitreal bevacizumab (IVB) has been recently used in the treatment of exudative AMD, showing both visual and anatomic improvement in the majority of cases.
   This interventional retrospective case series reports the effects of IVB in 17 eyes with subfoveal neovascular AMD that had undergone repeated PDT (combined or not with triamcinolone acetonide) or PDT followed by either IMP or TTT with poor results. The main outcome measures were visual acuity and tomographic signs of intra/subretinal fluid, as well as central retinal thickness.
   Most patients received a single IVB injection. The mean follow-up was 4.47 months. The mean logMAR visual acuity changed from 1.17 +/- 0.40 to 1.06 +/- 0.44 (P=0.17). The mean central retinal thickness decreased from 404.05 +/- 245.26 to 280.23 +/- 143.14 mu m (P=0.032). At the end of the study, lack of tomographic signs of intra/subretinal fluid was noted in four (23.5%) eyes. No ocular or systemic side effects were identified.
   Short-term results with IVB for the treatment of exudative AMD have been promising. However, the chronic retinal and pigment epithelium changes frequently present in eyes that underwent multiple previous treatments may limit complete visual recovery. To our knowledge, this is the first report on the use of IVB for this particular group of AMD patients.
C1 Alameda Jau, BR-01420000 Sao Paulo, SP, Brazil.
   Univ Fed Sao Paulo, Vis Inst, Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Melo, GB (通讯作者)，Alameda Jau, 150 Ap 21B, BR-01420000 Sao Paulo, SP, Brazil.
EM aggio@oftalmo.epm.br
RI Melo, Gustavo/AAD-3844-2019; Farah, Michel Eid E/F-3285-2012
OI Melo, Gustavo/0000-0001-5765-2008; Farah, Michel Eid
   E/0000-0001-5951-0193
CR Arevalo JF, 2005, GRAEF ARCH CLIN EXP, V243, P1180, DOI 10.1007/s00417-005-1177-y
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Connolly BP, 2003, OPHTHALMOLOGY, V110, P415, DOI 10.1016/S0161-6420(02)01561-0
   Costa RA, 2002, CURR EYE RES, V25, P287, DOI 10.1076/ceyr.25.5.287.13496
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 12
TC 33
Z9 36
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2007
VL 245
IS 2
BP 215
EP 220
DI 10.1007/s00417-006-0412-5
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 137LX
UT WOS:000244295200005
PM 17139490
DA 2022-11-30
ER

PT J
AU Karesvuo, P
   Gursoy, UK
   Pussinen, PJ
   Suominen, AL
   Huumonen, S
   Vesti, E
   Kononen, E
AF Karesvuo, Petteri
   Gursoy, Ulvi K.
   Pussinen, Pirkko J.
   Suominen, Anna L.
   Huumonen, Sisko
   Vesti, Eija
   Kononen, Eija
TI Alveolar Bone Loss Associated With Age-Related Macular Degeneration in
   Males
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE Alveolar bone loss; macular degeneration; periodontitis
ID C-REACTIVE PROTEIN; CHLAMYDIA-PNEUMONIAE INFECTION; COMPLEMENT FACTOR-H;
   PORPHYROMONAS-GINGIVALIS; CARDIOVASCULAR-DISEASE; PERIODONTAL PATHOGENS;
   VISUAL IMPAIRMENT; RISK-FACTOR; INFLAMMATION; ATHEROSCLEROSIS
AB Background: The aim of this study is to examine the relationship of selected systemic and oral health parameters and the salivary presence of six periodontal pathogens to age-related macular degeneration (AMD).
   Methods: The present cross-sectional study includes data on 1,751 individuals (>= 30 years old). General health information was obtained by questionnaires and interviews, including self-reported diagnosis of AMD, as well as by the general and oral health examination, including panoramic radiography and laboratory analyses. Fifty-four individuals with degenerative fundus changes formed the AMD group, and the other 1,697 formed the non-AMD group. Pearson chi(2) and analysis of variance tests were used for comparisons of categorical parameters and continuous parameters between the participant groups, respectively. A logistic regression analysis was performed to study the association of AMD with alveolar bone loss and the number of teeth by controlling for age, diabetic status, systolic blood pressure, education, and smoking, and also for the carriage of salivary bacteria.
   Results: Advanced age, systolic blood pressure, and diabetes were associated with AMD (P <0.001), whereas the carriage rates of the examined periodontal pathogens were not. In the whole study population, the participants with AMD had fewer teeth (P <0.001) and more alveolar bone loss (P = 0.004) compared with non-AMD participants. In a logistic regression model adjusted for age, smoking, and diabetes, alveolar bone loss was associated with AMD in males with an odds ratio of 4.3 (95% confidence interval = 1.3 to 14.6, P = 0.013).
   Conclusion: In this population-based health survey, alveolar bone loss is independently associated with AMD in males. J Periodontol 2013;84:58-67.
C1 [Karesvuo, Petteri; Vesti, Eija] Univ Turku, Dept Ophthalmol, Turku, Finland.
   [Gursoy, Ulvi K.; Huumonen, Sisko; Kononen, Eija] Univ Turku, Inst Dent, Turku, Finland.
   [Gursoy, Ulvi K.; Kononen, Eija] Natl Inst Hlth & Welf, Dept Infect Dis Surveillance & Control, Helsinki, Finland.
   [Pussinen, Pirkko J.] Univ Helsinki, Inst Dent, Helsinki, Finland.
   [Suominen, Anna L.] Natl Inst Hlth & Welf, Unit Living Condit Hlth & Wellbeing, Kuopio, Finland.
   [Suominen, Anna L.] Natl Inst Hlth & Welf, Dept Environm Hlth, Environm Epidemiol Unit, Kuopio, Finland.
   [Suominen, Anna L.] Univ Eastern Finland, Inst Dent, Kuopio, Finland.
   [Suominen, Anna L.] Kuopio Univ Hosp, Dept Oral & Maxillofacial Surg, SF-70210 Kuopio, Finland.
C3 University of Turku; University of Turku; Finland National Institute for
   Health & Welfare; University of Helsinki; Finland National Institute for
   Health & Welfare; Finland National Institute for Health & Welfare;
   University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland
RP Karesvuo, P (通讯作者)，Raisiontie 4 A 6, Helsinki 00280, Finland.
EM jupekar@utu.fi
RI Suominen, Anna L/AAE-6828-2021
OI Vesti, Eija/0000-0002-7099-8596; Kononen, Eija/0000-0002-1897-4263;
   Pussinen, Pirkko/0000-0003-3563-1876; Gursoy, Ulvi
   Kahraman/0000-0002-1225-5751
FU Finnish Dental Society Apollonia; Finnish Dental Association; Academy of
   Finland [E.K./73443, P.J.P./211129]; Finnish Eye Foundation; Mary and
   Georg C. Ehrnrooth Foundation; Sigrid Juselius Foundation; Finnish
   Cultural Foundation
FX The Health 2000 Survey, organized by the National Institute for Health
   and Welfare (the former National Public Health Institute) was partially
   supported by the Finnish Dental Society Apollonia and the Finnish Dental
   Association. The bacterial work has received financial support from the
   Academy of Finland (Grants E.K./73443 and P.J.P./211129). This project
   was also supported by personal grants from the Finnish Eye Foundation
   (PK), the Mary and Georg C. Ehrnrooth Foundation (PK), the Sigrid
   Juselius Foundation (PJP), and the Finnish Cultural Foundation (UKG).
   The authors report no conflicts of interest related to this study.
CR Aromaa A, 2004, HLTH FUNCTIONAL CAPA, VB12/2004
   Ashimoto A, 1996, ORAL MICROBIOL IMMUN, V11, P266, DOI 10.1111/j.1399-302X.1996.tb00180.x
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Barouch Fina C., 2007, International Ophthalmology Clinics, V47, P185, DOI 10.1097/IIO.0b013e3180377936
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Cordier J, 1965, Bull Soc Ophtalmol Fr, V65, P221
   Dietrich T, 2008, CIRCULATION, V117, P1668, DOI 10.1161/CIRCULATIONAHA.107.711507
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Elliot SJ, 2010, EXP EYE RES, V90, P10, DOI 10.1016/j.exer.2009.09.001
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gujral Dorothy M, 2008, J Med Case Rep, V2, P47, DOI 10.1186/1752-1947-2-47
   Guncu ON, 2011, EUR J DENT, V5, P337
   Gursoy UK, 2011, DIS MARKERS, V30, P299, DOI [10.1155/2011/621484, 10.3233/DMA-2011-0788]
   Gursoy UK, 2009, J CLIN PERIODONTOL, V36, P922, DOI 10.1111/j.1600-051X.2009.01480.x
   Ide R, 2011, J DENT RES, V90, P41, DOI 10.1177/0022034510381902
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Jeffcoat M, 2005, J PERIODONTOL, V76, P2125, DOI 10.1902/jop.2005.76.11-S.2125
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Kononen E, 2007, J CLIN MICROBIOL, V45, P2446, DOI 10.1128/JCM.02560-06
   Laitinen A, 2010, ACTA OPHTHALMOL, V88, P463, DOI 10.1111/j.1755-3768.2009.01566.x
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779
   Matto J, 1998, J CLIN MICROBIOL, V36, P157
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Palikhe A, 2008, TISSUE ANTIGENS, V71, P530, DOI 10.1111/j.1399-0039.2008.01038.x
   Paraskevas S, 2008, J CLIN PERIODONTOL, V35, P277, DOI 10.1111/j.1600-051X.2007.01173.x
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Premaraj T, 1999, J CLIN MICROBIOL, V37, P1057, DOI 10.1128/JCM.37.4.1057-1061.1999
   Pussinen PJ, 2007, ARTERIOSCL THROM VAS, V27, P1433, DOI 10.1161/ATVBAHA.106.138743
   Pussinen PJ, 2011, J CLIN PERIODONTOL, V38, P405, DOI 10.1111/j.1600-051X.2011.01703.x
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Scannapieco Frank A, 2003, Ann Periodontol, V8, P38, DOI 10.1902/annals.2003.8.1.38
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   SUOMINENTAIPALE L, 2008, ORAL HLTH FINNISH AD
   Susin C, 2011, J CLIN PERIODONTOL, V38, P326, DOI 10.1111/j.1600-051X.2011.01699.x
   Tran SD, 1999, J CLIN MICROBIOL, V37, P3504, DOI 10.1128/JCM.37.11.3504-3508.1999
   Tuomisto K, 2006, THROMB HAEMOSTASIS, V95, P511, DOI 10.1160/TH05-08-0571
   Umeda M, 1998, J PERIODONTOL, V69, P828, DOI 10.1902/jop.1998.69.7.828
   Wiedermann CJ, 1999, J AM COLL CARDIOL, V34, P1975, DOI 10.1016/S0735-1097(99)00448-9
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
NR 48
TC 17
Z9 17
U1 0
U2 9
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA
SN 0022-3492
J9 J PERIODONTOL
JI J. Periodont.
PD JAN
PY 2013
VL 84
IS 1
BP 58
EP 67
DI 10.1902/jop.2012.110643
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 087EO
UT WOS:000314744300007
PM 22414258
DA 2022-11-30
ER

PT J
AU Gibson, DM
AF Gibson, Diane M.
TI Diabetic Retinopathy and Age-Related Macular Degeneration in the U.S.
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; EYE CARE; HEALTH-INSURANCE;
   PREVALENCE; DISEASE; TELEMEDICINE; RANIBIZUMAB; QUALITY; ADULTS
AB Background: Diabetic retinopathy and age-related macular degeneration (AMD) are two of the most common eye diseases in the U.S. Effective treatments exist for some stages of these conditions.
   Purpose: This goal of this study was to examine the frequency and predictors of unawareness of diabetic retinopathy and AMD.
   Methods: The 2005-2008 National Health and Nutrition Examination Survey (NHANES) collected digital retinal images of survey participants aged >= 40 years that were graded for diabetic retinopathy and AMD using standard protocols. A sample of individuals with diabetic retinopathy was created, as was a separate sample of individuals with AMD. Individuals were categorized as unaware of their condition if they did not report that they had the condition. Separate logistic regression models of unawareness of diabetic retinopathy and AMD were estimated in 2011.
   Results: This study estimated that 73% of individuals with diabetic retinopathy and 84% of individuals with AMD were unaware of their condition. The odds of unawareness of diabetic retinopathy were higher for individuals with less-severe diabetic retinopathy, shorter diabetes duration, smaller families, or who had not had a recent eye exam. The odds of unawareness of AMD were higher for individuals with "early" AMD or who were younger, less educated, or not primarily English speakers.
   Conclusions: The very high frequency of unawareness of diabetic retinopathy and AMD suggests that unawareness of these conditions should be a major public health concern and that efforts are needed to increase the frequency of eye exams among those at risk for these conditions. (Am J Prev Med 2012;43(1):48-54) (C) 2012 American Journal of Preventive Medicine
C1 CUNY Bernard M Baruch Coll, Sch Publ Affairs, New York, NY 10010 USA.
C3 City University of New York (CUNY) System; Baruch College (CUNY)
RP Gibson, DM (通讯作者)，CUNY Bernard M Baruch Coll, Sch Publ Affairs, 17 Lexington Ave,Box D-901, New York, NY 10010 USA.
EM diane.gibson@baruch.cuny.edu
CR Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062
   American Academy of Ophthalmology, 2010, PREF PRACT PATT COMP
   American Academy of Ophthalmology, 2008, PREF PRACT PATT DIAB
   American Academy of Ophthalmology, 2008, PREF PRACT PATT AG R
   [Anonymous], 1991, Ophthalmology, V98, P786
   Au A, 2011, CURR OPIN OPHTHALMOL, V22, P194, DOI 10.1097/ICU.0b013e3283459508
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1566, DOI 10.1001/archophthalmol.2009.308
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   *CDC, 2005, AN REP GUID NAT HLTH
   Centers for Medicare and Medicaid Services, 2010, MED YOU
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DHHS, 2010, OFF DIS PREV HLTH PR
   Farley TF, 2008, ANN FAM MED, V6, P428, DOI 10.1370/afm.857
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   IOM, 2004, HLTH LIT PRESCR END
   Johnston DW, 2009, J HEALTH ECON, V28, P540, DOI 10.1016/j.jhealeco.2009.02.010
   Jones S, 2010, DIABETIC MED, V27, P249, DOI 10.1111/j.1464-5491.2009.02870.x
   Kaiser Commission on Medicaid and the Uninsured, 2010, MED PRIM KEY INF OUR
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R., 1995, DIABETES AM, V2nd ed., P293, DOI DOI 10.1063/1.1522643
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kolstad JT, 2009, MED CARE RES REV, V66, p28S, DOI 10.1177/1077558708325887
   Korn EL, 1999, ANAL HLTH SURVEYS
   Kutner M, 2006, HLTH LITERACY AM ADU
   Lee DJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P303, DOI 10.1001/archophthalmol.2008.567
   Morales LS, 2010, OPHTHALMOLOGY, V117, P207, DOI 10.1016/j.ophtha.2009.07.015
   Mukamel DB, 2004, INQUIRY-J HEALTH CAR, V41, P435, DOI 10.5034/inquiryjrnl_41.4.435
   *NAT DIAB DAT GROU, 1995, DIAB AM
   National Health and Nutrition Examination Survey, 2010, OPHTH RET IM DAT DOC
   Puent BD, 2005, OPTOMETRY VISION SCI, V82, P612, DOI 10.1097/01.opx.0000171334.54708.89
   Rein DB, 2011, HEALTH SERV RES, V46, P1534, DOI 10.1111/j.1475-6773.2011.01263.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudd RE, 2007, AM J HEALTH BEHAV, V31, pS8
   Saadine JB, 1992, OPHTHALMOLOGY, V99, P58
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Taylor CR, 2007, DIABETES CARE, V30, P574, DOI 10.2337/dc06-1509
   Varma R, 2008, MED CARE, V46, P497, DOI 10.1097/MLR.0b013e31816080fe
   Weiss BD., 2007, HLTH LITERACY PATIEN
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Zhang X, 2010, JAMA-J AM MED ASSOC, V204, P649
   Zhang XZ, 2007, ARCH OPHTHALMOL-CHIC, V125, P411, DOI 10.1001/archopht.125.3.411
   Zhang XZ, 2008, OPHTHAL EPIDEMIOL, V15, P418, DOI 10.1080/09286580802399102
   Zhang XP, 2007, AM J PREV MED, V33, P318, DOI 10.1016/j.amepre.2007.05.002
NR 50
TC 29
Z9 29
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD JUL
PY 2012
VL 43
IS 1
BP 48
EP 54
DI 10.1016/j.amepre.2012.02.028
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 959VJ
UT WOS:000305344000007
PM 22704745
DA 2022-11-30
ER

PT J
AU McGwin, G
   Xie, AY
   Owsley, C
AF McGwin, G
   Xie, AY
   Owsley, C
TI The use of cholesterol-lowering medications and age-related macular
   degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; BEAVER DAM EYE; RISK-FACTORS; ATHEROSCLEROSIS RISK;
   POOLED FINDINGS; 3 CONTINENTS; CARDIOVASCULAR-DISEASE; 5-YEAR INCIDENCE;
   STATIN USE; MACULOPATHY
AB Purpose: To evaluate the association between cholesterol-lowering medications and age-related macular degeneration (AMD).
   Design: Case-control study.
   Participants: The Atherosclerosis Risk in Communities study is a prospective, population-based, cohort study conducted in 4 communities across the United States. A total of 15792 individuals aged 45 to 65 years were enrolled between 1987 and 1989; fundus photographs were added to the study protocol at the 6-year follow-up (1993-1995). Cases were subjects who were identified as having AMD after applying a standard definition to their fundus photographs; controls did not have AMD.
   Methods: The use of cholesterol-lowering medications at any time during the study was determined and compared between cases and controls, adjusting for the potentially confounding effect of demographic, behavioral, and medical characteristics.
   Main Outcome Measures: Presence of AMD and the use of cholesterol-lowering medications.
   Results: A total of 871 AMD cases and 11 717 controls were identified. Of the AMD cases, 11% made use of cholesterol-lowering medications, as compared with 12.3% of controls (odds ratio [OR], 0.89; 95% confidence interval [CI], 0.71-1.11). Adjusting for the confounding influence of age, gender, and race revealed a statistically significant relationship between AMD and use of cholesterol-lowering medications (OR, 0.79; 95% CI, 0.63-0.99).
   Conclusions: The results of this study add to the growing body of evidence that cholesterol-lowering medications may reduce the risk of developing AMD. Additional research is needed to document the mechanism responsible for this association. A clinical trial of the impact of statins on AMD deserves consideration. (C) 2005 by the American Academy of Ophthalmology.
C1 Univ Alabama, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama, Sch Publ Hlth, Dept Epidemiol & Int Hlth, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP McGwin, G (通讯作者)，Univ Alabama, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM mcgwin@uab.edu
RI Owsley, Cynthia/B-7986-2014
FU NATIONAL EYE INSTITUTE [R21EY014071] Funding Source: NIH RePORTER; NEI
   NIH HHS [R21-EY14071] Funding Source: Medline
CR [Anonymous], [No title captured]
   Atherosclerosis Risk in Communities (ARIC) Study Research Group, 1996, ARIC RET READ CTR PR
   Atherosclerosis Risk in Communities (ARIC) Study Research Group, 1996, ARIC RET PHOT PROT M
   Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hennekens CH, 2001, CLIN CARDIOL, V24, pII2
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Jackson R, 1996, J CLIN EPIDEMIOL, V49, P1441, DOI 10.1016/0895-4356(95)00047-X
   Klein R, 2004, AM J OPHTHALMOL, V137, P747, DOI 10.1016/j.ajo.2004.01.037
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Miller LJ, 2004, ANN PHARMACOTHER, V38, P91, DOI 10.1345/aph.1D104
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Takeda T, 2003, ATHEROSCLEROSIS, V169, P155, DOI 10.1016/S0021-9150(03)00158-8
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Werner N, 2002, BASIC RES CARDIOL, V97, P105, DOI 10.1007/s003950200000
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 33
TC 50
Z9 50
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2005
VL 112
IS 3
BP 488
EP 494
DI 10.1016/j.ophtha.2004.10.027
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 900IY
UT WOS:000227209800022
PM 15745779
DA 2022-11-30
ER

PT J
AU Chan, CK
   Abraham, P
   Sarraf, D
   Nuthi, ASD
   Lin, SG
   McCannel, CA
AF Chan, C. K.
   Abraham, P.
   Sarraf, D.
   Nuthi, A. S. D.
   Lin, S. G.
   McCannel, C. A.
TI Earlier therapeutic effects associated with high dose (2.0mg)
   Ranibizumab for treatment of vascularized pigment epithelial detachments
   in age-related macular degeneration
SO EYE
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB; CLINICOPATHOLOGICAL CORRELATION; CHOROIDAL
   NEOVASCULARIZATION; RETINAL-DETACHMENT; VISUAL-ACUITY; TEARS;
   VERTEPORFIN
AB The Summary statement Intravitreal high dose (2 mg) ranibizumab may lead to quicker resolution of choroidal neovascularization (CNV) and associated retinal pigment epithelial detachment in eyes with exudative age-related macular degeneration, although it may possibly correlate with RPE tears in certain cases.
   Purpose This prospective study compared the outcomes of 0.5 vs 2.0mg intravitreal ranibizumab injections (RI) for treating vascularized pigment epithelial detachment (vPED) due to age-related macular degeneration.
   Methods Patients with vPED were randomized to receive 2.0 vs 0.5mg RI monthly for 12 months or for 4 months and then repeated on a pro-re nata basis. Optical coherence tomography, fundus photography, and fluorescein and indocyanine-green angiography were obtained at baseline and subsequent specific intervals. Outcome measures were best-corrected standardized visual acuities, central 1-mm thickness, surface area (SA), greatest linear diameter (GLD), heights (PED and CNV), and amount of subretinal fluid (SRF) and cystoid macular edema (CME).
   Results Both groups yielded reductions of the central 1-mm thickness, PED and CNV SA and PED height and GLD, SRF, and CME. Vision improvement and reduction in SRF and PED height occurred earlier for eyes receiving the 2.0mg dose. Cataract progression was similar but RPE tears developed more often with the 2.0mg dose.
   Conclusions There were similar visual and anatomical outcomes at the end of the study; however, the higher dose yielded more rapid reductions and more complete resolution of the PED, although there was possible increased tendency for an RPE tear with the higher dose.
C1 [Chan, C. K.; Nuthi, A. S. D.; Lin, S. G.] Southern Calif Desert Retinal Consultants, Palm Desert, CA USA.
   [Chan, C. K.] Loma Linda Univ, Dept Ophthalmol, Loma Linda, CA 92350 USA.
   [Abraham, P.] Black Hills Reg Eye Inst, Rapid City, SD USA.
   [Sarraf, D.] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA.
C3 Loma Linda University; University of California System; University of
   California Los Angeles
RP Chan, CK (通讯作者)，Southern Calif Desert Retinal Consultants, POB 2467, Palm Springs, CA 92263 USA.
EM CChan@desertretina.com
FU Roche-Genentech Inc.; Owen Locke Foundation; Kirchgessner Foundation
FX This Investigator Initiated Study has received grant supports from
   Roche-Genentech Inc., Owen Locke Foundation, and Kirchgessner
   Foundation. The authors have no financial or proprietary interest in any
   device or drug mentioned in this study.
CR Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Audrey L, 2007, J FR OPHTALMOL, V30, P155, DOI 10.1016/S0181-5512(07)89566-0
   Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chan CK, 2012, EYE, V26, P882, DOI 10.1038/eye.2012.90
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Mitamura Y, 2008, BRIT J OPHTHALMOL, V92, P717, DOI 10.1136/bjo.2008.139378
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   Veritti D, 2013, RETINA-J RET VIT DIS, V33, P982, DOI 10.1097/IAE.0b013e31826d8ff4
   Yeh PT, 2009, RETINA-J RET VIT DIS, V29, P768, DOI 10.1097/IAE.0b013e3181a3b7ef
NR 30
TC 20
Z9 22
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2015
VL 29
IS 1
BP 80
EP 87
DI 10.1038/eye.2014.233
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AY8FJ
UT WOS:000347789500006
PM 25277305
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Hogan, AC
   Kilmartin, DJ
AF Hogan, A. C.
   Kilmartin, D. J.
TI Low power vs standard power transpupillary thermotherapy in patients
   with age-related macular degeneration and subfoveal choroidal
   neovascularization ineligible for photodynamic therapy
SO EYE
LA English
DT Review
DE transpupillary thermotherapy; choroidal neovascularization; age-related
   macular degeneration
ID RANDOMIZED CLINICAL-TRIALS; LASER PHOTOCOAGULATION; OCCULT; VERTEPORFIN;
   MACULOPATHY; MANAGEMENT; LESIONS
AB Aim To assess the effect of standard power vs low power transpupillary thermotherapy (TTT) in patients with active subfoveal choroidal neovascularization secondary to age-related macular degeneration ineligible for photodynamic therapy (PDT) by original treatment of age-related macular degeneration with photodynamic therapy (TAP) study group recommendations.
   Methods Retrospective review of 79 patients with active predominantly occult subfoveal choroidal neovascularization or predominantly classic subfoveal choroidal neovascularization but Snellen visual acuity < 20/200. All patients were treated with TTT administered via a Mainster wide field fundus contact lens with a retinal power/diameter coefficient of 248mW/mm in the standard power (n = 27) and 181mW/mm in the low power group (n = 52). The primary outcome was stabilization (< 1 Snellen line change) or improvement (two or more Snellen lines) in visual acuity. Clinical and fluorescein angiographic resolution of overlying exudation was documented.
   Results At 24 month follow-up, 17 patients (63%) in the standard power and 36 patients (69%) in the low power group achieved stable or improved vision. Improved vision (mean three lines) was observed in 22% of the standard power and 23% of the low power group. Overlying exudation was reduced clinically with minimal or no leakage on fluorescein angiogram in 85% of standard power and 90% of low power group. Subgroup analysis in the low power group demonstrated a visual benefit in patients with subfoveal lesions, which had any classic component.
   Conclusions Low power TTT is as effective as standard power in stabilizing or improving vision and reducing overlying exudation in patients with active subfoveal choroidal neovascularization ineligible for PDT.
C1 Royal Coll Surgeons Ireland, Dept Ophthalmol, Royal Victorian Eye & Ear Hosp, Dublin 2, Ireland.
   Royal Victorian Eye & Ear Hosp, Res Fdn, Dublin, Ireland.
C3 Royal College of Surgeons - Ireland
RP Kilmartin, DJ (通讯作者)，Royal Coll Surgeons Ireland, Dept Ophthalmol, Royal Victorian Eye & Ear Hosp, Adelaide Rd, Dublin 2, Ireland.
EM djkilmartin@eircom.net
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Benner JD, 2002, AM J OPHTHALMOL, V134, P765, DOI 10.1016/S0002-9394(02)01694-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friberg T R, 2001, Semin Ophthalmol, V16, P70, DOI 10.1076/soph.16.2.70.4207
   Garcia-Arumi J, 2000, OPHTHALMOLOGY, V107, P351, DOI 10.1016/S0161-6420(99)00046-9
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Kim J E, 2001, Semin Ophthalmol, V16, P86, DOI 10.1076/soph.16.2.86.4212
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Murphree AL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1348, DOI 10.1001/archopht.1996.01100140548005
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Shields CL, 1996, OPHTHALMOLOGY, V103, P1642, DOI 10.1016/S0161-6420(96)30451-X
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Thach AB, 2003, ARCH OPHTHALMOL-CHIC, V121, P817, DOI 10.1001/archopht.121.6.817
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
NR 19
TC 4
Z9 4
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD JUN
PY 2006
VL 20
IS 6
BP 649
EP 654
DI 10.1038/sj.eye.6702028
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 060KU
UT WOS:000238801900003
PM 16082398
OA Bronze
DA 2022-11-30
ER

PT J
AU Heesterbeek, TJ
   Lores-Motta, L
   Hoyng, CB
   Lechanteur, YTE
   den Hollander, AI
AF Heesterbeek, Thomas J.
   Lores-Motta, Laura
   Hoyng, Carel B.
   Lechanteur, Yara T. E.
   den Hollander, Anneke, I
TI Risk factors for progression of age-related macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Review
DE age-related macular degeneration; epidemiology; genetics
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; LONG-TERM INCIDENCE;
   FUNDUS AUTOFLUORESCENCE PATTERNS; GEOGRAPHIC ATROPHY PROGRESSION;
   DIETARY FATTY-ACIDS; EYE DISEASE; 10-YEAR INCIDENCE; NATURAL-HISTORY;
   CHOROIDAL NEOVASCULARIZATION
AB Purpose Age-related macular degeneration (AMD) is a degenerative disease of the macula, often leading to progressive vision loss. The rate of disease progression can vary among individuals and has been associated with multiple risk factors. In this review, we provide an overview of the current literature investigating phenotypic, demographic, environmental, genetic, and molecular risk factors, and propose the most consistently identified risk factors for disease progression in AMD based on these studies. Finally, we describe the potential use of these risk factors for personalised healthcare.
   Recent findings While phenotypic risk factors such as drusen and pigment abnormalities become more important to predict disease progression during the course of the disease, demographic, environmental, genetic and molecular risk factors are more valuable at earlier disease stages. Demographic and environmental risk factors such as age and smoking are consistently reported to be related to disease progression, while other factors such as sex, body mass index (BMI) and education are less often associated. Of all known AMD variants, variants that are most consistently reported with disease progression are rs10922109 and rs570618 in CFH, rs116503776 in C2/CFB/SKIV2L, rs3750846 in ARMS2/HTRA1 and rs2230199 in C3. However, it seems likely that other AMD variants also contribute to disease progression but to a lesser extent. Rare variants have probably a large effect on disease progression in highly affected families. Furthermore, current prediction models do not include molecular risk factors, while these factors can be measured accurately in the blood. Possible promising molecular risk factors are High-Density Lipoprotein Cholesterol (HDL-C), Docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), zeaxanthin and lutein.
   Phenotypic, demographic, environmental, genetic and molecular risk factors can be combined in prediction models to predict disease progression, but the selection of the proper risk factors for personalised risk prediction will differ among individuals and is dependent on their current disease stage. Future prediction models should include a wider set of genetic variants to determine the genetic risk more accurately, and rare variants should be taken into account in highly affected families. In addition, adding molecular factors in prediction models may lead to preventive strategies and personalised advice.
C1 [Heesterbeek, Thomas J.; Lores-Motta, Laura; Hoyng, Carel B.; Lechanteur, Yara T. E.; den Hollander, Anneke, I] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Lores-Motta, Laura; den Hollander, Anneke, I] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.; den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
EM Anneke.denhollander@radboudumc.nl
RI Lehtimäki, Terho/AAD-1094-2022; Lechanteur, Yara/ABB-6875-2020;
   Heesterbeek, Thomas Johannes/E-7890-2017
OI Lehtimäki, Terho/0000-0002-2555-4427; Lechanteur,
   Yara/0000-0003-0951-4625; Heesterbeek, Thomas
   Johannes/0000-0002-3232-2587
FU Dutch Organization for Scientific Research [016.Vici.170.024]; Oogfonds;
   Landelijke Stichting voor Blinden en Slechtzienden; Macula Fonds;
   Vereniging Bartimeus Sonneheerdt [Uitzicht 2016-02, 2016-26]; European
   Union [634479]
FX This research was supported by the Dutch Organization for Scientific
   Research (016.Vici.170.024), Oogfonds, Landelijke Stichting voor Blinden
   en Slechtzienden, Macula Fonds, Vereniging Bartimeus Sonneheerdt
   (Uitzicht 2016-02 and 2016-26), and the European Union's Horizon 2020
   research and innovation program under grant agreement No. 634479
   (EYE-RISK).
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Armstrong J, 2006, INVEST OPHTH VIS SCI, V47, P2128
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Bai YJ, 2014, MOL VIS, V20, P1258
   Bailey ST, 2019, OPHTHALMOL RETINA, V3, P629, DOI 10.1016/j.oret.2019.03.008
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Biscetti Leonardo, 2017, Front Biosci (Elite Ed), V9, P174
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Brader HS, 2013, OPHTHALMOLOGY, V120, P1871, DOI 10.1016/j.ophtha.2013.01.049
   Brilliant MH, 2016, AM J MED, V129, P292, DOI 10.1016/j.amjmed.2015.10.015
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   BUITENDIJK G, 2013, INVEST OPHTH VIS SCI, V54
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Chen YJ, 2018, AM J NEPHROL, V48, P278, DOI 10.1159/000493924
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Connolly E, 2018, BRIT J OPHTHALMOL, V102, P1691, DOI 10.1136/bjophthalmol-2017-311673
   Conrady CD, 2017, INVEST OPHTH VIS SCI, V58, P3616, DOI 10.1167/iovs.17-21818
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Den Hollander AI, 2014, INVEST OPHTH VIS SCI, V55
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Duncan KG, 1999, OPHTHALMIC RES, V31, P399, DOI 10.1159/000055564
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gonzalez-Iglesias H, 2014, METALLOMICS, V6, P201, DOI 10.1039/c3mt00298e
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   Gopinath B, 2014, INVEST OPHTH VIS SCI, V55, P7799, DOI 10.1167/iovs.14-15575
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Hampton BM, 2015, CLIN OPHTHALMOL, V9, P873, DOI 10.2147/OPTH.S84155
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Heesterbeek TJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43144-3
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hoffman JD, 2016, INVEST OPHTH VIS SCI, V57, P2225, DOI 10.1167/iovs.15-18571
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hou HY, 2010, MOL THER, V18, P1837, DOI 10.1038/mt.2010.144
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaszubski PA, 2018, INT OPHTHALMOL, V38, P503, DOI 10.1007/s10792-017-0485-7
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Kersten E, 2017, JAMA OPHTHALMOL, V135, P1037, DOI 10.1001/jamaophthalmol.2017.3195
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   King JC, 2016, J NUTR, V146, p858S, DOI 10.3945/jn.115.220079
   Klein BEK, 2014, INVEST OPHTH VIS SCI, V55, P5855, DOI 10.1167/iovs.14-14602
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   KLEIN ML, 2004, INVEST OPHTH VIS S2, V45
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2019, OPHTHALMOLOGY, V126, P752, DOI 10.1016/j.ophtha.2018.12.026
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Korobelnik JF, 2017, JAMA OPHTHALMOL, V135, P1259, DOI 10.1001/jamaophthalmol.2017.3398
   Kortvely E, 2016, HUM MOL GENET, V25, P3143, DOI 10.1093/hmg/ddw162
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   LI ZY, 1985, INVEST OPHTH VIS SCI, V26, P1589
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Lin SY, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050902
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Liszewski MK, 2017, ANNU REV PATHOL-MECH, V12, P25, DOI 10.1146/annurev-pathol-012615-044145
   Locke CJ, 2014, EXP EYE RES, V129, P1, DOI 10.1016/j.exer.2014.10.010
   Farinha CVL, 2019, OPHTHALMIC RES, V61, P226, DOI 10.1159/000496393
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Ly A, 2018, CLIN EXP OPTOM, V101, P243, DOI 10.1111/cxo.12607
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Ma HW, 2014, P NATL ACAD SCI USA, V111, P3602, DOI 10.1073/pnas.1317041111
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   McGuinness MB, 2016, BRIT J OPHTHALMOL, V100, P1353, DOI 10.1136/bjophthalmol-2015-307663
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Mitsuhiro MRKH, 2003, ACTA OPHTHALMOL SCAN, V81, P630, DOI 10.1111/j.1395-3907.2003.00170.x
   Miyake M, 2015, INVEST OPHTH VIS SCI, V56, P5353, DOI 10.1167/iovs.14-16020
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Ngai LY, 2011, EYE, V25, P784, DOI 10.1038/eye.2011.56
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nirmalan PK, 2004, INVEST OPHTH VIS SCI, V45, P4273, DOI 10.1167/iovs.04-0285
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Rong SS, 2019, BRIT J OPHTHALMOL, V103, P1777, DOI 10.1136/bjophthalmol-2018-313277
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Rosen ES, 2014, J CATARACT REFR SURG, V40, P173, DOI 10.1016/j.jcrs.2013.11.022
   Roth GA, 2018, LANCET, V392, P1736, DOI 10.1016/s0140-6736(18)32203-7
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P374, DOI 10.1007/s10384-019-00680-9
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P257, DOI 10.1097/IAE.0000000000002399
   SanGiovanni John Paul, 2008, Arch Ophthalmol, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Serra R, 2020, RETINA-J RET VIT DIS, V40, P1224, DOI 10.1097/IAE.0000000000002604
   Shim SH, 2016, OPHTHAL EPIDEMIOL, V23, P80, DOI 10.3109/09286586.2015.1129425
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   SOUIED E, 2013, INVEST OPHTH VIS SCI, V54
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Taylor RL, 2019, OPHTHALMOLOGY, V126, P1410, DOI 10.1016/j.ophtha.2019.03.013
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toops KA, 2016, ADV EXP MED BIOL, V854, P3, DOI 10.1007/978-3-319-17121-0_1
   Torkamani A, 2018, NAT REV GENET, V19, P581, DOI 10.1038/s41576-018-0018-x
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Tsai CC, 2007, ARCH OPHTHALMOL-CHIC, V125, P1652, DOI 10.1001/archopht.125.12.1652
   Ugarte M, 2014, METALLOMICS, V6, P189, DOI 10.1039/c3mt00291h
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Vladan Bajic, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P74
   Wang IK, 2016, RETINA-J RET VIT DIS, V36, P1866, DOI 10.1097/IAE.0000000000001011
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu EW, 2014, ENVIRON RES, V133, P178, DOI 10.1016/j.envres.2014.05.023
   Wu J, 2017, AM J CLIN NUTR, V105, P1483, DOI 10.3945/ajcn.116.143453
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zhang Wenbo, 2011, J Cardiovasc Dis Res, V2, P96, DOI 10.4103/0975-3583.83035
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 238
TC 97
Z9 99
U1 4
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD MAR
PY 2020
VL 40
IS 2
SI SI
BP 140
EP 170
DI 10.1111/opo.12675
EA FEB 2020
PG 31
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KW1KZ
UT WOS:000515498600001
PM 32100327
OA Green Published, hybrid, Green Submitted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Hirasawa, M
   Takubo, K
   Osada, H
   Miyake, S
   Toda, E
   Endo, M
   Umezawa, K
   Tsubota, K
   Oike, Y
   Ozawa, Y
AF Hirasawa, Manabu
   Takubo, Keiyo
   Osada, Hideto
   Miyake, Seiji
   Toda, Eriko
   Endo, Motoyoshi
   Umezawa, Kazuo
   Tsubota, Kazuo
   Oike, Yuichi
   Ozawa, Yoko
TI Angiopoietin-like Protein 2 Is a Multistep Regulator of Inflammatory
   Neovascularization in a Murine Model of Age-related Macular Degeneration
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; GENERAL JAPANESE POPULATION;
   INTEGRIN ALPHA-5-BETA-1; INSULIN-RESISTANCE; METABOLIC SYNDROME;
   IN-VITRO; MACROPHAGE; EXPRESSION; MICE; METASTASIS
AB Choroidal neovascularization (CNV) is a pathogenic process of age-related macular degeneration, a vision-threatening disease. The retinal pigment epithelium and macrophages both influence CNV development. However, the underlying mechanisms remain obscure. Here, we focus on Angptl2 (angiopoietin-like protein 2), a cytokine involved in age-related systemic diseases. Angptl2 was originally identified as an adipocytokine and is also expressed in the eye. Using a laser-induced CNV model, we found that Angptl2 KO mice exhibited suppressed CNV development with reduced macrophage recruitment and inflammatory mediator induction. The mediators monocyte chemotactic protein-1, interleukin-1 beta (Il-1 beta), Il-6, matrix metalloprotease-9 (Mmp-9), and transforming growth factor-beta 1 (Tgf-beta 1) that were upregulated during CNV development were all suppressed in the retinal pigment epithelium-choroid of CNV models generated in the Angptl2 KO mice. Bone marrow transplantation using wild-type and KO mice suggested that both bone marrow-derived and host-derived Angptl2 were responsible for macrophage recruitment and CNV development. Peritoneal macrophages derived from Angptl2 KO mice expressed lower levels of the inflammatory mediators. In the wild-type peritoneal macrophages and RAW264.7 cells, Angptl2 induced the mediators via integrins alpha 4 and beta 2, followed by the downstream activation of NF-kappa B and ERK. The activation of NF-kappa B and ERK by Angptl2 also promoted macrophage migration. Therefore, Angptl2 from focal tissue might trigger macrophage recruitment, and that from recruited macrophages might promote expression of inflammatory mediators including Angptl2 in an autocrine and/or paracrine fashion to facilitate CNV development. Angptl2 might therefore represent a multistep regulator of CNV pathogenesis and serve as a new therapeutic target for age-related macular degeneration.
C1 [Hirasawa, Manabu; Osada, Hideto; Miyake, Seiji; Toda, Eriko; Ozawa, Yoko] Keio Univ, Sch Med, Lab Retinal Cell Biol, Tokyo 1608582, Japan.
   [Hirasawa, Manabu; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo 1608582, Japan.
   [Hirasawa, Manabu] Tokyo Dent Coll, Suidobashi Hosp, Dept Ophthalmol, Tokyo 1010061, Japan.
   [Endo, Motoyoshi; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Kumamoto 8608555, Japan.
   [Umezawa, Kazuo] Aichi Med Univ, Sch Med, Dept Mol Target Med Screening, Nagakute, Aichi 4801195, Japan.
   [Oike, Yuichi] Japan Agcy Med Res & Dev, Core Res Evolut Sci & Technol, Tokyo 1000004, Japan.
   [Takubo, Keiyo] Natl Ctr Global Hlth & Med, Res Inst, Dept Stem Cell Biol, Tokyo 1628655, Japan.
C3 Keio University; Keio University; Tokyo Dental College; Kumamoto
   University; Aichi Medical University; Japan Science & Technology Agency
   (JST); National Center for Global Health & Medicine - Japan
RP Ozawa, Y (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Lab Retinal Cell Biol,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
EM ozawa@a5.keio.jp
RI Endo, Motoyoshi/T-5840-2019; Ozawa, Yoko/AAH-9888-2020; Takubo,
   Keiyo/AAX-5546-2020
OI Takubo, Keiyo/0000-0002-1736-7592; Osada, Hideto/0000-0001-9971-8992
FU Japan Society for the Promotion of Science KAKENHI [80365345, 25462734];
   Grants-in-Aid for Scientific Research [25462734] Funding Source: KAKEN
FX This work was supported by Japan Society for the Promotion of Science
   KAKENHI Grants 80365345 and 25462734. The authors declare that they have
   no conflicts of interest with the contents of this article.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Aoi J, 2014, MOL CANCER RES, V12, P239, DOI 10.1158/1541-7786.MCR-13-0336
   Aoi J, 2011, CANCER RES, V71, P7502, DOI 10.1158/0008-5472.CAN-11-1758
   Belotti D, 2008, MOL CANCER RES, V6, P525, DOI 10.1158/1541-7786.MCR-07-0366
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Doi Y, 2013, DIABETES CARE, V36, P98, DOI 10.2337/dc12-0166
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Endo M, 2012, CANCER RES, V72, P1784, DOI 10.1158/0008-5472.CAN-11-3878
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2013, INVEST OPHTH VIS SCI, V54, P7439, DOI 10.1167/iovs.13-12546
   Farhat N, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000201
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fu ZY, 2013, BIOCHEM BIOPH RES CO, V430, P1126, DOI 10.1016/j.bbrc.2012.12.025
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Honda S, 2009, GRAEF ARCH CLIN EXP, V247, P515, DOI 10.1007/s00417-008-1010-5
   Horio E, 2014, ARTERIOSCL THROM VAS, V34, P790, DOI 10.1161/ATVBAHA.113.303116
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Kamizuru H, 2001, INVEST OPHTH VIS SCI, V42, P2664
   Kamoshita M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103013
   Kanda A, 2012, LAB INVEST, V92, P1553, DOI 10.1038/labinvest.2012.111
   Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lee HJ, 2013, BIOCHEM BIOPH RES CO, V430, P981, DOI 10.1016/j.bbrc.2012.11.127
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Meng QX, 2013, EXP THER MED, V5, P1631, DOI 10.3892/etm.2013.1045
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nagai T, 2007, INVEST OPHTH VIS SCI, V48, P5716, DOI 10.1167/iovs.07-1023
   NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411
   Odagiri H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004612
   Oike Y, 2004, INT J HEMATOL, V80, P21, DOI 10.1532/ijh97.04034
   Oike Y, 2009, CIRC J, V73, P2192, DOI 10.1253/circj.CJ-09-0710
   Okada T, 2010, AM J PATHOL, V176, P2309, DOI 10.2353/ajpath.2010.090865
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Ruderman NB, 2013, J CLIN INVEST, V123, P2764, DOI 10.1172/JCI67227
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tabata M, 2009, CELL METAB, V10, P178, DOI 10.1016/j.cmet.2009.08.003
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tazume H, 2012, ARTERIOSCL THROM VAS, V32, P1400, DOI 10.1161/ATVBAHA.112.247866
   Tian Z, 2013, J MOL CELL CARDIOL, V57, P1, DOI 10.1016/j.yjmcc.2013.01.004
   Toyono T, 2013, INVEST OPHTH VIS SCI, V54, P4278, DOI 10.1167/iovs.12-11497
   Usui T, 2013, CIRC J, V77, P2311, DOI 10.1253/circj.CJ-12-1548
   Wang WQ, 2011, INVEST OPHTH VIS SCI, V52, P7213, DOI 10.1167/iovs.10-7097
   Watanabe M, 2008, BIOCHEM BIOPH RES CO, V376, P310, DOI 10.1016/j.bbrc.2008.08.148
   Xu J, 2012, ANGIOGENESIS, V15, P213, DOI 10.1007/s10456-012-9254-4
   Yasukawa T, 2004, CURR EYE RES, V28, P359, DOI 10.1076/ceyr.28.5.359.28678
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
   Zarranz-Ventura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065434
NR 56
TC 20
Z9 20
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 1
PY 2016
VL 291
IS 14
BP 7373
EP 7385
DI 10.1074/jbc.M115.710186
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DW2BJ
UT WOS:000383447600014
PM 26839315
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kiss, S
   Liu, Y
   Brown, J
   Holekamp, NM
   Almony, A
   Campbell, J
   Kowalski, JW
AF Kiss, Szilard
   Liu, Ying
   Brown, Joseph
   Holekamp, Nancy M.
   Almony, Arghavan
   Campbell, Joanna
   Kowalski, Jonathan W.
TI Clinical Monitoring of Patients With Age- Related Macular Degeneration
   Treated With Intravitreal Bevacizumab or Ranibizumab
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; VISUAL IMPAIRMENT; EFFICACY;
   THERAPY; SAFETY; TRIAL
AB BACKGROUND AND OBJECTIVE: Patients with neovascular age-related macular degeneration (AMD) require frequent follow-up and regular anti-VEGF injections for optimal outcomes. Although studies suggest that injection frequency is suboptimal in clinical practice, monitoring frequency in this setting is unclear. This study evaluates annual monitoring patterns between 2008 and 2011.
   PATIENTS AND METHODS: This retrospective claims analysis included newly diagnosed neovascular AMD patients with at least one intravitreal bevacizumab or ranibizumab injection (8,811 and 2,877 patients, respectively). Patient monitoring and treatment patterns were assessed at 12-month intervals.
   RESULTS: From 2008 to 2010, the mean number of injections increased. In the 2010 cohort, among bevacizumab- and ranibizumab-treated patients, respectively, less than 23% and less than 40% had at least 10 ophthalmologist visits, and less than 14% and less than 21% had at least 10 optical coherence tomography scans.
   CONCLUSION: Patients with neovascular AMD in clinical settings during 2008 to 2011 were monitored less frequently and received fewer anti-VEGF injections than patients in major clinical trials, which may affect outcomes.
C1 [Kiss, Szilard] Weill Cornell Med Coll, New York, NY 10021 USA.
   [Liu, Ying; Campbell, Joanna; Kowalski, Jonathan W.] Allergan, Irvine, CA USA.
   [Brown, Joseph] IMS Hlth, Woodland Hills, CA USA.
   [Holekamp, Nancy M.] Washington Univ, Sch Med, St Louis, MO USA.
   [Almony, Arghavan] Carolina Eye Associates, Southern Pines, NC USA.
C3 Cornell University; AbbVie; Allergan; Washington University (WUSTL)
RP Kiss, S (通讯作者)，New York Presbyterian Hosp, Weill Cornell Med Coll, 1305 York Ave,11th Floor, New York, NY 10021 USA.
EM szk7001@med.cornell.edu
OI Kiss, Szilard/0000-0003-3433-8432
FU Allergan (Irvine, CA)
FX Supported by Allergan (Irvine, CA). The sponsor participated in the
   study design, interpretation of the data, and the preparation, review,
   and approval of the manuscript. Third-party writing assistance provided
   by Susan M. Kaup, PhD, and Andrew Fitton, PhD, of Evidence Scientific
   Solutions.
CR American Society of Retina Specialists (ASRS), 2012, ANN PREF TRENDS SURV
   Bandello F, 2012, INVEST OPHTH VIS SCI, V53, P2031
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cleary C A, 2011, Ir Med J, V104, P146
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   COHEN SP, 2013, RETINA, P33
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holekamp NM, 2012, INVEST OPHTH VIS SCI, V53, P4179
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Vedula SS, 2008, COCHRANE DB SYST REV, V16
   You JY, 2012, CURR EYE RES, V37, P438, DOI 10.3109/02713683.2011.647227
NR 32
TC 10
Z9 10
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUL-AUG
PY 2014
VL 45
IS 4
BP 285
EP 291
DI 10.3928/23258160-20140709-04
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AY0OP
UT WOS:000347296300003
PM 25037010
DA 2022-11-30
ER

PT J
AU Eghoj, MS
   Sorensen, TL
AF Eghoj, Maria Salling
   Sorensen, Torben Lykke
TI Tachyphylaxis during treatment of exudative age-related macular
   degeneration with ranibizumab
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB; EXPRESSION; CYTOKINES
AB Aim To determine whether tachyphylaxis occurs during treatment with ranibizumab (Lucentis, Genentech, Inc., South San Francisco, California, USA) for exudative age-related macular degeneration (AMD).
   Design Retrospective review of cases.
   Participants The treatment results of 1076 eyes (976 patients) treated with ranibizumab for exudative AMD was evaluated to identify patients with a potential tachyphylactic response. The participants had to have a minimum of 12 months follow-up.
   Methods Tachyphylaxis was defined as a lack of response to the drug at the time of reactivation of choroidal neovascularisation (CNV) in patients who had responded to the initial treatment. The authors considered it a lack of response to ranibizumab if a decrease in vision and an increase in central retinal thickness (CRT) were observed despite repeated injections. Hence a stabilisation in vision and/or stabilisation in CRT during treatment were not considered tachyphylaxis, and other unfavourable responses such as a tear in the retinal pigment epithelium and therefore a decrease in vision during treatment were also not considered as tachyphylaxis. Every patient in this cohort who has had an injection-free interval after primary inactivation of CNV and who has received retreatment at a later stage was identified. In this population, those cases that did not respond to retreatment (tachyphylaxis) were identified and characterised.
   Main outcome measures Number of patients who developed tachyphylaxis after treatment with ranibizumab.
   Results 20 patients (2%) developed tachyphylaxis during their treatment.
   Conclusion Tachyphylaxis can occur during the treatment of exudative AMD with ranibizumab. The precise mechanism for the development of tachyphylaxis is unclear. Both local and systemic factors might be involved.
C1 [Eghoj, Maria Salling; Sorensen, Torben Lykke] Copenhagen Univ Hosp Roskilde, Dept Ophthalmol, DK-4000 Roskilde, Denmark.
C3 University of Copenhagen
RP Eghoj, MS (通讯作者)，Copenhagen Univ Hosp Roskilde, Dept Ophthalmol, Kogevej 7-13, DK-4000 Roskilde, Denmark.
EM sallingmus@hotmail.com
RI Sørensen, Torben Lykke L/N-1417-2014
OI Sørensen, Torben Lykke L/0000-0002-6790-0199
CR ANDSERSON SD, 2006, CLIN REV ALLERG IMMU, V31, P163
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   FOROOGHIAN F, 2009, ACTA OPHTHALMOL, V7, P1
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Frank RN, 1997, OPHTHALMIC RES, V31, P243
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hoffman B.B., 2001, GOODMAN GILMANS PHAR, P115
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   TARTAR O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782
NR 20
TC 101
Z9 112
U1 0
U2 6
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2012
VL 96
IS 1
BP 21
EP 23
DI 10.1136/bjo.2011.203893
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 866EZ
UT WOS:000298364600005
PM 21733918
DA 2022-11-30
ER

PT J
AU Weiner, DE
   Tighiouart, H
   Reynolds, R
   Seddon, JM
AF Weiner, Daniel E.
   Tighiouart, Hocine
   Reynolds, Robyn
   Seddon, Johanna M.
TI Kidney function, albuminuria and age-related macular degeneration in
   NHANES III
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE age-related macular degeneration; albuminuria; chronic kidney disease;
   dense deposit disease; glomerular filtration rate
ID HEMOLYTIC-UREMIC SYNDROME; GLOMERULAR-FILTRATION-RATE; DENSE DEPOSIT
   DISEASE; COMPLEMENT FACTOR-H; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
   RISK; POPULATION; MACULOPATHY; DEFICIENCY; ACTIVATION
AB Background. Age-related macular degeneration (AMD) and kidney disease may have shared risk factors, including cardiovascular disease risk factors; additionally AMD and dense deposit disease share a common causal link, with both associated with polymorphisms in the complement pathway. Accordingly, we explored a population-based cohort of US adults to examine if markers of kidney disease identify a higher risk population for prevalent AMD.
   Methods. A cross-sectional nested case-control study matching on age, sex and race was performed using data on adult participants in the Third National Health and Nutrition Examination Survey. Predictor variables included urine albumin-to-creatinine ratio and estimated glomerular filtration rate (eGFR). Study outcomes included late AMD, defined as neovascular disease or geographic atrophy (5: 1 matching), and a composite of both early AMD, defined as soft drusen or pigment irregularities with or without any drusen, and late AMD (1: 1 matching).
   Results. There were 51 participants with late AMD and 865 with any AMD. In conditional logistic regression adjusting for diabetes, hypertension and total cholesterol, lower eGFR was independently associated with late AMD [odds ratio (OR) = 3.05, 95% confidence interval (CI): 1.51-6.13], while albuminuria was not significant. For any AMD, neither albuminuria nor eGFR were significant in adjusted models. In sensitivity analyses excluding diabetics, albuminuria was associated with any AMD (OR = 1.56, 95% CI: 1.11-1.29 and 1.57, 95% CI: 0.61-3.69 for micro and macroalbuminuria, respectively, P = 0.03).
   Conclusions. Late AMD is more common among individuals with reduced kidney function. Whether this association reflects a common causal pathway or shared risk factors such as hypertension requires additional investigation.
C1 [Weiner, Daniel E.] Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA.
   [Tighiouart, Hocine] Tufts Med Ctr, Dept Med, Biostat Res Ctr, Boston, MA USA.
   [Reynolds, Robyn; Seddon, Johanna M.] Tufts Med Ctr, Dept Ophthalmol, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Tufts Medical Center; Tufts Medical Center; Tufts Medical Center; Tufts
   University
RP Weiner, DE (通讯作者)，Tufts Med Ctr, Dept Med, Div Nephrol, Boston, MA USA.
EM dweiner@tuftsmedicalcenter.org
OI Weiner, Daniel/0000-0002-8775-394X
FU Genentech; NIH [K23DK71636]; National Institutes of Health (NIH)
   National Eye Institute [R01-EY11309]; Inc, North-boro, MA; New England
   Eye Center; Tufts Medical Center; Tufts University School of Medicine;
   NATIONAL EYE INSTITUTE [R01EY011309] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
   [K23DK071636] Funding Source: NIH RePORTER
FX J.M.S. has patents filed related to the diagnosis of AMD and has
   received financial support from Genentech. Other support includes the
   National Institutes of Health (NIH) National Eye Institute R01-EY11309,
   the Massachusetts Lions Eye Research Fund, Inc, North-boro, MA and the
   Macular Degeneration Research Fund, New England Eye Center, Tufts
   Medical Center, Tufts University School of Medicine. D.E.W. is supported
   by NIH grant K23DK71636.
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Atkinson JP, 2007, J EXP MED, V204, P1245, DOI 10.1084/jem.20070664
   Bergstralh EJ, 1996, EPIDEMIOLOGY, V7, P331
   Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Elsayed EF, 2007, ARCH INTERN MED, V167, P1130, DOI 10.1001/archinte.167.11.1130
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Hillege HL, 2002, CIRCULATION, V106, P1777, DOI 10.1161/01.CIR.0000031732.78052.81
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Lau KK, 2008, CLIN EXP NEPHROL, V12, P228, DOI 10.1007/s10157-008-0031-z
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   PICHETTE V, 1994, AM J KIDNEY DIS, V24, P936, DOI 10.1016/S0272-6386(12)81065-1
   Seddon J, 2007, PRINCIPLES PRACTICE, P413
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   Weiner DE, 2009, AM J KIDNEY DIS, V53, P438, DOI 10.1053/j.ajkd.2008.08.022
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 32
TC 27
Z9 27
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD OCT
PY 2011
VL 26
IS 10
BP 3159
EP 3165
DI 10.1093/ndt/gfr022
PG 7
WC Transplantation; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Transplantation; Urology & Nephrology
GA 839EW
UT WOS:000296349200017
PM 21339308
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Lommatzsch, A
   Hermans, P
   Muller, KD
   Bornfeld, N
   Bird, AC
   Pauleikhoff, D
AF Lommatzsch, A.
   Hermans, P.
   Mueller, K. D.
   Bornfeld, N.
   Bird, A. C.
   Pauleikhoff, D.
TI Are low inflammatory reactions involved in exudative age-related macular
   degeneration?
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; AMD pathogenesis; basal laminar and
   linear deposits; inflammation; histology
ID COMPLEMENT FACTOR-H; CHOROIDAL NEOVASCULAR MEMBRANES; BASAL LAMINAR
   DEPOSIT; BRUCHS MEMBRANE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
   ELECTRON-MICROSCOPY; DRUSEN; MACULOPATHY; VITRONECTIN; DISEASE
AB Purpose Basal laminar and linear deposits (BLD) are associated with the development of choroidal neovascularization (CNV). Therefore, analysis of BLD composition may provide further information concerning the pathogenesis of BLD and CNV in age-related macular degeneration (AMD).
   Methods BLD in 25 specimens of surgically removed CNV were examined, using histochemical and immunohistochemical methods, for extracellular matrix proteins and their modulating enzymes, and for cell markers and proteins involved in inflammatory processes. In addition, ultrastructural electron microscopic analysis (EM) was performed.
   Results The chemical and structural composition of all the BLD was similar. Only the inner aspect of the BLD contained laminin and collagen IV, which corresponded to a new RPE basal lamina upon EM analysis. The extracellular matrix protein predominantly found in all layers of BLD was vitronectin, which was seen as a homogeneous material within the BLD upon EM analysis. The metalloproteinases MMP-2 and MMP-9 could only be detected in the inner aspect, while MMP-7 and TIMP-3 were observed predominantly in the outer aspect of BLD. In this area, staining for phospholipids and less intensely for neutral lipids was also visible. The labelling of complement complexes C3 and C5b-9 was intensely positive, and vascular endothelial growth factor (VEGF) was detected in all BLDs.
   Conclusions Diffuse deposits such as BLD appear consistently with the development of CNV in AMD. They consist of extracellular matrix components and predominantly vitronectin. However, activated complement and VEGF could also be detected. The results of the current study may support the hypothesis that inflammatory processes are involved in the pathogenesis of BLD and CNV in AMD.
C1 [Lommatzsch, A.] St Franziskus Hosp, Dept Ophthalmol, D-48145 Munster, Germany.
   [Lommatzsch, A.; Hermans, P.; Pauleikhoff, D.] St Franziskus Hosp Munster, Dept Ophthalmol & Ophtha Lab, Munster, Germany.
   [Mueller, K. D.] Univ Essen Duisburg, Dept Microbiol, Essen, Germany.
   [Hermans, P.; Bornfeld, N.] Univ Essen Duisburg, Dept Ophthalmol, Essen, Germany.
   [Bird, A. C.] Moorfields Eye Hosp, London, England.
C3 St. Franziskus-Hospital; St. Franziskus-Hospital; University of Duisburg
   Essen; University of Duisburg Essen; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust
RP Lommatzsch, A (通讯作者)，St Franziskus Hosp, Dept Ophthalmol, Hohenzollernring 74, D-48145 Munster, Germany.
EM Albrecht.Lommatzsch@web.de
CR Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7
   Alexander JJ, 2005, J AM SOC NEPHROL, V16, P52, DOI 10.1681/ASN.2004090778
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   DEBOER HC, 1992, J BIOL CHEM, V267, P2264
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ekmekci H, 2002, J THROMB THROMBOLYS, V14, P221, DOI 10.1023/A:1025000810466
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hermans P, 2003, OPHTHALMOLOGE, V100, P378, DOI 10.1007/s00347-002-0742-6
   HIGH OB, 1984, ROYAL MICROSCOPICA S, V6
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Knupp C, 2002, J STRUCT BIOL, V139, P181, DOI 10.1016/S1047-8477(02)00534-8
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Lafaut BA, 2001, GRAEF ARCH CLIN EXP, V239, P5, DOI 10.1007/s004170000224
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   LOEFFLER KU, 1986, GRAEFES ARCH CLIN EX, V224, P493
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   SCOTT JE, 1965, HISTOCHEMISTRY, V5, P221, DOI 10.1007/BF00306130
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 50
TC 65
Z9 67
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2008
VL 246
IS 6
BP 803
EP 810
DI 10.1007/s00417-007-0749-4
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297PI
UT WOS:000255628200002
PM 18414889
DA 2022-11-30
ER

PT J
AU Ying, GS
   Huang, JY
   Maguire, MG
   Jaffe, GJ
   Grunwald, JE
   Toth, C
   Daniel, E
   Klein, M
   Pieramici, D
   Wells, J
   Martin, DF
AF Ying, Gui-shuang
   Huang, Jiayan
   Maguire, Maureen G.
   Jaffe, Glenn J.
   Grunwald, Juan E.
   Toth, Cynthia
   Daniel, Ebenezer
   Klein, Michael
   Pieramici, Dante
   Wells, John
   Martin, Daniel F.
CA Comparison Age-Related Macular
TI Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or
   Bevacizumab for Neovascular Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBGROUP ANALYSIS; HEMORRHAGE
AB Objective: To determine the baseline predictors of visual acuity (VA) outcomes 1 year after treatment with ranibizumab or bevacizumab for neovascular age-related macular degeneration (AMD).
   Design: Cohort study within the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
   Participants: A total of 1105 participants with neovascular AMD, baseline VA 20/25 to 20/320, and VA measured at 1 year.
   Methods: Participants were randomly assigned to ranibizumab or bevacizumab on a monthly or as-needed schedule. Masked readers evaluated fundus morphology and features on optical coherence tomography (OCT). Visual acuity was measured using electronic VA testing. Independent predictors were identified using regression techniques.
   Main Outcome Measures: The VA score, VA score change from baseline, and >= 3-line gain at 1 year.
   Results: At 1 year, the mean VA score was 68 letters, mean improvement from baseline was 7 letters, and 28% of participants gained >= 3 lines. Older age, larger area of choroidal neovascularization (CNV), and elevation of retinal pigment epithelium (RPE) were associated with worse VA (all P < 0.005), less gain in VA (all P < 0.02), and a lower proportion gaining >= 3 lines (all P < 0.04). Better baseline VA was associated with better VA at 1 year, less gain in VA, and a lower proportion gaining >= 3 lines (all P < 0.0001). Predominantly or minimally classic lesions were associated with worse VA than occult lesions (66 vs. 69 letters; P=0.0003). Retinal angiomatous proliferans (RAP) lesions were associated with more gain in VA (10 vs. 7 letters; P=0.03) and a higher proportion gaining >= 3 lines (odds ratio, 1.9; 95% confidence interval, 1.2-3.1). Geographic atrophy (GA) was associated with worse VA (64 vs. 68 letters; P=0.02). Eyes with total foveal thickness in the second quartile (325-425 mu m) had the best VA (P=0.01) and were most likely to gain >= 3 lines (P=0.004). Predictors did not vary by treatment group.
   Conclusions: For all treatment groups, older age, better baseline VA, larger CNV area, predominantly or minimally classic lesion, absence of RAP lesion, presence of GA, greater total fovea thickness, and RPE elevation on optical coherence tomography were independently associated with less improvement in VA at 1 year.
C1 [Ying, Gui-shuang; Huang, Jiayan; Maguire, Maureen G.; Grunwald, Juan E.; Daniel, Ebenezer] Univ Penn, Scheie Eye Inst, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Ying, Gui-shuang; Huang, Jiayan; Maguire, Maureen G.; Grunwald, Juan E.; Daniel, Ebenezer] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Ctr Prevent Ophthalmol & Biostat, Philadelphia, PA 19104 USA.
   [Ying, Gui-shuang; Maguire, Maureen G.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   [Jaffe, Glenn J.; Toth, Cynthia] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Klein, Michael] Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97201 USA.
   [Pieramici, Dante] Calif Retina Consultants, Santa Barbara, CA USA.
   [Wells, John] Palmetto Retina Ctr, W Columbia, SC USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine; Duke University; Oregon Health & Science
   University; Cleveland Clinic Foundation
RP Ying, GS (通讯作者)，3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM gsying@mail.med.upenn.edu
RI Ciulla, Thomas/AAA-1299-2020; Toth, Cynthia/L-5534-2019
OI Ciulla, Thomas/0000-0001-5557-6777; Toth, Cynthia/0000-0002-2324-0854;
   Vavvas, Demetrios/0000-0002-8622-6478; Losordo,
   Douglas/0000-0002-6857-7506; Folk, James/0000-0002-6271-2906; Daniel,
   Ebenezer/0000-0002-2027-2316
FU National Eye Institute, National Institutes of Health [U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828]; Department of Health and Human
   Services; NATIONAL EYE INSTITUTE [U10EY017825, U10EY017823, U10EY017828,
   U10EY017826] Funding Source: NIH RePORTER
FX Supported by cooperative agreements U10 EY017823, U10 EY017825, U10
   EY017826, and U10 EY017828 from the National Eye Institute, National
   Institutes of Health, and Department of Health and Human Services.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
NR 11
TC 224
Z9 231
U1 0
U2 53
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2013
VL 120
IS 1
BP 122
EP 129
DI 10.1016/j.ophtha.2012.07.042
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 063PI
UT WOS:000313011700019
PM 23047002
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Robison, CD
   Krebs, I
   Binder, S
   Barbazetto, IA
   Kotsolis, AI
   Yannuzzi, LA
   Sadun, AA
   Sebag, J
AF Robison, Craig D.
   Krebs, Ilse
   Binder, Susanne
   Barbazetto, Irene A.
   Kotsolis, Athanasios I.
   Yannuzzi, Lawrence A.
   Sadun, Alfredo A.
   Sebag, Jerry
TI Vitreomacular Adhesion in Active and End-Stage Age-related Macular
   Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POSTERIOR VITREOUS DETACHMENT; BODY-MASS INDEX; CIGARETTE-SMOKING;
   PHARMACOLOGICAL VITREOLYSIS; ENVIRONMENTAL ASSOCIATIONS; RISK-FACTORS;
   DISEASE; GENE; EYE; PATHOGENESIS
AB PURPOSE: To evaluate vitreomacular relations in different stages of age-related macular degeneration (AMD) without the influence of genetics and environmental factors.
   DESIGN: Retrospective, observational case series.
   METHODS: This was a multicenter study consisting of 29 previously untreated subjects with active exudative (wet) AMD in one eye and active nonexudative (dry) AMD in the fellow eye who were compared with 10 previously untreated subjects with end-stage geographic atrophy in one eye and an end stage fibrotic (disciform) scar in the fellow eye. All subjects were studied with ultrasonography to identify the presence of posterior vitreous detachment (PVD) and by optical coherence tomography to detect vitreomacular adhesion (VMA).
   RESULTS: The incidence of PVD in eyes with nonexudative AMD was 20 (69%) of 29, compared with 6 (21%) of 29 with active exudative AMD (P = .002). VMA was present in 11 (38%) of 29 of eyes with exudative AMD and in only 3 (10%) of 29 eyes with nonexudative AMD (P = .008). The incidence of PVD in geographic atrophy was 7 (70%) of 10, compared with 4 (40%) of 10 with disciform scar (P = .44). VMA was present in 2 (20%) of 10 eyes with disciform scars and in 0 (0%) of 10 eyes with geographic atrophy (P = .48).
   CONCLUSIONS: PVD may protect against exudative AMD, whereas VMA may promote exudative AMD. This phenomenon is not evident in end-stage disease because of an increased incidence of PVD and a decreased incidence of VMA in eyes with disciform scars. Genetic and environmental factors do not seem to influence these observations. (Am J Ophthalmol 2009; 148: 79-82. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Robison, Craig D.; Sebag, Jerry] VMR Inst, Huntington Beach, CA USA.
   [Robison, Craig D.; Sadun, Alfredo A.; Sebag, Jerry] Keck Univ So Calif, Sch Med, Doheny Eye Inst, Los Angeles, CA USA.
   [Krebs, Ilse; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
   [Barbazetto, Irene A.; Kotsolis, Athanasios I.; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Barbazetto, Irene A.] Columbia Univ, Coll Phys & Surg, ES Harkness Eye Inst, New York, NY USA.
C3 Doheny Eye Institute; Ludwig Boltzmann Institute; Vitreous Retina Macula
   Consultants of New York; Columbia University
RP Sebag, J (通讯作者)，7677 Ctr Ave,Suite 400, Huntington Beach, CA 92647 USA.
EM jsebag@VMRinstitute.com
RI Sebag, J./AAF-3602-2020
OI Sebag, J/0000-0001-8648-5747
FU THE BAXTER Foundation, Los Angeles, California; Macula Foundation Inc,
   New York, New York; University of Southern California Health Sciences
   Center IRB, Los Angeles, California
FX THIS STUDY WAS FUNDED THROUGH A USC MEDICAL STUDENT SUMMER RESEARCH
   FELLOWSHIP BY THE BAXTER Foundation, Los Angeles, California (Dr
   Robison) and the Macula Foundation Inc, New York, New York (Drs
   Barbazerto and Kotsolis). The authors indicate no financial conflict of
   interest. Involved in concept and design of study (I.K., S.B., L.A.Y.,
   A.A.S., J.S.); analysis and interpretation of data (C.D.R., I.A.B.,
   A.I.K., L.A.Y., J.S.); writing and critical revision the article
   (C.D.R., S.B., L.A.Y., A.A.S., J.S.); final approval of the article
   (C.D.R., S.B., L.A.Y., J.S.); data collection (C.D.R., I.K., I.A.B.,
   A.I.K., J.S.); provision of materials, patients, or resources (I.K.,
   S.B., I.A.B., A.I.K., L.A.Y.,J.S.); obtaining funding (S.B., L.A.Y.,
   A.A.S., J.S.); literature search (C.D.R., J.S.); and administrative,
   technical, or logistic support (S.B., L.A.Y., A.A.S., J.S.).
   Institutional review board (IRB) approval was obtained from the
   University of Southern California Health Sciences Center IRB, Los
   Angeles, California; the "Ethikkomission der Stadt Wien nach Wr. KAG,
   AMG und MPG," Vienna, Austria; and the Lenox Hill Hospital IRB, New
   York, New York.; The authors thank Dr Laurie Dustin, University of
   Southern California School of Medicine, Los Angeles, California, for
   performing the statistical analyses.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bishop PN, 2004, INVEST OPHTH VIS SCI, V45, P1041, DOI 10.1167/iovs.03-1017
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   HIKICHI T, 1995, OPHTHALMIC SURG LAS, V26, P39
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   O'Connell ED, 2008, AM J CLIN NUTR, V87, P712, DOI 10.1093/ajcn/87.3.712
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Sebag J, 2008, GRAEF ARCH CLIN EXP, V246, P329, DOI 10.1007/s00417-007-0743-x
   Sebag J, 2005, Trans Am Ophthalmol Soc, V103, P473
   Sebag J, 1996, OPHTHALMOLOGY, V103, P205
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Sebag J, 2002, RETINA-J RET VIT DIS, V22, P1, DOI 10.1097/00006982-200202000-00001
   Sebag J, 1998, RETINA-J RET VIT DIS, V18, P1
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Weber-Krause B, 1997, OPHTHALMOLOGE, V94, P619, DOI 10.1007/s003470050170
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 30
TC 104
Z9 113
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2009
VL 148
IS 1
BP 79
EP 82
DI 10.1016/j.ajo.2009.01.014
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464CE
UT WOS:000267481700013
PM 19327744
DA 2022-11-30
ER

PT J
AU Ach, T
   Hoeh, AE
   Ruppenstein, M
   Kretz, FTA
   Dithmar, S
AF Ach, Thomas
   Hoeh, Alexandra E.
   Ruppenstein, Mira
   Kretz, Florian T. A.
   Dithmar, Stefan
TI INTRAVITREAL BEVACIZUMAB IN VASCULAR PIGMENT EPITHELIUM DETACHMENT AS A
   RESULT OF SUBFOVEAL OCCULT CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; pigment epithelium
   detachment; vascularized; PED
ID VISUAL-ACUITY CHANGE; PHOTODYNAMIC THERAPY; AVASTIN; TRIAMCINOLONE;
   INJECTION
AB Purpose: The purpose of this study was to evaluate the effect of intravitreally administered bevacizumab on untreated vascularized pigment epithelium detachment (PED) in sub-or juxtafoveal occult choroidal neovascularization as a result of age-related macular degeneration.
   Methods: In this retrospective study, 28 untreated eyes of 26 patients (4 men, 22 women; mean age, 74.6 +/- 7.2 years) with PED and sub-or juxtafoveal occult choroidal neovascularization as a result of age-related macular degeneration and additional intra- and/or subretinal fluid were treated with intravitreal injections of 1.25 mg bevacizumab. Baseline and follow-up visits included best-corrected visual acuity, complete ophthalmic examination, and Stratus optical coherence tomography. Fluorescein angiography was performed at baseline. Reinjections were performed if intra- and/or subretinal fluid persisted or recurred or PED increased.
   Results: Patients received 3.2 +/- 1.8 injections (follow-up 37.9 +/- 18.3 weeks). Mean maximum PED height showed a tendency to decrease (372 +/- 150.5 mu m to 290.3 +/- 189 mu m; P = 0.094). In 14 eyes (53.8%), PED height was reduced at last visit, including complete flattening in 1 eye. Mean visual acuity remained stable (0.58 +/- 0.30 logarithm of the minimum angle of resolution to 0.58 +/- 0.37 logarithm of the minimum angle of resolution; P = 0.905). Pigment epithelium detachment response to treatment did not correlate with baseline PED height or visual acuity at baseline or at the last visit. One patient sustained a retinal pigment epithelium rip, and another patient sustained an extensive subretinal hemorrhage.
   Conclusion: During bevacizumab therapy, mean PED height decreases in 50% of patients. No predictive factors for the response of PED to bevacizumab treatment could be identified. Treatment of PED with bevacizumab might result in a long-term functional benefit compared with the natural course. RETINA 30: 1420-1425, 2010
C1 [Ach, Thomas; Hoeh, Alexandra E.; Ruppenstein, Mira; Kretz, Florian T. A.; Dithmar, Stefan] Univ Heidelberg, Dept Ophthalmol, D-69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Dithmar, S (通讯作者)，Univ Heidelberg, Dept Ophthalmol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
EM stefan.dithmar@med.uni-heidelberg.de
RI Ach, Thomas/AAE-7870-2021
OI Ach, Thomas/0000-0001-6583-8283; Kretz, Florian/0000-0002-8771-2187
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Axer-Siegel R, 2006, OPHTHAL SURG LAS IM, V37, P455, DOI 10.3928/15428877-20061101-02
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P370, DOI 10.1089/jop.2006.22.370
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Lazic R, 2007, COLLEGIUM ANTROPOL, V31, P77
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   PEDERSEN KB, 2008, ACTA OPHTHALMOL 1216
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
NR 18
TC 27
Z9 27
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2010
VL 30
IS 9
BP 1420
EP 1425
DI 10.1097/IAE.0b013e3181d87e97
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 659JC
UT WOS:000282561800010
PM 20543764
DA 2022-11-30
ER

PT J
AU Hagstrom, SA
   Ying, GS
   Pauer, GJT
   Sturgill-Short, GM
   Huang, JY
   Maguire, MG
   Martin, DF
AF Hagstrom, Stephanie A.
   Ying, Gui-Shuang
   Pauer, Gayle J. T.
   Sturgill-Short, Gwen M.
   Huang, Jiayan
   Maguire, Maureen G.
   Martin, Daniel F.
CA Comparison Age-Related Macular Deg
TI VEGFA and VEGFR2 Gene Polymorphisms and Response to Anti-Vascular
   Endothelial Growth Factor Therapy Comparison of Age-Related Macular
   Degeneration Treatments Trials (CATT)
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB; ASSOCIATION; PHARMACOGENETICS; BEVACIZUMAB;
   AMD
AB IMPORTANCE Individual variation in response and duration of anti-vascular endothelial growth factor (VEGF) therapy is seen among patients with neovascular age-related macular degeneration. Identification of genetic markers that affect clinical response may result in optimization of anti-VEGF therapy.
   OBJECTIVE To evaluate the pharmacogenetic relationship between genotypes of single-nucleotide polymorphisms (SNPs) in the VEGF signaling pathway and response to treatment with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
   DESIGN, SETTING. AND PARTICIPANTS In total, 835 of 1149 patients (72.7%) participating in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) at 43 CATT clinical centers.
   INTERVENTION Each patient was genotyped for 7 SNPs in VEGFA (rs699946, rs699947, rs833069, rs833070, rs1413711, rs2010963, and rs2146323) and 1 SNP in VEGFR2 (rs2071559) using TaqMan SNP genotyping assays.
   MAIN OUTCOMES AND MEASURES Genotypic frequencies were compared with clinical measures of response to therapy at 1 year, including the mean visual acuity, mean change in visual acuity, at least a 15-letter increase, retinal thickness, mean change in total foveal thickness, presence of fluid on optical coherence tomography, presence of leakage on fluorescein angiography, mean change in lesion size, and mean number of injections administered. Differences in response by genotype were evaluated with tests of linear trend calculated from logistic regression models for categorical outcomes and linear regression models for continuous outcomes. The method of controlling the false discovery rate was used to adjust for multiple comparisons.
   RESULTS For each of the measures of visual acuity evaluated, no association was observed with any of the genotypes or with the number of risk alleles. Four VEGFA SNPs demonstrated an association with retinal thickness: rs699947 (P =.03), rs833070 (P =.04), rs1413711 (P =.045), and rs2146323 (P =.006). However, adjusted P values for these associations were all statistically nonsignificant (range, P =.24 to P =.45). Among the participants in 2 as-needed groups, no association was found in the number of injections among the different genotypes or for the total number of risk alleles. The effect of risk alleles on each clinical measure did not differ by treatment group, drug, or dosing regimen (P >.01 for all).
   CONCLUSIONS AND RELEVANCE This study provides evidence that no pharmacogenetic associations exist between the studied VEGFA and VEGFR2 SNPs and response to anti-VEGF therapy.
C1 [Hagstrom, Stephanie A.; Pauer, Gayle J. T.; Sturgill-Short, Gwen M.; Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Hagstrom, Stephanie A.; Martin, Daniel F.] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Ying, Gui-Shuang; Huang, Jiayan; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 Cleveland Clinic Foundation; Case Western Reserve University; Cleveland
   Clinic Foundation; University of Pennsylvania
RP Hagstrom, SA (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM hagstrs@ccf.org
OI Losordo, Douglas/0000-0002-6857-7506; Ciulla,
   Thomas/0000-0001-5557-6777; Folk, James/0000-0002-6271-2906; Vavvas,
   Demetrios/0000-0002-8622-6478
FU National Eye Institute [U10 EY017823, U10 EY017825, U10 EY017826, U10
   EY017828]; NATIONAL EYE INSTITUTE [U10EY017828, U10EY017823,
   U10EY017826, U10EY017825] Funding Source: NIH RePORTER
FX This study was supported by cooperative agreements U10 EY017823, U10
   EY017825, U10 EY017826, and U10 EY017828 from the National Eye
   Institute.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Augustin Albert J, 2006, Expert Opin Emerg Drugs, V11, P725, DOI 10.1517/14728214.11.4.725
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Fang AM, 2009, MOL VIS, V15, P2710
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Flicek P, 2013, NUCLEIC ACIDS RES, V41, pD48, DOI 10.1093/nar/gks1236
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lazzeri S, 2012, SCI WORLD J, DOI 10.1100/2012/420190
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Lu Y, 2012, MOL BIOL REP, V39, P6547, DOI 10.1007/s11033-012-1483-5
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Pasqualetti G, 2007, PHARMACOGENOMICS, V8, P49, DOI 10.2217/14622416.8.1.49
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Vailati FB, 2012, INVEST OPHTH VIS SCI, V53, P6411, DOI 10.1167/iovs.12-9727
   Yuan HY, 2006, NUCLEIC ACIDS RES, V34, pW635, DOI 10.1093/nar/gkl236
NR 41
TC 45
Z9 48
U1 0
U2 13
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2014
VL 132
IS 5
BP 521
EP 527
DI 10.1001/jamaophthalmol.2014.109
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ7QW
UT WOS:000337892500002
PM 24652518
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kakigi, CLM
   Singh, K
   Wang, SY
   Enanoria, WT
   Lin, SC
AF Kakigi, Caitlin L. M.
   Singh, Kuldev
   Wang, Sophia Y.
   Enanoria, Wayne T.
   Lin, Shan C.
TI Self-reported Calcium Supplementation and Age-Related Macular
   Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID GLAUCOMA PREVALENCE; VITAMIN; MECHANISMS; ESTROGEN; CELLS; IRON; IONS
AB IMPORTANCE Despite widespread use of calcium supplementation among elderly people, little is known about the association between such consumption and the prevalence of age-related macular degeneration (AMD) in the United States.
   OBJECTIVE To investigate the association between self-reported supplementary calcium consumption and the prevalence of AMD in a representative US sample.
   DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study included 3191 participants 40 years and older in the 2007-2008 National Health and Nutrition Examination Survey (NHANES) who were evaluated for the presence or absence of AMD by fundus photography. Participants were interviewed regarding use of dietary supplements and antacids during the 30-day period preceding enrollment. Self-reported supplementary intake of calcium was aggregated and divided into quintiles. Fundus photographs were graded for the presence or absence of AMD. Information regarding demographics, comorbidities, and health-related behaviors was obtained via interview. Multivariable logistic regression models were created to determine the odds of an AMD diagnosis among participants in each quintile of self-reported calcium vs participants not self-reporting supplementary calcium consumption after adjusting for confounders.
   INTERVENTIONS Self-reported use of calcium supplements.
   MAIN OUTCOMES AND MEASURES Presence or absence of AMD by fundus photography.
   RESULTS A total of 248 participants (7.8%) were diagnosed with AMD. Mean ages were 67.2 years for those with AMD and 55.8 for those without AMD. After adjustment for potential confounding variables, study participants who self-reported consumption of more than 800 mg/d of supplementary calcium were found to have higher odds of an AMD diagnosis based on fundus photography evaluation compared with those not self-reporting supplementary calcium consumption (odds ratio, 1.85; 95% CI, 1.25-2.75). The association between self-reported supplementary calcium intake and AMD was stronger in older than younger individuals (odds ratio, 2.63; 95% CI, 1.52-4.54). A clear dose-response association between the quintiles of self-reported supplementary calcium intake and AMD was not established.
   CONCLUSIONS AND RELEVANCE Self-reported supplementary calcium consumption is associated with increased prevalence of AMD, with the findings suggesting a threshold rather than a dose-response relationship. The stronger association in older individuals may be due to relatively longer duration of calcium supplementation in older individuals.
C1 [Kakigi, Caitlin L. M.; Lin, Shan C.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Singh, Kuldev] Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA.
   [Wang, Sophia Y.] Univ Michigan, Dept Ophthalmol, Ann Arbor, MI USA.
   [Enanoria, Wayne T.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco;
   Stanford University; University of Michigan System; University of
   Michigan; University of California System; University of California San
   Francisco
RP Lin, SC (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,Room K301, San Francisco, CA 94143 USA.
EM LinS@vision.ucsf.edu
OI Wang, Sophia/0000-0003-0916-9403
FU Clinical and Translational Research Fellowship Program [TL1 TR000144];
   University of California, San Francisco; Clinical and Translational
   Science Institute - National Center for Advancing Translational
   Sciences, National Institutes of Health; Doris Duke Charitable
   Foundation; National Eye Institute [EY002162]; That Man May See Inc;
   Research to Prevent Blindness; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [TL1TR000144] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [P30EY002162] Funding Source: NIH RePORTER
FX This study was funded in part by grant TL1 TR000144 from the Clinical
   and Translational Research Fellowship Program, a program of the
   University of California, San Francisco, Clinical and Translational
   Science Institute that is sponsored in part by the National Center for
   Advancing Translational Sciences, National Institutes of Health, and the
   Doris Duke Charitable Foundation. The design and conduct of the study,
   analysis, interpretation of the data, and preparation of the manuscript
   were funded by the Clinical and Translational Research Fellowship
   Program. Analysis was funded by core grant EY002162 from the National
   Eye Institute, That Man May See Inc, and Research to Prevent Blindness.
CR [Anonymous], NHANES 2007 2008
   Bailey RL, 2010, J NUTR, V140, P817, DOI 10.3945/jn.109.118539
   BILEZIKIAN JP, 1994, JAMA-J AM MED ASSOC, V272, P1942, DOI 10.1001/jama.1994.03520240070044
   Bolland MJ, 2010, BMJ-BRIT MED J, V341, pc3691, DOI DOI 10.1136/BMJ.C3691
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Crish SD, 2011, NEUROSCIENCE, V176, P1, DOI 10.1016/j.neuroscience.2010.12.036
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Harvey H, 2014, EXP BRAIN RES, V232, P3363, DOI 10.1007/s00221-014-4078-7
   HEANEY RP, 1989, J BONE MINER RES, V4, P469
   HERFARTH K, 1992, EUR J CLIN CHEM CLIN, V30, P815
   HOROWITZ M, 1994, AM J CLIN NUTR, V60, P965, DOI 10.1093/ajcn/60.6.965
   Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218
   Karkkainen MUM, 2001, AM J CLIN NUTR, V74, P335
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lewis JR, 2012, J BONE MINER RES, V27, P719, DOI 10.1002/jbmr.1484
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Mann M, 2005, EUR J NEUROSCI, V22, P2735, DOI 10.1111/j.1460-9568.2005.04475.x
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   REID IR, 1986, AUST NZ J MED, V16, P193, DOI 10.1111/j.1445-5994.1986.tb01147.x
   Satia-Abouta J, 2003, AM J EPIDEMIOL, V157, P944, DOI 10.1093/aje/kwg039
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   ULSHAFER RJ, 1987, INVEST OPHTH VIS SCI, V28, P683
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wang SY, 2013, CURR EYE RES, V38, P1049, DOI 10.3109/02713683.2013.803124
   Wang SY, 2012, INVEST OPHTH VIS SCI, V53, P725, DOI 10.1167/iovs.11-9038
   Wojda U, 2008, IUBMB LIFE, V60, P575, DOI 10.1002/iub.91
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiao Q, 2013, JAMA INTERN MED, V173, P639, DOI 10.1001/jamainternmed.2013.3283
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
NR 34
TC 15
Z9 15
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2015
VL 133
IS 7
BP 746
EP 754
DI 10.1001/jamaophthalmol.2015.0514
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM6TO
UT WOS:000357823100021
PM 25856252
OA Bronze
DA 2022-11-30
ER

PT J
AU Simao, JM
   Farinha, CV
   Marques, JP
   Nunes, S
   Pires, IM
   Cachulo, ML
   Figueira, JP
   Murta, JN
   Silva, RM
AF Simao, Jorge M.
   Farinha, Claudia V.
   Marques, Joao P.
   Nunes, Sandrina
   Pires, Isabel M.
   Cachulo, Maria L.
   Figueira, Joao P.
   Murta, Joaquim N.
   Silva, Rufino M.
TI Polypoidal Choroidal Vasculopathy in Caucasians: Morphological Findings
   from Multimodal Retinal Imaging
SO OPHTHALMOLOGICA
LA English
DT Article
DE Choroid diseases; diagnosis; Choroidal neovascularization;
   classification; Choroidal neovascularization; diagnosis; Polyps;
   diagnosis; Retinal vessels; pathology
ID MACULAR DEGENERATION; EVEREST
AB Purpose: The aim of the study was to characterize the morphological features of polypoidal choroidal vasculopathy (PCV) in a large Caucasian population. Methods: We conducteda multicenter, cross-sectional study of treatment-naive patients with PCV. Baseline fundus photography, spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), and indocyanine green angiography (ICGA) were assessed by trained medical graders. Typical PCV features were explored, and retinal thickness (RT) and choroidal thickness (CT) measurements were performed. Results: Seventy-nine eyes of 73 patients (mean age, 72.6 +/- 11.9 years) were included. ICGA identified macular polyps in 89.9% of cases. SD-OCT revealed mostly subretinal fluid (93.6%) and a retinal pigment epithelium (RPE) detachment in 91.4%, with sharp protrusion in 67.0% of cases. Polyp-like structures were seen in 74.3% of cases, mostly adherent to an elevated RPE (69.6%). Type 1 neovascularization (NV) was identified in 74.7% of patients, while 16.5% had a mixed NV. The mean macular CT was 220.9 +/- 83.2 mu m (range, 67.9-403.6). Diffuse and focal pachychoroid were observed in 26.6 and 30.4% of patients, respectively. Soft drusen were reported in 62.0% of cases, but retinal hemorrhage occurred in only 19.0% of cases. Conclusion: The morphological features of PCV in Caucasians are similar to those reported in Asians. Pachychoroid signs were found in nearly half of our cohort. However, the mean age at presentation, high prevalence of soft drusen, and low prevalence of large subretinal hemorrhages make PCV closer to age-related macular degeneration in this ethnic group.
C1 [Simao, Jorge M.; Farinha, Claudia V.; Marques, Joao P.; Pires, Isabel M.; Cachulo, Maria L.; Figueira, Joao P.; Murta, Joaquim N.; Silva, Rufino M.] Ctr Hosp & Univ Coimbra CHUC, Dept Ophthalmol, Coimbra, Portugal.
   [Simao, Jorge M.; Farinha, Claudia V.; Marques, Joao P.; Nunes, Sandrina; Pires, Isabel M.; Cachulo, Maria L.; Figueira, Joao P.; Murta, Joaquim N.; Silva, Rufino M.] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Farinha, Claudia V.; Marques, Joao P.; Pires, Isabel M.; Cachulo, Maria L.; Figueira, Joao P.; Murta, Joaquim N.; Silva, Rufino M.] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal.
   [Marques, Joao P.; Murta, Joaquim N.; Silva, Rufino M.] Clin Acad Ctr Coimbra CACC, Coimbra, Portugal.
   [Murta, Joaquim N.; Silva, Rufino M.] Univ Coimbra, Ctr Innovat Biomed& Biotechnol CIBB, Coimbra, Portugal.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Universidade de Coimbra; Universidade
   de Coimbra; Universidade de Coimbra
RP Simao, JM (通讯作者)，Ctr Hosp & Univ Coimbra CHUC, Dept Ophthalmol, Coimbra, Portugal.; Simao, JM (通讯作者)，Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
EM jorgemsimao@gmail.com
RI Marques, João Pedro/J-3584-2012
OI Marques, João Pedro/0000-0002-1014-0483
FU EVICR.net; Bayer
FX This study was an investigator-initiated study financially supported by
   Bayer and sponsored by EVICR.net.
CR Alasil Tarek, 2017, Int J Retina Vitreous, V3, P9, DOI 10.1186/s40942-017-0060-4
   Bressler V., 2019, JAMA OPHTHALMOL, V137
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Gharehbagh SS, 2018, ACTA OPHTHALMOL, V96, pE94, DOI 10.1111/aos.13461
   Kim J-B., 2018, CURR OPHTHALMOL REP, V5
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai K., 2018, OPHTHALMIC SURG LASE, V49
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liew G, 2021, EYE, V35, P1011, DOI 10.1038/s41433-020-0834-z
   Lorentzen TD, 2018, ACTA OPHTHALMOL, V96, P475, DOI 10.1111/aos.13646
   Marques JP, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015785
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 31
TC 1
Z9 1
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD SEP
PY 2021
VL 244
IS 4
BP 315
EP 325
DI 10.1159/000515295
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UL6QG
UT WOS:000692773000007
DA 2022-11-30
ER

PT J
AU Oshima, Y
   Shinojima, A
   Sawa, M
   Mori, R
   Sekiryu, T
   Kato, A
   Hara, C
   Saito, M
   Sugano, Y
   Hirano, Y
   Asato, H
   Nakamura, M
   Kimura, E
   Yuzawa, M
   Ishibashi, T
   Ogura, Y
   Iida, T
   Gomi, F
   Yasukawa, T
AF Oshima, Yuji
   Shinojima, Ari
   Sawa, Miki
   Mori, Ryusaburo
   Sekiryu, Tetsuju
   Kato, Aki
   Hara, Chikako
   Saito, Masaaki
   Sugano, Yukinori
   Hirano, Yoshio
   Asato, Hitomi
   Nakamura, Mayumi
   Kimura, Erika
   Yuzawa, Mitsuko
   Ishibashi, Tatsuro
   Ogura, Yuichiro
   Iida, Tomohiro
   Gomi, Fumi
   Yasukawa, Tsutomu
TI Progression of age-related macular degeneration in eyes with abnormal
   fundus autofluorescence in a Japanese population: JFAM study report 3
SO PLOS ONE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; FELLOW EYES; INTRAVITREAL
   AFLIBERCEPT; COST-EFFECTIVENESS; RISK-FACTORS; 2ND EYE; RANIBIZUMAB;
   PATTERNS; ONSET
AB Purpose
   To evaluate the progression of early age-related macular degeneration to neovascular age-related macular degeneration (nAMD), and identify the abnormal fundus autofluorescence (FAF) patterns and markers of choroidal neovascularization (CNV) in fellow eyes of patients with unilateral nAMD.
   Methods
   Sixty-six patients with unilateral nAMD who developed abnormal FAF in the fellow eyes were enrolled in this multicenter, prospective, observational study, and followed-up for 5 years. FAF images on Heidelberg Retina Angiogram Digital Angiography System (HRA) or HRA2 were classified into eight patterns based on the International Fundus Autofluorescence Classification Group system. The patients in which the fellow eyes progressed to advanced nAMD, including those who did not develop nAMD, were assessed based on the following factors: baseline FAF patterns, age, sex, visual acuity, drusen, retinal pigmentation, baseline retinal sensitivity, family history, smoking, supplement intake, hypertension, body mass index, and hematological parameters.
   Results
   Of the 66 patients, 20 dropped out of the study. Of the remaining 46 patients, 14 (30.42%, male: 9, female: 5) progressed to nAMD during the 5-year follow-up. The most common (50% eyes) FAF pattern in the fellow eyes was the patchy pattern. According to the univariate analysis, CNV development was significantly associated with age, supplement intake, and low-density lipoprotein levels (p<0.05). Multivariable analysis revealed that patients who showed non-compliance with the supplement intake were more likely to develop nAMD (p<0.05). No significant association was found between the patchy pattern and CNV development (p = 0.86).
   Conclusion
   The fellow eyes (with abnormal FAF) of patients with unilateral nAMD may progress from early to advanced nAMD. However, no FAF pattern was found that predicted progression in nAMD.
C1 [Oshima, Yuji; Asato, Hitomi; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Oshima, Yuji] Fukuoka Dent Coll, Dept Med, Sect Ophthalmol, Fukuoka, Japan.
   [Shinojima, Ari; Mori, Ryusaburo; Yuzawa, Mitsuko] Nihon Univ, Dept Visual Sci, Div Ophthalmol, Sch Med, Tokyo, Japan.
   [Shinojima, Ari] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Sawa, Miki; Hara, Chikako; Gomi, Fumi] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Suita, Osaka, Japan.
   [Sekiryu, Tetsuju; Saito, Masaaki; Sugano, Yukinori; Iida, Tomohiro] Fukushima Med Univ, Dept Ophthalmol, Sch Med, Fukushima, Japan.
   [Kato, Aki; Hirano, Yoshio; Ogura, Yuichiro; Yasukawa, Tsutomu] Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Saito, Masaaki] Akita Univ, Grad Sch Med, Dept Ophthalmol, Akita, Japan.
   [Saito, Masaaki] Akita Univ, Fac Med, Akita, Japan.
   [Nakamura, Mayumi; Kimura, Erika] Santen Pharmaceut Co Ltd, Ikoma, Japan.
   [Kimura, Erika] Santen SERI Open Innovat Ctr, Singapore, Singapore.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Gomi, Fumi] Hyogo Coll Med, Dept Ophthalmol, Nishinomiya, Hyogo, Japan.
C3 Kyushu University; Fukuoka Dental College (FDC); Nihon University; Keio
   University; Osaka University; Fukushima Medical University; Nagoya City
   University; Akita University; Akita University; Santen Pharmaceutical Co
   Ltd; Tokyo Women's Medical University; Hyogo College of Medicine
RP Yasukawa, T (通讯作者)，Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Nagoya, Aichi, Japan.
EM yasukawa@med.nagoya-cu.ac.jp
OI Shinojima, Ari/0000-0003-2322-0332
FU JSPS KAKENHI [21K09677]
FX This study was funded by the JSPS KAKENHI Grant Number (Kiban C 21K09677
   (to Y. O.). The funders had no role in study design, data collection and
   analysis, decision to publish, and prepared of the manuscript.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Batioglu F, 2014, OPTOMETRY VISION SCI, V91, P950, DOI 10.1097/OPX.0000000000000321
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hernandez L, 2018, J MANAG CARE SPEC PH, V24, P608, DOI 10.18553/jmcp.2018.24.7.608
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shinojima A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229694
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Yanagi Y, 2017, J MED ECON, V20, P204, DOI 10.1080/13696998.2016.1245196
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yasukawa T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213161
NR 33
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 25
PY 2022
VL 17
IS 2
AR e0264703
DI 10.1371/journal.pone.026470
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 0U7EE
UT WOS:000787811000135
PM 35213672
DA 2022-11-30
ER

PT J
AU Shastry, BS
AF Shastry, BS
TI Evaluation of the ABCR and glutathione peroxidase-3 genes in familial
   and sporadic cases of exudative age-related macular degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE degeneration; macula; allele; retina; exudative; mutation
ID PROMOTER POLYMORPHISM; LIPID-PEROXIDATION; MACULOPATHY; ASSOCIATION;
   SUSCEPTIBILITY; SEVERITY; RETINA; REGION; SCAN
AB Age-related macular degeneration (ARMD) is the most common cause of blindness in older patients and is a major health care epidemic in developed countries. The exact cause of ARMD is not known. It has been recently reported that heterozygous missense ABCR mutations are associated with age-related macular degeneration. In addition, one of the susceptible loci for maculopathy is on chromosome 5 that is very close to the plasma glutathione peroxidase (GPX) gene. Since the retina is highly sensitive to peroxidation and the GPX gene product protects cells from oxidative damage, and the fact that the ABCR gene is considered as a major disease gene in macular degeneration we reasoned that they might serve as candidate genes in a subset of ARMD cases. To test our hypothesis, we have carried out a pilot study by analyzing 8 exudative ARMD patients for allelic variations in the GPX gene and three statistically significant mutations in the ABCR gene (R943Q, G1961E and D2177N). Our analysis failed to identify the above three major alterations in the ABCR gene as well as mutations in the coding sequence of the GPX gene. However, we have been able to identify two polymorphic heterozygous mutations in the promoter region of the GPX gene in one sporadic patient. These mutations have not been seen in any other patients. On the other hand, when 28 individuals from 6 different ethnic backgrounds with no evidence of ARMD were analyzed, four of them showed the same alterations in the GPX promoter region. Although we cannot completely exclude the possibility of alterations in the coding regions of the GPX gene, the promoter mutation identified in the present study statistically may not be associated with this disease. However, it may be associated with other additive factors as might be expected for a complex disorder.
C1 Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.
C3 Oakland University
RP Shastry, BS (通讯作者)，Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.
EM sliastry@oakland.edu
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Baugh JA, 2002, GENES IMMUN, V3, P170, DOI 10.1038/sj.gene.6363867
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bream JH, 2002, GENES IMMUN, V3, P165, DOI 10.1038/sj.gene.6363870
   CASTORINA C, 1992, NEUROCHEM RES, V17, P599, DOI 10.1007/BF00968789
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Conley YP, 1999, AM J HUM GENET, V65, pA104
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   FERIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hoogendoorn B, 2003, HUM MOL GENET, V12, P2249, DOI 10.1093/hmg/ddg246
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Morahan G, 2002, LANCET, V360, P455, DOI 10.1016/S0140-6736(02)09676-9
   Rozet JM, 1999, MOL GENET METAB, V68, P310, DOI 10.1006/mgme.1999.2925
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   SHASTRY BS, 2002, RRD BIO BIO, V2, P99
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545
   YOSHIMURA S, 1994, GENE, V145, P293
NR 25
TC 0
Z9 0
U1 0
U2 0
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD OCT
PY 2004
VL 14
IS 4
BP 753
EP 757
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 857GI
UT WOS:000224104000041
PM 15375613
DA 2022-11-30
ER

PT J
AU Farinha, C
   Santos, T
   Santos, AR
   Lopes, M
   Alves, D
   Silva, R
   Cunha-Vaz, J
AF Farinha, Claudia
   Santos, Torcato
   Santos, Ana Rita
   Lopes, Marta
   Alves, Dalila
   Silva, Rufino
   Cunha-Vaz, Jose
TI OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION Identification of Choroidal Neovascularization Activity by
   Location and Quantification of Abnormal Fluid Under Anti-Vascular
   Endothelial Growth Factor Therapy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF therapy; neovascular age-related macular degeneration; OCT-L;
   OCTA; retinal edema
ID AFLIBERCEPT; OUTCOMES; TREAT
AB Purpose: To test optical coherence tomography leakage in the identification and quantification of choroidal neovascularization-related fluid, its change after anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration eyes and its relation to functional outcome. Methods: Prospective analysis of a cohort of neovascular age-related macular degeneration cases treated with 2.0-mg intravitreal aflibercept. Eyes included were analyzed before, 1-week, and 1-month after one injection. Best-corrected visual acuity was assessed using Early Treatment Diabetic Retinopathy Study method. Optical coherence tomography leakage maps depicting low optical reflectivity (LOR) sites were acquired with OCT Cirrus AngioPlex (Zeiss, Dublin, CA). The LOR area ratio was correlated to retinal thickness and best-corrected visual acuity. Optical coherence tomography angiography was simultaneously performed. Results: Twenty-two eyes of 18 patients with neovascular age-related macular degeneration were included. The LOR ratio of the full retina scan and retinal pigment epithelium-Bruch layer decreased from baseline to Month 1 (P < 0.05). Changes in retinal thickness and LOR ratio were positively correlated (P < 0.05). Best-corrected visual acuity change correlated with the outer segment layer LOR change (rho = -0.53, P = 0.014), and LOR was inferior in better responders (P = 0.021). Optical coherence tomography leakage identified eyes with recurrent fluid in the external layers. Conclusion: Optical coherence tomography leakage identified and quantified the fluid related to choroidal neovascularization activity. Low optical reflectivity change in the outer segment layer correlates with functional outcome and increasing LOR in the external layers may be a marker of early recurrence. Combining optical coherence tomography angiography and optical coherence tomography leakage allows both for choroidal neovascularization morphology and activity analysis.
C1 [Farinha, Claudia; Santos, Torcato; Santos, Ana Rita; Lopes, Marta; Alves, Dalila; Silva, Rufino; Cunha-Vaz, Jose] AIBILI Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Farinha, Claudia; Silva, Rufino] Coimbra Hosp & Univ Ctr CHUC, Dept Ophthalmol, Coimbra, Portugal.
   [Farinha, Claudia; Silva, Rufino; Cunha-Vaz, Jose] Univ Coimbra FMUC, Fac Med, Coimbra, Portugal.
   [Santos, Ana Rita] Polytech Inst Porto, Super Sch Hlth Technol, Porto, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Universidade de Coimbra; Polytechnic
   Institute of Porto
RP Cunha-Vaz, J (通讯作者)，AIBILI Azinhaga Santa Comba, Celas, P-3000548 Coimbra, Portugal.
EM cunhavaz@aibili.pt
RI santos, ana/GWV-5678-2022; Farinha, Claudia/R-1392-2017
OI Silva, Rufino/0000-0001-8676-0833; Cunha-Vaz, Jose/0000-0002-0947-9850;
   Farinha, Claudia/0000-0003-4596-0913; Santos,
   Torcato/0000-0003-1873-4320
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Cunha-Vaz J, 2017, OPHTHALMOL RETINA, V1, P395, DOI 10.1016/j.oret.2017.02.002
   Cunha-Vaz J, 2016, INVEST OPHTH VIS SCI, V57, P6776, DOI 10.1167/iovs.16-19999
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Farinha C, 2017, OPHTHALMOL RETINA, V1, P486, DOI 10.1016/j.oret.2017.03.004
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Santos AR, 2019, RETINA-J RET VIT DIS, V39, P52, DOI 10.1097/IAE.0000000000001905
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xie P, 2017, BRIT J OPHTHALMOL, V101, P1003, DOI 10.1136/bjophthalmol-2017-310155
NR 15
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2020
VL 40
IS 5
BP 881
EP 890
DI 10.1097/IAE.0000000000002470
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LL2HK
UT WOS:000531376000012
PM 30689620
OA Green Published
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Lesauskaite, V
   Sinkunaite-Marsalkiene, G
   Zaliuniene, D
   Zaliuniene, D
   Zaliaduonyte-Peksiene, D
   Mizariene, V
   Gustiene, O
   Jasinskas, V
   Jariene, G
   Tamosiunas, A
AF Liutkeviciene, Rasa
   Lesauskaite, Vaiva
   Sinkunaite-Marsalkiene, Giedre
   Zaliuniene, Dalia
   Zaliuniene, Dalia
   Zaliaduonyte-Peksiene, Diana
   Mizariene, Vaida
   Gustiene, Olivija
   Jasinskas, Vytautas
   Jariene, Giedre
   Tamosiunas, Abdonas
TI The Role of Matrix Metalloproteinases Polymorphisms in Age-Related
   Macular Degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; gene polymorphism; matrix
   metalloproteinases
ID BRUCHS MEMBRANE; MATRIX-METALLOPROTEINASE-9; MACULOPATHY; DISEASE;
   DRUSEN
AB Background: Matrix metalloproteinases (MMP) are responsible for the degradation of extracellular matrix components and play an important role in the physiological and pathological remodeling of tissues.
   Purpose: To assess the impact of MMP-2 Rs2285053 (C -> T), MMP-3 Rs3025039 (5A -> 6A), and MMP-9 Rs3918242 (C -> T) single nucleotide polymorphism on the development of early age-related macular degeneration (AMD). Methods: The study group comprised 148 patients with AMD, and the control group enrolled 526 randomly selected persons. The genotyping of MMP-3 Rs3025039, MMP-2 Rs2285053, and MMP-9 Rs3918242 was performed by using the real-time PCR method.
   Results: The frequency of the MMP-2 (-735) C/T and MMP-3 (-1171) 5A/6A genotypes did not differ significantly between the patients with AMD and the control group, while the MMP-9 (-1562) C/C genotype was more frequently detected in patients with AMD than the control group (73.7% vs. 64.6%, p = 0.048). Logistic regression analysis showed that the MMP-9 (-1562) C/C genotype increased the likelihood of developing early AMD (OR=1.51, 95% CI: 1.01-2.21; p=0.046). After the subdivision into the groups by age, a significant difference only in the frequency of the MMP-9 (-1562) C/C genotype was found comparing the AMD patients and the control group younger than 65 years (79.7% vs. 66.4%, p = 0.039).
   Conclusions: Only MMP-9 Rs3918242 (C -> T) single nucleotide polymorphism was found to play a significant role in the development of AMD, and the effect was more pronounced at the age of less than 65 years.
C1 [Liutkeviciene, Rasa; Zaliuniene, Dalia; Jasinskas, Vytautas] Lithuanian Univ Hlth Sci, Dept Ophthalmol, Med Acad, Neurosci Inst, Kaunas, Lithuania.
   [Lesauskaite, Vaiva; Sinkunaite-Marsalkiene, Giedre; Jariene, Giedre; Tamosiunas, Abdonas] Lithuanian Univ Hlth Sci, Inst Cardiol, Med Acad, Kaunas, Lithuania.
   [Zaliaduonyte-Peksiene, Diana; Mizariene, Vaida; Gustiene, Olivija] Lithuanian Univ Hlth Sci, Dept Cardiol, Med Acad, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Dept Ophthalmol, Med Acad, Eiveniu 2, Kaunas, Lithuania.
EM rliutkeviciene@gmail.com
RI Tamosiunas, Abdonas/AAD-4274-2021
OI Lesauskaite, Vaiva/0000-0003-2736-3111
FU PHS HHS [IR0IAG23522-01] Funding Source: Medline; Wellcome Trust
   [064947/Z/01/Z] Funding Source: Medline
CR Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 2011, AM J OPHTHALMOL, V132, P668
   Atkinson SJ, 2001, FEBS LETT, V491, P222, DOI 10.1016/S0014-5793(01)02204-9
   Belkhiri A, 1997, LAB INVEST, V77, P533
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Chaer RA, 2004, CARDIOLOGY, V101, P122, DOI 10.1159/000075993
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Dollery CM, 2006, CARDIOVASC RES, V69, P625, DOI 10.1016/j.cardiores.2005.11.003
   Elliot SJ, 2010, EXP EYE RES, V90, P10, DOI 10.1016/j.exer.2009.09.001
   FIOTTI N, 2007, GENET MED, V4, P272
   GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619
   Grabauskas Vilius, 2003, Medicina (Kaunas), V39, P1215
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lesauskaite V, 2006, GERONTOLOGY, V52, P40, DOI 10.1159/000089824
   Lesauskaite V, 2008, MEDICINA-LITHUANIA, V44, P386, DOI 10.3390/medicina44050050
   Lim CS, 2010, CURR VASC PHARMACOL, V8, P75, DOI 10.2174/157016110790226697
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   Ortak H, 2013, OPHTHALMIC GENET
   Peasey A, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-255
   PETEN EP, 1992, AM J PHYSIOL, V263, pF951, DOI 10.1152/ajprenal.1992.263.5.F951
   Samnegard A, 2005, J INTERN MED, V258, P411, DOI 10.1111/j.1365-2796.2005.01561.x
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Seitzman RL, 2008, AM J EPIDEMIOL, V167, P1217, DOI 10.1093/aje/kwn024
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang JH, 2011, HEART, V97, P1542, DOI 10.1136/heartjnl-2011-300342
   Wieczorek E, 2012, NEOPLASMA, V59, P237, DOI 10.4149/neo_2012_031
   Zeng Jun, 2004, Yan Ke Xue Bao, V20, P191
   Zeng RP, 2013, MOL VIS, V19, P729
NR 36
TC 17
Z9 20
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD JUN
PY 2015
VL 36
IS 2
BP 149
EP 155
DI 10.3109/13816810.2013.838274
PG 7
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA CK9FG
UT WOS:000356545400009
PM 24079541
DA 2022-11-30
ER

PT J
AU Wang, JC
   Zhang, HP
   Ji, J
   Wang, LX
   Lv, WX
   He, Y
   Li, X
   Feng, GY
   Chen, KN
AF Wang, Jingchao
   Zhang, Hongpeng
   Ji, Jing
   Wang, Lixuan
   Lv, Wenxin
   He, Yuan
   Li, Xuan
   Feng, Guangyu
   Chen, Kinon
TI A histological study of atherosclerotic characteristics in age-related
   macular degeneration
SO HELIYON
LA English
DT Article
DE Histology; Staining; Atherosclerotic vascular disease; Atherosclerosis;
   Blood vessel
ID CORONARY-ARTERY-DISEASE; CHOROIDAL BLOOD-FLOW; BRUCHS MEMBRANE; CAROTID
   ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; DRUSEN; PATHOGENESIS;
   ASSOCIATION; DEPOSITS; EYES
AB This study investigated the pathogenesis of age-related macular degeneration (AMD) using histological methods that are commonly used for atherosclerotic vascular disease (ASVD). 1 normal, 3 early dry AMD, and 1 late dry AMD eyes were obtained from the Lions Eye Bank of Oregon and systematically dissected. They were stained with hematoxylin and eosin, Oil red O, Masson, Elastica van Gieson, Alizarin red, and Prussian blue. Additionally, the normal and late dry AMD eyes were immunostained for a-smooth muscle actin, CD45, and CD68 with Nile red and DAPI. Correlations were found between severity of AMD and lipid accumulation in the deep sclera (+), numbers of drusen between the Bruch's membrane and retinal pigment epithelium (RPE) (+), amount of collagen in the deep sclera (+), and amount of elastin in the deep sclera (-) (P < 0.1). Geographic atrophy, RPE detachment, and abnormal capillary shape and distribution in the choriocapillaris were observed in the fovea of late AMD. There were no stenosis, plaque, hemorrhage, and calcification. Additionally, late AMD tended to have higher smooth muscle thicknesses of the choroidal vascular walls, lower numbers of T lymphocytes in the choroid, and higher numbers of macrophages near the RPE and in the choroid relative to normal (P < 0.1). Macrophages-derived foam cells were detected near the Bruch's membrane in late AMD. Therefore, the present study showed many histological characteristics of ASVD in AMD, which suggests an association between them; however, there were also some histological characteristics of ASVD that were not found in AMD, which indicates that there exist pathogenic differences between them. The results generally support the vascular model of AMD, but some details still need clarification.
C1 [Wang, Jingchao; Ji, Jing; Wang, Lixuan; Lv, Wenxin; He, Yuan; Li, Xuan; Feng, Guangyu; Chen, Kinon] Beihang Univ, Key Lab Biomech & Mech, Beijing Adv Innovat Ctr Biomed Engn, Minist Educ,Sch Biol Sci & Med Engn, Beijing 100083, Peoples R China.
   [Zhang, Hongpeng] Chinese Peoples Liberat Army Gen Hosp, Dept Vasc Surg, Beijing 100853, Peoples R China.
C3 Beihang University; Chinese People's Liberation Army General Hospital
RP Chen, KN (通讯作者)，Beihang Univ, Key Lab Biomech & Mech, Beijing Adv Innovat Ctr Biomed Engn, Minist Educ,Sch Biol Sci & Med Engn, Beijing 100083, Peoples R China.
EM chen0606@umn.edu
OI Ji, Jing/0000-0001-8165-1582
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOBRYSHEV YV, 1995, ATHEROSCLEROSIS, V118, P9, DOI 10.1016/0021-9150(95)05588-N
   BROEKHUYSE RM, 1975, OPHTHALMOLOGICA, V171, P82, DOI 10.1159/000307448
   BROEKHUYSE RM, 1972, BIOCHIM BIOPHYS ACTA, V280, P637, DOI 10.1016/0005-2760(72)90143-9
   Cano M, 2011, AM J PATHOL, V179, P850, DOI 10.1016/j.ajpath.2011.04.010
   Chen K, 2014, ANN BIOMED ENG, V42, P678, DOI 10.1007/s10439-013-0936-x
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   COX RH, 1981, HYPERTENSION, V3, P485, DOI 10.1161/01.HYP.3.4.485
   Falk E, 2006, J AM COLL CARDIOL, V47, pC7, DOI 10.1016/j.jacc.2005.09.068
   Fernandez AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201000
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Gaballa MA, 1998, HYPERTENSION, V32, P437, DOI 10.1161/01.HYP.32.3.437
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   GIDDENS DP, 1993, J BIOMECH ENG-T ASME, V115, P588, DOI 10.1115/1.2895545
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Hayden JM, 2002, J LIPID RES, V43, P26
   He Y., 2020, J MECH BEHAV BIOMED, V114
   Holzapfel GA, 2003, CISM COURSES LECT, P109
   Holzapfel GA, 2004, J BIOMECH ENG-T ASME, V126, P657, DOI 10.1115/1.1800557
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McLaren JE, 2011, PROG LIPID RES, V50, P331, DOI 10.1016/j.plipres.2011.04.002
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nilsson J, 1987, ACTA MED SCAND, V715, P31
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Orlandi A, 2006, ATHEROSCLEROSIS, V188, P221, DOI 10.1016/j.atherosclerosis.2006.01.018
   Otsuka F, 2015, ATHEROSCLEROSIS, V241, P772, DOI 10.1016/j.atherosclerosis.2015.05.011
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Possek E, 1905, OPHTHALMOLOGICA, V13, P779
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Salunke NV, 2001, J BIOMED MATER RES, V55, P236, DOI 10.1002/1097-4636(200105)55:2<236::AID-JBM1010>3.0.CO;2-F
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schultz DS, 2008, INVEST OPHTH VIS SCI, V49, P4232, DOI 10.1167/iovs.08-1970
   STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512
   Taniguchi H, 2015, OPHTHALMOLOGICA, V233, P128, DOI 10.1159/000371716
   TONIZZO M, 1994, INT ANGIOL, V13, P208
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Popele NM, 2001, STROKE, V32, P454, DOI 10.1161/01.STR.32.2.454
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang SB, 2015, BRIT J OPHTHALMOL, V99, P365, DOI 10.1136/bjophthalmol-2014-305793
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang ZH, 2018, J BIOMED MATER RES A, V106, P2151, DOI 10.1002/jbm.a.36417
NR 58
TC 2
Z9 2
U1 3
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
EI 2405-8440
J9 HELIYON
JI Heliyon
PD MAR
PY 2022
VL 8
IS 3
AR e08973
DI 10.1016/j.heliyon.2022.e08973
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 0N8ZF
UT WOS:000783119000006
PM 35252605
OA Green Published
DA 2022-11-30
ER

PT J
AU Yamagishi, T
   Koizumi, H
   Yamazaki, T
   Kinoshita, S
AF Yamagishi, Tetsuya
   Koizumi, Hideki
   Yamazaki, Taizo
   Kinoshita, Shigeru
TI Fundus Autofluorescence in Polypoidal Choroidal Vasculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; JAPANESE PATIENTS;
   CLINICAL CHARACTERISTICS; CHINESE PATIENTS; NEOVASCULARIZATION; LESIONS;
   FEATURES; EYES
AB Purpose: To investigate and compare the characteristics of fundus autofluorescence (FAF) in polypoidal choroidal vasculopathy (PCV) with those in typical neovascular age-related macular degeneration (AMD).
   Design: Retrospective, observational, consecutive case series.
   Participants: Ninety-two patients with PCV (92 affected eyes and 86 unaffected fellow eyes) and 31 patients with typical neovascular occult AMD with no classic choroidal neovascularization (31 affected eyes and 24 unaffected fellow eyes).
   Methods: All study eyes underwent FAF photography with a fundus camera-based system. The incidence and distribution of hypoautofluorescence, that is, the manifestation of retinal pigment epithelium (RPE) damages, were evaluated.
   Main Outcome Measures: The characteristic FAF findings in PCV.
   Results: In the affected eyes with PCV, the sites of the neovascular lesions showed 2 distinct FAF patterns: (1) the confluent hypoautofluorescence at the polypoidal lesions and (2) the granular hypoautofluorescence at the branching choroidal vascular networks. The confluent hypoautofluorescence, most of which was surrounded by a hyperautofluorescent ring, was seen in 74 eyes (80.4%) with PCV but was seen in no eyes with typical neovascular AMD (P < 0.001). The granular hypoautofluorescence was seen in 91 eyes (98.9%) with PCV and 27 eyes (87.1%) with typical neovascular AMD (P = 0.014). In addition, the eyes with PCV more frequently showed hypoautofluorescence outside the macular area than those with typical neovascular AMD (P = 0.021). In the unaffected fellow eyes, the hypoautofluorescence was more frequently observed in patients with PCV than in those with typical neovascular AMD, inside the macular area and in the entire FAF image (P = 0.012, P = 0.003, respectively).
   Conclusions: In eyes with PCV, the polypoidal lesions and the branching choroidal vascular networks appeared to affect the RPE and induce peculiar FAF findings. When compared with the patients with typical neovascular AMD, widespread RPE damage was more frequently observed in the patients with PCV, both in the affected eyes and in the unaffected fellow eyes.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:1650-1657 (C) 2012 by the American Academy of Ophthalmology.
C1 [Koizumi, Hideki] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6020841, Japan.
C3 Kyoto Prefectural University of Medicine
RP Koizumi, H (通讯作者)，Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6020841, Japan.
EM hidekoiz@koto.kpu-m.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology-Japan
   [22791676]
FX Supported in part by Grant No. 22791676 from the Ministry of Education,
   Culture, Sports, Science and Technology-Japan (Dr. Koizumi).
CR Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2011, OPHTHALMOLOGY, V118, P700, DOI 10.1016/j.ophtha.2010.08.017
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 22
TC 21
Z9 25
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2012
VL 119
IS 8
BP 1650
EP 1657
DI 10.1016/j.ophtha.2012.02.016
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 982YA
UT WOS:000307080100024
PM 22512987
DA 2022-11-30
ER

PT J
AU Zurdel, J
   Finckh, U
   Menzer, G
   Nitsch, RM
   Richard, G
AF Zurdel, J
   Finckh, U
   Menzer, G
   Nitsch, RM
   Richard, G
TI CST3 genotype associated with exudative age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CYSTATIN-C GENE; RETINAL-PIGMENT EPITHELIUM; ROD OUTER SEGMENTS; BEAVER
   DAM EYE; STARGARDT-DISEASE; AMYLOID ANGIOPATHY; ABCR; MACULOPATHY;
   INHIBITOR; CELLS
AB Aims: To determine whether allelic variants of the cystatin C gene CST3 are genetically associated with exudative age related macular degeneration (ARMD). Cystatin C is a cysteine protease inhibitor that regulates the activity of cathepsin S, a protease with central regulatory functions in retinal pigment epithelial cells.
   Methods: CST3 of 167 patients with exudative ARMD was genotyped by using polymerase chain reaction of genomic DNA and restriction enzyme digestion with Kspl and compared with those of 517 control subjects. Patients and controls were white.
   Results: There was a significant difference in genotype counts between patients and controls (chi(2) 7.158, df = 2; Fisher's exact test: p=0.037). There was no significant difference in allele frequencies between patients and controls and between controls from Germany, Switzerland, Italy, and United States. The significant difference in genotype counts between patients and controls could be explained completely by an excess of the homozygous CST3 genotype B/B in patients with exudative ARMD (6.6%) over controls (2.3%), suggesting an odds ratio for ARMD in association with CST3 B/B of 2.97 (95% CI: 1.28-6.86). The results also suggest a stronger association of B/B with ARMD in males than in females. However, in both males and females there was a similar and significant effect of CST3 B/B on disease Free survival assessed by Kaplan-Meier analysis. The mean disease free survival time in pooled males and females with genotypes A/A or A/B was 85 years (SE 1; 95% CI: 83-86) and 76 years (SE 2; 95% CI: 72-79) respectively in B/B homozygotes (log rank p = 0.0006).
   Conclusion: Genotyping data, the absence of a significant difference in allele frequencies between patients and controls, and survival analyses suggest an increased susceptibility for ARMD in CST3 B/B homozygotes. Therefore, CST3 B may be a recessive risk allele, significantly contributing to disease risk in up to 6.6% of German ARMD patients. Functional correlates of the allelic CST3 variants A and B remain to be investigated.
C1 Univ Hamburg, Univ Hosp Hamburg Eppendorf, Dept Ophthalmol, Hamburg, Germany.
   Univ Hamburg, Univ Hosp Hamburg Eppendorf, Inst Human Genet, Hamburg, Germany.
   Univ Hamburg, Univ Hosp Hamburg Eppendorf, Ctr Mol Neurobiol, Hamburg, Germany.
   Univ Zurich, Dept Psychiat Res, CH-8006 Zurich, Switzerland.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf;
   University of Hamburg; University Medical Center Hamburg-Eppendorf;
   University of Hamburg; University Medical Center Hamburg-Eppendorf;
   University of Zurich
RP Zurdel, J (通讯作者)，Univ Eye Hosp Hamburg Eppendorf, Martinistr 52, D-20246 Hamburg, Germany.
CR ABRAHAMSON M, 1994, P NATL ACAD SCI USA, V91, P1416, DOI 10.1073/pnas.91.4.1416
   Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BALBIN M, 1991, HUM GENET, V87, P751
   BARKA T, 1994, ANAT REC, V239, P343, DOI 10.1002/ar.1092390312
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cruickshanks K. J., 1997, Investigative Ophthalmology and Visual Science, V38, pS471
   De La Paz M. A., 1997, Investigative Ophthalmology and Visual Science, V38, pS796
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finckh U, 2000, ARCH NEUROL-CHICAGO, V57, P1579, DOI 10.1001/archneur.57.11.1579
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   IVY GO, 1989, ADV EXP MED BIOL, V266, P31
   KATUNUMA N, 1995, METHOD ENZYMOL, V251, P382, DOI 10.1016/0076-6879(95)51142-3
   KATZ ML, 1989, MECH AGEING DEV, V49, P23, DOI 10.1016/0047-6374(89)90065-1
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   LEVY E, 1989, J EXP MED, V169, P1771, DOI 10.1084/jem.169.5.1771
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Rakoczy PE, 1996, EXP EYE RES, V63, P159, DOI 10.1006/exer.1996.0104
   RAKOCZY PE, 1994, INVEST OPHTH VIS SCI, V35, P4100
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   ROSENFELD PJ, 1999, AGE RELATED MACULAR, P69
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Wasselius J, 2001, INVEST OPHTH VIS SCI, V42, P1901
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
NR 35
TC 57
Z9 61
U1 0
U2 4
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2002
VL 86
IS 2
BP 214
EP 219
DI 10.1136/bjo.86.2.214
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 519QN
UT WOS:000173737100021
PM 11815350
OA Bronze, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU de Massougnes, S
   Dirani, A
   Mantel, I
AF de Massougnes, Sophie
   Dirani, Ali
   Mantel, Irmela
TI GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT Factors Influencing the
   Treatment Response
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; ranibizumab; angiogenesis; antiangiogenic drugs;
   intravitreal injection; retinal pigment epithelial detachment; vascular
   endothelial growth factor; visual impairment; neovascular age-related
   macular degeneration
ID INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB TREATMENT; SUBRETINAL FLUID;
   TREATMENTS TRIALS; VEGF TRAP; BEVACIZUMAB; ACUITY; EYES; MORPHOLOGY;
   THERAPY
AB Purpose: To evaluate baseline and treatment factors influencing the response of pigment epithelial detachment (PED) in patients with treatment-naive neovascular agerelated macular degeneration after 1 year of intravitreal anti-vascular endothelial growth factor treatment.
   Methods: This retrospective consecutive case series study included 104 eyes (94 patients) with treatment-naive neovascular age-related macular degeneration and associated PED >150 mu m treated with aflibercept (n = 41) or ranibizumab (n = 63) for at least 1 year. Stepwise linear regression was used to assess factors influencing best-corrected visual acuity and PED response.
   Results: At 1 year, the best-corrected visual acuity improved from 20/63(+1) (60.8 +/- 15.9 Early Treatment of Diabetic Retinopathy Study letters) at baseline to 20/40(-1) (69.0 +/- 15.0 letters) (P = 0.001), and PED maximal height decreased from 370.8 +/- 205.6 mu m to 238.8 +/- 178.5 mu m (P = 0.001). Multivariate analysis revealed an association of the visual improvement with lower best-corrected visual acuity at baseline (P = 0.001), the presence of foveal subretinal fluid (P = 0.001), and female gender (P = 0.047). Pigment epithelial detachment height reduction was dependent on higher baseline PED height (P = 0.001) and treatment drug (P = 0.008).
   Conclusion: Visual improvement in neovascular age-related macular degeneration with PED was equally achieved with ranibizumab and aflibercept, influenced mainly by baseline best-corrected visual acuity and foveal subretinal fluid. Pigment epithelial detachment height reduction was influenced by baseline height and the treatment drug, favoring aflibercept for a stronger effect. The clinical significance of this result warrants further studies.
C1 [de Massougnes, Sophie; Dirani, Ali; Mantel, Irmela] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Fdn Asile Aveugles, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Jules Gonin Eye Hosp, 15 Ave France,Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cho HJ, 2016, RETINA-J RET VIT DIS, V36, P1851, DOI 10.1097/IAE.0000000000001009
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Guber J, 2014, OPEN OPHTHALMOL J, V8, P3, DOI 10.2174/1874364101408010003
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Klettner A, 2014, BRIT J OPHTHALMOL, V98, P1448, DOI 10.1136/bjophthalmol-2014-305105
   Major JC, 2015, CAN J OPHTHALMOL, V50, P373, DOI 10.1016/j.jcjo.2014.12.012
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wolf A, 2013, RETINA-J RET VIT DIS, V33, P1843, DOI 10.1097/IAE.0b013e318287d9be
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zinkernagel MS, 2016, OPHTHALMOLOGICA, V235, P42, DOI 10.1159/000441428
NR 43
TC 9
Z9 9
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2018
VL 38
IS 4
BP 717
EP 724
DI 10.1097/IAE.0000000000001613
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2BD
UT WOS:000440623400016
PM 28368974
DA 2022-11-30
ER

PT J
AU Songstad, AE
   Wiley, LA
   Duong, K
   Kaalberg, E
   Flamme-Wiese, MJ
   Cranston, CM
   Riker, MJ
   Levasseur, D
   Stone, EM
   Mullins, RF
   Tucker, BA
AF Songstad, Allison E.
   Wiley, Luke A.
   Khahn Duong
   Kaalberg, Emily
   Flamme-Wiese, Miles J.
   Cranston, Cathryn M.
   Riker, Megan J.
   Levasseur, Dana
   Stone, Edwin M.
   Mullins, Robert F.
   Tucker, Budd A.
TI Generating iPSC-Derived Choroidal Endothelial Cells to Study Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE induced pluripotent stem cells; choroidal endothelial cells; macular
   degeneration
ID SUBRETINAL IMPLANTATION; GENE; TRANSTHYRETIN; PREVALENCE; SURVIVAL;
   DIFFERENTIATION; THICKNESS
AB PURPOSE. Age-related macular degeneration (AMD), the most common cause of incurable blindness in the western world, is characterized by the dysfunction and eventual death of choroidal endothelial (CECs), RPE, and photoreceptor cells. Stem cell-based treatment strategies designed to replace photoreceptor and RPE cells currently are a major scientific focus. However, the success of these approaches likely also will require replacement of the underlying, supportive choroidal vasculature. The purpose of this study was to generate stem cell-derived CECs to develop efficient differentiation and transplantation protocols.
   METHODS. Dermal fibroblasts from the Tie2-GFP mouse were isolated and reprogrammed into two independent induced pluripotent stem cell (iPSC) lines via viral transduction of the transcription factors Oct4, Sox2, Klf4, and c-Myc. Tie2-GFP iPSCs were differentiated into CECs using a coculture method with either the RF6A CEC line or primary mouse CECs. Induced pluripotent stem cell-derived CECs were characterized via RT-PCR and immunocytochemistry for EC- and CEC-specific markers.
   RESULTS. Induced pluripotent stem cells generated from mice expressing green fluorescent protein (GFP) under control of the endothelial Tie2 promoter display classic pluripotency markers and stem cell morphology. Induced pluripotent stem cell-derived CECs express carbonic anhydrase IV, eNOS, FOXA2, PLVAP, CD31, CD34, ICAM-1, Tie2, TTR, VE-cadherin, and vWF.
   CONCLUSIONS. Induced pluripotent stem cell-derived CECs will be a valuable tool for modeling of choriocapillaris-specific insults in AMD and for use in future choroidal endothelial cell replacement approaches.
C1 [Songstad, Allison E.; Wiley, Luke A.; Kaalberg, Emily; Flamme-Wiese, Miles J.; Cranston, Cathryn M.; Riker, Megan J.; Stone, Edwin M.; Mullins, Robert F.; Tucker, Budd A.] Univ Iowa, Stephen A Wynn Inst Vis Res, Dept Ophthalmol & Visual Sci, Iowa City, IA 52246 USA.
   [Khahn Duong; Levasseur, Dana] Univ Iowa, Dept Internal Med, Iowa City, IA 52246 USA.
   [Stone, Edwin M.] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52246 USA.
C3 University of Iowa; University of Iowa; Howard Hughes Medical Institute;
   University of Iowa
RP Tucker, BA (通讯作者)，Univ Iowa, Stephen A Wynn Inst Vis Res, 375 Newton Rd,MERF 4156, Iowa City, IA 52246 USA.
EM budd-tucker@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891; Wiley, Luke/0000-0003-0136-2364;
   Tucker, Budd/0000-0003-2178-1742; Stone, Edwin M./0000-0003-3343-4414
FU Elmer and Sylvia Sramek Charitable Foundation; National Institutes of
   Health (NIH; Bethesda, MD, USA) [EY-024605, 1-DP2-OD007483-01]; Research
   to Prevent Blindness; Stephen A. Wynn Foundation; Carver College of
   Medicine; Holden Comprehensive Cancer Center; Iowa City Veteran's
   Administration Medical Center; NATIONAL EYE INSTITUTE [R01EY024605]
   Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL
   INSTITUTES OF HEALTH [DP2OD007483] Funding Source: NIH RePORTER
FX Supported in part by The Elmer and Sylvia Sramek Charitable Foundation,
   National Institutes of Health (NIH; Bethesda, MD, USA) Grants EY-024605
   and 1-DP2-OD007483-01, Research to Prevent Blindness, and The Stephen A.
   Wynn Foundation. The University of Iowa Central Microscopy Research
   Facility is a core resource supported by the Vice President for Research
   & Economic Development, the Holden Comprehensive Cancer Center, and the
   Carver College of Medicine. The Flow Cytometry Facility at the
   University of Iowa is a Carver College of Medicine/Holden Comprehensive
   Cancer Center core research facility at the University of Iowa,
   supported by user fees and the Carver College of Medicine, Holden
   Comprehensive Cancer Center, and Iowa City Veteran's Administration
   Medical Center.
CR Almeida DRP, 2015, JAMA OPHTHALMOL, V133, P297, DOI 10.1001/jamaophthalmol.2014.5168
   Baba T, 2009, INVEST OPHTH VIS SCI, V50, P3503, DOI 10.1167/iovs.08-2614
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Duong KL, 2014, EXP HEMATOL, V42, P761, DOI 10.1016/j.exphem.2014.05.005
   DWORK AJ, 1990, INVEST OPHTH VIS SCI, V31, P489
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Levasseur DN, 2003, BLOOD, V102, P4312, DOI 10.1182/blood-2003-04-1251
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   PINO RM, 1986, AM J ANAT, V177, P63, DOI 10.1002/aja.1001770108
   Rufaihah AJ, 2013, AM J TRANSL RES, V5, P21
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   SMITH SS, 1989, J HISTOCHEM CYTOCHEM, V37, P1497, DOI 10.1177/37.10.2506267
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Tosi J, 2009, OPHTHALMOLOGY, V116, P971, DOI 10.1016/j.ophtha.2008.10.032
   Tucker Budd A, 2014, J Stem Cell Res Ther, V3, P161
   Tucker BA, 2013, ELIFE, V2, DOI 10.7554/eLife.00824
   Tucker BA, 2013, STEM CELL TRANSL MED, V2, P16, DOI 10.5966/sctm.2012-0040
   Tucker BA, 2011, P NATL ACAD SCI USA, V108, pE569, DOI 10.1073/pnas.1108918108
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Tucker BA, 2010, BIOMATERIALS, V31, P9, DOI 10.1016/j.biomaterials.2009.09.015
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Yao J, 2015, TISSUE ENG PT A, V21, P1247, DOI [10.1089/ten.tea.2013.0720, 10.1089/ten.TEA.2013.0720]
NR 36
TC 27
Z9 28
U1 0
U2 11
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2015
VL 56
IS 13
BP 8258
EP 8267
DI 10.1167/iovs.15-17073
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB1BU
UT WOS:000368243800080
PM 26720480
OA Green Published
DA 2022-11-30
ER

PT J
AU Logan, C
   Lyzogubov, V
   Bora, N
   Bora, P
AF Logan, Connor
   Lyzogubov, Valeriy
   Bora, Nalini
   Bora, Puran
TI Role of Adiponectin Peptide I (APNp1) in Age-Related Macular
   Degeneration
SO BIOMOLECULES
LA English
DT Article
DE age related macular degeneration; adiponectin; adiponectin receptor;
   neovascularization; adeno-associated virus; topical administration
ID INDUCED CHOROIDAL NEOVASCULARIZATION; RECEPTOR 1; MOUSE MODEL; ADIPOR1;
   CELL; PROLIFERATION; EXPRESSION; TACHYPHYLAXIS; BEVACIZUMAB; INHIBITION
AB Age-related macular degeneration (AMD) is an eye disease that can cause central vision loss, particularly in the elderly population. There are 2 classes of AMD, wet-type and dry-type. Wet-type involves excess angiogenesis around the macula, referred to as choroidal neovascularization (CNV). This can result in leaky vessels, often causing more severe vision loss than dry-type AMD. Adiponectin peptide 1 (APNp1) has been shown to slow the progression of CNV. Here, we used a mouse model and FITC-labeled APNp1 to determine if APNp1 could be delivered effectively as an eye drop. Our experiment revealed that topically applied FITC-APNp1 could reach the macula of the eye, which is crucial for treating wet-type AMD. We also tested delivery of APNp1 via injection of an adeno-associated virus (AAV) vector in a mouse model of CNV. AAV is a harmless virus easy to manipulate and is very often used for protein or peptide deliveries. Results revealed an increase in the expression of APNp1 in the retina and choroid over a 28-day period. Finally, we investigated the mechanism by which APNp1 affects CNV by examining the expression of adiponectin receptor 1 (AdipoR1) and proliferating cell nuclear antigen (PCNA) in the retinal and choroidal tissue of the mouse eyes. AdipoR1 and PCNA were overexpressed in these tissues in mice with laser-induced CNV compared to naive mice. Based on our data shown here, we think it will enhance our understanding of APNp1 as a therapeutic agent for wet-type AMD and possible treatment alternatives that could be more beneficial for patients.
C1 [Logan, Connor; Lyzogubov, Valeriy; Bora, Nalini; Bora, Puran] Univ Arkansas Med Sci, Pat & Willard Walker Eye Res Ctr, Jones Eye Inst, Dept Ophthalmol, 4301 West Markham, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences
RP Bora, P (通讯作者)，Univ Arkansas Med Sci, Pat & Willard Walker Eye Res Ctr, Jones Eye Inst, Dept Ophthalmol, 4301 West Markham, Little Rock, AR 72205 USA.
EM pbora@uams.edu
OI Bora, Puran/0000-0003-4781-1217
FU University of Arkansas for Medical Sciences; Pat and Willard Walker Eye
   Research Center, Little Rock
FX This research was funded by grants from the University of Arkansas for
   Medical Sciences and the Pat and Willard Walker Eye Research Center,
   Little Rock, AR, 72205.
CR Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Bora PS, 2007, FEBS LETT, V581, P1977, DOI 10.1016/j.febslet.2007.04.024
   Cai XJ, 2010, CELL BIOL INT, V34, P163, DOI 10.1042/CBI20090013
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Forooghian F, 2010, INVEST OPHTH VIS SCI, V51, P2388, DOI 10.1167/iovs.09-4065
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funahashi T, 1999, INTERNAL MED, V38, P202, DOI 10.2169/internalmedicine.38.202
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hageman G.S., 2008, WEBVISION ORG RETINA
   Heiker JT, 2010, BIOL CHEM, V391, P1005, DOI 10.1515/BC.2010.104
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Ishikawa M, 2007, CANCER SCI, V98, P1120, DOI 10.1111/j.1349-7006.2007.00486.x
   Iwabu M, 2010, NATURE, V464, P1313, DOI 10.1038/nature08991
   Kaarniranta K, 2012, NEUROSCI LETT, V513, P233, DOI 10.1016/j.neulet.2012.02.050
   Kadowaki T, 2011, COLD SH Q B, V76, P257, DOI 10.1101/sqb.2012.76.010587
   Kanazawa I, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-51
   Kong FS, 2010, EXP EYE RES, V90, P546, DOI 10.1016/j.exer.2010.01.011
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lebherz C, 2008, J GENE MED, V10, P375, DOI 10.1002/jgm.1126
   Lee MH, 2008, BIOCHEMISTRY-US, V47, P11682, DOI 10.1021/bi801451f
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luo XH, 2009, J BONE MINER RES, V24, P1461, DOI [10.1359/jbmr.090227, 10.1359/JBMR.090227]
   Lyzogubov VV, 2012, BBA-MOL CELL RES, V1823, P1264, DOI 10.1016/j.bbamcr.2012.05.017
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Modenese A, 2019, INT ARCH OCC ENV HEA, V92, P1, DOI 10.1007/s00420-018-1355-y
   Nakayama S, 2008, BREAST CANCER RES TR, V112, P405, DOI 10.1007/s10549-007-9874-3
   Ogunwobi OO, 2008, MOL CELL ENDOCRINOL, V285, P43, DOI 10.1016/j.mce.2008.01.023
   Patel SA, 2012, ENDOCRINOLOGY, V153, P5231, DOI 10.1210/en.2012-1368
   Pierre P, 2009, HUM REPROD, V24, P2890, DOI 10.1093/humrep/dep292
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Shibata MA, 1998, TOXICOL PATHOL, V26, P177, DOI 10.1177/019262339802600121
   Tang YT, 2005, J MOL EVOL, V61, P372, DOI 10.1007/s00239-004-0375-2
   Tsukada T, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-107
   Turer AT, 2012, DIABETOLOGIA, V55, P2319, DOI 10.1007/s00125-012-2598-x
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Yamauchi T, 2007, NAT MED, V13, P332, DOI 10.1038/nm1557
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhu XL, 2013, PEPTIDES, V40, P34, DOI 10.1016/j.peptides.2012.11.017
   Zubilewicz A, 2001, INVEST OPHTH VIS SCI, V42, P488
NR 49
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD SEP
PY 2022
VL 12
IS 9
AR 1232
DI 10.3390/biom12091232
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 4Q8BL
UT WOS:000856302100001
PM 36139070
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Venhuizen, FG
   van Ginneken, B
   van Asten, F
   van Grinsven, MJJP
   Fauser, S
   Hoyng, CB
   Theelen, T
   Sanchez, CI
AF Venhuizen, Freerk G.
   van Ginneken, Bram
   van Asten, Freekje
   van Grinsven, Mark J. J. P.
   Fauser, Sascha
   Hoyng, Carel B.
   Theelen, Thomas
   Sanchez, Clara I.
TI Automated Staging of Age-Related Macular Degeneration Using Optical
   Coherence Tomography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE retinal image analysis; automated grading; OCT; AMD classification;
   machine learning
ID SD-OCT; SEGMENTATION; RANIBIZUMAB; DRUSEN; CLASSIFICATION; IMAGES; RISK
AB PURPOSE. To evaluate a machine learning algorithm that automatically grades age-related macular degeneration (AMD) severity stages from optical coherence tomography (OCT) scans.
   METHODS. A total of 3265 OCT scans from 1016 patients with either no signs of AMD or with signs of early, intermediate, or advanced AMD were randomly selected from a large European multicenter database. A machine learning system was developed to automatically grade unseen OCT scans into different AMD severity stages without requiring retinal layer segmentation. The ability of the system to identify high-risk AMD stages and to assign the correct severity stage was determined by using receiver operator characteristic (ROC) analysis and Cohen's kappa statistics (kappa), respectively. The results were compared to those of two human observers. Reproducibility was assessed in an independent, publicly available data set of 384 OCT scans.
   RESULTS. The system achieved an area under the ROC curve of 0.980 with a sensitivity of 98.2% at a specificity of 91.2%. This compares favorably with the performance of human observers who achieved sensitivities of 97.0% and 99.4% at specificities of 89.7% and 87.2%, respectively. A good level of agreement with the reference was obtained (kappa = 0.713) and was in concordance with the human observers (kappa = 0.775 and kappa = 0.755, respectively).
   CONCLUSIONS. A machine learning system capable of automatically grading OCT scans into AMD severity stages was developed and showed similar performance as human observers. The proposed automatic system allows for a quick and reliable grading of large quantities of OCT scans, which could increase the efficiency of large-scale AMD studies and pave the way for AMD screening using OCT.
C1 [Venhuizen, Freerk G.; van Ginneken, Bram; van Grinsven, Mark J. J. P.; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Diagnost Image Anal Grp, Nijmegen, Netherlands.
   [Venhuizen, Freerk G.; van Asten, Freekje; van Grinsven, Mark J. J. P.; Hoyng, Carel B.; Theelen, Thomas; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Fauser, Sascha] Cologne Univ, Eye Clin, Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Basel, Switzerland.
C3 Radboud University Nijmegen; Radboud University Nijmegen; University of
   Cologne; Roche Holding
RP Venhuizen, FG (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Radiol & Nucl Med, Diagnost Image Anal Grp, Postbus 9101, NL-6500 HB Nijmegen, Netherlands.
EM freerk.venhuizen@radboudumc.nl
RI van Asten, Freekje/P-6028-2015; van Ginneken, Bram/A-3728-2012;
   Gutierrez, Clara Isabel Sanchez/N-3580-2014; Theelen,
   Thomas/A-3192-2012; Venhuizen, Freerk/P-5736-2015
OI van Asten, Freekje/0000-0002-8141-4234; van Ginneken,
   Bram/0000-0003-2028-8972; Theelen, Thomas/0000-0001-9067-1171; 
FU Macula Degeneratie (MD) fonds; Landelijke Stichting voor Blinden en
   Slechtzienden (LSBS) fonds; Oogfonds through UitZicht
FX Supported by the following foundations: Macula Degeneratie (MD) fonds,
   Landelijke Stichting voor Blinden en Slechtzienden (LSBS) fonds, and
   Oogfonds that contributed funds through UitZicht. The funding
   organizations had no role in the design or conduct of this research.
   They provided unrestricted grants.
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Albarrak A, 2013, P 2013 INT C MED IM, P59
   ALTMAN NS, 1992, AM STAT, V46, P175, DOI 10.2307/2685209
   Aly M, 2011, C P IEEE INT IMAG P, P1121
   Avni U, 2011, IEEE T MED IMAGING, V30, P733, DOI 10.1109/TMI.2010.2095026
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chen CL, 2013, INVEST OPHTH VIS SCI, V54, P7317, DOI 10.1167/iovs.13-12806
   De Fauw Jeffrey, 2016, F1000Res, V5, P1573
   EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552
   Enders P, 2016, EYE, V30, P1072, DOI 10.1038/eye.2016.97
   Esmaeili Mahdad, 2016, J Med Signals Sens, V6, P166
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   FORGY EW, 1965, BIOMETRICS, V21, P768
   Ho TK, 1998, IEEE T PATTERN ANAL, V20, P832, DOI 10.1109/34.709601
   Hu ZH, 2012, IEEE T MED IMAGING, V31, P1900, DOI 10.1109/TMI.2012.2206822
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kafieh Raheleh, 2013, J Med Signals Sens, V3, P45
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Lee H., 2011, P 14 INT C ART INT S, P215, DOI DOI 10.1177/1753193410390845
   Lee KM, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.14
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Liu YY, 2011, INVEST OPHTH VIS SCI, V52, P8316, DOI 10.1167/iovs.10-7012
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Rifkin R, 2004, J MACH LEARN RES, V5, P101
   Romeny MH., 2003, FRONT END VISION MUL
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Serrano-Aguilar P, 2012, BRIT J OPHTHALMOL, V96, P503, DOI 10.1136/bjophthalmol-2011-300660
   Sivic J, 2009, IEEE T PATTERN ANAL, V31, P591, DOI 10.1109/TPAMI.2008.111
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   van de Ven JPH, 2012, AM J OPHTHALMOL, V154, P560, DOI 10.1016/j.ajo.2012.03.012
   Venhuizen FG, 2015, P SOC PHOTO-OPT INS
   Waldstein SM, 2015, BRIT J OPHTHALMOL, V99, P794, DOI 10.1136/bjophthalmol-2014-305573
   Yehoshua Zohar, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS6, DOI 10.3928/15428877-20101031-19
   Zhang Y., 2014, EURASIP J ADV SIG PR, V2014, P1, DOI DOI 10.1016/J.ENGGE0.2014.08.024
NR 44
TC 59
Z9 61
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2017
VL 58
IS 4
BP 2318
EP 2328
DI 10.1167/iovs.16-20541
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ET9SY
UT WOS:000400649600045
PM 28437528
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Howes, KA
   Liu, Y
   Dunaief, JL
   Milam, A
   Frederick, JM
   Marks, A
   Baehr, W
AF Howes, KA
   Liu, Y
   Dunaief, JL
   Milam, A
   Frederick, JM
   Marks, A
   Baehr, W
TI Receptor for advanced glycation end products and age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS; INFLAMMATORY RESPONSES;
   MULTILIGAND RECEPTOR; GENE-EXPRESSION; GRADING SYSTEM; IN-VITRO; CELLS;
   RAGE; RPE
AB PURPOSE. Advanced glycation end products ( AGE) exacerbate disease progression through two general mechanisms: modifying molecules and forming nondegradable aggregates, thus impairing normal cellular/tissue functions, and altering cellular function directly through receptor-mediated activation. In the present study receptor for AGE ( RAGE)-mediated cellular activation was evaluated in the etiology of human retinal aging and disease.
   METHODS. The maculas of human donor retinas from normal eyes and eyes with early age-related macular degeneration (AMD) and advanced AMD with geographic atrophy (GA) were assayed for AGE and RAGE by immunocytochemistry. Cultured ARPE-19 cells were challenged with known ligands for RAGE, AGE, and S100B, to test for activation capacity. Immunocytochemistry, real-time RT-PCR, immunoblot analysis, and the TUNEL assay were used to determine the consequences of RPE cellular activation.
   RESULTS. Little to no immunolabeling for AGE or RAGE was found in photoreceptor and RPE cell layers in normal retinas. However, when small drusen were present, AGE and RAGE were identified in the RPE or both the RPE and photoreceptors. In early AMD and GA, the RPE and remnant photoreceptor cells showed intense AGE and RAGE immunolabeling. Both AGE and S100B activated cultured RPE cells, as revealed by upregulated expression of RAGE, NFkappaB nuclear translocation, and apoptotic cell death.
   CONCLUSIONS. Immunolocalization of RAGE in RPE and photoreceptors coincided with AGE deposits and macular disease in aged, early AMD, and GA retinas. Further, AGE stimulated RAGE-mediated activation of cultured ARPE-19 cells in a dose-dependent fashion. AGE accumulation, as occurs with normal aging and in disease, may induce receptor-mediated activation of RPE/photoreceptor cells, contributing to disease progression in the aging human retinas.
C1 Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Salt Lake City, UT 84112 USA.
   Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.
   Univ Utah, Dept Neurobiol & Anat, Salt Lake City, UT USA.
   Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   Univ Toronto, Banting & Best Dept Med Res, Toronto, ON, Canada.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Utah System of Higher Education;
   University of Utah; University of Pennsylvania; Pennsylvania Medicine;
   University of Toronto
RP Howes, KA (通讯作者)，Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, 15N-2030E EIHG, Salt Lake City, UT 84112 USA.
EM kim.howes@hsc.utah.edu
FU NATIONAL EYE INSTITUTE [R03EY014120, R01EY008123] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY014120, EY08123] Funding Source: Medline
CR Alizadeh M, 2001, INVEST OPHTH VIS SCI, V42, P2706
   Basta G, 2002, CIRCULATION, V105, P816, DOI 10.1161/hc0702.104183
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Farboud B, 1999, MOL VIS, V5, pU1
   Fehrenbach H, 2001, HEPATOLOGY, V34, P943, DOI 10.1053/jhep.2001.28788
   Glomb MA, 2001, J BIOL CHEM, V276, P41638, DOI 10.1074/jbc.M103557200
   Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Handa JT, 1998, EXP EYE RES, V66, P411, DOI 10.1006/exer.1997.0442
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2419
   Hou FF, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351296
   Hui YY, 2001, DIABETOLOGIA, V44, P1310, DOI 10.1007/s001250100646
   Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200
   Lentsch Alex B., 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P59
   Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Miyata TR, 1998, KIDNEY INT, V54, P1290, DOI 10.1046/j.1523-1755.1998.00093.x
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Nagai R, 2000, DIABETES, V49, P1714, DOI 10.2337/diabetes.49.10.1714
   Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012
   Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002
   Shanmugam N, 2003, J BIOL CHEM, V278, P34834, DOI 10.1074/jbc.M302828200
   Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Stern DM, 2002, AGEING RES REV, V1, P1, DOI 10.1016/S0047-6374(01)00366-9
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Sun H, 2001, J BIOL CHEM, V276, P11766, DOI 10.1074/jbc.M010152200
   Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013
   Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200
   Uetama T, 2003, J CELL PHYSIOL, V197, P77, DOI 10.1002/jcp.10342
   Valencia JV, 2004, ANAL BIOCHEM, V324, P68, DOI 10.1016/j.ab.2003.09.013
   Wendt Thoralf, 2002, Curr Atheroscler Rep, V4, P228, DOI 10.1007/s11883-002-0024-4
   Winkler BS, 1999, MOL VIS, V5
   Yan SD, 2000, NAT MED, V6, P643, DOI 10.1038/76216
   YOENKURA H, 2003, BIOCHEM J, V370, P1097
NR 49
TC 97
Z9 123
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2004
VL 45
IS 10
BP 3713
EP 3720
DI 10.1167/iovs.04-0404
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 857YB
UT WOS:000224154800045
PM 15452081
DA 2022-11-30
ER

PT J
AU Azar, G
   Vasseur, V
   Lahoud, C
   Favard, C
   De Bats, F
   Cochereau, I
   Yachvitz, A
   Mauget-Faysse, M
AF Azar, Georges
   Vasseur, Vivien
   Lahoud, Corinne
   Favard, Catherine
   De Bats, Flore
   Cochereau, Isabelle
   Yachvitz, Amelie
   Mauget-Faysse, Martine
TI Polypoidal Choroidal Vasculopathy Diagnosis and Neovascular Activity
   Evaluation Using Optical Coherence Tomography Angiography
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID CLASSIFICATION
AB Purpose. To examine choroidal neovascularization (CNV) characteristics in patients with exudative age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV), using swept-source optical coherence tomography angiography (SS-OCTA), and investigate agreement with OCT B-scan, fundus fluorescein angiography (FFA), and indocyanine green angiography (ICGA) by two different examiners. Methods. This is a retrospective multicentric study that involved patients with a history of AMD and PCV. Examiner A, who had access to OCTA, B-scan OCT, FFA, and ICGA imaging, had to differentiate between AMD and PCV, study the activity of AMD using Coscas' criteria (active vs. quiescent), and categorize PCV subtypes, while examiner B had only access to OCTA. Then, the diagnostic concordance was assessed between both examiners. Results. A total of 27 patients (11 females (40.7%) and 16 males (59.3%), P=0.231) were included in the analysis. Among those, 13 patients presented with neovascular AMD and 14 patients with PCV. There were 92.3% of correct answers regarding appropriate diagnosis and lesion characterization among AMD patients, against 61.5% of correct answers among PCV patients. The overall interrater reliability agreement between examiners, using Cohen's kappa coefficient (kappa) was 0.70 (0.5082-0.8916). Disagreement was found with one active AMD misdiagnosed as inactive AMD, three inactive PCV misdiagnosed as inactive AMD, and one inactive PCV misdiagnosed as active AMD. Conclusion. SS-OCTA alone remains limited in some specific phenotypes of PCV, which suggests the ongoing role of B-scan OCT associated with FFA and ICGA in the diagnosis of these conditions.
C1 [Azar, Georges; Cochereau, Isabelle] Rothschild Ophthalmol Fdn, Anterior Segment Dept, 25 Rue Manin, F-75940 Paris 19, France.
   [Vasseur, Vivien; Favard, Catherine; Yachvitz, Amelie; Mauget-Faysse, Martine] Rothschild Ophthalmol Fdn, Ctr Clin Invest, 25 Rue Manin, F-75940 Paris 19, France.
   [Lahoud, Corinne] Holy Spirit Univ Kaslik USEK, Fac Med, Kaslik, Lebanon.
   [De Bats, Flore] Val dOuest Clin, Pole Vis Ctr, 39 Chemin Vernique, F-69130 Ecully, France.
RP Azar, G (通讯作者)，Rothschild Ophthalmol Fdn, Anterior Segment Dept, 25 Rue Manin, F-75940 Paris 19, France.
EM georgesazar@hotmail.com; vvasseur@for.paris; corinne.lahoud@gmail.com;
   cathfavard@gmail.com; gonzalez_flore@yahoo.fr; icochereau@for.paris;
   ayachvitz@for.paris; mgfaysse@me.com
CR Chan SY, 2018, RETINA-J RET VIT DIS, V38, P1187, DOI 10.1097/IAE.0000000000001702
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Carlo TE, 2019, RETINA-J RET VIT DIS, V39, P1343, DOI 10.1097/IAE.0000000000002139
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Fujimoto JG, 2000, NEOPLASIA, V2, P9, DOI 10.1038/sj.neo.7900071
   Fujita A, 2020, RETINA-J RET VIT DIS, V40, P2296, DOI 10.1097/IAE.0000000000002760
   Ho CPS, 2018, INDIAN J OPHTHALMOL, V66, P1727, DOI 10.4103/ijo.IJO_975_18
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Peiretti E, 2019, RETINA-J RET VIT DIS, V39, P1693, DOI 10.1097/IAE.0000000000002234
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
NR 22
TC 3
Z9 3
U1 3
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD NOV 16
PY 2021
VL 2021
AR 1637377
DI 10.1155/2021/1637377
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA XI4BL
UT WOS:000726059100002
PM 34825001
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Teo, KYC
   Joe, AW
   Nguyen, V
   Invernizzi, A
   Arnold, JJ
   Barthelmes, D
   Gillies, M
AF Teo, Kelvin Yi Chong
   Joe, Aaron W.
   Vuong Nguyen
   Invernizzi, Alessandro
   Arnold, Jennifer J.
   Barthelmes, Daniel
   Gillies, Mark
TI PREVALENCE AND RISK FACTORS FOR THE DEVELOPMENT OF PHYSICIAN-GRADED
   SUBRETINAL FIBROSIS IN EYES TREATED FOR NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; subretinal fibrosis
AB Purpose: To assess the prevalence and incidence of and risk factors for subretinal fibrosis (SRFi) in eyes with neovascular age-related macular degeneration (nAMD) that underwent vascular endothelial growth factor inhibitor treatment for up to 10 years.
   Methods: A cross-sectional and longitudinal analysis was performed on data from a neovascular age-related macular degeneration registry. The presence and location of SRFi were graded by the treating practitioner. Visual acuity, lesion characteristics (type, morphology, and activity), and treatment administered at each visit was recorded.
   Results: The prevalence of SRFi in 2,914 eyes rose from 20.4% at year interval 0-1 to 40.7% at year interval 9 to 10. The incidence in 1,950 eyes was 14.3% at baseline and 26.3% at 24 months. Independent characteristics associated with SRFi included poorer baseline vision (adjusted odds ratio 5.33 [95% confidence interval 4.66-7.61] for visual acuity <= 35 letters vs. visual acuity >= 70 letters, P < 0.01), baseline lesion size (adjusted odds ratio 1.08 [95% confidence interval 1.08-1.14] per 1000 mm, P = 0.03), lesion type (adjusted odds ratio 1.42 [95% confidence interval 1.17-1.72] for predominantly classic vs. occult lesions, P = 0.02), and proportion of active visits (adjusted odds ratio 1.58 [95% confidence interval 1.25-2.01] for the group with the highest level of activity vs. the lowest level of activity, P < 0.01).
   Conclusion: Subretinal fibrosis was found in 40% of eyes after 10 years of treatment. High rates of lesion activity, predominantly classic lesions, poor baseline vision, and larger lesion size seem to be independent risk factors for SRFi.
C1 [Teo, Kelvin Yi Chong] Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Teo, Kelvin Yi Chong] Singapore Eye Res Inst, Singapore, Singapore.
   [Teo, Kelvin Yi Chong; Joe, Aaron W.; Invernizzi, Alessandro] Sydney Eye Hosp, Sydney Eye Hosp Fdn, Sydney, NSW, Australia.
   [Joe, Aaron W.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
   [Vuong Nguyen; Gillies, Mark] Univ Sydney, Sydney, NSW, Australia.
   [Invernizzi, Alessandro] Univ Milan, Eye Clin, Dept Biomed & Clin Sci Luigi Sacco, Luigi Sacco Hosp, Milan, Italy.
   [Arnold, Jennifer J.] Marsden Eye Specialist, Penrith, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Zurich, Switzerland.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; University of British Columbia;
   University of Sydney; University of Milan; Luigi Sacco Hospital;
   University of Zurich; University Zurich Hospital
RP Teo, KYC (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM kelvin.teo.y.c@singhealth.com.sg
OI Teo, Kelvin/0000-0002-7458-7081
FU Royal Australian NZ College of Ophthalmologists Eye Foundation; National
   Health and Medical Research Council, Australia (NHMRC); Macula Disease
   Foundation, Australia; Walter and Gertrud Siegenthaler Foundation
   Zurich, Switzerland; Swiss National Foundation
FX Supported by a grant from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009), a grant from the National
   Health and Medical Research Council, Australia (NHMRC 2010-2012), and a
   grant from the Macula Disease Foundation, Australia. M. Gillies is a
   Sydney Medical Foundation Fellow and is supported by an NHMRC
   practitioner fellowship. D. Barthelmes was supported by the Walter and
   Gertrud Siegenthaler Foundation Zurich, Switzerland, and the Swiss
   National Foundation.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gonzalez-Buendia L, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0544-x
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Kent D, 2003, MOL VIS, V9, P747
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Parravano M, 2012, EUR J OPHTHALMOL, V22, P598, DOI 10.5301/ejo.5000087
   R Development Core Team, 2017, R LANGUAGE ENV STAT
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
NR 24
TC 14
Z9 14
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2020
VL 40
IS 12
BP 2285
EP 2295
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QI4NW
UT WOS:000618957100005
PM 32073543
DA 2022-11-30
ER

PT J
AU Lazzeri, S
   Orlandi, P
   Figus, M
   Fioravanti, A
   Cascio, E
   Di Desidero, T
   Agosta, E
   Canu, B
   Sartini, MS
   Danesi, R
   Nardi, M
   Bocci, G
AF Lazzeri, Stefano
   Orlandi, Paola
   Figus, Michele
   Fioravanti, Anna
   Cascio, Elisa
   Di Desidero, Teresa
   Agosta, Elisa
   Canu, Bastianina
   Sartini, Maria Sole
   Danesi, Romano
   Nardi, Marco
   Bocci, Guido
TI The rs2071559 AA VEGFR-2 Genotype Frequency Is Significantly Lower in
   Neovascular Age-Related Macular Degeneration Patients
SO SCIENTIFIC WORLD JOURNAL
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; SINGLE NUCLEOTIDE POLYMORPHISMS; GENE
   POLYMORPHISMS; ASSOCIATION; RISK; MACULOPATHY; ROTTERDAM; DISEASE;
   ERRORS; PREVALENCE
AB In this prospective, case-control genetic study, 120 consecutive neovascular age-related macular degeneration (AMD) cases and 78 controls were enrolled. Two SNPs (rs2071559 and rs1870377) of VEGF-A receptor-2 (VEGFR-2) gene were analyzed with the technique of Real-Time PCR to investigate a genetic link between AMD and VEGFR-2 gene polymorphisms in Italian patients. The frequency of the VEGFR-2 genotype rs2071559 AA was significantly lower (18.33%) in patients with AMD than in the control subjects (34.62%; P = 0.0095, chi-square test; P-corr = 0.038; OR = 0.42, 95% CI 0.22 to 0.82). In conclusion, although with the limitations of a small sample size and the few SNPs studied, this study demonstrates a lower frequency of VEGFR-2 rs2071559 AA genotype in an AMD patient population, suggesting future studies on the role VEGFR-2 SNPs.
C1 [Orlandi, Paola; Fioravanti, Anna; Cascio, Elisa; Di Desidero, Teresa; Agosta, Elisa; Canu, Bastianina; Danesi, Romano; Bocci, Guido] Univ Pisa, Dept Internal Med, Div Pharmacol & Chemotherapy, I-56125 Pisa, Italy.
   [Lazzeri, Stefano; Figus, Michele; Sartini, Maria Sole; Nardi, Marco] Univ Hosp, Ophthalmol Unit, I-56124 Pisa, Italy.
C3 University of Pisa; University of Pisa; Azienda Ospedaliero
   Universitaria Pisana
RP Bocci, G (通讯作者)，Univ Pisa, Dept Internal Med, Div Pharmacol & Chemotherapy, Via Roma 55, I-56125 Pisa, Italy.
EM g.bocci@med.unipi.it
RI Danesi, Romano/J-7239-2018; Figus, Michele/AAD-6850-2020; Bocci,
   Guido/AAC-7515-2022; Figus, Michele/AAA-9808-2019; Danesi,
   Romano/AAC-9410-2019
OI Danesi, Romano/0000-0002-4414-8934; Figus, Michele/0000-0003-2243-9033;
   Danesi, Romano/0000-0002-4414-8934; nardi, marco/0000-0003-3422-9498; Di
   Desidero, Teresa/0000-0002-5487-071X
FU University of Pisa (Fondi di Ateneo)
FX The authors would like to thank Professor Mario Del Tacca and Professor
   Franco Bocci. The study has been funded by the University of Pisa (Fondi
   di Ateneo, ex-60%) (to G. Bocci).
CR Agosta E., PHARMACOGEN IN PRESS
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cimino L, 2010, INVEST OPHTH VIS SCI, V51, P4447, DOI 10.1167/iovs.09-4669
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2006, OPHTHALMOLOGY, V113, P509, DOI 10.1016/j.ophtha.2006.01.018
   Fang AM, 2009, MOL VIS, V15, P2710
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gordon D, 2002, HUM HERED, V54, P22, DOI 10.1159/000066696
   Gordon D, 2003, Pac Symp Biocomput, P490
   Gordon D, 2001, AM J HUM GENET, V69, P371, DOI 10.1086/321981
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hansen TF, 2010, VIRCHOWS ARCH, V456, P251, DOI 10.1007/s00428-009-0878-8
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Pabst S, 2010, CHEST, V137, P156, DOI 10.1378/chest.09-1003
   Pasqualetti G, 2007, PHARMACOGENOMICS, V8, P49, DOI 10.2217/14622416.8.1.49
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Schneider BP, 2008, BREAST CANCER RES TR, V111, P157, DOI 10.1007/s10549-007-9755-9
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sobel E, 2002, AM J HUM GENET, V70, P496, DOI 10.1086/338920
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang Y, 2007, J AM COLL CARDIOL, V50, P760, DOI 10.1016/j.jacc.2007.04.074
NR 30
TC 8
Z9 8
U1 0
U2 1
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1537-744X
J9 SCI WORLD J
JI Sci. World J.
PY 2012
AR 420190
DI 10.1100/2012/420190
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 999LL
UT WOS:000308313700001
PM 22919317
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Moreno, TA
   Kim, SJ
AF Moreno, Tomas A.
   Kim, Stephen J.
TI Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of
   Age-Related Macular Degeneration: An Economic Disparity of Eye Health
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Anti-VEGF; Avastin; economic disparity; Lucentis; macular degeneration
ID INTRAVITREAL INJECTION; PHARMACOKINETICS; ENDOPHTHALMITIS; TRIAL
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, and the advent of anti-vascular endothelial growth factor agents (VEGF) has revolutionized treatment for neovascular AMD. Two of the most popular anti-VEGF agents, ranibizumab (Lucentis; Genentech/Roche) and bevacizumab (Avastin; Genentech/Roche), effectively treat neovascular AMD but have a substantial difference in price. Multiple level 1 trials have demonstrated that bevacizumab is noninferior to ranibizumab in the treatment of neovascular AMD and that both have similar safety profiles. The decision to use one drug over the other is multifactorial with influences from industry as well as individual physician biases. However, the additional billions spent on ranibizumab result in a large economic disparity that is not rationalized by cost effectiveness models.
C1 [Moreno, Tomas A.; Kim, Stephen J.] Vanderbilt Eye Inst, Dept Ophthalmol, 2311 Pierce Ave, Nashville, TN 37232 USA.
C3 Vanderbilt University
RP Kim, SJ (通讯作者)，Vanderbilt Eye Inst, Dept Ophthalmol, 2311 Pierce Ave, Nashville, TN 37232 USA.
EM skim30@gmail.com
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chase M, 2007, WALL STREET J
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Department of Health and Human Services, 2012, MED PAYM DRUGS US TR
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Genentech Inc, NEW ENGLAND J MED
   George Williams, 2015, COMPREHENSIVE OPHTHA
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Goldstein J, 2008, WALL STREET J
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Harding SP, 2010, EYE, V24, P497, DOI 10.1038/eye.2009.316
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Jeng KW, 2014, RETINA-J RET VIT DIS, V34, P1796, DOI 10.1097/IAE.0000000000000182
   Kaufman Stephen R, 2010, Virtual Mentor, V12, P955, DOI 10.1001/virtualmentor.2010.12.12.oped1-1012
   Kim SJ, 2013, JAMA OPHTHALMOL, V131, P674, DOI 10.1001/jamaophthalmol.2013.2914
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Levinson DR, 2011, REV MED B
   Los M, 2007, ONCOLOGIST, V12, P443, DOI 10.1634/theoncologist.12-4-443
   Mantone J., 2007, WALL STREET J
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MICHELS S, 2004, RETIN PHYS, V1, P16
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Pollack A., 2010, NY TIMES
   Pollack A., 2007, NY TIMES
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spurling GK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000352
   Stein Joshua D, 2013, Trans Am Ophthalmol Soc, V111, P56
   Thomas A, 2014, NY TIMES
   Ubel PA, 2003, SOC SCI MED, V56, P1727, DOI 10.1016/S0277-9536(02)00167-3
   Ubel PA, 2003, ARCH INTERN MED, V163, P1637, DOI 10.1001/archinte.163.14.1637
   Whoriskey P, 2013, WASHINGTON POST
NR 47
TC 10
Z9 12
U1 0
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2016
VL 31
IS 4
SI SI
BP 378
EP 384
DI 10.3109/08820538.2016.1154174
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DT3SR
UT WOS:000381401700012
PM 27116030
DA 2022-11-30
ER

PT J
AU Tang, K
   Wang, W
   Wang, Q
   Wang, LQ
   Bai, H
   Jiang, YM
   Huang, YF
AF Tang, Kun
   Wang, Wei
   Wang, Qun
   Wang, Liqiang
   Bai, Hua
   Jiang, Yanming
   Huang, Yifei
TI Haplotypes of RHO polymorphisms and susceptibility to age-related
   macular degeneration
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Rhodopsin; age-related macular degeneration; haplotype; polymorphism
ID RHODOPSIN GENE; PREVALENCE; MUTATIONS
AB Objective: To investigate whether haplotypes of rhodopsin (RHO) polymorphisms including rs7984, rs2855552, rs2855557 and rs2410 were associated with age-related macular degeneration (AMD) risk in Chinese Han population. Methods: Genotypes of rs7984, rs2855552, rs2855557 and rs2410 were detected with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 186 cases and 196 healthy controls. Then, the haplotypes were established with Haploview 4.2 software. And the effects of clinical charactersitics on the frequency of GTTG haplotype were also analyzed. Odds ratios (ORs) with 95% confidence interval (95% CI) were utilized to assess the relationship of haplotypes and genotypes of RHO polymorphisms with susceptibility to AMD. Results: Genotype distribution of all polymorphisms in control group were all in agreement with HardyWeinberg equilibrium (HWE) (P> 0.05). In the analysis, we found that mutant alleles of rs7984 and rs2855557 were both associated with increased risk of AMD. For genotype analysis, rs7984 AA and rs2855557AA, rs2410GG genotypes all could increase the risk for AMD (OR= 1.905, 95% CI= 1.143-3.174; OR= 2.226, 95% CI= 1.261-3.932; OR= 2.073, 95% CI= 1.105-3.888). However, rs2855552 showed no effects on the onset of AMD. Compared with GTTA, the haplotypes of GGTG, ATAA and GTTG were all related with AMD susceptibility. Further analysis suggested that age, hypertension and hyperlipidemia history play important roles in the frequency alteration of GTTG haplotype. Conclusion: RHO polymorphisms (rs7984, rs2855557 and rs2410) and haplotypes may confer remarkable susceptibility to AMD. Further investigation showed that gene and environmental factors may work together in the pathogenesis of AMD.
C1 [Tang, Kun; Wang, Qun; Wang, Liqiang; Huang, Yifei] Gen Hosp Peoples Liberat Army, Dept Ophthalmol, Beijing 100853, Peoples R China.
   [Wang, Wei] Gen Hosp Beijing Command PLA, Dept Radiol, Beijing 100700, Peoples R China.
   [Bai, Hua] Gen Hosp Beijing Command PLA, Dept Ophthalmol, Beijing 100700, Peoples R China.
   [Jiang, Yanming] Second Artillery Gen Hosp, Dept Ophthalmol, Beijing 100088, Peoples R China.
RP Huang, YF (通讯作者)，Gen Hosp Peoples Liberat Army, Dept Ophthalmol, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM mabfegn-ba@126.com
RI Huang, Yifei/ABE-7566-2020; Tang, Kun/GSD-3218-2022; Huang,
   Yifei/ABE-4692-2020
OI Huang, Yifei/0000-0002-7089-6426
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Dryja TP, 2000, INVEST OPHTH VIS SCI, V41, P3124
   DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0
   DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GILBERT C, 1995, OPHTHALMIC GENET, V16, P1, DOI 10.3109/13816819509057847
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Katagiri S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/210947
   Ke XY, 2004, HUM MOL GENET, V13, P2557, DOI 10.1093/hmg/ddh294
   Kim KJ, 2006, GENOMICS, V88, P535, DOI 10.1016/j.ygeno.2006.03.003
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Natarajan S, 2011, INDIAN J OPHTHALMOL, V59, P343, DOI 10.4103/0301-4738.83608
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Stenkamp RE, 2005, ARCH PHARM, V338, P209, DOI 10.1002/ardp.200400995
   Stumpf MPH, 2004, EUR J HUM GENET, V12, P469, DOI 10.1038/sj.ejhg.5201179
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhang XL, 2006, LIFE SCI, V78, P1494, DOI 10.1016/j.lfs.2005.07.018
   Zhu WF, 2013, BIOTECHNOL LETT, V35, P515, DOI 10.1007/s10529-012-1115-0
NR 24
TC 2
Z9 3
U1 0
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 3
BP 3174
EP 3179
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA CJ2KD
UT WOS:000355312200103
PM 26045836
DA 2022-11-30
ER

PT J
AU Hara, C
   Sawa, M
   Gomi, F
   Nishida, K
AF Hara, Chikako
   Sawa, Miki
   Gomi, Fumi
   Nishida, Kohji
TI Questionnaire Survey on Driving among Patients with Age-Related Macular
   Degeneration in Japan
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; driving; questionnaire; signal colour;
   elderly persons
ID VISUAL-FIELD DEFECTS; CONTRAST SENSITIVITY; MOBILITY PERFORMANCE; CRASH
   INVOLVEMENT; OLDER DRIVERS; GLAUCOMA; RISK; MACULOPATHY; LUMINANCE
AB Purpose: This study aimed to assess driving capabilities in patients with exudative age-related macular degeneration (AMD) causing unilateral blindness or paracentral scotoma without vision deterioration. Methods: Of the 275 patients with AMD who responded to a questionnaire regarding car driving at Osaka University Hospital, we excluded 78 patients who answered that they had never driven. Finally, 197 patients were included (50 with bilateral and 142 with unilateral AMD). We investigated the relationship between the questionnaire findings and best-corrected visual acuity (BCVA). Results: The mean age was 74.8 +/- 6.9 years, and the mean BCVA in the right and left eyes were 0.48 and 0.47, respectively. A negative correlation was observed between the proportion of patients who stopped driving due to AMD and the vision in the worse eye (p < 0.0001); however, 66% of participants were still driving. Regardless of the BCVA, 84% of them wished to continue driving. Concerning perceived dangerous situations, all patients reported an oversight of people or signals and night driving; further, patients with unilateral and bilateral vision deterioration reported vision narrowness and difficulty with discerning signal colours, respectively. Conclusion: Despite the associated danger, patients with AMD continued driving. Close attention should be paid to the driving activities among patients with AMD, even if they have passed the relevant driving tests.
C1 [Hara, Chikako; Sawa, Miki; Gomi, Fumi; Nishida, Kohji] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Osaka 5650871, Japan.
   [Sawa, Miki] Sakai City Med Ctr, Dept Ophthalmol, Osaka 5938304, Japan.
   [Gomi, Fumi] Hyogo Coll Med, Dept Ophthalmol, Nishinomiya, Hyogo 6638501, Japan.
C3 Osaka University; Hyogo College of Medicine
RP Hara, C (通讯作者)，Osaka Univ, Grad Sch Med, Dept Ophthalmol, Osaka 5650871, Japan.
EM chikako.ueno@ophthal.med.osaka-u.ac.jp; sawamikimd@gmail.com;
   fgomi@hyo-med.ac.jp; knishida@ophthal.med.osaka-u.ac.jp
OI Hara, Chikako/0000-0001-9320-5408; Gomi, Fumi/0000-0003-0807-8817
FU y
FX We would like to thank Ryo Kawasaki (Osaka University) for statistical
   comparison. This research received no external funding.
CR Alexander L J, 1993, J Am Optom Assoc, V64, P822
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P788
   BROWN B, 1984, AM J OPTOM PHYS OPT, V61, P265
   Coeckelbergh TRM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1509, DOI 10.1001/archopht.120.11.1509
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   FISHMAN GA, 1981, BRIT J OPHTHALMOL, V65, P122, DOI 10.1136/bjo.65.2.122
   Freeman EE, 2008, OPHTHALMOLOGY, V115, P233, DOI 10.1016/j.ophtha.2007.04.050
   Friedman DS, 2007, OPHTHALMOLOGY, V114, P2232, DOI 10.1016/j.ophtha.2007.02.001
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Baselius NJH, 2021, ACTA OPHTHALMOL, V99, pE1360, DOI 10.1111/aos.14831
   Keay L, 2009, ACCIDENT ANAL PREV, V41, P995, DOI 10.1016/j.aap.2009.06.004
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McGwin G, 2005, INVEST OPHTH VIS SCI, V46, P4437, DOI 10.1167/iovs.05-0750
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881
   Owsley C, 2013, J GERONTOL A-BIOL, V68, P567, DOI 10.1093/gerona/gls185
   Pitta LSR, 2021, ARCH GERONTOL GERIAT, V95, DOI 10.1016/j.archger.2021.104414
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   SZLYK JP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1033, DOI 10.1001/archopht.1995.01100080085033
   SZLYK JP, 1992, ARCH OPHTHALMOL-CHIC, V110, P1709, DOI 10.1001/archopht.1992.01080240049027
   Tanabe S, 2011, INVEST OPHTH VIS SCI, V52, P4177, DOI 10.1167/iovs.10-6264
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 26
TC 1
Z9 1
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2021
VL 10
IS 21
AR 4845
DI 10.3390/jcm10214845
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA WX3UW
UT WOS:000718526000001
PM 34768365
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Subhi, Y
   Sorensen, TL
AF Subhi, Yousif
   Sorensen, Torben Lykke
TI Physical activity patterns in patients with early and late age-related
   macular degeneration
SO DANISH MEDICAL JOURNAL
LA English
DT Article
ID EYE DISEASE; MOBILITY; FEAR
AB INTRODUCTION: Age-related macular degeneration (AMD) leads to visual impairment that affects visual functioning and thereby the ability to be physically active. We investigated physical activity patterns in patients with AMD.
   METHODS: Patients with early and late AMD and elderly controls were recruited for this hospital-based cross-sectional study. All participants had their best-corrected visual acuity measured and were interviewed about their physical activity based on questions that covered regular physical activity, physical activity that would work up sweat, climbing the stairs and time spent on walking outdoors.
   RESULTS: We recruited 198 participants of whom 196 were eligible for inclusion in the analyses (68 controls, 25 with early AMD and 103 with late AMD). The frequency of regular physical activity did not differ between patients with early and late AMD and elderly controls. Lower best-corrected visual acuity in the best-seeing and the worse-seeing eye was associated with less engagement in physical activities that would work up sweat and a lower number of steps taken daily. Patients with bilateral vision loss from late AMD engaged in physical activities that were more controlled and less demanding of sharp central vision.
   CONCLUSION: Patients with late AMD may still be physically active even when the disease progresses and vision is lost, but activities may change into more controlled and less central vision-demanding ones.
C1 [Subhi, Yousif; Sorensen, Torben Lykke] Zealand Univ Hosp, Clin Eye Res Unit, Dept Ophthalmol, Roskilde, Denmark.
   [Subhi, Yousif; Sorensen, Torben Lykke] Univ Copenhagen, Dept Clin Med, Fac Hlth & Med Sci, DK-1168 Copenhagen, Denmark.
C3 University of Copenhagen
RP Subhi, Y (通讯作者)，Zealand Univ Hosp, Clin Eye Res Unit, Dept Ophthalmol, Roskilde, Denmark.; Subhi, Y (通讯作者)，Univ Copenhagen, Dept Clin Med, Fac Hlth & Med Sci, DK-1168 Copenhagen, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365
FU Lundbeck Foundation
FX The Lundbeck Foundation.
CR Acquadro C, 1996, QUALITY LIFE PHARMAC
   Curriero FC, 2013, JAMA OPHTHALMOL, V131, P1420, DOI 10.1001/jamaophthalmol.2013.4471
   Danish Health Authority, 2011, FYS AKT HANDB FOR BE
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Nguyen AM, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0062-8
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Rasul A, 2016, DAN MED J, V63
   SCHECHTMAN KB, 1991, AM J PUBLIC HEALTH, V81, P771, DOI 10.2105/AJPH.81.6.771
   Sengupta S, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-9
   Singh A, 2014, DAN MED J, V61
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Subhi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091227
   van Landingham SW, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-10
   Willis JR, 2013, JAMA OPHTHALMOL, V131, P1049, DOI 10.1001/jamaophthalmol.2013.316
NR 20
TC 5
Z9 5
U1 0
U2 2
PU DANISH MEDICAL ASSOC
PI COPENHAGEN
PA TRONDHJEMSGADE 9, DK-2100 COPENHAGEN, DENMARK
SN 2245-1919
J9 DAN MED J
JI Dan. Med. J.
PD NOV
PY 2016
VL 63
IS 11
AR A5303
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ED7HX
UT WOS:000389034700006
PM 27808038
DA 2022-11-30
ER

PT J
AU Scholl, HPN
   Dandekar, SS
   Peto, T
   Bunce, C
   Xing, W
   Jenkins, S
   Bird, AC
AF Scholl, HPN
   Dandekar, SS
   Peto, T
   Bunce, C
   Xing, W
   Jenkins, S
   Bird, AC
TI What is lost by digitizing stereoscopic fundus color slides for macular
   grading in age-related maculopathy and degeneration?
SO OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC-RETINOPATHY; OBSERVER; IMAGES; VARIABILITY; LESIONS
AB Objective: To compare 35-mm stereoscopic slide transparencies with digitized nonstereoscopic images (resolution 1024X768 pixels) for grading abnormalities in age-related maculopathy (ARM) and age-related macular degeneration (AMD).
   Design: Comparative observational case series.
   Participants: Twenty-five patients (50 eyes) with ARM and/or AMD.
   Methods. Twenty-five patients with ARM/AMD in at least 1 eye were randomly selected from a large ongoing collection of clinical data and DNA in a tertiary referral United Kingdom population. Retinal photography was performed with mydriasis using the Zeiss FF-series 30degrees fundus camera on Ektachrome slide transparency film. The images were centered on the macula. The color transparencies were then digitized. The grading process has been set up based on the International ARM Epidemiology Study Group. All images were independently graded by 3 retinal specialists. Both kappa statistics and exact agreement were calculated to assess agreement between and within observers and between the 2 master copies derived from the gradings of the color slides and digitized images.
   Main Outcome Measure: Agreement between the 2 master copies derived from the gradings obtained from stereoscopic slide transparencies and digitized nonstereoscopic images.
   Results: For small hard and intermediate soft drusen, agreement ranged between 77% and 91% (kappa, 0.56-0.72) and 83% and 93% (kappa, 0.31-0.64), respectively, for the 3 macular subfields. Agreement for the presence of hyperpigmentation was 12% to 56% (kappa, 0.00-0.27). Agreement was 94% to 96% (kappa, 0.80-0.82) for the presence of geographic atrophy and 93% (kappa, 0.78) for the area covered. For the presence of choroidal neovascularization (CNV), agreement was 94% to 98% (kappa, 0.81-0.88), and it was 95% (kappa, 0.83) for the area covered. For individual features of CNV, exact agreement was 88% to 96% (kappa, 0.22-0.49). In 3 cases of geographic atrophy and 2 cases of CNV, the lesion was missed on digitized images.
   Conclusions: Because of the close agreement for most categories between the grading of stereoscopic color slides and digitized images, digitized nonstereoscopic color images prove to be useful for grading ARM and AMD.
C1 Moorfields Eye Hosp, Inst Ophthalmol, London EC1 V2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Scholl, HPN (通讯作者)，Moorfields Eye Hosp, Inst Ophthalmol, 162 City Rd, London EC1 V2PD, England.
RI Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381; Bunce, Catey/0000-0002-0935-3713
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491
   George LD, 1997, DIABETIC MED, V14, P970, DOI 10.1002/(SICI)1096-9136(199711)14:11<970::AID-DIA484>3.0.CO;2-Y
   George LD, 1999, BRIT J OPHTHALMOL, V83, P911, DOI 10.1136/bjo.83.8.911
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lee MS, 2000, RETINA-J RET VIT DIS, V20, P275, DOI 10.1097/00006982-200005000-00008
   Lim JI, 2002, RETINA-J RET VIT DIS, V22, P59, DOI 10.1097/00006982-200202000-00011
   Lin D Y, 1999, Diabetes Technol Ther, V1, P477, DOI 10.1089/152091599317035
   Mainster MA, 1996, RETINA-J RET VIT DIS, V16, P1
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
NR 10
TC 26
Z9 27
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2004
VL 111
IS 1
BP 125
EP 132
DI 10.1016/j.ophtha.2003.05.003
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 760JA
UT WOS:000187806800020
PM 14711724
DA 2022-11-30
ER

PT J
AU Nguyen, V
   Barthelmes, D
   Gillies, MC
AF Nguyen, Vuong
   Barthelmes, Daniel
   Gillies, Mark C.
TI Neovascular age-related macular degeneration: A review of findings from
   the real-world Fight Retinal Blindness! registry
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE disease registry; neovascular age-related macular degeneration;
   real-world evidence; vascular endothelial growth factor inhibitors
ID PIGMENT EPITHELIAL TEARS; GROWTH-FACTOR THERAPY; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; VERTEPORFIN PHOTODYNAMIC THERAPY; EXTEND INTRAVITREAL
   THERAPY; ANTI-VEGF AGENTS; VISUAL-ACUITY; 12-MONTH OUTCOMES; ANGIOMATOUS
   PROLIFERATION; RANIBIZUMAB TREATMENT
AB The use of vascular endothelial growth factor (VEGF) inhibitors has revolutionised the treatment of neovascular age-related macular degeneration (nAMD) since the pivotal Phase III studies demonstrated their efficacy more than 10 years ago. The Fight Retinal Blindness! project was developed to track the treatment outcomes of patients with nAMD in real-world practice. Data from this registry have been used to answer several clinically relevant questions related to the treatment of nAMD including the effect of under-treatment, the comparative effectiveness of different anti-vascular endothelial growth factor agents, long-term treatment outcomes, identifying optimal treatment regimens and the rate and outcomes of rare adverse events. Observational studies are a valuable complement to the shortcomings of clinical trials and a combination of data from real-world settings and clinical trials are necessary to provide evidence on how to achieve the best outcomes for individual patients with nAMD.
C1 [Nguyen, Vuong; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Save Sight Inst, Sydney Med Sch, Discipline Ophthalmol, Sydney, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; University of Zurich; University Zurich Hospital
RP Gillies, MC (通讯作者)，Univ Sydney, Save Sight Inst, Sydney Med Sch, Discipline Ophthalmol, Sydney, NSW, Australia.
EM mark.gillies@sydney.edu.au
OI Nguyen, Vuong/0000-0001-9070-9803
FU RANZCO Eye Foundation; Australian National Health and Medical Research
   Council; Macular Disease Foundation Australia; Bayer; Novartis
FX The FRB project has been supported by grants from the RANZCO Eye
   Foundation, the Australian National Health and Medical Research Council,
   the Macular Disease Foundation Australia and unrestricted grants from
   Bayer and Novartis.
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Arts DGT, 2002, J AM MED INFORM ASSN, V9, P600, DOI 10.1197/jamia.M1087
   Barkmeier AJ, 2011, SEMIN OPHTHALMOL, V26, P94, DOI 10.3109/08820538.2011.571055
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Barthelmes D, 2015, BRIT J OPHTHALMOL, V99, P359, DOI 10.1136/bjophthalmol-2014-305514
   Bhandari S, 2020, OPHTHALMOLOGY, V127, P369, DOI 10.1016/j.ophtha.2019.10.006
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Daien V, 2020, BRIT J OPHTHALMOL, V104, P1064, DOI 10.1136/bjophthalmol-2019-315055
   Daien V, 2018, OPHTHALMOLOGY, V125, P66, DOI 10.1016/j.ophtha.2017.07.005
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Figueras-Roca M, 2021, GRAEF ARCH CLIN EXP, V259, P1463, DOI 10.1007/s00417-020-05016-9
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2017, OPHTHALMOLOGY, V124, pE31, DOI 10.1016/j.ophtha.2016.05.054
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P589, DOI 10.1016/j.ophtha.2014.10.001
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Invernizzi A, 2019, BRIT J OPHTHALMOL, V103, P1337, DOI 10.1136/bjophthalmol-2018-312944
   Invernizzi A, 2018, OPHTHALMOLOGY, V125, P237, DOI 10.1016/j.ophtha.2017.08.039
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Katkade VB, 2018, J MULTIDISCIP HEALTH, V11, P295, DOI 10.2147/JMDH.S160029
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Khurana RN, 2019, OPHTHALMOL RETINA, V3, P621, DOI 10.1016/j.oret.2019.04.013
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lestable L, 2020, J FR OPHTALMOL, V43, P761, DOI 10.1016/j.jfo.2019.11.016
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Nguyen V., 2020, RETINA-J RET VIT DIS, DOI [10.1097/IAE.0000000000003061, DOI 10.1097/IAE.0000000000003061]
   Nguyen V, 2019, OPHTHALMOL RETINA, V3, P623, DOI 10.1016/j.oret.2019.05.013
   Nguyen V, 2020, RETINA-J RET VIT DIS, V40, P866, DOI 10.1097/IAE.0000000000002485
   Razavi H, 2015, CLIN EXP OPHTHALMOL, V43, P707, DOI 10.1111/ceo.12658
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216
   Smith PG., 2015, FIELD TRIALS HLTH IN
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Spooner K, 2021, OPHTHALMOL RETINA, V5, P511, DOI 10.1016/j.oret.2020.09.019
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Talks J, 2019, SURV OPHTHALMOL, V64, P707, DOI 10.1016/j.survophthal.2019.02.008
   Teo KYC, 2020, RETINA-J RET VIT DIS, V40, P2285, DOI 10.1097/IAE.0000000000002779
   Teo KYC, 2020, OPHTHALMOL RETINA, V4, P871, DOI 10.1016/j.oret.2020.03.017
   Teo KYC, 2019, OPHTHALMOL RETINA, V3, P220, DOI 10.1016/j.oret.2018.11.003
   US Food and Drug Administration, 2017, USE REAL WORLD EVIDE
   Verbraak FD, 2021, ACTA OPHTHALMOL, V99, pE884, DOI 10.1111/aos.14712
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Vittorio AF, 2020, RETINA-J RET VIT DIS, V40, P1696, DOI 10.1097/IAE.0000000000002679
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Wiryasaputra S, 2020, CLIN EXP OPHTHALMOL, V48, P946, DOI 10.1111/ceo.13798
   Wolff B, 2020, CLIN EXP OPHTHALMOL, V48, P636, DOI 10.1111/ceo.13742
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
NR 89
TC 6
Z9 6
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD SEP
PY 2021
VL 49
IS 7
BP 652
EP 663
DI 10.1111/ceo.13949
EA JUN 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WA3UL
UT WOS:000664481600001
PM 34013534
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Choi, YJ
   Lim, D
   Byeon, SH
   Shin, EC
   Chung, H
AF Choi, Young Joon
   Lim, Daehan
   Byeon, Suk Ho
   Shin, Eui-Cheol
   Chung, Hyewon
TI Chemokine Receptor Profiles of T Cells in Patients with Age-Related
   Macular Degeneration
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE Age-related macular degeneration; T cells; chemokine receptor;
   chemokine; cytokine; aqueous humor
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; AQUEOUS-HUMOR; INFLAMMATION;
   EXPRESSION; GENERATION; SUBSETS; MEMORY; RISK
AB Purpose: To evaluate the expression of multiple chemokine receptors in peripheral blood T cells from patients with age-related macular degeneration (AMD).
   Materials and Methods: Peripheral blood mononuclear cells and/or aqueous humor were obtained from 24 AMD patients and 24 age- and sex-matched healthy controls. Chemokine receptor expression on T cells from peripheral blood was determined by multicolor flow cytometry. The levels of chemokines and cytokines in the aqueous humor from 12 AMD patients and six healthy controls were assessed.
   Results: AMD patients had increased expressions of CCR4 in CD4(+) T cells (p=0.007) and CRTh2 in CD8(+) T cells (p=0.002), and decreased expressions of CXCR3 in CD4(+) T cells (p=0.029) and CXCR3, CCR5, and CX(3)CR1 in CD8(+) T cells (p=0.005, 0.019, and 0.007, respectively). Monocyte chemoattractant protein-1 levels were increased in the aqueous humor from AMD patients (p=0.018), while the levels of interleukin (IL)-4 and IL-22 were significantly decreased compared to controls (p=0.018 and 0.041, respectively).
   Conclusion: The chemokine receptor profiles of T cells are altered in AMD patients compared to healthy controls without noticeable associations with chemokine levels in the aqueous humor. Further evaluation is needed to darify the role of these alterations in AMD pathogenesis.
C1 [Choi, Young Joon; Shin, Eui-Cheol] Korea Adv Inst Sci & Technol KAIST, Grad Sch Med Sci & Engn, Lab Immunol & Infect Dis, 291 Daehak Ro, Daejeon 34141, South Korea.
   [Choi, Young Joon] Ajou Univ, Dept Ophthalmol, Sch Med, Suwon, South Korea.
   [Lim, Daehan; Chung, Hyewon] Konkuk Univ, Dept Ophthalmol, Sch Med, Seoul, South Korea.
   [Byeon, Suk Ho] Yonsei Univ, Inst Vis Res, Dept Ophthalmol, Coll Med, Seoul, South Korea.
C3 Korea Advanced Institute of Science & Technology (KAIST); Ajou
   University; Konkuk University; Konkuk University Medical Center; Yonsei
   University; Yonsei University Health System
RP Shin, EC (通讯作者)，Korea Adv Inst Sci & Technol KAIST, Grad Sch Med Sci & Engn, Lab Immunol & Infect Dis, 291 Daehak Ro, Daejeon 34141, South Korea.; Chung, H (通讯作者)，Konkuk Univ, Med Ctr, Dept Ophthalmol, Sch Med, 120 Neungdong Ro, Seoul 05030, South Korea.
EM ecshin@kaist.ac.kr; hchung@kuh.ac.kr
FU Ministry of Science and ICT [NRF-2020R1A2C2101941]; new faculty research
   fund of Ajou University School of Medicine; National Research Foundation
   of Korea
FX This study was supported by the National Research Foundation of Korea
   and funded by the Ministry of Science and ICT (NRF-2020R1A2C2101941).
   This study was also supported by the new faculty research fund of Ajou
   University School of Medicine.
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Falk MK, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-22
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fujimura S, 2012, INVEST OPHTH VIS SCI, V53, P1999, DOI 10.1167/iovs.11-8232
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gerlach C, 2016, IMMUNITY, V45, P1270, DOI 10.1016/j.immuni.2016.10.018
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kara EE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003905
   Kohlmeier JE, 2011, J EXP MED, V208, P1621, DOI 10.1084/jem.20102110
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Liu F, 2016, MOL VIS, V22, P352
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   de Heredia FP, 2012, P NUTR SOC, V71, P332, DOI 10.1017/S0029665112000092
   Romagnani P, 2004, TRENDS IMMUNOL, V25, P201, DOI 10.1016/j.it.2004.02.006
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Seidler S, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-30
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
NR 40
TC 0
Z9 0
U1 1
U2 1
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD APR
PY 2022
VL 63
IS 4
BP 357
EP 364
DI 10.3349/ymj.2022.63.4.357
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0G6LS
UT WOS:000778154900007
PM 35352887
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Al Gwairi, O
   Thach, L
   Zheng, WH
   Osman, N
   Little, PJ
AF Al Gwairi, Othman
   Thach, Lyna
   Zheng, Wenhua
   Osman, Narin
   Little, Peter J.
TI Cellular and Molecular Pathology of Age-Related Macular Degeneration:
   Potential Role for Proteoglycans
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID VASCULAR SMOOTH-MUSCLE; ADULT HUMAN RETINA; BRUCHS MEMBRANE;
   DIFFERENTIAL DISTRIBUTION; APOLIPOPROTEIN-B; SERUM-LIPIDS; BIGLYCAN;
   DRUSEN; BINDING; PROTEIN
AB Age-related macular degeneration (AMD) is a retinal disease evident after the age of 50 that damages the macula in the centre of retina. It leads to a loss of central vision with retained peripheral vision but eventual blindness occurs in many cases. The initiation site of AMD development is Bruch's membrane (BM) where multiple changes occur including the deposition of plasma derived lipids, accumulation of extracellular debris, changes in cell morphology, and viability and the formation of drusen. AMD manifests as early and late stage; the latter involves cell proliferation and neovascularization in wet AMD. Current therapies target the later hyperproliferative and invasive wet stage whilst none target early developmental stages of AMD. In the lipid deposition disease atherosclerosis modified proteoglycans bind and retain apolipoproteins in the artery wall. Chemically modified trapped lipids are immunogenic and can initiate a chronic inflammatory process manifesting as atherosclerotic plaques and subsequent artery blockages, heart attacks, or strokes. As plasma derived lipoprotein deposits are found in BM in early AMD, it is possible that they arise by a similar process within the macula. In this review we consider aspects of the pathological processes underlying AMD with a focus on the potential role of modifications to secreted proteoglycans being a cause and therefore a target for the treatment of early AMD.
C1 [Al Gwairi, Othman; Osman, Narin; Little, Peter J.] RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic 3083, Australia.
   [Thach, Lyna; Little, Peter J.] Univ Queensland, Sch Pharm, Woolloongabba, Qld 4102, Australia.
   [Zheng, Wenhua] Univ Macau, Fac Hlth Sci, Taipa, Macau, Peoples R China.
   [Zheng, Wenhua] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Key Lab Ophthalmol, Guangzhou 510006, Guangdong, Peoples R China.
   [Osman, Narin] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia.
C3 Royal Melbourne Institute of Technology (RMIT); University of
   Queensland; University of Macau; Sun Yat Sen University; Monash
   University
RP Little, PJ (通讯作者)，RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic 3083, Australia.; Little, PJ (通讯作者)，Univ Queensland, Sch Pharm, Woolloongabba, Qld 4102, Australia.
EM p.little@uq.edu.au
RI Little, Peter J./F-9865-2015
OI Little, Peter J./0000-0002-0335-3835
FU Saudi Ministry of Higher Education
FX Othman Al Gwairi was supported by the Saudi Ministry of Higher
   Education.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ambreen F, 2014, J PAK MED ASSOC, V64, P664
   [Anonymous], 2006, EYE RES IMPACT AGE R
   Ballinger ML, 2010, J CELL MOL MED, V14, P1408, DOI 10.1111/j.1582-4934.2009.00902.x
   Ballinger ML, 2004, CELL MOL LIFE SCI, V61, P1296, DOI 10.1007/s00018-004-3389-4
   Barnett BR, 2013, GERONTOLOGY, V59, P297, DOI 10.1159/000346169
   Barzegar-Befroei N, 2012, RETINAL PHYS, V9, P20
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bressler NM, 2013, RETINA, P1183
   Burch ML, 2010, J BIOL CHEM, V285, P26798, DOI 10.1074/jbc.M109.092767
   Burch ML, 2010, CELL MOL LIFE SCI, V67, P2077, DOI 10.1007/s00018-010-0315-9
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dadlani H, 2008, J BIOL CHEM, V283, P7844, DOI 10.1074/jbc.M703125200
   Davari MH, 2013, J RES HEALTH SCI, V13, P98
   Elliott JG, 2012, OPTOMETRY, V83, P47, DOI 10.1016/j.optm.2011.11.006
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Getachew R, 2010, ENDOCRINOLOGY, V151, P4356, DOI 10.1210/en.2010-0027
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   Hohn A, 2013, J PROTEOMICS, V92, P132, DOI 10.1016/j.jprot.2013.01.004
   Hogg R., 2006, NUTR EYE, P205
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Huang YM, 2013, NUTRITION, V29, P387, DOI 10.1016/j.nut.2012.06.009
   Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5
   Ivey ME, 2008, THROMB RES, V123, P288, DOI 10.1016/j.thromres.2008.04.019
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   Khan M., 2014, MED J ARMED FORCES I, V70, P47
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kishan AU, 2013, INT J RADIAT ONCOL, V85, P583, DOI 10.1016/j.ijrobp.2012.07.2352
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Koike T, 2014, J BIOL CHEM, V289, P6695, DOI 10.1074/jbc.M113.520536
   Konstantinov IE, 2006, TEX HEART I J, V33, P417
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Little PJ, 2008, CURR OPIN LIPIDOL, V19, P448, DOI 10.1097/MOL.0b013e32830dd7c4
   Little PJ, 2007, VASC HEALTH RISK MAN, V3, P117
   Little PJ, 2013, J PHARM PHARMACOL, V65, P1055, DOI 10.1111/jphp.12064
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Querques G, 2014, SURV OPHTHALMOL, V59, P532, DOI 10.1016/j.survophthal.2014.01.001
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   Seddon JM, 2013, RETINA, P1134
   Toy B. C., 2013, AM J OPHTHALMOL, V156, P532
   Ueda-Arakawa N., 2013, AM J OPHTHALMOL, V155, P260
   Usha Chakravarthy J.E., 2010, BMJ-BRIT MED J, V340, P526
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yang SNY, 2010, J DIABETES, V2, P233, DOI 10.1111/j.1753-0407.2010.00089.x
   Yang Sundy N. Y., 2009, Archives of Physiology and Biochemistry, V115, P147, DOI 10.1080/13813450903110754
   Yang SNY, 2009, CLIN LIPIDOL, V4, P479, DOI 10.2217/CLP.09.37
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
   Zhang P., 2009, BIOSCIENCE HYPOTHESE, V2, P88
NR 72
TC 21
Z9 22
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2016
VL 2016
AR 2913612
DI 10.1155/2016/2913612
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DT4EH
UT WOS:000381432400001
PM 27563459
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Wormald, R
   Evans, J
   Smeeth, L
   Henshaw, K
AF Wormald, R.
   Evans, J.
   Smeeth, L.
   Henshaw, K.
TI Photodynamic therapy for neovascular age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   VERTEPORFIN THERAPY; VISUAL-ACUITY; TAP; OUTCOMES
AB Background In neovascular age-related macular degeneration (AMD) new vessels grow under the retina distorting vision and leading to scarring. This is exacerbated if the blood vessels leak. Photodynamic therapy (PDT) has been investigated as a way to treat the neovascular membranes without affecting the retina.
   Objectives The aim of this review was to examine the effects of PDT in the treatment of neovascular AMD.
   Search strategy We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which includes the Cochrane Eyes and Vision Group Trials Register) on The Cochrane Library (Issue 1, 2005), MEDLINE (1966 to January 2005), EMBASE (1980 to January 2005). We used the Science Citation Index to search for reports that cited relevant studies. We contacted experts in the field and searched the reference lists of relevant studies.
   Selection criteria We included randomised trials of PDT in people with choroidal neovascularisation due to AMD.
   Data collection and analysis Two authors independently extracted the data. Relative risks were combined using a fixed-effect model after testing for heterogeneity.
   Main results Two published trials were identified that randomised 948 participants to verteporfin therapy compared to 5% dextrose in water. Both trials were performed by the same investigators using largely the same clinical centres and funded by manufacturers of verteporfin. Outcome data were available at 12 and 24 months after the first treatment. Participants received on average five treatments over two years. The relative risk of losing three or more lines of visual acuity at 24 months comparing the intervention with the control group was 0.77 (95% confidence interval 0.69 to 0.87). The relative risk of losing six or more lines of visual acuity at 24 months comparing the intervention with the control group was 0.62 (95% confidence interval 0.50 to 0.76). The results at 12 months were similar to those at 24 months. The most serious adverse outcome, acute (within 7 days of treatment) severe visual acuity decrease, occurs in about one in 50 patients.
   Authors' conclusions Photodynamic therapy in people with choroidal neovascularisation due to AMD is probably effective in preventing visual loss though there is doubt about the size of the effect. Outcomes and potential adverse effects of this treatment should be monitored closely. Further independent trials of verteporfin are required to establish that the effects seen in this study are consistent and to examine important issues not yet addressed, particularly relating to quality of life and cost.
C1 Moorfields Eye Hosp, Dept Res & Dev, London EC1V 2PD, England.
   UCL, Inst Ophthalmol, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Wormald, R (通讯作者)，Moorfields Eye Hosp, Dept Res & Dev, City Rd, London EC1V 2PD, England.
EM r.wormald@ucl.ac.uk
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030
FU Medical Research Council [G108/492] Funding Source: Medline; MRC
   [G108/492] Funding Source: UKRI
CR Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bhavsar A, 2004, RETINA-J RET VIT DIS, V24, P512
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Borodoker N, 2002, AM J OPHTHALMOL, V133, P211, DOI 10.1016/S0002-9394(01)01341-1
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   Do DV, 2004, AM J OPHTHALMOL, V137, P558, DOI 10.1016/j.ajo.2003.08.001
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2
   Meads C, 2004, BRIT J OPHTHALMOL, V88, P212, DOI 10.1136/bjo.2003.019471
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Randolph CF, 1903, COLUMBIA LAW REV, V3, P168, DOI 10.2307/1109699
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001
NR 26
TC 30
Z9 30
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2005
IS 4
AR CD002030
DI 10.1002/14651858.CD002030.pub2
PG 23
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 096UK
UT WOS:000241402100113
PM 16235294
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Eandi, CM
   Giansanti, F
   Virgili, G
AF Eandi, Chiara M.
   Giansanti, Fabrizio
   Virgili, Gianni
TI Macular translocation for neovascular age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED PILOT-TRIAL;
   PHOTODYNAMIC THERAPY; 360-DEGREES RETINOTOMY; RETINAL SEPARATION;
   MANAGEMENT; DISPLACEMENT; PROGRESSION; PREVALENCE; HEMORRHAGE
AB Background
   Macular translocation has been proposed by vitreoretinal surgeons to displace the neuroretinal tissue onto healthy retinal pigment epithelium and choroid when the macula has been invaded by subretinal neovascularisation.
   Objectives
   This review aims at assessing the effectiveness of macular translocation for preserving or improving vision in patients with neovascular age-related macular degeneration (AMD).
   Search strategy
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in T h e Cochrane Library, MEDLINE, EMBASE and Caribbean Literature on Health Sciences (LILACS). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 21 July 2008.
   Selection criteria
   We included randomised or quasi randomised controlled trials comparing macular translocation with any other treatment or observation.
   Data collection and analysis
   Two authors independently extracted the data. The risk ratio (RR) of visual loss and visual gain was estimated at one year after treatment.
   Main results
   Only one small unblinded study on 50 people compared full macular translocation with photodynamic therapy (PDT) in AMD patients with predominantly classic subfoveal choroidal neovascularisation (CNV). At the last examination, performed in most of the cases after one year, there was no difference in the rate of visual loss of 3 or more lines (translocation versus PDT: RR 0.56, 95% confidence interval (CI) 0.22 to 1.43), as well as in the mean change of contrast sensitivity (1 letter favouring translocation; 95% CI-3.51 to 5.51) and the rate of recurrence of CNV (translocation versus PDT: RR 1.56, 95% CI 0.83 to 2.91). Other outcomes significantly favoured translocation, such as the gain of 3 or more ETDRS lines ( RR 21, 95% CI 1.30 to 340.02), the mean change of visual acuity (mean difference (MD) 14.60, 95% CI 5.39 to 23.81) and the mean change of near visual acuity score (MD 17.80, 95% CI 3.98 to 31.62) which is obtained with an algorithm. Serious complications reported after macular translocation were retinal detachment in 6/25 patients and diplopia requiring prismatic correction in 5/25 patients.
   Authors' conclusions
   There is insufficient evidence from randomised controlled trials on the effectiveness of macular translocation, which is also not free of important risks. Furthermore, this technique is difficult to perform and a long surgical training is required. Future studies might include patients with small neovascular lesions that failed to respond to current pharmacological therapies and are willing to accept the risks associated with surgery to try to improve visual acuity.
C1 [Eandi, Chiara M.] Univ Turin, Dept Clin Physiopathol, Eye Clin, I-10122 Turin, Italy.
   [Giansanti, Fabrizio] Univ Florence, Dept Neurootoophthalmol Surg Sci, Eye Clin, Florence, Italy.
   [Virgili, Gianni] Univ Florence, Dept Ophthalmol, Florence, Italy.
C3 University of Turin; University of Florence; University of Florence
RP Eandi, CM (通讯作者)，Univ Turin, Dept Clin Physiopathol, Eye Clin, Via Juvarra 19, I-10122 Turin, Italy.
EM chiara.eandi@unito.it
RI Giansanti, Fabrizio/I-2193-2012; Virgili, Gianni/P-6607-2014
OI Giansanti, Fabrizio/0000-0002-4107-2807; Virgili,
   Gianni/0000-0002-9960-2989; Eandi, Chiara Maria/0000-0003-3656-1689
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   de Juan E, 2001, EYE, V15, P413, DOI 10.1038/eye.2001.146
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt U, 1998, KLIN MONATSBL AUGENH, V212, P212, DOI 10.1055/s-2008-1034867
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P664
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujii Gildo Y, 2002, Ophthalmol Clin North Am, V15, P425, DOI 10.1016/S0896-1549(02)00046-9
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   Fujii GY, 2001, AM J OPHTHALMOL, V131, P90, DOI 10.1016/S0002-9394(00)00769-8
   Fujii GY, 2003, AM J OPHTHALMOL, V135, P109, DOI 10.1016/S0002-9394(02)01854-8
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   HERRIOT WJ, 1997, P 1997 UPD MAC SURG, P82
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA
   Ichibe M, 2002, AM J OPHTHALMOL, V134, P139, DOI 10.1016/S0002-9394(02)01502-7
   Imai K, 1998, AM J OPHTHALMOL, V125, P627, DOI 10.1016/S0002-9394(98)00023-3
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lambert H M, 2000, Semin Ophthalmol, V15, P92
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Luke M, 2007, GRAEF ARCH CLIN EXP, V245, P1831, DOI 10.1007/s00417-007-0558-9
   Luke C, 2003, GRAEF ARCH CLIN EXP, V241, P710, DOI 10.1007/s00417-003-0709-6
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   PAWLAK D, 2007, J FRANCAIS OPHTHAL 2, V27, P7
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Seaber JH, 1997, GRAEF ARCH CLIN EXP, V235, P76, DOI 10.1007/BF00941733
   Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2
   Simon P, 2002, J FR OPHTALMOL, V25, P694
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   TOTH C, 1997, MACULAR TRANSLOCATIO
   Trinh L, 2006, J FR OPHTALMOL, V29, P995, DOI 10.1016/S0181-5512(06)73887-6
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
   Vanderheyden P M, 2000, J Renin Angiotensin Aldosterone Syst, V1, P159, DOI 10.3317/jraas.2000.020
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   WOLF S, 1997, KLIN MONATSBL AUGENH, V210, P5
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Ziemssen F, 2008, GRAEF ARCH CLIN EXP, V246, P653, DOI 10.1007/s00417-007-0726-y
NR 48
TC 15
Z9 15
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2008
IS 4
AR CD006928
DI 10.1002/14651858.CD006928.pub2
PG 28
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 358CU
UT WOS:000259895000080
PM 18843739
DA 2022-11-30
ER

PT J
AU Chae, JB
   Jang, H
   Son, C
   Park, CW
   Choi, H
   Jin, S
   Lee, HY
   Lee, H
   Ryu, JH
   Kim, N
   Kim, C
   Chung, H
AF Chae, Jae-Byoung
   Jang, Hyoik
   Son, Chanok
   Park, Chul-Woo
   Choi, Huyeon
   Jin, Seongeon
   Lee, Ho-Yeon
   Lee, Hyungwoo
   Ryu, Ja-Hyoung
   Kim, Namshin
   Kim, Chaekyu
   Chung, Hyewon
TI Targeting senescent retinal pigment epithelial cells facilitates retinal
   regeneration in mouse models of age-related macular degeneration
SO GEROSCIENCE
LA English
DT Article
DE Aging; Age-related macular degeneration; Cellular senescence; Retina;
   Senolytic
ID CELLULAR SENESCENCE; SECRETORY PHENOTYPE; GEOGRAPHIC ATROPHY; CHOROIDAL
   NEOVASCULARIZATION; PREMATURE SENESCENCE; THERAPY; GROWTH; RPE;
   INFLAMMASOME; MEMBRANE
AB Although age-related macular degeneration (AMD) is a multifactorial disorder with angiogenic, immune, and inflammatory components, the most common clinical treatment strategies are antiangiogenic therapies. However, these strategies are only applicable to neovascular AMD, which accounts for less than 20% of all AMD cases, and there are no FDA-approved drugs for the treatment of dry AMD, which accounts for ~ 80% of AMD cases. Here, we report that the elimination of senescent cells is a potential novel therapeutic approach for the treatment of all types of AMD. We identified senescent retinal pigment epithelium (RPE) cells in animal models of AMD and determined their contributions to retinal degeneration. We further confirmed that the clearance of senescent RPE cells with the MDM2-p53 inhibitor Nutlin-3a ameliorated retinal degeneration. These findings provide new insights into the use of senescent cells as a therapeutic target for the treatment of AMD.
C1 [Chae, Jae-Byoung; Jang, Hyoik; Son, Chanok; Park, Chul-Woo; Chung, Hyewon] Konkuk Univ, Sch Med, Dept Ophthalmol, Seoul, South Korea.
   [Jin, Seongeon; Ryu, Ja-Hyoung; Kim, Chaekyu] Ulsan Natl Inst Sci & Technol, Dept Chem, Ulsan, South Korea.
   [Lee, Ho-Yeon; Kim, Namshin] Korea Res Inst Biosci & Biotechnol KRIBB, Genome Editing Res Ctr, Daejeon, South Korea.
   [Lee, Ho-Yeon; Kim, Namshin] Korea Univ Sci & Technol UST, KRIBB Sch Biosci, Dept Bioinformat, Daejeon, South Korea.
   [Lee, Hyungwoo; Chung, Hyewon] Konkuk Univ, Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Ulsan National
   Institute of Science & Technology (UNIST); Korea Research Institute of
   Bioscience & Biotechnology (KRIBB); University of Science & Technology
   (UST); Konkuk University; Konkuk University Medical Center
RP Chung, H (通讯作者)，Konkuk Univ, Sch Med, Dept Ophthalmol, Seoul, South Korea.; Kim, C (通讯作者)，Ulsan Natl Inst Sci & Technol, Dept Chem, Ulsan, South Korea.
EM chaekyu@unist.ac.kr; hchung@kuh.ac.kr
OI Chung, Hyewon/0000-0003-1312-6406
CR Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Baek A, 2017, AUTOPHAGY, V13, P248, DOI 10.1080/15548627.2016.1256932
   Baek JH, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0941-9
   Bailey TA, 2001, EXP EYE RES, V73, P851, DOI 10.1006/exer.2001.1089
   Baker DJ, 2018, J CLIN INVEST, V128, P1208, DOI 10.1172/JCI95145
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228840
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Bussian TJ, 2018, NATURE, V562, P578, DOI 10.1038/s41586-018-0543-y
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Chavala SH, 2013, J CLIN INVEST, V123, P4170, DOI 10.1172/JCI67315
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241
   Dolz-Marco R, 2017, RETINA-J RET VIT DIS, V37, P222, DOI 10.1097/IAE.0000000000001279
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Ivert L, 2005, GRAEF ARCH CLIN EXP, V243, P250, DOI 10.1007/s00417-004-0967-y
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kracikova M, 2013, CELL DEATH DIFFER, V20, P576, DOI 10.1038/cdd.2012.155
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Little K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.3
   Liu S, 2015, SCI REP-UK, V5, DOI 10.1038/srep17895
   Lopez-Luppo M, 2017, INVEST OPHTH VIS SCI, V58, P2832, DOI 10.1167/iovs.16-20312
   Lozono-Torres B, 2019, NAT REV CHEM, V3, P426, DOI 10.1038/s41570-019-0108-0
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Maejima Y, 2008, AGING CELL, V7, P125, DOI 10.1111/j.1474-9726.2007.00358.x
   Mahmoudi S, 2019, NAT CELL BIOL, V21, P32, DOI 10.1038/s41556-018-0206-0
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Markovets AM, 2011, AGING-US, V3, P44
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Moiseeva O, 2013, AGING CELL, V12, P489, DOI 10.1111/acel.12075
   Oganesian A, 1997, INT OPHTHALMOL, V21, P165, DOI 10.1023/A:1026402031902
   Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440
   Patrone C, 2014, LANCET DIABETES ENDO, V2, P256, DOI 10.1016/S2213-8587(13)70125-6
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Prasad PS, 2010, MATURITAS, V66, P46, DOI 10.1016/j.maturitas.2010.02.006
   Riessland M, 2019, CELL STEM CELL, V25, P514, DOI 10.1016/j.stem.2019.08.013
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Sreekumar PG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2583601
   Tan FCC, 2014, BIOGERONTOLOGY, V15, P643, DOI 10.1007/s10522-014-9532-1
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Valero T, 2014, CURR PHARM DESIGN, V20, P5507, DOI 10.2174/138161282035140911142118
   Voigt AP, 2020, MICROVASC RES, V131, DOI 10.1016/j.mvr.2020.104031
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wang R, 2017, AGING CELL, V16, P564, DOI 10.1111/acel.12587
   White RR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7790
   Wiley CD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20000-4
   Xu M, 2015, P NATL ACAD SCI USA, V112, pE6301, DOI 10.1073/pnas.1515386112
   Yao ZT, 2020, CANCER RES, V80, P1171, DOI 10.1158/0008-5472.CAN-19-2348
   Yu B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16312-7
   Zielke N, 2015, WIRES DEV BIOL, V4, P469, DOI 10.1002/wdev.189
NR 73
TC 14
Z9 14
U1 2
U2 21
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2509-2715
EI 2509-2723
J9 GEROSCIENCE
JI GeroScience
PD DEC
PY 2021
VL 43
IS 6
SI SI
BP 2809
EP 2833
DI 10.1007/s11357-021-00457-4
PG 25
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA XA1UH
UT WOS:000720440600013
PM 34601706
OA Green Published
DA 2022-11-30
ER

PT J
AU Park, DW
   Dugel, PV
   Thach, AB
   Adhikari, S
   Alvarado, C
   Blaisdell, J
   Cavanagh, J
   Cornelius, J
   Marcos, E
   Tysiac, K
   Jimenez, N
   Falcon, A
   Kosecki, S
   Slagle, C
   Tuttle, C
   Bohnen, SE
   Manor, BM
   Martin, J
   Monday, AC
   Johnson, RN
   Ai, E
   McDonald, HR
   Stolarczuk, M
   Wood, P
   Curren, K
   Rozenfeld, I
   Teske, B
   Apushkin, M
   Linares, S
   De-Boer, K
   Huggans, S
   Miller, J
   Uy, J
   Pavan, PR
   Billiris, KK
   Goldstein, B
   Iyer, M
   Menosky, MM
   Mines, J
   Pautler, SE
   Millard, SM
   Sherouse, S
   West, MD
   Carlton, S
   Saxon, W
   Sternberg, P
   Aaberg, T
   Hubbard, B
   Saperstein, D
   DuBois, L
   Ervin, A
   Brower, J
   Brown, J
   Browne, G
   Burian, G
   Schmitz, N
   Waldron, R
   Gilman, J
   Myles, BA
   Lyon, A
   Anderson-Nelson, S
   Jampol, LM
   Weinberg, DV
   Munana, A
   Rozenbajgier, Z
   Kaminski, L
   Koecher, J
   O'Donnell, L
   Swigost, R
   Volland, L
   Apushkin, M
   Habib, A
   Hulvey, P
   Shankle, J
   Yuhr, J
   Orth, D
   Cohen, J
   MacCumber, M
   Merrill, P
   Figliulo, C
   Porcz, L
   Violetto, CL
   Drefcinski, TN
   Nenadov, HP
   Rago, L
   Doherty, D
   McVicker, M
   Nash, D
   Folk, JC
   Boldt, HC
   Gehrs, KM
   Russell, SR
   Ivins, R
   Wallace, SA
   Hinz, C
   Harker, M
   Heffron, E
   Karakas, S
   Barr, CC
   Bloom, S
   Kritchman, B
   Whittington, G
   Bowyer, R
   Denning, D
   Goatley, J
   Nutting, J
   Swartz, J
   Temple, E
   Wilson, W
   Heier, J
   Frederick, AR
   Morley, MG
   Topping, T
   Hanner, T
   Doherty, M
   Davis, HL
   Beal, L
   Mahoney, S
   Ty, RA
   Jones, CM
   Rapp, E
   Bressler, SB
   Schachat, AP
   Pieramici, D
   Bressler, NM
   Doll, W
   Greenberg, E
   Jurao, RA
   Donohue, DF
   Frey, M
   Sheehan, S
   Porter, T
   Belt, JE
   Cain, DR
   Falk, R
   Herring, CM
   McDonald, JM
   Trese, M
   Capone, A
   Garretson, BR
   Hassan, TS
   Ruby, AJ
   Kulak, MM
   Manatrey, P
   Osentoski, T
   Vandell, L
   Cumming, K
   Mitchell, B
   Zajechowski, M
   Bridges, C
   Siedlak, P
   Streasick, P
   Szydlowski, L
   McCannel, CA
   Buettner, H
   Pach, JM
   Robertson, DM
   Ruszczyk, MJ
   Burrington, J
   LeBarron, K
   Stephan, CA
   Link, T
   Rostvold, JA
   Grand, G
   Blinder, K
   Holekamp, NM
   Joseph, DP
   Meredith, TA
   Shah, G
   Binning, JA
   Nobel, GS
   Wright, CM
   Boyd, L
   Gualdoni, J
   Light, P
   Soueidan, N
   Barts, B
   Dahl, J
   Holle, T
   Raeber, M
   Rogers, JM
   Antoszyk, AN
   Browning, DJ
   Ellsmore, T
   Helms, JV
   Lundy, L
   Stallings, AH
   Clark, L
   Efird, S
   Evans, M
   Jarrahi, F
   Mundy, K
   Murphy, H
   O'Marah, TL
   Wike, J
   Woodland, P
   Davis, L
   McOwen, M
   Leff, SR
   Friedman, E
   Green, SN
   Keyser, B
   Kushner, M
   Yarian, DL
   Hambrock, C
   Wagner, L
   Lucido, M
   Coffey, D
   Geddes, M
   Tantum, T
   Andersen, F
   Schlosser, A
   Singerman, LJ
   Miller, D
   Mittra, R
   Novak, M
   Pendergast, S
   Stockfish, JH
   Zegarra, H
   Marella, SD
   Schura, SA
   Smith-Brewer, S
   DuBois, K
   Hursky, JL
   Ilc, M
   Joyce, SL
   Tanner, V
   DuBois, J
   Greanoff, G
   Lehnhardt, DS
   Davidorf, FH
   Chambers, R
   Chorich, L
   Taylor, CS
   Salerno, J
   Deringer, MT
   Milliron, J
   Perry, J
   Savage, S
   Dreyer, RF
   Ma, C
   Bartholomew, P
   Crider, HL
   Kopfer, MR
   Larson, JR
   Armstrong, C
   DeShazer, D
   Hobbs, S
   Raunig, W
   Reichenberger, K
   Schmidt, S
   Sitts, D
   Daniel, H
   Johnson, M
   Logan, RJ
   Wohlsein, HJ
   Klein, ML
   Wilson, DJ
   Nolte, SK
   Lindstrom, PD
   Pope, S
   Vahrenwald, DR
   Gaultney, J
   Redenbo, E
   Rice, P
   Steinkamp, P
   Wallace, P
   Grunwald, JE
   Berger, JW
   Brucker, AJ
   Dunaief, J
   Fine, SL
   Ho, A
   Maguire, AM
   Tolentino, M
   Decker, S
   Hall, E
   Levin, J
   Mcray, MN
   Warley, G
   Boxley, S
   DuPont, J
   Geist, C
   Metelitsina, T
   Sheehan, M
   Devine, C
   Elkins, D
   Nyberg, W
   Weeney, L
   Fish, GE
   Anand, R
   Spencer, R
   Arnwine, J
   Harris, J
   Resmini, N
   Andrews, M
   Arceneaux, S
   McCarty, B
   Pierce, D
   Rollins, R
   Sanchez, B
   Aguado, HA
   Boleman, B
   Ellenich, PB
   King, JG
   Chandra, SR
   Altaweel, M
   Blodi, B
   Gottlieb, J
   Ip, M
   Nork, TM
   Soderling, ED
   Walker, W
   Perry-Raymond, J
   Blatz, M
   Buechner, JM
   Olson, S
   Pohlman, A
   Soderling, B
   Knutson, G
   Krolnik, D
   Peterson, J
   Fine, SL
   Katz, M
   Maguire, MG
   Atkins, K
   Brightwell-Arnold, M
   Harkins, S
   Holmes, CD
   James, A
   Jewell, M
   Khvatov, A
   Liu, CC
   O'Brien, L
   McWilliams, K
   Peskin, E
   Rees, R
   Ryan, S
   Stanford, N
   Taylor, K
   Whearry, C
   Ying, GS
   Alexander, J
   Berger, J
   Stoltz, R
   Begley, S
   Elsner, K
   Ho, A
   Javornik, N
   Mathias, K
   Madjarov, B
   Martin, R
   Zawacki, R
   Maguire, MG
   Ying, GS
   Alexander, J
   Browning, DJ
   Peskin, E
   Folk, JC
   Antoszyk, AN
   Grunwald, JE
   Klein, ML
   Lyon, A
   McCannel, CA
   Stoltz, RA
   Trese, M
   Fine, SL
AF Park, Donald W.
   Dugel, Pravin V.
   Thach, Allen B.
   Adhikari, Siru
   Alvarado, Christina
   Blaisdell, Jennifer
   Cavanagh, Jennifer
   Cornelius, Jennifer
   Marcos, Elena
   Tysiac, Kaz
   Jimenez, Norma
   Falcon, Adriana
   Kosecki, Sharon
   Slagle, Carol
   Tuttle, Cheri
   Bohnen, Scott E.
   Manor, Brian M.
   Martin, John
   Monday, Anne C.
   Johnson, Robert N.
   Ai, Everett
   McDonald, H. Richard
   Stolarczuk, Margaret
   Wood, Pat
   Curren, Kevan
   Rozenfeld, Irina
   Teske, Brandi
   Apushkin, Marsha
   Linares, Silvia
   De-Boer, Kelly
   Huggans, Sarah
   Miller, Jeremy
   Uy, John
   Pavan, Peter Reed
   Billiris, Karina K.
   Goldstein, Burton
   Iyer, Mohan
   Menosky, Matthew M.
   Mines, Jonathan
   Pautler, Scott E.
   Millard, Sharon M.
   Sherouse, Susan
   West, Michelle D.
   Carlton, Steve
   Saxon, Wyatt
   Sternberg, Paul, Jr.
   Aaberg, Thomas
   Hubbard, Baker, III
   Saperstein, David
   DuBois, Lindy
   Ervin, Ann
   Brower, Judy
   Brown, Jayne
   Browne, Gail
   Burian, Gabriela
   Schmitz, Natalie
   Waldron, Rhonda
   Gilman, James
   Myles, Bob A.
   Lyon, Alice
   Anderson-Nelson, Susan
   Jampol, Lee M.
   Weinberg, David V.
   Munana, Annie
   Rozenbajgier, Zuzanna
   Kaminski, Lori
   Koecher, Jill
   O'Donnell, Laima
   Swigost, Renata
   Volland, Lisa
   Apushkin, Marsha
   Habib, Alexander
   Hulvey, Pamela
   Shankle, Jonathan
   Yuhr, James
   Orth, David
   Cohen, Jack
   MacCumber, Matthew
   Merrill, Pauline
   Figliulo, Celeste
   Porcz, Liz
   Violetto, Carrie L.
   Drefcinski, Tana N.
   Nenadov, Hope P.
   Rago, Laurie
   Doherty, Donald
   McVicker, Marian
   Nash, David
   Folk, James C.
   Boldt, H. Culver
   Gehrs, Karen M.
   Russell, Stephen R.
   Ivins, Rachael
   Wallace, Steven A.
   Hinz, Connie
   Harker, Michael
   Heffron, Ed
   Karakas, Stefani
   Barr, Charles C.
   Bloom, Steve
   Kritchman, Brian
   Whittington, Greg
   Bowyer, Rhonda
   Denning, Den
   Goatley, Janice
   Nutting, Janet
   Swartz, Judy
   Temple, Evelyn
   Wilson, Wendy
   Heier, Jeffrey
   Frederick, Albert R., Jr.
   Morley, Michael G.
   Topping, Trexler
   Hanner, Tammy
   Doherty, Molly
   Davis, Heather L.
   Beal, Linda
   Mahoney, Sean
   Ty, Robin A.
   Jones, Cullen Mike
   Rapp, Elna
   Bressler, Susan B.
   Schachat, Andrew P.
   Pieramici, Dante
   Bressler, Neil M.
   Doll, Warren
   Greenberg, Ellen
   Jurao, Robert A.
   Donohue, Deborah F.
   Frey, Mary
   Sheehan, Siobhan
   Porter, Tracey
   Belt, Judith E.
   Cain, Dennis R.
   Falk, Rachel
   Herring, Charles M.
   McDonald, Jacquelyn M.
   Trese, Michael
   Capone, Antonio
   Garretson, Bruce R.
   Hassan, Tarek S.
   Ruby, Alan J.
   Kulak, Michelle M.
   Manatrey, Pat
   Osentoski, Tammy
   Vandell, Linda
   Cumming, Kristi
   Mitchell, Beth
   Zajechowski, Mary
   Bridges, Craig
   Siedlak, Patricia
   Streasick, Patricia
   Szydlowski, Lynette
   McCannel, Colin A.
   Buettner, Helmut
   Pach, John M.
   Robertson, Dennis M.
   Ruszczyk, Margaret J.
   Burrington, Jean
   LeBarron, Kathleen
   Stephan, Cindy A.
   Link, Thomas
   Rostvold, Jay A.
   Grand, Gilbert
   Blinder, Kevin
   Holekamp, Nancy M.
   Joseph, Daniel P.
   Meredith, Travis A.
   Shah, Gaurav
   Binning, Julie A.
   Nobel, Ginny S.
   Wright, Cindy M.
   Boyd, Linda
   Gualdoni, Janel
   Light, Pam
   Soueidan, Nancy
   Barts, Bryan
   Dahl, Jon
   Holle, Timothy
   Raeber, Matt
   Rogers, John Mark
   Antoszyk, Andrew N.
   Browning, David J.
   Ellsmore, Tonia
   Helms, Jennifer V.
   Lundy, Lori
   Stallings, Alison H.
   Clark, Loraine
   Efird, Sandy
   Evans, Mark
   Jarrahi, Fereshteh
   Mundy, Kara
   Murphy, Heather
   O'Marah, Tisha L.
   Wike, Jennifer
   Woodland, Patricia
   Davis, Linda
   McOwen, Mike
   Leff, Steven R.
   Friedman, Eric
   Green, Stuart N.
   Keyser, Bruce
   Kushner, Miriam
   Yarian, David L.
   Hambrock, Cheryl
   Wagner, Linda
   Lucido, Marge
   Coffey, Donna
   Geddes, Melinda
   Tantum, Thea
   Andersen, Finn
   Schlosser, Alex
   Singerman, Lawrence J.
   Miller, David
   Mittra, Robert
   Novak, Michael
   Pendergast, Scott
   Stockfish, Jeffrey H.
   Zegarra, Hernando
   Marella, Scott D.
   Schura, Stephanie A.
   Smith-Brewer, Sheila
   DuBois, Kimberly
   Hursky, Jacqueline L.
   Ilc, Mary
   Joyce, Sheri L.
   Tanner, Vivian
   DuBois, John
   Greanoff, Gregg
   Lehnhardt, David S.
   Davidorf, Frederick H.
   Chambers, Robert
   Chorich, Louis
   Taylor, Cynthia S.
   Salerno, Jill
   Deringer, Mary T.
   Milliron, Jill
   Perry, Jerilyn
   Savage, Scott
   Dreyer, Richard F.
   Ma, Colin
   Bartholomew, Patricia
   Crider, Harold L.
   Kopfer, Marcia R.
   Larson, Jeanette R.
   Armstrong, Cindy
   DeShazer, Debra
   Hobbs, Steve
   Raunig, Wendy
   Reichenberger, Katie
   Schmidt, Stephanie
   Sitts, Don
   Daniel, Howard 'Dan'
   Johnson, Milt
   Logan, R. Joseph
   Wohlsein, Harry J., Jr.
   Klein, Michael L.
   Wilson, David J.
   Nolte, Susan K.
   Lindstrom, Patricia D.
   Pope, Susan
   Vahrenwald, Debora R.
   Gaultney, Jessica
   Redenbo, Ellen
   Rice, Patrick
   Steinkamp, Peter
   Wallace, Patrick
   Grunwald, Juan E.
   Berger, Jeffrey W.
   Brucker, Alexander J.
   Dunaief, Josh
   Fine, Stuart L.
   Ho, Allen
   Maguire, Albert M.
   Tolentino, Michael
   Decker, Sharon
   Hall, Emily
   Levin, Jennifer
   McRay, Monique N.
   Warley, Gretchen
   Boxley, Stacey
   DuPont, Joan
   Geist, Claudette
   Metelitsina, Tatyana
   Sheehan, Michele
   Devine, Cheryl
   Elkins, Deborah
   Nyberg, William
   Weeney, Laurel
   Fish, Gary Edd
   Anand, Rajiv
   Spencer, Rand
   Arnwine, Jean
   Harris, Jeff
   Resmini, Nancy
   Andrews, Marilyn
   Arceneaux, Sally
   McCarty, Barbara
   Pierce, Dustin
   Rollins, Rubye
   Sanchez, Brenda
   Aguado, Hank A.
   Boleman, Bob
   Ellenich, Penny B.
   King, John G.
   Chandra, Suresh R.
   Altaweel, Michael
   Blodi, Barbara
   Gottlieb, Justin
   Ip, Michael
   Nork, T. Michael
   Soderling, Erika D.
   Walker, Wendy
   Perry-Raymond, Jennie
   Blatz, Margo
   Buechner, Jennifer M.
   Olson, Shelly
   Pohlman, Alyson
   Soderling, Barb
   Knutson, Gene
   Krolnik, Denise
   Peterson, John
   Fine, Stuart L.
   Katz, Marilyn
   Maguire, Maureen G.
   Atkins, Kate
   Brightwell-Arnold, Mary
   Harkins, Sandra
   Holmes, Christine D.
   James, Andrew
   Jewell, Margaret
   Khvatov, Alexander
   Liu, Chengcheng
   O'Brien, Lori
   McWilliams, Kathy
   Peskin, Ellen
   Rees, Renee
   Ryan, Susan
   Stanford, Nefertiti
   Taylor, Karen
   Whearry, Claressa
   Ying, Gui-Shuang
   Alexander, Judith
   Berger, Jeffrey
   Stoltz, Robert
   Begley, Steven
   Elsner, Keith
   Ho, Allen
   Javornik, Noreen
   Mathias, Kristin
   Madjarov, Bojidar
   Martin, Revell
   Zawacki, Renee
   Maguire, Maureen G.
   Ying, Gui-Shuang
   Alexander, Judith
   Browning, David J.
   Peskin, Ellen
   Folk, James C.
   Antoszyk, Andrew N.
   Grunwald, Juan E.
   Klein, Michael L.
   Lyon, Alice
   McCannel, Colin A.
   Stoltz, Robert A.
   Trese, Michael
   Fine, Stuart L.
CA CAPT Res Grp
TI Laser treatment in patients with bilateral large drusen - The
   complications of age-related macular degeneration prevention trial
SO OPHTHALMOLOGY
LA English
DT Article
ID GRID PHOTOCOAGULATION; CHOROIDAL NEOVASCULARIZATION; PROPHYLACTIC
   TREATMENT; MACULOPATHY; RISK; REDUCTION; PROGNOSIS
AB Objective: To evaluate the efficacy and safety of low-intensity laser treatment in the prevention of visual acuity (VA) loss among participants with bilateral large drusen.
   Design: Multicenter randomized clinical trial. One eye of each participant was assigned to treatment, and the contralateral eye was assigned to observation.
   Participants: A total of 1052 participants who had >= 10 large (> 125 mu m) drusen and VA :20/40 in each eye enrolled through 22 clinical centers.
   Intervention: The initial laser treatment protocol specified 60 barely visible burns applied in a grid pattern within an annulus between 1500 and 2500 mu m from the foveal center. At 12 months, eyes assigned to treatment that had sufficient drusen remaining were retreated with 30 burns by targeting drusen within an annulus between 1000 and 2000 mu m from the foveal center.
   Main Outcome Measure: Proportion of eyes at 5 years with loss of >= 3 lines of VA from baseline. Secondary outcome measures included the development of choroidal neovascularization or geographic atrophy (GA), change in contrast threshold, change in critical print size, and incidence of ocular adverse events.
   Results: At 5 years, 188 (20.5%) treated eyes and 188 (20.5%) observed eyes had VA scores >= 3 lines worse than at the initial visit (P=1.00). Cumulative 5-year incidence rates for treated and observed eyes were 13.3% and 13.3% (P=0.95) for choroidal neovascularization and 7.4% and 7.8% (P=0.64) for GA, respectively. The contrast threshold doubled in 23.9% of treated eyes and in 20.5% of observed eyes (P=0.40). The critical print size doubled in 29.6% of treated eyes and in 28.4% of observed eyes (P=0.70). Seven treated eyes and 14 observed eyes had an adverse event of a >= 6-line loss in VA in the absence of late age-related macular degeneration or cataract.
   Conclusion: As applied in the Complications of Age-Related Macular Degeneration Prevention Trial, low-intensity laser treatment did not demonstrate a clinically significant benefit for vision in eyes of people with bilateral large drusen. (c) 2006 by the American Academy of Ophthalmology.
C1 Univ Penn, Coordinating Ctr, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Park, DW (通讯作者)，Univ Penn, Coordinating Ctr, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
RI Pavan, Peter/B-6473-2013; Mittra, Robert/AAC-8249-2021
FU NATIONAL EYE INSTITUTE [U10EY012279] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY012279, EY012211, EY012261] Funding Source: Medline
CR [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], 1998, Ophthalmology, V105, P11
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   *EARL TREATM DIAB, 1991, OPHTHALMOLOGY S, V97, P741
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Frennesson CI, 2003, ACTA OPHTHALMOL SCAN, V81, P449, DOI 10.1034/j.1600-0420.2003.00143.x
   Frennesson I C, 1996, Eur J Ophthalmol, V6, P307
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hyver SW, 1997, ARCH OPHTHALMOL-CHIC, V115, P554, DOI 10.1001/archopht.1997.01100150556022
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mansfield JS, 1996, INVEST OPHTH VIS SCI, V37, P1492
   *NAT EY I, AG REL EY DIS STUD M
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Ruiz-Moreno JM, 2003, RETINA-J RET VIT DIS, V23, P315, DOI 10.1097/00006982-200306000-00005
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   Scorolli L, 2003, CAN J OPHTHALMOL, V38, P489, DOI 10.1016/S0008-4182(03)80028-5
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   *VER PHOT THER STU, 2001, AM J OPHTHALMOL, V131, P541
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Wetzig P C, 1988, Trans Am Ophthalmol Soc, V86, P276
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 44
TC 53
Z9 55
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2006
VL 113
IS 11
BP 1974
EP 1986
DI 10.1016/j.ophtha.2006.08.015
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 101CS
UT WOS:000241717100012
PM 17074563
DA 2022-11-30
ER

PT J
AU Zhang, N
   Hoffmeyer, GC
   Young, ES
   Burns, RE
   Winter, KP
   Stinnett, SS
   Toth, CA
   Jaffe, GJ
AF Zhang, Nanfei
   Hoffmeyer, Greg C.
   Young, Ellen S.
   Burns, Russell E.
   Winter, Katrina P.
   Stinnett, Sandra S.
   Toth, Cynthia A.
   Jaffe, Glenn J.
TI Optical coherence tomography reader agreement in Neovascular age-related
   macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; EDEMA; REPRODUCIBILITY
AB PURPOSE: To determine the interreader and in, trareader agreement at the Optical Coherence Tomogra phy (OCT) Reading Center at Duke for images produced for an interventional neovascular age-related macular degeneration (AMD) clinical trial.
   DESIGN: Retrospective, observational case series.
   METHODS: OCT was performed using the Stratus OCT Fast Macular Thickness Map (Carl Zeiss Meditec, Dublin, California, USA) scan mode and a 7-mm line scan centered on the fovea. Experienced OCT readers, certified to grade scans according to a standardized protocol, independently determined whether a scan was gradable. If gradable, each of the scans was graded for multiple morphologic characteristics. In addition, retinal thickness, subretinal fluid thickness, and choroidal neovascularization (CNV) thickness at the fovea were measured for each gradable scan. Interreader agreement was determined among three reader pairs. Readers regraded a subset of scans and intrareader agreement was deter. mined.
   RESULTS: The interreader agreement was high for scan gradability and scan grades among three reader pairs, ranging from 84% to 100% and from 84% to 96%, respectively. Similarly, the intrareader agreement for scan gradability and scan grade, including comparison of adjudicated scan grades with readjudicated scan grades, was high and ranged from 91% to 100% and from 79% to 98%, respectively, except for scan grades of retinal pigment epithelium atrophy, when CNV was present. Highly reproducible results also were found for quanti tative thickness measurements.
   CONCLUSIONS: Well trained OCT readers can grade independently, with a high level of interreader and intrareader agreement, multiple morphologic parameters of OCT scans obtained from eyes with neovascular AMD. Reproducible Stratus OCT scan data will be valuable to monitor treatment efficacy in interventional clinical trials of neovascular AMD.
C1 Duke Univ, Ctr Eye, Durham, NC 27710 USA.
   Duke Univ, OCT Reading Ctr Duke, Durham, NC USA.
C3 Duke University; Duke University
RP Zhang, N (通讯作者)，Duke Univ, Ctr Eye, Box 3802, Durham, NC 27710 USA.
EM Jaffe001@mc.duke.edu
RI toth, cynthia a/F-5614-2011; Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Stinnett, Sandra/0000-0001-7192-0195
CR Ahlers C, 2005, EUR J OPHTHALMOL, V15, P774, DOI 10.1177/112067210501500619
   Audren F, 2006, ACTA OPHTHALMOL SCAN, V84, P624, DOI 10.1111/j.1600-0420.2006.00700.x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Benson SE, 2006, EYE, V20, P1030, DOI 10.1038/sj.eye.6702073
   Browning DJ, 2006, OPHTHAL SURG LAS IM, V37, P399, DOI 10.3928/15428877-20060901-07
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Montero JA, 2003, GRAEF ARCH CLIN EXP, V241, P797, DOI 10.1007/s00417-003-0752-3
   Otani T, 1999, AM J OPHTHALMOL, V127, P688, DOI 10.1016/S0002-9394(99)00033-1
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Wilkins JR, 1996, OPHTHALMOLOGY, V103, P2142, DOI 10.1016/S0161-6420(96)30377-1
   [No title captured]
NR 18
TC 31
Z9 34
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2007
VL 144
IS 1
BP 37
EP 44
DI 10.1016/j.ajo.2007.03.056
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 187SD
UT WOS:000247867800006
PM 17509508
DA 2022-11-30
ER

PT J
AU Ichiyama, Y
   Sawada, T
   Kakinoki, M
   Sawada, O
   Nakashima, T
   Saishin, Y
   Kawamura, H
   Ohji, M
AF Ichiyama, Yusuke
   Sawada, Tomoko
   Kakinoki, Masashi
   Sawada, Osamu
   Nakashima, Tomoko
   Saishin, Yoshitsugu
   Kawamura, Hajime
   Ohji, Masahito
TI Anterior Chamber Paracentesis Might Prevent Sustained Intraocular
   Pressure Elevation after Intravitreal Injections of Ranibizumab for
   Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Intraocular pressure; Ranibizumab;
   Anterior chamber paracentesis
ID REPACKAGED BEVACIZUMAB; EYES
AB Background/Aims: To evaluate the efficacy of anterior chamber paracentesis for preventing sustained intraocular pressure (IOP) elevation after intravitreal ranibizumab (IVR) injections for age-related macular degeneration (AMD). Methods:The medical records for all cases of exudative AMD treated with IVR injections and followed monthly for 12 months or longer were reviewed retrospectively. Anterior chamber paracentesis was performed just before IVR injections. A sustained IOP elevation was defined as 22 mm Hg or higher during 2 consecutive visits with an increase exceeding 6 mm Hg from baseline. Results: One hundred and eleven eyes met the inclusion criteria, and none of these eyes had a sustained IOP elevation. Conclusions: Anterior chamber paracentesis before IVR injections may prevent sustained IOP elevations. (C) 2014 S. Karger AG, Basel
C1 [Ichiyama, Yusuke; Sawada, Tomoko; Kakinoki, Masashi; Sawada, Osamu; Nakashima, Tomoko; Saishin, Yoshitsugu; Kawamura, Hajime; Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga 5202192, Japan.
C3 Shiga University of Medical Science
RP Sawada, T (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga 5202192, Japan.
EM tsawada@belle.shiga-med.ac.jp
RI Ichiyama, Yusuke/AAN-5983-2021
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [24592668]; Novartis Pharmaceuticals Japan
FX This paper was supported in part by a grant from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (No.
   24592668). Shiga University of Medical Science and Dr. Ohji have
   received financial support from Novartis Pharmaceuticals Japan that is
   not directly related with this article. All the other authors declare no
   conflict of interest.
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   DRANCE SM, 1960, ARCH OPHTHALMOL-CHIC, V64, P494
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Jalil A, 2007, EYE, V21, P1541, DOI 10.1038/sj.eye.6703018
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Loukianou Eleni, 2011, International Ophthalmology, V31, P211, DOI 10.1007/s10792-010-9410-z
   Mathalone N, 2012, GRAEF ARCH CLIN EXP, V250, P1435, DOI 10.1007/s00417-012-1981-0
   Menke MN, 2013, OPHTHALMOLOGICA, V229, P168, DOI 10.1159/000346397
   Packer VA, 2001, BR J OPHTHALMOL, V85, P1303
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098
   Tonnu PA, 2005, BRIT J OPHTHALMOL, V89, P847, DOI 10.1136/bjo.2004.056614
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Wehrli SJ, 2012, RETINA-J RET VIT DIS, V32, P1295, DOI 10.1097/IAE.0b013e31823f0c95
   Zondor SD, 2004, ANN PHARMACOTHER, V38, P1258, DOI 10.1345/aph.1D470
NR 23
TC 9
Z9 9
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2014
VL 52
IS 4
BP 234
EP 238
DI 10.1159/000365253
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU5WU
UT WOS:000345675200008
PM 25401265
DA 2022-11-30
ER

PT J
AU Klettner, A
   Groteluschen, S
   Treumer, F
   Roider, J
   Hillenkamp, J
AF Klettner, Alexa
   Grotelueschen, Simon
   Treumer, Felix
   Roider, Johann
   Hillenkamp, Jost
TI Compatibility of recombinant tissue plasminogen activator (rtPA) and
   aflibercept or ranibizumab coapplied for neovascular age-related macular
   degeneration with submacular haemorrhage
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL HEMORRHAGE; GROWTH-FACTOR; BEVACIZUMAB; DISPLACEMENT;
   INJECTION; GAS
AB Background/aims Subretinal coapplication of recombinant tissue plasminogen activator (rtPA) and vascular endothelial growth factor (VEGF)-antagonists is a new treatment option for age-related macular degeneration complicated by submacular haemorrhage. Here, we investigate the compatibility of rtPA and aflibercept or ranibizumab in vitro because intraoperatively, rtPA or rtPA-induced plasmin may cleave aflibercept or ranibizumab.
   Methods Aflibercept and ranibizumab, respectively, were incubated with rtPA or plasmin, separated in gel electrophoresis and stained with Coomassie or silver. The antiangiogenic activity of the VEGF-antagonists was quantified by VEGF-ELISA after incubation with the supernatant of primary porcine retinal pigment epithelium cell cultures.
   Results In electrophoresis, ranibizumab displayed no additional fragments when it was coapplied with rtPA or plasmin. Its VEGF-inhibiting efficacy remained unchanged in coapplication with rtPA with or without blood, or plasmin. rtPA did not cleave or functionally compromise aflibercept. When aflibercept was coapplied with plasmin, electrophoresis displayed additional bands in Coomassie (30 kDa, 27 kDa, 19 kDa, 15 kDa) and silver staining (31 kDa, 26 kDa, 21 kDa, 19 kDa, 15 kDa). While at a clinical dosage (800 mu g/mL) VEGF was inhibited by aflibercept when coapplied with plasmin, at borderline concentrations (400 ng/mL) VEGF-binding ability of aflibercept was abolished.
   Conclusions Ranibizumab is not cleaved or functionally compromised by rtPA or plasmin. Aflibercept is cleaved and its VEGF-binding ability is reduced when coapplied with plasmin. In clinical practice, rtPA and ranibizumab can be coapplied as a treatment for neovascular age-related macular degeneration with submacular haemorrhage while the antiangiogenic activity of aflibercept may be compromised when coapplied with rtPA in the presence of plasmin.
C1 [Klettner, Alexa; Grotelueschen, Simon; Treumer, Felix; Roider, Johann; Hillenkamp, Jost] Univ Kiel, Univ Med Ctr Schleswig Holstein, Dept Ophthalmol, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Klettner, A (通讯作者)，Univ Kiel, Univ Med Ctr Schleswig Holstein, Dept Ophthalmol, Arnold Heller Str 3,Haus 25, D-24105 Kiel, Germany.
EM aklettner@auge.uni-kiel.de
RI Klettner, Alexa Karina/M-8344-2018
OI Klettner, Alexa/0000-0002-2709-1059
FU Novartis Pharma
FX Independent of this study, AK has been a consultant for and received
   research grants and lecture fees from Novartis Pharma. Independent of
   this study, JH has received lecture fees and travel grants from Novartis
   Pharma.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Klettner A., 2014, J BIOCH PHARM RES, V2, P8
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2014, GRAEF ARCH CLIN EXP, V252, P1593, DOI 10.1007/s00417-014-2719-y
   Klettner A, 2012, ARCH OPHTHALMOL-CHIC, V130, P875, DOI 10.1001/archophthalmol.2012.120
   MARS WM, 1993, AM J PATHOL, V143, P949
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
NR 20
TC 16
Z9 17
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2015
VL 99
IS 6
BP 864
EP 869
DI 10.1136/bjophthalmol-2014-306454
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CI7NO
UT WOS:000354950600027
PM 25740806
OA hybrid
DA 2022-11-30
ER

PT J
AU Greenlee, TE
   Wang, VY
   Kang, HN
   Ohlhausen, ME
   Chen, AX
   Hom, GL
   Conti, TF
   Briskin, I
   Babiuch, AS
   Singh, RP
AF Greenlee, Tyler E.
   Wang, Victoria Y.
   Kang, Hannah
   Ohlhausen, Marc E.
   Chen, Andrew X.
   Hom, Grant L.
   Conti, Thais F.
   Briskin, Isaac
   Babiuch, Amy S.
   Singh, Rishi P.
TI CONSEQUENCES OF LAPSES IN TREATMENT WITH VASCULAR ENDOTHELIAL GROWTH
   FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN
   ROUTINE CLINICAL PRACTICE
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor inhibitors; macula; neovascular age-related macular degeneration;
   optical coherence tomography; retina
ID RANIBIZUMAB; VERTEPORFIN
AB Purpose: Evaluating outcomes in patients receiving intravitreal antivascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration whom experience a lapse in treatment. Methods: A retrospective chart review evaluating 3,304 patients >= 18 years who experienced treatment lapses >= 3 months compared with control counterparts. Demographic information, macular thickness as measured by central subfield thickness, and visual acuity were collected at baseline, the first postlapse appointment, and at 3, 6, and 12 months after the lapse for the study group. Results: Lapse (n = 241) and control patients (n = 241) had similar baseline visual acuity and central subfield thickness (Early Treatment Diabetic Retinopathy Study: 58.9 +/- 20.2 [20/63] vs. 59.2 +/- 20.1 [20/63]; central subfield thickness: 252.4 +/- 63.2 mu m vs. 259.8 +/- 66.2 mu m, P = 0.21). Analysis revealed that lapse patients experienced a significant increase in central subfield thickness after lapse when compared with controls (279.4 +/- 86.9 mu m vs. 253.7 +/- 65.9 mu m, P < 0.01), which normalized on resumption of treatment (259.1 +/- 79 mu m vs. 246.8 +/- 57.6 mu m, P = 0.06). Study patients also experienced loss in the visual acuity after lapse when compared with controls (52.9 +/- 23.6 Early Treatment Diabetic Retinopathy Study [20/100] vs. 59.9 +/- 20.8 [20/63] Early Treatment Diabetic Retinopathy Study, P < 0.01) that did not recover through 12 months of follow-up. Conclusion: Patients with neovascular age-related macular degeneration who have lapses in care are at risk for poorer outcomes. Although macular thickness normalizes on resumption of treatment, their decline in the visual acuity does not recover.
C1 [Greenlee, Tyler E.; Chen, Andrew X.; Conti, Thais F.; Babiuch, Amy S.; Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, Ctr Ophthalm Bioinformat, Cleveland, OH 44195 USA.
   [Wang, Victoria Y.; Ohlhausen, Marc E.; Chen, Andrew X.; Hom, Grant L.; Singh, Rishi P.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Kang, Hannah] Case Western Reserve Univ, Coll Arts & Sci, Cleveland, OH 44106 USA.
   [Briskin, Isaac] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Case Western Reserve University; Case
   Western Reserve University; Cleveland Clinic Foundation
RP Singh, RP (通讯作者)，Cleveland Clin, I 32 Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM singhr@ccf.org
CR Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ehlers JP, 2013, BRIT J OPHTHALMOL, V97, P248, DOI 10.1136/bjophthalmol-2012-302489
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Nguyen QD, 2013, OPHTHALMOLOGY, V120, pS1, DOI 10.1016/j.ophtha.2013.01.053
   Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577
   RCoreTeam, 2021, R LANG ENV STAT COMP
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Soares RR, 2020, OPHTHALMOL RETINA, V4, P134, DOI 10.1016/j.oret.2019.07.010
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
NR 24
TC 8
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2021
VL 41
IS 3
BP 581
EP 587
DI 10.1097/IAE.0000000000002888
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL1OK
UT WOS:000656688600025
PM 32658164
DA 2022-11-30
ER

PT J
AU Baumann, B
   Gotzinger, E
   Pircher, M
   Sattmann, H
   Schutze, C
   Schlanitz, F
   Ahlers, C
   Schmidt-Erfurth, U
   Hitzenberger, CK
AF Baumann, Bernhard
   Goetzinger, Erich
   Pircher, Michael
   Sattmann, Harald
   Schuetze, Christopher
   Schlanitz, Ferdinand
   Ahlers, Christian
   Schmidt-Erfurth, Ursula
   Hitzenberger, Christoph K.
TI Segmentation and quantification of retinal lesions in age-related
   macular degeneration using polarization-sensitive optical coherence
   tomography
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE optical coherence tomography; polarization sensitive devices; medical
   imaging; ophthalmology; algorithms; segmentation; age-related macular
   degeneration
ID FLUID-FLOW VELOCITY; GEOGRAPHIC ATROPHY; PIGMENT EPITHELIUM; IN-VIVO;
   BIREFRINGENCE; OCT; THICKNESS; IMAGES; MACULOPATHY; TISSUE
AB We present polarization-sensitive optical coherence tomography (PS-OCT) for quantitative assessment of retinal pathologies in age-related macular degeneration (AMD). On the basis of the polarization scrambling characteristics of the retinal pigment epithelium, novel segmentation algorithms were developed that allow one to segment pathologic features such as drusen and atrophic zones in dry AMD as well as to determine their dimensions. Results from measurements in the eyes of AMD patients prove the ability of PS-OCT for quantitative imaging based on the retinal features polarizing properties. Repeatability measurements were performed in retinas diagnosed with drusen and geographic atrophy in order to evaluate the performance of the described methods. PS-OCT appears as a promising imaging modality for three-dimensional retinal imaging and ranging with additional contrast based on the structures' tissue-inherent polarization properties. (C) 2010 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3499420]
C1 [Baumann, Bernhard; Goetzinger, Erich; Pircher, Michael; Sattmann, Harald; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria.
   [Schuetze, Christopher; Schlanitz, Ferdinand; Ahlers, Christian; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Baumann, B (通讯作者)，Med Univ Vienna, Ctr Med Phys & Biomed Engn, Wahringer Str 13, A-1090 Vienna, Austria.
EM bernhard.baumann@meduniwien.ac.at;
   christoph.hitzenberger@meduniwien.ac.at
OI Baumann, Bernhard/0000-0001-6419-1932; Hitzenberger,
   Christoph/0000-0002-6608-8821; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Michael, Pircher/0000-0001-9285-7527
FU Austrian Science Fund (FWF) [P19624-B02]; European Union [201880]
FX The authors thank Martin Wurm and David Stifter at RECENDT GmbH as well
   as Christoph Wolfl at the Medical University of Vienna for their
   excellent technical support. Financial support by the Austrian Science
   Fund (FWF Grant No. P19624-B02) and from the European Union project FUN
   OCT (FP7 HEALTH, Contract No. 201880) is gratefully acknowledged.
CR Ahlers C., 2009, INVEST OPHTH VIS SCI, V51, P2149
   [Anonymous], 2014, 6082512014 IEC
   Baroni M, 2007, MED ENG PHYS, V29, P432, DOI 10.1016/j.medengphy.2006.06.003
   Baumann B, 2009, J BIOPHOTONICS, V2, P426, DOI 10.1002/jbio.200910031
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cense B, 2004, INVEST OPHTH VIS SCI, V45, P2606, DOI 10.1167/iovs.03-1160
   Chen ZP, 1997, OPT LETT, V22, P64, DOI 10.1364/OL.22.000064
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   deBoer JF, 1997, OPT LETT, V22, P934, DOI 10.1364/OL.22.000934
   Drexler W, 2008, BIOL MED PHYS BIOMED, P1, DOI 10.1007/978-3-540-77550-8
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Fabritius T, 2009, OPT EXPRESS, V17, P15659, DOI 10.1364/OE.17.015659
   Fercher AF, 2003, REP PROG PHYS, V66, P239, DOI 10.1088/0034-4885/66/2/204
   Ferguson RD, 2004, OPT LETT, V29, P2139, DOI 10.1364/OL.29.002139
   Fernandez DC, 2005, OPT EXPRESS, V13, P10200, DOI 10.1364/OPEX.13.010200
   Gotzinger E, 2009, OPT EXPRESS, V17, P4151, DOI 10.1364/OE.17.004151
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   HEE MR, 1992, J OPT SOC AM B, V9, P903, DOI 10.1364/JOSAB.9.000903
   Hitzenberger CK, 2001, OPT EXPRESS, V9, P780, DOI 10.1364/OE.9.000780
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huber R, 2006, OPT EXPRESS, V14, P3225, DOI 10.1364/OE.14.003225
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Koozekanani D, 2001, IEEE T MED IMAGING, V20, P900, DOI 10.1109/42.952728
   Leitgeb R, 2003, OPT EXPRESS, V11, P889, DOI 10.1364/OE.11.000889
   *LIA, 2000, 1361 ANSIZ
   Michels S, 2008, BRIT J OPHTHALMOL, V92, P204, DOI 10.1136/bjo.2007.130047
   Mishra A, 2009, OPT EXPRESS, V17, P23719, DOI 10.1364/OE.17.023719
   Morgner U, 2000, OPT LETT, V25, P111, DOI 10.1364/OL.25.000111
   Mujat M, 2005, OPT EXPRESS, V13, P9480, DOI 10.1364/OPEX.13.009480
   Pircher M, 2004, OPT EXPRESS, V12, P5940, DOI 10.1364/OPEX.12.005940
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Potsaid B, 2008, OPT EXPRESS, V16, P15149, DOI 10.1364/OE.16.015149
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Szkulmowski M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2771569
   WANG XJ, 1995, OPT LETT, V20, P1337, DOI 10.1364/OL.20.001337
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Yamanari M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2841024
NR 41
TC 77
Z9 80
U1 1
U2 8
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD NOV-DEC
PY 2010
VL 15
IS 6
AR 061704
DI 10.1117/1.3499420
PG 9
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 719AI
UT WOS:000287171100011
PM 21198152
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Davis, SJ
   Lyzogubov, VV
   Tytarenko, RG
   Safar, AN
   Bora, NS
   Bora, PS
AF Davis, Stephen J.
   Lyzogubov, Valeriy V.
   Tytarenko, Ruslana G.
   Safar, Ammar N.
   Bora, Nalini S.
   Bora, Puran S.
TI THE EFFECT OF NICOTINE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR
   THERAPY IN A MOUSE MODEL OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE adiponectin; age-related macular degeneration; bevacizumab; choroidal
   neovascularization; mouse model; nicotine acetylcholine receptor;
   platelet-derived growth factor; smoking; vascular endothelial growth
   factor; alpha-bungarotoxin
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; ACETYLCHOLINE-RECEPTORS;
   SMOKING; ADIPONECTIN; BEVACIZUMAB; MACULOPATHY; ANGIOGENESIS;
   INHIBITION; SEVERITY; CELLS
AB Purpose: The purpose of this article is to evaluate the effect of nicotine on anti-vascular endothelial growth factor therapy in the treatment of neovascular age-related macular degeneration.
   Methods: One group of mice received nicotine in drinking water and the other group received water only. Choroidal neovascularization (CNV) was induced with a laser. Nicotinic acetylcholine receptor-alpha 7 (nAChR alpha 7) expression was evaluated by immunohistochemistry. Bevacizumab or adiponectin peptide II (APNpII) was injected intravitreally on Day 7 post-laser, and the effects were evaluated on Days 14 and 21. alpha-Bungarotoxin was injected intraperitoneally on Days 2 to 5, and its effect was evaluated on Day 14.
   Results: Expression of nAChR alpha 7 was 2 to 7 times higher between Days 3 and 7 postlaser compared with naive mice. In water-fed mice, APNpII, bevacizumab, and alpha-bungarotoxin significantly reduced CNV size. In nicotine-fed mice, treatment with APNpII or bevacizumab did not significantly reduce CNV size, whereas alpha-bungarotoxin did have an effect. Comparing water- and nicotine-fed mice, CNV size was 61% to 86% smaller in water-fed mice except for the alpha-bungarotoxin group, where there was no difference. Platelet-derived growth factor and vascular endothelial growth factor expression was 1.5- to 2.5-fold higher at Day 14 in nicotine-treated mice.
   Conclusion: Nicotine significantly blocks the effect of anti-vascular endothelial growth factor therapy in the treatment of laser-induced neovascular age-related macular degeneration. nAChR alpha 7 is significantly upregulated during the formation of CNV, and treatment with an nAChR alpha 7 antagonist decreases CNV size irrespective of nicotine administration. RETINA 32:1171-1180, 2012
C1 [Davis, Stephen J.; Lyzogubov, Valeriy V.; Tytarenko, Ruslana G.; Safar, Ammar N.; Bora, Nalini S.; Bora, Puran S.] Univ Arkansas Med Sci, Jones Eye Inst, Dept Ophthalmol, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences
RP Bora, PS (通讯作者)，Univ Arkansas Med Sci, Jones Eye Inst, Dept Ophthalmol, 4301 W Markham,Mail Slot 523-7, Little Rock, AR 72205 USA.
EM pbora@uams.edu
RI Datta, Sayantan/D-1369-2010
OI Bora, Puran/0000-0003-4781-1217
FU National Institutes of Health [EY 014623, EY 013335]; Pat & Willard
   Walker Eye Research Center, Jones Eye Institute, University of Arkansas
   for Medical Sciences (Little Rock, AR) [1005705]; NATIONAL EYE INSTITUTE
   [R01EY013335, R01EY014623] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health Grants EY 014623 and EY
   013335 and the Pat & Willard Walker Eye Research Center Grant 1005705,
   Jones Eye Institute, University of Arkansas for Medical Sciences (Little
   Rock, AR).
CR Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Bora PS, 2007, FEBS LETT, V581, P1977, DOI 10.1016/j.febslet.2007.04.024
   Brakenhielm E, 2004, P NATL ACAD SCI USA, V101, P2476, DOI 10.1073/pnas.0308671100
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Cooke JP, 2008, TRENDS CARDIOVAS MED, V18, P247, DOI 10.1016/j.tcm.2008.11.007
   Dom AM, 2011, INVEST OPHTH VIS SCI, V52, P4428, DOI 10.1167/iovs.10-5461
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grozio A, 2007, ANTI-CANCER AGENT ME, V7, P461
   Heeschen C, 2002, J CLIN INVEST, V110, P527, DOI 10.1172/JCI200214676
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   Kaliappan S, 2008, FEBS LETT, V582, P3451, DOI 10.1016/j.febslet.2008.09.009
   Kiuchi K, 2008, INVEST OPHTH VIS SCI, V49, P1705, DOI 10.1167/iovs.07-0089
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Lyzogubov VV, 2009, CELL BIOL INT, V33, P765, DOI 10.1016/j.cellbi.2009.04.013
   Patil AJ, 2009, TOXICOLOGY, V259, P69, DOI 10.1016/j.tox.2009.02.004
   Pons M, 2011, INVEST OPHTHALMOL VI
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wu JCF, 2009, J CELL BIOCHEM, V108, P433, DOI 10.1002/jcb.22270
   Yu LL, 2008, INVEST OPHTH VIS SCI, V49, P522, DOI 10.1167/iovs.07-1175
   Ziemssen F, 2009, DRUG AGING, V26, P295, DOI 10.2165/00002512-200926040-00002
NR 31
TC 12
Z9 15
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2012
VL 32
IS 6
BP 1171
EP 1180
DI 10.1097/IAE.0b013e31823496b8
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 948VY
UT WOS:000304532100016
PM 22088983
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tranos, P
   Peter, NM
   Nath, R
   Singh, MV
   Wren, S
   Dimitrakos, S
   Rassam, S
   Kon, C
AF Tranos, P
   Peter, NM
   Nath, R
   Singh, MV
   Wren, S
   Dimitrakos, S
   Rassam, S
   Kon, C
TI Visual function following transpupillary thermotherapy with adjusted
   laser parameters for the treatment of exudative age-related macular
   degeneration: a pilot study
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   transpupillary thermotherapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; FUNCTION QUESTIONNAIRE
AB Purpose: To evaluate the efficacy of transpupillary thermotherapy (TTT) using adjusted laser parameters for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration.
   Methods: TTT was performed on patients with CNV using a diode laser (810 nm) for 60 s in a subthreshold manner. Power settings were varied between 460 and 1200 mW, depending on lesion size, presence of pigment epithelial detachment and the amount of fundal pigmentation and subretinal fluid. LogMAR visual acuity, contrast sensitivity (Pelli-Robson) and metamorphopsia (Amsler chart) were assessed prior to and 6 months following treatment. Subjects also self-administered the National Eye Institute 25-Item Visual Function Questionnaire.
   Results: Thirty occult/minimally classic and eight predominantly classic membranes were treated with TTT. At 6 months, absence or significant reduction of fluorescein leakage was observed in 20 (53%) patients. Stabilization of vision (loss of less than 15 letters) was observed in 25/30 (83%) eyes with occult/minimally classic CNV and 5/8 (63%) eyes with predominantly classic CNV. Improvement of contrast sensitivity was noted in 15 (35%) eyes, in 10 (26%) eyes it remained unchanged and in 13 (34%) eyes it deteriorated. There was no statistically significant effect of TTT on the National Eye Institute 25-Item Visual Function Questionnaire composite or subscale scores.
   Conclusions: TTT using adjusted parameters depending on fundal characteristics appears to be effective in stabilizing subjective and objective visual ability in a considerable number of patients with subfoveal CNV due to age-related macular degeneration. Larger-scale studies are required to confirm the benefit of this technique as opposed to the natural history of occult CNV.
C1 Worthing Gen Hosp, Worthing, England.
   AHEPA Gen Hosp, Thessaloniki, Greece.
C3 Aristotle University of Thessaloniki; Ahepa University Hospital
RP Peter, NM (通讯作者)，Western Eye Hosp, Marylebone Rd, London NW1 5YE, England.
EM neenapeter@yahoo.co.uk
OI Dimitrakos, Stavros/0000-0003-1742-0725
CR Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   ALI F, 2002, COMPREHENSIVE OVERVI
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Auer C, 2002, KLIN MONATSBL AUGENH, V219, P250, DOI 10.1055/s-2002-30649
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Ellis JD, 2000, EYE, V14, P307, DOI 10.1038/eye.2000.78
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1
   LEAT SJ, 1993, OPHTHAL PHYSL OPT, V13, P9, DOI 10.1111/j.1475-1313.1993.tb00420.x
   LENNERSTRAND G, 1989, ACTA OPHTHALMOL, V67, P225
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Nagpal Manish, 2003, Indian Journal of Ophthalmology, V51, P243
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   OOSTERHUIS JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P315, DOI 10.1001/archopht.1995.01100030071024
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   RUBIN GS, 2001, LOW VISION REHABILIT, P27
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
NR 23
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD APR
PY 2006
VL 34
IS 3
BP 226
EP 232
DI 10.1111/j.1442-9071.2006.01198.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 031PU
UT WOS:000236717300007
PM 16671902
DA 2022-11-30
ER

PT J
AU Krebs, I
   Brannath, W
   Guttenberg, C
   Zeiler, F
   Sebag, J
   Binder, S
AF Krebs, Ilse
   Brannath, Werner
   Guttenberg, Carl
   Zeiler, Florian
   Sebag, Jerry
   Binder, Susanne
TI Posterior vitreomacular adhesion: A potential risk factor for exudative
   age-related macular degeneration?
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; HUMAN VITREOUS STRUCTURE; EYE DISEASE;
   PHARMACOLOGICAL VITREOLYSIS; DIABETIC-RETINOPATHY; CIGARETTE-SMOKING; US
   TWIN; DETACHMENT; ASSOCIATIONS; PATHOGENESIS
AB PURPOSE: To compare the state of the posterior vitreous in exudative age-related macular degeneration (AMD) with eyes with nonexudative AMD and controls.
   DESIGN: Prospective, observational case series.
   METHODS: B-scan ultrasonography and optical coherence tomography (OCT) were performed in 163 eyes from 82 subjects older than 55 years, 50 eyes with exudative AMD, 57 with nonexudative AMD, and 56 control eyes. Main outcome measures were the number of eyes with complete posterior vitreous detachment (PVD) by ultrasound and the number of eyes with central vitreomacular adhesion by OCT.
   RESULTS: By ultrasonography, 17 (34.0%) of 50 eyes with exudative AMD had PVD as compared with 41 (71.9%) of 57 eyes with nonexudative AMD (P = .00002) and 34 (60.7%) of 56 controls (P = .017). OCT detected persistent central vitreoretinal adhesion surrounded by a detached posterior vitreous cortex in 18 (36%) of 50 eyes with exudative AMD, significantly higher than in nonexudative AMD (4/57 [7%]; P < .0001) and in controls (6/56 [10%]; P = .002).
   CONCLUSIONS: Persistent attachment of the posterior vitreous cortex to the macula may be another risk factor for the development of exudative AMD via vitreoretinal traction inducing chronic low-grade inflammation, by maintaining macular exposure to cytokines or free radicals in the vitreous gel, or by interfering in transvitreous oxygenation and nutrition of the macula. Inducing PVD may provide prophylactic benefit against exudative AMD.
C1 Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
   Med Univ, Core Unit Med Stat & Informat, Vienna, Austria.
   VMR Inst, Huntington Beach, CA USA.
   Univ So Calif, Dept Ophthalmol, Los Angeles, CA 90089 USA.
C3 Ludwig Boltzmann Institute; University of Southern California
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM Ilse.Krebs@wienkav.at
RI Sebag, J./AAF-3602-2020
OI Sebag, J/0000-0001-8648-5747
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bishop PN, 2004, INVEST OPHTH VIS SCI, V45, P1041, DOI 10.1167/iovs.03-1017
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FOOS R Y, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P480
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Ito Y, 2003, AM J OPHTHALMOL, V135, P351, DOI 10.1016/S0002-9394(02)01944-X
   JALKH A, 1982, ARCH OPHTHALMOL-CHIC, V100, P432
   Johnson Mark W, 2005, Trans Am Ophthalmol Soc, V103, P537
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Sebag J, 2005, Trans Am Ophthalmol Soc, V103, P473
   Sebag J, 1996, OPHTHALMOLOGY, V103, P205
   SEBAG J, 1993, GRAEF ARCH CLIN EXP, V231, P257, DOI 10.1007/BF00919101
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Sebag J, 2002, RETINA-J RET VIT DIS, V22, P1, DOI 10.1097/00006982-200202000-00001
   SEBAG J, 1991, ARCH OPHTHALMOL-CHIC, V109, P966, DOI 10.1001/archopht.1991.01080070078039
   SEBAG J, 1994, INVEST OPHTH VIS SCI, V35, P2976
   Sebag J, 1998, RETINA-J RET VIT DIS, V18, P1
   SEBAG J, 1987, GRAEF ARCH CLIN EXP, V225, P89, DOI 10.1007/BF02160337
   Sebag J, 2000, EUR J OPHTHALMOL, V10, P1
   SEBAG J, 1998, EUANES FDN CLIN OPTH, V1, pCH16
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Stitt AW, 2005, ANN NY ACAD SCI, V1043, P582, DOI 10.1196/annals.1338.066
   Weber-Krause B, 1997, OPHTHALMOLOGE, V94, P619, DOI 10.1007/s003470050170
   WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 36
TC 190
Z9 202
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2007
VL 144
IS 5
BP 741
EP 746
DI 10.1016/j.ajo.2007.07.024
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 229NO
UT WOS:000250811100016
PM 17884003
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Sinha, D
   Blasiak, J
   Kauppinen, A
   Vereb, Z
   Salminen, A
   Boulton, ME
   Petrovski, G
AF Kaarniranta, Kai
   Sinha, Debasish
   Blasiak, Janusz
   Kauppinen, Anu
   Vereb, Zoltan
   Salminen, Antero
   Boulton, Michael E.
   Petrovski, Goran
TI Autophagy and heterophagy dysregulation leads to retinal pigment
   epithelium dysfunction and development of age-related macular
   degeneration
SO AUTOPHAGY
LA English
DT Review
DE AMD; autophagy; heterophagy; inflammasome; lysosome; oxidative stress;
   phagocytosis; proteasome; RPE
ID PHOTORECEPTOR OUTER SEGMENTS; NLRP3 INFLAMMASOME ACTIVATION;
   MITOCHONDRIAL-DNA DAMAGE; OXIDATIVE STRESS; ALPHA-V-BETA-5 INTEGRIN;
   MOLECULAR-MECHANISMS; ALZHEIMERS-DISEASE; CYSTATIN C; RPE CELLS; NALP3
   INFLAMMASOME
AB Age-related macular degeneration (AMD) is a complex, degenerative and progressive eye disease that usually does not lead to complete blindness, but can result in severe loss of central vision. Risk factors for AMD include age, genetics, diet, smoking, oxidative stress and many cardiovascular-associated risk factors. Autophagy is a cellular housekeeping process that removes damaged organelles and protein aggregates, whereas heterophagy, in the case of the retinal pigment epithelium (RPE), is the phagocytosis of exogenous photoreceptor outer segments. Numerous studies have demonstrated that both autophagy and heterophagy are highly active in the RPE. To date, there is increasing evidence that constant oxidative stress impairs autophagy and heterophagy, as well as increases protein aggregation and causes inflammasome activation leading to the pathological phenotype of AMD. This review ties together these crucial pathological topics and reflects upon autophagy as a potential therapeutic target in AMD.
C1 [Kaarniranta, Kai; Kauppinen, Anu] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
   [Sinha, Debasish] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90131 Lodz, Poland.
   [Vereb, Zoltan; Petrovski, Goran] Univ Debrecen, Med & Hlth Sci Ctr, Dept Ophthalmol, H-4012 Debrecen, Hungary.
   [Vereb, Zoltan; Petrovski, Goran] Univ Debrecen, Med & Hlth Sci Ctr, Stem Cells & Eye Res Lab, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary.
   [Salminen, Antero] Univ Eastern Finland, Dept Neurol, Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
   [Boulton, Michael E.] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL USA.
   [Petrovski, Goran] Univ Debrecen, Med & Hlth Sci Ctr, Hungarian Acad Sci, Apoptosis & Genom Res Grp, H-4012 Debrecen, Hungary.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; Johns Hopkins University; Johns Hopkins Medicine;
   University of Lodz; University of Debrecen; University of Debrecen;
   University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; State University System of Florida; University of
   Florida; Hungarian Academy of Sciences; University of Debrecen
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
EM kai.kaarniranta@uef.fi
RI Vereb, Zoltan/AAR-4092-2020; Vereb, Zoltan/I-6356-2019
OI Vereb, Zoltan/0000-0002-9518-2155; Petrovski, Goran/0000-0003-2905-9252;
   Kaarniranta, Kai/0000-0003-2600-8679; /0000-0002-0035-1471; Blasiak,
   Janusz/0000-0001-9539-9584
FU EVO grants of Kuopio University Hospital; Finnish Cultural Foundation;
   North Savo Fund; Finnish Eye Foundation; Finnish Funding Agency for
   Technology and Innovation; Health Research Council of the Academy of
   Finland; Paivikki and Sakari Sohlberg Foundation; National Institutes of
   Health (USA) [EY019688, EY021626, EY019037-S]; Hungarian Scientific
   Research Fund [OTKA PD 101316]; TaMOP [4.2.2.A-11/1/KONV-2012-0023];
   European Social Fund; European Regional Development Fund; NATIONAL EYE
   INSTITUTE [R01EY019037, R21EY021626, R01EY019688] Funding Source: NIH
   RePORTER
FX This work was supported by the EVO grants of Kuopio University Hospital
   (K.K.), the Finnish Cultural Foundation and its North Savo Fund (K.K.),
   the Finnish Eye Foundation (K.K.), the Finnish Funding Agency for
   Technology and Innovation (K.K.), Health Research Council of the Academy
   of Finland (K.K., A.K.), and the Paivikki and Sakari Sohlberg Foundation
   (A.K.), National Institutes of Health (USA) grants EY019688 and EY021626
   (MEB), EY019037-S (D.S.) D.S. is a recipient of the Sybil B. Harrington
   Special Scholar award for Macular Degeneration from Research to Prevent
   Blindness, the Hungarian Scientific Research Fund (OTKA PD 101316) and
   the TaMOP 4.2.2.A-11/1/KONV-2012-0023 "VED-ELEM" project. The project is
   implemented through the New Hungary Development Plan co-financed by the
   European Social Fund and the European Regional Development Fund.
CR Alexeyev MF, 2009, FEBS J, V276, P5768, DOI 10.1111/j.1742-4658.2009.07269.x
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Baltazar GC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049635
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   BOK D, 1993, J CELL SCI, P189
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Boyault C, 2007, GENE DEV, V21, P2172, DOI 10.1101/gad.436407
   Braak H, 2011, J NEURAL TRANSM, V118, P809, DOI 10.1007/s00702-010-0508-2
   Brunk UT, 1995, GERONTOLOGY, V41, P201
   Caberoy NB, 2010, EMBO J, V29, P3898, DOI 10.1038/emboj.2010.265
   Chekhonin VP, 2012, CURR CANCER DRUG TAR
   Chen PM, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-10
   Choi JH, 2012, APMIS, V120, P597, DOI 10.1111/j.1600-0463.2012.02876.x
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Dejneka NS, 2004, MOL VIS, V10, P964
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   ELHIFNAWI E, 1995, ANN ANAT, V177, P11, DOI 10.1016/S0940-9602(11)80123-8
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Garron L K, 1963, Trans Am Ophthalmol Soc, V61, P545
   Geetha T, 2012, BIOMARKERS, V17, P99, DOI 10.3109/1354750X.2011.653986
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hammer M, 2006, MOL VIS, V12, P1348
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Hickley NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1506, DOI 10.1001/archophthalmol.2011.321
   Hohn A, 2010, FREE RADICAL BIO MED, V48, P1100, DOI 10.1016/j.freeradbiomed.2010.01.030
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Im E, 2007, EXP EYE RES, V84, P383, DOI 10.1016/j.exer.2006.05.017
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Jung T, 2007, ANN NY ACAD SCI, V1119, P97, DOI 10.1196/annals.1404.008
   Jung T, 2009, MOL ASPECTS MED, V30, P191, DOI 10.1016/j.mam.2009.04.001
   Juuti-Uusitalo K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030089
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 2012, FUTURE MED CHEM, V4, P2153, DOI [10.4155/FMC.12.169, 10.4155/fmc.12.169]
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim SH, 2008, J NEUROSCI RES, V86, P2943, DOI 10.1002/jnr.21738
   Kinchen JM, 2008, NAT REV MOL CELL BIO, V9, P781, DOI 10.1038/nrm2515
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107
   Koike M, 2003, MOL CELL NEUROSCI, V22, P146, DOI 10.1016/S1044-7431(03)00035-6
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Kurz T, 2008, BBA-GEN SUBJECTS, V1780, P1291, DOI 10.1016/j.bbagen.2008.01.009
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Kuusisto E, 2002, NEUROPATH APPL NEURO, V28, P228, DOI 10.1046/j.1365-2990.2002.00394.x
   Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liu J, 2008, INVEST OPHTH VIS SCI, V49, P772, DOI 10.1167/iovs.07-0675
   Mallavarapu M, 2010, ADV EXP MED BIOL, V664, P123, DOI 10.1007/978-1-4419-1399-9_15
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Mellen MA, 2008, CELL DEATH DIFFER, V15, P1279, DOI 10.1038/cdd.2008.40
   Michaelides M, 2011, ARCH OPHTHALMOL-CHIC, V129, P30, DOI 10.1001/archophthalmol.2010.321
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nakamura T, 2007, CELL MOL LIFE SCI, V64, P1609, DOI 10.1007/s00018-007-6525-0
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Nandrot EF, 2008, OPHTHALMIC RES, V40, P120, DOI 10.1159/000119861
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006
   Nishikawa T, 2010, ANGIOGENESIS, V13, P227, DOI 10.1007/s10456-010-9180-2
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Paraoan L, 2010, VISION RES, V50, P737, DOI 10.1016/j.visres.2009.10.022
   Pastore N, 2013, EMBO MOL MED, V5, P397, DOI 10.1002/emmm.201202046
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Qin SF, 2008, J BIOL CHEM, V283, P6744, DOI 10.1074/jbc.M708848200
   Reggiori Fulvio, 2012, Int J Cell Biol, V2012, P156272, DOI 10.1155/2012/156272
   Rodriguez-Muela N, 2012, CELL DEATH DIFFER, V19, P162, DOI 10.1038/cdd.2011.88
   Rolling F, 2006, Bull Mem Acad R Med Belg, V161, P497
   Russo R, 2013, CURR OPIN PHARMACOL, V13, P72, DOI 10.1016/j.coph.2012.09.004
   Ryhanen T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/798052
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Salminen A, 2012, AGING-US, V4, P166, DOI 10.18632/aging.100444
   Salminen A, 2012, PROG NEUROBIOL, V96, P87, DOI 10.1016/j.pneurobio.2011.11.005
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468
   Tong JJ, 2010, PROTEIN CELL, V1, P907, DOI 10.1007/s13238-010-0121-z
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Viiri J, 2010, MOL VIS, V16, P1399
   Vision 2020, RIGHT SIGHT BLINDN V
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang Yao, 2011, Chin J Cancer, V30, P690, DOI 10.5732/cjc.011.10056
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Wilkinson JE, 2012, AGING CELL, V11, P675, DOI 10.1111/j.1474-9726.2012.00832.x
   Winkler BS, 1999, MOL VIS, V5
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1968, J CELL BIOL, V39, P169, DOI 10.1083/jcb.39.1.169
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zigler JS, 2011, J CELL SCI, V124, P523, DOI 10.1242/jcs.078790
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 151
TC 229
Z9 238
U1 0
U2 43
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JUL 1
PY 2013
VL 9
IS 7
BP 973
EP 984
DI 10.4161/auto.24546
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 201WS
UT WOS:000323174300004
PM 23590900
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Colijn, JM
   Buitendijk, GHS
   Prokofyeva, E
   Alves, D
   Cachulo, ML
   Khawaja, AP
   Cougnard-Gregoire, A
   Merle, BMJ
   Korb, C
   Erke, MG
   Bron, A
   Anastasopoulos, E
   Meester-Smoor, MA
   Segato, T
   Piermarocchi, S
   de Jong, PTVM
   Vingerling, JR
   Topouzis, F
   Creuzot-Garcher, C
   Bertelsen, G
   Pfeiffer, N
   Fletcher, AE
   Foster, PJ
   Silva, R
   Korobelnik, JF
   Delcourt, C
   Klaver, CCW
AF Colijn, Johanna M.
   Buitendijk, Gabrielle H. S.
   Prokofyeva, Elena
   Alves, Dalila
   Cachulo, Maria L.
   Khawaja, Anthony P.
   Cougnard-Gregoire, Audrey
   Merle, Benedicte M. J.
   Korb, Christina
   Erke, Maja G.
   Bron, Alain
   Anastasopoulos, Eleftherios
   Meester-Smoor, Magda A.
   Segato, Tatiana
   Piermarocchi, Stefano
   de Jong, Paulus T. V. M.
   Vingerling, Johannes R.
   Topouzis, Fotis
   Creuzot-Garcher, Catherine
   Bertelsen, Geir
   Pfeiffer, Norbert
   Fletcher, Astrid E.
   Foster, Paul J.
   Silva, Rufino
   Korobelnik, Jean-Francois
   Delcourt, Cecile
   Klaver, Caroline C. W.
CA EYE-RISK Consortium
   European Eye Epidemiology E
TI Prevalence of Age-Related Macular Degeneration in Europe
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; BEAVER DAM EYE;
   VISUAL IMPAIRMENT; HEART-DISEASE; BIRTH COHORT; MACULOPATHY; POPULATION;
   BLINDNESS; TRENDS
AB Purpose: Age-related macular degeneration (AMD) is a frequent, complex disorder in elderly of European ancestry. Risk profiles and treatment options have changed considerably over the years, which may have affected disease prevalence and outcome. We determined the prevalence of early and late AMD in Europe from 1990 to 2013 using the European Eye Epidemiology (E3) consortium, and made projections for the future.
   Design: Meta-analysis of prevalence data. Participants: A total of 42 080 individuals 40 years of age and older participating in 14 population-based cohorts from 10 countries in Europe.
   Methods: AMD was diagnosed based on fundus photographs using the Rotterdam Classification. Prevalence of early and late AMD was calculated using random-effects meta-analysis stratified for age, birth cohort, gender, geographic region, and time period of the study. Best-corrected visual acuity (BCVA) was compared between late AMD subtypes; geographic atrophy (GA) and choroidal neovascularization (CNV).
   Main Outcome Measures: Prevalence of early and late AMD, BCVA, and number of AMD cases.
   Results: Prevalence of early AMD increased from 3.5% (95% confidence interval [CI] 2.1% -5.0%) in those aged 55-59 years to 17.6% (95% CI 13.6%-21.5%) in those aged >= 85 years; for late AMD these figures were 0.1% (95% CI 0.04%-0.3%) and 9.8% (95% CI 6.3%-13.3%), respectively. We observed a decreasing prevalence of late AMD after 2006, which became most prominent after age 70. Prevalences were similar for gender across all age groups except for late AMD in the oldest age category, and a trend was found showing a higher prevalence of CNV in Northern Europe. After 2006, fewer eyes and fewer >= 80-year-old subjects with CNV were visually impaired (P = 0.016). Projections of AMD showed an almost doubling of affected persons despite a decreasing prevalence. By 2040, the number of individuals in Europe with early AMD will range between 14.9 and 21.5 million, and for late AMD between 3.9 and 4.8 million.
   Conclusion: We observed a decreasing prevalence of AMD and an improvement in visual acuity in CNV occuring over the past 2 decades in Europe. Healthier lifestyles and implementation of anti-vascular endothelial growth factor treatment are the most likely explanations. Nevertheless, the numbers of affected subjects will increase considerably in the next 2 decades. AMD continues to remain a significant public health problem among Europeans. (C) 2017 by the American Academy of Ophthalmology.
C1 [Colijn, Johanna M.; Buitendijk, Gabrielle H. S.; Meester-Smoor, Magda A.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
   [Colijn, Johanna M.; Buitendijk, Gabrielle H. S.; Meester-Smoor, Magda A.; de Jong, Paulus T. V. M.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Prokofyeva, Elena] Sci Inst Publ Hlth WIV ISP, Brussels, Belgium.
   [Prokofyeva, Elena] Fed Agcy Med & Hlth Prod, Brussels, Belgium.
   [Cachulo, Maria L.; Silva, Rufino] Univ Coimbra FMUC, Fac Med, Coimbra, Portugal.
   [Cachulo, Maria L.; Silva, Rufino] CHUC, Dept Ophthalmol, Coimbra, Portugal.
   [Alves, Dalila; Cachulo, Maria L.; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Khawaja, Anthony P.] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Sch Clin Med, Cambridge, England.
   [Khawaja, Anthony P.; Foster, Paul J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Khawaja, Anthony P.; Cougnard-Gregoire, Audrey; Merle, Benedicte M. J.; Foster, Paul J.; Korobelnik, Jean-Francois; Delcourt, Cecile] UCL Inst Ophthalmol, London, England.
   [Korb, Christina; Pfeiffer, Norbert] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, INSERM, Team LEHA, Bordeaux, France.
   [Korb, Christina; Pfeiffer, Norbert] Univ Med Ctr Mainz, Dept Ophthalmol, Mainz, Germany.
   [Bertelsen, Geir] UiT Arctic Univ Norway, Univ Hosp North Norway, Tromso, Norway.
   [Erke, Maja G.] Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
   [Bron, Alain; Creuzot-Garcher, Catherine] Univ Hosp, Dept Ophthalmol, Eye & Nutr Res Grp, Dijon, France.
   [Anastasopoulos, Eleftherios; Topouzis, Fotis] Aristotle Univ Thessaloniki, Dept Ophthalmol, AHEPA Hosp, Thessaloniki, Greece.
   [Foster, Paul J.] UCL Inst Ophthalmol, Integrat Epidemiol, London, England.
   [Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Segato, Tatiana; Piermarocchi, Stefano] Univ Padua, Dept Ophthalmol, Padua, Italy.
   [de Jong, Paulus T. V. M.] AMC, NIN, Inst Royal Netherlands Acad Arts & Sci KNAW, Dept Ophthalmol, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] LUMC, Leiden, Netherlands.
   [Fletcher, Astrid E.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England.
   [Klaver, Caroline C. W.] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Universidade de Coimbra; Universidade de Coimbra;
   Universidade de Coimbra; University of Cambridge; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite de Bordeaux; Johannes Gutenberg University of
   Mainz; UiT The Arctic University of Tromso; University Hospital of North
   Norway; University of Oslo; CHU Dijon Bourgogne; Institut Agro; AgroSup
   Dijon; Universite de Bourgogne; Aristotle University of Thessaloniki;
   Ahepa University Hospital; University of London; University College
   London; CHU Bordeaux; University of Padua; Royal Netherlands Academy of
   Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW);
   University of Amsterdam; Academic Medical Center Amsterdam; University
   of London; London School of Hygiene & Tropical Medicine; Radboud
   University Nijmegen
RP Klaver, CCW (通讯作者)，Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM c.c.w.klaver@erasmusmc.nl
RI Bron, Alain/AAP-8010-2020; COUGNARD-GREGOIRE, Audrey/T-4443-2019; Silva,
   Rufino M/J-2817-2012; Kersten, Eveline/P-8173-2015; Bertelsen,
   Geir/ABB-9865-2021; Grauslund, Jakob/J-1031-2014; Calado, Sofia
   M./K-2202-2016; Pfeiffer, Norbert/AAO-7586-2020; Merle, Benedicte
   MJ/AAQ-5021-2021; Klaver, Caroline C.W./A-2013-2016; Foster,
   Paul/V-7288-2019; Hollander, Anneke den/N-4911-2014; Emri,
   Eszter/ABE-9363-2020; Delcourt, Cecile/I-2627-2013; Merle, Benedicte
   MJ/F-1247-2015; De la cerda, Berta/L-7039-2014; Arango-Gonzalez,
   Blanca/AAR-7427-2021; KOROBELNIK, Jean-Francois/A-5448-2016;
   Diaz-Corrales, Francisco J./L-7559-2014
OI Bron, Alain/0000-0002-7265-931X; COUGNARD-GREGOIRE,
   Audrey/0000-0002-1494-5764; Silva, Rufino M/0000-0001-8676-0833;
   Grauslund, Jakob/0000-0001-5019-0736; Calado, Sofia
   M./0000-0001-5509-4145; Merle, Benedicte MJ/0000-0003-1332-0954; Foster,
   Paul/0000-0002-4755-177X; Delcourt, Cecile/0000-0002-2099-0481; Merle,
   Benedicte MJ/0000-0003-1332-0954; De la cerda,
   Berta/0000-0001-5603-6473; Arango-Gonzalez, Blanca/0000-0002-9045-182X;
   Alves, Dalila/0000-0003-3296-179X; Michaelides,
   Michel/0000-0002-1552-7046; Mones, Jordi/0000-0003-3685-2160;
   Azuara-Blanco, Augusto/0000-0002-4805-9322; Nunes,
   Sandrina/0000-0001-5401-9637; Cachulo, Maria Luz/0000-0002-0900-4548;
   Rahi, Jugnoo/0000-0002-5718-9209; Topouzis, Fotis/0000-0002-8966-537X;
   Bertelsen, Geir/0000-0001-5605-4321; Verhoeven,
   Virginie/0000-0001-7359-7862; piermarocchi, stefano/0000-0003-0977-9287;
   Hammond, Christopher/0000-0002-3227-2620; Chakravarthy,
   Usha/0000-0002-2606-3734; Erke, Maja Gran/0000-0002-7476-0286; Biarnes,
   Marc/0000-0003-2584-4894; Diaz-Corrales, Francisco
   J./0000-0002-5752-0205; Pfeiffer, Norbert/0000-0002-5766-2617; Klaver,
   Caroline/0000-0002-2355-5258; Khawaja, Anthony/0000-0001-6802-8585;
   Vujosevic, Stela/0000-0001-6773-9967; Ribeiro, Maria
   Luisa/0000-0002-5801-8487; bhatia, vaibhav/0000-0003-4553-7824;
   Bretillon, Lionel/0000-0002-6957-100X; Schweitzer,
   Cedric/0000-0002-2162-9479; Bergen, Arthur/0000-0002-6333-9576
FU Netherlands Organization for the Health Research and Development
   (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Ministry
   of Education, Culture and Science, the Ministry for Health, Welfare and
   Sports; European Commission (DG XII); Municipality of Rotterdam;
   government of Rhineland-Palatinate ("Stiftung Rheinland-Pfalz fur
   Innovation,") [AZ 961-386261/733]; "Wissen schafft Zukunft" and " Center
   for Translational Vascular Biology (CTVB)" of the Johannes
   Gutenberg-University of Mainz; GHS; H2020-RIA, EYE-RISK [634479];
   Oogfonds; MaculaFonds; LSBS; Novartis Fonds; Erasmus Medical Center and
   Erasmus University, Rotterdam;  [2015-36]; MRC [MR/K023721/1] Funding
   Source: UKRI; Medical Research Council [MR/K023721/1] Funding Source:
   researchfish
FX The Rotterdam Study is funded by Erasmus Medical Center and Erasmus
   University, Rotterdam, Netherlands Organization for the Health Research
   and Development (ZonMw), the Research Institute for Diseases in the
   Elderly (RIDE), the Ministry of Education, Culture and Science, the
   Ministry for Health, Welfare and Sports, the European Commission (DG
   XII), and the Municipality of Rotterdam. The authors are grateful to the
   study participants, the staff from the Rotterdam Study, and the
   participating general practitioners and pharmacists.; The Gutenberg
   Health Study (GHS) is funded through the government of
   Rhineland-Palatinate ("Stiftung Rheinland-Pfalz fur Innovation,"
   contract AZ 961-386261/733), the research programs "Wissen schafft
   Zukunft" and " Center for Translational Vascular Biology (CTVB)" of the
   Johannes Gutenberg-University of Mainz, and its contract with Boehringer
   Ingelheim and PHILIPS Medical Systems, including an unrestricted grant
   for the GHS. The authors thank all study participants for their
   willingness to provide data for this research project and we are
   indebted to all coworkers for their enthusiastic commitment.; H2020-RIA,
   EYE-RISK, grant number: 634479. Uitzicht grant number: 2015-36,
   Oogfonds, MaculaFonds, LSBS, Novartis Fonds. The sponsors and funding
   organization had no role in the design or conduct of this research.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bauer P, 2008, KLIN MONATSBL AUGENH, V225, P376, DOI 10.1055/s-2008-1027264
   Bertram B, 2014, OPHTHALMOLOGE, V111, P757, DOI 10.1007/s00347-013-2966-z
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Cachulo MD, 2016, ACTA OPHTHALMOL, V94, pE442, DOI 10.1111/aos.12950
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Claessen H, 2012, EUR J EPIDEMIOL, V27, P519, DOI 10.1007/s10654-012-9705-7
   Crimmins EM, 2009, DEMOGRAPHY, V46, P627, DOI 10.1353/dem.0.0070
   Davies AR, 2007, EUR HEART J, V28, P2142, DOI 10.1093/eurheartj/ehm272
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 2016, EUR J EPIDEMIOL, V31, P197, DOI 10.1007/s10654-015-0098-2
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Granstam E, 2016, ACTA OPHTHALMOL, V94, P646, DOI 10.1111/aos.13187
   HALDANE JBS, 1956, ANN HUM GENET, V20, P309
   Heraghty J, 2012, AM J PUBLIC HEALTH, V102, P1655, DOI 10.2105/AJPH.2012.300657
   Hoeg TB, 2016, OPHTHAL EPIDEMIOL, V23, P53, DOI 10.3109/09286586.2015.1066396
   Huang GH, 2003, AM J EPIDEMIOL, V157, P721, DOI 10.1093/aje/kwg011
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Jungjohann SM, 2005, BRIT J NUTR, V93, P361, DOI 10.1079/BJN20041333
   Keenan TDL, 2012, BRIT J OPHTHALMOL, V96, P413, DOI 10.1136/bjophthalmol-2011-300338
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Koch MB, 2015, EUR J PREV CARDIOL, V22, P189, DOI 10.1177/2047487313509495
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Marques AP, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009006
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   OECD, 2015, OB AD 2013 NEAR YEAR
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Plessz M, 2015, BRIT J NUTR, V114, P979, DOI 10.1017/S0007114515002615
   Pot GK, 2015, EUR J CLIN NUTR, V69, P817, DOI 10.1038/ejcn.2014.223
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Satizabal CL, 2016, NEW ENGL J MED, V374, P523, DOI 10.1056/NEJMoa1504327
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   WANG J, 2016, BIOMED RES INT, V2016, DOI DOI 10.1155/2016/8212063
   Wang YT, 2016, JAMA OPHTHALMOL, V134, P222, DOI 10.1001/jamaophthalmol.2015.5332
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
NR 51
TC 235
Z9 238
U1 0
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2017
VL 124
IS 12
BP 1753
EP 1763
DI 10.1016/j.ophtha.2017.05.035
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM9JZ
UT WOS:000415586000014
PM 28712657
OA Green Published, Green Accepted, hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Cassels, NK
   Wild, JM
   Margrain, TH
   Chong, V
   Acton, JH
AF Cassels, Nicola K.
   Wild, John M.
   Margrain, Tom H.
   Chong, Victor
   Acton, Jennifer H.
TI The use of microperimetry in assessing visual function in age-related
   macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE microperimetry; age-related macular degeneration; optical coherence
   tomography; visual function; systematic review
ID OPTICAL-COHERENCE-TOMOGRAPHY; OUTER RETINAL TUBULATION; MEDIATED
   DARK-ADAPTATION; GEOGRAPHIC ATROPHY; MULTIFOCAL ELECTRORETINOGRAPHY;
   CHOROIDAL NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; RETICULAR
   PSEUDODRUSEN; READING SPEED; SENSITIVITY
AB Microperimetry is a novel technique for assessing visual function that appears particularly suitable for age-related macular degeneration (AMD). Compared with standard automated perimetry, microperimetry offers several unique features. It simultaneously images the fundus, incorporates an eye-tracking system to correct the stimulus location for fixation loss, and identifies any preferred retinal loci. We identified 52 articles that met the inclusion criteria for a systematic review of microperimetry in the assessment of visual function in AMD. We discuss microperimetry and AMD in relation to disease severity, structural imaging outcomes, other measures of visual function, and evaluation of the efficacy of surgical and/or medical therapies in clinical trials. The evidence for the use of microperimetry in the functional assessment of AMD is encouraging. Disruptions of the ellipsoid zone band and retinal pigment epithelium are clearly associated with reduced differential light sensitivity despite the maintenance of good visual acuity. Reduced differential light sensitivity is also associated with outer segment thinning and retinal pigment epithelium thickening in early AMD and with both a thickening and a thinning of the whole retina in choroidal neovascularization. Microperimetry, however, lacks the robust diffuse and focal loss age-corrected probability analyses associated with standard automated perimetry, and the technique is currently limited by this omission. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Cassels, Nicola K.; Wild, John M.; Margrain, Tom H.; Acton, Jennifer H.] Cardiff Univ, Cardiff Ctr Vis Sci, Cardiff, S Glam, Wales.
   [Chong, Victor] Oxford Univ Hosp NHS Trust, Oxford Eye Hosp, Oxford, England.
C3 Cardiff University; Oxford University Hospitals NHS Foundation Trust
RP Wild, JM (通讯作者)，Cardiff Univ, Cardiff Ctr Vis Sci, Coll Biomed & Life Sci, Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales.
EM wildjm@cardiff.ac.uk
RI Chong, Victor/Q-6565-2018; Acton, Jennifer/AAU-3307-2021
OI Chong, Victor/0000-0002-7693-522X; Acton, Jennifer/0000-0002-0347-7651
FU Cardiff University; Fight for Sight [1463/64]
FX Nicola Cassels is in receipt of a postgraduate research studentship from
   Cardiff University. Jennifer Acton was also in receipt of a grant by
   Fight for Sight (grant number 1463/64).
CR Acton JH, 2013, CAN J OPHTHALMOL, V48, P358, DOI 10.1016/j.jcjo.2013.03.021
   Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Acton JH, 2011, OPTOMETRY VISION SCI, V88, P1288, DOI 10.1097/OPX.0b013e31822b3746
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alexander P, 2012, EYE, V26, P678, DOI 10.1038/eye.2012.7
   Amore FM, 2013, CAN J OPHTHALMOL, V48, P420, DOI 10.1016/j.jcjo.2013.07.012
   Anastassiou G, 2013, RESTOR NEUROL NEUROS, V31, P571, DOI 10.3233/RNN-130322
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Chieh JJ, 2008, RETINA-J RET VIT DIS, V28, P1522, DOI 10.1097/IAE.0b013e318186c634
   Cho HJ, 2013, AM J OPHTHALMOL, V155, P118, DOI 10.1016/j.ajo.2012.07.009
   Denniss J, 2016, INVEST OPHTH VIS SCI, V57, P5449, DOI 10.1167/iovs.16-20222
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Dunavoelgyi R, 2011, ACTA OPHTHALMOL, V89, P166, DOI 10.1111/j.1755-3768.2009.01646.x
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Giacomelli G, 2013, INVEST OPHTH VIS SCI, V54, P4403, DOI 10.1167/iovs.12-10734
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Grenga PL, 2013, CAN J OPHTHALMOL, V48, P394, DOI 10.1016/j.jcjo.2013.04.006
   Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Hartmann KI, 2015, OSLI RETINA, V46, P824, DOI 10.3928/23258160-20150909-06
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hautamaki A, 2014, ACTA OPHTHALMOL, V92, P51, DOI 10.1111/j.1755-3768.2012.02556.x
   Heijl A, 1987, DOC OPHTHALMOL PROC, P153
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Iaculli C, 2015, RETINA-J RET VIT DIS, V35, P1979, DOI 10.1097/IAE.0000000000000609
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lazzeri S, 2015, OPHTHALMOLOGICA, V233, P74, DOI 10.1159/000371393
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   Mettu PS, 2011, RETINA-J RET VIT DIS, V31, P1637, DOI 10.1097/IAE.0b013e31821800e0
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Munk MR, 2013, AM J OPHTHALMOL, V156, P633, DOI 10.1016/j.ajo.2013.05.037
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Pilotto E, 2016, JAMA OPHTHALMOL, V134, P873, DOI 10.1001/jamaophthalmol.2016.1535
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sabour-Pickett S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/268438
   Sato T, 2015, RETINA-J RET VIT DIS, V35, P1292, DOI 10.1097/IAE.0000000000000505
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Schmetterer L, 2013, EUR J OPHTHALMOL, V23, P605
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Tao LW, 2016, CLIN EXP OPHTHALMOL, V44, P422, DOI 10.1111/ceo.12685
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   WEBB RH, 1981, IEEE T BIO-MED ENG, V28, P488, DOI 10.1109/TBME.1981.324734
   *WHO, PRIOR EYE DIS
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 80
TC 33
Z9 34
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN-FEB
PY 2018
VL 63
IS 1
BP 40
EP 55
DI 10.1016/j.survophthal.2017.05.007
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP5QF
UT WOS:000417673300003
PM 28579549
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Vallee, A
AF Vallee, Alexandre
TI Curcumin and Wnt/beta-catenin signaling in exudative age-related macular
   degeneration (Review)
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Review
DE age-related macular degeneration; Wnt; VEGF; curcumin; oxidative stress;
   inflammation; angiogenesis
ID ENDOTHELIAL GROWTH-FACTOR; LOW-DENSITY-LIPOPROTEIN; INDUCIBLE FACTOR-I;
   OXIDATIVE STRESS; LACTATE-DEHYDROGENASE; VEGF EXPRESSION; BETA-CATENIN;
   CCL2/CX3CR1-DEFICIENT MICE; MOLECULAR-MECHANISMS; DIETHYL DISUCCINATE
AB Curcumin is a natural product widely used due to its pharmacological effects. Nevertheless, only a limited number of studies concerning the effects of curcumin on exudative age-related macular degeneration (AMD) is currently available. Since ophthalmic diseases, including exudative AMD, have a marked impact on public health, the prevention and therapy of ophthalmic disorders remain of increasing concern. Exudative AMD is characterized by choroidal neovascularization (CNV) invading the subretinal space, ultimately enhancing exudation and hemorrhaging. The exudative AMD subtype corresponds to 10 to 15% of cases of macular degeneration; however, the occurrence of this subtype has been reported as the major cause of vision loss and blindness, with the occurrence of CNV being responsible for 80% of the cases with vision loss. In CNV increased expression of VEGF has been observed, stimulated by the overactivation of Wnt/beta-catenin signaling pathway. The stimulation of the Wnt/beta-catenin signaling pathway is responsible for the activation of several cellular mechanisms, simultaneously enhancing inflammation, oxidative stress and angiogenesis in numerous diseases, including ophthalmic disorders. Some studies have previously demonstrated the possible advantage of the use of curcumin for the inhibition of Wnt/beta-catenin signaling. In the present review article, the different mechanisms of curcumin are described concerning its effects on oxidative stress, inflammation and angiogenesis in exudative AMD, by interacting with Wnt/beta-catenin signaling.
C1 [Vallee, Alexandre] Foch Hosp, Dept Epidemiol data Biostat, Delegat Clin Res & Innovat dRcI, F-92150 Suresnes, France.
C3 Hospital Foch
RP Vallee, A (通讯作者)，Foch Hosp, Dept Epidemiol data Biostat, Delegat Clin Res & Innovat dRcI, F-92150 Suresnes, France.
EM alexandre.g.vallee@gmail.com
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93
   Al-Harthi L, 2012, J NEUROIMMUNE PHARM, V7, P725, DOI 10.1007/s11481-012-9412-x
   Allegri P, 2010, CLIN OPHTHALMOL, V4, P1201, DOI 10.2147/OPTH.S13271
   Ambacher KK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046885
   Ambati J, 2011, INVEST OPHTH VIS SCI, V52, P2166, DOI 10.1167/iovs.11-7328
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Gimenez-Bastida JA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157937
   Arbiser JL, 1998, MOL MED, V4, P376, DOI 10.1007/BF03401744
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548
   Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Birdsey GM, 2015, DEV CELL, V32, P82, DOI 10.1016/j.devcel.2014.11.016
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Brambilla D, 2008, NUTR J, V7, DOI 10.1186/1475-2891-7-29
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9
   Bucolo C, 2019, J CELL PHYSIOL, V234, P17295, DOI 10.1002/jcp.28347
   Cao K, 2018, J CLIN PATHOL, V71, P1090, DOI 10.1136/jclinpath-2018-205320
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Carpenter AC, 2015, DEVELOPMENT, V142, P972, DOI 10.1242/dev.120022
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Chen WH, 2005, CHINESE MED J-PEKING, V118, P2052
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Choi HJ, 2015, CANCER METAST REV, V34, P19, DOI 10.1007/s10555-014-9538-9
   Chu XK, 2013, BIOENGINEERED, V4, P130, DOI 10.4161/bioe.22949
   Clemons TE., 2005, AREDS REPORT NO 19 O, V112, P539, DOI [10.1016/j.ophtha.2004.10.047, DOI 10.1016/J.OPHTHA.2004.10.047]
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Coffe V, 2006, NEUROCHEM RES, V31, P103, DOI 10.1007/s11064-005-9236-7
   Compagni A, 2000, CANCER RES, V60, P7163
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Cruciat CM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015081
   da Cruz BO, 2020, NUTR REV, V78, P207, DOI 10.1093/nutrit/nuz058
   Dai ZY, 2013, J CELL BIOCHEM, V114, P1020, DOI 10.1002/jcb.24441
   Dhup S, 2012, CURR PHARM DESIGN, V18, P1319, DOI 10.2174/138161212799504902
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   DUGUID IGM, 1992, CURR EYE RES, V11, P153, DOI 10.3109/02713689208999526
   Easwaran V, 2003, CANCER RES, V63, P3145
   ELNER SG, 1992, LAB INVEST, V66, P200
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021
   Fuhrmann Sabine, 2008, Organogenesis, V4, P60
   Fujimura N, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00138
   Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-13
   Ghasemi F, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152556
   Giatromanolaki A, 2006, GYNECOL ONCOL, V103, P912, DOI 10.1016/j.ygyno.2006.05.043
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Grisanti S, 2015, RETINA-J RET VIT DIS, V35, P764, DOI 10.1097/IAE.0000000000000385
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Gururaj AE, 2002, BIOCHEM BIOPH RES CO, V297, P934, DOI 10.1016/S0006-291X(02)02306-9
   Hagglund AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081158
   Hatefi A, 2002, J CONTROL RELEASE, V80, P9, DOI 10.1016/S0168-3659(02)00008-1
   He MS, 2014, ONCOL REP, V32, P173, DOI 10.3892/or.2014.3206
   Howell JC, 2013, MOL VIS, V19, P544
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Huang W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152833
   Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jiang X, 2019, MED SCI MONITOR, V25, P7451, DOI 10.12659/MSM.918364
   Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje
   Kao YW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010212
   Katoh Y, 2006, INT J ONCOL, V28, P1585
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Kim HJ, 2013, MOL MED REP, V8, P282, DOI 10.3892/mmr.2013.1497
   Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07
   Kim YW, 2014, BLOOD, V123, P625, DOI 10.1182/blood-2013-09-512749
   Kim YW, 2013, J MOL MED, V91, P323, DOI 10.1007/s00109-013-1007-3
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kolb TM, 2004, TOXICOL SCI, V81, P233, DOI 10.1093/toxsci/kfh183
   Kolev Y, 2008, ANN SURG ONCOL, V15, P2336, DOI 10.1245/s10434-008-9955-5
   Kotha RR, 2019, MOLECULES, V24, DOI 10.3390/molecules24162930
   Koukourakis MI, 2003, BRIT J CANCER, V89, P877, DOI 10.1038/sj.bjc.6601205
   Koukourakis MI, 2011, CLIN CANCER RES, V17, P4892, DOI 10.1158/1078-0432.CCR-10-2918
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200
   Lee WH, 2014, EXPERT OPIN DRUG DEL, V11, P1183, DOI 10.1517/17425247.2014.916686
   Leow PC, 2014, EUR J MED CHEM, V71, P67, DOI 10.1016/j.ejmech.2013.10.073
   Leveillard T, 2017, CELL MOL LIFE SCI, V74, P3649, DOI 10.1007/s00018-016-2318-7
   Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967
   Li H, 2005, HUM GENE THER, V16, P1157, DOI 10.1089/hum.2005.16.1157
   Li KF, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6746907
   Li L, 2005, CANCER-AM CANCER SOC, V104, P1322, DOI 10.1002/cncr.21300
   Lii X, 2014, BIOMOL THER, V22, P27, DOI 10.4062/biomolther.2013.092
   Lin CH, 2013, BRIT J PHARMACOL, V168, P920, DOI 10.1111/j.1476-5381.2012.02227.x
   Lin JB, 2018, EXP EYE RES, V174, P107, DOI 10.1016/j.exer.2018.05.033
   Lin YG, 2007, CLIN CANCER RES, V13, P3423, DOI 10.1158/1078-0432.CCR-06-3072
   Liu WD, 2016, J DRUG TARGET, V24, P694, DOI 10.3109/1061186X.2016.1157883
   Liu XX, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-356
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lu SL, 2013, ANTIMICROB AGENTS CH, V57, P5366, DOI 10.1128/AAC.00322-13
   Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107
   Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378
   Machon O, 2010, GENESIS, V48, P86, DOI 10.1002/dvg.20583
   Malam Y, 2009, TRENDS PHARMACOL SCI, V30, P592, DOI 10.1016/j.tips.2009.08.004
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Manea A, 2010, CELL TISSUE RES, V342, P325, DOI 10.1007/s00441-010-1060-y
   Manjunatha H, 2006, FEBS J, V273, P4528, DOI 10.1111/j.1742-4658.2006.05458.x
   Marchiani A, 2014, CURR MED CHEM, V21, P204
   Mazzolani F, 2018, EUR REV MED PHARMACO, V22, P3617, DOI 10.26355/eurrev_201806_15189
   McBride JD, 2014, J INVEST DERMATOL, V134, P1725, DOI 10.1038/jid.2014.40
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Menon G, 2009, EYE, V23, pS1, DOI 10.1038/eye.2009.13
   Menon VP, 2007, ADV EXP MED BIOL, V595, P105
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Motterlini R, 2000, FREE RADICAL BIO MED, V28, P1303, DOI 10.1016/S0891-5849(00)00294-X
   Muangnoi C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48124-1
   Muangnoi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133367
   Naksuriya O, 2014, BIOMATERIALS, V35, P3365, DOI 10.1016/j.biomaterials.2013.12.090
   Nissen LJ, 2007, J CLIN INVEST, V117, P2766, DOI 10.1172/JCI32479
   Nusse R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011163
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Oguma K, 2010, FUTURE ONCOL, V6, P515, DOI [10.2217/fon.10.13, 10.2217/FON.10.13]
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ohori H, 2006, MOL CANCER THER, V5, P2563, DOI 10.1158/1535-7163.MCT-06-0174
   Olivera A, 2012, INT IMMUNOPHARMACOL, V12, P368, DOI 10.1016/j.intimp.2011.12.009
   Othman A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057254
   Park K, 2011, MOL CELL BIOL, V31, P3038, DOI 10.1128/MCB.01211-10
   Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598
   Pittala V, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1420892
   Piwocka K, 2001, FREE RADICAL BIO MED, V31, P670, DOI 10.1016/S0891-5849(01)00629-3
   Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016
   Prasad S, 2014, BIOTECHNOL ADV, V32, P1053, DOI 10.1016/j.biotechadv.2014.04.004
   Priyadarsini KI, 2014, MOLECULES, V19, P20091, DOI 10.3390/molecules191220091
   Priyadarsini KI, 2003, FREE RADICAL BIO MED, V35, P475, DOI 10.1016/S0891-5849(03)00325-3
   Qiu FF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01119-2
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Radomska-Lesniewska DM, 2019, CENT EUR J IMMUNOL, V44, P181, DOI 10.5114/ceji.2019.87070
   Radomska-Lesniewska DM, 2016, PHARMACOL REP, V68, P462, DOI 10.1016/j.pharep.2015.10.002
   Radomska-Lesniewska DM, 2015, CENT EUR J IMMUNOL, V40, P249, DOI 10.5114/ceji.2015.52839
   Radomska-Lesniewska DM, 2017, CENT EUR J IMMUNOL, V42, P370, DOI 10.5114/ceji.2017.72804
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruan Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031296
   Sai N, 2020, MOLECULES, V25, DOI 10.3390/molecules25010081
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   San-Millan I, 2017, CARCINOGENESIS, V38, P119, DOI 10.1093/carcin/bgw127
   Schneider C, 2006, J AM CHEM SOC, V128, P720, DOI 10.1021/ja056517y
   Schon S, 2014, INT J CANCER, V135, P1800, DOI 10.1002/ijc.28839
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Shen L, 2016, SCI REP-UK, V6, DOI 10.1038/srep20872
   Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Sprowl-Tanio S, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0159-3
   Subramanian P, 2016, INVEST OPHTH VIS SCI, V57, P4581, DOI 10.1167/iovs.15-19039
   Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010
   Sun M, 2012, NANOMEDICINE-UK, V7, P1085, DOI [10.2217/NNM.12.80, 10.2217/nnm.12.80]
   Takata S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09898
   Terasaki H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069994
   Thompson CB, 2014, EMBO J, V33, P1420, DOI 10.15252/embj.201488785
   Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Tuo JS, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.01.009
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Vallee A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072440
   Vallee A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030820
   Vallee A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1320-y
   Vallee A, 2018, NEUROSCI BULL, V34, P573, DOI 10.1007/s12264-018-0219-5
   Vallee A, 2017, LIFE SCI, V188, P123, DOI 10.1016/j.lfs.2017.09.008
   Vallee A, 2017, J MOL NEUROSCI, V62, P368, DOI 10.1007/s12031-017-0947-4
   Voorzanger-Rousselot N, 2009, BRIT J HAEMATOL, V145, P264, DOI 10.1111/j.1365-2141.2009.07587.x
   Vyas A, 2013, CURR PHARM DESIGN, V19, P2047
   Wang HB, 2016, MOL VIS, V22, P189
   Wang LL, 2013, MOL NUTR FOOD RES, V57, P1557, DOI 10.1002/mnfr.201200718
   Wang Y, 2016, MOL VIS, V22
   Wang ZX, 2019, PROG RETIN EYE RES, V70, P110, DOI 10.1016/j.preteyeres.2018.11.008
   Wang ZX, 2015, ARTERIOSCL THROM VAS, V35, P855, DOI 10.1161/ATVBAHA.114.304627
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719
   Yabas M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.609629
   Yadav UCS, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/690545
   Yallapu MM, 2010, COLLOID SURFACE B, V79, P113, DOI 10.1016/j.colsurfb.2010.03.039
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
   Yeung AWK, 2019, MOLECULES, V24, DOI 10.3390/molecules24071393
   Yin F, 2014, ANTIOXID REDOX SIGN, V20, P353, DOI 10.1089/ars.2012.4774
   Yokosako K, 2014, OPEN OPHTHALMOL J, V8, P39, DOI 10.2174/1874364101408010039
   Yoysungnoen P, 2006, CLIN HEMORHEOL MICRO, V34, P109
   Zahra FT, 2021, CANCERS, V13, DOI 10.3390/cancers13061422
   Zhang JM, 2013, MOL CELL BIOCHEM, V379, P295, DOI 10.1007/s11010-013-1654-2
   Zhang J, 2017, CURR EYE RES, V42, P1597, DOI 10.1080/02713683.2016.1242753
   Zhang J, 2013, SYNAPSE, V67, P515, DOI 10.1002/syn.21674
   Zhang L, 2012, INT J NANOMED, V7, P151, DOI 10.2147/IJN.S27639
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
   Zhang P, 2009, GRAEF ARCH CLIN EXP, V247, P633, DOI 10.1007/s00417-008-1031-0
   Zhang XB, 2001, CANCER RES, V61, P6050
   Zhang ZB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01181
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
   Zhou YL, 2014, J CLIN INVEST, V124, P3825, DOI 10.1172/JCI76431
   Zhu W, 2015, DRUG DES DEV THER, V9, P5337, DOI 10.2147/DDDT.S84979
   Zuo L, 2013, INVEST OPHTH VIS SCI, V54, P5097, DOI 10.1167/iovs.13-12157
NR 202
TC 0
Z9 0
U1 2
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JUN
PY 2022
VL 49
IS 6
AR 79
DI 10.3892/ijmm.2022.5135
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 1E2VX
UT WOS:000794354100001
PM 35445729
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Vilkeviciute, A
   Smalinskiene, A
   Tamosiunas, A
   Petkeviciene, J
   Zaliuniene, D
   Lesauskaite, V
AF Liutkeviciene, Rasa
   Vilkeviciute, Alvita
   Smalinskiene, Alina
   Tamosiunas, Abdonas
   Petkeviciene, Janina
   Zaliuniene, Dalia
   Lesauskaite, Vaiva
TI The role of apolipoprotein E (rs7412 and rs429358) in age-related
   macular degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; ApoE; gene polymorphism
ID BRUCHS MEMBRANE; TRANSGENIC MICE; HUMAN RETINA; E GENE; DRUSEN;
   ASSOCIATION; DEPOSITS; ALLELE; APOE; MACULOPATHY
AB Background: Age-related macular degeneration (AMD) is the most common cause of incurable visual impairment in the developed countries. The main pathological change in AMD is the formation of drusen containing 40% of lipids, dominated by esterified cholesterol (EC) and phosphatidylcholine (PC), and protein. Haplotype E4 of apolipoprotein E (ApoE) acts as a ligand for the low-density lipoprotein receptor and is involved in the maintenance and repair of neuronal cell membranes.
   Purpose: This study aimed to evaluate the association of AMD with ApoE gene polymorphism variants (rs7412 and rs429358).
   Methodology: A total of 2133 subjects were enrolled in our research. The study group comprised patients with early AMD (n = 413) and exudative AMD (n = 307), and the control group enrolled randomly selected persons (n = 1413). The genotyping of ApoE (rs7412 and rs429358) was performed using the real-time polymerase chain reaction (PCR) method.
   Results: Statistical analysis revealed that ApoE 4/2 genotype was less frequently observed in in older patients with exudative AMD compared to older healthy controls (0.4% vs. 4.0%, p = 0.003).
   Conclusion: Our data demonstrated that ApoE 4/2 genotype was less frequently observed in old patients (65 years and more) with exudative AMD compared to old healthy controls. It leads to hypothesis on the protective effect of ApoE 4/2 to develop AMD in the elderly.
C1 [Liutkeviciene, Rasa; Zaliuniene, Dalia] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Kaunas, Lithuania.
   [Liutkeviciene, Rasa; Vilkeviciute, Alvita] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
   [Smalinskiene, Alina; Tamosiunas, Abdonas; Lesauskaite, Vaiva] Lithuanian Univ Hlth Sci, Med Acad, Inst Cardiol, Kaunas, Lithuania.
   [Petkeviciene, Janina] Lithuanian Univ Hlth Sci, Med Acad, Fac Publ Hlth, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences; Lithuanian
   University of Health Sciences
RP Vilkeviciute, A (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
EM alvita.vilkeviciute@lsmuni.lt
RI Tamosiunas, Abdonas/AAD-4274-2021
OI Lesauskaite, Vaiva/0000-0003-2736-3111
FU Research Council of Lithuania [MIP-10330, SEN-11/2015]; Wellcome Trust
   [064947/Z/01/Z]; US National Institute on Aging [IR0I AG23522-01]; Oslo
   University College [57116]
FX Research Council of Lithuania [grant no. MIP-10330, SEN-11/2015] and
   Wellcome Trust [grant no. 064947/Z/01/Z]; the US National Institute on
   Aging [grant no. IR0I AG23522-01]; Oslo University College [grant no.
   57116].
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Ang LS, 2008, EXP GERONTOL, V43, P615, DOI 10.1016/j.exger.2008.03.010
   [Anonymous], 2011, AM J OPHTHALMOL, V132, P668
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bales KR, 2009, J NEUROSCI, V29, P6771, DOI 10.1523/JNEUROSCI.0887-09.2009
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Evans J. R., 2002, COCHRANE DB SYST REV, V2
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Garner A, 1994, PATHOBIOLOGY OCULAR, P642
   Gerdes LU, 2003, CLIN CHEM LAB MED, V41, P628, DOI 10.1515/CCLM.2003.094
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Joseph C., 2011, RETINA ITS DISORDERS, P830
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Lee SH, 2000, J BIOL CHEM, V275, P33679, DOI 10.1074/jbc.M004994200
   Lee SJ, 2007, J MICROBIOL BIOTECHN, V17, P1024
   Lesauskaite V, 2006, GERONTOLOGY, V52, P40, DOI 10.1159/000089824
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Lucotte G, 1997, HUM BIOL, V69, P253
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Peasey A, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-255
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Shen L, 2015, INVEST OPHTH VIS SCI, V56, P4290, DOI 10.1167/iovs.15-16533
   Smalinskiene A, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-120
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   van den Elzen P, 2005, NATURE, V437, P906, DOI 10.1038/nature04001
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zhang HL, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/357412
NR 54
TC 4
Z9 4
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2018
VL 39
IS 4
BP 457
EP 462
DI 10.1080/13816810.2018.1479429
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA GK9PB
UT WOS:000436582700007
PM 29851526
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Li, M
   Atmaca-Sonmez, P
   Othman, M
   Branham, KEH
   Khanna, R
   Wade, MS
   Li, Y
   Liang, LM
   Zareparsi, S
   Swaroop, A
   Abecasis, GR
AF Li, Mingyao
   Atmaca-Sonmez, Pelin
   Othman, Mohammad
   Branham, Kari E. H.
   Khanna, Ritu
   Wade, Michael S.
   Li, Yun
   Liang, Liming
   Zareparsi, Sepideh
   Swaroop, Anand
   Abecasis, Goncalo R.
TI CFH haplotypes without the Y402H coding variant show strong association
   with susceptibility to age-related macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; LINKAGE DISEQUILIBRIUM; RISK-FACTORS; GENOME SCAN;
   MACULOPATHY; POLYMORPHISM; DISEASE; LOC387715; SMOKING; TRAITS
AB In developed countries, age-related macular degeneration is a common cause of blindness in the elderly. A common polymorphism, encoding the sequence variation Y402H in complement factor H (CFH), has been strongly associated with disease susceptibility. Here, we examined 84 polymorphisms in and around CFH in 726 affected individuals (including 544 unrelated individuals) and 268 unrelated controls. In this sample, 20 of these polymorphisms showed stronger association with disease susceptibility than the Y402H variant. Further, no single polymorphism could account for the contribution of the CFH locus to disease susceptibility. Instead, multiple polymorphisms defined a set of four common haplotypes (of which two were associated with disease susceptibility and two seemed to be protective) and multiple rare haplotypes (associated with increased susceptibility in aggregate). Our results suggest that there are multiple disease susceptibility alleles in the region and that noncoding CFH variants play a role in disease susceptibility.
C1 Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
   Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Pennsylvania; University of Michigan System; University of Michigan
RP Abecasis, GR (通讯作者)，Univ Michigan, Dept Biostat, 1420 Washington Hts, Ann Arbor, MI 48109 USA.
EM swaroop@umich.edu; goncalo@umich.edu
RI Branham, Kari/AAA-8336-2022; Abecasis, Goncalo R/B-7840-2010
OI Branham, Kari/0000-0002-2492-254X; Swaroop, Anand/0000-0002-1975-1141;
   Abecasis, Goncalo/0000-0003-1509-1825
FU NATIONAL EYE INSTITUTE [R01EY016862] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY016862-01A1] Funding Source: Medline
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Abecasis GR, 2001, AM J HUM GENET, V69, P198
   Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HODGE SE, 1994, GENET EPIDEMIOL, V11, P329, DOI 10.1002/gepi.1370110403
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li MY, 2006, AM J HUM GENET, V78, P778, DOI 10.1086/503711
   Li MY, 2005, AM J HUM GENET, V76, P934, DOI 10.1086/430277
   Li N, 2003, GENETICS, V165, P2213
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Monks SA, 2004, AM J HUM GENET, V75, P1094, DOI 10.1086/426461
   RISCH N, 1990, AM J HUM GENET, V46, P222
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stephens M, 2005, AM J HUM GENET, V76, P449, DOI 10.1086/428594
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Valdes AM, 1997, AM J HUM GENET, V60, P703
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986
NR 30
TC 268
Z9 284
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD SEP
PY 2006
VL 38
IS 9
BP 1049
EP 1054
DI 10.1038/ng1871
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 078OC
UT WOS:000240112100023
PM 16936733
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Lai, TYY
   Liu, DTL
   Chan, KP
   Luk, FOJ
   Pang, CP
   Lam, DSC
AF Lai, Timothy Y. Y.
   Liu, David T. L.
   Chan, Kwok-Ping
   Luk, Fiona O. J.
   Pang, Chi-Pui
   Lam, Dennis S. C.
TI VISUAL OUTCOMES AND GROWTH FACTOR CHANGES OF TWO DOSAGES OF INTRAVITREAL
   BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A
   Randomized, Controlled Trial
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; vascular
   endothelial growth factor; pigment epithelial derived factor;
   bevacizumab; dosage
ID CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; AVASTIN TREATMENT;
   AQUEOUS-HUMOR; RANIBIZUMAB; INJECTION; VERTEPORFIN; SECONDARY; EFFICACY;
   SAFETY
AB Purpose: To evaluate the visual and growth factor changes of two different intravitreal bevacizumab dosages for neovascular age-related macular degeneration.
   Methods: Fifty eyes of 50 patients with neovascular age-related macular degeneration were randomized to receive 3 monthly intravitreal injections of 1.25 mg (24 eyes) or 2.5 mg (26 eyes) bevacizumab. Patients were observed for 6 months, and the logarithm of minimal angle of resolution best-corrected visual acuity, central foveal thickness, aqueous vascular endothelial growth factor, and pigment epithelial derived factor levels were assessed.
   Results: Both groups had significant central foveal thickness reductions at 6 months (P < 0.001). Six (23.1%) eyes in the 2.5-mg group lost 3 or more lines compared with none in the 1.25-mg group (P = 0.023). No significant difference in logarithm of minimal angle of resolution best-corrected visual acuity, central foveal thickness, or growth factors levels was found between the two groups at all visits. Eyes with persistent angiographic leakage at 3 months had significantly higher baseline aqueous vascular endothelial growth factor levels compared with eyes without leakage (P = 0.013). Logistic regression analysis showed that high baseline aqueous vascular endothelial growth factor level was the only significant factor associated with persistent leakage at 3 months (P = 0.040).
   Conclusion: Three monthly intravitreal 1.25-mg bevacizumab injections seemed to result in better visual outcome than 2.5 mg bevacizumab. Baseline aqueous vascular endothelial growth factor level might have a role in predicting angiographic response after bevacizumab injections. RETINA 29:1218-1226, 2009
C1 [Lai, Timothy Y. Y.; Liu, David T. L.; Chan, Kwok-Ping; Luk, Fiona O. J.; Pang, Chi-Pui; Lam, Dennis S. C.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Lai, Timothy Y. Y.; Luk, Fiona O. J.; Lam, Dennis S. C.] Hong Kong Eye Hosp, Kowloon, Hong Kong, Peoples R China.
   [Liu, David T. L.] Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital
RP Lai, TYY (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Hong Kong, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk
RI Pang, Chi P/I-5388-2014; Chan, Kwok Ping/E-6044-2016; Lam,
   Dennis/AAL-1211-2020; Lai, Timothy Y Y/AAC-2120-2020
OI Chan, Kwok Ping/0000-0003-2416-1995; Lai, Timothy Y
   Y/0000-0002-7832-6428
FU Chinese University of Hong Kong [445027]
FX Supported by Direct Grant for Research no. 445027 form The Chinese
   University of Hong Kong.
CR Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Heiduschka P, 2008, RETINA-J RET VIT DIS, V28, P46, DOI 10.1097/IAE.0b013e31815e9368
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KREBS I, 2008, ACTA OPHTHALMOL 1017
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
NR 28
TC 19
Z9 20
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2009
VL 29
IS 9
BP 1218
EP 1226
DI 10.1097/IAE.0b013e3181b32c45
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 506EF
UT WOS:000270755800002
PM 19934816
DA 2022-11-30
ER

PT J
AU Li, JQ
   Xu, JY
   Chen, YY
   Zhang, JJ
   Cao, YH
   Lu, PR
AF Li, Jianqing
   Xu, Jiayi
   Chen, Yiyi
   Zhang, Jiaju
   Cao, Yihong
   Lu, Peirong
TI Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes
   of Neovascular Age-Related Macular Degeneration: A Systematic Review and
   Meta-Analysis
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID RETINAL ANGIOMATOUS PROLIFERATION; COHERENCE TOMOGRAPHY ANGIOGRAPHY;
   BASE-LINE PREDICTORS; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; AFLIBERCEPT THERAPY; VISUAL OUTCOMES; RANIBIZUMAB; THICKNESS;
   TYPE-1
AB Purpose. Intravitreal antivascular endothelial growth factor (anti-VEGF) therapy has been widely used for the treatment of neovascularization (NV) secondary to age-related macular degeneration (AMD). This study aimed to compare the efficacy among different subtypes of neovascular age-related macular degeneration (nAMD). Methods. PubMed, Embase, and the Cochrane Library were searched for eligible studies. We performed meta-analysis using Review Manager 5.3 and Stata/SE 12.0. Results. A total of 24 studies met our inclusion criteria and were included in the systematic review. At 3 months, the mean logarithm of the minimum angle of resolution (logMAR) improvements were -0.09, -0.18, and -0.23 for type 1, 2, and 3, respectively, while the mean macular thickness (MT) changes were -104.83, -130.76, and -196.29 mu m. At 12 months, the mean changes in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters were 6.38, 8.12, and 9.37, while the MT decrease was 126.51, 126.52, and 139.85 mu m, respectively. However, statistically significant difference was only found between type 1 and 3 in vision improvement, both in the short term (p = 0.0002) and long term (p = 0.01). Conclusions. The reactivity to VEGF inhibitors varied among different subtypes of nAMD. The efficacy of intravitreal anti-VEGF therapy in type 3 nAMD was statistically better than type 1 when considering vision improvement at 3 and 12 months. Thus, the lesion subtype is a predictor for the treatment outcome which can help guide prognosis.
C1 [Li, Jianqing; Xu, Jiayi; Chen, Yiyi; Zhang, Jiaju; Cao, Yihong; Lu, Peirong] Soochow Univ, Affiliated Hosp 1, Dept Ophthalmol, 188 Shizi St, Suzhou 215006, Peoples R China.
C3 Soochow University - China
RP Lu, PR (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Ophthalmol, 188 Shizi St, Suzhou 215006, Peoples R China.
EM lupeirong@suda.edu.cn
OI Li, Jianqing/0000-0001-7868-8421
FU National Natural Science Foundation of China (NSFC) [81671641]; Jiangsu
   Provincial Medical Innovation Team [CXTDA2017039]; Jiangsu Provincial
   Natural Science Foundation [BK20151208]; Soochow Scholar Project of
   Soochow University [R5122001]
FX This work was supported by the National Natural Science Foundation of
   China (NSFC No. 81671641), Jiangsu Provincial Medical Innovation Team
   (No. CXTDA2017039), Jiangsu Provincial Natural Science Foundation (No.
   BK20151208), and the Soochow Scholar Project of Soochow University (No.
   R5122001).
CR American Academy of Ophthalmology Retina, 2015, PREF PRACT PATT GUID
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Castro-Navarro V, 2016, OPHTHALMOLOGICA, V236, P215, DOI 10.1159/000453281
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Chevreaud O, 2017, GRAEF ARCH CLIN EXP, V255, P743, DOI 10.1007/s00417-016-3564-y
   Coscas F, 2012, RETINA-J RET VIT DIS, V32, P1069, DOI 10.1097/IAE.0b013e318240a529
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gharbiya M, 2018, CURR EYE RES, V43, P391, DOI 10.1080/02713683.2017.1405045
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hufendiek Katerina, 2012, International Ophthalmology, V32, P259, DOI 10.1007/s10792-012-9562-0
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kano M, 2015, CLIN OPHTHALMOL, V9, P2049, DOI 10.2147/OPTH.S90932
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Kramann CA, 2012, ACTA OPHTHALMOL, V90, P487, DOI 10.1111/j.1755-3768.2010.01952.x
   Lai TYY, 2007, GRAEF ARCH CLIN EXP, V245, P1877, DOI 10.1007/s00417-007-0679-1
   Lee Ji Young, 2016, Korean J Ophthalmol, V30, P17, DOI 10.3341/kjo.2016.30.1.17
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Malgorzata F., 2011, MED SCI MONITOR, V17
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Mimura K, 2018, OPHTHALMOLOGICA, V239, P121, DOI 10.1159/000484099
   Park YG, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0172-2
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Shin JY, 2014, RETINA-J RET VIT DIS, V34, P2359, DOI 10.1097/IAE.0000000000000225
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 39
TC 13
Z9 16
U1 1
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2018
VL 2018
AR 1425707
DI 10.1155/2018/1425707
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ2HE
UT WOS:000449199300001
PM 30425852
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Izumi, T
   Koizumi, H
   Maruko, I
   Hasegawa, T
   Iida, T
AF Izumi, Takahiko
   Koizumi, Hideki
   Maruko, Ichiro
   Hasegawa, Taiji
   Iida, Tomohiro
TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FINDINGS OF CLASSIC CHOROIDAL
   NEOVASCULARIZATION IN POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE classic choroidal neovascularization; fluorescein angiography;
   indocyanine green angiography; naked polyp; optical coherence
   tomography; optical coherence tomography angiography; polypoidal
   choroidal vasculopathy; subretinal hyperreflective material
ID SUBRETINAL HYPERREFLECTIVE MATERIAL; MACULAR DEGENERATION;
   CLINICOPATHOLOGICAL CORRELATION; FEATURES
AB Purpose: To evaluate the flow signals in subretinal hyperreflective material (SHRM) that represents classic choroidal neovascularization (CNV) on fluorescein angiography in eyes with polypoidal choroidal vasculopathy.
   Methods: We retrospectively reviewed 20 eyes with polypoidal choroidal vasculopathy that appeared to have classic CNV on fluorescein angiography, accompanied by SHRM on optical coherence tomography (OCT) at the same location. Using OCT angiography (OCTA), we analyzed intrinsic flow signals in the SHRM (cross-sectional B-scans and en face). The possible association between pretreatment OCT angiography findings and fibrotic scar formation after antivascular endothelial growth factor (VEGF) treatment was evaluated.
   Results: Six of 20 eyes (30%) showed vascular SHRM; the remaining 14 eyes (70%) showed avascular SHRM at the classic CNV site at baseline. The SHRM corresponded with polypoidal lesions seen on indocyanine green angiography in 5 of 6 eyes with vascular SHRM and in all 14 eyes with avascular SHRM. After anti-VEGF treatment, all 6 eyes with vascular SHRM left a fibrotic scar, whereas all 14 eyes with avascular SHRM showed no scar formation (P < 0.001).
   Conclusion: Using OCT angiography, we evaluated the flow signals in SHRM that represented classic CNV in eyes with polypoidal choroidal vasculopathy and successfully differentiated true Type 2 macular neovascularization from pseudo classic CNV.
C1 [Izumi, Takahiko; Koizumi, Hideki; Maruko, Ichiro; Hasegawa, Taiji; Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Koizumi, Hideki] Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
C3 Tokyo Women's Medical University; University of Ryukyus
RP Koizumi, H (通讯作者)，Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM hkoizumi@med.u-ryukyu.ac.jp
RI Maruko, Ichiro/AFP-1311-2022
OI Maruko, Ichiro/0000-0001-5647-6372
CR Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kawashima Y, 2017, AM J OPHTHALMOL, V181, P61, DOI 10.1016/j.ajo.2017.06.015
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Liang ST, 2018, BRIT J OPHTHALMOL, V102, P1570, DOI 10.1136/bjophthalmol-2017-311518
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji Tsuyoshi, 2006, Nippon Ganka Gakkai Zasshi, V110, P454
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sia DIT, 2013, INT OPHTHALMOL, V33, P67, DOI 10.1007/s10792-012-9681-7
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200
NR 29
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2022
VL 42
IS 1
BP 123
EP 128
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XS3RA
UT WOS:000732829100025
PM 34292224
DA 2022-11-30
ER

PT J
AU Lains, I
   Mendez, K
   Nigalye, A
   Katz, R
   Douglas, VP
   Kelly, RS
   Kim, IK
   Miller, JB
   Vavvas, DG
   Liang, LM
   Lasky-Su, J
   Miller, JW
   Husain, D
AF Lains, Ines
   Mendez, Kevin
   Nigalye, Archana
   Katz, Raviv
   Douglas, Vivian Paraskevi
   Kelly, Rachel S.
   Kim, Ivana K.
   Miller, John B.
   Vavvas, Demetrios G.
   Liang, Liming
   Lasky-Su, Jessica
   Miller, Joan W.
   Husain, Deeba
TI Plasma Metabolomic Profiles Associated with Three-Year Progression of
   Age-Related Macular Degeneration
SO METABOLITES
LA English
DT Article
DE age-related macular degeneration; dark adaptation; metabolomics; plasma
ID DARK-ADAPTATION; OXIDATIVE STRESS; DISEASE; PATHOGENESIS; RETINA
AB Plasma metabolomic profiles have been shown to be associated with age-related macular degeneration (AMD) and its severity stages. However, all studies performed to date have been cross-sectional and have not assessed progression of AMD. This prospective, longitudinal, pilot study analyzes, for the first time, the association between plasma metabolomic profiles and progression of AMD over a 3-year period. At baseline and 3 years later, subjects with AMD (n = 108 eyes) and controls (n = 45 eyes) were imaged with color fundus photos for AMD staging and tested for retinal function with dark adaptation (DA). Fasting plasma samples were also collected for metabolomic profiling. AMD progression was considered present if AMD stage at 3 years was more advanced than at baseline (n = 26 eyes, 17%). Results showed that, of the metabolites measured at baseline, eight were associated with 3-year AMD progression (p < 0.01) and 19 (p < 0.01) with changes in DA. Additionally, changes in the levels (i.e., between 3 years and baseline) of 6 and 17 metabolites demonstrated significant associations (p < 0.01) with AMD progression and DA, respectively. In conclusion, plasma metabolomic profiles are associated with clinical and functional progression of AMD at 3 years. These findings contribute to our understanding of mechanisms of AMD progression and the identification of potential therapeutics for this blinding disease.
C1 [Lains, Ines; Nigalye, Archana; Katz, Raviv; Douglas, Vivian Paraskevi; Kim, Ivana K.; Miller, John B.; Vavvas, Demetrios G.; Miller, Joan W.; Husain, Deeba] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
   [Mendez, Kevin; Kelly, Rachel S.; Lasky-Su, Jessica] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02114 USA.
   [Liang, Liming] Brigham & Womens Hosp, Channing Div Network Med, Syst Genet & Genom Unit, Boston, MA 02114 USA.
   [Liang, Liming] Harvard Med Sch, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard T.H. Chan School of Public
   Health; Harvard University; Brigham & Women's Hospital; Harvard
   University; Harvard Medical School
RP Husain, D (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
EM Ines_Lains@meei.harvard.edu; Kevin_mendez@meei.harvard.edu;
   Archana_Nigalye@meei.harvard.edu; Raviv_katz@meei.harvard.edu;
   Vivianparaskevi_douglas@meei.harvard.edu; hprke@channing.harvard.edu;
   ivana_kim@meei.harvard.edu; John_miller@meei.harvard.edu;
   Demetrios_vavvas@meei.harvard.edu; Lliang@hsph.harvard.edu;
   Jessica.su@channing.harvard.edu; Joan_miller@meei.harvard.edu;
   Deeba_Husain@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
OI Lains, Ines/0000-0002-8136-4724; Kelly, Rachel/0000-0003-3023-1822
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Azcoitia I, 2011, TRENDS ENDOCRIN MET, V22, P467, DOI 10.1016/j.tem.2011.08.002
   Bonate PL, 2011, PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION, SECOND EDITION, P189, DOI 10.1007/978-1-4419-9485-1_6
   Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z
   Cascio C, 2015, STEROIDS, V103, P31, DOI 10.1016/j.steroids.2015.08.002
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   CHIOU WL, 1978, J PHARMACOKINET BIOP, V6, P539, DOI 10.1007/BF01062108
   Chong Jasmine, 2019, Curr Protoc Bioinformatics, V68, pe86, DOI 10.1002/cpbi.86
   COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908
   Cruzat V, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111564
   Curi R, 2005, J CELL PHYSIOL, V204, P392, DOI 10.1002/jcp.20339
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Gong CJ, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108219
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Han GG, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.49
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Ishikawa M, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/528940
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Kaarniranta K, 2015, CURR EYE RES, V40, P226, DOI 10.3109/02713683.2014.925933
   Kersten E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218457
   Lains I, 2021, RETINA-J RET VIT DIS, V41, P2098, DOI 10.1097/IAE.0000000000003152
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lains I, 2019, PROG RETIN EYE RES, V69, P57, DOI 10.1016/j.preteyeres.2018.11.002
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Li MX, 2012, HUM GENET, V131, P747, DOI 10.1007/s00439-011-1118-2
   Mendez KM, 2021, METABOLITES, V11, DOI 10.3390/metabo11030183
   Mo MS, 2013, NEUROSCIENCE, V228, P1, DOI 10.1016/j.neuroscience.2012.10.002
   Nicholson JK, 2012, NATURE, V491, P384, DOI 10.1038/nature11708
   Nuzzi R, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00066
   Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251
   Oliphant, 2006, A GUIDE TO NUMPY
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pundlik S, 2022, BRIT J OPHTHALMOL, V106, P1450, DOI 10.1136/bjophthalmol-2021-318806
   Schmidl D, 2015, CURR EYE RES, V40, P201, DOI 10.3109/02713683.2014.906625
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Sumner LW, 2007, METABOLOMICS, V3, P211, DOI 10.1007/s11306-007-0082-2
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tsikata E, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.3
   Ung C, 2021, ADV EXP MED BIOL, V1256, P295, DOI 10.1007/978-3-030-66014-7_12
   van den Berg RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-142
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wulff J. E., 2018, ADV BIOSCI BIOTECHNO, V09, P339, DOI [DOI 10.4236/ABB.2018.98022, 10.4236/abb.2018.98022]
   Zeleznik OA, 2020, CANCER RES, V80, P1357, DOI 10.1158/0008-5472.CAN-19-2567
NR 50
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-1989
J9 METABOLITES
JI Metabolites
PD JAN
PY 2022
VL 12
IS 1
AR 32
DI 10.3390/metabo12010032
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA ZB7MV
UT WOS:000757022800001
PM 35050154
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Aygun, FB
   Kadayifcilar, S
   Ozgul, RK
   Eldem, B
AF Bezci Aygun, Figen
   Kadayifcilar, Sibel
   Ozgul, Riza Koksal
   Eldem, Bora
TI Complement Factor I Gene Polymorphism in a Turkish Age-Related Macular
   Degeneration Population
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Complement factor I; Polymorphism;
   Turkish population
ID FACTOR-H; COMMON VARIANT; HIGH-RISK; ASSOCIATION; COMPONENT; CFI; C3
AB Objective: Evaluation of Complement Factor I (CFI) rs10033900 and rs2285714 polymorphism frequencies in patients with age-related macular degeneration (AMD) and healthy controls in a Turkish population. Methods: A total of 111 eyes of 111 AMD patients and 96 eyes of 96 healthy controls, only one eye of individuals, were included in the study; however, 2 patients' and 4 controls' samples were excluded as analyses could not be performed for rs10033900 polymorphism. The AMD patients and control group (>50 years) lacked corneal, lenticular, vitreal opacity. However, these patients did not have any retinal diseases apart from AMD. Venous blood samples of patients were collected. Central macular thickness, subfoveal choroidal thickness (SCT), presence of reticular drusen, epiretinal membrane, and pigment epithelial detachment were investigated using Spectral-Domain Optical Coherence Tomography, and the largest diameter of atrophic areas measured. Drusen properties were documented from fundus photographs. The lesion width was calculated by using fundus fluorescein angiography. Results: There was no difference between patient and control groups and polymorphism distributions. The frequency of the CT allele was higher in patients with dry-type AMD with retinal pigment epithelial abnormality (p = 0.041). SCT was significantly thinner in TT allele carriers with rs2285714 polymorphism (p = 0.030). No significant relationship was found between the other parameters and polymorphism distributions. Con-clusion: CFI rs10033900 and rs2285714 polymorphisms in a Turkish population were not associated with AMD.
C1 [Bezci Aygun, Figen] Kizilcahamam State Hosp, Dept Ophthalmol, TR-06890 Ankara, Turkey.
   [Kadayifcilar, Sibel; Eldem, Bora] Hacettepe Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
   [Ozgul, Riza Koksal] Hacettepe Univ, Sch Med, Dept Pediat Metab, Ankara, Turkey.
C3 Kizilcahamam State Hospital; Hacettepe University; Hacettepe University
RP Aygun, FB (通讯作者)，Kizilcahamam State Hosp, Dept Ophthalmol, TR-06890 Ankara, Turkey.
EM bezcifigen@gmail.com
FU Hacettepe University Scientific Research Project [THD-2017-13786]
FX Funding for this study was granted from Hacettepe University Scientific
   Research Project (THD-2017-13786).
CR Cipriani V, 2012, EUR J HUM GENET, V20, P1, DOI 10.1038/ejhg.2011.118
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kersten E, 2017, JAMA OPHTHALMOL, V135, P1037, DOI 10.1001/jamaophthalmol.2017.3195
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Qian DG, 2014, EUR J HUM GENET, V22, P1417, DOI 10.1038/ejhg.2014.37
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Wu Pei-bei, 2013, Zhonghua Yan Ke Za Zhi, V49, P350
   Yang F, 2014, OPHTHALMOLOGICA, V232, P37, DOI 10.1159/000358241
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2015, OSLI RETINA, V46, P772, DOI 10.3928/23258160-20150730-15
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 30
TC 4
Z9 4
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAY
PY 2020
VL 243
IS 3
BP 187
EP 194
DI 10.1159/000503327
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LO2CU
UT WOS:000533434600004
PM 31614353
DA 2022-11-30
ER

PT J
AU Kozak, I
   Cheng, LY
   Falkenstein, I
   Tammewar, AM
   Freeman, WR
AF Kozak, Igor
   Cheng, Lingyun
   Falkenstein, Iryna
   Tammewar, Ajay M.
   Freeman, William R.
TI Evaluation of subretinal triamcinolone acetonide in patients with
   exudative age-related macular degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID FACTOR-H POLYMORPHISM; INTRAVITREAL TRIAMCINOLONE; PHOTODYNAMIC THERAPY;
   SUBFOVEAL NEOVASCULARIZATION; CHOROIDAL NEOVASCULARIZATION; BRUCHS
   MEMBRANE; PREVALENCE; INJECTION; MACROPHAGES; COMBINATION
AB Purpose: The aim of this paper was to present the results of subretinal delivery of triamcinolone acetonide (TCA) in humans with choroidal neovascularization (CNV) caused by age-related macular degeneration (AMD).
   Methods: Twenty two (22) eyes of 22 patients underwent pars plana vitrectomy with subretinal TCA administration. Two milligrams (2 mg) of preservative-free TCA were delivered through a 32-gauge automatic subretinal injector in 20 mu L of volume. Visual acuity, fluorescein angiography (FA), and intraocular pressure (IOP) were recorded and compared pre- and postoperatively.
   Results: Preoperative average +/- standard deviation visual acuity in the treated eye was 1.408 +/- 0.129 (logMAR; median 20/400) and 1.403 +/- 0.114 (logMAR; median 20/300) postoperatively (P = 0.51). The mean area of pre- and postoperative FA leakage in the operated eyes was 21.31 +/- 1.125 and 19.29 +/- 1.108 mm(2), respectively (P = 0.04). The average IOP value before treatment was 15.3 +/- 0.78 mmHg. Three (3) months after surgery, it was 20.5 +/- 2.04 mmHg (P = 0.02). Six (6) months and 1 year after surgery, the average IOP was 17.0 +/- 0.66 mmHg (P = 0.9) and 15.6 +/- 1.02 mmHg (P = 0.6), respectively.
   Conclusions: Subretinal TCA stabilizes visual acuity, decreases FA leakage in eyes with CNV owing to AMD, and does not increase IOP, as seen with intravitreous injections.
C1 Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, La Jolla, CA 92037 USA.
C3 University of California System; University of California San Diego
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, 0946 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
RI Kozak, Igor/AAC-4645-2019
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Beeley NRF, 2005, J BIOMED MATER RES A, V73A, P437, DOI 10.1002/jbm.a.30294
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Cekic O, 2005, AM J OPHTHALMOL, V139, P993, DOI 10.1016/j.ajo.2005.01.022
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Equi RA, 2003, INVEST OPHTH VIS SCI, V44, pU420
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   KAYIKCIOGLU OR, 2006, IN PRESS RETINA
   Kertes PJ, 2005, CAN J OPHTHALMOL, V40, P573, DOI 10.1016/S0008-4182(05)80049-3
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kosobucki BR, 2006, BRIT J OPHTHALMOL, V90, P705, DOI 10.1136/bjo.2005.088278
   Larsson J, 2005, CLIN EXP OPHTHALMOL, V33, P544, DOI 10.1111/j.1442-9071.2005.01082.x
   Michels S, 2005, KLIN MONATSBL AUGENH, V222, P480, DOI 10.1055/s-2005-858315
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   TU AH, 2004, INVEST OPHTHALMOL VI, V45
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 39
TC 3
Z9 5
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD FEB
PY 2007
VL 23
IS 1
BP 46
EP 53
DI 10.1089/jop.2006.0092
PG 8
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 146DK
UT WOS:000244914500007
PM 17341150
DA 2022-11-30
ER

PT J
AU Nishiguchi, F
   Ishikawa, H
   Amaki, J
   Komuku, Y
   Kimura, A
   Gomi, F
AF Nishiguchi, Fumi
   Ishikawa, Hiroto
   Amaki, Junichi
   Komuku, Yuki
   Kimura, Akiko
   Gomi, Fumi
TI Effects of cataract surgery in Japanese patients with neovascular
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Patient satisfaction; Age-related macular degeneration; Cataract
   surgery; Intraocular lens; Postoperative survey; Metamorphopsia
ID QUALITY-OF-LIFE; PREVALENCE; MACULOPATHY; IMPAIRMENT; HISTORY; TRENDS;
   RISK
AB Purpose To investigate the effects of cataract surgery in Japanese patients with neovascular age-related macular degeneration (nAMD).
   Methods The primary endpoint in this prospective, observational study was patient satisfaction at 6 months after cataract surgery in patients with nAMD. Secondary endpoints comprised changes in best-corrected visual acuity (BCVA), M-chart score, central retinal thickness (CRT), AMD status, and number of AMD treatments. All examinations were performed before surgery, and at 1, 3, and 6 months postoperatively.
   Results Fifty patients (52 eyes) were included in this study (32 men; mean age, 76.1 +/- 7.1 years). Thirty-nine patients (75.0%) reported satisfaction with cataract surgery. BCVA significantly improved at all postoperative timepoints (all p < 0.0001), whereas differences in M-chart scores were not statistically significant. The number of eyes with BCVA <= 0.3 logarithm of the minimum angle of resolution (logMAR) increased from 21 to 38; however, CRT did not change. The number of AMD treatments did not change during follow-up. All questionnaire scores showed postoperative improvement. Univariate and multivariate analyses revealed that final BCVA <= 0.3 logMAR was significantly associated with patient satisfaction.
   Conclusion Cataract surgery significantly improved vision in Japanese patients with nAMD, without affecting AMD status. Patients were satisfied with cataract surgery, especially with respect to improvement of distance vision.
C1 [Nishiguchi, Fumi; Ishikawa, Hiroto; Amaki, Junichi; Komuku, Yuki; Kimura, Akiko; Gomi, Fumi] Hyogo Coll Med, Dept Ophthalmol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.
C3 Hyogo College of Medicine
RP Gomi, F (通讯作者)，Hyogo Coll Med, Dept Ophthalmol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.
EM gomi.fumi@gmail.com
OI Gomi, Fumi/0000-0003-0807-8817
FU AMO Japan K.K. (Japan)
FX The current study was supported by AMO Japan K.K. (Japan).
CR Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Chung SD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120003
   Fenner BJ, 2020, OPHTHALMOL RETINA, V4, P403, DOI 10.1016/j.oret.2019.10.019
   Gao Y, 2018, INVEST OPHTH VIS SCI, V59, P4307, DOI 10.1167/iovs.17-23747
   Gomi F, 2019, JPN J OPHTHALMOL, V63, P437, DOI 10.1007/s10384-019-00687-2
   Kernt M, 2009, J CATARACT REFR SURG, V35, P354, DOI 10.1016/j.jcrs.2008.10.052
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Lotfipour M, 2017, J CATARACT REFR SURG, V43, P49, DOI 10.1016/j.jcrs.2016.10.020
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Mainster MA, 2010, SURV OPHTHALMOL, V55, P272, DOI 10.1016/j.survophthal.2009.07.006
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Monestam E, 2012, J CATARACT REFR SURG, V38, P409, DOI 10.1016/j.jcrs.2011.09.041
   Nilsson SE, 2004, ACTA OPHTHALMOL SCAN, V82, P123, DOI 10.1111/j.1600-0420.2004.00248.x
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Tang YT, 2016, INVEST OPHTH VIS SCI, V57, P1193, DOI 10.1167/iovs.15-18380
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Xu KY, 2018, CAN J OPHTHALMOL, V53, P168, DOI 10.1016/j.jcjo.2017.08.006
   Yanagi Y, 2019, EYE, V33, P34, DOI 10.1038/s41433-018-0225-x
NR 24
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2021
VL 259
IS 5
BP 1145
EP 1151
DI 10.1007/s00417-020-05015-w
EA NOV 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RY3DR
UT WOS:000590205900002
PM 33205241
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Yang, JY
   Zhang, CX
   Wang, EQ
   Chen, YX
   Yu, WH
AF Yang, Jingyuan
   Zhang, Chenxi
   Wang, Erqian
   Chen, Youxin
   Yu, Weihong
TI Utility of a public-available artificial intelligence in diagnosis of
   polypoidal choroidal vasculopathy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Artificial intelligence; Deep learning; Diagnosis; Indocyanine green
   angiography; Machine learning; Polypoidal choroidal vasculopathy
ID DIABETIC-RETINOPATHY; MACULAR DEGENERATION
AB Purpose To investigate the feasibility of training an artificial intelligence (AI) on a public-available AI platform to diagnose polypoidal choroidal vasculopathy (PCV) using indocyanine green angiography (ICGA). Methods Two methods using AI models were trained by a data set including 430 ICGA images of normal, neovascular age-related macular degeneration (nvAMD), and PCV eyes on a public-available AI platform. The one-step method distinguished normal, nvAMD, and PCV images simultaneously. The two-step method identifies normal and abnormal ICGA images at the first step and diagnoses PCV from the abnormal ICGA images at the second step. The method with higher performance was used to compare with retinal specialists and ophthalmologic residents on the performance of diagnosing PCV. Results The two-step method had better performance, in which the precision was 0.911 and the recall was 0.911 at the first step, and the precision was 0.783, and the recall was 0.783 at the second step. For the test data set, the two-step method distinguished normal and abnormal images with an accuracy of 1 and diagnosed PCV with an accuracy of 0.83, which was comparable to retinal specialists and superior to ophthalmologic residents. Conclusion In this evaluation of ICGA images from normal, nvAMD, and PCV eyes, the models trained on a public-available AI platform had comparable performance to retinal specialists for diagnosing PCV. The utility of public-available AI platform might help everyone including ophthalmologists who had no AI-related resources, especially those in less developed areas, for future studies.
C1 [Yang, Jingyuan; Zhang, Chenxi; Wang, Erqian; Chen, Youxin; Yu, Weihong] Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, 1 Shuaifuyuan Wangfujing, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Dept Ophthalmol, Peking Union Med Coll Hosp, 1 Shuaifuyuan Wangfujing, Beijing 100730, Peoples R China.
EM chenyx@pumch.cn
OI Chen, Youxin/0000-0002-7231-5058
CR Anwar SM, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1088-1
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Guo J, 2018, HEALTH EQUITY, V2, P174, DOI 10.1089/heq.2018.0037
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   Lu W, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5278196
   Ozkaya A, 2016, EYE, V30, P958, DOI 10.1038/eye.2016.71
   Rohm M, 2018, OPHTHALMOLOGY, V125, P1028, DOI 10.1016/j.ophtha.2017.12.034
   Saleh E, 2018, ARTIF INTELL MED, V85, P50, DOI 10.1016/j.artmed.2017.09.006
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P2053, DOI 10.1007/s00417-018-4098-2
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Yuzawa M, 2015, INVEST OPHTH VIS SCI, V56, P3998, DOI 10.1167/iovs.15-17207
   Zoph B, 2016, NEURAL ARCHITECTURE
   Zoph B, 2018, PROC CVPR IEEE, P8697, DOI 10.1109/CVPR.2018.00907
NR 21
TC 6
Z9 6
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2020
VL 258
IS 1
BP 17
EP 21
DI 10.1007/s00417-019-04493-x
EA NOV 2019
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KI9XF
UT WOS:000493959300001
PM 31686211
DA 2022-11-30
ER

PT J
AU DeAngelis, MM
   Ji, F
   Kim, IK
   Adams, S
   Capone, A
   Ott, J
   Miller, JW
   Dryja, TP
AF DeAngelis, Margaret M.
   Ji, Fei
   Kim, Ivana K.
   Adams, Scott
   Capone, Antonio, Jr.
   Ott, Jurg
   Miller, Joan W.
   Dryja, Thaddeus P.
TI Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular
   age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; QUANTITATIVE TRAIT LOCI; APOLIPOPROTEIN-E GENE;
   DISCORDANT SIB PAIRS; POLYMORPHISM; ASSOCIATION; VARIANT; Y402H
AB Objective: To examine if the genes encoding complement factor H(CFH), apolipoprotein E (APOE), and elongation of very-long-chain fatty acids-like 4 (ELOVL4) confer risk of neovascular age-related macular degeneration (AMD) in an independent or interactive manner when controlling for smoking exposure.
   Methods: We studied 103 unrelated patients with neovascular AMD who each had at least 1 sibling with normal maculae. Smoking histories were obtained. Geno-typing was performed by analyzing amplified genomic fragments from CFH, APOE, and ELOVL4 by direct sequencing or by restriction endonuclease digests. Conditional logistic regression analysis was used to build a multifactor model.
   Results: For CFH, only the CC genotype carried a statistically significant elevation of disease risk (odds ratio, 49.37; 95% confidence interval, 6.20-393.22; P < .001). No significant association was observed between neovascular AMD and APOE or ELOVL4. No significant interactions were found between smoking and having the CFH or APOE genotype nor were significant interactions found between the CFH, ELOVL4, and APOE genotypes.
   Conclusions: Smoking and having the CFH CC genotype independently increase risk of neovascular AMD. APOE and ELOVL4 genotypes do not seem to modify risk.
   Clinical Relevance: Smoking 10 pack-years or more and having the CFH CC genotype increase one's risk of neovascular AMD 144-fold compared with smoking less than 10 pack-years and having the CT or TT genotype.
C1 Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
   Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   William Beaumont Hosp, Royal Oak, MI 48072 USA.
C3 Harvard University; Harvard Medical School; Harvard University;
   Massachusetts Eye & Ear Infirmary; Rockefeller University; Beaumont
   Health
RP DeAngelis, MM (通讯作者)，Harvard Univ, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM margaret_deangelis@hms.harvard.edu
RI DeAngelis, e/J-7863-2015
OI Miller, Joan/0000-0003-2046-3996; Kim, Ivana/0000-0003-0310-6129
FU NEI NIH HHS [EY014458, EY14104] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY014458, P30EY014104] Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Armitage P., 1987, STAT METHODS MED RES
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HIXSON JE, 1990, J LIPID RES, V31, P545
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   OTTMAN R, 1990, GENET EPIDEMIOL, V7, P177, DOI 10.1002/gepi.1370070302
   RISCH N, 1995, SCIENCE, V268, P1584, DOI 10.1126/science.7777857
   Risch NJ, 1996, AM J HUM GENET, V58, P836
   Rivolta C, 2003, MOL VIS, V9, P49
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 26
TC 86
Z9 91
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2007
VL 125
IS 1
BP 49
EP 54
DI 10.1001/archopht.125.1.49
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123ZQ
UT WOS:000243336800006
PM 17210851
DA 2022-11-30
ER

PT J
AU Cao, XG
   Shen, DF
   Patel, MM
   Tuo, JS
   Johnson, TM
   Olsen, TW
   Chan, CC
AF Cao, Xiaoguang
   Shen, Defen
   Patel, Mrinali M.
   Tuo, Jingsheng
   Johnson, T. Mark
   Olsen, Timothy W.
   Chan, Chi-Chao
TI Macrophage polarization in the maculae of age-related macular
   degeneration: A pilot study
SO PATHOLOGY INTERNATIONAL
LA English
DT Article
DE age-related macular degeneration (AMD); chemokine; choroidal
   neovascularization; M1 macrophage; M2 macrophage
ID CHOROIDAL NEOVASCULARIZATION; BRUCHS MEMBRANE; ACTIVATION; ANGIOGENESIS;
   INFLAMMATION; INVOLVEMENT; EXPRESSION; PHENOTYPE; GROWTH; SYSTEM
AB Macrophages can be polarized to exhibit either proinflammatory M1 or pro-angiogenic M2 phenotypes, but have high phenotypic plasticity. This pilot study investigated macrophage polarization in the macular retina and choroid of age-related macular degeneration (AMD) and non-AMD subjects, as well as in AMD choroidal neovascular membranes (CNVM). All specimens were evaluated for routine histopathology. Quantitative real-time polymerase chain reaction for representative M1 (CXCL11) and M2 (CCL22) transcripts were performed on macular choroidal trephines (MCT) of 19 AMD and nine non-AMD eye bank eyes, on the microdissected macular retinal cells from the archived slides of five geographic atrophic AMD, five exudative/neovascular AMD, and eight normal autopsied eyes, and on microdissected inflammatory cells from two surgically removed CNVM that did not respond to anti-vascular endothelial growth factor (VEGF) therapy. High M2-chemokine transcript and a low ratio of M1 to M2 chemokine transcript were found in aging non-AMD MCT. Advanced AMD maculae had a higher M1 to M2 chemokine transcript ratio compared to normal autopsied eyes. Macrophages in the two CNVM of patients unresponsive to anti-VEGF therapy were polarized toward either M1 or M2 phenotypes. The number of M2 macrophages was increased compared to M1 macrophages in normal aging eyes. A pathological shift of macrophage polarization may play a potential role in AMD pathogenesis.
C1 [Cao, Xiaoguang; Shen, Defen; Patel, Mrinali M.; Tuo, Jingsheng; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Johnson, T. Mark] Natl Retina Inst, Chevy Chase, MD USA.
   [Patel, Mrinali M.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Olsen, Timothy W.] Emory Univ, Emory Eye Ctr, Atlanta, GA 30322 USA.
   [Cao, Xiaoguang] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Harvard University; Massachusetts Eye & Ear Infirmary; Emory
   University; Peking University
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, 10 Ctr Dr,Bldg 10,Room 10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI du, zhao jiang/F-6229-2011
OI Tuo, Jingsheng/0000-0002-1372-7810
FU NEI; NATIONAL EYE INSTITUTE [ZIAEY000418, ZIAEY000222, ZICEY000461]
   Funding Source: NIH RePORTER
FX The NEI Intramural Research program supported the study.
CR Allavena P, 2008, IMMUNOL REV, V222, P155, DOI 10.1111/j.1600-065X.2008.00607.x
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Badylak SF, 2008, TISSUE ENG PT A, V14, P1835, DOI 10.1089/ten.tea.2007.0264
   Burns E A, 2004, J Nutr Health Aging, V8, P9
   CHAN CC, 1985, ARCH OPHTHALMOL-CHIC, V103, P198, DOI 10.1001/archopht.1985.01050020050017
   Chan Chi-Chao, 2005, International Ophthalmology Clinics, V45, P41, DOI 10.1097/01.iio.0000155936.98330.3d
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ferguson TA, 2008, SEMIN IMMUNOPATHOL, V30, P111, DOI 10.1007/s00281-008-0113-8
   FURUSATO E, 2011, HISTOL HIST IN PRESS
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Jager MJ, 2011, PROG RETIN EYE RES, V30, P129, DOI 10.1016/j.preteyeres.2010.11.004
   Kawamura K, 2009, PATHOL INT, V59, P300, DOI 10.1111/j.1440-1827.2009.02369.x
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mantovani A, 2009, ARTERIOSCL THROM VAS, V29, P1419, DOI 10.1161/ATVBAHA.108.180497
   Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Noonan DM, 2008, CANCER METAST REV, V27, P31, DOI 10.1007/s10555-007-9108-5
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Shen DF, 1998, OPHTHALMOLOGY, V105, P1664, DOI 10.1016/S0161-6420(98)99036-4
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   World Health Organization, 2009, VIS IMP BLINDN
NR 33
TC 144
Z9 163
U1 0
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1320-5463
J9 PATHOL INT
JI Pathol. Int.
PD SEP
PY 2011
VL 61
IS 9
BP 528
EP 535
DI 10.1111/j.1440-1827.2011.02695.x
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 821LO
UT WOS:000294976700004
PM 21884302
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Pham, TQ
   Wang, JJ
   Rochtchina, E
   Mitchell, P
AF Pham, TQ
   Wang, JJ
   Rochtchina, E
   Mitchell, P
TI Pterygium/pinguecula and the five-year incidence of age-related
   maculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUNLIGHT; EYE
AB PURPOSE: To assess the relationship between baseline pterygium and pinguecula and the five-year incidence of age related maculopathy (ARM).
   DESIGN: Population-based longitudinal study.
   METHODS: The Blue Mountains Eye Study examined 3654 residents aged 49+ years during 1992 to 1994 and then re,examined 2335 (75.1% of survivors) after five years. Retinal photographs were graded using the Wisconsin Age,Related Maculopathy Grading System. Slit, lamp examination recorded pterygium and pinguecula. Eye-specific data were analyzed using generalized estimating equation models.
   RESULTS: After adjusting for age, gender, and smoking, eyes with pterygium or previous pterygium surgery had a higher risk of incident late ARM, odds ratio (OR) 3.3, 95% confidence interval (CI) 1.1 to 10.3, early ARM (OR 1.8, CI 1.1 to 2.9) and soft drusen (OR 2.0, CI 1.9 to 3.4), than eyes without pterygium. We found no association between pinguecula and incident ARM.
   CONCLUSIONS: This study found that pterygium was associated with a two, to threefold increased risk of incident late and early ARM. (c) 2005 by Elsevier Inc. All rights reserved.
C1 Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead, NSW, Australia.
   Westmead Millennium Inst, Westmead, NSW, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM iiejin_wang@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   PERKINS ES, 1985, OPHTHALMIC RES, V17, P325, DOI 10.1159/000265395
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1481, DOI 10.1001/archopht.1989.01070020555039
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
NR 5
TC 16
Z9 18
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2005
VL 139
IS 3
BP 536
EP 537
DI 10.1016/j.ajo.2004.08.070
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907GO
UT WOS:000227704200020
PM 15767067
DA 2022-11-30
ER

PT J
AU Sugiyama, A
   Sakurada, Y
   Honda, S
   Miki, A
   Matsumiya, W
   Yoneyama, S
   Kikushima, W
   Iijima, H
AF Sugiyama, Atsushi
   Sakurada, Yoichi
   Honda, Shigeru
   Miki, Akiko
   Matsumiya, Wataru
   Yoneyama, Seigo
   Kikushima, Wataru
   Iijima, Hiroyuki
TI Retreatment of Exudative Age-Related Macular Degeneration after Loading
   3-Monthly Intravitreal Ranibizumab
SO OPHTHALMOLOGICA
LA English
DT Article
DE Ranibizumab; Age-related macular degeneration; Polypoidal choroidal
   vasculopathy; Retreatment-free period; ARMS2 A69S
ID GROWTH-FACTOR TREATMENT; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   TREAT-AND-EXTEND; ASSOCIATION; BEVACIZUMAB; POLYMORPHISMS; TRIAL; CATT
AB Purpose: The aim of this study was to investigate the clinical implications of required retreatment after 3-monthly intra-vitreal ranibizumab (IVR) injections followed by as-needed reinjections up to 5 years in eyes with exudative age-related macular degeneration (AMD). Methods: A retrospective cohort study was conducted for 165 treatment-naive eyes from 165 patients with exudative AMD. Visual changes were investigated in terms of the required retreatments. Results: Retreatment-free proportions were 37.0, 23.7, 16.6, 12.1, and 10.5% at 12, 24, 36, 48, and 60 months, respectively. Visual changes were significantly better in eyes which did not require retreatment at every yearly checkpoint within the 5 years. A multivariate logistic regression analysis revealed that requirement of additional IVR treatments in the first 1224 months was associated with the T allele (risk allele) of ARMS2 A69S (p = 0.010 and 0.015, respectively). Cox regression analysis revealed that older age (p = 0.046) and the T allele of ARMS2 A69S (p = 0.036) were associated with required retreatment within the 5-year follow-up period. Conclusions: Age and the T allele of ARMS2 A69S are the risk factors requiring retreatments, leading to poor visual change in eyes with exudative AMD following the initial 3-monthly IVR. (C) 2017 S. Karger AG, Basel
C1 [Sugiyama, Atsushi; Sakurada, Yoichi; Yoneyama, Seigo; Kikushima, Wataru; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
   [Honda, Shigeru; Miki, Akiko; Matsumiya, Wataru] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo, Japan.
C3 University of Yamanashi; Kobe University
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
EM sakurada@yamanashi.ac.jp
RI Honda, Shigeru/W-4761-2019
FU JSPS (Japan Society for the Promotion of Science) KAKENHI [26861441]
FX This study was supported in part by JSPS (Japan Society for the
   Promotion of Science) KAKENHI grant No. 26861441.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Bessho H, 2011, MOL VIS, V17, P977
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 23
TC 7
Z9 7
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 239
IS 1
BP 52
EP 59
DI 10.1159/000480439
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FQ8VP
UT WOS:000418641600007
PM 29045945
DA 2022-11-30
ER

PT J
AU Rumelt, S
   Pollack, A
AF Rumelt, S
   Pollack, A
TI Posterior capsule opacity and choroidal neovascularization in patients
   with age-related macular degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID QUALITY-OF-LIFE; CATARACT-EXTRACTION; MACULOPATHY
AB BACKGROUND AND OBJECTIVE: To present a series of 3 patients with the dry form of age-related macular degeneration (AMD) in whom choroidai neovascularization (CNV) was observed following neodymium: yttrium-aluminum-garnet (Nd:YAG) capsulotomy.
   PATIENTS AND METHODS: Three consecutive patients aged 80 to 87 years (average = 83.7 years) with hard drusen or retinal pigment epithelial changes underwent uneventful cataract extraction between 6 months and 20 years before undergoing Nd:YAG capsulotomy for posterior capsule opacity. The patients were examined for retinal changes before laser treatment and at regular intervals after treatment.
   RESULTS: All patients developed CNV between 12 days and 1 month after capsulotomy that caused a decrease in the visual acuity from 20/20-20/40 to 20/200-counting fingers at 4 feet. The fellow eye did not show a substantial change in AMD over a year of follow-up. Two of the fellow eyes had disciform scar due to CNV before the cataract surgery, and these patients remained legally blind.
   CONCLUSIONS: The development of CNV after Nd:YAG capsulotomy suggests a temporal association between the two and calls for further study. Because posterior capsule opacity may mask CNV, patients with dry AMD and posterior capsule opacity who experience decreased visual acuity or glare may undergo indocyanine green angiography before it is decided to perform Nd:YAG capsulotomy.
C1 Western Galilee Nahariya Med Ctr, Dept Ophthalmol, IL-22100 Nahariyya, Israel.
   Leumit Hlth Care Syst, Jerusalem, Israel.
   Kaplan Hosp, IL-76100 Rehovot, Israel.
C3 Western Galilee Hospital; Hebrew University of Jerusalem; Kaplan Medical
   Center
RP Rumelt, S (通讯作者)，Western Galilee Nahariya Med Ctr, Dept Ophthalmol, POB 21, IL-22100 Nahariyya, Israel.
CR Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Benhamou N, 1998, J FR OPHTALMOL, V21, P495
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   MILCH FA, 1987, INT OPHTHALMOL CLIN, V27, P205, DOI 10.1097/00004397-198702730-00009
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   WERB Z, 1983, AM J ANAT, V166, P237, DOI 10.1002/aja.1001660302
NR 13
TC 0
Z9 2
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JAN-FEB
PY 2006
VL 37
IS 1
BP 20
EP 24
DI 10.3928/1542-8877-20060101-05
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 002MG
UT WOS:000234615000003
PM 16468547
DA 2022-11-30
ER

PT J
AU Thibaut, M
   Delerue, C
   Boucart, M
   Tran, THC
AF Thibaut, M.
   Delerue, C.
   Boucart, M.
   Tran, T. H. C.
TI Visual exploration of objects and scenes in patients with age-related
   macular degeneration
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Low vision; Macular degeneration; Eye movement; Object recognition;
   Scene; Central scotoma
ID EYE-MOVEMENTS; LOW-VISION; RECOGNITION; FIXATION; DISEASE;
   IDENTIFICATION; CONTEXT; SEARCH; FACE
AB Objective. - Studies on people with age-related macular degeneration (AMD) have shown that they are able to detect briefly displayed objects and scenes with high accuracy (above 80%). However, in everyday life we explore our environment to search and to recognize objects. We assessed visual exploration in people with AMD during the identification of objects and scenes.
   Method. - Twenty patients with AMD, fifteen age-matched and twelve young controls participated. We used colored photographs of isolated objects, natural scenes and objects in scenes, displayed centrally on a monitor. Participants were asked to name the objects and scenes. Ocular movements were recorded during the identification task. Scan paths, saccades, fixations, and accuracy were also recorded.
   Results. - People with AMD exhibited lower accuracy (by about 30%). Eye movement parameters were impaired with a larger number of saccades, shorter fixation durations and a larger scan path than controls.
   Conclusions. - Our results are consistent with studies on artificial scotoma in normally sighted people showing that a central scotoma impairs oculomotricity. In contrast to detection tasks, people with central vision loss exhibit impaired performance in identification of objects and scenes (62 to 66%). Eye movement studies suggest that the lower accuracy in patients is likely due to the use of peripheral vision and instability of fixation. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Thibaut, M.; Delerue, C.; Boucart, M.; Tran, T. H. C.] Univ Lille Nord France, CNRS, Lab Neurosci Fonct & Pathol, F-59000 Lille, France.
   [Tran, T. H. C.] Hop St Vincent de Paul, Serv Ophtalmol Adulte, F-59020 Lille, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de Lille
   - ISITE; Universite de Lille
RP Tran, THC (通讯作者)，Univ Lille Nord France, CNRS, Lab Neurosci Fonct & Pathol, F-59000 Lille, France.
EM tran.thc@gmail.com
RI TRAN, Thi Ha Chau/AAF-2162-2020
OI TRAN, Thi Ha Chau/0000-0001-9066-7092
FU French National Research Agency; French ministry of research
FX The authors are grateful to Sebastien Szaffarczyk for technical help, to
   Christine Moroni for help in statistics and to all patients and controls
   for accepting to participate. The study was funded by a grant
   "LowVision" from the French National Research Agency and a PhD grant
   from the French ministry of research to the first author.
CR Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   Boucart M, 2013, VISION RES, V86, P35, DOI 10.1016/j.visres.2013.04.006
   Boucart M, 2013, INVEST OPHTH VIS SCI, V54, P1950, DOI 10.1167/iovs.12-9680
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   Costello MC, 2010, EXP AGING RES, V36, P249, DOI 10.1080/0361073X.2010.484719
   Crossland MD, 2006, VISION RES, V46, P590, DOI 10.1016/j.visres.2005.05.015
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Crossland MD, 2011, INVEST OPHTH VIS SCI, V52, P411, DOI 10.1167/iovs.10-5473
   Grill-Spector K, 2005, PSYCHOL SCI, V16, P152, DOI 10.1111/j.0956-7976.2005.00796.x
   Henderson JM, 1997, PERCEPT PSYCHOPHYS, V59, P323, DOI 10.3758/BF03211901
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Oliva A, 2000, COGNITIVE PSYCHOL, V41, P176, DOI 10.1006/cogp.1999.0728
   Poncet M, 2014, EUR J NEUROSCI, V39, P1508, DOI 10.1111/ejn.12513
   Porter G, 2010, CORTEX, V46, P621, DOI 10.1016/j.cortex.2009.04.013
   Pratt J, 2006, J MOTOR BEHAV, V38, P373, DOI 10.3200/JMBR.38.5.373-382
   Rubin GS, 2009, NEURO-OPHTHALMOLOGY, V33, P120, DOI 10.1080/01658100902998732
   Seiple W, 2013, OPTOMETRY VISION SCI, V90, P45, DOI 10.1097/OPX.0b013e3182794775
   Tatler BW, 2007, J VISION, V7, DOI 10.1167/7.14.4
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Thi HCT, 2012, OPTOMETRY VISION SCI, V89, P419, DOI 10.1097/OPX.0b013e31824c3a21
   Thi HCT, 2010, INVEST OPHTH VIS SCI, V51, P6868, DOI 10.1167/iovs.10-5517
   Thibaut M, 2015, OPHTHAL PHYSL OPT, V35, P336, DOI 10.1111/opo.12201
   Tran THC, 2012, J FR OPHTALMOL, V35, P58, DOI 10.1016/j.jfo.2011.08.002
   Van der Stigchel S, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00579
NR 25
TC 16
Z9 16
U1 0
U2 8
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD JAN
PY 2016
VL 39
IS 1
BP 82
EP 89
DI 10.1016/j.jfo.2015.08.010
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA DA9DY
UT WOS:000368109500019
PM 26707755
DA 2022-11-30
ER

PT J
AU Chen, YH
   Zeng, JX
   Zhao, C
   Wang, K
   Trood, E
   Buehler, J
   Weed, M
   Kasuga, D
   Bernstein, PS
   Hughes, G
   Fu, V
   Chin, J
   Lee, C
   Crocker, M
   Bedell, M
   Salasar, F
   Yang, ZL
   Goldbaum, M
   Ferreyra, H
   Freeman, WR
   Kozak, I
   Zhang, K
AF Chen, Yuhong
   Zeng, Jiexi
   Zhao, Chao
   Wang, Kevin
   Trood, Elizabeth
   Buehler, Jeanette
   Weed, Matthew
   Kasuga, Daniel
   Bernstein, Paul S.
   Hughes, Guy
   Fu, Victoria
   Chin, Jessica
   Lee, Clara
   Crocker, Maureen
   Bedell, Matthew
   Salasar, Francesca
   Yang, Zhenglin
   Goldbaum, Michael
   Ferreyra, Henry
   Freeman, William R.
   Kozak, Igor
   Zhang, Kang
TI Assessing Susceptibility to Age-Related Macular Degeneration With
   Genetic Markers and Environmental Factors
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; RISK-FACTORS; VARIANT; ASSOCIATION; DISEASE;
   POLYMORPHISM; LOC387715; CFH; MACULOPATHY; PROGRESSION
AB Objectives: To evaluate the independent and joint effects of genetic factors and environmental variables on advanced forms of age-related macular degeneration (AMD), including geographic atrophy and choroidal neo-vascularization, and to develop a predictive model with genetic and environmental factors included.
   Methods: Demographic information, including age at onset, smoking status, and body mass index, was collected for 1844 participants. Genotypes were evaluated for 8 variants in 5 genes related to AMD. Unconditional logistic regression analyses were performed to generate a risk predictive model.
   Results: All genetic variants showed a strong association with AMD. Multivariate odds ratios were 3.52 (95% confidence interval, 2.08-5.94) for complement factor H, CFH rs1061170 CC, 4.21 (2.30-7.70) for CFH rs2274700 CC, 0.46 (0.27-0.80) for C2 rs9332739 CC/CG, 0.44 (0.30-0.66) for CFB rs641153 TT/ CT, 10.99 (6.04-19.97) for HTRA1/LOC387715 rs10490924 TT, and 2.66 (1.43-4.96) for C3 rs2230199 GG. Smoking was independently associated with advanced AMD after controlling for age, sex, body mass index, and all genetic variants.
   Conclusion: CFH confers more risk to the bilaterality of geographic atrophy, whereas HTRA1/LOC387715 contributes more to the bilaterality of choroidal neovascularization. C3 confers more risk for geographic atrophy than choroidal neovascularization. Risk models with combined genetic and environmental factors have notable discrimination power.
C1 [Chen, Yuhong; Zeng, Jiexi; Zhao, Chao; Wang, Kevin; Trood, Elizabeth; Weed, Matthew; Kasuga, Daniel; Hughes, Guy; Fu, Victoria; Chin, Jessica; Lee, Clara; Crocker, Maureen; Kozak, Igor; Zhang, Kang] Univ Calif San Diego, Inst Genom Med, San Diego, CA 92103 USA.
   [Chen, Yuhong] Fudan Univ, Shanghai Med Sch, Eye & Ear Nose Throat Hosp, Dept Ophthalmol & Vis Sci, Shanghai 200433, Peoples R China.
   [Zeng, Jiexi] Cent S Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China.
   [Buehler, Jeanette; Bernstein, Paul S.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Zhang, Kang] Sichuan Univ, W China Hosp, Mol Med Res Ctr, Chengdu, Peoples R China.
   [Zhang, Kang] Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.
C3 University of California System; University of California San Diego;
   Fudan University; Central South University; Utah System of Higher
   Education; University of Utah; Sichuan University; Sichuan University
RP Zhang, K (通讯作者)，Univ Calif San Diego, Inst Genom Med, San Diego, CA 92103 USA.
EM kangzhang@gmail.com
RI Zhang, Kang/Y-2740-2019; Kozak, Igor/AAC-4645-2019; Goldbaum,
   Michael/AAG-4258-2020
OI Zhang, Kang/0000-0002-4549-1697; Goldbaum, Michael/0000-0002-7721-2736
FU National Eye Institute [N01-EY-0-2127]; National Institutes of Health;
   Veterans Affairs; Foundation Fighting Blindness; Macula Vision Research
   Foundation; Ruth and Milton Steinbach Fund Inc; Research to Prevent
   Blindness; Burroughs Wellcome Fund; Chinese National 985 Project;
   NATIONAL EYE INSTITUTE [N01EY002127, P30EY014800] Funding Source: NIH
   RePORTER
FX Funding support for the Age-Related Eye Disease Study (AREDS) was
   provided by grant N01-EY-0-2127 from the National Eye Institute. Dr
   Zhang is supported by grants from the National Institutes of Health, the
   Veterans Affairs Merit Award, the Foundation Fighting Blindness, the
   Macula Vision Research Foundation, the Ruth and Milton Steinbach Fund
   Inc, Research to Prevent Blindness, a Burroughs Wellcome Fund Clinical
   Scientist Award in Translational Research, and grants from Chinese
   National 985 Project to Sichuan University and West China Hospital.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Mailman MD, 2007, NAT GENET, V39, P1181, DOI 10.1038/ng1007-1181
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Pai ASI, 2009, ARCH OPHTHALMOL-CHIC, V127, P1339, DOI 10.1001/archophthalmol.2009.239
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhao JY, 2006, AM J HUM GENET, V79, P831, DOI 10.1086/508571
NR 33
TC 68
Z9 69
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 2011
VL 129
IS 3
BP 344
EP 351
DI 10.1001/archophthalmol.2011.10
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 734ID
UT WOS:000288326900017
PM 21402993
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Li, YY
   Wang, DL
AF Li, Yuanyuan
   Wang, Deliang
TI Association between PEDF gene polymorphisms and the risk of age-related
   macular degeneration
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE PEDF gene; polymorphisms; age-related macular degeneration
ID EPITHELIUM-DERIVED FACTOR; MET72THR POLYMORPHISM; THERAPY;
   NEOVASCULARIZATION
AB Objective: Pigment epithelium-derived factor (PEDF) strongly inhibits angiogenesis, and plays an important role in retinoblastoma cells. In this study we detect the association of PEDF gene polymorphisms (rs1136287 and rs12150053) and age-related macular degeneration (AMD) risk. Methods: This is a case-control study including 118 AMD patients and 121 healthy controls. PEDF gene polymorphisms were genotyped by TaqMan method. Hardy-Weinberg equilibrium (HWE) was used to detect the representativeness of the cases and controls. Differences of genotype and allele distributions of PEDF polymorphisms were calculated by Chi-square test. Odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs) were used to present the relative risk of AMD. Results: Genotype and allele distributions in controls were in accordance with HWE. Genotype and allele distributions of rs1136287 had no significant association with the susceptibility of AMD under five contrast models (P<0.05). CC genotype and C allele of rs12150053 were higher in cases than that in controls, and rs12150053 was obviously related to the risk of AMD under T vs. C model (P=0.044, OR=1.499, 95% CI=1.009-2.226). Conclusion: In this study, there was no obvious association between PEDF gene rs1136287 polymorphism and AMD susceptibility, and rs12150053T might act as a susceptible allele in the occurrence of AMD.
C1 [Li, Yuanyuan; Wang, Deliang] Shangluo Second Peoples Hosp, Dept Ophthalmol, Shangluo 726000, Shanxi, Peoples R China.
RP Li, YY (通讯作者)，Shangluo Second Peoples Hosp, Dept Ophthalmol, Shangluo 726000, Shanxi, Peoples R China.
EM yuanjiem@yeah.net
FU Science and Technology Support Fund [2013-123558]
FX Science and Technology Support Fund (2013-123558).
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Askou AL, 2014, ACTA OPHTHALMOL, V92, P1, DOI 10.1111/aos.12452
   Bai YJ, 2013, J OCUL PHARMACOL TH, V29, P619, DOI 10.1089/jop.2012.0225
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fang K, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/821918
   Filleur S, 2009, J CELL BIOCHEM, V106, P769, DOI 10.1002/jcb.22072
   Gunda Venugopal, 2013, J Cancer Sci Ther, V5, P417
   Iizuka H, 2007, BIOCHEM BIOPH RES CO, V361, P421, DOI 10.1016/j.bbrc.2007.07.025
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Klein R, 2014, OPHTHALMOLOGY, V121, P1220, DOI 10.1016/j.ophtha.2014.01.003
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Miyake M, 2013, INVEST OPHTH VIS SCI, V54, P4208, DOI 10.1167/iovs.13-12280
   Plestina-Borjan I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/804054
   Qu Y, 2011, CURR EYE RES, V36, P60, DOI 10.3109/02713683.2010.524343
   Rychli K, 2009, EXPERT OPIN THER TAR, V13, P1295, DOI 10.1517/14728220903241641
   Sivaprasad S, 2013, BRIT MED BULL, V105, P201, DOI 10.1093/bmb/ldt004
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Tsuchihashi T, 2014, CLIN OPHTHALMOL, V8, P2471, DOI 10.2147/OPTH.S71305
   Uthra S, 2010, OPHTHALMIC GENET, V31, P18, DOI 10.3109/13816810903426231
   Wu KF, 2012, CURR EYE RES, V37, P68, DOI 10.3109/02713683.2011.618289
   Yamagishi S, 2005, MED HYPOTHESES, V64, P1202, DOI 10.1016/j.mehy.2005.01.017
   Yamagishi S, 2002, INT J TISSUE REACT, V24, P137
NR 30
TC 0
Z9 0
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2017
VL 10
IS 12
BP 11814
EP 11818
PG 5
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA FQ9UL
UT WOS:000418707100053
PM 31966545
DA 2022-11-30
ER

PT J
AU Zhou, J
   Wang, D
   Zhang, JJ
   Zhang, MX
   Lu, F
   Qiu, GX
   Zhao, L
   Nguyen, DH
   Luo, HR
   Cao, GQ
   Zhang, W
   Jiang, W
   Li, G
   Zhang, K
   Zhang, M
   Su, ZG
AF Zhou, Jie
   Wang, Dan
   Zhang, Junjun
   Zhang, Meixia
   Lu, Fang
   Qiu, Guoxian
   Zhao, Ling
   Nguyen, Duy H.
   Luo, Hongrong
   Cao, Guiqun
   Zhang, Wei
   Jiang, Wei
   Li, Gen
   Zhang, Kang
   Zhang, Ming
   Su, Zhiguang
TI RAD51 gene is associated with advanced age-related macular degeneration
   in Chinese population
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE Age-related macular degeneration; Genetic polymorphism; RAD51
ID COMPLEMENT-FACTOR-H; PETERS-PLUS SYNDROME; SUSCEPTIBILITY; VARIANT;
   RISK; POLYMORPHISM; LOC387715; DISEASE; CANCER; INCREASES
AB Objectives: This study aims to investigate whether variations in RAD51, B3GALTL, TNFRSF10A and REST-C4ORF14-POLR2B-IGFBP7 are associated with advanced forms of age-related macular degeneration (AMD) in Chinese population.
   Design and methods: A total of 119 Chinese patients with AMD and 99 control individuals were recruited. Genomic DNA was extracted from peripheral blood leukocytes. Seven single nucleotide polymorphisms (SNPs) from CFH, HTRA1, RAD51, B3GALTL, TNFRSF10A and REST-C4ORF14-POLR2B-IGFBP7 were genotyped by polymerase chain reaction (PCR) followed by allele-specific restriction enzyme digestion or SNaPshot.
   Results: Rs10483810 in RAD51 was significantly associated with advanced AMD (P = 0.045). Compared with the wild-type genotype GG, the odds ratio for the risk of advanced AMD was 4.92 (95% confidence interval: 1.04-23.36) for the heterozygous TG genotype. Moreover, the GT genotype at rs10483810 confers significantly increased risk of bilateral AMD compared to unilateral AMD (OR = 12.04, 95% CI: 2.50-57.69, P = 0.002). R513278062 in TNFRSF10A, rs1713985 in REST-C4ORF14-POLR2B-IGFBP7 and rs9542236 in B3GALTL were not found to be associated with AMD (all P>0.05).
   Conclusion: Our data suggested that the risk allele T of rs10483810 in RAD51 gene is associated with an increased risk of advanced AMD, especially bilateral AMD, in Chinese population. (C) 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
C1 [Zhou, Jie; Wang, Dan; Zhao, Ling; Luo, Hongrong; Cao, Guiqun; Zhang, Wei; Jiang, Wei; Li, Gen; Zhang, Kang; Su, Zhiguang] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Mol Med Res Ctr, Chengdu 610041, Peoples R China.
   [Zhou, Jie; Wang, Dan; Zhang, Junjun; Zhang, Meixia; Lu, Fang; Qiu, Guoxian; Zhang, Kang; Zhang, Ming] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
   [Zhao, Ling; Nguyen, Duy H.; Luo, Hongrong; Zhang, Kang] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
C3 Sichuan University; Sichuan University; University of California System;
   University of California San Diego
RP Zhang, M (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
EM zhangmingscu@126.com; zhiguang_su@hotmail.com
RI Zhao, Ling/D-9005-2015; luo, hongrong/B-2714-2015; Zhang,
   Kang/Y-2740-2019; Nguyen, Duy/HDO-8098-2022; Su, Zhiguang/AFS-0022-2022
OI luo, hongrong/0000-0001-7994-1193; Zhang, Kang/0000-0002-4549-1697;
   Zhao, Ling/0000-0002-6644-2886
FU National Basic Research Program of China [2011CB510200]; National
   Natural Science Foundation of China [31071108, 81271019]; Program for
   New Century Excellent Talents in University [NCET-10-0600]
FX This study was supported by National Basic Research Program of China
   (No. 2011CB510200), National Natural Science Foundation of China (No.
   31071108, 81271019), and the Program for New Century Excellent Talents
   in University (NCET-10-0600).
CR Abu-Safieh L, 2011, AM J HUM GENET, V89, P313, DOI 10.1016/j.ajhg.2011.07.010
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He J, 2012, NUCLEIC ACIDS RES, V40, P6097, DOI 10.1093/nar/gks257
   Heinonen TYK, 2009, ANN MED, V41, P2, DOI 10.1080/07853890802301975
   Holz F.G., 2012, AGE RELATED MACULAR
   Islam MN, 2012, J BIOL CHEM, V287, P23808, DOI 10.1074/jbc.M112.375014
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Karpenshif Y, 2012, DNA REPAIR, V11, P781, DOI 10.1016/j.dnarep.2012.07.001
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Shimizu R, 2010, CONGENIT ANOM, V50, P197, DOI 10.1111/j.1741-4520.2010.00282.x
   Silverstein RL, 2002, J CELL BIOL, V159, P203, DOI 10.1083/jcb.200209138
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Wang ML, 2009, MUTAT RES-FUND MOL M, V661, P85, DOI 10.1016/j.mrfmmm.2008.11.009
   Xu L, 2008, OPHTHALMOLOGICA, V222, P378, DOI 10.1159/000151468
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yuan YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050848
NR 33
TC 6
Z9 6
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD NOV
PY 2013
VL 46
IS 16-17
BP 1689
EP 1693
DI 10.1016/j.clinbiochem.2013.07.002
PG 5
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 244BM
UT WOS:000326362100014
PM 23868022
DA 2022-11-30
ER

PT J
AU Kashani, AH
   Lebkowski, JS
   Rahhal, FM
   Avery, RL
   Salehi-Had, H
   Dang, W
   Lin, CM
   Mitra, D
   Zhu, DH
   Thomas, BB
   Hikita, ST
   Pennington, BO
   Johnson, LV
   Clegg, DO
   Hinton, DR
   Humayun, MS
AF Kashani, Amir H.
   Lebkowski, Jane S.
   Rahhal, Firas M.
   Avery, Robert L.
   Salehi-Had, Hani
   Dang, Wei
   Lin, Chih-Min
   Mitra, Debbie
   Zhu, Danhong
   Thomas, Biju B.
   Hikita, Sherry T.
   Pennington, Britney O.
   Johnson, Lincoln V.
   Clegg, Dennis O.
   Hinton, David R.
   Humayun, Mark S.
TI A bioengineered retinal pigment epithelial monolayer for advanced, dry
   age-related macular degeneration
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID GEOGRAPHIC ATROPHY; BRUCHS MEMBRANE; VISUAL-ACUITY; SUBRETINAL
   IMPLANTATION; STEM-CELLS; MACULOPATHY; PREVALENCE; SURVIVAL; EYES
AB Retinal pigment epithelium (RPE) dysfunction and loss are a hallmark of non-neovascular age-related macular degeneration (NNAMD). Without the RPE, a majority of overlying photoreceptors ultimately degenerate, leading to severe, progressive vision loss. Clinical and histological studies suggest that RPE replacement strategies may delay disease progression or restore vision. A prospective, interventional, U.S. Food and Drug Administration-cleared, phase 1/2a study is being conducted to assess the safety and efficacy of a composite subretinal implant in subjects with advanced NNAMD. The composite implant, termed the California Project to Cure Blindness-Retinal Pigment Epithelium 1 (CPCB-RPE1), consists of a polarized monolayer of human embryonic stem cell-derived RPE (hESC-RPE) on an ultrathin, synthetic parylene substrate designed to mimic Bruch's membrane. We report an interim analysis of the phase 1 cohort consisting of five subjects. Four of five subjects enrolled in the study successfully received the composite implant. In all implanted subjects, optical coherence tomography imaging showed changes consistent with hESC-RPE and host photoreceptor integration. None of the implanted eyes showed progression of vision loss, one eye improved by 17 letters and two eyes demonstrated improved fixation. The concurrent structural and functional findings suggest that CPCB-RPE1 may improve visual function, at least in the short term, in some patients with severe vision loss from advanced NNAMD.
C1 [Kashani, Amir H.; Mitra, Debbie; Thomas, Biju B.; Hinton, David R.; Humayun, Mark S.] Univ Southern Calif, Roski Eye Inst, USC Inst Biomed Therapeut, 1450 San Pablo, Los Angeles, CA 90033 USA.
   [Kashani, Amir H.; Mitra, Debbie; Thomas, Biju B.; Hinton, David R.; Humayun, Mark S.] USC, Keck Sch Med, Dept Ophthalmol, 1450 San Pablo, Los Angeles, CA 90033 USA.
   [Lebkowski, Jane S.; Johnson, Lincoln V.] Regenerat Patch Technol, 150 Gabarda Way, Portola Valley, CA 94028 USA.
   [Rahhal, Firas M.] Retina Vitreous Associates, Med Grp, 9001 Wilshire Blvd,Suite 301, Beverly Hills, CA 90211 USA.
   [Avery, Robert L.] Calif Retina Consultants, 525 East Micheltorena St, Santa Barbara, CA 93103 USA.
   [Salehi-Had, Hani] Atlantis Eyecare, 7777 Edinger Ave,Suite 234, Huntington Beach, CA 92647 USA.
   [Dang, Wei; Lin, Chih-Min] City Hope Natl Med Ctr, Beckman Res Inst, Ctr Biomed & Genet, 1500 East Duarte Rd, Duarte, CA 91010 USA.
   [Zhu, Danhong] USC, Keck Sch Med, Dept Pathol, 1441 Eastlake Ave,NRT 7503, Los Angeles, CA 90033 USA.
   [Hikita, Sherry T.; Pennington, Britney O.; Johnson, Lincoln V.; Clegg, Dennis O.] Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Stem Cell Biol & Engn, Mail Code 5060, Santa Barbara, CA 93016 USA.
   [Humayun, Mark S.] USC, Denney Res Ctr DRB 140, Dept Biomed Engn, 1042 Downey Way, Los Angeles, CA 90089 USA.
C3 University of Southern California; University of Southern California;
   University of Southern California Keck Hospital; Retina Vitreous
   Associates Medical Group; City of Hope; Beckman Research Institute of
   City of Hope; University of Southern California; University of Southern
   California Keck Hospital; University of California System; University of
   California Santa Barbara; University of Southern California
RP Kashani, AH; Humayun, MS (通讯作者)，Univ Southern Calif, Roski Eye Inst, USC Inst Biomed Therapeut, 1450 San Pablo, Los Angeles, CA 90033 USA.; Kashani, AH; Humayun, MS (通讯作者)，USC, Keck Sch Med, Dept Ophthalmol, 1450 San Pablo, Los Angeles, CA 90033 USA.; Humayun, MS (通讯作者)，USC, Denney Res Ctr DRB 140, Dept Biomed Engn, 1042 Downey Way, Los Angeles, CA 90089 USA.
EM ahkashan@usc.edu; humayun@usc.edu
OI Salehi-Had, Hani/0000-0003-2631-7754; Lin, Chih Min/0000-0003-2062-5131
FU California Institute for Regenerative Medicine and Regenerative Patch
   Technologies
FX This study received funding from California Institute for Regenerative
   Medicine and Regenerative Patch Technologies; gifts from the Lori Mars
   Foundation, the William K. Bowes Jr. Foundation, the Vermont Community
   Foundation, the Breaux Foundation, and the Wilcox Family Foundation; and
   unrestricted departmental support to the USC Roski Eye Institute from
   Research to Prevent Blindness.
CR Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Fernandes Rodrigo A Brant, 2017, Int J Retina Vitreous, V3, P41, DOI 10.1186/s40942-017-0095-6
   Fernandes RAB, 2016, OSLI RETINA, V47, P342, DOI 10.3928/23258160-20160324-07
   Hippert C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120415
   Kashani AH, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-17681
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Landa G, 2012, EYE, V26, P61, DOI 10.1038/eye.2011.237
   Lu B, 2014, DEV OPHTHALMOL, V53, P155, DOI 10.1159/000357375
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Pennington BO, 2016, J OCUL PHARMACOL TH, V32, P261, DOI 10.1089/jop.2015.0153
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Rosser DA, 2003, INVEST OPHTH VIS SCI, V44, P3278, DOI 10.1167/iovs.02-1100
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Tsukahara I, 2002, EXP EYE RES, V74, P255, DOI 10.1006/exer.2001.1123
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wakabayashi T, 2010, OPHTHALMOLOGY, V117, P1815, DOI 10.1016/j.ophtha.2010.01.017
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
NR 35
TC 169
Z9 171
U1 9
U2 36
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD APR 4
PY 2018
VL 10
IS 435
AR eaao4097
DI 10.1126/scitranslmed.aao4097
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GB5IW
UT WOS:000429098800005
PM 29618560
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Gibson, J
   Cree, A
   Collins, A
   Lotery, A
   Ennis, S
AF Gibson, Jane
   Cree, Angela
   Collins, Andrew
   Lotery, Andrew
   Ennis, Sarah
TI Determination of a gene and environment risk model for age-related
   macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SERPING1 GENE; ASSOCIATION; POLYMORPHISM; PREVALENCE
AB Background/aims We have recently identified an association between age-related macular degeneration (AMD) and genetic variants in the serpin peptidase inhibitor, clade G, member 1 (SERPING1) gene. In the current study we interrogated the genomic region in linkage disequilibrium (LD) with the SERPING1 gene, and modelled the contribution to disease of known genetic and environmental AMD risk factors.
   Methods We analysed genes neighbouring SERPING1 and examined haplotype association with AMD. A stepwise logistic regression model was developed including known genetic and environmental risk factors (age, sex and smoking). Individual risk scores were assessed between groups of cases and controls.
   Results In SERPING1 region rs2511989 remains most significantly associated (p=1.77X10(-5), OR 0.67). One haplotype, containing the rs2511989 variant and the majority of SERPING1, exhibits marginally stronger association (p=5.13X10(-6), OR 0.66). Our risk model includes six SNPs in CFH, C3, HTRA1 and SERPING1, showing independent effects, which together account for 45% of risk of developing AMD (p=1.65X10(-50)) with a combined population attributable risk of 87%.
   Conclusion Results implicate SERPING1, with no convincing evidence for involvement of other genes in the region. We demonstrate a multifactorial model with significant differences in risk scores for cases versus controls (p=9.813X10(-71)) and across Age-Related Eye Disease Study (AREDS) score-stratified cases (p=1.88X10(-11)).
C1 [Gibson, Jane; Collins, Andrew; Ennis, Sarah] Univ Southampton, Genet Epidemiol & Bioinformat Grp, Div Human Genet, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.
   [Cree, Angela; Lotery, Andrew] Univ Southampton, Clin Neurosci Div, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.
   [Lotery, Andrew] Southampton Gen Hosp, Southampton Eye Unit, Southampton, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton
RP Ennis, S (通讯作者)，Univ Southampton, Genet Epidemiol & Bioinformat Grp, Div Human Genet, Southampton Gen Hosp, Mailpoint 808, Southampton SO16 6YD, Hants, England.
EM se@soton.ac.uk
RI Collins, Andrew/S-2196-2019; Gibson, Jane/I-1630-2012; Collins,
   Andrew/A-6595-2010
OI Collins, Andrew/0000-0001-7108-0771; Gibson, Jane/0000-0002-0973-8285;
   Collins, Andrew/0000-0001-7108-0771; Lotery, Andrew/0000-0001-5541-4305;
   Cree, Angela/0000-0002-1987-8900
FU Macular Disease Society; Macular Vision Research Foundation; Brian
   Mercer Charitable Trust; National Institute for Health Research
   [NF-SI-0507-10094] Funding Source: researchfish
FX This work was supported by the Macular Disease Society, the Macular
   Vision Research Foundation and the Brian Mercer Charitable Trust.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   CARTER JG, 2009, ACTA OPHTHALMOL
   Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kralovicova J, 2009, LANCET, V373, P461, DOI 10.1016/S0140-6736(09)60168-9
   Kuo Tai-Yue, 2007, Methods Mol Biol, V376, P47
   Lu F, 2010, MOL VIS, V16, P1
   Meng XF, 2003, BIOCHEM GENET, V41, P99, DOI 10.1023/A:1022073917044
   Park KH, 2009, MOL VIS, V15, P200
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ramsden C., 2009, 59 ANN M AM SOC HUM
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 25
TC 21
Z9 22
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2010
VL 94
IS 10
BP 1382
EP 1387
DI 10.1136/bjo.2010.182568
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 666FB
UT WOS:000283097700025
PM 20576771
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
   Hegel, MT
   Hauck, WW
   Tasman, WS
AF Rovner, Barry W.
   Casten, Robin J.
   Hegel, Mark T.
   Hauck, Walter W.
   Tasman, William S.
TI Dissatisfaction with performance of valued activities predicts
   depression in age-related macular degeneration
SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE age-related macular degeneration; vision loss; depression; disability
ID CHRONIC DISEASE SCORE; VISUAL IMPAIRMENT; VISION FUNCTION; RATING-SCALE;
   OLDER ADULTS; QUESTIONNAIRE; DISABILITY; ABILITY; LIFE
AB Objective To determine whether dissatisfaction with performance of valued activities predicts depression in patients with age-related macular degeneration (AMD).
   Patients Two hundred and six patients with newly diagnosed neovascular AMD in one eye and pre-existing AMD in the fellow eye who were participating in a clinical trial of a psychosocial intervention to prevent depression.
   Measures Structured clinical evaluations of vision function, depression, visual acuity, contrast sensitivity and medical morbidity. Subjects were classified as dissatisfied if they indicated that they were dissatisfied with their performance of a valued activity.
   Results Subjects who were dissatisfied with performance of valued activities (n=71) had similar demographic characteristics to satisfied subjects (n = 135) but had worse visual acuity (p < 0.054), greater medical comorbidity (p < 0.006), and lower vision function (p < 0.001). Dissatisfied subjects were almost 2.5 times more likely (OR = 2.41; [95% CI 1.02, 5.65]; p = 0.044) to become depressed within 2 months than satisfied subjects independent of baseline visual acuity, vision function, and medical comorbidity.
   Conclusion Dissatisfaction with performance of valued activities in older persons with AMD predicts depression over a 2-month period. Assessing the ability to pursue valued activities may identify patients at risk for depression and prompt clinicians to initiate rehabilitative interventions and careful surveillance for depression. Copyright (c) 2007 John Wiley & Sons, Ltd.
C1 Jefferson Med Coll, Dept Psychiat & Neurol, Philadelphia, PA USA.
   Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA USA.
   Dartmouth Med Sch, Dept Psychiat & Community & Family Med, Lebanon, NH USA.
   Jefferson Med Coll, Div Biostat, Dept Pharmacol & Expt Therapeut, Philadelphia, PA USA.
   Jefferson Med Coll, Wills Eye Hosp, Dept Ophthalmol, Philadelphia, PA USA.
C3 Jefferson University; Jefferson University; Dartmouth College; Jefferson
   University; Jefferson University
RP Rovner, BW (通讯作者)，Jefferson Hosp Neurosci, 900 Walnut St,4th Floor, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu
FU NATIONAL EYE INSTITUTE [U01EY015839] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061331] Funding Source: NIH
   RePORTER; NEI NIH HHS [U01 EY015839] Funding Source: Medline; NIMH NIH
   HHS [R01 MH61331, R01 MH061331] Funding Source: Medline
CR CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   Hegel MT, 2003, PROBLEM SOLVING TREA
   HOLLADAY JT, 1991, AM J OPHTHALMOL, V111, P372, DOI 10.1016/S0002-9394(14)72328-1
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   PARMELEE PA, 1991, J GERONTOL, V46, pP15, DOI 10.1093/geronj/46.1.P15
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   West CG, 2002, J AM GERIATR SOC, V50, P136, DOI 10.1046/j.1532-5415.2002.50019.x
   West SK, 2005, ARCH OPHTHALMOL-CHIC, V123, P1242, DOI 10.1001/archopht.123.9.1242
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742
NR 20
TC 25
Z9 27
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-6230
EI 1099-1166
J9 INT J GERIATR PSYCH
JI Int. J. Geriatr. Psychiatr.
PD AUG
PY 2007
VL 22
IS 8
BP 789
EP 793
DI 10.1002/gps.1742
PG 5
WC Geriatrics & Gerontology; Gerontology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychiatry
GA 200VK
UT WOS:000248790700011
PM 17199237
DA 2022-11-30
ER

PT J
AU Hwang, DDJ
   Choi, S
   Ko, J
   Yoon, J
   Park, JI
   Hwang, JS
   Han, JM
   Lee, HJ
   Sohn, J
   Park, KH
   Han, JY
AF Hwang, Daniel Duck-Jin
   Choi, Seong
   Ko, Junseo
   Yoon, Jeewoo
   Park, Ji In
   Hwang, Joon Seo
   Han, Jeong Mo
   Lee, Hak Jun
   Sohn, Joonhong
   Park, Kyu Hyung
   Han, Jinyoung
TI Distinguishing retinal angiomatous proliferation from polypoidal
   choroidal vasculopathy with a deep neural network based on optical
   coherence tomography
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; TYPE-3 NEOVASCULARIZATION; FEATURES; OUTCOMES
AB This cross-sectional study aimed to build a deep learning model for detecting neovascular age-related macular degeneration (AMD) and to distinguish retinal angiomatous proliferation (RAP) from polypoidal choroidal vasculopathy (PCV) using a convolutional neural network (CNN). Patients from a single tertiary center were enrolled from January 2014 to January 2020. Spectral-domain optical coherence tomography (SD-OCT) images of patients with RAP or PCV and a control group were analyzed with a deep CNN. Sensitivity, specificity, accuracy, and area under the receiver operating characteristic curve (AUROC) were used to evaluate the model's ability to distinguish RAP from PCV. The performances of the new model, the VGG-16, Resnet-50, Inception, and eight ophthalmologists were compared. A total of 3951 SD-OCT images from 314 participants (229 AMD, 85 normal controls) were analyzed. In distinguishing the PCV and RAP cases, the proposed model showed an accuracy, sensitivity, and specificity of 89.1%, 89.4%, and 88.8%, respectively, with an AUROC of 95.3% (95% CI 0.727-0.852). The proposed model showed better diagnostic performance than VGG-16, Resnet-50, and Inception-V3 and comparable performance with the eight ophthalmologists. The novel model performed well when distinguishing between PCV and RAP. Thus, automated deep learning systems may support ophthalmologists in distinguishing RAP from PCV.
C1 [Hwang, Daniel Duck-Jin; Lee, Hak Jun; Sohn, Joonhong] Hangil Eye Hosp, Dept Ophthalmol, 35 Bupyeong Daero, Incheon 21388, South Korea.
   [Hwang, Daniel Duck-Jin] Catholic Kwandong Univ, Dept Ophthalmol, Coll Med, Incheon, South Korea.
   [Choi, Seong; Ko, Junseo; Yoon, Jeewoo; Han, Jinyoung] Sungkyunkwan Univ, Dept Appl Artificial Intelligence, 25-2 Sungkyunkwan Ro, Seoul 03063, South Korea.
   [Choi, Seong; Yoon, Jeewoo; Han, Jinyoung] RAON DATA, Seoul, South Korea.
   [Park, Ji In] Kangwon Natl Univ, Kangwon Natl Univ Hosp, Dept Med, Sch Med, Chunchon, Gangwon Do, South Korea.
   [Hwang, Joon Seo] Seoul Plus Eye Clin, Seoul, South Korea.
   [Han, Jeong Mo] Kong Eye Ctr, Seoul, South Korea.
   [Park, Kyu Hyung] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, Seongnam, South Korea.
C3 Catholic Kwandong University; Sungkyunkwan University (SKKU); Kangwon
   National University; Kangwon National University Hospital; Seoul
   National University (SNU)
RP Hwang, DDJ (通讯作者)，Hangil Eye Hosp, Dept Ophthalmol, 35 Bupyeong Daero, Incheon 21388, South Korea.; Hwang, DDJ (通讯作者)，Catholic Kwandong Univ, Dept Ophthalmol, Coll Med, Incheon, South Korea.; Han, JY (通讯作者)，Sungkyunkwan Univ, Dept Appl Artificial Intelligence, 25-2 Sungkyunkwan Ro, Seoul 03063, South Korea.; Han, JY (通讯作者)，RAON DATA, Seoul, South Korea.
EM daniel.dj.hwang@gmail.com; jinyounghan@skku.edu
OI Hwang, Daniel Duck-Jin/0000-0003-1808-3169
FU National Research Foundation of Korea (NRF) - Ministry of Education
   [NRF-2018R1D1A1A02085647]
FX The authors thank Zee Yoon Byun, MD, Sung Yeon Jun, MD, Jung Hwa Lee,
   MD, Jayoung Ahn, MD, and Kyu Hwan Jang, MD for the thoughtful advice and
   data analysis. This research was supported in part by Basic Science
   Research Program through the National Research Foundation of Korea (NRF)
   funded by the Ministry of Education (NRF-2018R1D1A1A02085647). The
   funding organizations had no role in the design or conduct of this
   research.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Bradley AP, 1997, PATTERN RECOGN, V30, P1145, DOI 10.1016/S0031-3203(96)00142-2
   Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kerbs I, 2009, OPHTHAL SURG LAS IM, V40, P285, DOI [10.9999/15428877-20090430-10, 10.3928/15428877-20090430-10]
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kim JH, 2016, RETINA-J RET VIT DIS, V36, P1506, DOI 10.1097/IAE.0000000000000932
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Matsumoto H, 2010, RETINA-J RET VIT DIS, V30, P425, DOI 10.1097/IAE.0b013e3181bd2d95
   Milletari F, 2016, INT CONF 3D VISION, P565, DOI 10.1109/3DV.2016.79
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Rouvas AA, 2010, EYE, V24, P1633, DOI 10.1038/eye.2010.134
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Selvaraju R. R., P IEEE INT C COMP VI, P618
   Shin HC, 2016, IEEE T MED IMAGING, V35, P1285, DOI 10.1109/TMI.2016.2528162
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Shorten C, 2019, J BIG DATA-GER, V6, DOI 10.1186/s40537-019-0197-0
   Simonyan K., P 3 INT C LEARNING R
   Szegedy C, P IEEE C COMP VIS PA, P2818
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Yoon J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75816-w
NR 43
TC 3
Z9 3
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 29
PY 2021
VL 11
IS 1
AR 9275
DI 10.1038/s41598-021-88543-7
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SK4SH
UT WOS:000656206800004
PM 33927240
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cheng, L
   Chen, C
   Guo, WK
   Liu, K
   Zhao, QQ
   Lu, P
   Yu, FD
   Xu, X
AF Cheng, Lu
   Chen, Chong
   Guo, Wenke
   Liu, Kun
   Zhao, Qianqian
   Lu, Ping
   Yu, Fudong
   Xu, Xun
TI EFEMP1 Overexpression Contributes to Neovascularization in Age-Related
   Macular Degeneration
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Age-related macular degeneration; EFEMP1; fibulin-3; choroidal
   neovascularization; biomarker; gene expression profiling
ID COMPLEMENT FACTOR-H; ABERRANT ACCUMULATION; MALATTIA LEVENTINESE; GENE;
   FIBULIN-3; SUSCEPTIBILITY; ANGIOGENESIS; PROTEIN; GROWTH; RISK
AB Purpose: Age-related macular degeneration (AMD) is one of the leading causes of blindness, and choroidal neovascularization (CNV) in AMD can lead to serious visual impairment. Gene expression profiling of human ocular tissues have a great potential to reveal the pathophysiology of AMD. This study aimed to identify novel molecular biomarkers and gene expression signatures of AMD.
   Methods: We analyzed transcriptome profiles in retinal-choroid tissues derived from donor patients with AMD in comparison with those from healthy controls using a publicly available dataset (GSE29801). We focused on the EFEMP1 gene, which was found to be differentially upregulated in AMD, especially in wet AMD eyes. Serological validation analysis was carried out to verify the expression of EFEMP1 in 39 wet AMD patients and 39 age- and gender-matched cataract controls, using an enzyme-linked immunosorbent assay (ELISA). We then investigated the role of EFEMP1 in angiogenesis through in vitro experiments involving EFEMP1 overexpression (OE) and knockdown in human umbilical vein endothelial cells (HUVECs).
   Results: An increase in EFEMP1 expression was observed in the retinal-choroid tissues of eyes with AMD, which was more significant in wet AMD than in dry AMD. In addition, there was a significant increase in serum fibulin-3 (EFEMP1 encoded protein) concentration in patients with wet AMD compared with that in the controls. Tube formation and proliferation of EFEMP1-OE HUVECs increased significantly, whereas those of EFEMP1 knockdown HUVECs decreased significantly compared with those of the control. Additional extracellular fibulin-3 treatments did not increase tube formation and proliferation of wildtype and EFEMP1 knockdown HUVECs, indicating that the proangiogenic properties of EFEMP1 are of cell origin. We also found that vascular endothelial growth factor expression in HUVECs was upregulated by EFEMP1 overexpression and downregulated by EFEMP1 knockdown.
   Conclusion: Our findings demonstrate EFEMP1 as a novel biomarker for CNV in AMD, providing a new target for the development of wet AMD-directed pharmaceuticals and diagnostics.
C1 [Cheng, Lu; Chen, Chong; Liu, Kun; Xu, Xun] Shanghai Jiao Tong Univ, Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai Engn Ctr Visual Sci & Photomed,Shanghai, Shanghai Key Lab Ocular Fundus Dis,Dept Ophthalmo, Shanghai, Peoples R China.
   [Guo, Wenke; Zhao, Qianqian; Lu, Ping; Yu, Fudong] Fudan Univ, Shanghai Inst Planned Parenthood Res, NHC Key Lab Reprod Regulat, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Fudan University
RP Xu, X (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai Engn Ctr Visual Sci & Photomed,Shanghai, Shanghai Key Lab Ocular Fundus Dis,Dept Ophthalmo, Shanghai, Peoples R China.; Yu, FD (通讯作者)，Fudan Univ, Shanghai Inst Planned Parenthood Res, NHC Key Lab Reprod Regulat, Shanghai, Peoples R China.
EM drxuxun@sjtu.edu.cn; fdyush@163.com
FU National Key R&D Program of China [2016YFC0904800, 2019YFC0840607];
   National Science and Technology Major Project of China [2017ZX09304010];
   National Natural Science Foundation of China [81800831, 81800835,
   82000880]; Shanghai Sailing Program [18YF1419700, 19YF1439400]; Shanghai
   "Rising Stars of Medical Talent" Youth Development Program (Youth
   Medical Talents Specialist Program); Cross-Research Foundation of
   Shanghai Jiaotong University [ZH2018QNA13]
FX This study was supported by the National Key R&D Program of China
   (2016YFC0904800, 2019YFC0840607); National Science and Technology Major
   Project of China (2017ZX09304010); National Natural Science Foundation
   of China (81800831, 81800835, and 82000880); Shanghai Sailing Program
   (18YF1419700 and 19YF1439400); Shanghai "Rising Stars of Medical Talent"
   Youth Development Program (Youth Medical Talents Specialist Program),
   and Cross-Research Foundation of Shanghai Jiaotong University
   (ZH2018QNA13). No author has a financial or proprietary interest in any
   material or method mentioned.
CR Albig AR, 2006, CANCER RES, V66, P2621, DOI 10.1158/0008-5472.CAN-04-4096
   Chen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078783
   Chen Y, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007532
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hu YJ, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-123
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200
   LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Nandhu MS, 2014, CANCER RES, V74, P5435, DOI 10.1158/0008-5472.CAN-14-0685
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Roybal CN, 2005, INVEST OPHTH VIS SCI, V46, P3973, DOI 10.1167/iovs.05-0070
   Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Seeliger H, 2009, MOL CANCER RES, V7, P189, DOI 10.1158/1541-7786.MCR-08-0132
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sohn EH, 2011, ARCH OPHTHALMOL-CHIC, V129, P1626, DOI 10.1001/archophthalmol.2011.338
   Song EL, 2011, GYNECOL ONCOL, V121, P174, DOI 10.1016/j.ygyno.2010.11.004
   Stanton JB, 2017, INVEST OPHTH VIS SCI, V58, P1455, DOI 10.1167/iovs.16-20955
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Wang X, 2019, CLIN EXP DERMATOL, V44, pE64, DOI 10.1111/ced.13720
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018
NR 34
TC 2
Z9 2
U1 3
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 15
PY 2021
VL 11
AR 547436
DI 10.3389/fphar.2020.547436
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA PZ1XC
UT WOS:000612532900001
PM 33584252
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Miere, A
   Semoun, O
   Cohen, SY
   El Ameen, A
   Srour, M
   Jung, C
   Oubraham, H
   Querques, G
   Souied, EH
AF Miere, Alexandra
   Semoun, Oudy
   Cohen, Salomon Yves
   El Ameen, Ala'a
   Srour, Mayer
   Jung, Camille
   Oubraham, Hassiba
   Querques, Giuseppe
   Souied, Eric H.
TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF SUBRETINAL FIBROSIS
   IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   anti-VEGF; subretinal fibrosis; optical coherence tomography
   angiography; angiogenesis; anti-PDGF
ID CHOROIDAL NEOVASCULARIZATION; GROWTH-FACTOR; RANIBIZUMAB; EYES;
   CLASSIFICATION; RETINOPATHY; THERAPY; MODEL; VEGF
AB Purpose: To report the imaging features of subretinal fibrosis secondary to exudative age-related macular degeneration (AMD) on optical coherence tomography angiography.
   Methods: All consecutive patients diagnosed with subretinal fibrosis complicating exudative AMD were imaged by color retinal photographs or multicolor imaging, fluorescein angiography, spectral domain optical coherence tomography, and optical coherence tomography angiography. Eyes with active exudative features observed during the last 6 months were compared with those without any sign of exudation >6 months.
   Results: Forty-nine eyes of 47 consecutive patients were included. A blood flow inside the fibrotic scar could be detected in 46 of 49 cases (93.8%). Three patterns of vascular networks could be distinguished, that were described as pruned vascular tree (26 of 49 eyes; 53.1%), tangled network (14 of 49; 28.6%), and/or vascular loop (25 of 49; 51.0%). Furthermore, 2 types of hyporeflective structures, large flow void, and/or dark halo were observed in 63% and in 65% of eyes, respectively. The observed patterns did not differ between eyes with active or inactive lesions.
   Conclusion: Optical coherence tomography angiography of subretinal fibrosis showed almost constantly a perfused, abnormal vascular network and collateral architectural changes in the outer retina and the choriocapillaris layer. These features were associated with both active and inactive fibrotic choroidal neovessels.
C1 [Miere, Alexandra; Semoun, Oudy; Cohen, Salomon Yves; El Ameen, Ala'a; Srour, Mayer; Oubraham, Hassiba; Querques, Giuseppe; Souied, Eric H.] Univ Paris Est, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Jung, Camille; Souied, Eric H.] Ctr Hosp Intercommunal Creteil, GRC Macula & Biol Ressources Ctr, Clin Res Ctr, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Souied, EH (通讯作者)，Univ Paris Est, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; JUNG, Camille/0000-0001-8486-8939;
   EL AMEEN, Ala'a/0000-0001-8013-3708; Querques,
   Giuseppe/0000-0002-3292-9581
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Cui W, 2014, INT J OPHTHALMOL-CHI, V7, P194, DOI 10.3980/j.issn.2222-3959.2014.02.02
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Dugel PU, 2015, ASS RES VIS OPHTH AN
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Furuhashi M, 2004, CANCER RES, V64, P2725, DOI 10.1158/0008-5472.CAN-03-1489
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Klaassen I, 2015, EXP EYE RES, V133, P37, DOI 10.1016/j.exer.2014.10.016
   Kumar V., 2014, ROBBINS COTRAN PATHO
   Lumbroso B, 2015, CLIN GUIDE ANGIO OCT
   Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059
   Reinmuth N, 2001, FASEB J, V15, P1239, DOI 10.1096/fj.00-0693fje
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P66, DOI 10.1001/jamaophthalmol.2014.3950
   Toth LA, 2015, RETINA-J RET VIT DIS, V35, P1957, DOI 10.1097/IAE.0000000000000583
   Wilkinson-Berka JL, 2004, AM J PATHOL, V164, P1263, DOI 10.1016/S0002-9440(10)63214-2
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068173
NR 28
TC 70
Z9 74
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2015
VL 35
IS 11
BP 2275
EP 2284
DI 10.1097/IAE.0000000000000819
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CV5LD
UT WOS:000364311100015
PM 26457397
DA 2022-11-30
ER

PT J
AU Dieguez, HH
   Fleitas, MFG
   Aranda, ML
   Calanni, JS
   Sarmiento, MIK
   Chianelli, MS
   Alaimo, A
   Sande, PH
   Romeo, HE
   Rosenstein, RE
   Dorfman, D
AF Dieguez, Hernan H.
   Fleitas, Maria F. Gonzalez
   Aranda, Marcos L.
   Calanni, Juan S.
   Sarmiento, Maria I. Keller
   Chianelli, Monica S.
   Alaimo, Agustina
   Sande, Pablo H.
   Romeo, Horacio E.
   Rosenstein, Ruth E.
   Dorfman, Damian
TI Melatonin protects the retina from experimental nonexudative age-related
   macular degeneration in mice
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Article
DE melatonin; nonexudative age-related macular degeneration; oxidative
   stress; retinal pigment epithelium; superior cervical ganglion
ID PIGMENT EPITHELIUM; OXIDATIVE STRESS; DNA DAMAGE; MITOCHONDRIAL;
   ANTIOXIDANT; CELLS; RPE; DISEASE; REPAIR
AB Nonexudative age-related macular degeneration (NE-AMD) represents the leading cause of blindness in the elderly. Currently, there are no available treatments for NE-AMD. We have developed a NE-AMD model induced by superior cervical ganglionectomy (SCGx) in C57BL/6J mice, which reproduces the disease hallmarks. Several lines of evidence strongly support the involvement of oxidative stress in NE-AMD-induced retinal pigment epithelium (RPE) and outer retina damage. Melatonin is a proven and safe antioxidant. Our aim was analysing the effect of melatonin in the RPE/outer retina damage within experimental NE-AMD. The treatment with melatonin starting 48 h after SCGx, which had no effect on the ubiquitous choriocapillaris widening, protected visual functions and avoided Bruch ' s membrane thickening, RPE melanin content, melanosome number loss, retinoid isomerohydrolase (RPE65)-immunoreactivity decrease, and RPE and hotoreceptor ultrastructural damage induced within experimental NE-AMD exclusively located at the central temporal (but not nasal) region. Melatonin also prevented the increase in outer retina/RPE oxidative stress markers and a decrease in mitochondrial mass at 6 weeks post-SCGx. Moreover, when the treatment with melatonin started at 4 weeks post-SCGx, it restored visual functions and reversed the decrease in RPE melanin content and RPE65-immunoreactivity. These findings suggest that melatonin could become a promising safe therapeutic strategy for NE-AMD.
C1 [Dieguez, Hernan H.; Fleitas, Maria F. Gonzalez; Aranda, Marcos L.; Calanni, Juan S.; Sarmiento, Maria I. Keller; Chianelli, Monica S.; Sande, Pablo H.; Rosenstein, Ruth E.; Dorfman, Damian] Univ Buenos Aires, Lab Retinal Neurochem & Expt Ophthalmol, Dept Human Biochem, Sch Med,CEFyBO,CONICET, Buenos Aires, DF, Argentina.
   [Alaimo, Agustina] Univ Buenos Aires, Interdisciplinary Lab Cellular Dynam & Nanotools, Dept Biol Chem, Sch Exact & Nat Sci,IQUIBICEN,CONICET, Buenos Aires, DF, Argentina.
   [Romeo, Horacio E.] Pontifical Catholic Univ Argentina, Sch Engn & Agr Sci, BIOMED, UCA,CONICET, Buenos Aires, DF, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University of Buenos Aires; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo
   Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Pontifical
   Catholic University of Argentina
RP Dorfman, D (通讯作者)，UBA, Dept Bioquim Humana, Fac Med, CEFyBO,CONICET, Paraguay 2155,5 P, RA-1121 Buenos Aires, DF, Argentina.
EM ddorfman@fmed.uba.ar
OI Gonzalez Fleitas, Maria Florencia/0000-0001-5795-8365; Ruth,
   Rosenstein/0000-0002-8804-4395; Aranda, Marcos/0000-0003-1891-3476
FU Universidad de Buenos Aires [20020100100678] Funding Source: Medline;
   Consejo Nacional de Investigaciones Científicas y Técnicas [PIP 0707]
   Funding Source: Medline; Agencia Nacional de Promoción Científica y
   Tecnológica [PICT 1563, PICT 2731] Funding Source: Medline
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Andersen LPH, 2016, J CLIN PHARMACOL, V56, P324, DOI 10.1002/jcph.592
   Aranda ML, 2016, J PINEAL RES, V60, P360, DOI 10.1111/jpi.12318
   Belforte NA, 2010, J PINEAL RES, V48, P353, DOI 10.1111/j.1600-079X.2010.00762.x
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chang CC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9015765
   Ciuffi M, 2003, J PHOTOCH PHOTOBIO B, V71, P59, DOI 10.1016/j.jphotobiol.2003.07.004
   Comer Grant M, 2005, Expert Opin Emerg Drugs, V10, P119, DOI 10.1517/14728214.10.2.441
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dayhaw-Barker P, 2002, INT J TOXICOL, V21, P451, DOI 10.1080/10915810290169873
   Dieguez HH, 2019, FREE RADICAL BIO MED, V131, P72, DOI 10.1016/j.freeradbiomed.2018.11.035
   Dieguez HH, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.031641
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Escribano BM, 2014, CNS NEUROL DISORD-DR, V13, P1096, DOI 10.2174/1871527313666140806160400
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   FOX MW, 1965, ANIM BEHAV, V13, P232, DOI 10.1016/0003-3472(65)90040-0
   Fu Y, 2012, FRONT BIOSCI-LANDMRK, V17, P1461, DOI 10.2741/3997
   Galano A, 2013, J PINEAL RES, V54, P245, DOI 10.1111/jpi.12010
   Garcia JJ, 2014, J PINEAL RES, V56, P225, DOI 10.1111/jpi.12128
   Gramajo AL, 2015, EYE, V29, P1037, DOI 10.1038/eye.2015.104
   Gu L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200417
   Sande PH, 2008, AM J PATHOL, V173, P1702, DOI 10.2353/ajpath.2008.080518
   Del Sole MJ, 2012, J PINEAL RES, V52, P29, DOI 10.1111/j.1600-079X.2011.00913.x
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Lim JHA, 2016, NAT NEUROSCI, V19, P1073, DOI 10.1038/nn.4340
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Mauriz JL, 2013, J PINEAL RES, V54, P1, DOI 10.1111/j.1600-079X.2012.01014.x
   Michels S, 2016, DEV OPHTHALMOL, V55, P112, DOI 10.1159/000434695
   Osborne NN, 1998, INVEST OPHTH VIS SCI, V39, P2374
   Reiter RJ, 2007, ADV MED SCI-POLAND, V52, P11
   Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4
   Reiter RJ, 2009, CRIT REV BIOCHEM MOL, V44, P175, DOI 10.1080/10409230903044914
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x
   Rosen RB, 2012, MOL VIS, V18, P1640
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Salido EM, 2013, J PINEAL RES, V54, P179, DOI 10.1111/jpi.12008
   Sande PH, 2014, BRIT J PHARMACOL, V171, P5696, DOI 10.1111/bph.12873
   Sande PH, 2016, VET OPHTHALMOL, V19, P184, DOI 10.1111/vop.12282
   Siu AW, 2006, J PINEAL RES, V40, P101, DOI 10.1111/j.1600-079X.2005.00304.x
   Steinle JJ, 2002, EXP EYE RES, V74, P761, DOI 10.1006/exer.2002.1182
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang GG, 2018, J TOXICOL SCI, V43, P659, DOI 10.2131/jts.43.659
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Yilmaz M, 2013, CURR BIOL, V23, P2011, DOI 10.1016/j.cub.2013.08.015
   Yu LM, 2017, SCI REP-UK, V7, DOI 10.1038/srep41337
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162
NR 60
TC 18
Z9 18
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3098
EI 1600-079X
J9 J PINEAL RES
JI J. Pineal Res.
PD MAY
PY 2020
VL 68
IS 4
AR e12643
DI 10.1111/jpi.12643
PG 13
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA LV0UI
UT WOS:000538158800004
PM 32133696
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tsai, YY
   Lin, WY
   Chen, SJ
   Ruamviboonsuk, P
   King, CH
   Tsai, CL
AF Tsai, Yu-Yeh
   Lin, Wei-Yang
   Chen, Shih-Jen
   Ruamviboonsuk, Paisan
   King, Cheng-Ho
   Tsai, Chia-Ling
TI Diagnosis of Polypoidal Choroidal Vasculopathy From Fluorescein
   Angiography Using Deep Learning
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; fluorescein angiography; deep
   learning; screening; segmentation
ID VERTEPORFIN PHOTODYNAMIC THERAPY; RANIBIZUMAB; EFFICACY; SAFETY
AB Purpose: To differentiate polypoidal choroidal vasculopathy (PCV) from choroidal neovascularization (CNV) and to determine the extent of PCV from fluorescein angiography (FA) using attention-based deep learning networks. Methods: We build two deep learning networks for diagnosis of PCV using FA, one for detection and one for segmentation. Attention-gated convolutional neural network (AG-CNN) differentiates PCV from other types of wet age-related macular degeneration. Gradient-weighted class activation map (Grad-CAM) is generated to highlight important regions in the image for making the prediction, which offers explainability of the network. Attention-gated recurrent neural network (AG-PCVNet) for spatiotemporal prediction is applied for segmentation of PCV. Results: AG-CNN is validated with a dataset containing 167 FA sequences of PCV and 70 FA sequences of CNV. AG-CNN achieves a classification accuracy of 82.80% at image level, and 86.21% at patient-level for PCV. Grad-CAM shows that regions contributing to decision-making have on average 21.91% agreement with pathological regions identified by experts. AG-PCVNet is validated with 56 PCV sequences from the EVEREST-I study and achieves a balanced accuracy of 81.132% and dice score of 0.54. Conclusions: The developed software provides a means of performing detection and segmentation of PCV on FA images for the first time. This study is a promising step in changing the diagnostic procedure of PCV and therefore improving the detection rate of PCV using FA alone. Translational Relevance: The developed deep learning system enables early diagnosis of PCV using FA to assist the physician in choosing the best treatment for optimal visual prognosis.
C1 [Tsai, Yu-Yeh; Lin, Wei-Yang; King, Cheng-Ho] Natl Chung Cheng Univ, Dept Comp Sci & Informat Engn, Chiayi, Taiwan.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan.
   [Ruamviboonsuk, Paisan] Rajavithi Hosp, Dept Ophthalmol, Bangkok, Thailand.
   [Tsai, Chia-Ling] CUNY Queens Coll, Dept Comp Sci, Queens, NY 11367 USA.
C3 National Chung Cheng University; Taipei Veterans General Hospital;
   National Yang Ming Chiao Tung University; Rajavithi Hospital; City
   University of New York (CUNY) System
RP Tsai, CL (通讯作者)，CUNY Queens Coll, Dept Comp Sci, Queens, NY 11367 USA.
EM ctsai@qc.cuny.edu
FU Ministry of Science and Technology, Taiwan [MOST 105-2221-E-194-049];
   PSC-CUNY Research Award [64450-00-52]
FX The authors thank the investigators in the EVEREST trial for sharing the
   image data: Adrian Koh, Won Ki Lee, Lee-Jen Chen, Hakyoung Kim, Timothy
   Lai and Tock-Han Lim. Supported by grants from the Ministry of Science
   and Technology, Taiwan (MOST 105-2221-E-194-049) and PSC-CUNY Research
   Award 64450-00-52.
CR Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Choe J, 2021, IEEE T PATTERN ANAL, V43, P4256, DOI 10.1109/TPAMI.2020.2999099
   Chou YB, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86526-2
   de Carlo TE, 2019, RETINA-J RET VIT DIS, V39, P1343, DOI 10.1097/IAE.0000000000002139
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Hwang DDJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88543-7
   Kim IK, 2021, BRIT J OPHTHALMOL, V105, P856, DOI 10.1136/bjophthalmol-2020-316108
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lin WY, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.7
   Ma D, 2020, INVEST OPHTH VIS SCI, V61
   Milletari F, 2016, INT CONF 3D VISION, P565, DOI 10.1109/3DV.2016.79
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74
   Shi XJ, 2015, ADV NEUR IN, V28
   Tan CS, 2019, CLIN EXP OPHTHALMOL, V47, P614, DOI 10.1111/ceo.13464
   Tsai CL, 2011, INVEST OPHTH VIS SCI, V52, P2767, DOI 10.1167/iovs.10-6048
   Tsai CL, 2010, IEEE T MED IMAGING, V29, P636, DOI 10.1109/TMI.2009.2030324
   Xu ZY, 2021, BRIT J OPHTHALMOL, V105, P561, DOI 10.1136/bjophthalmol-2020-315817
   Yang JY, 2020, GRAEF ARCH CLIN EXP, V258, P17, DOI 10.1007/s00417-019-04493-x
NR 22
TC 1
Z9 1
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD FEB
PY 2022
VL 11
IS 2
AR 6
DI 10.1167/tvst.11.2.6
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YV2SR
UT WOS:000752581800001
PM 35113129
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Islam, FMA
   Chong, EW
   Hodge, AM
   Guymer, RH
   Aung, KZ
   Makeyeva, GA
   Baird, PN
   Hopper, JL
   English, DR
   Giles, GG
   Robman, LD
AF Islam, Fakir M. Amirul
   Chong, Elaine W.
   Hodge, Allison M.
   Guymer, Robyn H.
   Aung, Khin Zaw
   Makeyeva, Galina A.
   Baird, Paul N.
   Hopper, John L.
   English, Dallas R.
   Giles, Graham G.
   Robman, Liubov D.
TI Dietary Patterns and Their Associations with Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID PRIMARY PREVENTION; FISH CONSUMPTION; CLUSTER-ANALYSIS; RISK; FAT;
   PREVALENCE; CANCER; INDEX; MACULOPATHY; AMD
AB Objective: To evaluate the association between dietary patterns and age-related macular degeneration (AMD).
   Design: Food frequency data were collected from Melbourne Collaborative Cohort Study (MCCS) participants at the baseline study in 1990-1994. During follow-up in 2003-2007, retinal photographs were taken and evaluated for AMD.
   Participants: At baseline, 41 514 participants aged 40 to 70 years and born in Australia or New Zealand (69%), or who had migrated from the United Kingdom, Italy, Greece, or Malta (31%) were recruited. Of these, 21 132 were assessed for AMD prevalence at follow-up.
   Methods: Principal component analysis was used to identify dietary patterns (Factors F1-6) among the food items. Logistic regression was used to assess associations of dietary patterns with AMD.
   Main Outcome Measures: Odds ratios (ORs) for early stages and advanced AMD in association with dietary patterns.
   Results: A total of 2508 participants (12.8%) had early stages of AMD, and 108 participants (0.6%) had advanced AMD. Six factors characterized by predominant intakes of fruits (F1); vegetables (F2); grains, fish, steamed or boiled chicken, vegetables, and nuts (F3); red meat (F4); processed foods comprising cakes, sweet biscuits, and desserts (F5); and salad (F6) were identified. Higher F3 scores were associated with a lower prevalence of advanced AMD(fourth vs. first quartile) (OR, 0.49; 95% confidence interval [CI], 0.28-0.87), whereas F4 scores greater than the median were associated with a higher prevalence of advanced AMD (OR, 1.46; 95% CI, 1.0-2.17).
   Conclusions: Rather than specific individual food items, these factors represent a broader picture of food consumption. A dietary pattern high in fruits, vegetables, chicken, and nuts and a pattern low in red meat seems to be associated with a lower prevalence of advanced AMD. No particular food pattern seemed to be associated with the prevalence of the earliest stages of AMD. (C) 2014 by the American Academy of Ophthalmology.
C1 [Islam, Fakir M. Amirul; Chong, Elaine W.; Guymer, Robyn H.; Aung, Khin Zaw; Makeyeva, Galina A.; Baird, Paul N.; Robman, Liubov D.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Hodge, Allison M.; Hopper, John L.; English, Dallas R.; Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
   [Hopper, John L.; English, Dallas R.; Giles, Graham G.] Univ Melbourne, Sch Publ Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Cancer Council Victoria; University of
   Melbourne
RP Robman, LD (通讯作者)，Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM lrobman@unimelb.edu.au
RI Islam, Fakir M Amirul/P-6665-2015; English, Dallas/AAH-5005-2019
OI Islam, Fakir M Amirul/0000-0003-3897-3302; English,
   Dallas/0000-0001-7828-8188; Baird, Paul/0000-0002-1305-3502; Guymer,
   Robyn/0000-0002-9441-4356; Giles, Graham/0000-0003-4946-9099; Hodge,
   Allison/0000-0001-5464-2197
FU Victoria Health; Cancer Council Victoria; National Health & Medical
   Research Council of Australia (NHMRC) [209057, 251533, 396414];
   Ophthalmic Research Institute of Australia; American Health Assistance
   Foundation; NHMRC Practitioner Fellowships; NHMRC Senior Research
   Fellowships; Macular Degeneration Foundation Blackmores Dr. Paul
   Beaumont Research Fellowship; NHMRC Centre for Clinical Research
   Excellence [529923]; Victorian Government
FX Victoria Health, The Cancer Council Victoria, and National Health &
   Medical Research Council of Australia (NHMRC) (*Program Grant 209057,
   Capacity Building Grant 251533, and Enabling Grant 396414) funded the
   MCCS study. Ophthalmic component was funded by the Ophthalmic Research
   Institute of Australia and American Health Assistance Foundation. People
   support was provided through the NHMRC Practitioner Fellowships
   (R.H.G.), NHMRC Senior Research Fellowships (P.N.B. and J.L.H.), and
   Macular Degeneration Foundation Blackmores Dr. Paul Beaumont Research
   Fellowship (L.D.R.). The Centre for Eye Research Australia is a
   recipient of the NHMRC Centre for Clinical Research Excellence Grant
   529923 and Operational Infrastructure Support from the Victorian
   Government.
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Giles G G, 2002, IARC Sci Publ, V156, P69
   Giles GG, 1990, P NUTR SOC AUST, V15, P61
   Guenther PM, 2007, DEV EVALUATION HLTH
   Hodge AM, 2007, AM J EPIDEMIOL, V165, P603, DOI 10.1093/aje/kwk061
   Hodge AM, 2006, THESIS U MELBOURNE M, P65
   Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002
   Ireland P, 1994, Asia Pac J Clin Nutr, V3, P19
   Jolliffe I.T., 2002, SPRINGER SERIES STAT, V2nd, P1, DOI DOI 10.1007/0-387-22440-8_10
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lewis J., 1995, NUTTAB95 NUTR DATA T
   Magalhaes B, 2012, EUR J CANCER PREV, V21, P15, DOI 10.1097/CEJ.0b013e3283472241
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Maruyama K, 2013, NUTR METAB CARDIOVAS, V23, P519, DOI 10.1016/j.numecd.2011.10.007
   McEvoy CT, 2013, INVEST OPHTH VIS SCI, V54, P1337, DOI 10.1167/iovs.12-11065
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Newby PK, 2004, NUTR REV, V62, P177, DOI [10.1111/j.1753-4887.2004.tb00040.x, 10.1301/rn.2004.may.177-203]
   Reedy J, 2010, AM J EPIDEMIOL, V171, P479, DOI 10.1093/aje/kwp393
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Slattery ML, 1999, AM J EPIDEMIOL, V150, P869, DOI 10.1093/oxfordjournals.aje.a010092
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Trevithick JR, 2004, OPHTHAL EPIDEMIOL, V11, P337, DOI 10.1080/09286580490888780
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Willett W, 1998, NUTR EPIDEMIOLOGY, V40, P101, DOI DOI 10.1093/AJCN/69.5.1020
NR 46
TC 48
Z9 48
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2014
VL 121
IS 7
BP 1428
EP U159
DI 10.1016/j.ophtha.2014.01.002
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2II
UT WOS:000341142800024
PM 24560564
DA 2022-11-30
ER

PT J
AU Oh, IK
   Huh, K
   Oh, J
AF Oh, In Kyung
   Huh, Kuhl
   Oh, Jaeryung
TI Risk Factors for Retinal Hemorrhage after Photodynamic Therapy in
   Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Photodynamic therapy; Retinal hemorrhage, risk factors; Macular
   degeneration, age-related
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   VERTEPORFIN THERAPY
AB Background: Subretinal or intraretinal hemorrhage may occur after photodynamic therapy (PDT). However, risk factors for post-PDT hemorrhage have not yet been investigated. Methods: We reviewed the medical records of patients who had undergone PDT for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Primary outcomes were the occurrences of hemorrhages at 2 and 12 weeks after PDT. To identify the risk factors of hemorrhages after treatment, ocular and systemic factors were investigated. The secondary outcome was visual acuity. Results: Ninety-two eyes from 92 patients were analyzed. New hemorrhages developed in 9 (9.8%) within 2 weeks and in 8 (8.3%) between 2 and 12 weeks after PDT. Hypertension [ odds ratio (OR) 356.9, 95% confidence interval (CI) 3.7-34,487.1], minimally classic lesion (OR 53.4, 95% CI 2-1,429) and advanced age (OR 1.2, 95% CI 1-1.5) were related to hemorrhagic events within 2 weeks after PDT. A tendency toward recurrent hemorrhage was noted after repeat treatments (p < 0.05). Forty-four percent of the patients with a hemorrhagic event within 2 weeks after PDT experienced decreased vision. Conclusion: Hypertension, minimally classic lesion, advanced age and a previous hemorrhagic event were associated with the development of hemorrhage within 2 weeks after PDT. Copyright (C) 2008 S. Karger AG, Basel
C1 [Oh, Jaeryung] Korea Univ, Coll Med, Dept Ophthalmol, Med Ctr, Seoul 136705, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Oh, J (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, Med Ctr, 126-1 Anam Dong 5-Ga, Seoul 136705, South Korea.
EM ojr4991@yahoo.co.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   DELANEY WV, 1982, ANN OPHTHALMOL, V14, P21
   Gelisken F, 2005, GRAEF ARCH CLIN EXP, V243, P198, DOI 10.1007/s00417-004-0959-y
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Iguchi Y, 2006, BRIT J OPHTHALMOL, V90, P1256, DOI 10.1136/bjo.2006.099259
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Theodossiadis GP, 2003, GRAEF ARCH CLIN EXP, V241, P13, DOI 10.1007/s00417-002-0579-3
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
NR 12
TC 8
Z9 8
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2009
VL 223
IS 2
BP 78
EP 84
DI 10.1159/000173715
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 407HY
UT WOS:000263355400002
PM 19023225
DA 2022-11-30
ER

PT J
AU Fang, Y
   Liu, XQ
   Su, J
AF Fang, Yue
   Liu, Xinquan
   Su, Jing
TI Network Pharmacology Analysis of Traditional Chinese Medicine Formula
   Shuang Di Shou Zhen Tablets Treating Nonexudative Age-Related Macular
   Degeneration
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID INDUCED INFLAMMATION; NEOVASCULARIZATION; DERIVATIVES; PREDICTION;
   APOPTOSIS; RESOURCE; CANCER; GENES; MICE
AB Objective. To analyze the pharmacological mechanism of the treatment of dry age-related macular degeneration (dry AMD) based on a network pharmacological approach of Shuang Di Shou Zhen Tablets (SDSZT) and to provide a new reference for the current lack of effective treatment of dry AMD. Methods. The main chemical constituents and their targets of Rehmanniae Radix Praeparata, Ligustrum lucidum, Mori Fructus, Paeonia albiflora, Rhizoma Dioscoreae, Alisma orientale, Schisandra chinensis, Radix Polygoni Multiflori Preparata, Ophiopogon japonicus, and Radix Rehmanniae were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and Traditional Chinese Medicine Integrated Database (TCMID). The active ingredients of traditional Chinese medicine were screened according to Absorption, Distribution, Metabolism, and Excretion (ADME), the gene names of the targets of each active ingredient were obtained from the Uniprot database, the main targets of dry AMD were obtained from GeneCards and DisGeNET database, and the protein interaction analysis was performed on the String database. The Metascape database was used to analyze the "drug-component-target" and the biological processes and networks involved, and then, Cytoscape 3.8.1 was used to construct the " SDSZT component-dry AMD target-pathway" network. Results. The main active ingredients of SDSZT for dry AMD treatment are quercetin, kaempferol, luteolin, beta-glutamine, beta-carotene, etc. And, the core targets are RAC-alpha serine/threonine-protein kinase (AKT1), prosta- glandin G/H synthase 1 (PTGS1), tumor necrosis factor (TNF), transcription factor AP-1 (JUN), apoptosis regulator Bcl-2 (BCL2), caspase-3 (CASP3), phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG), androgen receptor (AR), apoptosis regulator BAX (BAX), etc. The biological pathways for the treatment of age-related macular degeneration by SDSZT mainly act on pathways in cancer, fluid shear stress and atherosclerosis, and TNF signaling pathway, and the main function of SDSZT is to regulate intracellular cytokine receptor binding. Conclusion. This study initially reveals the multiconstituent, multitarget, and multipathway mechanism of action of SDSZT in the treatment of dry AMD and provides the basis for the clinical application of SDSZT.
C1 [Fang, Yue; Liu, Xinquan; Su, Jing] Shanghai Univ Tradit Chinese Med, Dept Ophthalmol, Longhua Hosp Affiliated, Shanghai 200032, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine
RP Su, J (通讯作者)，Shanghai Univ Tradit Chinese Med, Dept Ophthalmol, Longhua Hosp Affiliated, Shanghai 200032, Peoples R China.
EM sujinglucky@163.com
OI FANG, YUE/0000-0002-2665-5027
FU National Natural Science Foundation of China [81904257]
FX The authors acknowledge the web database platform and software for data
   analysis. This study was totally supported by the National Natural
   Science Foundation of China (Grant No. 81904257).
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Akyol E, 2020, BIOL-TARGETS THER, V14, P83, DOI 10.2147/BTT.S252581
   Antwi AO, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3984068
   Bing-lin H, 2021, J JIANG 11 U TCM, V33, P39
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Chen X, 2018, BIOMED PHARMACOTHER, V101, P87, DOI 10.1016/j.biopha.2018.02.054
   Demchak Barry, 2014, F1000Res, V3, P151, DOI 10.12688/f1000research.4492.2
   Due WW, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1610751
   Duncan RS, 2020, CELL SIGNAL, V66, DOI 10.1016/j.cellsig.2019.109494
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fishilevich S, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw030
   Gu X, 2018, PROG NEURO-PSYCHOPH, V81, P169, DOI 10.1016/j.pnpbp.2017.10.020
   Han DM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33552-2
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Huang L, 2018, NUCLEIC ACIDS RES, V46, pD1117, DOI 10.1093/nar/gkx1028
   Huang WC, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/9421340
   Hytti M, 2017, J NUTR BIOCHEM, V42, P37, DOI 10.1016/j.jnutbio.2016.12.014
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Jin XL, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5604610
   Jing S., 2017, J CHINESE OPHTHALMOL, V27, P223
   Jing S., 2017, HEBEI J TRADITIONAL, V39, P835
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kim YS, 2014, BMB REP, V47, P433, DOI 10.5483/BMBRep.2014.47.8.153
   Lennikov A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01903
   Li Guimin, 2017, Zhongguo Zhen Jiu, V37, P1294, DOI 10.13703/j.0255-2930.2017.12.011
   Li T, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1409-3
   Liao PC, 2018, J AGR FOOD CHEM, V66, P10748, DOI 10.1021/acs.jafc.8b04555
   Lin SY, 2017, ANN ONCOL, V28, P2575, DOI 10.1093/annonc/mdx402
   Michelini FM, 2016, STEROIDS, V115, P160, DOI 10.1016/j.steroids.2016.09.001
   Pawlowska E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9682318
   Pinero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tian S, 2012, MOL PHARMACEUT, V9, P2875, DOI 10.1021/mp300198d
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Vella D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23672-0
   Wang SL, 2017, ONCOTARGET, V8, P14549, DOI 10.18632/oncotarget.14675
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Yin YX, 2018, BIOORG MED CHEM LETT, V28, P1525, DOI 10.1016/j.bmcl.2018.03.073
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
   Zhu Q, 2019, ARTIF CELL NANOMED B, V47, P2010, DOI 10.1080/21691401.2019.1608217
NR 43
TC 4
Z9 4
U1 5
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD MAR 24
PY 2021
VL 2021
AR 6657521
DI 10.1155/2021/6657521
PG 14
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA RJ1NJ
UT WOS:000637368300002
PM 33815556
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dombi, T
   Kwok, KK
   Sultan, MB
AF Dombi, Theresa
   Kwok, Kenneth K.
   Sultan, Marla B.
TI A retrospective, pooled data analysis of the safety of pegaptanib sodium
   in the treatment of age-related macular degeneration in subjects with or
   without diabetes mellitus
SO BMC OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; ENDOTHELIAL GROWTH-FACTOR;
   CORONARY-HEART-DISEASE; RANIBIZUMAB LUCENTIS; RISK; MECHANISMS; STROKE;
   THERAPY
AB Background: To evaluate the safety of pegaptanib sodium 0.3 mg intravitreal injection in the treatment of neovascular age-related macular degeneration in subjects with or without diabetes mellitus.
   Methods: A pooled, retrospective, analysis was conducted of data from 9 sponsor-administered, randomized, open-label trials. Subjects who received pegaptanib by randomization or change in dose assignment, crossover design, or protocol amendment, were included. Reports of endophthalmitis, increased intraocular pressure, retinal injury, intraocular hemorrhage, traumatic cataract, hypersensitivity reactions, stroke, myocardial infarction, and other arterial thromboembolic events defined by the Antiplatelet Trialists' Collaboration were identified by Medical Dictionary for Regulatory Activities preferred terms. Adverse events were summarized from the first injection to 42 days after the last injection. The incidence of adverse events was stratified by the presence/absence of diabetes.
   Results: Of 1,586 subjects enrolled, 165 (10.4%) had a history of diabetes mellitus and 1,421 (89.6%) did not. The 2 populations were similar at baseline. Based on the comparison of prespecified ocular, hypersensitivity, and Antiplatelet Trialists' Collaboration event terms, the safety review did not identify any notable differences between the 2 populations.
   Conclusions: This retrospective analysis found no increased safety risk resulting from treatment with pegaptanib 0.3 mg in individuals with neovascular age-related macular degeneration and concomitant diabetes mellitus.
C1 [Dombi, Theresa] Pfizer Inc, Groton, CT 06340 USA.
   [Kwok, Kenneth K.; Sultan, Marla B.] Pfizer Inc, New York, NY USA.
   [Sultan, Marla B.] New York Eye & Ear Infirm, New York, NY 10003 USA.
C3 Pfizer; Pfizer; New York Eye & Ear Infirmary of Mount Sinai
RP Dombi, T (通讯作者)，Pfizer Inc, Groton, CT 06340 USA.
EM Theresa.Dombi@Pfizer.com
FU Pfizer Inc.
FX This study was sponsored by Pfizer Inc.; The authors wish to acknowledge
   Robert L. Wiseman for his contributions to the organization of the study
   findings. Editorial support, including contributing to the first draft
   of the paper, revising the paper based on author comments, and styling
   the paper for journal submission, was provided by Linda Whetter, PhD,
   DVM, of Zola Associates and was funded by Pfizer Inc. Additional
   editorial support to address reviewers' comments and associated
   revisions were provided by Mukund Nori, PhD, MBA, CMPP, of UBC Envision
   Group and was funded by Pfizer Inc.
CR Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   [Anonymous], 1988, BRIT MED J, V296, P320
   Apte RS, 2008, EXPERT OPIN PHARMACO, V9, P499, DOI [10.1517/14656566.9.3.499, 10.1517/14656566.9.3.499 ]
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Clark N, 2003, DIABETES CARE, V26, P3333
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Gardner TW, 2008, CURR DIABETES REP, V8, P263, DOI 10.1007/s11892-008-0047-5
   Giorda CB, 2007, STROKE, V38, P1154, DOI 10.1161/01.STR.0000260100.71665.2f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404
   Hornan D, 2010, EYE, V24, P1315, DOI 10.1038/eye.2010.14
   Hyvarinen M, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-17
   Ishibashi Tatsuro, 2011, Nippon Ganka Gakkai Zasshi, V115, P122
   Jeerakathil T, 2007, STROKE, V38, P1739, DOI 10.1161/STROKEAHA.106.481390
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Karim R, 2010, CLIN OPHTHALMOL, V4, P493
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Micieli JA, 2010, CAN J OPHTHALMOL, V45, P231, DOI 10.3129/i10-027
   Nicholson BP, 2010, GRAEF ARCH CLIN EXP, V248, P915, DOI 10.1007/s00417-010-1315-z
   Querques G, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/672178
   Querques G, 2009, ACTA OPHTHALMOL, V87, P623, DOI 10.1111/j.1755-3768.2009.01580.x
   Sarwar N, 2010, LANCET, V375, P2215, DOI 10.1016/S0140-6736(10)60484-9
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Schramm TK, 2008, CIRCULATION, V117, P1945, DOI 10.1161/CIRCULATIONAHA.107.720847
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Wirostko B, 2008, PROG RETIN EYE RES, V27, P608, DOI 10.1016/j.preteyeres.2008.09.002
NR 30
TC 11
Z9 11
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 8
PY 2012
VL 12
AR 37
DI 10.1186/1471-2415-12-37
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 027RB
UT WOS:000310369800001
PM 22871086
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lin, JM
   Tsai, YY
   Wan, L
   Lin, HJ
   Tsai, Y
   Lee, CC
   Tsai, CH
   Tsai, FJ
   Tseng, SH
AF Lin, Jane-Ming
   Tsai, Yi-Yu
   Wan, Lei
   Lin, Hui-Ju
   Tsai, Yushin
   Lee, Cheng-Chun
   Tsai, Chang-Hai
   Tsai, Fuu-Jen
   Tseng, Sung-Huei
TI COMPLEMENT FACTOR H VARIANT INCREASES THE RISK FOR EARLY AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE complement factor H; polymorphism; early age-related macular
   degeneration; Taiwan Chinese population
ID C-REACTIVE PROTEIN; GENE POLYMORPHISM; ASSOCIATION; MACULOPATHY;
   PREVALENCE; DRUSEN; Y402H; POPULATION; INFLAMMATION; ACTIVATION
AB Purpose: To investigate whether a polymorphism in the complement factor H gene determines the risk for the development of early age-related macular degeneration (AMD).
   Methods: In this retrospective case-control study, we enrolled 133 unrelated Taiwan Chinese patients with early AMD and 180 age- and sex-matched control subjects. Early AMD was defined as the presence of extensive intermediate drusen or any large, soft drusen (>= 125 mu m), possibly accompanied by drusenoid retinal pigment epithelial detachment, and the absence of signs of late AMD. Genomic DNA was extracted from peripheral blood obtained from all the AMD patients and control subjects. Polymerase chain reaction was performed to analyze the complement factor H polymorphism (Y402H, rs1061170).
   Results: The genotype distribution differed significantly between the early AMD patients (TT 80%; TC 14%; and CC 6%) and controls (TT 91%; TC 9%; CC 0%; P = 9 x 10(-4)). The C allele frequency was significantly higher in the early AMD patients than in the controls (13% vs. 4%, P = 1 x 10(-4), odds ratios = 3.26, 95% confidence intervals = 1.76-6.02).
   Conclusions: Our study demonstrated that the presence of the Y402H polymorphism in complement factor H is significantly associated with increased susceptibility to early AMD in Taiwan Chinese populations and that the C allele frequency is low in these populations.
C1 [Wan, Lei; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Genet, Taichung 404, Taiwan.
   [Lin, Jane-Ming; Tsai, Yi-Yu; Lin, Hui-Ju] China Med Univ Hosp, Dept Ophthalmol, Taichung 404, Taiwan.
   [Wan, Lei; Tsai, Yushin] China Med Univ, Grad Inst Chinese Med Sci, Taichung, Taiwan.
   [Tsai, Chang-Hai; Tsai, Fuu-Jen] Univ E Asia, Dept Biotechnol & Bioinformat, Taichung, Taiwan.
   [Tseng, Sung-Huei] Natl Cheng Kung Univ Hosp, Dept Ophthalmol, Tainan 70428, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan; National Cheng Kung
   University; National Cheng Kung University Hospital
RP Tsai, FJ (通讯作者)，China Med Univ Hosp, Dept Med Genet, 2 Yuh Der Rd, Taichung 404, Taiwan.
EM d0704@mail.cmuh.org.tw
RI Wan, Lei/F-4719-2010; Tsai, Fuu-Jen/J-4140-2015
OI Wan, Lei/0000-0002-9525-3232
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Chen LJ, 2006, MOL VIS, V12, P1536
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   MOLD C, 1984, J IMMUNOL, V133, P882
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Okamoto H, 2006, MOL VIS, V12, P156
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
NR 30
TC 20
Z9 21
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2008
VL 28
IS 10
BP 1416
EP 1420
DI 10.1097/IAE.0b013e318184661d
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 373LH
UT WOS:000260972600006
PM 18784628
DA 2022-11-30
ER

PT J
AU Hong, S
   Choi, M
   Yun, C
   Kim, SW
AF Hong, Suji
   Choi, Mihyun
   Yun, Cheolmin
   Kim, Seong-Woo
TI Retinal Vessel Density in Age-Related Macular Degeneration Patients with
   Geographic Atrophy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE geographic atrophy; optical coherence tomography angiography;
   age-related macular degeneration; intermediate AMD
ID OPTICAL COHERENCE TOMOGRAPHY; OCT ANGIOGRAPHY; LAYER; EYES;
   CHORIOCAPILLARIS; PHOTOCOAGULATION; CLASSIFICATION; DISEASE; AREA
AB We compared the retinal vessel density and inner retinal thickness in patients who had one eye with geographic atrophy (GA) and a fellow eye with intermediate age-related macular degeneration (iAMD). The vessel density from the superficial vascular complex (SVC) and deep vascular complex (DVC) through optical coherence tomography angiography and the thickness of the nerve fiber layer, ganglion cell-inner plexiform layer (GCIPL), inner nuclear layer (INL), outer nuclear layer (ONL) on a structural optical coherence tomography thickness map were measured in 28 eyes of 14 GA patients with iAMD in the fellow eye. GA eyes had significantly lower vessel density in the SVC (26.2 +/- 3.9% vs. 28.3 +/- 4.4%; p = 0.015) and DVC (24.2 +/- 2.6% vs. 26.8 +/- 1.9%; p = 0.003) than fellow eyes (iAMD). GCIPL and ONL were significantly thinner in GA eyes than in the fellow eyes (p = 0.032 and 0.024 in the foveal areas, p = 0.029 and 0.065 in the parafovea areas, respectively). Twenty-four eyes of 12 patients were followed up for 2 years and seven of the fellow eyes (58.3%) developed GA during the follow-up period and showed reduced vessel density in the SVC (26.4 +/- 3.0% vs. 23.8 +/- 2.9%; p = 0.087) and DVC (25.8 +/- 2.2% vs. 22.4 +/- 4.4%; p = 0.047) compared to baseline. Vessel density and GCIPL thickness map measurements are potential GA markers in non-neovascular AMD.
C1 [Hong, Suji; Choi, Mihyun; Kim, Seong-Woo] Korea Univ, Korea Univ Guro Hosp, Coll Med, Dept Ophthalmol, 148 Gurodong Ro, Seoul 08308, South Korea.
   [Yun, Cheolmin] Korea Univ, Korea Univ Ansan Hosp, Coll Med, Dept Ophthalmol, 123 Jeokgepm Ro, Ansan 15355, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine)
RP Choi, M (通讯作者)，Korea Univ, Korea Univ Guro Hosp, Coll Med, Dept Ophthalmol, 148 Gurodong Ro, Seoul 08308, South Korea.
EM ghdghd3596@gmail.com; mnyoung23@gmail.com; yuncheolmin@korea.ac.kr;
   ksw64723@korea.ac.kr
OI choi, mihyun/0000-0003-2420-0907
CR Abdolrahimzadeh S, 2019, CURR EYE RES, V44, P1000, DOI 10.1080/02713683.2019.1610179
   Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Alten F, 2017, GRAEF ARCH CLIN EXP, V255, P2347, DOI 10.1007/s00417-017-3813-8
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Budzynski E, 2008, INVEST OPHTH VIS SCI, V49, P380, DOI 10.1167/iovs.07-0065
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   GRUNWALD JE, 1986, OPHTHALMOLOGY, V93, P590
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Holmen IC, 2020, JAMA OPHTHALMOL, V138, P119, DOI 10.1001/jamaophthalmol.2019.4971
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P367, DOI 10.1001/jamaophthalmol.2015.5658
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Lee MW, 2019, BRIT J OPHTHALMOL, V103, P704, DOI 10.1136/bjophthalmol-2018-312516
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Mehta N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72358-z
   Nam KT, 2021, RETINA-J RET VIT DIS, V41, P1686, DOI 10.1097/IAE.0000000000003100
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Povazay B, 2003, OPT EXPRESS, V11, P1980, DOI 10.1364/OE.11.001980
   Ramkumar HL, 2018, RETINA-J RET VIT DIS, V38, P2159, DOI 10.1097/IAE.0000000000001867
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Sampson DM, 2017, INVEST OPHTH VIS SCI, V58, P3065, DOI 10.1167/iovs.17-21551
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shen LL, 2021, OPHTHALMOL RETINA, V5, P868, DOI 10.1016/j.oret.2020.12.002
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yao XC, 2020, EXP BIOL MED, V245, P301, DOI 10.1177/1535370219899893
   You QS, 2020, AM J OPHTHALMOL, V209, P206, DOI 10.1016/j.ajo.2019.09.004
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 38
TC 1
Z9 1
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2022
VL 11
IS 6
AR 1501
DI 10.3390/jcm11061501
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0C3HF
UT WOS:000775207700001
PM 35329825
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhao, B
   Wang, MY
   Xu, J
   Li, M
   Yu, YH
AF Zhao, Bin
   Wang, Mengya
   Xu, Jing
   Li, Min
   Yu, Yuhui
TI Identification of pathogenic genes and upstream regulators in
   age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Transcription factors; Differentially
   expressed genes; Integrated analysis
ID FUNCTIONAL-ANALYSIS; DNA MICROARRAY; OXIDATIVE STRESS; BRUCHS MEMBRANE;
   EXPRESSION; ANGIOGENESIS; CHOLESTEROL; MACULOPATHY
AB Background: Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in older individuals. Our study aims to identify the key genes and upstream regulators in AMD.
   Methods: To screen pathogenic genes of AMD, an integrated analysis was performed by using the microarray datasets in AMD derived from the Gene Expression Omnibus (GEO) database. The functional annotation and potential pathways of differentially expressed genes (DEGs) were further discovered by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. We constructed the AMD-specific transcriptional regulatory network to find the crucial transcriptional factors (TFs) which target the DEGs in AMD. Quantitative real time polymerase chain reaction (qRT-PCR) was performed to verify the DEGs and TFs obtained by integrated analysis.
   Results: From two GEO datasets obtained, we identified 1280 DEGs (730 up-regulated and 550 down-regulated genes) between AMD and normal control (NC). After KEGG analysis, steroid biosynthesis is a significantly enriched pathway for DEGs. The expression of 8 genes (TNC, GRP, TRAF6, ADAMTS5, GPX3, FAP, DHCR7 and FDFT1) was detected. Except for TNC and GPX3, the other 6 genes in qRT-PCR played the same pattern with that in our integrated analysis.
   Conclusions: The dysregulation of these eight genes may involve with the process of AMD. Two crucial transcription factors (c-rel and myogenin) were concluded to play a role in AMD. Especially, myogenin was associated with AMD by regulating TNC, GRP and FAP. Our finding can contribute to developing new potential biomarkers, revealing the underlying pathogenesis, and further raising new therapeutic targets for AMD.
C1 [Zhao, Bin; Yu, Yuhui] Taishan Med Coll, Affiliated Hosp, Dept Ophthlmol, 706 Taishan St, Tai An 271000, Shandong, Peoples R China.
   [Wang, Mengya] Peoples Hosp Feicheng, Dept Ophthlmol, 108 Xincheng Rd, Feicheng 271699, Peoples R China.
   [Xu, Jing] First Peoples Hosp Jining, Dept Ophthlmol, 6 Jiankang Rd, Jining 272011, Shandong, Peoples R China.
   [Li, Min] Third Peoples Hosp, Dept Ophthlmol, 127 Cuyang St, Tai An 271212, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical Sciences
RP Xu, J (通讯作者)，First Peoples Hosp Jining, Dept Ophthlmol, 6 Jiankang Rd, Jining 272011, Shandong, Peoples R China.
EM xujing152164@163.com
CR Afshari FT, 2010, BRAIN, V133, P448, DOI 10.1093/brain/awp319
   Augustin Albert J, 2006, Expert Opin Emerg Drugs, V11, P725, DOI 10.1517/14728214.11.4.725
   Bevitt DJ, 2003, BBA-GENE STRUCT EXPR, V1626, P83, DOI 10.1016/S0167-4781(03)00047-2
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Chen Y, 2013, EUR REV MED PHARMACO, V17, P1044
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Du JY, 2014, GENET MOL RES, V13, P64, DOI 10.4238/2014.January.8.5
   Emerson MV, 2007, BIODRUGS, V21, P245, DOI 10.2165/00063030-200721040-00005
   Geltzer A, 2013, COCHRANE DB SYST REV, V1, P92
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Green WR, 1999, MOL VIS, V5, P384
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hao Y, GENE SELECTION MICRO
   Hau VS, 2016, OPHTHALMOL THER, P1
   Heller JP, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.4
   Huang YD, 2013, ASIAN PAC J CANCER P, V14, P4553, DOI 10.7314/APJCP.2013.14.8.4553
   Ishikawa K, 2015, EXP EYE RES, V142
   Kang JH, 2007, CANCER LETT, V253, P273, DOI 10.1016/j.canlet.2007.02.007
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin CH, 2013, BRIT J PHARMACOL, V168, P920, DOI 10.1111/j.1476-5381.2012.02227.x
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Shi WY, 2010, CURR EYE RES, V35, P967, DOI 10.3109/02713683.2010.502294
   Tierney E, 2010, AM J MED GENET A, V152A, P91, DOI 10.1002/ajmg.a.33148
   VanderBeek BL, 2015, OPHTHALMOLOGY, V122, P2311, DOI 10.1016/j.ophtha.2015.07.005
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
NR 31
TC 12
Z9 12
U1 1
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUN 26
PY 2017
VL 17
AR 102
DI 10.1186/s12886-017-0498-z
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EY6CB
UT WOS:000404069000002
PM 28651595
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU DeCarlo, DK
   McGwin, G
   Searcey, K
   Gao, LY
   Snow, M
   Stevens, L
   Owsley, C
AF DeCarlo, Dawn K.
   McGwin, Gerald, Jr.
   Searcey, Karen
   Gao, Liyan
   Snow, Marsha
   Stevens, Lynne
   Owsley, Cynthia
TI Use of Prescribed Optical Devices in Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE low vision; age-related macular degeneration; magnification; reading;
   low vision devices
ID QUALITY-OF-LIFE; LOW-VISION REHABILITATION; VISUAL-ACUITY; DEPRESSION;
   IMPACT; MACULOPATHY; PROVISION; CATARACT; DISTRESS; SERVICES
AB Purpose. To evaluate prescribed optical device use in terms of frequency and perceived usefulness among people with age-related macular degeneration (AMD). We also sought to determine the tasks for which they were using their prescribed low vision device(s).
   Methods. One hundred ninety-nine patients with AMD presenting for the first time to the low vision service were recruited from a university-based clinic. Prior to the low vision evaluation and device prescription, they completed the National Eye Institute Visual Function Questionnaire 25, Center for Epidemiological Studies Depression Scale, Short Portable Mental Status Questionnaire, and a general health questionnaire. The low vision evaluation included best-corrected Early Treatment of Diabetic Retinopathy Study visual acuity, MNREAD testing, microperimetry, prescription, and dispensing of optical low vision devices. Telephone follow-up interviews were conducted about device usage 1-week, 1-month, and 3-months postintervention.
   Results. One hundred eighty-one participants were prescribed low vision devices. Of them, 93% completed all 3 follow-up interviews. Intensive users (>= 1 hours/day) of devices were similar in demographic and visual characteristics to non-intensive users (<1 hours/day), except for habitual reading acuity and speed as well as contrast sensitivity. Overall, device use increased slightly over 3 months of follow-up. Magnifiers were reported to be moderately-to-extremely useful by >80% of participants at all time points except the 1-month follow-up for hand magnifiers (75%). High plus spectacles were the least frequently prescribed device and rated as moderately-to-extremely useful by 70%, 74%, and 59% at 1 week, 1 month, and 3 months, respectively. Most participants used their devices for leisure reading, followed by managing bills. Very few devices (n = 3, <1%) were not used at any time point.
   Conclusions. Patients with AMD who are provided with prescribed optical low vision devices do use them and perceive them as useful, especially for leisure reading activities. High rates of usage were maintained over 3 month. (Optom Vis Sci 2012; 89: 1336-1342)
C1 [DeCarlo, Dawn K.; McGwin, Gerald, Jr.; Searcey, Karen; Gao, Liyan; Stevens, Lynne; Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35294 USA.
   [DeCarlo, Dawn K.; Snow, Marsha] Univ Alabama Birmingham, Sch Optometry, Dept Optometry, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Med, Dept Surg, Sect Trauma Burns & Surg Crit Care,Div Gen Surg, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP DeCarlo, DK (通讯作者)，UAB Ctr Low Vis Rehabil, CEFH 405,700 18th St S, Birmingham, AL 35233 USA.
EM ddecarlo@uab.edu
OI DeCarlo, Dawn/0000-0001-9078-9882
FU NEI NIH HHS [R15 EY015108, K23 EY018864] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [R15EY015108, K23EY018864] Funding Source: NIH
   RePORTER
CR Arditi A, 2005, INVEST OPHTH VIS SCI, V46, P2225, DOI 10.1167/iovs.04-1198
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Binns AM, 2012, SURV OPHTHALMOL, V57, P34, DOI 10.1016/j.survophthal.2011.06.006
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Capella-McDonnall NE, 2005, INT J GERIATR PSYCH, V20, P855, DOI 10.1002/gps.1368
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Dougherty BE, 2011, OPTOMETRY VISION SCI, V88, P1283, DOI 10.1097/OPX.0b013e31822a61e7
   Evans JR, 2007, OPHTHALMOLOGY, V114, P283, DOI 10.1016/j.ophtha.2006.10.006
   FECHNERBATES S, 1994, J CONSULT CLIN PSYCH, V62, P550, DOI 10.1037/0022-006X.62.3.550
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kuyk T, 2008, QUAL LIFE RES, V17, P497, DOI 10.1007/s11136-008-9336-3
   LEAT SJ, 1994, OPTOMETRY VISION SCI, V71, P199, DOI 10.1097/00006324-199403000-00009
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mansfield J.S., 1993, OPT SOC AM TECHNOL D, V3, P232
   Owsley C, 2002, JAMA-J AM MED ASSOC, V288, P841, DOI 10.1001/jama.288.7.841
   Owsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681, DOI 10.1001/archophthalmol.2009.55
   Pearce E, 2011, BRIT J OPHTHALMOL, V95, P105, DOI 10.1136/bjo.2009.175703
   PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x
   PONTE F, 1994, GRAEF ARCH CLIN EXP, V232, P469, DOI 10.1007/BF00195355
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rees G, 2010, INVEST OPHTH VIS SCI, V51, P2891, DOI 10.1167/iovs.09-5080
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Rovner BW, 2011, ARCH OPHTHALMOL-CHIC, V129, P885, DOI 10.1001/archophthalmol.2011.146
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Ryan B, 2010, OPHTHAL PHYSL OPT, V30, P358, DOI 10.1111/j.1475-1313.2010.00729.x
   Scilley K, 2004, OPHTHAL EPIDEMIOL, V11, P131, DOI 10.1076/opep.11.2.131.28159
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Watson GR, 1997, OPTOMETRY VISION SCI, V74, P249, DOI 10.1097/00006324-199705000-00019
NR 30
TC 11
Z9 12
U1 0
U2 22
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD SEP
PY 2012
VL 89
IS 9
BP 1336
EP 1342
DI 10.1097/OPX.0b013e3182678db5
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 001FH
UT WOS:000308445400014
PM 22902420
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sharma, NK
   Gupta, A
   Prabhakar, S
   Singh, R
   Sharma, SK
   Chen, W
   Anand, A
AF Sharma, Neel Kamal
   Gupta, Amod
   Prabhakar, Sudesh
   Singh, Ramandeep
   Sharma, Suresh Kumar
   Chen, Wei
   Anand, Akshay
TI Association between CFH Y402H Polymorphism and Age Related Macular
   Degeneration in North Indian Cohort
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT-FACTOR-H; CIGARETTE-SMOKING; RISK; VARIANT; GENE; POPULATION;
   PREVALENCE; SUSCEPTIBILITY; SUGGESTS; PROTEIN
AB The purpose of the study was to determine serum complement factor H (CFH) levels in patients of age related macular degeneration (AMD) and examine its association with CFH Y402H polymorphism. 115 AMD patients and 61 normal controls were recruited in this study. The single nucleotide polymorphism was assayed by real time PCR and serum CFH levels were measured by ELISA and standardized to total serum protein. Chi-square test was applied to polymorphism analysis while Mann Whitney U-statistic for CFH-levels. Mendelian randomization approach was used for determining causal relationship. The genotype frequency differed between the AMD patients (TT-18.3%, TC-41.3% and CC-40.4%) and controls (TT-76.3%, TC-13.6%, and CC-10.1%) (p = 0001). The frequency of alleles was also significantly different when AMD (T-39% and C-61%) was compared to controls (T-83% and C-17%) (p = 0.0001). Level of serum CFH was significantly lower in AMD patients as compared to normal controls (p = 0.001). Our data showed that the CFH Y402H polymorphism is a risk factor for AMD in the North Indian population. Mendelian randomization approach revealed that CFH Y402H polymorphism affects AMD risk through the modification of CFH serum levels.
C1 [Sharma, Neel Kamal; Prabhakar, Sudesh; Anand, Akshay] Post Grad Inst Med Educ & Res, Dept Neurol, Chandigarh, India.
   [Gupta, Amod; Singh, Ramandeep] Post Grad Inst Med Educ & Res, Dept Ophthalmol, Chandigarh, India.
   [Sharma, Suresh Kumar] Panjab Univ, Dept Stat, Chandigarh 160014, India.
   [Chen, Wei] UPMC, Childrens Hosp Pittsburgh, Div Pulm Med Allergy & Immunol, Pittsburgh, PA USA.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh; Panjab University; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh
RP Anand, A (通讯作者)，Post Grad Inst Med Educ & Res, Dept Neurol, Chandigarh, India.
EM akshay1anand@rediffmail.com
RI anand, Akshay/AAI-1586-2019; Gupta, Amod/V-7633-2017; Chen,
   Wei/AAX-5994-2020
OI Gupta, Amod/0000-0001-8427-5738; Chen, Wei/0000-0001-7196-8703
FU Indian Council of Medical research, India [45/11/2010-HUM/BMS]
FX The authors acknowledge Indian Council of Medical research, India for
   providing funds (45/11/2010-HUM/BMS). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Davey Smith G, 2008, ANN MED, V40, P524, DOI 10.1080/07853890802010709
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dhillon B, 2010, INVEST OPHTH VIS SCI, V51, P5858, DOI 10.1167/iovs.09-5124
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Greenfield JR, 2004, EUR J CLIN INVEST, V34, P590, DOI 10.1111/j.1365-2362.2004.01389.x
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kornsteiner M, 2008, ANN NUTR METAB, V52, P37, DOI 10.1159/000118629
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Palmer TM, 2011, AM J EPIDEMIOL, V173, P1392, DOI 10.1093/aje/kwr026
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sharma NK, 2013, GENE, V523, P106, DOI 10.1016/j.gene.2013.03.052
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Silva AS, 2012, MOL VIS, V18, P2288
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wener MH, 2000, J RHEUMATOL, V27, P2351
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 43
TC 42
Z9 42
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 29
PY 2013
VL 8
IS 7
AR e70193
DI 10.1371/journal.pone.0070193
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 204MP
UT WOS:000323369700156
PM 23922956
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Shim, SH
   Kim, SG
   Bae, JH
   Yu, HG
   Song, SJ
AF Shim, Seong Hee
   Kim, Soo-Geun
   Bae, Jeong Hun
   Yu, Hyeong Gon
   Song, Su Jeong
TI Risk Factors for Progression of Early Age-Related Macular Degeneration
   in Koreans
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE risk factors; progression; hypertension; Age-related macular
   degeneration; Koreans
ID BLUE-MOUNTAINS-EYE; LONG-TERM INCIDENCE; ANGELES LATINO EYE; BEAVER DAM
   EYE; CARDIOVASCULAR-DISEASE; JAPANESE POPULATION; 10-YEAR INCIDENCE;
   GRADING SYSTEM; MACULOPATHY; PREVALENCE
AB Purpose: To identify risk factors for the progression of early age-related macular degeneration (AMD) in Koreans.
   Methods: This study was conducted at a health-screening center and followed a prospective cohort study design. Of 10,890 participants older than 50 years, 318 (2.92%) presented with early AMD. Among these 318 participants, we re-examined 172 participants after a mean duration of 4.4 years. Progression was defined by the Age-Related Eye Disease Study (AREDS) simplified AMD severity scale. Multivariable logistic regression was used to examine associations between AMD progression and baseline physical, demographic, behavioral, and ocular characteristics.
   Results: Of the 172 participants with early AMD who were re-examined, 34 (19.8%) had progression. Multivariable analyses revealed that current smoking (odds ratio, OR, 7.0, 95% confidence interval, CI, 1.4-34.4, adjusted for age, alcohol consumption, body mass index, BMI, blood pressure, BP, total cholesterol, and high density lipoprotein, HDL, cholesterol) and hypertension (OR 10.3, 95% CI 1.9-55.7, adjusted for age, smoking status, alcohol consumption, BMI, total cholesterol, and HDL cholesterol) were independently associated with progression of early AMD. Additionally, the presence of a central drusen lesion within one-third disc diameter of the macula (age-adjusted OR 4.8, 95% CI 1.3-17.6) and 20 or more drusen (age adjusted OR 7.8, 95% CI 2.5-24.0) were independently associated with progression of early AMD.
   Conclusion: Current smoking, hypertension, central drusen location, and increasing number of drusen were associated with an increased risk of early AMD progression in Koreans.
C1 [Shim, Seong Hee; Bae, Jeong Hun; Song, Su Jeong] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Ophthalmol, 29 Saemunan Ro, Seoul 110746, South Korea.
   [Kim, Soo-Geun] Sungkyunkwan Univ, Kangbuk Samsung Med Ctr, Dept Occupat Environm Med, Seoul 110746, South Korea.
   [Yu, Hyeong Gon] Seoul Natl Univ, Med Res Ctr, Sensory Organs Inst, Seoul, South Korea.
   [Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Seoul National University
   (SNU); Seoul National University (SNU)
RP Song, SJ (通讯作者)，Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Ophthalmol, 29 Saemunan Ro, Seoul 110746, South Korea.
EM eye-su@hanmail.net
OI Yu, Hyeong Gon/0000-0002-1795-202X
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gemmy Cheung CM, 2013, AM J OPHTHALMOL, V155, pe761
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 41
TC 12
Z9 12
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD MAR 3
PY 2016
VL 23
IS 2
BP 80
EP 87
DI 10.3109/09286586.2015.1129425
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH4FU
UT WOS:000372741700003
PM 26950426
DA 2022-11-30
ER

PT J
AU Liu, L
   White, J
AF Liu, Lei
   White, Janis
TI Early Age-Related Macular Degeneration Impairs Tolerance to Stimulus
   Degradation
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; texture discrimination; psychophysics;
   detection
ID VISUAL TEXTURE DISCRIMINATION; TRIPLE CORRELATION UNIQUENESS; FOVEAL
   FLICKER SENSITIVITY; MEDIATED DARK-ADAPTATION; CONTRAST SENSITIVITY;
   RETINITIS-PIGMENTOSA; MULTIFOCAL ELECTRORETINOGRAM; ATTENTIONAL
   GUIDANCE; JULESZ CONJECTURE; MEMBRANE CHANGE
AB Purpose. Pathologic changes of retinal photoreceptors associated with early age-related macular degeneration (AMD) have been well established, but the disease is usually asymptomatic at the early stage, and traditional suprathreshold clinical tests often fail to reveal functional deficiencies. The aim of this study is to demonstrate subtle changes of one suprathreshold visual function in early AMD eyes.
   Methods. The quality of preattentively discriminable texture stimuli was systematically degraded through random deletion of texture checks. The task of the subject was to make a forced choice decision on whether two equally degraded patches contained samples of the same or different types of textures. Tolerance to texture stimulus degradation was measured in young and elderly normal controls and in patients with early AMD.
   Results. Subjects were trained to perform the texture discrimination task until they made few errors in discriminating intact textures. Texture discrimination deteriorated with increasing stimulus degradation in all subjects. There was no significant difference between performance of young and elderly normal controls. Early AMD eyes showed significantly less tolerance to stimulus degradation than age-similar normal controls at a range of degradation levels. After controlling for visual acuity, normal subjects still performed significantly better than early AMD eyes at similar to 22% check deletion. There was no significant difference between better eyes of early AMD patients and fellow eyes of late AMD eyes. Performance on the degraded texture task was not correlated with visual acuity. A mild blur of the stimulus had little effect on discrimination of degraded textures.
   Conclusions. Early AMD may not directly affect suprathreshold visual functions when the stimuli are intact and contain redundant information but may manifest itself as a reduction of tolerance to stimulus degradation in the form of localized information loss. The performance of patients with early AMD may be compromised when the visual stimulus contains less redundant information. (Optom Vis Sci 2010; 87: 532-542)
C1 [Liu, Lei] Univ Alabama Birmingham, Sch Optometry, Dept Optometry, Birmingham, AL 35226 USA.
   [White, Janis] New Jersey Hlth Care Syst, Dept Vet Affairs, E Orange, NJ USA.
C3 University of Alabama System; University of Alabama Birmingham; New
   Jersey Department of Health & Senior Services
RP Liu, L (通讯作者)，Univ Alabama Birmingham, Sch Optometry, Dept Optometry, Birmingham, AL 35226 USA.
EM Liul7788@uab.edu
OI Liu, Lei/0000-0002-1332-9724
FU National Institute of Health [EY014904]; Juvenile Diabetes Research
   Foundation; Helen Hoffritz Charitable Trust; NATIONAL EYE INSTITUTE
   [R03EY014904] Funding Source: NIH RePORTER
FX This study was supported partially by National Institute of Health
   research grant EY014904 and research grants from the Juvenile Diabetes
   Research Foundation and the Helen Hoffritz Charitable Trust.
CR ADAMS AJ, 1982, AM J OPTOM PHYS OPT, V59, P954
   ANDREWS DP, 1967, VISION RES, V7, P999, DOI 10.1016/0042-6989(67)90015-6
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   BAILEY IL, 1991, OPTOMETRY VISION SCI, V68, P911, DOI 10.1097/00006324-199112000-00001
   Bedell HE, 2009, OPTOMETRY VISION SCI, V86, P485, DOI 10.1097/OPX.0b013e31819fa6e2
   Bour LJ, 1996, INVEST OPHTH VIS SCI, V37, P2475
   BOWMAN KJ, 1980, AM J OPTOM PHYS OPT, V57, P145
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P788
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN L, 1983, OPHTHAL PHYSL OPT, V3, P7, DOI 10.1016/0275-5408(83)90082-0
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Burton-Danner K, 2001, EXP AGING RES, V27, P1, DOI 10.1080/036107301750046115
   CAELLI T, 1978, BIOL CYBERN, V28, P167, DOI 10.1007/BF00337138
   CAELLI T, 1978, BIOL CYBERN, V29, P201, DOI 10.1007/BF00337276
   CHARMAN W N, 1979, British Journal of Physiological Optics, V33, P10
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   Collins MJ, 1986, CLIN EXP OPTOM, V69, P223, DOI DOI 10.1111/J.1444-0938.1986.TB04596.X
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DOMEY RG, 1961, AM J OPHTHALMOL, V51, P1262, DOI 10.1016/0002-9394(61)92469-2
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   ELSNER AE, 1987, INVEST OPHTH VIS SCI, V28, P718
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   FLANNERY JG, 1989, INVEST OPHTH VIS SCI, V30, P191
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   FRISEN L, 1984, GRAEF ARCH CLIN EXP, V222, P71, DOI 10.1007/BF02150634
   GELLER AM, 1992, J OPT SOC AM A, V9, P472, DOI 10.1364/JOSAA.9.000472
   GREEVES AL, 1988, OPHTHAL PHYSL OPT, V8, P371, DOI 10.1111/j.1475-1313.1988.tb01171.x
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   Humphrey DG, 1997, PSYCHOL AGING, V12, P704, DOI 10.1037/0882-7974.12.4.704
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   JOHNSON CA, 1995, OPTOMETRY VISION SCI, V72, P359, DOI 10.1097/00006324-199506000-00003
   JOHNSON MA, 1987, APPL OPTICS, V26, P1449, DOI 10.1364/AO.26.001449
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   JOHNSRUDE I, 1994, NEUROPSYCHOLOGIA, V32, P77, DOI 10.1016/0028-3932(94)90070-1
   JULESZ B, 1975, SCI AM, V232, P34, DOI 10.1038/scientificamerican0475-34
   JULESZ B, 1980, PHILOS T R SOC B, V290, P83, DOI 10.1098/rstb.1980.0084
   JULESZ B, 1983, BELL SYST TECH J, V62, P1619, DOI 10.1002/j.1538-7305.1983.tb03502.x
   JULESZ B, 1978, BIOL CYBERN, V31, P137, DOI 10.1007/BF00336998
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kornzweig AL, 1954, SIGHT SAVING REV, V254, P130
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   LIU L, 1999, VISION SCI ITS APPL, P2
   Lovie-Kitchin JE, 1989, CLIN EXP OPTOM, V72, P79
   Madden DJ, 1999, PSYCHOL AGING, V14, P683, DOI 10.1037/0882-7974.14.4.683
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   MARMOR MF, 1988, OPHTHALMOLOGY, V95, P139
   MAYER MJ, 1988, J OPT SOC AM A, V5, P2201, DOI 10.1364/JOSAA.5.002201
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Nguyen-Tri D, 2003, INVEST OPHTH VIS SCI, V44, P3698, DOI 10.1167/iovs.02-1191
   OKEN BS, 1994, J GERIATR PSYCH NEUR, V7, P163, DOI 10.1177/089198879400700307
   Owsley C, 2004, OPHTHALMOLOGY, V111, P2259, DOI 10.1016/j.ophtha.2004.06.026
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   PITTS DG, 1982, J AM OPTOM ASSOC, V53, P37
   PLUDE DJ, 1989, PSYCHOL AGING, V4, P98, DOI 10.1037/0882-7974.4.1.98
   RUDDOCK K. H., 1965, VISION RES, V5, P37, DOI 10.1016/0042-6989(65)90073-8
   Schneck ME, 2004, VISION RES, V44, P2317, DOI 10.1016/j.visres.2004.04.018
   SEIPLE W, 1995, VISION RES, V35, P2057, DOI 10.1016/0042-6989(94)00289-X
   SLOANE ME, 1988, VISION RES, V28, P1235, DOI 10.1016/0042-6989(88)90039-9
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Stearne MR, 1998, BRIT MED J, V317, P713
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   STORANDT M, 1982, AGING HUMAN VISUAL F, P269
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   SZLYK JP, 1995, VISION RES, V35, P1633, DOI 10.1016/0042-6989(94)00275-Q
   TURANO K, 1992, INVEST OPHTH VIS SCI, V33, P2411
   Uttal W.R., 1975, AUTOCORRELATION THEO
   Victor JD, 2005, VISION RES, V45, P311, DOI 10.1016/j.visres.2004.08.013
   VICTOR JD, 1994, J OPT SOC AM A, V11, P1680, DOI 10.1364/JOSAA.11.001680
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935
   WEALE RA, 1975, T OPHTHAL SOC UK, V95, P36
   Weymuth F, 1960, VISION AGING PATIENT, P37
   Whiting WL, 2005, Q J EXP PSYCHOL-A, V58, P72, DOI 10.1080/02724980443000205
   YELLOTT JI, 1993, J OPT SOC AM A, V10, P777, DOI 10.1364/JOSAA.10.000777
   ZACKS JL, 1993, J EXP PSYCHOL HUMAN, V19, P798, DOI 10.1037/0096-1523.19.4.798
NR 88
TC 6
Z9 6
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2010
VL 87
IS 8
BP 532
EP 542
DI 10.1097/OPX.0b013e3181e3dc10
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 634AS
UT WOS:000280551000003
PM 20495501
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Tanner, CT
   Caserta, MS
   Clayton, MF
   Kleinshcmidt, JJ
   Bernstein, PS
   Guo, JW
AF Tanner, Corinna Trujillo
   Caserta, Michael S.
   Clayton, Margaret F.
   Kleinshcmidt, Julia J.
   Bernstein, Paul S.
   Guo, Jia-Wen
TI Posttraumatic Growth Among Older Adults With Age-Related Macular
   Degeneration
SO JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS
LA English
DT Article
DE age-related macular degeneration; social isolation; post-traumatic
   growth; depression; cognitive processing; meaning making
ID QUALITY-OF-LIFE; DEPRESSION; MEDIATION; HEALTH
AB Introduction: The term "post-traumatic growth" describes positive outcomes that accrue from the struggle with highly challenging life circumstances. The purpose of this study is to describe post-traumatic growth accruing from experience with vision loss caused by age-related macular degeneration (AMD) and to identify the relationships between depression, cognitive processing, social support, and post-traumatic growth. Methods: Individuals with vision loss caused by AMD completed an interviewer-administered composite questionnaire to identify elements of Tedeschi and Calhoun's theoretical model of the process of posttraumatic growth, including measures of distress (depression), intrusive and deliberate rumination (cognitive processing), and social support (quality and quantity of social ties). Relationships were examined using path analysis. Results: Eighty-nine participants completed the questionnaire (mean age = 85.3 years, range = 74-98 years). All paths, including from depression to social support (beta = -.363, p < .001), from social support to deliberate rumination (beta = .233; p <= .01), and from intrusive rumination to deliberate rumination (beta = .514, p < .01), were significant and consistent with the posttraumatic growth theoretical model. Deliberate rumination had a significant direct path to post-traumatic growth (beta = .38, p = .001). Discussion: The findings may illuminate elements of the process of post-traumatic growth among those with AMD. We found that as social support increased, depression decreased. Increased social support seemed to encourage positive deliberate rumination, which led directly to post-traumatic growth. Although intrusive rumination is often associated with negative outcomes, the model demonstrates that it also stimulates engagement in deliberate attempts to process one's experience. Deliberate cognitive processing is a direct precursor to post-traumatic growth. Implications for Practitioners: A focus on the process of growth and thriving can offer a broader view of the experience of living with vision loss. Interventions that foster post-traumatic growth among those with AMD should focus on enhancing social support and facilitating deliberate cognitive processing.
C1 [Tanner, Corinna Trujillo] Brigham Young Univ, Provo, UT 84602 USA.
   [Caserta, Michael S.; Guo, Jia-Wen] Univ Utah, Coll Nursing, Gerontol Interdisciplinary Program, Salt Lake City, UT 84112 USA.
   [Clayton, Margaret F.] Univ Utah, Coll Nursing, Salt Lake City, UT 84112 USA.
   [Kleinshcmidt, Julia J.; Bernstein, Paul S.] Univ Utah, Sch Med, Visual & Ophthalmol Sci, Salt Lake City, UT USA.
C3 Brigham Young University; Utah System of Higher Education; University of
   Utah; Utah System of Higher Education; University of Utah; Utah System
   of Higher Education; University of Utah
RP Tanner, CT (通讯作者)，Brigham Young Univ, Coll Nursing, Spencer W Kimball Tower,KMBL 432, Provo, UT 84602 USA.
EM corinna_tanner@byu.edu
OI Clayton, Margaret/0000-0002-0318-5210
FU National Institute of Nursing Research Grant [T32NR013456]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by the National Institute of Nursing Research Grant
   #T32NR013456.
CR Barskova T, 2009, DISABIL REHABIL, V31, P1709, DOI 10.1080/09638280902738441
   Bianchini V, 2017, Clin Pract Epidemiol Ment Health, V13, P10, DOI 10.2174/1745017901713010010
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Calhoun LG, 2000, J TRAUMA STRESS, V13, P521, DOI 10.1023/A:1007745627077
   Cann A, 2011, ANXIETY STRESS COPIN, V24, P137, DOI 10.1080/10615806.2010.529901
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Cheung GW, 2008, ORGAN RES METHODS, V11, P296, DOI 10.1177/1094428107300343
   Crews JE, 2014, OPHTHAL EPIDEMIOL, V21, P287, DOI 10.3109/09286586.2014.926556
   Helgeson VS, 2006, J CONSULT CLIN PSYCH, V74, P797, DOI 10.1037/0022-006X.74.5.797
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Kent EE, 2013, J PSYCHOSOC ONCOL, V31, P393, DOI 10.1080/07347332.2013.798759
   Kim H, 2014, MULTIVAR BEHAV RES, V49, P581, DOI 10.1080/00273171.2014.947352
   Kleim B, 2009, J TRAUMA STRESS, V22, P45, DOI 10.1002/jts.20378
   Lubben JE., 1988, FAM COMMUNITY HEALTH, V11, P42, DOI [10.1097/00003727-198811000-00008, DOI 10.1097/00003727-198811000-00008]
   Mallinckrodt B, 2006, J COUNS PSYCHOL, V53, P372, DOI 10.1037/0022-0167.53.3.372
   Moore B.A., 2021, PRACTICE INNOVATIONS, V6, P42, DOI [10.1037/pri0000136, DOI 10.1037/PRI0000136]
   Morrill EF, 2008, PSYCHO-ONCOLOGY, V17, P948, DOI 10.1002/pon.1313
   Nolen-Hoeksema S, 2000, J ABNORM PSYCHOL, V109, P504, DOI 10.1037/0021-843X.109.3.504
   Ord LM, 2015, J CLIN MED, V4, P1841, DOI 10.3390/jcm4091841
   Sawyer A, 2010, CLIN PSYCHOL REV, V30, P436, DOI 10.1016/j.cpr.2010.02.004
   Shah K, 2020, EYE, V34, P290, DOI 10.1038/s41433-019-0712-8
   SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
   Tanner C.T., 2019, J BLINDNESS INNOVATI, V9, DOI [10.5241/10-183, DOI 10.5241/10-183]
   Tedeschi R. G., 2016, POSTTRAUMATIC GROWTH
   Tedeschi R.G., 2018, POSTTRAUMATIC GROWTH
   Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1002/jts.2490090305
   Tesser A., 1996, ADV SOC COG, V9, P1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 28
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-482X
EI 1559-1476
J9 J VISUAL IMPAIR BLIN
JI J. Vis. Impair. Blind.
PD MAY
PY 2022
VL 116
IS 3
BP 323
EP 333
DI 10.1177/0145482X221108983
PG 11
WC Rehabilitation
WE Social Science Citation Index (SSCI)
SC Rehabilitation
GA 3P7QD
UT WOS:000837728800003
DA 2022-11-30
ER

PT J
AU Zaliuniene, D
   Jasinskas, V
   Jurkevicius, R
   Gustiene, O
   Zaliunas, R
AF Zaliuniene, D.
   Jasinskas, V.
   Jurkevicius, R.
   Gustiene, O.
   Zaliunas, R.
TI Endothelial function, intima-media thickness, and ankle-brachial index
   in patients with cataract and age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; ankle-brachial index; cataract;
   endothelial function; intima-media thickness
ID C-REACTIVE PROTEIN; RISK-FACTORS; ATHEROSCLEROSIS; ASSOCIATION;
   MACULOPATHY; DISEASE; PATHOGENESIS; ROTTERDAM; SURGERY; EYE
AB PURPOSE. To evaluate the association between cardiovascular risk factors, including endothelial dysfunction, increased intima-media thickness (IMT) of the carotid arteries, ankle-brachial index (ABI), and age-related macular degeneration (AMD), and cataract.
   METHODS. Forty-seven patients with AMD and cataract, 35 with cataract only, and 49 with AMD were included. Carotid ultrasound, ischemia-induced brachial artery reactivity test, and ABI in conjunction with investigation of conventional cardiovascular risk factors were performed.
   RESULTS. Increased levels ( more than 1.23 mg/L) of high-sensitivity C-reactive protein (hsCRP) and IMT ( more than 0.97 mm) increased prevalence odds for AMD and cataract 3.1 and 3.9 times, respectively.
   CONCLUSIONS. Elevated hsCRP or increased IMT of the carotid arteries are associated with comorbid cataract and AMD, whereas there were no reliable differences between groups in respect to endothelial function and ABI.
C1 [Zaliuniene, D.; Jasinskas, V.] Kaunas Univ Med, Dept Ophthalmol, LT-50009 Kaunas, Lithuania.
   [Jurkevicius, R.; Gustiene, O.; Zaliunas, R.] Kaunas Univ Med, Dept Cardiol, LT-50009 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Zaliuniene, D (通讯作者)，Kaunas Univ Med, Dept Ophthalmol, Eiveniu 2, LT-50009 Kaunas, Lithuania.
EM r.zaliunas@gmail.com
CR Brunner H, 2005, J HYPERTENS, V23, P233, DOI 10.1097/00004872-200502000-00001
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cimbalas Andrius, 2003, Medicina (Kaunas), V39, P1237
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Ginsburg Arthur P., 2003, International Ophthalmology Clinics, V43, P5
   Jasinskas Vytautas, 2006, Medicina (Kaunas), V42, P370
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Redberg Rita F., 2003, Journal of the American College of Cardiology, V41, P1886, DOI 10.1016/S0735-1097(03)00360-7
   Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Triggle CR, 2004, MOL CELL BIOCHEM, V263, P21, DOI 10.1023/B:MCBI.0000041845.62061.c9
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Zaliuniene D, 2007, EUR J OPHTHALMOL, V17, P919, DOI 10.1177/112067210701700609
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 23
TC 9
Z9 9
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2008
VL 18
IS 3
BP 384
EP 391
DI 10.1177/112067210801800312
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 317NQ
UT WOS:000257027300012
PM 18465721
DA 2022-11-30
ER

PT J
AU Bagewadi, S
   Parameswaran, S
   Krishnakumar, S
   Sethuraman, S
   Subramanian, A
AF Bagewadi, Shambhavi
   Parameswaran, Sowmya
   Krishnakumar, Subramanian
   Sethuraman, Swaminathan
   Subramanian, Anuradha
TI Tissue engineering approaches towards the regeneration of biomimetic
   scaffolds for age-related macular degeneration
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; AMNIOTIC MEMBRANE TRANSPLANTATION; HONEYCOMB
   POROUS FILMS; CELL TRANSPLANTATION; SUBRETINAL SPACE; BRUCHS MEMBRANE;
   ENHANCED DIFFERENTIATION; POLY(GLYCEROL SEBACATE); RCS RATS; RPE
AB Age-related macular degeneration (AMD) is the third major cause of blindness in people aged above 60 years. It causes dysfunction of the retinal pigment epithelium (RPE) and leads to an irreversible loss of central vision. The present clinical treatment options are more palliative in controlling the progression of the disease and do not functionally restore the degenerated RPE monolayer and photoreceptors. Currently, the clinical transplantation of RPE cells has shown poor engraftment potential due to the absence of an intact Bruch's membrane in AMD patients, thereby the vision is unable to be restored completely. Although tissue engineering strategies target the development of Bruch's membrane-mimetic substrates, the challenge still lies in the development of an ultrathin, biologically and mechanically equivalent membrane to restore visual acuity. Further, existing limitations such as cellular aggregation, surgical complications including retinal tissue damage, tissue rejection, disease transmission, inferior mechanical strength, and the loss of vision over time demand the search for an ideal strategy to restore the functional RPE. Hence, this review aims to provide insights into various approaches, from conventional cell therapy to 3D bioprinting, and their unmet challenges in treating AMD by outlining the pathophysiology of AMD and the host tissue response with respect to injury, treatment and preclinical animal models.
C1 [Bagewadi, Shambhavi; Sethuraman, Swaminathan; Subramanian, Anuradha] SASTRA Deemed Univ, Sch Chem & Biotechnol, Tissue Engn & Addit Mfg TEAM Lab, ABCDE Innovat Ctr,Ctr Nanotechnol & Adv Biomat, Thanjavur 613401, Tamil Nadu, India.
   [Parameswaran, Sowmya; Krishnakumar, Subramanian] Vis Res Fdn, Kamalnayan Bajaj Inst Res Vis & Ophthalmol, Radheshyam Kanoi Stem Cell Lab, Chennai, Tamil Nadu, India.
C3 Shanmugha Arts, Science, Technology & Research Academy (SASTRA)
RP Subramanian, A (通讯作者)，SASTRA Deemed Univ, Sch Chem & Biotechnol, Tissue Engn & Addit Mfg TEAM Lab, ABCDE Innovat Ctr,Ctr Nanotechnol & Adv Biomat, Thanjavur 613401, Tamil Nadu, India.
EM anuradha@bioengg.sastra.edu
RI Sowmya, Parameswaran/GZK-8635-2022
OI Bagewadi, Shambhavi/0000-0002-9243-1275; Subramanian,
   Anuradha/0000-0001-7333-0244
FU Department of Biotechnology [BT/PR26760/NNT/28/1433/2017]; Government of
   India
FX The authors acknowledge Department of Biotechnology
   (BT/PR26760/NNT/28/1433/2017), Government of India, for financial
   support.
CR Abe T, 2000, TOHOKU J EXP MED, V191, P7, DOI 10.1620/tjem.191.7
   Abe T, 2007, PROG RETIN EYE RES, V26, P302, DOI 10.1016/j.preteyeres.2007.01.003
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Akrami H, 2011, BIOCHEM GENET, V49, P313, DOI 10.1007/s10528-010-9409-1
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Azuara-Blanco A, 1999, BRIT J OPHTHALMOL, V83, P399, DOI 10.1136/bjo.83.4.399
   Baino F, 2014, ACTA BIOMATER, V10, P1064, DOI 10.1016/j.actbio.2013.12.014
   Baird P.N., 2011, ANIMAL MODELS RETINA, V100
   Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004
   Besch D, 2008, BRIT J OPHTHALMOL, V92, P1361, DOI 10.1136/bjo.2007.131961
   Bidarra SJ, 2014, ACTA BIOMATER, V10, P1646, DOI 10.1016/j.actbio.2013.12.006
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Butterwick A, 2009, EXP EYE RES, V88, P22, DOI 10.1016/j.exer.2008.09.018
   Cai H, 2006, ARCH OPHTHALMOL-CHIC, V124, P1276, DOI 10.1001/archopht.124.9.1276
   Calejo MT, 2017, ACTA BIOMATER, V54, P138, DOI 10.1016/j.actbio.2017.02.035
   Calejo MT, 2016, J BIOMED MATER RES A, V104, P1646, DOI 10.1002/jbm.a.35690
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   Chan SY, 2017, ACS OMEGA, V2, P8959, DOI 10.1021/acsomega.7b01604
   Chang Bo, 2013, Methods Mol Biol, V935, P27, DOI 10.1007/978-1-62703-080-9_2
   Chen S, 2018, BIOPRINTING, V12, P1
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   Chirila TV, 2008, TISSUE ENG PT A, V14, P1203, DOI [10.1089/ten.tea.2007.0224, 10.1089/tea.2007.0224]
   Christiansen AT, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/454295
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Dua HS, 2006, ESSENT OPHTHALMOL, P21
   Dua HS, 2004, SURV OPHTHALMOL, V49, P51, DOI 10.1016/j.survophthal.2003.10.004
   Duncan JL, 2003, INVEST OPHTH VIS SCI, V44, P826, DOI 10.1167/iovs.02-0438
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Fujii S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093077
   Galloway CA, 2018, INVEST OPHTH VIS SCI, V59, P2792, DOI 10.1167/iovs.17-23157
   Gandhi JK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227641
   Gandhi JK, 2018, ACTA BIOMATER, V67, P134, DOI 10.1016/j.actbio.2017.11.058
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Goncalves S, 2015, BIOMACROMOLECULES, V16, P1341, DOI 10.1021/acs.biomac.5b00129
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Harkin DG, 2011, BIOMATERIALS, V32, P2445, DOI 10.1016/j.biomaterials.2010.12.041
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Hollyfield JG, 1998, EXP EYE RES, V66, P241, DOI 10.1006/exer.1997.0422
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jiang F, 2019, BIOMATER SCI-UK, V7, P2335, DOI 10.1039/c8bm01579a
   Johnson M., 2013, RETINA-J RET VIT DIS, V284, P465
   Julien S, 2011, BIOMATERIALS, V32, P3890, DOI 10.1016/j.biomaterials.2011.02.016
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kim HS, 2019, INT J BIOL MACROMOL, V130, P220, DOI 10.1016/j.ijbiomac.2019.01.078
   Kim J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30481-y
   Koh AEH, 2019, J PHOTOCH PHOTOBIO B, V196, DOI 10.1016/j.jphotobiol.2019.111514
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Krishna L, 2020, ACS APPL BIO MATER, V3, P823, DOI 10.1021/acsabm.9b00897
   Krishna L, 2019, ACS BIOMATER SCI ENG, V5, P357, DOI 10.1021/acsbiomaterials.8b00769
   Krishna Y, 2011, BRIT J OPHTHALMOL, V95, P569, DOI 10.1136/bjo.2009.169953
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   Larsson J, 1997, INVEST OPHTH VIS SCI, V38, P1552
   Lee, 2014, J TISSUE ENG REGEN M, V12, P181
   Lee CJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1714
   Lew DS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01463
   Li M, 2013, J CHEM-NY, P7
   Liu XH, 2012, MACROMOL BIOSCI, V12, P911, DOI 10.1002/mabi.201100466
   Liu Y, 2013, TISSUE ENG PT A, V19, P135, DOI [10.1089/ten.tea.2012.0209, 10.1089/ten.TEA.2012.0209]
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Loh XJ, 2015, J MATER CHEM B, V3, P7641, DOI 10.1039/c5tb01048a
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Masaeli E, 2020, BIOFABRICATION, V12, DOI 10.1088/1758-5090/ab4a20
   Maya-Vetencourt JF, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.579141
   Maya-Vetencourt JF, 2020, NAT NANOTECHNOL, V15, P698, DOI 10.1038/s41565-020-0696-3
   Mazumder MAJ, 2012, J BIOMED MATER RES A, V100A, P1877, DOI 10.1002/jbm.a.34021
   McGill TJ, 2007, INVEST OPHTH VIS SCI, V48, P1906, DOI 10.1167/iovs.06-1117
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   Meyer U., 2009, FUNDAMENTALS TISSUE
   Mitrousis N, 2020, BIOMATERIALS, V257, DOI 10.1016/j.biomaterials.2020.120233
   Montezuma SR, 2006, INVEST OPHTH VIS SCI, V47, P3514, DOI 10.1167/iovs.06-0106
   Mu YL, 2014, INT J CLIN EXP MED, V7, P3843
   Neeley WL, 2008, BIOMATERIALS, V29, P418, DOI 10.1016/j.biomaterials.2007.10.007
   Ohno-Matsui K, 2005, MOL VIS, V11, P1
   Park E., 2019, SBIR STTR GRANTS INT, V1
   Park J, 2019, CELL TRANSPLANT, V28, P596, DOI 10.1177/0963689719825614
   Peng CH, 2016, ONCOTARGET, V7, P64631, DOI 10.18632/oncotarget.11502
   Picaud S, 2021, FRONT NEUROSCI-SWITZ, V15, P1
   Rahmani S, 2018, INT J POLYM MATER PO, V67, P27, DOI 10.1080/00914037.2017.1297939
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Rizzo S, 2019, RETINA-J RET VIT DIS, V39, P95, DOI 10.1097/IAE.0000000000002320
   Rose JB, 2014, MATERIALS, V7, P3106, DOI 10.3390/ma7043106
   Sangwan Virender S., 2007, Indian Journal of Ophthalmology, V55, P251
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seo JM, 2004, MAT SCI ENG C-BIO S, V24, P185, DOI 10.1016/j.msec.2003.09.019
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Shah V.A, 2006, ARCH OPHTHALMOL-CHIC, V119, P409
   Shi PJ, 2017, INT J BIOPRINTING, V3, P138, DOI 10.18063/IJB.2017.02.008
   Shin EY, 2019, MAT SCI ENG C-MATER, V103, DOI 10.1016/j.msec.2019.109787
   Singhal Shweta, 2005, Indian Journal of Ophthalmology, V53, P109
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Sprott R.L, 1999, STUD AGING, P105
   Stanzel BV, 2005, EXP EYE RES, V80, P103, DOI 10.1016/j.exer.2004.06.032
   Steedman MR, 2010, BIOMED MICRODEVICES, V12, P363, DOI 10.1007/s10544-009-9392-7
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundback CA, 2005, BIOMATERIALS, V26, P5454, DOI 10.1016/j.biomaterials.2005.02.004
   Surrao DC, 2017, ACTA BIOMATER, V64, P357, DOI 10.1016/j.actbio.2017.09.032
   Tan EYS, 2017, J MATER CHEM B, V5, P5616, DOI 10.1039/c7tb00376e
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Teymouri S, 2017, COGENT CHEM, V3, DOI 10.1080/23312009.2017.1292593
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thumann G, 2009, GRAEF ARCH CLIN EXP, V247, P363, DOI 10.1007/s00417-008-0998-x
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Tseng SCG, 2001, BIOSCIENCE REP, V21, P481, DOI 10.1023/A:1017995810755
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P416, DOI 10.1167/iovs.07-0992
   Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279
   Wang YD, 2003, J BIOMED MATER RES A, V66A, P192, DOI 10.1002/jbm.a.10534
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Yaji N, 2009, BIOMATERIALS, V30, P797, DOI 10.1016/j.biomaterials.2008.10.045
   Yao J, 2015, TISSUE ENG PT A, V21, P1247, DOI [10.1089/ten.tea.2013.0720, 10.1089/ten.TEA.2013.0720]
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Zernii EY, 2016, CNS NEUROL DISORD-DR, V15, P267, DOI 10.2174/1871527315666151110124957
NR 125
TC 1
Z9 1
U1 6
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050-750X
EI 2050-7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD AUG 14
PY 2021
VL 9
IS 30
BP 5935
EP 5953
DI 10.1039/d1tb00976a
EA JUN 2021
PG 19
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science
GA TU4PQ
UT WOS:000672410900001
PM 34254105
DA 2022-11-30
ER

PT J
AU Tan, SZ
   Laude, A
   Aspinall, PA
   Ambrecht, AM
   Vani, A
   Dhillon, B
AF Tan, Shi Zhuan
   Laude, Augustinus
   Aspinall, Peter A.
   Ambrecht, Anna M.
   Vani, Archana
   Dhillon, Baljean
TI Decisional answer tree analysis of exudative age-related macular
   degeneration treatment outcomes
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
ID SUBGROUP ANALYSIS; RANIBIZUMAB
AB The use of intravitreal ranibizumab in exudative age-related macular degeneration (eAMD) has become commonplace. We aim to investigate the early predictors of this treatment outcome. Seventy-one treatment-naive eyes of 71 patients with eAMD of all lesion subtypes who received intravitreal ranibizumab treatment and completed 12 months of follow-up were included. All patients were loaded with three injections of ranibizumab at monthly intervals. Further injections were given if clinically indicated based on logMAR best-corrected visual acuity (BCVA) and optical coherence tomography findings. Casenotes of eligible patients were reviewed retrospectively. The main outcome measure was logMAR BCVA change at month 12. The mean number of injections given over 12 months was 5.4 +/- A 1.9. A total of 88.7 % of the patients achieved visual stabilisation (loss of < 15 letters) and 15.0 % achieved visual improvement (gain of a parts per thousand yen15 letters). The mean letter change at 12 months was +0.3 letters. Regression analysis showed that baseline BCVA and letter change at month 3 predicted visual acuity outcome at month 12 (baseline BCVA: t = 6.97, p < 0.001; letter change: t = 5.84, p < 0.01) but age, gender and eAMD in the fellow eye were not predictive. Finally, a decisional answer tree model demonstrated that letter change at month 3 was a strong predictor of visual outcome at month 12 with an overall accuracy of 69 %. We found that letter change from baseline at month 3 was strongly predictive of visual outcome at month 12.
RP Laude, A (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM draugustinuslaude@googlemail.com
OI Tan, Shi Zhuan/0000-0001-7747-7219
CR Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown D.M., 2009, OPHTHALMOLOGY, V116, pe5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   LALWANI GA, 2009, AM J OPHTHALMOL, V148, P43, DOI DOI 10.1016/J.AJO.2009.01.024
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   NICE, 2008, PEG RAN TREATM AG RE
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 19
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD OCT
PY 2013
VL 33
IS 5
BP 467
EP 474
DI 10.1007/s10792-013-9717-7
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 223UP
UT WOS:000324837100004
PM 23359132
DA 2022-11-30
ER

PT J
AU Sullivan, RKP
   WoldeMussie, E
   Pow, DV
AF Sullivan, Robert K. P.
   WoldeMussie, Elizabeth
   Pow, David V.
TI Dendritic and synaptic plasticity of neurons in the human age-related
   macular degeneration retina
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MULTIFOCAL ELECTRORETINOGRAM; FUNCTIONAL RECOVERY; AXONAL PLASTICITY;
   MAMMALIAN RETINA; HORIZONTAL CELLS; A-WAVE; MACULOPATHY; ABNORMALITIES;
   BIPOLAR; GROWTH
AB PURPOSE. To determine whether structural plasticity is evident in human retinal tissues in response to age-related macular degeneration (AMD). Remodeling events such as sprouting of neuronal processes and the reconnection of synapses are essential elements in repairing any damage to adult nervous tissues such as might occur in response to insults such as strokes or in AMD.
   METHODS. The anatomic architecture of normal and AMD-affected human retinas was examined in the central, midperipheral, and far-peripheral regions. The retina, by virtue of its well-organized laminar structure, allows the identification and analysis of abnormal projections or connections of neuronal elements.
   RESULTS. In AMD-afflicted retinas, but not in normal aged human retinas, a large number of photoreceptor synapses across the entire retina retract into the outer nuclear layer. This event evokes the subsequent outgrowth of dendrites from the postsynaptic bipolar cells, again across the entire retina, and the subsequent reformation of synaptic contacts between photoreceptor and bipolar cells.
   CONCLUSIONS. These findings illustrate that there are anatomic changes in the AMD retina at all eccentricities, not just in the macular region. Aged human retinal neurons have the capacity to form new synapses, and this finding may be important when investigating possible means of repairing the damaged human retina.
C1 Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2308, Australia.
   Allergan Pharmaceut Inc, Dept Biol Sci, Irvine, CA USA.
C3 University of Newcastle; AbbVie; Allergan
RP Pow, DV (通讯作者)，Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2308, Australia.
EM david.pow@newcastle.edu.au
RI Pow, David/F-8198-2010; Sullivan, Robert KP/A-8639-2012; Pow, David
   V/A-2064-2016
OI Sullivan, Robert KP/0000-0003-3414-2448; Pow, David
   V/0000-0001-8522-4465
CR Adler R, 1999, MOL VIS, V5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0
   Cuenca N, 2005, EUR J NEUROSCI, V22, P1057, DOI 10.1111/j.1460-9568.2005.04300.x
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005
   DOWSON JH, 1973, HISTOCHEMISTRY, V37, P75, DOI 10.1007/BF00306861
   EDELINE JM, 1993, BEHAV NEUROSCI, V107, P539, DOI 10.1037/0735-7044.107.4.539
   Elston GN, 1997, CEREB CORTEX, V7, P422, DOI 10.1093/cercor/7.5.422
   Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8
   Feigl B, 2006, CURR EYE RES, V31, P635, DOI 10.1080/02713680600762739
   Fisher SK, 2005, PROG RETIN EYE RES, V24, P395, DOI 10.1016/j.preteyeres.2004.10.004
   Galvan VV, 2002, NEUROBIOL LEARN MEM, V77, P78, DOI 10.1006/nlme.2001.4044
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gong J, 2006, BRAIN RES, V1082, P73, DOI 10.1016/j.brainres.2006.01.111
   Haverkamp S, 2003, VISUAL NEUROSCI, V20, P589, DOI 10.1017/S0952523803206015
   Jackson GR, 2006, VISION RES, V46, P1422, DOI 10.1016/j.visres.2005.09.003
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321, DOI 10.1152/jn.1998.80.6.3321
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KOLB H, 1993, VISUAL NEUROSCI, V10, P341, DOI 10.1017/S0952523800003734
   Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004
   Lewis GP, 1998, INVEST OPHTH VIS SCI, V39, P424
   Libby RT, 2003, EXP EYE RES, V77, P731, DOI 10.1016/j.exer.2003.07.007
   Liets LC, 2006, P NATL ACAD SCI USA, V103, P12156, DOI 10.1073/pnas.0605211103
   Liu X, 2006, J NEUROSCI, V26, P3087, DOI 10.1523/JNEUROSCI.4797-05.2006
   MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144
   Peng YW, 2003, NEUROSCIENCE, V119, P813, DOI 10.1016/S0306-4522(03)00153-2
   Pow DV, 1999, VISUAL NEUROSCI, V16, P231, DOI 10.1017/S0952523899162047
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Rauen T, 2004, NEUROCHEM INT, V45, P1095, DOI 10.1016/j.neuint.2004.04.006
   Reye P, 2001, GLIA, V34, P311, DOI 10.1002/glia.1064
   Schwab ME, 1996, INT J DEV NEUROSCI, V14, P379, DOI 10.1016/S0736-5748(96)00024-X
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Tailby C, 2005, P NATL ACAD SCI USA, V102, P4631, DOI 10.1073/pnas.0402747102
   Tecchio F, 2006, NEUROIMAGE, V32, P1326, DOI 10.1016/j.neuroimage.2006.05.004
   Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798
NR 43
TC 73
Z9 77
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2007
VL 48
IS 6
BP 2782
EP 2791
DI 10.1167/iovs.06-1283
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 174UA
UT WOS:000246967100042
PM 17525213
DA 2022-11-30
ER

PT J
AU Fujii, GY
   De Juan, E
   Humayun, MS
   Sunness, JS
   Chang, TS
   Rossi, JV
AF Fujii, GY
   De Juan, E
   Humayun, MS
   Sunness, JS
   Chang, TS
   Rossi, JV
TI Characteristics of visual loss by scanning laser ophthalmoscope
   microperimetry in eyes with subfoveal choroidal neovascularization
   secondary to age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIALS; FUNDUS PERIMETRY; PHOTOCOAGULATION; LESIONS;
   SURGERY
AB PURPOSE: To evaluate the effects of subfoveal choroidal neovascularization secondary to age,related macular degeneration on functional parameters obtained by scanning laser ophthalmoscope microperimetry.
   DESIGN: Retrospective observational case series and cross,sectional study.
   METHODS: At the Doheny Retina Institute and Wilmer Eye Institute a consecutive series of 179 eyes of 175 patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration was studied. The onset of visual symptoms, best,corrected visual acuity, fluorescein angiography, evaluation of fundus microperimetry and fixation pattern using the Roden-stock scanning laser ophthalmoscope were obtained for each patient. The main outcome measures were central retinal sensitivity and fixation pattern (fixation location and fixation stability) in eyes with subfoveal choroidal neovascularization and their relationship to the length of disease, type and characteristics of choroidal neovascularization, and visual acuity.
   RESULTS: Of 179 eyes, 135 (75%) had central fixation, 27 (15%) had poor central fixation, and 17 (9%) had predominantly eccentric fixation. Seventy,six eyes (42%) had stable fixation, 70 eyes (39%) had relatively unstable fixation, and 33 eyes (18%) had unstable fixation. In 50 eyes (28%) a dense central scotoma was noted. Eighty,nine of 100 eyes (89%) with length of symptoms of less than 3 months had predominantly central fixation and 58 (58%) had stable fixation; 14 of 34 eyes (41%) with length of symptoms of more than 6 months had predominantly central fixation, and 5 eyes (15%) had stable fixation. In 15 eyes of patients who elected not to receive treatment, successive scanning laser ophthalmoscope micro-perimetry were obtained over time (follow-up of 18 months after onset of symptoms). Three months or less after the onset of symptoms, 13 eyes (87.7%) had predominantly central fixation and 9 eyes (60%) had stable fixation. More than 3 months and 6 months or less after the onset of symptoms, 10 eyes (66.7%) had predominantly central fixation and 7 eyes (46.7%) had stable fixation. This trend was further demonstrated in eyes more than 6 months after the onset of symptoms.
   CONCLUSIONS: We conclude that the sequence of events leading to visual function deterioration appears to involve an initial mild decrease in central retinal sensitivity and visual acuity followed by progressive fixation instability and, ultimately, development of an absolute central scotoma with totally eccentric fixation. Increased length of disease is associated with worse fixation pattern and retinal sensitivity deterioration as assessed by scan, ning laser ophthalmoscope microperimetry. A better understanding of the characteristics of visual loss assessed by fixation pattern evaluation and microperimetry in age,related macular degeneration may help optimize timing, patient selection, and treatment options in eyes with this condition. (C) 2003 by Elsevier Inc. All rights reserved.
C1 Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Retina Inst, Los Angeles, CA 90033 USA.
   Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Lions Vis Ctr, Baltimore, MD 21287 USA.
C3 Doheny Eye Institute; University of Southern California; Johns Hopkins
   University; Johns Hopkins Medicine
RP De Juan, E (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Retina Inst, 14560 San Pablo St,Room 3620, Los Angeles, CA 90033 USA.
OI Sunness, Janet/0000-0001-8823-0780
FU NATIONAL EYE INSTITUTE [R01EY008522] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY08522] Funding Source: Medline
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1994, ARCH OPHTHALMOL-CHIC, V112, P1176
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   GREEN WR, 1992, OPHTHALMOLOGY, V100, P1519
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Loewenstein A, 1998, AM J OPHTHALMOL, V125, P657, DOI 10.1016/S0002-9394(98)00014-2
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Rohrschneider K, 1998, AM J OPHTHALMOL, V126, P52, DOI 10.1016/S0002-9394(98)00065-8
   ROHRSCHNEIDER K, 1995, KLIN MONATSBL AUGENH, V207, P102, DOI 10.1055/s-2008-1035356
   Rohrschneider K, 1995, Ger J Ophthalmol, V4, P197
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
NR 17
TC 78
Z9 92
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2003
VL 136
IS 6
BP 1067
EP 1078
DI 10.1016/S0002-9394(03)00663-9
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 749MF
UT WOS:000186924000012
PM 14644217
DA 2022-11-30
ER

PT J
AU Perez-Canales, JL
   Rico-Sergado, L
   Perez-Santonja, JJ
AF Perez-Canales, Jose L.
   Rico-Sergado, Laura
   Perez-Santonja, Juan J.
TI Self-Reported Sleep Duration in Patients with Neovascular Age-Related
   Macular Degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE sleep quality; self-report; sleep; sleep duration; choroidal
   neovascularization; Age-related macular degeneration
ID BREAST-CANCER; MELATONIN; MORTALITY; INSOMNIA; RISK; EPIDEMIOLOGY;
   ASSOCIATION; PREVALENCE; SYMPTOMS; QUALITY
AB Purpose: To examine the relationship between self-reported sleep duration and neovascular age-related macular degeneration (nAMD).
   Methods: This case-control study comprised 165 subjects (57 patients with nAMD and 108 controls). Controls were matched to cases by age and sex. Participants completed a questionnaire that included questions about sleep duration and quality. Four categories of sleep duration were established; <6 hours, 6-7 hours, 7-8 hours and >8 hours. Association of sleep duration and nAMD was assessed by logistic regression analysis. Multiple logistic regression models were performed to control for possible confounders.
   Results: We found a significant association between short sleep duration and nAMD (for <6 hours, odds ratio, OR, 3.29, 95% confidence interval, CI, 1.32-8.27; for 6-7 hours, OR 2.25, 95% CI 0.80-6.32; and for >8 hours, OR 1.39, 95% CI 0.53-3.73) compared with the reference category of 7-8 hours. This association remained significant after adjustment for confounders (<6 hours, OR 3.09, 95% CI 1.20-7.97). In addition, a borderline significant association was observed between self-reported very bad sleep quality and nAMD (OR 2.84, 95% CI 1.02-7.88). The highest rate of sleep medication use was found in the nAMD group (p < 0.001).
   Conclusion: Our findings provide evidence to support an association between short sleep duration and nAMD. Considering strategies to improve sleep in these patients may prevent the negative effects of sleep deficiency.
C1 [Perez-Canales, Jose L.; Rico-Sergado, Laura; Perez-Santonja, Juan J.] Hosp Gen Univ Alicante, Dept Ophthalmol, Alicante, Spain.
   [Perez-Santonja, Juan J.] OftalVist Grp, Alicante, Spain.
C3 General University Hospital of Alicante
RP Perez-Canales, JL (通讯作者)，Hosp Gen Univ Alicante, Dept Oftalmol, Av Pintor Baeza 12, Alicante 03010, Spain.
EM jlpcanales@gmail.com
OI Perez-Santonja, Juan J./0000-0003-1892-2372
CR Bloom HG, 2009, J AM GERIATR SOC, V57, P761, DOI 10.1111/j.1532-5415.2009.02220.x
   Born J, 1997, J IMMUNOL, V158, P4454
   BRUGGER P, 1995, LANCET, V345, P1408, DOI 10.1016/S0140-6736(95)92600-3
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Campos Costa Ines, 2013, Am J Neurodegener Dis, V2, P228
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Girschik J, 2013, AM J EPIDEMIOL, V177, P316, DOI 10.1093/aje/kws422
   Haack M, 2007, SLEEP, V30, P1145, DOI 10.1093/sleep/30.9.1145
   Ikehara S, 2009, SLEEP, V32, P295, DOI 10.1093/sleep/32.3.295
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kinnucan Jami A, 2013, Gastroenterol Hepatol (N Y), V9, P718
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Lauderdale DS, 2008, EPIDEMIOLOGY, V19, P838, DOI 10.1097/EDE.0b013e318187a7b0
   Leger D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106950
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Lichstein KL, 2004, EPIDEMIOLOGY OF SLEEP AGE, GENDER, AND ETHNICITY, P1
   Marchiafava PL, 1999, J PINEAL RES, V26, P184, DOI 10.1111/j.1600-079X.1999.tb00582.x
   Marshall NS, 2008, SLEEP MED REV, V12, P289, DOI 10.1016/j.smrv.2008.03.001
   Miao H, 2012, MOL VIS, V18, P574
   Morin CM, 2006, SLEEP MED, V7, P123, DOI 10.1016/j.sleep.2005.08.008
   Nesmith BLW, 2014, RETINA-J RET VIT DIS, V34, P2423, DOI 10.1097/IAE.0000000000000247
   Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829
   Ohkuma T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078968
   Patel SR, 2004, SLEEP, V27, P440, DOI 10.1093/sleep/27.3.440
   Perlis Michael L, 2006, Behav Sleep Med, V4, P104, DOI 10.1207/s15402010bsm0402_3
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   Rosen R, 2009, MOL VIS, V15, P1673
   Skene DJ, 2003, EXP GERONTOL, V38, P199, DOI 10.1016/S0531-5565(02)00198-5
   Szklo-Coxe M, 2010, AM J EPIDEMIOL, V171, P709, DOI 10.1093/aje/kwp454
   Tamakoshi A, 2004, SLEEP, V27, P51
   Taylor DJ, 2007, SLEEP, V30, P213, DOI 10.1093/sleep/30.2.213
   US Department of Health and Human Services, 2018, PHYS ACT GUID AM, V2nd
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Verkasalo PK, 2005, CANCER RES, V65, P9595, DOI 10.1158/0008-5472.CAN-05-2138
   Youngstedt SD, 2004, SLEEP MED REV, V8, P159, DOI 10.1016/j.smrv.2003.10.002
NR 36
TC 9
Z9 9
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD JAN 2
PY 2016
VL 23
IS 1
BP 20
EP 26
DI 10.3109/09286586.2015.1119288
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DF3LF
UT WOS:000371244800004
PM 26786476
DA 2022-11-30
ER

PT J
AU Schmier, JK
   Covert, DW
   Lau, EC
AF Schmier, Jordana K.
   Covert, David W.
   Lau, Edmund C.
TI Patterns and Costs Associated With Progression of Age-Related Macular
   Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; RISK-FACTORS; VISUAL IMPAIRMENT; EYE DISEASE; RESOURCE
   UTILIZATION; POOLED FINDINGS; 3 CONTINENTS; IMPACT; MACULOPATHY; BURDEN
AB PURPOSE: To evaluate patterns of disease progression among individuals with age-related macular degeneration (AMD) and to compare costs over time.
   DESIGN: Retrospective data analysis using 5% Medicare claims data from 1997 through 2009.
   METHODS: Beneficiaries were included if they had no diagnosis of AMD in 1997, were 65 years of age or older, had data through 2009, and had no major ophthalmic conditions. Two cohorts were identified: those who had dry AMD in 1998 (cases) and matched controls who never had AMD.
   RESULTS: There were 52 607 beneficiaries who never had AMD and 1184 who were diagnosed with dry AMD in 1998. Among beneficiaries with dry AMD, the disease progressed in 20.4% to the wet form by 2009. From 1999 to 2009, average annual Medicare expenditures increased from $11 265 to $24 494 (cases whose disease did not progress) and from $11 712 to $34 308 (cases whose disease progressed). Among beneficiaries without AMD, expenditures also increased over time (from $4736 in 1999 to $17 473 in 2009), but consistently were lower than cases' expenditures. Considering ophthalmic expenditures, the pattern was more pronounced: beneficiaries without AMD had annual expenditures less than $100, those with dry AMD had expenditures at least 3 times more, and wet AMD beneficiaries' costs were at least 5-fold more than that of those with dry disease. A subgroup analysis of beneficiaries without hypertension revealed similar patterns, although expenditures were lower than in the general population.
   CONCLUSIONS: AMD progression seems to be associated with increased annual Medicare expenditures. Findings suggest that halting or slowing disease progression using proven treatment such as Age-Related Eye Disease Study-endorsed vitamins or novel technologies could have a substantial positive impact by lowering public health expenditures. (Am J Ophthalmol 2012;154: 675-681. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Schmier, Jordana K.] Exponent Inc, Alexandria, VA USA.
   [Covert, David W.] Alcon Res Ltd, Ft Worth, TX USA.
   [Lau, Edmund C.] Exponent Inc, Menlo Pk, CA USA.
C3 Exponent; Novartis; Alcon; Exponent
RP Schmier, JK (通讯作者)，1800 Diagonal Rd,Suite 500, Alexandria, VA 22314 USA.
EM jschmier@exponent.com
RI Schmier, Jordana/I-2994-2019
OI Schmier, Jordana/0000-0002-4662-8800
FU Alcon Research, Ltd
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF interest and the following were reported.
   Publication of this article was supported by a grant from Alcon
   Research, Ltd, of which Dr Covert is an employee. The sponsor thus was
   involved in the design of the study, interpretation of the data, and
   review and approval of the manuscript. Involved in Design of study
   (J.K.S., D.W.C.); Conduct of study (J.K.S., E.C.L.); Collection,
   management, and analysis of data (J.K.S., E.C.L.); Interpretation of
   data (J.K.S., D.W.C.); Preparation of manuscript (J.K.S.); Review of
   manuscript (D.W.C., E.C.L.); and Approval of manuscript (J.K.S., D.W.C.,
   E.C.L.). The data were obtained under and adhered to the requirements of
   the Data Use Agreement. No data were identifiable, thus institutional
   review board approval was not required.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Bernstein PS, 2009, ACTA HORTIC, V841, P103
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chia EM, 2003, BRIT J OPHTHALMOL, V87, P392, DOI 10.1136/bjo.87.4.392
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Halpern MT, 2006, HEALTH CARE FINANC R, V27, P37
   Ke KM, 2010, EUR J HEALTH ECON, V11, P525, DOI 10.1007/s10198-009-0207-9
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Macular Degeneration Partnership, WHAT IS AMD
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Schmier JK, 2006, DISABIL REHABIL, V28, P1331, DOI 10.1080/09638280600621436
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Sunness JS, 1999, MOL VIS, V5
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 37
TC 20
Z9 21
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2012
VL 154
IS 4
BP 675
EP 681
DI 10.1016/j.ajo.2012.04.017
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 018UK
UT WOS:000309691800008
PM 22835513
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Ong, PG
   Neelam, K
   Tan, PC
   Shi, Y
   Mitchell, P
   Wang, JJ
   Sabanayagam, C
   Cheng, CY
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Ong, Peng Guan
   Neelam, Kumari
   Tan, Pok Chien
   Shi, Yuan
   Mitchell, Paul
   Wang, Jie Jin
   Sabanayagam, Charumathi
   Cheng, Ching-Yu
   Wong, Tien Yin
TI Six-Year Incidence of Age-Related Macular Degeneration in Asian Malays
SO OPHTHALMOLOGY
LA English
DT Article
ID 5-YEAR INCIDENCE; SEVERITY SCALE; RISK-FACTORS; EYE DISEASE; 10-YEAR
   INCIDENCE; MACULOPATHY; SINGAPORE; PROGRESSION; POPULATION; PREVALENCE
AB Purpose: To determine the 6-year incidence of early and late age-related macular degeneration (AMD) in a Singaporean Malay population and to validate the Age-Related Eye Disease Study (AREDS) simplified severity scale in Asians.
   Design: Prospective, population cohort study.
   Participants: The Singapore Malay Eye Study baseline participants (age, >= 40 years; 2006-2008) were followed up in 2011 through 2013, and 1901 of 3280 of eligible participants (72.1%) took part.
   Methods: Fundus photographs were graded using the Wisconsin AMD grading system. Main Outcome Measures: Incidence of early and late AMD.
   Results: Gradable fundus photographs were available for 1809 participants who attended both baseline and 6-year follow-up examinations. The age-standardized incidences of early and late AMD were 5.89% (95% confidence interval [CI], 4.81-7.16) and 0.76% (95% CI, 0.42-1.29), respectively. The 5-year age-standardized incidence of early AMD (calculated based on the 6-year incidence) was lower in our population (5.58%; 95% CI, 4.43-7.01) compared with the Beaver Dam Eye Study population (8.19%). The incidence of late AMD in our population was similar to that of the Beaver Dam Eye Study population (0.98% [95% CI, 0.49-1.86] vs. 0.91%), the Blue Mountains Eye Study population (1.10% [95% CI, 0.52-9.56] vs. 1.10%), and the Hisayama Study population (1.09% [95% CI, 0.54-4.25] vs. 0.84%). The incidence of late AMD increased markedly with increasing baseline AREDS score (step 0, 0.23%; step 4, 9.09%).
   Conclusions: This study documented the incidence of early and late AMD in a Malay population. The AREDS simplified severity scale is useful in predicting the risk of late AMD development in Asians. (C) 2017 by the American Academy of Ophthalmology.
C1 [Cheung, Chui Ming Gemmy; Sabanayagam, Charumathi; Cheng, Ching-Yu; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Ong, Peng Guan; Neelam, Kumari; Tan, Pok Chien; Shi, Yuan; Sabanayagam, Charumathi; Cheng, Ching-Yu; Wong, Tien Yin] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Sabanayagam, Charumathi; Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Singapore, Dept Ophthalmol, Singapore, Singapore.
   [Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Sydney, NSW, Australia.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   University of Sydney
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM wong.tien.yin@singhealth.com.sg
RI Cheng, Ching-Yu/Y-2229-2019; Mitchell, Paul/P-1498-2014; Wang, Jie
   Jin/P-1499-2014; Wong, Tien Yin/AAC-9724-2020; Sabanayagam,
   Charumathi/C-1294-2011; wang, jie/GRS-0942-2022
OI Cheng, Ching-Yu/0000-0003-0655-885X; Wang, Jie Jin/0000-0001-9491-4898;
   Wong, Tien Yin/0000-0002-8448-1264; Sabanayagam,
   Charumathi/0000-0002-4042-4719; Cheung, Chui Ming
   Gemmy/0000-0003-3358-3516
FU National Medical Research Council, Singapore, Republic of Singapore
   [0796/2003]; Biomedical Research Council, Singapore, Republic of
   Singapore [501/25-5]
FX Supported by the National Medical Research Council, Singapore, Republic
   of Singapore (grant no.: 0796/2003); and the Biomedical Research
   Council, Singapore, Republic of Singapore (grant no.: 501/25-5).
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   Cheung CMG, 2016, JAMA OPHTHALMOL, V134, P1047, DOI 10.1001/jamaophthalmol.2016.2407
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Chin YC, 2014, OPHTHAL EPIDEMIOL, V21, P224, DOI 10.3109/09286586.2014.926941
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Joachim N, 2014, INVEST OPHTH VIS SCI, V55, P4421, DOI 10.1167/iovs.14-14476
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lavanya R, 2010, INVEST OPHTH VIS SCI, V51, P6247, DOI 10.1167/iovs.10-5229
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Rosman M, 2012, CLIN EXP OPHTHALMOL, V40, P557, DOI 10.1111/j.1442-9071.2012.02763.x
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Vitale S, 2016, JAMA OPHTHALMOL, V134, P1041, DOI 10.1001/jamaophthalmol.2016.2383
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 35
TC 24
Z9 24
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2017
VL 124
IS 9
BP 1305
EP 1313
DI 10.1016/j.ophtha.2017.03.056
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FD8RT
UT WOS:000407792500015
PM 28501376
OA Bronze
DA 2022-11-30
ER

PT J
AU Sabeti, F
   James, AC
   Essex, RW
   Maddess, T
AF Sabeti, Faran
   James, Andrew C.
   Essex, Rohan W.
   Maddess, Ted
TI Multifocal pupillography identifies retinal dysfunction in early
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Multifocal; Objective perimetry; Pupils; Age-related macular
   degeneration
ID CENTRAL VISUAL-FIELD; 5-YEAR INCIDENCE; DARK-ADAPTATION; FELLOW EYE;
   MACULOPATHY; SENSITIVITY; DRUSEN; PERIMETRY; MICROPERIMETRY;
   ABNORMALITIES
AB Early age-related macular degeneration (AMD) is common among the elderly. While only a small number progress to sight-threatening stages of AMD, identifying prognostic functional markers remains paramount. Here, we objectively evaluate retinal function in patients with large drusen by multifocal pupillographic objective perimetry (mfPOP). Different temporal presentation rates and luminances were compared to optimize parameters for high signal to noise ratios (SNR) and diagnosticity for early AMD.
   Pupil responses were recorded from 19 early AMD patients (30 eyes) and 29 age-matched control subjects. We compared a luminance-balanced stimulus ensemble and two unbalanced stimulus variants, each consisting of 44 independent stimulus regions per eye extending from fixation to 15Ee eccentricity. Video cameras recorded pupil responses for each eye under infrared illumination. The amplitudes and delays of the peak responses were analysed by multivariate linear models. The diagnostic accuracy of the stimulus variants was compared using areas under the curve (AUC) of receiver operator characteristic (ROC) plots.
   Early AMD eyes differed significantly from normal in their mean constriction amplitudes (-2.22 +/- 0.15 dB, t = -14.8) and delays (17.92 +/- 1.2 ms, t = 14.9). The brightest stimulus ensembles produced the highest median SNRs of 3.45 z-score units; however, the balanced method was found to be the most diagnostic. AUC values of 0.95 +/- 0.03 (mean +/- SE) for early AMD were obtained when the asymmetry of response amplitudes between eyes was considered.
   The mfPOP responses of early AMD eyes showed significant abnormality in response amplitudes and peak time. The ROC AUCs of 95 % suggest that mfPOP is a sensitive tool for detecting early abnormalities in AMD and longitudinal studies measuring progression of retinal dysfunction are warranted.
C1 [Sabeti, Faran; James, Andrew C.; Essex, Rohan W.; Maddess, Ted] Australian Natl Univ, John Curtin Sch Med Res, ARC Ctr Excellence Vis Sci, Canberra, ACT 0200, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Dept Ophthalmol, Canberra Hosp, Canberra, ACT, Australia.
C3 Australian National University; John Curtin School of Medical Research;
   Australian National University; Canberra Hospital
RP Sabeti, F (通讯作者)，Australian Natl Univ, John Curtin Sch Med Res, ARC Ctr Excellence Vis Sci, Bldg 131,Garran Rd, Canberra, ACT 0200, Australia.
EM faran.sabeti@anu.edu.au
RI Maddess, Teddy L/A-3200-2008; James, Andrew C/C-9307-2009; Sabeti,
   Faran/AAR-1767-2021
OI Maddess, Teddy L/0000-0003-4591-3658; James, Andrew
   C/0000-0002-2447-8549; Essex, Rohan/0000-0001-5323-0334; SABETI,
   Faran/0000-0001-9187-7569
FU Australian Research Council (ARC) through the ARC Centre of Excellence
   in Vision Science [CE0561903]; AusIndustry; Seeing Machines Ltd,
   Canberra
FX Financial Support: Australian Research Council (ARC) through the ARC
   Centre of Excellence in Vision Science (CE0561903), AusIndustry, and
   Seeing Machines Ltd, Canberra.
CR Bell A, 2010, INVEST OPHTH VIS SCI, V51, P602, DOI 10.1167/iovs.09-3659
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Egan J.P., 1975, SIGNAL DETECTION THE
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Hong S, 2001, INVEST OPHTH VIS SCI, V42, P957
   Hood DC, 1998, VISION RES, V38, P163, DOI 10.1016/S0042-6989(97)00143-0
   Ivers RQ, 2001, OPHTHALMOLOGY, V108, P968, DOI 10.1016/S0161-6420(00)00649-7
   James AC, 2005, VISUAL NEUROSCI, V22, P45, DOI 10.1017/S0952523805221053
   James AC, 2012, J GLAUCOMA, V21, P571, DOI 10.1097/IJG.0b013e31821e8413
   Kardon R, 2009, OPHTHALMOLOGY, V116, P1564, DOI 10.1016/j.ophtha.2009.02.007
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kolic M, 2009, ATTEMPTING BALANCED, P5280
   Maddess T, 2011, J GLAUCOMA, V20, P336, DOI 10.1097/IJG.0b013e3181efb097
   Maddess T, 2009, CLIN EXP OPHTHALMOL, V37, P678, DOI 10.1111/j.1442-9071.2009.02107.x
   Maddess TL, 2009, BALANCED LUMINANCE M
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Rosli Y, 2012, VISION RES, V69, P42, DOI 10.1016/j.visres.2012.07.019
   Sabeti F, 2012, INVEST OPHTH VIS SCI, V53, P253, DOI 10.1167/iovs.11-8004
   Sabeti F, 2011, OPTOMETRY VISION SCI, V88, P1477, DOI 10.1097/OPX.0b013e318235af61
   Sabeti F, 2011, VISION RES, V51, P303, DOI 10.1016/j.visres.2010.10.015
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   Takamine Y, 1998, GRAEF ARCH CLIN EXP, V236, P285, DOI 10.1007/s004170050079
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
NR 34
TC 13
Z9 13
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2013
VL 251
IS 7
BP 1707
EP 1716
DI 10.1007/s00417-013-2273-z
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 164CP
UT WOS:000320386700008
PM 23392820
DA 2022-11-30
ER

PT J
AU Marcus, DM
   Sheils, WC
   Young, JO
   McIntosh, SB
   Johnson, MH
   Alexander, J
   Samy, CN
AF Marcus, DM
   Sheils, WC
   Young, JO
   McIntosh, SB
   Johnson, MH
   Alexander, J
   Samy, CN
TI Radiotherapy for recurrent choroidal neovascularisation complicating age
   related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PROTON-BEAM IRRADIATION; RADIATION-THERAPY; TELETHERAPY; TRIAL;
   MEMBRANES
AB Aims: To report the safety and visual outcome data of external beam irradiation for recurrent choroidal neovascularisation complicating age related macular degeneration.
   Methods: Eighteen consecutive eyes received external beam irradiation with seven fractions of 2 Gy ( total dose 14 Gy). The next 16 consecutive eyes received external beam irradiation with five fractions of 3 Gy ( total dose 15 Gy). Main outcome measure was change in visual acuity. Secondary outcome variables were contrast sensitivity and fundus photographic/fluorescein angiographic progression.
   Results: The 3 Gy fraction group lost fewer lines of distance visual acuity at the three and six month follow up. At one year follow up, this difference was not maintained with 2 Gy fraction and 3 Gy fraction eyes. At one year follow up a decrease in visual acuity of three or more lines ( moderate visual loss) occurred in 58% of 2 Gy and 42% of 3 Gy fraction eyes (p< 0.36). At one year follow up a decrease in visual acuity of six or more lines ( severe visual loss) occurred in 41% of 2 Gy eyes and 17% of 3 Gy eyes (p< 0.23). At three months follow up, 3 Gy eyes were less likely (0%) than 2 Gy eyes (47%) to show moderate visual loss (p< 0.003). However, Kaplan Meier curves estimate a significantly lower rate of severe visual loss in the 3 Gy group ( p = 0.02). There were no significant differences in contrast sensitivity loss or fluorescein angiographic stabilisation rates. No evidence of radiation toxicity was observed.
   Conclusion: Our results are consistent with trends for a palliative benefit with higher fraction sizes and doses. The radiobiologic differences between low and high fraction size groups in this study are modest and correlate with the modest and short term difference in visual outcomes. These trends support further investigation of radiotherapy using fraction sizes of 4 Gy or higher.
C1 Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA.
   Med Coll Georgia, Dept Radiol, Sect Radiat Oncol, Augusta, GA 30912 USA.
   Med Coll Georgia, Off Biostat, Augusta, GA 30912 USA.
   Univ Penn Hlth Syst, Dept Ophthalmol, Philadelphia, PA USA.
   Ocala Eye Surg, Ocala, FL USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; University System of Georgia; Augusta
   University; University of Pennsylvania
RP Marcus, DM (通讯作者)，Med Coll Georgia, Dept Ophthalmol, 1120 15th St, Augusta, GA 30912 USA.
EM dmarcus@mail.mcg.edu
CR [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BERGINK GJ, 1995, DOC OPHTHALMOL, V90, P67, DOI 10.1007/BF01203296
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   D'Hollander F, 1998, Bull Soc Belge Ophtalmol, V270, P27
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Freire J, 1996, INT J RADIAT ONCOL, V36, P857, DOI 10.1016/S0360-3016(96)00428-2
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Holz FG, 1997, FRONT RADIAT THER ON, V30, P238
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   *MAC PHOT STUD GRO, 1991, ARCH OPHTHALMOL-CHIC, V170, P1232
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   MAGUIRE MG, 1995, ARCH OPHTHALMOL-CHIC, V113, P190
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SORENSON JA, 1985, OPHTHALMOLOGY, V92, P1059
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
NR 31
TC 10
Z9 11
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN 1
PY 2004
VL 88
IS 1
BP 114
EP 119
DI 10.1136/bjo.88.1.114
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 757EG
UT WOS:000187535400031
PM 14693787
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Mergen, B
   Ramsey, DJ
AF Mergen, Burak
   Ramsey, David J.
TI Underdiagnosis of glaucoma in patients with exudative age-related
   macular degeneration
SO EYE
LA English
DT Article
AB Objective To compare the rate of glaucoma-related diagnoses in patients with exudative or non-exudative age-related macular degeneration (AMD). Methods Patients above the age of 55 with a diagnosis of AMD were identified from billing records from 2015 to 2018. Out of the 3991 patients with AMD, two cohorts with 990 patients in each were formed by randomly age-matching patients with exudative AMD with those with non-exudative AMD; patients within each group were further classified by subtype and severity of glaucoma. Charts of AMD patients without glaucoma-related diagnoses were reviewed to determine potential underdiagnosis. We applied a set of broad clinical criteria that comprised an intraocular pressure >= 22 mmHg, a cup-to-disc ratio (CDR) >= 0.6, and/or CDR difference between eyes of >= 0.2. Results The rate of diagnosed, open-angle glaucoma was significantly lower in patients with exudative AMD (6.06%) compared to patients with non-exudative AMD (8.99%, P = 0.04). Similarly, the rate of suspected glaucoma was significantly lower in the first group compared to the second (12.12% versus 18.48%, respectively, P < 0.001). A greater number of patients with exudative AMD (13.94%, n = 138) met clinical risk criteria compared with those having non-exudative AMD (6.97%, n = 69, P < 0.001). When these at-risk patients were added to their respective groups, the rate of glaucoma, or its suspicion, became similar (chi(2) = 1.24, P = 0.539). Conclusions A significantly lower rate of diagnosed glaucoma, or its suspicion, was identified in patients with exudative compared to non-exudative AMD. This apparent underdiagnosis was resolved by the retrospective application of clinical criteria that may represent a risk of glaucoma.
C1 [Mergen, Burak] Univ Hlth Sci, Basaksehir Cam & Sakura City Hosp, Dept Ophthalmol, TR-34480 Istanbul, Turkey.
   [Mergen, Burak; Ramsey, David J.] Lahey Hosp & Med Ctr, Dept Ophthalmol, 1 Essex Ctr Dr, Peabody, MA 01960 USA.
   [Ramsey, David J.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Lahey Hospital & Medical Center; Tufts University
RP Ramsey, DJ (通讯作者)，Lahey Hosp & Med Ctr, Dept Ophthalmol, 1 Essex Ctr Dr, Peabody, MA 01960 USA.; Ramsey, DJ (通讯作者)，Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
EM David.J.Ramsey@lahey.org
RI Ramsey, David/AAW-2081-2021; Mergen, Burak/P-2950-2018
OI Ramsey, David/0000-0002-5504-812X; Mergen, Burak/0000-0002-8132-495X
FU Association for Research in Vision and Ophthalmology (ARVO) under a
   fellowship program (Developing Country Eye Researcher Travel
   Fellowship); Harry N. Lee Family Chair in Innovation, Lahey Hospital &
   Medical Center, Beth Israel Lahey Health, Peabody, MA
FX BM was supported by Association for Research in Vision and Ophthalmology
   (ARVO) to attend the 2020 annual meeting under a fellowship program
   (Developing Country Eye Researcher Travel Fellowship). DJR was supported
   by the Harry N. Lee Family Chair in Innovation, Lahey Hospital & Medical
   Center, Beth Israel Lahey Health, Peabody, MA.
CR Ali FS, 2009, OPHTHALMOLOGY, V116, P1232, DOI 10.1016/j.ophtha.2008.12.034
   Atchison EA, 2018, OPHTHALMOLOGY, V125, P676, DOI 10.1016/j.ophtha.2017.11.027
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Bearelly S, 2008, ARCH OPHTHALMOL-CHIC, V126, P986, DOI 10.1001/archopht.126.7.986
   Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Cui QN, 2019, GRAEF ARCH CLIN EXP, V257, P1931, DOI 10.1007/s00417-019-04362-7
   European Glaucoma Society, 2014, TERMINOLOGY GUIDELIN, V4th ed
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Fortune B, 2007, INVEST OPHTH VIS SCI, V48, P1173, DOI 10.1167/iovs.06-0561
   Foss AJE, 2016, BRIT J OPHTHALMOL, V100, P1662, DOI 10.1136/bjophthalmol-2015-307595
   Freund KB, 2015, OPHTHALMOLOGY, V122, P1802, DOI 10.1016/j.ophtha.2015.04.018
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gedde SJ, OPHTHALMOLOGY
   Gupta P, 2016, INVEST OPHTH VIS SCI, V57, P2905, DOI 10.1167/iovs.15-18469
   Haddock LJ, 2014, SEMIN OPHTHALMOL, V29, P257, DOI 10.3109/08820538.2014.959616
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hu CC, 2017, EYE, V31, P872, DOI 10.1038/eye.2016.325
   Iijima Hiroyuki, 2016, Nippon Ganka Gakkai Zasshi, V120, P190
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Leung EW, 2008, J GLAUCOMA, V17, P350, DOI 10.1097/IJG.0b013e31815c5f4f
   Lloyd MJ, 2013, J GLAUCOMA, V22, P343, DOI 10.1097/IJG.0b013e31824c9251
   Moraru Andreea, 2017, Rom J Ophthalmol, V61, P207
   Newman DK, 1998, EYE, V12, P921, DOI 10.1038/eye.1998.239
   Nwosu SNN, 2011, NIGER J CLIN PRACT, V14, P327, DOI 10.4103/1119-3077.86778
   Qiu M, 2017, OPHTHALMOLOGY, V124, P1229, DOI 10.1016/j.ophtha.2017.03.049
   Quillen DA, 1999, AM FAM PHYSICIAN, V60, P99
   Ramsey DJ, 2014, SEMIN OPHTHALMOL, V29, P263, DOI 10.3109/08820538.2014.959195
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 32
TC 2
Z9 2
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2021
VL 35
IS 12
BP 3350
EP 3357
DI 10.1038/s41433-021-01417-0
EA FEB 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XA1VU
UT WOS:000614314300002
PM 33536592
DA 2022-11-30
ER

PT J
AU Malamos, P
   Tsolkas, G
   Kanakis, M
   Mylonas, G
   Karatzenis, D
   Oikonomopoulos, N
   Lakoumentas, J
   Georgalas, I
AF Malamos, P.
   Tsolkas, G.
   Kanakis, M.
   Mylonas, G.
   Karatzenis, D.
   Oikonomopoulos, N.
   Lakoumentas, J.
   Georgalas, Ilias
TI OCT-Angiography for monitoring and managing neovascular age-related
   macular degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE OCT Angiography; OCT-A; neovascular AMD; monitoring; treatment
ID OPTICAL COHERENCE TOMOGRAPHY; AMPLITUDE-DECORRELATION ANGIOGRAPHY;
   CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY
AB Purpose: To evaluate the combined use of optical coherence tomography and angiography (OCT-A) for imaging choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD).
   Materials and Methods: This prospective observational study was conducted from May 2015 to April 2017. Included in the study were 54 patients (n = 63 eyes), all of whom had CNV secondary to nAMD and all of whom had been examined by OCT-A. Angioscans (3x3 and 6 x 6) and conventional B-scan OCT scans were obtained for all patients at baseline and at various times during the 24-month follow-up period. For diagnostic confirmation, conventional imaging methods fluorescein angiography (FA) and indocyanine green angiography (ICGA) were performed at baseline. A total of 13 patients (n = 15 eyes) underwent serial imaging during 34 follow-up visits. The main outcomes included (i) determination of OCT-A sensitivity for the detection of CNV (classic and occult) and (ii) the correlation between B-scan OCT and OCT-A vis-a-vis consecutive follow-up changes.
   Results: At baseline, the detection rate (i.e., overall sensitivity) of OCT-A for detecting CNV was 64.4% (75.7 and 48.0% for classic and occult CNV, respectively), independent of prior treatment status. In terms of quality, 6 x 6 angioscans were superior to 3 x 3. Moreover, specific CNV morphologic patterns by B-scan OCT did not correlate with lesion composition. Correspondence between OCT-A and B-scan OCT was observed in only 53% of the cases.
   Conclusions: OCT-A may prove to be a valuable adjunctive diagnostic tool for the interpretation of CNV, as it not only reduces the need for invasive angiographic procedures but also facilitates the follow-up process.
C1 [Malamos, P.; Tsolkas, G.; Karatzenis, D.; Oikonomopoulos, N.] Ypapanti Eye Clin, Retina & Macula Serv, Athens, Greece.
   [Kanakis, M.; Georgalas, Ilias] Univ Athens, G Genimatas Gen Hosp Athens, Univ Eye Clin 1, Med Sch, Athens, Greece.
   [Mylonas, G.] Acad Teaching Hosp St John God, Dept Ophthalmol, Vienna, Austria.
   [Lakoumentas, J.] Univ Patras, Sch Med, Dept Med Phys, Rion, Greece.
C3 National & Kapodistrian University of Athens; University of Patras
RP Georgalas, I (通讯作者)，Univ Athens, G Genimatas Gen Hosp Athens, Univ Eye Clin 1, Med Sch, Athens, Greece.
EM igeorgalas@yahoo.com
RI Georgalas, Ilias/AAD-5946-2019; Kanakis, Menelaos/Z-4185-2019
OI Georgalas, Ilias/0000-0002-6171-5865; Lakoumentas,
   John/0000-0003-0869-736X
CR Ahlers C, 2006, GRAEF ARCH CLIN EXP, V244, P1233, DOI 10.1007/s00417-006-0418-z
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Castillo MM, 2014, EYE, V28, P1399, DOI 10.1038/eye.2014.214
   Coscas G., 2005, ATLAS INDOCYANINE GR
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Fujita K, 2015, OPHTHALMOLOGY, V122, P555, DOI 10.1016/j.ophtha.2014.09.034
   Fukuchi T, 2001, GRAEF ARCH CLIN EXP, V239, P424, DOI 10.1007/s004170100296
   Gao SS, 2015, OPT LETT, V40, P2305, DOI 10.1364/OL.40.002305
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Hawkins BS, 1999, MOL VIS, V5
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   Ko TH, 2005, OPHTHALMOLOGY, pe1921
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Marques JP, 2016, OPHTHALMIC RES, V55, P145, DOI 10.1159/000442671
   Mastropasqua R, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/343515
   Meyer CH, 2008, OPHTHALMOLOGE, V1052, P140
   Muscat S, 2002, INVEST OPHTH VIS SCI, V43, P490
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Schmidt-Erfurth U, 2007, INVEST OPHTH VIS SCI, V48, P1751, DOI 10.1167/iovs.06-0686
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Shaimov T B, 2015, Vestn Oftalmol, V131, P4, DOI 10.17116/oftalma201513154-12
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 32
TC 12
Z9 12
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2017
VL 42
IS 12
BP 1689
EP 1697
DI 10.1080/02713683.2017.1356336
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FT0XR
UT WOS:000422853400019
PM 28937833
DA 2022-11-30
ER

PT J
AU Ladewig, MS
   Ladewig, K
   Guner, M
   Heidrich, H
AF Ladewig, MS
   Ladewig, K
   Guner, M
   Heidrich, H
TI Prostaglandin E-1 infusion therapy in dry age-related macular
   degeneration
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
ID ARTERIAL OCCLUSIVE DISEASE; STAGE-IV; CHORIOCAPILLARIS; MACULOPATHY;
   MEMBRANE; TRIAL; PGE1
AB Objective: The pilot study is intended to show whether prostaglandin E-1 (PGE(1)) infusions are able to stop the gradual vision loss in dry age-related macular degeneration (AMD) and, further, to stabilize or improve visual acuity.
   Methods: With PGE(1) infusions 11 patients with different forms of dry AMD were treated and compared with a control group of 10 untreated patients with dry AMD. The target parameter was the visual acuity, as determined with the ETDRS logMAR charts. Other examinations performed during the study were tests of contrast vision, colour vision and central visual fields, as well as autofluorescence and fluorescein angiography and multifocal electroretinography.
   Results: On termination of the infusions, six patients showed an increase in visual acuity by at least one line, an improvement that was seen in eight patients 2 months after the end of the infusion therapy. After 6 months, one patient exhibited an improvement of visual acuity by three lines and three patients an improvement by one line. Five patients were found to show no change of their baseline acuity values after 6 months, while two patients exhibited an impairment by one line. The visual acuity in the dry AMD control group without PGE(1) treatment had decreased by 0.8 lines on the average after 6 months. Contrast vision, central visual fields and the multifocal electroretinogram showed improvements on the termination of infusions and up to 2 months later; no substantial change of these parameters, as compared with the baseline findings, was seen 6 months after the termination of infusions.
   Summary: This pilot study suggests that PGE(1) infusions have a stabilizing or improving effect on the visual acuity of patients with dry AMD. Owing to the limitations of a pilot study, these results should, however, be validated in a larger, randomized and blinded study. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Franziskus Krankenhaus, Dept Internal Med, Berlin, Germany.
   Free Univ Berlin, Charite, Ophthalmol Clin, D-1000 Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin
RP Heidrich, H (通讯作者)，Franziskus Krankenhaus, Dept Internal Med, Berlin, Germany.
EM prof.heidrich@web.de
CR ALTSTAEDT HO, 1993, PROSTAG LEUKOTR ESS, V49, P573, DOI 10.1016/0952-3278(93)90163-Q
   *ARZN DTSCH ARZT, 2003, EMPF THER PER ART VE, P2
   BOHME H, 1989, MED WELT, V40, P1501
   Diehm C, 1988, PROSTAGLANDIN E1 WIR, P133
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   FERRIS FL, 1994, AM J OPHTHALMOL, P91
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Gass JD, 1967, AM J OPHTHALMOL S, V63, P1
   HEIDRICH H, 1989, KLIN MONATSBL AUGENH, V194, P282, DOI 10.1055/s-2008-1046371
   Heidrich H, 1994, INT J ANGIOLOGY, V3, P160
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   MELROSE MA, 1987, ANN OPHTHALMOL, V19, P396
   OLVER J, 1990, Investigative Ophthalmology and Visual Science, V31, P47
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Perry CM, 2003, DRUG AGING, V20, P597, DOI 10.2165/00002512-200320080-00005
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Scheider A, 1992, Ger J Ophthalmol, V1, P328
   Schmidt-Erfurth U, 2001, OPHTHALMOLOGE, V98, P216, DOI 10.1007/s003470170189
   Schror K, 2004, VASA-J VASCULAR DIS, V33, P119, DOI 10.1024/0301-1526.33.3.119
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Seeliger MW, 2001, OPHTHALMOLOGE, V98, P1112, DOI 10.1007/s003470170036
   Stiegler H, 1992, Vasa Suppl, V35, P164
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   TRUBESTEIN G, 1987, DEUT MED WOCHENSCHR, V112, P955, DOI 10.1055/s-2008-1068174
   Trubestein G, 1989, Vasa Suppl, V28, P44
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Whitson Jess T, 2002, Expert Opin Pharmacother, V3, P965, DOI 10.1517/14656566.3.7.965
NR 34
TC 8
Z9 20
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0952-3278
EI 1532-2823
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD APR
PY 2005
VL 72
IS 4
BP 251
EP 256
DI 10.1016/j.plefa.2004.11.006
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
GA 910EL
UT WOS:000227913000004
PM 15763436
DA 2022-11-30
ER

PT J
AU Pamphlett, R
   Cherepanoff, S
   Too, LK
   Jew, SK
   Doble, PA
   Bishop, DP
AF Pamphlett, Roger
   Cherepanoff, Svetlana
   Too, Lay Khoon
   Kum Jew, Stephen
   Doble, Philip A.
   Bishop, David P.
TI The distribution of toxic metals in the human retina and optic nerve
   head: Implications for age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID PIGMENT EPITHELIUM; SYSTEMIC EXPOSURE; MERCURY-VAPOR; MECHANISMS; LEAD;
   CADMIUM; ACCUMULATION; GENOTOXICITY; TRANSPORT; ELEMENTS
AB Objective
   Toxic metals are suspected to play a role in the pathogenesis of age-related macular degeneration. However, difficulties in detecting the presence of multiple toxic metals within the intact human retina, and in separating primary metal toxicity from the secondary uptake of metals in damaged tissue, have hindered progress in this field. We therefore looked for the presence of several toxic metals in the posterior segment of normal adult eyes using elemental bioimaging.
   Methods
   Paraffin sections of the posterior segment of the eye from seven tissue donors (age range 54-74 years) to an eye bank were examined for toxic metals in situ using laser ablation-inductively coupled plasma-mass spectrometry, a technique that detects multiple elements in tissues, as well as the histochemical technique of autometallography that demonstrates inorganic mercury, silver, and bismuth. No donor had a visual impairment, and no significant retinal abnormalities were seen on post mortem fundoscopy and histology.
   Results
   Metals found by laser ablation-inductively coupled plasma-mass spectrometry in the retinal pigment epithelium and choriocapillaris were lead (n = 7), nickel (n = 7), iron (n = 7), cadmium (n = 6), mercury (n = 6), bismuth (n = 5), aluminium (n = 3), and silver (n = 1). In the neural retina, mercury was present in six samples, and iron in one. Metals detected in the optic nerve head were iron (N = 7), mercury (N = 7), nickel (N = 4), and aluminium (N = 1). No gold or chromium was seen. Autometallography demonstrated probable inorganic mercury in the retinal pigment epithelium of one donor.
   Conclusion
   Several toxic metals are taken up by the human retina and optic nerve head. Injury to the retinal pigment epithelium from toxic metals could damage the neuroprotective functions of the retinal pigment epithelium and allow toxic metals to enter the outer neural retina. These findings support the hypothesis that accumulations of toxic metals in the retina could contribute to the pathogenesis of age-related macular degeneration.
C1 [Pamphlett, Roger; Kum Jew, Stephen] Univ Sydney, Discipline Pathol, Sch Med Sci, Brain & Mind Ctr, Sydney, NSW, Australia.
   [Pamphlett, Roger; Cherepanoff, Svetlana] Royal Prince Alfred Hosp, Dept Neuropathol, Sydney, NSW, Australia.
   [Cherepanoff, Svetlana] St Vincents Hosp, Sydpath, Sydney, NSW, Australia.
   [Cherepanoff, Svetlana] Univ New South Wales, St Vincents Clin Sch, Sydney, NSW, Australia.
   [Too, Lay Khoon] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.
   [Doble, Philip A.; Bishop, David P.] Univ Technol Sydney, Sch Math & Phys Sci, Elemental Bioimaging Facil, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; St Vincents Hospital Sydney;
   University of New South Wales Sydney; University of Sydney; University
   of Technology Sydney
RP Pamphlett, R (通讯作者)，Univ Sydney, Discipline Pathol, Sch Med Sci, Brain & Mind Ctr, Sydney, NSW, Australia.; Pamphlett, R (通讯作者)，Royal Prince Alfred Hosp, Dept Neuropathol, Sydney, NSW, Australia.
EM roger.pamphlett@sydney.edu.au
RI Too, Lay Khoon/L-2653-2018; Bishop, David/F-2891-2019
OI Too, Lay Khoon/0000-0002-5340-5744; Bishop, David/0000-0002-6533-4410;
   Pamphlett, Roger/0000-0003-3326-7273
FU Aimee Stacy Memorial and Ignacy Burnett bequests; Australian Research
   Council [DP170100036, DP190102361, DE180100194]; National Institute of
   Health [R21AR072950]
FX No specific funding for this project was received. RP is supported by
   the Aimee Stacy Memorial and Ignacy Burnett bequests. PAD is supported
   by Australian Research Council Discovery Project Grants DP170100036 and
   DP190102361. DPB is supported by an Australian Research Council
   Discovery Early Career Researcher Award DE180100194. PAD and DPB are
   supported by a National Institute of Health Grant R21AR072950. LKT was
   supported by Doctors Shirley and John Sarks. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aberami S, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107718
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Andrade V M, 2017, Adv Neurobiol, V18, P227, DOI 10.1007/978-3-319-60189-2_12
   Bilak S, 2019, HUM EXP TOXICOL, V38, P814, DOI 10.1177/0960327119842637
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bridges CC, 2007, TOXICOL APPL PHARM, V221, P251, DOI 10.1016/j.taap.2007.03.004
   BRUININK A, 1992, TOXICOL IN VITRO, V6, P285, DOI 10.1016/0887-2333(92)90018-M
   Cameron Keyuna S., 2011, Reviews on Environmental Health, V26, P81, DOI 10.1515/REVEH.2011.012
   Cherepanoff S, 2018, INVEST OPHTH VIS SCI, V59
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Clarkson TW, 2002, ENVIRON HEALTH PERSP, V110, P11, DOI 10.1289/ehp.02110s111
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Crespo-Lopez ME, 2009, PHARMACOL RES, V60, P212, DOI 10.1016/j.phrs.2009.02.011
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Danscher G, 2000, J HISTOCHEM CYTOCHEM, V48, P1503, DOI 10.1177/002215540004801107
   DANSCHER G, 1994, NEUROPATH APPL NEURO, V20, P454, DOI 10.1111/j.1365-2990.1994.tb00996.x
   Eichenbaum JW, 2000, J TOXICOL-CLIN TOXIC, V38, P377, DOI 10.1081/CLT-100100946
   Ekinci M, 2014, MED SCI MONITOR, V20, P1284, DOI 10.12659/MSM.890756
   El-Sherbeeny AM, 2006, CUTAN OCUL TOXICOL, V25, P173, DOI 10.1080/15569520600860215
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Expert Panel on Women's I, 2018, J AM COLL RADIOL, V15, pS365, DOI DOI 10.1016/J.JACR.2018.09.023
   Gaillet S, 2015, FOOD CHEM TOXICOL, V77, P58, DOI 10.1016/j.fct.2014.12.019
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hosoya K, 2013, ADV EXP MED BIOL, V763, P85
   HUTTON M, 1986, SCI TOTAL ENVIRON, V57, P129, DOI 10.1016/0048-9697(86)90018-5
   Jonas JB, 2003, INVEST OPHTH VIS SCI, V44, P5189, DOI 10.1167/iovs.03-0174
   Keizman D, 2017, CANCER EPIDEM BIOMAR, V26, P743, DOI 10.1158/1055-9965.EPI-16-0759
   KHAYAT A, 1984, ACTA PHARMACOL TOX, V55, P145
   Khayat A, 1983, J APPL TOXICOL, V3, P66, DOI 10.1002/jat.2550030203
   Kim Hyun Soo, 2015, J Cancer Prev, V20, P232, DOI 10.15430/JCP.2015.20.4.232
   Klotz K, 2017, DTSCH ARZTEBL INT, V114, P653, DOI 10.3238/arztebl.2017.0653
   Lin SY, 2017, ANN ONCOL, V28, P2575, DOI 10.1093/annonc/mdx402
   Lin SY, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050902
   Mackenzie PJ, 2008, CAN J OPHTHALMOL, V43, P308, DOI 10.3129/i08-042
   MANDYBUR TI, 1979, TOXICOL APPL PHARM, V50, P163, DOI 10.1016/0041-008X(79)90504-0
   Mao BH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20728-z
   Mecklenburg L, 2007, TOXICOL PATHOL, V35, P252, DOI 10.1080/01926230601178199
   Pamphlett R, 1998, J NEUROPATH EXP NEUR, V57, P360
   Pamphlett R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228226
   Pamphlett R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220859
   Park Jung-Duck, 2012, J Prev Med Public Health, V45, P344, DOI 10.3961/jpmph.2012.45.6.344
   Park SJ, 2015, OPHTHALMOLOGY, V122, P129, DOI 10.1016/j.ophtha.2014.07.039
   POTTS AM, 1976, EXP EYE RES, V22, P487, DOI 10.1016/0014-4835(76)90186-X
   Rizzolo LJ, 2007, INT REV CYTOL, V258, P195, DOI 10.1016/S0074-7696(07)58004-6
   ROSS JF, 1994, TOXICOL APPL PHARM, V124, P191, DOI 10.1006/taap.1994.1023
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streets DG, 2011, ENVIRON SCI TECHNOL, V45, P10485, DOI 10.1021/es202765m
   Tchounwou PB., 2012, EXP S, V101, P133, DOI [10.1007/978-3-7643-8340-4_6, DOI 10.1007/978-3-7643-8340-4_6]
   Toimela TA, 2001, TOXICOL IN VITRO, V15, P7, DOI 10.1016/S0887-2333(00)00057-6
   Too LK, 2017, ACTA HISTOCHEM, V119, P142, DOI 10.1016/j.acthis.2016.12.003
   Tsolaki E, 2019, MATERIALS, V12, DOI 10.3390/ma12193126
   ULSHAFER RJ, 1990, ARCH OPHTHALMOL-CHIC, V108, P113, DOI 10.1001/archopht.1990.01070030119041
   van Elteren JT, 2018, ANAL CHEM, V90, P2896, DOI 10.1021/acs.analchem.7b05134
   Vas J, 2008, ANN NY ACAD SCI, V1143, P240, DOI 10.1196/annals.1443.022
   Warfvinge K, 1996, TOXICOLOGY, V107, P189, DOI 10.1016/0300-483X(95)03257-G
   Warfvinge K, 2000, ENVIRON RES, V83, P102, DOI 10.1006/enrs.1999.4029
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wu EW, 2014, ENVIRON RES, V133, P178, DOI 10.1016/j.envres.2014.05.023
   Wu XY, 2016, ENVIRON SCI POLLUT R, V23, P8244, DOI 10.1007/s11356-016-6333-x
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 62
TC 10
Z9 10
U1 2
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 29
PY 2020
VL 15
IS 10
AR e0241054
DI 10.1371/journal.pone.0241054
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA PG8YH
UT WOS:000600013600087
PM 33119674
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Pertl, L
   Kern, S
   Weger, M
   Hausberger, S
   Trieb, M
   Gasser-Steiner, V
   Haas, A
   Scharnagl, H
   Heinemann, A
   Marsche, G
AF Pertl, Laura
   Kern, Sabine
   Weger, Martin
   Hausberger, Silke
   Trieb, Markus
   Gasser-Steiner, Vanessa
   Haas, Anton
   Scharnagl, Hubert
   Heinemann, Akos
   Marsche, Gunther
TI High-Density Lipoprotein Function in Exudative Age-Related Macular
   Degeneration
SO PLOS ONE
LA English
DT Article
ID CHOLESTEROL EFFLUX CAPACITY; RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   GENETIC-VARIANTS; HDL; ATHEROSCLEROSIS; ASSOCIATION; PREVALENCE;
   METABOLISM; BIOLOGY
AB Purpose
   High-density lipoproteins (HDL) have long been implicated in the pathogenesis of age-related macular degeneration (AMD). However, conflicting results have been reported with regard to the associations of AMD with HDL-cholesterol levels. The present study is the first to assess HDL composition and metrics of HDL function in patients with exudative AMD and control patients.
   Methods
   Blood samples were collected from 29 patients with exudative AMD and 26 age-matched control patients. Major HDL associated apolipoproteins were determined in apoB-depleted serum by immunoturbidimetry or ELISA, HDL-associated lipids were quantified enzymatically. To get an integrated measure of HDL quantity and quality, we assessed several metrics of HDL function, including cholesterol efflux capacity, anti-oxidative and anti-inflammatory activities using apoB-depleted serum from study participants.
   Results
   In our study, we observed that the HDL associated acute phase protein serum amyloid A (SAA) was significantly increased in AMD patients (p<0.01), whereas all other assessed apolipoproteins including ApoA-I, apoA-II, apoC-II, apoC-III and apoE as well as major HDL associated lipids were not altered. HDL efflux capacity, anti-oxidative capacity and arylesterase activity were not different in AMD patients when compared with the control group. The ability of apoB-depleted serum to inhibit monocyte NF-kappa B expression was significantly improved in AMD patients (mean difference (MD) -5.6, p<0.01). Moreover, lipoprotein-associated phospholipase A2 activity, a marker of vascular inflammation, was decreased in AMD subjects (MD -24.1, p<0.01).
   Conclusions
   The investigated metrics of HDL composition and HDL function were not associated with exudative AMD in this study, despite an increased content of HDL associated SAA in AMD patients. Unexpectedly, anti-inflammatory activity of apoB-depleted serum was even increased in our study. Our data suggest that the investigated parameters of serum HDL function showed no significant association with exudative AMD. However, we cannot exclude that alterations in locally produced HDL may be part of the AMD pathogenesis.
C1 [Pertl, Laura; Weger, Martin; Hausberger, Silke; Gasser-Steiner, Vanessa; Haas, Anton] Med Univ Graz, Dept Ophthalmol, Graz, Austria.
   [Kern, Sabine; Trieb, Markus; Heinemann, Akos; Marsche, Gunther] Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria.
   [Scharnagl, Hubert] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria.
C3 Medical University of Graz; Medical University of Graz; Medical
   University of Graz
RP Marsche, G (通讯作者)，Med Univ Graz, Inst Expt & Clin Pharmacol, Graz, Austria.
EM gunther.marsche@medunigraz.at
OI Heinemann, Akos/0000-0002-8554-2372; Marsche,
   Gunther/0000-0002-2422-5381
FU Austrian Science Fund FWF (Fonds zur Forderung der wissenschaftlichen
   Forschung) [P22976-B18, W1241, P22521-B18]
FX Funding was provided by Austrian Science Fund FWF (Fonds zur Forderung
   der wissenschaftlichen Forschung): Grant P22976-B18 and W1241 to GM and
   P22521-B18 to A. Heinemann.
CR Artl A, 2000, ARTERIOSCL THROM VAS, V20, P763, DOI 10.1161/01.ATV.20.3.763
   BANKA CL, 1995, J LIPID RES, V36, P1058
   Birner-Gruenberger R, 2014, PROG LIPID RES, V56, P36, DOI 10.1016/j.plipres.2014.07.003
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   COETZEE GA, 1986, J BIOL CHEM, V261, P9644
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0090973, DOI 10.1371/journal.pone.0090973]
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grosjean J, 2006, BIOCHEM BIOPH RES CO, V340, P984, DOI 10.1016/j.bbrc.2005.12.095
   Holzer M, 2013, BBA-MOL CELL BIOL L, V1831, P1442, DOI 10.1016/j.bbalip.2013.06.004
   Holzer M, 2012, J LIPID RES, V53, P1618, DOI 10.1194/jlr.M027367
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Javadzadeh A, 2012, RETINA-J RET VIT DIS, V32, P658, DOI 10.1097/IAE.0b013e31822529b1
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Khera AV, 2011, NEW ENGL J MED, V364, P127, DOI 10.1056/NEJMoa1001689
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Li FT, 2014, OPHTHALMIC RES, V51, P210, DOI 10.1159/000357978
   Marsche G, 2013, PHARMACOL THERAPEUT, V137, P341, DOI 10.1016/j.pharmthera.2012.12.001
   Mulero J, 2014, CLIN HEMORHEOL MICRO, V58, P447, DOI 10.3233/CH-141807
   Oczos J, 2013, AGE, V35, P1651, DOI 10.1007/s11357-012-9467-x
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rohatgi A, 2014, NEW ENGL J MED, V371, P2383, DOI 10.1056/NEJMoa1409065
   Saemann MD, 2010, EUR J CLIN INVEST, V40, P1131, DOI 10.1111/j.1365-2362.2010.02361.x
   So\ugut E, 2013, RETINA, V33, P1836, DOI [10.1097/IAE.0b013e318287da59, DOI 10.1097/IAE.0B013E318287DA59]
   Stafforini DM, 2013, FREE RADICAL BIO MED, V59, P100, DOI 10.1016/j.freeradbiomed.2012.05.031
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Wang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026871
NR 37
TC 5
Z9 5
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 12
PY 2016
VL 11
IS 5
AR e0154397
DI 10.1371/journal.pone.0154397
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DM8CQ
UT WOS:000376588600068
PM 27171197
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Adamis, AP
   de Juan, E
AF Adamis, Anthony P.
   de Juan, Eugene, Jr.
TI Development of the Port Delivery System with ranibizumab for neovascular
   age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE antivascular endothelial growth factor; neovascular age-related macular
   degeneration; Port Delivery System; ranibizumab
ID AFLIBERCEPT; BURDEN
AB Purpose of review This review provides background on the remaining unmet needs with antivascular endothelial growth factor (VEGF) therapies for the treatment of neovascular age-related macular degeneration (nAMD). We also discuss the developmental story of the Port Delivery System with ranibizumab (PDS; SUSVIMO, Genentech, Inc., South San Francisco, CA, USA). Recent findings Real-world studies have shown that undertreatment is a major reason for continued vision loss in the anti-VEGF era. As a result, there is a need for long-acting anti-VEGF treatment options for patients with nAMD, diabetic macular edema, and other retinal diseases. The PDS is a solid state, refillable, intraocular long-acting drug delivery system that continuously delivers a customized formulation of ranibizumab into the vitreous for 6 months. In a phase 3 trial, the PDS showed equivalent visual acuity improvements with monthly ranibizumab injections in patients with nAMD and adverse events associated with the PDS were well understood and manageable. The PDS is the first US Food and Drug Administration-approved treatment for nAMD that provides continuous delivery of an anti-VEGF molecule. The PDS offers a unique drug delivery system that has the potential to serve as a platform to be used with other molecules in the future.
C1 [Adamis, Anthony P.] Genentech Inc, San Francisco, CA 94080 USA.
   [de Juan, Eugene, Jr.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [de Juan, Eugene, Jr.] ForSight Labs, San Francisco, CA USA.
C3 Roche Holding; Genentech; University of California System; University of
   California San Francisco
RP Adamis, AP (通讯作者)，6586 W Atlantic Ave 1036, Delray Beach, FL 33446 USA.
EM anthonypeteradamis@gmail.com
FU Genentech, Inc.
FX The authors would like to thank Judy Bloom, PhD (Chameleon
   Communications International, with funding from Genentech, Inc.) for
   providing medical writing assistance.
CR [Anonymous], 2018, LUCENTIS PRESCRIBING
   [Anonymous], 2021, SUSVIMO PRESCRIBING
   Bantseev V, 2020, RETINA-J RET VIT DIS, V40, P1520, DOI 10.1097/IAE.0000000000002614
   Baumal CR, 2020, AM J MANAG CARE, V26, pS103, DOI 10.37765/ajmc.2020.43435
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chang DP, 2021, J PHARM SCI-US, V110, P860, DOI 10.1016/j.xphs.2020.09.043
   Chen YX, 2012, THER CLIN RISK MANAG, V8, P343, DOI 10.2147/TCRM.S32801
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Finger RP, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01554-2
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kent DL, 2014, MOL VIS, V20, P46
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Kiss S, 2020, J MANAG CARE SPEC PH, V26, P253, DOI 10.18553/jmcp.2020.19245
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loewenstein A, 2020, INVEST OPHTH VIS SCI, V61
   MacCumber MW, 2020, RETINA TODAY
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Pieramici DJ, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubio R.G., 2014, RETINA TODAY, P78
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Teo KYC, 2021, EYE, V35, P2793, DOI 10.1038/s41433-020-01315-x
   Tripti D, 2009, E-POLYMERS
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff C, 2021, UNMET NEEDS FUTURE W
NR 31
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2022
VL 33
IS 3
BP 131
EP 136
DI 10.1097/ICU.0000000000000851
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1M9RJ
UT WOS:000800301800002
PM 35266895
OA hybrid
DA 2022-11-30
ER

PT J
AU Raychaudhuri, S
   Iartchouk, O
   Chin, K
   Tan, PL
   Tai, AK
   Ripke, S
   Gowrisankar, S
   Vemuri, S
   Montgomery, K
   Yu, Y
   Reynolds, R
   Zack, DJ
   Campochiaro, B
   Campochiaro, P
   Katsanis, N
   Daly, MJ
   Seddon, JM
AF Raychaudhuri, Soumya
   Iartchouk, Oleg
   Chin, Kimberly
   Tan, Perciliz L.
   Tai, Albert K.
   Ripke, Stephan
   Gowrisankar, Sivakumar
   Vemuri, Soumya
   Montgomery, Kate
   Yu, Yi
   Reynolds, Robyn
   Zack, Donald J.
   Campochiaro, Betsy
   Campochiaro, Peter
   Katsanis, Nicholas
   Daly, Mark J.
   Seddon, Johanna M.
TI A rare penetrant mutation in CFH confers high risk of age-related
   macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; GENOME-WIDE ASSOCIATION; FACTOR-H
   POLYMORPHISM; GENE; VARIANTS; SUSCEPTIBILITY; INDIVIDUALS; HAPLOTYPE;
   LINKAGE; DISEASE
AB Two common variants in the gene encoding complement factor H (CFH), the Y402H substitution (rs1061170, c.1204C>T)(1-4) and the intronic rs1410996 SNP(5,6), explain 17% of age-related macular degeneration (AMD) liability. However, proof for the involvement of CFH, as opposed to a neighboring transcript, and knowledge of the potential mechanism of susceptibility alleles are lacking. Assuming that rare functional variants might provide mechanistic insights, we used genotype data and high-throughput sequencing to discover a rare, high-risk CFH haplotype with a c.3628C>T mutation that resulted in an R1210C substitution. This allele has been implicated previously in atypical hemolytic uremic syndrome, and it abrogates C-terminal ligand binding(7,8). Genotyping R1210C in 2,423 AMD cases and 1,122 controls demonstrated high penetrance (present in 40 cases versus 1 control, P = 7.0 x 10(-6)) and an association with a 6-year-earlier onset of disease (P = 2.3 x 10(-6)). This result suggests that loss-of-function alleles at CFH are likely to drive AMD risk. This finding represents one of the first instances in which a common complex disease variant has led to the discovery of a rare penetrant mutation.
C1 [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya; Iartchouk, Oleg; Gowrisankar, Sivakumar; Vemuri, Soumya; Montgomery, Kate] Partners HealthCare Ctr Personalized Genet Med, Boston, MA USA.
   [Raychaudhuri, Soumya; Ripke, Stephan; Daly, Mark J.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   [Chin, Kimberly; Yu, Yi; Reynolds, Robyn; Seddon, Johanna M.] Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, New England Eye Ctr, Boston, MA USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Ctr Human Dis Modeling, Dept Cell Biol, Durham, NC USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Dept Pediat, Durham, NC 27706 USA.
   [Tai, Albert K.] Tufts Univ, Sch Med, Dept Pathol, Study Ctr Immunogenet Infect Dis, Boston, MA 02111 USA.
   [Ripke, Stephan; Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
   [Zack, Donald J.; Campochiaro, Betsy; Campochiaro, Peter] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, McKusick Nathans Inst Genet Med,Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Brigham & Women's Hospital; Partners Healthcare System; Harvard
   University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Tufts Medical Center; Duke University; Duke University; Tufts
   University; Harvard University; Massachusetts General Hospital; Johns
   Hopkins University; Johns Hopkins Medicine; Tufts University
RP Raychaudhuri, S (通讯作者)，Brigham & Womens Hosp, Div Genet, 75 Francis St, Boston, MA 02115 USA.
EM soumya@broadinstitute.org; jseddon@tuftsmedicalcenter.org
RI Ripke, Stephan/AAK-5486-2021; Katsanis, Nicholas/E-1837-2012; Daly, Mark
   J/B-2453-2017; Mohammed, Imran/J-8271-2012
OI Daly, Mark J/0000-0002-0949-8752; Mohammed, Imran/0000-0002-8412-0768;
   Katsanis, Nicholas/0000-0002-2480-0171; Zack, Don/0000-0002-7966-1973;
   Raychaudhuri, Soumya/0000-0002-1901-8265; ripke,
   stephan/0000-0003-3622-835X
FU US National Institutes of Health (NIH) [RO1-EY11309, K08AR055688-01A1,
   U01 MH085520-01]; Massachusetts Lions Eye Research Fund, Inc.; American
   Macular Degeneration Research Fund; Foundation Fighting Blindness;
   Macular Vision Research Foundation; Research to Prevent Blindness
   Challenge Grant; Department of Ophthalmology; Tufts University School of
   Medicine; Ophthalmic Epidemiology and Genetics Service; New England Eye
   Center; Tufts Medical Center; NIH National Heart, Lung, and Blood
   Institute (NLBI) [R01HL087676]; NIH National Center for Research
   Resources (NCRR); NATIONAL EYE INSTITUTE [R01EY011309] Funding Source:
   NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087676]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND
   MUSCULOSKELETAL AND SKIN DISEASES [K08AR055688] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH085520] Funding
   Source: NIH RePORTER
FX We appreciate the contribution to the research of J.M.S. of an anonymous
   donor. This research was supported in part by grants RO1-EY11309
   (J.M.S.), K08AR055688-01A1 (S. Raychaudhuri) and U01 MH085520-01 (S.
   Ripke) from the US National Institutes of Health (NIH), and by the
   Massachusetts Lions Eye Research Fund, Inc., the American Macular
   Degeneration Research Fund, the Foundation Fighting Blindness, the
   Macular Vision Research Foundation, a Research to Prevent Blindness
   Challenge Grant to the New England Eye Center, Department of
   Ophthalmology, Tufts University School of Medicine, and the Macular
   Degeneration Research Fund of the Ophthalmic Epidemiology and Genetics
   Service, New England Eye Center, Tufts Medical Center, Tufts University
   School of Medicine. N.K. is a Distinguished Brumley Professor. The MIGen
   study was funded by grants from the NIH National Heart, Lung, and Blood
   Institute (NLBI) (R01HL087676) and the NIH National Center for Research
   Resources (NCRR). We acknowledge informal and helpful discussions from
   our colleagues B. Neale, R. Plenge, P. de Bakker, D. Reich, E. Stahl, B.
   Stranger and B. Voight.
CR Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Browning BL, 2009, AM J HUM GENET, V84, P210, DOI 10.1016/j.ajhg.2009.01.005
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Davila S, 2010, NAT GENET, V42, P772, DOI 10.1038/ng.640
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kathiresan S, 2009, NAT GENET, V41, P334, DOI 10.1038/ng.327
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Servais A, 2007, J MED GENET, V44, P193, DOI 10.1136/jmg.2006.045328
   Stephens M, 2006, NAT GENET, V38, P375, DOI 10.1038/ng1746
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
NR 45
TC 241
Z9 247
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD DEC
PY 2011
VL 43
IS 12
BP 1232
EP U91
DI 10.1038/ng.976
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 860EK
UT WOS:000297931400018
PM 22019782
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chiu, CJ
   Mitchell, P
   Klein, R
   Klein, BE
   Chang, ML
   Gensler, G
   Taylor, A
AF Chiu, Chung-Jung
   Mitchell, Paul
   Klein, Ronald
   Klein, Barbara E.
   Chang, Min-Lee
   Gensler, Gary
   Taylor, Allen
TI A Risk Score for the Prediction of Advanced Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID LOGISTIC-REGRESSION; MODELS; MACULOPATHY; PROGRESSION; PREVALENCE;
   DISEASE
AB Purpose: To develop a clinical eye-specific prediction model for advanced age-related macular degeneration (AMD).
   Design: The Age-Related Eye Disease Study (AREDS) cohort followed up for 8 years served as the training dataset, and the Blue Mountains Eye Study (BMES) cohort followed up for 10 years served as the validation dataset.
   Participants: A total of 4507 AREDS participants (contributing 1185 affected vs. 6992 unaffected eyes) and 2169 BMES participants (contributing 69 affected vs. 3694 unaffected eyes).
   Methods: Using Bayes' theorem in a logistic model, we used 8 baseline predictors-age, sex, education level, race, smoking status, and presence of pigment abnormality, soft drusen, and maximum drusen size-to devise and validate a macular risk scoring system (MRSS). We assessed the performance of the MRSS by calculating sensitivity, specificity, and the area under the receiver operating characteristic curve (i.e., c-index).
   Main Outcome Measures: Advanced AMD.
   Results: The internally validated c-index(AREDS) (0.88; 95% confidence interval, 0.87-0.89) and the externally validated c-index(BMES) (0.91; 95% confidence interval, 0.88-0.95) suggested excellent performance of the MRSS. The sensitivity and specificity at the optimal macular risk score cutoff point of 0 were 87.6% and 73.6%, respectively. An application for the iPhone and iPad also was developed as a practical tool for the MRSS.
   Conclusions: The MRSS was developed and validated to provide satisfactory accuracy and generalizability. It may be used to screen patients at risk of developing advanced AMD. (C) 2014 by the American Academy of Ophthalmology.
C1 [Chiu, Chung-Jung; Chang, Min-Lee; Taylor, Allen] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Chiu, Chung-Jung; Taylor, Allen] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Mitchell, Paul] Univ Sydney, Westmead Hosp, Ctr Vis Res, Westmead, NSW 2145, Australia.
   [Klein, Ronald; Klein, Barbara E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Gensler, Gary] EMMES Corp, Age Related Eye Dis Study Coordinating Ctr, Rockville, MD USA.
C3 Tufts University; United States Department of Agriculture (USDA); Tufts
   University; University of Sydney; University of Wisconsin System;
   University of Wisconsin Madison; Emmes Corporation
RP Chiu, CJ (通讯作者)，Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM cj.chiu@tufts.edu
RI Mitchell, Paul/P-1498-2014
OI CHANG, MIN-LEE/0000-0001-9868-4030
FU National Institutes of Health, Bethesda, Maryland [R01EY021826]; United
   States Department of Agriculture, Washington, D.C. [1950-5100-060-01A];
   NATIONAL EYE INSTITUTE [R01EY021826] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health, Bethesda, Maryland
   (grant no.: R01EY021826 [C-J.C.]), and the United States Department of
   Agriculture, Washington, D.C., (agreement nos.: 1950-5100-060-01A
   [C-J.C., A.T.]). The funding sources had no role in the design and
   conduct of the study; the collection, analysis, and interpretation of
   the data; or the preparation, review, or approval of the manuscript.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Brier G.W., 1950, MONTHLY WEATHER REVI, V78, P1, DOI DOI 10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2
   Chan SF, 2008, J CLIN EPIDEMIOL, V61, P52, DOI 10.1016/j.jclinepi.2007.02.012
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu CJ, 2002, J PUBLIC HEALTH DENT, V62, P28, DOI 10.1111/j.1752-7325.2002.tb03417.x
   Chou R, 2009, ANN INTERN MED, V151, P44, DOI 10.7326/0003-4819-151-1-200907070-00008
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cook NR, 2007, CIRCULATION, V115, P928, DOI 10.1161/CIRCULATIONAHA.106.672402
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   EFRON B, 1981, BIOMETRIKA, V68, P589, DOI 10.2307/2335441
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   IRWIG L, 1992, J CLIN EPIDEMIOL, V45, P1335, DOI 10.1016/0895-4356(92)90174-L
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1605, DOI 10.1001/archophthalmol.2011.372
   LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morise AP, 1996, MED DECIS MAKING, V16, P133, DOI 10.1177/0272989X9601600205
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Royston P, 2010, STAT MED, V29, P2508, DOI 10.1002/sim.3994
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
NR 32
TC 24
Z9 24
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2014
VL 121
IS 7
BP 1421
EP 1427
DI 10.1016/j.ophtha.2014.01.016
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2II
UT WOS:000341142800023
PM 24650555
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Iannaccone, A
   Giorgianni, F
   New, DD
   Hollingsworth, TJ
   Umfress, A
   Alhatem, AH
   Neeli, I
   Lenchik, NI
   Jennings, BJ
   Calzada, JI
   Satterfield, S
   Mathews, D
   Diaz, RI
   Harris, T
   Johnson, KC
   Charles, S
   Kritchevsky, SB
   Gerling, IC
   Beranova-Giorgianni, S
   Radic, MZ
AF Iannaccone, Alessandro
   Giorgianni, Francesco
   New, David D.
   Hollingsworth, T. J.
   Umfress, Allison
   Alhatem, Albert H.
   Neeli, Indira
   Lenchik, Nataliya I.
   Jennings, Barbara J.
   Calzada, Jorge I.
   Satterfield, Suzanne
   Mathews, Dennis
   Diaz, Rocio I.
   Harris, Tamara
   Johnson, Karen C.
   Charles, Steve
   Kritchevsky, Stephen B.
   Gerling, Ivan C.
   Beranova-Giorgianni, Sarka
   Radic, Marko Z.
CA Hlth ABC Study
TI Circulating Autoantibodies in Age-Related Macular Degeneration Recognize
   Human Macular Tissue Antigens Implicated in Autophagy, Immunomodulation,
   and Protection from Oxidative Stress and Apoptosis
SO PLOS ONE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; SUBRETINAL DRUSENOID DEPOSITS;
   CANCER-ASSOCIATED RETINOPATHY; ALPHA-ENOLASE AUTOANTIBODIES; FACTOR-H
   POLYMORPHISM; HEAT-SHOCK-RESPONSE; BRUCHS MEMBRANE; OPTICAL-DENSITY; EYE
   DISEASE; CHOROIDAL NEOVASCULARIZATION
AB Background
   We investigated sera from elderly subjects with and without age-related macular degeneration (AMD) for presence of autoantibodies (AAbs) against human macular antigens and characterized their identity.
   Methods
   Sera were collected from participants in the Age-Related Maculopathy Ancillary (ARMA) Study, a cross-sectional investigation ancillary to the Health ABC Study, enriched with participants from the general population. The resulting sample (mean age: 79.2 +/- 3.9 years old) included subjects with early to advanced AMD (n = 131) and controls (n = 231). Sera were tested by Western blots for immunoreactive bands against human donor macular tissue homogenates. Immunoreactive bands were identified and graded, and odds ratios (OR) calculated. Based on these findings, sera were immunoprecipitated, and subjected to 2D gel electrophoresis (GE). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to identify the targets recognized by circulating AAbs seen on 2D-GE, followed by ELI-SAs with recombinant proteins to confirm LC-MS/MS results, and quantify autoreactivities.
   Results
   In AMD, 11 immunoreactive bands were significantly more frequent and 13 were significantly stronger than in controls. Nine of the more frequent bands also showed stronger reactivity. OR estimates ranged between 4.06 and 1.93, and all clearly excluded the null value. Following immunoprecipitation, 2D-GE and LC-MS/MS, five of the possible autoreactivity targets were conclusively identified: two members of the heat shock protein 70 (HSP70) family, HSPA8 and HSPA9; another member of the HSP family, HSPB4, also known as alpha-crystallin A chain (CRYAA); Annexin A5 (ANXA5); and Protein S100-A9, also known as calgranulin B that, when complexed with S100A8, forms calprotectin. ELISA testing with recombinant proteins confirmed, on average, significantly higher reactivities against all targets in AMD samples compared to controls.
   Conclusions
   Consistent with other evidence supporting the role of inflammation and the immune system in AMD pathogenesis, AAbs were identified in AMD sera, including early-stage disease. Identified targets may be mechanistically linked to AMD pathogenesis because the identified proteins are implicated in autophagy, immunomodulation, and protection from oxidative stress and apoptosis. In particular, a role in autophagy activation is shared by all five autoantigens, raising the possibility that the detected AAbs may play a role in AMD via autophagy compromise and downstream activation of the inflammasome. Thus, we propose that the detected AAbs provide further insight into AMD pathogenesis and have the potential to contribute to disease biogenesis and progression.
C1 [Iannaccone, Alessandro; New, David D.; Hollingsworth, T. J.; Umfress, Allison; Alhatem, Albert H.; Neeli, Indira; Lenchik, Nataliya I.; Jennings, Barbara J.; Calzada, Jorge I.; Diaz, Rocio I.; Charles, Steve] Univ Tennessee, Ctr Hlth Sci, Hamilton Eye Inst, Dept Ophthalmol, Memphis, TN 38163 USA.
   [Giorgianni, Francesco; Beranova-Giorgianni, Sarka] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA.
   [Neeli, Indira; Radic, Marko Z.] Univ Tennessee, Ctr Hlth Sci, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA.
   [Lenchik, Nataliya I.; Gerling, Ivan C.] Univ Tennessee, Ctr Hlth Sci, Dept Internal Med Endocrinol, Memphis, TN 38163 USA.
   [Calzada, Jorge I.; Diaz, Rocio I.; Charles, Steve] Charles Retina Inst, Memphis, TN USA.
   [Satterfield, Suzanne; Johnson, Karen C.; Kritchevsky, Stephen B.] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA.
   [Mathews, Dennis] Eye Specialty Grp, Memphis, TN USA.
   [Mathews, Dennis] Southern Coll Optometry, Memphis, TN USA.
   [Harris, Tamara] NIA, NIH, Bethesda, MD 20892 USA.
   [Kritchevsky, Stephen B.] Wake Forest Univ, Sticht Ctr Aging, Winston Salem, NC 27109 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center; University of Tennessee System; University of Tennessee
   Health Science Center; University of Tennessee System; University of
   Tennessee Health Science Center; University of Tennessee System;
   University of Tennessee Health Science Center; National Institutes of
   Health (NIH) - USA; NIH National Institute on Aging (NIA); Wake Forest
   University
RP Iannaccone, A (通讯作者)，Univ Tennessee, Ctr Hlth Sci, Hamilton Eye Inst, Dept Ophthalmol, Memphis, TN 38163 USA.
EM aiannacc@yahoo.com
RI Hollingsworth, T.J./AAD-2814-2022
OI Hollingsworth, T.J./0000-0002-2119-521X; Alhatem,
   Albert/0000-0003-1826-6854; Radic, Marko/0000-0002-8004-282X;
   Iannaccone, Alessandro/0000-0001-5737-8424
FU National Institutes of Health/National Eye Institute [K23 EY000409, R21
   EY018416, R01 EY022706]; International Retinal Research Foundation;
   Research to Prevent Blindness, Inc. New York, NY; University of
   Tennessee Health Science Center College of Pharmacy; University of
   Tennessee Health Science Center, Neuroscience Undergraduate Merit
   Fellowship Award; National Institutes of Health/National Institute on
   Aging, Intramural Research Program; National Institutes of
   Health/National Institute on AgingH [N01 AG-62101, N01 AG-62103,
   N01-AG-62106]; NATIONAL EYE INSTITUTE [K23EY000409, R01EY022706,
   R21EY018416] Funding Source: NIH RePORTER
FX This work was funded by: National Institutes of Health/National Eye
   Institute grants K23 EY000409 (AI), R21 EY018416 (AI, PI; ICG and MRZ,
   co-investigators) and R01 EY022706 (AI, PI; MRZ, FG, ICG, and SBG,
   co-investigators) (https://nei.nih.gov); International Retinal Research
   Foundation (AI) (http://www.irrfonline.org); Research to Prevent
   Blindness, Inc. New York, NY (Career Development Award and Physician
   Scientist Award to AI and unrestricted grant to the UTHSC Hamilton Eye
   Institute, Memphis, TN, USA) (https://www.rpbusa.org/rpb/?); University
   of Tennessee Health Science Center College of Pharmacy, Intramural grant
   (FG and SBG) (http://www.uthsc.edu/pharmacy/); University of Tennessee
   Health Science Center, Neuroscience Undergraduate Merit Fellowship Award
   (AU) (http://www.uthsc.edu/neuroscience/); National Institutes of
   Health/National Institute on Aging, Intramural Research Program (TH)
   (https://www.nia.nih.gov). The Health ABC study was supported by:
   National Institutes of Health/National Institute on AgingH Contracts N01
   AG-62101 (SBK, PI: SS and KCJ, co-investigators), N01 AG-62103 (SBK, PI:
   SS and KCJ, co-investigators), and N01-AG-62106 (Health ABC Coordinating
   Center) (https://www.nia.nih.gov). The Health ABC Publications Committee
   and the National Institute on Aging reviewed and approved the manuscript
   for publication before submission. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adamus G, 1998, J AUTOIMMUN, V11, P523, DOI 10.1006/jaut.1998.0221
   Adamus G, 1997, INVEST OPHTH VIS SCI, V38, P283
   Adamus G, 1998, J AUTOIMMUN, V11, P671, DOI 10.1006/jaut.1998.0239
   Adamus G, 2003, AUTOIMMUN REV, V2, P63, DOI 10.1016/S1568-9972(02)00127-1
   Adamus Grazyna, 2004, BMC Ophthalmol, V4, P5, DOI 10.1186/1471-2415-4-5
   Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Adamus G, 2011, J OPHTHALMIC INFLAMM, V1, P111, DOI 10.1007/s12348-011-0028-8
   Adamus G, 2009, J AUTOIMMUN, V32, P133, DOI 10.1016/j.jaut.2009.02.001
   Adamus G, 2009, AUTOIMMUN REV, V8, P410, DOI 10.1016/j.autrev.2009.01.002
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alessandri C, 2011, AUTOIMMUN REV, V10, P609, DOI 10.1016/j.autrev.2011.04.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Bakar F, 2014, J CLIN ENDOCR METAB, V99, P932, DOI 10.1210/jc.2013-2592
   BERBERIAN PA, 1990, AM J PATHOL, V136, P71
   Bernstein SL, 2000, INVEST OPHTH VIS SCI, V41, P2857
   Bjork P, 2009, PLOS BIOL, V7, P800, DOI 10.1371/journal.pbio.1000097
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Borges TJ, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00095
   Casola C, 2015, J MOL NEUROSCI, V56, P228, DOI 10.1007/s12031-014-0485-2
   Cederholm A, 2005, IMMUNOBIOLOGY, V210, P761, DOI 10.1016/j.imbio.2005.10.007
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Cesaro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045478
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dhas D. B. B., 2012, Current Pediatric Research, V16, P83
   Dokladny K, 2015, AUTOPHAGY, V11, P200, DOI 10.1080/15548627.2015.1009776
   Dokladny K, 2013, J BIOL CHEM, V288, P14959, DOI 10.1074/jbc.M113.462408
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ethen CM, 2007, FEBS LETT, V581, P885, DOI 10.1016/j.febslet.2007.01.061
   Ferrington D., 2015, PROG RETIN EYE RES
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FOUQUERAY B, 1992, EUR J IMMUNOL, V22, P2983, DOI 10.1002/eji.1830221133
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gallaher KT, 2007, VISION RES, V47, P1253, DOI 10.1016/j.visres.2007.01.013
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Ghavami S, 2010, CELL RES, V20, P314, DOI 10.1038/cr.2009.129
   Ghislat G, 2012, J CELL SCI, V125, P92, DOI 10.1242/jcs.086728
   Giorgianni F, 2004, ANAL CHEM, V76, P7028, DOI 10.1021/ac0493368
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Grus FH, 2004, MOL VIS, V10, P132
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Hawkins BS, 1999, MOL VIS, V5
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hughes AE, 2006, NAT GENET
   Iaccarino L, 2011, AUTOIMMUN REV, V10, P553, DOI 10.1016/j.autrev.2011.04.007
   Iannaccone A, 2007, INVEST OPHTH VIS SCI, V48, P1458, DOI 10.1167/iovs.06-0438
   Iannaccone A, 2012, ADV EXP MED BIOL, V723, P11, DOI 10.1007/978-1-4614-0631-0_2
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jablonski MM, 2001, EXP EYE RES, V72, P573, DOI 10.1006/exer.2001.0987
   Jablonski MM, 2007, INVEST OPHTH VIS SCI, V48, P479, DOI 10.1167/iovs.06-0972
   Jia J, 2014, CELL, V159, P623, DOI 10.1016/j.cell.2014.09.032
   Joachim SC, 2007, CURR EYE RES, V32, P501, DOI 10.1080/02713680701375183
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kannan R, 2015, BIOCH BIOPHYS ACTA
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koike A, 2012, INFLAMMATION, V35, P409, DOI 10.1007/s10753-011-9330-8
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Li CS, 2009, BIOCHEM J, V422, P363, DOI 10.1042/BJ20090465
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022
   Magrys A, 2007, J CLIN IMMUNOL, V27, P181, DOI 10.1007/s10875-006-9065-8
   Mak SK, 2010, J BIOL CHEM, V285, P13621, DOI 10.1074/jbc.M109.074617
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Marx J, 2006, SCIENCE, V311, P1704, DOI 10.1126/science.311.5768.1704
   Matsumura Y, 2013, J BIOL CHEM, V288, P31069, DOI 10.1074/jbc.M113.479345
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   McGeer Patrick L, 2002, Sci Aging Knowledge Environ, V2002, pre3, DOI 10.1126/sageke.2002.29.re3
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Minoia M, 2014, MOL CELL BIOL, V34, P3570, DOI 10.1128/MCB.00698-14
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Nakatani Y, 2005, MEDIAT INFLAMM, P280, DOI 10.1155/MI.2005.280
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Ohguro H, 1999, INVEST OPHTH VIS SCI, V40, P3160
   Pabst MJ, 2008, PROTEOME SCI, V6, DOI 10.1186/1477-5956-6-13
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Philip LP, 2004, JAMA-J AM MED ASSOC, V292, P43, DOI 10.1001/jama.292.1.43-a
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rayborn ME, 2006, ADV EXP MED BIOL, V572, P75
   Ren GY, 2004, J AUTOIMMUN, V23, P161, DOI 10.1016/j.jaut.2004.06.003
   Riva M, 2012, IMMUNOLOGY, V137, P172, DOI 10.1111/j.1365-2567.2012.03619.x
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Saraswathy S, 2010, INVEST OPHTH VIS SCI, V51, P3680, DOI 10.1167/iovs.09-4575
   Schaumberg DA, 2014, JAMA OPHTHALMOL, V132, P84, DOI 10.1001/jamaophthalmol.2013.5506
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shiraga S, 2002, J NEUROIMMUNOL, V132, P72, DOI 10.1016/S0165-5728(02)00314-4
   Simard JC, 2011, J IMMUNOL, V186, P3622, DOI 10.4049/jimmunol.1002956
   Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Sreekumar PG, 2013, INVEST OPHTH VIS SCI, V54, P2787, DOI 10.1167/iovs.12-11571
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tahiri F, 2008, HEPATOLOGY, V47, P937, DOI 10.1002/hep.22149
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Thanos S, 2014, PROG RETIN EYE RES, V42, P145, DOI 10.1016/j.preteyeres.2014.06.004
   Tulapurkar ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118010
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x
   Vishwanathan R, 2014, AGE AGEING, V43, P271, DOI 10.1093/ageing/aft210
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yaung J, 2007, MOL VIS, V13, P566
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zetterstrom P, 2011, J BIOL CHEM, V286, P20130, DOI 10.1074/jbc.M111.218842
   Zigler JS, 2011, J CELL SCI, V124, P523, DOI 10.1242/jcs.078790
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 155
TC 34
Z9 35
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 30
PY 2015
VL 10
IS 12
AR e0145323
DI 10.1371/journal.pone.0145323
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DA0TN
UT WOS:000367510500028
PM 26717306
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Ebeling, MC
   Polanco, JR
   Qu, J
   Tu, CJ
   Montezuma, SR
   Ferrington, DA
AF Ebeling, Mara C.
   Polanco, Jorge R.
   Qu, Jun
   Tu, Chengjian
   Montezuma, Sandra R.
   Ferrington, Deborah A.
TI Improving retinal mitochondrial function as a treatment for age-related
   macular degeneration
SO REDOX BIOLOGY
LA English
DT Article
DE Age-related macular degeneration; Retinal pigment epithelium;
   Mitochondrial function; Rapamycin; Pyrroloquinoline quinone;
   Nicotinamide mononucleotide
ID PIGMENT EPITHELIUM; PYRROLOQUINOLINE QUINONE; PROGRESSIVE STAGES;
   BETA-CAROTENE; O-QUINONE; ACETYLCYSTEINE; AUTOPHAGY; RAPAMYCIN; BRAIN;
   PREVALENCE
AB Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly. Currently, there are no treatments for dry AMD, which is characterized by the death of retinal pigment epithelium (RPE) and photoreceptors. Reports from human donors with AMD suggest that RPE mitochondrial defects are a key event in AMD pathology. Thus, the most effective strategy for treating dry AMD is to identify compounds that enhance mitochondrial function and subsequently, preserve the RPE. In this study, primary cultures of RPE from human donors with (n = 20) or without (n = 8) AMD were used to evaluate compounds that are designed to protect mitochondria from oxidative damage (N-acetyl- L-cysteine; NAC), remove damaged mitochondria (Rapamycin), increase mitochondrial biogenesis (Pyrroloquinoline quinone; PQQ), and improve oxidative phosphorylation (Nicotinamide mononucleotide, NMN). Mitochondrial function measured after drug treatments showed an AMD- dependent response; only RPE from donors with AMD showed improvements. All four drugs caused a significant increase in maximal respiration (p < 0.05) compared to untreated controls. Treatment with Rapamycin, PQQ, or NMN significantly increased ATP production (p < 0.05). Only Rapamycin increased basal respiration (p < 0.05). Notably, robust responses were observed in only about 50% of AMD donors, with attenuated responses observed in the remaining AMD donors. Further, within the responders, individual donors exhibited a distinct reaction to each drug. Our results suggest drugs targeting pathways involved in maintaining healthy mitochondria can improve mitochondrial function in a select population of RPE from AMD donors. The unique response of individual donors to specific drugs supports the need for personalized medicine when treating AMD.
C1 [Ebeling, Mara C.; Polanco, Jorge R.; Montezuma, Sandra R.; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Qu, Jun; Tu, Chengjian] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14203 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo
RP Ferrington, DA (通讯作者)，380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM ebeli017@umn.edu; polan070@umn.edu; junqu@buffalo.edu;
   chengjian.tu@thermofisher.com; smontezu@umn.edu; ferri013@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU Foundation Fighting Blindness [TA-NMT-0613-0620-UMN]; National
   Institutes of Health/National Eye Institute [R01EY026012, R01EY028554];
   Office of the NIH Director [T35OD011118]; Elaine and Robert Larson
   Endowed Vision Research Chair; Lindsay Family Foundation
FX This work was supported in part by the Foundation Fighting Blindness
   (grant number TA-NMT-0613-0620-UMN); National Institutes of
   Health/National Eye Institute (grant numbers R01EY026012, R01EY028554);
   Office of the NIH Director (T35OD011118 to JRP); the Elaine and Robert
   Larson Endowed Vision Research Chair (to DAF); Lindsay Family
   Foundation; an anonymous benefactor for Age-Related Macular Degeneration
   Research. None of the funding agencies had a role in study design, in
   the collection, analysis and interpretation of data, in writing the
   manuscript, or in the decision to submit the manuscript for publication.
CR Agbaga MP, 2018, J LIPID RES, V59, P1586, DOI 10.1194/jlr.M082495
   Bauerly KA, 2006, BBA-GEN SUBJECTS, V1760, P1741, DOI 10.1016/j.bbagen.2006.07.009
   Blagosklonny MV, 2017, ONCOTARGET, V8, P35492, DOI 10.18632/oncotarget.18033
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chowanadisai W, 2010, J BIOL CHEM, V285, P142, DOI 10.1074/jbc.M109.030130
   Davila A, 2018, ELIFE, V7, DOI 10.7554/eLife.33246
   Dilger RN, 2007, J ANIM SCI, V85, P1712, DOI 10.2527/jas.2006-835
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Eichler W, 2008, EXP EYE RES, V87, P342, DOI 10.1016/j.exer.2008.06.017
   Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fisher Cody R., 2018, INVEST OPHTH VIS SCI, V59, P41, DOI DOI 10.1167/I0VS.18-24289
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005
   Goldberg AFX, 2016, PROG RETIN EYE RES, V55, P52, DOI 10.1016/j.preteyeres.2016.05.003
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Harris CB, 2013, J NUTR BIOCHEM, V24, P2076, DOI 10.1016/j.jnutbio.2013.07.008
   Jadeja RN, 2018, AGING-US, V10, P1306, DOI 10.18632/aging.101469
   Kagan DB, 2012, CLIN OPHTHALMOL, V6, P1471, DOI 10.2147/OPTH.S35139
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kanter MZ, 2006, AM J HEALTH-SYST PH, V63, P1821, DOI 10.2146/ajhp060050
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klawitter J, 2015, EXPERT OPIN DRUG SAF, V14, P1055, DOI 10.1517/14740338.2015.1040388
   Klimova N, 2019, J NEUROSCI RES, V97, P975, DOI 10.1002/jnr.24397
   Lamming DW, 2013, J CLIN INVEST, V123, P980, DOI 10.1172/JCI64099
   Lee SY, 2011, J CELL PHYSIOL, V226, P1843, DOI 10.1002/jcp.22508
   Li Q, 2014, BIOCHEM BIOPH RES CO, V444, P182, DOI 10.1016/j.bbrc.2014.01.032
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lin JB, 2016, CELL REP, V17, P69, DOI 10.1016/j.celrep.2016.08.073
   Long AN, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0272-x
   Malagelada C, 2010, J NEUROSCI, V30, P1166, DOI 10.1523/JNEUROSCI.3944-09.2010
   Maldonado M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056187
   Markoutsa E, 2017, MOL PHARMACEUT, V14, P1591, DOI 10.1021/acs.molpharmaceut.6b01028
   Massudi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042357
   Mills KF, 2016, CELL METAB, V24, P795, DOI 10.1016/j.cmet.2016.09.013
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Saihara K, 2017, BIOCHEMISTRY-US, V56, P6615, DOI 10.1021/acs.biochem.7b01185
   Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019
   Shahripour RB, 2014, BRAIN BEHAV, V4, P108, DOI 10.1002/brb3.208
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Stites T, 2006, J NUTR, V136, P390, DOI 10.1093/jn/136.2.390
   Stites TE, 2000, J NUTR, V130, P719, DOI 10.1093/jn/130.4.719
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Stromland O, 2019, BIOCHEM SOC T, V47, P119, DOI 10.1042/BST20180417
   Terluk MR, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5174957
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tsubota K, 2016, NPJ AGING MECH DIS, V2, DOI 10.1038/npjamd.2016.21
   Tu CJ, 2013, MOL CELL PROTEOMICS, V12, P3583, DOI 10.1074/mcp.M113.027847
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Whyte AJ, 2010, J EMERG MED, V39, P607, DOI 10.1016/j.jemermed.2008.05.007
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoshino J, 2018, CELL METAB, V27, P513, DOI 10.1016/j.cmet.2017.11.002
   Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001
   Zhang LL, 2012, J NEUROTRAUM, V29, P851, DOI 10.1089/neu.2011.1882
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhu XH, 2015, P NATL ACAD SCI USA, V112, P2876, DOI 10.1073/pnas.1417921112
NR 67
TC 20
Z9 20
U1 7
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD JUL
PY 2020
VL 34
AR 101552
DI 10.1016/j.redox.2020.101552
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA ME8MH
UT WOS:000544906900003
PM 32446621
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wyatt, MK
   Tsai, JY
   Mishra, S
   Campos, M
   Jaworski, C
   Fariss, RN
   Bernstein, SL
   Wistow, G
AF Wyatt, M. Keith
   Tsai, Jen-Yue
   Mishra, Sanghamitra
   Campos, Maria
   Jaworski, Cynthia
   Fariss, Robert N.
   Bernstein, Steven L.
   Wistow, Graeme
TI Interaction of Complement Factor H and Fibulin3 in Age-Related Macular
   Degeneration
SO PLOS ONE
LA English
DT Article
ID C-REACTIVE PROTEIN; MALATTIA LEVENTINESE; OXIDATIVE STRESS; TISSUE
   INHIBITOR; VARIANT; DRUSEN; RISK; POLYMORPHISM; GENE; SUSCEPTIBILITY
AB Age-related macular degeneration (AMD) is a major cause of vision loss. It is associated with development of characteristic plaque-like deposits (soft drusen) in Bruch's membrane basal to the retinal pigment epithelium (RPE). A sequence variant (Y402H) in short consensus repeat domain 7 (SCR7) of complement factor H (CFH) is associated with risk for "dry'' AMD. We asked whether the eye-targeting of this disease might be related to specific interactions of CFH SCR7 with proteins expressed in the aging human RPE/choroid that could contribute to protein deposition in drusen. Yeast 2-hybrid (Y2H) screens of a retinal pigment epithelium/choroid library derived from aged donors using CFH SCR7 baits detected an interaction with EFEMP1/Fibulin 3 (Fib3), which is the locus for an inherited macular degeneration and also accumulates basal to macular RPE in AMD. The CFH/Fib3 interaction was validated by co-immunoprecipitation of native proteins. Quantitative Y2H and ELISA assays with different recombinant protein constructs both demonstrated higher affinity for Fib3 for the disease-related CFH 402H variant. Immuno-labeling revealed colocalization of CFH and Fib3 in globular deposits within cholesterol-rich domains in soft drusen in two AMD donors homozygous for CFH 402H (H/H). This pattern of labeling was quite distinct from those seen in examples of eyes with Y/Y and H/Y genotypes. The CFH 402H/Fib3 interaction could contribute to the development of pathological aggregates in soft drusen in some patients and as such might provide a target for therapeutic intervention in some forms of AMD.
C1 [Wyatt, M. Keith; Mishra, Sanghamitra; Wistow, Graeme] NEI, Sect Mol Struct & Funct Genom, NIH, Bethesda, MD 20892 USA.
   [Tsai, Jen-Yue; Campos, Maria; Fariss, Robert N.] NEI, Biol Imaging Core, NIH, Bethesda, MD 20892 USA.
   [Jaworski, Cynthia] NEI, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.
   [Bernstein, Steven L.] Univ Maryland, Sch Med, Dept Ophthalmol, Baltimore, MD 21201 USA.
   [Bernstein, Steven L.] Univ Maryland, Sch Med, Dept Neurobiol & Genet, Baltimore, MD 21201 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); University System of Maryland; University of
   Maryland Baltimore; University System of Maryland; University of
   Maryland Baltimore
RP Wistow, G (通讯作者)，NEI, Sect Mol Struct & Funct Genom, NIH, Bethesda, MD 20892 USA.
EM graeme@helix.nih.gov
RI Fariss, Robert/ABI-1771-2020
OI Fariss, Robert/0000-0003-3227-7170
FU NEI Intramural Research Program; NATIONAL EYE INSTITUTE [ZIAEY000444,
   ZIAEY000433, ZICEY000459] Funding Source: NIH RePORTER
FX This work was supported by the NEI Intramural Research Program. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Fu L, 2007, HUM MOL GENET
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Legrain P, 2000, FEBS LETT, V480, P32, DOI 10.1016/S0014-5793(00)01774-9
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marmorstein LY, 2007, HUM MOL GENET
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Ono RN, 2009, J BIOL CHEM, V284, P16872, DOI 10.1074/jbc.M809348200
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   Serebriiskii IG, 2000, ANAL BIOCHEM, V285, P1, DOI 10.1006/abio.2000.4672
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Uno K, 2010, BIOMARK MED, V4, P361, DOI [10.2217/bmm.10.57, 10.2217/BMM.10.57]
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 59
TC 32
Z9 33
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 28
PY 2013
VL 8
IS 6
AR e68088
DI 10.1371/journal.pone.0068088
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 174IH
UT WOS:000321148400162
PM 23840815
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Derradji, Y
   Mosinska, A
   Apostolopoulos, S
   Ciller, C
   De Zanet, S
   Mantel, I
AF Derradji, Yasmine
   Mosinska, Agata
   Apostolopoulos, Stefanos
   Ciller, Carlos
   De Zanet, Sandro
   Mantel, Irmela
TI Fully-automated atrophy segmentation in dry age-related macular
   degeneration in optical coherence tomography
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GEOGRAPHIC ATROPHY; QUANTIFICATION; PREDICTION; FLUID
AB Age-related macular degeneration (AMD) is a progressive retinal disease, causing vision loss. A more detailed characterization of its atrophic form became possible thanks to the introduction of Optical Coherence Tomography (OCT). However, manual atrophy quantification in 3D retinal scans is a tedious task and prevents taking full advantage of the accurate retina depiction. In this study we developed a fully automated algorithm segmenting Retinal Pigment Epithelial and Outer Retinal Atrophy (RORA) in dry AMD on macular OCT. 62 SD-OCT scans from eyes with atrophic AMD (57 patients) were collected and split into train and test sets. The training set was used to develop a Convolutional Neural Network (CNN). The performance of the algorithm was established by cross validation and comparison to the test set with ground-truth annotated by two graders. Additionally, the effect of using retinal layer segmentation during training was investigated. The algorithm achieved mean Dice scores of 0.881 and 0.844, sensitivity of 0.850 and 0.915 and precision of 0.928 and 0.799 in comparison with Expert 1 and Expert 2, respectively. Using retinal layer segmentation improved the model performance. The proposed model identified RORA with performance matching human experts. It has a potential to rapidly identify atrophy with high consistency.
C1 [Derradji, Yasmine; Mantel, Irmela] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile de Aveugles, Dept Ophthalmol, 15 Ave France, CH-1004 Lausanne, Switzerland.
   [Mosinska, Agata; Apostolopoulos, Stefanos; Ciller, Carlos; De Zanet, Sandro] RetinAl Med AG, Freiburgstr 3, CH-3010 Bern, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile de Aveugles, Dept Ophthalmol, 15 Ave France, CH-1004 Lausanne, Switzerland.
EM irmela.mantel@fa2.ch
CR Apostolopoulos S., 2017, PATHOLOGICAL OCT RET, P294, DOI DOI 10.1007/978-3-319-66179-7_34
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Boski M, 2017, 2017 10TH INTERNATIONAL WORKSHOP ON MULTIDIMENSIONAL (ND) SYSTEMS (NDS)
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Ji ZX, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.1.1
   King DB, 2015, ACS SYM SER, V1214, P1
   Lin TY, 2017, IEEE I CONF COMP VIS, P2999, DOI 10.1109/ICCV.2017.324
   Lu W, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5278196
   Mantel I, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.4.17
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Niu SJ, 2016, BIOMED OPT EXPRESS, V7, P581, DOI 10.1364/BOE.7.000581
   Rahimy E, 2018, CURR OPIN OPHTHALMOL, V29, P254, DOI 10.1097/ICU.0000000000000470
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schlegl T., 2018, ARXIV180503278
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Tan MX, 2019, PR MACH LEARN RES, V97
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P2053, DOI 10.1007/s00417-018-4098-2
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Xu RB, 2019, COMPUT BIOL MED, V105, P102, DOI 10.1016/j.compbiomed.2018.12.013
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Zhang YH, 2019, I S BIOMED IMAGING, P565, DOI 10.1109/ISBI.2019.8759253
NR 31
TC 1
Z9 1
U1 1
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 8
PY 2021
VL 11
IS 1
AR 21893
DI 10.1038/s41598-021-01227-0
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WT8HZ
UT WOS:000716101700011
PM 34751189
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Vallee, A
   Lecarpentier, Y
   Guillevin, R
   Vallee, JN
AF Vallee, Alexandre
   Lecarpentier, Yves
   Guillevin, Remy
   Vallee, Jean-Noel
TI Aerobic Glycolysis Hypothesis Through WNT/Beta-Catenin Pathway in
   Exudative Age-Related Macular Degeneration
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Review
DE WNT/beta-catenin pathway; Aerobic glycolysis; Exudative AMD; Warburg
   effect; Choroidal neovascularization
ID NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; DENSITY-LIPOPROTEIN RECEPTOR; WNT
   SIGNALING PATHWAY; INDUCIBLE FACTOR-I; GLUCOSE-TRANSPORTER GLUT1;
   TUMOR-NECROSIS-FACTOR; BETA-CATENIN; LACTATE-DEHYDROGENASE; VEGF
   EXPRESSION
AB Exudative age-related macular degeneration (AMD) is characterized by molecular mechanisms responsible for the initiation of choroidal neovascularization (CNV). Inflammatory processes are associated with upregulation of the canonical WNT/beta-catenin pathway in exudative AMD. We focus this review on the link between WNT/beta-catenin pathway activation and neovascular progression in exudative AMD through activation of aerobic glycolysis for production of angiogenic factors. Increased WNT/beta-catenin pathway involves hexokinase 2 (HK2) and pyruvate kinase M2 (PKM2). WNT/beta-catenin pathway stimulates PI3K/Akt pathway and then HIF-1alpha which activates glycolytic enzymes: glucose transporter (Glut), pyruvate dehydrogenase kinase 1 (PDK1), lactate dehydrogenase A (LDH-A), and monocarboxylate lactate transporter (MCT-1). This phenomenon is called aerobic glycolysis or the Warburg effect. Consequently, phosphorylation of PDK-1 inhibits the pyruvate dehydrogenase complex (PDH). Thus, a large part of pyruvate cannot be converted into acetyl-CoA in mitochondria and only a part of acetyl-CoA can enter the tricarboxylic acid cycle. Cytosolic pyruvate is converted into lactate through the action of LDH-A. In exudative AMD, high level of cytosolic lactate is correlated with increase of VEGF expression, the angiogenic factor of CNV. Photoreceptors in retina cells can metabolize glucose through aerobic glycolysis to protect them against oxidative damage, as cancer cells do.
C1 [Vallee, Alexandre] Univ Poitiers, INSERM, U1084, Expt & Clin Neurosci Lab, Poitiers, France.
   [Vallee, Alexandre; Vallee, Jean-Noel] Univ Poitiers, CNRS, UMR 7348, LMA, 11 Blvd Marie & Pierre Curie, Poitiers, France.
   [Lecarpentier, Yves] Hop Meaux, Ctr Rech Clin, Meaux, France.
   [Guillevin, Remy] Univ Poitiers, CHU Poitiers, CNRS,Futuroscope, DACTIM,Lab Math & Applicat,UMR 7348,SP2MI, Futuroscope, Chasseneuil Du, France.
   [Vallee, Jean-Noel] UPJV, CHU Amiens Picardie, Amiens, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Poitiers; Centre National de la Recherche Scientifique
   (CNRS); CNRS - National Institute for Mathematical Sciences (INSMI);
   Universite de Poitiers; Centre National de la Recherche Scientifique
   (CNRS); CNRS - National Institute for Mathematical Sciences (INSMI); CHU
   Poitiers; Universite de Poitiers; Picardie Universites; Universite de
   Picardie Jules Verne (UPJV); CHU Amiens
RP Vallee, A (通讯作者)，Univ Poitiers, INSERM, U1084, Expt & Clin Neurosci Lab, Poitiers, France.; Vallee, A (通讯作者)，Univ Poitiers, CNRS, UMR 7348, LMA, 11 Blvd Marie & Pierre Curie, Poitiers, France.
EM alexandre.g.vallee@gmail.com
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Al-Harthi L, 2012, J NEUROIMMUNE PHARM, V7, P725, DOI 10.1007/s11481-012-9412-x
   Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101
   Ambacher KK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046885
   Ambati J, 2011, INVEST OPHTH VIS SCI, V52, P2166, DOI 10.1167/iovs.11-7328
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Anson M, 2012, J CLIN INVEST, V122, P586, DOI 10.1172/JCI43937
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060
   Bender T, 2016, BBA-MOL CELL RES, V1863, P2436, DOI 10.1016/j.bbamcr.2016.01.017
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Birdsey GM, 2015, DEV CELL, V32, P82, DOI 10.1016/j.devcel.2014.11.016
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9
   BURGNER JW, 1984, BIOCHEMISTRY-US, V23, P3636, DOI 10.1021/bi00311a010
   Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200
   Carpenter AC, 2015, DEVELOPMENT, V142, P972, DOI 10.1242/dev.120022
   Casson RJ, 2016, INVEST OPHTH VIS SCI, V57, P66, DOI 10.1167/iovs.15-17962
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chan ECY, 2011, NAT PROTOC, V6, P1483, DOI 10.1038/nprot.2011.375
   Chang CK, 2004, ANN THORAC SURG, V77, P1222, DOI 10.1016/j.athoracsur.2003.09.128
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Cho HH, 2008, FEBS LETT, V582, P616, DOI 10.1016/j.febslet.2008.01.029
   Cho HH, 2008, BBA-MOL CELL RES, V1783, P419, DOI 10.1016/j.bbamcr.2007.08.005
   Choi YS, 2007, NUCLEIC ACIDS RES, V35, P5511, DOI 10.1093/nar/gkm547
   Chu XK, 2013, BIOENGINEERED, V4, P130, DOI 10.4161/bioe.22949
   Coffe V, 2006, NEUROCHEM RES, V31, P103, DOI 10.1007/s11064-005-9236-7
   COHEN LH, 1960, J NEUROCHEM, V5, P253, DOI 10.1111/j.1471-4159.1960.tb13363.x
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Cruciat CM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015081
   Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103
   Dai ZY, 2013, J CELL BIOCHEM, V114, P1020, DOI 10.1002/jcb.24441
   de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83
   Dhup S, 2012, CURR PHARM DESIGN, V18, P1319, DOI 10.2174/138161212799504902
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   DUGUID IGM, 1992, CURR EYE RES, V11, P153, DOI 10.3109/02713689208999526
   Easwaran V, 2003, CANCER RES, V63, P3145
   Eleuteri E, 2009, FRONT BIOSCI-LANDMRK, V14, P2230, DOI 10.2741/3375
   ELNER SG, 1992, LAB INVEST, V66, P200
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021
   Fuhrmann Sabine, 2008, Organogenesis, V4, P60
   Fujimura N, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00138
   Giatromanolaki A, 2006, GYNECOL ONCOL, V103, P912, DOI 10.1016/j.ygyno.2006.05.043
   Gospe SM, 2010, J CELL SCI, V123, P3639, DOI 10.1242/jcs.072389
   Grisanti S, 2015, RETINA-J RET VIT DIS, V35, P764, DOI 10.1097/IAE.0000000000000385
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hagglund AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081158
   Harris RA, 2014, BIOGERONTOLOGY, V15, P559, DOI 10.1007/s10522-014-9534-z
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Huang W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152833
   Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jha Mithilesh Kumar, 2013, Brain Tumor Res Treat, V1, P57, DOI 10.14791/btrt.2013.1.2.57
   Jia D, 2015, CELL DEATH DIFFER, V22, P298, DOI 10.1038/cdd.2014.145
   Jin J, 2013, MOL CELL BIOCHEM, V381, P267, DOI 10.1007/s11010-013-1710-y
   Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141
   Katoh Y, 2006, INT J ONCOL, V28, P1585
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kolev Y, 2008, ANN SURG ONCOL, V15, P2336, DOI 10.1245/s10434-008-9955-5
   Koukourakis MI, 2003, BRIT J CANCER, V89, P877, DOI 10.1038/sj.bjc.6601205
   Koukourakis MI, 2011, CLIN CANCER RES, V17, P4892, DOI 10.1158/1078-0432.CCR-10-2918
   Krebs H A, 1972, Essays Biochem, V8, P1
   Kuphal S, 2004, ONCOGENE, V23, P8509, DOI 10.1038/sj.onc.1207831
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200
   Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200
   Leveillard T, 2017, CELL MOL LIFE SCI, V74, P3649, DOI 10.1007/s00018-016-2318-7
   Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967
   Li D, 2014, ONCOGENE, V33, P1239, DOI 10.1038/onc.2013.75
   Lin CH, 2013, BRIT J PHARMACOL, V168, P920, DOI 10.1111/j.1476-5381.2012.02227.x
   Lindsay KJ, 2014, P NATL ACAD SCI USA, V111, P15579, DOI 10.1073/pnas.1412441111
   Liu XX, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-356
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lu SL, 2013, ANTIMICROB AGENTS CH, V57, P5366, DOI 10.1128/AAC.00322-13
   Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107
   Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378
   Ma B, 2013, J BIOL CHEM, V288, P17552, DOI 10.1074/jbc.M113.453985
   Machon O, 2010, GENESIS, V48, P86, DOI 10.1002/dvg.20583
   McBride JD, 2014, J INVEST DERMATOL, V134, P1725, DOI 10.1038/jid.2014.40
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Menon G, 2009, EYE, V23, pS1, DOI 10.1038/eye.2009.13
   MICELI MV, 1990, INVEST OPHTH VIS SCI, V31, P277
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Nejak-Bowen K, 2013, HEPATOLOGY, V57, P763, DOI 10.1002/hep.26042
   Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105
   Oguma K, 2010, FUTURE ONCOL, V6, P515, DOI [10.2217/fon.10.13, 10.2217/FON.10.13]
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Park K, 2011, MOL CELL BIOL, V31, P3038, DOI 10.1128/MCB.01211-10
   Parra-Bonilla G, 2010, AM J PHYSIOL-LUNG C, V299, pL513, DOI 10.1152/ajplung.00274.2009
   Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655
   Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   POITRYYAMATE CL, 1995, J NEUROSCI, V15, P5179
   Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016
   Qiu FF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01119-2
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Reidel B, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002469
   Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saegusa M, 2007, J PATHOL, V213, P35, DOI 10.1002/path.2198
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sami A, 2013, TUMOR BIOL, V34, P1991, DOI 10.1007/s13277-013-0800-5
   San-Millan I, 2017, CARCINOGENESIS, V38, P119, DOI 10.1093/carcin/bgw127
   Schon S, 2014, INT J CANCER, V135, P1800, DOI 10.1002/ijc.28839
   Scholz CC, 2013, P NATL ACAD SCI USA, V110, P18490, DOI 10.1073/pnas.1309718110
   Schubert D, 2005, AGEING RES REV, V4, P240, DOI 10.1016/j.arr.2005.02.003
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1
   Semenza GL, 1999, ANN NY ACAD SCI, V874, P262, DOI 10.1111/j.1749-6632.1999.tb09241.x
   Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Shibuya K, 2015, ONCOTARGET, V6, P651, DOI 10.18632/oncotarget.2892
   Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Shu QM, 2014, J MOL NEUROSCI, V54, P243, DOI 10.1007/s12031-014-0281-z
   Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5
   Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010
   Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Takata S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09898
   Terasaki H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069994
   Thompson CB, 2014, EMBO J, V33, P1420, DOI 10.15252/embj.201488785
   Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Tuo JS, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.01.009
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Voorzanger-Rousselot N, 2009, BRIT J HAEMATOL, V145, P264, DOI 10.1111/j.1365-2141.2009.07587.x
   Waaler J, 2011, CANCER RES, V71, P197, DOI 10.1158/0008-5472.CAN-10-1282
   Wang HB, 2016, MOL VIS, V22, P189
   Wang HB, 2016, MOL VIS, V22, P116
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
   Wang L, 1997, INVEST OPHTH VIS SCI, V38, P48
   Wang XH, 2004, ARTERIOSCL THROM VAS, V24, P85, DOI 10.1161/01.ATV.0000104012.40720.c4
   Wang Y, 2016, MOL VIS, V22
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667
   Winkler BS, 2000, INVEST OPHTH VIS SCI, V41, P3183
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719
   Xu Y, 2014, J MOL NEUROSCI, V52, P331, DOI 10.1007/s12031-013-0153-y
   Yang XW, 2015, CELL MOL NEUROBIOL, V35, P1175, DOI 10.1007/s10571-015-0211-9
   Ye JP, 2003, AM J PHYSIOL-LUNG C, V284, pL386, DOI 10.1152/ajplung.00134.2002
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
   Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x
   Yokosako K, 2014, OPEN OPHTHALMOL J, V8, P39, DOI 10.2174/1874364101408010039
   Yun K, 2007, BIOCHEM BIOPH RES CO, V357, P589, DOI 10.1016/j.bbrc.2007.03.170
   Yun K, 2009, J IMMUNOL, V183, P5129, DOI 10.4049/jimmunol.0802744
   Zhang JM, 2013, MOL CELL BIOCHEM, V379, P295, DOI 10.1007/s11010-013-1654-2
   Zhang J, 2013, SYNAPSE, V67, P515, DOI 10.1002/syn.21674
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
   Zhang P, 2009, GRAEF ARCH CLIN EXP, V247, P633, DOI 10.1007/s00417-008-1031-0
   Zhang XB, 2001, CANCER RES, V61, P6050
   Zhang YH, 2009, DEV CELL, V17, P49, DOI 10.1016/j.devcel.2009.05.011
   Zhao WT, 2015, INFLAMMATION, V38, P1700, DOI 10.1007/s10753-015-0147-8
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
   Zhou YL, 2014, J CLIN INVEST, V124, P3825, DOI 10.1172/JCI76431
NR 191
TC 42
Z9 43
U1 0
U2 18
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD AUG
PY 2017
VL 62
IS 3-4
BP 368
EP 379
DI 10.1007/s12031-017-0947-4
PG 12
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA FD2HS
UT WOS:000407356600012
PM 28689265
DA 2022-11-30
ER

PT J
AU Fields, M
   Cai, H
   Gong, J
   Del Priore, L
AF Fields, Mark
   Cai, Hui
   Gong, Jie
   Del Priore, Lucian
TI Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating
   Age-Related Macular Degeneration (AMD)
SO CELLS
LA English
DT Review
DE age-related macular degeneration; induced pluripotent stem cell; retinal
   pigment epithelium; Bruch's membrane; disease modeling
ID RETINAL-PIGMENT EPITHELIUM; BRUCHS MEMBRANE; EXTRACELLULAR-MATRIX;
   PRECLINICAL MODEL; GENE-THERAPY; TRANSPLANTATION; DRUSEN; RPE;
   REATTACHMENT; DISEASE
AB The field of stem cell biology has rapidly evolved in the last few decades. In the area of regenerative medicine, clinical applications using stem cells hold the potential to be a powerful tool in the treatment of a wide variety of diseases, in particular, disorders of the eye. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are promising technologies that can potentially provide an unlimited source of cells for cell replacement therapy in the treatment of retinal degenerative disorders such as age-related macular degeneration (AMD), Stargardt disease, and other disorders. ESCs and iPSCs have been used to generate retinal pigment epithelium (RPE) cells and their functional behavior has been tested in vitro and in vivo in animal models. Additionally, iPSC-derived RPE cells provide an autologous source of cells for therapeutic use, as well as allow for novel approaches in disease modeling and drug development platforms. Clinical trials are currently testing the safety and efficacy of these cells in patients with AMD. In this review, the current status of iPSC disease modeling of AMD is discussed, as well as the challenges and potential of this technology as a viable option for cell replacement therapy in retinal degeneration.
C1 [Fields, Mark; Cai, Hui; Gong, Jie; Del Priore, Lucian] Yale Univ, Yale Sch Med, Dept Ophthalmol & Visual Sci, 300 George St,Suite 8100, New Haven, CT 06511 USA.
C3 Yale University
RP Fields, M (通讯作者)，Yale Univ, Yale Sch Med, Dept Ophthalmol & Visual Sci, 300 George St,Suite 8100, New Haven, CT 06511 USA.
EM mark.fields@yale.edu; huey.cai@yale.edu; jie.gong@yale.edu;
   lucian.delpriore@yale.edu
FU Research to Prevent Blindness (RPB), Inc., New York, NY, USA; Foundation
   Fighting Blindness, Columbia, MD, USA
FX This work has been supported in part by an unrestricted/challenge award
   to Yale Eye Center from the Research to Prevent Blindness (RPB), Inc.,
   New York, NY, USA; and the Foundation Fighting Blindness, Columbia, MD,
   USA. The authors would like to thank Luanna Bartholomew for her
   intellectual contribution and critical review of this manuscript.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   [Anonymous], 2016, JAPAN TIMES
   Araki R, 2013, NATURE, V494, P100, DOI 10.1038/nature11807
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Cai H, 2006, CURR EYE RES, V31, P181, DOI 10.1080/02713680500514628
   CALDWELL RB, 1989, CURR EYE RES, V8, P907
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Castellarin AA, 1998, EXP EYE RES, V66, P49, DOI 10.1006/exer.1997.0404
   Chakradhar S, 2016, NAT MED, V22, P116, DOI 10.1038/nm0216-116
   Cheng SK, 2016, AM J STEM CELLS, V5, P74
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   De Vos J, 2016, CURR RES TRANSL MED, V64, P91, DOI 10.1016/j.retram.2016.04.001
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   DELPRIORE LV, 1995, ARCH OPHTHALMOL-CHIC, V113, P939, DOI 10.1001/archopht.1995.01100070113034
   DESAI VN, 1995, ARCH OPHTHALMOL-CHIC, V113, P409, DOI 10.1001/archopht.1995.01100040023014
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Fields MA, 2013, STEM CELL BIOL REGEN, P1
   Fields MA, 2015, PROG MOL BIOL TRANSL, V134, P477, DOI 10.1016/bs.pmbts.2015.06.004
   Fields MA, 2015, INVEST OPHTH VIS SCI, V56, P4231, DOI 10.1167/iovs.15-16438
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Gong J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143272
   Guha P, 2013, CELL STEM CELL, V12, P407, DOI 10.1016/j.stem.2013.01.006
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   HENKIND P, 1983, T OPHTHAL SOC UK, V103, P444
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Inoue H, 2011, CLIN PHARMACOL THER, V89, P655, DOI 10.1038/clpt.2011.38
   Inoue H, 2014, EMBO J, V33, P409, DOI 10.1002/embj.201387098
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Kawamata S, 2015, J CLIN MED, V4, P159, DOI 10.3390/jcm4010159
   Kimbrel EA, 2015, NAT REV DRUG DISCOV, V14, P681, DOI 10.1038/nrd4738
   Klassen H, 2016, EXPERT OPIN BIOL TH, V16, P7, DOI 10.1517/14712598.2016.1093110
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kumar A, 2016, MOL NEUROBIOL
   KUWABARA T, 1981, OPHTHALMOLOGY, V88, P331
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Li J, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0050-z
   Li Y, 2016, ADV EXP MED BIOL, V854, P549, DOI 10.1007/978-3-319-17121-0_73
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Liao J, 2009, CELL STEM CELL, V4, P11, DOI 10.1016/j.stem.2008.11.013
   Liu HS, 2008, CELL STEM CELL, V3, P587, DOI 10.1016/j.stem.2008.10.014
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   MILLER FS, 1982, OPHTHALMOLOGY, V89, P1478
   Moreira EF, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.10
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Nguyen HV, 2015, J CLIN MED, V4, P567, DOI 10.3390/jcm4040567
   Okamoto S, 2011, INVEST OPHTH VIS SCI, V52, P8785, DOI 10.1167/iovs.11-8129
   Okano H, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-22
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Paik DC, 2001, CONNECT TISSUE RES, V42, P111, DOI 10.3109/03008200109014253
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pollack JS, 1996, BRIT J OPHTHALMOL, V80, P314, DOI 10.1136/bjo.80.4.314
   Reardon S, 2014, NATURE, V513, P287, DOI 10.1038/513287a
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shimada H, 2010, MOL REPROD DEV, V77, P2, DOI 10.1002/mrd.21117
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Song MJ, 2016, BRAIN RES, V1638, P2, DOI 10.1016/j.brainres.2015.12.011
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   TAKEUCHI M, 1992, Nippon Ganka Gakkai Zasshi, V96, P161
   Takeuchi Masamitsu, 1993, Nippon Ganka Gakkai Zasshi, V97, P17
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tezel TH, 1999, OPHTHALMIC RES, V31, P192, DOI 10.1159/000055532
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Trounson A, 2016, NAT REV MOL CELL BIO, V17, P194, DOI 10.1038/nrm.2016.10
   Tucker Budd A, 2014, J Stem Cell Res Ther, V3, P161
   VALENTINO TL, 1995, ARCH OPHTHALMOL-CHIC, V113, P932, DOI 10.1001/archopht.1995.01100070106033
   Wang H, 2004, EXP EYE RES, V78, P53, DOI 10.1016/j.exer.2003.09.024
   Wang Z, 2005, CURR EYE RES, V30, P691, DOI 10.1080/02713680590968259
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Westenskow P, 2015, JOVE-J VIS EXP, DOI 10.3791/52214
   Westenskow PD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8470263
   Wu N, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2361763
   Yamanaka S, 2009, CELL, V137, P13, DOI 10.1016/j.cell.2009.03.034
   Yoshihara M, 2016, STEM CELL REV
   Yvon C, 2015, COMPUT STRUCT BIOTEC, V13, P382, DOI 10.1016/j.csbj.2015.05.001
   Zinn KM, 1979, RETINAL PIGMENT EPIT
NR 100
TC 18
Z9 20
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD DEC
PY 2016
VL 5
IS 4
AR 44
DI 10.3390/cells5040044
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FR0XI
UT WOS:000418786900008
PM 27941641
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Usategui-Martin, R
   Pastor-Idoate, S
   Chamorro, AJ
   Fernandez, I
   Fernandez-Bueno, I
   Marcos-Martin, M
   Gonzalez-Sarmiento, R
   Pastor, JC
AF Usategui-Martin, Ricardo
   Pastor-Idoate, Salvador
   Chamorro, Antonio J.
   Fernandez, Itziar
   Fernandez-Bueno, Ivan
   Marcos-Martin, Miguel
   Gonzalez-Sarmiento, Rogelio
   Carlos Pastor, Jose
TI Meta-analysis of the rs243865 MMP-2 polymorphism and age-related macular
   degeneration risk
SO PLOS ONE
LA English
DT Article
ID MATRIX METALLOPROTEINASES; ASSOCIATION; GENE; CLASSIFICATION;
   PATHOGENESIS; MACULOPATHY; PREVALENCE; MEMBRANE; VARIANTS; COLLAGEN
AB Purpose
   Several researchers have suggested that the rs243865 (16q13-q21) polymorphism in the promoter region of the metalloproteinase-2 (MMP-2) gene could be associated with an increased risk of developing age-related macular degeneration (AMD). However, previous results remain inconclusive. To clarify this controversy, we conducted a meta-analysis of the relationship between rs243865 of MMP-2 and AMD.
   Methods
   We included 6 independent case-control studies involving 1,682 AMD patients and 2,295 healthy subjects. The association between the rs243865 polymorphism and AMD was examined by the overall odds ratio (OR) with a 95% confidence interval (CI). We used a recessive genetic model analysis, sensitivity analysis, and assessment of bias in our meta analysis.
   Results
   Our results showed that there was no significant association between the variant T allele (p-value = 0.10, OR [95%CI] = 0.95 [0.82-1.10]) or the CT+TT genotype (p-value = 0.16, OR [95%CI] = 0.92 [0.76-1.12]) of rs243865 MMP-2 polymorphism and the presence of AMD.
   Conclusions
   The rs243865 MMP-2 polymorphism was not associated with an increased risk of developing AMD. The MMP-2 (-1306 C>T) promoter variant is unlikely to have a major role in AMD risk susceptibility.
C1 [Usategui-Martin, Ricardo; Pastor-Idoate, Salvador; Fernandez, Itziar; Fernandez-Bueno, Ivan; Carlos Pastor, Jose] Univ Valladolid, Inst Univ Oftalmobiol Aplicada IOBA, Valladolid, Spain.
   [Pastor-Idoate, Salvador; Carlos Pastor, Jose] Hosp Clin Univ Valladolid, Dept Ophthalmol, Valladolid, Spain.
   [Pastor-Idoate, Salvador; Carlos Pastor, Jose] Inst Salud Carlos III, Oftared, Red Temat Invest Cooperat Salud RETICS, Valladolid, Spain.
   [Chamorro, Antonio J.; Marcos-Martin, Miguel] Univ Hosp Salamanca SACYL, Dept Internal Med, Salamanca, Spain.
   [Chamorro, Antonio J.; Marcos-Martin, Miguel; Gonzalez-Sarmiento, Rogelio] Univ Salamanca, Dept Med, Salamanca, Spain.
   [Fernandez, Itziar] Univ Valladolid, Dept Stat & Operat Res, Valladolid, Spain.
   [Marcos-Martin, Miguel; Gonzalez-Sarmiento, Rogelio] Inst Biomed Res Salamanca IBSAL, Salamanca, Spain.
   [Fernandez, Itziar] Bioengn Biomat & Nanomed CIBER BBN, Valladolid, Spain.
   [Fernandez-Bueno, Ivan; Carlos Pastor, Jose] Ctr Red Med Regenerat & Terapia Celular Castilla, Valladolid, Spain.
   [Gonzalez-Sarmiento, Rogelio] Univ Salamanca, CSIC, Inst Mol & Cellular Biol Canc IBMCC, Salamanca, Spain.
C3 Universidad de Valladolid; Instituto de Salud Carlos III; University of
   Salamanca; Universidad de Valladolid; University of Salamanca; CIBER -
   Centro de Investigacion Biomedica en Red; CIBERBBN; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia
   Molecular y Celular del Cancer de Salamanca (IBMCC); University of
   Salamanca
RP Usategui-Martin, R; Pastor-Idoate, S (通讯作者)，Univ Valladolid, Inst Univ Oftalmobiol Aplicada IOBA, Valladolid, Spain.; Pastor-Idoate, S (通讯作者)，Hosp Clin Univ Valladolid, Dept Ophthalmol, Valladolid, Spain.; Pastor-Idoate, S (通讯作者)，Inst Salud Carlos III, Oftared, Red Temat Invest Cooperat Salud RETICS, Valladolid, Spain.
EM rusategui@gmail.com; pastoridoate.salvador@gmail.com
RI Marcos, Miguel/B-3550-2008; Fernández, Itziar/AAF-9590-2020; Jimeno, J
   Carlos Pastor/AAP-1156-2020; Gonzalez-Sarmiento, Rogelio/V-5526-2019;
   Chamorro, Antonio-J/A-6257-2013; PASTOR-IDOATE, SALVADOR/G-2548-2016;
   Fernandez-Bueno, Ivan/H-4201-2015
OI Marcos, Miguel/0000-0003-1269-4487; Fernández,
   Itziar/0000-0002-5077-4448; Jimeno, J Carlos Pastor/0000-0001-5934-7306;
   Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; Chamorro,
   Antonio-J/0000-0002-2345-2873; PASTOR-IDOATE,
   SALVADOR/0000-0002-6463-4227; Fernandez-Bueno, Ivan/0000-0003-3380-4040
FU Consejeria de Educacion, Junta de Castilla y Leon, Fondos FEDER
   [VA077P17]; Gerencia Regional de Salud de Castilla y Leon [INT/M/06/18]
FX This work was supported in part by a grant from the Consejeria de
   Educacion, Junta de Castilla y Leon, Fondos FEDER (VA077P17) (JCP) and
   from Gerencia Regional de Salud de Castilla y Leon (INT/M/06/18) (AJC).
CR [Anonymous], 2014, REV MAN REVMAN COMP
   Atkinson SJ, 2001, FEBS LETT, V491, P222, DOI 10.1016/S0014-5793(01)02204-9
   Belkhiri A, 1997, LAB INVEST, V77, P533
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Cheng J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008190
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   Dollery CM, 2006, CARDIOVASC RES, V69, P625, DOI 10.1016/j.cardiores.2005.11.003
   Elliot SJ, 2010, EXP EYE RES, V90, P10, DOI 10.1016/j.exer.2009.09.001
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hageman GS, 1999, MOL VIS, V5
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Little J, 2009, PLOS MED, V6, P151, DOI 10.1371/journal.pmed.1000022
   Liutkeviciene R, 2018, INDIAN J OPHTHALMOL, V66, P551, DOI 10.4103/ijo.IJO_1050_17
   Liutkeviciene R, 2017, INT J OPHTHALMOL-CHI, V10, P1349, DOI 10.18240/ijo.2017.09.03
   Liutkeviciene R, 2016, OPHTHALMIC GENET, V37, P170, DOI 10.3109/13816810.2015.1020556
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Ortak H, 2013, OPHTHALMIC GENET, V34, P217, DOI 10.3109/13816810.2013.781192
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   PETEN EP, 1992, AM J PHYSIOL, V263, pF951, DOI 10.1152/ajprenal.1992.263.5.F951
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Price SJ, 2001, J BIOL CHEM, V276, P7549, DOI 10.1074/jbc.M010242200
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Seitzman RL, 2008, AM J EPIDEMIOL, V167, P1217, DOI 10.1093/aje/kwn024
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 36
TC 5
Z9 5
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 7
PY 2019
VL 14
IS 3
AR e0213624
DI 10.1371/journal.pone.0213624
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HO1AY
UT WOS:000460638800106
PM 30845235
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhang, JY
   Zhou, Y
AF Zhang, Junyu
   Zhou, Yu
TI Identification of Key Genes and Pathways Associated with Age-Related
   Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; EXPRESSION; PHOTORECEPTOR; INHIBITION;
   BLINDNESS; MODEL; ROCK
AB Age-related macular degeneration (AMD) is the leading cause of severe, permanent vision loss among the elderly in the developed world. The cellular and molecular pathogenesis of initiation and development of AMD remain poorly delineated. The limited resources of the human AMD RPE/choroid tissues impeded the extensive study of the disease. To better understand the molecular and pathway changes in human AMD RPE/choroid tissues, we searched the literature and found three independent studies using high-throughput technology to analyze gene expression in 54 human AMD RPE/choroid tissues and 46 age-matched healthy controls. We downloaded these data, pooled them together, and reanalyzed the difference between molecular and pathways by the Ingenuity Pathway Analysis (IPA) database. Totally, 353 differentially expressed genes (DEGs) were identified, among which 181 genes were downregulated and 172 genes were upregulated in RPE/choroid of AMD patients. Furthermore, several significantly enriched biological processes, including cancer, organismal injury and abnormalities, and ophthalmic disease, were identified associated with these DEGs. By analysis of canonical pathway, the phototransduction pathway and atherosclerosis signaling were the top two significant canonical pathways altered in RPE/choroid tissues in human AMD. As expected, several ophthalmic disease-related molecules, including RHO, PDE6A, 3 ',5 '-cyclic-GMP phosphodiesterase, and G protein alpha, were in the central nodes of disease network. The bioinformatics technology combined with the existing high-throughput data was applied to evaluate the underlying key genes and pathways in human AMD tissues, which may predict downstream and upstream biological processes and identify potential therapeutic intervention targets in human AMD.
C1 [Zhang, Junyu; Zhou, Yu] Univ Elect Sci & Technol China, Sichuan Prov Key Lab Human Dis Gene Study, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 611731, Peoples R China.
   [Zhang, Junyu] Shanghai Jiao Tong Univ, Sch Med, Int Peace Matern & Child Hlth Hosp, Shanghai, Peoples R China.
   [Zhang, Junyu] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Zhou, Yu] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Lab Med, Chengdu 610072, Peoples R China.
   [Zhou, Yu] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
   [Zhou, Yu] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA.
C3 Sichuan Provincial People's Hospital; University of Electronic Science &
   Technology of China; Shanghai Jiao Tong University; Harvard University;
   Brigham & Women's Hospital; Harvard Medical School; Sichuan Provincial
   People's Hospital; Harvard University; Dana-Farber Cancer Institute;
   Harvard University; Harvard Medical School
RP Zhou, Y (通讯作者)，Univ Elect Sci & Technol China, Sichuan Prov Key Lab Human Dis Gene Study, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 611731, Peoples R China.; Zhou, Y (通讯作者)，Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Lab Med, Chengdu 610072, Peoples R China.; Zhou, Y (通讯作者)，Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.; Zhou, Y (通讯作者)，Harvard Med Sch, Dept Genet, Boston, MA 02115 USA.
EM zhouyu422@yahoo.com
RI Zhang, Junyu/AAF-6658-2019
OI Zhang, Junyu/0000-0003-0239-6670
FU National Natural Science Foundation of China [81970825, 81401219];
   Chengdu Science and Technology Department [2018-YF05-01080-SN]; Sichuan
   Provincial Health Department [19PJ260]; Shanghai Municipal Commission of
   Science and Technology Program [19ZR1462300]; Municipal Human Resources
   Development Program for Outstanding Young Talents in Medical and Health
   Sciences in Shanghai [2018YQ39]; Shanghai Jiao Tong University Program
   [YG2017MS39]
FX This work was supported by the National Natural Science Foundation of
   China (no. 81970825 to YZ and no. 81401219 to JZ), Chengdu Science and
   Technology Department (no. 2018-YF05-01080-SN to YZ), Sichuan Provincial
   Health Department (no. 19PJ260 to YZ), the Shanghai Municipal Commission
   of Science and Technology Program (no. 19ZR1462300 to JZ), the Municipal
   Human Resources Development Program for Outstanding Young Talents in
   Medical and Health Sciences in Shanghai (no. 2018YQ39 to JZ), and the
   Shanghai Jiao Tong University Program (no. YG2017MS39 to JZ).
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arita R, 2013, INVEST OPHTH VIS SCI, V54, P2373, DOI 10.1167/iovs.12-10757
   Arita R, 2009, DIABETES, V58, P215, DOI 10.2337/db08-0762
   Barabas P, 2013, P NATL ACAD SCI USA, V110, P5181, DOI 10.1073/pnas.1214707110
   Bennis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141597
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Blair AB, 2019, J CLIN INVEST, V129, P1742, DOI 10.1172/JCI124077
   BOK D, 1993, J CELL SCI, P189
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gonzalez ER, 2002, ORG DIVERS EVOL, V2
   Hollanders K, 2015, INVEST OPHTH VIS SCI, V56, P1335, DOI 10.1167/iovs.14-15681
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Kanda A, 2010, MOL VIS, V16, P1317
   KIM EJ, 2018, SCI REP UK, V0008
   Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Olivares-Gonzalez L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166717
   Peck D, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r61
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337
   Sothilingam V, 2015, HUM MOL GENET, V24, P5486, DOI 10.1093/hmg/ddv275
   Strassheim D, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060551
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tang K, 2015, INT J CLIN EXP PATHO, V8, P3174
   Tanihara H, 2015, JAMA OPHTHALMOL, V133, P755, DOI 10.1001/jamaophthalmol.2015.0525
   Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117
   Vancura P, 2018, INVEST OPHTH VIS SCI, V59, P3789, DOI 10.1167/iovs.18-24558
   Vinberg F, 2015, HUM MOL GENET, V24, P5915, DOI 10.1093/hmg/ddv319
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yau KW, 2009, CELL, V139, P246, DOI 10.1016/j.cell.2009.09.029
   Zarbin M, 2019, STEM CELL TRANSL MED, V8, P466, DOI 10.1002/sctm.18-0282
   Zhang ZY, 2012, MOL VIS, V18, P2961
NR 41
TC 5
Z9 5
U1 1
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD AUG 21
PY 2020
VL 2020
AR 2714746
DI 10.1155/2020/2714746
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NK9SR
UT WOS:000567068800001
PM 32904543
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Solanki, A
   Smalling, R
   Parola, AH
   Nathan, I
   Kasher, R
   Pathak, Y
   Sutariya, V
AF Solanki, Aum
   Smalling, Rudy
   Parola, Abraham H.
   Nathan, Ilana
   Kasher, Roni
   Pathak, Yashwant
   Sutariya, Vijaykumar
TI Humanin Nanoparticles for Reducing Pathological Factors Characteristic
   of Age-related Macular Degeneration
SO CURRENT DRUG DELIVERY
LA English
DT Article
DE Nanoparticles; humanin peptide; age-related macular degeneration;
   vascular endothelial growth factor; ARPE-19 cells; chitosan
ID OXIDATIVE STRESS; DRUG-DELIVERY; CELL-DEATH; TRIAMCINOLONE;
   DEXAMETHASONE; PREVALENCE; APOPTOSIS; SYSTEMS; EDEMA
AB Background: Humanin is a novel neuronal peptide that has displayed potential in the treatment of Alzheimer's Disease through the suppression of inflammatory IL-6 cytokine receptors. Such receptors are found throughout the body, including the eye, suggesting its other potential applications. Age-related Macular Degeneration (AMD) is the leading cause of blindness in the developing world. There is no cure for this disease, and current treatments have several negative side effects associated with them, making finding other treatment options desirable.
   Objective: In this study, the potential applications in treating AMD for a more potent humanin derivative, AGA-HNG, were studied.
   Methods: AGA-HNG was synthesized and encapsulated in chitosan Nanoparticles (NPs), which were then characterized for their size, Encapsulation Efficiency (EE), and drug release. Their ability to suppress VEGF secretion and protect against oxidative apoptosis was studied in vitro using ARPE-19 cells. The chitosan NPs exhibited similar anti-VEGF properties and oxidative protection as the free protein while exhibiting superior pharmaceutical characteristics including biocompatibility and drug release.
   Results: Drug-loaded NPs exhibited a radius of 346nm with desirable pharmacokinetic properties including a stable surface charge (19.5 +/- 3.7 mV) and steady drug release capacity. AGA-HNG showed great promise in mediating apoptosis in hypoxic cells. They were also able to significantly reduce VEGF expression in vitro with reduced cellular toxicity compared to the free drug.
   Conclusion: The ability of this drug delivery system to reduce retinal apoptosis with desirable pharmacokinetic and biocompatible properties makes this a promising therapeutic option for AMD.
C1 [Solanki, Aum; Smalling, Rudy; Pathak, Yashwant; Sutariya, Vijaykumar] Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33647 USA.
   [Solanki, Aum] Univ S Florida, Morsani Coll ofMed, Tampa, FL 33647 USA.
   [Parola, Abraham H.] Ben Gurion Univ Negev, Fac Nat Sci, Dept Chem, Beer Sheva, Israel.
   [Nathan, Ilana] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem & Pharmacol, Beer Sheva, Israel.
   [Kasher, Roni] Ben Gurion Univ Negev, Blaustein Inst Desert Res, Zuckerberg Inst Water Res, Dept Desalinat & Water Treatment, Sede Boquer Campus, IL-8499000 Beer Sheva, Israel.
   [Pathak, Yashwant] Univ Airlangga, Fac Publ Hlth, Surabaya, Indonesia.
C3 State University System of Florida; University of South Florida; State
   University System of Florida; University of South Florida; Ben Gurion
   University; Ben Gurion University; Ben Gurion University; Airlangga
   University
RP Sutariya, V (通讯作者)，Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC 30, Tampa, FL 33612 USA.
EM vsaturiy@health.usf.edu
RI pathak, yashwant/AAN-3177-2021
OI Parola, Abraham H./0000-0002-3953-5454; Nathan,
   Ilana/0000-0003-0739-0884
CR Ahmadi F, 2017, INT J NANOMED, V12, P8545, DOI 10.2147/IJN.S146516
   Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Bhattacharyya K, 2018, B CHEM SOC JPN, V91, P447, DOI 10.1246/bcsj.20170377
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bisht R, 2018, WIRES NANOMED NANOBI, V10, DOI 10.1002/wnan.1473
   Charununtakorn ST, 2016, CARDIOVASC THER, V34, P107, DOI 10.1111/1755-5922.12168
   Cheng L, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00020
   Cohen A, 2015, MOL MED, V21, P505, DOI 10.2119/molmed.2015.00073
   Cunningham MA, 2008, SURV OPHTHALMOL, V53, P139, DOI 10.1016/j.survophthal.2007.12.005
   D'Souza Susan S, 2005, AAPS PharmSciTech, V6, pE323, DOI 10.1208/pt060242
   Duan SJ, 2018, CANCER BIOMARK, V21, P565, DOI 10.3233/CBM-170444
   Duvvuri S, 2003, EXPERT OPIN BIOL TH, V3, P45, DOI 10.1517/14712598.3.1.45
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GRAHAM RO, 1974, ARCH OPHTHALMOL-CHIC, V92, P149, DOI 10.1001/archopht.1974.01010010155016
   Grover A, 2014, AAPS PHARMSCITECH, V15, P1562, DOI 10.1208/s12249-014-0165-0
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jang KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.437
   Kaji H, 2018, ADV DRUG DELIVER REV, V128, P148, DOI 10.1016/j.addr.2017.07.002
   Kalam MA, 2016, INT J BIOL MACROMOL, V89, P127, DOI 10.1016/j.ijbiomac.2016.04.070
   Komiyama M, 2017, B CHEM SOC JPN, V90, P967, DOI 10.1246/bcsj.20170156
   Matsumoto H, 2014, INVEST OPHTH VIS SCI, V55, P4165, DOI 10.1167/iovs.14-14238
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Minasyan L, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1675230
   Nayak K, 2018, BIOMED PHARMACOTHER, V107, P1564, DOI 10.1016/j.biopha.2018.08.138
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Offord EA, 1999, INVEST OPHTH VIS SCI, V40, P1091
   Pozarowska D, 2016, CENT EUR J IMMUNOL, V41, P311, DOI 10.5114/ceji.2016.63132
   Raveendran S, 2017, MATERIALS, V10, DOI 10.3390/ma10080929
   Reichle Michelle L, 2005, Optometry, V76, P450, DOI 10.1016/j.optm.2005.06.013
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Telegina DV, 2017, ADV GERONTOL, V7, P17, DOI 10.1134/S2079057017010155
   URTTI A, 1993, SURV OPHTHALMOL, V37, P435, DOI 10.1016/0039-6257(93)90141-S
   Vakalis N, 2015, SCI REP-UK, V5, DOI 10.1038/srep08627
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
   Yu KY, 2018, INT J NANOMED, V13, P129, DOI 10.2147/IJN.S150319
NR 39
TC 7
Z9 7
U1 0
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2018
EI 1875-5704
J9 CURR DRUG DELIV
JI Curr. Drug Deliv.
PY 2019
VL 16
IS 3
BP 226
EP 232
DI 10.2174/1567201815666181031163111
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HJ9AH
UT WOS:000457490700004
PM 30381074
DA 2022-11-30
ER

PT J
AU Ahmad, S
   Bearelly, S
   Stinnett, SS
   Cooney, MJ
   Fekrat, S
AF Ahmad, Saad
   Bearelly, Srilaxmi
   Stinnett, Sandra S.
   Cooney, Michael J.
   Fekrat, Sharon
TI Photodynamic therapy for predominantly hemorrhagic lesions in
   neovascular age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL HEMORRHAGE; CHOROIDAL NEOVASCULARIZATION; SUBMACULAR
   HEMORRHAGE; PNEUMATIC DISPLACEMENT; NATURAL-HISTORY; MANAGEMENT
AB PURPOSE: To evaluate the response of eyes treated with photodynamic therapy (PDT) for predominantly hemorrhagic lesions in neovascular age-related macular degeneration (NVAMD).
   DESIGN: Consecutive, interventional case series.
   METHODS: A retrospective review was conducted of eyes with NVAMD that were treated with PDT for predominantly hemorrhagic subfoveal lesions. Baseline data recorded were patient age, use of aspirin or warfarin, history of previous PDT treatment, visual acuity (VA), extent of subretinal hemorrhage (SRH), and central foveal thickness (CFT) and total macular volume (TMV) measured by optical coherence tomography (OCT). Follow-up VA, SRH status, and complications were re, corded.
   RESULTS: Twenty,one eyes of 21 patients were identified with a mean posttreatment follow,up of 9.4 months. Mean pretreatment VA was 20/210, and mean SRH size was 16 disk areas. The SRH resolved in 18 eyes (86%) after a mean of six months, with a mean VA of 20/210. Mean VA for all eyes at most recent follow-up was 20/250. Thirteen (62%) of 21 eyes exhibited stable or improved VA at the most recent follow,up. VA one year after PDT inversely correlated with patient age (P = .045) and initial SRH size (P = .04) and positively correlated with pretreatment VA (P = .01). Previous PDT treatment, use of aspirin or warfarin, and OCT data did not significantly correlate with VA or SRH resolution.
   CONCLUSIONS: PDT may be an effective treatment for minimizing visual loss in eyes with NVAMD and predominantly hemorrhagic lesions. Further study is war, ranted to detail the risk-benefit ratio and compare PDT with other treatment modalities.
C1 [Ahmad, Saad; Bearelly, Srilaxmi; Stinnett, Sandra S.; Cooney, Michael J.; Fekrat, Sharon] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
C3 Duke University
RP Fekrat, S (通讯作者)，Duke Univ, Ctr Eye, Box 3802,Erwin Rd, Durham, NC 27710 USA.
EM fekra001@mc.duke.edu
OI Stinnett, Sandra/0000-0001-7192-0195
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bakri SJ, 2006, OPHTHAL SURG LAS IM, V37, P278, DOI 10.3928/15428877-20060701-03
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Hasler PW, 2007, ACTA OPHTHALMOL SCAN, V85, P577, DOI 10.1111/j.1600-0420.2007.00914.x
   Lauritzen Derek B., 2002, International Ophthalmology Clinics, V42, P87
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Ruiz-Moreno JM, 2006, EUR J OPHTHALMOL, V16, P426, DOI 10.1177/112067210601600311
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Stoltz RA, 2005, RETINA-J RET VIT DIS, V25, P498, DOI 10.1097/00006982-200506000-00016
NR 13
TC 14
Z9 15
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2008
VL 145
IS 6
BP 1052
EP 1057
DI 10.1016/j.ajo.2008.02.008
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 307PS
UT WOS:000256331400018
PM 18400198
DA 2022-11-30
ER

PT J
AU Wang, Y
   Zhang, YN
   Yao, ZM
   Zhao, RX
   Zhou, FF
AF Wang, Yu
   Zhang, Yaonan
   Yao, Zhaomin
   Zhao, Ruixue
   Zhou, Fengfeng
TI Machine learning based detection of age-related macular degeneration
   (AMD) and diabetic macular edema (DME) from optical coherence tomography
   (OCT) images
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID AUTOMATED DETECTION; DIAGNOSIS; SEGMENTATION; RETINOPATHY; FEATURES;
   SHAPE
AB Non-lethal macular diseases greatly impact patients' life quality, and will cause vision loss at the late stages. Visual inspection of the optical coherence tomography (OCT) images by the experienced clinicians is the main diagnosis technique. We proposed a computer-aided diagnosis (CAD) model to discriminate age-related macular degeneration (AMD), diabetic macular edema (DME) and healthy macula. The linear configuration pattern (LCP) based features of the OCT images were screened by the Correlation-based Feature Subset (CFS) selection algorithm. And the best model based on the sequential minimal optimization (SMO) algorithm achieved 99.3% in the overall accuracy for the three classes of samples. (C) 2016 Optical Society of America
C1 [Wang, Yu; Zhang, Yaonan; Yao, Zhaomin] Northeastern Univ, Sino Dutch Biomed & Informat Engn Sch, Shenyang 110169, Liaoning, Peoples R China.
   [Wang, Yu; Yao, Zhaomin] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen 518055, Guangdong, Peoples R China.
   [Zhang, Yaonan] Xian Siyuan Univ, Coll Elect & Informat Engn, Xian 710038, Peoples R China.
   [Zhao, Ruixue; Zhou, Fengfeng] Jilin Univ, Coll Comp Sci & Technol, Changchun 130012, Jilin, Peoples R China.
   [Zhao, Ruixue; Zhou, Fengfeng] Jilin Univ, Minist Educ, Key Lab Symbol Computat & Knowledge Engn, Changchun 130012, Jilin, Peoples R China.
C3 Northeastern University - China; Chinese Academy of Sciences; Shenzhen
   Institute of Advanced Technology, CAS; Jilin University; Jilin
   University
RP Zhang, YN (通讯作者)，Northeastern Univ, Sino Dutch Biomed & Informat Engn Sch, Shenyang 110169, Liaoning, Peoples R China.; Zhang, YN (通讯作者)，Xian Siyuan Univ, Coll Elect & Informat Engn, Xian 710038, Peoples R China.; Zhou, FF (通讯作者)，Jilin Univ, Coll Comp Sci & Technol, Changchun 130012, Jilin, Peoples R China.; Zhou, FF (通讯作者)，Jilin Univ, Minist Educ, Key Lab Symbol Computat & Knowledge Engn, Changchun 130012, Jilin, Peoples R China.
EM zhangyn@bmie.neu.edu.cn; FengfengZhou@gmail.com
RI Zhou, Fengfeng/A-8932-2008
OI Zhou, Fengfeng/0000-0002-8108-6007
FU Strategic Priority Research Program of the Chinese Academy of Sciences
   [XDB13040400]; Jilin University; major research projects of Xi'an Siyuan
   University [XASY-B1601]
FX This work was supported by the Strategic Priority Research Program of
   the Chinese Academy of Sciences (XDB13040400) and the startup grant from
   the Jilin University. Thanks for the help from the major research
   projects of Xi'an Siyuan University (XASY-B1601).
CR Albarrak A, 2013, P 2013 INT C MED IM, P59
   Bhargava N, 2013, P INT J ADV RES COMP, V3
   BREIMAN L, 2001, MACH LEARN, V0045
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Engelgau MM, 2004, ANN INTERN MED, V140, P945, DOI 10.7326/0003-4819-140-11-200406010-00035
   Ergin S, 2014, COMPUT BIOL MED, V51, P171, DOI 10.1016/j.compbiomed.2014.05.008
   Esener I. I., 2015, INT CONV INF COMM TE
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferreras A, 2008, ARCH OPHTHALMOL-CHIC, V126, P465, DOI 10.1001/archopht.126.4.465
   Fujimoto JG., 2004, OPTICAL COHERENCE TO, V2nd
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Ge RQ, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-0990-0
   Goldberg Y., 2008, P 46 ANN M ASS COMPU, P237
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Guo Y, 2011, BMVC, P1, DOI DOI 10.5244/C.25.119.PP.199.1-199.10
   Guo YM, 2011, PROCEEDINGS OF THE BRITISH MACHINE VISION CONFERENCE 2011, DOI 10.5244/C.25.119
   Hamilton N. Z., 1998, CORRELATION BASED FE
   Hassan B, 2016, J OPT SOC AM A, V33, P455, DOI 10.1364/JOSAA.33.000455
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Iejima Daisuke, 2015, J Stem Cells, V10, P193
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keerthi SS, 2001, NEURAL COMPUT, V13, P13
   Kertes PJ, 2007, EVIDENCE BASED EYE C
   Lazebnik S., 2006, 2006 IEEE COMPUTER S, V2, P2169, DOI DOI 10.1109/CVPR.2006.68
   Lee K, 2010, IEEE T MED IMAGING, V29, P159, DOI 10.1109/TMI.2009.2031324
   Liu YY, 2011, MED IMAGE ANAL, V15, P748, DOI 10.1016/j.media.2011.06.005
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Merl-Pham J, 2016, ADV EXP MED BIOL, V854, P785, DOI 10.1007/978-3-319-17121-0_105
   Mookiah MRK, 2015, COMPUT BIOL MED, V63, P208, DOI 10.1016/j.compbiomed.2015.05.019
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   OJALA T, 1994, INT C PATT RECOG, P582, DOI 10.1109/ICPR.1994.576366
   Oliva A, 2001, INT J COMPUT VISION, V42, P145, DOI 10.1023/A:1011139631724
   Rish I., 2001, ANAL DATA CHARACTERI, V30
   Schuman JS, 1996, OPHTHALMOLOGY, V103, P1889, DOI 10.1016/S0161-6420(96)30410-7
   Senthil Kumar E. N. G. T. K., 2015, EUROMEDITERRANEAN BI, V10, P99
   Smith TC, 2016, METHODS MOL BIOL, V1418, P353, DOI 10.1007/978-1-4939-3578-9_17
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Sudarshan VK, 2016, COMPUT BIOL MED, V71, P241, DOI 10.1016/j.compbiomed.2016.01.029
   Tapp RJ, 2003, DIABETES CARE, V26, P1731, DOI 10.2337/diacare.26.6.1731
   Vidyasagar M, 2014, P ROY SOC A-MATH PHY, V470, DOI 10.1098/rspa.2014.0081
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008081.pub3
   Werbos P.J., 1994, ROOTS BACKPROPAGATIO
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
   Zhou ML, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/910515
NR 46
TC 68
Z9 69
U1 0
U2 24
PU Optica Publishing Group
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD DEC 1
PY 2016
VL 7
IS 12
BP 4928
EP 4940
DI 10.1364/BOE.7.004928
PG 13
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA EF7DQ
UT WOS:000390490700008
PM 28018716
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Metelitsina, TI
   Grunwald, JE
   DuPont, JC
   Ying, GS
AF Metelitsina, TI
   Grunwald, JE
   DuPont, JC
   Ying, GS
TI Effect of systemic hypertension on foveolar choroidal blood flow in age
   related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID LASER-DOPPLER FLOWMETRY; RISK-FACTORS; CARDIOVASCULAR-DISEASE;
   MACULOPATHY; PREVALENCE; MEMBRANE; REGION; EYE
AB Aim: To investigate the effect of systemic hypertension (SH) on the foveolar choroidal circulation in patients with age related macular degeneration (AMD).
   Methods: This study included 163 study eyes with early AMD characteristics of 124 AMD patients. Study eyes had visual acuity of 20/40 or better, drusen >= 63 mm, and/or RPE hypertrophy. 56 of the AMD patients had a history of SH and 47 of these patients were receiving antihypertensive medications. Laser Doppler flowmetry (Oculix) was used to assess relative choroidal blood velocity (ChBVel), volume (ChBVol), and flow (ChBFlow) in the centre of the fovea of the study eyes. Differences in the mean haemodynamic parameters between groups of eyes were assessed using analysis of variance (ANOVA) and a test of linear trend, with adjustment for the correlation between eyes of the same patient.
   Results: AMD patients with SH showed decreased ChBFlow in comparison with those without SH (ANOVA, p = 0.02). This association was maintained after adjustments for multiple factors (p = 0.04).
   Conclusions: AMD patients with SH have lower ChBFlow than those without SH. This decrease in choroidal blood circulation may help explain the mechanism by which systemic hypertension may contribute to the progression of AMD and the development of choroidal neovascularisation.
C1 Univ Penn, Sch Med, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Grunwald, JE (通讯作者)，Univ Penn, Sch Med, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM juangrun@mail.med.upenn.edu
FU NEI NIH HHS [R01 EY012769, EY12769, 5 P30 EY 01583, P30 EY001583]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001583,
   R01EY012769] Funding Source: NIH RePORTER
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Niknam RM, 2004, BRIT J OPHTHALMOL, V88, P1263, DOI 10.1136/bjo.2003.038471
   Okanouchi T, 2003, JPN J OPHTHALMOL, V47, P572, DOI 10.1016/S0021-5155(03)00147-3
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Petrig BL, 1996, OCULAR BLOOD FLOW, P120
   Polak K, 2003, EYE, V17, P84, DOI 10.1038/sj.eye.6700246
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   RIVA CE, 1992, EXP EYE RES, V55, P499, DOI 10.1016/0014-4835(92)90123-A
   Riva CE, 1996, OCULAR BLOOD FLOW, P128
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Riva Charles E., 2001, International Ophthalmology, V23, P183, DOI 10.1023/A:1014433913240
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1978, 23 CONC OPHTH KYOT, P228
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Straubhaar M, 2000, ARCH OPHTHALMOL-CHIC, V118, P211
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
NR 39
TC 38
Z9 40
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2006
VL 90
IS 3
BP 342
EP 346
DI 10.1136/bjo.2005.082974
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 013QS
UT WOS:000235424800027
PM 16488959
OA Green Published
DA 2022-11-30
ER

PT J
AU Defay, R
   Pinchinat, S
   Lumbroso, S
   Sutan, C
   Delcourt, C
AF Defay, R
   Pinchinat, S
   Lumbroso, S
   Sutan, C
   Delcourt, C
CA POLA Study Grp
TI Sex steroids and age-related macular degeneration in older French women:
   The POLA study
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article
DE eye diseases; age-related macular degeneration; hormone replacement
   therapy; sex hormones; dehydroepiandrosterone sulfate; cross-sectional
   study
ID BEAVER DAM EYE; RISK-FACTORS; DEHYDROEPIANDROSTERONE-SULFATE; GRADING
   SYSTEM; MACULOPATHY; DHEA; PREVALENCE; DISEASE; CLASSIFICATION;
   ESTROGENS
AB PURPOSE: Postmenopausal women are reported to be at higher risk of eye diseases than men. The purpose of our study is to determine the relationships between endocrine status, specially plasma sex hormones levels, and the severity of age-related macular degeneration (AMD) in a large community-based sample of older French women.
   METHODS: The POLA (Pathologies Oculaires Liees A l'Age) Study is a population-based study on age-related eye diseases and their risk factors. The study enrolled 2584 residents of Southern France, among whom 1451 women aged 60 years or older were recruited between June 1995 and July 1997. A standardized international classification and grading system for AMD was used. Circulating sex hormones levels were measured from fasting blood samples.
   RESULTS: No association of hormone replacement therapy (HRT), hysterectomy, or oophorectomy was found with soft drusen, pigmentary abnormalities, or late AMD. After multivariate adjustment, higher plasma levels of dehydroepiandrosterone sulfate (DHEAS) were associated with a higher prevalence of soft drusen (OR = 1.21; 95% Cl = 1.01-1.44).
   CONCLUSION: These results may indicate no beneficial effect of HRT on AMD. The positive association of DHEAS with AMD requires further investigation. (C) 2003 Elsevier Inc. All rights reserved.
C1 INSERM Unite 500, F-34093 Montpellier 5, France.
   Hop Lapeyronie, Montpellier, France.
   Lab Biol & Biochim Lipides, Montpellier, France.
   Inst Natl Agron Paris Grignon, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier; CHU de Montpellier; AgroParisTech;
   UDICE-French Research Universities; Universite Paris Saclay
RP Defay, R (通讯作者)，INSERM Unite 500, 39 Ave Charles Flahault, F-34093 Montpellier 5, France.
EM defay@montp.inserm.fr
RI Delcourt, Cecile/I-2627-2013
OI Delcourt, Cecile/0000-0002-2099-0481
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Arlt W, 1999, J CLIN ENDOCR METAB, V84, P2170, DOI 10.1210/jc.84.6.2170
   Baulieu EE, 2000, P NATL ACAD SCI USA, V97, P4279, DOI 10.1073/pnas.97.8.4279
   Baulieu EE, 1996, J CLIN ENDOCR METAB, V81, P3147, DOI 10.1210/jc.81.9.3147
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2000, ARCH OPHTHALMOL-CHIC, V118, P385, DOI 10.1001/archopht.118.3.385
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Gurnell EM, 2001, EUR J ENDOCRINOL, V145, P103, DOI 10.1530/eje.0.1450103
   HAFFNER SM, 1995, AM J EPIDEMIOL, V142, P925, DOI 10.1093/oxfordjournals.aje.a117740
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Johannes CB, 1999, J CLIN EPIDEMIOL, V52, P95, DOI 10.1016/S0895-4356(98)00144-9
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Klein BEK, 2001, ARCH OPHTHALMOL-CHIC, V119, P428, DOI 10.1001/archopht.119.3.428
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kroboth PD, 1999, J CLIN PHARMACOL, V39, P327, DOI 10.1177/00912709922007903
   Labrie F, 1998, J ENDOCRINOL INVEST, V21, P399, DOI 10.1007/BF03350777
   Labrie F, 1997, J CLIN ENDOCR METAB, V82, P2396, DOI 10.1210/jc.82.8.2396
   Labrie F, 2001, FRONT NEUROENDOCRIN, V22, P185, DOI 10.1006/frne.2001.0216
   Laughlin GA, 2000, J CLIN ENDOCR METAB, V85, P645, DOI 10.1210/jc.85.2.645
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Roshan S, 1999, EUR J CLIN INVEST, V29, P210
   Smith M, 1997, INTERLEND DOC SUPPLY, V25, P3
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Watson RR, 1996, DRUG AGING, V9, P274, DOI 10.2165/00002512-199609040-00005
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 35
TC 27
Z9 29
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1047-2797
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD MAR
PY 2004
VL 14
IS 3
BP 202
EP 208
DI 10.1016/S1047-2797(03)00130-3
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 780KK
UT WOS:000189379700008
PM 15036224
DA 2022-11-30
ER

PT J
AU Alio, JL
   Mulet, EM
   Ruiz-Moreno, JM
   Sanchez, MJ
   Galal, A
AF Alio, JL
   Mulet, EM
   Ruiz-Moreno, JM
   Sanchez, MJ
   Galal, A
TI Intraocular telescopic lens evaluation in patients with age-related
   macular degeneration
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID PREVALENCE; CATARACT
AB Purpose: To evaluate the improvement of distance and near visual acuity after removal of cataract and implantation of an 3.0X intraocular miniaturized telescope (IMT) in patients with stable atrophic type age-related macular degeneration (ARMD).
   Settings: Instituto Oftalmologico de Alicante and a multicenter group.
   Methods: In this prospective noncomparative multinational consecutive study, 40 eyes of 40 patients with dry-type ARMD were implanted with IMTs at multiple centers. Standard phacoemulsification procedure followed by enlargement of the incision to 10 mm and implantation in the capsular bag of an 3.0X IMT was carried out in all the cases. Patients were followed for 12 months. Evaluation included the differences between preoperative and postoperative uncorrected and best corrected visual acuity for far and near, position of the IMT, intraocular pressure, and occurrence of any postoperative complications.
   Results: Mean preoperative uncorrected distance visual acuity (UCDVA) in the operated eye was 0.9 logMAR (0.125+/-0.01, range 0.1 to 0.3 in decimal values); at 1 year postoperatively, mean UCDVA in the operated eye was 0.6 logMAR (0.25+/-0.14, range 0.1 to 0.5 in decimal values). Mean preoperative uncorrected near visual acuity (UCNVA) in the operated eye was 0.8 logMAR (0.16+/-0.13, range 0.1 to 0.5 in decimal values); at 1 year postoperatively, mean UCNVA in the operated eye was 0.4 logMAR (0.4+/-0.26, range 0.1 to 1.0 in decimal values). The differences between pre- and postoperative distance and near visual acuities were statistically significant. Six cases were explanted, and 14 developed adverse effects, 7 of which were persistent. The corneal endothelium tolerated the procedure well.
   Conclusion: Implantation of IMT is feasible and plays an effective role in improving far and near visual acuity in patients with stable dry-type ARMD.
C1 Inst Oftalmol Alicante, Dept Refract Surg, Alicante 03015, Spain.
   Miguel Hernandez Univ, Sch Med, Dept Ophthalmol, Alicante, Spain.
   Res Inst Ophthalmol, Cairo, Egypt.
C3 Universidad Miguel Hernandez de Elche; Egyptian Knowledge Bank (EKB);
   General Organization of Teaching Hospitals & Institutes (GOTHI);
   Research Institute of Ophthalmology (RIO)
RP Alio, JL (通讯作者)，Inst Oftalmol Alicante, Dept Refract Surg, Avda Denia 111, Alicante 03015, Spain.
EM jlalio@oftalio.com
RI Ruiz-Moreno, José M/E-4644-2016
CR Choyce P, 1964, INTRAOCULAR LENSES I, P156
   DONN A, 1986, CLAO Journal, V12, P81
   Goldstein H, 1980, Adv Ophthalmol, V40, P1
   HUTCHINSON DR, 1997, TRIAL INVESTIGATORS, P44
   Kaskaloglu M, 2001, J CATARACT REFR SURG, V27, P1751, DOI 10.1016/S0886-3350(01)00976-2
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   KOZIOL JE, 1994, OPHTHALMIC SURG LAS, V25, P675
   Lipshitz I, 1997, OPHTHALMIC SURG LAS, V28, P513
   Peli E, 2002, OPTOMETRY VISION SCI, V79, P225, DOI 10.1097/00006324-200204000-00009
   PEYMAN GA, 1988, J CATARACT REFR SURG, V14, P421, DOI 10.1016/S0886-3350(88)80152-4
   Rinnert T, 1999, KLIN MONATSBL AUGENH, V215, P305, DOI 10.1055/s-2008-1034719
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 12
TC 16
Z9 18
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JUN
PY 2004
VL 30
IS 6
BP 1177
EP 1189
DI 10.1016/j.jcrs.2003.10.038
PG 13
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 846DR
UT WOS:000223295800012
PM 15177591
DA 2022-11-30
ER

PT J
AU Golestaneh, N
   Chu, Y
   Xiao, YY
   Stoleru, GL
   Theos, AC
AF Golestaneh, Nady
   Chu, Yi
   Xiao, Yang-Yu
   Stoleru, Gianna L.
   Theos, Alexander C.
TI Dysfunctional autophagy in RPE, a contributing factor in age-related
   macular degeneration
SO CELL DEATH & DISEASE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE
   STRESS; MITOCHONDRIAL DYSFUNCTION; MOLECULAR-MECHANISMS; DRUSEN
   FORMATION; CELL-DEATH; PATHOGENESIS; P62/SQSTM1; DISEASE
AB Age-related macular degeneration (AMD) is a devastating neurodegenerative disease and a major cause of blindness in the developed world. Owing to its complexity and the lack of an adequate human model that recapitulates key aspects of the disease, the molecular mechanisms of AMD pathogenesis remain poorly understood. Here we show that cultured human retinal pigment epithelium (RPE) from AMD donors (AMD RPE) are functionally impaired and exhibit distinct phenotypes compared with RPE cultured from normal donors (normal RPE). Accumulation of lipid droplets and glycogen granules, disintegration of mitochondria, and an increase in autophagosomes were observed in AMD RPE cultures. Compared with normal RPE, AMD RPE exhibit increased susceptibility to oxidative stress, produce higher levels of reactive oxygen species (ROS) under stress conditions, and showed reduced mitochondrial activity. Measurement of the ratio of LC3-II/LC3-I, revealed impaired autophagy in AMD RPE as compared with normal RPE. Autophagic flux was also reduced in AMD RPE as compared with normal RPE, as shown by inability of AMD RPE to downregulate p62 levels during starvation. Impaired autophagic pathways were further shown by analyzing late autophagic vesicles; immunostaining with lysosome-associated membrane protein 1 (LAMP-1) antibody revealed enlarged and annular LAMP-1-positive organelles in AMD RPE as opposed to smaller discrete puncta observed in normal RPE. Our study provides insights into AMD cellular and molecular mechanisms, proposes dysfunctional autophagy as an underlying mechanism contributing to the pathophysiology of the disease, and opens up new avenues for development of novel treatment strategies.
C1 [Golestaneh, Nady; Chu, Yi; Xiao, Yang-Yu; Stoleru, Gianna L.] Georgetown Univ, Med Ctr, Dept Ophthalmol, 3900 Reservoir Rd NW,Med Dent Bldg,Room NE203, Washington, DC 20007 USA.
   [Golestaneh, Nady] Georgetown Univ, Med Ctr, Dept Neurol, 3900 Reservoir Rd NW,Med Dent Bldg,Room NE203, Washington, DC 20007 USA.
   [Golestaneh, Nady] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20007 USA.
   [Theos, Alexander C.] Georgetown Univ, Dept Human Sci, Washington, DC USA.
C3 Georgetown University; Georgetown University; Georgetown University;
   Georgetown University
RP Golestaneh, N (通讯作者)，Georgetown Univ, Med Ctr, Dept Ophthalmol, 3900 Reservoir Rd NW,Med Dent Bldg,Room NE203, Washington, DC 20007 USA.; Golestaneh, N (通讯作者)，Georgetown Univ, Med Ctr, Dept Neurol, 3900 Reservoir Rd NW,Med Dent Bldg,Room NE203, Washington, DC 20007 USA.; Golestaneh, N (通讯作者)，Georgetown Univ, Med Ctr, Dept Biochem, 3900 Reservoir Rd NW,Med Dent Bldg,Room NE203, Washington, DC 20057 USA.; Golestaneh, N (通讯作者)，Georgetown Univ, Med Ctr, Dept Mol & Cellular Biol, 3900 Reservoir Rd NW,Med Dent Bldg,Room NE203, Washington, DC 20057 USA.
EM ncg8@georgetown.edu
OI Theos, Alexander/0000-0002-1826-8705
FU BrightFocus Foundation; Prevention of Blindness Society of Metropolitan
   Washington (POB)
FX We thank the donors of Macular Degeneration Research, a program of
   BrightFocus Foundation, and Prevention of Blindness Society of
   Metropolitan Washington (POB), for support of this research. The
   Georgetown-Lombardi Comprehensive Cancer Center Shared Resource
   facilities were used for qRT-PCR. We thank Dr. Yetrib Hathout,
   Children's National Health System, for sharing the normal and AMD RPE
   cells, Dr. Mones Abu-Asab, NEI/NIH for assistance in EM imaging.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326
   Cho YG, 2011, LAB INVEST, V91, P519, DOI 10.1038/labinvest.2010.184
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Dornonville de la Cour M, 1993, Acta Ophthalmol Suppl, P1
   DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923
   Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038
   Duran J, 2014, HUM MOL GENET, V23, P3147, DOI 10.1093/hmg/ddu024
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Field MG, 2012, OPHTHAL SURG LAS IM, V43, P358, DOI 10.3928/15428877-20120712-02
   Finn PF, 2006, NUTRITION, V22, P830, DOI 10.1016/j.nut.2006.04.008
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Fronk AH, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416650838
   Gamm DM, 2008, INVEST OPHTH VIS SCI, V49, P788, DOI 10.1167/iovs.07-0777
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gottlieb RA, 2010, AM J PHYSIOL-CELL PH, V299, pC203, DOI 10.1152/ajpcell.00097.2010
   Gu XR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038673
   Hamann S, 2002, INT REV CYTOL, V215, P395
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   KNORR HLJ, 1993, OPHTHALMIC RES, V25, P226, DOI 10.1159/000267318
   Kokkinaki M, 2013, J NEUROSCI, V33, P16346, DOI 10.1523/JNEUROSCI.0402-13.2013
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kuusisto E, 2008, NEUROPATH APPL NEURO, V34, P169, DOI 10.1111/j.1365-2990.2007.00884.x
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.pathmechdis.3.121806.151434
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Morita M, 2013, CELL METAB, V18, P698, DOI 10.1016/j.cmet.2013.10.001
   Murphy MP, 2013, CELL METAB, V18, P145, DOI 10.1016/j.cmet.2013.07.006
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   NEGI A, 1984, ARCH OPHTHALMOL-CHIC, V102, P445
   Nishikawa T, 2014, J HEPATOL, V60, P1203, DOI 10.1016/j.jhep.2014.02.014
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okamoto K, 2012, BBA-GEN SUBJECTS, V1820, P595, DOI 10.1016/j.bbagen.2011.08.001
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Ramanathan A, 2009, P NATL ACAD SCI USA, V106, P22229, DOI 10.1073/pnas.0912074106
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schonthal AH, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/857516
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Vessey KA, 2014, J COMP NEUROL, V522, P2928, DOI 10.1002/cne.23558
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Wang YJ, 2010, HEPATOLOGY, V52, P266, DOI 10.1002/hep.23645
   Wohlgemuth SE, 2014, J MOL CELL CARDIOL, V71, P62, DOI 10.1016/j.yjmcc.2014.03.007
   Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   Zhang Y, 2007, AUTOPHAGY, V3, P337, DOI 10.4161/auto.4127
NR 80
TC 186
Z9 186
U1 3
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JAN
PY 2017
VL 8
AR e2537
DI 10.1038/cddis.2016.453
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EK1IM
UT WOS:000393679000021
PM 28055007
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Dysli, C
   Wolf, S
   Zinkernagel, MS
AF Dysli, Chantal
   Wolf, Sebastian
   Zinkernagel, Martin S.
TI Autofluorescence Lifetimes in Geographic Atrophy in Patients With
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE fundus autofluorescence; fluorescence lifetimes; ophthalmic imaging; GA;
   geographic atrophy; AMD; age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; TIME-RESOLVED AUTOFLUORESCENCE; OPTICAL
   COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE; CHOROIDAL THICKNESS;
   FLUORESCENCE; PATTERNS; OPHTHALMOSCOPE; CLASSIFICATION; PROGRESSION
AB PURPOSE. To investigate fluorescence lifetime characteristics in patients with geographic atrophy (GA) in eyes with age-related macular degeneration and to correlate the measurements with clinical data and optical coherence tomography (OCT) findings.
   METHODS. Patients with GA were imaged with a fluorescence lifetime imaging ophthalmoscope. Retinal autofluorescence lifetimes were measured in a short and a long spectral channel (498-560 nm and 560-720 nm). Mean retinal fluorescence lifetimes were analyzed within GA and the surrounding retina, and data were correlated with best corrected visual acuity and OCT measurements.
   RESULTS. Fluorescence lifetime maps of 41 eyes of 41 patients (80 +/- 7 years) with GA were analyzed. Mean lifetimes within areas of atrophy were prolonged by 624 +/- 276 ps (+152%) in the short spectral channel and 418 +/- 186 ps (+83%) in the long spectral channel compared to the surrounding tissue. Autofluorescence lifetime abnormalities in GA occurred with particular patterns, similar to those seen in fundus autofluorescence intensity images. Within the fovea short mean autofluorescence lifetimes were observed, presumably representing macular pigment. Short lifetimes were preserved even in the absence of foveal sparing but were decreased in patients with advanced retinal atrophy in OCT. Short lifetimes in the fovea correlated with better best corrected visual acuity in both spectral channels.
   CONCLUSIONS. This study established that autofluorescence lifetime changes in GA present with explicit patterns. We hypothesize that the short lifetimes seen within the atrophy may be used to estimate damage induced by atrophy and to monitor disease progression in the context of natural history or interventional therapeutic studies.
C1 [Dysli, Chantal; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Univ Hosp Bern, Inselspital, Dept Ophthalmol, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Zinkernagel, MS (通讯作者)，Univ Hosp Bern, CH-3010 Bern, Switzerland.
EM m.zinkernagel@gmail.com
RI Wolf, Sebastian/B-8782-2008; Zinkernagel, Martin/C-3799-2017
OI Wolf, Sebastian/0000-0002-7467-7028; Zinkernagel,
   Martin/0000-0002-5622-114X; Zinkernagel, Martin S./0000-0003-3447-2359
FU Swiss National Science Foundation (Bern, Switzerland) [320030_156019]
FX Supported by a grant from the Swiss National Science Foundation
   (320030_156019; Bern, Switzerland).
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Digman MA, 2008, BIOPHYS J, V94, pL14, DOI 10.1529/biophysj.107.120154
   Dysli C, 2015, INVEST OPHTH VIS SCI, V56, P3329, DOI 10.1167/iovs.14-16203
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P2106, DOI 10.1167/iovs.13-13627
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2015, GRAEF ARCH CLIN EXP, V253, P7, DOI 10.1007/s00417-014-2858-1
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sauer L, 2015, INVEST OPHTH VIS SCI, V56, P4668, DOI 10.1167/iovs.14-15335
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2004, J BIOMED OPT, V9, P1214, DOI 10.1117/1.1806833
   Schweitzer D, 2012, INVEST OPHTH VIS SCI, V53, P3376, DOI 10.1167/iovs.11-8970
   Schweitzer D, 2010, ESSENT OPHTHALMOL, P107, DOI 10.1007/978-3-540-85540-8_10
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   Sparrow JR, 2010, INVEST OPHTH VIS SCI, V51, P4351, DOI 10.1167/iovs.10-5852
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
NR 34
TC 48
Z9 49
U1 1
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2016
VL 57
IS 6
BP 2479
EP 2487
DI 10.1167/iovs.15-18381
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO8OA
UT WOS:000378041700015
PM 27149697
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ehlers, JP
   Fintak, DR
   Gupta, OP
   Regillo, CD
   Fineman, MS
   Ho, AC
AF Ehlers, Justis P.
   Fintak, David R.
   Gupta, Omesh P.
   Regillo, Carl D.
   Fineman, Mitchell S.
   Ho, Allen C.
TI Pegaptanib for choroidal Neovascularization in treatment-naive exudative
   age-related macular degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID EFFICACY; SAFETY; SODIUM
AB BACKGROUND AND OBJECTIVE: To evaluate the use of intravitreal pegaptanib in the treatment of choroidal neovascularization secondary to age-related macular degeneration (AMD) in treatment-naive patients.
   PATIENTS AND METHODS: In a consecutive, retrospective case series, treatment-naive patients with exudative AMD were treated with intravitreal pegaptanib. Intravitreal injections were typically given every 6 weeks at the discretion of the treating physician. Snellen visual acuity (VA), clinical course, and adverse events were monitored. A minimum of three pegaptanib injections were given. Retreatment criteria included persistent submacular fluid, macular edema, new macular hemorrhage, and loss of vision.
   RESULTS: The average change in VA for all lesions was a loss of 2.9 lines. Fifteen (14%) patients gained more than 3 lines of VA. The average number of injections was 4.8. Ninety-two of 111 lesions were able to be categorized by size. Sixty-six patients had small lesions (< 4 disc areas) with an average change of -2.0 lines, and 26 had large lesions (>= 4 disc areas) with an average change of -5.4 lines (P <.02). Patients with larger lesions were at greater risk for severe visual loss (P <.0 1). The average follow-up was approximately 31 weeks (range: 12 to 82 weeks) after the first injection.
   CONCLUSIONS: Pegaptanib therapy resulted in a 2.9 average line loss in patients when all lesions were considered. Small lesions responded favorably, with 15% of patients gaining more than 3 lines of VA. Larger lesions had an increased risk of progression and poor visual outcome.
C1 Wilmer Eye Inst, Retina Serv, Philadelphia, PA 19107 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Ho, AC (通讯作者)，Wilmer Eye Inst, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
OI Ho, Allen/0000-0003-3921-608X
CR D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
NR 9
TC 6
Z9 6
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2007
VL 38
IS 5
BP 371
EP 377
DI 10.3928/15428877-20070901-03
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 212FF
UT WOS:000249578300004
PM 17955841
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Creuzot-Garcher, C
   Darmon, J
   Desmettre, T
   Korobelnik, JF
   Levrat, F
   Quentel, G
   Palie, S
   Sanchez, A
   De Gendre, AS
   Schluep, H
   Weber, M
   Delcourt, C
AF Cohen, S. Y.
   Creuzot-Garcher, C.
   Darmon, J.
   Desmettre, T.
   Korobelnik, J. F.
   Levrat, F.
   Quentel, G.
   Palie, S.
   Sanchez, A.
   De Gendre, A. Solesse
   Schluep, H.
   Weber, M.
   Delcourt, C.
TI Types of choroidal neovascularisation in newly diagnosed exudative
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE-GREEN VIDEOANGIOGRAPHY; PHOTODYNAMIC THERAPY; OCCULT;
   ANASTOMOSES; DETACHMENTS; VERTEPORFIN
AB Aim: To describe the types and location of choroidal neovascularisation (CNV) in exudative age-related macular degeneration (AMD), including vascularised pigment epithelial detatchments (PED), and most recently described subtypes, such as retinal choroidal anasmostosis, also termed "retinal angiomatous proliferation'' (RAP).
   Methods: Prospective multicentre consecutive descriptive case series. A total of 207 consecutive cases of newly diagnosed exudative AMD undergoing fluorescein angiography ( FA) were recruited by 7 French referral hospital-based or private centres. Indocyanine green angiography (ICG) also was performed, when judged necessary by investigators. Types and location of CNV were classified by two independent experts and adjudicated by a third when discordant.
   Results: All patients had FA, while ICG was performed in 50% of subjects. A total of 17.6% had classic CNV only, 5.4% and 8.3% had predominantly and minimally classic CNV, respectively. Occult CNV could be classified in occult CNV without PED (32.7%) and occult CNV with PED, ie, vascularised PED (23.9%). RAP was observed in 15.1% of cases, and accounted for 30% of vascularised PED. In 5.8% of the cases there was haemorrhagic AMD and 4.8% had fibrovascular scars. Lesions were mainly subfoveal (80%). Agreement between the centre's ophthalmologist and the final validated expert classification was moderate (kappa = 0.52 for location and 0.59 for type of lesion).
   Conclusion: This study confirms that newly diagnosed cases of exudative AMD are mainly occult and subfoveal. RAP appeared as a common lesion in patients with newly diagnosed exudative AMD.
C1 Ctr Ophtalmol Imagerie & Laser, F-75015 Paris, France.
   Ctr Hosp Univ, Dijon, France.
   Ctr Imagerie & Laser, Nice, France.
   Ctr Imagerie & Laser, Lambersart, France.
   Ctr Hosp Univ, Bordeaux, France.
   Pfizer, Paris, France.
   Biostatem Co, Nimes, France.
   Ctr Hosp Univ, Nantes, France.
   INSERM, U593, Bordeaux, France.
   Univ Victor Segalen, Bordeaux, France.
C3 CHU Dijon Bourgogne; CHU Bordeaux; Pfizer; Nantes Universite; CHU de
   Nantes; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux
RP Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycohen@club-internet.fr
RI KOROBELNIK, Jean-Francois/A-5448-2016; Delcourt, Cecile/I-2627-2013
OI Delcourt, Cecile/0000-0002-2099-0481
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Axer-Siegel R, 2002, OPHTHALMOLOGY, V109, P1726, DOI 10.1016/S0161-6420(02)01149-1
   Baumal CR, 1997, OPHTHALMOLOGY, V104, P761, DOI 10.1016/S0161-6420(97)30236-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Arevalo JF, 2005, RETINA-J RET VIT DIS, V25, P719, DOI 10.1097/00006982-200509000-00006
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Watzke RC, 2000, OPHTHALMOLOGY, V107, P1601, DOI 10.1016/S0161-6420(00)00218-9
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
NR 20
TC 92
Z9 93
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2007
VL 91
IS 9
BP 1173
EP 1176
DI 10.1136/bjo.2007.115501
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 202EN
UT WOS:000248884900023
PM 17383997
OA Green Published
DA 2022-11-30
ER

PT J
AU Hamelmann, V
   Helb, HM
   Meyer, CH
   Holz, FG
   Eter, N
AF Hamelmann, Victoria
   Helb, Hans-Martin
   Meyer, Carsten H.
   Holz, Frank G.
   Eter, Nicole
TI Intravitreal bevacizumab for pigment epithelial detachments in
   age-related macular degeneration
SO SPEKTRUM DER AUGENHEILKUNDE
LA English
DT Article
DE Age-related macular degeneration; AMD; Avastin; Bevacizumab; Fluorescein
   angiography; OCT; Optical coherence tomography; PED; Pigment epithelial
   detachment
ID OCCULT CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   COMBINED PHOTODYNAMIC THERAPY; NATURAL-HISTORY; RANIBIZUMAB; INJECTION;
   AVASTIN; TEARS; AMD; TRIAMCINOLONE
AB To evaluate the efficacy and safety of intravitreal bevacizumab injections in patients with pigment epithelial detachments (PEDs) secondary to age-related macular degeneration (AMD).
   In a retrospective interventional case series, 62 eyes of 61 patients were treated with 1.5 mg bevacizumab intravitreally. Baseline and follow-up visits included best-corrected visual acuity and optical coherence tomography (OCT) examinations. Follow-up visits were performed 1, 3, and 6 months after initial treatment. Morphological effects on PED were quantified by repetitively measuring the highest elevation on two perpendicular OCT cross-sections. If height of PED was increased by 50 microns, or intraretinal fluid appeared or increased, or visual acuity decreased more than 5 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, patients were reinjected.
   On OCT, PED decreased from 346 +/- A 148 A mu m at baseline to 241 +/- A 159 A mu m (p < 0.001) at 1 month, 227 +/- A 193 A mu m (p < 0.001) at 3 months, and 166 +/- A 170 A mu m (p < 0.001) at 6 months. Mean best corrected visual acuity (BCVA) increased from 49 +/- A 18 letters at baseline to 52 +/- A 21 letters (p = 0.062) at 1 month. However, 3 and 6 months after initial injection mean BCVA returned to baseline levels (3 months: 49 +/- A 19 letters, p = 0.518; 6 months: 49 +/- A 20 letters, p = 0.053). On average, patients received 2.5 injections during the observation period of 6 months. Except for one retinal pigment epithelial (RPE) tear no other ocular or systemic adverse events were noticed. Ocular inflammation was not found in any of the investigated patients.
   The presented data demonstrate a therapeutic effect of intravitreal bevacizumab in patients with specific classes of pigment epithelial detachments secondary to AMD.
C1 [Eter, Nicole] Univ Munster, Dept Ophthalmol, D-48149 Munster, Germany.
   [Hamelmann, Victoria; Helb, Hans-Martin; Meyer, Carsten H.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Hamelmann, Victoria] Augentagesklin MVZ ADTC Dusseldorf, Dusseldorf, Germany.
   [Helb, Hans-Martin] Augenzentrum Westpfalz, Kaiserslautern, Germany.
   [Meyer, Carsten H.] Klin Pallas, Dept Ophthalmol, Olten, Switzerland.
C3 University of Munster; University of Bonn
RP Eter, N (通讯作者)，Univ Munster, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
EM eter@uni-muenster.de
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Axer-Siegel R, 2006, OPHTHAL SURG LAS IM, V37, P455, DOI 10.3928/15428877-20061101-02
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, N ENGL J MED, V355, P1432
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chan CK, 2009, RETINA, V30, P203
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P1
   Cohen SY, 2007, J FR OPHTALMOL, V30, P330, DOI 10.1016/S0181-5512(07)89602-1
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   el Matri L, 2010, GRAEF ARCH CLIN EXP, V248, P779, DOI 10.1007/s00417-010-1302-4
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Eter N, 2004, OPHTHALMOLOGE, V101, P794, DOI 10.1007/s0034-004-1052-y
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Frimpong-Boateng A, 2008, OPHTHALMOLOGE, V105, P661, DOI 10.1007/s00347-007-1655-1
   Fujimoto JG., 2004, OPTICAL COHERENCE TO, V2nd
   Gass J Donald M, 2003, Retina, V23, P205
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Green W Richard, 2005, Retina, V25, P615, DOI 10.1097/00006982-200507001-00011
   Hajouli N, 2010, J FR OPHTALMOL, V33, P487, DOI 10.1016/j.jfo.2010.03.010
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Lommatzsch AP, 2008, KLIN MONATSBL AUGENH, V225, P874, DOI 10.1055/s-2008-1027454
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   Meyer CH, 2008, OPHTHALMOLOGE, V105, P125, DOI 10.1007/s00347-008-1702-6
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Murphy R P, 1985, Trans Am Ophthalmol Soc, V83, P63
   Mylonas G, 2009, BRIT J OPHTHALMOL, V93, P1453, DOI 10.1136/bjo.2008.153643
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Pece A, 2007, RETINA-J RET VIT DIS, V27, P342, DOI 10.1097/01.iae.0000239253.78495.8c
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Ruppenstein M, 2010, OPHTHALMOLOGE, V107, P827, DOI 10.1007/s00347-010-2166-z
   Schaal KB, 2008, OPHTHALMOLOGE, V105, P538, DOI 10.1007/s00347-007-1638-2
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Smretschnig E, 2010, GRAEF ARCH CLIN EXP, V248, P1693, DOI 10.1007/s00417-010-1415-9
   Subramanyam Anand, 2007, Indian J Ophthalmol, V55, P483
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 65
TC 0
Z9 0
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-4282
EI 1613-7523
J9 SPEKTRUM AUGENHEILKD
JI Spektrum Augenheilkd.
PD AUG
PY 2013
VL 27
IS 4
BP 184
EP 195
DI 10.1007/s00717-013-0177-2
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 215NC
UT WOS:000324215900004
DA 2022-11-30
ER

PT J
AU Lv, XW
   Li, WQ
   Fang, ZY
   Xue, XF
   Pan, CL
AF Lv, Xuewen
   Li, Weiqi
   Fang, Zhiyu
   Xue, Xiaofei
   Pan, Chunling
TI Periodontal Disease and Age-Related Macular Degeneration: A
   Meta-Analysis of 112,240 Participants
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH; RISK-FACTORS;
   INFLAMMATION; ASSOCIATION
AB Objective. Epidemiological studies have shown a correlation between periodontal disease (PD) and age-related macular degeneration (AMD). However, the results have been inconsistent, and no relevant meta-analysis has been performed on this topic. Hence, we performed a meta-analysis to evaluate whether the two diseases are related.Material and Methods. The PubMed, Embase, Cochrane Library, and Web of Science databases were searched up to April 20, 2020, for related articles. Two authors independently conducted literature screening and data extraction and then used the Stata 15.1 software to calculate the relative risk (RRs) and 95% confidence intervals (CIs) to assess the association between PD and AMD.Results. A total of 5 observational studies involving 112,240 participants and 5,005 AMD patients were included. The results of meta-analysis using the random-effects model showed that the incidence of AMD in PD patients was 1.35 times that of non-PD patients; the difference was statistically significant (RR=1.35,95%CI=1.07-1.70,P=0.011). Sensitivity analysis showed that the results were stable.Conclusions. PD patients have a higher risk of AMD, but the causal relationship between PD and AMD has not been confirmed. Further research should be carried out to verify the exact relationship between the two.
C1 [Lv, Xuewen; Li, Weiqi; Fang, Zhiyu; Xue, Xiaofei; Pan, Chunling] China Med Univ, Sch & Hosp Stomatol, Shenyang, Peoples R China.
   [Lv, Xuewen; Li, Weiqi; Fang, Zhiyu; Xue, Xiaofei; Pan, Chunling] Liaoning Prov Key Lab Oral Dis, Shenyang, Peoples R China.
C3 China Medical University
RP Pan, CL (通讯作者)，China Med Univ, Sch & Hosp Stomatol, Shenyang, Peoples R China.; Pan, CL (通讯作者)，Liaoning Prov Key Lab Oral Dis, Shenyang, Peoples R China.
EM 1215757653@qq.com; 296406985@qq.com; 1770158225@qq.com;
   422724855@qq.com; chunlingpan@163.com
FU National Natural Science Foundation of China [81500862]
FX This work was supported by the National Natural Science Foundation of
   China (No.81500862).
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bailey JNC, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017186
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Bourgeois D, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7100424
   D'Aiuto F, 2018, LANCET DIABETES ENDO, V6, P954, DOI [10.1016/s2213-8587(18)30038-x, 10.1016/S2213-8587(18)30038-X]
   da Rocha BM, 2018, SCHIZOPHRENIA BULL, V44, P114, DOI 10.1093/schbul/sbx036
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Falcao A, 2019, PERIODONTOL 2000, V79, P117, DOI 10.1111/prd.12249
   Genco RJ, 2013, PERIODONTOL 2000, V62, P59, DOI 10.1111/j.1600-0757.2012.00457.x
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Iheozor-Ejiofor Zipporah, 2017, Cochrane Database Syst Rev, V6, pCD005297, DOI 10.1002/14651858.CD005297.pub3
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Karesvuo P, 2013, J PERIODONTOL, V84, P58, DOI 10.1902/jop.2012.110643
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, P17038, DOI [DOI 10.1038/NRDP.2017.38, 10.1038/nrdp.2017.38]
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Lockhart PB, 2012, CIRCULATION, V125, P2520, DOI 10.1161/CIR.0b013e31825719f3
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Ronksley Paul E, 2011, BMJ, V342, pd671, DOI 10.1136/bmj.d671
   Ryden L, 2016, CIRCULATION, V133, P576, DOI 10.1161/CIRCULATIONAHA.115.020324
   Shao J, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00601
   Shin YU, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006418
   Sun KT, 2020, RETINA-J RET VIT DIS, V40, P2312, DOI 10.1097/IAE.0000000000002750
   Takeuchi K, 2019, J DENT RES, V98, P534, DOI 10.1177/0022034519833630
   The Cochrane Collaboration, 2011, COCHRANE DB SYST REV, V11, DOI [10.1002/14651858.CD009197, DOI 10.1002/14651858.CD009197]
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Van Dyke TE, 2017, MOL ASPECTS MED, V58, P21, DOI 10.1016/j.mam.2017.04.006
   Wagley S, 2015, RETINA-J RET VIT DIS, V35, P982, DOI 10.1097/IAE.0000000000000427
   Wilson ME, 2020, JAMA-J AM MED ASSOC, V323, P455, DOI 10.1001/jama.2019.22343
   Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690
NR 39
TC 1
Z9 2
U1 1
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD SEP 29
PY 2020
VL 2020
AR 4753645
DI 10.1155/2020/4753645
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA OG9WH
UT WOS:000582224700009
PM 33062680
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Khanani, AM
   Eichenbaum, D
   Schlottmann, PG
   Tuomi, L
   Sarraf, D
AF Khanani, Arshad M.
   Eichenbaum, David
   Schlottmann, Patricio G.
   Tuomi, Lisa
   Sarraf, David
TI OPTIMAL MANAGEMENT OF PIGMENT EPITHELIAL DETACHMENTS IN EYES WITH
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; neovascularization; pigment epithelial detachment; retinal
   pigment epithelium; retinal pigment epithelial tear; visual acuity
ID GROWTH-FACTOR THERAPY; ANTI-VEGF THERAPY; VISUAL-ACUITY; INTRAVITREAL
   RANIBIZUMAB; TEARS; AFLIBERCEPT; SECONDARY; BEVACIZUMAB; INJECTION;
   FLUID
AB Purpose: This review aimed to determine the optimal management of retinal pigment epithelial detachments (PEDs) in neovascular age-related macular degeneration (nAMD) based on review of available evidence in the literature.
   Methods: A comprehensive literature review evaluates previous retrospective and prospective studies that assessed the treatment of PEDs in nAMD.
   Results: Studies illustrated that anti-vascular endothelial growth factor (VEGF) therapy can be effective in eyes with PED secondary to nAMD. Similar visual outcomes are associated with different anti-VEGF treatments. Higher anti-VEGF doses may improve anatomical response, without correlation with vision improvement. Fibrovascular PEDs may be difficult to treat, but even these eyes can gain vision with anti-VEGF therapy. A retinal pigment epithelial tear may develop in 15% to 20% of eyes with PEDs after anti-VEGF therapy, especially in PEDs greater than 500 mm to 600 mm in height; however, vision may stabilize with continued therapy. Atrophy may complicate eyes with PED and nAMD after anti-VEGF therapy, especially in association with complete PED resolution.
   Conclusion: Available literature suggests that anti-VEGF therapy is safe and efficacious for PED and nAMD. Treatment should focus on vision gains rather than PED resolution because there is no apparent correlation between anatomical and functional improvement in most eyes with PED and nAMD.
EM Arshad.khanani@gmail.com
OI Eichenbaum, David/0000-0003-0654-0668; Schlottmann,
   Patricio/0000-0003-0196-0452
FU Genentech, Inc.
FX Third-party writing assistance was provided by Jack W. Pike, PhD, of
   Envision Scientific Solutions, and funded by Genentech, Inc.
CR Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Figurska M, 2012, MED SCI MONITOR, V18, pCR32, DOI 10.12659/MSM.882198
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Iordanous Y, 2014, CAN J OPHTHALMOL, V49, P367, DOI 10.1016/j.jcjo.2014.05.010
   Kalouda P, 2015, SEMIN OPHTHALMOL, V30, P6, DOI 10.3109/08820538.2013.807852
   Kocak I, 2017, INT OPHTHALMOL, V37, P531, DOI 10.1007/s10792-016-0294-4
   Major JC, 2015, CAN J OPHTHALMOL, V50, P373, DOI 10.1016/j.jcjo.2014.12.012
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P1083, DOI 10.1097/IAE.0b013e318207d1a3
   Sarraf D, 2016, ASS RES VIS OPHTH 20
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   Varshney N, 2013, CAN J OPHTHALMOL, V48, P210, DOI 10.1016/j.jcjo.2013.01.023
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Xu L, 2015, GEOGRAPHIC ATROPHY P, V35, P177
   Yuksel H, 2013, ARQ BRAS OFTALMOL, V76, P209, DOI 10.1590/S0004-27492013000400002
   Zhao C, 2016, MED SCI MONITOR, V22, P833, DOI 10.12659/MSM.895528
   Zinkernagel MS, 2016, OPHTHALMOLOGICA, V235, P42, DOI 10.1159/000441428
NR 49
TC 20
Z9 22
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2018
VL 38
IS 11
BP 2103
EP 2117
DI 10.1097/IAE.0000000000002195
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VZ
UT WOS:000454007400001
PM 29697591
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Hutchinson, JN
   Fagerness, J
   Kirby, A
   Reynolds, R
   Zak, A
   Gimelbrant, A
   Plenge, R
   Daly, M
   Chess, A
   Seddon, JM
AF Hutchinson, John N.
   Fagerness, Jes
   Kirby, Andrew
   Reynolds, Robyn
   Zak, Alex
   Gimelbrant, Alexander
   Plenge, Robert
   Daly, Mark
   Chess, Andrew
   Seddon, Johanna M.
TI (Epi)Genetic Analyses of Age-Related Macular Degeneration: Case-Control
   and Discordant Twin Studies
SO HUMAN HEREDITY
LA English
DT Article
DE Allele-specific methylation; Age-related macular degeneration; Copy
   number variation; Epigenetic analysis; Monozygotic twin pairs
ID COMPLEMENT FACTOR-H; DNA METHYLATION; GENE-EXPRESSION; IL17RC PROMOTER;
   US TWIN; POLYMORPHISM; GENOME; RISK; ASSOCIATION; BLOOD
AB Background/Aims: Phenotypic discordance in monozygotic (MZ) twin pairs can have an epigenetic or genetic basis. Although age-related macular degeneration (AMD) has a strong genetic component, few studies have addressed its epigenetic basis. Methods: Using SNP arrays, we evaluated differences in copy number variation (CNV) and allele-specific methylation (ASM) patterns (via methyl-sensitive restriction enzyme digestion of DNA) in MZ twin pairs from the US Twin Study of AMD. Further analyses examined the relationship between ASM and CNVs with AMD by both case/control analysis of ASM at candidate regions and by analysis of ASM and CNVs in twins discordant for AMD. Results: The frequency of ASM sites differs between cases and controls in regions surrounding the AMD candidate genes CFH, C2 and CFB. While ASM patterns show a substantial dependence on local sequence polymorphisms, we observed dissimilar patterns of ASM between MZ twins. The genes closest to the sites where discordant MZ twins have dissimilar patterns of ASM are enriched for genes implicated in gliosis, a process associated with neovascular AMD. Similar twin-based analyses revealed no AMD-associated CNVs. Conclusions: Our results provide evidence of epigenetic influences beyond the known genetic susceptibility and implicate inflammatory responses and gliosis in the etiology of AMD. (C) 2014 S. Karger AG, Basel
C1 [Hutchinson, John N.; Fagerness, Jes; Kirby, Andrew; Daly, Mark; Chess, Andrew] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Reynolds, Robyn; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Zak, Alex; Gimelbrant, Alexander] Harvard Univ, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
   [Gimelbrant, Alexander] Harvard Univ, Harvard Med Sch, Dept Genet, Boston, MA 02115 USA.
   [Plenge, Robert] Harvard Univ, Brigham & Womens Hosp, Dept Rheumatol Immunol, Boston, MA 02115 USA.
   [Plenge, Robert] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA.
   [Chess, Andrew] Mt Sinai Sch Med, Dept Genet & Genom Sci, Fishberg Dept Neurosci, Dept Dev & Regenerat Biol, New York, NY 10029 USA.
   [Chess, Andrew] Mt Sinai Sch Med, Friedman Brain Inst, New York, NY 10029 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
C3 Harvard University; Massachusetts General Hospital; Tufts Medical
   Center; Harvard University; Dana-Farber Cancer Institute; Harvard
   University; Harvard Medical School; Harvard University; Brigham &
   Women's Hospital; Harvard University; Harvard Medical School; Icahn
   School of Medicine at Mount Sinai; Icahn School of Medicine at Mount
   Sinai; Tufts University; Tufts University
RP Chess, A (通讯作者)，Tufts Med Ctr, 800 Washington St 450, Boston, MA 02111 USA.
EM andrew.chess@mssm.edu; jseddon@tuftsmedicalcenter.org
RI Daly, Mark J/B-2453-2017; Hutchinson, John/AAA-1976-2020
OI Daly, Mark J/0000-0002-0949-8752; Hutchinson, John/0000-0002-7804-7576;
   Gimelbrant, Alexander/0000-0001-6986-0285
FU National Institutes of Health, Bethesda, Md [R01-EY11309]; Massachusetts
   Lions Eye Research Fund, Inc; Research to Prevent Blindness, Inc., New
   York, N.Y; American Macular Degeneration Foundation, Northampton, Mass;
   Ophthalmic Epidemiology and Genetics Service, New England Eye Center,
   Tufts Medical Center, Tufts University School of Medicine, Boston, Mass;
   NATIONAL EYE INSTITUTE [R01EY011309] Funding Source: NIH RePORTER
FX We thank Yi Yu and Lillian Merriam for their constructive criticism of
   the manuscript. This work was supported in part by grants R01-EY11309
   from the National Institutes of Health, Bethesda, Md.; Massachusetts
   Lions Eye Research Fund, Inc.; unrestricted grant from Research to
   Prevent Blindness, Inc., New York, N.Y.; the American Macular
   Degeneration Foundation, Northampton, Mass.; donations to the Macular
   Degeneration Research Fund of the Ophthalmic Epidemiology and Genetics
   Service, New England Eye Center, Tufts Medical Center, Tufts University
   School of Medicine, Boston, Mass.
CR Aberg K, 2012, EUR J HUM GENET, V20, P953, DOI 10.1038/ejhg.2012.33
   [Anonymous], DAT SINGL NUCL POL D
   Aranyi T, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-431
   Baranzini SE, 2010, NATURE, V464, P1351, DOI 10.1038/nature08990
   Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100
   Boks MP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006767
   Boumber YA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000162
   Bruder CEG, 2008, AM J HUM GENET, V82, P763, DOI 10.1016/j.ajhg.2007.12.011
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Dempster EL, 2011, HUM MOL GENET, V20, P4786, DOI 10.1093/hmg/ddr416
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Gertz J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002228
   Glossop JR, 2013, EPIGENETICS-US, V8, P1188, DOI 10.4161/epi.26265
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Hellman A, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-11
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416
   JABLON S, 1967, AM J HUM GENET, V19, P133
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Javierre BM, 2010, GENOME RES, V20, P170, DOI 10.1101/gr.100289.109
   Kang MY, 2008, CANCER-AM CANCER SOC, V112, P1699, DOI 10.1002/cncr.23335
   Kerkel K, 2008, NAT GENET, V40, P904, DOI 10.1038/ng.174
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Korn JM, 2008, NAT GENET, V40, P1253, DOI 10.1038/ng.237
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U
   RAMIREZ JM, 1994, VISION RES, V34, P1935, DOI 10.1016/0042-6989(94)90024-8
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schalkwyk LC, 2010, AM J HUM GENET, V86, P196, DOI 10.1016/j.ajhg.2010.01.014
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Shoemaker R, 2010, GENOME RES, V20, P883, DOI 10.1101/gr.104695.109
   Stepanow S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017711
   Stone JL, 2008, NATURE, V455, P237, DOI 10.1038/nature07239
   Wang XL, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-87
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang YY, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000438
NR 65
TC 13
Z9 13
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5652
EI 1423-0062
J9 HUM HERED
JI Hum. Hered.
PY 2014
VL 78
IS 2
BP 59
EP 72
DI 10.1159/000362814
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AN7WW
UT WOS:000340812700001
PM 25033836
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Westborg, I
   Rosso, A
AF Westborg, Inger
   Rosso, Aldana
TI Risk Factors for Discontinuation of Treatment for Neovascular
   Age-Related Macular Degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE nAMD; machine learning; ranibizumab; aflibercept
ID MEDICARE BENEFICIARIES; TREATMENT PATTERNS; VISUAL-ACUITY; RANIBIZUMAB;
   THERAPY
AB Purpose: To investigate risk factors for treatment discontinuation for neovascular age-related macular degeneration (nAMD).
   Methods: Data from the Swedish Macula Register and the Skane Healthcare Register are reported on the treatment received by 932 nAMD patients diagnosed 2013-2015. Treatment discontinuation is defined as having a termination visit or lacking a control or treatment visit during the period of 10-14months after the diagnostic visit. The risk of treatment discontinuation during the first year is estimated using a Poisson model and a classification tree.
   Results: 503 eyes (50.9%) discontinued the treatment within the first year. Patients with visual acuity below 60 ETDRS letters (20/60 Snellen) at baseline, serious comorbidities, or treated at the university hospital have a 42% (95% CI 25-61%, P<0.001), 27% (95% CI 13-43%, P=0.001) and 30% (95% CI 15-46%, P<0.001) increased risk to discontinue treatment compared with similar patients. Patients on ranibizumab therapy have a 45% (95% CI 28-63%, P<0.001) increased risk for treatment discontinuation during year 1 compared with patients on aflibercept therapy. The classification tree also shows that patients on ranibizumab therapy and those with low VA at baseline are at a higher risk of terminating treatment.
   Conclusions: Almost half of the patients starting anti-VEGF therapy discontinue treatment during the first year. Patients with risk factors may require additional support to continue with the treatment. Aflibercept therapy could be an alternative to patients at risk of treatment discontinuation.
C1 [Westborg, Inger] Umea Univ, Dept Clin Sci Ophthalmol, Umea, Sweden.
   [Rosso, Aldana] Skane Univ Hosp, Ctr Registers South, Lund, Sweden.
   [Rosso, Aldana] Lund Univ, Inst Translat Med, Radiol Diagnost, SUS Malmo,Entrance 44,Inga Marie Nilssons Gata 49, Malmo, Sweden.
C3 Umea University; Lund University; Skane University Hospital; Lund
   University
RP Rosso, A (通讯作者)，Lund Univ, Inst Translat Med, Radiol Diagnost, SUS Malmo,Entrance 44,Inga Marie Nilssons Gata 49, Malmo, Sweden.
EM aldana.rosso@med.lu.se
RI Westborg, Inger/AAD-7108-2021
OI Rosso, Aldana/0000-0001-6603-2855
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   DF M, 2011, NEW ENGL J MED, V364, P1897, DOI DOI 10.1056/NEJMOA1102673
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Inger Westborg SA, 2015, ANN REPORT SWEDISH M
   L L-Am R, 2014, RECOMMENDATION TREAT
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Lemon SC, 2003, ANN BEHAV MED, V26, P172, DOI 10.1207/S15324796ABM2603_02
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarwar S, 2016, COCHRANE DB SYST REV, V2
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Westborg I, 2017, RETINA-J RET VIT DIS, V37, P2035, DOI 10.1097/IAE.0000000000001431
NR 20
TC 13
Z9 13
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2018
VL 25
IS 2
BP 176
EP 182
DI 10.1080/09286586.2017.1397701
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FU0VH
UT WOS:000423568000011
PM 29131696
DA 2022-11-30
ER

PT J
AU Othman, H
   Saadat, I
   Farvardin-Jahromi, M
   Saadat, M
AF Othman, Hasan
   Saadat, Iraj
   Farvardin-Jahromi, Majid
   Saadat, Mostafa
TI Susceptibility to exudative age-related macular degeneration and three
   genetic polymorphisms of glutathione S-transferase Z1 (GSTZ1)
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; GSTZ1; Susceptibility
ID OXIDATIVE STRESS; BREAST-CANCER; XRCC1; METAANALYSIS; GSTT1; ZETA; T1;
   DETOXIFICATION; PATHOGENESIS; MACULOPATHY
AB PURPOSE. To investigate whether genetic polymorphisms of GSTZ1 contribute to the development of exudative age-related macular degeneration (AMD).
   METHODS. The present case-control study consisted of 112 patients (44 female, 68 male) with exudative AMD and 112 sex frequency-matched healthy controls were randomly selected from unrelated volunteers in the same clinic. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism-based method.
   RESULTS. There was no significant association between study polymorphisms and susceptibility to exudative AMD. Considering the significant difference in age distribution between cases and controls, age was used as a covariate in further analysis. After odds ratio adjustment for age, the same results were observed. The study polymorphisms showed linkage disequilibrium. Analysis revealed that there was no difference between cases and controls for the prevalence of the haplotypes of GSTZ1.
   CONCLUSIONS. Our study did not support any association between susceptibility to exudative AMD and polymorphisms of GSTZ1.
C1 [Othman, Hasan; Saadat, Iraj; Saadat, Mostafa] Shiraz Univ, Coll Sci, Dept Biol, Shiraz 71454, Iran.
   [Saadat, Iraj; Saadat, Mostafa] Shiraz Univ, Inst Biotechnol, Shiraz 71454, Iran.
   [Farvardin-Jahromi, Majid] Shiraz Univ Med Sci, Poostchi Eye Res Ctr, Dept Ophthalmol, Shiraz, Iran.
C3 Shiraz University; Shiraz University; Shiraz University of Medical
   Science
RP Saadat, M (通讯作者)，Shiraz Univ, Coll Sci, Dept Biol, Shiraz 71454, Iran.
EM saadat@susc.ac.ir
RI farvardin, majid/K-6950-2016
OI farvardin, majid/0000-0001-9047-0329; Saadat,
   Mostafa/0000-0002-0021-4055; Saadat, Iraj/0000-0002-8169-4707
FU Shiraz University; Shiraz University of Medical Sciences
FX This study was supported by Shiraz University and Shiraz University of
   Medical Sciences.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blackburn AC, 2006, MOL PHARMACOL, V69, P650, DOI 10.1124/mol.105.018911
   Blackburn AC, 2000, PHARMACOGENETICS, V10, P49, DOI 10.1097/00008571-200002000-00007
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Fang YY, 2006, PHARMACOGENET GENOM, V16, P307, DOI 10.1097/01.fpc.0000205000.07054.b3
   Guven M, 2011, OPHTHALMIC RES, V46, P31, DOI 10.1159/000321940
   Hu ZB, 2005, CANCER EPIDEM BIOMAR, V14, P1810, DOI 10.1158/1055-9965.EPI-04-0793
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Masoudi M, 2010, BREAST CANCER RES TR, V120, P263, DOI 10.1007/s10549-009-0521-z
   Mohamadynejad P, 2008, MOL BIOL REP, V35, P669, DOI 10.1007/s11033-007-9138-7
   Nafissi S, 2011, PSYCHIAT RES, V187, P314, DOI 10.1016/j.psychres.2010.11.024
   Nafissi S, 2011, MOL BIOL REP, V38, P3391, DOI 10.1007/s11033-010-0447-x
   Othman H, MOL BIOL REP
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   Rafiee L, 2010, MOL BIOL REP, V37, P155, DOI 10.1007/s11033-009-9565-8
   Saadat M, 2006, CANCER SCI, V97, P505, DOI 10.1111/j.1349-7006.2006.00207.x
   Saadat M, 2004, J ALLERGY CLIN IMMUN, V113, P996, DOI 10.1016/j.jaci.2004.02.007
   Saadat M, 2007, PSYCHIAT RES, V153, P87, DOI 10.1016/j.psychres.2006.03.024
   Saadat M, 2009, BREAST CANCER RES TR, V115, P137, DOI 10.1007/s10549-008-0051-0
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 24
TC 3
Z9 3
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2012
VL 22
IS 3
BP 431
EP 435
DI 10.5301/ejo.5000053
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 969ZZ
UT WOS:000306099200022
PM 21948024
DA 2022-11-30
ER

PT J
AU Kadry, S
   Rajinikanth, V
   Crespo, RG
   Verdu, E
AF Kadry, Seifedine
   Rajinikanth, V
   Crespo, Ruben Gonzalez
   Verdu, Elena
TI Automated detection of age-related macular degeneration using a
   pre-trained deep-learning scheme
SO JOURNAL OF SUPERCOMPUTING
LA English
DT Article
DE Retinal abnormality; AMD; VGG16; Serial concatenation; Automated
   detection
ID ARTIFICIAL-INTELLIGENCE; DISEASE DETECTION; CLASSIFICATION; ABNORMALITY;
   FRAMEWORK; FEATURES; SIGNALS; IMAGES
AB An eye disease affects the entire sensory operation, and an unrecognised and untreated eye disease may lead to loss of vision. The proposed work aims to develop an automated age-related macular degeneration (AMD) detection system using a Deep-Learning (DL) scheme with serially concatenated deep and handcrafted features. The research includes the following phases: initial data processing, deep-features extraction with VGG16, handcrafted feature extraction, optimal feature selection using Mayfly-Algorithm, serial features concatenation, and binary classification and validation. In this work, the handcrafted features, such as local binary pattern (LBP), pyramid histogram of oriented gradients (PHOG), and discrete wavelet transform (DWT), are extracted from the test images and concatenated with the deep-features of VGG16. The performance of the developed system is separately tested using fundus retinal images (FRI) and optical coherence tomography (OCT) images. A binary classification with a fivefold cross validation is employed and the best outcome of this trial is chosen as the result. The performance of VGG16 is then compared with that of VGG19, ResNet50, and AlexNet. The experimental outcome of this research confirms that the proposal of VGG16 with concatenated features achieves AMD detection accuracies of 97.08 and 97.50 for FRI and OCT images, respectively.
C1 [Kadry, Seifedine] Noroff Univ Coll, Fac Appl Comp & Technol, Kristiansand, Norway.
   [Rajinikanth, V] St Josephs Coll Engn, Dept Elect & Instrumentat Engn, Chennai 600119, Tamil Nadu, India.
   [Crespo, Ruben Gonzalez; Verdu, Elena] Univ Int La Rioja, Sch Engn & Technol, Logrono, Spain.
C3 St. Joseph's College of Engineering, Chennai; Universidad Internacional
   de La Rioja (UNIR)
RP Verdu, E (通讯作者)，Univ Int La Rioja, Sch Engn & Technol, Logrono, Spain.
EM elena.verdu@unir.net
RI Verdu, Elena/A-5021-2019; Rajinikanth, V./AAC-1204-2021; Kadry,
   Seifedine/C-7437-2011; Rajinikanth, V/X-9395-2018; Gonzalez Crespo,
   Ruben/P-8601-2018
OI Verdu, Elena/0000-0002-3040-7077; Rajinikanth, V./0000-0003-3897-4460;
   Kadry, Seifedine/0000-0002-1939-4842; Rajinikanth,
   V/0000-0003-3897-4460; Gonzalez Crespo, Ruben/0000-0001-5541-6319
CR Afzal S, 2021, INT J INTERACT MULTI, V6, P26, DOI 10.9781/ijimai.2021.04.005
   Ali R, 2021, IEEE T IND INFORM, V17, P2476, DOI 10.1109/TII.2020.3000204
   Zapata MA, 2020, CLIN OPHTHALMOL, V14, P419, DOI 10.2147/OPTH.S235751
   Badar M, 2020, COMPUT SCI REV, V35, DOI 10.1016/j.cosrev.2019.100203
   Bakiya A, 2021, PHYS ENG SCI MED, V44, P1095, DOI 10.1007/s13246-021-01046-7
   Bakiya A, 2020, MULTIMED TOOLS APPL, V79, P11051, DOI 10.1007/s11042-018-6561-9
   Bhandary A, 2020, PATTERN RECOGN LETT, V129, P271, DOI 10.1016/j.patrec.2019.11.013
   Bobadilla J, 2020, INT J INTERACT MULTI, V6, P68, DOI 10.9781/ijimai.2020.02.006
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Cao K, 2019, INT J OPHTHALMOL-CHI, V12, P1158, DOI 10.18240/ijo.2019.07.17
   Chang RI, 2020, J SUPERCOMPUT, V76, P8641, DOI 10.1007/s11227-020-03152-x
   Choe HC, 1997, P SOC PHOTO-OPT INS, V3078, P480, DOI 10.1117/12.271772
   De Fauw Jeffrey, 2016, F1000Res, V5, P1573
   Deivasigamani S, 2016, INT J IMAG SYST TECH, V26, P277, DOI 10.1002/ima.22199
   Fernandes SL, 2019, IEEE CONSUM ELECTR M, V8, P31, DOI 10.1109/MCE.2019.2923926
   Gao Z., 2020, J PHYS C SER, V1684, DOI 10.1088/1742-6596/1684/1/012077
   Geng L, 2019, COMPUT ASSIST SURG, V24, P27, DOI 10.1080/24699322.2019.1649071
   Gholami P, 2020, COMPUT ELECTR ENG, V81, DOI 10.1016/j.compeleceng.2019.106532
   Gonzalez-Gonzalo C, 2020, ACTA OPHTHALMOL, V98, P368, DOI 10.1111/aos.14306
   Gour N, 2020, PATTERN RECOGN LETT, V137, P3, DOI 10.1016/j.patrec.2019.04.004
   Gudigar A, 2019, PATTERN RECOGN LETT, V125, P35, DOI 10.1016/j.patrec.2019.03.027
   Guo XK, 2021, ENERGY REP, V7, P1234, DOI 10.1016/j.egyr.2021.02.042
   Guo ZH, 2010, IEEE T IMAGE PROCESS, V19, P1657, DOI 10.1109/TIP.2010.2044957
   Han Song, 2015, NIPS
   Hashmi MF, 2013, INT CONF INTELL SYST, P188, DOI 10.1109/ISDA.2013.6920733
   Jin X, 2020, INT J INTERACT MULTI, V6, P113, DOI 10.9781/ijimai.2020.11.007
   Khan MA, 2020, IEEE ACCESS, V8, P132850, DOI 10.1109/ACCESS.2020.3010448
   Koh JEW, 2018, APPL INTELL, V48, P1379, DOI 10.1007/s10489-017-1048-3
   Kowsalya N., 2018, 2018 Fourth International Conference on Biosignals, Images and Instrumentation (ICBSII), P206, DOI 10.1109/ICBSII.2018.8524655
   Prabha PL, 2021, J SUPERCOMPUT, V77, P10289, DOI 10.1007/s11227-021-03676-w
   Liang LM, 2020, J MED IMAG HEALTH IN, V10, P326, DOI 10.1166/jmihi.2020.2905
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Montenegro-Marin CE, 2021, INT J INTERACT MULTI, P1, DOI [10.9781/ijimai.2021.05.004, DOI 10.9781/IJIMAI.2021.05.004]
   Padmasini N, 2020, J MED IMAG HEALTH IN, V10, P316, DOI 10.1166/jmihi.2020.2973
   Pead E, 2019, SURV OPHTHALMOL, V64, P498, DOI 10.1016/j.survophthal.2019.02.003
   Polat O, 2021, J SUPERCOMPUT, V77, P7236, DOI 10.1007/s11227-020-03572-9
   Rajinikanth V, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10103429
   Redies C, 2012, LECT NOTES COMPUT SC, V7583, P522, DOI 10.1007/978-3-642-33863-2_54
   Rim TH, 2021, BRIT J OPHTHALMOL, V105, P1133, DOI 10.1136/bjophthalmol-2020-316984
   Samanta A, 2020, ASIA-PAC J OPHTHALMO, V9, P250, DOI 10.1097/APO.0000000000000291
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Sengupta S, 2020, ARTIF INTELL MED, V102, DOI 10.1016/j.artmed.2019.101758
   Shree TDV, 2018, PROCEDIA COMPUT SCI, V125, P157, DOI 10.1016/j.procs.2017.12.022
   Singh R, 2021, INT J INTERACT MULTI, V6, P25, DOI 10.9781/ijimai.2020.11.005
   [宋克臣 Song Kechen], 2013, [自动化学报, Acta Automatica Sinica], V39, P730
   Phan TV, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/5893601
   The Mathworks, 2021, CHOOS CLASS OPT
   Venkatraman K, 2020, J MED IMAG HEALTH IN, V10, P566, DOI 10.1166/jmihi.2020.2980
   Xie H, 2020, NEURAL NETWORKS, V132, P477, DOI 10.1016/j.neunet.2020.09.005
   Xie Z, 2020, J MED SYST, V44, DOI 10.1007/s10916-020-01561-2
   Yepuganti K, 2020, INT J IMAG SYST TECH, V30, P1337, DOI 10.1002/ima.22451
   You QS, 2020, AM J OPHTHALMOL, V209, P206, DOI 10.1016/j.ajo.2019.09.004
   Zervoudakis K, 2020, COMPUT IND ENG, V145, DOI 10.1016/j.cie.2020.106559
   Zhang BC, 2010, IEEE T IMAGE PROCESS, V19, P533, DOI 10.1109/TIP.2009.2035882
NR 55
TC 2
Z9 2
U1 13
U2 22
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-8542
EI 1573-0484
J9 J SUPERCOMPUT
JI J. Supercomput.
PD APR
PY 2022
VL 78
IS 5
BP 7321
EP 7340
DI 10.1007/s11227-021-04181-w
EA NOV 2021
PG 20
WC Computer Science, Hardware & Architecture; Computer Science, Theory &
   Methods; Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering
GA ZV6YD
UT WOS:000716301900001
DA 2022-11-30
ER

PT J
AU Parravano, M
   Costanzo, E
   Scondotto, G
   Trifiro, G
   Virgili, G
AF Parravano, Mariacristina
   Costanzo, Eliana
   Scondotto, Giulia
   Trifiro, Gianluca
   Virgili, Gianni
TI Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular
   Degeneration: An Update
SO BIODRUGS
LA English
DT Review
ID TREAT-AND-EXTEND; INTRAVITREAL RANIBIZUMAB; PHARMACOKINETIC PROPERTIES;
   OPEN-LABEL; SAFETY; BEVACIZUMAB; AFLIBERCEPT; EFFICACY; OUTCOMES; TRIAL
AB Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in older adults. The prognosis for the neovascular type of advanced AMD improved with the introduction of biological drugs with antiangiogenic properties, beginning with off-label bevacizumab, which was first used intravitreally in 2006. These drugs target newly formed vessels that grow beneath the center of the retina, causing loss of central vision, and they can help to maintain or improve vision. Repeated intravitreal injections are needed to achieve prolonged inhibition of proangiogenic cytokines, primarily vascular endothelial growth factor (VEGF). Major regulatory agencies have approved several molecules for AMD treatment, including ranibizumab, aflibercept, and brolucizumab. The development of further drugs was mainly targeted at prolonging anti-VEGF inhibition-thus reducing the frequency of injections-and expanding the biological targets of proangiogenic cytokine inhibition. Finally, biosimilars are already being marketed in some countries, allowing the containment of costs of AMD treatment, which are growing steadily in many settings because of the need for long-term treatment. This review summarizes the properties and clinical profiles of anti-VEGF biological drugs that are approved to treat neovascular AMD as well as ongoing research on molecules that may be marketed in the near future.
C1 [Parravano, Mariacristina; Costanzo, Eliana] IRCCS Fdn Bietti, Via Livenza 3, I-00198 Rome, Italy.
   [Scondotto, Giulia] AOU G Martino, Clin Pharmacol Unit, Messina, Italy.
   [Trifiro, Gianluca] Univ Verona, Dept Diagnost & Publ Hlth, Verona, Italy.
   [Trifiro, Gianluca] Azienda Osped Univ G Martino, Sci Responsible Acad Spin Off INSPIRE Innovat Sol, Messina, Italy.
   [Virgili, Gianni] Univ Firenze, Dept Neurosci Psychol Drug Res & Child Hlth NEURO, Florence, Italy.
   [Virgili, Gianni] AOU Careggi, Florence, Italy.
   [Virgili, Gianni] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; AOU Policlinico Gaetano Martino; University of Verona; AOU
   Policlinico Gaetano Martino; University of Florence; University of
   Florence; Azienda Ospedaliero Universitaria Careggi; Queens University
   Belfast
RP Parravano, M (通讯作者)，IRCCS Fdn Bietti, Via Livenza 3, I-00198 Rome, Italy.
EM mcparravano@gmail.com
RI Virgili, Gianni/P-6607-2014
OI Virgili, Gianni/0000-0002-9960-2989
FU Italian Ministry of Health; Fondazione Roma
FX The research for this paper was in part financially supported by the
   Italian Ministry of Health and Fondazione Roma. The funders had no role
   in the study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   [Anonymous], 2018, LANCET, V392, P1090, DOI 10.1016/S0140-6736(18)32291-8
   [Anonymous], 2020, AM SOC RET SPEC ASRS
   Assi L, 2021, JAMA OPHTHALMOL, V139, P526, DOI 10.1001/jamaophthalmol.2021.0146
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chakraborty D, 2021, OPHTHALMOL THER, V10, P337, DOI 10.1007/s40123-021-00345-2
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Chandrasekaran PR, 2021, THER ADV OPHTHALMOL, V13, DOI 10.1177/25158414211027708
   Chaney, 2019, OPHTH INN SUMM
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Christoforidis JB, 2012, CURR EYE RES, V37, P1171, DOI 10.3109/02713683.2012.727521
   Christoforidis JB, 2017, INVEST OPHTH VIS SCI, V58, P5636, DOI 10.1167/iovs.17-22431
   Cutroneo PM, 2017, DRUG SAFETY, V40, P1131, DOI 10.1007/s40264-017-0553-y
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dugel PU, 2020, OPHTHALMOL RETINA, V4, P250, DOI 10.1016/j.oret.2019.10.008
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ehlers JP, 2013, BRIT J OPHTHALMOL, V97, P248, DOI 10.1136/bjophthalmol-2012-302489
   EyePoint Pharmaceuticals Inc., 2021, EYEPOINT PHARM ANN 1
   Farhat F, 2018, ONCOLOGIST, V23, P346, DOI 10.1634/theoncologist.2017-0126
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gelfman CM, 2021, J OCUL PHARMACOL TH, V37, P181, DOI 10.1089/jop.2021.0001
   Gonzales CR, 2017, INVEST OPHTH VIS SCI, V58
   Griaud F, 2017, MABS-AUSTIN, V9, P1337, DOI 10.1080/19420862.2017.1366395
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hollingworth W, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018289
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jones M, 2020, OPHTHAL EPIDEMIOL, V27, P399, DOI 10.1080/09286586.2020.1762229
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2018-000185
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Khurana RN, 2021, OPHTHALMOLOGY, V128, P1027, DOI 10.1016/j.ophtha.2020.11.017
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kniggendorf V, 2020, ARQ BRAS OFTALMOL, V83, P552, DOI 10.5935/0004-2749.20200082
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kulkarni S, 2021, INDIAN J OPHTHALMOL, V69, P671, DOI 10.4103/ijo.IJO_2614_20
   Kumar R, 2009, BRIT J CANCER, V101, P1717, DOI 10.1038/sj.bjc.6605366
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maloney MH, 2021, OPHTHALMOLOGY, V128, P417, DOI 10.1016/j.ophtha.2020.07.062
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mirshahi A, 2021, J OPHTHAL VIS RES, V16, P28, DOI 10.18502/jovr.v16i1.8248
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Patel S, 2018, OPHTHALMOL RETINA, V2, P785, DOI 10.1016/j.oret.2017.12.006
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Samanta A, 2020, ASIA-PAC J OPHTHALMO, V9, P250, DOI 10.1097/APO.0000000000000291
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schr?der J., 2018, J NEUROL RES THER, V2, P10, DOI [10.14302/issn.2470-5020.jnrt-18-2258, DOI 10.14302/ISSN.2470-5020.JNRT-18-2258]
   Sen S, 2021, SEMIN OPHTHALMOL, V36, P413, DOI 10.1080/08820538.2021.1896746
   Sharma A, 2021, AM J OPHTHALMOL, V224, P36, DOI 10.1016/j.ajo.2020.11.017
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Sharma S, 2021, INT J RETINA VITR, V7, DOI 10.1186/s40942-021-00293-w
   Sharma S, 2020, OPHTHALMOL THER, V9, P103, DOI 10.1007/s40123-019-00228-7
   Sharma S, 2019, OPHTHALMOLOGICA, V241, P24, DOI 10.1159/000488602
   Sheth JU, 2021, INDIAN J OPHTHALMOL, V69, P352, DOI 10.4103/ijo.IJO_2703_20
   Shin HT, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-01830-9
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Stewart MW, 2016, AM J OPHTHALMOL, V170, P228, DOI 10.1016/j.ajo.2016.05.023
   Sultana J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00315
   Taylor P, 2021, EUROPE HAS ITS 1 LUC
   Trifiro G, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00608
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Verma L, 2021, INDIAN J OPHTHALMOL, V69, P347, DOI 10.4103/ijo.IJO_2516_20
   Wells JA, 2018, OSLI RETINA, V49, P336, DOI 10.3928/23258160-20180501-07
   Woo SJ, 2021, JAMA OPHTHALMOL, V139, P68, DOI 10.1001/jamaophthalmol.2020.5053
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yip JLY, 2021, BMJ OPEN OPHTHALMOL, V6, DOI 10.1136/bmjophth-2020-000585
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 100
TC 4
Z9 5
U1 1
U2 10
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-8804
EI 1179-190X
J9 BIODRUGS
JI Biodrugs
PD NOV
PY 2021
VL 35
IS 6
BP 673
EP 692
DI 10.1007/s40259-021-00499-2
EA OCT 2021
PG 20
WC Oncology; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology; Pharmacology & Pharmacy
GA XC7RU
UT WOS:000708220400001
PM 34655434
DA 2022-11-30
ER

PT J
AU Miyake, M
   Saito, M
   Yamashiro, K
   Sekiryu, T
   Yoshimura, N
AF Miyake, Masahiro
   Saito, Masaaki
   Yamashiro, Kenji
   Sekiryu, Tetsuju
   Yoshimura, Nagahisa
TI Complement factor H R1210C among Japanese patients with age-related
   macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Complement factor H; Genetics; Rare
   variant; R1210C
ID HIGH-RISK; PREVALENCE; VARIANTS; ASSOCIATION; LOCI; C3; MUTATIONS;
   CONFERS; GENE; CFI
AB To evaluate the genotype distribution of a rare age-related macular degeneration (AMD)-susceptibility variant, complement factor H (CFH) R1210C, among a large Japanese cohort with AMD.
   One thousand three hundred and sixty-four Japanese patients with neovascular AMD were evaluated. We screened for CFH R1210C (rs121913059) by genotyping with the Taqman method; the mutation was confirmed by Sanger sequencing. We also searched for this mutation in the human genome variant database, which contains the whole-exome sequencing data for 1208 Japanese individuals. The detailed characteristics of patients with this mutation were reviewed.
   The mean age of the patients was 74.5 years (standard deviation 8.7); men accounted for 71.8 % of the patients. The CFH R1210C variant was found in only 1 of the 1364 AMD patients, and was heterozygous (minor allele frequency (MAF) = 0.037 %); it was not found in any of the 1208 individuals in the control group (MAF = 0 %). The patient with CFH R1210C was a 70-year-old woman whose main complaint was visual loss in the right eye. Dilated fundus examination, optical coherence tomography, and fluorescein and indocyanine angiography revealed polypoidal choroidal neovasculopathy (PCV), but no drusen in either eye. Despite treatment, her visual acuity had decreased to 1/50 by 6.8 years after her first visit.
   The CFH R1210C variant was found to be rare among Japanese patients with AMD. The patient with the mutation did have the PCV subtype, but no drusen formation. Considering their ethnicity-specific nature, such rare variants should be studied by use of next-generation sequencing for each ethnicity.
C1 [Miyake, Masahiro; Yamashiro, Kenji; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol, Sch Med, Kyoto 606, Japan.
   [Saito, Masaaki; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
C3 Kyoto University; Fukushima Medical University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Dept Ophthalmol, Sch Med, Kyoto 606, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Saito, Masaaki/ABI-2783-2020; Miyake, Masahiro/V-1261-2019
OI Saito, Masaaki/0000-0003-1494-6350; Miyake,
   Masahiro/0000-0001-7410-3764; Sekiryu, Tetsuju/0000-0001-8042-2729;
   Yamashiro, Kenji/0000-0001-9354-8558
FU Research Grant for Intractable Diseases from the Japanese Ministry of
   Health, Labour, and Welfare [201238002A]
FX Creation of the Human Genetic Variation Database was supported by a
   Research Grant for Intractable Diseases (no. 201238002A) from the
   Japanese Ministry of Health, Labour, and Welfare.
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cho HJ, 2015, JPN J OPHTHALMOL, V59, P29, DOI 10.1007/s10384-014-0349-x
   Fan XP, 2013, MOL IMMUNOL, V54, P238, DOI 10.1016/j.molimm.2012.12.006
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Inoue M, 2015, JPN J OPHTHALMOL, V59, P173, DOI 10.1007/s10384-015-0374-4
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Nakata I, 2013, INVEST OPHTH VIS SCI, V54, P6068, DOI 10.1167/iovs.13-11605
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Ogino K, 2014, JPN J OPHTHALMOL, V58, P155, DOI 10.1007/s10384-013-0295-z
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Servais A, 2007, J MED GENET, V44, P193, DOI 10.1136/jmg.2006.045328
   Takeuchi F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046385
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 27
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2015
VL 59
IS 5
BP 273
EP 278
DI 10.1007/s10384-015-0394-0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR1GD
UT WOS:000361072000001
PM 26215151
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Knudtson, MD
AF Klein, R
   Klein, BEK
   Knudtson, MD
TI Frailty and age-related macular degeneration: The Beaver Dam Eye Study.
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To investigate the associations of measures of frailty to prevalent age-related maculopathy (ARM).
   DESIGN: Cross-sectional population-based study.
   METHODS: Time to walk a measured course (gait-time) handgrip strength, peak expiratory flow rate, ability to stand from a sitting position without using arms, self. reported co-morbidities, and ARM were assessed at the third examination of the Beaver Dam Eye Study (n = 2,962). ARM was determined by grading stereoscopic color fundus photographs.
   RESULTS: While controlling for age, smoking, and the number of co-morbid conditions, weaker handgrip strength was associated with early ARM (odds ratio [OR]/10 kg decrease 1.28, confidence interval [CI] 1.08, 1.5 2, P = .004) and late ARM (OR 1.5 5, 95% CI 1.02, 2.36) in men but not women. Other measures of frailty were not related to ARM.
   CONCLUSIONS: A weak cross,sectional association of handgrip strength with ARM (in men) was found after controlling for co-morbid conditions. These data suggest that ARM is due to a specific disease process, albeit age-related, rather than to biologic aging, as reflected by measures of frailty.
C1 Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Room 405 WARF,610 N Walnut St, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
CR HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein Barbara E K, 2003, Trans Am Ophthalmol Soc, V101, P191
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1999, BEAVER DAM EYE STUDY, V3
NR 6
TC 23
Z9 24
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2005
VL 140
IS 1
BP 129
EP 131
DI 10.1016/j.ajo.2004.12.049
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 949IN
UT WOS:000230778700020
PM 16038655
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Petrovski, G
   Vereb, Z
   Facsko, A
   Kaarniranta, K
AF Blasiak, Janusz
   Petrovski, Goran
   Vereb, Zoltan
   Facsko, Andrea
   Kaarniranta, Kai
TI Oxidative Stress, Hypoxia, and Autophagy in the Neovascular Processes of
   Age-Related Macular Degeneration
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; CHOROIDAL BLOOD-FLOW; DNA-DAMAGE;
   EXPRESSION; THROMBOSPONDIN-1; DEHYDROGENASE; MITOCHONDRIAL; ACTIVATION;
   INDUCTION; RELEVANCE
AB Age-related macular degeneration (AMD) is the leading cause of severe and irreversible loss of vision in the elderly in developed countries. AMD is a complex chronic neurodegenerative disease associated with many environmental, lifestyle, and genetic factors. Oxidative stress and the production of reactive oxygen species (ROS) seem to play a pivotal role in AMD pathogenesis. It is known that the macula receives the highest blood flow of any tissue in the body when related to size, and anything that can reduce the rich blood supply can cause hypoxia, malfunction, or disease. Oxidative stress can affect both the lipid rich retinal outer segment structure and the light processing in the macula. The response to oxidative stress involves several cellular defense reactions, for example, increases in antioxidant production and proteolysis of damaged proteins. The imbalance between production of damaged cellular components and degradation leads to the accumulation of detrimental products, for example, intracellular lipofuscin and extracellular drusen. Autophagy is a central lysosomal clearance system that may play an important role in AMD development. There are many anatomical changes in retinal pigment epithelium (RPE), Bruch's membrane, and choriocapillaris in response to chronic oxidative stress, hypoxia, and disturbed autophagy and these are estimated to be crucial components in the pathology of neovascular processes in AMD.
C1 [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
   [Petrovski, Goran; Facsko, Andrea] Univ Szeged, Dept Ophthalmol, Fac Med, H-6720 Szeged, Hungary.
   [Petrovski, Goran; Vereb, Zoltan] Univ Debrecen, Stem Cells & Eye Res Lab, Dept Biochem & Mol Biol, Med & Hlth Sci Ctr, H-4010 Debrecen, Hungary.
   [Petrovski, Goran; Vereb, Zoltan] Univ Debrecen, Hungarian Acad Sci, Apoptosis & Genom Res Grp, H-4010 Debrecen, Hungary.
   [Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70211, Finland.
C3 University of Lodz; Szeged University; University of Debrecen; Hungarian
   Academy of Sciences; University of Debrecen; University of Eastern
   Finland; Kuopio University Hospital; University of Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70211, Finland.
EM kai.kaarniranta@kuh.fi
RI Vereb, Zoltan/I-6356-2019; Vereb, Zoltan/AAR-4092-2020
OI Vereb, Zoltan/0000-0002-9518-2155; Blasiak, Janusz/0000-0001-9539-9584;
   Kaarniranta, Kai/0000-0003-2600-8679; /0000-0002-0035-1471; Petrovski,
   Goran/0000-0003-2905-9252
CR Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Bek T, 2009, ACTA OPHTHALMOL, V87, P362, DOI 10.1111/j.1755-3768.2008.01429.x
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bickler PE, 2004, J EXP BIOL, V207, P3243, DOI 10.1242/jeb.00977
   Blasiak J., 2012, FRONTIERS BIOSCIENCE, V5, P412
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Caprara C, 2012, PROG RETIN EYE RES, V31, P89, DOI 10.1016/j.preteyeres.2011.11.003
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Cullen V, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-5
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Du HL, 2012, INT J ONCOL, V40, P2049, DOI 10.3892/ijo.2012.1415
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Frede S, 2006, BIOCHEM J, V396, P517, DOI 10.1042/BJ20051839
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   Hyttinen J. M., 2013, BIOCHIM BIOPHYS ACTA, V1833, P503
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kalas W, 2013, ANTICANCER RES, V33, P1429
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kundu M, 2011, ANTIOXID REDOX SIGN, V14, P1953, DOI 10.1089/ars.2010.3809
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Loenarz C, 2011, EMBO REP, V12, P63, DOI 10.1038/embor.2010.170
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   ONeil J, 1997, FREE RADICAL BIO MED, V23, P215, DOI 10.1016/S0891-5849(96)00612-0
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Rogers BS, 2007, INVEST OPHTH VIS SCI, V48, P438, DOI 10.1167/iovs.06-0528
   Rose RC, 1998, P SOC EXP BIOL MED, V217, P397, DOI 10.3181/00379727-217-44250
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   SCHNEEWEIS DM, 1995, SCIENCE, V268, P1053, DOI 10.1126/science.7754386
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Sheibani N, 1999, HISTOL HISTOPATHOL, V14, P285, DOI 10.14670/HH-14.285
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viiri J, 2010, MOL VIS, V16, P1399
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Weidberg H, 2011, ANNU REV BIOCHEM, V80, P125, DOI 10.1146/annurev-biochem-052709-094552
   Winkler B S, 1999, Mol Vis, V5, P32
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zucchi PC, 2011, MOL BIOL CELL, V22, P4635, DOI 10.1091/mbc.E11-08-0680
NR 58
TC 170
Z9 175
U1 1
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 768026
DI 10.1155/2014/768026
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AC7PQ
UT WOS:000332723400001
PM 24707498
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Neubauer, AS
   Thiel, M
   Priglinger, S
   Chryssafis, C
   Alge, C
   Welge-Lussen, U
   Kampik, A
AF Neubauer, AS
   Thiel, M
   Priglinger, S
   Chryssafis, C
   Alge, C
   Welge-Lussen, U
   Kampik, A
TI Mapping of the retinal pigment epithelium in exudative age related
   macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age related macular degeneration; choroidal neovascularisation; imaging
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; QUANTITATIVE ASSESSMENT; THICKNESS MEASUREMENTS; ANGIOGRAPHY;
   OCT; DIFFERENTIATION; TOPOGRAPHY; ANALYZER
AB Purpose: To evaluate a novel technique for three-dimensional mapping of the retinal pigment epithelium (RPE) layer in patients with subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration. Methods: Scanning with a recent generation retinal thickness analyzer (RTA) was performed in consecutive patients undergoing fluorescein angiography. From a 3x3mm area centered on the fovea, three-dimensional area maps of the RPE level were calculated by external spreadsheet software. Included were 18 eyes with classic CNV, 18 eyes with occult CNV and 18 eyes from age-matched normal subjects. Repeatability was assessed by measuring 17 eyes with CNV 3 times. In ten additional patients, RTA imaging results were compared with cross-sections obtained by optical coherence tomography. Results: By both methods, distinctive changes in RPE level maps were observed in classic and occult CNV. In classic CNV with the lesion extending over the RPE, only focal irregularities in the anteriorly displaced RPE surface were observed. In contrast, mapping of occult CNV showed a more irregular displacement of the RPE layer. The RPE map standard deviation indicating surface irregularity differed statistically significantly between the groups, with coefficients of variance of 5.9% for controls, 6.1% for classic and 8.8% for occult CNV (P < 0.001). Regarding repeatability, RPE level maps showed 1.2% coefficient of variance and an intra-class correlation coefficient of 0.87 for triplicate measurements in CNV patients. Conclusions: Topographic mapping of CNV lesions offers a fast, reproducible method for obtaining three-dimensional morphometric information on the RPE level and to quantify changes.
C1 Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
C3 University of Munich
RP Neubauer, AS (通讯作者)，Univ Munich, Dept Ophthalmol, Mathildenstr 8, D-80336 Munich, Germany.
EM aljoscha.neubauer@med.uni-muenchen.de
CR Baba T, 2002, ACTA OPHTHALMOL SCAN, V80, P82, DOI 10.1034/j.1600-0420.2002.800116.x
   Bermig J, 2002, GRAEF ARCH CLIN EXP, V240, P169, DOI 10.1007/s00417-001-0378-2
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brumm G, 2002, KLIN MONATSBL AUGENH, V219, P791, DOI 10.1055/s-2002-36320
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Fukuchi T, 2001, GRAEF ARCH CLIN EXP, V239, P424, DOI 10.1007/s004170100296
   Fukuchi T, 2001, GRAEF ARCH CLIN EXP, V239, P41, DOI 10.1007/s004170000205
   Gieser JP, 2001, RETINA-J RET VIT DIS, V21, P352, DOI 10.1097/00006982-200108000-00010
   Hawkins BS, 1999, MOL VIS, V5
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Iida T, 2000, AM J OPHTHALMOL, V130, P763, DOI 10.1016/S0002-9394(00)00708-X
   Kaiser RS, 2002, RETINA-J RET VIT DIS, V22, P683, DOI 10.1097/00006982-200212000-00001
   Kim SG, 2003, YONSEI MED J, V44, P821, DOI 10.3349/ymj.2003.44.5.821
   Koozekanani D, 2000, INVEST OPHTH VIS SCI, V41, P1486
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Montero JA, 2003, GRAEF ARCH CLIN EXP, V241, P797, DOI 10.1007/s00417-003-0752-3
   Mueller AJ, 2002, BRIT J OPHTHALMOL, V86, P1194, DOI 10.1136/bjo.86.10.1194
   Neubauer AS, 2001, RETINA-J RET VIT DIS, V21, P596, DOI 10.1097/00006982-200112000-00006
   Oshima Y, 1999, BRIT J OPHTHALMOL, V83, P54, DOI 10.1136/bjo.83.1.54
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Schmidt-Erfurth U, 2001, INVEST OPHTH VIS SCI, V42, P2386
   SHAHIDI M, 1991, ARCH OPHTHALMOL-CHIC, V109, P1115, DOI 10.1001/archopht.1991.01080080075032
   Shahidi M, 2002, BRIT J OPHTHALMOL, V86, P623, DOI 10.1136/bjo.86.6.623
   SINGERMAN LJ, 1988, ANN OPHTHALMOL, V20, P415
   Spraul CW, 1998, KLIN MONATSBL AUGENH, V212, P141, DOI 10.1055/s-2008-1034850
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Zeimer R, 1996, INVEST OPHTH VIS SCI, V37, P1994
   ZEIMER RC, 1989, INVEST OPHTH VIS SCI, V30, P2099
NR 35
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2006
VL 244
IS 3
BP 342
EP 351
DI 10.1007/s00417-005-0056-x
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 021QY
UT WOS:000236001000010
PM 16133030
DA 2022-11-30
ER

PT J
AU Tian, Y
   Kijlstra, A
   Webers, CAB
   Berendschot, TTJM
AF Tian, Yuan
   Kijlstra, Aize
   Webers, Carroll A. B.
   Berendschot, Tos T. J. M.
TI Lutein and Factor D: Two intriguing players in the field of age-related
   macular degeneration
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Review
DE Lutein; Age-related macular degeneration; Factor D; Complement system
ID COMPLEMENT FACTOR-D; INDUCED CHOROIDAL NEOVASCULARIZATION; ALTERNATIVE
   PATHWAY CONVERTASE; MEMBRANE ATTACK COMPLEX; FACTOR-H POLYMORPHISM;
   ADIPOSE-TISSUE; OXIDATIVE STRESS; CAROTENOID CONCENTRATIONS;
   DIETARY-INTAKE; RISK-FACTORS
AB Age-related macular degeneration (AMD) is a progressive eye disease that impairs central vision among elderly populations in Western, industrialized countries. In this review we will focus on the role of factor D (FD) and lutein in AMD. FD is a rate-limiting enzyme of the alternative complement activation pathway that may play an important role in the development of AMD. Several independent studies have shown a significant increase in the level of a number of complement factors of the alternative pathway, including factor D in the blood of AMD patients as compared to healthy individuals, which suggests a systemic involvement in the pathogenesis of AMD.
   FD, also called adipsin, is mainly produced by adipose tissue. Besides playing a role in the activation of the alternative pathway, FD is also known to regulate the immune system. Of interest is our preliminary finding that lutein supplementation of early AMD cases was shown to lower the level of systemic FD. If confirmed, these findings provide further support for the application of anti-factor D intervention as a new approach to control the development of this disease. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Tian, Yuan; Kijlstra, Aize; Webers, Carroll A. B.; Berendschot, Tos T. J. M.] Univ Eye Clin Maastricht, NL-6202 AZ Maastricht, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC)
RP Berendschot, TTJM (通讯作者)，Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM tberendschot@maastrichtuniversity.nl
RI Webers, Carroll A.B./D-1130-2010; Berendschot, Tos TJM/M-8509-2016
OI Berendschot, Tos TJM/0000-0002-8101-939X; Tian, Yuan/0000-0002-9551-9061
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Bamashmus MA, 2004, EYE, V18, P257, DOI 10.1038/sj.eye.6700606
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   BARNUM SR, 1984, J IMMUNOL METHODS, V67, P303, DOI 10.1016/0022-1759(84)90470-8
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Birke K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076766
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113
   Chen L, 2003, CURR EYE RES, V26, P291, DOI 10.1076/ceyr.26.4.291.15432
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   CHONN A, 1991, J IMMUNOL, V146, P4234
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Dwyer JH, 2001, CIRCULATION, V103, P2922, DOI 10.1161/01.CIR.103.24.2922
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El-Sohemy A, 2002, AM J CLIN NUTR, V76, P172, DOI 10.1093/ajcn/76.1.172
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halberg N, 2008, ENDOCRIN METAB CLIN, V37, P753, DOI 10.1016/j.ecl.2008.07.002
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuno Noriyuki, 2011, Curr Mol Pharmacol, V4, P196
   Lee EH, 2004, J INVEST DERMATOL, V122, P510, DOI 10.1046/j.0022-202X.2004.22227.x
   LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498
   Li SY, 2009, INVEST OPHTH VIS SCI, V50, P836, DOI 10.1167/iovs.08-2310
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Matsumoto M, 1997, P NATL ACAD SCI USA, V94, P8720, DOI 10.1073/pnas.94.16.8720
   Mayne ST, 2003, J NUTR, V133, p933S, DOI 10.1093/jn/133.3.933S
   Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x
   Mousavi M., 2013, J OPTOM, V6, P176, DOI [10.1016/j.optom.2013.07.002, DOI 10.1016/j.optom.2013.07.002]
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Pangburn M.K., 1984, ALTERNATIVE PATHWAY, P163
   PASCUAL M, 1988, KIDNEY INT, V34, P529, DOI 10.1038/ki.1988.214
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   REID KBM, 1986, ESSAYS BIOCHEM, V22, P27
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Tian Y., ACTA OPHTHA IN PRESS
   Tian Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073387
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   Torreira E, 2009, P NATL ACAD SCI USA, V106, P882, DOI 10.1073/pnas.0810860106
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Tucker KL, 1999, J NUTR, V129, P438, DOI 10.1093/jn/129.2.438
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   WHITE RT, 1992, J BIOL CHEM, V267, P9210
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Xu YY, 2001, IMMUNOL REV, V180, P123, DOI 10.1034/j.1600-065X.2001.1800111.x
   YANG A, 1992, AUST J AGR RES, V43, P1809, DOI 10.1071/AR9921809
   Yang PZ, 2005, CURR EYE RES, V30, P943, DOI 10.1080/02713680500263606
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2013, AGE RELATED MACULAR, P263, DOI [DOI 10.1007/978-3-642-22107-1_17, 10.1007/978-3-642-22107-1_17]
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 87
TC 14
Z9 15
U1 1
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD APR 15
PY 2015
VL 572
SI SI
BP 49
EP 53
DI 10.1016/j.abb.2015.01.019
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CG5XJ
UT WOS:000353368900008
PM 25637656
OA Green Published
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Pearce, E
   Chong, V
AF Sivaprasad, S.
   Pearce, E.
   Chong, V.
TI Quality of fixation in eyes with neovascular age-related macular
   degeneration treated with ranibizumab
SO EYE
LA English
DT Article
DE fixation stability; antiVEGF; neovascular age-related macular
   degeneration; microperimetry
ID TRIAMCINOLONE ACETONIDE INJECTION; VISUAL-ACUITY; EDEMA; MICROPERIMETRY;
   STABILITY; DISEASE
AB Aims To define factors that determine the location and stability of fixation in patients with neovascular age-related macular degeneration (NV-AMD) treated with intravitreal ranibizumab injections.
   Methods The location and stability of fixation using microperimetry were determined in 77 eyes treated with ranibizumab for NV-AMD for at least 12 months. All patients were treated with three injections of ranibizumab 0.5 mg, 1 month apart and retreated according to predefined criteria. The fixation parameters were correlated to the visual acuity, and quantitative measures on OCT.
   Results The location of fixation was predominantly central in 52.6%, poor central fixation in 9.2%, and predominantly eccentric fixation in 38.2%. The fixation was stable in 65%, relatively unstable in 25%, and unstable in 10%. Visual acuity was the only factor that determined the stability and location of fixation. The characteristics of fixation were not related to the macular thickness or volume as measured by OCT.
   Conclusions Better visual outcome ensures central and stable fixation. Quantitative measures of OCT parameters do not determine fixation. Further studies on morphological features of the macula may provide some insight into the determinants of fixation. Eye (2011) 25, 1612-1616; doi:10.1038/eye.2011.223; published online 16 September 2011
C1 [Sivaprasad, S.; Pearce, E.] Kings Coll Hosp, Laser & Retinal Res Unit, Dept Ophthalmol, London SE5 9RS, England.
   [Chong, V.] John Radcliffe Hosp, Oxford OX3 9DU, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of Oxford
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp, Laser & Retinal Res Unit, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Chong, Victor/Q-6565-2018; Sivaprasad, S./D-6876-2015
OI Chong, Victor/0000-0002-7693-522X; Sivaprasad, S./0000-0001-8952-0659
FU Novartis; Allergan; c Pfizer; Pfizer; Bayers
FX Sobha Sivaprasad has received research grants from Novartis, Allergan, c
   Pfizer. Victor Chong has received research grants from Pfizer, Novartis,
   Allergan, and Bayers.
CR Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Falkenberg HK, 2007, VISION RES, V47, P126, DOI 10.1016/j.visres.2006.09.014
   FRISEN L, 1979, A VONGRAEFES ARCH KL, V2, P69
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gonzalez EG, 2011, INVEST OPHTH VIS SCI, V52, P4208, DOI 10.1167/iovs.10-7026
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Ishiko S, 2010, CURR EYE RES, V35, P651, DOI 10.3109/02713681003707235
   Karacorlu M, 2010, ACTA OPHTHALMOL, V88, P558, DOI 10.1111/j.1755-3768.2008.01497.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Ozdemir H, 2008, EUR J OPHTHALMOL, V18, P799, DOI 10.1177/112067210801800522
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Pearce E, 2011, EYE, V25, P149, DOI 10.1038/eye.2010.167
   Putnam NM, 2005, J VISION, V5, P632, DOI 10.1167/5.7.3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Senturk F, 2010, RETINA-J RET VIT DIS, V30, P1254, DOI 10.1097/IAE.0b013e3181dcfbe7
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Vujosevic S, 2008, RETINA-J RET VIT DIS, V28, P1443, DOI 10.1097/IAE.0b013e318183571e
NR 23
TC 7
Z9 7
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD DEC
PY 2011
VL 25
IS 12
BP 1612
EP 1616
DI 10.1038/eye.2011.223
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 863HG
UT WOS:000298152800014
PM 21921956
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Sallo, FB
   Peto, T
   Leung, I
   Xing, W
   Bunce, C
   Bird, AC
AF Sallo, Ferenc B.
   Peto, Tunde
   Leung, Irene
   Xing, Wen
   Bunce, Catey
   Bird, Alan C.
TI The International Classification System and the Progression of
   Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE AMD; classification; longitudinal study; macula; phenotype
ID VARIABILITY; MACULOPATHY; OBSERVER
AB Purpose: To determine whether grading based on the International Classification (IC) for age-related macular degeneration (AMD) allows recognition of change during the progression of the disease. Methods: Stereoscopic color fundus photographs of 50 eyes of 25 patients with AMD and at least 5 years of review were graded in a random and masked fashion for changes over time in the characteristics of drusen, pigmentary changes, and end-stage disease, according to the system defined by the IC for AMD, by two independent graders (F.B.S., I.L.). Fundus images were also analyzed in time sequence for clinical changes by a senior grader (I.L.) and two ophthalmologists (A.C.B., T.P.) without access to the grading forms of the IC grading. Clinical change, as recorded by the IC grading and the individual analysis, were compared. Results: There was 97.8% ( = 0.70) concordance in identification of change. In four cases, the clinical classification differed from the IC grading: Two cases of drusen and two of end-stage disease grading. Inter-observer agreement for the IC grading was 89.4% for predominant phenotype ( = 0.84), 89.36-91.49% for presence of choroidal neovascularization (CNV) ( = 0.79-0.83), 87.23-89.36% for geographic atrophy (GA) ( = 0.62-0.74) and 55.32% for area covered by drusen ( = 0.31). Conclusions: Overall, progression from earlier stages of AMD to either of the two forms of advanced AMD were reflected accurately by the IC grading in the vast majority of cases.
C1 [Sallo, Ferenc B.] Moorfields Eye Hosp, Dept Res & Dev, Reading Ctr, London EC1V 2PD, England.
   [Bird, Alan C.] UCL, Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Sallo, FB (通讯作者)，Moorfields Eye Hosp, Dept Res & Dev, Reading Ctr, 162 City Rd, London EC1V 2PD, England.
EM fbsallo@yahoo.com
RI Mitchell, Paul/P-1498-2014; Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381; Bunce, Catey/0000-0002-0935-3713
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Davis MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P289
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   LANDIS JR, 1977, BIOMETRICS, V33, P174
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 10
TC 11
Z9 22
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2009
VL 34
IS 3
BP 238
EP 240
AR PII 909311674
DI 10.1080/02713680802714058
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 416GB
UT WOS:000263992600010
PM 19274532
DA 2022-11-30
ER

PT J
AU Chen, LJ
   Liu, DTL
   Tam, POS
   Chan, WM
   Liu, K
   Chong, KKL
   Lam, DSC
   Pang, CP
AF Chen, Li Jia
   Liu, David TL.
   Tam, Pancy OS.
   Chan, Wai Man
   Liu, Ke
   Chong, Kelvin KL.
   Lam, Dennis SC.
   Pang, Chi Pui
TI Association of complement factor H polymorphisms with exudative
   age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID GENE; RISK; VARIANT; Y402H; SUSCEPTIBILITY; POPULATION; DISEASE;
   CHINESE; MACULOPATHY; PREVALENCE
AB PURPOSE: Variants in the complement factor H (CFH) gene have been reported to be associated with age-related macular degeneration (AMD). We conducted a case-control association study to investigate the association of 6 single nucleotide polymorphisms (SNPs) in CFH with exudative AMD in the Chinese population.
   METHODS: We recruited 163 cases and 244 controls, all ethnic Chinese, with complete ophthalmic examination including fundus investigation. Cigarette smoking was recorded. Six SNPs (dbSNP ID: rs3753394, rs800292, rs1061147, rs1061170, rs380390, and rs1329428) in the CFH gene were genotyped by Taqman assays.
   RESULTS: Y402H (1277 T > C) has low frequencies in our study population, 5.8% in patients and 3.9% in controls. It was not associated with exudative AMD adjusted for age, gender and smoking. Significant associations were detected for AMD with rs3753394 (p=0.003, p(corr)=0.018), rs800292 (p=0.00053, p(corr)=0.0032), and rs1329428 (p=0.00092, p(corr)=0.0028), p(corr) values obtained after adjustment for multicomparison. A haplotype containing these four SNPs (TGTC) was found to confer a significantly increased likelihood of exudative AMD with an odds ratio of 1.68 (95% CI: 1.26-2.23) p=0.0003 (p(corr)=0.0026 after correction by permutation test). Logistic regression analysis detected no interactions between the SNPs and age, gender or smoking.
   CONCLUSIONS: We have found differences in the association between the CFH gene and exudative AMD in Chinese from Caucasians and Japanese. We detected SNP rs3753394 in the CFH promoter carrying a significantly increased risk for exudative AMD.
C1 Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, Kowloon, Hong Kong, Peoples R China.
   Shantou Univ, Coll Med, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
C3 Chinese University of Hong Kong; Shantou University
RP Pang, CP (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk
RI Chen, Li Jia/I-5078-2014; Lam, Dennis/AAL-1211-2020; Chong, Kelvin
   Kam-Lung/K-4929-2016; Pang, Chi P/I-5388-2014
OI Chen, Li Jia/0000-0003-3500-5840; CHONG, Kelvin
   Kam-lung/0000-0003-2587-1323
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Baum L, 2003, OPHTHALMOLOGICA, V217, P111, DOI 10.1159/000068553
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brosnan JT, 2006, J NUTR, V136, p207S, DOI 10.1093/jn/136.1.207S
   BYLSMA GW, 2005, XLIN EXP OPTOM, V88, P322
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Doll R, 1999, B WORLD HEALTH ORGAN, V77, P84
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hosmer DW., 1989, APPL LOGISTIC REGRES
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Okamoto H, 2006, MOL VIS, V12, P156
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Souied EH, 2005, MOL VIS, V11, P1135
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Van Newkirk M R, 1997, Trans Am Ophthalmol Soc, V95, P715
   Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010
   Ward HM, 1997, IMMUNOL CELL BIOL, V75, P508, DOI 10.1038/icb.1997.79
   Warwicker P, 1997, IMMUNOGENETICS, V46, P437, DOI 10.1007/s002510050300
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
NR 40
TC 87
Z9 97
U1 0
U2 9
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 5
PY 2006
VL 12
IS 172-76
BP 1536
EP 1542
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 121AS
UT WOS:000243129400005
PM 17167412
DA 2022-11-30
ER

PT J
AU Sharma, NK
   Gupta, A
   Prabhakar, S
   Singh, R
   Bhatt, AK
   Anand, A
AF Sharma, Neel Kamal
   Gupta, Amod
   Prabhakar, Sudesh
   Singh, Ramandeep
   Bhatt, Arvind Kumar
   Anand, Akshay
TI CC chemokine receptor-3 as new target for age-related macular
   degeneration
SO GENE
LA English
DT Article
DE CCR3; Inflammation; Chemokines; Single nucleotide polymorphism;
   Population study; AMD
ID POLYMORPHISMS; EOSINOPHILS; DIAGNOSIS; ASTHMA; MODEL; VEGF
AB CC chemokine receptor-3 (CCR3) is involved in angiogenic processes. Recently, CCR3 was accounted to participate in choroidal neovascularization (CNV) and CCR3 targeting was reported to be superior to standard antivascular endothelial growth factor-A (VEGF-A) administration when tested in an artificially induced CNV in animals. As human CCR3 studies are lacking in age-related macular degeneration (AMD) patients we sought to determine if CCR3 has any association with inflammatory processes that occur in CNV. A total of 176 subjects were included on the basis of inclusion criteria. Real time PCR was used to analyze the single nucleotide polymorphism in CCR3 of AMD (115) and normal controls (n = 61). Genotype frequency was adjusted for possible confounders like cigarette smoking, alcohol, meat consumption and other risk factors. Chi-square test was used for analysis of polymorphism. The genotype distribution of CCR3 (rs3091250) polymorphism was significantly different in AMD patients in the Indian population. GT (heterozygous) and TT (homozygous) at the rs3091250 SNP increased risk of AMD as compared to the GG genotypes (OR = 4.8, CI 95% = 2.2-10.8 and OR = 4.1, CI 95% = 1.6-10.1 respectively). Subgroup analysis of AMD patients in wet and dry revealed no significant differences. There was no significant difference for rs3091312 in AMD and control group. A significant association between AMD and CCR3 (rs3091250) polymorphism localized on chromosome 3p21.3 was detected. The results suggest the possible contribution of rs3091250, a new predisposing allele in AMD. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Sharma, Neel Kamal; Prabhakar, Sudesh; Anand, Akshay] PGIMER, Dept Neurol, Chandigarh, India.
   [Gupta, Amod; Singh, Ramandeep] PGIMER, Dept Ophthalmol, Chandigarh, India.
   [Bhatt, Arvind Kumar] Himachal Pradesh Univ, Dept Biotechnol, Shimla, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh; Himachal Pradesh University
RP Anand, A (通讯作者)，PGIMER, Dept Neurol, Chandigarh, India.
EM akshay1anand@rediffmail.com
RI anand, Akshay/AAI-1586-2019; Gupta, Amod/V-7633-2017
OI Gupta, Amod/0000-0001-8427-5738
FU Department of Science and Technology, India [SR/SO/HS-109/205]
FX The study was carried out at the Department of Neurology, PGIMER,
   Chandigarh, India. We acknowledge the Department of Science and
   Technology, India for providing funds (F. no. SR/SO/HS-109/205 dated
   1-05-2007). We are grateful to the volunteers involved in the study,
   laboratory staff and all those who contributed in terms of time and
   effort
CR Ahmad I, 2011, INVEST OPHTH VIS SCI, V52, P2868, DOI 10.1167/iovs.10-6608
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Fukunaga K, 2001, EUR RESPIR J, V17, P59, DOI 10.1183/09031936.01.17100590
   Grimaldi JC, 1999, J LEUKOCYTE BIOL, V65, P846, DOI 10.1002/jlb.65.6.846
   Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145
   Kim SH, 2008, J CLIN IMMUNOL, V28, P336, DOI 10.1007/s10875-008-9190-7
   Lee JH, 2007, J ALLERGY CLIN IMMUN, V120, P1110, DOI 10.1016/j.jaci.2007.08.041
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mizutani N, 2009, J IMMUNOL, V183, P4039, DOI 10.4049/jimmunol.0901468
   Moorthy S, 2011, AM J OPHTHALMOL, V151, P375, DOI 10.1016/j.ajo.2010.09.001
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Pope SM, 2005, J IMMUNOL, V175, P5341, DOI 10.4049/jimmunol.175.8.5341
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sharma NK, 2009, ANN NEUROSCI, V16, P62, DOI 10.5214/ans.0972.7531.2009.160208
   Sun YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035415
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wang TN, 2007, ALLERGY, V62, P1125, DOI 10.1111/j.1398-9995.2007.01485.x
NR 27
TC 32
Z9 32
U1 0
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD JUL 1
PY 2013
VL 523
IS 1
BP 106
EP 111
DI 10.1016/j.gene.2013.03.052
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 160WB
UT WOS:000320150100017
PM 23566847
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Tao, Y
   Schlichtenbrede, FC
AF Jonas, Jost B.
   Tao, Yong
   Schlichtenbrede, Frank C.
TI Intravitreal Bevacizumab for Exudative Age-Related Macular Degeneration
   in Clinical Practice
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE;
   VISUAL-ACUITY; AVASTIN(R); RANIBIZUMAB; THERAPY
AB Purpose: The purpose of this study was to evaluate whether baseline visual acuity and baseline anatomy of the macula influence visual outcome in patients receiving intravitreal bevacizumab as treatment of exudative age-related macular degeneration (AMD) in clinical practice.
   Methods: This clinical case series study included 319 patients (406 eyes) who consecutively received intravitreal injections of bevacizumab for treatment of exudative AMD. The intervals between injections were 6 weeks and postinjection examinations were performed at 4 weeks after injection. Mean follow-up was 3.6 months.
   Results: After 3 injections of bevacizumab, best-corrected visual acuity (BCVA) significantly (P < 0.01) improved in eyes with a baseline BCVA of less than 0.2 (group 1; 138 eyes; -0.10 +/- 0.43 LogMAR) and in eyes with a baseline BCVA >= 0.2 and <0.4 (group 2; 117 eyes; -0.06 +/- 0.24 LogMAR), but BCVA deteriorated in eyes with a baseline BCVA of >= 0.4 (group 3; 151 eyes; 0.09 +/- 0.32 LogMAR). Correspondingly, regression analysis revealed that improvement in BCVA after 3 intravitreal bevacizumab injections was significantly (P = 0.001) associated with a low baseline BCVA. After the first injection of bevacizumab, changes in optical coherent tomography measurements of the macula (height of subretinal fluid, macular tissue thickness) were statistically significant for group 1 (P = 0.03, P = 0.03, respectively) and group 2 (P = 0.01, P = 0.02, respectively), but not for group 3 (P = 0.85, P = 0.22, respectively).
   Conclusions: In clinical practice, patients with exudative AMD and a baseline BCVA of < 0.2 have a better prognosis for an increase in BCVA after intravitreal bevacizumab injections than patients with a higher baseline BCVA.
C1 [Jonas, Jost B.; Tao, Yong; Schlichtenbrede, Frank C.] Univ Heidelberg, Dept Ophthalmol, Med Fac Mannheim, Heidelberg, Germany.
   [Tao, Yong] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
C3 Ruprecht Karls University Heidelberg; Peking University
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jost.jonas@augen.ma.uni-heidelberg.de
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Forte R, 2010, ACTA OPHTHALMOL, V88, pe305, DOI 10.1111/j.1755-3768.2010.02021.x
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Jonas JB, 2011, ACTA OPHTHALMOL, V89, pE105, DOI 10.1111/j.1755-3768.2009.01820.x
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, P630, DOI 10.1111/j.1755-3768.2008.01502.x
   Krebs I, 2009, ACTA OPHTHALMOL, V87, P611, DOI 10.1111/j.1755-3768.2008.01312.x
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   MEKJAVIC PJ, 2009, ACTA OPHTHALMOL
   Pedersen KB, 2009, ACTA OPHTHALMOL, V87, P714, DOI 10.1111/j.1755-3768.2008.01346.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 21
TC 5
Z9 5
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD OCT
PY 2011
VL 27
IS 5
BP 467
EP 470
DI 10.1089/jop.2011.0038
PG 4
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 841GP
UT WOS:000296501100007
PM 21682590
DA 2022-11-30
ER

PT J
AU Altay, L
   Sitnilska, V
   Schick, T
   Widmer, G
   Duchateau-Nguyen, G
   Piraino, P
   Jayagopal, A
   Drawnel, FM
   Fauser, S
AF Altay, L.
   Sitnilska, V.
   Schick, T.
   Widmer, G.
   Duchateau-Nguyen, G.
   Piraino, P.
   Jayagopal, A.
   Drawnel, F. M.
   Fauser, S.
TI Early local activation of complement in aqueous humour of patients with
   age-related macular degeneration
SO EYE
LA English
DT Article
ID BASAL DEPOSITS; RPE CELLS; FACTOR-H; RISK; RARE; C3A
AB Objective To investigate complement activation in aqueous humour of patients with early, intermediate and neovascular age-related macular degeneration (AMD).
   Patients and methods Aqueous humour of 79 AMD patients (early, intermediate and neovascular) and 77 age-matched controls was prospectively collected. The levels of the complement protein 3 (C3), activation products complement factor 3a (C3a) and Ba, C3b/iC3b, complement factors B, H and I (CFB, CFH and CFI), and total protein concentration were measured. Data were modelled using covariate analysis to assess the impact of age and glaucoma status of patients and total protein concentration of samples on complement protein concentration across groups.
   Results C3a concentration was significantly increased in the aqueous humour of early (p = 0.016), intermediate (p = 0.003) and neovascular (p = 0.018) AMD patients, whilst C3 concentration was significantly increased in early AMD patients only (p = 0.019). Levels of CFB and CFH were significantly increased in the aqueous humour of neovascular AMD patients (p = 0.023 and p = 0.018, respectively).
   Conclusions Our findings provide evidence for early local complement dysregulation in AMD patients, suggesting that complement pathway inhibition may be a clinically relevant intervention for early stages of AMD.
C1 [Altay, L.; Sitnilska, V.; Schick, T.; Drawnel, F. M.; Fauser, S.] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Widmer, G.; Duchateau-Nguyen, G.; Jayagopal, A.; Fauser, S.] Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, 124 Grenzacherstr, CH-4070 Basel, Switzerland.
   [Piraino, P.] P Value Res SRL, I-29015 Castel San Giovanni, PC, Italy.
C3 University of Cologne; Roche Holding
RP Drawnel, FM (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
EM faye.drawnel@roche.com
FU F. Hoffmann-La Roche, Ltd.
FX This work was funded by F. Hoffmann-La Roche, Ltd.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bailey JNC, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017186
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hajishengallis G, 2017, NAT IMMUNOL, V18, P1288, DOI 10.1038/ni.3858
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Miller AJ, 2002, SUBSET SELECTION REG
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Takabayashi T, 1996, J IMMUNOL, V156, P3455
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 24
TC 13
Z9 13
U1 1
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2019
VL 33
IS 12
BP 1859
EP 1864
DI 10.1038/s41433-019-0501-4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JR5GE
UT WOS:000499652600005
PM 31267090
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Neumaier, M
AF Jonas, Jost B.
   Neumaier, Michael
TI Vascular endothelial growth factor and basic fibroblast growth factor in
   exudative age-related macular degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE vascular endothelial growth factor; basic fibroblast growth factor;
   exudative age-related macular degeneration; diabetic macular edema
ID INTRAVITREAL BEVACIZUMAB AVASTIN; EPITHELIUM-DERIVED FACTOR; COHERENCE
   TOMOGRAPHY FINDINGS; DIABETIC-RETINOPATHY; CHOROIDAL NEOVASCULARIZATION;
   IRIS NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE; RETINAL ISCHEMIA;
   NONHUMAN PRIMATE; VITREOUS LEVELS
AB Background: To evaluate the concentrations of vascular endothelial growth factor ( VEGF) and basic fibroblast growth factor ( bFGF) in neovascular or edematous retinal diseases. Methods: In the clinical comparative interventional study, VEGF and bFGF concentrations in aqueous humor samples of 35 patients with exudative age- related macular degeneration ( AMD), 21 patients with diabetic macular edema and 24 patients of a control group were measured using a solid-phase chemiluminescence immunoassay. Results: Concentrations of VEGF and bFGF, respectively, were significantly higher in the diabetic group ( 184.7 +/- 107.0 and 5.0 +/- 10.2 pg/l) than in the AMD group ( 107.7 +/- 73.0 pg/l, p = 0.002; 2.2 +/- 7.4 pg/ l, p = 0.002) and the control group ( 71.5 +/- 94.7 pg/ l, p = 0.001; 0.00 pg/ l, p = 0.001). The two latter groups did not vary significantly ( p = 0.10). Conclusions: VEGF and bFGF are present in considerably higher concentrations in eyes with diabetic macular edema than in eyes with exudative AMD or normal eyes. The differences were more marked for VEGF than for bFGF. Copyright (c) 2007 S. Karger AG, Basel.
C1 Univ Heidelberg, Fac Clin Med Mannheim, Dept Ophthalmol, D-6900 Heidelberg, Germany.
   Univ Heidelberg, Fac Clin Med Mannheim, Inst Clin Chem, D-6900 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg
RP Jonas, JB (通讯作者)，Univ Mannheim, Augenklin, Theodoe Kutzer Ufer 1-3, DE-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Funatsu H, 2006, OPHTHALMOLOGY, V113, P294, DOI 10.1016/j.ophtha.2005.10.030
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Jonas JB, 2006, OPHTHALMIC RES, V38, P218, DOI 10.1159/000093796
   Kitaoka T, 1997, CURR EYE RES, V16, P396, DOI 10.1076/ceyr.16.4.396.10685
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   NOMA H, 2006, EYE
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
NR 26
TC 43
Z9 47
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHAL RES
JI Ophthalmic Res.
PY 2007
VL 39
IS 3
BP 139
EP 142
DI 10.1159/000102935
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 175RB
UT WOS:000247029600003
PM 17505145
DA 2022-11-30
ER

PT J
AU Kang, JH
   Choung, SY
AF Kang, Jung-Hwan
   Choung, Se-Young
TI Protective effects of resveratrol and its analogs on age-related macular
   degeneration in vitro
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article
DE ARPE-19 cell; A2E; Blue light; Age-related macular degeneration;
   Resveratrol analogs
ID PIGMENT EPITHELIAL-CELLS; ARPE-19 CELLS; A2E; LIPOFUSCIN; DAMAGE;
   INVOLVEMENT; METABOLITES; APOPTOSIS; MODEL; MICE
AB Damage of retinal pigment epithelial (RPE) cells by A2E may be critical for age-related macular degeneration (AMD) management. Accumulation and photooxidation of A2E are known to be one of the critical causes in AMD. Here, we evaluated the protective effect of resveratrol (RES), piceatannol (PIC) and RES glycones on blue-light-induced RPE cell death caused by A2E photooxidation. A2E treatment followed by blue light exposure caused significant damages on human RPE cells (ARPE-19). But the damages were attenuated by post- and pre-treatment of RES and PIC in our in vitro models. The results of cell free system and FAB-MS analysis clearly showed that the reduction of A2E by blue light exposure was significantly rescued, and that oxidized forms of A2E were significantly reduced by RES or PIC treatment. Besides, RES or PIC inhibited the intracellular accumulation of A2E. Not only RES and PIC but RES glycones showed protection of ARPE-19 cells against A2E and blue-light-induced photo-damage. These findings demonstrate that RES and its analogs may have protective effects against A2E and blue-light-induced ARPE-19 cell death through regulation of A2E accumulation as well as photooxidation of A2E. Thus RES and its analogs may be beneficial for AMD treatment.
C1 [Kang, Jung-Hwan; Choung, Se-Young] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci Pharm, Coll Pharm, Seoul, South Korea.
   [Choung, Se-Young] Kyung Hee Univ, Dept Prevent Pharm & Toxicol, Coll Pharm, 26 Kyungheedae Ro, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Choung, SY (通讯作者)，Kyung Hee Univ, Dept Life & Nanopharmaceut Sci Pharm, Coll Pharm, Seoul, South Korea.; Choung, SY (通讯作者)，Kyung Hee Univ, Dept Prevent Pharm & Toxicol, Coll Pharm, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM sychoung@khu.ac.kr
RI Choung, Young/AAH-9208-2020
OI Choung, Se Young/0000-0001-7619-6263
CR Barreiro S, 2005, INVEST OPHTH VIS SCI, V46, P250
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Bhosale P, 2009, ARCH BIOCHEM BIOPHYS, V483, P175, DOI 10.1016/j.abb.2008.09.012
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, P256
   Chen Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018139
   Das S, 2010, J PHARM SCI-US, V99, P840, DOI 10.1002/jps.21880
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Fabre KM, 2011, CANCER BIOL THER, V12, P915, DOI 10.4161/cbt.12.10.17714
   Fang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21018
   Farjo KM, 2012, MOL CELL BIOL, V32, P5103, DOI 10.1128/MCB.00820-12
   Heeboll S, 2014, WORLD J HEPATOL, V6, P188, DOI 10.4254/wjh.v6.i4.188
   Hohn A, 2010, FREE RADICAL BIO MED, V48, P1100, DOI 10.1016/j.freeradbiomed.2010.01.030
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Hung C-F, 2015, FASEB J, V29, P9
   Hunter A, 2012, INVEST OPHTH VIS SCI, V52, P5980
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Jin HL, 2016, J PHARMACEUT BIOMED, V117, P560, DOI 10.1016/j.jpba.2015.10.010
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kelsey NA, 2010, MOLECULES, V15, P7792, DOI 10.3390/molecules15117792
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   Lancon A, 2013, J SCI FOOD AGR, V93, P3155, DOI 10.1002/jsfa.6228
   Lanzilli G, 2012, INFLAMMATION, V35, P240, DOI 10.1007/s10753-011-9310-z
   Lin HS, 2009, BIOMED CHROMATOGR, V23, P1308, DOI 10.1002/bmc.1254
   Lu XW, 2009, INT J PHARMACEUT, V375, P89, DOI 10.1016/j.ijpharm.2009.03.021
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Mimura T, 2013, EXP EYE RES, V116, P17, DOI 10.1016/j.exer.2013.07.017
   Oliveira BF, 2010, THESCIENTIFICWORLDJO, V10, P1121, DOI 10.1100/tsw.2010.94
   Palamoor M, 2013, COLLOID SURFACE B, V112, P474, DOI 10.1016/j.colsurfb.2013.07.039
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pezzuto JM, 2013, EXPERT OPIN THER PAT, V23, P1529, DOI 10.1517/13543776.2013.834888
   Polonini HC, 2013, BIOORGAN MED CHEM, V21, P964, DOI 10.1016/j.bmc.2012.11.052
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Romano AD, 2009, J NEPHROL, V23, pS29
   Ruweler M, 2009, CHEM-BIOL INTERACT, V182, P128, DOI 10.1016/j.cbi.2009.09.003
   Sadowska-Bartosz I, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/404680
   Sale S, 2004, BRIT J CANCER, V90, P736, DOI 10.1038/sj.bjc.6601568
   Santos AC, 2011, EXPERT OPIN DRUG DEL, V8, P973, DOI 10.1517/17425247.2011.581655
   Shakibaei M, 2009, MOL NUTR FOOD RES, V53, P115, DOI 10.1002/mnfr.200800148
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Suri S, 2010, BRIT J PHARMACOL, V159, P566, DOI 10.1111/j.1476-5381.2009.00556.x
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Svajger U, 2012, INT REV IMMUNOL, V31, P202, DOI 10.3109/08830185.2012.665108
   Szekeres T, 2011, ANN NY ACAD SCI, V1215, P89, DOI 10.1111/j.1749-6632.2010.05864.x
   Szekeres T, 2010, PHARM RES-DORDR, V27, P1042, DOI 10.1007/s11095-010-0090-1
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Torres P, 2011, ADV SYNTH CATAL, V353, P1077, DOI 10.1002/adsc.201000968
   Tribolo S, 2008, ATHEROSCLEROSIS, V197, P50, DOI 10.1016/j.atherosclerosis.2007.07.040
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang W, 2014, J CONTROL RELEASE, V191, P4, DOI 10.1016/j.jconrel.2014.04.028
   Wang W, 2010, DISCOV MED, V9, P13
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wenzel E, 2005, MOL NUTR FOOD RES, V49, P482, DOI 10.1002/mnfr.200500003
   Westlund B, 2009, APOPTOSIS, V14, P31, DOI 10.1007/s10495-008-0285-7
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Wong YT, 2011, AGE, V33, P229, DOI 10.1007/s11357-010-9174-4
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Yoon SM, 2016, ARCH PHARM RES, V39, P21, DOI 10.1007/s12272-015-0683-7
   Zhao Z, 2014, FOOD CHEM TOXICOL, V74, P216, DOI 10.1016/j.fct.2014.10.001
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 70
TC 18
Z9 18
U1 1
U2 14
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
EI 1976-3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD DEC
PY 2016
VL 39
IS 12
BP 1703
EP 1715
DI 10.1007/s12272-016-0839-0
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EG9QV
UT WOS:000391395300011
PM 27659166
DA 2022-11-30
ER

PT J
AU Merle, BMJ
   Benlian, P
   Puche, N
   Bassols, A
   Delcourt, C
   Souied, EH
AF Merle, Benedicte M. J.
   Benlian, Pascale
   Puche, Nathalie
   Bassols, Ana
   Delcourt, Cecile
   Souied, Eric H.
CA Nutr AMD Treatment 2 Study Grp
TI Circulating Omega-3 Fatty Acids and Neovascular Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; omega-3 fatty acids; epidemiology;
   case-control study
ID PLASMA EICOSAPENTAENOIC ACID; POLYUNSATURATED FATTY-ACIDS; DIETARY-FAT;
   LONG-CHAIN; FISH INTAKE; DEPRESSIVE SYMPTOMATOLOGY; FRENCH POPULATION;
   RISK-FACTORS; MACULOPATHY; HEALTH
AB PURPOSE. We assessed the associations of serum, red blood cell membranes (RBCM) and dietary long-chain n-3 polyunsaturated fatty acids (LC-PUFAs) with neovascular age-related macular degeneration (AMD).
   METHODS. We included 290 patients of the Nutritional AMD Treatment 2 Study (NAT2) with neovascular AMD in one eye and early AMD lesions in the other eye, and 144 normal vision controls without AMD. Dietary intake of seafood was estimated by food frequency questionnaire. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) composition in serum and RBCM were determined by gas chromatography from 12-hour fasting blood samples and was expressed as percentages of total fatty acids profile. Logistic regressions estimated associations of neovascular AMD with dietary intake of seafood and circulating n-3 LC-PUFAs.
   RESULTS. Dietary oily fish and seafood intake were significantly lower in AMD patients than in controls. After adjustment for all potential confounders (age, sex, CFH Y402H, ARMS2 A69S, and ApoE4 polymorphisms, plasma triglycerides, hypertension, hypercholesterolemia, and family history of AMD), serum EPA was associated significantly with a lower risk for neovascular AMD (odds ratio [OR] = 0.41; 95% confidence interval [CI], 0.22-0.77; P = 0.005). Analysis of RBCM revealed that EPA and EPA + DHA were associated significantly with a lower risk for neovascular AMD (OR = 0.25; 95% CI, 0.13-0.47; P < 0.0001 and OR = 0.52; 95% CI, 0.29-0.94; P = 0.03, respectively).
   CONCLUSIONS. The RBCM EPA and EPA+DHA, as long-term biomarkers of n-3 dietary PUFA status, were associated strongly with neovascular AMD and may represent an objective marker identifying subjects at high risk for neovascular AMD, who may most benefit from nutritional interventions. (http://www.controlled-trials.com/isrctn number, ISRCTN98246501.)
C1 [Merle, Benedicte M. J.; Puche, Nathalie; Souied, Eric H.] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Benlian, Pascale] CHRU Lille, Biochem & Mol Biol Inst, Mol Med Metab Dis U4M, F-59037 Lille, France.
   [Benlian, Pascale] Univ Lille 2, Sch Med, Dept Biochem & Mol Biol, Lille, France.
   [Bassols, Ana] Lab Bausch & Lomb, Montpellier, France.
   [Delcourt, Cecile] INSERM, Ctr INSERM, U897 Epidemiol Biostat, Bordeaux, France.
   [Delcourt, Cecile] Univ Bordeaux, ISPED, Bordeaux, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite de Lille - ISITE; CHU Lille; Universite de Franche-Comte;
   Universite de Lille - ISITE; CHU Lille; Universite de Lille; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Universite de Bordeaux
RP Merle, BMJ (通讯作者)，CHIC Creteil, Serv Ophtalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM benedicte.merle@u-bordeaux.fr
RI Merle, Benedicte MJ/AAQ-5021-2021; Merle, Benedicte MJ/F-1247-2015;
   Delcourt, Cecile/I-2627-2013; Benlian, Pascale/I-7964-2016
OI Merle, Benedicte MJ/0000-0003-1332-0954; Merle, Benedicte
   MJ/0000-0003-1332-0954; Delcourt, Cecile/0000-0002-2099-0481; Nicolas,
   Leveziel/0000-0001-8533-9457; Benlian, Pascale/0000-0002-3423-8979;
   Querques, Giuseppe/0000-0002-3292-9581
FU Laboratoire Bausch & Lomb, Clinical Research, Montpellier, France;
   Federation des aveubles et handicaps visuels de France; Fondation Nestle
   France
FX Supported by Laboratoire Bausch & Lomb, Clinical Research, Montpellier,
   France, and by a grant from Federation des aveubles et handicaps visuels
   de France and from Fondation Nestle France (BMJM).
CR Age-Related Eye Disease Research Group, 2013, JAMA-J AM MED ASSOC, P1
   Arab L, 2003, J NUTR, V133, p925S, DOI 10.1093/jn/133.3.925S
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   Benlian P, 2000, CLIN CHEM, V46, P493
   Bonifacj C, 1997, EUR J CLIN NUTR, V51, P217, DOI 10.1038/sj.ejcn.1600387
   Carriere I, 2007, INT J VITAM NUTR RES, V77, P57, DOI 10.1024/0300-9831.77.1.57
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   Djousse L, 2011, AM J CLIN NUTR, V94, P527, DOI 10.3945/ajcn.111.013334
   DOLE VP, 1960, J BIOL CHEM, V235, P2595
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Favier JC, 1995, REPERTOIRE GEN ALIME
   Feart C, 2008, AM J CLIN NUTR, V87, P1156, DOI 10.1093/ajcn/87.5.1156
   Hercberg S, 2005, TABLE COMPOSITION AL
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Kroger E, 2009, AM J CLIN NUTR, V90, P184, DOI 10.3945/ajcn.2008.26987
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3
   Samieri C, 2008, AM J CLIN NUTR, V88, P714, DOI 10.1093/ajcn/88.3.714
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Serra-Majem L, 2012, BRIT J NUTR, V107, pS64, DOI 10.1017/S000711451200147X
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   von Schacky C, 2011, PROSTAG OTH LIPID M, V96, P94, DOI 10.1016/j.prostaglandins.2011.06.008
   Wilk JB, 2012, AM J CLIN NUTR, V96, P882, DOI 10.3945/ajcn.112.042671
NR 49
TC 69
Z9 72
U1 1
U2 30
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2014
VL 55
IS 3
BP 2010
EP 2019
DI 10.1167/iovs.14-13916
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AE0HZ
UT WOS:000333645900039
PM 24557349
DA 2022-11-30
ER

PT J
AU Ye, J
   Xu, YF
   He, JJ
   Lou, LX
AF Ye, Juan
   Xu, Yu-Feng
   He, Jin-Jing
   Lou, Li-Xia
TI Association Between Aspirin Use and Age-Related Macular Degeneration: A
   Meta-Analysis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE aspirin; age-related macular degeneration; meta-analysis
ID BLUE MOUNTAINS EYE; BEAVER DAM EYE; RISK-FACTORS; 5-YEAR INCIDENCE;
   CHOROIDAL NEOVASCULARIZATION; INTRAOCULAR HEMORRHAGE;
   CARDIOVASCULAR-DISEASE; CIRCULATING MARKERS; ARTERIAL THROMBOSIS;
   10-YEAR INCIDENCE
AB PURPOSE. We conducted a meta-analysis of randomized controlled trials (RCTs) and observational studies to evaluate the association between aspirin use and age-related macular degeneration (AMD).
   METHODS. The pertinent studies were identified via literature search through four databases (MEDLINE, Web of Science, Cochrane Library, Embase) and reference lists of retrieved studies. Randomized controlled trials and cohort and case-control studies meeting the predefined criteria were included. We extracted relative risk (RR) or odds ratio (OR) or hazard ratio (HR) and 95% confidence interval (CI) from each study. Overall and study-specific risk estimates were pooled using fixed-effects and random-effects models, respectively. Subgroup analyses based on several stratified factors were also performed.
   RESULTS. In total, two RCTs, three cohort studies, and four case-control studies involving 177,683 subjects were included. The pooled effect of all nine studies showed no significant association between aspirin use and occurrence of AMD (RR, 1.00; 95% CI 0.96-1.04), and no significant association was observed in any specific study design (RR, 0.93; 95% CI 0.71-1.22 for RCT; RR, 1.02; 95% CI 0.87-1.20 for cohort study; RR, 1.00; 95% CI 0.96-1.04 for case-control study). However, subgroup analysis showed aspirin use to be significantly associated with an increased risk of neovascular AMD (RR, 1.59; 95% CI 1.09-2.31).
   CONCLUSIONS. The pooled effects from current literature suggest that aspirin use is not associated with AMD, but it increased the risk of the neovascular form of AMD.
C1 [Ye, Juan; Xu, Yu-Feng; He, Jin-Jing; Lou, Li-Xia] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Ophthalmol, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Ye, J (通讯作者)，Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Ophthalmol, Jiefang Rd 88, Hangzhou 310009, Zhejiang, Peoples R China.
EM Yejuan@zju.edu.cn
FU Natural Science Foundation of China [81070756]; National Twelfth
   Five-Year Plan for Science & Technology Support of China [2012BAI08B01];
   Zhejiang Provincial Program for Cultivation of High-Level Innovative
   Health Talents; Specialized Key Science & Technology Foundation of
   Zhejiang Provincial Science & Technology Department [2012C13023-2];
   Zhejiang Provincial Key Project of Medicine and Health [2011ZDA014]
FX Supported by Natural Science Foundation of China (81070756); National
   Twelfth Five-Year Plan for Science & Technology Support of China
   (2012BAI08B01); Zhejiang Provincial Program for Cultivation of
   High-Level Innovative Health Talents; Specialized Key Science &
   Technology Foundation of Zhejiang Provincial Science & Technology
   Department (2012C13023-2); and Zhejiang Provincial Key Project of
   Medicine and Health (2011ZDA014).
CR Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Alderson P, 2004, COCHRANE LIB, P102
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Battinelli EM, 2011, BLOOD, V118, P1359, DOI 10.1182/blood-2011-02-334524
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   Cheung N, 2013, BRIT J OPHTHALMOL, V97, P785, DOI 10.1136/bjophthalmol-2012-302253
   Cheung N, 2012, CLIN EXP OPHTHALMOL, V40, P106
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   CHRISTEN WG, 1994, AM J MED, V97, pS14, DOI 10.1016/0002-9343(94)90293-3
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gagne JJ, 2010, NEUROLOGY, V74, P995, DOI 10.1212/WNL.0b013e3181d5a4a3
   Gemmy Cheung CM, 2013, AM J OPHTHALMOL, V155, pe763
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grosser N, 2003, ARTERIOSCL THROM VAS, V23, P1345, DOI 10.1161/01.ATV.0000083296.57581.AE
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hall Nigel F, 2002, Expert Opin Pharmacother, V3, P803
   Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013
   HANSCH GM, 1981, CLIN IMMUNOL IMMUNOP, V21, P228, DOI 10.1016/0090-1229(81)90211-7
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   KLEIN ML, 1991, JAMA-J AM MED ASSOC, V266, P2279
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Maloney SC, 2009, RETINA-J RET VIT DIS, V29, P176, DOI 10.1097/IAE.0b013e3181884fa6
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Moon BG, 2012, J KOREAN MED SCI, V27, P537, DOI 10.3346/jkms.2012.27.5.537
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073
   Rudnicka AR, 2010, EYE, V24, P1199, DOI 10.1038/eye.2010.8
   Rudnicka AR, 2009, BRIT J HAEMATOL, V145, P38
   Samoocha David, 2010, J Med Internet Res, V12, pe23, DOI 10.2196/jmir.1286
   SanGiovanni JP, 2007, J MOL NEUROSCI, V33, P142
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Sharpe D, 1997, CLIN PSYCHOL REV, V17, P881, DOI 10.1016/S0272-7358(97)00056-1
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Swanson MW, 2008, OPTOMETRY VISION SCI, V85, P947, DOI 10.1097/OPX.0b013e31818883e0
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Warner TD, 2002, P NATL ACAD SCI USA, V99, P13371, DOI 10.1073/pnas.222543099
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Yang WS, 2011, AM J CLIN NUTR, V94, P1575, DOI 10.3945/ajcn.111.020966
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 74
TC 15
Z9 16
U1 0
U2 18
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2014
VL 55
IS 4
BP 2687
EP 2696
DI 10.1167/iovs.13-13206
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AH1WS
UT WOS:000335913100091
PM 24508796
DA 2022-11-30
ER

PT J
AU Seiple, W
   Szlyk, JP
   McMahon, T
   Pulido, J
   Fishman, GA
AF Seiple, W
   Szlyk, JP
   McMahon, T
   Pulido, J
   Fishman, GA
TI Eye-movement training for reading in patients with age-related macular
   degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PREFERRED RETINAL LOCI; LOW-VISION; CENTRAL SCOTOMA; PERIPHERAL-VISION;
   OLDER ADULTS; PSYCHOPHYSICS; DISEASE; FIXATION; PERFORMANCE; SPEED
AB PURPOSE. To determine whether training oculomotor control, without direct practice in reading sentences, could increase reading speed in patients with age-related macular degeneration (AMD).
   METHODS. Sixteen patients with AMD participated in the study ( age range, 65 - 87 years; mean, 77). The training program consisted of a series of exercises that were designed to allow the patients to practice eye movements. At the beginning of training, the subjects practiced small horizontal saccades in response to cognitively easy stimuli ( e. g., dots). The training then progressed to practicing larger eye movements and then to practicing saccades with single letters, pairs of letters, and three-letter words. Reading of sentences was practiced in only one exercise, during the last session of the 8-week training.
   RESULTS. The difference between average reading speeds before and after training was 24.7 wpm ( difference between medians, 17.9 wpm). The increase in speed was statistically significant ( Wilcoxon signed rank test = 124.0, P < 0.001). There was no significant relationship between change in maximum reading speed and ETDRS ( Early Treatment Diabetic Retinopathy Study) acuity (r = - 0.14, P = 0.76) or between change in maximum reading speed and age ( r = 0.25, P = 0.45).
   CONCLUSIONS. The results indicate that a training curriculum that concentrates on eye-movement control can increase reading speed in patients with AMD. This finding is especially interesting, because the training involved little direct practice in reading sentences but instead concentrated on having subjects practice control of eye positions and eye movements.
C1 NYU, Sch Med, Dept Ophthalmol, New York, NY 10016 USA.
   Jessie Brown VA Med Ctr, Chicago, IL USA.
   Univ Illinois, Coll Med, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
C3 New York University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Jesse Brown VA Medical Center; University of
   Illinois System; University of Illinois Chicago; University of Illinois
   Chicago Hospital
RP Seiple, W (通讯作者)，NYU, Sch Med, Dept Ophthalmol, BEL 5N15,550 1st Ave, New York, NY 10016 USA.
EM whs4@nyu.edu
OI Seiple, William/0000-0002-5750-650X
CR BALDASARE J, 1986, J VISUAL IMPAIR BLIN, V80, P785
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   CHA K, 1992, J OPT SOC AM A, V9, P673, DOI 10.1364/JOSAA.9.000673
   CIUFFREDA KJ, 1976, AM J OPTOM PHYS OPT, V53, P389
   CIUFFREDA KJ, 1985, AM J OPTOM PHYS OPT, V62, P844
   Contestabile MT, 2002, EYE, V16, P472, DOI 10.1038/sj.eye.6700046
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   CULHAM LE, 1992, OPHTHAL PHYSL OPT, V12, P281, DOI 10.1111/j.1475-1313.1992.tb00398.x
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   Fine EM, 1999, OPTOMETRY VISION SCI, V76, P468, DOI 10.1097/00006324-199907000-00022
   Fine EM, 1999, VISION RES, V39, P4274, DOI 10.1016/S0042-6989(99)00132-7
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Frennesson C, 1995, DOC OPHTHALMOL, V91, P9, DOI 10.1007/BF01204619
   GOODRICH GL, 1977, AM J OPTOM PHYS OPT, V54, P312
   GOODRICH GL, 1977, J VISUAL IMPAIR BLIN, V71, P377
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   HALL EC, 2001, J BEHAV OPTOM, V12, P87
   Han Y, 2004, BRAIN RES PROTOC, V14, P1, DOI 10.1016/j.brainresprot.2004.06.002
   HESS RF, 1994, VISUAL NEUROSCI, V11, P1033, DOI 10.1017/S0952523800003977
   Holocomb J G, 1976, J Am Optom Assoc, V47, P1438
   Hooge ITC, 1999, VISION RES, V39, P1567, DOI 10.1016/S0042-6989(98)00213-2
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Legge GE, 1997, VISION RES, V37, P1999, DOI 10.1016/S0042-6989(97)00017-5
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1987, VISION RES, V27, P1165, DOI 10.1016/0042-6989(87)90028-9
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   LEGGE GE, 1991, OPTOMETRY VISION SCI, V68, P763, DOI 10.1097/00006324-199110000-00001
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   LEVI DM, 1987, VISION RES, V27, P581, DOI 10.1016/0042-6989(87)90044-7
   Lott LA, 2001, OPTOMETRY VISION SCI, V78, P316, DOI 10.1097/00006324-200105000-00015
   Mackeben M, 1999, SPATIAL VISION, V12, P51, DOI 10.1163/156856899X00030
   Mansfield JS, 1996, INVEST OPHTH VIS SCI, V37, P1492
   MAPLESDEN C, 1984, J VISUAL IMPAIR BLIN, V78, P5
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   MORRISON RE, 1984, J EXP PSYCHOL HUMAN, V10, P667, DOI 10.1037/0096-1523.10.5.667
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   QUILLMAN RD, 1980, LOW VISION TRAINING
   Raasch T W, 1993, J Am Optom Assoc, V64, P15
   RAYNER K, 1979, SCIENCE, V206, P468, DOI 10.1126/science.504987
   ROVAMO J, 1979, EXP BRAIN RES, V37, P495, DOI 10.1007/bf00236819
   ROVAMO J, 1992, VISION RES, V32, P631, DOI 10.1016/0042-6989(92)90179-M
   RUBIN GS, 1992, VISION RES, V32, P895, DOI 10.1016/0042-6989(92)90032-E
   RUBIN GS, 1994, VISION RES, V34, P1723, DOI 10.1016/0042-6989(94)90129-5
   Seiple W, 2004, J REHABIL RES DEV, V41, P359, DOI 10.1682/JRRD.2003.07.0111
   Seiple W, 2002, VISION RES, V42, P1513, DOI 10.1016/S0042-6989(02)00079-2
   SEKULER R, 1986, J OPT SOC AM A, V3, P864, DOI 10.1364/JOSAA.3.000864
   SHAPIRO KL, 1989, ACTA PSYCHOL, V71, P217, DOI 10.1016/0001-6918(89)90010-3
   SHARMA MK, 2002, P 3 NAT M REH RES DE, P150
   SOLAN HA, 1995, OPTOMETRY VISION SCI, V72, P139, DOI 10.1097/00006324-199502000-00012
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Valmaggia C, 2001, BRIT J OPHTHALMOL, V85, P169, DOI 10.1136/bjo.85.2.169
   Watson G, 1976, J Am Optom Assoc, V47, P1407
   WATSON GR, 1992, J VISUAL IMPAIR BLIN, V86, P37
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   WOODCOCK RW, 2000, W JOHNSON III TESTS
   XING J, 1994, VISION RES, V34, P1901, DOI 10.1016/0042-6989(94)90314-X
NR 64
TC 88
Z9 91
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2005
VL 46
IS 8
BP 2886
EP 2896
DI 10.1167/iovs.04-1296
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 949AB
UT WOS:000230756100033
PM 16043863
DA 2022-11-30
ER

PT J
AU Strunz, T
   Pollmann, M
   Gamulescu, MA
   Tamm, S
   Weber, BHF
AF Strunz, Tobias
   Poellmann, Michael
   Gamulescu, Maria-Andreea
   Tamm, Svenja
   Weber, Bernhard H. F.
TI Genetic Association Analysis of Anti-VEGF Treatment Response in
   Neovascular Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration; AMD; anti-VEGF treatment;
   observational study; genetic analysis
ID RANIBIZUMAB; THERAPY
AB Anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) has been FDA-approved in 2004, and since then has helped tens of thousands of patients worldwide to preserve vision. Still, treatment responses vary widely, emphasizing the need for genetic biomarkers to robustly separate responders from non-responders. Here, we report the findings of an observational study compromising 179 treatment-naive nAMD patients and their reaction to treatment after three monthly doses of anti-VEGF antibodies. We show that established criteria of treatment response such as visual acuity and central retinal thickness successfully divides our cohort into 128 responders and 51 non-responders. Nevertheless, retinal thickness around the fovea revealed significant reaction to treatment even in the formally categorized non-responders. To elucidate genetic effects underlying our criteria, we conducted an undirected genome-wide association study followed by a directed replication study of 30 previously reported genetic variants. Remarkably, both approaches failed to result in significant findings, suggesting study-specific effects were confounding the present and previous discovery studies. Of note, all studies so far are greatly underpowered, hampering interpretation of genetic findings. In consequence, we highlight the need for an extensive phenotyping study with sample sizes exceeding at least 15,000 to reliably assess anti-VEGF treatment responses in nAMD.
C1 [Strunz, Tobias; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Poellmann, Michael; Gamulescu, Maria-Andreea; Tamm, Svenja] Regensburg Univ, Dept Ophthalmol, Med Ctr, D-93053 Regensburg, Germany.
   [Weber, Bernhard H. F.] Univ Hosp Regensburg, Inst Clin Human Genet, D-93053 Regensburg, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.; Tamm, S (通讯作者)，Regensburg Univ, Dept Ophthalmol, Med Ctr, D-93053 Regensburg, Germany.; Weber, BHF (通讯作者)，Univ Hosp Regensburg, Inst Clin Human Genet, D-93053 Regensburg, Germany.
EM tobias.strunz@klinik.uni-regensburg.de;
   michael.poellmann@klinik.uni-regensburg.de;
   andreea.gamulescu@klinik.uni-regensburg.de;
   svenja.tamm@klinik.uni-regensburg.de; bweb@klinik.uni-regensburg.de
OI Weber, Bernhard H.F./0000-0002-8808-7723; Strunz,
   Tobias/0000-0002-3744-9595
FU Institute of Human Genetics Regensburg, Germany [TG77]
FX The study was supported in part by institutional funds (TG77) of the
   Institute of Human Genetics Regensburg, Germany. Funding bodies had no
   influence on the design of the study, the collection, analysis, and
   interpretation of data, and or on the writing of the manuscript.
CR Akiyama M, 2018, J HUM GENET, V63, P1083, DOI 10.1038/s10038-018-0493-0
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8
   Chaudhary V, 2022, RETINA-J RET VIT DIS, V42, P589, DOI 10.1097/IAE.0000000000003283
   Chaudhary V, 2022, OPHTHALMOL THER, V11, P1119, DOI 10.1007/s40123-022-00491-1
   Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330
   Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Greene EJ, 2017, J STAT SOFTW, V77, P1, DOI 10.18637/jss.v077.c01
   Grunin M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.48
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Howie B, 2011, G3-GENES GENOM GENET, V1, P457, DOI 10.1534/g3.111.001198
   Kuan V, 2021, JAMA OPHTHALMOL, V139, P1299, DOI 10.1001/jamaophthalmol.2021.4601
   Lores-Motta L, 2018, JAMA OPHTHALMOL, V136, P875, DOI 10.1001/jamaophthalmol.2018.2019
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Metrangolo C, 2021, J OPHTHALMOL, V2021, DOI 10.1155/2021/9994098
   Moore CM, 2020, HUM HERED, V84, P256, DOI 10.1159/000508558
   Moraes G, 2021, OPHTHALMOLOGY, V128, P693, DOI 10.1016/j.ophtha.2020.09.025
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   pubmed.ncbi.nlm.nih.gov, US
   R Core Team. R: A, 2018, LANGUAGE ENV STAT CO
   Riaz M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37924
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100972
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   Turner S.D., 2014, J OPEN SOURCE SOFTW, V3, P1731
   Wang ZL, 2022, ACTA OPHTHALMOL, V100, pE669, DOI 10.1111/aos.14970
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Zheng XW, 2012, BIOINFORMATICS, V28, P3326, DOI 10.1093/bioinformatics/bts606
   Zhou YL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0487-2
NR 41
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2022
VL 23
IS 11
AR 6094
DI 10.3390/ijms23116094
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 2A4PO
UT WOS:000809486200001
PM 35682771
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Luibl, V
   Isas, JM
   Kayed, R
   Glabe, CG
   Langen, R
   Chen, J
AF Luibl, V
   Isas, JM
   Kayed, R
   Glabe, CG
   Langen, R
   Chen, J
TI Drusen deposits associated with aging and age-related macular
   degeneration contain nonfibrillar amyloid oligomers
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID FACTOR-H POLYMORPHISM; TRANSGENIC MICE; ALZHEIMERS-DISEASE; PRECURSOR
   PROTEIN; BETA-PEPTIDE; COMPLEMENT ACTIVATION; OCULAR DRUSEN;
   THIOFLAVIN-T; COMMON; A-BETA(1-42)
AB Protein misfolding and aggregation are thought to underlie the pathogenesis of many amyloid diseases, such as Alzheimer and Parkinson diseases, whereby a stepwise protein misfolding process begins with the conversion of soluble protein monomers to prefibrillar oligomers and progresses to the formation of insoluble amyloid fibrils. Drusen are extracellular deposits found in aging eyes and in eyes afflicted with age-related macular degeneration (AMD). Recent characterizations of drusen have revealed protein components that are shared with amyloid deposits. However, characteristic amyloid fibrils have thus far not been identified in drusen. In this study, we tested the hypothesis that nonfibrillar oligomers may be a common link in amyloid diseases. Oligomers consisting of distinct amyloidogenic proteins and peptides can be detected by a recently developed antibody that is thought to recognize a common structure. Notably, oligomers exhibit cellular toxicity, which suggests that they play a role in the pathogenesis of neurodegenerative diseases. Through use of the anti-oligomer antibody, we came to observe the presence of nonfibrillar, toxic oligomers in drusen. Conversely, no reactivity was observed in age-matched control eyes without drusen. These results suggest that amyloid oligomers may be involved in drusen biogenesis and that similar protein misfolding processes may occur in AMD and amyloid diseases.
C1 Univ So Calif, Zilkha Neurogenet Inst, Keck Sch Med, Los Angeles, CA 90033 USA.
   Univ So Calif, Beckman Macular Res Ctr, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA.
   Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA USA.
   Univ So Calif, Dept Cell & Neurobiol, Keck Sch Med, Los Angeles, CA USA.
   Univ So Calif, Dept Ophthalmol, Keck Sch Med, Los Angeles, CA USA.
C3 University of Southern California; Doheny Eye Institute; University of
   Southern California; University of California System; University of
   California Irvine; University of Southern California; University of
   Southern California; University of Southern California
RP Chen, J (通讯作者)，Univ So Calif, Zilkha Neurogenet Inst, Keck Sch Med, 1501 San Pablo St,ZNI-227, Los Angeles, CA 90033 USA.
EM jeannie@usc.edu
FU NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY03040, P30 EY003040] Funding Source: Medline; NIA NIH HHS
   [AG05142, P50 AG005142] Funding Source: Medline
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anguiano M, 2002, BIOCHEMISTRY-US, V41, P11338, DOI 10.1021/bi020314u
   Butler AE, 2004, DIABETES, V53, P1509, DOI 10.2337/diabetes.53.6.1509
   Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142
   Cecchi C, 2005, J CELL SCI, V118, P3459, DOI 10.1242/jcs.02473
   Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5
   Koistinaho M, 2001, P NATL ACAD SCI USA, V98, P14675, DOI 10.1073/pnas.261562998
   Krebs MRH, 2005, J STRUCT BIOL, V149, P30, DOI 10.1016/j.jsb.2004.08.002
   Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448
   LeVine H, 2004, ANAL BIOCHEM, V335, P81, DOI 10.1016/j.ab.2004.08.014
   LeVine H, 1999, METHOD ENZYMOL, V309, P274
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265
   Miller DL, 2003, BIOCHEMISTRY-US, V42, P11682, DOI 10.1021/bi030100s
   Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483
   Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355
   Reixach N, 2004, P NATL ACAD SCI USA, V101, P2817, DOI 10.1073/pnas.0400062101
   Sanbe A, 2004, P NATL ACAD SCI USA, V101, P10132, DOI 10.1073/pnas.0401900101
   Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007
   Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007
   Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200
   Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4
   Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a
NR 45
TC 157
Z9 174
U1 0
U2 13
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD FEB
PY 2006
VL 116
IS 2
BP 378
EP 385
DI 10.1172/JCI25843
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 008MA
UT WOS:000235043600013
PM 16453022
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
   Leiby, BE
AF Rovner, Barry W.
   Casten, Robin J.
   Leiby, Benjamin E.
TI Variability in Depressive Symptoms Predicts Cognitive Decline in
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Depression; mood variability; cognitive decline
ID QUALITY-OF-LIFE; ALZHEIMER-DISEASE; MAJOR DEPRESSION; INFORMANT
   QUESTIONNAIRE; ELDERLY IQCODE; RATING-SCALE; DEMENTIA; RISK; IMPAIRMENT;
   HISTORY
AB Objective: The measurement of affective symptoms in older persons who decline cognitively is uncertain. The authors investigated whether mood variability predicts dementia in patients with age-related macular degeneration (AMD). Design: Three-year observational study after a clinical trial. Setting: Community follow-up of outpatients ascertained from retina clinics. Participants: One hundred sixty patients with AMD. Measurements: Geriatric Depression Scale (GDS) administered every 2 weeks for 6 months to subjects; Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) administered to subjects' knowledgeable informants. Results: Twenty-three subjects (14.4%) declined cognitively. Age, education, baseline GDS score >= 5, and variability in GDS scores (i.e., fluctuations between adjacent time points) were associated with cognitive decline. For GDS variability, each 1 unit increase in the residual standard deviation (SD) of the GDS increased the risk for cognitive decline by 93% (IDR = 1.92; 95% CI [1.27-2.91]). Thus, subjects with a residual SD of 1 were nearly twice as likely to become demented as subjects with no variability in GDS scores. The risk for subjects with SDs of 2 increased more than threefold (IDR = 3.68; 95% CI [1.61-8.47]). A multiple regression analysis showed that GDS variability was a significant risk factor for dementia after controlling for significant covariates. Conclusion: These data suggest a useful approach to conceptualizing and measuring depressive symptoms in older persons. Variability in self-reported mood may be an early sign of dementia and may offer new insights into the neurobiological mechanisms linking depression and cognition. (Am J Geriatr Psychiatry 2009; 17:574-581)
C1 [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat, Philadelphia, PA 19107 USA.
   [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurol, Philadelphia, PA 19107 USA.
   [Casten, Robin J.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
   [Leiby, Benjamin E.] Thomas Jefferson Univ, Jefferson Med Coll, Div Biostat, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University; Jefferson University;
   Jefferson University
RP Rovner, BW (通讯作者)，Jefferson Hosp Neurosci, 900 Walnut St,4th Floor, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu
FU NIMH [RO 1, MH61331]; NATIONAL EYE INSTITUTE [U01EY015839] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASES [T32DK060455] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTH [R01MH061331] Funding Source: NIH RePORTER
FX This work was supported by NIMH grant RO 1, MH61331, NEI grant U01 EY
   015839, and the Farber, Institute for Neurosciences of Thomas Jefferson
   University.
CR Berger AK, 1999, NEUROLOGY, V53, P1998, DOI 10.1212/WNL.53.9.1998
   Breitner JCS, 2006, J GERIATR PSYCH NEUR, V19, P129, DOI 10.1177/0891988706291081
   BURKE WJ, 1995, J AM GERIATR SOC, V43, P674, DOI 10.1111/j.1532-5415.1995.tb07205.x
   BURKE WJ, 1992, J AM GERIATR SOC, V40, P1227, DOI 10.1111/j.1532-5415.1992.tb03647.x
   Chodosh J, 2007, AM J GERIAT PSYCHIAT, V15, P406, DOI 10.1097/01.JGP.0b013e31802c0c63
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Devanand DP, 1996, ARCH GEN PSYCHIAT, V53, P175
   Dotson VM, 2008, AM J GERIAT PSYCHIAT, V16, P318, DOI 10.1097/JGP.0b013e3181662a9c
   DZURILLA TJ, 2000, PROBLEM SOLVING THER, P95
   FEHER EP, 1992, J AM GERIATR SOC, V40, P906, DOI 10.1111/j.1532-5415.1992.tb01988.x
   Ganguli M, 2006, ARCH GEN PSYCHIAT, V63, P153, DOI 10.1001/archpsyc.63.2.153
   Geerlings MI, 2008, NEUROLOGY, V70, P1258, DOI 10.1212/01.wnl.0000308937.30473.d1
   HOLLADAY JT, 1991, AM J OPHTHALMOL, V111, P372, DOI 10.1016/S0002-9394(14)72328-1
   JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X
   Jorm AF, 2001, AUST NZ J PSYCHIAT, V35, P776, DOI 10.1046/j.1440-1614.2001.00967.x
   Jorm AF, 2004, INT PSYCHOGERIATR, V16, P275, DOI 10.1017/S1041610204000390
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449
   MacQueen GM, 2003, P NATL ACAD SCI USA, V100, P1387, DOI 10.1073/pnas.0337481100
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MCGIVNEY SA, 1994, J AM GERIATR SOC, V42, P490, DOI 10.1111/j.1532-5415.1994.tb04969.x
   Modrego PJ, 2004, ARCH NEUROL-CHICAGO, V61, P1290, DOI 10.1001/archneur.61.8.1290
   Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530
   PARMELEE PA, 1991, J GERONTOL, V46, pP15, DOI 10.1093/geronj/46.1.P15
   PARMELEE PA, 1989, J CONSULT CLIN PSYCH, V4, P331
   Patterson C, 2008, CAN MED ASSOC J, V178, P548, DOI 10.1503/cmaj.070796
   Rabins PV, 2007, CNS SPECTRUMS, V12, P17, DOI 10.1017/S1092852900025979
   Rapp MA, 2006, ARCH GEN PSYCHIAT, V63, P161, DOI 10.1001/archpsyc.63.2.161
   Reischies FM, 1997, BRIT J PSYCHIAT, V171, P449, DOI 10.1192/bjp.171.5.449
   Reyes-Ortiz CA, 2005, J AM GERIATR SOC, V53, P681, DOI 10.1111/j.1532-5415.2005.53219.x
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
   Sheline YI, 1999, J NEUROSCI, V19, P5034
   Steffens DC, 2006, ARCH GEN PSYCHIAT, V63, P130, DOI 10.1001/archpsyc.63.2.130
   Stelmack J, 2001, OPTOMETRY VISION SCI, V78, P335, DOI 10.1097/00006324-200105000-00017
   Sun XY, 2008, ARCH GEN PSYCHIAT, V65, P542, DOI 10.1001/archpsyc.65.5.542
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742
   Wilson RS, 2008, ARCH GEN PSYCHIAT, V65, P439, DOI 10.1001/archpsyc.65.4.439
   Wilson RS, 2002, NEUROLOGY, V59, P364, DOI 10.1212/WNL.59.3.364
   WYOSHIDA T, 2005, J CLIN INVEST, V115, P2793
   ZUBENKO GS, 1990, ARCH NEUROL-CHICAGO, V47, P209, DOI 10.1001/archneur.1990.00530020117023
NR 44
TC 15
Z9 17
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUL
PY 2009
VL 17
IS 7
BP 574
EP 581
DI 10.1097/JGP.0b013e31819a7f46
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychiatry
GA 465KJ
UT WOS:000267582500005
PM 19554672
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Abouammoh, M
   Sharma, S
AF Abouammoh, Marwan
   Sharma, Sanjay
TI Ranibizumab versus bevacizumab for the treatment of neovascular
   age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE adverse events; bevacizumab; effectiveness; incremental
   cost-effectiveness ratio; intraocular inflammation; ranibizumab; safety
ID VERTEPORFIN PHOTODYNAMIC THERAPY; VISION-RELATED FUNCTION; RANDOMIZED
   CLINICAL-TRIAL; INTRAVITREAL BEVACIZUMAB; SUBGROUP ANALYSIS;
   UNITED-STATES; INJECTION; ANCHOR; EYE; POPULATION
AB Purpose of review
   This paper reviews the recent literature regarding the effectiveness, efficacy and safety of intravitreal bevacizumab as compared with ranibizumab for the treatment of neovascular age-related macular degeneration (nAMD).
   Recent findings
   Numerous randomized clinical trials have demonstrated the safety and efficacy of ranibizumab for the treatment of nAMD. Bevacizumab, developed, labeled and approved for the management of colorectal cancer, has been used off-label for the management of nAMD. However, given its lower cost and effectiveness, it is commonly used for many cases of nAMD. Recent clinical trials have demonstrated similar effectiveness between the two compounds in terms of visual acuity and central macular thickness. However, emerging data have suggested that these two compounds may have different ocular and systemic adverse event profiles; bevacizumab has been linked to both a higher risk of severe intraocular inflammation and a higher risk of incident arterial thromboembolic events. This incremental risk for both ocular and systemic adverse events may have an impact on the incremental cost-effectiveness ratio derived from health economic models that directly compare one anti-vascular endothelial growth factor (VEGF) compound to the other.
   Summary
   Numerous clinical trials, including the Comparison of AMD Treatment Trial, are underway examining the comparative efficacy of ranibizumab versus bevacizumab for the treatment of nAMD. While these studies may demonstrate clinical noninferiority of one anti-VEGF compound over another, they may not be adequately powered to detect important differences in ocular and systemic safety. Large-scale, appropriately powered safety studies need to be conducted to evaluate differences in safety.
C1 [Sharma, Sanjay] Hop Hotel Dieu, Dept Ophthalmol, Unit Cost Effect Ocular Hlth Policy, Kingston, ON K7L 5S9, Canada.
   [Abouammoh, Marwan; Sharma, Sanjay] Queens Univ, Dept Ophthalmol, Kingston, ON, Canada.
   [Abouammoh, Marwan] King Saud Univ, Coll Med, Dept Ophthalmol, Riyadh 11461, Saudi Arabia.
C3 Queens University - Canada; Queens University - Canada; King Saud
   University
RP Sharma, S (通讯作者)，Hop Hotel Dieu, Dept Ophthalmol, Unit Cost Effect Ocular Hlth Policy, Johnson 6,166 Brock St, Kingston, ON K7L 5S9, Canada.
EM sanjay_sharma60@hotmail.com
RI Abouammoh, Marwan A/B-2404-2012
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chong DY, 2010, RETINA-J RET VIT DIS, V30, P1432, DOI 10.1097/IAE.0b013e3181dc04da
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   HEIER JS, 1913, OPHTHALMOLOGY, V113
   Johnson D, 2010, CAN J OPHTHALMOL, V45, P239, DOI 10.3129/i10-013
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Los M, 2007, ONCOLOGIST, V12, P443, DOI 10.1634/theoncologist.12-4-443
   Luu ST, 2010, CLIN EXP OPHTHALMOL, V38, P659, DOI 10.1111/j.1442-9071.2010.02309.x
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   SHARMA S, 2010, RETROSPECTIVE ANAL C
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   SUBRAMANIAN ML, 2010, EYE LOND
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   GEFAL STUDY
   CATT STUDY
   EQUAL STUDY
   LUCAS STUDY
   IVAN STUDY
   VIBERA STUDY
   MANTA STUDY
NR 41
TC 28
Z9 30
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2011
VL 22
IS 3
BP 152
EP 158
DI 10.1097/ICU.0b013e32834595d0
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 749YQ
UT WOS:000289508400003
PM 21483262
DA 2022-11-30
ER

PT J
AU van Leeuwen, R
   Boekhoorn, S
   Vingerling, JR
   Witteman, JCM
   Klaver, CCW
   Hofman, A
   de Jong, PTVM
AF van Leeuwen, R
   Boekhoorn, S
   Vingerling, JR
   Witteman, JCM
   Klaver, CCW
   Hofman, A
   de Jong, PTVM
TI Dietary intake of antioxidants and risk of age-related macular
   degeneration
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID VITAMIN-E SUPPLEMENTATION; BEAVER DAM EYE; 5-YEAR INCIDENCE; ZINC
   INTAKE; MACULOPATHY; ROTTERDAM; QUESTIONNAIRE; PATHOGENESIS; VALIDATION;
   TRIAL
AB Context Age-related macular degeneration (AMD) is the most prevalent cause of irreversible blindness in developed countries. Recently, high-dose supplementation with beta carotene, vitamins C and E, and zinc was shown to slow the progression of AMD.
   Objective To investigate whether regular dietary intake of antioxidants is associated with a lower risk of incident AMD.
   Design Dietary intake was assessed at baseline in the Rotterdam Study (19901993) using a semiquantitative food frequency questionnaire. Incident AMD until final follow-up in 2004 was determined by grading fundus color transparencies in a masked way according to the International Classification and Grading System.
   Setting Population-based cohort of all inhabitants aged 55 years or older in a middle-class suburb of Rotterdam, the Netherlands.
   Participants Of 5836 persons at risk of AMD at baseline, 4765 had reliable dietary data and 4170 participated in the follow-up.
   Main Outcome Measure Incident AMD, defined as soft distinct drusen with pigment alterations, indistinct or reticular drusen, geographic atrophy, or choroidal neovascularization.
   Results Incident AMD occurred in 560 participants after a mean follow-up of 8.0 years (range, 0.3-13.9 years). Dietary intake of both vitamin E and zinc was inversely associated with incident AMD. The hazard ratio (H R) per standard deviation increase of intake for vitamin E was 0.92 (95% confidence interval [CI], 0.84-1.00) and for zinc was 0.91 (95% Cl, 0.83-0.98). An above-median intake of all 4 nutrients, beta carotene, vitamin C, vitamin E, and zinc, was associated with a 35% reduced risk (HR, 0.65; 95% Cl, 0.46-0.92) of AMD. Exclusion of supplement users did not affect the results.
   Conclusion In this study, a high dietary intake of beta carotene, vitamins C and E, and zinc was associated with a substantially reduced risk of AMD in elderly persons.
C1 Royal Netherlands Acad Arts & Sci, Netherlands Ophthalm Res Inst, KNAW, NL-1105 BA Amsterdam, Netherlands.
   Erasmus Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Erasmus Med Ctr, Dept Ophthalmol, Rotterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; University of Amsterdam;
   Academic Medical Center Amsterdam
RP de Jong, PTVM (通讯作者)，Royal Netherlands Acad Arts & Sci, Netherlands Ophthalm Res Inst, KNAW, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
EM p.dejong@ioi.knaw.nl
RI Klaver, Caroline C.W./A-2013-2016
OI Klaver, Caroline/0000-0002-2355-5258
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   GOLDBOHM RA, 1994, EUR J CLIN NUTR, V48, P253
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klipstein-Grobusch K, 1998, EUR J CLIN NUTR, V52, P588, DOI 10.1038/sj.ejcn.1600611
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   Ott A, 1998, AM J EPIDEMIOL, V147, P574
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   *VOORL VOED, 2001, DUTCH FOOD COMP TABL
   Willett W., 2013, NUTR EPIDEMIOLOGY, V3rd
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 27
TC 244
Z9 254
U1 1
U2 23
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 28
PY 2005
VL 294
IS 24
BP 3101
EP 3107
DI 10.1001/jama.294.24.3101
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 997UL
UT WOS:000234274200026
PM 16380590
DA 2022-11-30
ER

PT J
AU Martinez, B
   Peplow, PV
AF Martinez, Bridget
   Peplow, Philip V.
TI MicroRNAs as diagnostic and prognostic biomarkers of age-related macular
   degeneration: advances and limitations
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; ALZHEIMERS-DISEASE; CHOROIDAL
   NEOVASCULARIZATION; POTENTIAL BIOMARKERS; TUMOR-GROWTH; ANGIOGENESIS;
   MIRNAS; VEGF; EXPRESSION; ATROPHY
AB A main cause of vision loss in the elderly is age-related macular degeneration (AMD). Among the cellular, biochemical, and molecular changes linked to this disease, inflammation and angiogenesis appear as being crucial in AMD pathogenesis and progression. There are two forms of the disease: dry AMD, accounting for 80-90% of cases, and wet AMD. The disease usually begins as dry AMD associated with retinal pigment epithelium and photoreceptor degeneration, whereas wet AMD is associated with choroidal neovascularization resulting in severe vision impairment. The new vessels are largely malformed, leading to blood and fluid leakage within the disrupted tissue, which provokes inflammation and scar formation and results in retinal damage and detachment. MicroRNAs are dysregulated in AMD and may facilitate the early detection of the disease and monitoring disease progression. Two recent reviews of microRNAs in AMD had indicated weaknesses or limitations in four earlier investigations. Studies in the last three years have shown considerable progress in overcoming some of these concerns and identifying specific microRNAs as biomarkers for AMD. Further large-scale studies are warranted using appropriate statistical methods to take into account gender and age disparity in the study populations and confounding factors such as smoking status.
C1 [Martinez, Bridget] Los Alamos Natl Lab, Chem Div, Phys Chem & Appl Spect, Los Alamos, NM USA.
   [Martinez, Bridget] St Georges Univ, Sch Med, Dept Med, True Blue, Grenada.
   [Peplow, Philip V.] Univ Otago, Dept Anat, Dunedin, New Zealand.
C3 United States Department of Energy (DOE); Los Alamos National
   Laboratory; University of Otago
RP Peplow, PV (通讯作者)，Univ Otago, Dept Anat, Dunedin, New Zealand.
EM phil.peplow@otago.ac.nz
CR Abdollahi A, 2010, DRUG RESIST UPDATE, V13, P16, DOI 10.1016/j.drup.2009.12.001
   Agrawal Saloni, 2014, World J Biol Chem, V5, P1, DOI 10.4331/wjbc.v5.i1.1
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186
   Askou AL, 2018, ACTA OPHTHALMOL, V96, P9, DOI 10.1111/aos.13407
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bhise NS, 2011, EXPERT OPIN DRUG DEL, V8, P485, DOI 10.1517/17425247.2011.558082
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Castillo-Carranza DL, 2014, IMMUNOTARGETS THER, V3, P19, DOI 10.2147/ITT.S40131
   Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Elbay A, 2019, SCAND J CLIN LAB INV, V79, P388, DOI 10.1080/00365513.2019.1637931
   Ertekin S, 2014, MOL VIS, V20, P1057
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   Feehan M, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-83
   Frost S, 2016, CURR ALZHEIMER RES, V13, P1259, DOI 10.2174/1567205013666160603003800
   Garcia-Layana A, 2017, OPTICAL COHERENCE TO
   Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Harvard Clinic, DRY MAC DEG
   Hassel D, 2012, CIRC RES, V111, P1421, DOI 10.1161/CIRCRESAHA.112.279711
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Heiferman MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217805
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kanitz A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049568
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawa M, 2014, J BIOCH PHARM RES, V2, P21
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lai YL, 2013, INT J ONCOL, V42, P776, DOI 10.3892/ijo.2012.1743
   Lasser C, 2012, EXPERT OPIN BIOL TH, V12, pS189, DOI 10.1517/14712598.2012.680018
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104
   Lin JB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120157
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liu LT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026285
   Loscher CJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r248
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinez B, 2020, NEURAL REGEN RES, V15, P606, DOI 10.4103/1673-5374.266905
   Martinez B, 2019, NEURAL REGEN RES, V14, P1858, DOI 10.4103/1673-5374.259602
   Martinez B, 2019, NEURAL REGEN RES, V14, P242, DOI 10.4103/1673-5374.244784
   Meister G, 2007, CELL, V131, P25, DOI 10.1016/j.cell.2007.09.021
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mens MMJ, 2018, STEM CELL REV REP, V14, P309, DOI 10.1007/s12015-018-9808-y
   Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116
   Natoli R, 2018, ADV EXP MED BIOL, V1074, P37, DOI 10.1007/978-3-319-75402-4_5
   Pankratz F, 2015, CIRCULATION, V131, P1575, DOI 10.1161/CIRCULATIONAHA.114.014579
   Peplow PV, 2019, MICRORNAS DIS DISORD
   Pogue AI, 2018, CELL MOL NEUROBIOL, V38, P1021, DOI 10.1007/s10571-017-0572-3
   Puertas-Neyra K, 2020, NEURAL REGEN RES, V15, P1631, DOI 10.4103/1673-5374.276324
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Ren CD, 2017, CELL PHYSIOL BIOCHEM, V41, P1413, DOI 10.1159/000467941
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Sasahira T, 2012, BRIT J CANCER, V107, P700, DOI 10.1038/bjc.2012.330
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Senger DR, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005090
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Skeie JM, 2011, MOL VIS, V17, P576
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Szemraj M, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.902366
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Ulanczyk Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225750
   Vempati P, 2014, CYTOKINE GROWTH F R, V25, P1, DOI 10.1016/j.cytogfr.2013.11.002
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   Wang L, 2016, J PHYSIOL BIOCHEM, V72, P583, DOI 10.1007/s13105-016-0496-2
   Wang L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060895
   Wang RZ, 2013, HEPATOLOGY, V58, P642, DOI 10.1002/hep.26373
   Williams MA, 2014, J ALZHEIMERS DIS, V42, P909, DOI 10.3233/JAD-140243
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005
   Xu Q, 2012, NUCLEIC ACIDS RES, V40, P761, DOI 10.1093/nar/gkr730
   Yoon SP, 2019, OPHTHALMOL RETINA, V3, P489, DOI 10.1016/j.oret.2019.02.002
   Zhao JJ, 2009, CHILD NERV SYST, V25, P13, DOI 10.1007/s00381-008-0701-x
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 96
TC 8
Z9 8
U1 0
U2 61
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD MAR
PY 2021
VL 16
IS 3
BP 440
EP 447
DI 10.4103/1673-5374.293131
PG 8
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA NZ5AQ
UT WOS:000577108400006
PM 32985463
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Strunz, T
   Kiel, C
   Sauerbeck, BL
   Weber, BHF
AF Strunz, Tobias
   Kiel, Christina
   Sauerbeck, Bastian L.
   Weber, Bernhard H. F.
TI Learning from Fifteen Years of Genome-Wide Association Studies in
   Age-Related Macular Degeneration
SO CELLS
LA English
DT Review
DE age-related macular degeneration; GWAS; eQTL; TWAS; analytical review
ID GENETIC-VARIATION; ACTIVATION; PROTEIN; TRAITS; ATLAS; SCALE
AB Over the last 15 years, genome-wide association studies (GWAS) have greatly advanced our understanding of the genetic landscape of complex phenotypes. Nevertheless, causal interpretations of GWAS data are challenging but crucial to understand underlying mechanisms and pathologies. In this review, we explore to what extend the research community follows up on GWAS data. We have traced the scientific activities responding to the two largest GWAS conducted on age-related macular degeneration (AMD) so far. Altogether 703 articles were manually categorized according to their study type. This demonstrates that follow-up studies mainly involve "Review articles" (33%) or "Genetic association studies" (33%), while 19% of publications report on findings from experimental work. It is striking to note that only three of 16 AMD-associated loci described de novo in 2016 were examined in the four-year follow-up period after publication. A comparative analysis of five studies on gene expression regulation in AMD-associated loci revealed consistent gene candidates for 15 of these loci. Our random survey highlights the fact that functional follow-up studies on GWAS results are still in its early stages hampering a significant refinement of the vast association data and thus a more accurate insight into mechanisms and pathways.
C1 [Strunz, Tobias; Kiel, Christina; Sauerbeck, Bastian L.; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Weber, Bernhard H. F.] Univ Hosp Regensburg, Inst Clin Human Genet, D-93053 Regensburg, Germany.
C3 University of Regensburg; University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.; Weber, BHF (通讯作者)，Univ Hosp Regensburg, Inst Clin Human Genet, D-93053 Regensburg, Germany.
EM Tobias.Strunz@klinik.uni-regensburg.de;
   Christina.Kiel@klinik.uni-regensburg.de;
   Bastian.Sauerbeck@klinik.uni-regensburg.de;
   bweb@klinik.uni-regensburg.de
RI Strunz, Tobias/ABD-9798-2021; Strunz, Tobias/ABB-6300-2020
OI Strunz, Tobias/0000-0002-3744-9595; Kiel, Christina/0000-0003-3154-4847;
   Weber, Bernhard H.F./0000-0002-8808-7723
FU Institute of Human Genetics Regensburg, Germany [TG77]; Helmut Ecker
   Foundation (Ingolstadt, Germany) [05/17]
FX The work has been supported in part by institutional funds (TG77) of the
   Institute of Human Genetics Regensburg, Germany, and by a grant from the
   Helmut Ecker Foundation (Ingolstadt, Germany) to B.H.F.W. (No. 05/17).
CR Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bowman SL, 2019, TRAFFIC, V20, P404, DOI 10.1111/tra.12646
   Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406
   Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120
   Cano-Gamez E, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00424
   Cotsapas C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002254
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gamazon ER, 2015, NAT GENET, V47, P1091, DOI 10.1038/ng.3367
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506
   Haeussler M, 2019, NUCLEIC ACIDS RES, V47, pD853, DOI 10.1093/nar/gky1095
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Huizing M, 2020, HUM MUTAT, V41, P543, DOI 10.1002/humu.23968
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liutkeviciene R, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/9602949
   Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Mousseau DD, 2000, J BIOL CHEM, V275, P4467, DOI 10.1074/jbc.275.6.4467
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Popp NA, 2017, CURR EYE RES, V42, P470, DOI 10.1080/02713683.2016.1196708
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Roh M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.20
   Ruan Y, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080761
   Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107
   Scott I, 2012, BIOCHEM J, V443, P655, DOI 10.1042/BJ20120118
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shiratori I, 2004, J EXP MED, V199, P525, DOI 10.1084/jem.20031885
   Spain SL, 2015, HUM MOL GENET, V24, pR111, DOI 10.1093/hmg/ddv260
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Strunz T, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008934
   Strunz T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58510-9
   Strunz T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24219-z
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   UCSC, GEN BROWS HOM
   Ulirsch JC, 2016, CELL, V165, P1530, DOI 10.1016/j.cell.2016.04.048
   Uyar B., 2020, RES REV, DOI [10.1016/j.arr.2020.101156, DOI 10.1016/J.ARR.2020.101156]
   Voigt AP, 2019, EXP EYE RES, V184, P234, DOI 10.1016/j.exer.2019.05.001
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wainberg M, 2019, NAT GENET, V51, P592, DOI 10.1038/s41588-019-0385-z
   Wang J, 2017, HUM HERED, V83, P117, DOI 10.1159/000489761
   Wang YJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010073
   Ward LD, 2012, NAT BIOTECHNOL, V30, P1095, DOI 10.1038/nbt.2422
   Webster BR, 2013, J CELL SCI, V126, P4843, DOI 10.1242/jcs.131300
   Westra HJ, 2014, BBA-MOL BASIS DIS, V1842, P1896, DOI 10.1016/j.bbadis.2014.04.024
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yates AD, 2020, NUCLEIC ACIDS RES, V48, pD682, DOI 10.1093/nar/gkz966
NR 58
TC 6
Z9 6
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD OCT
PY 2020
VL 9
IS 10
AR 2267
DI 10.3390/cells9102267
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OJ7NH
UT WOS:000584142600001
PM 33050425
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, AX
   Haueisen, A
   Rasendran, C
   Hom, GL
   Conti, TF
   Conti, FF
   Greenlee, TE
   Briskin, IN
   Bena, JF
   Singh, RP
   Talcott, KE
AF Chen, Andrew X.
   Haueisen, Alexander
   Rasendran, Chandruganesh
   Hom, Grant L.
   Conti, Thais F.
   Conti, Felipe F.
   Greenlee, Tyler E.
   Briskin, Isaac N.
   Bena, James F.
   Singh, Rishi P.
   Talcott, Katherine E.
TI Visual outcomes following cataract surgery in age-related macular
   degeneration patients
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID QUALITY-OF-LIFE; GEOGRAPHIC ATROPHY; EYE DISEASE; ACUITY; PROGRESSION
AB Objective: To evaluate visual acuity (VA) outcomes, prognostic factors, and changes in disease severity in patients with age-related macular degeneration (AMD) undergoing cataract surgery.
   Design: Retrospective cohort study
   Participants: Patients with AMD or healthy control patients who underwent cataract surgery between 2012 and 2017.
   Methods: Eyes were categorized into 3 AMD groups- intermediate AMD (iAMD), fovea-involving geographic atrophy (GA), neovascular AMD (nAMD)-and 3 preoperative VA-matched control groups (iAMDc), fovea-involving geographic atrophy control (GAc), neovaascular AMD control (nAMDc).
   Results: We compared 216 iAMD, 35 GA, and 184 nAMD eyes with 130, 31, and 129 controls. At postoperative month 12 (POM12), VA increased significantly in iAMD and nAMD (+10.1 +/- 14.5 and +9.7 +/- 18.9 letters, p < 0.001), but not in GA (p = 0.68). All control groups showed significant VA gains (iAMDc: +17.1 +/- 9.7, GAc: +30 +/- 12.9, and nAMDc: +26.4 +/- 15.6 letters, p < 0.001). For AMD groups, POM12 VA and gain in VA were significantly lower than that of controls (p < 0.01), and better preoperative VA predicted smaller VA gains (p <= 0.007). Longer duration of AMD in iAMD, ellipsoid zone disruption in nAMD, and lower central subfield thickness in GA were associated with poorer VA outcomes (p < 0.05). Development of nAMD occurred in 8 iAMD eyes and was associated with longer duration of disease (p = 0.001). For nAMD eyes, injection frequency did not vary between the 12-month pre- and postoperative periods (p = 0.051).
   Conclusions: Cataract surgery improves VA for patients with iAMD and nAMD, albeit not to the level of those without retinal pathology. Preoperative VA, AMD duration, and optical coherence tomography parameters may be important prognostic factors for cataract surgery in patients with AMD.
C1 [Chen, Andrew X.; Haueisen, Alexander; Rasendran, Chandruganesh; Singh, Rishi P.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Chen, Andrew X.; Hom, Grant L.; Conti, Thais F.; Conti, Felipe F.; Greenlee, Tyler E.; Singh, Rishi P.; Talcott, Katherine E.] Cleveland Clin Fdn, Ctr Ophthalm Bioinformat, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Briskin, Isaac N.; Bena, James F.] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation; Cleveland
   Clinic Foundation
RP Talcott, KE (通讯作者)，Cole Eye Inst, Ctr Ophthalm Bioinformat, Cleveland, OH 44195 USA.
EM talcotk@ccf.org
OI Briskin, Isaac/0000-0002-4022-0441; Rasendran,
   Chandruganesh/0000-0003-3133-0750; Greenlee, Tyler/0000-0003-0785-9099;
   Bena, James/0000-0002-7592-0480; Conti, Thais/0000-0003-4729-0706
CR Amesbury EC, 2009, J CATARACT REFR SURG, V35, P1505, DOI 10.1016/j.jcrs.2009.04.031
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Chew EY, 2015, INVEST OPHTH VIS SCI, V56
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Daien V, 2018, AM J OPHTHALMOL, V190, P50, DOI 10.1016/j.ajo.2018.03.012
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Ehmann DS, 2017, CURR OPIN OPHTHALMOL, V28, P58, DOI 10.1097/ICU.0000000000000331
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Figurska M, 2018, MED SCI MONITOR, V24, P6517, DOI 10.12659/MSM.909652
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Garcia-Layana A, 2017, OPTICAL COHERENCE TO
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grixti Andre, 2014, ISRN Ophthalmol, V2014, P417603, DOI 10.1155/2014/417603
   Keane PA, 2011, SAUDI J OPHTHALMOL, V25, P145, DOI 10.1016/j.sjopt.2011.01.003
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kessel L, 2016, ACTA OPHTHALMOL, V94, P755, DOI 10.1111/aos.13120
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Morris D, 2007, CLIN INTERV AGING, V2, P105, DOI 10.2147/ciia.2007.2.1.105
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Rappoport Daniel, 2017, Harefuah, V156, P79
   Rohart C, 2008, J FR OPHTALMOL, V31, P571, DOI 10.1016/S0181-5512(08)75457-3
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Starr MR, 2018, AM J OPHTHALMOL, V192, P91, DOI 10.1016/j.ajo.2018.05.014
   Sull AC, 2010, RETINA-J RET VIT DIS, V30, P235, DOI 10.1097/IAE.0b013e3181bd2c3b
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   Teh BL, 2017, SURV OPHTHALMOL, V62, P346, DOI 10.1016/j.survophthal.2016.12.003
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 35
TC 3
Z9 3
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD DEC
PY 2021
VL 56
IS 6
BP 348
EP 354
DI 10.1016/j.jcjo.2021.01.018
EA NOV 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XB1KZ
UT WOS:000721094800016
PM 33609442
DA 2022-11-30
ER

PT J
AU Dimitrov, PN
   Robman, LD
   Varsamidis, M
   Aung, KZ
   Makeyeva, GA
   Guymer, RH
   Vingrys, AJ
AF Dimitrov, Peter N.
   Robman, Liubov D.
   Varsamidis, Mary
   Aung, Khin Zaw
   Makeyeva, Galina A.
   Guymer, Robyn H.
   Vingrys, Algis J.
TI Visual Function Tests as Potential Biomarkers in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FOVEAL FLICKER SENSITIVITY; MEDIATED DARK-ADAPTATION; FUNDUS
   AUTOFLUORESCENCE; BRUCHS MEMBRANE; GLARE RECOVERY; FELLOW EYE;
   HIGH-RISK; MACULOPATHY; ROD; LUMINANCE
AB PURPOSE. To evaluate the potential of psychophysical assessments of retinal function to provide diagnostic biomarkers of early age-related macular degeneration (AMD).
   METHODS. Unilateral visual function was assessed in 221 participants (72.86 +/- 9.94 years; 67% women) with early AMD (visual acuity better than 20/60) and 109 controls (73.07 +/- 10.32 years; 65% women). Psychophysical assessment included steady state thresholds (4- and 14-Hz flicker and red and blue color) and dynamic tests (photostress recovery [PSR] and dark adaptation [DA]). All test parameters were compared in terms of their diagnostic capacity (sensitivity and specificity), reproducibility, and clinical applicability (test duration and participant's perception of test difficulty). AMD status was determined by digital photography, according to the International Classification and Grading System.
   RESULTS. All functional measurements were significantly worse, on average, in the AMD group than in the control group (P < 0.001). Static and dynamic parameters showed weak correlations (range, 0.003-0.225). Rod recovery in DA and cone recovery in PSR had the best diagnostic capacity (area under curve [AUC], receiver operating characteristic [ROC] analysis, 0.93 +/- 0.016 and 0.85 +/- 0.021, respectively). Considering diagnostic capacity together with test reproducibility and clinical applicability, the 14-Hz flicker gave the best outcome, followed by PSR. Combination of these two tests detected 71% of abnormal early AMD cases.
   CONCLUSIONS. All the visual function tests had good diagnostic capacity. Combination of the 14-Hz flicker thresholds and dynamics of the PSR test provided optimal quantitative assessment of retinal function in early AMD, suggesting that this set is a potentially useful clinical tool for following progression of early AMD and assessing the efficacy of interventions. (Invest Ophthalmol Vis Sci. 2011; 52: 9457-9469) DOI:10.1167/iovs.10-7043
C1 [Dimitrov, Peter N.; Robman, Liubov D.; Varsamidis, Mary; Aung, Khin Zaw; Makeyeva, Galina A.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Dimitrov, Peter N.; Vingrys, Algis J.] Univ Melbourne, Dept Optometry & Vis Sci, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne
RP Dimitrov, PN (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM dimitrov@unimelb.edu.au
OI Vingrys, Algis/0000-0001-5920-4604; Guymer, Robyn/0000-0002-9441-4356
FU NHMRC (National Health and Medical Research Council) [350224];
   Australian Research Council [ARC-LP0211474]; RVEEH Research Committee;
   Macular Vision Loss Support Society of Australia; NHMRC CCRE; RVEEH
FX Supported by NHMRC (National Health and Medical Research Council)
   Project Grant 350224 (RHG, AJV), Australian Research Council Linkage
   Project ARC-LP0211474, NHMRC CCRE, an NHMRC Career Development Award
   (RHG), an NHMRC Practitioner Fellowship (RHG), an RVEEH Wagstaff
   Fellowship (LR), the RVEEH Research Committee, and the Macular Vision
   Loss Support Society of Australia. CERA receives Operational
   Infrastructure Support from the Victorian Government.
CR Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Bartlett H, 2004, OPHTHAL PHYSL OPT, V24, P594, DOI 10.1111/j.1475-1313.2004.00245.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P788
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   Brown B, 2009, CLIN EXP OPTOM, V70, P112
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   COLLINS M, 1989, CLIN VISION SCI, V4, P145
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Formaz F, 1997, CURR EYE RES, V16, P1252, DOI 10.1076/ceyr.16.12.1252.5021
   FRUMKES TE, 1973, VISION RES, V13, P1269, DOI 10.1016/0042-6989(73)90202-2
   Garhofer G, 2004, VISION RES, V44, P833, DOI 10.1016/j.visres.2003.11.013
   GITTINGS NS, 1986, EXP GERONTOL, V21, P423, DOI 10.1016/0531-5565(86)90047-1
   GOLDBERG SH, 1983, SCIENCE, V221, P180, DOI 10.1126/science.6857279
   Gravetter F. J., 1992, STAT BEHAV SCI
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Linden A, 2006, J EVAL CLIN PRACT, V12, P132, DOI 10.1111/j.1365-2753.2005.00598.x
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MACLEOD DIA, 1972, NATURE, V235, P173, DOI 10.1038/235173a0
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Mei M, 2007, INVEST OPHTH VIS SCI, V48, P3419, DOI 10.1167/iovs.06-0731
   METHA AB, 1993, BEHAV RES METH INSTR, V25, P371, DOI 10.3758/BF03204528
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Motulsky, 2003, PRISM 4 STAT GUIDE S, P122
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Phipps JA, 1999, AUST NZ J OPHTHALMOL, V27, P265, DOI 10.1046/j.1440-1606.1999.00193.x
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Pianta MJ, 2000, J PHYSIOL-LONDON, V528, P591, DOI 10.1111/j.1469-7793.2000.00591.x
   Rosati P, 2004, ULTRASOUND OBST GYN, V23, P599, DOI 10.1002/uog.958
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Shakoor A, 2006, INVEST OPHTH VIS SCI, V47, P4962, DOI 10.1167/iovs.06-0291
   Siderov J, 1999, ACTA OPHTHALMOL SCAN, V77, P673, DOI 10.1034/j.1600-0420.1999.770613.x
   SLOANE ME, 1988, J OPT SOC AM A, V5, P2181, DOI 10.1364/JOSAA.5.002181
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stanga P. E., 2001, International Ophthalmology, V23, P191, DOI 10.1023/A:1014476430078
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   TAYLOR HR, 1989, AUST NZ J OPHTHALMOL, V17, P81, DOI 10.1111/j.1442-9071.1989.tb00492.x
   THIBOS LN, 1993, OPTOMETRY VISION SCI, V70, P279, DOI 10.1097/00006324-199304000-00006
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vingrys AJ, 1999, OPTOMETRY VISION SCI, V76, P588, DOI 10.1097/00006324-199908000-00028
NR 79
TC 90
Z9 93
U1 0
U2 28
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2011
VL 52
IS 13
BP 9457
EP 9469
DI 10.1167/iovs.10-7043
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 869WC
UT WOS:000298628200026
PM 22003115
DA 2022-11-30
ER

PT J
AU Wang, YF
   Han, Y
   Zhang, R
   Qin, L
   Wang, MX
   Ma, L
AF Wang, Ya-Feng
   Han, Yue
   Zhang, Rui
   Qin, Li
   Wang, Ming-Xu
   Ma, Le
TI CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related
   macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; OXIDATIVE STRESS; VARIANTS; INFLAMMATION; RISK;
   LIPC; HERITABILITY; METAANALYSIS; IMPACT; TIMP3
AB Three high-density lipoprotein (HDL)-related loci have been reported to be associated with age-related macular degeneration (AMD), but the results were inconsistent. In this study, the cholesteryl ester transfer protein (CETP) rs3764261 variant was significantly associated with an increased risk of AMD (odds ratio [OR] = 1.13, 95% confidence interval [CI]: 1.05-1.21, P < 0.001), and the hepatic lipase (LIPC) rs10468017 variant was associated with a significantly decreased risk of AMD (OR = 0.81, CI: 0.76-0.86, P < 0.001). Individuals carrying the lipoprotein lipase (LPL) rs12678919 polymorphism (A -> G) had no significant change in the risk of developing AMD (OR = 1.01, CI: 0.92-1.10, P = 0.17). After adjusting for the complement factor H (CFH) gene, both CETP and LPL conferred a significantly increased AMD risk (ORCETP = 1.17, CI: 1.08-1.26, P < 0.001; ORLPL = 1.11, CI: 1.01-1.22, P = 0.02). Subgroup analysis based on ethnicity revealed a significant association between the CETP variant and AMD in both Americans (OR = 1.12, CI: 1.02-1.23, P = 0.01) and Europeans (OR = 1.10, CI: 1.01-1.19, P = 0.011). This meta-analysis revealed that both CETP rs3764261 and LIPC rs10468017 polymorphisms were significantly associated with AMD risk. After adjustment for the CFH gene, CETP/LPL conferred a significantly increased susceptibility to the disease, indicating potential interactions among genes in the complement system and the lipid metabolism pathway.
C1 [Wang, Ya-Feng; Han, Yue; Zhang, Rui; Wang, Ming-Xu; Ma, Le] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Xian 710049, Peoples R China.
   [Qin, Li] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian 710049, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University
RP Ma, L (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Xian 710049, Peoples R China.
EM male@mail.xjtu.edu.cn
RI wang, yafeng/J-4829-2017
OI ma, le/0000-0001-7592-9779
FU National Natural Science Foundation of China [NSFC-81202198,
   NSFC-81473059]; Natural Science Foundation of Shaanxi Province of China
   [2013JQ4008]; China Postdoctoral Science Special Foundation
   [2015T81036]; China Postdoctoral Science Foundation Funded Project
   [2014M560790]
FX This study was partially supported by grants from the National Natural
   Science Foundation of China (NSFC-81202198, NSFC-81473059); the Natural
   Science Foundation of Shaanxi Province of China (2013JQ4008); and the
   China Postdoctoral Science Special Foundation (2015T81036); and the
   China Postdoctoral Science Foundation Funded Project (2014M560790).
CR Abu-Asab MS, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/453934
   Barter PJ, 2012, J LIPID RES, V53, P1755, DOI 10.1194/jlr.R024075
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bjelakovic G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074558
   Borm GF, 2009, J CLIN EPIDEMIOL, V62, P825, DOI 10.1016/j.jclinepi.2008.08.010
   Carvalho LSF, 2014, ATHEROSCLEROSIS, V237, P840, DOI 10.1016/j.atherosclerosis.2014.10.103
   Chapman MJ, 2010, EUR HEART J, V31, P149, DOI 10.1093/eurheartj/ehp399
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P821, DOI 10.1097/OPX.0000000000000285
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Eren Esin, 2012, Open Biochem J, V6, P78, DOI 10.2174/1874091X01206010078
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Koskela A, 2014, MOL VIS, V20, P760
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Lee J, 2013, EYE, V27, P266, DOI 10.1038/eye.2012.276
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Millett GA, 2008, JAMA-J AM MED ASSOC, V300, P1674, DOI 10.1001/jama.300.14.1674
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Montecucco F, 2015, HANDB EXP PHARMACOL, V224, P455, DOI 10.1007/978-3-319-09665-0_14
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Rao G H.B., 2011, CHOLESTEROL, V2011
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Seddon JM, 2010, MOL VIS, V16, P2412
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Song FJ, 1998, BRIT MED J, V316, P471
   Soyal SM, 2011, ATHEROSCLEROSIS, V216, P374, DOI 10.1016/j.atherosclerosis.2011.01.052
   Thorlund K, 2011, USER MANUAL TRIAL SE, P88
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Wang D., 2014, OPHTHALMIC GENET
   Wells GA., NEWCASTLE OTTAWA SCA
   Xie S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06630
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zhang SM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04642
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zuk O, 2012, P NATL ACAD SCI USA, V109, P1193, DOI 10.1073/pnas.1119675109
NR 46
TC 22
Z9 24
U1 0
U2 14
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 27
PY 2015
VL 5
AR 15711
DI 10.1038/srep15711
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CU3TR
UT WOS:000363448800001
PM 26503844
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, MM
   Agron, E
   Chew, E
   Meyerle, C
   Ferris, FL
   Chan, CC
   Tuo, JS
AF Liu, Melissa M.
   Agron, Elvira
   Chew, Emily
   Meyerle, Catherine
   Ferris, Frederick L., III
   Chan, Chi-Chao
   Tuo, Jingsheng
TI Copy Number Variations in Candidate Genes in Neovascular Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID REAL-TIME PCR; COMPLEMENT FACTOR-H; PARKINSONS-DISEASE; HUMAN GENOME;
   HAN CHINESE; POLYMORPHISMS; EXPRESSION; RISK; CFH; NUCLEOTIDE
AB PURPOSE. The pathogenesis of age-related macular degeneration (AMD) is strongly influenced by genetic factors, and single nucleotide polymorphisms have been consistently linked to AMD. Copy number variation (CNV), or variation in the number of copies of a particular segment of DNA, may also contribute to AMD pathogenesis. This study evaluated CNVs in candidate genes that have been reported to be linked to AMD.
   METHODS. Study participants were 131 patients with neovascular AMD and 103 elderly persons without AMD who were evaluated by retinal specialists at the National Eye Institute. DNA was collected from peripheral whole blood, and duplex RT-PCR based copy number (CN) assays were performed for the genes CCR3, CFH, CX3CR1, ERCC6, HTRA1, and VEGF. Quantitative CNs (CN = 0, 1, 2, or 3+) were determined.
   RESULTS. Novel CNVs were discovered in CCR3, CX3CR1, and ERCC6. The unadjusted data suggested that CN = 3+ for CX3CR1 might be mildly protective against AMD, but this trend did not persist after adjustment for age. AMD patients appeared to have an elevated mean CFH CN relative to controls (2.13 [95% confidence interval (CI), 2.05-2.21] vs. 2.01 [95% CI, 1.92-2.09 copies]; P = 0.05). No significant associations between CNV and AMD were observed for the remaining genes.
   CONCLUSIONS. The methods described are suitable for quantitative characterization of CNV in candidate genes. The authors identified CNVs in AMD-associated genes but did not find strong evidence for a link with neovascular AMD. (Invest Ophthalmol Vis Sci. 2011;52:3129-3135) DOI:10.1167/iovs.10-6735
C1 [Liu, Melissa M.; Chan, Chi-Chao; Tuo, Jingsheng] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Agron, Elvira; Chew, Emily; Meyerle, Catherine; Ferris, Frederick L., III] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Liu, Melissa M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Johns Hopkins University
RP Tuo, JS (通讯作者)，10-10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM tuoj@nei.nih.gov
OI Tuo, Jingsheng/0000-0002-1372-7810; Ferris,
   Frederick/0000-0002-4933-0639
FU National Eye Institute; American Health Assistance Foundation
   [M2007037]; NATIONAL EYE INSTITUTE [ZIAEY000523, ZIAEY000489,
   ZIAEY000485, ZIAEY000524, ZIAEY000222, ZIAEY000418, ZIAEY000497,
   ZIAEY000526, T32EY007143, ZIAEY000527] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute Intramural Research Program and
   American Health Assistance Foundation Grant M2007037.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bediaga NG, 2008, ANAL BIOCHEM, V378, P221, DOI 10.1016/j.ab.2008.04.010
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516
   de Smith AJ, 2008, CYTOGENET GENOME RES, V123, P17, DOI 10.1159/000184688
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fanciulli M, 2010, CLIN GENET, V77, P201, DOI 10.1111/j.1399-0004.2009.01342.x
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hinds DA, 2006, NAT GENET, V38, P82, DOI 10.1038/ng1695
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Norskov MS, 2009, CLIN BIOCHEM, V42, P201, DOI 10.1016/j.clinbiochem.2008.10.020
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045
   Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329
   Rose-Zerilli MJ, 2009, CLIN CHEM, V55, P1680, DOI 10.1373/clinchem.2008.120105
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278
   Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   *TCAG, TCAG DAT GEN VAR
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Zhang F, 2009, ANNU REV GENOM HUM G, V10, P451, DOI 10.1146/annurev.genom.9.081307.164217
   Zhou J, 2010, INVEST OPHTH VIS SCI, V51, P3924, DOI 10.1167/iovs.10-5240
   1999, CONTROLLED CLIN TRIA, V20, P573
   ABI GENEASSIST COPY
NR 36
TC 19
Z9 19
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2011
VL 52
IS 6
BP 3129
EP 3135
DI 10.1167/iovs.10-6735
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 770PN
UT WOS:000291100800035
PM 21273533
OA Green Published
DA 2022-11-30
ER

PT J
AU Jiang, YM
   Liang, G
   Wang, LQ
   Jiang, JJ
   Du, GP
   Huang, YF
AF Jiang, Yanming
   Liang, Ge
   Wang, Liqiang
   Jiang, Jingjing
   Du, Gaiping
   Huang, Yifei
TI Association between vascular endothelial growth factor+936 C/T gene
   polymorphism and age-related macular degeneration
SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
LA English
DT Article
DE Age-related macular degeneration; gene polymorphism; polymerase chain
   reaction; restriction fragment length polymorphism; vascular endothelial
   growth factor
ID BODY-MASS INDEX; VEGF GENE; RISK-FACTOR; CANCER; SUSCEPTIBILITY;
   HAPLOTYPES; SMOKING
AB Objectives: The pathogenesis of age-related macular degeneration (AMD) remains unknown. Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and a target for inhibition therapy in wet AMD. This study investigated the association between the VEGF +936 C/T gene polymorphism and AMD, in a Chinese Han population.
   Methods: Patients with AMD, and age-and sex-matched controls were enrolled. Restriction fragment length polymorphism was used to analyse the VEGF +936 polymorphism in the promoter and the 3' untranslated region of the gene.
   Results: The study included 200 AMD patients and 200 control subjects. There was a significantly higher prevalence of the TT genotype among AMD patients (9.0%) compared with controls (3.5%); the odds ratio for this genotype in AMD patients was 2.73 (95% confidence intervals 1.11, 6.68). There were no significant associations between any genotype and AMD subphenotypic categories (early, geographic atrophy, choroidal neovascularization).
   Conclusions: The present study findings suggested that the VEGF +936 TT genotype was associated with AMD among Han Chinese patients.
C1 [Jiang, Yanming; Wang, Liqiang; Jiang, Jingjing; Du, Gaiping; Huang, Yifei] Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing 100853, Peoples R China.
   [Jiang, Yanming; Liang, Ge] Chinese PLA Second Artillery Gen Hosp, Dept Ophthalmol, Beijing, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Huang, YF (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM yfeihuang@hotmail.com
RI Huang, Yifei/ABE-4692-2020; Huang, Yifei/ABE-7566-2020
OI Huang, Yifei/0000-0002-7089-6426; 
CR Ajaz S, 2011, GENET TEST MOL BIOMA, V15, P653, DOI 10.1089/gtmb.2011.0029
   Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Bae SJ, 2008, ANTICANCER RES, V28, P1271
   Bao G, 2011, GENET TEST MOL BIOMA, V15, P103, DOI 10.1089/gtmb.2010.0141
   Belo VA, 2011, DNA CELL BIOL, V30, P709, DOI 10.1089/dna.2011.1260
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Cao C, 2010, ARCH MED RES, V41, P548, DOI 10.1016/j.arcmed.2010.09.006
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Cheng CY, 2008, ORAL SURG ORAL MED O, V106, P79, DOI 10.1016/j.tripleo.2007.10.009
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeBlack Susan Sanders, 2003, Optometry, V74, P99
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fang AM, 2009, MOL VIS, V15, P2710
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Goncalves FM, 2010, DNA CELL BIOL, V29, P357, DOI 10.1089/dna.2010.1025
   He Y, 2010, DNA CELL BIOL, V29, P393, DOI 10.1089/dna.2009.1015
   Hughes AE, 2011, MOL VIS, V17, P983
   Ikuhashi Y, 2007, ACTA OBSTET GYN SCAN, V86, P1352, DOI 10.1080/00016340701644991
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Kaufman SR, 2009, GERIATRICS, V64, P16
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Krippl P, 2003, INT J CANCER, V106, P468, DOI 10.1002/ijc.11238
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lu Y, 2012, MOL BIOL REP, V39, P6547, DOI 10.1007/s11033-012-1483-5
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Mittal RD, 2011, DNA CELL BIOL, V30, P309, DOI 10.1089/dna.2010.1138
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Seddon JM, 2010, MOL VIS, V16, P2412
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Soysal Y, 2012, DNA CELL BIOL, V31, P322, DOI 10.1089/dna.2011.1214
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   Synowiec E, 2012, MOL BIOL REP, V39, P2081, DOI 10.1007/s11033-011-0955-3
   Szaflik Jacek P, 2009, Klin Oczna, V111, P125
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   Tong Y, 2010, MOL VIS, V16, P1958
   Vincenti V, 1996, CIRCULATION, V93, P1493, DOI 10.1161/01.CIR.93.8.1493
   Vojnikovic B, 2009, COLLEGIUM ANTROPOL, V33, P747
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yang SY, 2011, GENET TEST MOL BIOMA, V15, P737, DOI 10.1089/gtmb.2011.0054
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Zhang L, 2011, GENET TEST MOL BIOMA, V15, P117, DOI 10.1089/gtmb.2010.0166
NR 54
TC 9
Z9 9
U1 1
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-0605
EI 1473-2300
J9 J INT MED RES
JI J. Int. Med. Res.
PD APR
PY 2013
VL 41
IS 2
BP 317
EP 324
DI 10.1177/0300060513475570
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 147YD
UT WOS:000319206600009
PM 23569009
OA gold
DA 2022-11-30
ER

PT J
AU Wang, MH
   Zhang, MZ
   Chen, X
   Zhang, HP
AF Wang, Minghui
   Zhang, Meizhuo
   Chen, Xiang
   Zhang, Heping
TI Detecting Genes and Gene-Gene Interactions for Age-Related Macular
   Degeneration with a Forest-based Approach
SO STATISTICS IN BIOPHARMACEUTICAL RESEARCH
LA English
DT Article
DE Genome-wide association; Haplotype; Random forest
ID CLASSIFICATION TREES; GENOME; POLYMORPHISM; ASSOCIATION; SMOKING;
   DISEASE; SCAN
AB Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly. Genetic mechanisms underlying AMD are complex. Understanding the etiology of AMD is important because of the significant health and social concerns. In this article, we describe a forest-based approach to systematically identifying multiple genes, gene-gene interactions, and gene-environment interactions underlying complex diseases in genome-wide case-control studies and the application of this approach to a published dataset on AMD. Our analysis not only confirmed two known haplotypes, ACTCCG (on chromosome 1 with a p-value of 1.98e-6) and TCTGGACGACA (on chromosome 7 with a p-value of 9.81e-3), but also revealed two novel haplotypes, GATAGT (on chromosome 5 with a p-value of 3.46e-3) and TCTTACGTAGA (on chromosome 12 with a p-value of 3.16e-2). Thus, the significance of this work is two-fold. First, we propose a powerful and robust method to identify high-risk haplotypes and their interactions; second, we reveal potential genetic variants associated with AMD.
C1 [Wang, Minghui; Zhang, Meizhuo; Chen, Xiang; Zhang, Heping] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA.
C3 Yale University
RP Zhang, HP (通讯作者)，Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA.
EM heping.zhang@yale.edu
RI Zhang, He/GXN-0028-2022; Chen, Xiang/N-2524-2018
OI Chen, Xiang/0000-0002-2499-8261
FU Yale University Biomedical High Performance Computing Center (NIH)
   [RR19895]; National Institutes on Drug Abuse [K02DA017713, R01DA016750];
   NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019895] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA017713, R01DA016750]
   Funding Source: NIH RePORTER
FX We thank the Yale University Biomedical High Performance Computing
   Center (NIH grant: RR19895) for computational resources. Funding: This
   research is supported in part by grants K02DA017713 and R01DA016750 from
   the National Institutes on Drug Abuse.
CR Bastone L, 2004, HUM HERED, V58, P82, DOI 10.1159/000083029
   BREIMAN L, 2001, MACH LEARN, V0045
   Carlborg O, 2004, NAT REV GENET, V5, P618, DOI 10.1038/nrg1407
   Ccok NR, 2004, STAT MED, V23, P1439, DOI 10.1002/sim.1749
   Chen X, 2007, P NATL ACAD SCI USA, V104, P19199, DOI 10.1073/pnas.0709868104
   CLAYTON D, 2006, SNPHAP PROGRAM ESTIM
   Daiger SP, 2005, SCIENCE, V308, P362, DOI 10.1126/science.1111655
   Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Foulkes AS, 2004, J ROY STAT SOC C-APP, V53, P311, DOI 10.1046/j.1467-9876.2003.05094.x
   Frankel WN, 1996, NAT GENET, V14, P371, DOI 10.1038/ng1296-371
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heinzen EL, 2007, AM J HUM GENET, V80, P876, DOI 10.1086/516650
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Kallberg H, 2007, AM J HUM GENET, V80, P867, DOI 10.1086/516736
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Marx J, 2006, SCIENCE, V314, P405
   Musani SK, 2007, HUM HERED, V63, P67, DOI 10.1159/000099179
   Nelson MR, 2001, GENOME RES, V11, P458, DOI 10.1101/gr.172901
   Schwender H, 2008, BIOSTATISTICS, V9, P187, DOI 10.1093/biostatistics/kxm024
   Tiwari HK, 1997, GENET EPIDEMIOL, V14, P1131, DOI 10.1002/(SICI)1098-2272(1997)14:6<1131::AID-GEPI95>3.3.CO;2-7
   TIWARI HK, 1998, THEORETICAL POPULATI, V54, P61
   Wan X, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-13
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Ye YQ, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-S1-S135
   Zhang HP, 2000, GENET EPIDEMIOL, V19, P323, DOI 10.1002/1098-2272(200012)19:4<323::AID-GEPI4>3.0.CO;2-5
   Zhang HP, 2003, P NATL ACAD SCI USA, V100, P4168, DOI 10.1073/pnas.0230559100
   Zhang HP, 1998, J AM STAT ASSOC, V93, P180, DOI 10.2307/2669615
   Zhang HP, 1999, RECURSIVE PARTITIONI
NR 33
TC 12
Z9 13
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1946-6315
J9 STAT BIOPHARM RES
JI Stat. Biopharm. Res.
PD NOV
PY 2009
VL 1
IS 4
BP 424
EP 430
DI 10.1198/sbr.2009.0046
PG 7
WC Mathematical & Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology; Mathematics
GA V17ZL
UT WOS:000207975000012
PM 20161521
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Singh, RP
   Yu, JS
   Guruprasad, B
   Agashivala, N
AF Singh, Rishi P.
   Yu, Justin S.
   Guruprasad, B.
   Agashivala, Neetu
TI Anti-VEGF Treatment Patterns in Patients With Wet Age-Related Macular
   Degeneration in Clinical Practice
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID GROWTH-FACTOR THERAPY; RANIBIZUMAB; OUTCOMES; AFLIBERCEPT
AB BACKGROUND AND OBJECTIVE: To characterize on-label anti-vascular endothelial growth factor (VEGF) treatment patterns in patients with wet age-related macular degeneration (AMD) in clinical practice in the U.S.
   PATIENTS AND METHODS: Retrospective cohort analysis using administrative claims data from the IQVIA Open Source Databases. Treatment-naive patients in the U.S. who received one or more wet AMD-related anti-VEGF injection from July 1, 2013, to April 30, 2017, were included. The main outcome was the injection interval closest to Month 12.
   RESULTS: This study included 21,960 patients who initiated an anti-VEGF agent (ranibizumab, aflibercept, or bevacizumab): 5,489 initiated aflibercept and 4,253 initiated ranibizumab. Among ranibizumab, aflibercept, and all anti-VEGF eyes, 38.1% (n = 2,035), 33.5% (n = 3,262). and 40.0% (n = 12,505) of patient eyes had injection intervals of less than 8 weeks, respectively, at Month 12 with the mean (standard deviation) number of injections over 12 months being 8.0 (2.4), 7.6 (2.4), and 7.8 (2.5).
   CONCLUSION: A substantial proportion of patients receive injections more frequently than every 8 weeks within the first year of treatment.
C1 [Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, Ctr Ophthalm Bioinformat, Cleveland, OH 44195 USA.
   [Yu, Justin S.; Guruprasad, B.; Agashivala, Neetu] Novartis Pharmaceut, E Hanover, NJ USA.
C3 Cleveland Clinic Foundation; Novartis
RP Singh, RP (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave,I-32, Cleveland, OH 44195 USA.
EM singhr@ccf.org
FU Novartis Pharmaceuticals Corporation
FX Supported by Novartis Pharmaceuticals Corporation. The sponsor had a
   role in the study design, data collection, data analysis, and manuscript
   preparation. The authors would like to thank Write All, LLC for
   editorial and writing services provided.
CR [Anonymous], The 20th Annual ASRS PAT Survey.
   [Anonymous], Harness the power of Real World Data
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Hussain R. M, 2018, REV OPTHALMOLOGY
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kiss S, 2020, J MANAG CARE SPEC PH, V26, P253, DOI 10.18553/jmcp.2020.19245
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Skelly Adrian, 2019, Vision (Basel), V3, DOI 10.3390/vision3030041
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Stewart MW, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010021
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
NR 26
TC 0
Z9 0
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAY
PY 2021
VL 52
IS 5
BP 263
EP +
DI 10.3928/23258160-20210429-04
PG 14
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA SJ5YU
UT WOS:000655611000004
PM 34044715
DA 2022-11-30
ER

PT J
AU Telegina, DV
   Kozhevnikova, OS
   Kolosova, NG
AF Telegina, D. V.
   Kozhevnikova, O. S.
   Kolosova, N. G.
TI Changes in Retinal Glial Cells with Age and during Development of
   Age-Related Macular Degeneration
SO BIOCHEMISTRY-MOSCOW
LA English
DT Review
DE aging; retina; age-related macular degeneration; astrocytes; Muller
   cells; microglia
ID FIBRILLARY ACIDIC PROTEIN; PHOTORECEPTOR DEGENERATION; MICROGLIAL
   ACTIVATION; RETINITIS-PIGMENTOSA; INFLAMMATION; MICE; ACCUMULATION;
   MECHANISMS; EXPRESSION; SYSTEM
AB Age is the major risk factor in the age-related macular degeneration (AMD) which is a complex multifactor neurodegenerative disease of the retina and the main cause of irreversible vision loss in people over 60 years old. The major role in AMD pathogenesis belongs to structure-functional changes in the retinal pigment epithelium cells, while the onset and progression of AMD are commonly believed to be caused by the immune system dysfunctions. The role of retinal glial cells (Muller cells, astrocytes, and microglia) in AMD pathogenesis is studied much less. These cells maintain neurons and retinal vessels through the synthesis of neurotrophic and angiogenic factors, as well as perform supporting, separating, trophic, secretory, and immune functions. It is known that retinal glia experiences morphological and functional changes with age. Age-related impairments in the functional activity of glial cells are closely related to the changes in the expression of trophic factors that affect the status of all cell types in the retina. In this review, we summarized available literature data on the role of retinal macro- and microglia and on the contribution of these cells to AMD pathogenesis.
C1 [Telegina, D. V.; Kozhevnikova, O. S.; Kolosova, N. G.] Russian Acad Sci, Inst Cytol & Genet, Siberian Branch, Novosibirsk 630090, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS
RP Kolosova, NG (通讯作者)，Russian Acad Sci, Inst Cytol & Genet, Siberian Branch, Novosibirsk 630090, Russia.
EM kolosova@bionet.nsc.ru
RI Kolosova, Nataliya G/P-3178-2015; Telegina, Darya/AAQ-6062-2020;
   Kozhevnikova, Oyuna S./H-3588-2016; Kolosova, Nataliya G/AAR-7409-2020
OI Kolosova, Nataliya G/0000-0003-2398-8544; Telegina,
   Darya/0000-0001-8096-0519; Kozhevnikova, Oyuna S./0000-0001-6475-4061;
   Kolosova, Nataliya G/0000-0003-2398-8544
FU Russian Foundation for Basic Research [18-315-00216]; Government of the
   Russian Federation [2017-220-06-735576001]
FX The work was supported by the Russian Foundation for Basic Research
   (project no. 18-315-00216) and the Government of the Russian Federation
   (project no. 2017-220-06-735576001).
CR Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   BELECKY-ADAMS T. L., 2013, NEURAL STEM CELLS NE
   Bhattacharya S, 2008, STEM CELLS, V26, P2611, DOI 10.1634/stemcells.2008-0222
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Coorey NJ, 2012, CLIN EXP OPTOM, V95, P266, DOI 10.1111/j.1444-0938.2012.00741.x
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   de Hoz R, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2954721
   Dubois-Dauphin M, 2000, NEUROSCIENCE, V95, P9
   Edwards MM, 2016, EXP EYE RES, V150, P44, DOI 10.1016/j.exer.2015.07.016
   Fu RY, 2014, MOL NEUROBIOL, V49, P1422, DOI 10.1007/s12035-013-8620-6
   Gallina D, 2014, EXP EYE RES, V123, P121, DOI 10.1016/j.exer.2013.06.019
   Ganesh BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018305
   Goldman D, 2014, NAT REV NEUROSCI, V15, P431, DOI 10.1038/nrn3723
   Goureau O, 2004, DEV NEUROSCI-BASEL, V26, P359, DOI 10.1159/000082278
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hamon A, 2016, DEV DYNAM, V245, P727, DOI [10.1002/DVDY.24375, 10.1002/dvdy.24375]
   Hippert C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120415
   Hol EM, 2015, CURR OPIN CELL BIOL, V32, P121, DOI 10.1016/j.ceb.2015.02.004
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hurley JB, 2014, VERTEBRATE PHOTORECE, P91
   Jadhav AP, 2006, P NATL ACAD SCI USA, V103, P18998, DOI 10.1073/pnas.0608155103
   Jadhav AP, 2009, PROG RETIN EYE RES, V28, P249, DOI 10.1016/j.preteyeres.2009.05.002
   Kalloniatis M, 2016, EXP EYE RES, V150, P106, DOI 10.1016/j.exer.2015.10.019
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010
   Kim JH, 2006, J BIOCHEM MOL BIOL, V39, P339
   Kimura A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091584
   Kolomeyer AM, 2014, SURV OPHTHALMOL, V59, P134, DOI 10.1016/j.survophthal.2013.09.004
   Kozhevnikova OS, 2018, BIOGERONTOLOGY, V19, P223, DOI 10.1007/s10522-018-9751-y
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luna G, 2010, MOL VIS, V16, P2511
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Nakazawa T, 2007, INVEST OPHTH VIS SCI, V48, P2760, DOI 10.1167/iovs.06-1398
   Newman EA, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0195
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Ohsawa K, 2004, J NEUROCHEM, V88, P844, DOI 10.1046/j.1471-4159.2003.02213.x
   Paglinawan R, 2003, GLIA, V44, P219, DOI 10.1002/glia.10286
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Perry VH, 2013, SEMIN IMMUNOPATHOL, V35, P601, DOI 10.1007/s00281-013-0382-8
   Polazzi E, 2010, PROG NEUROBIOL, V92, P293, DOI 10.1016/j.pneurobio.2010.06.009
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Rossi D, 2015, PROG NEUROBIOL, V130, P86, DOI 10.1016/j.pneurobio.2015.04.003
   Santos AM, 2010, J COMP NEUROL, V518, P477, DOI 10.1002/cne.22227
   Schey KL, 2014, BBA-GEN SUBJECTS, V1840, P1513, DOI 10.1016/j.bbagen.2013.10.037
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Sheridan GK, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.130181
   Telegina DV, 2017, ADV GERONTOL, V7, P17, DOI 10.1134/S2079057017010155
   Telegina DV, 2017, SCI REP-UK, V7, DOI 10.1038/srep41533
   Telegina DV, 2015, CELL CYCLE, V14, P3544, DOI 10.1080/15384101.2015.1080399
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Verkhratsky A, 2014, CELL TISSUE RES, V357, P493, DOI 10.1007/s00441-014-1814-z
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Webster MK, 2017, NEUROSCIENCE, V346, P437, DOI 10.1016/j.neuroscience.2017.01.029
   Xia XH, 2016, INT J STEM CELLS, V9, P169, DOI 10.15283/ijsc16020
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zhang X, 2004, INVEST OPHTH VIS SCI, V45, P2374, DOI 10.1167/iovs.03-1239
NR 79
TC 35
Z9 37
U1 0
U2 9
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 1608-3040
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PD SEP
PY 2018
VL 83
IS 9
BP 1009
EP 1017
DI 10.1134/S000629791809002X
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GU3FB
UT WOS:000445160500002
PM 30472939
DA 2022-11-30
ER

PT J
AU Kosmidou, C
   Efstathiou, NE
   Hoang, MV
   Notomi, S
   Konstantinou, EK
   Hirano, M
   Takahashi, K
   Maidana, DE
   Tsoka, P
   Young, L
   Gragoudas, ES
   Olsen, TW
   Morizane, Y
   Miller, JW
   Vavvas, DG
AF Kosmidou, Cassandra
   Efstathiou, Nikolaos E.
   Hoang, Mien V.
   Notomi, Shoji
   Konstantinou, Eleni K.
   Hirano, Masayuki
   Takahashi, Kosuke
   Maidana, Daniel E.
   Tsoka, Pavlina
   Young, Lucy
   Gragoudas, Evangelos S.
   Olsen, Timothy W.
   Morizane, Yuki
   Miller, Joan W.
   Vavvas, Demetrios G.
TI Issues with the Specificity of Immunological Reagents for NLRP3:
   Implications for Age-related Macular Degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; INFLAMMASOME ACTIVATION; ALU RNA; ARPE-19
   CELLS; VEGF-A; INTERLEUKIN-18; IL-1-BETA; DISEASE; RPE; RELEASE
AB Contradictory data have been presented regarding the implication of the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome in age-related macular degeneration (AMD), the leading cause of vision loss in the Western world. Recognizing that antibody specificity may explain this discrepancy and in line with recent National Institutes of Health (NIH) guidelines requiring authentication of key biological resources, the specificity of anti-NLRP3 antibodies was assessed to elucidate whether non-immune RPE cells express NLRP3. Using validated resources, NLRP3 was not detected in human primary or human established RPE cell lines under multiple inflammasomepriming conditions, including purported NLRP3 stimuli in RPE such as DICER1 deletion and Mu RNA transfection. Furthermore, NLRP3 was below detection limits in ex vivo macular RPE from AMD patients, as well as in human induced pluripotent stem cell (hiPSC)-derived RPE from patients with overactive NLRP3 syndrome (Chronic infantile neurologic cutaneous and articulate, CINCA syndrome). Evidence presented in this study provides new data regarding the interpretation of published results reporting NLRP3 expression and upregulation in RPE and addresses the role that this inflammasome plays in AMD pathogenesis.
C1 [Kosmidou, Cassandra; Efstathiou, Nikolaos E.; Hoang, Mien V.; Notomi, Shoji; Konstantinou, Eleni K.; Maidana, Daniel E.; Tsoka, Pavlina; Young, Lucy; Gragoudas, Evangelos S.; Miller, Joan W.; Vavvas, Demetrios G.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, Boston, MA 02114 USA.
   [Hirano, Masayuki; Takahashi, Kosuke; Morizane, Yuki] Okayama Univ, Dept Ophthalmol, Grad Sch Med, Okayama 7008558, Japan.
   [Olsen, Timothy W.] Mayo Clin, Dept Ophthalmol, 200 First St SW, Rochester, MN 55905 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Okayama University; Mayo Clinic
RP Vavvas, DG (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, Boston, MA 02114 USA.
RI Konstantinou, Eleni/ABD-1753-2020; Hoang, Mien V/H-8270-2012
OI Hoang, Mien V/0000-0003-0859-2170; Kosmidou,
   Cassandra/0000-0003-2236-246X; Vavvas, Demetrios/0000-0002-8622-6478;
   Efstathiou, Nikolaos/0000-0002-6635-0391
FU NEI grant [EY014104]; Bayer Healthcare Global Ophthalmology Awards
   Programme; STAMATIOU foundation scholarship; Physician Scientist Award
   from RPB; Alcon Research Institute Young Investigator Award; NEI
   [R21EY023079-01A1, R01-EY025362-01]; Research to Prevent Blindness
   foundation; Yeatts Family Foundation; Loefflers Family Fund; Macula
   Society Research Grant award; NATIONAL EYE INSTITUTE [R21EY023079,
   P30EY014104, R01EY025362] Funding Source: NIH RePORTER
FX This work was supported by: NEI R21EY023079-01A1, R01-EY025362-01 (DGV);
   the Yeatts Family Foundation (DGV, JWM); the Loefflers Family Fund (DGV,
   JWM); the 2013 Macula Society Research Grant award (DGV); a Physician
   Scientist Award from RPB and the Alcon Research Institute Young
   Investigator Award (DGV), an unrestricted grant from the Research to
   Prevent Blindness foundation (JWM); NEI grant EY014104 (MEEI Core
   Grant), the Bayer Healthcare Global Ophthalmology Awards Programme (DEM)
   and the STAMATIOU foundation scholarship (NEE). The authors would like
   to thank and acknowledge Dr. S.A. Trauger from the Small Molecule Mass
   Spectrometry facility at Harvard University for the protein sequencing
   analysis.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Baker M, 2015, NATURE, V521, P274, DOI 10.1038/521274a
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Berglund L, 2008, MOL CELL PROTEOMICS, V7, P2019, DOI 10.1074/mcp.R800013-MCP200
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Campbell M, 2014, EXPERT REV CLIN IMMU, V10, P1273, DOI 10.1586/1744666X.2014.950231
   Campbell M, 2014, ADV EXP MED BIOL, V801, P409, DOI 10.1007/978-1-4614-3209-8_52
   Campbell M, 2013, J MOL MED, V91, P1059, DOI 10.1007/s00109-013-1050-0
   Canna SW, 2017, INVEST OPHTH VIS SCI, V58, P1764, DOI 10.1167/iovs.17-21697
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Dollfus H, 2000, ARCH OPHTHALMOL-CHIC, V118, P1386
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Goodman SN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5027
   Guarda G, 2011, J IMMUNOL, V186, P2529, DOI 10.4049/jimmunol.1002720
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Iqbal SA, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002333
   Janssen R, 2004, ARTHRITIS RHEUM, V50, P3329, DOI 10.1002/art.20494
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Kovarova M, 2012, J IMMUNOL, V189, P2006, DOI 10.4049/jimmunol.1201065
   Lauer M, 2016, AUTHENTICATION KEY B
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Marneros AG, 2016, ADV EXP MED BIOL, V854, P79, DOI 10.1007/978-3-319-17121-0_12
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Miller JW, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.9
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Prager P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165653
   Prinz F, 2011, NAT REV DRUG DISCOV, V10, P712, DOI 10.1038/nrd3439-c1
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shi GP, 2015, INVEST OPHTH VIS SCI, V56, P1658, DOI 10.1167/iovs.14-14557
   Shi HQ, 2015, BIOCHEM BIOPH RES CO, V463, P1071, DOI 10.1016/j.bbrc.2015.06.060
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Wang K, 2016, J BIOCH MOL TOXICOL
   Wang L, 2016, J PATHOL, V240, P495, DOI 10.1002/path.4811
   Wang YC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071036
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2017, PREV BLINDN VIS IMP
   Zhang SJ, 2016, INVEST OPHTH VIS SCI, V57, P312, DOI 10.1167/iovs.15-17578
NR 56
TC 31
Z9 32
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 11
PY 2018
VL 8
AR 461
DI 10.1038/s41598-017-17634-1
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FS6XF
UT WOS:000419941000002
PM 29323137
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yeh, JH
   Cheng, CK
   Chiu, HC
AF Yeh, Jiann-Horng
   Cheng, Cheng-Kuo
   Chiu, Hou-Chang
TI A Case Report of Double-Filtration Plasmapheresis for the Treatment of
   Age-related Macular Degeneration
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE Age-related macular degeneration; Best-corrected vision;
   Double-filtration plasmapheresis; Plasma viscosity; Rheopheresis
ID MEMBRANE DIFFERENTIAL FILTRATION; THERAPEUTIC APHERESIS; MACULOPATHY;
   IMPROVEMENT; POPULATION; PREVALENCE; PERFUSION; EYE
AB An 85-year-old man with dry type age-related macular degeneration (AMD) in his right eye and a disciform scar in his left eye received double-filtration plasmapheresis (DFPP) for the treatment of his right eye. The protocol for plasmapheresis followed the Multicenter Investigation of Rheopheresis for AMD (MIRA) trial and consisted of four pulses of paired sessions of plasmapheresis with a two-day interval within 10 weeks. The pre-DFPP best corrected visual acuity (BCVA) for the right eye was 6/15 (0.4). Six months after DFPP treatment, the BCVA of the right eye was 6/10 (0.6) and remained unchanged at the 12th month; however, comparison of the right eye fundus picture, fluorescein angiogram, and optical coherence tomography of the macular area before and 6 and 12 months after plasmapheresis revealed no discernable changes. The per-session and per-course clearance rates were highest for IgM (63.8% and 90.8%) and lowest for albumin (11% and 15.4%). No plasmapheresis-related complications, such as hypotension, hemolysis or infection, occurred. Thus, DFPP treatment can provide effective treatment for dry type AMD with minimal side-effects.
C1 [Cheng, Cheng-Kuo] Shin Kong Wu Ho Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Yeh, Jiann-Horng; Chiu, Hou-Chang] Shin Kong Wu Ho Mem Hosp, Dept Neurol, Taipei, Taiwan.
   [Yeh, Jiann-Horng; Cheng, Cheng-Kuo; Chiu, Hou-Chang] Fu Jen Catholic Univ, Coll Med, Taipei, Taiwan.
C3 Shin Kong Wu Ho Su Memorial Hospital; Shin Kong Wu Ho Su Memorial
   Hospital; Fu Jen Catholic University
RP Cheng, CK (通讯作者)，Shin Kong Wu Ho Mem Hosp, Dept Ophthalmol, 95 Wen Chang Rd, Taipei, Taiwan.
EM ckcheng.md@yahoo.com.tw
CR Abdelgadir WS, 1998, INT J FOOD MICROBIOL, V44, P1, DOI 10.1016/S0168-1605(98)00090-7
   AGISHI T, 1980, T AM SOC ART INT ORG, V26, P406
   Berrouschot J, 1998, ACTA NEUROL SCAND, V97, P126
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P41, DOI 10.1016/j.transci.2005.09.001
   Bosch T, 2005, THER APHER DIAL, V9, P459, DOI 10.1111/j.1744-9987.2005.00306.x
   Brunner R, 1996, TRANSFUS SCI, V17, P493, DOI 10.1016/S0955-3886(96)90083-1
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Donaldson MJ, 2006, CURR OPIN OPHTHALMOL, V17, P267, DOI 10.1097/01.icu.0000193101.13551.e5
   HARKNESS J, 1971, Biorheology, V8, P171
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Kambic H E, 1997, Ther Apher, V1, P83, DOI 10.1111/j.1744-9987.1997.tb00020.x
   Klingel R, 2002, THER APHER, V6, P271, DOI 10.1046/j.1526-0968.2002.00418.x
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Luke C, 2001, J CLIN APHERESIS, V16, P23, DOI 10.1002/jca.1004
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Widder RA, 1998, BLOOD PURIFICAT, V16, P15, DOI 10.1159/000014308
   Yeh JH, 1999, ACTA NEUROL SCAND, V99, P147, DOI 10.1111/j.1600-0404.1999.tb07336.x
NR 20
TC 9
Z9 9
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-9979
EI 1744-9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD DEC
PY 2008
VL 12
IS 6
BP 500
EP 504
DI 10.1111/j.1744-9987.2008.00641.x
PG 5
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Urology & Nephrology
GA 389PJ
UT WOS:000262106700008
PM 19140849
DA 2022-11-30
ER

PT J
AU Cho, YG
   Cao, XG
   Shen, DF
   Tuo, JS
   Parver, LM
   Rickles, FR
   Chan, CC
AF Cho, Youngeun
   Cao, Xiaoguang
   Shen, DeFen
   Tuo, Jingsheng
   Parver, Leonard M.
   Rickles, Frederick R.
   Chan, Chi-Chao
TI Evidence for enhanced tissue factor expression in age-related macular
   degeneration
SO LABORATORY INVESTIGATION
LA English
DT Article
DE age-related macular degeneration; inflammation; oxidative stress;
   retina; retinal pigment epithelium; tissue factor
ID CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL-CELLS; MOUSE MODEL; FACTOR
   GENE; ANGIOGENESIS; THROMBOSIS; DRUSEN; INFLAMMATION; DISEASE;
   IMMUNOTHERAPY
AB Tissue factor (TF) is the primary initiator of blood coagulation. In addition to hemostasis, TF can initiate intracellular signaling and promote inflammation and angiogenesis, the key processes underlying the pathogenesis of age-related macular degeneration (AMD). AMD, the leading cause of irreversible blindness among the elderly, involves many genetic and environmental risk factors, including oxidative stress and inflammation. In this study, TF expression was examined in human AMD tissue and in the eyes of a model of AMD, the Ccl2(-/-)/Cx3cr1(-/-) (DKO) mouse, as well as in the ARPE-19 cell line after lipopolysaccharide (LPS) and H2O2 stimulation. Total RNA was extracted from tissue samples and further analyzed by real-time RT-PCR. Immunohistochemistry was performed to evaluate TF protein expression. In the human retina, a 32-fold increase of TF mRNA expression was detected in AMD macular lesions compared with normal maculae. TF protein expression was also enhanced in human AMD maculae. Similarly, TF transcript and protein expression were moderately increased in retinal lesions, neuroretinal tissue, and cultured RPE cells of DKO mice compared with age-matched wild-type mice. TF expression level correlated with age in both wild-type and DKO mice. In order to better understand how AMD might lead to enhanced TF expression, 1, 5, and 10 mu g/ml LPS as well as 100 and 200 mu M H2O2 were used to stimulate ARPE-19 cells for 24 and 2 h, respectively. LPS treatment consistently increased TF transcript and protein expression. H2O2 alone or in combination with LPS also moderately enhanced TF expression. These results indicate that upregulated TF expression may be associated with AMD, and inflammatory and oxidative stress may contribute to TF expression in AMD eyes. Laboratory Investigation (2011) 91, 519-526; doi:10.1038/labinvest.2010.184; published online 1 November 2010
C1 [Cho, Youngeun; Cao, Xiaoguang; Shen, DeFen; Tuo, Jingsheng; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Cao, Xiaoguang] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100871, Peoples R China.
   [Parver, Leonard M.] Georgetown Univ, Sch Med, Dept Ophthalmol, Washington, DC USA.
   [Rickles, Frederick R.] George Washington Univ, Sch Med & Hlth Sci, Dept Med, Washington, DC 20052 USA.
   [Rickles, Frederick R.] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA.
   [Rickles, Frederick R.] George Washington Univ, Sch Med & Hlth Sci, Dept Physiol & Pharmacol, Washington, DC 20052 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Peking University; Georgetown University; George Washington
   University; George Washington University; George Washington University
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, 10 Ctr Dr,10-10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
OI Tuo, Jingsheng/0000-0002-1372-7810
FU National Eye Institute, National Institutes of Health; NATIONAL EYE
   INSTITUTE [ZIAEY000222, ZICEY000461] Funding Source: NIH RePORTER
FX This study was supported by the Intramural Research Program of the
   National Eye Institute, National Institutes of Health.
CR Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Belting M, 2005, ARTERIOSCL THROM VAS, V25, P1545, DOI 10.1161/01.ATV.0000171155.05809.bf
   Belting M, 2004, NAT MED, V10, P502, DOI 10.1038/nm1037
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   BRISSEAU GF, 1995, BLOOD, V85, P1025, DOI 10.1182/blood.V85.4.1025.bloodjournal8541025
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen J, 2001, THROMB HAEMOSTASIS, V86, P334
   Chiarugi V, 2000, ONCOL RES, V12, P1
   Chu AJ, 2006, CELL BIOCHEM FUNCT, V24, P173, DOI 10.1002/cbf.1200
   Chu AJ, 2006, FRONT BIOSCI-LANDMRK, V11, P256, DOI 10.2741/1796
   Chu AJ, 2005, ARCH BIOCHEM BIOPHYS, V440, P123, DOI 10.1016/j.abb.2005.06.005
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cunningham MA, 1999, BLOOD, V94, P3413, DOI 10.1182/blood.V94.10.3413.422k24_3413_3420
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   DRAKE TA, 1989, AM J PATHOL, V134, P1087
   DVORAK HF, 2006, HEMOSTASIS THROMBOSI, P851
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Mackman N, 1996, HAEMOSTASIS, V26, P17
   Mallat Z, 2001, CIRC RES, V88, P998, DOI 10.1161/hh1001.090571
   MESZAROS K, 1994, BLOOD, V83, P2516
   MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Norris LA, 2006, THROMB RES, V117, P475, DOI 10.1016/j.thromres.2005.03.009
   Oeth P, 1997, ARTERIOSCL THROM VAS, V17, P365, DOI 10.1161/01.ATV.17.2.365
   Panes O, 2007, BLOOD, V109, P5242, DOI 10.1182/blood-2006-06-030619
   Penn MS, 1999, CIRCULATION, V99, P1753, DOI 10.1161/01.CIR.99.13.1753
   Redecha P, 2007, BLOOD, V110, P2423, DOI 10.1182/blood-2007-01-070631
   Rickles FR, 2006, PATHOPHYSIOL HAEMO T, V35, P103, DOI 10.1159/000093551
   Stephens AC, 2008, THROMB RES, V122, P99, DOI 10.1016/j.thromres.2007.08.021
   Takano S, 2000, BRIT J CANCER, V82, P1967
   Tezel TH, 2007, OCUL IMMUNOL INFLAMM, V15, P3, DOI 10.1080/09273940601147760
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Verma V, 2008, CURR EYE RES, V33, P701, DOI 10.1080/02713680802236185
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591
   Cho Y, 2010, EXPERT REV OPHTHALMO, V5, P27, DOI 10.1586/EOP.09.58
   ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451
NR 40
TC 28
Z9 29
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD APR
PY 2011
VL 91
IS 4
BP 519
EP 526
DI 10.1038/labinvest.2010.184
PG 8
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 742JE
UT WOS:000288937400004
PM 21042291
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Spandau, UH
   Kamppeter, BA
   Vossmerbaeumer, U
   Harder, B
AF Jonas, Jost B.
   Spandau, Ulrich H.
   Kamppeter, Bernd A.
   Vossmerbaeumer, Urs
   Harder, Bjoern
TI Repeated intravitreal injection of triamcinolone for exudative
   age-related macular degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE intravitreal triamcinolone acetonide; intravitreal steroids; age-related
   macular degeneration; intraocular neovascularization; macular disease
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; SUBRETINAL
   NEOVASCULARIZATION; ACETONIDE; VERTEPORFIN; PREVALENCE; MACULOPATHY;
   RECURRENCE; STEROIDS
AB Background: Intravitreal triamcinolone acetonide has been discussed as treatment for exudative age-related macular degeneration (AMD). Objectives: To give an updated report on repeated intravitreal injections of triamcinolone acetonide (IVTA) for the treatment of exudative AMD. Methods: The case-series study included 24 patients ( 24 eyes) with progressive exudative AMD who had shown an increase in, or stabilization of, visual acuity after a first IVTA, and who eventually experienced a deterioration of visual acuity. The 24 (6.5%) eyes were selected out of a total group of 369 eyes who had received IVTA for exudative AMD within the last 5 years. All patients of the study received a second IVTA ( approximately 20 mg) 3.7-38.5 months after the first injection. Main outcome measure was visual acuity. Results: After the first injection, best corrected visual acuity improved significantly (p = 0.001) from 0.75 +/- 0.34 logMAR to a minimum of 0.58 +/- 0.30 logMAR during follow-up, with 10 (42%) eyes improving in visual acuity by two or more Snellen lines. Towards the end of follow-up after the first injection, best corrected visual acuity decreased significantly (p = 0.03) compared with the baseline value. After the second injection, visual acuity did not change markedly from baseline to a mean maximal visual acuity during follow-up. Comparing the last postoperative examination at the end of the follow-up after the second IVTA with the preoperative examination, a significantly (p = 0.001) higher number of eyes lost in visual acuity [19 (79%) eyes] than gained in visual acuity [3 (12%) eyes]. Conclusions: In selected eyes with an increase in visual acuity after a first IVTA (20 mg), repeated IVTA temporarily stabilizes visual acuity with a drop in visual acuity towards the end of follow-up. Copyright (c) 2006 S. Karger AG, Basel.
C1 Heidelberg Univ, Fac Clin Med Mannheim, Dept Ophthalmol, D-6900 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Heidelberg Univ, Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Arevalo JF, 2005, GRAEF ARCH CLIN EXP, V243, P1180, DOI 10.1007/s00417-005-1177-y
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Kaiser PK, 2005, CURR MED RES OPIN, V21, P705, DOI 10.1185/030079905X43659
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spandau UHM, 2005, AM J OPHTHALMOL, V139, P712, DOI 10.1016/j.ajo.2004.09.059
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 35
TC 7
Z9 8
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2006
VL 38
IS 6
BP 324
EP 328
DI 10.1159/000096226
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 101YA
UT WOS:000241776200003
PM 17047404
DA 2022-11-30
ER

PT J
AU Helgason, H
   Sulem, P
   Duvvari, MR
   Luo, HR
   Thorleifsson, G
   Stefansson, H
   Jonsdottir, I
   Masson, G
   Gudbjartsson, DF
   Walters, GB
   Magnusson, OT
   Kong, A
   Rafnar, T
   Kiemeney, LA
   Schoenmaker-Koller, FE
   Zhao, L
   Boon, CJF
   Song, YJ
   Fauser, S
   Pei, M
   Ristau, T
   Patel, S
   Liakopoulos, S
   van de Ven, JPH
   Hoyng, CB
   Ferreyra, H
   Duan, Y
   Bernstein, PS
   Geirsdottir, A
   Helgadottir, G
   Stefansson, E
   den Hollander, AI
   Zhang, K
   Jonasson, F
   Sigurdsson, H
   Thorsteinsdottir, U
   Stefansson, K
AF Helgason, Hannes
   Sulem, Patrick
   Duvvari, Maheswara R.
   Luo, Hongrong
   Thorleifsson, Gudmar
   Stefansson, Hreinn
   Jonsdottir, Ingileif
   Masson, Gisli
   Gudbjartsson, Daniel F.
   Walters, G. Bragi
   Magnusson, Olafur Th
   Kong, Augustine
   Rafnar, Thorunn
   Kiemeney, Lambertus A.
   Schoenmaker-Koller, Frederieke E.
   Zhao, Ling
   Boon, Camiel J. F.
   Song, Yaojun
   Fauser, Sascha
   Pei, Michelle
   Ristau, Tina
   Patel, Shirrina
   Liakopoulos, Sandra
   van de Ven, Johannes P. H.
   Hoyng, Carel B.
   Ferreyra, Henry
   Duan, Yaou
   Bernstein, Paul S.
   Geirsdottir, Asbjorg
   Helgadottir, Gudleif
   Stefansson, Einar
   den Hollander, Anneke I.
   Zhang, Kang
   Jonasson, Fridbert
   Sigurdsson, Haraldur
   Thorsteinsdottir, Unnur
   Stefansson, Kari
TI A rare nonsynonymous sequence variant in C3 is associated with high risk
   of age-related macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; CFH; MACULOPATHY; IMPUTATION; FRAMEWORK;
   DISEASES; LOCI
AB Through whole-genome sequencing of 2,230 Icelanders, we detected a rare nonsynonymous SNP (minor allele frequency = 0.55%) in the C3 gene encoding a p. Lys155Gln substitution in complement factor 3, which, following imputation into a set of Icelandic cases with age-related macular degeneration (AMD) and controls, associated with disease (odds ratio (OR) = 3.45; P = 1.1 x 10(-7)). This signal is independent of the previously reported common SNPs in C3 encoding p. Pro314Leu and p. Arg102Gly that associate with AMD. The association of p. Lys155Gln was replicated in AMD case-control samples of European ancestry with OR = 4.22 and P = 1.6 x 10-10, resulting in OR = 3.65 and P = 8.8 x 10-16 for all studies combined. In vitro studies have suggested that the p. Lys155Gln substitution reduces C3b binding to complement factor H, potentially creating resistance to inhibition by this factor. This resistance to inhibition in turn is predicted to result in enhanced complement activation.
C1 [Helgason, Hannes; Sulem, Patrick; Thorleifsson, Gudmar; Stefansson, Hreinn; Jonsdottir, Ingileif; Masson, Gisli; Gudbjartsson, Daniel F.; Walters, G. Bragi; Magnusson, Olafur Th; Kong, Augustine; Rafnar, Thorunn; Thorsteinsdottir, Unnur; Stefansson, Kari] deCODE Genet Amgen, Reykjavik, Iceland.
   [Helgason, Hannes; Gudbjartsson, Daniel F.; Kong, Augustine] Univ Iceland, Sch Engn & Nat Sci, Reykjavik, Iceland.
   [Duvvari, Maheswara R.; Schoenmaker-Koller, Frederieke E.; Boon, Camiel J. F.; van de Ven, Johannes P. H.; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Luo, Hongrong; Zhao, Ling; Song, Yaojun; Pei, Michelle; Patel, Shirrina; Ferreyra, Henry; Duan, Yaou; Zhang, Kang] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
   [Luo, Hongrong; Zhao, Ling; Song, Yaojun; Pei, Michelle; Patel, Shirrina; Ferreyra, Henry; Duan, Yaou; Zhang, Kang] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Luo, Hongrong; Duan, Yaou; Zhang, Kang] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu 610064, Peoples R China.
   [Luo, Hongrong; Duan, Yaou; Zhang, Kang] Sichuan Univ, West China Hosp, Mol Med Res Ctr, Chengdu 610064, Peoples R China.
   [Jonsdottir, Ingileif; Stefansson, Einar] Natl Univ Hosp Reykjavik, Dept Immunol, Reykjavik, Iceland.
   [Jonsdottir, Ingileif; Jonasson, Fridbert; Thorsteinsdottir, Unnur; Stefansson, Kari] Univ Iceland, Fac Med, Reykjavik, Iceland.
   [Kiemeney, Lambertus A.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, NL-6525 ED Nijmegen, Netherlands.
   [Kiemeney, Lambertus A.] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 ED Nijmegen, Netherlands.
   [Fauser, Sascha; Ristau, Tina; Liakopoulos, Sandra] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Bernstein, Paul S.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA.
   [Geirsdottir, Asbjorg; Helgadottir, Gudleif; Stefansson, Einar; Jonasson, Fridbert; Sigurdsson, Haraldur] Natl Univ Hosp Reykjavik, Dept Ophthalmol, Reykjavik, Iceland.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Inst Genet & Metab Dis, NL-6525 ED Nijmegen, Netherlands.
   [Zhang, Kang] Vet Affairs Healthcare Syst, San Diego, CA USA.
C3 University of Iceland; Radboud University Nijmegen; University of
   California System; University of California San Diego; University of
   California System; University of California San Diego; Sichuan
   University; Sichuan University; Landspitali National University
   Hospital; University of Iceland; Radboud University Nijmegen; Radboud
   University Nijmegen; University of Cologne; Utah System of Higher
   Education; University of Utah; Landspitali National University Hospital;
   Radboud University Nijmegen; Radboud University Nijmegen
RP Sulem, P (通讯作者)，deCODE Genet Amgen, Reykjavik, Iceland.
EM patrick.sulem@decode.is; kstefans@decode.is
RI luo, hongrong/B-2714-2015; Hoyng, C.B./H-8050-2014; Zhao,
   Ling/D-9005-2015; Stefansson, Kari/AAE-7187-2019; Hollander, Anneke
   den/N-4911-2014; Walters, G. Bragi/L-4215-2013; Jonasson,
   Fridbert/ABA-9889-2021; Zhang, Kang/Y-2740-2019; Kiemeney, Lambertus
   A./D-3357-2009; Boon, CJF/P-7534-2014
OI luo, hongrong/0000-0001-7994-1193; Walters, G.
   Bragi/0000-0002-5415-6487; Zhang, Kang/0000-0002-4549-1697; Kiemeney,
   Lambertus A./0000-0002-2368-1326; Stefansson,
   Hreinn/0000-0002-9331-6666; Gudbjartsson, Daniel/0000-0002-5222-9857;
   Kong, Augustine/0000-0001-8193-5438; Zhao, Ling/0000-0002-6644-2886;
   Boon, CJF/0000-0002-6737-7932
FU 973 program [2013CB967504]; National Science Foundation of China
   [81130017]; NEI/US National Institutes of Health; Veterans Affairs Merit
   Award; Netherlands Organization for Scientific Vidi Innovational
   Research Award [016.096.309]; Foundation Fighting Blindness
   [C-GE-0811-0548-RAD04]
FX The authors would like to thank the individuals who participated in the
   study and whose contributions made this work possible. We thank our
   valued colleagues who contributed to data collection, sample handling,
   genotyping and data analysis. H. L., Y.D. and K.Z. are supported in part
   by 973 program grant 2013CB967504, National Science Foundation of China
   grant 81130017, the NEI/US National Institutes of Health and a Veterans
   Affairs Merit Award. The Dutch replication study was supported by the
   Netherlands Organization for Scientific Vidi Innovational Research Award
   016.096.309 to A.J.d.H.) and the Foundation Fighting Blindness (grant
   C-GE-0811-0548-RAD04 to A.J.d.H.).
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Kong A, 2008, NAT GENET, V40, P1068, DOI 10.1038/ng.216
   Kong A, 2009, NATURE, V462, P868, DOI 10.1038/nature08625
   KUTYAVIN LV, 2006, NUCLEIC ACIDS RES, V34, pE128
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   MILLER E, 2012, NAT GENET, V40, P1307
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Tennessen JA, 2012, SCIENCE, V337, P64, DOI 10.1126/science.1219240
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   ZHAN X, 2013, NAT GENET, DOI DOI 10.1038/NG.2578
NR 22
TC 99
Z9 100
U1 1
U2 29
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD NOV
PY 2013
VL 45
IS 11
BP 1371
EP U153
DI 10.1038/ng.2740
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 244JL
UT WOS:000326384100019
PM 24036950
DA 2022-11-30
ER

PT J
AU Keenan, TDL
   Vanderford, EK
   de Silva, T
   Sieving, PA
   Cukras, CA
AF Keenan, Tiarnan D. L.
   Vanderford, Elliott K.
   de Silva, Tharindu
   Sieving, Paul A.
   Cukras, Catherine A.
TI MASSIVE ADVANCING NONEXUDATIVE TYPE 1 CHOROIDAL NEOVASCULARIZATION IN
   CTRP5 LATE-ONSET RETINAL DEGENERATION Longitudinal Findings on
   Multimodal Imaging and Implications for Age-Related Macular Degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE nonexudative choroidal neovascularization; CTRP5; late-onset retinal
   degeneration; age-related macular degeneration; indocyanine green
   angiography
ID ANTERIOR LENS ZONULES; PIGMENT-EPITHELIUM; CHORIOCAPILLARIS; INSIGHTS;
   DEPOSITS; GENE
AB Purpose: To describe longitudinal multimodal imaging findings of nonexudative choroidal neovascularization in CTRP5 late-onset retinal degeneration.
   Methods: Four patients with CTRP5-positive late-onset retinal degeneration underwent repeated ophthalmoscopic examination and multimodal imaging. All four patients (two siblings and their cousins, from a pedigree described previously) had the heterozygous S163R mutation.
   Results: All four patients demonstrated large subretinal lesions in the mid-peripheral retina of both eyes. The lesions were characterized by confluent hypercyanescence with hypocyanescent borders on indocyanine green angiography, faintly visible branching vascular networks with absent/minimal leakage on fluorescein angiography, Type 1 neovascularization on optical coherence tomography angiography, and absent retinal fluid, consistent with nonexudative choroidal neovascularization. The neovascular membranes enlarged substantially over time and the birth of new membranes was observed, but all lesions remained nonexudative/minimally exudative. Without treatment, all involved retinal areas remained free of atrophy and subretinal fibrosis.
   Conclusion: We report the existence of massive advancing nonexudative Type 1 choroidal neovascularization in CTRP5 late-onset retinal degeneration. These findings have implications for age-related macular degeneration. They provide a monogenic model system for studying the mechanisms underlying the distinct events of choroidal neovascularization development, enlargement, progression to exudation, and atrophy in age-related macular degeneration. They suggest that choroidal hypoperfusion precedes neovascularization and that nonexudative neovascularization may protect against atrophy.
C1 [Keenan, Tiarnan D. L.; Vanderford, Elliott K.; de Silva, Tharindu; Cukras, Catherine A.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Sieving, Paul A.] Univ Calif Davis, UC Davis Eye Ctr, Ctr Ocular Regenerat Therapy, Sacramento, CA 95817 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of California System; University of California Davis
RP Cukras, CA (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
EM cuk-rasc@nei.nih.gov
CR Ayyagari R, 2005, INVEST OPHTH VIS SCI, V46, P3363, DOI 10.1167/iovs.05-0159
   Ayyagari R, 2000, ARCH OPHTHALMOL-CHIC, V118, P85
   Borooah S, 2009, BRIT J OPHTHALMOL, V93, P284, DOI 10.1136/bjo.2008.150151
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Chekuri A, 2019, AGING CELL, V18, DOI 10.1111/acel.13011
   Chen L, 2020, OPHTHALMOLOGY
   Cukras C, 2016, RETINA-J RET VIT DIS, V36, P2348, DOI 10.1097/IAE.0000000000001113
   De Silva T, 2021, BIOMED OPT EXPRESS, V12, P619, DOI 10.1364/BOE.408573
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Hwang CK, 2021, OPHTHALMOL RETINA, V5, P108, DOI 10.1016/j.oret.2020.10.008
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Keiner CM, 2019, CLIN OPHTHALMOL, V13, P1613, DOI 10.2147/OPTH.S204344
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Laiginhas R, 2020, OPHTHALMOL RETINA, V4, P651, DOI 10.1016/j.oret.2020.02.016
   Mendrinos E, 2009, ACTA OPHTHALMOL, V87, P290, DOI 10.1111/j.1755-3768.2008.01247.x
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Subrayan V, 2005, AM J OPHTHALMOL, V140, P1127, DOI 10.1016/j.ajo.2005.06.023
   Vanderford EK, 2021, RETINA-J RET VIT DIS, V41, P1701, DOI 10.1097/IAE.0000000000003082
   Yamashiro K, 2020, J CLIN MED, P9
NR 30
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2021
VL 41
IS 11
BP 2236
EP 2245
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZB6BH
UT WOS:000756924700007
PM 33990119
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nashine, S
   Nesburn, AB
   Kuppermann, BD
   Kenney, MC
AF Nashine, Sonali
   Nesburn, Anthony B.
   Kuppermann, Baruch D.
   Kenney, M. Cristina
TI Age-related macular degeneration (AMD) mitochondria modulate epigenetic
   mechanisms in retinal pigment epithelial cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; AMD; Epigenetics; AMD mitochondria;
   Methylation; Acetylation
ID NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; VEGF RECEPTOR GENES; HISTONE
   DEACETYLASE; TRICHOSTATIN-A; DNA METHYLATION; DECITABINE
   5-AZA-2'-DEOXYCYTIDINE; DOWN-REGULATION; EXPRESSION; INHIBITION
AB Mitochondrial damage and epigenetic modifications have been implicated in the pathogenesis of Age-related Macular Degeneration (AMD). This study was designed to investigate the effects of AMD/normal mitochondria on epigenetic regulation in human transmitochondrial retinal pigment epithelial (RPE) cells in vitro. Human RPE cybrid cell lines were created by fusing mitochondria-deficient (Rho0) ARPE-19 cells with platelets obtained from either AMD patients (AMD cybrids) or normal subjects (normal cybrids). Therefore, all cybrids had identical nuclei (derived from ARPE-19 cells) but mitochondria derived from either AMD patients or age-matched normal subjects. AMD cybrids demonstrated increased RNA/protein levels for five methylation-related and four acetylation-related genes, along with lower levels of two methylation and three acetylation genes compared to normal cybrids. Demethylation using 5-Aza-2'-deoxycytidine (DAC) led to decreased expression of VEGF-A gene in AMD cells. Trichostatin A (TSA), an HDAC inhibitor, also influenced protein levels of VEGF-A, HIF1 alpha, NF kappa B, and CFH in AMD cells. Our findings suggest that retrograde signaling leads to mitochondria-nucleus interactions that influence the epigenetic status of the RPE cells and this may help in the identification of future potential therapeutic targets for AMD.
C1 [Nashine, Sonali; Nesburn, Anthony B.; Kuppermann, Baruch D.; Kenney, M. Cristina] Univ Calif Irvine, Dept Ophthalmol, Gavin Herbert Eye Inst, Irvine, CA USA.
   [Nesburn, Anthony B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA USA.
C3 University of California System; University of California Irvine; Cedars
   Sinai Medical Center; University of California System; University of
   California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Ophthalmol Res Lab, Gavin Herbert Eye Inst, Hewitt Hall,Room 2028,843 Hlth Sci Rd, Irvine, CA 92697 USA.
EM mkenney@uci.edu
RI NASHINE, SONALI/AAG-1474-2020
FU Arnold and Mabel Beckman Foundation; UCI School of Medicine, Institute
   of Clinical and Translational Science at UCI; Iris and B. Gerald Cantor
   Foundation; NEI [R01EY027363]; RPB; 2017 Genentech/ARVO AMD
   Translational Research Fellowship; 2016 RPB (Research to Prevent
   Blindness) pilot research grant; Discovery Eye Foundation; Wendy and Ken
   Ruby/Ruby Family Foundation; NATIONAL EYE INSTITUTE [R01EY027363]
   Funding Source: NIH RePORTER
FX This research work was supported by the 2017 Genentech/ARVO AMD
   Translational Research Fellowship (awarded to SN), the 2016 RPB
   (Research to Prevent Blindness) pilot research grant (awarded to SN),
   Arnold and Mabel Beckman Foundation, UCI School of Medicine, Institute
   of Clinical and Translational Science at UCI, Discovery Eye Foundation,
   Polly and Michael Smith, Iris and B. Gerald Cantor Foundation, Edith and
   Roy Carver, Wendy and Ken Ruby/Ruby Family Foundation, NEI R01EY027363
   grant, and departmental unrestricted grant from RPB.
CR ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481
   Ando T, 2000, LEUKEMIA, V14, P1915, DOI 10.1038/sj.leu.2401914
   Atilano SR, 2015, HUM MOL GENET, V24, P4491, DOI 10.1093/hmg/ddv173
   Bardai FH, 2011, J NEUROSCI, V31, P1746, DOI 10.1523/JNEUROSCI.5704-10.2011
   Bellizzi D, 2013, DNA RES, V20, P537, DOI 10.1093/dnares/dst029
   Bellizzi D, 2012, EPIGENOMICS-UK, V4, P17, DOI [10.2217/EPI.11.109, 10.2217/epi.11.109]
   Berner AK, 2016, ADV EXP MED BIOL, V854, P39, DOI 10.1007/978-3-319-17121-0_6
   Bhat RV, 2004, J NEUROCHEM, V89, P1313, DOI 10.1111/j.1471-4159.2004.02422.x
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Cedar H, 2012, ANNU REV BIOCHEM, V81, P97, DOI 10.1146/annurev-biochem-052610-091920
   Choudhury S, 2014, ADV EXP MED BIOL, V801, P455, DOI 10.1007/978-1-4614-3209-8_58
   Cyr AR, 2011, ANTIOXID REDOX SIGN, V15, P551, DOI 10.1089/ars.2010.3492
   Daly C, 2016, ADV EXP MED BIOL, V854, P455, DOI 10.1007/978-3-319-17121-0_61
   De Souza C, 2015, RECENT PAT ANTI-CANC, V10, P145
   Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110
   Durham B., 2012, BIOSCI HORIZ, V5, P1, DOI [10.1093/biohorizons/hzs003., DOI 10.1093/biohorizons/hzs003]
   Ea CK, 2009, P NATL ACAD SCI USA, V106, P18972, DOI 10.1073/pnas.0910439106
   Fan J, 2013, INVEST OPHTH VIS SCI, V54, P4072, DOI 10.1167/iovs.12-11529
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   FUTAMURA M, 1995, ONCOGENE, V10, P1119
   Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954
   Guan JS, 2009, NATURE, V459, P55, DOI 10.1038/nature07925
   Gutierrez H, 2011, TRENDS NEUROSCI, V34, P316, DOI 10.1016/j.tins.2011.03.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakami NY, 2016, J CELL MOL MED, V20, P1932, DOI 10.1111/jcmm.12885
   Hornan DM, 2007, INVEST OPHTH VIS SCI, V48, P5388, DOI 10.1167/iovs.07-0355
   HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248
   Hrebackova Jana, 2009, Interdiscip Toxicol, V2, P205, DOI 10.2478/v10102-009-0019-x
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Jiang N, 2015, INT J OPHTHALMOL-CHI, V8, P448, DOI 10.3980/j.issn.2222-3959.2015.03.03
   Jim Yeung S.-C., 2007, ADV MOL CELL ENDOCRI, V4, P117
   Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1
   Jin J, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0812-4
   Kaluza D, 2013, ARTERIOSCL THROM VAS, V33, P533, DOI 10.1161/ATVBAHA.112.300415
   Kang FW, 2012, ONCOL REP, V28, P193, DOI 10.3892/or.2012.1784
   Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200
   Karahoca M, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-3
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Kim CH, 2017, BIOCHEM BIOPH RES CO, V482, P735, DOI 10.1016/j.bbrc.2016.11.103
   Kim JY, 2009, EPIGENETICS-US, V4, P313, DOI 10.4161/epi.4.5.9160
   Kim J, 2012, EPIGENETICS-US, V7, P191, DOI 10.4161/epi.7.2.18973
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Kowluru RA, 2017, FREE RADICAL BIO MED, V103, P155, DOI 10.1016/j.freeradbiomed.2016.12.030
   Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li Y, 2018, EXP EYE RES, V174, P98, DOI 10.1016/j.exer.2018.05.027
   Liao J, 2015, NAT GENET, V47, P469, DOI 10.1038/ng.3258
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lobera M, 2013, NAT CHEM BIOL, V9, P319, DOI [10.1038/NCHEMBIO.1223, 10.1038/nchembio.1223]
   Lores-Motta L, 2018, JAMA OPHTHALMOL, V136, P875, DOI 10.1001/jamaophthalmol.2018.2019
   Lu T, 2015, CANCER RES, V75, P3692, DOI 10.1158/0008-5472.CAN-15-1022
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   McQuown SC, 2011, J NEUROSCI, V31, P764, DOI 10.1523/JNEUROSCI.5052-10.2011
   Miki K, 2000, ONCOL RES, V12, P335, DOI 10.3727/096504001108747783
   Nashine S, 2019, AGING-US, V11, P1177, DOI 10.18632/aging.101820
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Nashine S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063205
   Nasonkin IO, 2011, J COMP NEUROL, V519, P1914, DOI 10.1002/cne.22613
   Oehme I, 2013, P NATL ACAD SCI USA, V110, pE2592, DOI 10.1073/pnas.1300113110
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Ouyang H, 2012, J BIOL CHEM, V287, P2317, DOI 10.1074/jbc.M111.273730
   Palii CG, 2014, CELL STEM CELL, V14, P644, DOI 10.1016/j.stem.2014.03.003
   Pennington KL, 2015, J EXP NEUROSCI, V9, P51, DOI 10.4137/JEN.S25513
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Pisani F, 2018, J CELL MOL MED, V22, P613, DOI 10.1111/jcmm.13348
   Place RF, 2005, BIOCHEM PHARMACOL, V70, P394, DOI 10.1016/j.bcp.2005.04.030
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833
   Pozniak PD, 2014, J NEUROIMMUNE PHARM, V9, P133, DOI 10.1007/s11481-013-9517-x
   Quentmeier H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-19
   Rai K, 2006, MOL CELL BIOL, V26, P7077, DOI 10.1128/MCB.00312-06
   Rai K, 2010, J BIOL CHEM, V285, P4110, DOI 10.1074/jbc.M109.073676
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rhee KD, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.165
   Rogstad DK, 2009, CHEM RES TOXICOL, V22, P1194, DOI 10.1021/tx900131u
   Rombouts K, 2002, J HEPATOL, V37, P788, DOI 10.1016/S0168-8278(02)00275-1
   Salminen A, 2008, CELL MOL LIFE SCI, V65, P1049, DOI 10.1007/s00018-008-7461-3
   Sawa Hiroki, 2002, Brain Tumor Pathol, V19, P77, DOI 10.1007/BF02478931
   SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x
   Schwartsmann G, 1997, LEUKEMIA, V11, pS28
   SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960
   Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744
   Spencer NFL, 1997, INT IMMUNOL, V9, P1581, DOI 10.1093/intimm/9.10.1581
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stirban A, 2014, MOL METAB, V3, P94, DOI 10.1016/j.molmet.2013.11.006
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thaker K, 2016, NEUROBIOL DIS, V93, P64, DOI 10.1016/j.nbd.2016.04.005
   Trivedi MS, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00444
   TSUJI N, 1976, J ANTIBIOT, V29, P1, DOI 10.7164/antibiotics.29.1
   Turunen MP, 2011, CARDIOVASC RES, V90, P441, DOI 10.1093/cvr/cvr109
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Villagra A, 2009, NAT IMMUNOL, V10, P92, DOI 10.1038/ni.1673
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wu TH, 2002, INVEST OPHTH VIS SCI, V43, P2834
   Xie MY, 2014, MOL VIS, V20, P1411
   Yang JD, 2011, J KOREAN MED SCI, V26, P1428, DOI 10.3346/jkms.2011.26.11.1428
   Yang QC, 2006, J EXP CLIN CANC RES, V25, P593
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   YOSHIDA M, 1990, J ANTIBIOT, V43, P1101, DOI 10.7164/antibiotics.43.1101
   Zeng HY, 2008, MOL VIS, V14, P1075
   Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928
NR 106
TC 14
Z9 14
U1 3
U2 21
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2019
VL 189
AR 107701
DI 10.1016/j.exer.2019.107701
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JU0SW
UT WOS:000501390500017
PM 31226340
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tan, CS
   Ngo, WK
   Lim, LW
   Tan, NW
   Lim, TH
AF Tan, Colin S.
   Ngo, Wei K.
   Lim, Louis W.
   Tan, Nikolle W.
   Lim, Tock H.
TI EVEREST study report 4: Fluorescein angiography features predictive of
   polypoidal choroidal vasculopathy
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE EVEREST; fluorescein angiography; neovascular age-related macular
   degeneration; polypoidal choroidal vasculopathy; ranibizumab
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION;
   NEOVASCULARIZATION; RANIBIZUMAB; PREVALENCE; FREQUENCY; EFFICACY; SAFETY
AB Importance It is important to identify features of polypoidal choroidal vasculopathy (PCV) that differentiate it from typical neovascular age-related macular degeneration (nAMD) on various imaging modalities, including fluorescein angiography (FA). Background PCV was thought to be indistinguishable from nAMD using FA alone. In real-world practice, indocyanine-green angiography may often be unavailable or contraindicated. Design Analysis of FA images from a prospective, multicentre study. Participants Study images of both PCV and nAMD patients from the EVEREST study. Methods FA features at baseline were independently graded by masked graders (fellowship-trained ophthalmologists) using standardized diagnostic algorithms. Main Outcome Measures Predictive indicators (sensitivity, specificity, positive and negative predictive values) for PCV. Results Of the 95 patients screened, 61 had PCV. Of the 34 screening failures, 15 were diagnosed as nAMD. Hyperfluorescent nodules on FA were observed in 80% of patients with PCV vs 20% with nAMD (P < 0.001). Blocked fluorescence on FA, which corresponded to the presence of subretinal haemorrhage, occurred more frequently among patients with PCV vs nAMD (61.7% vs 13.3%, P = 0.001). Similarly, the leakage characteristic of occult choroidal neovascularization occurred more frequently among patients with PCV vs nAMD (95.0% vs 73.3%, P = 0.026). The positive predictive value for PCV was 94.1% for hyperfluorescent nodules, 94.9% for blocked fluorescence, 83.8% for occult choroidal neovascularization and 82.0% for pigment epithelial detachment. Conclusions and Relevance This study demonstrated that certain FA features can be predictive of PCV and may be considered as an indication for retina specialists to perform indocyanine green angiography as confirmatory test.
C1 [Tan, Colin S.; Lim, Tock H.] Natl Healthcare Grp Eye Inst, Fundus Image Reading Ctr, Singapore, Singapore.
   [Tan, Colin S.; Ngo, Wei K.; Lim, Louis W.; Tan, Nikolle W.; Lim, Tock H.] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
C3 Tan Tock Seng Hospital
RP Tan, CS (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
EM colintan_eye@yahoo.com.sg
RI Tan, Nikolle/GXH-5775-2022; Tan, Colin S/K-8972-2012
OI Tan, Colin S/0000-0003-3088-5690
FU Norvatis Pharma AG
FX Norvatis Pharma AG
CR [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   ClinicalTrials. gov, EFF SAF VERT ADD RAN
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Iranmanesh R, 2007, EUR J OPHTHALMOL, V17, P75, DOI 10.1177/112067210701700111
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Maruko I, 2010, GRAEF ARCH CLIN EXP, V248, P361, DOI 10.1007/s00417-009-1276-2
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
NR 25
TC 6
Z9 6
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2019
VL 47
IS 5
BP 614
EP 620
DI 10.1111/ceo.13464
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA II9GP
UT WOS:000475504600007
PM 30652395
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Asikgarip, N
   Temel, E
   Ornek, K
AF Asikgarip, Nazife
   Temel, Emine
   Ornek, Kemal
TI Macular ganglion cell complex changes in eyes treated with aflibercept
   for neovascular age-related macular degeneration
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Macular ganglion cell complex; Neovascular age-related macular
   degeneration; Aflibercept injection; Optical coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR; INNER PLEXIFORM LAYER; BEVACIZUMAB;
   RANIBIZUMAB; INJECTIONS
AB Background: To evaluate the effect of intravitreal aflibercept injection on macular ganglion cell complex (GCC) in patients with neovascular age-related macular degeneration (nAMD). Methods: In total, 36 eyes of 36 treatment-naive patients with nAMD (18 female and 18 male) and 36 eyes of 36 healthy subjects (20 female and 16 male) as controls were included in this retrospective study. Spectral-domain optical coherence tomography images were evaluated after each injection for 3 months and at 12 months. Mean GCC thickness of the center, inner ring, and outer ring of the ETDRS grid was automatically quantified. Results: Mean foveal thickness was statistically significantly decreased at 3 months and at 12 months compared with baseline in the patient group. Ganglion cell layer thickness in the center was statistically significantly decreased in eyes with nAMD at baseline. There was a statistically significant decrease for mean retinal nerve fiber layer, ganglion cell layer, and inner plexiform layer thickness at 12 months compared with baseline. Conclusions: Macular GCC thickness was decreased after intravitreal aflibercept injection in patients with nAMD, in particular at 12 months.
C1 [Asikgarip, Nazife; Temel, Emine] Kirsehir Ahi Evran Training & Res Hosp, Dept Opthalmol, Kirsehir, Turkey.
   [Ornek, Kemal] Kirsehir Ahi Evran Univ, Dept Opthalmol, Sch Med, Kirsehir, Turkey.
C3 Ahi Evran University; Ahi Evran University
RP Temel, E (通讯作者)，Kirsehir Ahi Evran Training & Res Hosp, Dept Opthalmol, Kirsehir, Turkey.
EM emine912@hotmail.com
RI Örnek, Kemal/AFL-3613-2022
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Brar VS, 2010, MOL VIS, V16, P1848
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Cheng CK, 2009, RETINA-J RET VIT DIS, V29, P306, DOI 10.1097/IAE.0b013e3181909404
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   Entezari Morteza, 2014, J Ophthalmic Vis Res, V9, P449, DOI 10.4103/2008-322X.150815
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Jeganathan VSE, 2009, CURR OPIN OPHTHALMOL, V20, P223, DOI 10.1097/ICU.0b013e328329b656
   Kim KS, 2008, ACTA OPHTHALMOL, V86, DOI 10.1111/j.1755-3768.2008.01175.x
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee Ji Min, 2017, Korean J Ophthalmol, V31, P360, DOI 10.3341/kjo.2017.0054
   Lee WJ, 2017, J GLAUCOMA, V26, P980, DOI 10.1097/IJG.0000000000000776
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666
   Zinkernagel MS, 2015, INVEST OPHTH VIS SCI, V56, P1894, DOI 10.1167/iovs.14-16204
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 21
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2021
VL 35
AR 102383
DI 10.1016/j.pdpdt.2021.102383
EA JUN 2021
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UO8BE
UT WOS:000694915500013
PM 34102332
DA 2022-11-30
ER

PT J
AU Mete, A
   Saygili, O
   Mete, A
   Gungor, K
   Bayram, M
   Bekir, N
AF Mete, Ahmet
   Saygili, Oguzhan
   Mete, Alper
   Gungor, Kivanc
   Bayram, Metin
   Bekir, Necdet
TI Does Ranibizumab (Lucentis (R)) Change Retrobulbar Blood Flow in
   Patients with Neovascular Age-Related Macular Degeneration?
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Color Doppler imaging; Intravitreal ranibizumab; Neovascular age-related
   macular degeneration; Retrobulbar blood flow
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; DOPPLER
   ULTRASONOGRAPHY; HEMODYNAMICS; ORBIT; RESOLUTION; VELOCITY; SURGERY; EYE
AB Purpose: To investigate the effects of intravitreal ranibizumab on retrobul bar blood flow in patients with neovascular age-related macular degeneration (AMD). Methods: Thirty-one eyes of 30 patients with neovascular AMD were examined prospectively by both color Doppler imaging and fundus fluorescein angiography. Color Doppler imaging was used to measure the maximum and minimum velocities of the central retinal vein, peak systolic/end-diastolic velocities of blood flows, and pulsatility index and resistivity index values in the central retinal artery, nasal/temporal posterior ciliary arteries (NPCA/TPCA) and ophthalmic artery. The t test for paired samples was used for comparing retrobulbar blood flow values before and after intravitreal ranibizumab (Lucentis (R)) injection in the study and control groups. Results:There was a statistically significant (p < 0.05) difference between the pre-injection and post-injection end-diastolic velocities of the NPCA and TPCA and resistivity index values of TPCA. The other parameters showed no statistically significant difference. Conclusion: Our results show that intravitreal ranibizumab injection increases retrobulbar blood flow. Copyright (C) 2011 S. Karger AG, Basel
C1 [Mete, Ahmet; Bayram, Metin] Gaziantep Univ, Dept Radiol, Sch Med, TR-27310 Sahinbey, Gaziantep, Turkey.
   [Saygili, Oguzhan; Mete, Alper; Gungor, Kivanc; Bekir, Necdet] Gaziantep Univ, Dept Ophtalmol, Sch Med, TR-27310 Sahinbey, Gaziantep, Turkey.
C3 Gaziantep University; Gaziantep University
RP Mete, A (通讯作者)，Gaziantep Univ, Dept Radiol, Sch Med, TR-27310 Sahinbey, Gaziantep, Turkey.
EM dr.meteahmet@gmail.com; dr.meteahmet@gmail.com
RI Gungor, Kivanc/AAH-5406-2020; Bekir, Necdet/AAH-5385-2020; Mete,
   Alper/AAH-7332-2020
OI Bekir, Necdet/0000-0002-6755-2550; Mete, Alper/0000-0002-1712-5163
CR Akyuz Unsal AI, 2007, J AAPOS, V11, P277, DOI 10.1016/j.jaapos.2006.12.059
   Augustin Albert J, 2006, Expert Opin Emerg Drugs, V11, P725, DOI 10.1517/14728214.11.4.725
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Cekic Osman, 2007, International Ophthalmology, V27, P313, DOI 10.1007/s10792-007-9080-7
   ERICKSON SJ, 1989, RADIOLOGY, V173, P511, DOI 10.1148/radiology.173.2.2678264
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Grunwald JE, 1996, BRIT J OPHTHALMOL, V80, P327, DOI 10.1136/bjo.80.4.327
   GUTHOFF RF, 1991, ARCH OPHTHALMOL-CHIC, V109, P532, DOI 10.1001/archopht.1991.01080040100037
   HANSEN NB, 1983, PEDIATRICS, V72, P526
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Koz OG, 2007, ACTA OPHTHALMOL SCAN, V85, P838, DOI 10.1111/j.1600-0420.2007.00960.x
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   Mariampillai A, 2007, OPT EXPRESS, V15, P1627, DOI 10.1364/OE.15.001627
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   SANTOS L, 1994, GRAEF ARCH CLIN EXP, V232, P666, DOI 10.1007/BF00171381
   Tosun O, 2007, ACTA RADIOL, V48, P763, DOI 10.1080/02841850701348713
   Wang YM, 2009, OPT EXPRESS, V17, P4061, DOI 10.1364/OE.17.004061
   Wang YM, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2998480
   Williamson TH, 1996, SURV OPHTHALMOL, V40, P255, DOI 10.1016/S0039-6257(96)82001-7
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
NR 25
TC 10
Z9 13
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2012
VL 47
IS 3
BP 141
EP 145
DI 10.1159/000330509
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 917TW
UT WOS:000302202500005
PM 22042133
DA 2022-11-30
ER

PT J
AU Cougnard-Gregoire, A
   Merle, BMJ
   Korobelnik, JF
   Rougier, MB
   Delyfer, MN
   Le Goff, M
   Samieri, C
   Dartigues, JF
   Delcourt, C
AF Cougnard-Gregoire, Audrey
   Merle, Benedicte M. J.
   Korobelnik, Jean-Francois
   Rougier, Marie-Benedicte
   Delyfer, Marie-Noelle
   Le Goff, Melanie
   Samieri, Cecilia
   Dartigues, Jean-Francois
   Delcourt, Cecile
TI Olive Oil Consumption and Age-Related Macular Degeneration: The Alienor
   Study
SO PLOS ONE
LA English
DT Article
ID PLASMA EICOSAPENTAENOIC ACID; DIETARY-FAT; MEDITERRANEAN DIET;
   DEPRESSIVE SYMPTOMATOLOGY; GENETIC SUSCEPTIBILITY; 10-YEAR INCIDENCE;
   BORDEAUX SAMPLE; EYE DISEASE; RISK; MACULOPATHY
AB Background
   Olive oil provides a mixture of lipids and antioxidant nutrients which may help preventing age-related diseases such as age-related macular degeneration (AMD). However, little is known about the associations between olive oil consumption and the risk of AMD.
   Objective
   To examine associations between olive oil use and AMD prevalence in elderly subjects.
   Methods
   Alienor (Antioxydants, Lipides Essentiels, Nutrition et maladies OculaiRes) is a populationbased study on eye diseases performed in elderly residents of Bordeaux (France). In 1999-2000, frequencies of consumption of main categories of dietary fats used were collected. In 2006-2088, AMD was graded from non mydriatic retinal photographs into three exclusive stages: no AMD, early AMD, and late AMD. Two categories of preferred dietary fat used (olive oil, n-3 rich oils, n-6 rich oils, mixed oils, butter and margarine) were defined: "no use" and "regular use" (using fat for spreading and/or cooking and/or dressing). Associations of AMD with each fat use were estimated using Generalized Estimating Equation logistic regressions models.
   Results
   Our study included 654 subjects (1269 eyes) with complete data (n = 268 eyes with early AMD and n = 56 with late AMD). After adjustment for potential confounders, regular use of olive oil was significantly associated with a decreased risk of late AMD (odds ratio [OR] = 0.44, 95% confidence interval [CI]: 0.21; 0.91). In contrast, regular use of olive oil was not significantly associated with early AMD (OR = 0.84, 95% CI: 0.59; 1.21). No associations were found between regular consumption of n-3 rich oils, n-6 rich oils, mixed oils, butter and margarine and AMD, whatever the stage.
   Conclusions
   This study suggests a protective effect of olive oil consumption for late AMD in this elderly community-dwelling population. Characterization of the mediating nutrients deserves further research.
C1 [Cougnard-Gregoire, Audrey; Merle, Benedicte M. J.; Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Delyfer, Marie-Noelle; Le Goff, Melanie; Samieri, Cecilia; Dartigues, Jean-Francois; Delcourt, Cecile] Univ Bordeaux, ISPED, F-33000 Bordeaux, France.
   [Cougnard-Gregoire, Audrey; Merle, Benedicte M. J.; Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Delyfer, Marie-Noelle; Le Goff, Melanie; Samieri, Cecilia; Dartigues, Jean-Francois; Delcourt, Cecile] Inserm U1219 Bordeaux Populat Hlth Res Ctr, F-33000 Bordeaux, France.
   [Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Delyfer, Marie-Noelle] CHU Bordeaux, Serv Ophtalmol, F-33000 Bordeaux, France.
C3 UDICE-French Research Universities; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); CHU Bordeaux
RP Cougnard-Gregoire, A (通讯作者)，Univ Bordeaux, ISPED, F-33000 Bordeaux, France.; Cougnard-Gregoire, A (通讯作者)，Inserm U1219 Bordeaux Populat Hlth Res Ctr, F-33000 Bordeaux, France.
EM Audrey.Cougnard-Gregoire@isped.fr
RI Samieri, Cecilia/T-3267-2019; Delcourt, Cecile/I-2627-2013; Merle,
   Benedicte MJ/AAQ-5021-2021; Merle, Benedicte MJ/F-1247-2015; KOROBELNIK,
   Jean-Francois/A-5448-2016; COUGNARD-GREGOIRE, Audrey/T-4443-2019;
   Delyfer, Marie-Noelle/T-3304-2019; Samieri, Cécilia/E-3334-2014;
   DARTIGUES, Jean François/T-4513-2019; LE GOFF, Mélanie/A-3541-2016
OI Samieri, Cecilia/0000-0001-9809-7506; Delcourt,
   Cecile/0000-0002-2099-0481; Merle, Benedicte MJ/0000-0003-1332-0954;
   Merle, Benedicte MJ/0000-0003-1332-0954; COUGNARD-GREGOIRE,
   Audrey/0000-0002-1494-5764; Samieri, Cécilia/0000-0001-9809-7506; LE
   GOFF, Melanie/0000-0003-2848-6287
FU Laboratoires Thea (Clermont-Ferrand, France); Fondation Voir et Entendre
   (Paris, France); Caisse Nationale de Solidarite pour l'Autonomie CNSA
   (CNSA)
FX This study received financial support from Laboratoires Thea
   (Clermont-Ferrand, France); Fondation Voir et Entendre (Paris, France);
   Caisse Nationale de Solidarite pour l'Autonomie CNSA (CNSA).
   Laboratoires Thea participated in the design of the study, but none of
   the sponsors participated in the collection, management, statistical
   analysis and interpretation of the data, nor in the preparation, review
   or approval of the present manuscript.
CR Agostoni C, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2033
   Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Barberger-Gateau P, 2007, NEUROLOGY, V69, P1921, DOI 10.1212/01.wnl.0000278116.37320.52
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Buckland G, 2012, BRIT J NUTR, V108, P2075, DOI 10.1017/S000711451200298X
   Buckland G, 2012, AM J CLIN NUTR, V96, P142, DOI 10.3945/ajcn.111.024216
   Bulotta S, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0219-9
   Castaner O, 2012, AM J CLIN NUTR, V95, P1238, DOI 10.3945/ajcn.111.029207
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Cicerale S, 2010, INT J MOL SCI, V11, P458, DOI 10.3390/ijms11020458
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2011, INVEST OPHTH VIS SCI, DOI [10.11673443.10-6235, DOI 10.1167/IOVS910-6235]
   Delcourt C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1077, DOI 10.1001/archophthalmol.2012.420
   Feart C, 2008, AM J CLIN NUTR, V87, P1156, DOI 10.1093/ajcn/87.5.1156
   Feart C, 2007, BRIT J NUTR, V98, P1046, DOI 10.1017/S0007114507756520
   Feart C, 2013, P NUTR SOC, V72, P140, DOI 10.1017/S0029665112002959
   Feart C, 2009, JAMA-J AM MED ASSOC, V302, P638, DOI 10.1001/jama.2009.1146
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Guasch-Ferre M, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-78
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Larrieu S, 2004, J Nutr Health Aging, V8, P497
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Martin-Pelaez S, 2013, MOL NUTR FOOD RES, V57, P760, DOI 10.1002/mnfr.201200421
   Martinez-Gonzalez MA, 2014, BRIT J NUTR, V112, P248, DOI 10.1017/S0007114514000713
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Ollivier D, 2003, J AGR FOOD CHEM, V51, P5723, DOI 10.1021/jf034365p
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Parkinson L, 2014, INT J MOL SCI, V15, P12323, DOI 10.3390/ijms150712323
   Pelletier A, 2015, ALZHEIMERS DEMENT, V11, P1023, DOI 10.1016/j.jalz.2015.06.1888
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Samieri C, 2011, NEUROLOGY, V77, P418, DOI 10.1212/WNL.0b013e318220abeb
   Samieri C, 2008, AM J CLIN NUTR, V88, P714, DOI 10.1093/ajcn/88.3.714
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schleicher M, 2013, NUTRIENTS, V5, P2405, DOI 10.3390/nu5072405
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
   Zhu L, 2010, J NUTR BIOCHEM, V21, P1089, DOI 10.1016/j.jnutbio.2009.09.006
NR 63
TC 22
Z9 22
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 28
PY 2016
VL 11
IS 7
AR e0160240
DI 10.1371/journal.pone.0160240
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DT5IL
UT WOS:000381516100137
PM 27467382
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Moorthy, S
   Cheung, N
   Klein, R
   Shahar, E
   Wong, TY
AF Moorthy, Sonia
   Cheung, Ning
   Klein, Ronald
   Shahar, Eyal
   Wong, Tien Y.
TI Are Lung Disease and Function Related to Age-Related Macular
   Degeneration?
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; ATHEROSCLEROSIS RISK; 10-YEAR INCIDENCE; MEDICAL
   PROGRESS; MACULOPATHY; INFLAMMATION; SMOKING
AB PURPOSE: To describe the relationship of lung disease and function with early age-related macular degeneration (AMD) in a population-based study.
   DESIGN: A population-based, cross-sectional study of 12 596 middle-aged participants from the Atherosclerosis Risk in Communities Study. "
   METHODS: Lung function was assessed by spirometry. Physician diagnosis of asthma and lung disease was ascertained from a standardized questionnaire. AMD signs were graded from fundus photographs according to the Wisconsin grading protocol.
   RESULTS: Among the study population, 587 (4.7%) had early AMD, 638 (5.1%) had asthma, and 581 (4.6%) had lung disease. After adjusting for age, gender, smoking, and hypertension, each 1-L increase in predicted forced expiratory volume in 1 second (odds ratio [OR], 1.27; 95% confidence interval [CI], 0.89 to 1.80), forced vital capacity (OR, 1.18; 95% CI, 0.93 to 1.51), and peak expiratory flow rate (OR, 1.12; 95% CI, 0.95 to 1.33) were not significantly associated with early AMD. Forced expiratory volume in 1 second-to-forced vital capacity ratio (second quartile OR, 1.61; 95% Cl, 0.88 to 2.93, third quartile OR, 1.65; 95% CI 0.90 to 3.03; fourth quartile OR, 1.28; 95% CI 0.68 to 2.40) was not associated significantly with early AMD. Similarly, asthma (OR, 1.06; 95% CI, 0.86 to 1.27) and other lung diseases (OR, 1.08; 95% CI, 0.90 to 1.29) were not associated with early AMD.
   CONCLUSIONS: Our data do not support a cross-sectional association between lung disease and risk of early AMD. (Am J Ophthalmol 2011;151;375-379. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Moorthy, Sonia; Cheung, Ning; Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   [Shahar, Eyal] Univ Arizona, Div Epidemiol & Biostat, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Wisconsin System; University of Wisconsin Madison; University of
   Arizona; National University of Singapore; Singapore National Eye Center
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Cheung, Ning Danny/F-2043-2013
OI Wong, Tien Yin/0000-0002-8448-1264; Klein, Ronald/0000-0002-4428-6237
FU National Heart, Lung, and Blood Institute, National Institutes of
   Health, Bethesda, Maryland [N01-HC-55015, N01-HC-55016, N01-HC-55018,
   N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022]; DIVISION OF
   EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055021, N01HC055018,
   N01HC055019, N01HC055020, N01HC055015, N01HC055022, N01HC055016] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R41HL055019, R42HL055018, R21HL077166, R41HL055018] Funding Source: NIH
   RePORTER
FX THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY (ARIC) IS CARRIED OUT AS A
   COLLABORATIVE STUDY SUPPORTED BY Contracts N01-HC-55015, N01-HC-55016,
   N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022
   from the National Heart, Lung, and Blood Institute, National Institutes
   of Health, Bethesda, Maryland. The authors indicate no financial
   conflict of interest. Involved in Concept and design (N.C., T.Y.W.);
   Data collection (S.M., N.C.); Provision of materials, patients, or
   resources (N.C., T.Y.W.); Statistical expertise (S.M., N.C., R.K., E.S.,
   T.Y.W.); Analysis and interpretation of data (S.M., N.C., R.K., E.S.,
   T.Y.W.); Obtaining funding (N.C., T.Y.W.); Literature search (S.M.,
   N.C.); Administrative, technical, or logistic support (N.C., T.Y.W.);
   Writing the article (S.M., N.C., R.K., E.S., T.Y.W.); Critical revision
   of the article (S.M., N.C., R.K., E.S., T.Y.W.); and Final approval of
   the article (S.M., N.C., R.K., E.S., T.Y.W.). Institutional review
   boards at each study site approved the study. Written informed consent
   was obtained from all participants at each examination. The study was
   performed adhering to tenets of Declaration of Helsinki. Further details
   on study procedures and protocols, investigators, study sites, and
   queries can be found on the website
   http://www.cscc.unc.edu/aric/index.php. The authors thank the staff and
   participants of the ARIC study for their important contributions.
CR [Anonymous], 1979, AM REV RESPIR DIS, V119, P831
   [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202
   Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Cheung N, 2007, BRIT J OPHTHALMOL, V91, P430, DOI 10.1136/bjo.2006.106054
   CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659
   DELANEY WV, 1982, ANN OPHTHALMOL, V14, P21
   FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1
   Fogarty AW, 2007, THORAX, V62, P515, DOI 10.1136/thx.2006.066969
   GOLD, GLOB STRAT DIAGN MAN
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2005, AM J OPHTHALMOL, V140, P129, DOI 10.1016/j.ajo.2004.12.049
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P840, DOI 10.1001/archopht.126.6.840
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P472, DOI 10.1001/archophthalmol.2010.25
   MCGOWAN SE, 1989, NEW ENGL J MED, V321, P968, DOI 10.1056/NEJM198910053211410
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   NIEWOEHNER DE, 1988, J LAB CLIN MED, V111, P15
   Schroeder EB, 2003, AM J EPIDEMIOL, V158, P1171, DOI 10.1093/aje/kwg276
   SHAHAR E, 1994, NEW ENGL J MED, V331, P228, DOI 10.1056/NEJM199407283310403
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 31
TC 8
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2011
VL 151
IS 2
BP 375
EP 379
DI 10.1016/j.ajo.2010.09.001
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 712ZX
UT WOS:000286705900027
PM 21168814
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Scott, IU
   Feuer, WJ
   Jacko, JA
AF Scott, IU
   Feuer, WJ
   Jacko, JA
TI Impact of visual function on computer task accuracy and reaction time in
   a cohort of patients with age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VITREORETINAL SURGERY OUTCOMES; CONTRAST SENSITIVITY;
   CATARACT-SURGERY; LOW-VISION; UTILITY VALUES; IMPAIRMENT; DISABILITY;
   PERCEPTIONS; PERFORMANCE
AB Purpose: To investigate the impact of visual function parameters on computer task performance in patients with age,related macular degeneration (AMD).
   Design: Interventional case series.
   Methods: Eighteen patients with visual impairment due to age,related macular degeneration underwent evaluation of visual acuity using the Early Treatment Diabetic Retinopathy Study protocol, contrast sensitivity using a Pelli-Robson chart, binocular simultaneous visual field using the Esterman program on an automated perimeter, and color vision using Farnsworth D-15. Each subject then completed 125 computer icon identification tasks. Relationships be. tween computer task performance (accuracy and speed) and visual function parameters (visual acuity, contrast sensitivity, visual field, and color vision) were analyzed.
   Results: Visual acuity and contrast sensitivity in the better eye, weighted average contrast sensitivity, and color vision defects are significantly associated with computer task accuracy. Visual acuity in the better eye, weighted average visual acuity, and color vision defects are significantly associated with performance speed. Visual function parameters and clinical features significantly associated with computer task accuracy in a multiple regression model include weighted average contrast sensitivity (P=0.001), protan color vision defect (P=0.002), cataract severity in the better,seeing eye (P=0.036), and geographic atrophy outside the central macula (P=0.046). Visual function parameters and clinical features significantly associated with computer task speed in a multiple regression model include color vision defects (deutan, P<0.001; protan, P<0.001) and gender (P=0.05).
   Conclusions: Among this cohort of patients with AMD, visual acuity, contrast sensitivity, and color vision defects are significant predictors of computer task performance. Visual function parameters of the better eye played a more significant role than parameters of the worse eye, and contrast sensitivity is the most significant predictor of computer task accuracy. (Am J Ophthalmol 2002;133:350-357. (C) 2002 by Elsevier Science Inc. All rights reserved.).
C1 Univ Miami, Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33101 USA.
   Georgia Inst Technol, Dept Ind & Syst Engn, Atlanta, GA 30332 USA.
C3 Bascom Palmer Eye Institute; University of Miami; University System of
   Georgia; Georgia Institute of Technology
RP Scott, IU (通讯作者)，Univ Miami, Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, POB 016880, Miami, FL 33101 USA.
OI Scott, Ingrid/0000-0002-3908-7153
CR *AM MED ASS, 1994, GUID EV PERM IMP, P209
   APPLEGATE WB, 1987, JAMA-J AM MED ASSOC, V257, P1064
   BERNTHPETERSEN P, 1981, ACTA OPHTHALMOL, V59, P198
   Birch J., 1979, CONGENITAL ACQUIRED, P83
   BRENNER MH, 1993, ARCH OPHTHALMOL-CHIC, V111, P680, DOI 10.1001/archopht.1993.01090050114040
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 1998, INT OPHTHALMOL, V22, P307, DOI 10.1023/A:1006311910304
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   CASSARD SD, 1995, ARCH OPHTHALMOL-CHIC, V113, P1508, DOI 10.1001/archopht.1995.01100120038005
   Courtright P, 1998, Ophthalmic Epidemiol, V5, P13, DOI 10.1076/opep.5.1.13.1498
   DAMIANO AM, 1995, MED CARE, V33, P120
   Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868
   ELLIOTT DB, 1990, EYE, V4, P712, DOI 10.1038/eye.1990.100
   ELLIOTT DB, 1990, OPTOMETRY VISION SCI, V67, P822, DOI 10.1097/00006324-199011000-00006
   ESTERMAN B, 1982, OPHTHALMOLOGY, V89, P1226
   Esterman B., 1985, DOC OPHTHALMOL P SER, V42, P333
   Farnsworth D., 1947, FARNSWORTH DICHOTOMO, P1
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   HESS R, 1978, INVEST OPHTH VIS SCI, V17, P428
   Jacko JA, 2000, INT J HUM-COMPUT INT, V12, P135, DOI 10.1207/S15327590IJHC1201_6
   Jacko JA, 2000, INT J HUM-COMPUT INT, V12, P151, DOI 10.1207/S15327590IJHC1201_7
   JACKO JA, 1999, P 9 ANN INT C HUM CO, P975
   Kirchner C., 1985, DATA BLINDNESS VISUA
   LEAT SJ, 1993, OPHTHAL PHYSL OPT, V13, P9, DOI 10.1111/j.1475-1313.1993.tb00420.x
   LEGRO MW, 1991, OPHTHALMIC SURG LAS, V22, P431
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LENNERSTRAND G, 1989, ACTA OPHTHALMOL, V67, P225
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   MACKENZIE PJ, IN PRESS OPHTHALMOLO
   MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017
   MANGIONE CM, 1992, MED CARE, V30, P111
   MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P205
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   MILLS RP, 1986, OPHTHALMOLOGY, V93, P371
   *NAT ADV EYE COUNC, 1993, NATL I HLTH, P305
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   Pappas C.J, 1999, P ASS COMP MACH C HU, P330
   PARRISH RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P777
   PAULSSON LE, 1980, INVEST OPHTH VIS SCI, V19, P401
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   ROSS JE, 1984, BRIT J OPHTHALMOL, V68, P821, DOI 10.1136/bjo.68.11.821
   RUBIN GS, 1989, VISION RES, V29, P79, DOI 10.1016/0042-6989(89)90175-2
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   RUBIN GS, 1986, LOW VISION PRINCIPLE, P323
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 1998, OPHTHALMOLOGY, V105, P795, DOI 10.1016/S0161-6420(98)95017-5
   Scott IU, 1997, OPHTHALMOLOGY, V104, P1041, DOI 10.1016/S0161-6420(97)30189-4
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   SEARS A, 1998, P 42 ANN M HUM FACT
   STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P195
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   University of Maryland School of Medicine, 1980, EARL TREATM DIAB RET, P1
NR 58
TC 48
Z9 52
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2002
VL 133
IS 3
BP 350
EP 357
AR PII S0002-9394(01)01406-4
DI 10.1016/S0002-9394(01)01406-4
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 528WX
UT WOS:000174268600008
PM 11860972
DA 2022-11-30
ER

PT J
AU Frost, S
   Guymer, R
   Aung, KZ
   Macaulay, SL
   Sohrabi, HR
   Bourgeat, P
   Salvado, O
   Rowe, CC
   Ames, D
   Masters, CL
   Martins, RN
   Kanagasingam, Y
AF Frost, Shaun
   Guymer, Robyn
   Aung, Khin Zaw
   Macaulay, S. Lance
   Sohrabi, Hamid R.
   Bourgeat, Pierrick
   Salvado, Olivier
   Rowe, Christopher C.
   Ames, David
   Masters, Colin L.
   Martins, Ralph N.
   Kanagasingam, Yogesan
CA AIBL Res Grp
TI Alzheimer's Disease and the Early Signs of Age-Related Macular
   Degeneration
SO CURRENT ALZHEIMER RESEARCH
LA English
DT Article
DE Aging; diagnosis; Alzheimer's; retina; eye; vision disorders
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARDIOVASCULAR RISK-FACTORS;
   APOLIPOPROTEIN-E GENE; COGNITIVE IMPAIRMENT; AMYLOID-BETA; RETINAL
   PATHOLOGY; COMPLEMENT ACTIVATION; DEMENTIA; DRUSEN; ABNORMALITIES
AB This study investigated signs of age related macular degeneration (AMD) in Alzheimer's disease (AD). These age-related diseases primarily affect different parts of the central nervous system but are substantially similar in terms of abnormal extracellular deposits, metabolic and oxidative stress, neuroinflammation and microvascular abnormalities. While AMD is a retinal disease, AD is reported to affect not only the brain but also the retina, with A beta deposits, neurodegeneration and vascular changes. Large population based studies have provided conflicting results regarding the comorbidity of AD and AMD.
   This study investigated signs of AMD in a small but well characterized cohort from the Australian Imaging Biomarkers and Lifestyle study of aging (AIBL). The cohort consisted of 22 AD patients (age 70.2 +/- 9.0 yrs, 13 male, 9 female) and 101 cognitively normal (CN) participants (age 71.3 +/- 6.0 yrs, 40 male, 61 female).
   In comparison with the CN group, the AD group had a greater proportion of participants with early AMD (p < 0.0001, odds ratio 18.67, 95% CI 4.42 -78.80). A logistic model for early AMD found a significant association with AD diagnosis (p < 0.0001), after adjusting for confounders (age, smoking, hypertension, high and low density lipoproteins, cataract surgery and APOE epsilon 4 carrier status). The results of this study are consistent with an increased risk of AMD in AD. While the pathophysiology of these diseases are unclear, understanding the shared features between them may provide further knowledge about their pathogenesis and could lead to accelerated development of therapies for both diseases.
C1 [Frost, Shaun; Kanagasingam, Yogesan] CSIRO Australian E Hlth Res Ctr, Digital Prod Flagship, Perth, WA, Australia.
   [Guymer, Robyn; Aung, Khin Zaw] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Parkville, Vic, Australia.
   [Macaulay, S. Lance] CSIRO Food & Nutr Flagship, Parkville, Vic, Australia.
   [Sohrabi, Hamid R.] Edith Cowan Univ, Alzheimers Dis Res Lab, Perth, WA, Australia.
   [Sohrabi, Hamid R.] Edith Cowan Univ, McCusker Alzheimers Res Fdn, Sch Med Sci, Perth, WA, Australia.
   [Bourgeat, Pierrick; Salvado, Olivier] CSIRO Australian E Hlth Res Ctr, Digital Prod Flagship, Brisbane, Qld, Australia.
   [Rowe, Christopher C.] Austin Hlth, Dept Nucl Med, Heidelberg, Vic, Australia.
   [Rowe, Christopher C.] Austin Hlth, Ctr PET, Heidelberg, Vic, Australia.
   [Ames, David] Natl Ageing Res Inst, Melbourne, Vic, Australia.
   [Masters, Colin L.] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia.
   [Martins, Ralph N.] Edith Cowan Univ, Sir James McCusker Alzheimers Dis Res Unit, Ctr Excellence Alzheimers Dis Res & Care, Perth, WA, Australia.
   [AIBL Res Grp] AIBL, Melbourne, Vic, Australia.
C3 Commonwealth Scientific & Industrial Research Organisation (CSIRO);
   Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Commonwealth Scientific & Industrial Research
   Organisation (CSIRO); Edith Cowan University; Edith Cowan University;
   Commonwealth Scientific & Industrial Research Organisation (CSIRO);
   Austin Research Institute; Florey Institute of Neuroscience & Mental
   Health; Austin Research Institute; Florey Institute of Neuroscience &
   Mental Health; National Ageing Research Institute; Florey Institute of
   Neuroscience & Mental Health; Edith Cowan University
RP Frost, S (通讯作者)，CSIRO, Private Bag 5, Wembley, WA 6913, Australia.
EM shaun.frost@csiro.au
RI Sohrabi, Hamid/D-2744-2013; Rowe, Christopher/AAX-8748-2021; Frost,
   Shaun M/A-7580-2011; Sohrabi, Hamid Reza/ABY-5173-2022; Salvado,
   Olivier/C-8910-2009; Bourgeat, Pierrick T/A-1419-2010; Kanagasingam,
   Yogesan/C-4631-2011
OI Sohrabi, Hamid/0000-0001-8017-8682; Frost, Shaun M/0000-0002-1681-8224;
   Salvado, Olivier/0000-0002-2720-8739; Bourgeat, Pierrick
   T/0000-0002-2605-4766; Kanagasingam, Yogesan/0000-0001-7321-7495;
   Guymer, Robyn/0000-0002-9441-4356; Masters, Colin/0000-0003-3072-7940;
   Martins, Ralph/0000-0002-4828-9363
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753
   Bayer AU, 2002, EUR NEUROL, V47, P165, DOI 10.1159/000047976
   Berisha F, 2007, INVEST OPHTH VIS SCI, V48, P2285, DOI 10.1167/iovs.06-1029
   BLANKS JC, 1989, BRAIN RES, V501, P364, DOI 10.1016/0006-8993(89)90653-7
   Blanks JC, 1996, NEUROBIOL AGING, V17, P377, DOI 10.1016/0197-4580(96)00010-3
   Blanks JC, 1996, NEUROBIOL AGING, V17, P385, DOI 10.1016/0197-4580(96)00009-7
   Bourgeat P, 2010, NEUROLOGY, V74, P121, DOI 10.1212/WNL.0b013e3181c918b5
   Breitner JCS, 2001, NEW ENGL J MED, V345, P1567, DOI 10.1056/NEJM200111223452110
   BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cai J, 2012, EMBO MOL MED, V4, P980, DOI 10.1002/emmm.201101084
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chong EW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137322
   Christen William G, 2014, Evid Based Med, V19, pe6, DOI 10.1136/eb-2013-101358
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Danesh-Meyer HV, 2006, NEUROLOGY, V67, P1852, DOI 10.1212/01.wnl.0000244490.07925.8b
   de la Torre JC, 2009, INT REV NEUROBIOL, V84, P35, DOI 10.1016/S0074-7742(09)00403-6
   Dentchev T., 2003, AM J OPHTHALMOL, V136, P787
   Ding J, 2008, BRIT J OPHTHALMOL, V92, P1017, DOI 10.1136/bjo.2008.141994
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Ellis KA, 2009, INT PSYCHOGERIATR, V21, P672, DOI 10.1017/S1041610209009405
   Fagan AM, 2006, ANN NEUROL, V59, P512, DOI 10.1002/ana.20730
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Frost S, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.150
   Gorelick PB, 2011, STROKE, V42, P2672, DOI 10.1161/STR.0b013e3182299496
   Guymer R, 2015, GRAEF ARCH CLIN EXP, V253, P1347, DOI 10.1007/s00417-015-2970-x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804
   HIXSON JE, 1990, J LIPID RES, V31, P545
   in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178
   Ingelsson M, 2003, CURRENT PROTOCOLS HU
   Iseri PK, 2006, J NEURO-OPHTHALMOL, V26, P18, DOI 10.1097/01.wno.0000204645.56873.26
   Jaturapatporn D, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006378.pub2
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klunk WE, 2005, J NEUROSCI, V25, P10598, DOI 10.1523/JNEUROSCI.2990-05.2005
   Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009
   Knopman DS, 2007, BRIT J RADIOL, V80, pS121, DOI 10.1259/bjr/75681080
   Knopman DS, 2012, NEUROLOGY, V78, P1032, DOI 10.1212/WNL.0b013e31824e8fb4
   Koronyo Y, 2012, NEURODEGENER DIS, V10, P285, DOI 10.1159/000335154
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Lui JK, 2010, J ALZHEIMERS DIS, V20, P1233, DOI 10.3233/JAD-2010-090249
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   McGeer PL, 2007, NEUROBIOL AGING, V28, P639, DOI 10.1016/j.neurobiolaging.2006.03.013
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   Morris JC, 2009, ARCH NEUROL-CHICAGO, V66, P1469, DOI 10.1001/archneurol.2009.269
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Okello A, 2009, NEUROLOGY, V73, P754, DOI 10.1212/WNL.0b013e3181b23564
   Paquet C, 2007, NEUROSCI LETT, V420, P97, DOI 10.1016/j.neulet.2007.02.090
   Parisi V, 2001, CLIN NEUROPHYSIOL, V112, P1860, DOI 10.1016/S1388-2457(01)00620-4
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Pike KE, 2007, BRAIN, V130, P2837, DOI 10.1093/brain/awm238
   Ravona-Springer R, 2003, CNS SPECTRUMS, V8, P824, DOI 10.1017/S109285290001926X
   Rosendoff C, 2007, AM J GERIATR CARDIOL, V16, P143, DOI 10.1111/j.1076-7460.2007.06696.x
   Rowe CC, 2010, NEUROBIOL AGING, V31, P1275, DOI 10.1016/j.neurobiolaging.2010.04.007
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Ruitenberg A, 2005, ANN NEUROL, V57, P789, DOI 10.1002/ana.20493
   SADUN AA, 1990, OPHTHALMOLOGY, V97, P9
   SADUN AA, 1990, RES P ARNMD, V67, P331
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Smith JD, 2000, ANN MED, V32, P118, DOI 10.3109/07853890009011761
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003
   Szekely CA, 2004, NEUROEPIDEMIOLOGY, V23, P159, DOI 10.1159/000078501
   Tamura H, 2006, J NEUROL SCI, V246, P79, DOI 10.1016/j.jns.2006.02.009
   Thal DR, 2003, J NEUROPATH EXP NEUR, V62, P1287, DOI 10.1093/jnen/62.12.1287
   Thal LJ, 2006, ALZ DIS ASSOC DIS, V20, P6, DOI 10.1097/01.wad.0000191420.61260.a8
   TSAI CS, 1991, ARCH OPHTHALMOL-CHIC, V109, P199, DOI 10.1001/archopht.1991.01080020045040
   van Splunder J, 2004, OPHTHALMOLOGY, V111, P1457, DOI 10.1016/j.ophtha.2003.12.051
   Villemagne V, 2008, J NUCL MED, V49, P34
   Williams MA, 2014, J ALZHEIMERS DIS, V42, P909, DOI 10.3233/JAD-140243
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   World Health Organization, 2012, GLOB DAT VIS IMP
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 94
TC 31
Z9 32
U1 0
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2050
EI 1875-5828
J9 CURR ALZHEIMER RES
JI Curr. Alzheimer Res.
PY 2016
VL 13
IS 11
BP 1259
EP 1266
DI 10.2174/1567205013666160603003800
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EF4XN
UT WOS:000390335400006
PM 27335042
DA 2022-11-30
ER

PT J
AU Zhou, HJ
   Zhang, HN
   Yu, AQ
   Xie, JJ
AF Zhou, Hongjie
   Zhang, Huina
   Yu, Aiqing
   Xie, Jiajun
TI Association between sunlight exposure and risk of age-related macular
   degeneration: a meta-analysis
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Sunlight; Macular degeneration; Meta-analysis; Risk factor
ID NUTRITION EXAMINATION SURVEY; 10-YEAR INCIDENCE; NATIONAL-HEALTH; IRIS
   COLOR; VITAMIN-D; LIGHT; MACULOPATHY; SENSITIVITY; PREVALENCE; RADIATION
AB BackgroundA substantial number of epidemiological studies have investigated the possible associations between sunlight exposure and Age-related Macular Degeneration (AMD), but the results from studies are inconsistent. The aim of this meta-analysis was to evaluate the association between sunlight exposure and the risk of AMD.MethodsRelevant studies were searched using databases including PubMed, EMBASE, and Web of Science database. Two authors independently extracted data and assessed study quality. The random-effects model was used to calculate the pooled covariates-adjusted odds ratio (OR). Subgroup analyses based on study design, stage of AMD, method of exposure assessment, and study latitude were carried out. The heterogeneity across the studies was tested, as was publication bias.ResultsFourteen eligible studies including 43,934 individuals based on the inclusion criteria were analyzed. The pooled OR for sunlight exposure and AMD was 1.10 (95% CI=0.98-1.23). In addition, similar insignificant results were observed in further subgroup analyses based on stage of AMD, method of exposure assessment, and study latitude. Sun-avoidance behavior did not decrease the risk of AMD (OR=1.12, 95% CI=0.76-1.67). Moderate heterogeneity was observed in most of analyses.ConclusionThe results indicate that sunlight exposure may not be associated with increased risk of AMD based on current published data.
C1 [Zhou, Hongjie; Yu, Aiqing] Hangzhou Hosp Prevent & Treatment Occupat Dis, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Huina; Xie, Jiajun] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Ophthalmol, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Zhou, HJ (通讯作者)，Hangzhou Hosp Prevent & Treatment Occupat Dis, Hangzhou, Zhejiang, Peoples R China.
EM zhjwood@163.com
OI Zhou, Hongjie/0000-0002-7156-188X
FU Medical and Health Science and Technology Program of Zhejiang Province
   [2018KY416]; Zhejiang Provincial Natural Science Foundation of China
   [LQ19H120006]
FX This work is supported by project foundation: The Medical and Health
   Science and Technology Program of Zhejiang Province (2018KY416);
   Zhejiang Provincial Natural Science Foundation of China (LQ19H120006).
CR Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Bai ZL, 2005, INT J OPHTHALMOL, V5, P1114
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bullock MD, 2012, BIOL CELL, V104, P3, DOI 10.1111/boc.201100115
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Nano ME, 2013, ARQ BRAS OFTALMOL, V76, P80, DOI 10.1590/S0004-27492013000200005
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hirakawa M, 2008, BRIT J OPHTHALMOL, V92, P630, DOI 10.1136/bjo.2007.130575
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lazreg S, 2016, OPHTHALMIC RES, V56, P145, DOI 10.1159/000446844
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Oliva Matthew S., 2005, International Ophthalmology Clinics, V45, P1
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pham TQ, 2009, OPHTHAL EPIDEMIOL, V16, P136, DOI 10.1080/09286580701299395
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P5228, DOI 10.1167/iovs.14-14299
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
   Yam JCS, 2014, INT OPHTHALMOL, V34, P383, DOI 10.1007/s10792-013-9791-x
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Youn HY, 2011, MOL VIS, V17
NR 43
TC 21
Z9 22
U1 1
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 20
PY 2018
VL 18
AR 331
DI 10.1186/s12886-018-1004-y
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF2XQ
UT WOS:000454100400001
PM 30572865
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yan, Q
   Ding, Y
   Liu, Y
   Sun, T
   Fritsche, LG
   Clemons, T
   Ratnapriya, R
   Klein, ML
   Cook, RJ
   Liu, Y
   Fan, RZ
   Wei, L
   Abecasis, GR
   Swaroop, A
   Chew, EY
   Weeks, DE
   Chen, W
AF Yan, Qi
   Ding, Ying
   Liu, Yi
   Sun, Tao
   Fritsche, Lars G.
   Clemons, Traci
   Ratnapriya, Rinki
   Klein, Michael L.
   Cook, Richard J.
   Liu, Yu
   Fan, Ruzong
   Wei, Lai
   Abecasis, Goncalo R.
   Swaroop, Anand
   Chew, Emily Y.
   Weeks, Daniel E.
   Chen, Wei
CA AREDS2 Res Grp
TI Genome-wide analysis of disease progression in age-related macular
   degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID SUSCEPTIBILITY GENES; EYE DISEASE; RISK; ASSOCIATION; CFH; MACULOPATHY;
   VARIANTS; MODELS; AREDS; CELLS
AB Family- and population-based genetic studies have successfully identified multiple disease-susceptibility loci for Age-related macular degeneration (AMD), one of the first batch and most successful examples of genome-wide association study. However, most genetic studies to date have focused on case-control studies of late AMD (choroidal neovascularization or geographic atrophy). The genetic influences on disease progression are largely unexplored. We assembled unique resources to perform a genome-wide bivariate time-to-event analysis to test for association of time-to-late-AMD with similar to 9 million variants on 2721 Caucasians from a large multi-center randomized clinical trial, the Age-Related Eye Disease Study. To our knowledge, this is the first genome-wide association study of disease progression (bivariate survival outcome) in AMD genetic studies, thus providing novel insights to AMD genetics. We used a robust Cox proportional hazards model to appropriately account for between-eye correlation when analyzing the progression time in the two eyes of each participant. We identified four previously reported susceptibility loci showing genome-wide significant association with AMD progression: ARMS2-HTRA1 (P = 8.1 x 10(-43)), CFH (P = 3.5 x 10(-37)), C2-CFB-SKIV2L (P = 8.1 x 10(-10)) and C3 (P = 1.2 x 10(-9)). Furthermore, we detected association of rs58978565 near TNR (P = 2.3 x 10(-8)), rs28368872 near ATF7IP2 (P = 2.9 x 10(-8)) and rs142450006 near MMP9 (P = 0.0006) with progression to choroidal neovascularization but not geographic atrophy. Secondary analysis limited to 34 reported risk variants revealed that LIPC and CTRB2-CTRB1 were also associated with AMD progression (P < 0.0015). Our genome-wide analysis thus expands the genetics in both development and progression of AMD and should assist in early identification of high risk individuals.
C1 [Yan, Qi; Liu, Yi; Sun, Tao; Chen, Wei] Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC, Dept Pediat,Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15224 USA.
   [Ding, Ying; Liu, Yi; Sun, Tao; Weeks, Daniel E.; Chen, Wei] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Fritsche, Lars G.; Abecasis, Goncalo R.] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Clemons, Traci] Emmes Corp, Rockville, MD 20850 USA.
   [Ratnapriya, Rinki; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [Cook, Richard J.] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada.
   [Liu, Yu; Wei, Lai] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510030, Guangdong, Peoples R China.
   [Fan, Ruzong] Georgetown Univ, Med Ctr, Dept Biostat Bioinformat & Biomath, Washington, DC 20007 USA.
   [Chew, Emily Y.; AREDS2 Res Grp] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Weeks, Daniel E.; Chen, Wei] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of Michigan System;
   University of Michigan; Emmes Corporation; National Institutes of Health
   (NIH) - USA; NIH National Eye Institute (NEI); Oregon Health & Science
   University; University of Waterloo; Sun Yat Sen University; Georgetown
   University; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Chen, W (通讯作者)，Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC, Dept Pediat,Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15224 USA.; Weeks, DE; Chen, W (通讯作者)，Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.; Weeks, DE; Chen, W (通讯作者)，Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
EM weeks@pitt.edu; wei.chen@chp.edu
RI Weeks, Daniel E/B-2995-2012; Chen, Wei/AAX-5994-2020; Fritsche, Lars
   G/AAF-9387-2019
OI Weeks, Daniel E/0000-0001-9410-7228; Chen, Wei/0000-0001-7196-8703;
   Fritsche, Lars G/0000-0002-2110-1690; Sun, Tao/0000-0003-4447-3005;
   Cook, Richard/0000-0002-1414-4908; Ratnapriya, Rinki/0000-0002-0469-4631
FU National Institutes of Health [EY024226, EY022005, EY021532]; Intramural
   Research Program of the National Eye Institute [EY000474, EY000546]; RPB
   unrestricted departmental grant; Intramural Research Program of the
   National Eye Institute (AREDS contract) [NOI-EY-02127]; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002369] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [ZIAEY000489, R01EY021532, R01EY022005,
   R01EY024226, ZIAEY000546, N01EY002127] Funding Source: NIH RePORTER
FX National Institutes of Health (EY024226 to W.C., EY022005 to G.R.A. and
   EY021532 to M.L.K.); Intramural Research Program of the National Eye
   Institute (EY000474 and EY000546 to A.S., and AREDS contract
   NOI-EY-02127 to E.Y.C.); and RPB unrestricted departmental grant (to
   M.L.K).
CR Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Lambert C, 2014, ARTHRITIS RHEUMATOL, V66, P960, DOI 10.1002/art.38315
   Lee EW, 1992, SURVIVAL ANAL STATE, P237
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Zhang MJ, 2002, CANC TREAT, V113, P59
NR 24
TC 38
Z9 38
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAR 1
PY 2018
VL 27
IS 5
BP 929
EP 940
DI 10.1093/hmg/ddy002
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA FY5AJ
UT WOS:000426838200013
PM 29346644
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Hori, K
   Saito, S
   Tamai, M
AF Hori, K
   Saito, S
   Tamai, M
TI Effect of irradiation on neovascularization in rat skinfold chambers:
   Implications for clinical trials of low-dose radiotherapy for wet-type
   age-related macular degeneration
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
DE neovascularization; irradiation; blood flow; microhemodynamics; rat
   transparent chamber
ID TUMOR BLOOD-FLOW; RABBIT EAR CHAMBER; RADIATION-THERAPY; EXTERNAL
   RADIOTHERAPY; ANGIOTENSIN-II; RADIOSENSITIVITY; ANGIOGENESIS;
   CAPILLARIES; RECEPTOR; INVIVO
AB Purpose: Wet-type age-related macular degeneration is a refractory eye disease that involves choroidal neovascularization. Randomized controlled trials of low-dose radiotherapy for this disease performed in Japan showed that, at 12 months of follow-up, visual acuity was significantly well preserved and the neovascular membrane size decreased. Because understanding the effect of irradiation on new vascular networks is an important prerequisite for clinical trials, we used a rat skinfold chamber technique to investigate X-ray-induced changes in neovasculature microcirculation.
   Methods and Materials: Neovascularization was induced in rat skinfold chambers via polyvinyl chloride resin plates. Neovessels were irradiated in a single 10-Gy dose, after which, changes in vascular density, blood velocity, tissue blood flow, and interstitial fluid pressure (IFP), were measured.
   Results: Vascular density, tissue blood flow, and IFP measurements in resin-induced inflammatory tissue were much higher than those measurements in normal tissue. Although overall blood velocity was low and sluggish or blood-flow stasis occurred in the neovascular network, after a single 10-Gy dose of radiation, the velocity increased, stasis improved markedly, and many dilated vessels narrowed. Thereafter, vascular density, blood flow, and IFP significantly decreased and approached normal values.
   Conclusion: These findings may help explain clinical results related to radiotherapy-induced changes in neovascular membranes in age-related macular degeneration. Both vascular morphology and vascular function in inflammatory tissue returned to normal, without vessel destruction, after an appropriate radiation dose. (C) 2004 Elsevier Inc.
C1 Tohoku Univ, Inst Dev Aging & Canc, Div Canc Control, Dept Vasc Biol,Aoba Ku, Sendai, Miyagi 9808575, Japan.
   Tohoku Univ, Grad Sch Med, Div Ophthalmol & Visual Sci, Dept Ophthalmol & Otolaryngol, Sendai, Miyagi 980, Japan.
   Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan.
C3 Tohoku University; Tohoku University; Tohoku University
RP Hori, K (通讯作者)，Tohoku Univ, Inst Dev Aging & Canc, Div Canc Control, Dept Vasc Biol,Aoba Ku, 4-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.
EM k-hori@idac.tohoku.ac.jp
CR Akmansu M, 1998, INT J RADIAT ONCOL, V40, P923, DOI 10.1016/S0360-3016(97)00859-6
   AUKLAND K, 1964, CIRC RES, V14, P164, DOI 10.1161/01.RES.14.2.164
   Berson AM, 1996, INT J RADIAT ONCOL, V36, P861, DOI 10.1016/S0360-3016(96)00338-0
   Brady LW, 1997, INT J RADIAT ONCOL, V39, P945, DOI 10.1016/S0360-3016(97)00708-6
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   DIMITRIEVICH GS, 1977, RADIAT RES, V69, P276, DOI 10.2307/3574436
   Freire J, 1996, INT J RADIAT ONCOL, V36, P857, DOI 10.1016/S0360-3016(96)00428-2
   HORI K, 1985, J NATL CANCER I, V74, P453
   HORI K, 1990, JPN J CANCER RES, V81, P279, DOI 10.1111/j.1349-7006.1990.tb02562.x
   HORI K, 1991, JPN J CANCER RES, V82, P1309, DOI 10.1111/j.1349-7006.1991.tb01797.x
   HORI K, 1993, CANCER RES, V53, P5528
   Hori K, 2002, BRIT J CANCER, V86, P1604, DOI 10.1038/sj.bjc.6600296
   HORI K, 1986, JPN J CANCER RES, V77, P65
   HORI K, 1985, KOSANKINBYO KENKYUSH, V37, P269
   KETY SS, 1945, AM J PHYSIOL, V143, P53, DOI 10.1152/ajplegacy.1945.143.1.53
   Mandai M, 2000, JPN J OPHTHALMOL, V44, P530, DOI 10.1016/S0021-5155(00)00217-3
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Miyamoto H, 1999, CURR EYE RES, V19, P53, DOI 10.1076/ceyr.19.1.53.5338
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   RAND P W, 1970, Microvascular Research, V2, P508, DOI 10.1016/0026-2862(70)90044-0
   REINHOLD HS, 1973, BRIT J RADIOL, V46, P54, DOI 10.1259/0007-1285-46-541-54
   Sasai K, 1997, INT J RADIAT ONCOL, V39, P173, DOI 10.1016/S0360-3016(97)00296-4
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   SUZUKI M, 1983, CLIN EXP METASTAS, V1, P163, DOI 10.1007/BF00121495
   Valmaggia Christophe, 2001, Documenta Ophthalmologica, V103, P201, DOI 10.1023/A:1013047722865
   VANDENBRENK HAS, 1959, AMER J ROENTGENOL RA, V81, P859
   YAMAURA H, 1984, J RADIAT RES, V25, P296, DOI 10.1269/jrr.25.296
   YAMAURA H, 1976, INT J RADIAT BIOL, V30, P179, DOI 10.1080/09553007614550931
   2003, NIPPON GANKA GAKKAI, V107, P326
NR 30
TC 7
Z9 7
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD DEC 1
PY 2004
VL 60
IS 5
BP 1564
EP 1571
DI 10.1016/j.ijrobp.2004.06.208
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 877SX
UT WOS:000225591600027
PM 15590188
DA 2022-11-30
ER

PT J
AU Alexander, MS
   Lajoie, K
   Neima, DR
   Strath, RA
   Robinovitch, SN
   Marigold, DS
AF Alexander, M. Scott
   Lajoie, Kim
   Neima, David R.
   Strath, Robert A.
   Robinovitch, Stephen N.
   Marigold, Daniel S.
TI Effect of Ambient Light and Age-Related Macular Degeneration on
   Precision Walking
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE macular degeneration; low vision; mobility; motion; locomotion
ID EDGE-CONTRAST SENSITIVITY; OLDER-ADULTS; VISUAL-FIELD; MOBILITY
   PERFORMANCE; WATERLOO VISION; INJURIOUS FALLS; GAZE BEHAVIOR; EYE
   DISEASE; MACULOPATHY; RISK
AB Purpose. To determine how age-related macular degeneration (AMD) and changes in ambient light affect the control of foot placement while walking.
   Methods. Ten older adults with AMD and 11 normal-sighted controls performed a precision walking task under normal (similar to 600 lx), dim (similar to 0.7 lx), and after a sudden reduction (similar to 600 to 0.7 lx) of light. The precision walking task involved subjects walking and stepping to the center of a series of irregularly spaced, low-contrast targets. Habitual visual acuity and contrast sensitivity and visual field function were also assessed.
   Results. There were no differences between groups when performing the walking task in normal light (p > 0.05). In reduced lighting, older adults with AMD were less accurate and more variable when stepping across the targets compared to controls (p < 0.05). A sudden reduction of light proved the most challenging for this population. In the AMD group, contrast sensitivity and visual acuity were not significantly correlated with walking performance. Visual field thresholds in the AMD group were only associated with greater foot placement error and variability in the dim light walking condition (r = -0.69 to -0.87, p < 0.05).
   Conclusions. While walking performance is similar between groups in normal light, poor ambient lighting results in decreased foot placement accuracy in older adults with AMD. Improper foot placement while walking can lead to a fall and possible injury. Thus, to improve the mobility of those with AMD, strategies to enhance the environment in reduced lighting situations are necessary.
C1 [Alexander, M. Scott; Lajoie, Kim; Strath, Robert A.; Robinovitch, Stephen N.; Marigold, Daniel S.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC V5A 1S6, Canada.
   [Robinovitch, Stephen N.] Simon Fraser Univ, Sch Engn Sci, Burnaby, BC V5A 1S6, Canada.
C3 Simon Fraser University; Simon Fraser University
RP Marigold, DS (通讯作者)，Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.
EM daniel_marigold@sfu.ca
OI Robinovitch, Stephen/0000-0003-3881-6227; Alexander,
   Scott/0000-0002-2691-0999
FU Canadian National Institute for the Blind Baker Applied Research grant
FX The authors wish to thank the staff at Dr. Neima's office, and Drs. Lim,
   Parsons, and Tischler and their staff for help with recruiting patients.
   A Canadian National Institute for the Blind Baker Applied Research grant
   supported this study.
CR Berg K., 1992, CAN J PUB HLTH, V2, pS7
   Bohannon Richard W, 2006, J Geriatr Phys Ther, V29, P64
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P733
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chapman GJ, 2007, GAIT POSTURE, V26, P59, DOI 10.1016/j.gaitpost.2006.07.010
   Chapman GJ, 2006, GAIT POSTURE, V24, P288, DOI 10.1016/j.gaitpost.2005.10.002
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Eisenbarth W, 2008, GRAEF ARCH CLIN EXP, V246, P27, DOI 10.1007/s00417-007-0641-2
   Figueiro MG, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-49
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geruschat DR, 2006, OPTOMETRY VISION SCI, V83, P550, DOI 10.1097/01.opx.0000232219.23362.a6
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   HOLLANDS MA, 1995, J MOTOR BEHAV, V27, P155, DOI 10.1080/00222895.1995.9941707
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Johnson L, 2007, INVEST OPHTH VIS SCI, V48, P1466, DOI 10.1167/iovs.06-0586
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kuyk T, 1998, OPTOMETRY VISION SCI, V75, P538, DOI 10.1097/00006324-199807000-00023
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Leat SJ, 2008, OPTOMETRY VISION SCI, V85, P1049, DOI 10.1097/OPX.0b013e31818b949d
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Lord SR, 2002, J AM GERIATR SOC, V50, P1760, DOI 10.1046/j.1532-5415.2002.50502.x
   Marigold DS, 2007, NEUROSCIENCE, V144, P302, DOI 10.1016/j.neuroscience.2006.09.006
   Marigold DS, 2008, EXERC SPORT SCI REV, V36, P145, DOI 10.1097/JES.0b013e31817bff72
   Marigold DS, 2008, EXP BRAIN RES, V188, P23, DOI 10.1007/s00221-008-1335-7
   Marigold DS, 2007, EXP BRAIN RES, V176, P32, DOI 10.1007/s00221-006-0598-0
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Nelson-Quigg JM, 2000, INVEST OPHTH VIS SCI, V41, P2212
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Patla AE, 1998, ECOL PSYCHOL, V10, P287, DOI 10.1207/s15326969eco103&4_7
   Patla AE, 2003, EXP BRAIN RES, V148, P133, DOI 10.1007/s00221-002-1246-y
   PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Smid KA, 2013, GAIT POSTURE, V38, P242, DOI 10.1016/j.gaitpost.2012.11.019
   SPAULDING SJ, 1994, OPTOMETRY VISION SCI, V71, P770, DOI 10.1097/00006324-199412000-00007
   SPAULDING SJ, 1995, GAIT POSTURE, V3, P227
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Szabo SM, 2008, J AM GERIATR SOC, V56, P800, DOI 10.1111/j.1532-5415.2008.01666.x
   Timmis MA, 2012, INVEST OPHTH VIS SCI, V53, P4120, DOI 10.1167/iovs.12-9897
   Turano KA, 2005, VISION RES, V45, P3117, DOI 10.1016/j.visres.2005.06.017
   VERBAKEN JH, 1986, AM J OPTOM PHYS OPT, V63, P724
   Wang MY, 2012, INVEST OPHTH VIS SCI, V53, P7967, DOI 10.1167/iovs.12-10701
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Zietz D, 2011, GAIT POSTURE, V34, P279, DOI 10.1016/j.gaitpost.2011.05.017
NR 48
TC 8
Z9 8
U1 1
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 990
EP 999
DI 10.1097/OPX.0000000000000316
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500023
PM 24987813
DA 2022-11-30
ER

PT J
AU Hadziahmetovic, M
   Song, Y
   Wolkow, N
   Lacovelli, J
   Kautz, L
   Roth, MP
   Dunaief, JL
AF Hadziahmetovic, Majda
   Song, Ying
   Wolkow, Natalie
   Lacovelli, Jared
   Kautz, Leon
   Roth, Marie-Paule
   Dunaief, Joshua L.
TI Bmp6 Regulates Retinal Iron Homeostasis and Has Altered Expression in
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID HEPCIDIN EXPRESSION; OXIDATIVE DAMAGE; GENE-EXPRESSION; MOUSE RETINA;
   LIGHT DAMAGE; PROTEIN; BONE; DISEASE; GROWTH; ACERULOPLASMINEMIA
AB Iron-induced oxidative stress causes hereditary macular degeneration in patients with aceruloplastninemia. Similarly, retinal iron accumulation in age-related macular degeneration (AMD) may exacerbate the disease. The cause of retinal iron accumulation in AMD is poorly understood. Given that bone morphogenetic protein 6 (Bmp6) is a major regulator of systemic iron, we examined the role of Bmp6 in retinal iron regulation and in AMD pathogenesis. Bmp6 was detected in the retinal pigment epithelium (RPE), a major site of pathology in AMD. In cultured RPE cells, Bmp6 was down-regulated by oxidative stress and upregulated by iron. Intraocular Bmp6 protein injection in mice up-regulated retinal hepcidin, an iron regulatory hormone, and altered retinal labile iron levels. Bmp6(-/-) mice had age-dependent retinal iron accumulation and degeneration. Postmortem RPE from patients with early AMD exhibited decreased Bmp6 levels. Because oxidative stress is associated with AMD pathogenesis and down-regulates Bmp6 in cultured RPE cells, the diminished Bmp6 levels observed in RPE cells in early AMD may contribute to iron 'build-up in AMD. This may in turn propagate a vicious cycle of oxidative stress and iron accumulation, exacerbating AMD and other diseases with hereditary or acquired iron excess. (Am J Pathol 2011, 179:335-344. DOI: 10.1016/j.ajpath.2011.03.033)
C1 [Hadziahmetovic, Majda; Song, Ying; Wolkow, Natalie; Lacovelli, Jared; Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Kautz, Leon; Roth, Marie-Paule] Univ Paul Sabatier UPS, INSERM, U563, Univ Toulouse, Toulouse, France.
   [Kautz, Leon; Roth, Marie-Paule] Univ Paul Sabatier UPS, Univ Toulouse, Ctr Physiopathol Toulouse Purpan, Toulouse, France.
C3 University of Pennsylvania; Pennsylvania Medicine; Universite de
   Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la
   Recherche Scientifique (CNRS); Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse
   III - Paul Sabatier; Centre National de la Recherche Scientifique
   (CNRS); Institut National de la Sante et de la Recherche Medicale
   (Inserm)
RP Dunaief, JL (通讯作者)，305 Stellar Chance Labs, 422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@upenn.edu
RI Mohammed, Imran/J-8271-2012; Roth, Marie-Paule/Q-2866-2018
OI Mohammed, Imran/0000-0002-8412-0768; Roth,
   Marie-Paule/0000-0001-9691-4234; Wolkow, Natalie/0000-0003-1524-115X;
   Kautz, Leon/0000-0002-2320-0457
FU NIH [R01EY015240]; American Health Assistance Foundation; Pennsylvania
   Lions Eye Research Foundation; F.M. Kirby Foundation; Paul and Evanina
   Bell Mackall Foundation Trust; University of Pennsylvania Biomedical
   Imaging Core; NATIONAL EYE INSTITUTE [R01EY015240] Funding Source: NIH
   RePORTER
FX Supported by the NIH (R01EY015240 to J.L.D.), the American Health
   Assistance Foundation, the Pennsylvania Lions Eye Research Foundation,
   the F.M. Kirby Foundation, and the Paul and Evanina Bell Mackall
   Foundation Trust.; We thank Christine Curcio (University of Alabama) for
   frozen human retinas and Ray Meade and Xinyu (Jasmine) Zhao (University
   of Pennsylvania Biomedical Imaging Core) for research support.
CR Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071
   Andriopoulos B, 2009, NAT GENET, V41, P482, DOI 10.1038/ng.335
   Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777
   Belecky-Adams TL, 2002, DEVELOPMENT, V129, P3795
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843
   Chen L, 2004, EXP EYE RES, V79, P239, DOI 10.1016/j.exer.2004.05.002
   Corradini E, 2009, GASTROENTEROLOGY, V137, P1489, DOI 10.1053/j.gastro.2009.06.057
   CUNNINGHAM NS, 1995, GROWTH FACTORS, V12, P99, DOI 10.3109/08977199509028956
   Dentchev T, 2007, MOL VIS, V13, P190
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Gitlin JD, 1998, PEDIATR RES, V44, P271, DOI 10.1203/00006450-199809000-00001
   Gnana-Prakasam JP, 2008, BIOCHEM J, V411, P79, DOI 10.1042/BJ20071377
   Gnana-Prakasam JP, 2010, IUBMB LIFE, V62, P363, DOI 10.1002/iub.326
   Hadziahmetovic M, 2010, INVEST OPHTH VIS SCI, V52, P109
   HADZIAHMETOVIC M, 2010, INVEST OPHTH VIS SCI, V52, P959
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2004, MOL VIS, V10, P598
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   HICKS D, 1990, EXP EYE RES, V51, P119, DOI 10.1016/0014-4835(90)90063-Z
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kautz L, 2008, BLOOD, V112, P1503, DOI 10.1182/blood-2008-03-143354
   Kautz L, 2009, BLOOD, V114, P2515, DOI 10.1182/blood-2009-02-206771
   Lavery K, 2008, J BIOL CHEM, V283, P20948, DOI 10.1074/jbc.M800850200
   Lee DW, 2010, J NEUROCHEM, V112, P332, DOI 10.1111/j.1471-4159.2009.06470.x
   Lesbordes-Brion JC, 2006, BLOOD, V108, P1402, DOI 10.1182/blood-2006-02-003376
   Meynard D, 2009, NAT GENET, V41, P478, DOI 10.1038/ng.320
   Miyajima H, 2002, BLOOD CELL MOL DIS, V29, P433, DOI 10.1006/bcmd.2002.0561
   Muckenthaler MU, 2008, ANNU REV NUTR, V28, P197, DOI 10.1146/annurev.nutr.28.061807.155521
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Reddi H, 1995, Adv Dent Res, V9, P13
   Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5
   ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shen JK, 2007, INVEST OPHTH VIS SCI, V48, P4335, DOI 10.1167/iovs.07-0113
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7
   Smith MA, 2010, J ALZHEIMERS DIS, V19, P363, DOI 10.3233/JAD-2010-1239
   Snyder AM, 2009, BBA-GEN SUBJECTS, V1790, P606, DOI 10.1016/j.bbagen.2008.08.005
   Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.0.CO;2-8
   TORRANCE J D, 1968, South African Journal of Medical Sciences, V33, P9
   Trousse F, 2001, J NEUROSCI, V21, P1292
   Viatte L, 2009, BIOCHIMIE, V91, P1223, DOI 10.1016/j.biochi.2009.06.012
   Weinberg ED, 2008, HEMOGLOBIN, V32, P117, DOI 10.1080/03630260701680805
   Zacharski LR, 2008, JNCI-J NATL CANCER I, V100, P996, DOI 10.1093/jnci/djn209
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
NR 54
TC 37
Z9 38
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUL
PY 2011
VL 179
IS 1
BP 335
EP 348
DI 10.1016/j.ajpath.2011.03.033
PG 14
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 865JL
UT WOS:000298307100033
PM 21703414
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Benner, JD
   Ahuja, RM
   Butler, JW
AF Benner, JD
   Ahuja, RM
   Butler, JW
TI Macular infarction after transpupillary thermotherapy for subfoveal
   choroidal neovascularization in age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB PURPOSE: To report the complication of macular infarction after transpupillary thermotherapy (TTT) for the treatment of subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
   DESIGN: Interventional case reports.
   METHODS: Among 107 consecutive patients with subfoveal CNV due to AMD, a 73 year old woman with recurrent subfoveal classic choroidal neovascularization and a 76,year old man with subfoveal occult choroidal neovascularization with adjacent areas of geographic retinal pigment epithelium atrophy noted a severe de crease in visual acuity and photopsias within hours of undergoing TTT.
   RESULTS: Both patients had marked whitening of the macula clinically and closure of the perifoveal capillaries on fluorescein angiography. Immediately after treatment their visual acuity decreased from 20/200 to 6/200 and from 20/400 to 2/200, respectively. Several months later, all exudation had resolved and their visual acuity had stabilized at 20/100 and 20/200, respectively.
   CONCLUSIONS: Macular infarction is a rare complication that occurred in two of 107 patients undergoing TTT for subfoveal CNV due to AMD. The presence of geographic retinal pigment epithelium atrophy or a previous laser treatment scar in the macular region may predispose patients to this complication. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Delmarva Vitreoretinal Ctr, Salisbury, MD USA.
   Univ Maryland, Dept Ophthalmol, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore
RP Benner, JD (通讯作者)，1415 Wesley Dr, Salisbury, MD 21801 USA.
CR Ahuja R M, 2001, Semin Ophthalmol, V16, P81, DOI 10.1076/soph.16.2.81.4215
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Miller-Rivero NE, 2000, INVEST OPHTH VIS SCI, V41, pS179
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
NR 5
TC 23
Z9 26
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2002
VL 134
IS 5
BP 765
EP 768
DI 10.1016/S0002-9394(02)01694-X
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 614DT
UT WOS:000179173600019
PM 12429257
DA 2022-11-30
ER

PT J
AU Tong, Y
   Zhou, YL
   Wang, YX
   Zhao, PQ
   Wang, ZY
AF Tong, Yao
   Zhou, Ya-Li
   Wang, Yi-Xiao
   Zhao, Pei-Quan
   Wang, Zhao-Yang
TI Retinal pigment epithelium cell-derived exosomes: Possible relevance to
   CNV in wet-age related macular degeneration
SO MEDICAL HYPOTHESES
LA English
DT Article
ID PATHOGENESIS; PREVALENCE
AB Exosomes are small vesicles that are released by almost every cell type and play a crucial role in many physiological and pathological processes associated with different diseases. Specifically, they promote angiogenesis in the pathogenesis of some diseases. According to previous research, the proteins of exosomes taken from the aqueous humor (AH) of patients with wet-age related macular degeneration (AMD) may function as a new diagnostic biomarker of AMD, suggesting that exosomes may play an important role in the occurrence and development of choroidal neovascularization (CNV). Moreover, additional research has revealed that the levels of some protein makers of exosomes are up-regulated in aged retinal pigment epithelium (RPE) and that drusen and oxidative stress may promote the secretion of exosomes derived from RPE cells. Consequently, we hypothesize that RPE cell-derived exosomes may be relevant to CNV in wet AMD. If this hypothesis is proven correct, future studies based on this link may also help to elucidate the molecular mechanisms of wet AMD and to find new therapeutic targets for the treatment of AMD. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Tong, Yao; Zhou, Ya-Li; Wang, Yi-Xiao; Wang, Zhao-Yang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Ophthalmol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Tong, Yao; Zhao, Pei-Quan] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Ophthalmol, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Wang, ZY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Ophthalmol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM zhaokekewzy@hotmail.com
FU Project of the National Natural Science Funds of China [81371040];
   Shanghai Pujiang Program [15PJD028]
FX Project of the National Natural Science Funds of China (No. 81371040);
   Shanghai Pujiang Program (No. 15PJD028).
CR Atienzar-Aroca S, 2016, J CELL MOL MED, V21
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Dimov I, 2009, THESCIENTIFICWORLDJO, V9, P1107, DOI 10.1100/tsw.2009.128
   Dutta S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097580
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garcia NA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138849
   Guduric-Fuchs J, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-357
   Hajrasouliha AR, 2013, J BIOL CHEM, V288, P28058, DOI 10.1074/jbc.M113.470765
   Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507
   Hu GW, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt546
   Inal JM, 2013, BBA-PROTEINS PROTEOM, V1834, P2317, DOI 10.1016/j.bbapap.2013.04.005
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Y, 2016, CANCER LETT, V370, P125, DOI 10.1016/j.canlet.2015.10.011
   Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285
   Nolte-'t Hoen ENM, 2012, NUCLEIC ACIDS RES, V40, P9272, DOI 10.1093/nar/gks658
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Sulaiman RS, 2015, J OCUL PHARMACOL TH, V31, P447, DOI 10.1089/jop.2015.0049
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Villarroya-Beltri C, 2014, SEMIN CANCER BIOL, V28, P3, DOI 10.1016/j.semcancer.2014.04.009
   Villarroya-Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980
   Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152
   Yi H, 2015, INT J CLIN EXP PATHO, V8, P5062
   Yuan MJ, 2016, INT J MED SCI, V13, P113, DOI 10.7150/ijms.14112
   Zhang HG, 2011, CLIN CANCER RES, V17, P959, DOI 10.1158/1078-0432.CCR-10-1489
NR 35
TC 12
Z9 12
U1 0
U2 14
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD DEC
PY 2016
VL 97
BP 98
EP 101
DI 10.1016/j.mehy.2016.10.027
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA ED9CD
UT WOS:000389166900021
PM 27876140
DA 2022-11-30
ER

PT J
AU Tanaka, N
   Ikawa, M
   Mata, NL
   Verma, IM
AF Tanaka, N
   Ikawa, M
   Mata, NL
   Verma, IM
TI Choroidal neovascularization in transgenic mice expressing prokineticin
   1: An animal model for age-related macular degeneration
SO MOLECULAR THERAPY
LA English
DT Article
DE prokineticin 1; age-related macular degeneration; choroidal
   neovascularization; lipofuscin; animal model; transgenesis; lentiviral
   vector
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; KRYPTON LASER
   PHOTOCOAGULATION; BRUCHS MEMBRANE; LIPOFUSCIN FLUOROPHORE; LENTIVIRAL
   VECTORS; GENE-EXPRESSION; CELLS; EYE; ULTRASTRUCTURE
AB The prognosis of choroidal neovascularization (CNV) in age-related macular degeneration (AMD) is poor and existing treatments are limited in retarding the progression of disease. The development of an animal model for AMD will be beneficial for finding potential treatments, including gene therapy. Recently prokineticin 1 (hPK1) was identified as a mitogen of fenestrated endothelium. We hypothesized that hPK1 could induce CNV, a hallmark of the exudative or wet form of AMD, since the endothelium of the choriocapillaris, but not retinal endothelium, has fenestration. We generated transgenic mice expressing hPK1 in the retina using the rhodopsin promoter. In these transgenic mice, an enlarged vascular bed of choroid resembling CNV was observed without any morphological changes in the retinal vasculature. In addition, the major fluorophore of lipofuscin, N-retinylidene-N-retinylethanolamine, which has several potential cytotoxic effects on the RPE, was accumulated approximately twice as much in the transgenic mouse eyes compared to controls. hPK1 could be one of the causative factors of AMD and the transgenic mouse exhibiting CNV may be useful to establish treatments for the wet form of AMD.
C1 Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA.
   Sytera Inc, La Jolla, CA USA.
C3 Salk Institute
RP Verma, IM (通讯作者)，Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA.
EM verma@salk.edu
RI ikawa, masahito/A-5315-2009
OI ikawa, masahito/0000-0001-9859-6217
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   HO YG, 1995, MOL REPROD DEV, V41, P232, DOI 10.1002/mrd.1080410214
   Ikawa M, 2003, MOL THER, V8, P666, DOI 10.1016/S1525-0016(03)00240-5
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kim SR, 2004, P NATL ACAD SCI USA, V101, P11668, DOI 10.1073/pnas.0403499101
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LAITINEN L, 1987, HISTOCHEM J, V19, P225, DOI 10.1007/BF01680633
   LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li M, 2001, MOL PHARMACOL, V59, P692, DOI 10.1124/mol.59.4.692
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998
   Mousseau N, 1999, COMPUT SCI ENG, V1, P74, DOI 10.1109/5992.753050
   NAITO K, 1992, HUM REPROD, V7, P281, DOI 10.1093/oxfordjournals.humrep.a137633
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Okamoto N, 1997, AM J PATHOL, V151, P281
   POLLACK A, 1986, ARCH OPHTHALMOL-CHIC, V104, P1372, DOI 10.1001/archopht.1986.01050210126039
   POLLACK A, 1986, ARCH OPHTHALMOL-CHIC, V104, P1377, DOI 10.1001/archopht.1986.01050210131040
   Ramezani A, 2000, MOL THER, V2, P458, DOI 10.1006/mthe.2000.0190
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   SOUBRANE G, 1994, CURR EYE RES, V13, P183, DOI 10.3109/02713689408995776
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   SPITZNAS M, 1975, INVEST OPHTH VISUAL, V14, P98
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4
NR 32
TC 13
Z9 20
U1 1
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD MAR
PY 2006
VL 13
IS 3
BP 609
EP 616
DI 10.1016/j.ymthe.2005.08.024
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 027VX
UT WOS:000236445000017
PM 16263331
OA hybrid
DA 2022-11-30
ER

PT J
AU Kim, K
   Kim, ES
   Kim, Y
   Yang, JH
   Yu, SY
   Kwak, HW
AF Kim, Kiyoung
   Kim, Eung Suk
   Kim, Yonguk
   Yang, Ji Ho
   Yu, Seung-Young
   Kwak, Hyung Woo
TI OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL
   DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; pigment epithelial
   detachment; subretinal fluid; aflibercept
ID VEGF TRAP; RANIBIZUMAB; TACHYPHYLAXIS; BEVACIZUMAB
AB Purpose: To investigate the outcomes of intravitreal aflibercept in refractory pigment epithelial detachment (PED) with or without subretinal fluid (SRF) in patients with neovascular age-related macular degeneration.
   Methods: A prospective, nonrandomized, interventional case series involved 40 patients with persistent vascularized PED previously treated with at least 3 injections of intravitreal bevacizumab or ranibizumab. Intravitreal aflibercept was administered as 3 initial loading doses every 4 weeks, followed by pro re nata retreatment every 8 weeks over 48 weeks. Pigment epithelial detachment was classified into solid-, hollow-, or mixed-type according to the reflective properties visualized using optical coherence tomography. The mean changes in best-corrected visual acuity, central subfield thickness, and the volumes of SRF and PED were analyzed.
   Results: The PED volume (baseline: 0.43 +/- 0.55 mm3) significantly reduced to 0.23 +/- 0.32 mm(3) at Week 8 (P = 0.003) and increased to 0.36 +/- 0.41 mm(3) at Week 48 (P = 0.345). The SRF volume (baseline: 0.52 +/- 0.64 mm(3)) significantly reduced to 0.24 +/- 0.43 mm(3) at Week 48 (P = 0.021). The mean baseline best-corrected visual acuity was 20/75 (47.5 letters); it showed no significant difference at Week 48 (+ 4.4 letters; P = 0.125). The baseline central subfield thickness was 323.2 +/- 92.3 mm; it significantly reduced to 281.2 +/- 90.7 mm at Week 48 (P = 0.001). In solid-type PEDs, there were poorer improvements in central subfield thickness, best-corrected visual acuity, and the volumes of the SRF and PED, with newly developed intraretinal cysts.
   Conclusion: Intravitreal aflibercept in treatment-resistant neovascular age-related macular degeneration led to significant reduction in PED and SRF volume, central subfield thickness, and best-corrected visual acuity preserved, over 12 months. However, solidtype PED showed less improvement than hollow-or mixed-type PED.
C1 [Kim, Kiyoung; Kim, Eung Suk; Kim, Yonguk; Yu, Seung-Young; Kwak, Hyung Woo] Kyung Hee Univ, Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Yang, Ji Ho] Seonam Univ, Myongji Hosp, Dept Ophthalmol, Goyang, South Korea.
C3 Kyung Hee University; Myongji Hospital; Seonam University
RP Yu, SY (通讯作者)，Kyung Hee Univ Hosp, Dept Ophthalmol, 23,Kyungheedae Ro, Seoul 02447, South Korea.
EM syyu@khu.ac.kr
RI KIM, KIYOUNG/GWM-6103-2022
FU Bayer
FX Funded by Bayer through an investigator-initiated trial. Bayer played no
   role in the design, execution, or analysis of the data, or in the
   writing of the report.
CR Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Geus SJR, 2013, ACTA OPHTHALMOL, V91, pE411, DOI 10.1111/aos.12090
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   He LM, 2016, RETINA-J RET VIT DIS, V36, P492, DOI 10.1097/IAE.0000000000000749
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Zinkernagel MS, 2016, OPHTHALMOLOGICA, V235, P42, DOI 10.1159/000441428
NR 25
TC 7
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2019
VL 39
IS 2
BP 303
EP 313
DI 10.1097/IAE.0000000000001947
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4RW
UT WOS:000480739100011
PM 29160779
DA 2022-11-30
ER

PT J
AU Kucukerdonmez, C
   Gelisken, F
   Yoeruek, E
   Bartz-Schmidt, KU
   Leitritz, MA
AF Kucukerdonmez, Cem
   Gelisken, Faik
   Yoeruek, Efdal
   Bartz-Schmidt, Karl Ulrich
   Leitritz, Martin Alexander
TI Switching intravitreal anti-VEGF treatment in neovascular age-related
   macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-vascular endothelial growth
   factor; Drug switch; Treatment
ID RANIBIZUMAB; BEVACIZUMAB; TACHYPHYLAXIS; ASSOCIATION; THERAPY
AB Purpose: To compare the outcomes after switching between bevacizumab and ranibizumab therapy due to poor treatment effect in neovascular age-related macular degeneration (AMD).
   Methods: This is a retrospective review of patients with neovascular AMD with first treatment using intravitreal bevacizumab (group 1) or ranibizumab (group 2) who switched to the other drug due to poor treatment effect. Primary outcome measures were change in mean best-corrected visual acuity (BCVA) and mean central retinal thickness (CRT) at 1 year and last visit.
   Results: Eighty-seven eyes met the inclusion criteria. In group 1 (43 eyes), the mean BCVA decreased from 20/94 to 20/100 at 1 year after being switched (p = 0.573) and to 20/150 (p = 0.015) at final visit (mean 29.2 months, range 12-53). In group 2 (44 eyes), mean BCVA decreased from 20/72 to 20/90 (p = 0.401) and 20/100 (p = 0.081) at 1 year after switch and at final visit (mean 20.1 months, range 10-40), respectively. The mean CRT at switch, 1 year after switch, and at final visit were 344.4 +/- 140 mu m (mean +/- SD), 286.26 +/- 155 mu m (p = 0.019), and 290.58 +/- 196 mu m (p = 0.009) in group 1 and 329.36 +/- 144 mu m, 302.0 +/- 179 mu m (p = 0.215), and 309.5 +/- 220 mu m (p = 0.154) in group 2, respectively.
   Conclusions: The mean BCVA decreased over time in both groups; however, nearly 30% of the eyes in each group showed vision improvement after switching. Mean CRT decreased in both groups, which was more pronounced after being switched from bevacizumab to ranibizumab. In neovascular AMD, a switch between ranibizumab and bevacizumab can be considered as a further therapy option if poor treatment effect is seen with the initial therapy.
C1 [Kucukerdonmez, Cem] Izmir Univ, Fac Med, Dept Ophthalmol, TR-35350 Izmir, Turkey.
   [Gelisken, Faik; Yoeruek, Efdal; Bartz-Schmidt, Karl Ulrich; Leitritz, Martin Alexander] Univ Tubingen, Ctr Ophthalmol, Tubingen, Germany.
C3 Izmir University; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital
RP Kucukerdonmez, C (通讯作者)，Izmir Univ, Fac Med, Dept Ophthalmol, Gursel Aksel Bulvari 14, TR-35350 Izmir, Turkey.
EM drcemk@hotmail.com
OI Leitritz, Martin/0000-0001-5179-2536
CR Almony A, 2011, CAN J OPHTHALMOL, V46, P182, DOI 10.3129/i10-095
   Aslankurt M, 2013, EUR J OPHTHALMOL, V23, P553, DOI 10.5301/ejo.5000268
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Ehlers JP, 2010, OPHTHAL SURG LAS IM, V41, P182, DOI 10.3928/15428877-20100303-05
   Forooghian F, 2011, ACTA OPHTHALMOL, V89, pE206, DOI 10.1111/j.1755-3768.2009.01773.x
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Johnson DW, 2013, AMER MADE MUSIC SER, P205
   Kaiser RS, 2012, OPHTHAL SURG LAS IM, V43, P13, DOI 10.3928/15428877-20111006-01
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P457
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kent JS, 2012, CAN J OPHTHALMOL, V47, P159, DOI 10.1016/j.jcjo.2012.01.003
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moutray T, 2011, THER ADV CHRONIC DIS, V2, P325, DOI 10.1177/2040622311415895
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Wang VM, 2012, MOL VIS, V18, P2578
NR 20
TC 8
Z9 8
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2015
VL 25
IS 1
BP 51
EP 56
DI 10.5301/ejo.5000480
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE9YU
UT WOS:000352200400009
PM 24980110
DA 2022-11-30
ER

PT J
AU Akuffo, KO
   Beatty, S
   Peto, T
   Stack, J
   Stringham, J
   Kelly, D
   Leung, I
   Corcoran, L
   Nolan, JM
AF Akuffo, Kwadwo Owusu
   Beatty, Stephen
   Peto, Tunde
   Stack, Jim
   Stringham, Jim
   Kelly, David
   Leung, Irene
   Corcoran, Laura
   Nolan, John M.
TI The Impact of Supplemental Antioxidants on Visual Function in
   Nonadvanced Age-Related Macular Degeneration: A Head-to-Head Randomized
   Clinical Trial
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE randomized clinical trial; lutein; zeaxanthin; meso-zeaxanthin; macular
   pigment; age-related macular degeneration; visual function; visual
   acuity; contrast sensitivity; macular pigment; NEI VFQ-25; photostress
   recovery time; reading performance; glare disability; retinal straylight
ID BASE-LINE-CHARACTERISTICS; CONTRAST SENSITIVITY; EYE DISEASE; SURGICAL
   REMOVAL; ZEAXANTHIN; PIGMENT; LUTEIN; CAROTENOIDS; CATARACT; PREVALENCE
AB PURPOSE. The purpose of this study was to evaluate the impact of supplemental macular carotenoids (including versus not including meso-zeaxanthin) in combination with coantioxidants on visual function in patients with nonadvanced age-related macular degeneration.
   METHODS. In this study, 121 participants were randomly assigned to group 1 (Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc and an addition of 10 mg meso-zeaxanthin; n = 60) or group 2 (Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc; n = 61). Visual function was assessed using best-corrected visual acuity, contrast sensitivity (CS), glare disability, retinal straylight, photostress recovery time, reading performance, and the National Eye Institute Visual Function Questionnaire-25. Macular pigment was measured using customized heterochromatic flicker photometry.
   RESULTS. There was a statistically significant improvement in the primary outcome measure (letter CS at 6 cycles per degree [6 cpd]) over time (P = 0.013), and this observed improvement was statistically comparable between interventions (P = 0.881). Statistically significant improvements in several secondary outcome visual function measures (letter CS at 1.2 and 2.4 cpd; mesopic and photopic CS at all spatial frequencies; mesopic glare disability at 1.5, 3, and 6 cpd; photopic glare disability at 1.5, 3, 6, and 12 cpd; photostress recovery time; retinal straylight; mean and maximum reading speed) were also observed over time (P < 0.05, for all), and were statistically comparable between interventions (P > 0.05, for all). Statistically significant increases in macular pigment at all eccentricities were observed over time (P < 0.0005, for all), and the degree of augmentation was statistically comparable between interventions (P > 0.05).
   CONCLUSIONS. Antioxidant supplementation in patients with nonadvanced age-related macular degeneration results in significant increases in macular pigment and improvements in CS and other measures of visual function.
C1 [Akuffo, Kwadwo Owusu; Beatty, Stephen; Stack, Jim; Kelly, David; Corcoran, Laura; Nolan, John M.] Waterford Inst Technol, Nutr Res Ctr Ireland, Sch Hlth Sci, Macular Pigment Res Grp, Waterford, Ireland.
   [Peto, Tunde] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Stringham, Jim] Univ Georgia, Dept Physiol & Pharmacol, Nutr Neurosci Lab, Athens, GA 30602 USA.
   [Leung, Irene] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Leung, Irene] UCL Inst Ophthalmol, London, England.
C3 South East Technological University (SETU); Queens University Belfast;
   University System of Georgia; University of Georgia; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London
RP Nolan, JM (通讯作者)，Waterford Inst Technol, Macular Pigment Res Grp, Nutr Res Ctr Ireland, West Campus, Carriganore X91 K236, Waterford, Ireland.
EM jmnolan@wit.ie
RI Peto, Tunde/G-8812-2018; Akuffo, Kwadwo Owusu/J-2036-2019; Nolan,
   John/N-4921-2014
OI Peto, Tunde/0000-0001-6265-0381; Akuffo, Kwadwo
   Owusu/0000-0001-6683-249X; Nolan, John/0000-0002-5503-7084
FU European Research Council [281096]; National Institute of Health
   Research Biomedical Research Centre at Moorfields Eye Hospital;
   University College London Institute of Ophthalmology
FX The authors thank the Whitfield Clinic Pharmacy, Waterford, Ireland, for
   their support with randomization and intervention assignment (Catherine
   Kelly [Chief Pharmacist] and Lisa O'Brien [Pharmacy Technician]). They
   also thank Moorfields Eye Hospital Reading Centre, London, United
   Kingdom, for retinal photograph grading where Tunde Peto and Irene Leung
   have been funded by the National Institute of Health Research Biomedical
   Research Centre at Moorfields Eye Hospital and University College London
   Institute of Ophthalmology. They also thank Elizabeth Johnson from Tufts
   University, Boston, Massachusetts, United States, for permission to use
   the "L/Z screener" for estimating dietary intake of lutein and
   zeaxanthin in this study. They also thank the CREST Data Safety and
   Monitoring Committee (James Loughman [Chairperson and Vision Scientist],
   Ailbhe Whyte [Medical Ophthalmologist], Michael Harrison [Research
   Ethics Committee member], and Frank Leonard [Statistician]) for their
   support and guidance during the Central Retinal Enrichment
   Supplementation Trials study.; Supported by the European Research
   Council Grant 281096.
CR Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Akuffo KO, 2017, BRIT J OPHTHALMOL, V101, P190, DOI 10.1136/bjophthalmol-2016-308418
   Akuffo KO, 2016, INVEST OPHTH VIS SCI, V57, P2552, DOI 10.1167/iovs.16-19141
   Akuffo KO, 2015, INVEST OPHTH VIS SCI, V56, P8207, DOI 10.1167/iovs.15-17822
   Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Akuffo KO, 2014, OPHTHAL EPIDEMIOL, V21, P111, DOI 10.3109/09286586.2014.888085
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bovier ER, 2015, ARCH BIOCHEM BIOPHYS, V572, P54, DOI 10.1016/j.abb.2014.11.012
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Charalampidou S, 2011, ARCH OPHTHALMOL-CHIC, V129, P1155, DOI 10.1001/archophthalmol.2011.111
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Choudhury F, 2016, JAMA OPHTHALMOL, V134, P683, DOI 10.1001/jamaophthalmol.2016.0794
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P1338
   Crosby-Nwaobi R, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S102798
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Fletcher LM, 2014, OPTOMETRY VISION SCI, V91, P1089, DOI 10.1097/OPX.0000000000000355
   Hammond BR, 2012, AM J CLIN NUTR, V96, p1207S, DOI 10.3945/ajcn.112.034876
   Hammond BR, 2012, VISION RES, V63, P58, DOI 10.1016/j.visres.2012.04.019
   Huang YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/564738
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Leat SJ, 1999, OPTOMETRY VISION SCI, V76, P198, DOI 10.1097/00006324-199904000-00023
   LEGGE GE, 1987, VISION RES, V27, P1165, DOI 10.1016/0042-6989(87)90028-9
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mainster MA, 2012, AM J OPHTHALMOL, V153, P587, DOI 10.1016/j.ajo.2012.01.008
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Maynard ML, 2016, ACTA OPHTHALMOL, V94, pE772, DOI 10.1111/aos.13112
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Nolan JM, 2009, INVEST OPHTH VIS SCI, V50, P4777, DOI 10.1167/iovs.08-3277
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Owsley C, 1999, SURV OPHTHALMOL, V43, P535, DOI 10.1016/S0039-6257(99)00035-1
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   Pelli DG, 2013, VISION RES, V90, P10, DOI 10.1016/j.visres.2013.04.015
   Renzi LM, 2010, OPHTHAL PHYSL OPT, V30, P351, DOI 10.1111/j.1475-1313.2010.00720.x
   Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Stringham JM, 2007, OPTOMETRY VISION SCI, V84, P859, DOI 10.1097/OPX.0b013e3181559c2b
   Stringham JM, 2017, INVEST OPHTH VIS SCI, V58, P2291, DOI 10.1167/iovs.16-21087
   Stringham NT, 2015, PERCEPTION, V44, P1400, DOI 10.1177/0301006615607119
   Vos J. J., 1984, CIE Journal, V3, P39
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
NR 47
TC 28
Z9 28
U1 2
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2017
VL 58
IS 12
BP 5347
EP 5360
DI 10.1167/iovs.16-21192
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL5JN
UT WOS:000414272100036
PM 29053808
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Droz, I
   Mantel, I
   Ambresin, A
   Faouzi, M
   Schorderet, DF
   Munier, FL
AF Droz, I.
   Mantel, I.
   Ambresin, A.
   Faouzi, M.
   Schorderet, D. F.
   Munier, F. L.
TI Genotype-phenotype correlation of age-related macular degeneration:
   influence of complement factor H polymorphism
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID JAPANESE POPULATION; STRONG ASSOCIATION; CIGARETTE-SMOKING; SEVERITY
   SCALE; Y402H VARIANT; RISK; MACULOPATHY; SUSCEPTIBILITY; GENE; CFH
AB Background/aims: Complement factor H ( CFH) Y402H polymorphism shows a strong association with age-related macular degeneration (AMD). Although the phenotypic concordance of AMD has been shown in sibling/twin studies, little is known about the genotype phenotype association. In this study, we investigated whether CFH Y402H is associated with early phenotypic features.
   Methods: Statistical analysis was performed on 420 patients with AMD with complete clinical and genetic data ( graded colour fundus photographs, according to the International Classification and Grading System for AMD and successful testing for CFH Y402H).
   Results: In this Swiss population, an OR of 2.95 was confirmed for AMD in the presence of at least one risk C allele and OR of 9.05 for the CC homozygotes, corrected for age and sex. No difference was found between the AMD stages. Patients homozygous for the risk allele showed significant association with peripheral drusen ( p= 0.028) and for central drusen location ( p= 0.049). No trend was found for other drusen criteria ( size, total surface, location nasal to disc) and for pigmentary changes.
   Conclusions: The CFH Y402H polymorphism showed a genotype - phenotype association for some drusen features. Additional genetic factors are likely to influence drusen phenotype.
C1 [Droz, I.; Mantel, I.; Ambresin, A.; Munier, F. L.] Univ Lausanne, Dept Ophthalmol, Jules Gonin Eye Hosp, CH-1015 Lausanne, Switzerland.
   [Faouzi, M.] Univ Lausanne Hosp, Ctr Epidemiol Clin, Lausanne, Switzerland.
   [Schorderet, D. F.] Univ Lausanne, Inst Rech & Ophtalmol, CH-1015 Lausanne, Switzerland.
   [Schorderet, D. F.] Swiss Fed Inst Technol, EPFL, CH-1015 Lausanne, Switzerland.
C3 University of Lausanne; University of Lausanne; Centre Hospitalier
   Universitaire Vaudois (CHUV); University of Lausanne; Swiss Federal
   Institutes of Technology Domain; Ecole Polytechnique Federale de
   Lausanne
RP Mantel, I (通讯作者)，Univ Eye Hosp Jules Gonin, 15 Av France Case Postale 133,Lausanne 7, CH-1000 Lausanne, Switzerland.
EM irmela.mantel@ophtal.vd.ch
CR Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen LJ, 2006, MOL VIS, V12, P1536
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Dandekar SS, 2006, BRIT J OPHTHALMOL, V90, P724, DOI 10.1136/bjo.2005.086355
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   GORIN MB, 1993, RETINAL DEGENERATION, P35
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MORI K, 2007, INVEST OPHTHALMOL VI, V48
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Okamoto H, 2006, MOL VIS, V12, P156
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   ROBMAN L, 2007, INVEST OPHTHALMOL VI, V48
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Scholl HPN, 2007, MOL VIS, V13, P196
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2005, MOL VIS, V11, P1135
   SVERRISSON T, 1995, INVEST OPHTH VIS SCI, V36, pS10
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 66
TC 29
Z9 30
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2008
VL 92
IS 4
BP 513
EP 517
DI 10.1136/bjo.2007.127811
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 279XH
UT WOS:000254388200019
PM 18211923
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Hunter, AA
   Smit-McBride, Z
   Anderson, R
   Bordbari, MH
   Ying, GS
   Kim, ES
   Park, SS
   Telander, DG
   Dunaief, JL
   Hjelmeland, LM
   Morse, LS
AF Hunter, Allan A., III
   Smit-McBride, Zeljka
   Anderson, Rachel
   Bordbari, Matthew H.
   Ying, Gui-shuang
   Kim, Esther S.
   Park, Susanna S.
   Telander, David G.
   Dunaief, Joshua L.
   Hjelmeland, Leonard M.
   Morse, Lawrence S.
TI GSTM1 and GSTM5 Genetic Polymorphisms and Expression in Age-Related
   Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration (AMD); expression repression; genomic
   copy number; glutathione-S-transferase; oxidative stress
ID GLUTATHIONE-S-TRANSFERASE; LARYNX CANCER-RISK; OXIDATIVE STRESS; HUMAN
   GENOME; STRUCTURAL VARIATION; GSTT1; SUSCEPTIBILITY; GENOTYPES; RETINA;
   GSTP1
AB Purpose: Previously, two cytosolic antioxidant enzymes, Glutathione S-transferase Mu 1 (GSTM1) and Mu 5 (GSTM5), were reduced in retinas with age-related macular degeneration (AMD). This study compared genomic copy number variations (gCNV) of these two antioxidant enzymes in AMD versus controls.
   Methods: Genomic copy number (gCN) assays were performed using Taqman Gene Copy Number Assays (Applied Biosystems, Darmstadt, Germany) in technical quadruplicate for both GSTM1 and GSTM5. Peripheral leukocyte RNA levels were compared with controls in technical triplicates. Statistical comparisons were performed in SAS v9.2 (SAS Institute Inc., Cary, NC).
   Results: A large percentage of patients in both AMD and age-matched control groups had no copies of GSTM1 (0/0). The mean gCN of GSTM1 was 1.40 (range 0-4) and 1.61 (range 0-5) for AMD and control, respectively (p = 0.29). A greater percentage of control patients had>3 gCNs of GSTM1 compared with AMD, respectively (15.3% versus 3.0%, p = 0.004). The gCN of GSTM5 was 2 in all samples except one control sample. The relative quantification of GSTM1 and GSTM5 mRNA from peripheral blood leukocytes in patients showed significant differences in relative expression in AMD versus control (p<0.05). Peripheral blood leukocyte mRNA and gCN were not significantly correlated (p = 0.27).
   Conclusion: Since high copy numbers of GSTM1 are found more frequently in controls than in AMD, it is possible that high copy number leads to increased retinal antioxidant defense. Genomic polymorphisms of GSTM1 and GSTM5 do not significantly affect the peripheral blood leukocyte mRNA levels.
C1 [Hunter, Allan A., III; Smit-McBride, Zeljka; Anderson, Rachel; Bordbari, Matthew H.; Kim, Esther S.; Park, Susanna S.; Telander, David G.; Hjelmeland, Leonard M.; Morse, Lawrence S.] Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, 4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
   [Ying, Gui-shuang; Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, Perelman Sch Med, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of California System; University of California Davis;
   University of Pennsylvania; Pennsylvania Medicine
RP Hunter, AA (通讯作者)，Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, 4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
EM hunter.allan.a@gmail.com
RI Hunter, Allan/AAJ-5848-2020
OI Smit-McBride, Zeljka/0000-0003-0275-8088; Bordbari,
   Matthew/0000-0002-8699-2826; Morse, Lawrence/0000-0002-1758-2348
FU Research to Prevent Blindness (RBP); University of California, Davis
   Macular Degeneration Research Funds; PENN Vision Clinical Scientist
   Program [5K12EY015398]; Research to Prevent Blindness Unrestricted
   Departmental Grant; NATIONAL EYE INSTITUTE [K12EY015398, P30EY001583,
   P30EY012576] Funding Source: NIH RePORTER
FX This work was supported by grant(s) from the Research to Prevent
   Blindness (RBP) to the University of California, Davis and by the
   University of California, Davis Macular Degeneration Research Funds
   (LSM). This study was supported in part by PENN Vision Clinical
   Scientist Program (Grant Number 5K12EY015398) and Research to Prevent
   Blindness Unrestricted Departmental Grant.
CR BALIN AK, 1986, DERMATOL CLIN, V4, P347, DOI 10.1016/S0733-8635(18)30798-8
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Brasch-Andersen C, 2004, HUM MUTAT, V24, P208, DOI 10.1002/humu.20074
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DelaPaz MA, 1996, BRIT J OPHTHALMOL, V80, P445, DOI 10.1136/bjo.80.5.445
   Dumanski JP, 2012, METHODS MOL BIOL, V838, P249, DOI 10.1007/978-1-61779-507-7_12
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Grayson BL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015393
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guven M, 2011, OPHTHALMIC RES, V46, P31, DOI 10.1159/000321940
   HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416
   Jahnke V, 1996, AM J SURG, V172, P671, DOI 10.1016/S0002-9610(96)00298-X
   Joshi PM, 2009, INVEST OPHTHALMOL VI, V2009
   Jourenkova N, 1998, CANCER EPIDEM BIOMAR, V7, P19
   Jourenkova-Mironova N, 1999, CANCER EPIDEM BIOMAR, V8, P185
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keys SA, 1999, EXP EYE RES, V68, P693, DOI 10.1006/exer.1999.0657
   Kidd JM, 2008, NATURE, V453, P56, DOI 10.1038/nature06862
   Kihara M, 1997, CANCER LETT, V112, P257, DOI 10.1016/S0304-3835(96)04584-3
   LAFUENTE A, 1993, CANCER LETT, V68, P49, DOI 10.1016/0304-3835(93)90218-X
   Lee JA, 2006, NEURON, V52, P103, DOI 10.1016/j.neuron.2006.09.027
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Lupski JR, 2007, NEW ENGL J MED, V356, P1169, DOI 10.1056/NEJMcibr067658
   Martinez-Lara E, 2003, NEUROBIOL AGING, V24, P501, DOI 10.1016/S0197-4580(02)00139-2
   Michaelson JJ, 2012, CELL, V151, P1431, DOI 10.1016/j.cell.2012.11.019
   Mirza S, 2010, MOL VIS, V16, P2425
   NAKAJIMA T, 1995, CARCINOGENESIS, V16, P707, DOI 10.1093/carcin/16.4.707
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Olshan AF, 2000, CANCER EPIDEM BIOMAR, V9, P185
   ORGANISCIAK DT, 1992, CURR EYE RES, V11, P231, DOI 10.3109/02713689209001774
   Peinado MA, 1997, ANAT REC, V247, P420
   PETROVA L I, 1975, Prikladnaya Biokhimiya i Mikrobiologiya, V11, P63
   Piacentini S, 2013, ANN HUM GENET, V77, P409, DOI 10.1111/ahg.12025
   Rebbeck TR, 1997, CANCER EPIDEM BIOMAR, V6, P733
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918
   Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001
   SIES H, 1991, AM J MED, V91, pS31, DOI 10.1016/0002-9343(91)90281-2
   SINGH SV, 1984, CURR EYE RES, V3, P1273, DOI 10.3109/02713688409007413
   Strange RC, 2000, TOXICOL LETT, V112, P357, DOI 10.1016/S0378-4274(99)00230-1
   Wang YC, 2011, J NEPHROL, V24, P351, DOI 10.5301/JN.2010.5816
   YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139
NR 45
TC 5
Z9 5
U1 2
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2016
VL 41
IS 3
BP 410
EP 416
DI 10.3109/02713683.2015.1016179
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL1NP
UT WOS:000375399200018
PM 25897651
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Paun, CC
   Lechanteur, YTE
   Groenewoud, JMM
   Altay, L
   Schick, T
   Daha, MR
   Fauser, S
   Hoyng, CB
   den Hollander, AI
   de Jong, EK
AF Paun, Constantin C.
   Lechanteur, Yara T. E.
   Groenewoud, Joannes M. M.
   Altay, Lebriz
   Schick, Tina
   Daha, Mohamed R.
   Fauser, Sascha
   Hoyng, Carel B.
   den Hollander, Anneke I.
   de Jong, Eiko K.
TI A Novel Complotype Combination Associates with Age-Related Macular
   Degeneration and High Complement Activation Levels in vivo
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FACTOR-H; ALTERNATIVE PATHWAY; FACTOR-B; RISK; PROTEIN; VARIANT; SYSTEM;
   C3B; INFLAMMATION; POLYMORPHISM
AB The complement system is the first line of defense against foreign intruders, and deregulation of this system has been described in multiple diseases. In age-related macular degeneration (AMD), patients have higher complement activation levels compared to controls. Recently, a combination of three single nucleotide polymorphisms (SNPs) in genes of the complement system, referred to as a complotype, has been described to increase complement activation in vitro. Here we describe a novel complotype composed of CFB (rs4151667)-CFB (rs641153)-CFH (rs800292), which is strongly associated with both AMD disease status (p = 5.84*10(-13)) and complement activation levels in vivo (p = 8.31*10(-9)). The most frequent genotype combination of this complotype was associated with the highest complement activation levels in both patients and controls. These findings are relevant in the context of complement-lowering treatments for AMD that are currently under development. Patients with a genetic predisposition to higher complement activation levels will potentially benefit the most of such treatments.
C1 [Paun, Constantin C.; Lechanteur, Yara T. E.; Hoyng, Carel B.; den Hollander, Anneke I.; de Jong, Eiko K.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Paun, Constantin C.; den Hollander, Anneke I.; de Jong, Eiko K.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands.
   [Groenewoud, Joannes M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, NL-6525 ED Nijmegen, Netherlands.
   [Altay, Lebriz; Schick, Tina; Fauser, Sascha] Univ Hosp, Dept Ophthalmol, Cologne, Germany.
   [Daha, Mohamed R.] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; University of Cologne; Leiden University; Leiden
   University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud
   University Nijmegen
RP de Jong, EK (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.; de Jong, EK (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, NL-6525 ED Nijmegen, Netherlands.
EM Eiko.deJong@radboudumc.nl
RI Lechanteur, Yara/ABB-6875-2020; de Jong, Eiko/P-3407-2015; Hollander,
   Anneke den/N-4911-2014; Groenewoud, Hans JMM/R-3588-2017; Lehtimäki,
   Terho/AAD-1094-2022
OI Lechanteur, Yara/0000-0003-0951-4625; de Jong, Eiko/0000-0001-6520-0407;
   Groenewoud, Hans JMM/0000-0002-4974-150X; Lehtimäki,
   Terho/0000-0002-2555-4427
FU Foundation Fighting Blindness Center, Columbia, MD, USA
   [C-GE-0811-0548-RAD04]; European Research Council under the European
   Union [310644]; Stichting A.F. Deutman Oogheelkunde Researchfonds
   Nijmegen (Nijmegen, Gelderland, the Netherlands)
FX This work was supported by the Foundation Fighting Blindness Center
   Grant to the Radboud University Medical Center (grant
   C-GE-0811-0548-RAD04, Columbia, MD, USA), European Research Council
   under the European Union's Seventh Framework Programme (FP/2007-2013) /
   ERC Grant Agreement no. 310644 (MACULA), and the Stichting A.F. Deutman
   Oogheelkunde Researchfonds Nijmegen (Nijmegen, Gelderland, the
   Netherlands). We thank Ngaisah Klar, Bjorn Bakker and Bert Janssen for
   the excellent technical support.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   de Jong P. T., 2006, NEW ENGL J MED, V355, P1474, DOI [10.1056/NEJMra062326, DOI 10.1056/NEJMRA062326]
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Harris CL, 2012, TRENDS IMMUNOL, V33, P513, DOI 10.1016/j.it.2012.06.001
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109
   Lay E, 2015, CLIN EXP IMMUNOL, V181, P314, DOI 10.1111/cei.12437
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366
   Nielsen R, 2005, PLOS BIOL, V3, P976, DOI 10.1371/journal.pbio.0030170
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856
   Pechtl IC, 2011, J BIOL CHEM, V286, P11082, DOI 10.1074/jbc.M110.211839
   PEITSCH M C, 1991, Current Opinion in Cell Biology, V3, P710, DOI 10.1016/0955-0674(91)90045-Z
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 38
TC 23
Z9 23
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 31
PY 2016
VL 6
AR 26568
DI 10.1038/srep26568
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DN2DI
UT WOS:000376873900001
PM 27241480
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Uka, J
   Tamura, H
   Kobayashi, T
   Yamane, K
   Kawakami, H
   Minamoto, A
   Mishima, HK
AF Uka, Junko
   Tamura, Hiroki
   Kobayashi, Takayuki
   Yamane, Ken
   Kawakami, Hideshi
   Minamoto, Atsushi
   Mishima, Hiromu K.
TI No association of complement factor H gene polymorphism and age-related
   macular degeneration in the Japanese population
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; complement factor H; Japanese;
   polymorphism; prevalence
ID PREVALENCE; SUSCEPTIBILITY; ALLELES; VARIANT
AB Purpose: The aim of this study was to determine whether genetic polymorphism of complement factor H (CFH) is associated with age-related macular degeneration (AMD) in the Japanese population.
   Methods: Genomic DNA was examined in a cohort of 67 Japanese patients with AMD and 107 controls. TT/TC/CC genotypes on exon 9 were screened for sequence alternation by polymerase chain reaction analysis and through sequencing.
   Results: The mean ages +/- SD of AMD patients and control subjects were 73 +/- 8.5 years and 72 +/- 8.7 years, respectively. There was no significant difference between CFH genotypes in the AMD group (TT, 76%; TC, 19%; CC, 5%) and the control group (TT, 80%; TC, 17%; CC, 3%). The frequencies of T and C alleles were 86% and 14%, respectively, in the AMD group and 89% and 11 %, respectively, in the control group.
   Conclusion: CFH gene polymorphism is not associated with AMD in the Japanese population. Moreover, the frequency of the C allele is low among the Japanese population.
C1 Hiroshima Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, Hiroshima 730, Japan.
   Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Epidemiol, Hiroshima 730, Japan.
   W Japan Railway Co, Hiroshima Gen Hosp, Hiroshima, Japan.
   Minamoto Eye Clin, Hiroshima, Japan.
C3 Hiroshima University; Hiroshima University
RP Minamoto, A (通讯作者)，17-12-101 Higashihon Ura, Hiroshima 7340025, Japan.
EM minamoto@beach.ocn.ne.jp
RI Kawakami, Hideshi/A-2086-2009; Kawakami, Hideshi/ABE-4077-2021
OI Kawakami, Hideshi/0000-0002-1405-0901; Kawakami,
   Hideshi/0000-0002-1405-0901
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Okamoto H, 2006, MOL VIS, V12, P156
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 15
TC 61
Z9 66
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2006
VL 26
IS 9
BP 985
EP 987
DI 10.1097/01.iae.0000244068.18520.3e
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 175AZ
UT WOS:000246985700001
PM 17151483
DA 2022-11-30
ER

PT J
AU Ren, CD
   Yu, J
AF Ren, Chengda
   Yu, Jing
TI Potential gene identification and pathway crosstalk analysis of
   age-related macular degeneration
SO FRONTIERS IN GENETICS
LA English
DT Article
DE GO analyses; pathway crosstalk; gene identification; AMD; lipid
   metabolism
ID RETINAL-PIGMENT EPITHELIUM; GENOME-WIDE ASSOCIATION; FACTOR-H; DISEASE;
   RISK; POLYMORPHISM; PREDISPOSES; ACTIVATION; EXPRESSION; BIOMARKERS
AB Age-related macular degeneration (AMD), the most prevalent visual disorder among the elderly, is confirmed as a multifactorial disease. Studies demonstrated that genetic factors play an essential role in its pathogenesis. Our study aimed to make a relatively comprehensive study about biological functions of AMD related genes and crosstalk of their enriched pathways. 1691 AMD genetic studies were reviewed, GO enrichment and pathway crosstalk analyses were conducted to elucidate the biological features of these genes and to demonstrate the pathways that these genes participate. Moreover, we identified novel AMD-specific genes using shortest path algorithm in the context of human interactome. We retrieved 176 significantly AMD-related genes. GO results showed that the most significant term in each of these three GO categories was: signaling receptor binding (P-BH = 4.835 x 10(-7)), response to oxygen-containing compound (P-BH = 2.764 x 10(-21)), and extracellular space (P-BH = 2.081 x 10(-19)). The pathway enrichment analysis showed that complement pathway is the most enriched. The pathway crosstalk study showed that the pathways could be divided into two main modules. These two modules were connected by cytokine-cytokine receptor interaction pathway. 42 unique genes potentially participating AMD development were obtained. The aberrant expression of the mRNA of FASN and LRP1 were validated in AMD cell and mouse models. Collectively, our study carried out a comprehensive analysis based on genetic association study of AMD and put forward several evidence-based genes for future study of AMD.
C1 [Ren, Chengda; Yu, Jing] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Tongji University
RP Yu, J (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
EM dryujing@aliyun.com
FU NSFC; Fundamental Research Funds for the Central Universities; 
   [82101130];  [22120180509]
FX Funding This work was supported by NSFC (82000903) and NSFC (82101130)
   and Fundamental Research Funds for the Central Universities
   (22120180509).
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Atkinson JP, 2007, J EXP MED, V204, P1245, DOI 10.1084/jem.20070664
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Carido M, 2014, INVEST OPHTH VIS SCI, V55, P5431, DOI 10.1167/iovs.14-14325
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Chen L, 2016, MOL MED REP, V13, P3249, DOI 10.3892/mmr.2016.4890
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dubrac A, 2016, CIRCULATION, V133, P409, DOI 10.1161/CIRCULATIONAHA.115.017537
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Elliot S, 2006, INVEST OPHTH VIS SCI, V47, P1696, DOI 10.1167/iovs.05-1258
   Fang AM, 2009, MOL VIS, V15, P2710
   Feldman I, 2008, P NATL ACAD SCI USA, V105, P4323, DOI 10.1073/pnas.0701722105
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Glazko GV, 2009, BIOINFORMATICS, V25, P2348, DOI 10.1093/bioinformatics/btp406
   Goeman JJ, 2007, BIOINFORMATICS, V23, P980, DOI 10.1093/bioinformatics/btm051
   Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Han XK, 2021, INT J EPIDEMIOL, V50, P325, DOI 10.1093/ije/dyaa178
   Hu YS, 2017, MOL NEUROBIOL, V54, P4452, DOI 10.1007/s12035-016-9998-8
   Issa PC, 2018, JAMA OPHTHALMOL, V136, P761, DOI 10.1001/jamaophthalmol.2018.1621
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jia PL, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-S3-S12
   Jia PL, 2011, BIOINFORMATICS, V27, P95, DOI 10.1093/bioinformatics/btq615
   Jiang M, 2013, MOL BIOSYST, V9, P2720, DOI 10.1039/c3mb70089e
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Li Y, 2022, J HEALTHC ENG, V2022, DOI 10.1155/2022/3787567
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Menche J, 2015, SCIENCE, V347, DOI 10.1126/science.1257601
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Owen LA, 2014, INVEST OPHTH VIS SCI, V55, P3543, DOI 10.1167/iovs.14-14047
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Schmitz G, 2002, CURR OPIN LIPIDOL, V13, P513, DOI 10.1097/00041433-200210000-00007
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Storck SE, 2016, J CLIN INVEST, V126, P123, DOI 10.1172/JCI81108
   Sullivan PF, 2004, AM J MED GENET B, V126B, P23, DOI 10.1002/ajmg.b.20138
   Tao Z, 2013, MOL NEUROBIOL, V47, P241, DOI 10.1007/s12035-012-8366-6
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Wysokinski D, 2013, EXP EYE RES, V106, P14, DOI 10.1016/j.exer.2012.10.003
   Xu JZ, 2006, BIOINFORMATICS, V22, P2800, DOI 10.1093/bioinformatics/btl467
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhang J, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/523415
   Zhang QW, 2013, BIOINFORMATICS, V29, P2509, DOI 10.1093/bioinformatics/btt430
NR 67
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD SEP 6
PY 2022
VL 13
AR 992328
DI 10.3389/fgene.2022.992328
PG 24
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 4Q3XV
UT WOS:000856018000001
PM 36147504
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wu, CM
   Su, FH
   Wang, WC
   Lin, CP
   Kamiza, AB
   Chang, SN
   Yeh, CC
AF Wu, Chia-Min
   Su, Fu-Hsiung
   Wang, Wen-Chang
   Lin, Chang-Ping
   Kamiza, Abram Bunya
   Chang, Shih-Ni
   Yeh, Chih-Ching
TI Association of chronic hepatitis B virus infection with age-related
   macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; epidemiology; HBV infection; risk
   factors
ID NUTRITION EXAMINATION SURVEY; KOREAN NATIONAL-HEALTH; GEOGRAPHIC
   ATROPHY; 10-YEAR INCIDENCE; RISK-FACTORS; PREVALENCE; PROGRESSION;
   ADULTS
AB Purpose To study the association between chronic hepatitis B virus (HBV) and age-related macular degeneration (AMD). Methods Data used in this retrospective, frequency-matched cohort study were acquired from the Longitudinal Health Insurance Database 2000, which includes medical claims and registration files for 1 000 000 enrolees in the Taiwan National Health Insurance programme. The HBV cohort contained 17 796 patients who received a diagnosis of chronic HBV infection between January 1, 2000 and December 31, 2012. The non-HBV cohort contained 71 184 participants who were frequency-matched by age, sex and year of index date for comparison. Participants were followed until the end of 2013, and those who developed AMD during the study period were identified. A Cox proportional hazards regression model was used to compare the risk of AMD between cohorts. Results The incidence of any type of AMD in all participants was 3.88 per 1000 person-years (PY; 2.27 per 1000 PY in the HBV cohort; 1.61 per 1000 PY in the non-HBV cohort). Compared with the non-HBV cohort, the adjusted hazard ratio (HR) for any type of AMD in the HBV cohort was 1.41 [95% confidence interval (CI) 1.23-1.63; p AMD (adjusted HR = 1.74, 95% CI: 1.01-2.99). Conclusion Our results suggest that patients with chronic HBV infection in Taiwan have a significantly elevated risk of developing any type of AMD and that HBV infection may accelerate the progression of AMD.
C1 [Wu, Chia-Min] Taipei Med Univ, Shuang Ho Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Wu, Chia-Min; Kamiza, Abram Bunya; Yeh, Chih-Ching] Taipei Med Univ, Sch Publ Hlth, Coll Publ Hlth, 250 Wu Hsing St, Taipei 110, Taiwan.
   [Su, Fu-Hsiung] Fu Jen Catholic Univ, Cardinal Tien Hosp, Dept Family Med, New Taipei, Taiwan.
   [Su, Fu-Hsiung] Fu Jen Catholic Univ Hosp, Sch Med, Coll Med, New Taipei, Taiwan.
   [Su, Fu-Hsiung] Flinders Univ S Australia, Sch Med, Bedford Pk, SA, Australia.
   [Wang, Wen-Chang] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translat Med, Taipei, Taiwan.
   [Lin, Chang-Ping] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chang, Shih-Ni] China Med Univ Hosp, Big Data Ctr, Taichung, Taiwan.
   [Chang, Shih-Ni] China Med Univ, Grad Inst Clin Med Sci, Sch Med, Coll Med, Taichung, Taiwan.
   [Yeh, Chih-Ching] China Med Univ, Dept Publ Hlth, Coll Publ Hlth, Taichung, Taiwan.
C3 Taipei Medical University; Shuang Ho Hospital; Taipei Medical
   University; Fu Jen Catholic University; Fu Jen Catholic University; Fu
   Jen Catholic University Hospital; Flinders University South Australia;
   Taipei Medical University; National Taiwan University; National Taiwan
   University Hospital; China Medical University Taiwan; China Medical
   University Hospital - Taiwan; China Medical University Taiwan; China
   Medical University Taiwan
RP Yeh, CC (通讯作者)，Taipei Med Univ, Sch Publ Hlth, Coll Publ Hlth, 250 Wu Hsing St, Taipei 110, Taiwan.
EM ccyeh@tmu.edu.tw
RI Su, Fu-Hsiung/AAO-5468-2021
OI Yeh, Chih-Ching/0000-0001-6483-1100; Kamiza, Abram
   Bunya/0000-0002-3919-7651; Su, Fu-Hsiung/0000-0002-9867-7655
FU Taiwan Ministry of Health and Welfare Clinical Trial and Research Center
   of Excellence [MOHW106-TDU-B-212-113004]; China Medical University
   Hospital; Academia Sinica Taiwan Biobank Stroke Biosignature Project
   [BM10501010037]; NRPB Stroke Clinical Trial Consortium [MOST
   104-2325-B-039-005]
FX This manuscript was edited by Wallace Academic Editing. This study was
   supported in part by grants from the Taiwan Ministry of Health and
   Welfare Clinical Trial and Research Center of Excellence
   (MOHW106-TDU-B-212-113004), China Medical University Hospital, the
   Academia Sinica Taiwan Biobank Stroke Biosignature Project
   (BM10501010037), and the NRPB Stroke Clinical Trial Consortium (MOST
   104-2325-B-039-005).
CR Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   BREZIN AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P297, DOI 10.1001/archopht.1995.01100030051021
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li JF, 2015, MBIO, V6, DOI 10.1128/mBio.02459-14
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Njiric S, 2007, COLLEGIUM ANTROPOL, V31, P107
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Park S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13283-6
   Rodrigues C, 2001, Indian J Med Microbiol, V19, P141
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   SINGH VK, 1990, J IMMUNOL, V144, P1282
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yi YH, 2018, WORLD J GASTROENTERO, V24, P3163, DOI 10.3748/wjg.v24.i28.3163
NR 24
TC 7
Z9 8
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2019
VL 97
IS 5
BP E713
EP E718
DI 10.1111/aos.14032
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IH9DK
UT WOS:000474806400019
PM 30690913
OA Bronze
DA 2022-11-30
ER

PT J
AU Li, X
   Zhang, Y
   Zhang, ZR
   Xu, YY
   Zhang, MX
AF Li, Xun
   Zhang, Yun
   Zhang, Zirong
   Xu, Yunyi
   Zhang, Meixia
TI One-Year Outcomes of Intravitreal Conbercept for Treatment-Resistant
   Neovascular Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Treatment-resistant; Anti-vascular
   endothelial growth factor therapy; Conbercept
ID AFLIBERCEPT; RANIBIZUMAB; RECEPTOR; THERAPY; DOMAIN; FLUID
AB Purpose: To evaluate the efficacy of intravitreal conbercept injections in patients with treatment-resistant neovascular age-related macular degeneration (nvAMD). Methods: Retrospective review of patients with resistance (persistent exudation) to ranibizumab (0.5 mg) that were switched to treatment with 3 monthly intravitreal injections of conbercept (0.5 mg), followed by dosing on an as-needed basis. The demographic data, visual acuities, central retinal thickness (CRT), and the maximum pigment epithelial detachment (PED) height were reviewed. Results: Outcomes observed in 34 eyes from 26 patients with a mean of 7.68 (range 6-14) previous ranibizumab injections were compiled. Twelve months after switching to conbercept, there were significant reductions of CRT (402.59 +/- 163.85 vs. 473.18 +/- 164.84 mu m, p = 0.002) and maximum PED height (218.59 +/- 106.89 vs. 295.32 +/- 179.80 mu m, p = 0.006) compared with the baseline. No statistical change in visual acuity logarithm of the minimal angle of resolution occurred after 12 months (0.68 +/- 0.48 vs. 0.78 +/- 0.63 letters, p = 0.17) despite 27 of 34 eyes (79.41%) remaining stable or having improvement visual acuity. Conclusions: Intravitreal injections of conbercept appear to be beneficial in patients with nvAMD who exhibit persistent fluid despite previous treatment with ranibizumab.
C1 [Li, Xun; Zhang, Yun; Zhang, Zirong; Zhang, Meixia] Sichuan Univ, West China Hosp, Dept Ophthalmol, 37 Guoxue Lane, Chengdu 610041, Sichuan, Peoples R China.
   [Xu, Yunyi] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University
RP Zhang, MX (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, 37 Guoxue Lane, Chengdu 610041, Sichuan, Peoples R China.
EM meixiazhang@foxmail.com
RI Zhang, meixia/AAH-6247-2019
OI XUN, LI/0000-0002-0315-9223
FU National Nature Science Foundation of China [81271019]; Department of
   Science and Technology of Sichuan Province [2015SZ0087]
FX This study was supported by National Nature Science Foundation of China
   (81271019) and Department of Science and Technology of Sichuan Province
   (CN; 2015SZ0087), and these funding organizations had no role in the
   design or conduct of this research.
CR Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Cui J, 2017, EYE LOND
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lai K, 2015, EXPERT REV CLIN PHAR, V8, P135, DOI 10.1586/17512433.2015.990379
   Lazzeri S, 2015, ANGIOGENESIS, V18, P397, DOI 10.1007/s10456-015-9483-4
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 29
TC 2
Z9 2
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2019
VL 62
IS 2
BP 93
EP 100
DI 10.1159/000500118
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IL9EM
UT WOS:000477588000004
PM 31121579
DA 2022-11-30
ER

PT J
AU Bulgu, Y
   Cetin, GO
   Caner, V
   Cetin, EN
   Yaylali, V
   Yildirim, C
AF Bulgu, Yunus
   Cetin, Gokhan Ozan
   Caner, Vildan
   Cetin, Ebru Nevin
   Yaylali, Volkan
   Yildirim, Cem
TI Vascular endothelial growth factor gene polymorphisms in age-related
   macular degeneration in a Turkish population
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; vascular endothelial growth factor;
   single nucleotide polymorphism
ID INTRAVITREAL RANIBIZUMAB; VEGF GENE; ASSOCIATION; COHORT; RISK
AB AIM: To assess the association between age-related macular degeneration (AMD) and three single nucleotide polymorphisms (SNPs) related to the vascular endothelial growth factor (VEGF) gene.
   METHODS: The patients who were diagnosed with AMD were included in this prospective study. Three SNPs (rs1413711, rs2146323, and rs3025033) of the VEGF gene were genotyped by real-time polymerase chain reaction in the genomic DNA isolated from peripheral blood samples of the 82 patients and 80 controls.
   RESULTS: The genotype frequencies of rs1413711 and rs2146323 were not significantly different between the study group and the control group (P=0.072 and P=0.058). However, there was a significant difference in the genotype frequencies of these SNPs between the wet type AMD and dry type AMD (P=0.005 and P=0.010, respectively). One of the SNPs (rs1413711) was also found to be associated with the severity of AMD (P=0.001) with significant genotype distribution between early, intermediate, and advanced stages of the disease. The ancestral alleles were protective for both SNPs while the polymorphic alleles increased the risk for dry AMD.
   CONCLUSION: VEGF SNPs rs1413711 and rs2146323 polymorphisms are significantly associated with AMD subtypes in our population.
C1 [Bulgu, Yunus; Cetin, Ebru Nevin; Yaylali, Volkan; Yildirim, Cem] Pamukkale Univ, Dept Ophthalmol, Sch Med, TR-20070 Denizli, Turkey.
   [Cetin, Gokhan Ozan] Pamukkale Univ, Dept Med Genet, Sch Med, TR-20070 Denizli, Turkey.
   [Caner, Vildan] Pamukkale Univ, Dept Med Biol, Sch Med, TR-20070 Denizli, Turkey.
C3 Pamukkale University; Pamukkale University; Pamukkale University
RP Yildirim, C (通讯作者)，Pamukkale Univ, Dept Ophthalmol, TR-20070 Denizli, Turkey.
EM yildirimc@hotmail.com
RI cetin, ebru/AAF-2986-2020; Caner, Vildan/ABI-5029-2020
OI Caner, Vildan/0000-0003-0980-9335
FU Pamukkale University Scientific Research Unit [2011TPF025]
FX Supported by Pamukkale University Scientific Research Unit
   (No.2011TPF025)
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Veloso CED, 2014, OPHTHALMIC RES, V51, P1, DOI 10.1159/000354328
   Fang AM, 2009, MOL VIS, V15, P2710
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Green W R, 1999, Mol Vis, V5, P27
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hawkins BS, 1999, MOL VIS, V5
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lu Y, 2012, MOL BIOL REP, V39, P6547, DOI 10.1007/s11033-012-1483-5
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Yuan DQ, 2013, OPHTHALMOLOGICA, V230, P227, DOI 10.1159/000355068
NR 20
TC 4
Z9 5
U1 0
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD OCT 18
PY 2014
VL 7
IS 5
BP 773
EP 777
DI 10.3980/j.issn.2222-3959.2014.05.06
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR0PD
UT WOS:000343272900006
PM 25349791
DA 2022-11-30
ER

PT J
AU Yiu, G
   Chiu, SJ
   Petrou, PA
   Stinnett, S
   Sarin, N
   Farsiu, S
   Chew, EY
   Wong, WT
   Toth, CA
AF Yiu, Glenn
   Chiu, Stephanie J.
   Petrou, Philip A.
   Stinnett, Sandra
   Sarin, Neeru
   Farsiu, Sina
   Chew, Emily Y.
   Wong, Wai T.
   Toth, Cynthia A.
TI Relationship of Central Choroidal Thickness With Age-Related Macular
   Degeneration Status
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR THERAPY; AUTOMATIC SEGMENTATION; GEOGRAPHIC ATROPHY;
   BLOOD-FLOW; EYES; CHORIOCAPILLARIS; DRUSEN; LAYERS; SDOCT; YOUNG
AB PURPOSE: To compare choroidal thickness in patients with intermediate or advanced age-related macular degeneration (AMD) and control subjects using enhanced-depth imaging optical coherence tomography (EDI-OCT).
   DESIGN: Retrospective cross-sectional study of 325 eyes from 164 subjects who underwent EDI-OCT for the Age-Related Eye Disease Study (AREDS) 2 Ancillary Spectral Domain OCT study.
   METHODS: Choroidal thickness was measured by semiautomated segmentation of EDI-OCT images from 1.5 mm nasal to 1.5 mm temporal to the fovea. Multivariate linear regression was used to evaluate the association of subfoveal choroidal thickness or average choroidal thickness across the central 3-mm segment with systemic and ocular variables. Choroidal thickness measurements were compared between eyes with no AMD (n = 154) (ie, controls), intermediate A/vfD (n = 109), and advanced AMD (n = 62). "
   RESULTS: Both subfoveal and average chorciidal thicknesses were associated with age (P < .001) and refractive error (P < .001), but not other variables tested. Mean average choroidal thickness was significantly reduced in advanced AMD as compared with control eyes (P =.008), with no significant difference between advanced and intermediate AMD eyes (P = .152) or between intermediate AMD and control eyes (P = .098). Choroidal thinning was also noted from 1.5 mm nasal to 1.5 mm temporal to the fovea when comparing advanced AIYID with control eyes (P < .05 at all 0.5 mm interval locations). After adjustment for age and refractive error, however, there was no significant difference in subfoveal (P = .675) or average choroidal thickness (P = .746) across all 3 groups. "
   CONCLUSIONS: When adjusted for age and refractive error, central choroidal thickness may not be significantly influenced by AMD status based on AREDS categorization. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Yiu, Glenn; Stinnett, Sandra; Sarin, Neeru; Farsiu, Sina; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Chiu, Stephanie J.; Farsiu, Sina] Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA.
   [Petrou, Philip A.; Chew, Emily Y.; Wong, Wai T.] NEI, NIH, Bethesda, MD 20892 USA.
   [Yiu, Glenn] Univ Calif Davis, Dept Ophthalmol, Sacramento, CA 95817 USA.
C3 Duke University; Duke University; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); University of California System;
   University of California Davis
RP Toth, CA (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, 2351 Erwin Rd,Box 3802, Durham, NC 27710 USA.
EM cynthia.toth@duke.edu
RI Wong, Wai/B-6118-2017; Yiu, Glenn/AAF-2858-2020; Toth,
   Cynthia/L-5534-2019
OI Wong, Wai/0000-0003-0681-4016; Toth, Cynthia/0000-0002-2324-0854;
   Stinnett, Sandra/0000-0001-7192-0195; Farsiu, Sina/0000-0003-4872-2902;
   Yiu, Glenn/0000-0003-3061-3310
FU AREDS2 Ancillary (A2A) SDOCT Study (Clinical-Trials.gov identifier
   [NCT00734487]; American Health Assistance Foundation; Research to
   Prevent Blindness; Genentech (San Francisco, California) [IST-4400S];
   Alcon Laboratories (unrestricted grant; Fort Worth, Texas); National Eye
   Institute (Bethesda, Maryland) [HHS-N-260-2005-00007-C]; ADB
   [N01-EY-5-0007]; Heed Ophthalmic Foundation; Ronald G. Michels
   Fellowship Foundation; NATIONAL EYE INSTITUTE [ZIAEY000489, ZIAEY000485]
   Funding Source: NIH RePORTER
FX This research was supported by the AREDS2 Ancillary (A2A) SDOCT Study
   (Clinical-Trials.gov identifier: NCT00734487), the American Health
   Assistance Foundation (S.F.), and Research to Prevent Blindness (S.F.).
   The A2A SDOCT study is supported predominantly by Genentech (IST-4400S
   grant; San Francisco, California), and in part by Bioptigen (equipment;
   'Morrisville, North Carolina) and Alcon Laboratories (unrestricted
   grant; Fort Worth, Texas). The AREDS2 Trial is sponsored by the National
   Eye Institute (Bethesda, Maryland; contract #HHS-N-260-2005-00007-C and
   ADB Contract #N01-EY-5-0007). Dr Yiu is funded in part by the Heed
   Ophthalmic Foundation and the Ronald G. Michels Fellowship Foundation.
   The sponsor or funding organizations had no role in the design or
   conduct of this research.
CR Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Fein JG, 2014, OPHTHAL SURG LAS IM, V45, P32, DOI 10.3928/23258160-20131220-04
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Goldenberg D, 2012, OPHTHAL SURG LAS IM, V43, P296, DOI 10.3928/15428877-20120426-02
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim M, 2012, INVEST OPHTH VIS SCI, V53, P7710, DOI 10.1167/iovs.12-10464
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Ko A, 2013, RETINA-J RET VIT DIS, V33, P1005, DOI 10.1097/IAE.0b013e31827d266e
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lee Hyo Kyung, 2013, Korean J Ophthalmol, V27, P433, DOI 10.3341/kjo.2013.27.6.433
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Ouyang YL, 2011, INVEST OPHTH VIS SCI, V52, P7019, DOI 10.1167/iovs.11-8046
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sogawa K, 2012, AM J OPHTHALMOL, V153, P1129, DOI 10.1016/j.ajo.2011.11.005
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yiu G, 2014, AM J OPHTHALMOL, V158, P745, DOI 10.1016/j.ajo.2014.06.006
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 47
TC 68
Z9 68
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2015
VL 159
IS 4
BP 617
EP 626
DI 10.1016/j.ajo.2014.12.010
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE4FV
UT WOS:000351787400001
PM 25526948
DA 2022-11-30
ER

PT J
AU Shima, N
   Markowitz, SN
   Reyes, SV
AF Shima, Noboru
   Markowitz, Samuel N.
   Reyes, Sophia V.
TI Concept of a functional retinal locus in age-related macular
   degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE low vision rehabilitation; preferred retinal locus; retinal sensitivity;
   age-related macular degeneration
ID VISUAL-ACUITY; FIXATION
AB Purpose: Preferred retinal loci used for eccentric fixation in patients with age-related macular degeneration (AMD) may be different from the eccentric neighbouring loci of highest retinal sensitivity. This study was designed to highlight the conceptual difference between the 2 and the concept of a functional retinal locus encompassing both the preferred retinal locus and the locus with highest retinal sensitivity.
   Design: Prospective, nonrandomized, observational case series.
   Participants: We recruited I S adults with documented AMD, low vision, and best-corrected visual acuity of 20/50-20/400 in the better eye.
   Methods: Automated microperimetry methods were used to assess topographic retinal sensitivity and location of preferred retinal loci.
   Results: Mean (SD) age for the group was 85.1 (6.5) years. Mean (SD) best-corrected visual acuity measured was 0.88 (0.25) logMar units (20/150). The mean (SD) eccentricity of the preferred retinal locus used for fixation was different from the eccentricity of the area with highest retinal sensitivity in the same eye (7.53 degrees [2.47 degrees] vs 9.30 degrees [2.93 degrees], respectively; p < 0.0003). The oculomotor efficiency score measured 82%. The mean (SID) retinal sensitivity at the preferred retinal loci was inferior to that of loci with highest retinal sensitivity (5.83 [4.26] vs 8.60 [3.06] dB, respectively; p < 0.0007). The highest correlation was measured between potential visual acuity estimates and estimates of retinal sensitivity at the highest retinal sensitivity loci (p < 0.0048).
   Conclusions: Preferred retinal loci and highest retinal sensitivity loci are not identical in AMD cases. A new concept of functional retinal locus is proposed to define their relation. A new concept of an oculomotor efficiency score is proposed to define oculomotor abilities when macular function is lost.
C1 [Shima, Noboru; Markowitz, Samuel N.; Reyes, Sophia V.] Univ Toronto, Dept Ophthalmol & Vis Sci, Low Vis Serv, Univ Hlth Network Hosp, Toronto, ON, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto
RP Markowitz, SN (通讯作者)，1225 Davenport Rd, Toronto, ON M6H 2H1, Canada.
EM snm1@rogers.com
FU Eye Foundation of Canada
FX This work was supported by a grant from the Eye Foundation of Canada.
   The authors thank Luminita Tarita-Nisror, PhD, Martin Steinbach, PhD,
   and Esther Gonzalez, PhD, for data collection.
CR Al-Karmi R, 2006, CAN J OPHTHALMOL, V41, P313, DOI 10.1139/I06-016
   Bellmann C, 2004, OPHTHALMOLOGY, V111, P2265, DOI 10.1016/j.ophtha.2004.06.019
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Giorgi RG, 2009, OPTOMETRY VISION SCI, V86, P492, DOI 10.1097/OPX.0b013e31819f9e4d
   Gonzalez EG, 2007, INVEST OPHTH VIS SCI, V48, P4838, DOI 10.1167/iovs.06-1240
   Kuyk TK, 2005, VISION RES, V45, P3224, DOI 10.1016/j.visres.2005.07.019
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   LIN SJ, 2004, INVEST OPHTHALMOL VI, V45
   Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027
   Okada K, 2006, EYE, V20, P805, DOI 10.1038/sj.eye.6702014
   Rees AL, 2005, INT C SER, V1282, P694, DOI DOI 10.1016/J.ICS.2005.05.172
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   SCHUCHARD RA, 1994, OPHTHALMOLOGY CLIN N, V7, P243
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
NR 21
TC 28
Z9 29
U1 0
U2 10
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD FEB
PY 2010
VL 45
IS 1
BP 62
EP 66
DI 10.3129/i09-236
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 558YD
UT WOS:000274783900012
PM 20130713
DA 2022-11-30
ER

PT J
AU Kaushik, S
   Wang, JJ
   Flood, V
   Tan, JSL
   Barclay, AW
   Wong, TY
   Brand-Miller, J
   Mitchell, P
AF Kaushik, Shweta
   Wang, Jie Jin
   Flood, Victoria
   Tan, Jennifer Sue Ling
   Barclay, Alan W.
   Wong, Tien Y.
   Brand-Miller, Jennie
   Mitchell, Paul
TI Dietary glycemic index and the risk of age-related macular degeneration
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID BLUE-MOUNTAINS-EYE; FOOD-FREQUENCY QUESTIONNAIRE;
   CARDIOVASCULAR-DISEASE; DIABETIC COMPLICATIONS; CARBOHYDRATE INTAKE;
   GRADING SYSTEM; BETA-CAROTENE; VITAMIN-E; MACULOPATHY; LOAD
AB Background: Dietary factors are known risk factors for age-related macular degeneration (AMD)-the leading cause of visual loss among persons aged >= 65 y. High-glycemic-index diets have been hypothesized as a risk factor for AMD, but prospective data are unavailable.
   Objective: The objective was to examine the association between dietary glycemic index and the 10-y incidence of AMD in the Blue Mountain Eye Study population.
   Design: This was a population-based cohort study with 3654 participants (>= 49 y) examined at baseline (1992 - 1994); 2335 patients were reexamined after 5 y and 1952 after 10 y. The Wisconsin System was used to grade 10-y incident early and late AMD from retinal photographs. A food-frequency questionnaire was used to collect dietary information at baseline, and an Australian database was used to calculate the mean glycemic index.
   Results: Over 10 y, 208 of 1810 persons (cumulative incidence: 14.1%) developed early AMD. After age, smoking, other risk factors, and dietary constituents were adjusted for, a higher mean dietary glycemic index was associated with an increased 10-y risk of early AMD in a comparison of quartiles 1 and 4 [relative risk (RR): 1.77; 95% CI: 1.13, 2.78; P for trend = 0.03]. Conversely, a greater consumption of cereal fiber (RR: 0.68; 95% CI: 0.44, 1.04; P for trend = 0.05) and breads and cereals (predominantly lower glycemic index foods such as oatmeal) (RR: 0.67; 95% CI: 0.44, 1.02; P for trend = 0.03) was associated with a reduced risk of incident early AMD. No relation was observed with late AMD.
   Conclusions: A high-glycemic-index diet is a risk factor for early AMD-the recognized precursor of sight-threatening late AMD. Low-glycemic-index foods such as oatmeal may protect against early AMD.
C1 [Wang, Jie Jin; Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Kaushik, Shweta; Wang, Jie Jin; Flood, Victoria; Tan, Jennifer Sue Ling; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Kaushik, Shweta; Wang, Jie Jin; Flood, Victoria; Tan, Jennifer Sue Ling; Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Flood, Victoria; Barclay, Alan W.; Brand-Miller, Jennie] Univ Sydney, Human Nutr Unit, Dept Mol & Microbial Biosci, Sydney, NSW 2006, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Sydney; Westmead Institute for Medical Research; University of
   Sydney; University of Sydney; National University of Singapore
RP Mitchell, P (通讯作者)，Univ Sydney, Ctr Vis Res, Westmead Millennium Inst, Westmead Hosp,Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Brand-Miller, Jennie C/A-6835-2013; Flood, Victoria/H-2279-2011; Flood,
   Victoria M/A-8732-2016; Wong, Tien Yin/AAC-9724-2020; wang,
   jie/GRS-0942-2022; Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014
OI Brand-Miller, Jennie C/0000-0002-6797-8754; Flood, Victoria
   M/0000-0001-5310-7221; Wong, Tien Yin/0000-0002-8448-1264; Wang, Jie
   Jin/0000-0001-9491-4898; 
FU Australian National Health; Medical Research Council
FX Supported by the Australian National Health and Medical Research
   Council.
CR Barclay AW, 2008, PUBLIC HEALTH NUTR, V11, P573, DOI 10.1017/S1368980007001103
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Ceriello A, 2004, ARCH INTERN MED, V164, P2090, DOI 10.1001/archinte.164.19.2090
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dickinson S, 2005, CURR OPIN LIPIDOL, V16, P69, DOI 10.1097/00041433-200502000-00012
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Levitan EB, 2004, ARCH INTERN MED, V164, P2147, DOI 10.1001/archinte.164.19.2147
   Liu SM, 2002, AM J CLIN NUTR, V75, P492, DOI 10.1093/ajcn/75.3.492
   Liu SM, 1999, AM J CLIN NUTR, V70, P412
   Meigs JB, 2002, DIABETES CARE, V25, P1845, DOI 10.2337/diacare.25.10.1845
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P406, DOI 10.1016/S0161-6420(98)93019-6
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oh K, 2005, AM J EPIDEMIOL, V161, P161, DOI 10.1093/aje/kwi026
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ross CM, 2005, AM J EPIDEMIOL, V161, P995, DOI 10.1093/oxfordjournals.aje.a000180
   Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472
   Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Weickert MO, 2005, DIABETOLOGIA, V48, P2343, DOI 10.1007/s00125-005-1941-x
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   WOLEVER TMS, 1990, AM J CLIN NUTR, V51, P72, DOI 10.1093/ajcn/51.1.72
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   World Health Organization, 1999, DEF DIAGN CLASS DI 1
NR 46
TC 71
Z9 72
U1 0
U2 7
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT 1
PY 2008
VL 88
IS 4
BP 1104
EP 1110
DI 10.1093/ajcn/88.4.1104
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 358FX
UT WOS:000259903600032
PM 18842800
OA Bronze
DA 2022-11-30
ER

PT J
AU Margrain, TH
   Boulton, M
   Marshall, J
   Sliney, DH
AF Margrain, TH
   Boulton, M
   Marshall, J
   Sliney, DH
TI Do blue light filters confer protection against age-related macular
   degeneration?
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; SHORT-WAVELENGTH LIGHT; INTRAOCULAR-LENS;
   ULTRAVIOLET-RADIATION; PHOTOCHEMICAL LESIONS; OPERATING MICROSCOPE;
   GEOGRAPHIC ATROPHY; OXIDATIVE STRESS; INDUCED DAMAGE; VISIBLE-LIGHT
AB Age-related macular degeneration (AMD) is a major health problem in the developed world accounting for approximately half of all blind registrations. Current treatment options are unsuitable for the majority of patients and therefore the identification of modifiable risk factors that may inform disease prevention programmes is a priority. This review evaluates the long-held belief that blue light exposure has a role in the pathogenesis of AMD. Laboratory evidence has demonstrated that photochemical reactions in the oxygen-rich environment of the outer retina lead to the liberation of cytotoxic reactive oxygen species (ROS). These ROS cause oxidative stress which is known to contribute to the development of AMD. The precise chromopore that may be involved in the pathogenesis of AMD is unclear but the age pigment lipofuscin is a likely candidate. Its aerobic photoreactivity and adverse effects on antioxidant activity combined with its gradual accumulation over time suggests that its in vivo phototoxicity increases with age despite changes in the absorption characteristics of the crystalline lens. Evidence from animal studies confirms blue light's damaging potential but the results are not directly applicable to macular degeneration in humans. Studies of human macular pigment density and the risk of AMD progression following cataract surgery lend further weight to the hypothesis that blue light exposure has a role in the pathogenesis of AMD but the epidemiological evidence is equivocal. On balance the evidences suggests but does not yet confirm that blue light is a risk factor for AMD. Given the socio-economic impact of this disease and urgent need to identify modifiable risk factors, future work should include a large-scale clinical trial to evaluate the effect of blue blocking filters on AMD progression rates. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Univ Wales Coll Cardiff, Sch Optometry & Vis Sci, Cardiff CF10 3NB, S Glam, Wales.
   St Thomas Hosp, Rayne Inst, Dept Ophthalmol, London SE1 7EH, England.
   USA, Ctr Hlth Promot & Prevent Med, Aberdeen Proving Ground, MD 21010 USA.
C3 Cardiff University; Guy's & St Thomas' NHS Foundation Trust; University
   of London; King's College London
RP Margrain, TH (通讯作者)，Univ Wales Coll Cardiff, Sch Optometry & Vis Sci, Redwood Bldg,King Edward VII Ave, Cardiff CF10 3NB, S Glam, Wales.
EM margrainth@cardiff.ac.uk
OI Margrain, Tom/0000-0003-1280-0809
CR Barja G, 2002, AGEING RES REV, V1, P397, DOI 10.1016/S1568-1637(02)00008-9
   BARKER FM, 1991, 785346 FDA
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262
   BERSON EL, 1980, VISION RES, V20, P1179, DOI 10.1016/0042-6989(80)90057-7
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   DAVIDSON PC, 1993, AM J OPHTHALMOL, V116, P497, DOI 10.1016/S0002-9394(14)71411-4
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DILLON J, 1991, J PHOTOCH PHOTOBIO B, V10, P23, DOI 10.1016/1011-1344(91)80209-Z
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FISHMAN GA, 1986, SURV OPHTHALMOL, V31, P119, DOI 10.1016/0039-6257(86)90079-2
   FRENNESSON IC, 1993, DOC OPHTHALMOL, V84, P135, DOI 10.1007/BF01206248
   Grimm C, 2000, INVEST OPHTH VIS SCI, V41, P3984
   HAM WT, 1982, AM J OPHTHALMOL, V93, P299, DOI 10.1016/0002-9394(82)90529-3
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hao WS, 2002, NAT GENET, V32, P254, DOI 10.1038/ng984
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAFFE GJ, 1988, OPHTHALMOLOGY, V95, P1130
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KILBRIDE PE, 1989, VISION RES, V29, P663, DOI 10.1016/0042-6989(89)90028-X
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KRAFF MC, 1985, OPHTHALMOLOGY, V92, P366
   Kremers J.J.M., 1988, LASERS LIGHT OPHTHAL, V2, P41
   LEAT SJ, 1990, OPHTHAL PHYSL OPT, V10, P219, DOI 10.1111/j.1475-1313.1990.tb00855.x
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Mainster MA, 2003, BRIT J OPHTHALMOL, V87, P1523, DOI 10.1136/bjo.87.12.1523
   Margrain TH, 1999, BRIT MED J, V318, P1504, DOI 10.1136/bmj.318.7197.1504
   MARSHALL J, 1985, OPHTHAL PHYSL OPT, V5, P241, DOI 10.1111/j.1475-1313.1985.tb00666.x
   Mellerio J, 2002, CURR EYE RES, V25, P37, DOI 10.1076/ceyr.25.1.37.9961
   Mellerio J., 1994, PRINCIPLES PRACTICE, V1, P1326
   MICHELS M, 1992, AM J OPHTHALMOL, V114, P287, DOI 10.1016/S0002-9394(14)71792-1
   MICHELS M, 1990, SURV OPHTHALMOL, V34, P237, DOI 10.1016/0039-6257(90)90025-Q
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   NOELL WK, 1971, SCIENCE, V172, P76, DOI 10.1126/science.172.3978.76
   ORGANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1, DOI 10.1016/1350-9462(94)90003-5
   ORGANISCIAK DT, 1977, INVEST OPHTH VIS SCI, V16, P188
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   RAPP LM, 1992, INVEST OPHTH VIS SCI, V33, P3367
   Rosenblum YZ, 2000, OPHTHAL PHYSL OPT, V20, P335, DOI 10.1016/S0275-5408(00)00006-5
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Ruby NF, 2002, SCIENCE, V298, P2211, DOI 10.1126/science.1076701
   RUFFOLO JJ, 1984, INVEST OPHTH VIS SCI, V25, P893
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHALCH W, 1992, FREE RADICALS AGING, P280
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   SIMONS K, 1993, ARCH OPHTHALMOL-CHIC, V111, P297, DOI 10.1001/archopht.1993.01090030015002
   Sliney DH, 2001, J PHOTOCH PHOTOBIO B, V64, P166, DOI 10.1016/S1011-1344(01)00229-9
   SLINEY DH, 1991, SUSCEPTIBLE VISUAL A, V16, P20
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SYKES SM, 1981, INVEST OPHTH VIS SCI, V20, P425
   Tabandeh H, 1998, AM J OPHTHALMOL, V126, P707, DOI 10.1016/S0002-9394(98)00133-0
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   WEITER JJ, 1988, AM J OPHTHALMOL, V106, P286, DOI 10.1016/0002-9394(88)90363-7
   WERNER A, 1975, J AM OPTOM ASSOC, V46, P380
   WERNER JS, 1989, OPHTHALMOLOGY, V96, P1552
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wolffsohn JS, 2000, OPTOMETRY VISION SCI, V77, P73, DOI 10.1097/00006324-200002000-00011
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 77
TC 178
Z9 200
U1 1
U2 46
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2004
VL 23
IS 5
BP 523
EP 531
DI 10.1016/j.preteyeres.2004.05.001
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 850XC
UT WOS:000223646700003
PM 15302349
DA 2022-11-30
ER

PT J
AU Sacconi, R
   Cicinelli, MV
   Borrelli, E
   Savastano, MC
   Rispoli, M
   Lumbroso, B
   Corbelli, E
   Casaluci, M
   Bandello, F
   Querques, G
AF Sacconi, Riccardo
   Cicinelli, Maria Vittoria
   Borrelli, Enrico
   Savastano, Maria Cristina
   Rispoli, Marco
   Lumbroso, Bruno
   Corbelli, Eleonora
   Casaluci, Marco
   Bandello, Francesco
   Querques, Giuseppe
TI Haller's vessels patterns in non-neovascular age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Drusen; En face optical coherence
   tomography; Geographic atrophy; Reticular pseudodrusen; Choroidal
   patterns
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL THICKNESS; RETICULAR
   PSEUDODRUSEN; MORPHOMETRIC-ANALYSIS; CHORIOCAPILLARIS; PREVALENCE;
   INSIGHTS
AB Purpose To investigate the optical coherence tomography (OCT) en face reconstruction of the choroid in different phenotypes of non-neovascular age-related macular degeneration (AMD), to identify the relative distribution of the vascular patterns of the Haller's layer in each AMD category. Methods Retrospective study enrolling consecutive patients with non-neovascular AMD. Patients were divided into the following: (1) those with reticular pseudodrusen (RPD); (2) those with small (< 63 mu m) or medium-large drusen (63-124 mu m); (3) those with geographic atrophy (GA). Qualitative analysis of the en face images provided by CIRRUS HD-OCT 5000 (Carl Zeiss Meditech, Inc., Dublin, USA) was performed, identifying five arrangements of Haller's vessels: temporal herringbone, branched from below, laterally diagonal, double arcuate, and reticular. Choroidal thickness (CT) was measured from structural OCT. Healthy age-matched subjects were included as a control group. Results Fifty-eight eyes of 58 patients (20 eyes with RPD; 22 eyes with drusen; 16 eyes with GA) and 18 control eyes were enrolled. The laterally diagonal configuration was the most prevalent (40.0%) in the RPD group; the reticular pattern was the most frequent in the drusen group (50.0%); the double arcuate (62.5%) was the most recurrent pattern in patients with GA. In the control group, the temporal herringbone (38.9%) arrangement was the most represented. The CT associated with the temporal herringbone and reticular arrangement was significantly higher compared to the branched from below (p < 0.001), the laterally diagonal (p = 0.014), and the double arcuate pattern (p = 0.009). Conclusion Different phenotypes of non-neovascular AMD present a specific distribution of vascular arrangement on en face OCT. The temporal herringbone and the reticular pattern (the ones more associated in a physiological setting) disclosed a thicker choroid compared to the arrangements more represented in non-neovascular AMD-correlated phenotypes.
C1 [Sacconi, Riccardo; Cicinelli, Maria Vittoria; Borrelli, Enrico; Corbelli, Eleonora; Casaluci, Marco; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Sacconi, Riccardo; Cicinelli, Maria Vittoria; Borrelli, Enrico; Corbelli, Eleonora; Casaluci, Marco; Bandello, Francesco; Querques, Giuseppe] IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.
   [Savastano, Maria Cristina; Rispoli, Marco; Lumbroso, Bruno] Ctr Italiano Macula, Rome, Italy.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.; Querques, G (通讯作者)，IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Savastano, Maria Cristina/I-5355-2015; cicinelli, maria
   vittoria/M-1611-2019; rispoli, marco/N-1054-2016
OI Savastano, Maria Cristina/0000-0003-1397-4333; cicinelli, maria
   vittoria/0000-0003-2938-0409; bandello, francesco/0000-0003-3238-9682;
   rispoli, marco/0000-0003-2689-9002; Sacconi,
   Riccardo/0000-0003-2891-2012; Querques, Giuseppe/0000-0002-3292-9581;
   Borrelli, Enrico/0000-0003-2815-5031
CR Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P770, DOI 10.1136/bjophthalmol-2016-309115
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   De Bats Flore, 2013, ISRN Ophthalmol, V2013, P273085, DOI 10.1155/2013/273085
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P6017, DOI 10.1167/iovs.12-9692
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P1058, DOI 10.1097/IAE.0000000000001752
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Savastano MC, 2018, RETINA-J RET VIT DIS, V38, P1211, DOI 10.1097/IAE.0000000000001678
   Savastano MC, 2015, OSLI RETINA, V46, P561, DOI 10.3928/23258160-20150521-07
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tan KA, 2016, SURV OPHTHALMOL, V61, P566, DOI 10.1016/j.survophthal.2016.02.007
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Wilde C, 2016, EYE, V30, P817, DOI 10.1038/eye.2016.46
   Zhao J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22745-4
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P482, DOI 10.1097/IAE.0b013e3181f056ce
NR 28
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2020
VL 258
IS 10
BP 2163
EP 2171
DI 10.1007/s00417-020-04769-7
EA JUN 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OC3WJ
UT WOS:000539932400002
PM 32535671
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Alten, F
   Steinberg, JS
   Jaffe, GJ
   Fleckenstein, M
   Mukesh, BN
   Hohman, TC
   Holz, FG
AF Schmitz-Valckenberg, Steffen
   Alten, Florian
   Steinberg, Julia S.
   Jaffe, Glenn J.
   Fleckenstein, Monika
   Mukesh, Bickol N.
   Hohman, Thomas C.
   Holz, Frank G.
CA Geographic Atrophy Progression GAP
TI Reticular Drusen Associated with Geographic Atrophy in Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; FUNDUS AUTOFLUORESCENCE PATTERNS; HIGH-RISK;
   MACULOPATHY; EYE; PSEUDODRUSEN; POLYMORPHISM; DISEASE; PROGRESSION;
   PREVALENCE
AB PURPOSE. To characterize reticular drusen (RDR) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in a prospective, multicenter, natural history study.
   METHODS. Confocal scanning laser ophthalmoscopy (cSLO) three-field fundus autofluorescence (FAF; exc., 488; em., 500-700 nm), near-infrared reflectance (IR; 820 nm), and blue reflectance (BR; 488 nm) images as well as red-free (RF) and color fundus (CF) camera photographs were recorded in 458 GA patients. The digital images were evaluated by two independent readers with subsequent senior reader arbitration for prevalence and topographic distribution of RDR using a modified Early Treatment Diabetic Retinopathy Study grid.
   RESULTS. RDR were detected with at least one cSLO modality in 286 of 458 (62%) patients in either eye (bilateral 207 [45%]) and were visible in fundus camera photographs in 66 of 371 (18%) patients (bilateral 48 [13%]). Prevalence of RDR by cSLO imaging was associated with increasing age (P = 0.007) and female sex (P = 0.007), but not with GA total lesion area (P = 0.38). Cohen kappa statistics showed good interobserver agreement for FAF (0.81) and IR (0.82) imaging modes, and moderate agreement was found for BR (0.48), RF (0.48), and CF (0.40). On three-field FAF images RDR were present most frequently superior to the fovea (99%).
   CONCLUSIONS. RDR represent a common phenotypic hallmark in GA eyes. RDR are readily identified using cSLO imaging technology. These observations may explain the high prevalence deter-mined herein, in contrast to previous reports based on fundus photographs. Incorporation of these novel imaging modalities in future natural history studies may facilitate efforts aimed at defining the role and predictive value of RDR in the progression of AMD. (ClinicalTrials.gov number, NCT00599846.) (Invest Ophthalmol Vis Sci. 2011; 52: 5009-5015) DOI: 10.1167/iovs.11-7235
C1 [Schmitz-Valckenberg, Steffen; Alten, Florian; Steinberg, Julia S.; Fleckenstein, Monika; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Jaffe, Glenn J.] Duke Univ, Ctr Eye, Dept Ophthalmol, Durham, NC 27710 USA.
   [Mukesh, Bickol N.; Hohman, Thomas C.] Alcon Labs Inc, Res & Dev Retina, Ft Worth, TX 76101 USA.
C3 University of Bonn; Duke University; Novartis; Alcon
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
RI Sahel, Jose-Alain/F-3172-2017
OI Sahel, Jose-Alain/0000-0002-4831-1153; Fleckenstein,
   Monika/0000-0001-8321-8037; Russell, Stephen/0000-0003-3776-1367
FU Alcon Laboratories Inc., Fort Worth, TX
FX Supported by Alcon Laboratories Inc., Fort Worth, TX. The GAP Study was
   funded, designed, and conducted by the sponsor. The primary and
   secondary study objects are not the aim of the current publication and
   will be reported elsewhere. The data presented are an additional
   analysis that was conducted without any extra funding by the sponsor.
   The manuscript was reviewed and approved by the sponsor.
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Fleckenstein M, 2009, INVEST OPHTH VIS SCI, V51, P637
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   SARKS J, 2010, BR J OPHTHALMOL
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Scholl HPN, 2007, MOL VIS, V13, P196
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1029, DOI 10.1007/s00347-005-1270-y
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   ZWEIFEL SA, OPHTHALMOLOGY, V117, P1775
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 32
TC 145
Z9 147
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2011
VL 52
IS 9
BP 5009
EP 5015
DI 10.1167/iovs.11-7235
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 815SI
UT WOS:000294548300001
PM 21498612
DA 2022-11-30
ER

PT J
AU Michalska-Malecka, K
   Spiewak, D
   Luksa, D
AF Michalska-Malecka, Katarzyna
   Spiewak, Dorota
   Luksa, Dorota
TI Three-Month Results of Brolucizumab Intravitreal Therapy in Patients
   with Wet Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE brolucizumab; wet age-related macular degeneration; anti-VEGF;
   intravitreal injections
AB The purpose of the study was to evaluate changes in best corrected visual acuity, central retinal thickness, area and flow in the neovascular membrane and to compare therapeutic outcomes from baseline in patients who received three doses of Beovu (brolucizumab) at three-month follow-up. Material and methods: A prospective observational study conducted at the Prof. K. Gibinski University Clinical Center of the Medical University of Silesia in Katowice. Eight patients with exudative form of age-related macular degeneration (AMD) were observed. Results: The mean best corrected visual acuity (BCVA) outcome increased with each subsequent visit. The mean central retinal thickness (CRT) result also improved (decreased) with each subsequent visit, except for the last measurement. A statistically significant change in neovascular membrane area was observed after the first injection. In further treatment, the membrane area underwent changes that were not statistically significant. A statistically significant change in neovascular membrane flow was demonstrated after the first and second injections. Discussion: Our study confirmed the efficacy of brolucizumab in the treatment of patients with exudative AMD in terms of improvements in best corrected visual acuity (BCVA), central retinal thickness (CRT), neovascular membrane area, and neovascular membrane flow area.
C1 [Michalska-Malecka, Katarzyna; Spiewak, Dorota; Luksa, Dorota] Univ Hosp Med Univ Silesia, Univ Clin Ctr, PL-40514 Katowice, Poland.
   [Michalska-Malecka, Katarzyna] Med Univ Silesia, Dept Ophthalmol, PL-40514 Katowice, Poland.
C3 Medical University Silesia
RP Michalska-Malecka, K (通讯作者)，Univ Hosp Med Univ Silesia, Univ Clin Ctr, PL-40514 Katowice, Poland.; Michalska-Malecka, K (通讯作者)，Med Univ Silesia, Dept Ophthalmol, PL-40514 Katowice, Poland.
EM k.michalska.malecka@gmail.com; dorota.spiewak7@gmail.com;
   dorota.luksa@gmail.com
OI MICHALSKA-MALECKA, KATARZYNA/0000-0002-0550-8386
CR Alexandru Malciolu Radu, 2016, Rom J Ophthalmol, V60, P9
   Avaylon J, 2020, INT MED CASE REP J, V13, P145, DOI 10.2147/IMCRJ.S252260
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Iyer Prashanth G, 2020, Am J Ophthalmol Case Rep, V20, P100989, DOI 10.1016/j.ajoc.2020.100989
   Mavija M, 2014, MED ARCH, V68, P204, DOI DOI 10.5455/MEDARH.2014.68.204-208
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Sharma A, 2020, BRIT J OPHTHALMOL, V104, P1631, DOI 10.1136/bjophthalmol-2020-317528
   Tadayoni R, 2021, OPHTHALMOLOGICA, V244, P93, DOI 10.1159/000513048
NR 10
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD AUG
PY 2021
VL 18
IS 16
AR 8450
DI 10.3390/ijerph18168450
PG 11
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA UI3QK
UT WOS:000690526000001
PM 34444199
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zysset-Burri, DC
   Keller, I
   Berger, LE
   Largiader, CR
   Wittwer, M
   Wolf, S
   Zinkernagel, MS
AF Zysset-Burri, Denise C.
   Keller, Irene
   Berger, Lieselotte E.
   Largiader, Carlo R.
   Wittwer, Matthias
   Wolf, Sebastian
   Zinkernagel, Martin S.
TI Associations of the intestinal microbiome with the complement system in
   neovascular age-related macular degeneration
SO NPJ GENOMIC MEDICINE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; FACTOR-H POLYMORPHISM; COMPONENT 2
   C2; FACTOR-B BF; 10-YEAR INCIDENCE; VITAMIN-C; GENES; OBESITY; RISK;
   MACULOPATHY
AB Age-related macular degeneration (AMD) is a leading cause of severe vision loss in the aged population. The etiology of AMD is multifactorial including nutritional factors, genetic variants mainly in the complement pathway, environmental risk factors and alterations in the intestinal microbiome. However, it remains unexplored whether there is an interdependency of these factors leading to the development of AMD. To investigate this issue, a shotgun metagenomics analysis of 57 neovascular AMD and 58 healthy controls as well as of 16 complement C3-deficient mice and 16 wildtypes was performed. Whereas the classNegativicuteswas more abundant in patients, the genusOscillibacterand speciesBacteroideshad a significantly higher prevalence in persons without AMD. Similar taxonomic features were identified that distinguished wildtype mice from C3-deficient mice. Moreover, several purine signaling pathways were associated with both, neovascular AMD and C3 deficiency. While SNPs within thecomplement factor Bgene were more abundant in controls, SNPs within thehigh temperature requirement A serine peptidase 1andcomplement factor H(CFH) genes were associated with neovascular AMD. Using a classification model,Negativicuteswas identified as a potential biomarker for AMD and furthermore, it positively correlated with CFH. This study suggests an association between the intestinal microbiome and the complement system in neovascular AMD.
C1 [Zysset-Burri, Denise C.; Berger, Lieselotte E.; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Bern Univ Hosp, Inselspital, Dept Ophthalmol, Bern, Switzerland.
   [Zysset-Burri, Denise C.; Keller, Irene; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Dept BioMed Res, Bern, Switzerland.
   [Keller, Irene] Univ Bern, Interfac Bioinformat Unit, Bern, Switzerland.
   [Keller, Irene] Univ Bern, Swiss Inst Bioinformat, Bern, Switzerland.
   [Largiader, Carlo R.] Univ Bern, Bern Univ Hosp, Inselspital, Dept Clin Chem, Bern, Switzerland.
   [Wittwer, Matthias] Fed Off Civil Protect, Spiez Lab, Austr, Spiez, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University of Bern; Swiss Institute of Bioinformatics; University of
   Bern; University of Bern; University Hospital of Bern
RP Zysset-Burri, DC (通讯作者)，Univ Bern, Bern Univ Hosp, Inselspital, Dept Ophthalmol, Bern, Switzerland.; Zysset-Burri, DC (通讯作者)，Univ Bern, Dept BioMed Res, Bern, Switzerland.
EM denise.zysset@insel.ch
RI Largiader, Carlo R/B-8798-2008; Wolf, Sebastian/B-8782-2008
OI Largiader, Carlo R/0000-0002-0889-8922; Wolf,
   Sebastian/0000-0002-7467-7028; Zysset, Denise/0000-0002-4147-5374
CR Abubucker S, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002358
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1111/j.1442-9993.2001.01070.pp.x
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Dray S, 2007, J STAT SOFTW, V22, P1, DOI 10.18637/jss.v022.i04
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hirata FE, 2015, OPHTHALMIC GENET, V36, P224, DOI 10.3109/13816810.2013.867449
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Longhi MS, 2017, J MOL MED, V95, P915, DOI 10.1007/s00109-017-1545-1
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mathur R, 2015, EXPERT REV GASTROENT, V9, P1087, DOI 10.1586/17474124.2015.1051029
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209
   Morgan XC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r79
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Richardson AJ, 2010, INVEST OPHTH VIS SCI, V51, P4932, DOI 10.1167/iovs.09-5114
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Segata N, 2012, NAT METHODS, V9, P811, DOI [10.1038/NMETH.2066, 10.1038/nmeth.2066]
   Sun YY, 2013, INVEST OPHTH VIS SCI, V54, P8199, DOI 10.1167/iovs.13-12867
   Tap J, 2009, ENVIRON MICROBIOL, V11, P2574, DOI 10.1111/j.1462-2920.2009.01982.x
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Wang X, 2013, INT J OPHTHALMOL-CHI, V6, P861, DOI 10.3980/j.issn.2222-3959.2013.06.21
   Wang YQ, 2016, CHEM-BIOL INTERACT, V254, P1, DOI 10.1016/j.cbi.2016.05.019
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu Pei-bei, 2013, Zhonghua Yan Ke Za Zhi, V49, P350
   Yu Y, 2015, INT J CLIN EXP PATHO, V8, P11635
   Zeng RP, 2012, OPHTHALMIC GENET, V33, P139, DOI 10.3109/13816810.2011.643440
   Zhang MX, 2015, GENET MOL RES, V14, P12567, DOI 10.4238/2015.October.16.24
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zysset-Burri DC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51698-5
NR 55
TC 16
Z9 17
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2056-7944
J9 NPJ GENOM MED
JI npj Genom. Med.
PD SEP 1
PY 2020
VL 5
IS 1
AR 34
DI 10.1038/s41525-020-00141-0
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA NI2FG
UT WOS:000565170800001
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jhingan, M
   Singh, SR
   Samanta, A
   Arora, S
   Tucci, D
   Amarasekera, S
   Cagini, C
   Lupidi, M
   Chhablani, J
AF Jhingan, Mahima
   Singh, Sumit Randhir
   Samanta, Anindya
   Arora, Supriya
   Tucci, Davide
   Amarasekera, Sohani
   Cagini, Carlo
   Lupidi, Marco
   Chhablani, Jay
TI Drusen ooze: Predictor for progression of dry age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Drusen ooze; Dry AMD; Non-neovascular AMD; Progression; iRORA; cRORA; GA
AB Background To evaluate natural history of drusen ooze and its role as a predictor for progression of dry age-related macular degeneration (AMD) longitudinally. Methods Multi-centric retrospective observational case series of 72 eyes (72 patients) with dry AMD with a minimum follow-up of 4 years. Drusen types were identified on volume scans on optical coherence tomography (OCT) and were characterized for occurrence of drusen ooze at baseline until last visit. Drusen ooze was defined as hyperreflective dots overlying a collapsing drusen or pseudodrusen, or hyperreflective RPE above drusen or isoreflective dots at the level of outer nuclear layer. The consequent incidence of incomplete retinal pigment epithelium and outer retinal atrophy (iRORA), complete retinal pigment epithelium and outer retinal atrophy (cRORA), and neovascular AMD (nAMD) were evaluated statistically. Results In total, 72 eyes with a mean follow-up of 68.89 (+/- 25.57 months) were studied. At presentation, 11 eyes (15.3%) had a single drusen type, whereas 61 eyes (84.7%) had mixed drusen. Reticular pseudodrusen were most common (84.7%) followed by soft drusen (66.6%). Drusen ooze was seen in 47 eyes (65.2%) at presentation. The presence of drusen ooze at baseline (p < 0.01) and baseline best corrected visual acuity (BCVA) (p = 0.04) significantly correlated with development of iRORA and cRORA. In total, 14 eyes progressed from iRORA to cRORA over a mean follow up of 29.14 (+/- 24.33) months. Odds of progression to iRORA or cRORA were 20.3 times greater for eyes with drusen ooze at baseline (95% C.I., 4.4-94.2). Conclusions In dry AMD, drusen ooze is a useful sign for predicting progression to iRORA and cRORA over time.
C1 [Jhingan, Mahima; Singh, Sumit Randhir] Univ Calif San Diego, Jacobs Retina Ctr, San Diego, CA 92103 USA.
   [Samanta, Anindya] Texas Tech Univ, Hlth Sci Ctr, Dept Ophthalmol, Lubbock, TX 79430 USA.
   [Arora, Supriya] Princess Margaret Hosp, Dept Surg, Div Ophthalmol, Nassau, Bahamas.
   [Tucci, Davide; Cagini, Carlo; Lupidi, Marco] Univ Perugia, Sect Ophthalmol, Dept Biomed & Surg Sci, Perugia, Italy.
   [Amarasekera, Sohani; Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15260 USA.
C3 University of California System; University of California San Diego;
   Texas Tech University System; Texas Tech University; Texas Tech
   University Health Science Center; University of Perugia; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Chhablani, J (通讯作者)，Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15260 USA.
EM jay.chhablani@gmail.com
RI Cagini, Carlo/H-3431-2019; Cagini, Carlo/L-2914-2016
OI Cagini, Carlo/0000-0002-3812-9219; Cagini, Carlo/0000-0002-3812-9219;
   Chhablani, Jay/0000-0003-1772-3558
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Mones J, 2017, OPHTHALMOL RETINA, V1, P461, DOI 10.1016/j.oret.2017.02.006
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Paavo M, 2017, INVEST OPHTH VIS SCI, V58, P4769, DOI 10.1167/iovs.17-22338
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P257, DOI 10.1097/IAE.0000000000002399
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
NR 20
TC 5
Z9 5
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2021
VL 259
IS 9
BP 2687
EP 2694
DI 10.1007/s00417-021-05147-7
EA MAR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UD4CF
UT WOS:000628181800004
PM 33710471
DA 2022-11-30
ER

PT J
AU Mookiah, MRK
   Acharya, UR
   Fujita, H
   Koh, JEW
   Tan, JH
   Chua, CK
   Bhandary, SV
   Noronha, K
   Laude, A
   Tong, L
AF Mookiah, Muthu Rama Krishnan
   Acharya, U. Rajendra
   Fujita, Hamido
   Koh, Joel E. W.
   Tan, Jen Hong
   Chua, Chua Kuang
   Bhandary, Sulatha V.
   Noronha, Kevin
   Laude, Augustinus
   Tong, Louis
TI Automated detection of age-related macular degeneration using empirical
   mode decomposition
SO KNOWLEDGE-BASED SYSTEMS
LA English
DT Article
DE Age-related macular degeneration; Fundus imaging; Empirical mode
   decomposition; Locality sensitive discriminant analysis; Decision
   support system
ID DIABETIC-RETINOPATHY; DRUSEN DETECTION; RETINAL IMAGES; SEGMENTATION;
   DIAGNOSIS; IDENTIFICATION; EXTRACTION; FEATURES; SIGNALS; QUANTIFICATION
AB Age-related Macular Degeneration (AMD) is the posterior segment eye disease affecting elderly people and may lead to loss of vision. AMD is diagnosed using clinical features like drusen, Geographic Atrophy (GA) and Choroidal NeoVascularization (CNV) present in the fundus image. It is mainly classified into dry and wet type. Dry AMD is most common among elderly people. At present there is no treatment available for dry AMD. Early diagnosis and treatment to the affected eye may reduce the progression of disease. Manual screening of fundus images is time consuming and subjective. Hence in this study we are proposing an Empirical Mode Decomposition (EMD)-based nonlinear feature extraction to characterize and classify normal and AMD fundus images. EMD is performed on 1D Radon Transform (RT) projections to generate different Intrinsic Mode Functions (IMF). Various nonlinear features are extracted from the IMFs. The dimensionality of the extracted features are reduced using Locality Sensitive Discriminant Analysis (LSDA). Then the reduced LSDA features are ranked using minimum Redundancy Maximum Relevance (mRMR), Kullback-Leibler Divergence (KLD) and Chernoff Bound and Bhattacharyya Distance (CBBD) techniques. Ranked LSDA components are sequentially fed to Support Vector Machine (SVM) classifier to discriminate normal and AMD classes. The performance of the current study is experimented using private and two public datasets namely Automated Retinal Image Analysis (ARIA) and STructured Analysis of the Retina (STARE). The 10-fold cross validation approach is used to evaluate the performance of the classifiers and obtained highest average classification accuracy of 100%, sensitivity of 100% and specificity of 100% for STARE dataset using only two ranked LSDA components. Our results reveal that the proposed system can be used as a decision support tool for clinicians for mass AMD screening. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Mookiah, Muthu Rama Krishnan; Acharya, U. Rajendra; Koh, Joel E. W.; Tan, Jen Hong; Chua, Chua Kuang] Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
   [Acharya, U. Rajendra] SIM Univ, Sch Sci & Technol, Dept Biomed Engn, Singapore 599491, Singapore.
   [Acharya, U. Rajendra] Univ Malaya, Fac Engn, Dept Biomed Engn, Kuala Lumpur 50603, Malaysia.
   [Fujita, Hamido] Iwate Prefectural Univ, Fac Software & Informat Sci, Takizawa, Iwate 0200693, Japan.
   [Bhandary, Sulatha V.] Kasturba Med Coll & Hosp, Dept Ophthalmol, Manipal 576104, Karnataka, India.
   [Noronha, Kevin] St Francis Inst Technol, Dept Elect & Telecommun, Bombay 400103, Maharashtra, India.
   [Laude, Augustinus] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.
   [Tong, Louis] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Tong, Louis] Singapore Eye Res Inst, Ocular Surface Res Grp, Singapore 168751, Singapore.
   [Tong, Louis] Duke NUS Grad Med Sch, Singapore 169857, Singapore.
   [Tong, Louis] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117597, Singapore.
C3 Singapore University of Social Sciences (SUSS); Universiti Malaya; Iwate
   Prefectural University; Manipal Academy of Higher Education (MAHE);
   Kasturba Medical College, Manipal; Tan Tock Seng Hospital; Singapore
   National Eye Center; National University of Singapore; Singapore
   National Eye Center; National University of Singapore; National
   University of Singapore
RP Mookiah, MRK (通讯作者)，Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
EM mkm2@np.edu.sg
RI Acharya, Rajendra U/E-3791-2010; Tan, Jenhong/AAD-3664-2020; Fujita,
   Hamido/D-6249-2012; Mookiah, Muthu Rama Krishnan/G-4033-2011; NORONHA,
   KEVIN/AAV-1433-2020; Tan, Jen Hong/ABE-6525-2020
OI Acharya, Rajendra U/0000-0003-2689-8552; Fujita,
   Hamido/0000-0001-5256-210X; Mookiah, Muthu Rama
   Krishnan/0000-0001-6437-1482; NORONHA, KEVIN/0000-0002-8753-5918;
   Bhandary, Sulatha/0000-0002-3150-707X
FU Social Innovation Research Fund (SIRE), Singapore [T1202]
FX Authors thank Social Innovation Research Fund (SIRE/Project Code:
   T1202), Singapore for providing grant for this research. Also authors
   would like to acknowledge Head of Department and all staff members of
   Department of Ophthalmology, Kasturba Medical College, Manipal, India
   for sharing the images for this study.
CR Acharya R, 2005, COMPUT METH PROG BIO, V80, P37, DOI 10.1016/j.cmpb.2005.06.011
   Acharya UR, 2012, BIOMED SIGNAL PROCES, V7, P401, DOI 10.1016/j.bspc.2011.07.007
   Acharya UR, 2011, INT J NEURAL SYST, V21, P199, DOI 10.1142/S0129065711002808
   Acharya UR, 2009, J MECH MED BIOL, V9, P539, DOI 10.1142/S0219519409003152
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   [Anonymous], 1998, STAT LEARNING THEORY
   Barriga E, 2009, IEEE INT S COMP BAS, P1
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Ben Sbeh Z, 2001, IEEE T MED IMAGING, V20, P1321, DOI 10.1109/42.974927
   Bhuiyan A., 2014, J COMPUT SCI SYST BI, V7
   Brandon L, 2003, LECT NOTES COMPUT SC, V2878, P618
   Bressan M, 2003, IEEE T PATTERN ANAL, V25, P1312, DOI 10.1109/TPAMI.2003.1233904
   Burlina P, 2011, IEEE ENG MED BIO, P3962, DOI 10.1109/IEMBS.2011.6090984
   Chen JK, 2014, ENTROPY-SWITZ, V16, P3009, DOI 10.3390/e16063009
   Cheng J, 2012, IEEE IMAGE PROC, P2805, DOI 10.1109/ICIP.2012.6467482
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Chua KC, 2010, MED ENG PHYS, V32, P679, DOI 10.1016/j.medengphy.2010.04.009
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Duda RO, 2007, PATTERN CLASSIFICATI
   Fleureau J, 2011, SIGNAL PROCESS, V91, P2783, DOI 10.1016/j.sigpro.2011.01.018
   Freund DE, 2009, I S BIOMED IMAGING, P61, DOI 10.1109/ISBI.2009.5192983
   Gao QX, 2014, NEURAL NETWORKS, V54, P49, DOI 10.1016/j.neunet.2014.02.009
   Haleem MS, 2013, COMPUT MED IMAG GRAP, V37, P581, DOI 10.1016/j.compmedimag.2013.09.005
   Hijazi M. H. A., 2015, INT J SIMUL SYST SCI, P57
   Hijazi MHA, 2010, P INT JOINT C NEUR N, P3501
   Hijazi MHA, 2012, KNOWL-BASED SYST, V29, P83, DOI 10.1016/j.knosys.2011.07.002
   Huang NE, 1998, P ROY SOC A-MATH PHY, V454, P903, DOI 10.1098/rspa.1998.0193
   Jadhav DV, 2009, NEUROCOMPUTING, V72, P1951, DOI 10.1016/j.neucom.2008.05.001
   Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Khushaba RN, 2011, IEEE T BIO-MED ENG, V58, P121, DOI 10.1109/TBME.2010.2077291
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Liang ZY, 2010, IEEE ENG MED BIO, P4100, DOI 10.1109/IEMBS.2010.5627289
   Mandic DP, 2013, IEEE SIGNAL PROC MAG, V30, P74, DOI 10.1109/MSP.2013.2267931
   Martis RJ, 2012, INT J NEURAL SYST, V22, DOI 10.1142/S012906571250027X
   Molinari F, 2015, COMPUT BIOL MED, V59, P1, DOI 10.1016/j.compbiomed.2015.01.011
   Mookiah MRK, 2015, COMPUT BIOL MED, V63, P208, DOI 10.1016/j.compbiomed.2015.05.019
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   Mookiah MRK, 2013, COMPUT BIOL MED, V43, P2136, DOI 10.1016/j.compbiomed.2013.10.007
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Nikias CL, 1993, P 15 ANN INT C IEEE, P319, DOI DOI 10.1109/IEMBS.1993.978564
   Nunes J, 2005, MACH VISION APPL, V16, P177, DOI 10.1007/s00138-004-0170-5
   Pachori RB, 2015, EXPERT SYST APPL, V42, P4567, DOI 10.1016/j.eswa.2015.01.051
   Pal S, 2012, COMPUT BIOL MED, V42, P83, DOI 10.1016/j.compbiomed.2011.10.012
   Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159
   PIZER SM, 1987, COMPUT VISION GRAPH, V39, P355, DOI 10.1016/S0734-189X(87)80186-X
   Quellec G, 2011, IEEE T MED IMAGING, V30, P523, DOI 10.1109/TMI.2010.2089383
   RADON J, 1986, IEEE T MED IMAGING, V5, P170, DOI 10.1109/TMI.1986.4307775
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Santos-Villalobos H, 2011, IEEE ENG MED BIO, P6236, DOI 10.1109/IEMBS.2011.6091540
   Sharma R, 2015, ENTROPY-SWITZ, V17, P669, DOI 10.3390/e17020669
   Singh K., BOOTSTRAP STAT UNPUB
   Soliz P, 2008, 2008 IEEE SOUTHWEST SYMPOSIUM ON IMAGE ANALYSIS & INTERPRETATION, P65, DOI 10.1109/SSIAI.2008.4512286
   Tanaka T, 2007, IEEE SIGNAL PROC LET, V14, P101, DOI 10.1109/LSP.2006.882107
   TOWERS S, 2002, P ADV STAT TECHN PAR, P107
   Venturas S., 2005, ALGORITHMS MOL BIOL, V4
   Webber Jr C.L., 2005, NONLINEAR METHODS BE, P26
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
   Zhou Kun, 2007, P JOINT C ART INT IJ, P708
NR 63
TC 19
Z9 19
U1 0
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0950-7051
EI 1872-7409
J9 KNOWL-BASED SYST
JI Knowledge-Based Syst.
PD NOV
PY 2015
VL 89
BP 654
EP 668
DI 10.1016/j.knosys.2015.09.012
PG 15
WC Computer Science, Artificial Intelligence
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA CV4PU
UT WOS:000364249800047
DA 2022-11-30
ER

PT J
AU Wygledowska-Promienska, D
   Piotrowska-Gwozdz, A
   Piotrowska-Seweryn, A
   Mazur-Piotrowska, G
   Rokicki, W
AF Wygledowska-Promienska, Dorota
   Piotrowska-Gwozdz, Anna
   Piotrowska-Seweryn, Agnieszka
   Mazur-Piotrowska, Grazyna
   Rokicki, Wojciech
TI Combination of bevacizumab and bromfenac therapy in age-related macular
   degeneration: A pilot study
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Anti-Inflammatory Agents, Non-Steroidal; Macular Degeneration; Vascular
   Endothelial Growth Factor, Endocrine-Gland-Derived
AB Background: According to recent studies, the newest strategy for the treatment of exudative age-related macular degeneration is to combine anti-VEGF agents with non-steroid anti-inflammatory drugs (NSAIDs) such as nepafenac and bromfenac to decrease the frequency of intravitreal injections. Since most research has focused on ranibizumab, the aim of this study is to evaluate whether an alternative drug such as bevacizumab could lead to similar outcomes.
   Material/Methods: The study was conducted on a group of 26 patients who were administered intravitreal bevacizumab and topical bromfenac (study group) and 26 patients with single bevacizumab therapy (control group). Cases that were not qualified for ranibizumab therapy were included in the study group.
   Results: The study revealed that the visual acuity and parameters observed in OCT improved more in the study group than in the control group. However, the correlations between the above factors and the frequency of intravitreal injections were statistically significant only in visual acuity.
   Conclusions: We recommend the combined therapy of bevacizumab and bromfenac as an alternative and beneficial method of treatment in patients with exudative AMD who do not qualify for ranibizumab therapy. This combined therapy might efficiently reduce the number of intravitreal injections of bevacizumab.
C1 [Wygledowska-Promienska, Dorota; Piotrowska-Gwozdz, Anna; Mazur-Piotrowska, Grazyna; Rokicki, Wojciech] Med Univ Silesia, Dept Clin Ophthalmol, Katowice, Poland.
C3 Medical University Silesia
RP Wygledowska-Promienska, D (通讯作者)，Med Univ Silesia, Dept Clin Ophthalmol, Katowice, Poland.
EM agapio.fm@interia.pl
OI Piotrowska-Seweryn, Agnieszka/0000-0003-1733-1167;
   Wygledowska-Promienska, Dorota/0000-0001-5336-3460
CR Biarnes M, 2011, EUR J OPHTHALMOL, V21, P282, DOI 10.5301/EJO.2010.5766
   Chen E, 2010, CLIN OPHTHALMOL, V4, P1249, DOI 10.2147/OPTH.S14092
   Das UN, 2013, NUTRITION, V29, P1, DOI 10.1016/j.nut.2012.02.003
   Das UN, 2012, MED SCI MONITOR, V18, pLE1, DOI 10.12659/MSM.882187
   Figurska M, 2011, MED SCI MONITOR, V17, pCR485, DOI 10.12659/MSM.881934
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   GRANT CA, 2008, INVEST OPHTHALMOL VI, V49
   Kim SJ, 2010, SURV OPHTHALMOL, V55, P108, DOI 10.1016/j.survophthal.2009.07.005
   Lukacs Regina, 2013, Orv Hetil, V154, P1790, DOI 10.1556/OH.2013.29729
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   Nowak MS, 2012, MED SCI MONITOR, V18, pCR374, DOI 10.12659/MSM.882907
   Schalnus R, 2003, OPHTHALMOLOGICA, V217, P89, DOI 10.1159/000068563
   Stevenson CE, 2012, FUTURE ONCOL, V8, P403, DOI [10.2217/FON.12.22, 10.2217/fon.12.22]
   Strickler JH, 2012, ONCOLOGIST, V17, P513, DOI 10.1634/theoncologist.2012-0003
   Su Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035629
   Van Meter MEM, 2010, CURR OPIN ONCOL, V22, P586, DOI 10.1097/CCO.0b013e32833edc0c
   Warren KA, 2010, RETINA-J RET VIT DIS, V30, P260, DOI 10.1097/IAE.0b013e3181b8628e
   Zweifel SA, 2009, RETINA-J RET VIT DIS, V29, P1527, DOI 10.1097/IAE.0b013e3181b32f4c
NR 20
TC 6
Z9 6
U1 0
U2 1
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD JUL 9
PY 2014
VL 20
BP 1168
EP 1175
DI 10.12659/MSM.890671
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA VI3QP
UT WOS:000475298700001
PM 25006692
OA Green Published
DA 2022-11-30
ER

PT J
AU Aisenbrey, S
   Lafaut, BA
   Szurman, P
   Grisanti, S
   Luke, C
   Krott, R
   Thumann, G
   Fricke, J
   Neugebauer, A
   Hilgers, RD
   Esser, P
   Walter, P
   Bartz-Schmidt, KU
AF Aisenbrey, S
   Lafaut, BA
   Szurman, P
   Grisanti, S
   Luke, C
   Krott, R
   Thumann, G
   Fricke, J
   Neugebauer, A
   Hilgers, RD
   Esser, P
   Walter, P
   Bartz-Schmidt, KU
TI Macular translocation with 360 degrees retinotomy for exudative
   age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; DOUBLE-MASKED TRIAL; FOVEAL
   TRANSLOCATION; PIGMENT-EPITHELIUM; SURGICAL EXCISION; MEMBRANES;
   SURGERY; MANAGEMENT; REMOVAL; TRANSPLANTATION
AB Background: Macular rotation surgery comprises surgical extraction of choroidal neovascular membranes in age-related macular degeneration (AMD) and translocation of the foveal neural retina over adjacent retinal pigment epithelium.
   Objective: To determine whether macular translocation with 360degrees retinotomy can stabilize and/or improve visual acuity in patients with subfoveal choroidal neovascularization (CNV) secondary to AMD.
   Design: This study consisted of a standardized surgical procedure on a series of 90 consecutive patients and follow-up examinations at fixed intervals for 12 months.
   Participants: All patients in this study had experienced recent visual loss resulting from subfoveal CNV caused by AMD. Twenty-six patients had major macular subretinal hemorrhage, 39 patients had occult subfoveal CNV, and 25 patients had classic subfoveal CNV.
   Methods: Macular translocation surgery was performed between 1997 and 1999. The patients were examined preoperatively and at 3, 6, and 12 months postoperatively, including visual acuity, microperimetry, angiography, and orthoptic assessment,
   Results: Visual acuity increased by 15 or more letters in 24 patients, remained stable in 37 patients, and deteriorated by 15 or more letters in 29 patients at 12 months postoperatively. A secondary procedure was necessary in 17 patients because of severe complications; proliferative vitreoretinopathy was observed in 17 eyes, macular pucker in 5 eyes, and macular hole in I patient.
   Conclusion: Macular translocation is a technically demanding surgical procedure. Although the procedure has a high rate of surgical and postoperative complications, the functional and anatomical results appear to be promising for selected patients with subfoveal CNV secondary to AMD.
C1 Univ Tubingen, Eye Clin, Dept 1, D-72076 Tubingen, Germany.
   Univ Cologne, Dept Vitreoretinal Surg, Cologne, Germany.
   Univ Cologne, Dept Strabismus Therapy & Neuroophthalmol, Cologne, Germany.
   State Univ Ghent Hosp, Dept Ophthalmol, B-9000 Ghent, Belgium.
   Rhein Westfal TH Aachen, Dept Med Biometry, D-5100 Aachen, Germany.
C3 Eberhard Karls University of Tubingen; University of Cologne; University
   of Cologne; Ghent University; Ghent University Hospital; RWTH Aachen
   University
RP Bartz-Schmidt, KU (通讯作者)，Univ Tubingen, Eye Clin, Dept 1, Schleichstr 12-16, D-72076 Tubingen, Germany.
RI Hilgers, Ralf-Dieter/C-7090-2013; Walter, Peter/L-5982-2018
OI Hilgers, Ralf-Dieter/0000-0002-5945-1119; Walter,
   Peter/0000-0001-8745-6593
CR Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   Bereczki A, 2000, BRIT J OPHTHALMOL, V84, P550
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt Claus, 1996, Ophthalmologe, V93, P688, DOI 10.1007/s003470050059
   Eckardt U, 1998, KLIN MONATSBL AUGENH, V212, P212, DOI 10.1055/s-2008-1034867
   Faude F, 1999, RETINA-J RET VIT DIS, V19, P173, DOI 10.1097/00006982-199902000-00018
   Freedman SF, 2000, J AAPOS, V4, P75, DOI 10.1067/mpa.2000.102925
   Fricke J, 2000, GRAEF ARCH CLIN EXP, V238, P664, DOI 10.1007/s004170000170
   Fujikado T, 1998, AM J OPHTHALMOL, V125, P647, DOI 10.1016/S0002-9394(98)00021-X
   Fujikado T, 1998, AM J OPHTHALMOL, V126, P839, DOI 10.1016/S0002-9394(98)00201-3
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Imai K, 1998, AM J OPHTHALMOL, V125, P627, DOI 10.1016/S0002-9394(98)00023-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   LINDSEY P, 1983, INVEST OPHTHALMOL  S, V24, P242
   Luke C, 2001, BRIT J OPHTHALMOL, V85, P928, DOI 10.1136/bjo.85.8.928
   MACHAN L, 1998, TECH VASC INTERVENT, V1, P25
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Nakagawa N, 2000, ARCH OPHTHALMOL-CHIC, V118, P965
   Ninomiya Y, 1996, AM J OPHTHALMOL, V122, P613, DOI 10.1016/S0002-9394(14)70479-9
   Potter MJ, 2000, AM J OPHTHALMOL, V129, P547, DOI 10.1016/S0002-9394(99)00480-8
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   Wong D, 2000, BRIT J OPHTHALMOL, V84, P670
NR 44
TC 100
Z9 107
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2002
VL 120
IS 4
BP 451
EP 459
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 538JU
UT WOS:000174813300003
PM 11934318
DA 2022-11-30
ER

PT J
AU Perrott-Reynolds, R
   Cann, R
   Cronbach, N
   Neo, YN
   Ho, V
   McNally, O
   Madi, HA
   Cochran, C
   Chakravarthy, U
AF Perrott-Reynolds, Rhianon
   Cann, Robert
   Cronbach, Nicola
   Neo, Yan Ning
   Ho, Vivian
   McNally, Orla
   Madi, Haifa A.
   Cochran, Claire
   Chakravarthy, Usha
TI The diagnostic accuracy of OCT angiography in naive and treated
   neovascular age-related macular degeneration: a review
SO EYE
LA English
DT Review
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; TYPE-3
   NEOVASCULARIZATION
AB Optical coherence tomography angiography (OCTA) is a non-invasive retinal imaging innovation that has been gaining popularity for the evaluation of the retinal vasculature. Of clinical importance is its current use either as an alternative or in conjunction with conventional dye-based angiography in neovascular age-related macular degeneration. OCTA is not without limitations and these include image artefact, a relatively small field of view and failure of the segmentation algorithms, which can confound the interpretation of findings. While there are numerous publications on OCTA in neovascular AMD, few have examined the diagnostic accuracy of this new technology compared with the accepted gold standard of fundus fluorescein angiography (FFA). In this review, we summarise the literature on the clinical application of OCTA in nAMD. In particular, we have reviewed the published articles that have reported the sensitivity and specificity of OCTA in the diagnosis of nAMD, and those that have described and or correlated the morphological findings and compared them to dye-based angiography.
C1 [Perrott-Reynolds, Rhianon] Univ Hosp Wales, Dept Ophthalmol, Cardiff CF14 4XW, S Glam, Wales.
   [Cann, Robert] Mid Yorkshire Hosp NHS Trust, Wakefield WF1 4DG, W Yorkshire, England.
   [Cronbach, Nicola] Buckinghamshire Healthcare NHS trust, Oxford, England.
   [Neo, Yan Ning] Hillingdon Hosp NHS Trust, Uxbridge UB8 3NN, Middx, England.
   [Ho, Vivian] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool L14 3LB, Merseyside, England.
   [McNally, Orla] Belfast Hlth & Social Care Trust, Belfast BT9 7AB, Antrim, North Ireland.
   [Madi, Haifa A.] Sunderland Eye Infirm, Sunderland SR2 9HP, Tyne & Wear, England.
   [Cochran, Claire] Univ Aberdeen, EDNA Study Team, Aberdeen AB25 2ZD, Scotland.
   [Chakravarthy, Usha] Queens Univ Belfast, Ophthalmol & Vis Sci, Belfast BT7 1NN, Antrim, North Ireland.
   [Chakravarthy, Usha] Belfast Hlth & Social Care Trust, Dept Ophthalmol, Belfast BT9 7AB, Antrim, North Ireland.
C3 Cardiff University; Royal Liverpool & Broadgreen University Hospitals
   NHS Trust; Royal Liverpool University Hospital; University of Aberdeen;
   Queens University Belfast
RP Perrott-Reynolds, R (通讯作者)，Univ Hosp Wales, Dept Ophthalmol, Cardiff CF14 4XW, S Glam, Wales.
EM Rhianon.reynolds@wales.nhs.uk
RI Neo, Yan Ning/G-7332-2015
OI Cochran, Claire/0000-0001-7349-7685; Neo, Yan Ning/0000-0001-8319-7889;
   Cann, Robert/0000-0001-9325-7638
FU EDNA study office based at the University of Aberdeen
FX We wish to acknowledge the support of the EDNA study office based at the
   University of Aberdeen, with special thanks to Dr Kathryn Bannister.
   With thanks to David Wright, MRC Innovation Fellow, Health Data Research
   UK, Centre for Public Health, Queen's University Belfast for generation
   of the Forest plots.
CR Amoroso F, 2018, BRIT J OPHTHALMOL, V102, P821, DOI 10.1136/bjophthalmol-2017-310569
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   Chen CL, 2017, BIOMED OPT EXPRESS, V8, P1056, DOI 10.1364/BOE.8.001056
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Liang MC, 2016, RETINA-J RET VIT DIS, V36, P2265, DOI 10.1097/IAE.0000000000001102
   Lindner M, 2016, INVEST OPHTH VIS SCI, V57, P6342, DOI 10.1167/iovs.16-19741
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
NR 22
TC 33
Z9 34
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2019
VL 33
IS 2
BP 274
EP 282
DI 10.1038/s41433-018-0229-6
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HK5MG
UT WOS:000458009500016
PM 30382236
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Pahl, L
   Schubert, S
   Skawran, B
   Sandbothe, M
   Schmidtke, J
   Stuhrmann, M
AF Pahl, Lisa
   Schubert, Stephanie
   Skawran, Britta
   Sandbothe, Maria
   Schmidtke, Joerg
   Stuhrmann, Manfred
TI 1,25-Dihydroxyvitamin D decreases HTRA1 promoter activity in the rhesus
   monkey - A plausible explanation for the influence of vitamin D on
   age-related macular degeneration?
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; HTRA1; vitamin D; VDR; rhesus monkey
ID SERINE-PROTEASE HTRA1; SUSCEPTIBILITY GENES; ARMS2; DRUSEN; ASSOCIATION;
   RISK; BETA; MACULOPATHY; VARIANTS; GROWTH
AB Age-related macular degeneration is the major cause of blindness in the elderly worldwide and the risk is influenced by both environmental and genetic risk factors. One important disease-associated region in humans is located on 10q26 and includes the two candidate genes ARMS2 and HTRA1. However, determination of the causative gene has not yet been possible and examining the situation in the rhesus monkey may help understand the situation in humans. In a recent paper, we characterized the rhesus monkey 10q26-orthologue region on chromosome 9 in detail and identified the drusen-associated HTRA1 promoter SNP rs196357513 as a putative risk factor. In this study, we predicted 9 binding sites for the vitamin D-dependent transcription factor vitamin D receptor in the rhesus HTRA1 promoter, one of which is destroyed by the rs196357513-risk allele. As patients with vitamin D deficit are at increased risk for age-related macular degeneration, a luciferase assay in transiently transfected ARPE19-cells was performed to evaluate the influence of the SNP rs196357513 and of 1,25-dihydroxyvitamin D on the rhesus monkey HTRA1 promoter activity. This revealed that the luciferase activity of the promoter construct containing the rs196357513 wild type allele was significantly reduced after vitamin D stimulation. An in silico analysis and literature search imply that this regulation could also play a role in human HTRA1 expression. Moreover, HTRA1 promoter activity of the construct containing the rs196357513 risk allele appeared diminished in comparison to the construct with the wild type allele, albeit this difference was not significant. The lower promoter activity due to the rhesus monkey rs196357513 risk allele apparently contradicts the common hypothesis for the human HTRA1 promoter risk allele of SNP rs11200638, for which a higher promoter activity has been observed. Our data point to a yet unexpected effect of decreased HTRA1 expression on drusen pathogenesis. Thus not only a higher HTRA1 expression, but an imbalance of HTRA1 might be disease-relevant. Both findings require closer analysis, but if relevance for humans proves true, it would impact current age-related macular degeneration research and treatment. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Pahl, Lisa; Schubert, Stephanie; Schmidtke, Joerg; Stuhrmann, Manfred] Hannover Med Sch, Inst Humangenet, D-30625 Hannover, Germany.
   [Skawran, Britta; Sandbothe, Maria] Hannover Med Sch, Inst Cellular & Mol Pathol, D-30625 Hannover, Germany.
C3 Hannover Medical School; Hannover Medical School
RP Pahl, L (通讯作者)，Hannover Med Sch, Inst Humangenet, OE 6300,Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM pahl.lisa@mh-hannover.de
OI Schubert, Stephanie/0000-0001-8634-7299
FU Studienstiftung des deutschen Volkes
FX This work was supported by a grant of the Studienstiftung des deutschen
   Volkes to LP. We thank Malte Regelin (Institute of Immunology, Hannover
   Medical School) for providing support with the TRANSFAC database. We
   thank Dr. rer. nat. Ulrike Friedrich (Institute of Human Genetics,
   University of Regensburg) for her advice concerning cell culture and
   transfection of ARPE19-cells. We thank Dr. rer. nat. Reena Buurmann
   (Institute for Cellular and Molecular Pathology) for providing support
   with the development of the luciferase assay, and Dr. W. Burke (Clinic
   for Laryngology, Rhinology and Otology, Hannover Medical School) for a
   linguistic revision of this manuscript.
CR Alsalem J., 2010, ROLE 125OH2 VITAMIND
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   BOUILLON R, 1981, J CLIN INVEST, V67, P589, DOI 10.1172/JCI110072
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   CHOUVET C, 1986, J STEROID BIOCHEM, V24, P373, DOI 10.1016/0022-4731(86)90085-3
   Dentchev T, 2003, MOL VIS, V9, P184
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   ELMOFTY A, 1978, EXP EYE RES, V27, P499, DOI 10.1016/0014-4835(78)90027-1
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Grob S, 2012, EYE, V26, P1106, DOI 10.1038/eye.2012.107
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lu JF, 2005, J INVEST DERMATOL, V124, P778, DOI 10.1111/j.0022-202X.2005.23641.x
   Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143
   Melissa S, 2012, EXP EYE RES, V94, P4, DOI 10.1016/j.exer.2010.07.006
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mold M, 2012, J ALZHEIMERS DIS, V29, P875, DOI 10.3233/JAD-2012-120076
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pahl L, 2012, EXP EYE RES, V98, P75, DOI 10.1016/j.exer.2012.03.007
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
NR 41
TC 11
Z9 11
U1 0
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2013
VL 116
BP 234
EP 239
DI 10.1016/j.exer.2013.09.012
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 259YP
UT WOS:000327562500027
PM 24076413
DA 2022-11-30
ER

PT J
AU Mandic, K
   Vukojevic, N
   Jukic, T
   Katusic, D
   Mandic, JJ
AF Mandic, Kresimir
   Vukojevic, Nenad
   Jukic, Tomislav
   Katusic, Damir
   Mandic, Jelena Juni
TI CHANGES OF DRUSEN NUMBER AND CENTRAL RETINAL THICKNESS IN AGE-RELATED
   MACULAR DEGENERATION PATIENTS OVER TWO YEARS
SO ACTA CLINICA CROATICA
LA English
DT Article
DE Macular degeneration, aged; Retinal drusen; Retina; Sex; Male; Female
ID OPTICAL COHERENCE TOMOGRAPHY; RISK-FACTORS; PREVALENCE; HISTORY; EYES
AB Age-related macular degeneration (ARMD) is the leading cause of blindness in developed world but there are still much unknown facts about the disease itself. Age, genetic factors and smoking are the three main risk factors for the development of ARMD, but the exact pathophysiological mechanism of the disease remains unknown. Current high resolution optical coherence tomography devices provide ample new information on retinal layers, drusen characteristics and their interaction. In this study, we analyzed 44 eyes with drusiform dry ARMD using high resolution optical coherence tomography over a 2-year period. Our results showed a statistically significant increase in drusen number in both females and males in the 2-year period. On average, increment by 4 and 5 drusen per eye during the 2-year period was recorded in female and male patients with drusiform dry ARMD, respectively. Also, statistical analysis of the central retinal thickness showed that women with drusiform dry ARMD had a statistically significantly thinner macula than their male counterparts.
C1 [Mandic, Kresimir; Vukojevic, Nenad; Jukic, Tomislav; Katusic, Damir; Mandic, Jelena Juni] Univ Zagreb, Ctr Hosp, Sch Med, Dept Clin Ophthalmol, Zagreb, Croatia.
C3 University of Zagreb; University of Zagreb, School of Dental Medicine
RP Mandic, K (通讯作者)，Dobri Dol 40, HR-10000 Zagreb, Croatia.
EM kresimir_mandic@yahoo.com
RI Mandić, Jelena Juri/T-9211-2019
OI Mandić, Jelena Juri/0000-0003-0211-7491
CR Adhi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037638
   Charbel Issa P., 2010, GRAEFES ARCH CLIN EX, V249, P163, DOI DOI 10.1007/S00417-010-1568-6.EPUB
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Garcia CAD, 2013, RETINA-J RET VIT DIS, V33, P1558, DOI 10.1097/IAE.0b013e318285cbd2
   Evans JR, 1998, EYE, V12, P256, DOI 10.1038/eye.1998.60
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GOPINATH B, MATURITAS, V77, P263, DOI DOI 10.1016/J.MATURITAS.2013.12.001.EPUB
   Gupta P, 2013, INVEST OPHTH VIS SCI, V54, P7968, DOI 10.1167/iovs.13-12436
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Myers CE, 2015, AM J OPHTHALMOL, V159, P445, DOI 10.1016/j.ajo.2014.11.025
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Ooto S, 2015, CURR EYE RES, V40, P213, DOI 10.3109/02713683.2014.952828
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Song WK, 2010, INVEST OPHTH VIS SCI, V51, P3913, DOI 10.1167/iovs.09-4189
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Vrabec R, 2007, ACTA CLIN CROAT, V46, P161
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 27
TC 6
Z9 6
U1 0
U2 3
PU SESTRE MILOSRDNICE UNIV HOSPITAL
PI ZAGREB
PA VINOGRADSKA C 29, ZAGREB, HR-10000, CROATIA
SN 0353-9466
EI 1333-9451
J9 ACTA CLIN CROAT
JI Acta Clin. Croat.
PD SEP
PY 2016
VL 55
IS 3
BP 354
EP 359
DI 10.20471/acc.2016.55.03.02
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EC2HX
UT WOS:000387933900002
PM 29045093
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU ElShelmani, H
   Wride, MA
   Saad, T
   Rani, S
   Kelly, DJ
   Keegan, D
AF ElShelmani, Hanan
   Wride, Michael A.
   Saad, Tahira
   Rani, Sweta
   Kelly, David J.
   Keegan, David
TI The Role of Deregulated MicroRNAs in Age-Related Macular Degeneration
   Pathology
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; biomarkers; microRNAs; pathology
AB Purpose: We previously identified three microRNAs (miRNAs) with significantly increased expression in the serum of patients with age-related macular degeneration (AMD) compared with healthy controls. Our objective was to identify potential functional roles of these upregulated miRNAs (miR-19a, miR-126, and miR-410) in AMD, using computational tools for miRNAs prediction and identification, and to demonstrate the miRNAs target genes and signaling pathways. We also aim to demonstrate the pathologic role of isolated sera-derived exosomes from patients with AMD and controls using in vitro models. Methods: miR-19a, miR-126, and miR-410 were investigated using bioinformatic approaches, including DIANA-mirPath and miR TarBase. Data on the resulting target genes and signaling pathways were incorporated with the differentially expressed miRNAs in AMD. Apoptosis markers, human apoptosis miRNAs polymerase chain reaction arrays and angiogenesis/vasculogenesis assays were performed by adding serum-isolated AMD patient or control patient derived exosomes into an in vitro human angiogenesis model and ARPE-19 cell lines. Results: A number of pathways known to be involved in AMD development and progression were predicted, including the vascular endothelial growth factor signaling, apoptosis, and neurodegenerative pathways. The study also provides supporting evidence for the involvement of serum-isolated AMD-derived exosomes in the pathology of AMD, via apoptosis and/or angiogenesis. Conclusions: miR-19a, miR-126, miR-410 and their target genes had a significant correlation with AMD pathogenesis. As such, they could be potential new targets as predictive biomarkers or therapies for patients with AMD. Translational Relevance: The functional analysis and the pathologic role of altered miRNA expression in AMD may be applicable in developing new therapies for AMD through the disruption of individual or multiple pathophysiologic pathways.
C1 [ElShelmani, Hanan; Wride, Michael A.] Univ Dublin, Trinity Coll Dublin, Ocular Dev & Neurobiol Res Grp, Zool Dept,Sch Nat Sci, Dublin 2, Ireland.
   [ElShelmani, Hanan; Saad, Tahira; Keegan, David] Mater Misericordiae Univ Hosp, Mater Retina Res Grp, Eccles St, Dublin 7, Ireland.
   [Rani, Sweta] Waterford Inst Technol, Dept Sci, Waterford, Ireland.
   [Kelly, David J.] Univ Dublin, Trinity Coll Dublin, Sch Nat Sci, Zool Dept, Dublin, Ireland.
C3 Trinity College Dublin; Mater Misericordiae University Hospital;
   University College Dublin; South East Technological University (SETU);
   Trinity College Dublin
RP Keegan, D (通讯作者)，Mater Misericordiae Univ Hosp, Eccles St, Dublin 7, Ireland.
EM dkeegan@mater.ie
OI Rani, Sweta/0000-0003-0937-0094
FU Irish Research Council for Science, Engineering and Technology/EMBARK
   Initiative; Mater Vision Institute; Libyan Ministry of Higher Education
   and Scientific Research (The Arab Medical University); Fighting
   Blindness Ireland [FB14 SAA]; Irish Research Council for Science,
   Engineering and Technology/EMBARKS Initiative; Libyan Ministry of Higher
   Education and Scientific Research; Waterford Institute of Technology
FX The authors are grateful to the Irish Research Council for Science,
   Engineering and Technology/EMBARK Initiative, the Mater Vision
   Institute, the Libyan Ministry of Higher Education and Scientific
   Research (The Arab Medical University) for their support, Fighting
   Blindness Ireland (FB14 SAA), and funders of the CARMA trial (Waterford
   Institute of Technology).; Financial support was provided by the Irish
   Research Council for Science, Engineering and Technology/EMBARKS
   Initiative, the Mater Vision Institute, the Libyan Ministry of Higher
   Education and Scientific Research, Fighting Blindness Ireland (FB14
   SAA), and funders of CARMAtrial (Waterford Institute of Technology).
CR Anand Sudarshan, 2011, Genes Cancer, V2, P1134, DOI 10.1177/1947601911423032
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Brogan AP, 2005, P NATL ACAD SCI USA, V102, P10433, DOI 10.1073/pnas.0504721102
   Cantaluppi V, 2012, KIDNEY INT, V82, P412, DOI 10.1038/ki.2012.105
   Chen N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095665
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cornel Stefan, 2015, Rom J Ophthalmol, V59, P235
   Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855
   Doebele C, 2010, BLOOD, V115, P4944, DOI 10.1182/blood-2010-01-264812
   Elbay A, 2019, SCAND J CLIN LAB INV, V79, P388, DOI 10.1080/00365513.2019.1637931
   Elshelmani H, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.28
   Govindaraju VK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182420
   Ha Tai-You, 2011, Immune Netw, V11, P11, DOI [10.4110/in.2011.11.3.135, 10.4110/in.2011.11.1.11]
   Hill JM, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00232
   Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107
   Huang PR, 2017, INVEST OPHTH VIS SCI, V58, P1726, DOI 10.1167/iovs.16-20043
   Huang RS, 2011, RNA BIOL, V8, P692, DOI 10.4161/rna.8.4.16029
   Huntley RP, 2018, RNA, V24, P1005, DOI 10.1261/rna.065565.118
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Jaber VR, 2019, MOL NEUROBIOL, V56, P8101, DOI 10.1007/s12035-019-1632-0
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Lee JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084256
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Li L, 2010, MAMM GENOME, V21, P1, DOI 10.1007/s00335-009-9241-2
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Lukiw WJ, 2012, NEUROREPORT, V23, P621, DOI [10.1097/00001756-201207110-00009, 10.1097/WNR.0b013e32835542b0]
   Maia J, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00018
   Makarev E, 2014, AGING-US, V6, P1064, DOI 10.18632/aging.100711
   Marcuzzo S, 2014, EXP NEUROL, V253, P91, DOI 10.1016/j.expneurol.2013.12.007
   Maronas O, 2020, CURR MED CHEM, V27, P549, DOI 10.2174/0929867326666190711105325
   Martinez B, 2021, NEURAL REGEN RES, V16, P440, DOI 10.4103/1673-5374.293131
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Min H, 2010, EXP MOL MED, V42, P233, DOI 10.3858/emm.2010.42.4.032
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   Nikolic Iva, 2010, J Angiogenes Res, V2, P9, DOI 10.1186/2040-2384-2-9
   O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pogue AI, 2018, CELL MOL NEUROBIOL, V38, P1021, DOI 10.1007/s10571-017-0572-3
   Rana S, 2013, NEOPLASIA, V15, P281, DOI 10.1593/neo.122010
   Rawlings-Goss RA, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-53
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Ribeiro Mara Fernandes, 2013, Curr Angiogenes, V2, P54
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Russ R, 2012, PULM MED, V2012, DOI 10.1155/2012/791234
   Smit-McBride ZS, 2018, MOL VIS, V24, P633
   Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Su SA, 2017, ONCOTARGET, V8, P25700, DOI 10.18632/oncotarget.14878
   Thai TH, 2010, DISCOV MED, V10, P184
   Todoerti K, 2010, HAEMATOL-HEMATOL J, V95, P260, DOI 10.3324/haematol.2009.012088
   van Balkom BWM, 2013, BLOOD, V121, P3997, DOI 10.1182/blood-2013-02-478925
   van Niel G, 2006, J BIOCHEM, V140, P13, DOI 10.1093/jb/mvj128
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Xu XL, 2014, ANN THORAC SURG, V97, P1037, DOI 10.1016/j.athoracsur.2013.10.042
   Yang L, 2013, MOL MED REP, V8, P1272, DOI 10.3892/mmr.2013.1634
   Yu LL, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3634563
   Zhang FJ, 2012, TOXICOL SCI, V128, P103, DOI 10.1093/toxsci/kfs142
   Zhao YH, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00059
NR 68
TC 6
Z9 6
U1 1
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD FEB
PY 2021
VL 10
IS 2
DI 10.1167/tvst.10.2.12
PG 19
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RG2VZ
UT WOS:000635403100012
PM 34003896
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Rajendran, A
   Dhoble, P
   Sundaresan, P
   Saravanan, V
   Vashist, P
   Nitsch, D
   Smeeth, L
   Chakravarthy, U
   Ravindran, RD
   Fletcher, AE
AF Rajendran, Anand
   Dhoble, Pankaja
   Sundaresan, Periasamy
   Saravanan, Vijayan
   Vashist, Praveen
   Nitsch, Dorothea
   Smeeth, Liam
   Chakravarthy, Usha
   Ravindran, Ravilla D.
   Fletcher, Astrid E.
TI Genetic risk factors for late age-related macular degeneration in India
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMMON VARIANTS; POLYMORPHISM; ASSOCIATION; PREVALENCE; INDEYE; LOCI;
   APOE; CFH
AB Background/Aims There are limited data from India on genetic variants influencing late age-related macular degeneration (AMD). We have previously reported associations from a population-based study in India (the India age-related eye disease study (INDEYE)) of early AMD and single nucleotide polymorphisms (SNPs) in ARMS2/HTRA1 and no association with CFH, C2 or CFB. Late AMD cases were too few for meaningful analyses. We aimed to investigate SNPs for late AMD through case enrichment and extend the loci for early AMD.
   Methods Fundus images of late AMD hospital cases were independently graded by the modified Wisconsin AMD grading scheme. In total 510 cases with late AMD (14 geographic atrophy and 496 neovascular AMD (nvAMD)), 1876 with early AMD and 1176 with no signs of AMD underwent genotyping for selected SNPs. We investigated genotype and per-allele additive associations (OR and 95% CIs) with nvAMD or early AMD. Bonferroni adjusted P values are presented.
   Results We found associations with nvAMD for CFHY402H variant (rs1061170) (OR=1.99, 95% CI 1.67 to 2.37, P=10(-6)), ARMS2 (rs10490924) (OR=2.94, 95% CI 2.45 to 3.52, P=10(-9)), C2 (rs547154) (OR=0.67, 95% CI 0.53 to 0.85, P=0.01), ABCA1 (rs1883025) (OR=0.77, 95% CI 0.65 to 0.92, P=0.04) and an SNP near VEGFA (rs4711751) (OR=0.64, 95% CI 0.54 to 0.77, P=10(-3)). We found no associations of TLR3 (rs3775291), CFD (rs3826945), FRK (rs1999930) or L1PC (rs10468017) or APOE epsilon 4 alleles with nvAMD or early AMD, nor between early AMD and rs1883025 or rs4711751.
   Conclusions The major genetic determinants of nvAMD risk in India are similar to those in other ancestries, while findings for early AMD suggest potential differences in the pathophysiology of AMD development.
C1 [Rajendran, Anand; Ravindran, Ravilla D.] Aravind Eye Hosp, Madurai, Tamil Nadu, India.
   [Dhoble, Pankaja] Aravind Eye Hosp, Pondicherry, Tamil Nadu, India.
   [Sundaresan, Periasamy; Saravanan, Vijayan] Aravind Med Res Fdn, Dept Genet, Dr G Venkataswamy Res Inst, Madurai, Tamil Nadu, India.
   [Vashist, Praveen] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi, India.
   [Nitsch, Dorothea; Smeeth, Liam; Fletcher, Astrid E.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Chakravarthy, Usha] Queens Univ, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences; University of London; London
   School of Hygiene & Tropical Medicine; Queens University Belfast
RP Fletcher, AE (通讯作者)，London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
RI .P, Sundaresan/AAR-8426-2021; Smeeth, Liam/X-5862-2018
OI Nitsch, Dorothea/0000-0001-5767-248X; Smeeth, Liam/0000-0002-9168-6022
FU Wellcome Trust UK [G073300, G082571]
FX Wellcome Trust UK Grants G073300 and G082571.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Pemberton TJ, 2008, BMC GENET, V9, DOI 10.1186/1471-2156-9-13
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 18
TC 9
Z9 10
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2018
VL 102
IS 9
BP 1213
EP 1217
DI 10.1136/bjophthalmol-2017-311384
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GU2ON
UT WOS:000445109700008
PM 29259020
OA hybrid, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU McCloud, C
   Lake, S
AF McCloud, C.
   Lake, S.
TI Understanding the patient's lived experience of neovascular age-related
   macular degeneration: a qualitative study
SO EYE
LA English
DT Article
ID RISK-FACTORS; RANIBIZUMAB; GROWTH
AB Purpose In industrialised populations age-related macular degeneration (ARMD) is the leading cause of visual disability of the elderly. Successful new treatment with anti-endothelial growth factors for neovascular-classified ARMD has led to a divergence in treatment and experiences of people ARMD. This study aimed to understand the participant's experience of neovascular ARMD, including ongoing treatment with anti-vascular endothelial growth factor.
   Methods Twenty-five participants from one clinical site were qualitatively interviewed to elicit their experiences of treatment for neovascular ARMD.
   Results Two major themes were identified. A life negotiated by neovascular ARMD captures the participants' experience of living with the condition and treatment regime for neovascular ARMD. The second major theme: Uncertainty displayed their appraisal of life, treatment and their perceived future.
   Conclusions Anxieties concerning the injections, new limitations to lifestyles, and an uncertain future all emerged from the data analysis. However, thankfulness for the treatment, the importance of familiar patterns in treatments and recovery and a guarded optimism also emerged. Knowledge of the experiences, anxieties and concerns of this patient population can be used to inform clinical practice and lead to patient-centred care.
C1 [McCloud, C.] Flinders Univ S Australia, Fac Med Nursing & Hlth Sci, Bedford Pk, SA 5049, Australia.
   [Lake, S.] Flinders Med Ctr, Adelaide, SA, Australia.
C3 Flinders University South Australia; Flinders Medical Centre
RP McCloud, C (通讯作者)，Flinders Univ S Australia, Sch Nursing & Midwifery, Univ Dr, Bedford Pk, SA 5049, Australia.
EM christine.mccloud@flinders.edu.au
RI lake, stewart/AAH-6265-2021
OI lake, stewart/0000-0003-0078-3319
FU Flinders University Faculty Start Up grant
FX This work was supported by Flinders University Faculty Start Up grant
   2013-14.
CR Baird PN, 2014, CLIN EXP OPHTHALMOL, V42, P53, DOI 10.1111/ceo.12235
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Brown G, 2010, CURR OPIN OPHTHALMOL, V21, P169, DOI 10.1097/ICU.0b013e3283388605
   Burton AE, 2013, BRIT J VISUAL IMPA, V31, P178, DOI 10.1177/0264619613490517
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Cimberle M, 2002, OCUL SURG NEWS, V20, P1
   Comer GM, 2004, DRUG AGING, V21, P967, DOI 10.2165/00002512-200421150-00002
   Creswell J.W., 2014, CONCISE INTRO MIXED
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Galvin K., 2015, RES PROCESS NURSING, P211
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Hasson M, 2007, OCUL SURG NEWS, V25, P6
   Heywood D., 2005, RES METHODS SOCIAL S, P114
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lathlean, 2015, RES PROCESS NURSING, P173
   Lathlean J., 2015, RES PROCESS NURSING, P469
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Owsley C, 2007, OPHTHAL EPIDEMIOL, V14, P188, DOI 10.1080/09286580701410315
   Polit D, 2012, NURSING RES GENERATI, P800
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   TITCHEN A, 2005, RES METHODS SOCIAL S, P121
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 28
TC 24
Z9 24
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2015
VL 29
IS 12
BP 1561
EP 1569
DI 10.1038/eye.2015.167
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CY7UC
UT WOS:000366613800009
PM 26381099
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Parmeggiani, F
   Sorrentino, FS
   Romano, MR
   Costagliola, C
   Semeraro, F
   Incorvaia, C
   D'Angelo, S
   Perri, P
   De Nadai, K
   Roversi, EB
   Franceschelli, P
   Sebastiani, A
   Rubini, M
AF Parmeggiani, Francesco
   Sorrentino, Francesco S.
   Romano, Mario R.
   Costagliola, Ciro
   Semeraro, Francesco
   Incorvaia, Carlo
   D'Angelo, Sergio
   Perri, Paolo
   De Nadai, Katia
   Roversi, Elia Bonomo
   Franceschelli, Paola
   Sebastiani, Adolfo
   Rubini, Michele
TI Mechanism of Inflammation in Age-Related Macular Degeneration: An
   Up-to-Date on Genetic Landmarks
SO MEDIATORS OF INFLAMMATION
LA English
DT Review
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; GENOME-WIDE ASSOCIATION;
   RECEPTOR CLASS-B; BRUCHS MEMBRANE; CHOLESTEROL HOMEOSTASIS; TISSUE
   INHIBITOR; COMMON VARIANTS; ELEVATED LEVELS; FAMILY-HISTORY
AB Age-related macular degeneration (AMD) is the most common cause of irreversible visual impairment among people over 50 years of age, accounting for up to 50% of all cases of legal blindness in Western countries. Although the aging represents the main determinant of AMD, it must be considered a multifaceted disease caused by interactions among environmental risk factors and genetic backgrounds. Mounting evidence and/or arguments document the crucial role of inflammation and immune-mediated processes in the pathogenesis of AMD. Proinflammatory effects secondary to chronic inflammation (e. g., alternative complement activation) and heterogeneous types of oxidative stress (e. g., impaired cholesterol homeostasis) can result in degenerative damages at the level of crucial macular structures, that is photoreceptors, retinal pigment epithelium, and Bruch's membrane. In the most recent years, the association of AMD with genes, directly or indirectly, involved in immunoinflammatory pathways is increasingly becoming an essential core for AMD knowledge. Starting from the key basic-research notions detectable at the root of AMD pathogenesis, the present up-to-date paper reviews the best-known and/or the most attractive genetic findings linked to the mechanisms of inflammation of this complex disease.
C1 [Parmeggiani, Francesco; Sorrentino, Francesco S.; Incorvaia, Carlo; D'Angelo, Sergio; Perri, Paolo; De Nadai, Katia; Sebastiani, Adolfo] Univ Ferrara, Ophthalmol Unit, Dept Biomed & Specialty Surg Sci, I-44121 Ferrara, Italy.
   [Romano, Mario R.] Ist Clin Humanitas, Dept Ophthalmol, Milan, Italy.
   [Romano, Mario R.; Costagliola, Ciro] Univ Molise, Dept Hlth Sci, Campobasso, Italy.
   [Semeraro, Francesco] Univ Brescia, Dept Ophthalmol, Brescia, Italy.
   [De Nadai, Katia] Ctr Retinitis Pigmentosa Veneto Reg, ULSS Alta Padovana 15, Camposampiero, Italy.
   [Roversi, Elia Bonomo; Franceschelli, Paola; Rubini, Michele] Univ Ferrara, Med Genet Unit, Dept Biomed & Specialty Surg Sci, I-44121 Ferrara, Italy.
C3 University of Ferrara; IRCCS Humanitas Research Hospital; University of
   Molise; University of Brescia; University of Ferrara
RP Parmeggiani, F (通讯作者)，Univ Ferrara, Ophthalmol Unit, Dept Biomed & Specialty Surg Sci, Corso Giovecca 203, I-44121 Ferrara, Italy.
EM francesco.parmeggiani@unife.it
RI Rubini, Michele/AFF-8477-2022; Costagliola, Ciro/G-5707-2012; Semeraro,
   Francesco fs/K-8667-2016; Perri, Paolo/L-3047-2015
OI Rubini, Michele/0000-0003-1448-9516; Costagliola,
   Ciro/0000-0001-8477-6188; Semeraro, Francesco fs/0000-0002-2275-4917;
   Perri, Paolo/0000-0003-4652-9842; D'Angelo, Sergio/0000-0003-1118-3845
CR Albert AD, 2005, PROG LIPID RES, V44, P99, DOI 10.1016/j.plipres.2005.02.001
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Atkinson JP, 2006, J CLIN INVEST, V116, P1215, DOI 10.1172/JCI28622
   Ault BH, 2000, PEDIATR NEPHROL, V14, P1045, DOI 10.1007/s004670050069
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bischoff ED, 2010, J LIPID RES, V51, P900, DOI [10.1194/jlr.M900096-JLR200, 10.1194/jlr.M900096]
   Bjorkhem I, 2009, MOL ASPECTS MED, V30, P171, DOI 10.1016/j.mam.2009.02.001
   BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P20727
   Borel P, 2012, MOL NUTR FOOD RES, V56, P228, DOI 10.1002/mnfr.201100322
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   Brown AJ, 2009, MOL ASPECTS MED, V30, P111, DOI 10.1016/j.mam.2009.02.005
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cavelier C, 2006, BBA-MOL CELL BIOL L, V1761, P655, DOI 10.1016/j.bbalip.2006.04.012
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen J, 2013, CELL METAB, V17, P471, DOI 10.1016/j.cmet.2013.03.010
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Claudepierre T, 2010, MOL CELL NEUROSCI, V43, P164, DOI 10.1016/j.mcn.2009.10.007
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cruz-Gonzalez F., 2013, OPHTHALMIC GENETICS
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   de la Llera-Moya M, 2001, J LIPID RES, V42, P1969
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dzeletovic S, 1995, CHEM PHYS LIPIDS, V78, P119, DOI 10.1016/0009-3084(95)02489-6
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054
   Feldmann R, 2013, NUCLEIC ACIDS RES, V41, P3518, DOI 10.1093/nar/gkt034
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   FLIESLER SJ, 1993, FEBS LETT, V335, P234, DOI 10.1016/0014-5793(93)80736-E
   Fliesler SJ, 1997, INT J BIOCHEM CELL B, V29, P877, DOI 10.1016/S1357-2725(97)00018-6
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gallenga C. E., 2013, INFLAMMATION RES
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   GIROTTI AW, 1992, J PHOTOCH PHOTOBIO B, V13, P105, DOI 10.1016/1011-1344(92)85050-5
   Girotti AW, 2000, METHOD ENZYMOL, V319, P85
   Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goldstein JL, 2001, SCIENCE, V292, P1310, DOI 10.1126/science.1061815
   Goodship THJ, 2006, KIDNEY INT, V70, P12, DOI 10.1038/sj.ki.5001612
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakamata H, 1998, J Atheroscler Thromb, V5, P66
   He SK, 2013, MOL VIS, V19, P665
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hughes AE, 2011, MOL VIS, V17, P983
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ioannidis JPA, 2011, JAMA-J AM MED ASSOC, V305, P2200, DOI 10.1001/jama.2011.713
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kajimoto H, 2007, CIRCULATION, V115, P1777, DOI 10.1161/CIRCULATIONAHA.106.649566
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2013, MOL VIS, V19, P822
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   KORYTOWSKI W, 1992, PHOTOCHEM PHOTOBIOL, V56, P1, DOI 10.1111/j.1751-1097.1992.tb09594.x
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Lee J, 2013, EYE, V27, P266, DOI 10.1038/eye.2012.276
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liao WL, 2011, J PROTEOME RES, V10, P241, DOI 10.1021/pr1008898
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lommatzsch A, 2007, GRAEF ARCH CLIN EXP, V245, P1713, DOI 10.1007/s00417-007-0649-7
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lordan S, 2009, J NUTR BIOCHEM, V20, P321, DOI 10.1016/j.jnutbio.2009.01.001
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   McKay GJ, 2013, OPHTHALMOLOGY, V120, P1632, DOI 10.1016/j.ophtha.2013.01.030
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   MOLD C, 1984, J IMMUNOL, V133, P882
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Naik E, 2011, J EXP MED, V208, P417, DOI 10.1084/jem.20110367
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Olkkonen VM, 2009, MOL ASPECTS MED, V30, P123, DOI 10.1016/j.mam.2009.02.004
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Peter I, 2010, AM J OPHTHALMOL, V150, P450, DOI 10.1016/j.ajo.2010.06.012
   Pfrieger FW, 2003, CELL MOL LIFE SCI, V60, P1158, DOI 10.1007/s00018-003-3018-7
   Phillips SE, 2008, J NEUROSCI, V28, P6569, DOI 10.1523/JNEUROSCI.5529-07.2008
   Poli G, 2009, MOL ASPECTS MED, V30, P180, DOI 10.1016/j.mam.2009.02.003
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Ryu E, 2010, MOL VIS, V16, P2811
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sawitzke J, 2011, OPHTHALMOLOGY, V118, P2442, DOI 10.1016/j.ophtha.2011.05.027
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seimon T, 2009, J LIPID RES, V50, pS382, DOI 10.1194/jlr.R800032-JLR200
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Spitzer D, 2007, J IMMUNOL, V179, P2600, DOI 10.4049/jimmunol.179.4.2600
   Stadler N, 2004, ARTERIOSCL THROM VAS, V24, P949, DOI 10.1161/01.ATV.0000124892.90999.cb
   Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890
   Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675
   Tajik P, 2011, HUM GENET, V130, P15, DOI 10.1007/s00439-011-0986-9
   Takabayashi T, 1998, J INFECT DIS, V177, P1622, DOI 10.1086/515316
   Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Torocsik D, 2009, MOL ASPECTS MED, V30, P134, DOI 10.1016/j.mam.2009.02.002
   Tong Y, 2010, MOL VIS, V16, P1958
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Vejux A, 2009, MOL ASPECTS MED, V30, P153, DOI 10.1016/j.mam.2009.02.006
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Williams DL, 1999, CURR OPIN LIPIDOL, V10, P329, DOI 10.1097/00041433-199908000-00007
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang K, 2013, ADV EXP MED BIOL, V735, P301, DOI 10.1007/978-1-4614-4118-2_21
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zeng RP, 2012, OPHTHALMIC GENET, V33, P139, DOI 10.3109/13816810.2011.643440
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 185
TC 47
Z9 50
U1 0
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2013
VL 2013
AR 435607
DI 10.1155/2013/435607
PG 13
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA 265SW
UT WOS:000327973200001
PM 24369445
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Khanani, AM
   Zarbin, MA
   Barakat, MR
   Albini, TA
   Kaiser, PK
   Guruprasad, B
   Agashivala, N
   Yu, JS
   Wykoff, CC
   MacCumber, MW
AF Khanani, Arshad M.
   Zarbin, Marco A.
   Barakat, Mark R.
   Albini, Thomas A.
   Kaiser, Peter K.
   Guruprasad, B.
   Agashivala, Neetu
   Yu, Justin S.
   Wykoff, Charles C.
   MacCumber, Mathew W.
TI Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular
   Degeneration Results From the IRIS Registry and Komodo Healthcare Map
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID REAL-WORLD EFFICACY; RELAPSE
AB IMPORTANCE Limited data exist on the real-world safety outcomes of patients with neovascular age-related macular degeneration treated with brolucizumab (Beovu).
   OBJECTIVE To determine the real-world incidence of intraocular inflammation (IOI), including retinal vasculitis (RV) and/or retinal vascular occlusion (RO), for patients with neovascular age-related macular degeneration who underwent brolucizumab treatment. Additionally, potential risk factors associated with these adverse events were evaluated.
   DESIGN, SETTING, AND PARTICIPANTS This cohort study included patients with neovascular age-related macular degeneration in the Intelligent Research in Sight (IRIS) Registry and Komodo Healthcare Map. Patients initiating and receiving 1 or more brolucizumab injections from October 8, 2019, to June 5, 2020, with up to 6 months of follow-up were included.
   INTERVENTION Brolucizumab injections.
   MAIN OUTCOME AND MEASURES Incidence of IOI(including RV) and/or RO and RV and/or RO and risk stratification for the identified risk factors.
   RESULTS Of 10 654 and 11 161 included eyes (from the IRIS Registry and Komodo Health database, respectively), the median follow-up times were 97 and 95 days. Most eyes switched from another anti-vascular endothelial growth factor agent (9686 of 10 654 [90.9%] and 10 487 of 11 161 [94.0%], respectively), most commonly aflibercept (7160 of 9686 [73.9%] and 7156 of 10 487 [68.2%]), and most were from women (6105 of 10 654 [57.3%] and 6452 of 11 161 [57.8%]). The overall incidence of IOI and/or RO was 2.4%(255 of 10 654 eyes) and 2.4%(268 of 11 161 eyes) for the IRIS and Komodo groups, respectively, and RV and/or RO, 0.6%(59 of 10 654 eyes and 63 of 11 161 eyes), respectively. Patients with a history of IOI and/or RO in the 12 months before brolucizumab initiation had an increased observed risk rate (8.7%[95% CI, 6.0%-11.4%] and 10.6%[95% CI, 7.5%-13.7%]) for an IOI and/or RO event in the 6 months following the first brolucizumab treatment compared with patients without prior IOI and/or RO (2.0% in both data sets). There was an increased estimated incidence rate in women (2.9% [95% CI, 2.5%-3.3%] and 3.0% [95% CI, 2.6%-3.4%]) compared with men (1.3%[95% CI, 1.0%-1.7%] and 1.4%[95% CI, 1.0%-1.7%]), but this risk was not as large as that of a prior IOI and/or RO. Similar findings were observed for patients with RV and/or RO events.
   CONCLUSIONS AND RELEVANCE The incidence rate of IOI and/or RO was approximately 2.4%. Patient eyes with IOI and/or RO in the 12 months prior to first brolucizumab injection had the highest observed risk rate for IOI and/or RO in the early months after the first brolucizumab treatment. However, given study limitations, the identified risk factors cannot be used as predictors of IOI and/or RO events, and causality with brolucizumab cannot be assessed.
C1 [Khanani, Arshad M.] Sierra Eye Associates, 950 Ryland St, Reno, NV 89502 USA.
   [Khanani, Arshad M.] Univ Nevada, Reno Sch Med, Reno, NV 89557 USA.
   [Zarbin, Marco A.] Rutgers State Univ, Rutgers New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ USA.
   [Barakat, Mark R.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Albini, Thomas A.] Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Kaiser, Peter K.] Cleveland Clin, Cleveland, OH USA.
   [Agashivala, Neetu; Yu, Justin S.] Novartis Pharmaceut, E Hanover, NJ USA.
   [Wykoff, Charles C.] Retina Consultants Texas, Houston, TX USA.
   [Wykoff, Charles C.] Houston Methodist Hosp, Blanton Eye Inst, Houston, TX 77030 USA.
   [MacCumber, Mathew W.] Rush Univ, Med Ctr, Dept Ophthalmol, Chicago, IL 60612 USA.
   [MacCumber, Mathew W.] Illinois Retina Associates SC, Chicago, IL USA.
C3 Nevada System of Higher Education (NSHE); University of Nevada Reno;
   Rutgers State University Newark; Rutgers State University New Brunswick;
   Rutgers State University Medical Center; Bascom Palmer Eye Institute;
   Cleveland Clinic Foundation; Novartis; The Methodist Hospital System;
   The Methodist Hospital - Houston; Rush University
RP Khanani, AM (通讯作者)，Sierra Eye Associates, 950 Ryland St, Reno, NV 89502 USA.
EM arshad.khanani@gmail.com
FU Novartis Pharmaceuticals Corporation
FX This study was sponsored by Novartis Pharmaceuticals Corporation.
CR American Academy of Ophthalmology, 2020, IRIS REG
   Aziz AA, 2021, INVEST OPHTH VIS SCI, V62
   Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Braun D, 2021, AM J OPHTHALMOL, V224, P282, DOI 10.1016/j.ajo.2020.12.013
   Centers for Disease Control and Prevention, 2020, COMM EYE DIS
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Enriquez AB, 2021, JAMA OPHTHALMOL, V139, P441, DOI 10.1001/jamaophthalmol.2020.7085
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Grunwald L, 2011, OPHTHALMOLOGY, V118, P1911, DOI 10.1016/j.ophtha.2011.02.044
   Hamou SJ, 2021, INVEST OPHTH VIS SCI, V62
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Holzner, 2020, SUBSPECIALTY NEWS LA
   Izadi R, 2021, PHYS, V6, P1
   Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Natkunarajah M, 2007, BRIT J OPHTHALMOL, V91, P330, DOI 10.1136/bjo.2005.083725
   Novartis Pharmaceuticals Corporation, 2020, BEOV PACK INS
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Parke DW, 2017, OPHTHALMOLOGY, V124, P1572, DOI 10.1016/j.ophtha.2017.08.035
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Sekeroglu MA, 2022, EUR J OPHTHALMOL, V32, P1064, DOI 10.1177/11206721211010613
   Walter SD, 2021, INVEST OPHTH VIS SCI, V62
   Wasser Lauren M, 2020, SN Compr Clin Med, V2, P2546, DOI 10.1007/s42399-020-00614-4
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
NR 26
TC 14
Z9 14
U1 2
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JAN
PY 2022
VL 140
IS 1
BP 20
EP 28
DI 10.1001/jamaophthalmol.2021.4585
EA NOV 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3DG
UT WOS:000722720300004
PM 34817566
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Bailey, JNC
   Pericak-Vance, MA
   Haines, JL
AF Bailey, Jessica N. Cooke
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI Genome-Wide Association Studies: Getting to Pathogenesis, the Role of
   Inflammation/Complement in Age-Related Macular Degeneration
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID COMPLEMENT FACTOR-H; HIGH-RISK; SUSCEPTIBILITY LOCI; Y402H VARIANT;
   GENETIC RISK; FACTOR-B; MACULOPATHY; SCAN; POLYMORPHISM; LOC387715
AB Age-related macular degeneration (AMD) is a chronic, degenerative, and significant cause of visual impairment and blindness in the elderly. Genetic and epidemiological studies have confirmed that AMD has a strong genetic component, which has encouraged the application of increasingly sophisticated genetic techniques to uncover the important underlying genetic variants. Although various genes and pathways have been implicated in the risk for AMD, complement activation has been emphasized repeatedly throughout the literature as having a major role both physiologically and genetically in susceptibility to and pathogenesis of this disease. This article explores the research efforts that brought about the discovery and characterization of the role of inflammatory and immune processes (specifically complement) in AMD. The focus herein is on the genetic evidence for the role of complement in AMD as supported specifically by genome-wide association (GWA) studies, which interrogate hundreds of thousands of variants across the genome in a hypothesis-free approach, and other genetic interrogation methods.
C1 [Bailey, Jessica N. Cooke; Haines, Jonathan L.] Case Western Reserve Univ, Med Ctr, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, Hussman Inst Human Genom, Miami, FL 33136 USA.
C3 Case Western Reserve University; University of Miami
RP Haines, JL (通讯作者)，Case Western Reserve Univ, Med Ctr, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
EM jonathan.haines@case.edu
RI Bailey, Jessica Cooke/Q-5062-2019; Cooke Bailey, Jessica
   Nicole/AFQ-5925-2022; Haines, Jonathan/C-3374-2012; Mitchell,
   Paul/P-1498-2014
OI Bailey, Jessica Cooke/0000-0002-4001-8702; Cooke Bailey, Jessica
   Nicole/0000-0002-4001-8702; Haines, Jonathan/0000-0002-4351-4728; 
FU National Institutes of Health [EY012118, EY023164, T32 EY007157, T32
   EY21453-2]; NATIONAL EYE INSTITUTE [T32EY007157, T32EY021453,
   R01EY023164, U10EY012118, R01EY012118] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health grants
   EY012118 (J.L.H., M.A.P.V.), EY023164 (J.L.H., M.A.P.V.), T32 EY007157
   (J.N.C.B.), and T32 EY21453-2 (J.N.C.B.).
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cipriani V, 2012, IMMUNOBIOLOGY, V217, P158, DOI 10.1016/j.imbio.2011.09.002
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Degn SE, 2011, AM J HUM GENET, V88, P689, DOI 10.1016/j.ajhg.2011.05.011
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2007, AM J OPHTHALMOL, V144, P961, DOI 10.1016/j.ajo.2007.08.016
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee PH, 2012, BIOINFORMATICS, V28, P1797, DOI 10.1093/bioinformatics/bts191
   Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Marchini J, 2010, NAT REV GENET, V11, P499, DOI 10.1038/nrg2796
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MORGAN BP, 1995, CRIT REV CL LAB SCI, V32, P265, DOI 10.3109/10408369509084686
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ryu E, 2010, MOL VIS, V16, P2811
   Sawitzke J, 2011, OPHTHALMOLOGY, V118, P2442, DOI 10.1016/j.ophtha.2011.05.027
   Scheetz TE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058657
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Souied EH, 2005, MOL VIS, V11, P1135
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yaspan BL, 2011, HUM GENET, V129, P563, DOI 10.1007/s00439-011-0956-2
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 89
TC 9
Z9 9
U1 0
U2 14
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD DEC
PY 2014
VL 4
IS 12
AR a017186
DI 10.1101/cshperspect.a017186
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AW8PB
UT WOS:000346523200004
PM 25213188
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Pece, A
   Sannace, C
   Menchini, U
   Virgili, G
   Galli, L
   Isola, V
   Brancato, R
AF Pece, A
   Sannace, C
   Menchini, U
   Virgili, G
   Galli, L
   Isola, V
   Brancato, R
TI Fluorescein angiography and indocyanine green angiography for
   identifying occult choroidal neovascularization in age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; fluorescein angiography; indocyanine
   green angiography; occult CNV
ID VIDEOANGIOGRAPHY
AB PURPOSE. To assess whether fluorescein angiography (FA) alone without indocyanine green angiography (ICGA) can identify and localize occult choroidal neovascularization (CNV) in age-related macular degeneration (ARMD).
   METHODS. Seventy-nine eyes of 77 consecutive patients with occult CNV were evaluated independently by two skilled physicians at first with FA alone and then with FA combined with ICGA by fundus camera.
   RESULTS. The agreement between FA and ICGA was 73% and 68% for the two physicians (K=0.585 and 0.512, respectively). The first operator correctly identified 20/27 as plaque CNV, six had different sizes and locations. The second operator identified 25/30, with one mistaken for size and location. For focal CNV the first operator identified 34/39, and the second one 23/15.
   CONCLUSIONS. Comparing the FA results with ICGA, CNV was correctly identified in about 60% of cases. Therefore, ICGA should be considered an indispensable diagnostic test to identify the presence, the type, and the location of occult CNV (Eur J Ophthalmol 2005; 15: 759-63)
C1 Hosp Melegnano, Dept Ophthalmol, I-20077 Vizzolo Predabissi, MI, Italy.
   Univ Hosp S Raffaele, Dept Ophthalmol & Visual Sci, Milan, Italy.
   Univ Florence, Dept Ophthalmol, Florence, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   University of Florence
RP Pece, A (通讯作者)，Hosp Melegnano, Dept Ophthalmol, Via Pandina 1, I-20077 Vizzolo Predabissi, MI, Italy.
EM pece.retina@mclink.it
RI Galli, Laura/B-1161-2016; Virgili, Gianni/P-6607-2014
OI Virgili, Gianni/0000-0002-9960-2989; Galli, Laura/0000-0001-8046-0290
CR Brancato R, 2000, RETINA-J RET VIT DIS, V20, P134, DOI 10.1097/00006982-200003000-00004
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Kramer M, 2000, AM J OPHTHALMOL, V129, P495, DOI 10.1016/S0002-9394(99)00388-8
   LAMY, 2005, ATLAS ICG ANGIOGRAPH
   Pece A, 1998, OPHTHALMOLOGICA, V212, P295, DOI 10.1159/000027311
NR 6
TC 9
Z9 9
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2005
VL 15
IS 6
BP 759
EP 763
DI 10.1177/112067210501500616
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 990KX
UT WOS:000233742900016
PM 16329062
DA 2022-11-30
ER

PT J
AU Ozawa, Y
AF Ozawa, Yoko
TI Oxidative stress in the light-exposed retina and its implication in
   age-related macular degeneration
SO REDOX BIOLOGY
LA English
DT Review
DE Oxidative stress; Antioxidants; Tissue repair; Inflammation; Age-related
   macular degeneration; Retina
ID PIGMENT EPITHELIUM; VITAMIN-C; LUTEIN; INDUCTION; DAMAGE
AB The retina continuously receives light to enable vision, and the related processes require a marked amount of energy. During active metabolism, reactive oxygen species (ROS) are generated in exchange. Although physiologically generated ROS may be removed by endogenous antioxidant systems, and the effects of oxidative stress may be recovered by repair systems to retain homeostasis and health, when ROS and oxidative stress exceed the capacity of the antioxidant and repair systems, the condition becomes pathological. Multiple mechanisms of oxidative stress and the effects of antioxidant and repair systems in the retina have long been analyzed using light-induced retinal degeneration models. Among the mechanisms, a positive feedback loop of oxidative stress and related inflammation may be involved in the pathogenesis of a blinding aging disease, age-related macular degeneration. Treatments for suppressing ROS and oxidative stress by administrating antioxidant products may support the tissue-protective function of antioxidant systems. Moreover, recent studies have proposed a new concept for maintaining homeostasis by supplying sufficient energy to activate the repair systems. The current review will help elucidate the influence of oxidative stress and guide future analyses to explore new therapeutic approaches for oxidative stress-mediated diseases.
C1 [Ozawa, Yoko] St Lukes Int Univ, Dept Ophthalmol, St Lukes Int Hosp, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.
   [Ozawa, Yoko] Keio Univ, Sch Med, Dept Ophthalmol, Lab Retinal Cell Biol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
C3 St. Luke's International Hospital; Keio University
RP Ozawa, Y (通讯作者)，St Lukes Int Univ, Dept Ophthalmol, St Lukes Int Hosp, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan.
EM ozawa@a5.keio.jp
OI Ozawa, Yoko/0000-0003-4797-5705
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Ban N, 2017, NPJ AGING MECH DIS, V3, DOI 10.1038/s41514-017-0017-8
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Harris JJ, 2012, NEURON, V75, P762, DOI 10.1016/j.neuron.2012.08.019
   Hata M, 2017, SCI REP-UK, V7, DOI 10.1038/srep44873
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawashima H, 2020, FASEB J, V34, P5016, DOI 10.1096/fj.201902387RR
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Miyake S, 2014, BIOCHEM BIOPH RES CO, V446, P535, DOI 10.1016/j.bbrc.2014.02.135
   Muraoka Y, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00624
   Nagai N, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051347
   Nagai N, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040888
   Nakamura M, 2017, BIOL PHARM BULL, V40, P1219, DOI 10.1248/bpb.b16-01008
   Nakazawa M, 2019, J VET MED SCI, V81, P1249, DOI 10.1292/jvms.19-0016
   Narimatsu T, 2015, EXP EYE RES, V132, P48, DOI 10.1016/j.exer.2015.01.003
   Narimatsu T, 2014, FREE RADICAL BIO MED, V71, P176, DOI 10.1016/j.freeradbiomed.2014.03.020
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Osada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178627
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Sasaki M, 2012, J NUTR BIOCHEM, V23, P423, DOI 10.1016/j.jnutbio.2011.01.006
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Young AJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P20, DOI 10.1006/abbi.2000.2149
NR 26
TC 22
Z9 22
U1 2
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD OCT
PY 2020
VL 37
AR 101779
DI 10.1016/j.redox.2020.101779
PG 4
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA PO2BH
UT WOS:000604974200005
PM 33172789
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Levy, O
   Calippe, B
   Lavalette, S
   Hu, SLJ
   Raoul, W
   Dominguez, E
   Housset, M
   Paques, M
   Sahel, JA
   Bemelmans, AP
   Combadiere, C
   Guillonneau, X
   Sennlaub, F
AF Levy, Olivier
   Calippe, Bertrand
   Lavalette, Sophie
   Hu, Shulong J.
   Raoul, William
   Dominguez, Elisa
   Housset, Michael
   Paques, Michel
   Sahel, Jose-Alain
   Bemelmans, Alexis-Pierre
   Combadiere, Christophe
   Guillonneau, Xavier
   Sennlaub, Florian
TI Apolipoprotein E promotes subretinal mononuclear phagocyte survival and
   chronic inflammation in age-related macular degeneration
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; apolipoprotein E; interleukin 6;
   mononuclear phagocyte; neuroinflammation
ID REVERSE CHOLESTEROL TRANSPORT; RETINAL DEGENERATION; HUMAN MONOCYTES;
   APOPROTEIN-E; MACROPHAGES; EXPRESSION; MICROGLIA; APOPTOSIS; APOE;
   ACTIVATION
AB Physiologically, the retinal pigment epithelium (RPE) expresses immunosuppressive signals such as FAS ligand (FASL), which prevents the accumulation of leukocytes in the subretinal space. Age-related macular degeneration (AMD) is associated with a breakdown of the subretinal immunosuppressive environment and chronic accumulation of mononuclear phagocytes (MPs). We show that subretinal MPs in AMD patients accumulate on the RPE and express high levels of APOE. MPs of Cx3cr1(-/-) mice that develop MP accumulation on the RPE, photoreceptor degeneration, and increased choroidal neovascularization similarly express high levels of APOE. ApoE deletion in Cx3cr1(-/-) mice prevents pathogenic age-and stress-induced subretinal MP accumulation. We demonstrate that increased APOE levels induce IL-6 in MPs via the activation of the TLR2-CD14-dependent innate immunity receptor cluster. IL-6 in turn represses RPE FasL expression and prolongs subretinal MP survival. This mechanism may account, in part, for the MP accumulation observed in Cx3cr1(-/-) mice. Our results underline the inflammatory role of APOE in sterile inflammation in the immunosuppressive subretinal space. They provide rationale for the implication of IL-6 in AMD and open avenues toward therapies inhibiting pathogenic chronic inflammation in late AMD.
C1 [Levy, Olivier; Calippe, Bertrand; Lavalette, Sophie; Hu, Shulong J.; Raoul, William; Dominguez, Elisa; Housset, Michael; Paques, Michel; Sahel, Jose-Alain; Bemelmans, Alexis-Pierre; Guillonneau, Xavier; Sennlaub, Florian] INSERM, Paris, France.
   [Levy, Olivier; Calippe, Bertrand; Lavalette, Sophie; Hu, Shulong J.; Raoul, William; Dominguez, Elisa; Housset, Michael; Paques, Michel; Sahel, Jose-Alain; Bemelmans, Alexis-Pierre; Guillonneau, Xavier; Sennlaub, Florian] Univ Paris 06, Inst Vis, UMR S 968, Paris, France.
   [Levy, Olivier; Calippe, Bertrand; Lavalette, Sophie; Hu, Shulong J.; Raoul, William; Dominguez, Elisa; Housset, Michael; Paques, Michel; Sahel, Jose-Alain; Bemelmans, Alexis-Pierre; Guillonneau, Xavier; Sennlaub, Florian] Ctr Hosp Natl Ophtalmol Quinze Vingts, INSERM DHOS CIC 503, Paris, France.
   [Bemelmans, Alexis-Pierre] CEA, DSV, I2BM, Mol Imaging Res Ctr MIRCen, Fontenay Aux Roses, France.
   [Bemelmans, Alexis-Pierre] CNRS, CEA URA 2210, Fontenay Aux Roses, France.
   [Combadiere, Christophe] Univ Paris 06, Univ Sorbonne, CR7, Ctr Immunol & Malad Infect CIMI Paris, Paris, France.
   [Combadiere, Christophe] INSERM, CIMI Paris, U1135, Paris, France.
   [Combadiere, Christophe] CNRS, CIMI Paris, ERL 8255, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; CHNO des
   Quinze-Vingts; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite; CEA;
   UDICE-French Research Universities; Universite Paris Saclay; Centre
   National de la Recherche Scientifique (CNRS); UDICE-French Research
   Universities; Sorbonne Universite; Institut National de la Sante et de
   la Recherche Medicale (Inserm); Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   UDICE-French Research Universities; Universite Paris Cite
RP Sennlaub, F (通讯作者)，INSERM, Paris, France.
EM florian.sennlaub@inserm.fr
RI guillonneau, xavier/AAF-9495-2021; Sahel, Jose-Alain/F-3172-2017;
   Guillonneau, xavier/E-3995-2017; Bemelmans, Alexis-Pierre/H-4476-2019;
   Combadiere, Christophe/I-5639-2013; Sennlaub, Florian/F-2756-2017;
   Raoul, William/H-2118-2018
OI guillonneau, xavier/0000-0001-7379-3935; Sahel,
   Jose-Alain/0000-0002-4831-1153; Guillonneau, xavier/0000-0001-7379-3935;
   Bemelmans, Alexis-Pierre/0000-0001-7605-5225; Combadiere,
   Christophe/0000-0002-1755-4531; Sennlaub, Florian/0000-0003-4412-1341;
   Raoul, William/0000-0002-5040-3372
FU INSERM; ANR Maladies Neurologiques et Psychiatriques [ANR-08-MNPS-003];
   ANR Geno [R09099DS]; Labex Lifesenses; Carnot; ERC [ERC-2007 St.G.
   210345]; HUMANIS
FX The authors wish to thank Christopher Brent Murray for critical review,
   Stephane Fouquet from the Plateforme d'imagerie of the Institut de la
   Vision, and Louise Boyeldieu and Denis Ayache for tonsillectomy surgical
   samples from the Fondation Ophtalmologique Adolphe de Rothschild. This
   work was supported by grants from INSERM, ANR Maladies Neurologiques et
   Psychiatriques (ANR-08-MNPS-003), ANR Geno 2009 (R09099DS), Labex
   Lifesenses, Carnot, and ERC starting Grant (ERC-2007 St.G. 210345) and
   HUMANIS.
CR Ali K, 2005, CIRC RES, V97, P922, DOI 10.1161/01.RES.0000187467.67684.43
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Ayroldi E, 1998, BLOOD, V92, P4212, DOI 10.1182/blood.V92.11.4212.423k42_4212_4219
   Azzam KM, 2012, TRENDS ENDOCRIN MET, V23, P169, DOI 10.1016/j.tem.2012.02.001
   BASU SK, 1982, J BIOL CHEM, V257, P9788
   Berbee JFP, 2005, J ENDOTOXIN RES, V11, P97, DOI 10.1179/096805105X35215
   Camelo S, 2012, ANGIOGENESIS, V15, P609, DOI 10.1007/s10456-012-9290-0
   Chang B, 2013, INVEST OPHTH VIS SCI, V54, P4974, DOI 10.1167/iovs.13-12289
   Chen M, 2013, INVEST OPHTH VIS SCI, V54, P682, DOI 10.1167/iovs.12-10888
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chow A, 2011, NAT REV IMMUNOL, V11, P788, DOI 10.1038/nri3087
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053
   Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004
   Gautier EL, 2013, BLOOD, V122, P2714, DOI 10.1182/blood-2013-01-478206
   Greaney P, 2006, LEUKEMIA RES, V30, P415, DOI 10.1016/j.leukres.2005.08.006
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Guo L, 2004, J MOL NEUROSCI, V23, P205, DOI 10.1385/JMN:23:3:205
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Heeren J, 2004, J BIOL CHEM, V279, P55483, DOI 10.1074/jbc.M409324200
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738
   Kezic JM, 2013, INVEST OPHTH VIS SCI, V54, P854, DOI 10.1167/iovs.12-10876
   Kiener PA, 1997, J EXP MED, V185, P1511, DOI 10.1084/jem.185.8.1511
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Matsuura F, 2006, J CLIN INVEST, V116, P1435, DOI 10.1172/JCI27602
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50
   Mooijaart SP, 2006, PLOS MED, V3, P874, DOI 10.1371/journal.pmed.0030176
   Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Park DR, 2003, J IMMUNOL, V170, P6209, DOI 10.4049/jimmunol.170.12.6209
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Peri F, 2008, CELL, V133, P916, DOI 10.1016/j.cell.2008.04.037
   Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Riddell DR, 2008, J NEUROSCI, V28, P11445, DOI 10.1523/JNEUROSCI.1972-08.2008
   ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sather S, 2007, BLOOD, V109, P1026, DOI 10.1182/blood-2006-05-021634
   Schmitz G, 2002, CURR OPIN LIPIDOL, V13, P513, DOI 10.1097/00041433-200210000-00007
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233
   Smoak KA, 2010, CELL METAB, V11, P493, DOI 10.1016/j.cmet.2010.04.006
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Um HD, 1996, J IMMUNOL, V156, P3469
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Zhao LZ, 2009, J NEUROSCI, V29, P3603, DOI 10.1523/JNEUROSCI.5302-08.2009
   Zieger M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106562
NR 69
TC 81
Z9 84
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD FEB
PY 2015
VL 7
IS 2
BP 211
EP 226
DI 10.15252/emmm.201404524
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CD0MG
UT WOS:000350767300007
PM 25604058
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Brody, BL
   Field, LC
   Roch-Levecq, AC
   Moutier, CY
   Edland, SD
   Brown, SI
AF Brody, Barbara L.
   Field, Linda C.
   Roch-Levecq, Anne-Catherine
   Moutier, Christine Y.
   Edland, Steven D.
   Brown, Stuart I.
TI Treatment of depression associated with age-related macular
   degeneration: A double-blind, randomized, controlled study
SO ANNALS OF CLINICAL PSYCHIATRY
LA English
DT Article
DE age-related macular degeneration; major depression; minor depression;
   escitalopram; crossover trial
ID QUALITY-OF-LIFE; SELF-MANAGEMENT; HEART-FAILURE; VISUAL-ACUITY;
   SYMPTOMS; METAANALYSIS; IMPAIRMENT; DISABILITY; DISORDERS; MORTALITY
AB BACKGROUND: Depression is frequently found in patients with age-related macular degeneration (AMD). The purpose of this study was to assess the effectiveness of escitalopram in treating major and minor depression in AMD patients.
   METHODS: We. conducted a crossover, randomized, double-blind, placebo-controlled, 16-week study comparing escitalopram with placebo. Inclusion criteria included reduced vision from AMD and major or minor depression, with a 17-item Hamilton Rating Scale for Depression (HAMD-17) score of >= 10. Participants were randomly assigned to receive either escitalopram or placebo for 8 weeks and then crossed over to the other treatment. The primary outcome was change on the total HAMD-17 score with escitalopram treatment compared with placebo.
   RESULTS: We enrolled 16 AMD patients (mean age 79.1), 12 with major depression and 4 with minor depression. Mean HAMD-17 score at enrollment was 16.1 +/- 4.2, and mean visual acuity in the better eye was 20/70. During escitalopram treatment, participants showed a significant reduction in HAMD-17 scores compared with placebo treatment (P = .01).
   CONCLUSIONS: These findings suggest escitalopram may be an effective treatment for depressive symptoms associated with major or minor depression in AMD patients with vision loss.
C1 [Moutier, Christine Y.] Univ Calif San Diego, Sch Med, Dept Psychiat, La Jolla, CA 92093 USA.
   [Brody, Barbara L.] Univ Calif San Diego, Dept Ophthalmol, Dept Family & Prevent Med, SDE,Div Biostat, La Jolla, CA 92093 USA.
   [Edland, Steven D.] Univ Calif San Diego, Dept Neurosci, Dept Family & Prevent Med, SDE,Div Biostat, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Moutier, CY (通讯作者)，Univ Calif San Diego, Sch Med, Dept Psychiat, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM cmoutier@ucsd.edu
FU Forest Laboratories, Inc.; Shiley Awards in Health Education; Arts.
   Forest Laboratories
FX The study was funded in part by an investigator-initiated grant from
   Forest Laboratories, Inc., and by Shiley Awards in Health Education and
   the Arts. Forest Laboratories also supplied the escitalopram and
   placebo. The funding sources did not play any part in the study design;
   the collection, analysis, or interpretation of data; or the writing of
   this report.
CR American Psychiatric Association, 2000, HDB PSYCH MEAS
   Ang DC, 2005, J RHEUMATOL, V32, P1013
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Banerjee A, 2008, INDIAN J OPHTHALMOL, V56, P469
   Bekelman DB, 2007, J CARD FAIL, V13, P643, DOI 10.1016/j.cardfail.2007.05.005
   Brody BL, 2006, J AM GERIATR SOC, V54, P1557, DOI 10.1111/j.1532-5415.2006.00881.x
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Cimpean D, 2011, EPIDEMIOL PSYCH SCI, V20, P141, DOI 10.1017/S2045796011000345
   First M, 1997, USERS GUIDE STRUCTUR
   Fleiss JL., 1986, DESIGN ANAL CLIN EXP
   Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x
   Hamilton M., 1960, NEUROL NEUROSURG PSY, V23, P56
   Kanner AM, 2003, EPILEPSY BEHAV, V4, pS3, DOI 10.1016/j.yebeh.2003.08.018
   Katon Wayne J, 2011, Dialogues Clin Neurosci, V13, P7
   KATZMAN R, 1983, AM J PSYCHIAT, V140, P734
   Lebowitz BD, 1997, JAMA-J AM MED ASSOC, V278, P1186, DOI 10.1001/jama.278.14.1186
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   R Development Core Team, R PROJ STAT COMP
   Rapaport MH, 1998, J AFFECT DISORDERS, V48, P227, DOI 10.1016/S0165-0327(97)00196-1
   Rickards H, 2005, J NEUROL NEUROSUR PS, V76, pI48, DOI 10.1136/jnnp.2004.060426
   Rovner BW, 2006, AM J GERIAT PSYCHIAT, V14, P718, DOI 10.1097/01.JGP.0000214494.93087.7c
   Sullivan M, 2004, J CARD FAIL, V10, P390, DOI 10.1016/j.cardfail.2004.01.011
   van Melle JP, 2004, PSYCHOSOM MED, V66, P814, DOI 10.1097/01.psy.0000146294.82810.9c
   Wade A, 2002, INT CLIN PSYCHOPHARM, V17, P95, DOI 10.1097/00004850-200205000-00001
   WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742
NR 30
TC 6
Z9 6
U1 0
U2 9
PU DOWDEN HEALTH MEDIA
PI MONTVALE
PA 110 SUMMIT AVE, MONTVALE, NJ 07645-1712 USA
SN 1040-1237
J9 ANN CLIN PSYCHIATRY
JI Ann. Clin. Psychiatry
PD NOV
PY 2011
VL 23
IS 4
BP 277
EP 284
PG 8
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA 848EY
UT WOS:000297034500007
PM 22073385
DA 2022-11-30
ER

PT J
AU Fulcher, C
   Hazel, CA
   Pacey, I
   Ali, H
   Ghanchi, FD
AF Fulcher, Corinne
   Hazel, Charlotte A.
   Pacey, Ian
   Ali, Hasan
   Ghanchi, Faruque D.
TI Predicting visual outcomes in patients treated with aflibercept for
   neovascular age-related macular degeneration: Data from a real-world
   clinical setting
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; aflibercept; predicting response;
   real-world; neovascular age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL RANIBIZUMAB; SUBGROUP ANALYSIS;
   BEVACIZUMAB; NONRESPONSE; HEMORRHAGE
AB Background/objectives:
   There is a significant variation in the way neovascular age-related macular degeneration patients respond to anti-vascular endothelial growth factor treatment. Both the financial and time cost of treatment are significant. As such, being able to predict patient response to treatment is valuable.
   Subjects/methods:
   72 eyes treated with intravitreal aflibercept were retrospectively included in analysis. For each subject, visual acuity (letters) and central retinal thickness (mu m) at baseline, second, third and fourth visits, as well as 12-month visits, were collated; a plot of visual acuity versus time was generated and a slope of the first three (slope3) and first four (slope4) visits was calculated. Differences in visual acuity at each visit compared to baseline were determined, as well as percentage differences in central retinal thickness at each visit compared to baseline. Lesion sub-type and the presence of fluid and haemorrhage were also recorded.
   Results:
   The average change in visual acuity over 12 months was +3.2 +/- 13.4 letters with 91.2% of patients losing <15 letters. Slope4 was the only significant predictive factor for 'visual acuity change over 12 months' (p < 0.001). Change in central retinal thickness, lesion sub-type, haemorrhage at baseline and the location of fluid at baseline were not useful predictive factors in long-term outcome.
   Conclusion:
   Aflibercept is an effective treatment option for neovascular age-related macular degeneration; however, the long-term response should not be predicted until at least three loading dose injections have been given. Visual acuity measures at each visit should be examined, as it is the trend in visual acuity across the first four visits (slope4) rather than the difference in visual acuity between two visits that is the predictive factor.
C1 [Fulcher, Corinne; Hazel, Charlotte A.; Ghanchi, Faruque D.] Bradford Teaching Hosp NHS Fdn Trust, Bradford Ophthalmol Res Network, Bradford, W Yorkshire, England.
   [Pacey, Ian; Ali, Hasan] Univ Bradford, Sch Optometry & Vis Sci, Bradford, W Yorkshire, England.
C3 University of Bradford
RP Fulcher, C (通讯作者)，Bradford Royal Infirm, Dept Ophthalmol, Duckworth Lane, Bradford BD9 6RJ, W Yorkshire, England.
EM corinne.fulcher@bthft.nhs.uk
RI Ali, Md Hasan/GZH-1120-2022
OI Fulcher, Corinne/0000-0002-6668-2396
CR Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HOCKING RR, 1976, BIOMETRICS, V32, P1, DOI 10.2307/2529336
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Karagiannis D, 2017, CLIN INTERV AGING, V12, P1829, DOI 10.2147/CIA.S145893
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Kherani S, 2018, AM J OPHTHALMOL, V189, P86, DOI 10.1016/j.ajo.2018.02.015
   Kim HS, 2015, EYE, V29, P1142, DOI 10.1038/eye.2015.131
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Pedhazur EJ., 1997, MULTIPLE REGRESSION
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 29
TC 6
Z9 6
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2020
VL 30
IS 3
BP 543
EP 549
DI 10.1177/1120672119839299
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LM6YG
UT WOS:000532395300025
PM 30935224
DA 2022-11-30
ER

PT J
AU Doyle, SL
   Ozaki, E
   Brennan, K
   Humphries, MM
   Mulfaul, K
   Keaney, J
   Kenna, PF
   Maminishkis, A
   Kiang, AS
   Saunders, SP
   Hams, E
   Lavelle, EC
   Gardiner, C
   Fallon, PG
   Adamson, P
   Humphries, P
   Campbell, M
AF Doyle, Sarah L.
   Ozaki, Ema
   Brennan, Kiva
   Humphries, Marian M.
   Mulfaul, Kelly
   Keaney, James
   Kenna, Paul F.
   Maminishkis, Arvydas
   Kiang, Anna-Sophia
   Saunders, Sean P.
   Hams, Emily
   Lavelle, Ed C.
   Gardiner, Clair
   Fallon, Padraic G.
   Adamson, Peter
   Humphries, Peter
   Campbell, Matthew
TI IL-18 Attenuates Experimental Choroidal Neovascularization as a
   Potential Therapy for Wet Age-Related Macular Degeneration
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID NLRP3 INFLAMMASOME ACTIVATION; AUTOPHAGY; BEVACIZUMAB; SB-485232; CELLS
AB Age-related macular degeneration (AMD) is the most common form of central retinal blindness globally. Distinct processes of the innate immune system, specifically activation of the NLRP3 inflammasome, have been shown to play a central role in the development of both "dry" and neovascular ("wet") forms of the disease. We show that the inflammatory cytokine interleukin-18 (IL-18) can regulate choroidal neovascularization formation in mice. We observed that exogenous administration of mature recombinant IL-18 has no effect on retinal pigment epithelial (RPE) cell viability, but that overexpression of pro-IL-18 or pro-IL-1 beta alone can cause RPE cell swelling and subsequent atrophy, a process that can be inhibited by the promotion of autophagy. A direct comparison of local and systemic administration of mature recombinant IL-18 with current anti-VEGF (vascular endothelial growth factor)-based therapeutic strategies shows that IL-18 treatment works effectively alone and more effectively in combination with anti-VEGF therapy and represents a novel therapeutic strategy for the treatment of wet AMD.
C1 [Doyle, Sarah L.; Mulfaul, Kelly] Univ Dublin Trinity Coll, Sch Med, Dept Clin Med, Dublin 2, Ireland.
   [Doyle, Sarah L.; Mulfaul, Kelly] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin 12, Ireland.
   [Ozaki, Ema; Humphries, Marian M.; Keaney, James; Kenna, Paul F.; Kiang, Anna-Sophia; Humphries, Peter; Campbell, Matthew] Univ Dublin Trinity Coll, Smurfit Inst Genet, Ocular Genet Unit, Dublin 2, Ireland.
   [Brennan, Kiva; Lavelle, Ed C.; Gardiner, Clair] Univ Dublin Trinity Coll, Sch Biochem & Immunol, Immunol Res Ctr, Trinity Biomed Sci Inst, Dublin 2, Ireland.
   [Kenna, Paul F.] Royal Victorian Eye & Ear Hosp, Res Fdn, Dublin 2, Ireland.
   [Maminishkis, Arvydas] NEI, NIH, Bethesda, MD 20892 USA.
   [Saunders, Sean P.; Hams, Emily; Fallon, Padraic G.] Univ Dublin Trinity Coll, Sch Med, Trinity Biomed Sci Inst, Dublin 2, Ireland.
   [Adamson, Peter] GlaxoSmithKline, Ophthiris Discovery Performance Unit, Stevenage SG1 2NY, Herts, England.
C3 Trinity College Dublin; National Children's Research Centre (NCRC); Our
   Ladys Children Hospital Crumlin; Trinity College Dublin; Trinity College
   Dublin; Trinity College Dublin; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); Trinity College Dublin;
   GlaxoSmithKline
RP Doyle, SL (通讯作者)，Univ Dublin Trinity Coll, Sch Med, Dept Clin Med, Dublin 2, Ireland.
EM sarah.doyle@tcd.ie; matthew.campbell@tcd.ie
RI Fallon, Padraic/Y-2711-2019; Doyle, Sarah/C-1453-2014; Lavelle,
   Ed/A-1716-2008
OI Fallon, Padraic/0000-0002-8401-7293; Lavelle, Ed/0000-0002-3167-1080;
   Brennan, Kiva/0000-0003-4960-7076; Saunders, Sean/0000-0003-1689-3598;
   Hams, Emily/0000-0002-9745-3246; Maminishkis,
   Arvydas/0000-0003-3345-3375; Gardiner, Clair/0000-0001-5643-9432; Doyle,
   Sarah/0000-0002-6294-9380; Mulfaul, Kelly/0000-0003-4441-4806
FU Enterprise Ireland; GSK; Science Foundation Ireland (SFI) [12/YI/B2614];
   BrightFocus Foundation; SFI; Health Research Board of Ireland; Irish
   Research Council for Science Engineering and Technology; United States
   Department of Defense (Telemedicine and Advanced Technology Research
   Center); European Research Council; NATIONAL EYE INSTITUTE [ZIAEY000419,
   ZIAEY000481] Funding Source: NIH RePORTER
FX Funding: Enterprise Ireland, GSK, Science Foundation Ireland (SFI)
   (12/YI/B2614), and BrightFocus Foundation. The Ocular Genetics Unit at
   TCD is supported by SFI, the Health Research Board of Ireland, Irish
   Research Council for Science Engineering and Technology, the United
   States Department of Defense (Telemedicine and Advanced Technology
   Research Center), and the European Research Council.
CR Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Compan V, 2012, IMMUNITY, V37, P487, DOI 10.1016/j.immuni.2012.06.013
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Golab J, 2005, CURR OPIN MOL THER, V7, P85
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Robbie SJ, 2013, INVEST OPHTH VIS SCI, V54, P1490, DOI 10.1167/iovs.12-10169
   Robertson MJ, 2008, CLIN CANCER RES, V14, P3462, DOI 10.1158/1078-0432.CCR-07-4740
   Robertson MJ, 2006, CLIN CANCER RES, V12, P4265, DOI 10.1158/1078-0432.CCR-06-0121
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tarhini AA, 2009, CANCER-AM CANCER SOC, V115, P859, DOI 10.1002/cncr.24100
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
NR 28
TC 75
Z9 80
U1 2
U2 19
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD APR 2
PY 2014
VL 6
IS 230
AR 230ra44
DI 10.1126/scitranslmed.3007616
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA AE3UX
UT WOS:000333905000002
PM 24695684
OA Green Published
DA 2022-11-30
ER

PT J
AU Li, SS
   Hu, ADN
   Wang, W
   Ding, XY
   Lu, L
AF Li, Songshan
   Hu, Andina
   Wang, Wei
   Ding, Xiaoyan
   Lu, Lin
TI Combinatorial treatment with topical NSAIDs and anti-VEGF for
   age-related macular degeneration, a meta-analysis
SO PLOS ONE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; KETOROLAC EYEDROPS; BROMFENAC; RANIBIZUMAB;
   THERAPY
AB Inflammation is a key pathogenic factor in age-related macular degeneration (AMD). However, the clinical importance of combining anti-VEGF agents and topical NSAIDs to reduce inflammation remains unclear. In this study, we systematically reviewed clinical trials comparing combined treatment versus anti-VEGF alone in AMD patients. We quantified treatment effects via meta-analysis. The pooled weighted mean difference (WMD, -0.91, 95% CI: -1.39 to -0.42, P = 0.0003) demonstrates that combined treatment may reduce required anti-VEGF injection number, probably by means of decreasing central retina thickness (CRT) (WMD = -22.9, 95% CI: -41.20 to -4.59, P = 0.01). The best corrected visual acuity (BCVA) did not change significantly between these two groups (WMD = -0.01, 95% CI: -0.23 to 0.20, P = 0.90). Topical NSAIDs slightly increased the incidence of foreign body sensation (Odds Ratio [OR] = 2.63, 95% Cl: 1.06 to 6.52, P = 0.76). Combining topical NSAIDs and anti-VEGF agents may provide a new strategy for AMD treatment.
C1 [Li, Songshan; Hu, Andina; Wang, Wei; Ding, Xiaoyan; Lu, Lin] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Retina Div, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Ding, XY; Lu, L (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Retina Div, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
EM dingxy75@gmail.com; lulin888@126.com
CR Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Baklayan GA, 2008, J OCUL PHARMACOL TH, V24, P392, DOI 10.1089/jop.2007.0082
   Chen E, 2010, CLIN OPHTHALMOL, V4, P1249, DOI 10.2147/OPTH.S14092
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   Russo A, 2013, BRIT J OPHTHALMOL, V97, P1273, DOI 10.1136/bjophthalmol-2013-303417
   Semeraro F, 2015, RETINA-J RET VIT DIS, V35, P1547, DOI 10.1097/IAE.0000000000000525
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Warren KA, 2010, RETINA-J RET VIT DIS, V30, P260, DOI 10.1097/IAE.0b013e3181b8628e
   Waterbury LD, 2006, CURR MED RES OPIN, V22, P1133, DOI 10.1185/030079906X112471
   Wygledowska-Promienska D, 2015, MED SCI MONITOR, V21, P3906, DOI 10.12659/MSM.895977
   Wygledowska-Promienska D, 2014, MED SCI MONITOR, V20, P1168, DOI 10.12659/MSM.890671
   Yoshinaga N, 2011, LAB INVEST, V91, P1277, DOI 10.1038/labinvest.2011.101
   Zweifel SA, 2009, RETINA-J RET VIT DIS, V29, P1527, DOI 10.1097/IAE.0b013e3181b32f4c
NR 16
TC 10
Z9 10
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 6
PY 2017
VL 12
IS 10
AR e0184998
DI 10.1371/journal.pone.0184998
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FJ1QR
UT WOS:000412493000003
PM 28985220
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Caputo, V
   Strafella, C
   Termine, A
   Fabrizio, C
   Ruffo, P
   Cusumano, A
   Giardina, E
   Ricci, F
   Cascella, R
AF Caputo, Valerio
   Strafella, Claudia
   Termine, Andrea
   Fabrizio, Carlo
   Ruffo, Paola
   Cusumano, Andrea
   Giardina, Emiliano
   Ricci, Federico
   Cascella, Raffaella
TI Epigenomic signatures in age-related macular degeneration: Focus on
   their role as disease modifiers and therapeutic targets
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; (epi)genomics; miRNAs; DNA
   methylation; histone modification; chromatin conformation; epimutation;
   biomarkers; precision medicine
ID LONG NONCODING RNAS; GENE-EXPRESSION; IL17RC PROMOTER; DNA METHYLATION;
   POLYMORPHISMS; RETINA; PHARMACOEPIGENETICS; NEOVASCULARIZATION;
   HYPOMETHYLATION; EPIGENETICS
AB Epigenetics is characterized by molecular modifications able to shape gene expression profiles in response to inner and external stimuli. Therefore, epigenetic elements are able to provide intriguing and useful information for the comprehension and management of different human conditions, including aging process, and diseases. On this subject, Age-related Macular Degeneration (AMD) represents one of the most frequent age-related disorders, dramatically affecting the quality of life of older adults worldwide. The etiopathogenesis is characterized by an interplay among multiple genetic and non-genetic factors, which have been extensively studied. Nevertheless, a deeper dissection of molecular machinery associated with risk, onset, progression and effectiveness of therapies is still missing. In this regard, epigenetic signals may be further explored to disentangle disease etiopathogenesis, the possible therapeutic avenues and the differential response to AMD treatment. This review will discuss the epigenomic signatures mostly investigated in AMD, which could be applied to improve the knowledge of disease mechanisms and to set-up novel or modified treatment options.
C1 [Caputo, Valerio; Strafella, Claudia; Termine, Andrea; Fabrizio, Carlo; Ruffo, Paola; Giardina, Emiliano] IRCCS Santa Lucia Fdn, Genom Med Lab UILDM, Rome, Italy.
   [Caputo, Valerio; Strafella, Claudia; Cascella, Raffaella] Tor Vergata Univ, Dept Biomed & Prevent, Med Genet Lab, Rome, Italy.
   [Cusumano, Andrea] UOSD Ophthalmol PTV Fdn Policlin Tor Vergata, Rome, Italy.
   [Giardina, Emiliano] Tor Vergata Univ, UILDM Lazio ONLUS Fdn, Dept Biomed & Prevent, Rome, Italy.
   [Ricci, Federico] UNIT Retinal Dis PTV Fdn Policlin Tor Vergata, Viale Oxford 81, I-00133 Rome, Lazio, Italy.
   [Cascella, Raffaella] Catholic Univ Our Lady Good Counsel, Dept Biomed Sci, Tirana, Albania.
C3 IRCCS Santa Lucia; University of Rome Tor Vergata; University of Rome
   Tor Vergata
RP Ricci, F (通讯作者)，UNIT Retinal Dis PTV Fdn Policlin Tor Vergata, Viale Oxford 81, I-00133 Rome, Lazio, Italy.
EM rccfrc00@gmail.com
RI Fabrizio, Carlo/GYA-1274-2022; Fabrizio, Carlo/ABF-3261-2021; Caputo,
   Valerio/AAB-6481-2019; Ruffo, Paola/ABB-6376-2021; Giardina,
   Emiliano/J-1965-2012; Termine, Andrea/AAC-2253-2022
OI Fabrizio, Carlo/0000-0002-7824-8423; Fabrizio,
   Carlo/0000-0002-7824-8423; Caputo, Valerio/0000-0002-3503-3318; Ruffo,
   Paola/0000-0001-6246-5901; Termine, Andrea/0000-0003-4374-7430; ricci,
   federico/0000-0002-4224-9280
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Ajana S, 2021, OPHTHALMOLOGY, V128, P587, DOI 10.1016/j.ophtha.2020.08.031
   Anderson KW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126592
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Cascella R, 2015, PHARMACOGENOMICS, V16, P1039, DOI [10.2217/PGS.15.59, 10.2217/pgs.15.59]
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chen ACH, 2020, WORLD J STEM CELLS, V12, P761, DOI 10.4252/wjsc.v12.i8.761
   Chen X, 2020, MOL THER-NUCL ACIDS, V19, P1015, DOI 10.1016/j.omtn.2019.12.040
   Ciuculete DM, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00884-8
   Corso-Diaz X, 2018, PROG RETIN EYE RES, V65, P1, DOI 10.1016/j.preteyeres.2018.03.002
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   Diakatou M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102542
   Ertekin S, 2014, MOL VIS, V20, P1057
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Furrow RE, 2011, GENETICS, V189, P1377, DOI 10.1534/genetics.111.131912
   Gemenetzi M, 2020, CELL MOL LIFE SCI, V77, P807, DOI 10.1007/s00018-019-03421-w
   Gemenetzi M, 2014, EYE, V28, P1407, DOI 10.1038/eye.2014.225
   Ghanbari M, 2017, HUM MUTAT, V38, P827, DOI 10.1002/humu.23226
   Gil-Martinez M, 2020, CURR MED CHEM, V27, P583, DOI 10.2174/0929867326666190726121711
   Glossop JR, 2017, EPIGENOMICS-UK, V9, P419, DOI [10.2217/epi-2016-0042, 10.2217/epi-2016-0144]
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gorenjak V, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00874-w
   Goyal D, 2019, J ENDOCRINOL, V242, pT105, DOI 10.1530/JOE-19-0009
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Guilloteau P, 2009, J PHYSIOL PHARMACOL, V60, P17
   Guo DG, 2021, RHEUMATOLOGY, V60, P1512, DOI 10.1093/rheumatology/keaa369
   Gupta R, 2016, J INVEST DERMATOL, V136, P603, DOI 10.1016/j.jid.2015.12.009
   Harding P, 2019, J DEV BIOL, V7, DOI 10.3390/jdb7030016
   Horsthemke B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05445-5
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Kim J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau6732
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lazzeri S, 2016, PHARMACOGENOMICS, V17, P27, DOI 10.2217/pgs.15.153
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lecamwasam A, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090341
   Lepre T, 2011, AM J OPHTHALMOL, V152, P325, DOI 10.1016/j.ajo.2011.04.021
   Li XH, 2020, AGING DIS, V11, P1219, DOI 10.14336/AD.2019.1126
   Ligthart S, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1119-5
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Lopomo A, 2018, EXPERT REV GASTROENT, V12, P49, DOI 10.1080/17474124.2017.1374853
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Luu J, 2020, HUM MOL GENET, V29, P2611, DOI 10.1093/hmg/ddaa158
   Maloney SC, 2013, RETINA-J RET VIT DIS, V33, P862, DOI 10.1097/IAE.0b013e31826af556
   Martinelli S, 2013, EPIGENETICS-US, V8, P720, DOI 10.4161/epi.24947
   Matuskova V, 2018, OPHTHALMIC GENET, V39, P4, DOI 10.1080/13816810.2017.1326508
   Meigs JB, 2000, DIABETES, V49, P2201, DOI 10.2337/diabetes.49.12.2201
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Furtado CLM, 2019, EPIGENETICS-US, V14, P1164, DOI 10.1080/15592294.2019.1640546
   Norrie JL, 2019, NEURON, V104, P512, DOI 10.1016/j.neuron.2019.08.002
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Onwuka JU, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07194-5
   Parmeggiani F, 2015, INT J MOL SCI, V16, P19796, DOI 10.3390/ijms160819796
   Peng CH, 2010, SENSORS-BASEL, V10, P6172, DOI 10.3390/s100606172
   Pennington KL, 2015, J EXP NEUROSCI, V9, P51, DOI 10.4137/JEN.S25513
   Pool FM, 2020, NPJ AGING MECH DIS, V6, DOI 10.1038/s41514-019-0039-5
   Popp NA, 2016, ENVIRON MOL MUTAGEN, V57, P58, DOI 10.1002/em.21982
   Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2
   Reich S, 2003, MOL VIS, V9, P210
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   SanGiovanni JP, 2017, CLIN CHEM LAB MED, V55, P763, DOI 10.1515/cclm-2016-0898
   Sato K, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01134
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Strafella C, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.626066
   Strafella C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071578
   Strunz T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58510-9
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Tan LZ, 2019, NAT STRUCT MOL BIOL, V26, P297, DOI 10.1038/s41594-019-0205-2
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   Umlauf D, 2019, SEMIN CELL DEV BIOL, V90, P128, DOI 10.1016/j.semcdb.2018.07.002
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   You QS, 2018, RETINA-J RET VIT DIS, V38, P1156, DOI 10.1097/IAE.0000000000001726
   Yu AM, 2016, DRUG METAB DISPOS, V44, P308, DOI 10.1124/dmd.115.067470
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zentner GE, 2013, NAT STRUCT MOL BIOL, V20, P259, DOI 10.1038/nsmb.2470
   Zerti D, 2020, CURR EYE RES, V45, P385, DOI 10.1080/02713683.2019.1697453
   Zhang JY, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/2714746
   Zhang LW, 2020, INT J MED SCI, V17, P292, DOI 10.7150/ijms.37804
   Zhang PF, 2020, CURR EYE RES, V45, P1403, DOI 10.1080/02713683.2020.1748659
   Zoghbi HY, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019497
NR 86
TC 4
Z9 4
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2021
VL 31
IS 6
BP 2856
EP 2867
DI 10.1177/11206721211028054
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XA5GJ
UT WOS:000720674800029
PM 34798695
DA 2022-11-30
ER

PT J
AU Mulyukov, Z
   Weber, S
   Pigeolet, E
   Clemens, A
   Lehr, T
   Racine, A
AF Mulyukov, Zufar
   Weber, Sebastian
   Pigeolet, Etienne
   Clemens, Andreas
   Lehr, Thorsten
   Racine, Amy
TI Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of
   Natural Disease Progression and Ranibizumab Treatment Effect
SO CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
LA English
DT Article
ID TREATMENT REGIMEN; EXTEND; EFFICACY; MECHANISMS; OUTCOMES; SAFETY; TRIAL
AB Intravitreal ranibizumab is a first-line therapy for neovascular age-related macular degeneration (nAMD), but there is a need to optimize patient outcomes while minimizing treatment burden. Here, we developed an indirect response, nonlinear, mixed effects model of disease progression and drug effect in anti-vascular endothelial growth factor (VEGF) treatment-naive patients. A total of 1,524 treatment-naive patients and 29,754 visual acuity observations from the ANCHOR, MARINA, PIER, and EXCITE clinical trials informed the model. The model accurately described natural nAMD disease progression and predicted mean visual acuity gains in the HARBOR study, notably with a 2.0mg ranibizumab dose not used for model development. Furthermore, individualized treatment regimens were shown by simulation to be a viable alternative to the commonly used pro re nata or fixed monthly dosing regimen approaches. Therefore, this model could be a useful tool to predict the outcomes of different, more patient-tailored treatment regimens in nAMD.
C1 [Mulyukov, Zufar; Weber, Sebastian; Pigeolet, Etienne; Clemens, Andreas; Racine, Amy] Novartis Pharma AG, Basel, Switzerland.
   [Clemens, Andreas] Freiburg Univ, Fac Med Cardiol & Angiol 1, Ctr Heart, Freiburg, Germany.
   [Lehr, Thorsten] Saarland Univ, Clin Pharm, Saarbrucken, Germany.
C3 Novartis; University of Freiburg; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; Saarland University
RP Mulyukov, Z (通讯作者)，Novartis Pharma AG, Basel, Switzerland.
EM zufar.mulyukov@novartis.com
OI Lehr, Thorsten/0000-0002-8372-1465
FU Novartis Pharma AG
FX Zufar Mulyukov, Sebastian Weber, Etienne Pigeolet, Andreas Clemens, and
   Amy Racine are employed by Novartis Pharma AG. Writing support was
   funded by the study Novartis Pharma AG.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Dansirikul C, 2008, J PHARMACOKINET PHAR, V35, P269, DOI 10.1007/s10928-008-9088-2
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Mager DE, 2003, DRUG METAB DISPOS, V31, P510, DOI 10.1124/dmd.31.5.510
   Murphy W, 2016, HDB BIOMATERIAL PROP
   Raftery A., 1995, SOCIOL METHODOL, P1
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
NR 32
TC 7
Z9 7
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2163-8306
J9 CPT-PHARMACOMET SYST
JI CPT-PHARMACOMET. SYST. PHARMACOL.
PD OCT
PY 2018
VL 7
IS 10
BP 660
EP 669
DI 10.1002/psp4.12322
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GY7KE
UT WOS:000448788100006
PM 30043524
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Camacho, P
   Dutra-Medeiros, M
   Paris, L
AF Camacho, Pedro
   Dutra-Medeiros, Marco
   Paris, Liliana
TI Ganglion Cell Complex in Early and Intermediate Age-Related Macular
   Degeneration: Evidence by SD-OCT Manual Segmentation
SO OPHTHALMOLOGICA
LA English
DT Article
DE Ganglion cell layer; Ganglion cell complex; Age-related macular
   degeneration; Spectral-domain optical coherence tomography
ID RETINAL NERVE-FIBER; CHOROIDAL THICKNESS; LAYER THICKNESSES;
   REPRODUCIBILITY; REPEATABILITY; DRUSEN; MACULOPATHY; EYES
AB Purpose: To evaluate ganglion cell layer (GCL) and ganglion cell complex (GCC) thickness manually by spectral-domain optical coherence tomography in subjects with early and intermediate age-related macular degeneration (AMD) in 12 locations on the horizontal meridian. Methods: A total of 450 eyes (specifically, 246 eyes classified as having early/intermediate AMD plus 204 control eyes) were studied. Mann-Whitney U and Kruskal-Wallis tests were used to compare values between the healthy controls and the AMD group and also between the subgroups under study. Diagnostic performance was also compared calculating the areas under the receiver operating characteristic curve. Results: The manual layer segmentation showed clear boundaries between the GCL and the GCC. It was in the temporal GCC that more changes were found. Conclusions: The GCC, especially in the temporal region, allowed the discrimination of differences between various subgroups that have faint variations as well as between early AMD and the first signs of aging. (C) 2017 S. Karger AG, Basel
C1 [Camacho, Pedro; Paris, Liliana] Univ Nova Lisboa, Ophtalmol Inst Dr Gama Pinto, Lisbon, Portugal.
   [Dutra-Medeiros, Marco] Univ Nova Lisboa, Cent Lisbon Hosp Ctr, Lisbon, Portugal.
   [Camacho, Pedro; Dutra-Medeiros, Marco] Univ Nova Lisboa, Retina Inst Lisbon, Lisbon, Portugal.
   [Dutra-Medeiros, Marco] Univ Nova Lisboa, NOVA Med Sch, Lisbon, Portugal.
   [Camacho, Pedro] Lisbon Sch Hlth Technol, Lisbon, Portugal.
C3 Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade
   Nova de Lisboa; Universidade Nova de Lisboa
RP Camacho, P (通讯作者)，Ophthalmol Inst Dr Gama Pinto, Travessa Larga 2, PT-1169019 Lisbon, Portugal.
EM pedro.camacho@estesl.ipl.pt
RI Camacho, Pedro/AAD-1757-2020; Camacho, Pedro/K-8682-2019
OI Camacho, Pedro/0000-0002-2986-5652; Paris, Liliana/0000-0002-9312-9924;
   Dutra Medeiros, Marco/0000-0003-0421-1211
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   American Academy of Ophthalmology, 2015, PREF PRACT PATT GUID
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   Camacho P, 2016, COMMUNICATION
   Carneiro A, 2010, AMD AGE RELATED MACU, P33
   Ctori I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129005
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Delcourt C., 2010, AMD AGE RELATED MACU, P13
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57
   Ehnes A, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.1.1
   Eriksson U, 2012, ACTA OPHTHALMOL, V90, P620, DOI 10.1111/j.1755-3768.2011.02112.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Garcia-Martin E, 2011, ACTA OPHTHALMOL, V89, pE23, DOI 10.1111/j.1755-3768.2010.02045.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hanumunthadu D, 2016, AM J OPHTHALMOL, V166, P154, DOI 10.1016/j.ajo.2016.03.052
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Krebs I, 2010, OPHTHALMOLOGY, V117, P1577, DOI 10.1016/j.ophtha.2010.04.032
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Leung CKS, 2007, OPHTHALMOLOGY, V114, P263, DOI 10.1016/j.ophtha.2006.06.059
   Liu XT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087996
   Loduca AL, 2010, AM J OPHTHALMOL, V150, P849, DOI 10.1016/j.ajo.2010.06.034
   Lutty G, 1999, MOL VIS, V5
   Mansouri K, 2014, AM J OPHTHALMOL, V157, P1022, DOI 10.1016/j.ajo.2014.02.008
   Oberwahrenbrock T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137316
   Ooto S, 2011, INVEST OPHTH VIS SCI, V52, P8769, DOI 10.1167/iovs.11-8388
   Parravano M, 2010, INVEST OPHTH VIS SCI, V51, P4788, DOI 10.1167/iovs.09-4976
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Rebolleda G, 2015, SAUDI J OPHTHALMOL, V29, P9, DOI 10.1016/j.sjopt.2014.09.016
   Rufino S, 2010, AMD AGE RELATED MACU, P129
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yamashita T, 2012, INVEST OPHTH VIS SCI, V53, P1102, DOI 10.1167/iovs.11-8836
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
NR 44
TC 10
Z9 11
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 238
IS 1-2
BP 31
EP 43
DI 10.1159/000468965
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FC1MB
UT WOS:000406600200005
PM 28505617
DA 2022-11-30
ER

PT J
AU Curcio, CA
   Johnson, M
   Huang, JD
   Rudolf, M
AF Curcio, Christine A.
   Johnson, Mark
   Huang, Jiahn-Dar
   Rudolf, Martin
TI Aging, age-related macular degeneration, and the response-to-retention
   of apolipoprotein B-containing lipoproteins
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Retinal pigment epithelium; Bruch's
   membrane; Drusen; Basal deposits; Lipoproteins; Cholesterol; Retinyl
   ester; Apolipoprotein B
ID RETINAL-PIGMENT EPITHELIUM; TRIGLYCERIDE TRANSFER PROTEIN;
   LOW-DENSITY-LIPOPROTEIN; ENDOTHELIAL GROWTH-FACTOR; BASAL LAMINAR
   DEPOSIT; HUMAN ATHEROSCLEROTIC LESIONS; CHOLESTEROL-FED RABBITS; ROD
   OUTER SEGMENTS; C-REACTIVE PROTEIN; LIPID-RICH CORE
AB The largest risk factor for age-related macular degeneration (ARMD) is advanced age. A prominent age-related change in the human retina is the accumulation of histochemically detectable neutral lipid in normal Bruch's membrane (BrM) throughout adulthood. This change has the potential to have a major impact on physiology of the retinal pigment epithelium (RPE). It occurs in the same compartment as drusen and basal linear deposit, the pathognomonic extracellular, lipid-containing lesions of ARMD. Here we present evidence from light microscopic histochemistry, ultrastructure, lipid profiling of tissues and isolated lipoproteins, and gene expression analysis that this deposition can be accounted for by esterified cholesterol-rich, apolipoprotein B-containing lipoprotein particles constitutively produced by the RPE. This work collectively allows ARMD lesion formation and its aftermath to be conceptualized as a response to the retention of a sub-endothelial apolipoprotein B lipoprotein, similar to a widely-accepted model of atherosclerotic coronary artery disease (CAD) (Tabas et al., 2007). This approach provides a wide knowledge base and sophisticated clinical armamentarium that can be readily exploited for the development of new model systems and the future benefit of ARMD patients. (C) 2009 Published by Elsevier Ltd.
C1 [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35294 USA.
   [Johnson, Mark] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
   [Huang, Jiahn-Dar] NEI, NIH, Bethesda, MD 20892 USA.
   [Rudolf, Martin] Univ Klinikum Schleswig Holstein, Univ Eye Hosp Lubeck, D-23538 Lubeck, Germany.
C3 University of Alabama System; University of Alabama Birmingham;
   Northwestern University; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); University of Kiel; Schleswig Holstein
   University Hospital
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, Callahan Eye Fdn Hosp, Sch Med, 700 S 18th St,Room H020, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Mitchell, Paul/P-1498-2014; Johnson, Mark/B-6921-2009
FU NIH [EY06109, EY014662]; International Retinal Research Foundation;
   American Health Assistance Foundation; EyeSight Foundation of Alabama;
   Research to Prevent Blindness, Inc.; Macula Vision Research Foundation;
   Roger Johnson Prize in Macular Degeneration Research; Deutsche
   Forschungsgemeinschaft; NATIONAL EYE INSTITUTE [R01EY014662,
   R01EY006109] Funding Source: NIH RePORTER
FX We are grateful for support from NIH grants EY06109 and EY014662,
   International Retinal Research Foundation, American Health Assistance
   Foundation, EyeSight Foundation of Alabama, Research to Prevent
   Blindness, Inc., Macula Vision Research Foundation, Roger Johnson Prize
   in Macular Degeneration Research, and Deutsche Forschungsgemeinschaft.
   CAC thanks especially the Alabama Eye Bank, members of Lipid Breakfast
   (Atherosclerosis Research Unit, J.P. Segrest, MD, Phl), Director,
   Department of Medicine, UAB), Lanning B. Kline, MD, Peter A. Dudley,
   Phl), John Guyton, MD, Howard Kruth, MD, and Clyde Guidry, Phl). David
   Fisher provided graphical design.
CR ADAMS CWM, 1975, TECHNIQUES BIOCH BIO, P100
   Adiels M, 2008, ARTERIOSCL THROM VAS, V28, P1225, DOI 10.1161/ATVBAHA.107.160192
   Afshari FT, 2009, EYE
   Alaupovic Petar, 2003, Curr Atheroscler Rep, V5, P459, DOI 10.1007/s11883-003-0036-8
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   ANDERSON LJ, 1989, J LIPID RES, V30, P1819
   Anderson M, 2006, VET OPHTHALMOL, V9, P201, DOI 10.1111/j.1463-5224.2006.00463.x
   Athar H, 2004, J LIPID RES, V45, P764, DOI 10.1194/jlr.D300026-JLR200
   BAIRATI A, 1963, J ULTRA MOL STRUCT R, V9, P484, DOI 10.1016/S0022-5320(63)80080-5
   BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S
   BAZAN HEP, 1990, INVEST OPHTH VIS SCI, V31, P1433
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200
   BJORKHEM I, 2004, ARTERIOSCLER THROMB, V5, P5
   BOCAN TMA, 1986, AM J PATHOL, V123, P413
   BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P18867
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   BROEKHUYSE RM, 1972, BIOCHIM BIOPHYS ACTA, V280, P637, DOI 10.1016/0005-2760(72)90143-9
   Burtis C. A., 1999, TIETZ TXB CLIN CHEM
   Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   CasaroliMarano RP, 1996, J LIPID RES, V37, P1037
   Cavelier C, 2006, BBA-MOL CELL BIOL L, V1761, P655, DOI 10.1016/j.bbalip.2006.04.012
   CERAMI A, 1986, J CELL BIOCHEM, V30, P111, DOI 10.1002/jcb.240300203
   Chang MY, 2001, J LIPID RES, V42, P824
   CHAO FF, 1990, AM J PATHOL, V136, P169
   CHEN HM, 1992, CURR EYE RES, V11, P793, DOI 10.3109/02713689209000752
   Chowers I, 2001, EYE, V15, P525, DOI 10.1038/eye.2001.167
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   Chung BH, 2005, BBA-MOL CELL BIOL L, V1733, P76, DOI 10.1016/j.bbalip.2004.12.002
   CHUNG BH, 1994, ARTERIOSCLER THROMB, V14, P622, DOI 10.1161/01.ATV.14.4.622
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Contois JH, 2009, CLIN CHEM, V55, P407, DOI 10.1373/clinchem.2008.118356
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crispin S, 2002, PROG RETIN EYE RES, V21, P169, DOI 10.1016/S1350-9462(02)00004-6
   Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, VISION RES, V45, P3496, DOI 10.1016/j.visres.2005.07.038
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Turco EBR, 1999, J NEUROSCI RES, V57, P479
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   DESILVA HV, 1990, J BIOL CHEM, V265, P13240
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Dougan SK, 2007, J EXP MED, V204, P533, DOI 10.1084/jem.20062006
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Eckhart L, 2000, BIOCHEM BIOPH RES CO, V271, P726, DOI 10.1006/bbrc.2000.2716
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   ELBABA F, 1986, AM J OPHTHALMOL, V101, P576
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Ethier CR, 2004, ANNU REV BIOMED ENG, V6, P249, DOI 10.1146/annurev.bioeng.6.040803.140055
   FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FEENEYBURNS L, 1981, ARCH OPHTHALMOL-CHIC, V99, P664, DOI 10.1001/archopht.1981.03930010664013
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FIJALKOWSKI N, 2009, INVEST OPHTH VIS SCI, V50, pE774
   FINE BS, 1978, INVEST OPHTH VIS SCI, V17, P1059
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Fliesler SJ, 1997, INT J BIOCHEM CELL B, V29, P877, DOI 10.1016/S1357-2725(97)00018-6
   FORTE TM, 1986, METHOD ENZYMOL, V128, P442
   FRANK JS, 1989, J LIPID RES, V30, P967
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Gaynor PM, 1996, J LIPID RES, V37, P1849
   Giambernardi TA, 1998, BIOTECHNIQUES, V25, P564, DOI 10.2144/98254bm03
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GOLDBERG IJ, 2009, J LIPID RES
   Gonzalez-Fernandez F, 2008, EXP EYE RES, V86, P169, DOI 10.1016/j.exer.2006.09.003
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4
   GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628
   Grant CA, 2001, INT OPHTHALMOL CLIN, V41, P103, DOI 10.1097/00004397-200101000-00010
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   Gullapalli VK, 2008, EXP EYE RES, V86, P189, DOI 10.1016/j.exer.2007.10.009
   GUYTON JR, 1993, AM J PATHOL, V143, P1444
   GUYTON JR, 1989, AM J PATHOL, V134, P705
   Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4
   GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P644, DOI 10.1161/01.ATV.5.6.644
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hacquebard M, 2005, CURR OPIN CLIN NUTR, V8, P133, DOI 10.1097/00075197-200503000-00005
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Handa James T., 2007, International Ophthalmology Clinics, V47, P15, DOI 10.1097/IIO.0b013e31802bd546
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008
   HAVEL RJ, 2001, METABOLIC MOL BASIS, P2707
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   HEWITT AT, 1989, INVEST OPHTH VIS SCI, V30, P478
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P4529, DOI 10.1167/iovs.04-0919
   HIROSAWA K, 1976, TOKYO JAPANESE J OPH
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Holm C, 1999, METH MOL B, V109, P109
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   HUANG JD, 2009, TRANSPORT L IN PRESS
   HUANG JD, 2007, AGING BRUCHS MEMBRAN
   HUANG JD, 2008, INVEST OPHTH VIS SCI, V49, pE1752
   HUANG JD, 2007, INVEST OPHTHALMOL VI
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Hussain MM, 2008, CURR OPIN LIPIDOL, V19, P277, DOI 10.1097/MOL.0b013e3282feea85
   Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200
   Iglesias A, 1996, CLIN CHIM ACTA, V248, P157, DOI 10.1016/0009-8981(95)06251-3
   Iqbal J, 2003, J BIOL CHEM, V278, P31610, DOI 10.1074/jbc.M301177200
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jackson GR, 2005, MACULAR DEGENERATION, P45, DOI 10.1007/3-540-26977-0_3
   JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549
   Javitt NB, 2008, STEROIDS, V73, P149, DOI 10.1016/j.steroids.2007.10.004
   Joffre C, 2007, CURR EYE RES, V32, P271, DOI 10.1080/02713680601187951
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   Jonas A., 2002, BIOCH LIPIDS LIPOPRO, P483
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ SS, 1980, J BIOL CHEM, V255, P9753
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   KILLINGSWORTH MC, 1987, GRAEF ARCH CLIN EXP, V225, P406, DOI 10.1007/BF02334166
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Knupp C, 2000, J STRUCT BIOL, V129, P38, DOI 10.1006/jsbi.1999.4202
   Kouchi M, 2006, VET OPHTHALMOL, V9, P145, DOI 10.1111/j.1463-5224.2006.00453.x
   Kovanen PT, 1999, TRENDS CARDIOVAS MED, V9, P86, DOI 10.1016/S1050-1738(99)00013-4
   KRUTH HS, 1984, AM J PATHOL, V114, P201
   KRUTH HS, 1984, ATHEROSCLEROSIS, V51, P281, DOI 10.1016/0021-9150(84)90175-8
   Kruth HS, 1997, CURR OPIN LIPIDOL, V8, P246, DOI 10.1097/00041433-199710000-00002
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Lakkaraju A, 2008, TRENDS CELL BIOL, V18, P199, DOI 10.1016/j.tcb.2008.03.002
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   LAUBER, 1924, BER U D DTSCH OPHTH, V44, P216
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Lee JW, 2006, EXP EYE RES, V83, P465, DOI 10.1016/j.exer.2005.11.018
   LEIPER JM, 1994, J BIOL CHEM, V269, P21951
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Lin MY, 2007, MOL VIS, V13, P1203
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Luna L.G., 1968, MANUAL HISTOLOGIC ST, Vthird
   Lusis AJ, 2004, CIRCULATION, V110, P1868, DOI 10.1161/01.CIR.0000143041.58692.CC
   Madsen EM, 2004, J BIOL CHEM, V279, P55271, DOI 10.1074/jbc.M411404200
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   McCarty WJ, 2008, J APPL PHYSIOL, V105, P621, DOI 10.1152/japplphysiol.01245.2007
   MESSINGER JD, 2009, INVEST OPHTHALMOL VI
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Moghadasian MH, 2002, LIFE SCI, V70, P855, DOI 10.1016/S0024-3205(01)01479-5
   Mohler PJ, 2007, J BIOL CHEM, V282, P26981, DOI 10.1074/jbc.M700500200
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mori M, 2002, INVEST OPHTH VIS SCI, V43, P1384
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NAKAIZUMI Y, 1964, ARCH OPHTHALMOL-CHIC, V72, P395, DOI 10.1001/archopht.1964.00970020395018
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Nickle B, 2007, CELL MOL LIFE SCI, V64, P2917, DOI 10.1007/s00018-007-7253-1
   Nielsen LB, 1998, CIRCULATION, V98, P13, DOI 10.1161/01.CIR.98.1.13
   NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   O'Brien KD, 2004, ATHEROSCLEROSIS, V177, P29, DOI 10.1016/j.atherosclerosis.2004.07.007
   Oksjoki R, 2007, FRONT BIOSCI-LANDMRK, V12, P4696, DOI 10.2741/2419
   Olofsson SO, 2005, J INTERN MED, V258, P395, DOI 10.1111/j.1365-2796.2005.01556.x
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Pauleikhoff D, 2000, OPHTHALMOLOGE, V97, P243, DOI 10.1007/s003470050520
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   Pentikainen MO, 1997, J BIOL CHEM, V272, P25283, DOI 10.1074/jbc.272.40.25283
   Pentikainen MO, 2000, J BIOL CHEM, V275, P5694, DOI 10.1074/jbc.275.8.5694
   Pentikainen MO, 2002, ARTERIOSCL THROM VAS, V22, P211, DOI 10.1161/hq0102.101551
   Qtaishat NM, 2003, INVEST OPHTH VIS SCI, V44, P1435, DOI 10.1167/iovs.02-0679
   Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686
   Ramirez AI, 2006, EXP EYE RES, V83, P1423, DOI 10.1016/j.exer.2006.07.023
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   REALE E, 2008, CELLS TISSUES ORGANS
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6
   Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993
   Rittmann BE, 2007, REJUV RES, V10, P359, DOI 10.1089/rej.2007.0594
   ROBISON WG, 1977, INVEST OPHTH VIS SCI, V16, P1110
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Rones B, 1937, ARCH OPHTHALMOL-CHIC, V18, P388
   Ruberg FL, 2006, J LIPID RES, V47, P310, DOI 10.1194/jlr.M500431-JLR200
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Ruiz A, 1996, BIOCHEM BIOPH RES CO, V226, P467, DOI 10.1006/bbrc.1996.1379
   Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536
   Sadaba LM, 2008, EXP EYE RES, V86, P470, DOI 10.1016/j.exer.2007.11.020
   Salazar JJ, 2007, EXP EYE RES, V84, P412, DOI 10.1016/j.exer.2006.10.012
   SALLO FB, 2009, EXP EYE RES
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmidt-Erfurth U, 2008, INVEST OPHTH VIS SCI, V49, P390, DOI 10.1167/iovs.07-0227
   Schonfeld G, 2003, J LIPID RES, V44, P878, DOI 10.1194/jlr.R300002-JLR200
   SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895
   SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P908, DOI 10.1161/01.ATV.9.6.908
   SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903
   Segrest JP, 1999, J LIPID RES, V40, P1401
   SEIFERT PS, 1989, LAB INVEST, V60, P747
   SELKOE DJ, 1982, SCIENCE, V215, P1243, DOI 10.1126/science.6120571
   Sellers JA, 2001, J LIPID RES, V42, P1897
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Shah PK, 2007, CURR OPIN LIPIDOL, V18, P492, DOI 10.1097/MOL.0b013e3282efa326
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SHOTTON DM, 1995, RAPID FREEZING FREEZ, P1
   Shoulders CC, 2005, CURR TOP MED CHEM, V5, P283, DOI 10.2174/1568026053544560
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804
   SMALL DM, 1974, SCIENCE, V185, P222, DOI 10.1126/science.185.4147.222
   SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103
   Smith E B, 1974, Adv Lipid Res, V12, P1
   SMITH EB, 1973, NUTR METAB, V15, P17
   SMITH EB, 1967, J ATHEROSCLER RES, V7, P171, DOI 10.1016/S0368-1319(67)80079-6
   SMITH EB, 1972, ATHEROSCLEROSIS, V15, P37, DOI 10.1016/0021-9150(72)90036-6
   Smith JD, 2002, AGEING RES REV, V1, P345, DOI 10.1016/S1568-1637(02)00005-3
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   SPARKS CE, 1981, CAN J BIOCHEM CELL B, V59, P693, DOI 10.1139/o81-096
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STARY HC, 1992, CIRCULATION, V85, P391, DOI 10.1161/01.CIR.85.1.391
   Steinberg D, 2005, J LIPID RES, V46, P179, DOI 10.1194/jlr.R400012-JLR200
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   Sun K, 2007, MOL VIS, V13, P2310
   Suzuki M, 2007, MOL VIS, V13, P772
   Tabas I, 1999, ANNU REV NUTR, V19, P123, DOI 10.1146/annurev.nutr.19.1.123
   Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Tamminen M, 1999, ARTERIOSCL THROM VAS, V19, P847, DOI 10.1161/01.ATV.19.4.847
   Temel RE, 2007, J LIPID RES, V48, P1618, DOI 10.1194/jlr.M700109-JLR200
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Torzewski M, 1998, ARTERIOSCL THROM VAS, V18, P369, DOI 10.1161/01.ATV.18.3.369
   Trivino A, 2006, EXP EYE RES, V83, P357, DOI 10.1016/j.exer.2005.12.020
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206
   Varnava AM, 2002, CIRCULATION, V105, P939, DOI 10.1161/hc0802.104327
   Veniant MM, 2008, CURR DRUG TARGETS, V9, P174
   VERHOEFF F. H., 1926, ARCH OPHTHALMOL, V55, P125
   VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131
   WALTON KW, 1974, J PATHOL, V114, P217, DOI 10.1002/path.1711140406
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang XS, 2001, J PATHOL, V195, P244, DOI 10.1002/path.935
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   WAUGH DA, 1984, LAB INVEST, V51, P702
   WETTERAU JR, 1992, SCIENCE, V258, P999
   Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3
   White C Roger, 2009, Vasc Dis Prev, V6, P122
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
   Williams KJ, 2005, ARTERIOSCL THROM VAS, V25, P1536, DOI 10.1161/01.ATV.0000174795.62387.d3
   Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yao ZM, 1997, J LIPID RES, V38, P1937
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yokota T, 2001, P NATL ACAD SCI USA, V98, P15185, DOI 10.1073/pnas.261456098
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yuan C, 1997, ARTERIOSCL THROM VAS, V17, P1496, DOI 10.1161/01.ATV.17.8.1496
   Zacho J, 2008, NEW ENGL J MED, V359, P1897, DOI 10.1056/NEJMoa0707402
   Zak Z, 2002, J LIPID RES, V43, P2164, DOI 10.1194/jlr.M200253-JLR200
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang WY, 1996, J BIOL CHEM, V271, P28641, DOI 10.1074/jbc.271.45.28641
NR 339
TC 177
Z9 183
U1 1
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2009
VL 28
IS 6
BP 393
EP 422
DI 10.1016/j.preteyeres.2009.08.001
PG 30
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 527LV
UT WOS:000272369500001
PM 19698799
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kabanarou, SA
   Xirou, TN
   Mangouritsas, G
   Garnavou-Xirou, C
   Boutouri, E
   Gkizis, I
   Chatziralli, I
AF Kabanarou, Stamatina A.
   Xirou, Tina
   Mangouritsas, George
   Garnavou-Xirou, Christina
   Boutouri, Eirini
   Gkizis, Ilias
   Chatziralli, Irini
TI Full-thickness macular hole formation following anti-VEGF injections for
   neovascular age-related macular degeneration
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE macular hole; age-related macular degeneration; anti-VEGF
ID OPTICAL-COHERENCE-TOMOGRAPHY; GROWTH-FACTOR INJECTIONS; VITREOMACULAR
   ADHESION; RANIBIZUMAB; DETACHMENT; INTERFACE; TRACTION; DISEASE
AB Purpose: Macular hole (MH) is part of a group of age-related degenerative diseases characterized by pathology of vitreomacular interface. Similarly, neovascular age-related macular degeneration (nAMD) affects older patients and is a leading cause of irreversible visual loss. The purpose of this case series is to describe the development of full-thickness MH in patients with nAMD, following antivascular endothelial growth factor (anti-VEGF) treatment.
   Methods: Participants in this case series were four patients with nAMD, who received anti-VEGF injections with variable therapeutic response to treatment. Patients were examined at baseline (when AMD was diagnosed) and monthly thereafter. The examination included visual acuity measurement, slit-lamp biomicroscopy, and optical coherence tomography.
   Results: All patients were found to develop full-thickness MH within 1-4 months after the last anti-VEGF injection, even in the absence of pre-existing vitreomacular interface abnormalities in some cases. The median number of injections before the MH formation was 3.
   Conclusion: MH formation may represent an adverse effect of anti-VEGF treatment in patients with nAMD and could be also coexisting pathology with nAMD in older individuals.
C1 [Kabanarou, Stamatina A.; Xirou, Tina; Mangouritsas, George; Boutouri, Eirini; Gkizis, Ilias] Hellen Red Cross Hosp, Retina Dept Korgialeneio Benakeio, 1 Erithrou Stavrou St, Athens 11526, Greece.
   [Garnavou-Xirou, Christina] Kings Coll Hosp London, Retina Dept, London, England.
   [Chatziralli, Irini] Univ Athens, Dept Ophthalmol 2, Athens, Greece.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   National & Kapodistrian University of Athens
RP Kabanarou, SA (通讯作者)，Hellen Red Cross Hosp, Retina Dept Korgialeneio Benakeio, 1 Erithrou Stavrou St, Athens 11526, Greece.
EM stamatina_k@hotmail.com
RI Chatziralli, Irini/AAG-4779-2020
OI Chatziralli, Irini/0000-0001-8523-1024
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Clemens CR, 2010, J OCUL PHARMACOL TH, V26, P297, DOI 10.1089/jop.2009.0140
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Gass J Donald M, 2003, Retina, V23, P629
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   Geck U, 2013, GRAEF ARCH CLIN EXP, V251, P1691, DOI 10.1007/s00417-013-2266-y
   Grigoropoulos V, 2010, EUR J OPHTHALMOL, V20, P469, DOI 10.1177/112067211002000235
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Moisseiev E, 2010, CASE REP OPHTHALM, V1, P36, DOI 10.1159/000319827
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Mukherjee C, 2015, OPEN OPHTHALMOL J, V9, P177, DOI 10.2174/1874364101509010177
   Oshima Y, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0021-3
   Querques G, 2009, ACTA OPHTHALMOL, V87, P235, DOI 10.1111/j.1755-3768.2008.01226.x
   Raiji Veena R, 2013, Retin Cases Brief Rep, V7, P91, DOI 10.1097/ICB.0b013e31826f090d
   Regatieri Caio V, 2012, Retin Cases Brief Rep, V6, P125, DOI 10.1097/ICB.0b013e3182160952
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Tanner V, 2001, BRIT J OPHTHALMOL, V85, P1092, DOI 10.1136/bjo.85.9.1092
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 25
TC 8
Z9 10
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2017
VL 12
BP 911
EP 915
DI 10.2147/CIA.S135364
PG 5
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA EW1YV
UT WOS:000402293600002
PM 28603410
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Menon, M
   Mohammadi, S
   Davila-Velderrain, J
   Goods, BA
   Cadwell, TD
   Xing, Y
   Stemmer-Rachamimov, A
   Shalek, AK
   Love, JC
   Kellis, M
   Hafler, BP
AF Menon, Madhvi
   Mohammadi, Shahin
   Davila-Velderrain, Jose
   Goods, Brittany A.
   Cadwell, Tanina D.
   Xing, Yu
   Stemmer-Rachamimov, Anat
   Shalek, Alex K.
   Love, John Christopher
   Kellis, Manolis
   Hafler, Brian P.
TI Single-cell transcriptomic atlas of the human retina identifies cell
   types associated with age-related macular degeneration
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; MULLER CELLS; EXPRESSION; GLIA; IRON;
   ASTROCYTES; NEURONS
AB Genome-wide association studies (GWAS) have identified genetic variants associated with age-related macular degeneration (AMD), one of the leading causes of blindness in the elderly. However, it has been challenging to identify the cell types associated with AMD given the genetic complexity of the disease. Here we perform massively parallel single-cell RNA sequencing (scRNA-seq) of human retinas using two independent platforms, and report the first single-cell transcriptomic atlas of the human retina. Using a multi-resolution network-based analysis, we identify all major retinal cell types, and their corresponding gene expression signatures. Heterogeneity is observed within macroglia, suggesting that human retinal glia are more diverse than previously thought. Finally, GWAS-based enrichment analysis identifies glia, vascular cells, and cone photoreceptors to be associated with the risk of AMD. These data provide a detailed analysis of the human retina, and show how scRNA-seq can provide insight into cell types involved in complex, inflammatory genetic diseases.
C1 [Menon, Madhvi; Mohammadi, Shahin; Davila-Velderrain, Jose; Goods, Brittany A.; Shalek, Alex K.; Love, John Christopher; Kellis, Manolis; Hafler, Brian P.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Menon, Madhvi; Hafler, Brian P.] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
   [Menon, Madhvi; Hafler, Brian P.] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA.
   [Menon, Madhvi; Cadwell, Tanina D.; Xing, Yu; Kellis, Manolis; Hafler, Brian P.] Harvard Med Sch, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA.
   [Mohammadi, Shahin; Davila-Velderrain, Jose; Kellis, Manolis] MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Goods, Brittany A.; Shalek, Alex K.] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Goods, Brittany A.; Shalek, Alex K.] MIT, Dept Chem, Cambridge, MA 02139 USA.
   [Goods, Brittany A.; Shalek, Alex K.; Love, John Christopher] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02142 USA.
   [Goods, Brittany A.; Shalek, Alex K.] MIT & Harvard, Ragon Inst MGH, Cambridge, MA 02139 USA.
   [Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
   [Hafler, Brian P.] Yale Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06510 USA.
C3 Harvard University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School; Harvard University; Harvard Medical
   School; Massachusetts Institute of Technology (MIT); Massachusetts
   Institute of Technology (MIT); Massachusetts Institute of Technology
   (MIT); Massachusetts Institute of Technology (MIT); Harvard University;
   Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard
   University; Massachusetts General Hospital; Yale University
RP Hafler, BP (通讯作者)，Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Hafler, BP (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.; Hafler, BP (通讯作者)，Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA.; Hafler, BP (通讯作者)，Harvard Med Sch, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA.; Hafler, BP (通讯作者)，Yale Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06510 USA.
EM brian.hafler@yale.edu
RI Davila-Velderrain, Jose/AGL-4662-2022; Kellis, Manolis/ABE-7385-2020
OI Kellis, Manolis/0000-0001-7113-9630; Davila-Velderrain,
   Jose/0000-0003-0271-6267; Menon, Madhvi/0000-0003-2516-9438; Love,
   John/0000-0003-0921-3144
FU NEI [K08-EY026652]; NIAID [P01-AI039671, F32-AI136459]; NIH
   [U01-MH119509, R01-AG062335, U01-NS110453]; NATIONAL EYE INSTITUTE
   [K08EY026652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASES [F32AI136459] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH119509] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND
   STROKE [U01NS110453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   AGING [R01AG062335] Funding Source: NIH RePORTER
FX This work was supported by NEI K08-EY026652 (to B.P.H.), NIAID
   P01-AI039671 (to M.M.), F32-AI136459 (to B.A.G.), NIH U01-MH119509, NIH
   R01-AG062335, and NIH U01-NS110453 (to M.K.). We thank Vijay Kuchroo for
   helpful discussions, Advancing Sight Network for timely retrieval of
   donor eyes, and John Dewitt, Nathan Clement, Wesley Samore, and Erik
   Williams for assistance with collecting the eyes from autopsies.
CR Anava O., 2016, ADV NEURAL INFORM PR, P4916
   Anezary L, 2001, J COMP NEUROL, V438, P32, DOI 10.1002/cne.1300
   Bahrami Shahram, 2016, Advances in Biological Regulation, V62, P37, DOI 10.1016/j.jbior.2016.05.001
   Baumann B, 2017, INVEST OPHTH VIS SCI, V58, P4223, DOI 10.1167/iovs.17-21743
   Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314
   Boije H, 2010, DEV DYNAM, V239, P1858, DOI 10.1002/dvdy.22309
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bryois J., 2019, BIORXIV, DOI [10.1101/528463, DOI 10.1101/528463]
   Bryois J, 2019, EUR NEUROPSYCHOPHARM, V29, pS799, DOI 10.1016/j.euroneuro.2017.08.033
   Chang ML, 2007, J ANAT, V210, P54, DOI 10.1111/j.1469-7580.2006.00671.x
   Cheng L, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00020
   de Leeuw CA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004219
   DISTLER C, 1993, J COMP NEUROL, V333, P134, DOI 10.1002/cne.903330111
   Finucane HK, 2018, NAT GENET, V50, P621, DOI 10.1038/s41588-018-0081-4
   Fischer AJ, 2009, GLIA, V57, P1538, DOI 10.1002/glia.20868
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gierahn TM, 2017, NAT METHODS, V14, P395, DOI 10.1038/nmeth.4179
   Goldman D, 2014, NAT REV NEUROSCI, V15, P431, DOI 10.1038/nrn3723
   Haghverdi L, 2018, NAT BIOTECHNOL, V36, P421, DOI 10.1038/nbt.4091
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Jansen IE, 2019, NAT GENET, V51, P404, DOI 10.1038/s41588-018-0311-9
   Kitzman JO, 2016, NAT BIOTECHNOL, V34, P296, DOI 10.1038/nbt.3500
   Li MF, 2018, SCIENCE, V362, P1264, DOI 10.1126/science.aat7615
   Luecken MD, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188746
   Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   Mohammadi S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03933-2
   Peng YR, 2019, CELL, V176, P1222, DOI 10.1016/j.cell.2019.01.004
   Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200
   Qi JH, 2009, J BIOL CHEM, V284, P19927, DOI 10.1074/jbc.M109.013763
   Rauen T, 1998, CELL TISSUE RES, V291, P19
   Rheaume BA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05134-3
   Savige J, 2010, INVEST OPHTH VIS SCI, V51, P1621, DOI 10.1167/iovs.08-3323
   Scott RA, 2017, DIABETES, V66, P2888, DOI 10.2337/db16-1253
   Shekhar K, 2016, CELL, V166, P1308, DOI 10.1016/j.cell.2016.07.054
   Skene NG, 2018, NAT GENET, V50, P825, DOI 10.1038/s41588-018-0129-5
   Too LK, 2017, ACTA HISTOCHEM, V119, P142, DOI 10.1016/j.acthis.2016.12.003
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Yao K, 2018, NATURE, V560, P484, DOI 10.1038/s41586-018-0425-3
   Zhang T, 2019, ELIFE, V8, DOI 10.7554/eLife.43598
   Zhang Y, 2016, NEURON, V89, P37, DOI 10.1016/j.neuron.2015.11.013
   Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049
NR 43
TC 106
Z9 109
U1 5
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 25
PY 2019
VL 10
AR 4902
DI 10.1038/s41467-019-12780-8
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JH5VD
UT WOS:000492836000009
PM 31653841
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ebner, C
   Wernigg, C
   Schutze, C
   Weingessel, B
   Vecsei-Marlovits, PV
AF Ebner, Christian
   Wernigg, Clara
   Schuetze, Christopher
   Weingessel, Birgit
   Vecsei-Marlovits, Pia-Veronika
TI Retinal pigment epithelial characteristics in eyes with neovascular
   age-related macular degeneration Long-term retinal changes under
   anti-vascular endothelial growth factor treatment
SO WIENER KLINISCHE WOCHENSCHRIFT
LA English
DT Article
DE Bevacizumab; Ranibizumab; Hyperreflective intraretinal foci; Retina;
   Spectral domain optical coherence tomography
ID GEOGRAPHIC ATROPHY; RANIBIZUMAB; BEVACIZUMAB; PROGRESSION; TUBULATION;
   PREVALENCE
AB Purpose The aim of this study was to assess retinal pigment epithelial (RPE) and retinal structural changes in eyes with neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) during long-term follow-up and to evaluate morphological markers potentially influencing prognosis. Methods A total of 18 eyes of 18 patients with neovascular AMD were examined subsequent to completion of the Avastin Versus Lucentis in Age Related Macular Degeneration (MANTA) study following a mean period of 84 months (range 69-93 months). After receiving a loading dose of 3 intravitreal anti-VEGF injections subsequent to baseline of the MANTA study, patients were treated as needed (pro re nata, PRN). Functional and morphological changes were assessed, the latter using spectral domain optical coherence tomography (SD-OCT). Results Retinal/RPE atrophy generally increased significantly during follow-up compared to baseline (fibrosis 28% vs. 89%,p & x202f;= 0.0001, geographic atrophy, GA 0% vs. 67%,p & x202f;= 0.0002, RPE porosity 61% vs. 100%,p & x202f;= 0.009) whereas regenerative alterations tendentially increased until 3 months and then subsequently declined until the last visit (RPE thickening 28% vs. 11%,p & x202f;= 0.22 and intraretinal hyperreflective foci 89% vs. 78%,p & x202f;= 0.39). Conclusion Atrophic alterations of the retina and RPE are progressive and may partly be induced by anti-VEGF. Morphological findings may aid in the identification of prognostic markers in the progression of neovascular AMD. This could lead to a more targeted education of affected patients.
C1 [Ebner, Christian; Wernigg, Clara; Schuetze, Christopher; Weingessel, Birgit; Vecsei-Marlovits, Pia-Veronika] Hietzing Hosp, Dept Ophthalmol, Wolkersbergenstr 1,Pavillon 2a & 2b, A-1130 Vienna, Austria.
   [Ebner, Christian; Wernigg, Clara; Schuetze, Christopher; Weingessel, Birgit; Vecsei-Marlovits, Pia-Veronika] Karl Landsteiner Inst Proc Optimizat & Qual Manag, Wolkersbergenstr 1, A-1130 Vienna, Austria.
C3 Hietzing Hospital
RP Vecsei-Marlovits, PV (通讯作者)，Hietzing Hosp, Dept Ophthalmol, Wolkersbergenstr 1,Pavillon 2a & 2b, A-1130 Vienna, Austria.; Vecsei-Marlovits, PV (通讯作者)，Karl Landsteiner Inst Proc Optimizat & Qual Manag, Wolkersbergenstr 1, A-1130 Vienna, Austria.
EM veronika.vecsei-marlovits@wienkav.at
RI Weingessel, Birgit/AAM-6617-2021; Weingessel, Birgit/ABD-5201-2021
OI Weingessel, Birgit/0000-0002-1110-0432; Ebner,
   Christian/0000-0003-2344-0677
CR Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P865, DOI 10.1097/IAE.0b013e318251a3a8
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Thavikulwat AT, 2017, OPHTHALMOL RETINA, V1, P34, DOI 10.1016/j.oret.2016.09.005
   TSUBOI S, 1987, INVEST OPHTH VIS SCI, V28, P1788
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 24
TC 2
Z9 3
U1 0
U2 3
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0043-5325
EI 1613-7671
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
PD FEB
PY 2021
VL 133
IS 3-4
BP 123
EP 130
DI 10.1007/s00508-020-01718-6
EA AUG 2020
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA QF2QM
UT WOS:000556651400001
PM 32761460
DA 2022-11-30
ER

PT J
AU Cheong, KX
   Teo, AWJ
   Cheung, CMG
   Too, IHK
   Chakravarthy, U
   Teo, KYC
AF Cheong, Kai Xiong
   Teo, Alvin Wei Jun
   Cheung, Chui Ming Gemmy
   Too, Issac Horng Khit
   Chakravarthy, Usha
   Teo, Kelvin Yi Chong
TI Association between retinal thickness variation and visual acuity change
   in neovascular age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE anti&#8208; vascular endothelial growth factor inhibitor; neovascular
   age&#8208; related macular degeneration; retinal thickness; variation;
   visual acuity
ID SUBGROUP ANALYSIS; RANIBIZUMAB; PARAMETERS; MARINA
AB Background To assess the association between variation in retinal central subfield thickness (CSFT) with best-corrected visual acuity (BCVA) change in patients receiving vascular endothelial growth factor (VEGF) inhibitor therapy for neovascular age-related macular degeneration (nAMD).
   Methods CSFT measurements were obtained from 141 eyes (total 1300 scans). SD of CSFT was calculated. The eyes were categorised into CSFT variation tertiles. Multiple linear regression was used to examine the association between the CSFT tertiles and BCVA change at 12 mo, adjusting for differences in baseline demographic and clinical characteristics.
   Results At 12 mo, the mean BCVA of the high CSFT variation group (50.6 letters) was significantly lower than the low and moderate CSFT variation groups (57.5 and 59.8 letters, respectively), P = .02. The adjusted mean BCVA gains were +1.7, +7.2, and +7.8 letters in the high, moderate and low CSFT variation groups, respectively (P = .03).
   Conclusions A greater variation in retinal thickness during VEGF inhibitor therapy for nAMD is associated with a less favourable visual outcome. CSFT stability is useful in prognosticating visual outcomes in VEGF inhibitor therapy for nAMD.
C1 [Cheong, Kai Xiong; Teo, Alvin Wei Jun; Cheung, Chui Ming Gemmy; Teo, Kelvin Yi Chong] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Teo, Kelvin Yi Chong] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Too, Issac Horng Khit] Novartis Singapore Pte Ltd, Singapore, Singapore.
   [Chakravarthy, Usha] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Novartis; Queens University Belfast
RP Teo, KYC (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM kelvin.teo.y.c@singhealth.com.sg
OI Teo, Kelvin/0000-0002-7458-7081
FU Novartis Singapore Pte Ltd; National Medical Research Council Open Fund
   Large Collaborative [NMRC/LCG/004/2018]; Biomedical Research Council
   Singapore [SPF2014/002]; Duke/Duke-NUS Research Collaborations
   [Duke/Duke-NUS/RECA(Pilot)2016/0020]
FX Novartis Singapore Pte Ltd; National Medical Research Council Open Fund
   Large Collaborative, Grant/Award Number: NMRC/LCG/004/2018; Biomedical
   Research Council Singapore, Grant/Award Number: SPF2014/002;
   Duke/Duke-NUS Research Collaborations, Grant/Award Number:
   Duke/Duke-NUS/RECA(Pilot)2016/0020
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chakravarthy U, 2021, EYE, V35, P2983, DOI 10.1038/s41433-020-01354-4
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cheong KX, 2021, SURV OPHTHALMOL, V66, P68, DOI 10.1016/j.survophthal.2020.05.003
   Cheong KX, 2020, EYE, V34, P2257, DOI 10.1038/s41433-020-0803-6
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2011, SAUDI J OPHTHALMOL, V25, P145, DOI 10.1016/j.sjopt.2011.01.003
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Ou WC, 2017, AM J OPHTHALMOL, V180, P8, DOI 10.1016/j.ajo.2017.05.014
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Schechet SA, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000271
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Teo KYC, 2020, OPHTHALMOL RETINA, V4, P871, DOI 10.1016/j.oret.2020.03.017
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   YAYLALI S, 2012, INT OPHTHALMOL, V32, P25, DOI DOI 10.1007/S10792-012-9519-3
NR 29
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2021
VL 49
IS 5
BP 430
EP 438
DI 10.1111/ceo.13927
EA MAY 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TK6WO
UT WOS:000648505500001
PM 33856734
DA 2022-11-30
ER

PT J
AU Thorell, MR
   Goldhardt, R
   Nunes, RP
   Garcia, CAD
   Abbey, AM
   Kuriyan, AE
   Modi, YS
   Gregori, G
   Yehoshua, Z
   Feuer, W
   Sadda, S
   Rosenfeld, PJ
AF Thorell, Mariana R.
   Goldhardt, Raquel
   Nunes, Renata Portella
   de Amorim Garcia Filho, Carlos Alexandre
   Abbey, Ashkan M.
   Kuriyan, Ajay E.
   Modi, Yasha S.
   Gregori, Giovanni
   Yehoshua, Zohar
   Feuer, William
   Sadda, SriniVas
   Rosenfeld, Philip J.
TI Association Between Subfoveal Choroidal Thickness, Reticular
   Pseudodrusen, and Geographic Atrophy in Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID COMPLEMENT INHIBITION; HEALTHY EYES; RISK-FACTOR; DRUSEN; PREVALENCE;
   VOLUME
AB BACKGROUND AND OBJECTIVE: To compare subfoveal choroidal thickness (CT) measurements in eyes with nonexudative age-related macular degeneration (AMD) in the presence or absence of reticular pseudodrusen (RPD).
   PATIENTS AND METHODS: Subfoveal CT measurements obtained from patients with AMD enrolled in the COMPLETE study (30 drusen-only eyes and 30 eyes with geographic atrophy [GA]) were compared with an age-distributed normal control group. Multimodal images were evaluated to detect the presence of RPD.
   RESULTS: After controlling for age and axial length, the mean CT was significantly thinner in the GA group with RPD (213.7 +/- 53.1 mu m) than in the GA group without RPD (335.3 +/- 123.2 mu m; P =.001). The mean CT in the GA group without RPD was not statistically different from the mean CT in the normal control group (P = .076) or the drusen group without RPD (P = .45). In eyes without RPD, there was a correlation between the increasing size of GA and a decrease in CT measurements.
   CONCLUSION: Subfoveal choroidal thinning in eyes with nonexudative AMD was associated with the presence of RPD. In the absence of RPD, CT only decreased as the size of GA increased.
C1 [Thorell, Mariana R.; Goldhardt, Raquel; Nunes, Renata Portella; de Amorim Garcia Filho, Carlos Alexandre; Abbey, Ashkan M.; Kuriyan, Ajay E.; Modi, Yasha S.; Gregori, Giovanni; Yehoshua, Zohar; Feuer, William; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Nunes, Renata Portella; de Amorim Garcia Filho, Carlos Alexandre] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Sadda, SriniVas] Univ Calif Los Angeles, Sch Med, Dept Ophthalmol, Doheny Eye Inst, Los Angeles, CA 90024 USA.
C3 Bascom Palmer Eye Institute; University of Miami; Universidade Federal
   de Sao Paulo (UNIFESP); Doheny Eye Institute; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Thorell, Mariana/AAA-9246-2021
FU Alexion Pharmaceuticals; Carl Zeiss Meditec (Dublin, California); Macula
   Vision Research Foundation; Research to Prevent Blindness; Feig Family
   Foundation; Emma Clyde Hodge Memorial Foundation; National Eye Institute
   [R01EY024158, P30EY014801]; Carl Zeiss Meditec; Acucela; Advanced Cell
   Technology; GlaxoSmithKline; Bayer; Genentech; Allergan; Optos; NATIONAL
   EYE INSTITUTE [P30EY014801, R01EY024158] Funding Source: NIH RePORTER
FX Supported by a grant from Alexion Pharmaceuticals, Carl Zeiss Meditec
   (Dublin, California), the Macula Vision Research Foundation, an
   unrestricted grant from Research to Prevent Blindness, the Feig Family
   Foundation, the Emma Clyde Hodge Memorial Foundation, and grants
   R01EY024158 and P30EY014801 from the National Eye Institute.; Drs.
   Thorell, Gregori, and Rosenfeld received research support from Carl
   Zeiss Meditec. Dr. Gregori and the University of Miami co-own a patent
   that is licensed to Carl Zeiss Meditec. Dr. Rosenfeld received research
   support from Acucela, Advanced Cell Technology, Alexion Pharmaceuticals,
   and GlaxoSmithKline, and he is a consultant for Acucela, Alcon,
   Boehringer Ingelheim, Chengdu Kanghong Biotech, Healios K.K., Merck,
   Oraya, Roche, and Xcovery Vision. Dr. Kuriyan receives research support
   from Bayer. Dr. Sadda serves as a consultant for and receives research
   support from Genentech, Allergan, Optos, and Carl Zeiss Meditec. The
   remaining authors report no relevant financial disclosures.
CR Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Fein JG, 2014, OPHTHAL SURG LAS IM, V45, P32, DOI 10.3928/23258160-20131220-04
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Ko A, 2013, RETINA-J RET VIT DIS, V33, P1005, DOI 10.1097/IAE.0b013e31827d266e
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 38
TC 33
Z9 33
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAY
PY 2015
VL 46
IS 5
BP 513
EP 521
DI 10.3928/23258160-20150521-02
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CO6UQ
UT WOS:000359292500002
PM 26057754
DA 2022-11-30
ER

PT J
AU Brantley, MA
   Edelstein, SL
   King, JM
   Apte, RS
   Kymes, SM
   Shiels, A
AF Brantley, Milam A., Jr.
   Edelstein, Sean L.
   King, Jennifer M.
   Apte, Rajendra S.
   Kymes, Steven M.
   Shiels, Alan
TI Clinical phenotypes associated with the complement factor h Y402H
   variant in age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GENE POLYMORPHISM; NO ASSOCIATION; RISK; DRUSEN; CFH; POPULATION;
   COMMON; SUSCEPTIBILITY; INFLAMMATION; INCREASES
AB PURPOSE: To determine whether the complement factor H (CFH) Y402H variant is associated with specific age-related macular degeneration (AMD) clinical phenol types.
   DESIGN: Retrospective, case-control study.
   METHODS: One hundred and eightyeight white subjects with AMD and 189 control subjects were genotyped for the T-to-C polymorphism in exon 9 of the CFH gene by restriction-fragment length analysis and deoxyribonucleic acid (DNA) sequencing using genomic DNA from mouthwash samples. AMD phenotypes were characterized by clinical examination, fundus photography, and fluorescein angiography.
   RESULTS: Heterozygosity for the at-risk genotype (TC) increased the likelihood for AMD 2.1-fold (95% confidence interval [CI], 1.3 to 3.3), whereas homozygosity for the genotype (CC) increased the likelihood for AMD 6.5-fold (95% Cl, 3.4 to 12.5) in our population. The C allele was associated significantly with predominantly classic choroidal neovascularization (odds ratio [OR], 2.01; 95% Cl, 1.34 to 3.30). Neovascular lesion size was similar among the three genotypes (P=.67).
   CONCLUSIONS: The Y402H CFH variant carried a significantly increased risk for developing AMD in our population. Genotype and phenotype correlationsregarding choroidal neovascular lesion type were observed.
C1 Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   Barnes Retina Inst, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Brantley, MA (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
EM brantley@vision.wustt.edu
FU NEI NIH HHS [R01 EY012284-07S1, R01 EY012284, EY12284] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [R01EY012284] Funding Source: NIH
   RePORTER
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   KAUR I, 2006, OPHTHALMOLOGY, V47, P3729
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   PAULEIKHOFF D, 2005, RETINA, V25, P10065
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 30
TC 35
Z9 38
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2007
VL 144
IS 3
BP 404
EP 408
DI 10.1016/j.ajo.2007.05.018
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 209TW
UT WOS:000249411900010
PM 17631852
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Frennesson, CI
AF Frennesson, CI
TI Photodynamic therapy with verteporfin in patients with age-related
   macular degeneration and juxtafoveal choroidal neovascularization
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE photodynamic therapy; verteporfin; juxtafoveal choroidal
   neovascularization; age-related macular degeneration
ID RANDOMIZED CLINICAL-TRIAL; LASER PHOTOCOAGULATION; LESIONS
AB Purpose: To investigate the effects of photodynamic therapy (PDT) on juxtafoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in a clinical patient material.
   Methods: Thirty eyes in 30 consecutive patients with AMD and a juxtafoveal CNV underwent PDT with verteporfin with standard parameters. The patients were followed up for 12 months and retreated every 12 weeks in the event of leakage from CNV. Nineteen patients (63.3%) had a predominantly classic CNV, eight (26.7%) had a 100% occult CNV and three (10%) had a minimally classic lesion. In 27 patients (90%) the lesion was less than or equal to3 MPS (Macular Photocoagulation Study) disc diameters and less than or equal to3 MPS disc areas.
   Results: There was a positive correlation between duration of symptoms and loss of visual acuity at 12 months (p < 0.02). For predominantly classic lesions, there was a positive correlation between duration of symptoms and lesion size (p < 0.005). At 12 months, leakage had stopped after 3.3 +/- 0.9 treatments in 80% of the patients. Visual acuity remained stable in 63.3% of the patients.
   Conclusion: Photodynamic therapy appears to be beneficial in patients with AMD and juxtafoveal CNV.
C1 Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
C3 Linkoping University
RP Frennesson, CI (通讯作者)，Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
EM Christina.Frennesson@lio.se
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   *FRENN CI NILS SEG, 2004, ACTA OPHTHALMOL SCAN, V82
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   TAP and VIP Study Group, 2002, RETINA, V22, P6
NR 7
TC 6
Z9 6
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD DEC
PY 2004
VL 82
IS 6
BP 651
EP 655
DI 10.1111/j.1600-0420.2004.00382.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 884NT
UT WOS:000226093000004
PM 15606459
DA 2022-11-30
ER

PT J
AU Marmorstein, LHY
   Munier, FL
   Arsenijevic, Y
   Schorderet, DF
   McLaughlin, PJ
   Chung, D
   Traboulsi, E
   Marmorstein, AD
AF Marmorstein, LHY
   Munier, FL
   Arsenijevic, Y
   Schorderet, DF
   McLaughlin, PJ
   Chung, D
   Traboulsi, E
   Marmorstein, AD
TI Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia
   Leventinese and age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HONEYCOMB RETINAL DYSTROPHY; PROTEIN; MACULOPATHY; PREVALENCE; PRODUCT
AB Malattia Leventinese (ML), an inherited macular degenerative disease, is closely reminiscent of age-related macular degeneration (AMD), the most common cause of incurable blindness. Both ML and AMD are characterized by extracellular deposits known as drusen between the retinal pigment epithelium (RPE) and Bruch's membrane. The mechanism underlying drusen formation is unknown. An Arg to Trp mutation in a gene of unknown function, EFEMP1, is responsible for ML, indicating EFEMP1 may be important in drusen formation. Here, we show that wild-type EFEMP1 is a secreted protein whereas mutant EFEMP1 is misfolded, secreted inefficiently, and retained within cells. In normal eyes, EFEMP1 is not present at the site of drusen formation. However, in ML eyes, EFEMP1 accumulates within the RPE cells and between the RPE and drusen, but does not appear to be a major component of drusen. Furthermore, in AMD eyes, EFEMP1 is found to accumulate beneath the RPE immediately overlaying drusen, but not in the region where there is no apparent retinal pathology observed. These data present evidence that misfolding and aberrant accumulation of EFEMP1 may cause drusen formation and cellular degeneration and play an important role in the etiology of both ML and AMD.
C1 Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA.
   CHU Vaudois, Div Med Genet, CH-1004 Lausanne, Switzerland.
   CHU Vaudois, Hop Ophtalm Jules Gonin, Unite Oculogenet, CH-1004 Lausanne, Switzerland.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of
   Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of
   Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)
RP Marmorstein, LHY (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
RI Traboulsi, Elias/AAY-7443-2020
OI Arsenijevic, Yvan/0000-0001-6960-1291
FU NEI NIH HHS [EY13847, R56 EY013160, R01 EY013847, R01 EY013160] Funding
   Source: Medline; NATIONAL EYE INSTITUTE [R01EY013847] Funding Source:
   NIH RePORTER
CR Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Collins T., 1913, OPHTHALMOSCOPE, V11, P537
   Doyne R., 1899, T OPHTHAL SOC UK, V19, P71
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Evans K, 1997, ARCH OPHTHALMOL-CHIC, V115, P904, DOI 10.1001/archopht.1997.01100160074012
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3
   Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3
   GERBER D, 2002, IN PRESS INVEST OPHT
   Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985
   Giltay R, 1999, MATRIX BIOL, V18, P469, DOI 10.1016/S0945-053X(99)00038-4
   Ikegawa S, 1996, GENOMICS, V35, P590, DOI 10.1006/geno.1996.0402
   KLAINGUTI R, 1932, KLIN MONATSBL AUGENH, V89, P253
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P3248, DOI 10.1073/pnas.070049497
   Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869
   Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4
   Ozaki T, 1997, BIOCHEM BIOPH RES CO, V237, P245, DOI 10.1006/bbrc.1997.7122
   PIGUET B, 1995, EYE, V9, P34, DOI 10.1038/eye.1995.5
   Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VOGT A, 1925, HDB GESAMTEN AUGENHE, V3, P1
NR 26
TC 144
Z9 150
U1 0
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 1
PY 2002
VL 99
IS 20
BP 13067
EP 13072
DI 10.1073/pnas.202491599
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 600LK
UT WOS:000178391700103
PM 12242346
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ueda-Consolvo, T
   Hayashi, A
   Ozaki, M
   Nakamura, T
   Yagou, T
   Abe, S
AF Ueda-Consolvo, Tomoko
   Hayashi, Atsushi
   Ozaki, Mayumi
   Nakamura, Tomoko
   Yagou, Takaaki
   Abe, Shinya
TI The relationship between vascular endothelial dysfunction and treatment
   frequency in neovascular age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Endothelial dysfunction;
   Antivascular endothelial growth factor; Peripheral arterial tonometry;
   Reactive hyperemia index
ID RISK-FACTORS
AB To assess the correlation between endothelial dysfunction and frequency of antivascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (nAMD).
   We examined 64 consecutive patients with nAMD who were evaluated for endothelial function by use of peripheral arterial tonometry (EndoPAT 2000; Itamar Medical, Caesarea, Israel) at Toyama University Hospital from January 2015. We tallied the number of anti-VEGF treatments between January 2014 and December 2015 and determined the correlation between the number of anti-VEGF injections and endothelial function expressed as the reactive hyperemia index (RHI). Multiple regression analysis was also performed to identify the independent predictors of a larger number of injections.
   The mean number of anti-VEGF injections was 8.2 +/- 3.3. The mean lnRHI was 0.47 +/- 0.17. The lnRHI correlated with the number of anti-VEGF injections (r = -0.56; P = 0.030). The multiple regression analysis revealed that endothelial function, neovascular subtypes, and treatment regimens were associated with the number of injections.
   Endothelial dysfunction may affect the efficacy of anti-VEGF therapy. Neovascular subtypes may also predict a larger number of injections.
C1 [Ueda-Consolvo, Tomoko; Hayashi, Atsushi; Ozaki, Mayumi; Nakamura, Tomoko; Yagou, Takaaki; Abe, Shinya] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Ophthalmol, 2630 Sugitani, Toyama 9300194, Japan.
C3 University of Toyama
RP Ueda-Consolvo, T (通讯作者)，Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Ophthalmol, 2630 Sugitani, Toyama 9300194, Japan.
EM cutomoko@med.u-toyama.ac.jp
CR Akiyama E, 2012, J AM COLL CARDIOL, V60, P1778, DOI 10.1016/j.jacc.2012.07.036
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Hamburg N.M., 2006, MOL MECH ATHEROSCLER
   Hamburg NM, 2008, CIRCULATION, V117, P2467, DOI 10.1161/CIRCULATIONAHA.107.748574
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Nohria A, 2006, J APPL PHYSIOL, V101, P545, DOI 10.1152/japplphysiol.01285.2005
   Rubinshtein R, 2010, EUR HEART J, V31, P1142, DOI 10.1093/eurheartj/ehq010
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Widlansky ME, 2003, J AM COLL CARDIOL, V42, P1149, DOI 10.1016/S0735-1097(03)00994-X
NR 16
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2017
VL 61
IS 4
BP 347
EP 353
DI 10.1007/s10384-017-0515-z
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EZ4DU
UT WOS:000404663100007
PM 28447271
DA 2022-11-30
ER

PT J
AU Zafrilla, P
   Losada, M
   Perez, A
   Caravaca, G
   Mulero, J
AF Zafrilla, P.
   Losada, M.
   Perez, A.
   Caravaca, G.
   Mulero, J.
TI Biomarkers of oxidative stress in patients with wet age related macular
   degeneration
SO JOURNAL OF NUTRITION HEALTH & AGING
LA English
DT Article
DE Protein carbonyl groups; GSH/GSSH; age related macular degeneration
   (ARMD); antioxidant enzymes
ID ANTIOXIDANT ENZYME-ACTIVITIES; LIPID-PEROXIDATION; CHINESE PATIENTS;
   GLUTATHIONE; DAMAGE; ASSOCIATION; POPULATION; BLOOD
AB The aim of this study was to analyze biomarkers of oxidative stress in patients with wet age related macular degeneration (AMD).
   Case-control study that includes 163 patients with wet AMD (age group of 55-82 years with the mean age of 71 years and 170 age-matched healthy controls in the age group of 55-78 years with the mean age of 71 years. The following parameters were determined: reduced and oxidized Glutathione (GSH/GSSH), protein carbonyl groups, total antioxidant activity in plasma and the activity of endogenous antioxidant enzymes, such as, gluthatione peroxidase, gluthatione reductase and superoxide dismutase.
   We observed total antioxidant activity higher in control group (CG) compared with patients with wet AMD (7.1 +/- 1.2 mu M Trolox vs 5.8 +/- 1.1 mu M Trolox). Values of superoxide dismutase activity (SOD), gluthatione reductase (GR) and gluthatione peroxidase (GPx) are higher in control group than in patients with wet AMD. According to the GSH/GSSH results, average values were higher in the CG than in patients with wet AMD and data were not significantly different.. Values of protein carbonyl groups were higher in patients with wet AMD than in CG and significant differences were found.
   The finding of the present study suggests that the patients with wet AMD are an altered metabolic state of oxidation-reduction and that it is convenient to give therapeutic interventions with antioxidants. We have demonstrated that systematic oxidative stress, measured by different biomarkers is closely associated with the wet AMD.
C1 [Zafrilla, P.; Perez, A.; Caravaca, G.] Catholic Univ San Antonio, Dept Food Technol & Nutr, Murcia 30107, Spain.
C3 Universidad Catolica de Murcia
RP Zafrilla, P (通讯作者)，Catholic Univ San Antonio, Dept Food Technol & Nutr, Murcia 30107, Spain.
EM mpzafrilla@ucam.edu
RI Perez-Garrido, Alfonso/D-5762-2013; Zafrilla, Pilar/H-8132-2012
OI Perez-Garrido, Alfonso/0000-0002-3141-1086; Caravaca Lopez,
   Gabriel/0000-0002-6997-815X
FU Pfizer laboratory
FX The authors acknowledge the financial support of Pfizer laboratory
CR ANDERSON JW, 1983, PLANTA, V158, P442, DOI 10.1007/BF00397738
   Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1
   Babizhayev MA, 2009, CLIN INTERV AGING, V4, P31
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Brubaker RF, 2000, INVEST OPHTH VIS SCI, V41, P1681
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Davalos A, 2004, J AGR FOOD CHEM, V52, P48, DOI 10.1021/jf0305231
   Davies MJ, 1999, FREE RADICAL BIO MED, V27, P1151, DOI 10.1016/S0891-5849(99)00206-3
   DelmasBeauvieux MC, 1996, AM J CLIN NUTR, V64, P101, DOI 10.1093/ajcn/64.1.101
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Jia LH, 2011, AGING CLIN EXP RES, V23, P264, DOI 10.1007/BF03324965
   JULIUS M, 1994, J CLIN EPIDEMIOL, V47, P1021, DOI 10.1016/0895-4356(94)90117-1
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Likidlilid Atip, 2010, Journal of the Medical Association of Thailand, V93, P682
   Plagia DE, 1967, J LAB CLIN MED, V70, P158
   Popovici I, 1994, BIOCH ASPECTS J PREV, V12, P22
   PRASHAR S, 1993, ACTA OPHTHALMOL, V71, P214
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Serap Y, 2011, ACTA PHYSL S686, V203, P686
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Siess H, 1991, AM J MED, V91, P38
   Uno K, 2010, BIOMARK MED, V4, P361, DOI [10.2217/bmm.10.57, 10.2217/BMM.10.57]
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
NR 28
TC 17
Z9 17
U1 0
U2 12
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 1279-7707
J9 J NUTR HEALTH AGING
JI J. Nutr. Health Aging
PD MAR
PY 2013
VL 17
IS 3
BP 219
EP 222
DI 10.1007/s12603-012-0095-z
PG 4
WC Geriatrics & Gerontology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Nutrition & Dietetics
GA 105NC
UT WOS:000316077100004
PM 23459973
DA 2022-11-30
ER

PT J
AU Daien, V
   Finger, RP
   Talks, JS
   Mitchell, P
   Wong, TY
   Sakamoto, T
   Eldem, BM
   Korobelnik, JF
AF Daien, Vincent
   Finger, Robert P.
   Talks, James S.
   Mitchell, Paul
   Wong, Tien Y.
   Sakamoto, Taiji
   Eldem, Bora M.
   Korobelnik, Jean-Francois
TI Evolution of treatment paradigms in neovascular age-related macular
   degeneration: a review of real-world evidence
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Epidemiology; Macula; Neovascularisation; Retina; Vision
ID VISUAL-ACUITY OUTCOMES; GROWTH-FACTOR THERAPY; EXTEND INTRAVITREAL
   THERAPY; ANTI-VEGF TREATMENT; 2-YEAR OUTCOMES; CHOROIDAL
   NEOVASCULARIZATION; BASE-LINE; AFLIBERCEPT; RANIBIZUMAB; REGIMEN
AB The aim of this work was to evaluate the contribution of real-world evidence (RWE) in changing anti-vascular endothelial growth factor (VEGF) therapy treatment practices and improving real-world treatment strategies for neovascular age-related macular degeneration (nAMD). A PubMed literature search was performed to review the large number of English-language studies conducted to investigate the real-world effectiveness of anti-VEGF (aflibercept and ranibizumab) treatment paradigms available for nAMD. The evidence for pro re nata (PRN), treat-and-extend (T&E) and fixed bimonthly dosing regimens for anti-VEGF treatment of nAMD were reviewed and findings are summarised. RWE demonstrated that T&E regimens optimise visual outcomes while reducing burden on patients, clinics and physicians, compared with both fixed-dose and PRN regimens. RWE has helped to develop and improve real-world treatment strategies in nAMD, with the aim of optimising visual outcomes and reducing treatment burden in clinical practice. Of the various regimens, a T&E regimen is most likely to adequately balance clinical outcomes and treatment burden for patients with nAMD.
C1 [Daien, Vincent] Gui Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Talks, James S.] Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne, Tyne & Wear, England.
   [Mitchell, Paul] Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.
   [Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Y.] Duke NUS Med Sch, Singapore, Singapore.
   [Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima, Japan.
   [Eldem, Bora M.] Hacettepe Univ, Ophthalmol Dept, Fac Med, Ankara, Turkey.
   [Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, Talence, France.
C3 Universite de Montpellier; CHU de Montpellier; University of Sydney;
   University of Bonn; Newcastle University - UK; University of Sydney;
   Westmead Institute for Medical Research; National University of
   Singapore; Singapore National Eye Center; National University of
   Singapore; Kagoshima University; Hacettepe University; CHU Bordeaux;
   UDICE-French Research Universities; Universite de Bordeaux
RP Daien, V (通讯作者)，Gui Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
EM vincent.daien@gmail.com
RI Wong, Tien Yin/AAC-9724-2020; Daien, Vincent/Z-5516-2019
OI Wong, Tien Yin/0000-0002-8448-1264; Daien, Vincent/0000-0001-5675-0861;
   Sakamoto, Taiji/0000-0003-0287-3801; Talks, James/0000-0001-6126-6476
FU Bayer Consumer Health AG, Pharmaceuticals, Basel
FX Bayer Consumer Health AG, Pharmaceuticals, Basel organised the author
   meetings and provided funding for medical writing support. Medical
   writing and editorial support for the preparation of this manuscript
   (under the guidance of the authors) were provided by Katie McLaughlin
   (ApotheCom, UK). Katie McLaughlin has no conflict of interest to
   declare.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Aflibercept SmPC, AFL 40 MG ML INTR US
   Airody A, 2015, ACTA OPHTHALMOL, V93, pE511, DOI 10.1111/aos.12618
   Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Annemans L, REAL LIFE DATA GROWI
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Beykin G, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0019-x
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Castro-Navarro V, 2017, Arch Soc Esp Oftalmol, V92, P112, DOI 10.1016/j.oftal.2016.09.005
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Faure C., 2018, 9 C CONTR OPHTH EUR, DOI [10.1136/bmjophth-2017-000109, DOI 10.1136/BMJOPHTH-2017-000109]
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Framme C., 2017, EURETINA, DOI [10.1186/s12886-020-01468-z, DOI 10.1186/S12886-020-01468-Z]
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guo MY, 2018, PHARMACOTHERAPY, V38, P197, DOI 10.1002/phar.2079
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG., 2017, EURETINA, DOI [10.1097/IAE.0000000000002624, DOI 10.1097/IAE.0000000000002624]
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Ito A, 2017, OPHTHALMOLOGICA, V238, P236, DOI 10.1159/000479937
   Jacob J, 2017, INT J OPHTHALMOL-CHI, V10, P81, DOI 10.18240/ijo.2017.01.14
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mekjavic PJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00125
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Ohnaka M, 2017, GRAEF ARCH CLIN EXP, V255, P657, DOI 10.1007/s00417-016-3507-7
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Ozkaya Abdullah, 2017, Korean J Ophthalmol, V31, P424, DOI 10.3341/kjo.2016.0125
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Ranibizumab SmPC, RAN 10 MG ML INTR US
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Ricci F, 2016, EYE, V30, P1077, DOI 10.1038/eye.2016.95
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Sakamoto S, 2018, CLIN OPHTHALMOL, V12, P1137, DOI 10.2147/OPTH.S160961
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Souied E, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/j.1755-3768.2017.01111
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Szabo SM, 2015, CURR MED RES OPIN, V31, P2031, DOI 10.1185/03007995.2015.1084909
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Varano M, 2016, CLIN OPHTHALMOL, V10, P257, DOI 10.2147/OPTH.S92616
   Vardarinos A, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0451-1
   Vogel RN, 2017, RETINA-J RET VIT DIS, V37, P257, DOI 10.1097/IAE.0000000000001150
   Nguyen V, 2019, OPHTHALMOLOGY, V126, P64, DOI 10.1016/j.ophtha.2018.08.023
   Wagner SK, 2018, INVEST OPHTH VIS SCI, V59
   Warwick AN, 2016, INT J OPHTHALMOL-CHI, V9, P1156, DOI 10.18240/ijo.2016.08.12
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 83
TC 16
Z9 16
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2021
VL 105
IS 11
BP 1475
EP 1479
DI 10.1136/bjophthalmol-2020-317434
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WM4MV
UT WOS:000711061800003
PM 33130553
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Grewal, MK
   Chandra, S
   Bird, A
   Jeffery, G
   Sivaprasad, S
AF Grewal, Manjot Kaur
   Chandra, Shruti
   Bird, Alan
   Jeffery, Glen
   Sivaprasad, Sobha
TI Scotopic thresholds on dark-adapted chromatic perimetry in healthy aging
   and age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; PSYCHOPHYSICAL EVIDENCE; RETICULAR
   PSEUDODRUSEN; ROD SENSITIVITY; ADAPTATION; CLASSIFICATION;
   REPEATABILITY; VULNERABILITY; PREVALENCE
AB To evaluate the effect of aging, intra- and intersession repeatability and regional scotopic sensitivities in healthy and age-related macular degeneration (AMD) eyes. Intra- and intersession agreement and effect of age was measured in healthy individuals. The mean sensitivity (MS) and pointwise retinal sensitivities (PWS) within the central 24 degrees with 505 nm (cyan) and 625 nm (red) stimuli were evaluated in 50 individuals (11 healthy and 39 AMD eyes). The overall intra- and intersession had excellent reliability (intraclass correlation coefficient, ICC>0.90) and tests were highly correlated (Spearman r(s)=0.75-0.86). Eyes with subretinal drusenoid deposit (SDD) had reduced PWS centrally, particularly at inferior and nasal retinal locations compared with controls and intermediate AMD (iAMD) without SDD. There was no difference in MS or PWS at any retinal location between iAMD without SDD and healthy individuals nor between iAMD with SDD and non-foveal atrophic AMD groups. Eyes with SDD have reduced rod function compared to iAMD without SDD and healthy eyes, but similar to eyes with non-foveal atrophy. Our results highlight rod dysfunction is not directly correlated with drusen load and SDD location.
C1 [Grewal, Manjot Kaur; Chandra, Shruti; Bird, Alan; Jeffery, Glen; Sivaprasad, Sobha] UCL, Inst Ophthalmol, London EC1V 9EL, England.
   [Grewal, Manjot Kaur; Chandra, Shruti; Sivaprasad, Sobha] Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, London, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Sivaprasad, S (通讯作者)，UCL, Inst Ophthalmol, London EC1V 9EL, England.; Sivaprasad, S (通讯作者)，Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, London, England.
EM sobha.sivaprasad@nhs.net
OI Sivaprasad, Sobha/0000-0001-8952-0659
FU Fight for Sight [1905b]; NIHR Biomedical Research Centre at Moorfields
   Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology;
   NIHR Moorfields Clinical Research Facility
FX The research was funded by Fight for Sight (Ref 1905b) and supported by
   the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology and the NIHR
   Moorfields Clinical Research Facility. The views expressed are those of
   the author(s) and not necessarily those of the NHS, the NIHR or the
   Department of Health.
CR Arden GB., 1991, PRINCIPLES PRACTICE, P475
   Bennett LD, 2019, INVEST OPHTH VIS SCI, V60, P1122, DOI 10.1167/iovs.18-25473
   Bennett LD, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.15
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   Cozzi M, 2020, OPHTHALMOL RETINA, V4, P987, DOI 10.1016/j.oret.2020.04.013
   Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Grewal MK, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092832
   Hammond BR, 1998, OPTOMETRY VISION SCI, V75, P867, DOI 10.1097/00006324-199812000-00008
   Hecht S, 1935, J GEN PHYSIOL, V19, P321, DOI 10.1085/jgp.19.2.321
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Luu CD, 2018, OPHTHALMOL RETINA, V2, P1206, DOI 10.1016/j.oret.2018.06.016
   Nebbioso M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/671529
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   PULOS E, 1989, INVEST OPHTH VIS SCI, V30, P1738
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   Steinberg JS, 2015, OPHTHALMOLOGICA, V233, P35, DOI 10.1159/000368168
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sturr JF, 1997, VISION RES, V37, P475, DOI 10.1016/S0042-6989(96)00196-4
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Tan RS, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.3
   TIPTON DA, 1984, AVIAT SPACE ENVIR MD, V55, P145
   Uddin D, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.31
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
NR 38
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 14
PY 2021
VL 11
IS 1
AR 10349
DI 10.1038/s41598-021-89677-4
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SL5ME
UT WOS:000656961400002
PM 33990634
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Cheng, CY
   Yamashiro, K
   Chen, LJ
   Ahn, J
   Huang, LL
   Huang, LZ
   Cheung, CMG
   Miyake, M
   Cackett, PD
   Yeo, IY
   Laude, A
   Mathur, R
   Pang, JX
   Sim, KS
   Koh, AH
   Chen, P
   Lee, SY
   Wong, D
   Chan, CM
   Loh, BK
   Sun, YY
   Davila, S
   Nakata, I
   Nakanishi, H
   Akagi-Kurashige, Y
   Gotoh, N
   Tsujikawa, A
   Matsuda, F
   Mori, K
   Yoneya, S
   Sakurada, Y
   Iijima, H
   Iida, T
   Honda, S
   Lai, TYY
   Tam, POS
   Chen, H
   Tang, S
   Ding, XY
   Wen, F
   Lu, F
   Zhang, XZ
   Shi, Y
   Zhao, PQ
   Zhao, BW
   Sang, JH
   Gong, B
   Dorajoo, R
   Yuan, JM
   Koh, WP
   van Dam, RM
   Friedlander, Y
   Lin, Y
   Hibberd, ML
   Foo, JN
   Wang, NL
   Wong, CH
   Tan, GS
   Park, SJ
   Bhargava, M
   Gopal, L
   Naing, T
   Liao, JM
   Ong, PG
   Mitchell, P
   Zhou, P
   Xie, XF
   Liang, JL
   Mei, JP
   Jin, X
   Saw, SM
   Ozaki, M
   Mizoguchi, T
   Kurimoto, Y
   Woo, SJ
   Chung, H
   Yu, HG
   Shin, JY
   Park, DH
   Kim, IT
   Chang, W
   Sagong, M
   Lee, SJ
   Kim, HW
   Lee, JE
   Li, Y
   Liu, JJ
   Teo, YY
   Heng, CK
   Lim, TH
   Yang, SK
   Song, K
   Vithana, EN
   Aung, T
   Bei, JX
   Zeng, YX
   Tai, ES
   Li, XX
   Yang, ZL
   Park, KH
   Pang, CP
   Yoshimura, N
   Wong, TY
   Khor, CC
AF Cheng, Ching-Yu
   Yamashiro, Kenji
   Chen, Li Jia
   Ahn, Jeeyun
   Huang, Lulin
   Huang, Lvzhen
   Cheung, Chui Ming G.
   Miyake, Masahiro
   Cackett, Peter D.
   Yeo, Ian Y.
   Laude, Augustinus
   Mathur, Ranjana
   Pang, Junxiong
   Sim, Kar Seng
   Koh, Adrian H.
   Chen, Peng
   Lee, Shu Yen
   Wong, Doric
   Chan, Choi Mun
   Loh, Boon Kwang
   Sun, Yaoyao
   Davila, Sonia
   Nakata, Isao
   Nakanishi, Hideo
   Akagi-Kurashige, Yumiko
   Gotoh, Norimoto
   Tsujikawa, Akitaka
   Matsuda, Fumihiko
   Mori, Keisuke
   Yoneya, Shin
   Sakurada, Yoichi
   Iijima, Hiroyuki
   Iida, Tomohiro
   Honda, Shigeru
   Lai, Timothy Yuk Yau
   Tam, Pancy Oi Sin
   Chen, Haoyu
   Tang, Shibo
   Ding, Xiaoyan
   Wen, Feng
   Lu, Fang
   Zhang, Xiongze
   Shi, Yi
   Zhao, Peiquan
   Zhao, Bowen
   Sang, Jinghong
   Gong, Bo
   Dorajoo, Rajkumar
   Yuan, Jian-Min
   Koh, Woon-Puay
   van Dam, Rob M.
   Friedlander, Yechiel
   Lin, Ying
   Hibberd, Martin L.
   Foo, Jia Nee
   Wang, Ningli
   Wong, Chang Hua
   Tan, Gavin S.
   Park, Sang Jun
   Bhargava, Mayuri
   Gopal, Lingam
   Naing, Thet
   Liao, Jiemin
   Ong, Peng Guan
   Mitchell, Paul
   Zhou, Peng
   Xie, Xuefeng
   Liang, Jinlong
   Mei, Junpu
   Jin, Xin
   Saw, Seang-Mei
   Ozaki, Mineo
   Mizoguchi, Takanori
   Kurimoto, Yasuo
   Woo, Se Joon
   Chung, Hum
   Yu, Hyeong-Gon
   Shin, Joo Young
   Park, Dong Ho
   Kim, In Taek
   Chang, Woohyok
   Sagong, Min
   Lee, Sang-Joon
   Kim, Hyun Woong
   Lee, Ji Eun
   Li, Yi
   Liu, Jianjun
   Teo, Yik Ying
   Heng, Chew Kiat
   Lim, Tock Han
   Yang, Suk-Kyun
   Song, Kyuyoung
   Vithana, Eranga N.
   Aung, Tin
   Bei, Jin Xin
   Zeng, Yi Xin
   Tai, E. Shyong
   Li, Xiao Xin
   Yang, Zhenglin
   Park, Kyu-Hyung
   Pang, Chi Pui
   Yoshimura, Nagahisa
   Wong, Tien Yin
   Khor, Chiea Chuen
TI New loci and coding variants confer risk for age-related macular
   degeneration in East Asians
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; HIGH-DENSITY-LIPOPROTEIN; ESTER TRANSFER
   PROTEIN; COMMON VARIANTS; SUSCEPTIBILITY LOCUS; DISEASE; IDENTIFICATION;
   MUTATION; GENE; BEVACIZUMAB
AB Age- related macular degeneration ( AMD) is a major cause of blindness, but presents differently in Europeans and Asians. Here, we perform a genome- wide and exome- wide association study on 2,119 patients with exudative AMD and 5,691 controls, with independent replication in 4,226 patients and 10,289 controls, all of East Asian descent, as part of The Genetics of AMD in Asians ( GAMA) Consortium. We find a strong association between CETP Asp442Gly ( rs2303790), an East Asian- specific mutation, and increased risk of AMD ( odds ratio ( OR) 1.70, P 5.60 10 22). The AMD risk allele ( 442Gly), known to protect from coronary heart disease, increases HDL cholesterol levels by 0.17 mmol l 1 ( P 5.82 10 21) in East Asians ( n 7,102). We also identify three novel AMD loci: C6orf223 Ala231Ala ( OR 0.78, P 6.19 10 18), SLC44A4 Asp47Val ( OR 1.27, P 1.08 10 11) and FGD6 Gln257Arg ( OR 0.87, P 2.85 10 8). Our findings suggest that some of the genetic loci conferring AMD susceptibility in East Asians are shared with Europeans, yet AMD in East Asians may also have a distinct genetic signature.
C1 [Cheng, Ching-Yu; Cheung, Chui Ming G.; Liao, Jiemin; Ong, Peng Guan; Saw, Seang-Mei; Vithana, Eranga N.; Aung, Tin; Wong, Tien Yin; Khor, Chiea Chuen] Singapore Eye Res Inst, Singapore 169856, Singapore.
   [Cheng, Ching-Yu; Koh, Woon-Puay; Saw, Seang-Mei; Vithana, Eranga N.; Tai, E. Shyong; Wong, Tien Yin] Natl Univ Singapore, Duke NUS Grad Med Sch, Singapore 169857, Singapore.
   [Cheng, Ching-Yu; Davila, Sonia; Bhargava, Mayuri; Gopal, Lingam; Naing, Thet; Liao, Jiemin; Saw, Seang-Mei; Vithana, Eranga N.; Aung, Tin; Wong, Tien Yin] Natl Univ Singapore, Dept Ophthalmol, Singapore 119228, Singapore.
   [Cheng, Ching-Yu; Davila, Sonia; Bhargava, Mayuri; Gopal, Lingam; Naing, Thet; Liao, Jiemin; Saw, Seang-Mei; Vithana, Eranga N.; Aung, Tin; Wong, Tien Yin] Natl Univ Hlth Syst, Singapore 119228, Singapore.
   [Cheng, Ching-Yu; Cheung, Chui Ming G.; Cackett, Peter D.; Yeo, Ian Y.; Mathur, Ranjana; Lee, Shu Yen; Wong, Doric; Chan, Choi Mun; Loh, Boon Kwang; Aung, Tin; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Yamashiro, Kenji; Miyake, Masahiro; Nakata, Isao; Nakanishi, Hideo; Akagi-Kurashige, Yumiko; Gotoh, Norimoto; Tsujikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
   [Chen, Li Jia; Lai, Timothy Yuk Yau; Tam, Pancy Oi Sin; Chen, Haoyu; Li, Yi; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Ahn, Jeeyun] Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Dept Ophthalmol, Seoul 156707, South Korea.
   [Huang, Lulin; Lu, Fang; Gong, Bo; Yang, Zhenglin] China & Sichuan Prov Peoples Hosp, Hosp Univ Elect Sci & Technol, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu 610072, Peoples R China.
   [Huang, Lulin; Lu, Fang; Shi, Yi; Gong, Bo; Yang, Zhenglin] Univ Elect Sci & Technol China, Sch Med, Chengdu 610072, Peoples R China.
   [Huang, Lvzhen; Sun, Yaoyao; Li, Xiao Xin] Minist Educ China, Key Lab Vis Loss & Restorat, Beijing 100044, Peoples R China.
   [Huang, Lvzhen; Sun, Yaoyao; Li, Xiao Xin] Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing 100871, Peoples R China.
   [Huang, Lvzhen; Sun, Yaoyao; Li, Xiao Xin] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100871, Peoples R China.
   [Miyake, Masahiro; Nakata, Isao; Akagi-Kurashige, Yumiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Inserm U852, Kyoto 6068507, Japan.
   [Cackett, Peter D.] Princess Alexandra Eye Pavil, Edinburgh EH3 9HA, Midlothian, Scotland.
   [Laude, Augustinus] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.
   [Pang, Junxiong; Sim, Kar Seng; Davila, Sonia; Dorajoo, Rajkumar; Hibberd, Martin L.; Foo, Jia Nee; Wong, Chang Hua; Li, Yi; Liu, Jianjun; Teo, Yik Ying; Khor, Chiea Chuen] Genome Inst Singapore, Div Human Genet, Singapore 138672, Singapore.
   [Koh, Adrian H.] Camden Med Ctr, Singapore 248649, Singapore.
   [Chen, Peng; Koh, Woon-Puay; van Dam, Rob M.; Saw, Seang-Mei; Tai, E. Shyong; Khor, Chiea Chuen] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117549, Singapore.
   [Chen, Peng; Koh, Woon-Puay; van Dam, Rob M.; Liu, Jianjun; Teo, Yik Ying; Tai, E. Shyong; Khor, Chiea Chuen] Natl Univ Hlth Syst, Singapore 117549, Singapore.
   [Mori, Keisuke; Yoneya, Shin] Saitama Med Univ, Dept Ophthalmol, Iruma, Saitama 3500495, Japan.
   [Sakurada, Yoichi; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Yamanashi 4093898, Japan.
   [Iida, Tomohiro] TokyoWomens Med Univ Hosp, Dept Ophthalmol, Tokyo 1628666, Japan.
   [Honda, Shigeru] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 6500017, Japan.
   [Chen, Haoyu] Shantou Univ, Chinese Univ Hong Kong, Joint Shantou Int Eye Ctr, Shantou 515041, Peoples R China.
   [Tang, Shibo; Ding, Xiaoyan; Wen, Feng; Zhang, Xiongze] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
   [Tang, Shibo] Cent South Univ, Aier Sch Ophthalmol, Changsha 410000, Peoples R China.
   [Zhao, Peiquan] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp Affiliated, Dept Ophthalmol, Shanghai 200025, Peoples R China.
   [Zhao, Bowen; Sang, Jinghong; Wang, Ningli] Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.
   [Yuan, Jian-Min] Univ Pittsburgh, Inst Canc, Canc Control & Populat Sci, Pittsburgh, PA 15260 USA.
   [Yuan, Jian-Min] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
   [Friedlander, Yechiel] Hebrew Univ Jerusalem, Sch Publ Hlth, IL-91120 Jerusalem, Israel.
   [Park, Sang Jun; Woo, Se Joon; Park, Kyu-Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Gyeonggi 463707, South Korea.
   [Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Sydney, NSW 2145, Australia.
   [Mitchell, Paul] Westmead Millennium Inst, Sydney, NSW 2145, Australia.
   [Zhou, Peng] Fudan Univ, Eye & ENT Hosp, Shanghai 200433, Peoples R China.
   [Xie, Xuefeng; Liang, Jinlong; Mei, Junpu; Jin, Xin] BGI Shenzhen, Shenzhen 518083, Peoples R China.
   [Ozaki, Mineo] Ozaki Eye Hosp, Miyazaki 8830066, Japan.
   [Mizoguchi, Takanori] Mizoguchi Eye Hosp, Nagasaki 8570016, Japan.
   [Kurimoto, Yasuo] Kobe City Gen Hosp, Dept Ophthalmol, Kobe, Hyogo 6500046, Japan.
   [Woo, Se Joon; Chung, Hum; Yu, Hyeong-Gon; Shin, Joo Young] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul Natl Univ Hosp, Seoul 110744, South Korea.
   [Park, Dong Ho; Kim, In Taek] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu 700721, South Korea.
   [Chang, Woohyok; Sagong, Min] Yeungnam Univ, Coll Med, Dept Ophthalmol, Daegu 705802, South Korea.
   [Lee, Sang-Joon] Kosin Univ, Coll Med, Dept Ophthalmol, Pusan 606701, South Korea.
   [Kim, Hyun Woong] Inje Univ, Coll Med, Pusan Paik Hosp, Dept Ophthalmol, Pusan 614735, South Korea.
   [Lee, Ji Eun] Pusan Natl Univ Hosp, Dept Ophthalmol, Pusan 602739, South Korea.
   [Lee, Ji Eun] Pusan Natl Univ, Med Res Inst, Pusan 602739, South Korea.
   [Heng, Chew Kiat] Natl Univ Hlth Syst, Dept Pediat, Singapore 119228, Singapore.
   [Heng, Chew Kiat] Natl Univ Singapore, Singapore 119228, Singapore.
   [Yang, Suk-Kyun] Asan Med Ctr, Dept Gastroenterol, Seoul 138736, South Korea.
   [Yang, Suk-Kyun] Univ Ulsan, Coll Med, Seoul 138736, South Korea.
   [Song, Kyuyoung] Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea.
   [Bei, Jin Xin; Zeng, Yi Xin] State Key Lab Oncol Southern China, Guangzhou 510060, Guangdong, Peoples R China.
   [Bei, Jin Xin; Zeng, Yi Xin] Sun Yat Sen Univ, Ctr Canc, Dept Expt Res, Guangzhou 510080, Guangdong, Peoples R China.
   [Zeng, Yi Xin] Chinese Acad Med Sci, Peking Union Med Coll, Beijing 100730, Peoples R China.
   [Tai, E. Shyong] Natl Univ Hlth Syst, Dept Med, Singapore 119228, Singapore.
   [Tai, E. Shyong] Natl Univ Singapore, Singapore 119228, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   National University of Singapore; Singapore National Eye Center; Kyoto
   University; Chinese University of Hong Kong; Seoul National University
   (SNU); Seoul National University Hospital; Sichuan Provincial People's
   Hospital; University of Electronic Science & Technology of China;
   University of Electronic Science & Technology of China; Ministry of
   Education, China; Peking University; Kyoto University; Tan Tock Seng
   Hospital; Agency for Science Technology & Research (A*STAR); A*STAR -
   Genome Institute of Singapore (GIS); National University of Singapore;
   National University of Singapore; Saitama Medical University; University
   of Yamanashi; Kobe University; Shantou University; Sun Yat Sen
   University; Central South University; Shanghai Jiao Tong University;
   Capital Medical University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh; Hebrew
   University of Jerusalem; Seoul National University (SNU); University of
   Sydney; University of Sydney; Westmead Institute for Medical Research;
   Fudan University; Beijing Genomics Institute (BGI); Kobe City Medical
   Center General Hospital; Seoul National University (SNU); Seoul National
   University Hospital; Kyungpook National University; Yeungnam University;
   Inje University; Pusan National University; Pusan National University
   Hospital; Pusan National University; National University of Singapore;
   National University of Singapore; University of Ulsan; Asan Medical
   Center; University of Ulsan; University of Ulsan; State Key Lab Oncology
   South China; Sun Yat Sen University; Chinese Academy of Medical Sciences
   - Peking Union Medical College; Peking Union Medical College; National
   University of Singapore; National University of Singapore
RP Cheng, CY (通讯作者)，Singapore Eye Res Inst, Singapore 169856, Singapore.
EM chingyu.cheng@duke-nus.edu.sg; wong.tien.yin@snec.com.sg;
   khorcc@gis.a-star.edu.sg
RI Bei, Jin-Xin/AAO-1259-2020; van Dam, Rob M/F-9674-2010; Miyake,
   Masahiro/V-1261-2019; Liu, Jianjun/AAK-4989-2020; Chen,
   Peng/E-5546-2015; Pang, Junxiong/AAI-5115-2021; Chen, Li
   Jia/I-5078-2014; Jin, Xin/ABF-1329-2020; Foo, Jia Nee/D-6069-2014;
   Mitchell, Paul/P-1498-2014; Lai, Timothy Y Y/AAC-2120-2020; Wong, Tien
   Yin/AAC-9724-2020; Chen, Haoyu/A-7432-2013; Chu, Kai On/E-2325-2016;
   KOSUGI, Shinji/GYR-2946-2022; Heng, Chew-Kiat/A-5530-2009; Cheng,
   Ching-Yu/Y-2229-2019; Honda, Shigeru/W-4761-2019; Lee, Sang
   Joon/AAG-2448-2019
OI van Dam, Rob M/0000-0002-7354-8734; Miyake,
   Masahiro/0000-0001-7410-3764; Liu, Jianjun/0000-0002-3255-3019; Chen,
   Peng/0000-0002-1422-4641; Chen, Li Jia/0000-0003-3500-5840; Jin,
   Xin/0000-0001-7554-4975; Foo, Jia Nee/0000-0001-9899-2308; Lai, Timothy
   Y Y/0000-0002-7832-6428; Wong, Tien Yin/0000-0002-8448-1264; Chen,
   Haoyu/0000-0003-0676-4610; Heng, Chew-Kiat/0000-0002-7309-9473; Cheng,
   Ching-Yu/0000-0003-0655-885X; Yu, Hyeong Gon/0000-0002-1795-202X;
   Yamashiro, Kenji/0000-0001-9354-8558; Hibberd,
   Martin/0000-0001-8587-1849; Cheung, Chui Ming Gemmy/0000-0003-3358-3516;
   Sim, Kar Seng/0000-0002-3822-7759; Ahn, Jeeyun/0000-0001-9017-1652;
   Dorajoo, Rajkumar/0000-0001-6608-2051; Khor, Chiea
   Chuen/0000-0002-1128-4729; Tsujikawa, Akitaka/0000-0003-0779-7799; Tai,
   E Shyong/0000-0003-2929-8966; Pang, Junxiong,
   Vincent/0000-0002-9788-701X; Wong, Damon/0000-0003-4601-9121
FU NCI NIH HHS [R35 CA053890, R01 CA144034, R01 CA80205, R01 CA080205, R01
   CA055069] Funding Source: Medline; NATIONAL CANCER INSTITUTE
   [R01CA080205, R35CA053890, R01CA055069, R01CA144034] Funding Source: NIH
   RePORTER
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Barter PJ, 2003, ARTERIOSCL THROM VAS, V23, P160, DOI 10.1161/01.ATV.0000054658.91146.64
   Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Flanagan SE, 2010, GENET TEST MOL BIOMA, V14, P533, DOI 10.1089/gtmb.2010.0036
   Freeman DJ, 2003, EUR HEART J, V24, P1833, DOI 10.1016/j.ehj.2003.07.001
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grundy SM, 2002, CIRCULATION, V106, P2526, DOI 10.1161/01.CIR.0000038419.53000.D6
   Hankin JH, 2001, NUTR CANCER, V39, P187, DOI 10.1207/S15327914nc392_5
   Hara R, 2010, GRAEF ARCH CLIN EXP, V248, P931, DOI 10.1007/s00417-010-1343-8
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Howard BV, 2000, ARTERIOSCL THROM VAS, V20, P830, DOI 10.1161/01.ATV.20.3.830
   Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Huyghe JR, 2013, NAT GENET, V45, P197, DOI 10.1038/ng.2507
   INAZU A, 1994, J CLIN INVEST, V94, P1872, DOI 10.1172/JCI117537
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Kathiresan S, 2008, NAT GENET, V40, P189, DOI 10.1038/ng.75
   Khor CC, 2011, NAT GENET, V43, P1241, DOI 10.1038/ng.981
   Kumar V, 2011, NAT GENET, V43, P455, DOI 10.1038/ng.809
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Lee S, 2012, BIOSTATISTICS, V13, P762, DOI 10.1093/biostatistics/kxs014
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509
   O'Regan S, 2000, P NATL ACAD SCI USA, V97, P1835, DOI 10.1073/pnas.030339697
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Sabanayagam C, 2009, J HYPERTENS, V27, P2209, DOI 10.1097/HJH.0b013e328330141d
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Su Z, 2012, NAT GENET, V44, P1131, DOI 10.1038/ng.2408
   TAKAHASHI K, 1993, J CLIN INVEST, V92, P2060, DOI 10.1172/JCI116802
   Takeuchi F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046385
   Uhl J, 2002, FEBS LETT, V521, P19, DOI 10.1016/S0014-5793(02)02748-5
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Vithana EN, 2012, NAT GENET, V44, P1142, DOI 10.1038/ng.2390
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 51
TC 116
Z9 118
U1 3
U2 38
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2015
VL 6
AR 6063
DI 10.1038/ncomms7063
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CA3TT
UT WOS:000348830300010
PM 25629512
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Cho, M
   Athanikar, A
   Paccione, J
   Wald, KJ
AF Cho, Minhee
   Athanikar, Aditya
   Paccione, Jeffrey
   Wald, Kenneth J.
TI Optical coherence tomography features of acute central serous
   chorioretinopathy versus neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; FOVEAL PHOTORECEPTOR LAYER; ANGIOGRAPHY;
   OLDER
AB Objective To compare the optical coherence tomography (OCT) features of acute central serous chorioretinopathy (CSC) versus neovascular age-related macular degeneration (AMD), and to determine if OCT features can distinguish between these two entities.
   Methods A retrospective, observational study of 50 eyes with CSC and 50 eyes with neovascular AMD. Stratus OCT line scans (5 mm) were reviewed for presence of subretinal/intraretinal fluid and retinal pigment epithelium detachment. The height of the fluid and detachments were measured using the OCT manual callipers, and the morphology of the highly reflective line was described.
   Results Intraretinal fluid (IRF), pigment epithelial detachment (PED), irregularities, thickening and attenuation of the highly reflective line were more often associated with AMD. When present, the PED was significantly greater in AMD than CSC. Patients with CSC were more likely to have subretinal fluid (SRF), and when present, the SRF height was significantly greater in CSC. Patients CSC also had more hypertrophic outer retinal changes on OCT compared with AMD.
   Conclusion Neovascular AMD and acute CSC have distinguishing features on OCT that may help clinicians to differentiate accurately between the two conditions primarily using OCT.
C1 [Athanikar, Aditya; Paccione, Jeffrey; Wald, Kenneth J.] Retina Associates New York, New York, NY 10021 USA.
   [Cho, Minhee] NYU, Dept Ophthalmol, Sch Med, Manhattan Eye Ear & Throat Hosp, New York, NY 10016 USA.
C3 Manhattan Eye Ear & Throat Hospital; New York University
RP Wald, KJ (通讯作者)，Retina Associates New York, 140 E 80th St, New York, NY 10021 USA.
EM kwaldmd@aol.com
CR Ahlers C, 2006, GRAEF ARCH CLIN EXP, V244, P1233, DOI 10.1007/s00417-006-0418-z
   HEE MR, 1995, AM J OPHTHALMOL, V120, P65, DOI 10.1016/S0002-9394(14)73760-2
   Hirami Y, 2007, CLIN EXP OPHTHALMOL, V35, P225, DOI 10.1111/j.1442-9071.2006.01447.x
   Hussain Deeba, 1998, Indian Journal of Ophthalmology, V46, P131
   Iida T, 2003, RETINA-J RET VIT DIS, V23, P1, DOI 10.1097/00006982-200302000-00001
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Mitarai K, 2006, GRAEF ARCH CLIN EXP, V244, P1415, DOI 10.1007/s00417-006-0277-7
   Montero JA, 2005, BRIT J OPHTHALMOL, V89, P562, DOI 10.1136/bjo.2004.049403
   Ojima Y, 2007, OPHTHALMOLOGY, V114, P2197, DOI 10.1016/j.ophtha.2007.02.015
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Pons ME, 2005, OPHTHALMOLOGY, V112, P1079, DOI 10.1016/j.ophtha.2004.11.061
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   SCHATZ H, 1992, OPHTHALMOLOGY, V99, P63
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Wang M, 2005, ACTA OPHTHALMOL SCAN, V83, P691, DOI 10.1111/j.1600-0420.2005.00582.x
NR 15
TC 13
Z9 13
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2010
VL 94
IS 5
BP 597
EP 599
DI 10.1136/bjo.2008.149724
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 592JH
UT WOS:000277374500015
PM 19822922
DA 2022-11-30
ER

PT J
AU Mullins, RF
   Faidley, EA
   Daggett, HT
   Jomary, C
   Lotery, AJ
   Stone, EM
AF Mullins, Robert F.
   Faidley, Elizabeth A.
   Daggett, Heather T.
   Jomary, Catherine
   Lotery, Andrew J.
   Stone, Edwin M.
TI Localization of complement 1 inhibitor (C1INH/SERPING1) in human eyes
   with age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE macular degeneration; RPE; choroid; retina; complement
ID FACTOR-H POLYMORPHISM; PROTEIN C1 INHIBITOR; CHOROIDAL
   NEOVASCULARIZATION; LEUKOCYTE ADHESION; DRUSEN FORMATION; SERPING1 GENE;
   OCULAR DRUSEN; ACTIVATION; DISEASE; RETINA
AB Age-related macular degeneration (AMD) is a common degenerative disease resulting in injury to the retina, retinal pigment epithelium and choriocapillaris. Recent data from histopathology, animal models and genetic studies have implicated altered regulation of the complement system as a major factor in the incidence and progression of this disease. A variant in the gene SERPING1, which encodes C1INH, an inhibitor of the classical and lectin pathways of complement activation, was recently shown to be associated with AMD. In this study we sought to determine the localization of C1INH in human donor eyes. Immuno fluorescence studies using a monoclonal antibody directed against ClINH revealed localization to photoreceptor cells, inner nuclear layer neurons, choriocapillaris, and choroidal extracellular matrix. Drusen did not exhibit labeling. Genotype at rs2511989 did not appear to affect C1INH abundance or localization, nor was it associated with significant molecular weight differences when evaluated by Western blot. In a small number of eyes (n = 7 AMD and n = 7 control) AMD affection status was correlated with increased abundance of choroidal ClINH. These results indicate that ClINH protein is present in the retina and choroid, where it may regulate complement activation. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Mullins, Robert F.; Faidley, Elizabeth A.; Daggett, Heather T.; Stone, Edwin M.] Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Family Ctr Macular Degenerat, Iowa City, IA 52242 USA.
   [Jomary, Catherine; Lotery, Andrew J.] Univ Southampton, Clin Neurosci Div, Southampton SO9 5NH, Hants, England.
   [Stone, Edwin M.] Howard Hughes Med Inst, Chevy Chase, MD USA.
C3 University of Iowa; University of Southampton; Howard Hughes Medical
   Institute
RP Mullins, RF (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Family Ctr Macular Degenerat, 4135E MERF,375 Newton Rd, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Jomary, Catherine/A-2854-2011; Mullins, Robert F/I-6717-2013
OI Lotery, Andrew/0000-0001-5541-4305; Mullins, Robert/0000-0002-5006-0891;
   Stone, Edwin M./0000-0003-3343-4414
FU NIH [EY-017451, EY-016822]; Macula Vision Research Foundation; American
   Health Assistance Foundation; Foundation Fighting Blindness; National
   Institute for Health Research [NF-SI-0507-10094] Funding Source:
   researchfish; NATIONAL EYE INSTITUTE [R01EY016822, R01EY017451] Funding
   Source: NIH RePORTER
FX Supported in part by NIH grants EY-017451 (RFM), EY-016822 (EMS), the
   Macula Vision Research Foundation (RFM and AJL), American Health
   Assistance Foundation (AJL) and a center grant from the Foundation
   Fighting Blindness. EMS is an investigator in the Howard Hughes Medical
   Institute. The authors gratefully acknowledge the Iowa Lions Eye Bank
   and the eye donors and their families.
CR BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Cai SH, 2005, J IMMUNOL, V174, P6462, DOI 10.4049/jimmunol.174.10.6462
   Cai SH, 2003, J IMMUNOL, V171, P4786, DOI 10.4049/jimmunol.171.9.4786
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Ferguson TA, 2008, SEMIN IMMUNOPATHOL, V30, P111, DOI 10.1007/s00281-008-0113-8
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerl VB, 2002, INVEST OPHTH VIS SCI, V43, P1104
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kralovicova J, 2009, LANCET, V373, P461, DOI 10.1016/S0140-6736(09)60168-9
   Kuehn MH, 2008, EXP EYE RES, V87, P89, DOI 10.1016/j.exer.2008.04.012
   Kuehn MH, 2006, EXP EYE RES, V83, P620, DOI 10.1016/j.exer.2006.03.002
   Liu DX, 2004, INFECT IMMUN, V72, P1946, DOI 10.1128/IAI.72.4.1946-1955.2004
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Ma JX, 1996, EXP EYE RES, V63, P19, DOI 10.1006/exer.1996.0087
   MULLINS R, 2003, INVEST OPHTHALMOL VI, V44
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RF, 2005, MOL VIS, V11, P509
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 1997, DEGENERATIVE RETINAL DISEASES, P1
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Park KH, 2009, MOL VIS, V15, P200
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Phipps JA, 2009, HYPERTENSION, V53, P175, DOI 10.1161/HYPERTENSIONAHA.108.117663
   ROHRER B, 2009, INVEST OPHTHALMOL VI
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   SKEIE J, 2008, EYE
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vazquez-Chona F, 2004, INVEST OPHTH VIS SCI, V45, P2737, DOI 10.1167/iovs.03-1047
   Wagenaar-Bos IGA, 2006, IMMUNOL ALLERGY CLIN, V26, P615, DOI 10.1016/j.iac.2006.08.004
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang HM, 2007, BIOCHEM BIOPH RES CO, V358, P1120, DOI 10.1016/j.bbrc.2007.05.058
NR 45
TC 19
Z9 20
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2009
VL 89
IS 5
BP 767
EP 773
DI 10.1016/j.exer.2009.07.001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 507KA
UT WOS:000270850800020
PM 19607829
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ranjan, R
   Kayastha, AM
   Sinha, N
AF Ranjan, Renuka
   Kayastha, Arvind M.
   Sinha, Neeraj
TI Interactions Between Amyloid-beta (1-42) and Hydroxyapatite-Cholesterol
   Spherules Associated with Age-Related Macular Degeneration
SO PROTEIN JOURNAL
LA English
DT Article
DE Amyloid; NMR; TEM; Thioflavin-T; Drusen
ID AGGREGATION; INSIGHT; EYE
AB Drusen deposition on sub-retinal pigment epithelium is the causal factor for age-related macular degeneration for the old-aged individuals. These deposits contain hydroxyapatite-cholesterol spherules on which several proteins and lipids accumulate to cover the retina and choroid, causing blurred vision and blindness. Amyloid-beta, the known culprit in Alzheimer's disease, is one among the few major proteins known to occur in these deposits. In the present article, we report preliminary analyses of interactions between amyloid-beta and hydroxyapatite-cholesterol composites using Thioflavin-T binding kinetics, solid-state NMR and transmission electron microscopy (TEM). Thioflavin-T fluorescence kinetics shows that amyloid-beta (1-42) aggregates only under certain conditions of concentration of cholesterol in the hydroxyapatite-cholesterol composites prepared by two different methods. These results were confirmed by 1D C-13 CPMAS solid-state NMR. TEM imaging revealed that there is an exposure of the cholesterol surface in the composites prepared by sonication method. These imaging experiments explain the dependence of aggregation kinetics on the exposure and availability of cholesterol surface in the composites to a certain extent.
   [GRAPHICS]
   .
C1 [Ranjan, Renuka; Sinha, Neeraj] SGPGIMS Campus, Ctr Biomed Res, Raebareily Rd, Lucknow 226014, Uttar Pradesh, India.
   [Ranjan, Renuka; Kayastha, Arvind M.] Banaras Hindu Univ, Inst Sci, Sch Biotechnol, Varanasi 221005, Uttar Pradesh, India.
C3 Banaras Hindu University (BHU)
RP Sinha, N (通讯作者)，SGPGIMS Campus, Ctr Biomed Res, Raebareily Rd, Lucknow 226014, Uttar Pradesh, India.; Kayastha, AM (通讯作者)，Banaras Hindu Univ, Inst Sci, Sch Biotechnol, Varanasi 221005, Uttar Pradesh, India.
EM kayasthabhu@gmail.com; neeraj.sinha@cbmr.res.in
RI RANJAN, RENUKA/GPC-5766-2022
OI Kayastha, Arvind M./0000-0002-5090-7159
FU Council of Scientific and Industrial Research, New Delhi, India
   [09/916(0085)/2015-EMR-I]; SERB India [EMR/2015/001758]
FX RR acknowledges Senior Research Fellowship from the Council of
   Scientific and Industrial Research, New Delhi, India, for funding (File
   no. 09/916(0085)/2015-EMR-I. NS acknowledges financial assistance from
   SERB India (Grant No. EMR/2015/001758). We thank Prof. Swasti Tiwari,
   Department of Molecular Medicine, SGPGIMS, Lucknow for providing
   fluorescence spectrometer facilities. We acknowledge Jaideep Saha and
   Vandana Jaiswal for assistance in the preparation of cholesterol
   micelles at CBMR. We thank Advanced Imaging Centre, IIT Kanpur, for TEM
   Imaging. RR and NS acknowledge useful discussions with Prof. Imre
   Lengyel (Queen's University, Belfast).
CR Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Chen GF, 2017, ACTA PHARMACOL SIN, V38, P1205, DOI 10.1038/aps.2017.28
   Colvin MT, 2015, J AM CHEM SOC, V137, P7509, DOI 10.1021/jacs.5b03997
   Ha C, 2007, BIOCHEMISTRY-US, V46, P6118, DOI 10.1021/bi7000032
   Habchi J, 2018, NAT CHEM, V10, P673, DOI 10.1038/s41557-018-0031-x
   Hoarau M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161209
   Isaacs AM, 2006, J BIOL CHEM, V281, P27916, DOI 10.1074/jbc.M602061200
   Itkin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018250
   Lengyel, 2017, US PATENT, V9, P801
   Ranjan R, 2020, BIOPHYS CHEM, V265, DOI 10.1016/j.bpc.2020.106430
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Sadigh-Eteghad S, 2015, MED PRIN PRACT, V24, P1, DOI 10.1159/000369101
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Song JX, 2009, FEBS LETT, V583, P953, DOI 10.1016/j.febslet.2009.02.022
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Teplow DB, 2006, METHOD ENZYMOL, V413, P20, DOI 10.1016/S0076-6879(06)13002-5
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tougu V, 2011, METALLOMICS, V3, P250, DOI 10.1039/c0mt00073f
   Trimpin S, 2009, BIOTECHNIQUES, V46, P409, DOI [10.2144/000113135, 10.2144/000113168]
   Vestergaard M, 2010, CURR ALZHEIMER RES, V7, P262, DOI 10.2174/156720510791050821
   Villar-Pique A, 2015, METHODS MOL BIOL, V1258, P99, DOI 10.1007/978-1-4939-2205-5_6
   Walsh DM, 2009, FEBS J, V276, P1266, DOI 10.1111/j.1742-4658.2008.06862.x
   Xue C, 2017, ROY SOC OPEN SCI, V4, DOI 10.1098/rsos.160696
NR 23
TC 0
Z9 0
U1 3
U2 16
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1572-3887
EI 1573-4943
J9 PROTEIN J
JI Protein J.
PD DEC
PY 2021
VL 40
IS 6
BP 849
EP 856
DI 10.1007/s10930-021-10026-5
EA OCT 2021
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA WX8XE
UT WOS:000713072100001
PM 34718942
DA 2022-11-30
ER

PT J
AU Menke, MN
   Salam, A
   Framme, C
   Wolf, S
AF Menke, Marcel N.
   Salam, Adzura
   Framme, Carsten
   Wolf, Sebastian
TI Long-Term Intraocular Pressure Changes in Patients with Neovascular
   Age-Related Macular Degeneration Treated with Ranibizumab
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Intraocular pressure; Ranibizumab;
   Anti-vascular endothelial growth factor
ID GROWTH-FACTOR THERAPY; INTRAVITREAL INJECTION; BEVACIZUMAB; LUCENTIS;
   VERTEPORFIN; GLAUCOMA
AB Background/Aims: To investigate the long-term effects of multiple intravitrea I injections (IVTs) of ranibizumab (Lucentis) on intraocular pressure (IOP) in patients with neovascular age-related macular degeneration. Methods: In 320 eyes, IOP measurements were performed at baseline prior to injection and compared with IOP measurements of the last visit. Correlations between mean IOP change and total number of IVTs, visual acuity or patient age were tested. Results: The mean IOP increase was 0.8 +/- 3.1 mm Hg (p < 0.0001). Seven eyes showed final IOP values between 22 and 25 mm Hg. The mean follow-up was 22.7 +/- 14.1 months. No further correlations between IOP change and number of IVTs, visual acuity or patient age have been found. Conclusions: This study demonstrated a statistically significant IOP increase in patients treated with repeated injections of ranibizumab. However, IOP increase required no glaucoma treatment during the study. Therefore, repeated injections with ranibizumab can be considered safe with regard to long-term IOP changes in patients without ocular hypertension or glaucoma. Copyright (C) 2013 S. Karger AG, Basel
C1 [Menke, Marcel N.; Framme, Carsten; Wolf, Sebastian] Univ Hosp Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
   [Menke, Marcel N.; Framme, Carsten; Wolf, Sebastian] Univ Bern, Bern, Switzerland.
   [Salam, Adzura] Int Islam Univ Malaysia, Dept Ophthalmol, Pahang, Malaysia.
C3 University of Bern; University Hospital of Bern; University of Bern;
   International Islamic University Malaysia
RP Menke, MN (通讯作者)，Inselspital Bern, Dept Ophthalmol, CH-3010 Bern, Switzerland.
EM marcel.menke@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Menke, Marcel/0000-0002-6561-6178
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   [Anonymous], 2010, PROD MON LUC AMD
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bolz M, 2008, 8 EURETINA C VIENN M
   Bonomi L, 1998, OPHTHALMOLOGY, V105, P209, DOI 10.1016/S0161-6420(98)92665-3
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Jalil A, 2007, EYE, V21, P1541, DOI 10.1038/sj.eye.6703018
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   KLEIN BEK, 1992, INVEST OPHTH VIS SCI, V33, P2224
   Knecht PB, 2009, RETINA-J RET VIT DIS, V29, P1175, DOI 10.1097/IAE.0b013e3181aade74
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rochtchina E, 2002, CLIN EXP OPHTHALMOL, V30, P173, DOI 10.1046/j.1442-9071.2002.00519.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Wu SY, 1997, ARCH OPHTHALMOL-CHIC, V115, P1572, DOI 10.1001/archopht.1997.01100160742012
NR 31
TC 18
Z9 22
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 229
IS 3
BP 168
EP 172
DI 10.1159/000346397
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 126RT
UT WOS:000317639600007
PM 23548723
DA 2022-11-30
ER

PT J
AU Dag, E
   Otrnek, N
   Ornek, K
   Gunay, F
   Turkel, Y
AF Dag, E.
   Otrnek, N.
   Ornek, K.
   Gunay, F.
   Turkel, Y.
TI Mini mental state exam versus Montreal cognitive assessment in patients
   with age-related macular degeneration
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Age-related macular degeneration; Cognitive impairment; MMSE; MoCA
ID ALZHEIMERS-DISEASE; IMPAIRMENT; MOCA; DEMENTIA; VALIDITY; MMSE
AB OBJECTIVE: To compare the ability of the MMSE and MoCA to identify cognitive dysfunction in patients with age-related macular degeneration (AMD).
   PATIENTS AND METHODS: The study included 81 (29 female, 52 male) AMD patients who were recruited from the Ophthalmology Department of Kirikkale University during 2012. Participants were screened for cognitive impairment using the MMSE and MoCA. The scores were recorded for all participants. The primary outcome measure was the proportion of patients with a score less than 21 on either test.
   RESULTS: The percentage of subjects who scored below a cut off of 21/30 was higher on the MoCA (48.1%) than on the MMSE (18.5%) (p = 0.05). The range and standard deviation of scores was larger with the MoCA (7-30, 5.34) than with the MMSE (19-30, 3.26). There was a more pronounced ceiling effect of the MMSE than of the MoCA. The mean MMSE scores of dry-and wet-type AMD patients was significantly higher than the MoCA scores of the same patients (p = 0.000 and p = 0.000).
   CONCLUSIONS: The MoCA seems to be more sensitive than the MMSE to early cognitive impairment in AMD patients.
C1 [Dag, E.] Kirikkale Univ, Sch Med, Dept Neurol, Kirikkale, Turkey.
   [Otrnek, N.; Ornek, K.; Gunay, F.; Turkel, Y.] Kirikkale Univ, Sch Med, Dept Ophthalmol, Kirikkale, Turkey.
C3 Kirikkale University; Kirikkale University
RP Ornek, K (通讯作者)，Kirikkale Univ, Sch Med, Dept Neurol, Kirikkale, Turkey.
EM kemalornek@hotmail.com
RI Örnek, Kemal/AFL-3613-2022; Örnek, Nurgül/V-1751-2018
OI Örnek, Nurgül/0000-0003-3068-1831
CR Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Hoops S, 2009, NEUROLOGY, V73, P1738, DOI 10.1212/WNL.0b013e3181c34b47
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Lonie JA, 2009, INT J GERIATR PSYCH, V24, P902, DOI 10.1002/gps.2208
   Mitchell AJ, 2009, J PSYCHIATR RES, V43, P411, DOI 10.1016/j.jpsychires.2008.04.014
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   Nazem S, 2009, J AM GERIATR SOC, V57, P304, DOI 10.1111/j.1532-5415.2008.02096.x
   Pendlebury ST, 2012, STROKE, V43, P464, DOI 10.1161/STROKEAHA.111.633586
   Pendlebury ST, 2010, STROKE, V41, P1290, DOI 10.1161/STROKEAHA.110.579888
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Selekler K, 2010, TURK J GERIATR, V13, P166
   Smith T, 2007, CAN J PSYCHIAT, V52, P329, DOI 10.1177/070674370705200508
   TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
NR 15
TC 8
Z9 11
U1 0
U2 5
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD OCT
PY 2014
VL 18
IS 20
BP 3025
EP 3028
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CF0CK
UT WOS:000352210000008
PM 25392099
DA 2022-11-30
ER

PT J
AU Sasaki, M
   Kawasaki, R
   Yanagi, Y
AF Sasaki, Mariko
   Kawasaki, Ryo
   Yanagi, Yasuo
TI Early Stages of Age-Related Macular Degeneration: Racial/Ethnic
   Differences and Proposal of a New Classification Incorporating Emerging
   Concept of Choroidal Pathology
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE age-related macular degeneration (AMD); early AMD; macular
   neovascularization (MNV); drusen; pigmentary abnormalities;
   pachychoroid; multimodal imaging; optical coherence tomography (OCT);
   classification; ethnicity
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS;
   GEOGRAPHIC ATROPHY; PIGMENT-EPITHELIUM; REFRACTILE DRUSEN; VASCULAR
   NETWORKS; SEVERITY SCALE; PREVALENCE; NEOVASCULARIZATION; MACULOPATHY
AB The progression of age-related macular degeneration (AMD) is determined by environmental and genetic factors, and phenotypic or molecular risk factors have been investigated extensively. Interestingly, risk factor profiles for advanced AMD differ among individuals, and one of the causes of variation may be explained by their ethnic background. Recent advances in retinal imaging technology have led to the identification of previously unrecognized risk factors for advanced AMD on optical coherence tomography (OCT) and OCT angiography, which expands the concept of traditional imaging risk factors such as drusen and pigmentary abnormalities visible on color fundus photographs. This OCT imaging modality has identified novel pathognomonic changes for early AMD, including the associated photoreceptor, retinal pigment epithelium, and underlying choroidal changes. Regarding features of multimodal imaging associated with the presence or progression of geographic atrophy, there is an international expert consensus classification system; however, features associated with the progression of macular neovascularization (MNV) are still obscure. To make a consensus towards understanding features associated with the risk of MNV, this review focuses on the early stages of AMD by summarizing imaging characteristics and early signs and classifications in view of advanced multimodal imaging technology. Recent evidence suggests that neovascular AMD is not a single disease entity but a heterogeneous disease characterized by MNV. Besides drusen, OCT features associated with pigment abnormalities, such as shallow irregular RPE elevation (SIRE, also known as double-layer sign), pachychoroid pigment epitheliopathy, and choriocapillaris ischemia, seem to confer a high risk of MNV developing, especially for Asian populations.
C1 [Sasaki, Mariko] Keio Univ, Sch Med, Dept Ophthalmol, 35 Shinanomachi,Shinju Ku, Tokyo 1608582, Japan.
   [Sasaki, Mariko] Tokyo Med Ctr, Dept Ophthalmol, Tokyo 1528902, Japan.
   [Kawasaki, Ryo] Osaka Univ, Grad Sch Med, Dept Vis Informat Topcon, Osaka 5650871, Japan.
   [Yanagi, Yasuo] Yokohama City Univ, Dept Ophthalmol & Microtechnol, Kanazawa 2360027, Japan.
   [Yanagi, Yasuo] Singapore Natl Eye Centre, Singapore Eye Res Inst, Singapore 169608, Singapore.
C3 Keio University; Osaka University; Yokohama City University; National
   University of Singapore; Singapore National Eye Center
RP Sasaki, M (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, 35 Shinanomachi,Shinju Ku, Tokyo 1608582, Japan.; Sasaki, M (通讯作者)，Tokyo Med Ctr, Dept Ophthalmol, Tokyo 1528902, Japan.
EM marii.kt@gmail.com
OI Sasaki, Mariko/0000-0001-5608-0546; Kawasaki, Ryo/0000-0002-7492-6303
FU Japan Society for the Promotion of Science, Japan (JSPS KAKENHI)
   [20K10490]
FX This study was partly supported by a Grant-in-Aid for Scientific
   Research from the Japan Society for the Promotion of Science, Japan
   (JSPS KAKENHI, 20K10490) to MS.
CR Abdin AD, 2021, OPHTHALMOLOGE, V118, P865, DOI 10.1007/s00347-021-01379-4
   Baek J, 2019, EYE, V33, P419, DOI 10.1038/s41433-018-0228-7
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bui PTA, 2022, EYE, V36, P2013, DOI 10.1038/s41433-021-01747-z
   Chandra S, 2022, OPHTHALMOL RETINA, V6, P196, DOI 10.1016/j.oret.2021.07.009
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chiang TTK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.59
   Corvi F, 2021, GRAEF ARCH CLIN EXP, V259, P2887, DOI 10.1007/s00417-021-05167-3
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P957, DOI 10.1097/IAE.0000000000001655
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fragiotta S, 2021, CLIN OPHTHALMOL, V15, P3877, DOI 10.2147/OPTH.S272345
   Fragiotta Serena, 2018, Int J Retina Vitreous, V4, P44, DOI 10.1186/s40942-018-0148-5
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Grewal MK, 2022, EYE, V36, P398, DOI 10.1038/s41433-021-01488-z
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Hagag AM, 2022, AM J OPHTHALMOL, V236, P271, DOI 10.1016/j.ajo.2021.10.021
   Hata M, 2019, OPHTHALMOL RETINA, V3, P1016, DOI 10.1016/j.oret.2019.06.013
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P2069, DOI 10.1097/IAE.0000000000001457
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Jaffe GJ, 2021, OPHTHALMOL RETINA, V5, P855, DOI 10.1016/j.oret.2020.12.009
   Kang HG, 2021, GRAEF ARCH CLIN EXP, V259, P2391, DOI 10.1007/s00417-021-05180-6
   Karacorlu M, 2018, GRAEF ARCH CLIN EXP, V256, P2319, DOI 10.1007/s00417-018-4144-0
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   Kim KL, 2022, ACTA OPHTHALMOL, V100, pE710, DOI 10.1111/aos.14960
   Kim YH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84650-7
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2020, OPHTHALMOLOGY, V127, pS122, DOI 10.1016/j.ophtha.2020.01.033
   Lee JH, 2019, RETINA-J RET VIT DIS, V39, P1562, DOI 10.1097/IAE.0000000000002187
   Lee J, 2019, AM J OPHTHALMOL, V208, P103, DOI 10.1016/j.ajo.2019.07.013
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Lee M, 2018, INVEST OPHTH VIS SCI, V59, P4896, DOI 10.1167/iovs.18-25018
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lyssenko NN, 2018, J LIPID RES, V59, P1927, DOI 10.1194/jlr.M087361
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nittala MG, 2019, RETINA-J RET VIT DIS, V39, P1540, DOI 10.1097/IAE.0000000000002210
   Nittala MG, 2019, OPHTHALMOL RETINA, V3, P112, DOI 10.1016/j.oret.2018.09.017
   Notomi S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255213
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Ou WC, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.10
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rim TH, 2020, OPHTHALMOLOGY, V127, P1371, DOI 10.1016/j.ophtha.2020.04.019
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P657, DOI 10.1097/IAE.0000000000002635
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P257, DOI 10.1097/IAE.0000000000002399
   Sasaki M, 2021, OPHTHALMOL RETINA, V5, P528, DOI 10.1016/j.oret.2020.09.001
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sato-Akushichi Miki, 2021, Ophthalmol Sci, V1, P100081, DOI 10.1016/j.xops.2021.100081
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Spaide RF, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100973
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P231, DOI 10.1097/IAE.0000000000003057
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P12, DOI 10.1097/IAE.0000000000002362
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Takahashi A, 2021, OPHTHALMOL RETINA, V5, P910, DOI 10.1016/j.oret.2020.12.004
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Teo KYC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87083-4
   Tiosano L, 2020, GRAEF ARCH CLIN EXP, V258, P2353, DOI 10.1007/s00417-020-04837-y
   Tsujikawa A, 2018, JPN J OPHTHALMOL, V62, P127, DOI 10.1007/s10384-017-0556-3
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang YW, 2022, EYE, V36, P733, DOI 10.1038/s41433-020-01390-0
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
   Yanagi Y, 2019, EYE, V33, P34, DOI 10.1038/s41433-018-0225-x
   Zhang YH, 2018, RETINA-J RET VIT DIS, V38, P29, DOI 10.1097/IAE.0000000000001504
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 100
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD NOV
PY 2022
VL 11
IS 21
AR 6274
DI 10.3390/jcm11216274
PG 23
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 6B3LT
UT WOS:000881239400001
PM 36362505
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bui, YT
   Starr, MR
   Kung, FF
   Mejia, CA
   Bakri, SJ
AF Bui, Yvonne T.
   Starr, Matthew R.
   Kung, Felix F.
   Mejia, Camilo A.
   Bakri, Sophie J.
TI Long-Term Visual Outcomes in Exudative Age-Related Macular Degeneration
   Patients With Unanticipated Gaps in Therapy
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID TREAT-AND-EXTEND; ANTI-VEGF AGENTS; FOLLOW-UP; RANIBIZUMAB; ADHERENCE;
   TRIAL
AB BACKGROUND AND OBJECTIVES: This study's objec-tive was to describe long-term visual outcomes of patients with age-related macular degeneration (AMD) treated with intravitreal anti-vascular en-dothelial growth factor injections who were lost to follow-up and then resumed treatment with anti -vascular endothelial growth factor injections.MATERIALS AND METHODS: This was a retrospective cohort study of eyes with at least 7 years of follow-up following the initiation of treatment for wet AMD with and without gaps in therapy.RESULTS: The baseline mean logMAR visual acuity was 0.65 +/- 0.5 (Snellen acuity 20/89) in eyes with gaps in therapy and 0.53 +/- 0.3 (20/68) in eyes without gaps. In the initial 7-year follow-up period, the eyes with gaps in therapy had significantly worse visual acuity (P < .001) and this remained significant when accounting for baseline visual acuity (P < .001).CONCLUSIONS: Gaps in intravitreal injection therapy for exudative AMD were negatively associated with visual acuity. Adherence to therapy is important to address in the care of patients with exudative AMD.
C1 [Bui, Yvonne T.; Kung, Felix F.; Mejia, Camilo A.] Mayo Clin, Alix Sch Med, Rochester, MN USA.
   [Starr, Matthew R.; Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
   [Starr, Matthew R.] Mayo Clin, Dept Ophthalmol, 200 First St Southwest, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Starr, MR (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 First St Southwest, Rochester, MN 55905 USA.
EM starr.matthew2@mayo.edu
CR Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Atchison EA, 2017, RETINA-J RET VIT DIS, V37, P1371, DOI 10.1097/IAE.0000000000001372
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Engman SJ, 2011, SEMIN OPHTHALMOL, V26, P380, DOI 10.3109/08820538.2011.622337
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Kung FF, 2020, OPHTHALMOL RETINA, V4, P1047, DOI 10.1016/j.oret.2020.05.005
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Starr MR, 2020, RETINA-J RET VIT DIS, V40, P1665, DOI 10.1097/IAE.0000000000002668
   Wecker T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38934-8
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 30
TC 0
Z9 0
U1 1
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2022
VL 53
IS 9
BP 481
EP 489
DI 10.3928/23258160-20220819-02
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 4Z5YM
UT WOS:000862283800002
PM 36107628
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Fleckenstein, M
   Chew, EY
   Strunz, T
   Schmitz-Valckenberg, S
   Gobel, AP
   Klein, ML
   Ratnapriya, R
   Swaroop, A
   Holz, FG
   Weber, BHF
AF Grassmann, Felix
   Fleckenstein, Monika
   Chew, Emily Y.
   Strunz, Tobias
   Schmitz-Valckenberg, Steffen
   Goebel, Arno P.
   Klein, Michael L.
   Ratnapriya, Rinki
   Swaroop, Anand
   Holz, Frank G.
   Weber, Bernhard H. F.
TI Clinical and Genetic Factors Associated with Progression of Geographic
   Atrophy Lesions in Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID DISEASE PROGRESSION; NATURAL-HISTORY; MESSENGER-RNA; EYE DISEASE;
   FACTOR-H; COMPLEMENT; RISK; AMD; ARMS2; NEUROGENESIS
AB Worldwide, age-related macular degeneration (AMD) is a serious threat to vision loss in individuals over 50 years of age with a pooled prevalence of approximately 9%. For 2020, the number of people afflicted with this condition is estimated to reach 200 million. While AMD lesions presenting as geographic atrophy (GA) show high inter-individual variability, only little is known about prognostic factors. Here, we aimed to elucidate the contribution of clinical, demographic and genetic factors on GA progression. Analyzing the currently largest dataset on GA lesion growth (N = 388), our findings suggest a significant and independent contribution of three factors on GA lesion growth including at least two genetic factors (ARMS2_rs10490924 [P < 0.00088] and C3_rs2230199 [P < 0.00015]) as well as one clinical component (presence of GA in the fellow eye [P < 0.00023]). These correlations jointly explain up to 7.2% of the observed inter-individual variance in GA lesion progression and should be considered in strategy planning of interventional clinical trials aimed at evaluating novel treatment options in advanced GA due to AMD.
C1 [Grassmann, Felix; Strunz, Tobias; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Fleckenstein, Monika; Schmitz-Valckenberg, Steffen; Goebel, Arno P.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Chew, Emily Y.; Ratnapriya, Rinki; Swaroop, Anand] NEI, NIH, Bethesda, MD 20892 USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Macular Degenerat Ctr, Casey Eye Inst, Portland, OR 97239 USA.
   [Klein, Michael L.] Devers Eye Inst, Portland, OR 97239 USA.
C3 University of Regensburg; University of Bonn; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); Oregon Health &
   Science University; Devers Eye Institute
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Mitchell, Paul/P-1498-2014; Strunz, Tobias/ABB-6300-2020; Strunz,
   Tobias/ABD-9798-2021
OI Strunz, Tobias/0000-0002-3744-9595; Swaroop, Anand/0000-0002-1975-1141;
   Ratnapriya, Rinki/0000-0002-0469-4631; Grassmann,
   Felix/0000-0003-1390-7528; Weber, Bernhard H.F./0000-0002-8808-7723;
   Fleckenstein, Monika/0000-0001-8321-8037
FU Deutsche Forschungsgemeinschaft [WE 1259/19-2]; Alcon Research
   Institute; Intramural Research program of the National Eye Institute;
   National Eye Institute, National Institutes of Health, Bethesda, MD
   [R01-EY021532]; NATIONAL EYE INSTITUTE [ZIAEY000489, ZIAEY000485,
   R01EY021532, ZIAEY000546] Funding Source: NIH RePORTER
FX This study was supported in parts by the Deutsche Forschungsgemeinschaft
   (WE 1259/19-2 to BHFW), the Alcon Research Institute (to BHFW, EYC, and
   AS), the Intramural Research program of the National Eye Institute (EYC
   and AS), and by grants from the National Eye Institute, National
   Institutes of Health, Bethesda, MD (R01-EY021532 to MLK). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   [Anonymous], 2010, R LANG ENV STAT COMP
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Caire J, 2014, JAMA OPHTHALMOL
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Griffiths MR, 2009, J IMMUNOL, V182, P4368, DOI 10.4049/jimmunol.0800205
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Pekny M, 2007, INT REV NEUROBIOL, V82, P95, DOI 10.1016/S0074-7742(07)82005-8
   Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004
   Ramaglia V, 2012, P NATL ACAD SCI USA, V109, P965, DOI 10.1073/pnas.1111924109
   Sallo FB, 2009, CURR EYE RES, V34, P238, DOI 10.1080/02713680802714058
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Steiner B, 2006, REGEN MED, V1, P15, DOI 10.2217/17460751.1.1.15
   Steiner T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092404
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   van Beek J, 2001, NEUROREPORT, V12, P289, DOI 10.1097/00001756-200102120-00022
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 41
TC 51
Z9 53
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2015
VL 10
IS 5
AR e0126636
DI 10.1371/journal.pone.0126636
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CI1YY
UT WOS:000354542500128
PM 25962167
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ridder, WH
   Comer, G
   Oquindo, C
   Yoshinaga, P
   Engles, M
   Burke, J
AF Ridder, William H., III
   Comer, George
   Oquindo, Caren
   Yoshinaga, Pat
   Engles, Michael
   Burke, James
TI Contrast Sensitivity in Early to Intermediate Age-Related Macular
   Degeneration (AMD)
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Contrast sensitivity; low luminance contrast sensitivity; temporal
   contrast sensitivity; age-related macular degeneration; visual acuity
ID VISUAL-ACUITY; INTERSESSION REPEATABILITY; SEVERITY SCALE; LETTER-CHART;
   EYES; MACULOPATHY; PREVALENCE; VISION; ROD; RELIABILITY
AB Purpose Previous studies indicated that advanced age-related macular degeneration (AMD) affects contrast sensitivity (CS) in humans. The CS results for early/intermediate AMD patients are contradictory. The purpose of this study was to determine if CS testing discriminates early/intermediate AMD patients with normal acuity from normal patients. Methods Forty-nine subjects (25 control and 24 early/intermediate AMD patients) were chosen for this project. The age (p = .16) and acuity (p = .34) was not significantly different between the groups. The average simplified AREDS AMD grade for the AMD patients was 2.75 +/- 1.03. Three CS functions employing a descending method of limits were measured at the fovea (1. stationary stimulus and, 2. 16 Hz counter-phase stimulus under photopic conditions and 3. the stationary stimulus viewed through a 2 log unit neutral density filter (mesopic condition, background luminance of 1 cd/m(2))) and at 4 deg right or left of the fovea with a horizontally oriented sine wave grating (5 deg diameter) viewed on a VPixx monitor (luminance of 100 cd/m(2)). Results The early AMD patients were no different from the control patients for any test condition. The intermediate AMD patients were significantly different from the control patients for the mesopic CS function (p = .05). Post-hoc 2-sample t-tests for the intermediate AMD patients were significantly different from the control patients under the stationary photopic and mesopic conditions for the 1.5 cycle per degree stimulus. Conclusions Group differences in CS were only found in intermediate AMD patients. The loss in CS increased for the intermediate AMD patients under low light levels. Thus, CS may not be the optimal test to discriminate early AMD from control patients so other tests measured under dark adapted conditions should be investigated.
C1 [Ridder, William H., III; Comer, George; Oquindo, Caren; Yoshinaga, Pat] Marshall B Ketchum Univ, Southern Calif Coll Optometry, Fullerton, CA 92831 USA.
   [Engles, Michael; Burke, James] AbbVie Inc, Biol Res, Irvine, CA USA.
C3 AbbVie
RP Ridder, WH (通讯作者)，Marshall B Ketchum Univ, Southern Calif Coll Optometry, Fullerton, CA 92831 USA.
EM wridder@ketchum.edu
FU Allergan
FX Partially funded by Allergan (prior to acquisition by AbbVie).
CR ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Arditi A, 2005, INVEST OPHTH VIS SCI, V46, P2225, DOI 10.1167/iovs.04-1198
   Aslam T, 2014, GRAEF ARCH CLIN EXP, V252, P201, DOI 10.1007/s00417-013-2421-5
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P788
   CORWIN TR, 1989, OPTOMETRY VISION SCI, V66, P864, DOI 10.1097/00006324-198912000-00011
   CRASSINI B, 1988, PERCEPTION, V17, P315, DOI 10.1068/p170315
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Faber Jorge, 2014, Dental Press J. Orthod., V19, P27, DOI 10.1590/2176-9451.19.4.027-029.ebo
   Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   GINSBURG AP, 1984, AM J OPTOM PHYS OPT, V61, P403
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holopigian K, 2010, DOC OPHTHALMOL, V121, P215, DOI 10.1007/s10633-010-9249-7
   Hosmer DW, 2000, APPL LOGISTIC REGRES, P143, DOI DOI 10.1002/0471722146.CH5
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   JOHNSTON A, 1987, J OPT SOC AM A, V4, P1583, DOI 10.1364/JOSAA.4.001583
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KIORPES L, 1993, VISION RES, V33, P2301, DOI 10.1016/0042-6989(93)90107-8
   Kiser AK, 2005, OPTOMETRY VISION SCI, V82, P946, DOI 10.1097/01.opx.0000187863.12609.7b
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Lott LA, 2021, OPHTHAL EPIDEMIOL, V28, P93, DOI 10.1080/09286586.2020.1793371
   MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030
   Maynard ML, 2016, ACTA OPHTHALMOL, V94, pE772, DOI 10.1111/aos.13112
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Nusinowitz S, 2007, EXP EYE RES, V84, P1104, DOI 10.1016/j.exer.2007.02.009
   OU W, 2021, AM J OPHTHALMOL, V226
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Patel PJ, 2011, INVEST OPHTH VIS SCI, V52, P3089, DOI 10.1167/iovs.10-6208
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P2621, DOI 10.1167/iovs.08-2407
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   REGAN D, 1983, OPHTHALMOLOGY, V90, P1192
   Ridder WH, 2006, VISION RES, V46, P902, DOI 10.1016/j.visres.2005.09.006
   Ridder WH, 2019, DOC OPHTHALMOL, V139, P207, DOI 10.1007/s10633-019-09712-8
   Ridder WH, 2019, VISUAL NEUROSCI, V36, DOI 10.1017/S0952523819000051
   Rosser DA, 2003, INVEST OPHTH VIS SCI, V44, P3278, DOI 10.1167/iovs.02-1100
   ROVAMO J, 1984, VISION RES, V24, P1127, DOI 10.1016/0042-6989(84)90166-4
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Stockman A, 2006, OPHTHAL PHYSL OPT, V26, P225, DOI 10.1111/j.1475-1313.2006.00325.x
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Venkataraman AP, 2017, VISION RES, V133, P145, DOI 10.1016/j.visres.2017.02.002
NR 59
TC 1
Z9 1
U1 1
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD FEB 1
PY 2022
VL 47
IS 2
BP 287
EP 296
DI 10.1080/02713683.2021.1966478
EA AUG 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZT7WE
UT WOS:000686431500001
PM 34412522
DA 2022-11-30
ER

PT J
AU Li, LC
   Yu, Y
   Lin, S
   Hu, JM
AF Li, Licheng
   Yu, Yang
   Lin, Shu
   Hu, Jianmin
TI Changes in best-corrected visual acuity in patients with dry age-related
   macular degeneration after stem cell transplantation: systematic review
   and meta-analysis
SO STEM CELL RESEARCH & THERAPY
LA English
DT Review
DE Meta-analysis; Stem cell transplantation; Dry age-related macular
   degeneration
ID OPTIC-NERVE INJURY; EPITHELIAL-CELLS; IMPLANTATION; THERAPY; ATROPHY
AB Background Stem cell transplantation may improve visual acuity in patients with dry age-related macular degeneration. Herein, we aimed to summarise the evidence on the risks and benefits of stem cell transplantation for improving visual acuity, including the risk of adverse events. Methods Data were obtained from the PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials databases, and each database was interrogated from the date of inception until 19 March 2022. The rates of visual acuity outcomes and adverse events associated with stem cell transplantation were examined. All statistical analyses were conducted using Review Manager 5.4. The study was registered with PROSPERO (CRD 42022322902). Results The analysis examined 10 studies (102 patients), including one and three, randomised and non-randomised clinical trials, and one and five, multicentre prospective and prospective clinical trials, respectively. Meta-analysis showed changes in best-corrected visual acuity in the study eyes after stem cell transplantation (6 months: risk ratio [RR] = 17.00, 95% confidence interval [CI] 6.08-47.56, P < 0.00001; 12 months: RR = 11.00, 95% CI 2.36-51.36, P = 0.002). Subgroup analysis showed that different stem cell types achieved better best-corrected visual acuity at post-operative 6 months, compared to that observed at baseline. Four cases of related ocular adverse events and no related systemic adverse events were reported. Conclusion This meta-analysis suggests that stem cell transplantation may improve best-corrected visual acuity in dry age-related macular degeneration, based on small sample sizes and fewer randomised controlled trials.
C1 [Li, Licheng; Yu, Yang; Hu, Jianmin] Fujian Med Univ, Affiliated Hosp 2, Dept Ophthalmol,Fujian Prov Univ, Engn Res Ctr Assist Technol Visual Impairment, 34 North Zhongshan Rd, Quanzhou 362000, Fujian, Peoples R China.
   [Lin, Shu] Fujian Med Univ, Ctr Neurol & Meta bolic Res, Affiliated Hosp 2, 34 North Zhongshan Rd, Quanzhou 362000, Fujian, Peoples R China.
   [Lin, Shu] Garvan Inst Med Res, Grp Neuroendocrinol, 384 Victoria St, Sydney, NSW, Australia.
   [Hu, Jianmin] Fujian Med Univ, Sch Med Technol & Engn, Fuzhou, Fujian, Peoples R China.
C3 Fujian Medical University; Fuzhou University; Fujian Medical University;
   Garvan Institute of Medical Research; Fujian Medical University
RP Hu, JM (通讯作者)，Fujian Med Univ, Affiliated Hosp 2, Dept Ophthalmol,Fujian Prov Univ, Engn Res Ctr Assist Technol Visual Impairment, 34 North Zhongshan Rd, Quanzhou 362000, Fujian, Peoples R China.; Lin, S (通讯作者)，Fujian Med Univ, Ctr Neurol & Meta bolic Res, Affiliated Hosp 2, 34 North Zhongshan Rd, Quanzhou 362000, Fujian, Peoples R China.
EM shulin1956@126.com; doctorhjm@163.com
OI lin, shu/0000-0002-4239-2028; Li, Licheng/0000-0001-7195-3624
FU National Key R&D Programmes of China [2018YFC2002602]; Science and
   Technology Bureau of Quanzhou [2020CT003]
FX This work was supported by the National Key R&D Programmes of China
   (grant number 2018YFC2002602) and the Science and Technology Bureau of
   Quanzhou (grant number 2020CT003).
CR Bammidi S, 2019, CURR NEUROVASC RES, V16, P187, DOI 10.2174/1567202616666190618123931
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Chakradhar S, 2016, NAT MED, V22, P116, DOI 10.1038/nm0216-116
   Cotrim CC, 2017, CLIN OPHTHALMOL, V11, P931, DOI 10.2147/OPTH.S133502
   El-Kadiry AE, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.756029
   Fleckenstein M., 2015, CHEM COMMUN, V48, P353
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Hu ZL, 2017, INT J OPHTHALMOL-CHI, V10, P35, DOI 10.18240/ijo.2017.01.06
   Huang HY, 2018, CELL TRANSPLANT, V27, P310, DOI 10.1177/0963689717746999
   Hussain RM, 2019, OSLI RETINA, V50, P125, DOI 10.3928/23258160-20190129-11
   Ilmarinen T, 2019, ACTA OPHTHALMOL, V97, pE688, DOI 10.1111/aos.14004
   Jin ZB, 2019, PROG RETIN EYE RES, V69, P38, DOI 10.1016/j.preteyeres.2018.11.003
   Jones MK, 2017, PROG RETIN EYE RES, V58, P1, DOI 10.1016/j.preteyeres.2017.01.004
   Kahraman NS, 2021, INT J STEM CELLS, V14, P47, DOI 10.15283/ijsc20025
   Kashani AH, 2022, CURR OPIN OPHTHALMOL, V33, P211, DOI 10.1097/ICU.0000000000000838
   Kashani AH, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.10.13
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Khan Muhammad, 2014, ISRN Ophthalmol, V2014, P608390, DOI 10.1155/2014/608390
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Li X, 2018, MOL MED REP, V17, P2529, DOI 10.3892/mmr.2017.8103
   Limoli PG, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02351-4
   Limoli PG, 2018, JOVE-J VIS EXP, DOI 10.3791/56469
   Limoli PG, 2016, ONCOTARGET, V7, P46913, DOI 10.18632/oncotarget.10442
   Limoli PG, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000355
   Maberley D, 2009, OPHTHALMOLOGY, V116, P2149, DOI 10.1016/j.ophtha.2009.04.032
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Nittala MG, 2021, OPHTHALMOL RETINA, V5, P32, DOI 10.1016/j.oret.2020.06.012
   Oner A, 2018, CELL REPROGRAM, V20, P329, DOI 10.1089/cell.2018.0045
   Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1016/j.ijsu.2021.105906, 10.1136/bmj.n71]
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Saraf SS, 2017, OSLI RETINA, V48, P772, DOI 10.3928/23258160-20170829-16
   Schmidt-Erfurth U, 2009, PROG RETIN EYE RES, V28, P145, DOI 10.1016/j.preteyeres.2009.01.001
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Sun JN, 2015, STEM CELLS, V33, P1543, DOI 10.1002/stem.1960
   Wang LJ, 2018, EUR REV MED PHARMACO, V22, P1196, DOI 10.26355/eurrev_201803_14458
   Wen YT, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042117
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Westenskow PD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8470263
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 47
TC 0
Z9 0
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD JUN 7
PY 2022
VL 13
IS 1
AR 237
DI 10.1186/s13287-022-02931-y
PG 11
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 1X6GR
UT WOS:000807551400001
PM 35672801
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wu, KX
   Yeo, NJY
   Ng, CY
   Chioh, FWJ
   Fan, Q
   Tian, XF
   Yang, BX
   Narayanan, G
   Tay, HM
   Hou, HW
   Dunn, NR
   Su, XY
   Cheung, CMG
   Cheung, C
AF Wu, Kan Xing
   Yeo, Natalie Jia Ying
   Ng, Chun Yi
   Chioh, Florence Wen Jing
   Fan, Qiao
   Tian, Xianfeng
   Yang, Binxia
   Narayanan, Gunaseelan
   Tay, Hui Min
   Hou, Han Wei
   Dunn, N. Ray
   Su, Xinyi
   Cheung, Chui Ming Gemmy
   Cheung, Christine
TI Hyaluronidase-1-mediated glycocalyx impairment underlies endothelial
   abnormalities in polypoidal choroidal vasculopathy
SO BMC BIOLOGY
LA English
DT Article
DE Endothelial dysfunction; Glycocalyx; Hyaluronidase-1; Polypoidal
   choroidal vasculopathy; Age-related macular degeneration
ID MACULAR DEGENERATION; HYALURONIC-ACID; SHEAR-STRESS; CULTURED
   ENDOTHELIUM; PROGENITOR CELLS; HEPARAN-SULFATE; GENE; EXPRESSION;
   MURINE; PURIFICATION
AB Background Polypoidal choroidal vasculopathy (PCV), a subtype of age-related macular degeneration (AMD), is a global leading cause of vision loss in older populations. Distinct from typical AMD, PCV is characterized by polyp-like dilatation of blood vessels and turbulent blood flow in the choroid of the eye. Gold standard anti-vascular endothelial growth factor (anti-VEGF) therapy often fails to regress polypoidal lesions in patients. Current animal models have also been hampered by their inability to recapitulate such vascular lesions. These underscore the need to identify VEGF-independent pathways in PCV pathogenesis. Results We cultivated blood outgrowth endothelial cells (BOECs) from PCV patients and normal controls to serve as our experimental disease models. When BOECs were exposed to heterogeneous flow, single-cell transcriptomic analysis revealed that PCV BOECs preferentially adopted migratory-angiogenic cell state, while normal BOECs undertook proinflammatory cell state. PCV BOECs also had a repressed protective response to flow stress by demonstrating lower mitochondrial functions. We uncovered that elevated hyaluronidase-1 in PCV BOECs led to increased degradation of hyaluronan, a major component of glycocalyx that interfaces between flow stress and vascular endothelium. Notably, knockdown of hyaluronidase-1 in PCV BOEC improved mechanosensitivity, as demonstrated by a significant 1.5-fold upregulation of Kruppel-like factor 2 (KLF2) expression, a flow-responsive transcription factor. Activation of KLF2 might in turn modulate PCV BOEC migration. Barrier permeability due to glycocalyx impairment in PCV BOECs was also reversed by hyaluronidase-1 knockdown. Correspondingly, hyaluronidase-1 was detected in PCV patient vitreous humor and plasma samples. Conclusions Hyaluronidase-1 inhibition could be a potential therapeutic modality in preserving glycocalyx integrity and endothelial stability in ocular diseases with vascular origin.
C1 [Wu, Kan Xing; Yeo, Natalie Jia Ying; Ng, Chun Yi; Chioh, Florence Wen Jing; Tian, Xianfeng; Hou, Han Wei; Dunn, N. Ray; Cheung, Christine] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Fan, Qiao; Tian, Xianfeng; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Fan, Qiao] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Yang, Binxia; Su, Xinyi; Cheung, Christine] Agcy Sci Technol & Res, Inst Mol & Cell Biol, Singapore, Singapore.
   [Narayanan, Gunaseelan; Dunn, N. Ray] Agcy Sci Technol & Res, Inst Med Biol, Singapore, Singapore.
   [Tay, Hui Min; Hou, Han Wei] Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore, Singapore.
   [Dunn, N. Ray] Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore.
   [Su, Xinyi] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Su, Xinyi; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Su, Xinyi] Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore, Singapore.
C3 Nanyang Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; National University of
   Singapore; National University of Singapore; Agency for Science
   Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell
   Biology (IMCB); Agency for Science Technology & Research (A*STAR);
   A*STAR - Institute of Medical Biology (IMB); Nanyang Technological
   University & National Institute of Education (NIE) Singapore; Nanyang
   Technological University; Nanyang Technological University & National
   Institute of Education (NIE) Singapore; Nanyang Technological
   University; National University of Singapore; National University of
   Singapore; Singapore National Eye Center; National University of
   Singapore
RP Cheung, C (通讯作者)，Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.; Cheung, C (通讯作者)，Agcy Sci Technol & Res, Inst Mol & Cell Biol, Singapore, Singapore.
EM ccheung@ntu.edu.sg
RI Cheung, Christine/J-9721-2017
OI Cheung, Christine/0000-0001-7127-9107; Yeo, Natalie/0000-0002-1158-1432
FU Nanyang Assistant Professorship; Academic Research Fund Tier 2 grant
   from the Ministry of Education, Singapore [MOE2018-T2-1-042]; Nanyang
   President's Graduate Scholarship; SERI-IMCB Program in Retinal
   Angiogenic Diseases (SIPRAD) grant from Agency for Science, Technology
   and Research, Singapore [SPF2014/002]; National Research Foundation
   (Singapore) [CRP21-2018-00103]
FX The team from Nanyang Technological University Singapore was funded by
   the Nanyang Assistant Professorship and Academic Research Fund Tier 2
   grant (MOE2018-T2-1-042) from the Ministry of Education, Singapore.
   N.J.Y.Y is supported by the Nanyang President's Graduate Scholarship.
   C.C. and C.M.G.C. were funded by the SERI-IMCB Program in Retinal
   Angiogenic Diseases (SIPRAD) grant (SPF2014/002) from Agency for
   Science, Technology and Research, Singapore. X.S. is funded by a grant
   (CRP21-2018-00103) from the National Research Foundation (Singapore).
CR AFIFY AM, 1993, ARCH BIOCHEM BIOPHYS, V305, P434, DOI 10.1006/abbi.1993.1443
   Ajami NE, 2017, P NATL ACAD SCI USA, V114, P10990, DOI 10.1073/pnas.1707517114
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Atkins GB, 2007, CIRC RES, V100, P1686, DOI 10.1161/01.RES.0000267856.00713.0a
   Bode L, 2008, J CLIN INVEST, V118, P229, DOI 10.1172/JCI32335
   Bourguignon V, 2016, FASEB J, V30, P2108, DOI 10.1096/fj.201500178R
   Carbon S, 2021, NUCLEIC ACIDS RES, V49, pD325, DOI 10.1093/nar/gkaa1113
   Cavallini M, 2013, AESTHET SURG J, V33, P1167, DOI 10.1177/1090820X13511970
   Chen HY, 2012, MOL VIS, V18, P816
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dardik A, 2005, J VASC SURG, V41, P869, DOI 10.1016/j.jvs.2005.01.020
   Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046
   Dogne S, 2016, DIABETES, V65, P2742, DOI 10.2337/db15-1662
   Dubrovskyi O, 2013, LAB INVEST, V93, P254, DOI 10.1038/labinvest.2012.159
   Finak G, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0844-5
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Florian JA, 2003, CIRC RES, V93, pE136, DOI 10.1161/01.RES.0000101744.47866.D5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773
   Fu BMM, 2013, WIRES SYST BIOL MED, V5, P381, DOI 10.1002/wsbm.1211
   Gasingirwa MC, 2010, BIOCHEM J, V430, P305, DOI 10.1042/BJ20100711
   Givens C, 2016, ANTIOXID REDOX SIGN, V25, P373, DOI 10.1089/ars.2015.6493
   Gouverneur M, 2006, AM J PHYSIOL-HEART C, V290, pH458, DOI 10.1152/ajpheart.00592.2005
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hebbel RP, 2017, J CLIN INVEST, V127, P1613, DOI 10.1172/JCI93649
   Henry CBS, 1999, AM J PHYSIOL-HEART C, V277, pH508, DOI 10.1152/ajpheart.1999.277.2.H508
   Hur J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   LEY K, 1989, BLOOD, V73, P1324
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lin CY, 2019, EBIOMEDICINE, V48, P425, DOI 10.1016/j.ebiom.2019.09.014
   Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071
   Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Lukowski SW, 2019, CELL REP, V27, P2748, DOI 10.1016/j.celrep.2019.04.102
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   McQuin C, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005970
   Medina RJ, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-18
   Mochizuki S, 2003, AM J PHYSIOL-HEART C, V285, pH722, DOI 10.1152/ajpheart.00691.2002
   Nakatsu Martin N, 2007, J Vis Exp, P186, DOI 10.3791/186
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   Ormiston ML, 2015, JOVE-J VIS EXP, DOI 10.3791/53384
   Pang XQ, 2019, FARADAY DISCUSS, V219, P168, DOI 10.1039/c9fd00015a
   Parmar KM, 2006, J CLIN INVEST, V116, P49, DOI 10.1172/JCI24787
   Paschalaki KE, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00295
   Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893
   Puissant E, 2014, TRAFFIC, V15, P500, DOI 10.1111/tra.12162
   Rebhun CB, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.6.4
   Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8
   Scheitlin CG, 2014, CELL MOL BIOENG, V7, P483, DOI 10.1007/s12195-014-0357-4
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun RJ, 2002, EUR BIOPHYS J BIOPHY, V30, P605, DOI 10.1007/s00249-001-0195-x
   Tarbell JM, 2005, ANN BIOMED ENG, V33, P1719, DOI 10.1007/s10439-005-8775-z
   Tarbell JM, 2006, J INTERN MED, V259, P339, DOI 10.1111/j.1365-2796.2006.01620.x
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Vink H, 2000, AM J PHYSIOL-HEART C, V278, pH285, DOI 10.1152/ajpheart.2000.278.1.H285
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Warboys CM, 2019, ATHEROSCLEROSIS, V285, P170, DOI 10.1016/j.atherosclerosis.2019.04.210
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   Wu KX., 2022, GENE EXPRESSION OMNI
   Xanthis I, 2019, J CELL SCI, V132, DOI 10.1242/jcs.229542
   Yanagi Y, 2019, EYE, V33, P34, DOI 10.1038/s41433-018-0225-x
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhu GZ, 2018, AESTHET SURG J, V38, P12, DOI 10.1093/asj/sjw216
NR 81
TC 2
Z9 2
U1 2
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1741-7007
J9 BMC BIOL
JI BMC Biol.
PD FEB 15
PY 2022
VL 20
IS 1
AR 47
DI 10.1186/s12915-022-01244-z
PG 21
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA YZ0BG
UT WOS:000755148000001
PM 35164755
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Koolen, L
   Gagliardi, G
   ten Brink, SCA
   de Breuk, A
   Heesterbeek, TJ
   Hoyng, CB
   Albert, S
   den Hollander, AI
AF Koolen, Louet
   Gagliardi, Giuliana
   ten Brink, Sofie C. A.
   de Breuk, Anita
   Heesterbeek, Thomas J.
   Hoyng, Carel B.
   Albert, Silvia
   den Hollander, Anneke I.
TI Generation and characterization of human induced pluripotent stem cells
   (iPSCs) from three patients with age-related macular degeneration
   carrying rare variants in the CFH gene
SO STEM CELL RESEARCH
LA English
DT Article
AB Age-related macular degeneration (AMD) is a major cause of vision loss among the elderly in the Western world. AMD is multifactorial eye disease with a strong genetic contribution. Here, we report the generation and characterization of induced pluripotent stem cells (iPSCs) derived from peripheral blood mononuclear cells of three patients with AMD carrying rare variants in the complement factor H (CFH) gene. These cell lines were generated for cellular studies investigating the disease mechanisms and developing therapeutic interventions for AMD.
C1 [Koolen, Louet; Gagliardi, Giuliana; ten Brink, Sofie C. A.; de Breuk, Anita; Heesterbeek, Thomas J.; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Albert, Silvia; den Hollander, Anneke I.] Radboud Univ Nijmegen, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP Koolen, L (通讯作者)，Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
EM louet.koolen@radboudumc.nl
RI Brink, Sofie ten/AAZ-4663-2020
OI Brink, Sofie ten/0000-0001-7127-025X
FU Stichting Toegepast Wetenschappelijk Instituut voor Neuromodulatie
   (TWIN) under the project 'Inflammation and Edema in an Organ-on-a-Chip
   Model of Wet Age-Related Macular Degeneration"
FX The authors acknowledge the funding received from Stichting Toegepast
   Wetenschappelijk Instituut voor Neuromodulatie (TWIN) under the project
   'Inflammation and Edema in an Organ-on-a-Chip Model of Wet Age-Related
   Macular Degeneration' "The authors wish to thank the Radboudumc Stem
   Cell Technology Center
   (https://www.radboudumc.nl/en/research/radboud-technology-centers/stem-c
   ells) for reprogramming and characterizing the patient cell lines.
CR de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   De Jong, HUM MOL GENET
   Duvvari MR, 2015, MOL VIS, V21, P285
   van de Ven J.P., 2012, ARCH OPHTHALMOL-CHIC, V130
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD APR
PY 2022
VL 60
AR 102669
DI 10.1016/j.scr.2022.102669
PG 5
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA 0Z7DV
UT WOS:000791235400011
PM 35063911
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sitnilska, V
   Enders, P
   Cursiefen, C
   Fauser, S
   Altay, L
AF Sitnilska, Vasilena
   Enders, Philip
   Cursiefen, Claus
   Fauser, Sascha
   Altay, Lebriz
TI Association of imaging biomarkers and local activation of complement in
   aqueous humor of patients with early forms of age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Complement; Age-related macular degeneration; Imaging biomarkers;
   Aqueous humor
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY; RETICULAR
   PSEUDODRUSEN; HYPERREFLECTIVE FOCI; PROGRESSION; PREVALENCE; DISEASE;
   COMMON; RISK; OCT
AB Purpose To investigate a possible correlation between established imaging biomarkers for age-related macular degeneration and local complement system activation, measured in aqueous humor (AH) of patients with early stages of age-related macular degeneration (AMD) and controls. Methods This analysis included prospectively acquired AH samples of 106 eyes (35 with early/intermediate AMD, 71 controls). The levels of complement protein 3 (C3), 4 (C4), 5 (C5); activation products of complement factor 3a (C3a) and Ba, C3b/iC3b; complement factors B, D, H, I (CFB, CFD, CFH, CFI); and total protein concentration were analyzed. Quantitative levels of complement factors were correlated to the presence of reticular pseudodrusen (RPD), the presence of hyperreflective foci (HRF), and total drusen volume (DV) graded on imaging by spectral-domain optical coherence tomography and using Spearman's rank correlation test. Results DV correlated with C3b/iC3b (r= 0.285;P= 0.034), C3a (r= 0.200;P= 0.047), Ba (r= 0.262;P= 0.009), and C5 (r= 430;P= 0.005), and showed a tendency towards correlation with C3a (r= 0.198;P= 0.057). HRF correlated significantly with C5 (r= 0.388;P= 0.011) and RPD showed a tendency towards correlation with CFB (r= 0.196;P= 0.050). Conclusion In patients with early AMD, HRF and drusen parameters but not RPD show low to fair levels of correlation with local complement activation in patients' AH. Better understanding of complement activation could provide some insights into the pathogenesis of AMD. Imaging biomarkers could be useful to identify suitable patients for future clinical trials with complement-modulating therapies.
C1 [Sitnilska, Vasilena; Enders, Philip; Cursiefen, Claus; Fauser, Sascha; Altay, Lebriz] Univ Cologne, Fac Med, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
   [Sitnilska, Vasilena; Enders, Philip; Cursiefen, Claus; Fauser, Sascha; Altay, Lebriz] Univ Cologne, Univ Hosp Cologne, Kerpener Str 62, D-50924 Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche & Cie AG, Basel, Switzerland.
C3 University of Cologne; University of Cologne; Roche Holding
RP Altay, L (通讯作者)，Univ Cologne, Fac Med, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.; Altay, L (通讯作者)，Univ Cologne, Univ Hosp Cologne, Kerpener Str 62, D-50924 Cologne, Germany.
EM lebriz.altay@uk-koeln.de
RI Cursiefen, Claus/ABE-5284-2020
OI cursiefen, claus/0000-0002-1958-411X
FU Projekt DEAL; F. Hoffmann-La Roche, Ltd.
FX Open Access funding provided by Projekt DEAL. This work was funded by F.
   Hoffmann-La Roche, Ltd. We thank all technical experts of our imaging
   laboratory and FOR 2240 "(Lymph-) Angiogenesis and Cellular Immunity in
   Inflammatory Diseases of the Eye" for their support (www.for2240.de)
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Altay L, 2019, EYE, V33, P1859, DOI 10.1038/s41433-019-0501-4
   Altay L, 2016, INVEST OPHTH VIS SCI, V57, P4315, DOI 10.1167/iovs.15-18855
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baek JH, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0941-9
   BAILEY JNC, 2014, COLD SPRING HARBOR P, V4
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Chavali VRM, 2015, J CLIN MED, V4, P304, DOI 10.3390/jcm4020304
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hu XF, 2020, RETINA-J RET VIT DIS, V40, P1070, DOI 10.1097/IAE.0000000000002531
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lin LY, 2018, JAMA OPHTHALMOL, V136, P682, DOI 10.1001/jamaophthalmol.2018.1231
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oeverhaus M, 2017, OPHTHALMOLOGICA, V238, P6, DOI 10.1159/000468949
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Reinehr S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01381
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2019, INVEST OPHTH VIS SCI, V60, P4469, DOI 10.1167/iovs.19-27475
   Sitnilska V, 2020, OPHTHALMOLOGICA, V243, P444, DOI 10.1159/000507196
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Williams PA, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0091-6
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 63
TC 7
Z9 8
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2021
VL 259
IS 3
BP 623
EP 632
DI 10.1007/s00417-020-04910-6
EA SEP 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QM0ZA
UT WOS:000565661700001
PM 32876798
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Schalnus, R
   Meyer, CH
   Kuhli-Hattenbach, C
   Luchtenberg, M
AF Schalnus, Rainer
   Meyer, Carsten H.
   Kuhli-Hattenbach, Claudia
   Luechtenberg, Marc
TI Time between Symptom Onset and Assessment in Age-Related Macular
   Degeneration with Subfoveal Choroidal Neovascularization
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Anti-vascular endothelial growth
   factor; Choroidal neovascularization; Quality of life; Visual function;
   Visual loss; Ranibizumab
ID QUALITY-OF-LIFE; COST-UTILITY; VISUAL-LOSS; RANIBIZUMAB; INFORMATION;
   PARAMETERS; PEGAPTANIB; MEMBRANES; THERAPY; BURDEN
AB Background: Therapy delay in neovascular age-related macular degeneration (NV-AMD) is associated with risk of visual deterioration. Methods: Retrospective cross section analysis including patients with NV-AMD who received fluorescein angiography (FA). The time elapsed from symptom onset to assessment was analysed in relation to different factors. Inclusion criteria were: age >50 years, symptom onset within 6 months before assessment, no previous AMD therapy, indication for vascular endothelial growth factor inhibitor treatment. Results: Mean duration of symptoms was 2.272 +/- 1.683 months (n = 220); percentiles 25, 50, 75 and 90 corresponded to 1, 2, 3 and 5.383 months. A significant increase (p = 0.033) in mean symptom duration was found between age groups 65-74, 75-84 and over 84 years. Privately insured persons (assessment 1.242 +/- 1.060 months after symptom onset; n = 14) received FA 1.083 months earlier (p = 0.0089) than patients with a statutory health insurance assessment 2.325 +/- 1.661 months after symptom onset; n = 194). Conclusion: In order to avoid progressive visual deterioration in patients with NV-AMD earlier assessment of these individuals should be aimed for. Copyright (C) 2009 S. Karger AG, Basel
C1 [Schalnus, Rainer; Kuhli-Hattenbach, Claudia; Luechtenberg, Marc] Goethe Univ Frankfurt, Dept Ophthalmol, Mainz, Germany.
   [Meyer, Carsten H.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
C3 Goethe University Frankfurt; University of Bonn
RP Schalnus, R (通讯作者)，Goethe Univ Frankfurt, Dept Ophthalmol, Theodor Stern Kai 7, DE-60590 Frankfurt, Germany.
EM schalnus@em.uni-frankfurt.de
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298
FU Novartis Pharma GmbH, Nurnberg, Germany
FX This study was supported by Novartis Pharma GmbH, Nurnberg, Germany.
CR Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Bohm MRR, 2007, KLIN MONATSBL AUGENH, V224, P129, DOI 10.1055/s-2007-962955
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Kroll P, 2006, BRIT J OPHTHALMOL, V90, P128, DOI 10.1136/bjo.2005.083337
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Luchtenberg M, 2008, OPHTHALMOLOGICA, V222, P187, DOI 10.1159/000126082
   Luchtenberg M, 2008, KLIN MONATSBL AUGENH, V225, P1075, DOI 10.1055/s-2008-1027636
   MACULAR P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Meyer CH, 2008, KLIN MONATSBL AUGENH, V225, P629, DOI 10.1055/s-2008-1027475
   Meyer CH, 2008, OPHTHALMOLOGE, V105, P125, DOI 10.1007/s00347-008-1702-6
   Meyer CH, 2008, OPHTHALMOLOGICA, V222, P364, DOI 10.1159/000151246
   Neubauer AS, 2007, KLIN MONATSBL AUGENH, V224, P727, DOI 10.1055/s-2007-963470
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Pauleikhoff D, 2009, OPHTHALMOLOGE, V106, P242, DOI 10.1007/s00347-008-1797-9
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
   2007, OPHTHALMOLOGE, V104, P628
NR 31
TC 9
Z9 9
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2010
VL 224
IS 3
BP 176
EP 182
DI 10.1159/000239236
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 513KU
UT WOS:000271322000008
PM 19776657
DA 2022-11-30
ER

PT J
AU von der Burchard, C
   Sudkamp, H
   Tode, J
   Ehlken, C
   Purtskhvanidze, K
   Moltmann, M
   Heimes, B
   Koch, P
   Munst, M
   Vom Endt, M
   Kepp, T
   Theisen-Kunde, D
   Konig, I
   Huttmann, G
   Roider, J
AF von der Burchard, Claus
   Sudkamp, Helge
   Tode, Jan
   Ehlken, Cristoph
   Purtskhvanidze, Konstantine
   Moltmann, Moritz
   Heimes, Britta
   Koch, Peter
   Muenst, Michael
   Vom Endt, Malte
   Kepp, Timo
   Theisen-Kunde, Dirk
   Koenig, Inke
   Huettmann, Gereon
   Roider, Johann
TI Self-Examination Low-Cost Full-Field Optical Coherence Tomography
   (SELFF-OCT) for neovascular age-related macular degeneration: a
   cross-sectional diagnostic accuracy study
SO BMJ OPEN
LA English
DT Article
DE medical retina; vetreoretinal; ophthalmology
ID RANIBIZUMAB; TOOL
AB Objectives Self-Examination Low-Cost Full-Field Optical Coherence Tomography (SELFF-OCT) is a novel OCT technology that was specifically designed for home monitoring of neovascular age-related macular degeneration (AMD). First clinical findings have been reported before. This trial investigates an improved prototype for patients with AMD and focusses on device operability and diagnostic accuracy compared with established spectral-domain OCT (SD-OCT). Design Prospective single-arm diagnostic accuracy study. Setting Tertiary care centre (University Eye Clinic). Participants 46 patients with age-related macular degeneration. Interventions Patients received short training in device handling and then performed multiple self-scans with the SELFF-OCT according to a predefined protocol. Additionally, all eyes were examined with standard SD-OCT, performed by medical personnel. All images were graded by at least 2 masked investigators in a reading centre. Primary outcome measure Rate of successful self-measurements. Secondary outcome measures Sensitivity and specificity of SELFF-OCT versus SD-OCT for different biomarkers and necessity for antivascular endothelial growth factor (anti-VEGF) treatment. Results In 86% of all examined eyes, OCT self-acquisition resulted in interpretable retinal OCT volume scans. In these patients, the sensitivity for detection of anti-VEGF treatment necessity was 0.94 (95% CI 0.79 to 0.99) and specificity 0.95 (95% CI 0.82 to 0.99). Conclusions SELFF-OCT was used successfully for retinal self-examination in most patients, and it could become a valuable tool for retinal home monitoring in the future. Improvements are in progress to reduce device size and to improve handling, image quality and success rates.
C1 [von der Burchard, Claus; Tode, Jan; Ehlken, Cristoph; Purtskhvanidze, Konstantine; Roider, Johann] Univ Klinikum Schleswig Holstein, Dept Ophthalmol, Kiel, Germany.
   [Sudkamp, Helge; Moltmann, Moritz; Koch, Peter; Muenst, Michael; Vom Endt, Malte; Kepp, Timo; Theisen-Kunde, Dirk; Huettmann, Gereon] Med Laser Ctr Lubeck GmbH, Lubeck, Germany.
   [Tode, Jan] Hannover Med Sch, Dept Ophthalmol, Hannover, Germany.
   [Heimes, Britta] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Koenig, Inke] Univ Lubeck, Inst Med Biometry & Stat, Lubeck, Germany.
   [Huettmann, Gereon] Univ Lubeck, Inst Biomed Opt, Lubeck, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; Hannover
   Medical School; St. Franziskus-Hospital; University of Lubeck;
   University of Lubeck
RP von der Burchard, C (通讯作者)，Univ Klinikum Schleswig Holstein, Dept Ophthalmol, Kiel, Germany.
EM claus.vonderburchard@uksh.de
RI von der Burchard, Claus/GZG-4104-2022; König, Inke R/A-4544-2009
OI König, Inke R/0000-0003-0504-6465; vom Endt, Malte/0000-0002-8596-4698;
   Heimes-Bussmann, Britta/0000-0003-3898-1679
FU Federal Ministry of Education and Research (BMBF) [13N13766]
FX The study is supported by Federal Ministry of Education and Research
   (BMBF) (Grant numbrer: 13N13766).
CR Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Bruender MC, 2018, GRAEF ARCH CLIN EXP, V256, P1565, DOI 10.1007/s00417-018-4021-x
   Chamard C, 2019, J FR OPHTALMOL, V42, P1049, DOI 10.1016/j.jfo.2019.02.017
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Gesellschaft DO, 2015, OPHTHALMOLOGE, P237, DOI [10.1007/s00347-014-3222-x, DOI 10.1007/S00347-014-3222-X]
   Gisbert G, SELF SUPERVISED DENO
   Hoerster R, 2011, BRIT J OPHTHALMOL, V95, P1424, DOI 10.1136/bjo.2010.201129
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kepp T., 2020, SPIE MED IMAGING
   Maloca P, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.8
   Nahen K, 2020, KLIN MONATSBL AUGENH, V237, P1410, DOI 10.1055/a-1271-6834
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Querques G, 2011, INVEST OPHTH VIS SCI, V52, P7012, DOI 10.1167/iovs.11-7517
   R Development Core Team, 2022, R LANG ENV STAT COMP
   Romo-Bucheli D, 2020, BIOMED OPT EXPRESS, V11, P346, DOI 10.1364/BOE.379978
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Song G, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.61
   Sudkamp H, 2018, OPT LETT, V43, P4224, DOI 10.1364/OL.43.004224
   Sudkamp H, 2016, OPT LETT, V41, P4987, DOI 10.1364/OL.41.004987
   Thomas M, 2012, INVESTIG OPHTHALMOL, V53, P3825
   von der Burchard C, 2021, GRAEF ARCH CLIN EXP, V259, P1503, DOI 10.1007/s00417-020-05035-6
   von der Burchard C, 2018, GRAEF ARCH CLIN EXP, V256, P1623, DOI 10.1007/s00417-018-4040-7
NR 26
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD JUN
PY 2022
VL 12
IS 6
AR e055082
DI 10.1136/bmjopen-2021-055082
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 2O1NV
UT WOS:000818834200002
PM 35760534
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lee, SC
   Rusakevich, AM
   Amin, A
   Tran, S
   Emami-Naeini, P
   Moshiri, A
   Park, SS
   Yiu, G
AF Lee, Sophie C.
   Rusakevich, Alexander M.
   Amin, Aana
   Tran, Steven
   Emami-Naeini, Parisa
   Moshiri, Ala
   Park, Susanna S.
   Yiu, Glenn
TI Long-Term Retinal Vascular Changes in Age- Related Macular Degeneration
   Measured Using Optical Coherence Tomography Angiography
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID VESSEL DENSITY; HEMODYNAMIC MODEL; NEOVASCULARIZATION
AB BACKGROUND AND OBJECTIVE: To determine if age -related macular degeneration (AMD) status affects longitudinal retinal vessel changes.PATIENTS AND METHODS: Retrospective, cohort study of 125 eyes (75 patients) with AMD, follow-ing retinal vessel density (VD) and foveal avascular zone (FAZ) measurements using optical coherence tomography angiography (OCT-A) over 24 months.RESULTS: FAZ area (P < .001) and perimeter (P < .001) increased over 2 years, with no difference between nonexudative and exudative AMD (P = .134-.976). Eyes with geographic atrophy (GA) showed greater progressive VD loss (P = .023-.038), and greater in-crease in FAZ area (P = .044) and perimeter (P = .040) compared to eyes without GA. Neither baseline nor 2-year change in vascular parameters were associated with choroidal neovascularization (CNV) or GA incidence in nonexudative AMD, or anti-VEGF injection frequency in exudative AMD (P = .070-.952).CONCLUSION: AMD eyes with GA undergo more rapid loss of retinal vessel density and FAZ enlarge-ment over 2 years, suggesting a relationship between the retinal vasculature and AMD pathophysiology.
C1 [Lee, Sophie C.; Rusakevich, Alexander M.; Amin, Aana; Tran, Steven; Emami-Naeini, Parisa; Moshiri, Ala; Park, Susanna S.; Yiu, Glenn] Univ Calif Davis, UC Davis Hlth Eye Ctr, Dept Ophthalmol & Vis Sci, Sacramento, CA USA.
   [Rusakevich, Alexander M.] Touro Univ, Coll Osteopath Med, Vallejo, CA USA.
   [Yiu, Glenn] Univ Calif Davis Hlth, Eye Ctr, Dept Ophthalmol & Vis Sci, 4860 Y Street,Suite 2400, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis; Touro
   University California
RP Yiu, G (通讯作者)，Univ Calif Davis Hlth, Eye Ctr, Dept Ophthalmol & Vis Sci, 4860 Y Street,Suite 2400, Sacramento, CA 95817 USA.
EM gyiu@ucdavis.edu
CR Cennamo G, 2020, OPHTHALMOL THER, V9, P77, DOI 10.1007/s40123-019-00221-0
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Di Pierdomenico J, 2019, NEURAL REGEN RES, V14, P1186, DOI 10.4103/1673-5374.251204
   Durbin MK, 2017, JAMA OPHTHALMOL, V135, P370, DOI 10.1001/jamaophthalmol.2017.0080
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Garcia-Ayuso D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184649
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Ho J, 2019, RETINA-J RET VIT DIS, V39, P259, DOI 10.1097/IAE.0000000000001951
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jones Bryan W, 2005, Clin Exp Optom, V88, P282
   Lee MW, 2019, BRIT J OPHTHALMOL, V103, P704, DOI 10.1136/bjophthalmol-2018-312516
   Lee SC, 2020, AM J OPHTHALMOL, V212, P7, DOI 10.1016/j.ajo.2019.11.031
   Lei JQ, 2017, JAMA OPHTHALMOL, V135, P1092, DOI 10.1001/jamaophthalmol.2017.3431
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Pfeiffer RL, 2016, EXP EYE RES, V150, P62, DOI 10.1016/j.exer.2016.04.022
   Qiang W, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.734860
   Roesch Karin, 2012, Mol Vis, V18, P1197
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2022, AM J OPHTHALMOL, V235, P291, DOI 10.1016/j.ajo.2021.08.015
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Snyder K, 2018, JAMA OPHTHALMOL, V136, P1008, DOI 10.1001/jamaophthalmol.2018.2650
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   VillegasPerez MP, 1996, NEUROREPORT, V7, P1995, DOI 10.1097/00001756-199608120-00028
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   You QS, 2020, AM J OPHTHALMOL, V209, P206, DOI 10.1016/j.ajo.2019.09.004
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 29
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD OCT
PY 2022
VL 53
IS 10
BP 529
EP 536
DI 10.3928/23258160-20220919-01
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 5S7XP
UT WOS:000875398000001
PM 36239679
DA 2022-11-30
ER

PT J
AU Petrarca, R
   Dugel, PU
   Nau, J
   Slakter, JS
   Jaffe, GJ
   Jackson, TL
AF Petrarca, Robert
   Dugel, Pravin U.
   Nau, Jeffrey
   Slakter, Jason S.
   Jaffe, Glenn J.
   Jackson, Timothy L.
TI Macular Epiretinal Brachytherapy in Treated Age-related Macular
   Degeneration (MERITAGE) Month 12 Optical Coherence Tomography and
   Fluorescein Angiography
SO OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; VISUAL-ACUITY; 12-MONTH SAFETY;
   BEVACIZUMAB; THERAPY
AB Purpose: To report the optical coherence tomography (OCT) and fundus fluorescein angiography (FFA) results of the Macular Epiretinal Brachytherapy in Treated Age-Related Macular Degeneration study.
   Design: Prospective, multicenter, interventional, noncontrolled clinical trial.
   Participants: Fifty-three eyes of 53 participants with chronic, active neovascular age-related macular degeneration (AMD) requiring frequent anti-vascular endothelial growth factor retreatment.
   Methods: Participants underwent pars plana vitrectomy with a single 24-gray dose of epimacular brachytherapy (EMB), delivered with an intraocular, handheld, cannula containing a strontium 90/yttrium 90 source positioned over the active lesion. Participants were retreated with ranibizumab administered monthly as needed, using predefined retreatment criteria. Patients underwent FFA at baseline, month 1, and month 12. Patients underwent optical coherence tomography (OCT) at baseline and then monthly for 12 months. The FFA and OCT images were evaluated by independent, central reading facilities.
   Main Outcome Measures: Change in OCT centerpoint thickness and angiographic lesion size 12 months after EMB.
   Results: Mean centerpoint thickness increased by 50 mu m, from 186 to 236 mu m (P = 0.292), but 70% of participants had an increase of less than the mean, with a median increase of only 1.8 mu m. The FFA total lesion size increased slightly by 0.79 mm(2), from 14.69 to 15.48 mm(2) (P = 0.710). Total choroidal neovascularization (CNV) area increased by 1.17 mm(2), from 12.94 to 14.12 mm(2) (P = 0.556). The classic CNV area decreased substantially by 3.70 mm(2), from 3.90 to 0.20 mm(2) (P = 0.01). Predominantly classic lesions showed the greatest response, with mean Early Treatment Diabetic Retinopathy Study visual acuity improving by 1.5 letters (versus -4.0 for all participants combined); mean centerpoint thickness decreased by 43 mu m (P = 0.875). The angiographic and OCT response did not correlate with lesion size at baseline.
   Conclusions: In chronic, active, neovascular AMD, EMB is associated with nonsignificant changes in centerpoint thickness and FFA total lesion size over 12 months.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2013;120:328-333 (C) 2013 by the American Academy of Ophthalmology.
C1 [Petrarca, Robert; Jackson, Timothy L.] Kings Coll Hosp, London SE5 9RS, England.
   [Petrarca, Robert; Jackson, Timothy L.] Kings Coll London, London, England.
   [Dugel, Pravin U.; Nau, Jeffrey] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Nau, Jeffrey] NeoVista, Newark, CA USA.
   [Slakter, Jason S.] Digital Angiog Reading Ctr, New York, NY USA.
   [Jaffe, Glenn J.] Duke Univ, Ctr Eye, Duke Reading Ctr, Durham, NC USA.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; King's College London; Duke University
RP Jackson, TL (通讯作者)，Kings Coll Hosp, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM t.jackson1@nhs.net
OI Petrarca, Robert/0000-0001-8693-3423; Jackson,
   Timothy/0000-0001-7618-1555
FU NeoVista, Inc.
FX Timothy L. Jackson: Financial support-NeoVista, Inc.
CR Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Petrarca Robert, 2012, Retin Cases Brief Rep, V6, P353, DOI 10.1097/ICB.0b013e31823c12a3
NR 7
TC 14
Z9 14
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2013
VL 120
IS 2
BP 328
EP 333
DI 10.1016/j.ophtha.2012.07.091
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 085WX
UT WOS:000314646100017
PM 23178157
DA 2022-11-30
ER

PT J
AU Cho, HJ
   Song, MY
   Yoon, W
   Yoon, J
   Na, SK
   Lee, J
   Kim, J
   Kim, JW
AF Cho, Han Joo
   Song, Mi Yeon
   Yoon, Wontae
   Yoon, Jihyun
   Na, Seung Kwan
   Lee, Jihyun
   Kim, Jaemin
   Kim, Jong Woo
TI Neovascular age-related macular degeneration in which exudation
   predominantly occurs as a subretinal fluid during anti-vascular
   endothelial growth factor treatment
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL DETACHMENT;
   VISUAL-ACUITY; MORPHOLOGY; THERAPY; IMPACT
AB We investigated the characteristics of neovascular age-related macular degeneration (AMD) in which exudation predominantly occurs as a subretinal fluid (SRF) during anti-vascular endothelial growth factor (VEGF) treatment. A total of 509 treatment-naive neovascular AMD patients treated with anti-VEGF for 24 months were retrospectively analyzed. The baseline characteristics to determine the odds of occurrence of SRF alone were evaluated using multivariate modeling. SRF was the sole manifestation of lesion activity in 209 (40.9%) eyes during follow-up. The visual outcome of eyes with only SRF occurrence during follow-up was comparable to that of eyes without exudative recurrence. In addition, the incidence of macular atrophy was significantly lower in eyes with only SRF occurrence (9.6%, 20 of 208 eyes) than in eyes without exudative recurrence (16.7%, 9 of 54 eyes, P = 0.018). Multivariate analysis revealed that better best-corrected visual acuity (BCVA) at baseline (odds ratio [OR], 0.306; P = 0.001), presence of SRF alone at baseline (OR, 5.256; P < 0.001), lower pigment epithelial detachment (PED) height (less than 100 mu m; OR, 4.113; P = 0.025), and aneurysmal type 1 macular neovascularization (MNV) (OR, 2.594; P = 0.002) were associated with an increased likelihood of SRF occurrence during follow-up. In conclusion, the eyes with only SRF occurrence during anti-VEGF treatment showed more favorable visual outcomes and a lower incidence of macular atrophy. The baseline characteristics, including better baseline BCVA, presence of SRF alone at baseline, lower PED height, and MNV subtype, might influence the predominant development of SRF during anti-VEGF treatment.
C1 [Cho, Han Joo; Song, Mi Yeon; Yoon, Wontae; Yoon, Jihyun; Na, Seung Kwan; Lee, Jihyun; Kim, Jaemin; Kim, Jong Woo] Konyang Univ, Kims Eye Hosp, Coll Med, 156,4ga, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Cho, HJ (通讯作者)，Konyang Univ, Kims Eye Hosp, Coll Med, 156,4ga, Seoul, South Korea.
EM chojoo@kimeye.com
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Cho HJ, 2022, AM J OPHTHALMOL, V234, P6, DOI 10.1016/j.ajo.2021.07.026
   Cho HJ, 2021, ACTA OPHTHALMOL, V99, pE540, DOI 10.1111/aos.14631
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fu DJ, 2021, JAMA OPHTHALMOL, V139, P57, DOI 10.1001/jamaophthalmol.2020.5044
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Llorente-Gonzalez S, 2022, ACTA OPHTHALMOL, V100, pE521, DOI 10.1111/aos.14905
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Pelosini L, 2011, INVEST OPHTH VIS SCI, V52, P2741, DOI 10.1167/iovs.09-4493
   Reiter GS, 2021, RETINA-J RET VIT DIS, V41, P1318, DOI 10.1097/IAE.0000000000003023
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Rouvas AA, 2010, EYE, V24, P1633, DOI 10.1038/eye.2010.134
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma A., 2021, RETINA-J RET VIT DIS, DOI [10.1097/IAE.0000000000003261, DOI 10.1097/IAE.0000000000003261]
   Sharma A, 2021, BRIT J OPHTHALMOL, V105, P149, DOI 10.1136/bjophthalmol-2020-317933
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Skondra D, 2012, SEMIN OPHTHALMOL, V27, P209, DOI 10.3109/08820538.2012.708807
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
NR 30
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 24
PY 2022
VL 12
IS 1
AR 3167
DI 10.1038/s41598-022-07108-4
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZI0FQ
UT WOS:000761303400006
PM 35210516
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU McGuinness, MB
   Karahalios, A
   Simpson, JA
   Guymer, RH
   Robman, LD
   Hodge, AM
   Cerin, E
   Giles, GG
   Finger, RP
AF McGuinness, Myra B.
   Karahalios, Amalia
   Simpson, Julie A.
   Guymer, Robyn H.
   Robman, Luba D.
   Hodge, Allison M.
   Cerin, Ester
   Giles, Graham G.
   Finger, Robert P.
TI Past physical activity and age-related macular degeneration: the
   Melbourne Collaborative Cohort Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Macula; Neovascularisation; Epidemiology; Retina
ID UNITED-STATES; RISK-FACTORS; PREVALENCE; EYE; MORTALITY; EXERCISE;
   PATTERNS; OBESITY; ADULTS; HEALTH
AB Background/aims To assess the association between past physical activity and early, intermediate and late age-related macular degeneration (AMD) in a community-based cohort study in Melbourne, Australia.
   Methods Diet and lifestyle information was recorded at baseline (1990-1994) and total recreational activity was derived from walking, vigorous and non-vigorous exercise. At follow-up (2003-2007), digital macular photographs were graded for early, intermediate and late AMD. Data were analysed using multinomial logistic regression controlling for age, sex, smoking, region of descent, diet and alcohol. Effect modification by sex was investigated.
   Results Out of 20816 participants, early, intermediate and late AMD were detected at follow-up in 4244 (21%), 2661 (13%) and 122 (0.6%) participants, respectively. No association was detected between past total recreational physical activity and early, intermediate or late AMD. Frequent (3 times/week) and less frequent (1-2 times/week) vigorous exercise were associated with lower odds of intermediate and late AMD in univariable models. After controlling for confounders, there was evidence of effect modification by sex and frequent vigorous exercise was associated with a 22% decrease in the odds of intermediate AMD (95% CI 4% to 36%) in women, but no association was found for men.
   Conclusions Past frequent vigorous exercise may be inversely related to the presence of intermediate AMD in women. Further studies are needed to confirm whether physical activity and exercise have a protective effect for AMD.
C1 [McGuinness, Myra B.; Guymer, Robyn H.; Robman, Luba D.; Finger, Robert P.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [McGuinness, Myra B.; Karahalios, Amalia; Simpson, Julie A.; Giles, Graham G.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia.
   [McGuinness, Myra B.; Guymer, Robyn H.; Robman, Luba D.; Giles, Graham G.; Finger, Robert P.] Univ Melbourne, Dept Ophthalmol, Melbourne, Vic, Australia.
   [Hodge, Allison M.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
   [Cerin, Ester] Deakin Univ, Sch Exercise & Nutr Sci, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; University of
   Melbourne; Cancer Council Victoria; Deakin University
RP Finger, RP (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Dept Ophthalmol, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM robert.finger@ukb.uni-bonn.de
RI Cerin, Ester/Z-2011-2019; Cerin, Ester/L-1271-2015; McGuinness,
   Myra/G-4900-2017
OI Cerin, Ester/0000-0002-7599-165X; Cerin, Ester/0000-0002-7599-165X;
   McGuinness, Myra/0000-0002-5422-040X; Hodge,
   Allison/0000-0001-5464-2197; Simpson, Julie/0000-0002-2660-2013; Guymer,
   Robyn/0000-0002-9441-4356; Finger, Robert P/0000-0003-4253-7597; Giles,
   Graham/0000-0003-4946-9099
FU VicHealth and Cancer Council Victoria; National Health & Medical
   Research Council of Australia (NHMRC) [209057, 251533, 396414];
   Ophthalmic Research Institute of Australia; American Health Assistance
   Foundation [M2008-082]; Jack Brockhoff Foundation; John Reid Charitable
   Trust; Perpetual; NHMRC Centre of Clinical Research Excellence grant
   [529923]; Victorian Government; NHMRC [300052, 529905]; Charles Viertel
   Charitable Foundation; Lloyd and Kathleen Ansell Ophthalmology
   Foundation; Mankiewicz-Zelkin Fellowship of the University of Melbourne;
   ARC Future Fellowship [FT140100085]; Australian Postgraduate Award;
   studentship courtesy of Victorian Centre for Biostatistics (NHMRC:
   Centre of Research Excellence grant) [1035261]
FX Cohort recruitment was funded by VicHealth and Cancer Council Victoria.
   Further Melbourne Collaborative Cohort Study funding: the National
   Health & Medical Research Council of Australia (NHMRC) Program Grant
   209057, Capacity Building Grant 251533 and Enabling Grant 396414. The
   ophthalmic component was funded by the Ophthalmic Research Institute of
   Australia; American Health Assistance Foundation (M2008-082), Jack
   Brockhoff Foundation, John Reid Charitable Trust, Perpetual Trustees.
   The Centre for Eye Research Australia is a recipient of the NHMRC Centre
   of Clinical Research Excellence grant (529923) and Operational
   Infrastructure Support from the Victorian Government. People support was
   provided through the NHMRC Career Development (300052) and Practitioner
   (529905) Fellowships to RHG. The presented analysis was supported by the
   Charles Viertel Charitable Foundation, the Lloyd and Kathleen Ansell
   Ophthalmology Foundation and the Mankiewicz-Zelkin Fellowship of the
   University of Melbourne to RPF. EC is supported by an ARC Future
   Fellowship (FT140100085). MBM is funded by an Australian Postgraduate
   Award and a studentship courtesy of Victorian Centre for Biostatistics
   (NHMRC: Centre of Research Excellence grant 1035261). This work was
   supported by infrastructure from the Cancer Council Victoria.
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Ainsworth B.E., 2011, COMPENDIUM PHYS ACTI
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Caspersen CJ, 2000, MED SCI SPORT EXER, V32, P1601
   Committee PAGA, 2008, PHYS ACT GUID AM, P56
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dandona R, 2001, BRIT J OPHTHALMOL, V85, P1484, DOI 10.1136/bjo.85.12.1484
   Dhurandhar NV, 2015, INT J OBESITY, V39, P1109, DOI 10.1038/ijo.2014.199
   DiPietro L, 2001, J GERONTOL A-BIOL, V56, P13, DOI 10.1093/gerona/56.suppl_2.13
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gopinath B, 2014, INVEST OPHTH VIS SCI, V55, P7799, DOI 10.1167/iovs.14-15575
   Ireland P, 1994, Asia Pac J Clin Nutr, V3, P19
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804
   Penedo FJ, 2005, CURR OPIN PSYCHIATR, V18, P189, DOI 10.1097/00001504-200503000-00013
   Radak Z, 2001, EXERC IMMUNOL REV, V7, P90
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   WALDRON I, 1993, SOC SCI MED, V36, P451, DOI 10.1016/0277-9536(93)90407-U
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 27
TC 18
Z9 18
U1 0
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2016
VL 100
IS 10
BP 1353
EP 1358
DI 10.1136/bjophthalmol-2015-307663
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DX8YW
UT WOS:000384679400009
PM 26787681
DA 2022-11-30
ER

PT J
AU Capuano, V
   Farci, R
   Miere, A
   Amoroso, F
   Bandello, F
   Souied, EH
   Querques, G
AF Capuano, Vittorio
   Farci, Roberta
   Miere, Alexandra
   Amoroso, Francesca
   Bandello, Francesco
   Souied, Eric H.
   Querques, Giuseppe
TI Centrifugal Extension of Retinal Atrophy in Retinal Pigment Epithelium
   Tears Secondary to Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; GROWTH-FACTOR THERAPY; FUNDUS
   AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; PROGRESSION
AB BACKGROUND AND OBJECTIVE: To investigate the progression of retinal atrophy in patients with retinal pigment epithelium (RPE) tears secondary to neovascular age-related macular degeneration.
   PATIENTS AND METHODS: In this retrospective case series, patients were analyzed at two high-volume referral centers. The extension of the areas without RPE was analyzed yearly from baseline to last examination through fundus autofluorescence (FAF) imaging using Region Finder (Heidelberg Engineering, Heidelberg, Germany).
   RESULTS: Sixteen eyes of 14 patients were included in the study. Mean follow-up was 70.11 months +/- 15.5 months. The average area of atrophy was 6.89 mm(2) +/- 5.4 mm(2) at baseline and 9.21 mm(2) +/- 7.7 mm(2) at the last visit (P < .0001). This accounts for a progression of 0.36 mm(2) +/- 0.46 mm(2)/year. In all cases, FAF revealed centrifugal extension of retinal atrophy.
   CONCLUSIONS: In this series, the area of retinal atrophy enlarged over time. Atrophy enlargement is characterized by centrifugal extension from the base of the tear.
C1 [Capuano, Vittorio; Farci, Roberta; Miere, Alexandra; Amoroso, Francesca; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Farci, Roberta] Univ Cagliari, Dept Ophthalmol, Cagliari, Italy.
   [Bandello, Francesco] Univ Vita Salute, IRCCS, Osped San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   University of Cagliari; Vita-Salute San Raffaele University; IRCCS
   Ospedale San Raffaele
RP Querques, G (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
RI Miere, Alexandra/AIC-4074-2022; bandello, francesco/AAH-2405-2019
OI Miere, Alexandra/0000-0003-4123-8210; bandello,
   francesco/0000-0003-3238-9682; Querques, Giuseppe/0000-0002-3292-9581
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Adi M, 2014, RETINA, V34, P306
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Cavallero E, 2016, J FR OPHTALMOL, V39, P64, DOI 10.1016/j.jfo.2015.05.010
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Christoph RC, 2014, ACTA OPHTHALMOL, V92, pe50
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Empeslidis T, 2014, OPEN OPHTHALMOL J, V8, P101, DOI 10.2174/1874364101408010101
   Erol MK, 2015, ARQ BRAS OFTALMOL, V78, P168, DOI 10.5935/0004-2749.20150043
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Hirano Y, 2014, ACTA OPHTHALMOL, V92, P94, DOI 10.1111/j.1755-3768.2012.02561.x
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Mouallem A, 2016, RETINA-J RET VIT DIS, V36, P2197, DOI 10.1097/IAE.0000000000001062
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Panthier C, 2014, RETINA-J RET VIT DIS, V34, P576, DOI 10.1097/01.iae.0000433986.32991.1e
   Pece A, 2010, OPHTHALMOLOGICA, V224, P159, DOI 10.1159/000236910
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Sato Taku, 2014, Retin Cases Brief Rep, V8, P120, DOI 10.1097/ICB.0000000000000019
   Saxena Sandeep, 2012, J Ocul Biol Dis Infor, V5, P70, DOI 10.1007/s12177-013-9105-6
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
NR 25
TC 1
Z9 1
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2017
VL 48
IS 9
BP 705
EP 710
DI 10.3928/23258160-20170829-04
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA FN5TY
UT WOS:000416072300003
PM 28902330
DA 2022-11-30
ER

PT J
AU Maguire, MG
   Daniel, E
   Shah, AR
   Grunwald, JE
   Hagstrom, SA
   Avery, RL
   Huang, JY
   Martin, RW
   Roth, DB
   Castellarin, AA
   Bakri, SJ
   Fine, SL
   Martin, DF
AF Maguire, Maureen G.
   Daniel, Ebenezer
   Shah, Ankoor R.
   Grunwald, Juan E.
   Hagstrom, Stephanie A.
   Avery, Robert L.
   Huang, Jiayan
   Martin, Revell W.
   Roth, Daniel B.
   Castellarin, Alessandro A.
   Bakri, Sophie J.
   Fine, Stuart L.
   Martin, Daniel F.
CA Comparison Age-Related Macular
TI Incidence of Choroidal Neovascularization in the Fellow Eye in the
   Comparison of Age-related Macular Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB AVASTIN; RISK-FACTORS;
   INTRAVITREAL INJECTION; DIABETIC-RETINOPATHY; SEVERITY SCALE;
   PLASMA-LEVELS; VISION LOSS; 2ND EYE; RANIBIZUMAB
AB Objective: To assess the influence of drug; dosing regimen; and traditional, nontraditional, and genetic risk factors on the incidence of choroidal neovascularization (CNV) in the fellow eye of patients treated for CNV with ranibizumab or bevacizumab.
   Design: Cohort study of patients enrolled in a multicenter, randomized clinical trial.
   Participants: Patients with no CNV in the fellow eye at the time of enrollment in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
   Methods: Eligibility criteria for the clinical trial required that study eyes have evidence on fluorescein angiography and optical coherence tomography of CNV secondary to age-related macular degeneration (AMD) and visual acuity between 20/25 and 20/320. Treatment for the study eye was assigned randomly to either ranibizumab or bevacizumab and to 3 different regimens for dosing over a 2-year period. The genotypes for 4 single nucleotide polymorphisms (SNPs) associated with risk of AMD were determined. Only patients without CNV in the fellow eye at baseline were considered at risk. The CATT ophthalmologists examined patients every 4 weeks through 2 years and recorded treatment for CNV in the fellow eye.
   Main Outcome Measures: Development of CNV in the fellow eye.
   Results: Among 1185 CATT participants, 727 (61%) had no CNV in the fellow eye at enrollment. At 2 years, CNV had developed in 75 (20.6%) of 365 patients treated with ranibizumab and in 60 (16.6%) of 362 patients treated with bevacizumab (absolute difference, 4.0%; 95% confidence interval [CI], -1.7% to 9.6%; P = 0.17). The risk ratio for pro re nata dosing relative to monthly dosing was 1.1 (95% CI, 0.8-1.6). Greater elevation of the retinal pigment epithelium and fluid in the foveal center of the study eye were associated with increased incidence of CNV in the fellow eye. Incidence was not associated with genotype on rs1061170 (CFH), rs10490924 (ARMS2), rs11200638 (HTRA1), and rs2230199 (C3; P>0.35).
   Conclusions: Through 2 years, there was no statistically significant difference between ranibizumab and bevacizumab in incidence of CNV in the fellow eye. Genotype on 4 SNPs previously found to be associated with AMD did not affect the risk of CNV in the fellow eye among CATT patients.
C1 [Maguire, Maureen G.; Daniel, Ebenezer; Shah, Ankoor R.; Grunwald, Juan E.; Huang, Jiayan; Martin, Revell W.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Hagstrom, Stephanie A.; Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Avery, Robert L.; Castellarin, Alessandro A.] Calif Retina Consultants, Santa Barbara, CA USA.
   [Roth, Daniel B.] Retina Vitreous Ctr, New Brunswick, NJ USA.
   [Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
   [Fine, Stuart L.] Univ Colorado Denver, Dept Ophthalmol, Aurora, CO USA.
C3 University of Pennsylvania; Cleveland Clinic Foundation; Mayo Clinic;
   Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus
RP Maguire, MG (通讯作者)，Univ Penn, CATT Coordinating Ctr, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
OI Daniel, Ebenezer/0000-0002-2027-2316
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828];
   NATIONAL EYE INSTITUTE [U10EY017823, U10EY017828, U10EY017825,
   U10EY017826] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (cooperative agreement nos.: U10 EY017823, U10
   EY017825, U10 EY017826, and U10 EY017828). ClinicalTrials.gov
   registration number, NCT00593450.
CR Acharya NR, 2011, RETINA-J RET VIT DIS, V31, P1871, DOI 10.1097/IAE.0b013e318213da43
   Al-Dhibi H, 2009, J AAPOS, V13, P400, DOI 10.1016/j.jaapos.2009.03.006
   [Anonymous], 2013, LUC RAN INJ
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2012, J AAPOS, V16, P2, DOI 10.1016/j.jaapos.2011.11.002
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Davidovic SP, 2012, EUR J OPHTHALMOL, V22, P792, DOI 10.5301/ejo.5000118
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Qian J, 2011, RETINA-J RET VIT DIS, V31, P161, DOI 10.1097/IAE.0b013e3181e46ad8
   Sato T, 2012, AM J OPHTHALMOL, V153, P327, DOI 10.1016/j.ajo.2011.07.005
   Sinapis CI, 2011, CLIN OPHTHALMOL, V5, P697, DOI 10.2147/OPTH.S19555
   Submacular Surgery Trials Research Group, 2007, Arch Ophthalmol, V125, P1323
   Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Ziemssen Focke, 2009, International Ophthalmology, V29, P213, DOI 10.1007/s10792-008-9221-7
NR 40
TC 55
Z9 56
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2013
VL 120
IS 10
BP 2035
EP 2041
DI 10.1016/j.ophtha.2013.03.017
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 227CQ
UT WOS:000325086400020
PM 23706946
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Grosso, A
   Mosley, TH
   Klein, R
   Couper, DJ
   Tikellis, G
   Wong, TY
AF Grosso, Andrea
   Mosley, Thomas H.
   Klein, Ronald
   Couper, David J.
   Tikellis, Gabriella
   Wong, Tien Y.
CA Atherosclerosis Risk Communities S
TI Is early age-related macular degeneration associated with cerebral MRI
   changes? The atherosclerosis risk in communities study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ALZHEIMERS-DISEASE; MACULOPATHY; ATROPHY
AB PURPOSE: To examine the relation of early age-related macular degeneration (AMD) with cerebral magnetic resonance imaging (MRI) changes.
   DESIGN: Population-based, cross,sectional study.
   METHODS: A sample of 1,684 persons ages 51 to 72 years with no history of stroke had cerebral MRI and retinal photography. MRI scans were graded for severity of white matter lesions (WML), sulcal widening (SW), and ventricular enlargement (VE). AMD was graded from retinal photographs.
   RESULTS: After adjustment for age, gender, race, or center, early AMD (5.0% of participants) was not significantly associated with WML (odds ratio [OR] 1.0, 95% confidence intervals [CI], 0.6 to 1.6), SW (OR 0.6, 95% CI, 0.4 to 1.2), or VE (OR 1.0, 95% CI, 0.6 to 1.8).
   CONCLUSIONS: These data showed no statistically significant association of early AMD with cerebral MRI changes, but the study was limited by a small number of cases with wide CIs. Further studies may clarify these associations.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Univ Turin, Sect Ophthalmol, Dept Clin Physiopathol, Turin, Italy.
   Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA.
   Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   Univ N Carolina, Dept Biostat, Chapel Hill, NC USA.
   Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Turin; University of Mississippi; University of Mississippi Medical
   Center; University of Wisconsin System; University of Wisconsin Madison;
   University of North Carolina; University of North Carolina Chapel Hill;
   National University of Singapore; Singapore National Eye Center
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Couper, David/0000-0002-4313-9235
FU NHLBI NIH HHS [N01 HC 55018, N01 HC 55021, N01 HC 55022, N01 HC 55020,
   N01 HC 55019, N01 HC 55016, N01 HC 55015] Funding Source: Medline;
   DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055018,
   N01HC055019, N01HC055015, N01HC055016, N01HC055020, N01HC055022,
   N01HC055021] Funding Source: NIH RePORTER
CR Fox NC, 2004, LANCET, V363, P392, DOI 10.1016/S0140-6736(04)15441-X
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Wong TY, 2002, JAMA-J AM MED ASSOC, V288, P67, DOI 10.1001/jama.288.1.67
   Wong TY, 2003, NEUROLOGY, V61, P806, DOI 10.1212/01.WNL.0000086372.05488.8D
NR 7
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2007
VL 143
IS 1
BP 157
EP 159
DI 10.1016/j.ajo.2006.07.040
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123QY
UT WOS:000243311700027
PM 17188055
DA 2022-11-30
ER

PT J
AU Amarakoon, S
   Martinez-Ciriano, JP
   Baarsma, S
   van den Born, LI
   Missotten, T
AF Amarakoon, Sankha
   Martinez-Ciriano, Jose P.
   Baarsma, Seerp
   van den Born, L. Ingeborgh
   Missotten, Tom
TI Reactivation of CNV after Discontinuation of Bevacizumab Treatment of
   Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Reactivation; Recurrence; Choroidal neovascularization; Age-related
   macular degeneration
ID CHOROIDAL NEOVASCULARIZATION; AFLIBERCEPT TREATMENT; OUTCOMES;
   RECURRENCE; RANIBIZUMAB; THERAPY; TRIAL; AMD
AB Introduction: Treatment of exudative age-related macular degeneration (ARMD) has shifted to pro re nata and treat-extend-stop strategies. However, a rational discontinuation strategy is lacking. To develop such a strategy, it is important to determine choroidal neovascularization (CNV) recurrence rates after anti-VEGF treatment is discontinued. Here we report prospective data on persistent and recurrent CNV activity after discontinuation of bevacizumab treatment. Methods: This prospective, single-center clinical trial enrolled 191 patients with exudative ARMD. Patients were randomly assigned to receiving intravitreal bevacizumab injections every 4, 6, or 8 weeks for 1 year. CNV activity was determined in the 157 patients who completed the 1-year treatment regimen. Patients with inactive CNV were then followed for signs of CNV reactivation. Results: After 1 year of treatment, 66 (42%) of the 157 patients still had signs of persistent active CNV. Of the remaining 91 (58%) patients, 61 (67%) needed retreatment for active CNV within the first year after discontinuation of treatment (mean 4.28 +/- 0.29 months). CNV was reactivated in 50 (80%) of the 61 patients within 6 months after their final treatment for CNV. Conclusion: Based on quiescent disease, anti-VEGF therapy was discontinued in 58% of the patients after they received bevacizu-mab injections every 4, 6, or 8 weeks for 1 year; 67% showed reactivated CNV within a year after discontinuation. The high reactivation rate of CNV shown in this study should help clinicians to develop rational discontinuation protocols.
C1 [Amarakoon, Sankha; Martinez-Ciriano, Jose P.; Baarsma, Seerp; van den Born, L. Ingeborgh; Missotten, Tom] Rotterdam Eye Hosp, Rotterdam, Netherlands.
   [Amarakoon, Sankha] Rotterdam Ophthalm Inst, Rotterdam, Netherlands.
C3 Rotterdam Eye Hospital
RP Amarakoon, S (通讯作者)，Rotterdam Eye Hosp, Rotterdam, Netherlands.; Amarakoon, S (通讯作者)，Rotterdam Ophthalm Inst, Rotterdam, Netherlands.
EM sankhaamarakoon@gmail.com
FU SWOO-Flieringa (Rotterdam, The Netherlands); Stichting voor Ooglijders
   (Rotterdam, The Netherlands)
FX This study was funded by SWOO-Flieringa (Rotterdam, The Netherlands) and
   Stichting voor Ooglijders (Rotterdam, The Netherlands). These funding
   organizations had no role in the design or conduction of this research.
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Berendschot T, 2014, NEDERLANDS OOGHEELKU
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Haddad WM, 2017, RETINA-J RET VIT DIS, V37, P951, DOI 10.1097/IAE.0000000000001282
   Kim JH, 2020, J OCUL PHARMACOL TH, V36, P703, DOI 10.1089/jop.2019.0158
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nguyen V, 2019, OPHTHALMOL RETINA, V3, P623, DOI 10.1016/j.oret.2019.05.013
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Real JP, 2018, GRAEF ARCH CLIN EXP, V256, P1079, DOI 10.1007/s00417-018-3974-0
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   Wakazono T, 2017, RETINA-J RET VIT DIS, V37, P2062, DOI 10.1097/IAE.0000000000001451
NR 23
TC 1
Z9 1
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD JUL
PY 2021
VL 244
IS 3
BP 200
EP 207
DI 10.1159/000514539
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TF3RY
UT WOS:000670635600005
PM 33465772
DA 2022-11-30
ER

PT J
AU Thiele, S
   Nadal, J
   Pfau, M
   Sassmannshausen, M
   Fleckenstein, M
   Holz, FG
   Schmid, M
   Schmitz-Valckenberg, S
AF Thiele, Sarah
   Nadal, Jennifer
   Pfau, Maximilian
   Sassmannshausen, Marlene
   Fleckenstein, Monika
   Holz, Frank G.
   Schmid, Matthias
   Schmitz-Valckenberg, Steffen
TI Prognostic value of intermediate age-related macular degeneration
   phenotypes for geographic atrophy progression
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE imaging; macula; retina; degeneration
ID RETICULAR PSEUDODRUSEN; VISUAL IMPAIRMENT; DRUSEN; PREVALENCE; EYES;
   SECONDARY; PATTERNS
AB Background
   To characterise early stages of geographic atrophy (GA) development in age-related macular degeneration (AMD) and to determine the prognostic value of structural precursor lesions in eyes with intermediate (i) AMD on the subsequent GA progression.
   Methods
   Structural precursor lesions for atrophic areas (lesion size at least 0.5 mm(2) in fundus autofluorescence images) were retrospectively identified based on multimodal imaging and evaluated for association with the subsequent GA enlargement rates (square-root transformed, sqrt). A linear mixed-effects model was used to account for the hierarchical nature of the data with a Tukey post hoc test to assess the impact of the local precursor on the subsequent GA progression rate.
   Results
   A total of 39 eyes with GA of 34 patients with a mean age of 74.4 +/- 6.7 (+/- SD) years were included in this study. Five precursor lesions (phenotypes 1-5) preceding GA development were identified: large, sub-retinal pigment epithelial drusen (n=19), reticular pseudodrusen (RPD, n=10), refractile deposits (n=4), pigment epithelial detachment (n=4) and vitelliform lesions (n=2). Precursor lesions exhibited a significant association with the subsequent (sqrt) GA progression rates (p=0.0018) with RPD (phenotype 2) being associated with the fastest GA enlargement (2.29 +/- 0.52 (+/- SE) mm/year.
   Conclusions
   The results indicate the prognostic relevance of iAMD phenotyping for subsequent GA progression highlighting the role of structural AMD features across different AMD stages.
C1 [Thiele, Sarah; Pfau, Maximilian; Sassmannshausen, Marlene; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Nordrhein Westf, Germany.
   [Nadal, Jennifer; Schmid, Matthias] Univ Hosp Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Nordrhein Westf, Germany.
   [Pfau, Maximilian] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.
C3 University of Bonn; University of Bonn; Stanford University
RP Thiele, S (通讯作者)，Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Nordrhein Westf, Germany.
EM sarah.thiele@ukbonn.de
OI Schmid, Matthias/0000-0002-0788-0317; Pfau,
   Maximilian/0000-0001-9761-9640
FU BONFOR GEROK Program, Faculty of Medicine, University of Bonn
   [O-137.0026, O-137.0022, O-137.0025]; Deutsche Forschungsgemeinschaft
   [FL658/4-1, FL658/4-2, PF 950/1-1]; Federal Ministry of Education and
   Research of Germany (BMBF) [FKZ 13N10349]
FX This work was supported by the BONFOR GEROK Program, Faculty of
   Medicine, University of Bonn, grant numbers O-137.0026 to ST, O-137.0022
   and O-137.0025 to MP, by the Deutsche Forschungsgemeinschaft, grant
   numbers FL658/4-1 and FL658/4-2 to MF, PF 950/1-1 to MP; by the Federal
   Ministry of Education and Research of Germany (BMBF), scholarship FKZ
   13N10349.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Bonnet C, 2014, RETINA-J RET VIT DIS, V34, P1524, DOI 10.1097/IAE.0000000000000165
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fleckenstein M, 2016, INVEST OPHTH VIS SCI, V57, P2463, DOI 10.1167/iovs.15-18593
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Pfau M, 2019, RETINA-J RET VIT DIS, V39, P1527, DOI 10.1097/IAE.0000000000002206
   Pfau M, 2018, BRIT J OPHTHALMOL, V102, P1054, DOI 10.1136/bjophthalmol-2017-311012
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P257, DOI 10.1097/IAE.0000000000002399
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness Janet S, 2008, Retin Cases Brief Rep, V2, P83, DOI 10.1097/IAE.0b013e31802fa25d
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Thiele S, 2020, OPHTHALMOL RETINA, V4, P31, DOI 10.1016/j.oret.2019.08.003
   Thiele S, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23315
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 39
TC 10
Z9 10
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2021
VL 105
IS 2
BP 239
EP 245
DI 10.1136/bjophthalmol-2020-316004
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QB6HE
UT WOS:000614238600017
PM 32269061
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Skeie, JM
   Mullins, RF
AF Skeie, Jessica M.
   Mullins, Robert F.
TI Elastin-Mediated Choroidal Endothelial Cell Migration: Possible Role in
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BRUCHS MEMBRANE; NEOVASCULAR MEMBRANES; EXTRACELLULAR-MATRIX; POSTMORTEM
   EYES; GROWTH-FACTOR; RISK-FACTORS; FIBULIN-5; ANGIOGENESIS; INDUCTION;
   PEPTIDES
AB PURPOSE. Endothelial cell (EC) migration is a key event in angiogenesis, and is likely to play an important role in choroidal neovascularization in age-related macular degeneration (AMD). Altered elastin metabolism has been described in AMD, and the present study sought to determine the effects of elastin-derived peptides (EDPs) on choroidal EC migration and proliferation.
   METHODS. Migration of the chorioretinal EC line Rf/6a and a primary culture of human choroidal ECs through polycarbonate membrane inserts was quantified in the presence of elastin bioactive hexapeptides (BPs), EDPs, bovine serum albumin (BSA), or balanced salt solution. Proliferation assays and in vitro wound closure experiments were also performed in the presence of elastin fragments or balanced salt solution (control). Elastin overlay experiments were performed on sections of human eyes.
   RESULTS. For both Rf/6a and human primary choroidal ECs exposed to EDPs or BPs, the number of ECs that migrated through the polycarbonate membrane was significantly higher than ECs exposed to balanced salt solution alone or to BSA (P < 0.05) in all experiments. In contrast, the rate of EC proliferation did not significantly change in comparison to controls. Elastin binding sites were identified on choroidal ECs in human eyes.
   CONCLUSIONS. Elastin fragments increase choroidal EC migration, whereas they do not appear to increase or decrease EC proliferation. Local or systemic abnormalities in elastin physiology may participate in pathologic neovascular membrane formation in AMD. (Invest Ophthalmol Vis Sci. 2008; 49: 5574-5580) DOI:10.1167/iovs.08-1984
C1 [Skeie, Jessica M.; Mullins, Robert F.] Univ Iowa, Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Skeie, Jessica M.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa
RP Mullins, RF (通讯作者)，Univ Iowa, Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, 375 Newton Rd, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891
FU NEI [EY017451]; Macula Vision Research Foundation; The Foundation
   Fighting Blindness; Alcon Research, Ltd.; NATIONAL EYE INSTITUTE
   [R01EY017451, F32EY022280] Funding Source: NIH RePORTER
FX Supported in part by NEI Grant EY017451 (RFM), Macula Vision Research
   Foundation (RFM), a center grant from The Foundation Fighting Blindness,
   and Alcon Research, Ltd. (RFM).
CR BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Brooke BS, 2003, TRENDS CELL BIOL, V13, P51, DOI 10.1016/S0962-8924(02)00007-7
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   DeCarlo AA, 2008, J PERIODONTAL RES, V43, P246, DOI 10.1111/j.1600-0765.2007.01015.x
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
   Green W R, 1999, Mol Vis, V5, P27
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Hayden MR, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475-2840-4-9
   Hogan M J, 1967, Trans Ophthalmol Soc U K, V87, P113
   McLaughlin AP, 2001, AM J PHYSIOL-CELL PH, V281, pC1448, DOI 10.1152/ajpcell.2001.281.5.C1448
   Mullins RF, 2005, MOL VIS, V11, P509
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a
   Pepper MS, 1998, J CELL PHYSIOL, V177, P439, DOI 10.1002/(SICI)1097-4652(199812)177:3<439::AID-JCP7>3.0.CO;2-2
   Robinet A, 2005, J CELL SCI, V118, P343, DOI 10.1242/jcs.01613
   SCHNEEBE.EE, 1968, J CELL BIOL, V37, P781, DOI 10.1083/jcb.37.3.781
   Sivaprasad S, 2005, INVEST OPHTH VIS SCI, V46, P3046, DOI 10.1167/iovs.04-1277
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Stone EM, 2006, NEW ENGL J MED, V355, P1493, DOI 10.1056/NEJMe068191
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a
   Yu HG, 2008, INVEST OPHTH VIS SCI, V49, P2599, DOI 10.1167/iovs.07-1508
NR 29
TC 24
Z9 27
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2008
VL 49
IS 12
BP 5574
EP 5580
DI 10.1167/iovs.08-1984
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 376OW
UT WOS:000261193900054
PM 18708613
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Matsuura, T
   Takayama, K
   Kaneko, H
   Ye, FX
   Fukukita, H
   Tsunekawa, T
   Kataoka, K
   Hwang, SJ
   Nagasaka, Y
   Ito, Y
   Terasaki, H
AF Matsuura, Toshiyuki
   Takayama, Kei
   Kaneko, Hiroki
   Ye, Fuxiang
   Fukukita, Hiroshi
   Tsunekawa, Taichi
   Kataoka, Keiko
   Hwang, Shiang-Jyi
   Nagasaka, Yosuke
   Ito, Yasuki
   Terasaki, Hiroko
TI Nutritional Supplementation Inhibits the Increase in Serum
   Malondialdehyde in Patients with Wet Age-Related Macular Degeneration
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; LIPID-PEROXIDATION PRODUCTS; OXIDATIVE STRESS;
   EYE DISEASE; ANTIOXIDANT; AMD; PATHOGENESIS; PROGRESSION; PLASMA; LUTEIN
AB Purpose. To compare serum levels of malondialdehyde (MDA) in patients with wet age-related macular degeneration (wAMD), patients with dryAMD(dAMD), and patients without AMD and to evaluate the efficacy of nutritional supplementation for treating elevated serum MDA in patients with wAMD. Methods. MDA levels were measured in sera from 20 patients with wAMD, 20 with dAMD, and 24 without AMD. Patients with wAMD were randomized to receive or not receive nutritional supplementation (10 patients in each group), and MDA levels were measured after 3 months of treatment. Results. MDA levels in patients with wAMD were significantly greater compared with patients without AMD. In eyes with wAMD, there was a significant correlation between MDA levels and choroidal neovascularization lesion area. Serum MDA levels decreased in most patients that received supplementation and significantly increased in those who did not. Conclusion. Baseline serum MDA levels were elevated in patients with wAMD, and MDA levels were directly correlated with choroidal neovascularization lesion area. In addition, nutritional supplementation appeared to exert a protective effect against oxidative stress in patients with wAMD.
C1 [Matsuura, Toshiyuki; Takayama, Kei; Kaneko, Hiroki; Ye, Fuxiang; Fukukita, Hiroshi; Tsunekawa, Taichi; Kataoka, Keiko; Hwang, Shiang-Jyi; Nagasaka, Yosuke; Ito, Yasuki; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4668550, Japan.
   [Ye, Fuxiang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol, Shanghai 200240, Peoples R China.
   [Hwang, Shiang-Jyi] Nagoya Univ, Grad Sch Med, Dept Obstet & Gynecol Collaborat Res, Lab Bell Res Ctr, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University; Shanghai Jiao Tong University; Nagoya University
RP Kaneko, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4668550, Japan.
EM h-kaneko@med.nagoya-u.ac.jp
RI Ito, Yasuki/M-4876-2014; Kaneko, Hiroki/O-7695-2015; Kaneko,
   Hiroki/AHA-2461-2022; Kataoka, Keiko/B-2806-2016
OI Ito, Yasuki/0000-0001-9219-9261; Kaneko, Hiroki/0000-0003-0731-6465;
   Kaneko, Hiroki/0000-0003-0731-6465; Ye, Fuxiang/0000-0003-2550-2173;
   Takayama, Kei/0000-0002-1477-9014; Kataoka, Keiko/0000-0002-8795-6536
FU Chukyo Longevity Medical and Promotion Foundation; Takeda Medical
   Research Foundation; Takeda Science Foundation;  [15H04994]
FX The authors give heartfelt thanks to all the patients who participated
   in this study. The authors also thank Reona Kimoto, Chisato Ishizuka,
   Keigo Ohmori, and Kumi Fujiwara for technical assistance. This work was
   partially supported by Grants-in-Aid for Scientific Research B (Hiroko
   Terasaki; 15H04994), Chukyo Longevity Medical and Promotion Foundation
   (Hiroki Kaneko), Takeda Medical Research Foundation (Hiroki Kaneko), and
   Takeda Science Foundation (Hiroki Kaneko). Mishima Saiichi-kinen
   Gankakenkyu Kokusaikouryu Kikin (Hiroki Kaneko) and Itoh-Chubei
   Foundation (Hiroki Kaneko) are also acknowledged.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergmann M, 2011, GRAEF ARCH CLIN EXP, V249, P1477, DOI 10.1007/s00417-011-1682-0
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P1104, DOI 10.1016/j.ajo.2011.12.010
   Brzek P, 2014, J EXP BIOL, V217, P1504, DOI 10.1242/jeb.100073
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Del Rio D, 2005, NUTR METAB CARDIOVAS, V15, P316, DOI 10.1016/j.numecd.2005.05.003
   Du Hongjun, 2016, Open J Ophthalmol, V6, P43
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Holz FG, 2015, GRAEF ARCH CLIN EXP, V253, P7, DOI 10.1007/s00417-014-2858-1
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Li X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047600
   Li Y, 2014, REDOX BIOL, V2, P485, DOI 10.1016/j.redox.2014.01.023
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Njie-Mbye YF, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00366
   Okuyama H, 1996, PROG LIPID RES, V35, P409, DOI 10.1016/S0163-7827(96)00012-4
   Ramsden C. E., 2013, BRIT MED J, V346
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Spickett CM, 2013, REDOX BIOL, V1, P145, DOI 10.1016/j.redox.2013.01.007
   Takayama K., 2016, GRAEFEARCH CLIN EX
   Takayama K., RETINA IN PRESS
   Takayama K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8694641
   Takayama K, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004978
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Wang X, 2014, OPHTHALMIC RES, V52, P198, DOI 10.1159/000363327
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
   Ye FX, 2015, SCI REP-UK, V5, DOI 10.1038/srep07705
   Yildirim O, 2004, OPHTHALMOLOGICA, V218, P202, DOI 10.1159/000076845
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 50
TC 12
Z9 12
U1 1
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2017
VL 2017
AR 9548767
DI 10.1155/2017/9548767
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EK7TK
UT WOS:000394127900001
PM 28243361
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU van Dijk, EHC
   Holtz, JK
   Sirks, MJ
   Larsson, JME
   Diederen, RMH
   Schlingemann, RO
   Boon, CJF
   Subhi, Y
AF van Dijk, Elon H. C.
   Holtz, Jeppe K.
   Sirks, Marc J.
   Larsson, Janni M. E.
   Diederen, Roselie M. H.
   Schlingemann, Reinier O.
   Boon, Camiel J. F.
   Subhi, Yousif
TI European Prevalence of Polypoidal Choroidal Vasculopathy: A Systematic
   Review, Meta-Analysis, and Forecasting Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE polypoidal choroidal vasculopathy; prevalence; Europe; systematic
   review; meta-analysis; forecasting
ID MACULAR DEGENERATION; DISEASE
AB The purpose of this study was to provide an estimate of the number of current and future patients with polypoidal choroidal vasculopathy (PCV) in Europe. We systematically searched 11 literature databases on 18 May 2022 for studies on the prevalence of PCV among a consecutive and representative group of patients with suspected neovascular age-related macular degeneration (AMD). Prevalence of PCV in patients with suspected neovascular AMD was summarized and included in a prevalence meta-analysis. We then used current population data and population forecasts by Eurostat and the Office for National Statistics to determine current and future number of patients with neovascular AMD in Europe. Then, we calculated the number of patients with PCV with our calculated estimate of the prevalence of PCV among Europeans suspected with neovascular AMD. A total of five eligible studies were identified which included a total of 1359 patients. All these studies used the gold standard of indocyanine green angiography as a routine part of their diagnostic approach. Among patients undergoing detailed retinal examination for suspected neovascular AMD, our meta-analysis calculated the prevalence of PCV to be 8.3% (95% confidence interval: 6.8-9.8%). Our population estimates find that a total of 217,404 patients with PCV exist in Europe in the year 2022, which constitutes 0.04% of the entire population of Europe. This number is estimated to increase to 287,517 patients in the year 2040. Our estimates are important for different healthcare stakeholders, especially when planning and allocating expensive resources.
C1 [van Dijk, Elon H. C.; Boon, Camiel J. F.] Leiden Univ, Med Ctr, Dept Ophthalmol, NL-2333 ZA Leiden, Netherlands.
   [Holtz, Jeppe K.] Odense Univ Hosp, Dept Ophthalmol, DK-5000 Odense, Denmark.
   [Holtz, Jeppe K.] Odense Univ Hosp, Dept Otolaryngol, DK-5000 Odense, Denmark.
   [Sirks, Marc J.; Diederen, Roselie M. H.; Schlingemann, Reinier O.; Boon, Camiel J. F.] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Ophthalmol, NL-1012 WX Amsterdam, Netherlands.
   [Larsson, Janni M. E.; Subhi, Yousif] Rigshosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark.
   [Schlingemann, Reinier O.] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile Aveugles, Dept Ophthalmol, CH-1015 Lausanne, Switzerland.
   [Subhi, Yousif] Univ Southern Denmark, Dept Clin Res, DK-5230 Odense, Denmark.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; University of Southern Denmark; Odense
   University Hospital; University of Southern Denmark; Odense University
   Hospital; University of Amsterdam; Rigshospitalet; University of
   Lausanne; University of Southern Denmark
RP Subhi, Y (通讯作者)，Rigshosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark.; Subhi, Y (通讯作者)，Univ Southern Denmark, Dept Clin Res, DK-5230 Odense, Denmark.
EM ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365; Sirks, Marc/0000-0002-8788-7753; van
   Dijk, Elon/0000-0002-6351-7942
FU Foundation MB
FX This research received funding from the Foundation MB.
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Chung WH, 2017, CLIN OPHTHALMOL, V11, P63, DOI 10.2147/OPTH.S122568
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gharehbagh SS, 2018, ACTA OPHTHALMOL, V96, pE94, DOI 10.1111/aos.13461
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Ilginis T, 2012, ACTA OPHTHALMOL, V90, pe487, DOI 10.1111/j.1755-3768.2011.02329.x
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lee K, 2020, GRAEF ARCH CLIN EXP, V258, P1157, DOI 10.1007/s00417-020-04620-z
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Lorentzen TD, 2018, ACTA OPHTHALMOL, V96, P475, DOI 10.1111/aos.13646
   Potapenko I, 2021, ACTA OPHTHALMOL, V99, pE1348, DOI 10.1111/aos.14802
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sedeh FB, 2017, DAN MED J, V64
   Sirks MJ, 2022, ACTA OPHTHALMOL, V100, pE1522, DOI 10.1111/aos.15148
   Spaide RF, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100973
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Subhi Y, 2017, CASE REP OPHTHALMOL, V2017, DOI 10.1155/2017/9650287
   van Dijk EHC, 2021, GRAEF ARCH CLIN EXP, V259, P351, DOI 10.1007/s00417-020-04844-z
   van Dijk EHC, 2020, OPHTHALMOL THER, V9, P329, DOI 10.1007/s40123-020-00250-0
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yannuzzi L.A, 1982, P MACULA SOC M
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
NR 39
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2022
VL 11
IS 16
AR 4766
DI 10.3390/jcm11164766
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 4B0YJ
UT WOS:000845514200001
PM 36013005
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dias, JRD
   Zhang, Q
   Garcia, JMB
   Zheng, F
   Motulsky, EH
   Roisman, L
   Miller, A
   Chen, CL
   Kubach, S
   de Sisternes, L
   Durbin, MK
   Feuer, W
   Wang, RK
   Wang, RKK
   Rosenfeld, PJ
AF Dias, Joao R. de Oliveira
   Zhang, Qinqin
   Garcia, Jose M. B.
   Zheng, Fang
   Motulsky, Elie H.
   Roisman, Luiz
   Miller, Andrew
   Chen, Chieh-Li
   Kubach, Sophie
   de Sisternes, Luis
   Durbin, Mary K.
   Feuer, William
   Wang, Ruikang K.
   Gregori, Giovanni
   Rosenfeld, Philip J.
TI Natural History of Subclinical Neovascularization in Nonexudative
   Age-Related Macular Degeneration Using Swept-Source OCT Angiography
SO OPHTHALMOLOGY
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; QUIESCENT CHOROIDAL
   NEOVASCULARIZATION; INDOCYANINE-GREEN VIDEOANGIOGRAPHY; RETINAL-PIGMENT
   EPITHELIUM; SPECTRAL-DOMAIN; OPTICAL MICROANGIOGRAPHY;
   MICRO-ANGIOGRAPHY; DRUSEN; CLASSIFICATION; EYES
AB Purpose: Swept-source (SS) OCT angiography (OCTA) was used to determine the prevalence, incidence, and natural history of subclinical macular neovascularization (MNV) in eyes with nonexudative age-related macular degeneration (AMD).
   Design: Prospective, observational, consecutive case series.
   Participants: Patients with intermediate AMD (iAMD) or geographic atrophy (GA) secondary to nonexudative AMD in 1 eye and exudative AMD in the fellow eye.
   Methods: All patients were imaged using both the 3 x 3 mm and 6 x 6 mm SS OCTA fields of view (PLEX Elite 9000; Carl Zeiss Meditec, Inc, Dublin, CA). The en face slab used to detect the MNV extended from the outer retina to the choriocapillaris, and projection artifacts were removed using a proprietary algorithm.
   Main Outcome Measures: Prevalence of subclinical MNV and time to exudation with Kaplan-Meier cumulative estimates of exudation at 1 year.
   Results: From August 2014 through March 2017, 160 patients underwent SS OCTA (110 eyes with iAMD and 50 eyes with GA). Swept-source OCTA identified subclinical MNV at the time of first imaging in 23 of 160 eyes, for a prevalence of 14.4%. Six eyes demonstrated subclinical MNV during the follow-up. Of 134 eyes with follow-up visits, a total of 13 eyes demonstrated exudation, and of these 13 eyes, 10 eyes were found to have pre-existing subclinical MNV. By 12 months, the Kaplan-Meier cumulative incidence of exudation for all 134 eyes was 6.8%. For eyes with subclinical MNV at the time of first SS OCTA imaging, the incidence was 21.1%, and for eyes without subclinical MNV, the incidence was 3.6%. There was no difference in the cumulative incidence of exudation from pre-existing MNV in eyes with iAMD or GA (P = 0.847, log-rank test). After the detection of subclinical MNV, the risk of exudation was 15.2 times (95% confidence interval, 4.2-55.4) greater compared with eyes without subclinical MNV.
   Conclusions: By 12 months, the risk of exudation was greater for eyes with documented subclinical MNV compared with eyes without detectable MNV. For eyes with subclinical MNV, recommendations include more frequent follow-up and home monitoring. Intravitreal therapy is not recommended until prospective studies are performed. (C) 2017 by the American Academy of Ophthalmology
C1 [Dias, Joao R. de Oliveira; Garcia, Jose M. B.; Zheng, Fang; Motulsky, Elie H.; Roisman, Luiz; Miller, Andrew; Feuer, William; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
   [Zhang, Qinqin; Chen, Chieh-Li; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Zheng, Fang] Tianjin Med Univ, Gen Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
   [Kubach, Sophie; de Sisternes, Luis; Durbin, Mary K.] Carl Zeiss Meditec Inc, Res & Dev, Dublin, CA USA.
C3 Bascom Palmer Eye Institute; University of Miami; University of
   Washington; University of Washington Seattle; Tianjin Medical
   University; Carl Zeiss AG
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
RI Wang, Ruikang/L-3889-2019; roisman, luiz/AAD-3822-2019
OI Wang, Ruikang/0000-0001-5169-8822; 
FU Carl Zeiss Meditec, Inc.; Apellis; Carl Zeiss Meditec, Inc; Genentech;
   Tyrogenex; Dublin; California; National Eye Institute, National
   Institutes of Health, Bethesda, Maryland [R01EY024158, P30EY014801];
   Research to Prevent Blindness, Inc, New York, New York; CAPES
   Foundation, Ministry of Education of Brazil, Brasilia, Brazil; NATIONAL
   CANCER INSTITUTE [R01CA176001] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [R01EY024158, P30EY014801] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): J.R.d.O.D.:
   Financial support - Carl Zeiss Meditec, Inc.; Q.Z.: Financial support -
   Carl Zeiss Meditec, Inc.; E.H.M.: Financial support - Carl Zeiss
   Meditec, Inc.; R.K.W.: Financial support and Patent - Carl Zeiss
   Meditec, Inc; Equity owner - Carl Zeiss Meditec, Inc, Kowa, Inc.; G.G.:
   Financial support and Patent - Carl Zeiss Meditec, Inc.; P.J.R.:
   Consultant - Carl Zeiss Meditec, Inc, Acucela, Boehringer-Ingelheim,
   Cell Cure Neurosciences, Chengdu Kanghong Biotech, Genentech, Healios
   K.K, F. Hoffmann-La Roche Ltd, Isarna Pharmaceuticals, MacRegen, Inc,
   Ocudyne, Ocunexus Therapeutics, Tyrogenex, Unity Biotechnology;
   Financial support - Carl Zeiss Meditec, Inc, Apellis, Genentech,
   Tyrogenex; Equity owner - Apellis, Digisight, Ocudyne; Supported by Carl
   Zeiss Meditec, Inc, Dublin, California; the National Eye Institute,
   National Institutes of Health, Bethesda, Maryland (grant nos.:
   R01EY024158 and P30EY014801 [Department of Ophthalmology, University of
   Miami Miller School of Medicine]); an unrestricted grant from the
   Research to Prevent Blindness, Inc, New York, New York (R.K.W.); and the
   CAPES Foundation, Ministry of Education of Brazil, Brasilia, Brazil
   (L.R.). The funding organizations had no role in the design or conduct
   of this research.
CR Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Nehemy MB, 2015, OSLI RETINA, V46, P1056, DOI 10.3928/23258160-20151027-13
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P2433, DOI 10.1097/IAE.0000000000000761
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Reif R, 2012, INT J BIOMED IMAGING, V2012, DOI 10.1155/2012/509783
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Wei W, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.3.036005
   Yin X, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.8.086020
   Zhang AQ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.10.100901
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P1919, DOI 10.1364/BOE.6.001919
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 31
TC 115
Z9 115
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2018
VL 125
IS 2
BP 255
EP 266
DI 10.1016/j.ophtha.2017.08.030
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FT0FN
UT WOS:000422797600026
PM 28964581
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Merle, BMJ
   Barthes, S
   Feart, C
   Cougnard-Gregoire, A
   Korobelnik, JF
   Rougier, MB
   Delyfer, MN
   Delcourt, C
AF Merle, Benedicte M. J.
   Barthes, Stephanie
   Feart, Catherine
   Cougnard-Gregoire, Audrey
   Korobelnik, Jean-Francois
   Rougier, Marie-Benedicte
   Delyfer, Marie-Noelle
   Delcourt, Cecile
TI B Vitamins and Incidence of Advanced Age-Related Macular Degeneration:
   The Alienor Study
SO NUTRIENTS
LA English
DT Article
DE age-related macular degeneration; vitamins B; folate; epidemiology;
   nutrition; cohort; risk; population
ID GENOME-WIDE ASSOCIATION; PLASMA HOMOCYSTEINE; GENETIC SUSCEPTIBILITY;
   FOLIC-ACID; FOLATE; RISK; MACULOPATHY; PROGRESSION; DETERMINANTS;
   CAROTENOIDS
AB B vitamins may protect against age-related macular degeneration (AMD). We evaluated the associations of dietary intake and serum vitamins with the incidence of advanced AMD in the Alienor study. The Alienor study is a prospective population-based cohort of 963 residents of Bordeaux, France, who were 73 years or older at baseline (2006-2008). Examinations were performed every two years over an eight-year period. The incidence of AMD is based on retinal fundus photographs and spectral-domain optical coherence tomography examinations. Among the 861 included participants, 93 developed incident AMD during a median follow-up time of 9.8 years. Participants with normal serum folate (>= 10 nmol/L) significantly had a 51% reduced risk for AMD in the fully adjusted Cox model (HR, 0.49 [95% CI, 0.25-0.95], p = 0.036). Participants with a higher dietary intake of B5 and B6 vitamins had a lower risk for developing AMD of up to 28% (HR, 0.72 for 1-SD increase [0.53-0.99], p = 0.049; HR, 0.90 [0.81-0.99], p = 0.049, respectively). This cohort study of older adults suggests a strong association between a normal serum folate status, a high dietary intake of B5 and B6 and a lower risk for developing advanced AMD. Adopting a healthy diet rich in B vitamins may help to reduce vision loss due to AMD.
C1 [Merle, Benedicte M. J.; Barthes, Stephanie; Feart, Catherine; Cougnard-Gregoire, Audrey; Korobelnik, Jean-Francois; Delyfer, Marie-Noelle; Delcourt, Cecile] Univ Bordeaux, UMR1219, Bordeaux Populat Hlth BPH, INSERM, F-33000 Bordeaux, France.
   [Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Delyfer, Marie-Noelle] CHU Bordeaux, Dept Ophtalmol, F-33000 Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux
RP Merle, BMJ (通讯作者)，Univ Bordeaux, UMR1219, Bordeaux Populat Hlth BPH, INSERM, F-33000 Bordeaux, France.
EM benedicte.merle@u-bordeaux.fr; bastephanie@hotmail.fr;
   catherine.feart-couret@u-bordeaux.fr;
   audrey.cougnard-gregoire@u-bordeaux.fr;
   jean-francois.korobelnik@chu-bordeaux.fr;
   marie-benedicte.rougier@chu-bordeaux.fr;
   marie-noelle.delyfer@chu-bordeaux.fr; cecile.delcourt@u-bordeaux.fr
RI Delcourt, Cecile/I-2627-2013; COUGNARD-GREGOIRE, Audrey/T-4443-2019;
   Merle, Benedicte MJ/F-1247-2015
OI Delcourt, Cecile/0000-0002-2099-0481; COUGNARD-GREGOIRE,
   Audrey/0000-0002-1494-5764; FEART, Catherine/0000-0002-7959-1610;
   Korobelnik, Jean-Francois/0000-0002-4438-9535; Merle, Benedicte
   MJ/0000-0003-1332-0954; rougier, marie-benedicte/0000-0002-0900-7941
FU Thea Pharma; Fondation Voir et Entendre; Agence Nationale de la
   Recherche [ANR 2010-PRSP-011 VISA]; French Ministry of Health [PHRC
   12_157]; CFSR Recherche (Club Francais des Specialistes de la Retine);
   Fondation Visio; CNSA (Caisse Nationale pour la Solidarite et
   l'Autonomie)
FX Alienor study is funded by Thea Pharma, Fondation Voir et Entendre,
   Agence Nationale de la Recherche (ANR 2010-PRSP-011 VISA), French
   Ministry of Health (PHRC 12_157, ECLAIR), CFSR Recherche (Club Francais
   des Specialistes de la Retine), Fondation Visio and CNSA (Caisse
   Nationale pour la Solidarite et l'Autonomie). Laboratoires Thea
   participated in the design of the Alienor study, but none of the
   sponsors participated in the collection, management, statistical
   analysis and interpretation of the data, or in the preparation, review
   or approval of the present manuscript.
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   ANSES, 2015, AV AG NAT SEC SAN AL
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Christen WG, 2018, OPHTHAL EPIDEMIOL, V25, P79, DOI 10.1080/09286586.2017.1362009
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Eilers PHC, 1996, STAT SCI, V11, P89, DOI 10.1214/ss/1038425655
   Favier JC, 1995, REPERTOIRE GEN ALIME
   Feart C, 2007, BRIT J NUTR, V98, P1046, DOI 10.1017/S0007114507756520
   Fenech M, 2012, MUTAT RES-FUND MOL M, V733, P21, DOI 10.1016/j.mrfmmm.2011.11.003
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gopinath B, 2017, BRIT J OPHTHALMOL, V101, P1027, DOI 10.1136/bjophthalmol-2016-309490
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Hercberg S., 1994, PORTIONS ALIMENTAIRE
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Keenan TD, 2020, OPHTHALMOLOGY, V127, P1515, DOI 10.1016/j.ophtha.2020.04.030
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Leffondre K, 2014, NEPHROL DIAL TRANSPL, V29, P1806, DOI 10.1093/ndt/gft500
   Lionaki E, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11020214
   LUI A, 1985, J LAB CLIN MED, V106, P491
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   McLean E, 2008, FOOD NUTR BULL, V29, pS38, DOI 10.1177/15648265080292S107
   Merle BMJ, 2021, NUTRIENTS, V13, DOI 10.3390/nu13062047
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Mikkelsen K, 2018, SUBCELL BIOCHEM, V90, P451, DOI 10.1007/978-981-13-2835-0_15
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Park LK, 2012, P NUTR SOC, V71, P75, DOI 10.1017/S0029665111003302
   Pinna A, 2018, ACTA OPHTHALMOL, V96, pE269, DOI 10.1111/aos.13343
   Renaud S., 1979, TABLE COMPOSITION AL, P105
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Souci SW., 2000, FOOD COMPOSITION NUT
   STABLER SP, 1995, J AM GERIATR SOC, V43, P1290, DOI 10.1111/j.1532-5415.1995.tb07408.x
   Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Willett W, 1998, NUTR EPIDEMIOLGY, V2nd
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 49
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUL
PY 2022
VL 14
IS 14
AR 2821
DI 10.3390/nu14142821
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 3G6VQ
UT WOS:000831490100001
PM 35889778
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Taniguchi, H
   Yoshida, I
   Sakamoto, M
   Maeno, T
AF Taniguchi, Hikari
   Yoshida, Izumi
   Sakamoto, Masashi
   Maeno, Takatoshi
TI Epiretinal membrane appearance or progression after intravitreal
   injection in age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Epiretinal membrane; Age-related macular degeneration; Intravitreal
   injection; Posterior vitreous detachment
AB Background The purpose of this study is to evaluate the influence of anti-vascular endothelial growth factor (VEGF) in the appearance or progression of epiretinal membranes (ERMs) in age-related macular degeneration (ARMD) and investigate confounding factors causing ERMs. Methods Seventy-six eyes that were treated for more than 36 months from the first anti-VEGF injection were assessed. Binary logistic regression analysis was performed between smoking, lens status, subretinal hemorrhage, posterior vitreous detachment (PVD) status, peripheral retinal degeneration, type of AMD, conditions of contralateral eye, and the number of injections as independent variables and appearance or progression of ERMs during 36 months as dependent variables. Results The presence of vitreomacular adhesion (VMA) or development of PVD during the observation period was significantly associated (Odds ratio [OR]: 5.77; 95% confidence interval [CI], 1.72-19.4; p = 0.005) with the appearance or progression of ERMs. Moreover, peripheral retinal degeneration was significantly associated (OR: 3.87; 95% CI, 1.15-13.0; p = 0.029). Injection number of anti-VEGF was not significantly associated (OR: 1.02; 95% CI, 0.90-1.16; p = 0.72). Conclusion This study suggests possibilities that anti-VEGF injections alone are unable to cause the development of ERMs, that VMA or developing PVD has a prior impact on the developing ERMs in ARMD similar to that of idiopathic ERMs, and that peripheral retinal degenerations and vitreomacular adhesion were both related to ERMs development and pathogenesis of ARMD.
C1 [Taniguchi, Hikari; Yoshida, Izumi; Sakamoto, Masashi; Maeno, Takatoshi] Toho Univ, Sakura Med Ctr, Sakura, Chiba 2858741, Japan.
   [Yoshida, Izumi] Toho Kamagaya Hosp, Kamagaya, Chiba 2730132, Japan.
C3 Toho University
RP Yoshida, I (通讯作者)，Toho Univ, Sakura Med Ctr, Sakura, Chiba 2858741, Japan.; Yoshida, I (通讯作者)，Toho Kamagaya Hosp, Kamagaya, Chiba 2730132, Japan.
EM izumi.yoshida@med.toho-u.ac.jp
OI Yoshida, Izumi/0000-0001-8921-052X
CR APPIAH AP, 1989, OPHTHALMOLOGY, V96, P389, DOI 10.1016/S0161-6420(89)32881-8
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Byon IS, 2015, OPHTHALMOLOGICA, V234, P91, DOI 10.1159/000437058
   Chatziralli I, 2018, SEMIN OPHTHALMOL, V33, P651, DOI 10.1080/08820538.2017.1395892
   Checa M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150383
   Cho HJ, 2017, J OCUL PHARMACOL TH, V33, P452, DOI 10.1089/jop.2016.0178
   Cosgrove GP, 2004, AM J RESP CRIT CARE, V170, P242, DOI 10.1164/rccm.200308-1151OC
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Donati G, 1997, INVEST OPHTH VIS SCI, V38, P1450
   Edwards MM, 2016, EXP EYE RES, V150, P44, DOI 10.1016/j.exer.2015.07.016
   Eurlings IMJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107757
   Fraser-Bell S, 2003, OPHTHALMOLOGY, V110, P34, DOI 10.1016/S0161-6420(02)01443-4
   Gardiner TA, 2005, AM J PATHOL, V166, P637, DOI 10.1016/S0002-9440(10)62284-5
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Kampik A., 2012, RETINA-J RET VIT DIS, V32, P197, DOI [10.1097/IAE.0b013e31821e9fa3, DOI 10.1097/IAE.0B013E31821E9FA3]
   Karaca EE, 2015, RETINA-J RET VIT DIS, V35, P1540, DOI 10.1097/IAE.0000000000000531
   Klein R, 1994, Trans Am Ophthalmol Soc, V92, P403
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Marticorena J, 2011, BRIT J OPHTHALMOL, V95, P391, DOI 10.1136/bjo.2009.177287
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P1033, DOI 10.1016/S0161-6420(97)30190-0
   Munk MR, 2018, OPHTHALMOL RETINA, V2, P288, DOI 10.1016/j.oret.2017.07.010
   Nivison-Smith L, 2018, OPHTHAL PHYSL OPT, V38, P584, DOI 10.1111/opo.12589
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Ota A., 2015, CLIN OPHTHALMOL, V10, P7
   Pierro L, 2012, CLIN OPHTHALMOL, V6, P219, DOI 10.2147/OPTH.S27656
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
   Wang SS, 2016, SCI REP-UK, V6, DOI 10.1038/srep22757
   Wilkins JR, 1996, OPHTHALMOLOGY, V103, P2142, DOI 10.1016/S0161-6420(96)30377-1
   WIZNIA RA, 1986, AM J OPHTHALMOL, V102, P196, DOI 10.1016/0002-9394(86)90144-3
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 33
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 28
PY 2021
VL 21
IS 1
AR 190
DI 10.1186/s12886-021-01944-0
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RU0HW
UT WOS:000644834100001
PM 33906612
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Schick, T
   Ersoy, L
   Lechanteur, YTE
   Saksens, NTM
   Hoyng, CB
   Den Hollander, AI
   Kirchhof, B
   Fauser, S
AF Schick, Tina
   Ersoy, Lebriz
   Lechanteur, Yara T. E.
   Saksens, Nicole T. M.
   Hoyng, Carel B.
   Den Hollander, Anneke I.
   Kirchhof, Bernd
   Fauser, Sascha
TI HISTORY OF SUNLIGHT EXPOSURE IS A RISK FACTOR FOR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; sunlight exposure; occupation type;
   eye color
ID BEAVER DAM EYE; SKIN SUN SENSITIVITY; BLUE MOUNTAINS EYE; 10-YEAR
   INCIDENCE; CATARACT-SURGERY; IRIS COLOR; 5-YEAR INCIDENCE; LATE-STAGE;
   MACULOPATHY; POPULATION
AB Purpose:To evaluate effects of current and past sunlight exposure and iris color on early and late age-related macular degeneration (AMD).Methods:Of 3,701 individuals from the EUGENDA database, 752 (20.3%) showed early AMD, 1,179 (31.9%) late AMD, and 1,770 (47.8%) were controls. Information about current and past sunlight exposure, former occupation type, subdivided in indoor working and outdoor working, and iris color were obtained by standardized interviewer-assisted questionnaires. Associations between environmental factors adjusted for age, gender, and smoking and early and late AMD were performed by multivariate regression analysis.Results:Current sunlight exposure showed no association with early AMD or late AMD, but past sunlight exposure (8 hours outside daily) was significantly associated with early AMD (odds ratio: 5.54, 95% confidence interval 1.25-24.58, P = 0.02) and late AMD (odds ratio: 2.77, 95% confidence interval 1.25-6.16, P = 0.01). Outside working was found to be associated with late AMD (odds ratio: 2.57, 95% confidence interval 1.89-3.48, P = 1.58 x 10(-9)). No association was observed between iris color and early or late AMD.Conclusion:Sunlight exposure during working life is an important risk factor for AMD, whereas sunlight exposure after retirement seems to have less influence on the disease development. Therefore, preventive measures, for example, wearing sunglasses to minimize sunlight exposure, should start early to prevent development of AMD later in life.
C1 [Schick, Tina; Ersoy, Lebriz; Kirchhof, Bernd; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Kerpener St 62, D-50924 Cologne, Germany.
   [Lechanteur, Yara T. E.; Saksens, Nicole T. M.; Hoyng, Carel B.; Den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
C3 University of Cologne; Radboud University Nijmegen
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener St 62, D-50924 Cologne, Germany.
EM sascha.fauser@gmail.com
RI Lechanteur, Yara/ABB-6875-2020; Lehtimäki, Terho/AAD-1094-2022;
   Hollander, Anneke den/N-4911-2014
OI Lechanteur, Yara/0000-0003-0951-4625; Lehtimäki,
   Terho/0000-0002-2555-4427; 
CR Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Delcourt C, 2014, INVEST OPHTH VIS SCI, V55, P7619, DOI 10.1167/iovs.14-14471
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Klein BEK, 2014, INVEST OPHTH VIS SCI, V55, P5855, DOI 10.1167/iovs.14-14602
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pham TQ, 2009, OPHTHAL EPIDEMIOL, V16, P136, DOI 10.1080/09286580701299395
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Rozanowska M, 2004, INVEST OPHTH VIS SCI, V45, P1052, DOI 10.1167/iovs.03-0277
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2003, OPHTHALMOLOGY, V110, P1526, DOI 10.1016/S0161-6420(03)00539-6
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
NR 27
TC 56
Z9 60
U1 0
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2016
VL 36
IS 4
BP 787
EP 790
DI 10.1097/IAE.0000000000000756
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DJ0IC
UT WOS:000373884700018
PM 26441265
DA 2022-11-30
ER

PT J
AU Zhou, Q
   Daniel, E
   Maguire, MG
   Grunwald, JE
   Martin, ER
   Martin, DF
   Ying, GS
AF Zhou, Qiang
   Daniel, Ebenezer
   Maguire, Maureen G.
   Grunwald, Juan E.
   Martin, E. Revell
   Martin, Daniel F.
   Ying, Gui-shuang
CA Comparison Age-Related Macular
TI Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in
   Fellow Eyes in the Comparison of Age-Related Macular Degeneration
   Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; RETICULAR PSEUDODRUSEN;
   GEOGRAPHIC-ATROPHY; CHOROIDAL NEOVASCULARIZATION; CLINICAL
   CHARACTERISTICS; RISK-FACTOR; MACULOPATHY; PREVALENCE; SEVERITY;
   FEATURES
AB Purpose: To evaluate the association between pseudodrusen and incidence of late age-related macular degeneration (AMD) in fellow eyes of patients with unilateral neovascular AMD (nAMD).
   Design: Cohort study within the Comparison of AMD Treatments Trials (CATT).
   Participants: Patients with neither nAMD nor geographic atrophy (GA) in the fellow eye at baseline.
   Methods: Presence and type (dot, reticular, or confluent) of baseline pseudodrusen were assessed using digital color fundus photography (CFP) viewed under full color, green channel, and blue channel; red-free images; and fluorescein angiography (FA). Incidence of nAMD was based on monthly clinical examination and reading center evaluation of images at years 1 and 2. Incidence of GA was based on read ing center evaluation of CFP and FA images at years 1 and 2. Associations of baseline pseudodrusen with incident nAMD and GA were summarized with adjusted risk ratios (aRRs) and their 95% confidence intervals (CIs) from multivariate Cox models, with adjustment of covariates identified through backward stepwise selection.
   Main Outcome Measures: Incident nAMD and GA.
   Results: Among 620 fellow eyes, 176 (28.4%) had baseline pseudodrusen (55% dot, 82% reticular, 35% confluent). Within 2 years, nAMD occurred in 54 eyes (30.7%) with pseudodrusen and in 72 eyes (16.2%) without pseudodrusen (aRR, 2.05; 95% CI, 1.43-2.93); GA occurred in 27 eyes (15.3%) with pseudodrusen and in 37 eyes (8.3%) without pseudodrusen (aRR, 1.89; 95% CI, 1.13-3.17); late AMD occurred in 73 eyes (41.5%) with pseudodrusen and in 101 eyes (22.8%) without pseudodrusen (aRR, 2.07; 95% CI, 1.51-2.83). Dot pseudodrusen were associated independently with nAMD (aRR, 2.53; 95% CI, 1.60-4.00), whereas confluent pseudodrusen were associated independently with GA (aRR, 4.35; 95% CI, 1.69-11.2). Eyes with pseudodrusen had increased incidence of late AMD regardless of whether the Age-Related Eye Diseases Study (AREDS) severity score was 2 (28.7% vs. 10.3%), 3 (34.9% vs. 13.7%), or 4 (50.5% vs. 32.0%).
   Conclusions: In fellow eyes of CATT participants, pseudodrusen were associated independently with a higher incidence of both nAMD and GA. Dot pseudodrusen were associated with nAMD, whereas confluent pseudodrusen were associated with GA. Pseudodrusen should be considered along with the AREDS severity score for predicting late AMD. (C) 2016 by the American Academy of Ophthalmology.
C1 [Zhou, Qiang] Capital Med Univ, Beijing Chaoyang Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Daniel, Ebenezer; Maguire, Maureen G.; Grunwald, Juan E.; Martin, E. Revell; Ying, Gui-shuang] Univ Penn, Perelman Sch Med, Scheie Eye Inst, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 Capital Medical University; University of Pennsylvania; Pennsylvania
   Medicine; Cleveland Clinic Foundation
RP Ying, GS (通讯作者)，Univ Penn, Perelman Sch Med, Scheie Eye Inst, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM gsying@mail.med.upenn.edu
OI Zhou, Qiang/0000-0002-2351-3621
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828,
   R21EY023689]; NATIONAL EYE INSTITUTE [U10EY017825, U10EY017823,
   U10EY017828, U10EY017826, R21EY023689] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (cooperative agreement nos.: U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828, and R21EY023689).
CR Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Szatmari P, 1999, GENET EPIDEMIOL, V16, P368, DOI 10.1002/(SICI)1098-2272(1999)16:4<368::AID-GEPI4>3.0.CO;2-A
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 48
TC 58
Z9 60
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2016
VL 123
IS 7
BP 1530
EP 1540
DI 10.1016/j.ophtha.2016.02.043
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP3KC
UT WOS:000378391100025
PM 27040149
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Cavichini, M
   Dans, KC
   Jhingan, M
   Amador-Patarroyo, MJ
   Borooah, S
   Bartsch, DU
   Nudleman, E
   Freeman, WR
AF Cavichini, Melina
   Dans, Kunny C.
   Jhingan, Mahima
   Amador-Patarroyo, Manuel J.
   Borooah, Shyamanga
   Bartsch, Dirk-Uwe
   Nudleman, Eric
   Freeman, William R.
TI Evaluation of the clinical utility of optical coherence tomography
   angiography in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina; Imaging; Degeneration; Macula; Neovascularisation
ID INDOCYANINE GREEN ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; OCT
   ANGIOGRAPHY
AB Background/Aims To evaluate the ability of optical coherence tomography angiography (OCTA) to identify the presence or absence of choroidal neovascularisation (CNV) and CNV activity in age-related macular degeneration (AMD). Methods Clinical parameters, fundus fluorescein angiogram and spectral-domain optical coherence tomography (SD-OCT) were used as the gold standard to determine disease activity. OCTA imaging was performed on the same day and was graded by two masked retina specialists for the presence or absence of CNV. Traditional multimodal imaging and OCTA findings were compared. Results One hundred and fifty-two eyes of 106 patients with AMD were retrospectively reviewed. Of these, 59 eyes had wet AMD and 93 had dry AMD with high-risk drusen. OCTA had 85.4% and 79.3% specificity and sensitivity, respectively, in determining the presence or absence of CNV. OCTA was 69.5% accurate in determining active CNV. False positives and negatives were 21.6% and 8.0%, respectively. Conclusions This study suggests that en-face OCTA images allow a moderate ability to identify CNV and that OCTA alone is weak at recognising active CNV requiring treatment in AMD.
C1 [Cavichini, Melina; Dans, Kunny C.; Jhingan, Mahima; Amador-Patarroyo, Manuel J.; Bartsch, Dirk-Uwe; Nudleman, Eric] Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, 9415 Campus Point Dr 0946, La Jolla, CA 92093 USA.
   [Cavichini, Melina] Fac Med ABC, Ophthalmol, Santo Andre, SP, Brazil.
   [Jhingan, Mahima] Aravind Eye Hosp, Madurai, Tamil Nadu, India.
   [Amador-Patarroyo, Manuel J.] Escuela Super Oftalmol, Inst Barraquer Amer, Ophthalmol, Bogota, Colombia.
   [Borooah, Shyamanga] Univ Calif San Diego, Ophthalmol, La Jolla, CA 92093 USA.
   [Borooah, Shyamanga] Univ Edinburgh, Sch Clin Sci, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland.
   [Freeman, William R.] UCSD, Jacobs Retina Ctr, Shiley Eye, La Jolla, CA USA.
C3 University of California System; University of California San Diego;
   Faculdade de Medicina do ABC; University of California System;
   University of California San Diego; University of Edinburgh; University
   of California System; University of California San Diego
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, 9415 Campus Point Dr 0946, La Jolla, CA 92093 USA.
EM wrfreeman@health.ucsd.edu
FU UCSD Vision Research Center [P30EY022589]; Research to Prevent
   Blindness, NY
FX This study was supported in part by UCSD Vision Research Center Core
   Grant P30EY022589, an unrestricted grant from Research to Prevent
   Blindness, NY (WRF).
CR Adhi M, 2014, AM J OPHTHALMOL, V157, P1272, DOI 10.1016/j.ajo.2014.02.034
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chicco D, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-019-6413-7
   Cicinelli MV, 2018, SURV OPHTHALMOL, V63, P236, DOI 10.1016/j.survophthal.2017.06.005
   Coscas G., 2009, OPTICAL COHERENCE TO, pP159
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dans KC, 2019, GRAEF ARCH CLIN EXP, V257, P741, DOI 10.1007/s00417-018-04232-8
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kiang Lee, 2016, Yan Ke Xue Bao (Hong Kong), V31, P243, DOI 10.3978/j.issn.1000-4432.2016.11.02
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P516, DOI 10.1097/IAE.0000000000001572
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Powers DMW., 2011, INT J MACH LEARN TEC, V2, P37
   Soomro T, 2018, EYE, V32, P662, DOI 10.1038/eye.2018.2
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Stehman SV, 1997, REMOTE SENS ENVIRON, V62, P77, DOI 10.1016/S0034-4257(97)00083-7
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 32
TC 1
Z9 1
U1 1
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2021
VL 105
IS 7
BP 983
EP 988
DI 10.1136/bjophthalmol-2020-316622
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TB1QQ
UT WOS:000667719500017
PM 32826223
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Schneider, U
   Gelisken, F
   Inhoffen, W
AF Schneider, U
   Gelisken, F
   Inhoffen, W
TI Natural course of occult choroidal neovascularization in age-related
   macular degeneration: development of classic lesions in fluorescein
   angiography
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE age-related macular degeneration; occult choroidal neovascularization;
   predominantly classic choroidal neovascularization; minimally classic
   choroidal neovascularization; classic choroidal neovascularization;
   photodynamic therapy; fluorescein angiography
ID POPULATION; PREVALENCE; BLINDNESS
AB Purpose: To analyse the frequency of conversion from occult with no classic choroidal neovascularization (CNV) and occult with minimally classic CNV into predominantly classic CNV secondary to age-related macular degeneration.
   Methods: Retrospective evaluation of baseline and repeat angiograms of 54 eyes with a follow-up of 6-12 months.
   Results: In the group with initially occult with no classic CNV, nine of 40 eyes (23%) progressed to a predominantly classic lesion, whereas in the group of occult with a minimally classic CNV, 10 of 14 eyes (71%) eyes developed a predominantly classic CNV.
   Conclusions: The proportion of eyes that develop predominantly classic CNV is much higher in eyes with initially occult and minimally classic CNV, compared with eyes with initially occult and no classic CNV. Our data suggest that the natural course of CNV secondary to AMD begins as occult and progresses to classic CNV.
C1 Univ Eye Clin Tubingen, Dept 1, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Schneider, U (通讯作者)，Univ Eye Clin Tubingen, Dept 1, Schleichstr 12, D-72076 Tubingen, Germany.
EM ulrike.schneider@uni-tuebingen.de
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bermig J, 2002, GRAEF ARCH CLIN EXP, V240, P169, DOI 10.1007/s00417-001-0378-2
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Olsen TW, 2001, INVEST OPHTH VIS SCI, V42, pS311
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   *TAP VIP, 2000, RETINA, V22, P6
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
NR 18
TC 13
Z9 14
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD APR
PY 2005
VL 83
IS 2
BP 141
EP 147
DI 10.1111/j.1600-0420.2005.00443.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 910ZB
UT WOS:000227969600001
PM 15799723
OA Bronze
DA 2022-11-30
ER

PT J
AU Schubert, T
   Gleiser, C
   Heiduschka, P
   Franz, C
   Nagel-Wolfrum, K
   Sahaboglu, A
   Weisschuh, N
   Eske, G
   Rohbock, K
   Rieger, N
   Paquet-Durand, F
   Wissinger, B
   Wolfrum, U
   Hirt, B
   Singer, W
   Ruttiger, L
   Zimmermann, U
   Knipper, M
AF Schubert, Timm
   Gleiser, Corinna
   Heiduschka, Peter
   Franz, Christoph
   Nagel-Wolfrum, Kerstin
   Sahaboglu, Ayse
   Weisschuh, Nicole
   Eske, Gordon
   Rohbock, Karin
   Rieger, Norman
   Paquet-Durand, Francois
   Wissinger, Bernd
   Wolfrum, Uwe
   Hirt, Bernhard
   Singer, Wibke
   Ruettiger, Lukas
   Zimmermann, Ulrike
   Knipper, Marlies
TI Deletion of myosin VI causes slow retinal optic neuropathy and
   age-related macular degeneration (AMD)-relevant retinal phenotype
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Bipolar cell; Inner retina; Outer retina; Synapse; Stereocilia;
   Translocator protein TSPO; Choriocapillaris; Mouse model
ID SNELLS-WALTZER MICE; MOUSE RETINA; OSCILLATORY POTENTIALS;
   PIGMENT-EPITHELIUM; HAIR-CELLS; MICROARRAY ANALYSIS; TEMPORAL ASPECTS;
   VEIN OCCLUSION; HUMAN HOMOLOG; OUTER RETINA
AB The unconventional myosin VI, a member of the actin-based motor protein family of myosins, is expressed in the retina. Its deletion was previously shown to reduce amplitudes of the a- and b-waves of the electroretinogram. Analyzing wild-type and myosin VI-deficient Snell's Waltzer mice in more detail, the expression pattern of myosin VI in retinal pigment epithelium, outer limiting membrane, and outer plexiform layer could be linked with differential progressing ocular deficits. These encompassed reduced a-waves and b-waves and disturbed oscillatory potentials in the electroretinogram, photoreceptor cell death, retinal microglia infiltration, and formation of basal laminar deposits. A phenotype comprising features of glaucoma (neurodegeneration) and age-related macular degeneration could thus be uncovered that suggests dysfunction of myosin VI and its variable cargo adaptor proteins for membrane sorting and autophagy, as possible candidate mediators for both disease forms.
C1 [Schubert, Timm; Eske, Gordon] Univ Tubingen, Werner Reichardt Ctr Integrat Neurosci CIN, Inst Ophthalm Res, D-72076 Tubingen, Germany.
   [Gleiser, Corinna; Hirt, Bernhard] Univ Tubingen, Inst Anat, Dept Clin Anat & Cell Anal, D-72076 Tubingen, Germany.
   [Heiduschka, Peter] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Expt Vitreoretinal Surg, D-72076 Tubingen, Germany.
   [Franz, Christoph; Rohbock, Karin; Singer, Wibke; Ruettiger, Lukas; Zimmermann, Ulrike; Knipper, Marlies] Univ Tubingen, Tubingen Hearing Res Ctr, Dept Otolaryngol Head & Neck Surg, Mol Physiol Hearing, D-72076 Tubingen, Germany.
   [Nagel-Wolfrum, Kerstin; Wolfrum, Uwe] Johannes Gutenberg Univ Mainz, Inst Zool Cell & Matrix, D-55128 Mainz, Germany.
   [Sahaboglu, Ayse; Rieger, Norman; Paquet-Durand, Francois] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Cell Death Mech Grp, D-72076 Tubingen, Germany.
   [Weisschuh, Nicole; Wissinger, Bernd] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Mol Genet, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University of Tubingen; Eberhard Karls University Hospital; Eberhard
   Karls University of Tubingen; Eberhard Karls University Hospital;
   Johannes Gutenberg University of Mainz; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; Eberhard Karls University
   of Tubingen; Eberhard Karls University Hospital
RP Knipper, M (通讯作者)，Univ Tubingen, Tubingen Hearing Res Ctr, Dept Otolaryngol Head & Neck Surg, Mol Physiol Hearing, Elfriede Aulhorn Str 5, D-72076 Tubingen, Germany.
EM timm.schubert@uni-tuebingen.de;
   corinna.gleiser@klinikum.uni-tuebingen.de;
   peter.heiduschka@ukmuenster.de; ch.franz@gmail.com;
   nagelwol@uni-Mainz.de; ayse.sahaboglu-tekgoez@klinikum.uni-tuebingen.de;
   nicole.weisschuh@uni-tuebingen.de;
   gordon.eske@klinikum.uni-tuebingen.de; KarinRohbock@yahoo.de;
   norman.rieger@medizin.uni-tuebingen.de;
   francois.paquet-durand@klinikum.uni-tuebingen.de;
   wissinger@uni-tuebingen.de; wolfrum@uni-mainz.de;
   bernhard.hirt@klinikum.uni-tuebingen.de; wibke.singer@uni-tuebingen.de;
   lukas.ruettiger@uni-tuebingen.de; ulrike.zimmermann@uni-tuebingen.de;
   marlies.knipper@uni-tuebingen.de
RI Heiduschka, Peter/AAX-3882-2021; Nagel-Wolfrum, Kerstin/AAX-6477-2020;
   Paquet-Durand, Francois/G-6709-2015
OI Paquet-Durand, Francois/0000-0001-7355-5742; Sahaboglu,
   Ayse/0000-0003-3241-0672
FU Deutsche Forschungsgemeinschaft (DFG) [GRK 1044, EXC 307, KN 316-10-1,
   FOR 2060]; ProRetina Stiftung; FAUN Stiftung Nuremberg; European
   Community [FP7/2009/241955, FP7/2009/242013]; BMBF [0314106]; ERA-Net
   for Research on Rare Diseases [58]; Kerstan Foundation Tubingen;
   Foundation Fighting Blindness (FFP) [TA-NMT-0611-0538-JGU]; Royal
   National Institute for Deaf People (RNID) [G54]
FX This study was funded by the Deutsche Forschungsgemeinschaft (DFG, GRK
   1044 to UW; EXC 307, CIN to TS; KN 316-10-1 to MK; FOR 2060 to MK/LR),
   the ProRetina Stiftung to UW; the FAUN Stiftung Nuremberg to UW/KNW; the
   European Community FP7/2009/241955 (SYSCILIA) to UW and FP7/2009/242013
   (TREATRUSH) to UW; BMBF, grant 0314106 (HOPE2) to UW, and under the
   frame of E-Rare-2, the ERA-Net for Research on Rare Diseases No 58
   (EUR-USH) to KNW; the Kerstan Foundation Tubingen to FPD, AS, NR; the
   Foundation Fighting Blindness (FFP; TA-NMT-0611-0538-JGU) to UW/KNW; and
   the Royal National Institute for Deaf People (RNID, G54) to LR. Authors
   thank Elisabeth Sehn and Ulrich Mattheus for excellent technical
   assistance. We thank Dr. Ulrich Luhmann, University College London, for
   generously supplying rd8 positive controls.
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Ahmed F, 2004, INVEST OPHTH VIS SCI, V45, P1247, DOI 10.1167/iovs.03-1123
   Ahmed ZM, 2003, AM J HUM GENET, V72, P1315, DOI 10.1086/375122
   Arango-Gonzalez B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112142
   Avraham KB, 1997, HUM MOL GENET, V6, P1225, DOI 10.1093/hmg/6.8.1225
   AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369
   BERSON EL, 1969, ARCH OPHTHALMOL-CHIC, V81, P207
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Breckler J, 2000, EXP EYE RES, V70, P121, DOI 10.1006/exer.1999.0758
   BRESNICK GH, 1987, ARCH OPHTHALMOL-CHIC, V105, P660
   BRETON ME, 1991, OPHTHALMOLOGY, V98, P1845
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Buss F, 2008, BIOCHEM BIOPH RES CO, V369, P165, DOI 10.1016/j.bbrc.2007.11.150
   Collaco A, 2010, J BIOL CHEM, V285, P17177, DOI 10.1074/jbc.M110.127613
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 2012, RETINA
   Duncker SV, 2013, J NEUROSCI, V33, P9508, DOI 10.1523/JNEUROSCI.5689-12.2013
   ELIZABETH RP, 2006, EXP EYE RES, V82, P741, DOI DOI 10.1016/J.EXER.2005.10.012
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fortune B, 2002, INVEST OPHTH VIS SCI, V43, P2638
   FUERST DJ, 1984, ARCH OPHTHALMOL-CHIC, V102, P214
   Gobel K, 2014, KLIN MONATSBL AUGENH, V231, P130, DOI 10.1055/s-0033-1360316
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Haq W, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00108
   Hasson T, 1996, J BIOL CHEM, V271, P16431, DOI 10.1074/jbc.271.28.16431
   Haverkamp S, 2000, J COMP NEUROL, V424, P1
   Heidrych P, 2009, HUM MOL GENET, V18, P2779, DOI 10.1093/hmg/ddp213
   Hertzano R, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000207
   Karlstetter M, 2014, ADV EXP MED BIOL, V801, P207, DOI 10.1007/978-1-4614-3209-8_27
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   KERGOAT H, 1990, ELECTROEN CLIN NEURO, V75, P306, DOI 10.1016/0013-4694(90)90109-W
   Kitamoto J, 2005, EXP EYE RES, V81, P116, DOI 10.1016/j.exer.2005.02.014
   Kofoed PK, 2013, ACTA OPHTHALMOL, V91, P728, DOI 10.1111/j.1755-3768.2012.02438.x
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Larsson J, 2000, ACTA OPHTHALMOL SCAN, V78, P187, DOI 10.1034/j.1600-0420.2000.078002187.x
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luu CD, 2010, INVEST OPHTH VIS SCI, V51, P482, DOI 10.1167/iovs.09-4069
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Melchionda S, 2001, AM J HUM GENET, V69, P635, DOI 10.1086/323156
   Mirza M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075963
   Nakayama M, 2013, NAT CELL BIOL, V15, P249, DOI 10.1038/ncb2679
   PERLMAN I, 1983, BRIT J OPHTHALMOL, V67, P443, DOI 10.1136/bjo.67.7.443
   PONJAVIC V, 1994, ACTA OPHTHALMOL, V72, P537
   Rezaie T, 2005, GENOMICS, V85, P131, DOI 10.1016/j.ygeno.2004.10.011
   RIZZO JF, 1986, OPHTHALMOLOGY, V93, P1452
   Rusten TE, 2009, J CELL SCI, V122, P2179, DOI 10.1242/jcs.050021
   Sahaboglu A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.208
   Sahlender DA, 2005, J CELL BIOL, V169, P285, DOI 10.1083/jcb.200501162
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Samuels IS, 2013, INVEST OPHTH VIS SCI, V54, P7223, DOI 10.1167/iovs.13-12887
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Scheetz TE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058657
   Schuetz E, 2004, CURR DRUG TARGETS, V5, P619, DOI 10.2174/1389450043345164
   Self T, 1999, DEV BIOL, V214, P331, DOI 10.1006/dbio.1999.9424
   Sherry DM, 2003, J COMP NEUROL, V465, P480, DOI 10.1002/cne.10838
   Smith BJ, 2014, DOC OPHTHALMOL, V128, P155, DOI 10.1007/s10633-014-9433-2
   Steele MR, 2006, INVEST OPHTH VIS SCI, V47, P977, DOI 10.1167/iovs.05-0865
   TREMBLAY F, 1995, VISION RES, V35, P2383, DOI 10.1016/0042-6989(95)00006-L
   Trenholm S, 2012, J PHYSIOL-LONDON, V590, P2501, DOI 10.1113/jphysiol.2011.225060
   Tumbarello DA, 2013, J CELL SCI, V126, P2561, DOI 10.1242/jcs.095554
   Wachtmeister L, 1998, PROG RETIN EYE RES, V17, P485, DOI 10.1016/S1350-9462(98)00006-8
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Wang X, 2000, EXP BRAIN RES, V132, P476, DOI 10.1007/s002210000360
   Weisschuh N, 2005, MOL VIS, V11, P284
   Weleber RG, 1998, EYE, V12, P580, DOI 10.1038/eye.1998.148
   Wierzbowska Joanna, 2008, Klin Oczna, V110, P370
NR 73
TC 8
Z9 8
U1 0
U2 16
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD NOV
PY 2015
VL 72
IS 20
BP 3953
EP 3969
DI 10.1007/s00018-015-1913-3
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CR7XZ
UT WOS:000361566700010
PM 25939269
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Landowski, M
   Rickman, CB
AF Landowski, Michael
   Rickman, Catherine Bowes
TI Targeting Lipid Metabolism for the Treatment of Age-Related Macular
   Degeneration: Insights from Preclinical Mouse Models
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE mouse models; lipid metabolism; complement; therapeutics; age-related
   macular degeneration; retinal pigmented epithelium
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; LOW-DENSITY
   LIPOPROTEINS; INDUCED CHOROIDAL NEOVASCULARIZATION; MITOCHONDRIAL
   OXIDATIVE STRESS; GENOME-WIDE ASSOCIATION; ELOVL4 TRANSGENIC MICE; A
   REDUCTASE INHIBITORS; ROD OUTER SEGMENTS; KNOCK-IN MICE
AB Age-related macular degeneration (AMD) is a major leading cause of irreversible visual impairment in the world with limited therapeutic interventions. Histological, biochemical, genetic, and epidemiological studies strongly implicate dysregulated lipid metabolism in the retinal pigmented epithelium (RPE) in AMD pathobiology. However, effective therapies targeting lipid metabolism still need to be identified and developed for this blinding disease. To test lipid metabolism-targeting therapies, preclinical AMD mouse models are needed to establish therapeutic efficacy and the role of lipid metabolism in the development of AMD-like pathology. In this review, we provide a comprehensive overview of current AMD mouse models available to researchers that could be used to provide preclinical evidence supporting therapies targeting lipid metabolism for AMD. Based on previous studies of AMD mouse models, we discuss strategies to modulate lipid metabolism as well as examples of studies evaluating lipid-targeting therapeutics to restore lipid processing in the RPE. The use of AMD mouse models may lead to worthy lipid-targeting candidate therapies for clinical trials to prevent the blindness caused by AMD.
C1 [Landowski, Michael] Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA.
   [Landowski, Michael] Univ Wisconsin, McPherson Eye Res Inst, Madison, WI USA.
   [Landowski, Michael] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Rickman, Catherine Bowes] Duke Univ, Dept Ophthalmol, Med Ctr, Box 3802 AERI Rm 5010, Durham, NC 27710 USA.
   [Rickman, Catherine Bowes] Duke Univ, Dept Cell Biol, Med Ctr, Durham, NC 27710 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Duke
   University; Duke University
RP Rickman, CB (通讯作者)，Duke Univ, Dept Ophthalmol, Med Ctr, Box 3802 AERI Rm 5010, Durham, NC 27710 USA.
EM bowes007@duke.edu
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   Ivanescu AA, 2015, NUTRIENTS, V7, P5423, DOI 10.3390/nu7075229
   Al-Holou SN, 2015, OPHTHALMOLOGY, V122, P2490, DOI 10.1016/j.ophtha.2015.08.028
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anderson DMG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17402-1
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Barathi VA, 2014, INVEST OPHTH VIS SCI, V55, P460, DOI 10.1167/iovs.13-11636
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Bennis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141597
   Bergen WG, 2005, J NUTR, V135, P2499, DOI 10.1093/jn/135.11.2499
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   BOWES C, 1993, P NATL ACAD SCI USA, V90, P2955, DOI 10.1073/pnas.90.7.2955
   BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0
   Cachafeiro M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.303
   Cankova Z, 2011, EXP EYE RES, V93, P947, DOI 10.1016/j.exer.2011.10.016
   Charles MA, 2012, J LIPID RES, V53, P1451, DOI 10.1194/jlr.R027011
   Chavali VRM, 2011, HUM MOL GENET, V20, P2000, DOI 10.1093/hmg/ddr080
   Chen L, 2004, EXP EYE RES, V79, P239, DOI 10.1016/j.exer.2004.05.002
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen Y, 2013, J CLIN INVEST, V123, P5119, DOI 10.1172/JCI69076
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chhetri J, 2014, EYE, V28, P367, DOI 10.1038/eye.2014.19
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Choi R, 2018, OPHTHALMIC GENET, V39, P307, DOI 10.1080/13816810.2018.1430240
   Choudhary M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131928
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Choudhary M, 2015, J PATHOL, V235, P101, DOI 10.1002/path.4433
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Cingolani C, 2006, FREE RADICAL BIO MED, V40, P660, DOI 10.1016/j.freeradbiomed.2005.09.032
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Demetrius Lloyd, 2005, EMBO Rep, V6 Spec No, pS39
   Dhingra A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115764
   Dhingra A, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00351
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dinculescu A, 2015, INVEST OPHTH VIS SCI, V56, P6971, DOI 10.1167/iovs.15-17166
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   Dong A, 2006, J CELL PHYSIOL, V208, P516, DOI 10.1002/jcp.20683
   Dornstauder B, 2012, INVEST OPHTH VIS SCI, V53, P2256, DOI 10.1167/iovs.11-8569
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dunbar RL, 2017, CTS-CLIN TRANSL SCI, V10, P455, DOI 10.1111/cts.12487
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Ersoy L, 2014, INVEST OPHTH VIS SCI, V55, P1842, DOI 10.1167/iovs.13-13420
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Faber C, 2012, INVEST OPHTH VIS SCI, V53, P6324, DOI 10.1167/iovs.12-10385
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fisher EA, 2012, ARTERIOSCL THROM VAS, V32, P2813, DOI 10.1161/ATVBAHA.112.300133
   Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Fu ZJ, 2017, INVEST OPHTH VIS SCI, V58, P3862, DOI 10.1167/iovs.17-21796
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gestri G, 2012, DEV NEUROBIOL, V72, P302, DOI 10.1002/dneu.20919
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Gong Y, 2016, ARTERIOSCL THROM VAS, V36, P1919, DOI 10.1161/ATVBAHA.116.307558
   GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8
   Gordon SM, 2015, J PROTEOME RES, V14, P2686, DOI 10.1021/acs.jproteome.5b00213
   Grimm Christian, 2013, Methods Mol Biol, V935, P87, DOI 10.1007/978-1-62703-080-9_6
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harkewicz R, 2012, J BIOL CHEM, V287, P11469, DOI 10.1074/jbc.M111.256073
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Higuchi H, 2015, MAMM GENOME, V26, P21, DOI 10.1007/s00335-014-9546-7
   Hogarth CA, 2003, COMP BIOCHEM PHYS B, V135, P219, DOI 10.1016/S1096-4959(03)00046-0
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hoshino A, 2017, DEV CELL, V43, P763, DOI 10.1016/j.devcel.2017.10.029
   Houten SM, 2016, ANNU REV PHYSIOL, V78, P23, DOI 10.1146/annurev-physiol-021115-105045
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Huang H, 2020, EXP EYE RES, V196, DOI 10.1016/j.exer.2020.108061
   Huang H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173716
   Huang JC, 2019, THERANOSTICS, V9, P1170, DOI 10.7150/thno.26281
   Huang YD, 2014, NEUROBIOL DIS, V72, P3, DOI 10.1016/j.nbd.2014.08.025
   Huberman AD, 2011, TRENDS NEUROSCI, V34, P464, DOI 10.1016/j.tins.2011.07.002
   Huebbe P, 2017, AGEING RES REV, V37, P146, DOI 10.1016/j.arr.2017.06.002
   Hullin-Matsuda F, 2009, PROSTAG LEUKOTR ESS, V81, P313, DOI 10.1016/j.plefa.2009.09.006
   Ibbett P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43906-z
   Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Ingram NT, 2020, P NATL ACAD SCI USA, V117, P19599, DOI 10.1073/pnas.2001776117
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Kelly UL, 2020, J BIOL CHEM, V295, P13601, DOI 10.1074/jbc.RA119.012305
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Kolesnikov AV, 2010, J NEUROSCI, V30, P11222, DOI 10.1523/JNEUROSCI.4239-09.2010
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Landowski M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.12.16
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Lennikov A, 2021, LAB INVEST, V101, P228, DOI 10.1038/s41374-020-00491-4
   Lennikov A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01903
   Lesher AM, 2013, J AM SOC NEPHROL, V24, P53, DOI 10.1681/ASN.2012060570
   Li C, 2007, ARCH OPHTHALMOL-CHIC, V125, P795, DOI 10.1001/archopht.125.6.795
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Li F, 2009, MOL VIS, V15, P1185
   Lin B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1198-1
   Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y
   Logan S, 2014, ADV EXP MED BIOL, V801, P447, DOI 10.1007/978-1-4614-3209-8_57
   Logan S, 2013, P NATL ACAD SCI USA, V110, P5446, DOI 10.1073/pnas.1217251110
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Lyssenko NN, 2018, J LIPID RES, V59, P1927, DOI 10.1194/jlr.M087361
   Lyzogubov VV, 2016, AM J PATHOL, V186, P2088, DOI 10.1016/j.ajpath.2016.03.021
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   Maeda A, 2009, INVEST OPHTH VIS SCI, V50, P5435, DOI 10.1167/iovs.09-3944
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mandal NA, 2014, INVEST OPHTH VIS SCI, V55, P2705, DOI 10.1167/iovs.13-13198
   Mandas A, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00309
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Mast N, 2018, DRUG METAB DISPOS, V46, P1528, DOI 10.1124/dmd.118.083345
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   Montalban-Soler L, 2012, MOL VIS, V18, P675
   Mori H, 2019, GRAEF ARCH CLIN EXP, V257, P289, DOI 10.1007/s00417-018-4184-5
   Morita M, 2015, CELL CYCLE, V14, P473, DOI 10.4161/15384101.2014.991572
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mustafi D, 2016, HUM MOL GENET, V25, P4376, DOI 10.1093/hmg/ddw268
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Navab M, 2010, ARTERIOSCL THROM VAS, V30, P164, DOI 10.1161/ATVBAHA.109.187518
   Neale Benjamin M, 2010, Proc Natl Acad Sci U S A, V107, P7395, DOI 10.1073/pnas.0912019107
   Neuner SM, 2019, NEURON, V101, P399, DOI 10.1016/j.neuron.2018.11.040
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Ory DS, 2004, CIRC RES, V95, P660, DOI 10.1161/01.RES.0000143422.83209.be
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Qi JH, 2009, J BIOL CHEM, V284, P19927, DOI 10.1074/jbc.M109.013763
   Qi XP, 2017, MOL THER, V25, P917, DOI 10.1016/j.ymthe.2017.01.015
   Qiu YT, 2015, CURR EYE RES, V40, P415, DOI 10.3109/02713683.2014.927507
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Raghow R, 2008, TRENDS ENDOCRIN MET, V19, P65, DOI 10.1016/j.tem.2007.10.009
   Rajala A, 2018, ADV EXP MED BIOL, V1074, P491, DOI 10.1007/978-3-319-75402-4_61
   Rajeshuni N, 2019, EYE, V33, P163, DOI 10.1038/s41433-018-0195-z
   Rao SR, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000979
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Ro S, 2013, CELL RES, V23, P759, DOI 10.1038/cr.2013.37
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Rudolf M, 2019, INVEST OPHTH VIS SCI, V60, P461, DOI 10.1167/iovs.18-25786
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Rudolf M, 2014, BRIT J OPHTHALMOL, V98, P698, DOI 10.1136/bjophthalmol-2013-304226
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Saadane A, 2018, J LIPID RES, V59, P2368, DOI 10.1194/jlr.M090043
   Saint-Geniez M., 2019, LIFE SCI ALLIANCE, V2, P1
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Savarese G, 2015, INT J CARDIOL, V201, P247, DOI 10.1016/j.ijcard.2015.08.103
   Schmidt S, 2000, MOL VIS, V6, P287
   Schnabolk G, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.11
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seo SJ, 2012, EXP EYE RES, V101, P60, DOI 10.1016/j.exer.2012.05.013
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smith EN, 2019, STEM CELL REP, V12, P1342, DOI 10.1016/j.stemcr.2019.04.012
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Song DL, 2018, INVEST OPHTH VIS SCI, V59, P3405, DOI 10.1167/iovs.18-24133
   Starr CR, 2019, INVEST OPHTH VIS SCI, V60, P4849, DOI 10.1167/iovs.19-27512
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Su F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194807
   Suda K, 2017, J CONTROL RELEASE, V266, P301, DOI 10.1016/j.jconrel.2017.09.036
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   Sundberg JP, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.035360
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tardif JC, 2014, EUR HEART J, V35, P3277, DOI 10.1093/eurheartj/ehu171
   Terao R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010112
   Toomey CB, 2018, INVEST OPHTH VIS SCI, V59, P662, DOI 10.1167/iovs.17-23134
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Toops KA, 2014, EXP EYE RES, V124, P74, DOI 10.1016/j.exer.2014.05.003
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Varga T, 2011, BBA-MOL BASIS DIS, V1812, P1007, DOI 10.1016/j.bbadis.2011.02.014
   Vasireddy V, 2006, INVEST OPHTH VIS SCI, V47, P4558, DOI 10.1167/iovs.06-0353
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Venkatesh A, 2015, J CLIN INVEST, V125, P1446, DOI 10.1172/JCI79766
   Vergnes L, 2003, J BIOL CHEM, V278, P42774, DOI 10.1074/jbc.M306022200
   Vielle A, 2021, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.667880
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Wang B, 2018, NAT REV ENDOCRINOL, V14, P452, DOI 10.1038/s41574-018-0037-x
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Watson CE, 2011, J LIPID RES, V52, P361, DOI 10.1194/jlr.M011098
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Williams BL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103617118
   Williams GA, 2007, VISION RES, V47, P2037, DOI 10.1016/j.visres.2007.03.023
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wolf NS, 2000, EXP EYE RES, V70, P683, DOI 10.1006/exer.2000.0835
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright CB, 2020, P NATL ACAD SCI USA, V117, P2579, DOI 10.1073/pnas.1909761117
   Wu BX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133032
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Yagasaki R, 2014, EXP EYE RES, V129, P127, DOI 10.1016/j.exer.2014.11.005
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yanai R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196037
   Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111
   Yang P, 2017, INVEST OPHTH VIS SCI, V58, P3073, DOI 10.1167/iovs.16-20083
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yazdi MH, 2015, EXPERT OPIN BIOL TH, V15, P1349, DOI 10.1517/14712598.2015.1057565
   Yin LL, 2011, CURR EYE RES, V36, P379, DOI 10.3109/02713683.2010.537427
   Yiu G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14715-z
   Yu AL, 2009, EXP EYE RES, V88, P495, DOI 10.1016/j.exer.2008.10.028
   Yu C, 2020, TRENDS NEUROSCI, V43, P433, DOI 10.1016/j.tins.2020.03.012
   Yu M, 2012, J LIPID RES, V53, P494, DOI 10.1194/jlr.M021386
   Yvan-Charvet L, 2010, ARTERIOSCL THROM VAS, V30, P139, DOI 10.1161/ATVBAHA.108.179283
   Zambarakji HJ, 2006, INVEST OPHTH VIS SCI, V47, P2623, DOI 10.1167/iovs.05-0855
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhang QT, 2021, AGING-US, V13, P10866, DOI 10.18632/aging.202974
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao ZY, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15166
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zheng KH, 2020, ATHEROSCLEROSIS, V311, P13, DOI 10.1016/j.atherosclerosis.2020.08.004
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zhou Q, 2009, CURR PHARM DESIGN, V15, P467, DOI 10.2174/138161209787315684
   Zhu LP, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-1113-z
NR 321
TC 3
Z9 3
U1 4
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JAN 1
PY 2022
VL 38
IS 1
BP 3
EP 32
DI 10.1089/jop.2021.0067
EA NOV 2021
PG 30
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA YY2SL
UT WOS:000719851200001
PM 34788573
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Shah, SU
   Pilli, S
   Telander, DG
   Morse, LS
   Park, SS
AF Shah, Sanket U.
   Pilli, Suman
   Telander, David G.
   Morse, Lawrence S.
   Park, Susanna S.
TI Survey of patients with age-related macular degeneration: knowledge and
   adherence to recommendations
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID EYE DISEASE; DIETARY-SUPPLEMENT; UNITED-STATES; RISK-FACTORS;
   PREVALENCE; AREDS; ADULTS; HEALTH
AB Objective: To evaluate the patient's understanding of the importance and adherence to the various lifestyle and Age-Related Eye Disease Study (AREDS) supplement recommendations for age-related macular degeneration (AMD).
   Design: Cross-sectional study.
   Participants: Patients with AMD treated at the vitreoretinal service clinic.
   Methods: Telephone questionnaire survey was administered to assess knowledge and adherence to various recommendations made to patients with AMD about lifestyle and AREDS supplements in this single-institution study.
   Results: Among 92 patients with AMD contacted, dietary modification, exercise and weight reduction, smoking cessation, and AREDS supplementation recommendations were recalled by 47 (51%), 21 (23%), 5 (5%), and 90 (98%) patients, respectively. The necessity of making these interventions was believed by 29 (62%), 16 (76%), 4 (80%), and 67 (74%) patients, respectively. Patient adherence to dietary modification was 81%, to exercise and weight reduction was 76%, to smoking cessation was 0%, and to AREDS supplementation was 88% (71% on correct dose). Financially, 29% of the patients noted a mean increase of $88 per month in expenditure because of making dietary modifications, but most reported such as justified; 61% noted a mean increase of $25 per month in expenditure from consumption of AREDS supplements, and most (96%) believed this was justified.
   Conclusions: Patients with AMD recalled recommendations for AREDS supplementation more often than other lifestyle changes but generally felt recommendations were necessary and affordable. Adherence to smoking cessation recommendation was poor (0%), but to other recommendations was good.
C1 [Shah, Sanket U.; Pilli, Suman; Telander, David G.; Morse, Lawrence S.; Park, Susanna S.] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Ctr Eye, Vitreoretinal Serv, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis
RP Park, SS (通讯作者)，Univ Calif Davis, Dept Ophthalmol & Vis Sci, Ctr Eye, 4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
EM susanna.park@ucdmc.ucdavis.edu
OI Morse, Lawrence/0000-0002-1758-2348
FU Research to Prevent Blindness, Unrestricted Departmental Grant, New York
FX This study was supported by Research to Prevent Blindness, Unrestricted
   Departmental Grant, New York, N.Y.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hochstetler BS, 2010, RETINA-J RET VIT DIS, V30, P1166, DOI 10.1097/IAE.0b013e3181cea5c6
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Radimer K, 2004, AM J EPIDEMIOL, V160, P339, DOI 10.1093/aje/kwh207
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
NR 12
TC 14
Z9 14
U1 0
U2 6
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2013
VL 48
IS 3
BP 204
EP 209
DI 10.1016/j.jcjo.2013.01.013
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA5OD
UT WOS:000331148400024
PM 23769783
DA 2022-11-30
ER

PT J
AU de Jong, S
   Gagliardi, G
   Garanto, A
   de Breuk, A
   Lechanteur, YTE
   Katti, S
   van den Heuvel, LP
   Volokhina, EB
   den Hollander, AI
AF de Jong, Sarah
   Gagliardi, Giuliana
   Garanto, Alejandro
   de Breuk, Anita
   Lechanteur, Yara T. E.
   Katti, Suresh
   van den Heuvel, Lambert P.
   Volokhina, Elena B.
   den Hollander, Anneke I.
TI Implications of genetic variation in the complement system in
   age-related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Complement system; Genetic variants;
   Model systems; Clinical trials
ID PIGMENT EPITHELIAL-CELLS; MEMBRANE ATTACK COMPLEX; HEMOLYTIC-UREMIC
   SYNDROME; REGULATORY PROTEIN CD46; GENOME-WIDE ASSOCIATION; FACTOR-H
   POLYMORPHISM; FACTOR-I; BRUCHS MEMBRANE; HIGH-RISK;
   MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
AB Age-related macular degeneration (AMD) is the main cause of vision loss among the elderly in the Western world. While AMD is a multifactorial disease, the complement system was identified as one of the main pathways contributing to disease risk. The strong link between the complement system and AMD was demonstrated by genetic associations, and by elevated complement activation in local eye tissue and in the systemic circulation of AMD patients. Several complement inhibitors have been and are being explored in clinical trials, but thus far with limited success, leaving the majority of AMD patients without treatment options to date. This indicates that there is still a gap of knowledge regarding the functional implications of the complement system in AMD pathogenesis and how to bring these towards clinical translation. Many different experimental set-ups and disease models have been used to study complement activation in vivo and in vitro, and recently emerging patientderived induced pluripotent stem cells and genome-editing techniques open new opportunities to study AMD disease mechanisms and test new therapeutic strategies in the future. In this review we provide an extensive overview of methods employed to understand the molecular processes of complement activation in AMD pathogenesis. We discuss the findings, advantages and challenges of each approach and conclude with an outlook on how recent, exciting developments can fill in current knowledge gaps and can aid in the development of effective complement-targeting therapeutic strategies in AMD.
C1 [de Jong, Sarah; Gagliardi, Giuliana; de Breuk, Anita; Lechanteur, Yara T. E.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, NL-6525 GA Nijmegen, Netherlands.
   [Garanto, Alejandro; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 GA Nijmegen, Netherlands.
   [Gagliardi, Giuliana] Radboud Univ Nijmegen, Med Ctr, Dept Pediat, NL-6525 GA Nijmegen, Netherlands.
   [Garanto, Alejandro; van den Heuvel, Lambert P.; Volokhina, Elena B.] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, NL-6525 GA Nijmegen, Netherlands.
   [Garanto, Alejandro; van den Heuvel, Lambert P.; Volokhina, Elena B.] Radboud Univ Nijmegen, Med Ctr, Amalia Childrens Hosp, NL-6525 GA Nijmegen, Netherlands.
   [Katti, Suresh] Gemini Therapeut Inc, Cambridge, MA 02139 USA.
   [van den Heuvel, Lambert P.; Volokhina, Elena B.] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, NL-6525 GA Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; Radboud University Nijmegen; Radboud University
   Nijmegen; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol & Human Genet, NL-6525 GA Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI Garanto, Alejandro/D-5022-2014; Volokhina, Elena/L-4725-2015
OI Garanto, Alejandro/0000-0001-5721-1560; Volokhina,
   Elena/0000-0002-4294-8460; de Jong, Sarah/0000-0002-3705-3371;
   Gagliardi, Giuliana/0000-0001-8118-0629
FU Dutch Research Council [016. Vici.170.024]; Foundation Fighting
   Blindness USA [PPA-0517-0717-RAD]; Algemene Nederlandse Vereniging ter
   Voorkoming van Blindheid; Stichting Blinden-Penning; Landelijke
   Stichting voor Blinden en Slechtzienden; Stichting Oogfonds Nederland
   [2019-17]; Rotterdamse Stichting Blindenbelangen; Stichting Blindenhulp;
   Gemini Therapeutics, Inc.
FX This work was supported by the Dutch Research Council (016. Vici.170.024
   to AIdH) and by a collaborative research agreement with Gemini
   Therapeutics, Inc.; AG is supported by the Foundation Fighting Blindness
   USA (grant no. PPA-0517-0717-RAD) and Algemene Nederlandse Vereniging
   ter Voorkoming van Blindheid, Stichting Blinden-Penning, Landelijke
   Stichting voor Blinden en Slechtzienden, Stichting Oogfonds Nederland
   (who contributed through UitZicht, 2019-17) together with the
   Rotterdamse Stichting Blindenbelangen, Stichting Blindenhulp.
CR Achberger K, 2019, ELIFE, V8, DOI 10.7554/eLife.46188
   Achberger K, 2019, ADV DRUG DELIVER REV, V140, P33, DOI 10.1016/j.addr.2018.05.005
   Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   Ajana S, 2021, OPHTHALMOLOGY, V128, P587, DOI 10.1016/j.ophtha.2020.08.031
   Altay L, 2019, EYE, V33, P1859, DOI 10.1038/s41433-019-0501-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Arya S, 2018, EXP EYE RES, V172, P21, DOI 10.1016/j.exer.2018.03.023
   Baek JH, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0941-9
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Ben Jehuda R, 2018, STEM CELL REV REP, V14, P323, DOI 10.1007/s12015-018-9811-3
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bhatia SN, 2014, NAT BIOTECHNOL, V32, P760, DOI 10.1038/nbt.2989
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Borras C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00443
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Burnight ER, 2018, PROG RETIN EYE RES, V65, P28, DOI 10.1016/j.preteyeres.2018.03.003
   Busch C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00703
   Calaza KC, 2015, NEUROBIOL AGING, V36, P2869, DOI 10.1016/j.neurobiolaging.2015.06.010
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Cardone J, 2011, CLIN EXP IMMUNOL, V164, P301, DOI 10.1111/j.1365-2249.2011.04400.x
   Carvalho C., 2018, ANIMALS BASEL, P9
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chang M, 2020, INVEST OPHTH VIS SCI, V61
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Chen LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03788-5
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chen SD, 2014, EXPERT REV OPHTHALMO, V9, P285, DOI 10.1586/17469899.2014.939171
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Chu PH, 2020, CHEM RES TOXICOL, V33, P751, DOI 10.1021/acs.chemrestox.9b00363
   Chung M, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700028
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clare AJ, 2020, J CELL MOL MED, V24, P13546, DOI 10.1111/jcmm.16000
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Clutterbuck AL, 2009, CURR DRUG TARGETS, V10, P1245, DOI 10.2174/138945009789753264
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cowan CS, 2020, CELL, V182, P1623, DOI 10.1016/j.cell.2020.08.013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cserhalmi M, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101341
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Diebolder CA, 2014, SCIENCE, V343, P1260, DOI 10.1126/science.1248943
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ekdahl KN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02237
   Ellis S, 2020, INVEST OPHTH VIS SCI, V61
   Emri E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103051
   Fanelli G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15212-z
   Feng GP, 2020, P NATL ACAD SCI USA, V117, P24022, DOI 10.1073/pnas.2006515117
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gallemore RP, 2016, INVEST OPHTH VIS SCI, V57
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Geerlings MJ, 2018, CLIN GENET, V94, P330, DOI 10.1111/cge.13392
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Goel M, 2010, OPEN OPHTHALMOL J, V4, P52, DOI 10.2174/1874364101004010052
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Guymer R, 2015, GRAEF ARCH CLIN EXP, V253, P1347, DOI 10.1007/s00417-015-2970-x
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Harboe M, 2008, J CELL MOL MED, V12, P1074, DOI 10.1111/j.1582-4934.2008.00350.x
   Harboe M, 2011, ADV DRUG DELIVER REV, V63, P976, DOI 10.1016/j.addr.2011.05.010
   Harris CL, 2012, TRENDS IMMUNOL, V33, P513, DOI 10.1016/j.it.2012.06.001
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P673, DOI 10.1016/j.oret.2020.01.019
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hockemeyer D, 2016, CELL STEM CELL, V18, P573, DOI 10.1016/j.stem.2016.04.013
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hopps E, 2015, EUR REV MED PHARMACO, V19, P2583
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hughes AE, 2016, INVEST OPHTH VIS SCI, V57, P2763, DOI 10.1167/iovs.15-18744
   Hunt NC, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800226
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Java A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.37
   Java A, 2019, KIDNEY INT REP, V4, P1007, DOI 10.1016/j.ekir.2019.04.003
   Jiao HH, 2020, MOL VIS, V26, P679
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kaushal S., 2009, INVEST OPHTH VIS SCI, V50, P5010
   Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Khanani A.M., 2020, AM AC OPHTH ANN M NO
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Kremlitzka M, 2018, HUM MOL GENET, V27, P2678, DOI 10.1093/hmg/ddy178
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Langer HF, 2010, BLOOD, V116, P4395, DOI 10.1182/blood-2010-01-261503
   Lashkari K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195751
   Le Goff MM, 2008, EYE, V22, P1214, DOI 10.1038/eye.2008.21
   Liang QN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12917-9
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Liu X, 2020, BIOFABRICATION, V12, DOI 10.1088/1758-5090/ab76a1
   Long Q, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6958752
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Lukowski SW, 2019, EMBO J, V38, DOI 10.15252/embj.2018100811
   Luo MY, 2018, INT J OPHTHALMOL-CHI, V11, P150, DOI 10.18240/ijo.2018.01.23
   Lyzogubov V, 2014, AM J PATHOL, V184, P2537, DOI 10.1016/j.ajpath.2014.06.001
   Lyzogubov VV, 2016, AM J PATHOL, V186, P2088, DOI 10.1016/j.ajpath.2016.03.021
   Makou E, 2013, BIOCHEMISTRY-US, V52, P3949, DOI 10.1021/bi4003452
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mannes M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.596415
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Ponce-Castro IM, 2008, MOL IMMUNOL, V45, P2764, DOI 10.1016/j.molimm.2008.02.008
   Merinero HM, 2018, KIDNEY INT, V93, P470, DOI 10.1016/j.kint.2017.07.015
   May-Simera HL, 2018, CELL REP, V22, P189, DOI 10.1016/j.celrep.2017.12.038
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mohlin C, 2018, UPSALA J MED SCI, V123, P28, DOI 10.1080/03009734.2018.1431744
   Mohlin FC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01813
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Morgan BP, 2016, IMMUNOBIOLOGY, V221, P747, DOI 10.1016/j.imbio.2015.04.006
   Morgan BP, 2016, IMMUNOL REV, V274, P141, DOI 10.1111/imr.12461
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314
   Nilsson SC, 2007, MOL IMMUNOL, V44, P1835, DOI 10.1016/j.molimm.2006.10.005
   Nilsson SC, 2010, J BIOL CHEM, V285, P6235, DOI 10.1074/jbc.M109.097212
   Nilsson SC, 2010, EUR J IMMUNOL, V40, P172, DOI 10.1002/eji.200939280
   Nilsson SC, 2009, EUR J IMMUNOL, V39, P310, DOI 10.1002/eji.200838702
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Paek J, 2019, ACS NANO, V13, P7627, DOI 10.1021/acsnano.9b00686
   Pandi SPS, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108404
   Park JE, 2019, AM J PRIMATOL, V81, DOI 10.1002/ajp.22931
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Pauly D, 2019, CELL REP, V29, P2835, DOI 10.1016/j.celrep.2019.10.084
   Paun CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26568
   Pechtl IC, 2011, J BIOL CHEM, V286, P11082, DOI 10.1074/jbc.M110.211839
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Pilotti C, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.19
   Pouw RB, 2015, MOL IMMUNOL, V67, P12, DOI 10.1016/j.molimm.2015.03.011
   Prohaszka Z, 2016, IMMUNOBIOLOGY, V221, P1247, DOI 10.1016/j.imbio.2016.06.008
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Recalde S, 2016, J AM SOC NEPHROL, V27, P1305, DOI 10.1681/ASN.2015050580
   Ren XY, 2016, EXP EYE RES, V145, P352, DOI 10.1016/j.exer.2016.02.004
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rodriguez E, 2014, BIOSCIENCE REP, V34, P635, DOI 10.1042/BSR20140117
   Rooijakkers SHM, 2009, NAT IMMUNOL, V10, P721, DOI 10.1038/ni.1756
   Rose KL, 2008, J CLIN INVEST, V118, P608, DOI 10.1172/JCI32525
   Roumenina LT, 2012, BLOOD, V119, P4182, DOI 10.1182/blood-2011-10-383281
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Samuel W, 2017, MOL VIS, V23, P60
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Schafer N, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090793
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schori C, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-24122
   Schramm EC, 2015, BLOOD, V125, P2359, DOI 10.1182/blood-2014-10-609073
   Seddon JM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.32
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Serna M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10587
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Sharma NK, 2013, DNA CELL BIOL, V32, P549, DOI 10.1089/dna.2013.2072
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shi Y, 2017, NAT REV DRUG DISCOV, V16, P115, DOI 10.1038/nrd.2016.245
   Silva AS, 2012, MOL VIS, V18, P2288
   Silverman SM, 2019, ADV EXP MED BIOL, V1185, P33, DOI 10.1007/978-3-030-27378-1_6
   Sivapathasuntharam C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37673-6
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Skeie JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127567
   Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith DW, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100845
   Smith EN, 2019, STEM CELL REP, V12, P1342, DOI 10.1016/j.stemcr.2019.04.012
   Songstad AE, 2017, STEM CELL TRANSL MED, V6, P1533, DOI 10.1002/sctm.16-0399
   Songstad AE, 2015, INVEST OPHTH VIS SCI, V56, P8258, DOI 10.1167/iovs.15-17073
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Strunz T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58510-9
   Strunz T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24219-z
   Studer L, 2015, CELL STEM CELL, V16, P591, DOI 10.1016/j.stem.2015.05.004
   Sugita S, 2018, INVEST OPHTH VIS SCI, V59, P4198, DOI 10.1167/iovs.18-24769
   Sung JH, 2019, ANAL CHEM, V91, P330, DOI 10.1021/acs.analchem.8b05293
   Szarvas N, 2016, MOL IMMUNOL, V71, P10, DOI 10.1016/j.molimm.2016.01.003
   Tan P.L., 2017, INVESTIGATIVE OPTHAL, V58
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tian J, 2005, BRIT J OPHTHALMOL, V89, P1510, DOI 10.1136/bjo.2005.072108
   Toomey CB, 2018, INVEST OPHTH VIS SCI, V59, P662, DOI 10.1167/iovs.17-23134
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Trakkides TO, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110548
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Doorn KJ, 2013, CLIN KIDNEY J, V6, P216, DOI 10.1093/ckj/sfs190
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Volokhina E, 2012, PEDIATR NEPHROL, V27, P1519, DOI 10.1007/s00467-012-2183-z
   Vyse TJ, 1996, J CLIN INVEST, V97, P925, DOI 10.1172/JCI118515
   Wang JCC, 2015, MOL VIS, V21, P264
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Weinberger AWA, 2014, OPHTHALMIC RES, V51, P59, DOI 10.1159/000351624
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright C, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.49
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang SC, 2014, DEV COMP IMMUNOL, V46, P3, DOI 10.1016/j.dci.2014.01.010
   Zhang Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129945
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zhou Ru, 2010, F1000 Biol Rep, V2, DOI 10.3410/B2-3
NR 264
TC 17
Z9 17
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2021
VL 84
AR 100952
DI 10.1016/j.preteyeres.2021.100952
EA SEP 2021
PG 31
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UR8XL
UT WOS:000697024800003
PM 33610747
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Han, XK
   Gharahkhani, P
   Mitchell, P
   Liew, G
   Hewitt, AW
   MacGregor, S
AF Han, Xikun
   Gharahkhani, Puya
   Mitchell, Paul
   Liew, Gerald
   Hewitt, Alex W.
   MacGregor, Stuart
TI Genome-wide meta-analysis identifies novel loci associated with
   age-related macular degeneration
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID GENETIC EPIDEMIOLOGY RESEARCH; RETINAL VASCULAR CALIBER; ADULT HEALTH;
   MACULOPATHY; PREVALENCE; VARIANTS; MUTATION; GWAS; VEGF; PDGF
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness among the elderly population. To accelerate the understanding of the genetics of AMD, we conducted a meta-analysis of genome-wide association studies (GWAS) combining data from the International AMD Genomics Consortium AMD-2016 GWAS (16,144 advanced AMD cases and 17,832 controls), AMD-2013 GWAS (17,181 cases and 60,074 controls), and new data on 4017 AMD cases and 14,984 controls from Genetic Epidemiology Research on Aging study. We identified 12 novel AMD loci near or withinC4BPA-CD55,ZNF385B,ZBTB38,NFKB1,LINC00461,ADAM19,CPN1,ACSL5,CSK,RLBP1,CLUL1, andLBP. We then replicated the associations of the novel loci in independent cohorts, UK Biobank (5860 cases and 126,726 controls) and FinnGen (1266 cases and 47,560 control). In general, the concordance in effect sizes was very high (correlation in effect size estimates 0.89), 11 of 12 novel loci were in the expected direction, 5 were associated with AMD at a nominal significance level, and rs3825991 (near geneRLBP1) after Bonferroni correction. We identified an additional 21 novel genes using a gene-based test. Most of the novel genes are expressed in retinal tissue and could be involved in the pathogenesis of AMD (i.e., complement, inflammation, and lipid pathways). These findings enhance our understanding of the genetic architecture of AMD and shed light on the biological process underlying AMD pathogenesis.
C1 [Han, Xikun; Gharahkhani, Puya; MacGregor, Stuart] QIMR Berghofer Med Res Inst, Stat Genet, Brisbane, Qld, Australia.
   [Han, Xikun] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
   [Mitchell, Paul; Liew, Gerald] Univ Sydney, Ctr Vis Res, Westmead Inst Med Res, Dept Ophthalmol, Sydney, NSW, Australia.
   [Hewitt, Alex W.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.
   [Hewitt, Alex W.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 QIMR Berghofer Medical Research Institute; University of Queensland;
   University of Sydney; Westmead Institute for Medical Research;
   University of Tasmania; Menzies Institute for Medical Research; Centre
   for Eye Research Australia; University of Melbourne
RP Han, XK (通讯作者)，QIMR Berghofer Med Res Inst, Stat Genet, Brisbane, Qld, Australia.; Han, XK (通讯作者)，Univ Queensland, Sch Med, Brisbane, Qld, Australia.
EM Xikun.Han@qimrberghofer.edu.au
RI Macgregor, Stuart/C-6442-2009; Han, Xikun/AAN-9012-2020; Liew,
   Gerald/AAB-6870-2022
OI Macgregor, Stuart/0000-0001-6731-8142; Han, Xikun/0000-0002-3823-7308;
   Gharahkhani, Puya/0000-0002-4203-5952
FU Medical Research Council [MC_PC_17228, MC_QA137853] Funding Source:
   Medline
CR Banda Y, 2015, GENETICS, V200, P1285, DOI 10.1534/genetics.115.178616
   Bharadwaj AS, 2013, PROG RETIN EYE RES, V32, P102, DOI 10.1016/j.preteyeres.2012.08.004
   Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4
   Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burstedt MSL, 2001, ARCH OPHTHALMOL-CHIC, V119, P260
   Bycroft C, 2017, GENOME WIDE GENETIC, DOI [10.1101/166298v1, DOI 10.1101/166298V1]
   Cohen-Tayar Y, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.163691
   Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656
   de Leeuw CA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004219
   Fan Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11008
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gao XR, 2019, HUM MOL GENET, V28, P1162, DOI 10.1093/hmg/ddy422
   Grove J, 2019, NAT GENET, V51, P431, DOI 10.1038/s41588-019-0344-8
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Kvale MN, 2015, GENETICS, V200, P1051, DOI 10.1534/genetics.115.178905
   Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824
   Liu L, 2015, INT J OPHTHALMOL-CHI, V8, P11, DOI 10.3980/j.issn.2222-3959.2015.01.02
   Ma KN, 2010, INVEST OPHTH VIS SCI, V51, P6776, DOI 10.1167/iovs.10-5887
   MacGregor S, 2018, NAT GENET, V50, P1067, DOI 10.1038/s41588-018-0176-y
   Masuzzo A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00127
   Mencarelli MA, 2007, AM J MED GENET A, V143A, P858, DOI 10.1002/ajmg.a.31602
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Oliver PL, 2015, CEREB CORTEX, V25, P3572, DOI 10.1093/cercor/bhu196
   Persad PJ, 2017, INVEST OPHTH VIS SCI, V58, P4027, DOI 10.1167/iovs.17-21734
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rajkumar A, 2018, METABOLISM, V83, P271, DOI 10.1016/j.metabol.2018.03.019
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Scerri TS, 2017, NAT GENET, V49, P559, DOI 10.1038/ng.3799
   Scimone C, 2017, HUM GENOMICS, V11, DOI 10.1186/s40246-017-0114-6
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Siedlecki J, 2017, GRAEF ARCH CLIN EXP, V255, P963, DOI 10.1007/s00417-017-3595-z
   Sturgill GM, 2006, OPHTHALMIC GENET, V27, P151, DOI 10.1080/13816810600976871
   Sun C, 2009, SURV OPHTHALMOL, V54, P74, DOI 10.1016/j.survophthal.2008.10.003
   Tanabe C, 2007, BIOCHEM BIOPH RES CO, V352, P111, DOI 10.1016/j.bbrc.2006.10.181
   Turley P, 2018, NAT GENET, V50, P229, DOI 10.1038/s41588-017-0009-4
   Wagner AH, 2013, EXP EYE RES, V111, P105, DOI 10.1016/j.exer.2013.03.004
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01261-5
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Winkler TW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194321
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu TH, 2002, INVEST OPHTH VIS SCI, V43, P2834
   Yang J, 2012, NAT GENET, V44, P369, DOI 10.1038/ng.2213
   Zhu ZH, 2016, NAT GENET, V48, P481, DOI 10.1038/ng.3538
NR 55
TC 27
Z9 27
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD AUG
PY 2020
VL 65
IS 8
BP 657
EP 665
DI 10.1038/s10038-020-0750-x
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA ME6OU
UT WOS:000544773500003
PM 32277175
DA 2022-11-30
ER

PT J
AU Jivraj, J
   Jivraj, I
   Tennant, M
   Rudnisky, C
AF Jivraj, Jamil
   Jivraj, Imran
   Tennant, Matthew
   Rudnisky, Chris
TI Prevalence and impact of depressive symptoms in patients with
   age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL IMPAIRMENT; OLDER-ADULTS; PEOPLE; HEALTH
AB Objective: This study sought to identify the point prevalence of depressive symptoms, quality-of-life (QOL) impairment, and demographic parameters associated with depression in patients with age-related macular degeneration (AMD) attending a retina clinic in Edmonton, Alberta.
   Design: A cross-sectional design was used.
   Methods: Consecutive patients with AMD were invited to participate in the study. Demographic data, as well as ophthalmic, medical, and psychiatric histories, were collected. Participants completed the Center for Epidemiological Studies Depression Scale (CES-D) and the Visual Function Questionnaire (VFQ-25) scales to quantify the burden of depressive symptoms and vision-related QOL impairment.
   Results: The study enrolled 101 patients, of whom 7 (6.9%) had a previous history of depression. Twenty (21.3%) of the remaining patients endorsed severe symptoms of depression that had not yet been diagnosed. Significant differences in vision-related QOL between depressed and not depressed patients were identified. Depressed patients were also found to have worse visual acuity (p = 0.047) and were less likely to live with others (p = 0.020) than those who were not depressed.
   Conclusions: After excluding patients with a history of diagnosed depression, 20 (21.3%) patients demonstrated severe symptoms of depression. Development of depression screening protocols for patients with AMD would improve identification and referral of patients at risk. The finding that patients who lived with others had a lower prevalence of depressive symptoms suggests that further research into the relationship between mood symptoms and environmental supports is merited.
C1 Univ Alberta, Royal Alexandra Hosp, Dept Pediat, Edmonton, AB, Canada.
   Univ Alberta, Royal Alexandra Hosp, Dept Ophthalmol, Edmonton, AB, Canada.
C3 Royal Alexandra Hospital; University of Alberta; Royal Alexandra
   Hospital; University of Alberta
RP Jivraj, J (通讯作者)，Dept Ophthalmol, 2316,10240 Kingsway Ave, Edmonton, AB T5H 3V9, Canada.
EM jivraj.jamil@gmail.com
CR Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Blazer DG, 2003, J GERONTOL A-BIOL, V58, P249
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   FECHNERBATES S, 1994, J CONSULT CLIN PSYCH, V62, P550, DOI 10.1037/0022-006X.62.3.550
   Fenwick EK, 2009, OPTOMETRY VISION SCI, V86, P948, DOI 10.1097/OPX.0b013e3181b2f599
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Hayman KJ, 2007, OPTOMETRY VISION SCI, V84, P1024, DOI 10.1097/OPX.0b013e318157a6b1
   Heikkinen RL, 2004, ARCH GERONTOL GERIAT, V38, P239, DOI 10.1016/j.archger.2003.10.004
   Jones GC, 2009, REHABIL PSYCHOL, V54, P164, DOI 10.1037/a0015910
   Luanaigh CO, 2008, INT J GERIATR PSYCH, V23, P1213, DOI 10.1002/gps.2054
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rovner BW, 2007, INT J GERIATR PSYCH, V22, P789, DOI 10.1002/gps.1742
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Tolman J, 2005, GERONTOLOGIST, V45, P747, DOI 10.1093/geront/45.6.747
   TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x
   Tournier M, 2008, J POPUL THER CLIN PH, V15, pE22
   Whyte EM, 2006, INT J GERIATR PSYCH, V21, P746, DOI 10.1002/gps.1555
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
NR 26
TC 17
Z9 18
U1 0
U2 8
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD AUG
PY 2013
VL 48
IS 4
BP 269
EP 273
DI 10.1016/j.jcjo.2013.03.007
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA AA5OI
UT WOS:000331148900027
PM 23931465
DA 2022-11-30
ER

PT J
AU Pulido, JS
   Sanders, D
   Kjtngel, R
AF Pulido, JS
   Sanders, D
   Kjtngel, R
TI Rheopheresis for age-related macular degeneration: clinical results and
   putative mechanism of action
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; macular degeneration; rheopheresis
ID MEMBRANE DIFFERENTIAL FILTRATION; TISSUE INHIBITOR; GROWTH-FACTOR;
   PATHOGENESIS; ASSOCIATION; BIOMARKERS; PROTEINS; TIMP3
AB Background: Rheopheresis is being evaluated in a clinical trial. The rationale and available results are presented.
   Methods: We reviewed the literature about the pathophysiology of age-related macular degeneration (AMD) that might support the use of rheopheresis. In addition, we reviewed the previously published results of the use of rheopheresis for AMD.
   Results: There appears to be a diffusion barrier caused by accumulation of crosslinked proteins known as advanced macular oxidation products (AMOPS) in AMD. Rheopheresis allows removal of uncross-linked proteins and facilitates antioxidant entry into Bruch's membrane, preventing further accumulation of AMOPS. The Multicenter Investigation of Rheopheresis for AMD (MIRA- 1), an ongoing double-masked randomized trial, should determine the efficacy of rheopheresis in preventing the progression of AMD. The interim results, from an analysis of visual acuity data for 43 patients, are encouraging, confirming the potential of rheopheresis as a therapeutic option for dry AMD. The benefit was evident immediately after treatment and remained essentially stable throughout the 12-month period of evaluation. Eyes with late-stage, high-risk, dry AMD appeared to be at significant risk for substantial vision loss over the 12 months if not treated. Subgroup analysis demonstrated that the timing of rheopheresis in the course of a patient's disease may have a pronounced effect on outcome.
   Interpretation: There appears to be a rationale for the use of rheopheresis in AMD. Further results of the clinical trial are awaited.
C1 Mayo Clin & Mayo Fdn, Dept Ophthalmol, Rochester, MN 55905 USA.
   Univ Illinois, Coll Med, Dept Ophthalmol, Chicago, IL USA.
   Apheresis Res Inst, Cologne, Germany.
C3 Mayo Clinic; University of Illinois System; University of Illinois
   Chicago; University of Illinois Chicago Hospital
RP Pulido, JS (通讯作者)，Mayo Clin & Mayo Fdn, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM pulido.jose@mayo.edu
CR Batioglu F, 2003, RETINA-J RET VIT DIS, V23, P261, DOI 10.1097/00006982-200304000-00026
   Brunner R, 1996, TRANSFUS SCI, V17, P493, DOI 10.1016/S0955-3886(96)90083-1
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Brunner R, 1995, INT J ARTIF ORGANS, V18, P794, DOI 10.1177/039139889501801208
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Ida H, 2004, INVEST OPHTH VIS SCI, V45, P2348, DOI 10.1167/iovs.03-1337
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   King GL, 2000, NEW ENGL J MED, V342, P349, DOI 10.1056/NEJM200002033420511
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Klingel T, 2003, THER APHER DIAL, V7, P444, DOI 10.1046/j.1526-0968.2003.00082.x
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   PREISSNER KT, 1995, HISTOL HISTOPATHOL, V10, P239
   Pulido J S, 1996, Trans Am Ophthalmol Soc, V94, P1029
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Soboleva G, 2003, J CELL PHYSIOL, V197, P149, DOI 10.1002/jcp.10361
   SOUDAVAR F, 1998, INVEST OPHTH VIS SCI, V39, P386
   STOCKMANN A, 1993, J BIOL CHEM, V268, P22874
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Suckfull M, 2002, LANCET, V360, P1811, DOI 10.1016/S0140-6736(02)11768-5
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Swartz M, 1999, INVEST OPHTH VIS SCI, V40, pS319
   TAMAI M, 1982, INVEST OPHTH VIS SCI, V22, P439
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Widder RA, 2002, INVEST OPHTH VIS SCI, V43, P2906
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 37
TC 22
Z9 23
U1 0
U2 2
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 332
EP 340
DI 10.1016/S0008-4182(05)80076-6
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400009
PM 15947803
DA 2022-11-30
ER

PT J
AU ElSheikh, RH
   Chauhan, MZ
   Sallam, AB
AF ElSheikh, Reem H.
   Chauhan, Muhammad Z.
   Sallam, Ahmed B.
TI Current and Novel Therapeutic Approaches for Treatment of Neovascular
   Age-Related Macular Degeneration
SO BIOMOLECULES
LA English
DT Review
DE neovascular age-related macular degeneration; neovascular AMD; wet AMD;
   anti-VEGF; faricimab
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   VERTEPORFIN PHOTODYNAMIC THERAPY; ANTI-VEGF ANTIBODY; QUALITY-OF-LIFE;
   RANIBIZUMAB TREATMENT; VISUAL-ACUITY; PHASE-II; INTRAVITREAL
   RANIBIZUMAB; CLINICAL-PRACTICE
AB Age-related macular degeneration AMD is one of the leading causes of blindness in the elderly population. An advanced form of AMD known as neovascular AMD (nAMD) is implicated as the main attributor of visual loss among these patients. The hallmark feature of nAMD is the presence of neovascular structures known as choroidal neovascular membranes (CNVs), along with fluid exudation, hemorrhages, and subretinal fibrosis. These pathological changes eventually result in anatomical and visual loss. A type of proangiogenic factor known as vascular endothelial growth factor (VEGF) has been known to mediate the pathological process behind nAMD. Therefore, therapy has transitioned over the years from laser therapy that ablates the lesions to using Anti-VEGF to target the pathology directly. In this work, we provide an overview of current and emerging therapies for the treatment of nAMD. Currently approved Anti-VEGF agents include ranibizumab, aflibercept, and brolucizumab. Bevacizumab, also an Anti-VEGF agent, is used to manage nAMD even though this is an off-label use. While Anti-VEGF agents have provided a favorable prognosis for nAMD, they are associated with a substantial financial burden for patients and the healthcare system, due to their high cost as well as the need for frequent repeat treatments and visits. Emerging therapies and studies aim to extend the intervals between required treatments and introduce new treatment modalities that would improve patients' compliance and provide superior results.
C1 [ElSheikh, Reem H.; Chauhan, Muhammad Z.; Sallam, Ahmed B.] Univ Arkansas Med Sci, Harvey & Bernice Jones Eye Inst, Dept Ophthalmol, Little Rock, AR 72207 USA.
   [ElSheikh, Reem H.] Cairo Univ Hosp, Dept Ophthalmol, Cairo 11261, Egypt.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   Egyptian Knowledge Bank (EKB); Cairo University
RP Sallam, AB (通讯作者)，Univ Arkansas Med Sci, Harvey & Bernice Jones Eye Inst, Dept Ophthalmol, Little Rock, AR 72207 USA.
EM ahmedsallam11@yahoo.com
CR [Anonymous], 1986, Arch Ophthalmol, V104, P694
   [Anonymous], EXTENSION STUDY PORT
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arepalli S, 2021, INT J RETINA VITR, V7, DOI 10.1186/s40942-021-00325-5
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Awan MA, 2006, SURG-J R COLL SURG E, V4, P231, DOI 10.1016/S1479-666X(06)80065-X
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bilgic A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10184153
   Bilgic A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132758
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Breen EC, 2007, J CELL BIOCHEM, V102, P1358, DOI 10.1002/jcb.21579
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chan CK, 2022, OPHTHALMOL RETINA, V6, P484, DOI 10.1016/j.oret.2022.01.019
   Chaney P., 2019, P OPHTH INN SUMM SAN
   Chang MA, 2022, JAMA OPHTHALMOL, V140, P771, DOI 10.1001/jamaophthalmol.2022.1091
   Chavan R, 2014, CLIN OPHTHALMOL, V8, P717, DOI 10.2147/OPTH.S60763
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   clinicaltrials, NCT03452527
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cox JT, 2021, J CLIN MED, V10, DOI 10.3390/jcm10050981
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Dugel PU, 2020, OPHTHALMOL RETINA, V4, P250, DOI 10.1016/j.oret.2019.10.008
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eldem BM, 2015, ACTA OPHTHALMOL, V93, pE458, DOI 10.1111/aos.12540
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Gonzales CR, 2017, INVEST OPHTH VIS SCI, V58
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hamid MA, 2021, INT J RETINA VITR, V7, DOI 10.1186/s40942-021-00299-4
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Heier JS, 2021, JAMA OPHTHALMOL, V139, P542, DOI 10.1001/jamaophthalmol.2021.0221
   Heier JS, 2021, RETINA-J RET VIT DIS, V41, P1, DOI 10.1097/IAE.0000000000003003
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Holz F.G., 2007, INVESTIG OPHTHALMOL, V48, P4566
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   investors.molecularpartners, NEWS RELEASES
   Ishibashi K, 2021, THER ADV OPHTHALMOL, V13, DOI 10.1177/2515841420984586
   Joussen AM, 2021, EYE, V35, P1305, DOI 10.1038/s41433-020-01377-x
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Khanani AM, 2022, INVEST OPHTH VIS SCI, V63
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Khurana RN, 2021, OPHTHALMOLOGY, V128, P1027, DOI 10.1016/j.ophtha.2020.11.017
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee J, 2022, J CLIN MED, V11, DOI 10.3390/jcm11061543
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Loewenstein A, 2020, INVEST OPHTH VIS SCI, V61
   Luksa D, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57121293
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Patel S.S., 2020, INVESTIG OPHTHALMOL, V61, P4286
   Pearce I, 2022, EYE, V36, P1725, DOI 10.1038/s41433-022-02008-3
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Providencia J, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9276580
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Regillo C, 2022, INVEST OPHTH VIS SCI, V63
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   Silva RM, 2004, GRAEF ARCH CLIN EXP, V242, P368, DOI 10.1007/s00417-003-0844-0
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Wallsh JO, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051049
   Wells JA, 2018, OSLI RETINA, V49, P336, DOI 10.3928/23258160-20180501-07
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Zarbin M, 2007, OPTOMETRY VISION SCI, V84, pE559, DOI 10.1097/OPX.0b013e3180de4dd7
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 109
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD NOV
PY 2022
VL 12
IS 11
AR 1629
DI 10.3390/biom12111629
PG 27
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 6A8HK
UT WOS:000880889500001
PM 36358978
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shuai, P
   Ye, ZM
   Liu, YP
   Qu, C
   Liu, XQ
   Luo, HC
   Feng, XY
   Li, XL
   Shi, Y
   Gong, B
AF Shuai, Ping
   Ye, Zimeng
   Liu, Yuping
   Qu, Chao
   Liu, Xiaoqi
   Luo, Huaichao
   Feng, Xiaoyun
   Li, Xiulan
   Shi, Yi
   Gong, Bo
TI Association between SKIV2L polymorphism rs429608 and age-related macular
   degeneration: A meta-analysis
SO OPHTHALMIC GENETICS
LA English
DT Article
DE AMD; meta-analysis; SKIV2L; SNP
ID CHINESE POPULATION; GENE; RISK; EPIDEMIOLOGY; PREVALENCE; VARIANTS;
   COMPLEX; QUALITY; DRUSEN
AB Purpose: This study was conducted to comprehensively evaluate the potential association of SKIV2L polymorphism rs429608 with age-related macular degeneration (AMD) through a meta-analysis.
   Methods: We performed a literature search in EMBASE, PubMed, Web of Science, and the Chinese Biomedical Database for AMD genetic studies published before August 30, 2015. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for single-nucleotide polymorphisms (SNPs) using fixed-effect models or random effect models according to between-study heterogeneity. Publication bias analyses were conducted using Egger's test.
   Results: A total of five studies from published articles were included, and a total number of 2789 AMD cases and 3451 healthy controls were tested in this meta-analysis. The results demonstrated that SKIV2L rs429608 is associated with AMD under allelic model (A vs. G; OR = 0.52, 95% CI 0.44-0.62, p < 0.001), heterozygous model (AG vs. GG; OR = 0.51; 95%CI, 0.38-0.68; p < 0.001; P-Q = 0.48; I-2 = 0) and dominant model (AA+AG vs. GG; OR = 0.49; 95%CI 0.37-0.65; p < 0.001; P-Q = 0.44; I-2 = 0), but not under other genetic models.
   Conclusions: This meta-analysis showed that SKIV2L rs429608 was statistically associated with AMD and it might exert a protective effect on AMD. Further investigations are needed to validate the association and confirm the role of SKIV2L in AMD.
C1 [Shuai, Ping; Ye, Zimeng; Liu, Xiaoqi; Shi, Yi] Southwest Jiaotong Univ, Coll Life Sci & Engn, Chengdu, Peoples R China.
   [Shuai, Ping; Ye, Zimeng; Liu, Xiaoqi; Luo, Huaichao; Feng, Xiaoyun; Li, Xiulan; Shi, Yi; Gong, Bo] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Peoples R China.
   [Shuai, Ping; Ye, Zimeng; Liu, Yuping; Qu, Chao; Liu, Xiaoqi; Luo, Huaichao; Feng, Xiaoyun; Li, Xiulan; Shi, Yi; Gong, Bo] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu, Peoples R China.
   [Shuai, Ping; Liu, Yuping] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Hlth Management Ctr, Chengdu, Peoples R China.
   [Qu, Chao] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Dept Ophthalmol, Chengdu, Peoples R China.
C3 Southwest Jiaotong University; Sichuan Provincial People's Hospital;
   University of Electronic Science & Technology of China; Sichuan
   Provincial People's Hospital; University of Electronic Science &
   Technology of China; Sichuan Provincial People's Hospital; University of
   Electronic Science & Technology of China; Sichuan Provincial People's
   Hospital; University of Electronic Science & Technology of China
RP Gong, B (通讯作者)，Sichuan Acad Med Sci, Sichuan Key Lab Human Dis Gene Study, 32 First Ring Rd West 2, Chengdu 610072, Sichuan, Peoples R China.; Gong, B (通讯作者)，Sichuan Prov Peoples Hosp, 32 First Ring Rd West 2, Chengdu 610072, Sichuan, Peoples R China.
EM gongbo2007@hotmail.com
FU Natural Science Foundation of China [81371048, 81170882, 81570888];
   Department of Science and Technology of Sichuan Province, China
   [2015HH0031, 2014JZ0004, 2016JQ0026]; Science and Technology Innovation
   & Talent Project of Sichuan Province [2014-58]; Youth Innovation Medical
   Science Project of Sichuan Provincial Medical Association [Q14048]
FX This study was supported by grants from the Natural Science Foundation
   of China (81371048 (B.G.), 81170882 (Y.S.) and 81570888(Y.S.)); The
   Department of Science and Technology of Sichuan Province, China
   (2015HH0031(B.G.), 2014JZ0004 (Y.S.), 2016JQ0026 (Y.S.)); The Science
   and Technology Innovation & Talent Project of Sichuan Province
   (2014-58(P.S.)); and The Youth Innovation Medical Science Project of
   Sichuan Provincial Medical Association (Q14048 (P.S.)).
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5
   Chen H, 2015, MOL VIS, V18, P816
   Fernando MMA, 2007, PLOS GENET, V3, P2109, DOI 10.1371/journal.pgen.0030192
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gharahkhani P, 2014, NAT GENET, V46, P1120, DOI 10.1038/ng.3079
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jia LH, 2011, BIOMED ENVIRON SCI, V24, P506, DOI 10.3967/0895-3988.2011.05.008
   Karunakaran DKP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075964
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Lu F, 2013, INVEST OPHTH VIS SCI, V54, P2911, DOI 10.1167/iovs.12-11381
   Morrison BA, 2010, AUTOIMMUNITY, V43, P690, DOI 10.3109/08916930903567492
   Okur V, 2015, CLIN EXP OPHTHALMOL, V43, P47, DOI 10.1111/ceo.12376
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Synek S, 2010, COLLEGIUM ANTROPOL, V34, P25
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yang ZY, 2001, FRONT BIOSCI-LANDMRK, V6, pD927, DOI 10.2741/Yang
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Yoneyama S, 2014, OPHTHALMIC GENET, V35, P151, DOI 10.3109/13816810.2014.921313
NR 28
TC 2
Z9 2
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2017
VL 38
IS 3
BP 245
EP 251
DI 10.1080/13816810.2016.1210650
PG 7
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA EW7CF
UT WOS:000402666700009
PM 27484132
DA 2022-11-30
ER

PT J
AU Tang, NP
   Zhou, B
   Wang, B
   Yu, RB
AF Tang, Na-Ping
   Zhou, Bo
   Wang, Bin
   Yu, Rong-Bin
TI HTRA1 Promoter Polymorphism and Risk of Age-Related Macular
   Degeneration: A Meta-Analysis
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article
DE HTRA1 Polymorphism; Age-Related Macular Degeneration; Meta-Analysis
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CASE-CONTROL SAMPLES; JAPANESE
   POPULATION; GEOGRAPHIC ATROPHY; CHINESE POPULATION; GENE POLYMORPHISM;
   CFH; ASSOCIATION; VARIANT; LOC387715
AB PURPOSE: To clarify the role of human high-temperature requirement A-1 (HTRA1) gene promoter polymorphism (-512G > A) in age-related macular degeneration (AMD).
   METHODS: Relevant studies were identified by searching PubMed and EMBASE database. A logistic regression analysis proposed for molecular association Studies was carried Out to estimate the genetic effect and the possible genetic model of action.
   RESULTS: Fourteen case-control studies were included in this meta-analysis. There was strong evidence for an association between HTRA1 -512G > A polymorphism and AMD (p < 0.001). The genetic model test indicated that the genetic model was most likely to be co-dominant. Overall, our meta-analysis showed that AA and GA genotypes were associated with increased risk of AMD (AA vs. GG: odds ratio, [OR(1)] = 7.46; 95% confidence interval [CI] = 6.16-9.04; GA vs. GG: OR(2) = 2.27, 95% CI = 2.02-2.55). In stratified analysis by ethnicity and age, the genetic effect seemed to be stronger in Caucasians and Subjects >= 73 years of age than in Asians and Subjects <73 years of age. When Subgroup analysis was conducted by AMD type, significant association was noted for wet AMD but not for dry AMD.
   CONCLUSIONS: This meta-analysis summarizes the strong evidence for an association between HTRA1 -512G > A polymorphism and AMD and indicates a co-dominant model of action. Ann Epidemiol 2009;19:740-745. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Tang, Na-Ping] Shanghai Inst Pharmaceut Ind, Natl Shanghai Ctr New Drug Safety Evaluat & Res, Shanghai 201203, Peoples R China.
   [Zhou, Bo] Jiangsu Ctr Safety Evaluat Drugs, Nanjing, Jiangsu Prov, Peoples R China.
   [Wang, Bin] Nanjing Med Univ, Dept Pharmacol, Nanjing, Jiangsu Prov, Peoples R China.
   [Yu, Rong-Bin] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Nanjing, Jiangsu Prov, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Tang, NP (通讯作者)，Shanghai Inst Pharmaceut Ind, Natl Shanghai Ctr New Drug Safety Evaluat & Res, 199 Guoshoujing Rd,Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China.
EM naping.tang@gmail.com
CR Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   CHEN W, 2008, EXP EYE RES IN PRESS
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   Marx J, 2006, SCIENCE, V311, P1704, DOI 10.1126/science.311.5768.1704
   Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Scholl HPN, 2007, MOL VIS, V13, P196
   Shastry BS, 2007, J HUM GENET, V52, P384, DOI 10.1007/s10038-007-0120-y
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Weger M, 2007, MOL VIS, V13, P1274
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
NR 51
TC 18
Z9 19
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1047-2797
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD OCT
PY 2009
VL 19
IS 10
BP 740
EP 745
DI 10.1016/j.annepidem.2009.03.002
PG 6
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 499BR
UT WOS:000270192000008
PM 19375943
DA 2022-11-30
ER

PT J
AU Wang, JJ
   Ross, RJ
   Tuo, JS
   Burlutsky, G
   Tan, AG
   Chan, CC
   Favaloro, EJ
   Williams, A
   Mitchell, P
AF Wang, Jie Jin
   Ross, Robert J.
   Tuo, Jingsheng
   Burlutsky, George
   Tan, Ava G.
   Chan, Chi-Chao
   Favaloro, Emmanuel J.
   Williams, Andrew
   Mitchell, Paul
TI The LOC387715 polymorphism, inflammatory markers, smoking, and
   age-related macular degeneration - A population-based case-control study
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; BLUE MOUNTAINS EYE; BODY-MASS
   INDEX; VISUAL IMPAIRMENT; ENVIRONMENTAL ASSOCIATIONS; MACULOPATHY; RISK;
   GENE; PREVALENCE
AB Objective: To assess combined effects on the risk of age-related macular degeneration (AMD) by the LOC387715 polymorphism, smoking, and inflammatory or hemostatic factors.
   Design: Population-based case-control study.
   Participants: Two hundred seventy-eight AMD cases (224 early, 54 late) and 557 controls matched for age, gender, and smoking, drawn from the Blue Mountains Eye Study cohort.
   Methods: Subjects were genotyped for the LOC387715 Ala69Ser polymorphism (rs# 10490924). Smoking was self-reported. Serum high-sensitivity C-reactive protein (CRP), interleukin 6 (IL-6), soluble intercellular adhesion molecule 1 (slCAM-1), fibrinogen, homocysteine, plasminogen activator inhibitor 1 (PAI-1), von Willebrand factor, and white cell count (WCC) were measured. Combined effects of this genetic variant plus any of these study factors on AMD risk were assessed using logistic regression models, adjusted for age and smoking. We defined interaction if the influence of 2 factors departed from the multiplicative scale, confirmed by a statistically significant interaction term. Otherwise, the combined effect was used.
   Main Outcome Measures: Age-related macular degeneration was graded using the Wisconsin grading system.
   Results: Combined effects on the likelihood of early or late AMD were demonstrated for the LOC387715 Ala69Ser G/T and T/T genotypes with the markers high-sensitivity CRP (odds ratios [ORs], 1.2 for the highest tertile alone, 1.6 for G/T and T/T genotypes alone, and 2.2 for both G/T and T/T genotypes plus the highest tertile, compared with the G/G genotype with the 2 lower tertiles), IL-6 (corresponding ORs, 1.1, 1.6, and 2.2), slCAM-1 (ORs, 1.0, 1.5, and 2.3, respectively), and PAI-1 (ORs, 1.3, 1.7, and 2.3, respectively), but not with WCC, fibrinogen, homocysteine, and von Willebrand factor. Findings were similar for early and late AMD separately. Current smokers with G/T and T/T genotypes had strong combined effects on late AMD risk compared with those who never smoked or past smokers with the G/G genotype (ORs, 1.2 for current smokers alone, 1.8 for G/T and T/T genotypes alone, and 6.1 for current smokers plus G/T and T/T genotypes).
   Conclusions: We found no significant interaction but combined effects for the LOC387715 genotypes with 3 inflammatory markers and PAW on the risk of early or late AMD, and with current smoking on the risk of late AMD.
C1 [Wang, Jie Jin; Burlutsky, George; Tan, Ava G.; Mitchell, Paul] Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Westmead, NSW 2145, Australia.
   [Wang, Jie Jin; Burlutsky, George; Tan, Ava G.; Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Ross, Robert J.; Tuo, Jingsheng; Chan, Chi-Chao] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Favaloro, Emmanuel J.] Westmead Hosp, Dept Hematol, Inst Clin Pathol & Med Res, Sydney, NSW, Australia.
   [Williams, Andrew] Royal Prince Alfred Hosp, Dept Clin Immunol, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); University of Sydney; University of Sydney
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Favaloro, Emmanuel J./J-7689-2019; Mitchell, Paul/P-1498-2014; Wang, Jie
   Jin/P-1499-2014; wang, jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; Favaloro, Emmanuel
   J/0000-0002-2103-1661; Tuo, Jingsheng/0000-0002-1372-7810; Tan, Ava
   Grace/0000-0003-3344-0339
FU NATIONAL EYE INSTITUTE [ZIAEY000418, ZIAEY000222, Z01EY000222,
   Z01EY000418] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01
   EY000418-04] Funding Source: Medline
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Botto LD, 2001, AM J EPIDEMIOL, V153, P1016, DOI 10.1093/aje/153.10.1016
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Favaloro EJ, 1997, CLIN APPL THROMB-HEM, V3, P110, DOI 10.1177/107602969700300208
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2005, AM J OPHTHALMOL, V139, P405, DOI 10.1016/j.ajo.2004.11.050
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ng MKC, 2002, ARTERIOSCL THROM VAS, V22, P1136, DOI 10.1161/01.ATV.0000022167.80130.A6
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Roberts WL, 2000, CLIN CHEM, V46, P461
   Rodriguez J, 2002, OPHTHALMOLOGY, V109, P737, DOI 10.1016/S0161-6420(01)01008-9
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   SCHMIDT S, 2007, MOL VIS, V18, P941
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Souied EH, 2005, MOL VIS, V11, P1135
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 51
TC 46
Z9 47
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2008
VL 115
IS 4
BP 693
EP 699
DI 10.1016/j.ophtha.2007.05.038
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 281CU
UT WOS:000254475100016
PM 17675241
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kananen, F
   Strandberg, T
   Loukovaara, S
   Immonen, I
AF Kananen, Fabian
   Strandberg, Timo
   Loukovaara, Sirpa
   Immonen, Ilkka
TI Early middle age cholesterol levels and the association with age-related
   macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age&#8208; related macular degeneration; cardiovascular risk factors;
   drusen; genetics; lipids
AB Purpose To examine whether serum cholesterol in early middle age is associated with age-related macular degeneration (AMD) later in life.
   Methods A group of Helsinki Businessmen Study (HBS) participants (n = 209) were recruited for the study. Total cholesterol (TC), triglyceride and body mass index (BMI) were measured at the HBS baseline visit in 1964-1973. Lipid subfractions, BMI, smoking status and statin use were recorded in 2011 and fundus photographs graded for AMD in 2005-2012. The subjects were genotyped for the main AMD risk single nucleotide polymorphisms (SNPs).
   Results TC measured at baseline 1964-1973 was significantly higher in subjects later developing intermediate or late AMD (6.67 mmol/l versus 6.20 mmol/l, p = 0.024) or with drusen size of >= 125 mu m (6.68 mmol/l versus 6.21 mmol/l, p = 0.030) compared with the rest of the study population. TC, LDL and TG values at follow-up 2011 were lower in subjects with AMD compared to those without, whereas HDL levels showed no difference. In multivariate analysis, baseline TC associated with intermediate or late AMD (OR 1.59, p = 0.004) and drusen size >= 125 mu m (OR 1.57, p = 0.006) when corrected for age, BMI, AMD risk SNPs and smoking. Lipid values measured 2011 had no associations after correction.
   Conclusions High systemic total cholesterol in early middle age may have a role in the initial development of AMD, especially in patients later developing large drusen.
C1 [Kananen, Fabian; Strandberg, Timo; Loukovaara, Sirpa; Immonen, Ilkka] Univ Helsinki, Helsinki, Finland.
   [Kananen, Fabian] Orebro Univ Hosp, Dept Ophthalmol, S-70185 Orebro, Sweden.
   [Strandberg, Timo] Helsinki Univ Hosp, Dept Geriatr, Helsinki, Finland.
   [Loukovaara, Sirpa; Immonen, Ilkka] Helsinki Univ Hosp, Dept Ophthalmol, Helsinki, Finland.
C3 University of Helsinki; Orebro University; University of Helsinki;
   Helsinki University Central Hospital; University of Helsinki; Helsinki
   University Central Hospital
RP Kananen, F (通讯作者)，Orebro Univ Hosp, Dept Ophthalmol, S-70185 Orebro, Sweden.
EM fabian.kananen@regionorebrolan.se
OI strandberg, timo/0000-0001-6299-925X
FU Silmasaatio Foundation (Helsinki, Finland)
FX The project has received funding from Silmasaatio Foundation (Helsinki,
   Finland). The sponsor or funding organization had no role in the design
   or conduct of this research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Borodulin K, 2015, EUR J PUBLIC HEALTH, V25, P539, DOI 10.1093/eurpub/cku174
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   Kaarniranta K, 2012, NEUROSCI LETT, V513, P233, DOI 10.1016/j.neulet.2012.02.050
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Strandberg TE, 2016, INT J EPIDEMIOL, V45, P1074, DOI 10.1093/ije/dyv310
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
NR 28
TC 5
Z9 5
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2021
VL 99
IS 7
BP E1063
EP E1069
DI 10.1111/aos.14774
EA FEB 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WD6YR
UT WOS:000614033300001
PM 33533136
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Hussain, RM
   Ciulla, TA
AF Hussain, Rehan M.
   Ciulla, Thomas A.
TI Emerging vascular endothelial growth factor antagonists to treat
   neovascular age-related macular degeneration
SO EXPERT OPINION ON EMERGING DRUGS
LA English
DT Article
DE Abicipar pegol; brolucizumab; neovascular age-related macular
   degeneration; gene therapy; nesvacumab; platelet-derived growth factor;
   pegpleranib; Tie-2 receptor; vascular endothelial growth factor; X-82
ID GENE-THERAPY; VEGF-TRAP; FOLLOW-UP; PDGF-B; RANIBIZUMAB; EYE; SAFETY;
   BEVACIZUMAB; PREVALENCE; EXPRESSION
AB Introduction: Evolving anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) include long acting agents, combination strategies involving new pathways, topical agents, sustained-release, and genetic therapy strategies.
   Areas covered: Brolucizumab and abicipar pegol have smaller molecular size, facilitating higher concentrations and potentially longer duration than current anti-VEGF agents. Agents being combined with anti-VEGFs include OPT-302 (to inhibit VEGF-C and VEGF-D); pegpleranib and rinucumab (to inhibit platelet derived growth factor, PDGF - but both failed to show consistently improved visual outcomes compared to anti-VEGF monotherapy); and RG7716, ARP-1536 and nesvacumab (to activate the Tie-2 tyrosine kinase receptor, which reduces permeability). X-82 is an oral anti-VEGF and anti-PDGF being tested in phase 2 studies. Topical anti-VEGF +/- anti-PDGF drugs under study include pazopanib, PAN-90806, squalamine lactate, regorafinib, and LHA510. Sustained-release anti-VEGF delivery treatments, such as the ranibizumab Port Delivery System, GB-102, NT-503, hydrogel depot, Durasert, and ENV1305 aim to reduce the burden of frequent injections. Gene therapies with new viral vectors hold the potential to induce sustained expression of anti-angiogenic proteinsvia the retina's cellular apparatus, and include AVA-101/201, ADVM-202/302, AAV2-sFLT01, RGX314, and Retinostat.
   Expert opinion: There are many emerging anti-VEGF treatments that aim to improve visual outcomes and reduce the treatment burden of nAMD.
C1 [Hussain, Rehan M.; Ciulla, Thomas A.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Ciulla, Thomas A.] Midwest Eye Inst, Retina Serv, Indianapolis, IN 46290 USA.
C3 Indiana University System; Indiana University Bloomington
RP Ciulla, TA (通讯作者)，Midwest Eye Inst, Retina Serv, Indianapolis, IN 46290 USA.
EM Thomasciulla@gmail.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
CR Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   [Anonymous], 2016, OPHTH INN SUMM AM SO
   [Anonymous], 2014, RETINA TODAY
   [Anonymous], 2016, OPHTH INN SUMM AM AC
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Baek SU, 2016, CUTAN OCUL TOXICOL, V35, P310, DOI 10.3109/15569527.2015.1124886
   Barthelmes D, 2017, RETINA
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Boyer DS, 2016, AM SOC AC OPHTH ANN
   Braimah IZ, 2017, BR J OPHTHALMOL
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2016, AM AC OPHTH ANN M OC
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Chakravarthy U, 2016, ASS RES VIS OPHTH AN
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chaney P, 2016, OPHTH INN SUMM AM AC
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   COHEN D, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.G2006
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Davis S, 1999, CURR TOP MICROBIOL, V237, P173
   Dugel P, 2016, ASS RES VIS OPHTH AN
   Dugel PU, 2017, OPHTHALMOLOGY
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hansen TM, 2010, CELL SIGNAL, V22, P527, DOI 10.1016/j.cellsig.2009.11.007
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2017, LANCET
   Hellstrom M, 1999, DEVELOPMENT, V126, P3047
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Hussain RM, 2016, AM SOC RET SPEC ANN
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Jackson TL, 2017, JAMA OPHTHALMOL
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Joussen A, 2016, ASS RES VIS OPHTH AN
   Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lowenstein A, 2015, ASS RES VIS OPHTH AN
   Lurker N., 2016, OPHTH INN SUMM A AC
   Mansour AM, 2016, BRIT J OPHTHALMOL, V100, P1629, DOI 10.1136/bjophthalmol-2015-308319
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Ohr Pharmaceutical Inc, 2016, OPHTH INN SUMM AM AC
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rayess N, 2016, AM J OPHTHALMOL, V165, P88, DOI 10.1016/j.ajo.2016.02.028
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shalaby AK, 2016, EYE, V30, P1404, DOI 10.1038/eye.2016.154
   Singerman LJ, 2015, ASS RES VIS OPHTH AN
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Stefanini FR, 2013, WORLD J DIABETES, V4, P19, DOI [10.4239/wjd.v4.i6.231, 10.4239/wjd.v4.i2.19]
   Syed BA, 2012, NAT REV DRUG DISCOV, V11, P827, DOI 10.1038/nrd3790
NR 66
TC 60
Z9 64
U1 2
U2 19
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8214
EI 1744-7623
J9 EXPERT OPIN EMERG DR
JI Expert Opin Emerg. Drugs
PY 2017
VL 22
IS 3
BP 235
EP 246
DI 10.1080/14728214.2017.1362390
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FH1OS
UT WOS:000410909900004
PM 28756707
DA 2022-11-30
ER

PT J
AU Levine, JP
   Marcus, I
   Sorenson, JA
   Spaide, RF
   Cooney, MJ
   Freund, KB
AF Levine, Jonathan P.
   Marcus, Inna
   Sorenson, John A.
   Spaide, Richard F.
   Cooney, Michael J.
   Freund, K. Bailey
TI MACULAR HEMORRHAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AFTER
   STABILIZATION WITH ANTIANGIOGENIC THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; ranibizumab; subretinal hemorrhage
ID RANIBIZUMAB
AB Purpose: To study patients with neovascular age-related macular degeneration (AMD) who experienced a macular hemorrhage after stabilization with intravitreal antivascular endothelial growth factor (anti-VEGF) agents to improve current treatment regimens and prevent disease progression.
   Methods: Retrospective chart review of six patients. The main outcome measures included time between last intravitreal anti-VEGF treatment and date of hemorrhage, time between last office visit and date of hemorrhage, and visual acuity before and after hemorrhage.
   Results: Three of 6 eyes had a macular hemorrhage within 4 weeks of a stable examination. One eye had optical coherence tomography (OCT) that demonstrated no fluid 1 day before the macular hemorrhage. The average time between the date of the last injection and macular hemorrhage was 16.8 weeks (range, 7.3-28.9 weeks). The average time between the last stable examination and an event was 4.2 weeks (range, 1 day to 7.3 weeks). Three of six patients had a persistent decline in vision after the hemorrhage. Among the 4 patients, who had better than 201200 vision before the macular hemorrhage, 2 dropped to 20/200 or worse.
   Conclusion: Sight-threatening macular hemorrhages from AMD can occur within days to weeks after a stable examination and absence of fluid on OCT. Regimens that treat "as needed" based on clinical findings and OCT may not be appropriate for certain patients. RETINA 29:1074-1079, 2009
C1 [Sorenson, John A.; Spaide, Richard F.; Cooney, Michael J.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Levine, Jonathan P.] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Marcus, Inna] NYU, Sch Med, New York, NY 10003 USA.
   [Sorenson, John A.; Spaide, Richard F.; Cooney, Michael J.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Yeshiva University;
   Albert Einstein College of Medicine; New York University; Manhattan Eye
   Ear & Throat Hospital
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM vrmny@aol.com
RI Spaide, Richard/ABD-7368-2020; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU The LuEsther T. Mertz Retinal Research Center of the Manhattan Eye, Ear,
   & Throat Hospital; The Macula Foundation, Inc
FX Supported in part by The LuEsther T. Mertz Retinal Research Center of
   the Manhattan Eye, Ear, & Throat Hospital and The Macula Foundation,
   Inc.
CR AVERY RL, 2006, OPHTHALMOLOGY, V113
   BARBAZETTO, 2008, ANN M RET SOC SEPT
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stone EM, 2006, NEW ENGL J MED, V355, P1493, DOI 10.1056/NEJMe068191
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
NR 12
TC 14
Z9 15
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2009
VL 29
IS 8
BP 1074
EP 1079
DI 10.1097/IAE.0b013e3181b09443
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 497IG
UT WOS:000270051800004
PM 19734761
DA 2022-11-30
ER

PT J
AU Ferris, FL
   Davis, MD
   Clemons, TE
   Lee, LY
   Chew, EY
   Lindblad, AS
   Milton, RC
   Bressler, SB
   Klein, R
AF Ferris, FL
   Davis, MD
   Clemons, TE
   Lee, LY
   Chew, EY
   Lindblad, AS
   Milton, RC
   Bressler, SB
   Klein, R
CA Age-Related Eye Disease Study Res
TI A simplified severity scale for age-related macular degeneration - AREDS
   report no. 18
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY; PROGRESSION; RISK
AB Objective: To develop a simplified clinical scale defining risk categories for development of advanced age-related macular degeneration (AMD).
   Methods: Following development of a detailed scale for individual eyes based on gradings of fundus photographs in the Age-Related Eye Disease Study, rates of progression to advanced AMD were assessed in cross-tabulations of presence or absence in each eye of 2 easily identified retinal abnormalities, drusen and pigment abnormalities. Large drusen and any pigment changes were particularly predictive of developing advanced AMD.
   Results: The scoring system developed for patients assigns to each eye 1 risk factor for the presence of 1 or more large ( >= 125 mu m, width of a large vein at disc margin) drusen and 1 risk factor for the presence of any pigment abnormality. Risk factors are summed across both eyes, yielding a 5-step scale (0-4) on which the approximate 5-year risk of developing advanced AMD in at least one eye increases in this easily remembered sequence: 0 factors, 0.5%; 1 factor, 3%; 2 factors, 12%; 3 factors, 25%; and 4 factors, 50%. For persons with no large drusen, presence of intermediate drusen in both eyes is counted as 1 risk factor.
   Conclusion: This simplified scale provides convenient risk categories for development of advanced AMD that can be determined by clinical examination or by less demanding photographic procedures than used in the Age-Related Eye Disease Study.
C1 EMMES Corp, AREDS Coordinat Ctr, Rockville, MD 20850 USA.
C3 Emmes Corporation
RP Ferris, FL (通讯作者)，EMMES Corp, AREDS Coordinat Ctr, 401 N Washington St,Suite 700, Rockville, MD 20850 USA.
OI Ferris, Frederick/0000-0002-4933-0639
FU Intramural NIH HHS [ZIA EY000489-01, Z99 EY999999] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [Z01EY000394] Funding Source: NIH
   RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P823
   Au Eong KG, 2002, AGE RELATED MACULAR, P389
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 13
TC 482
Z9 500
U1 2
U2 26
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2005
VL 123
IS 11
BP 1570
EP 1574
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 981BM
UT WOS:000233062100011
PM 16286620
DA 2022-11-30
ER

PT J
AU Smeeth, L
   Cook, C
   Chakravarthy, U
   Hubbard, R
   Fletcher, AE
AF Smeeth, L
   Cook, C
   Chakravarthy, U
   Hubbard, R
   Fletcher, AE
TI A case control study of age related macular degeneration and use of
   statins
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PRACTICE RESEARCH DATABASE; CHOLESTEROL-LOWERING MEDICATIONS; VISUAL
   IMPAIRMENT; RISK-FACTORS; MACULOPATHY
AB Aims: Age related macular degeneration (AMD) is the leading cause of blindness in industrialised countries. Previous studies have suggested that statins may have a protective effect against the disease; however, existing studies have had limited power to reliably detect or exclude an effect and have produced conflicting results. The authors assessed the risk of AMD associated with the use of statins.
   Methods: Population based case control study using the United Kingdom General Practice Research Database. 18 007 people with diagnosed AMD were compared with 86 169 controls matched on age, sex, and general practice. The primary outcome was the odds ratio for the association between exposure to statins and AMD.
   Results: The crude odds ratio for the association between any recorded exposure to statins and AMD was 1.32 (95% CI 1.17 to 1.48), but this reduced to 0.93 (95% CI 0.81 to 1.07, p=0.33) after adjustment for consultation rate, smoking, alcohol intake, body mass index, atherosclerotic disease, hyperlipidaemia, heart failure, diabetes mellitus, hypertension, use of other cardiovascular drugs, and use of fibrates. There was no evidence that the risk varied by dose of statin, duration of use, or that the risk varied for individual statins.
   Conclusion: In the short and medium term statin use is not associated with a decreased risk of AMD. Whether subgroups of patients with specific forms of AMD (particularly choroidal neovascularisation) benefit from statin therapy remains a possibility.
C1 Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   Queens Univ Belfast, Inst Clin Sci, Royal Hosp, Ctr Vis Sci, Belfast, Antrim, North Ireland.
   Univ Nottingham, City Hosp Nottingham, Div Resp Med, Nottingham NG7 2RD, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   Queens University Belfast; Nottingham University Hospital NHS Trust;
   Nottingham City Hospital; University of Nottingham
RP Smeeth, L (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM liam.smeeth@lshtm.ac.uk
RI ; Smeeth, Liam/X-5862-2018
OI Chakravarthy, Usha/0000-0002-2606-3734; Smeeth, Liam/0000-0002-9168-6022
FU MRC [G108/492] Funding Source: UKRI; Medical Research Council [G108/492]
   Funding Source: Medline; Wellcome Trust Funding Source: Medline
CR Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766
   Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaye JA, 2000, BRIT J CANCER, V83, P1556, DOI 10.1054/bjoc.2000.1493
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Meier CR, 1998, LANCET, V351, P1467, DOI 10.1016/S0140-6736(97)11084-4
   NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32
   Office for National Statistics, 1998, KEY HLTH STAT GEN PR
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   van Leeuwen R, 2001, BRIT MED J, V323, P1308, DOI 10.1136/bmj.323.7324.1308a
   Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
NR 23
TC 49
Z9 49
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2005
VL 89
IS 9
BP 1171
EP 1175
DI 10.1136/bjo.2004.064477
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 956PW
UT WOS:000231313300027
PM 16113375
OA Green Submitted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Hoyng, CB
   Tromp, AI
   Meulendijks, CFM
   Leys, A
   van der Maazen, RWM
   Deutman, AF
   Vingerling, JR
AF Hoyng, CB
   Tromp, AI
   Meulendijks, CFM
   Leys, A
   van der Maazen, RWM
   Deutman, AF
   Vingerling, JR
TI Side effects after radiotherapy of age-related macular degeneration with
   the Nijmegen technique
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RADIATION RETINOPATHY; TRIAL
AB Background: In a randomized trial concerning radiotherapy for age-related macular degeneration, fluorescein angiograms were taken of controls and patients. In this study the frequency of side effects in eyes receiving radiotherapy with the Nijmegen technique is compared with the findings in the eyes of controls. Methods: Patients receiving treatment were irradiated by two isocentric photon beams in four fractions of 6 Gy that were directed to the macular area at 30degrees and -30degrees with regard to the optical axis. The most recent fluorescein angiograms of the randomized eyes (32 treated and 31 control eyes) were scored by two independent researchers, using a scoring form with nine features of radiation retinopathy: nonperfusion, macular edema, microaneurysms, retinal hemorrhages, cotton-wool spots, perifoveal telangiectasis, vascular sheathing, retinal neovascularization, and radiation-associated choroidal neovasculopathy. The results were graded as: no retinopathy (grade 0), mild retinopathy (grade 1), moderate retinopathy (grade 2), and severe retinopathy (grade 3). Results: In the treated group 6 patients (18.8%) were grade 1, 10 patients (31.2%) were grade 2 and 7 patients (21.9%) were grade 3. In the control group 9 patients (29.0%) were grade 1, 11 patients (35.5%) were grade 2 and 2 patients (6.5%) were grade 3. There were no patients with retinal neovascularization. Conclusion: With the Nijmegen technique a relatively high dose of radiation can be applied to a small retinal area. In only a minority of cases does some evidence of radiation retinopathy occur.
C1 Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6500 HB Nijmegen, Netherlands.
   Katholieke Univ Leuven Hosp, Dept Ophthalmol, Louvain, Belgium.
   Univ Nijmegen, Med Ctr, Dept Radiol, Nijmegen, Netherlands.
   Erasmus Univ, Sch Med, Dept Ophthalmol, Rotterdam, Netherlands.
C3 Radboud University Nijmegen; Flanders Institute for Biotechnology (VIB);
   KU Leuven; University Hospital Leuven; Radboud University Nijmegen;
   Erasmus University Rotterdam
RP Hoyng, CB (通讯作者)，Univ Nijmegen, Med Ctr, Dept Ophthalmol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
RI van der Maazen, R.W.M./L-4498-2015; Hoyng, C.B./H-8050-2014
CR AMOAKU WMK, 1990, EYE, V4, P195, DOI 10.1038/eye.1990.26
   AMOAKU WMK, 1990, EYE, V4, P657, DOI 10.1038/eye.1990.93
   ARCHER D B, 1991, Eye (London), V5, P239
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BROWN GC, 1982, OPHTHALMOLOGY, V89, P1494
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Donati G, 1999, BRIT J OPHTHALMOL, V83, P646, DOI 10.1136/bjo.83.6.646
   GORDON KB, 1995, INT J RADIAT ONCOL, V31, P1123, DOI 10.1016/0360-3016(95)00062-4
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Maberley DAL, 1999, OPHTHALMOLOGY, V106, P2248, DOI 10.1016/S0161-6420(99)90523-7
   Mauget-Faysse M, 2000, J FR OPHTALMOL, V23, P127
   Mauget-Faysse M, 1999, BRIT J OPHTHALMOL, V83, P923
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   Staar S, 1999, INT J RADIAT ONCOL, V45, P467, DOI 10.1016/S0360-3016(99)00186-8
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
NR 17
TC 6
Z9 6
U1 0
U2 1
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2002
VL 240
IS 5
BP 337
EP 341
DI 10.1007/s00417-002-0428-4
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 564TQ
UT WOS:000176330000002
PM 12073055
DA 2022-11-30
ER

PT J
AU Evans, JR
AF Evans, Jennifer R.
TI Ginkgo biloba extract for age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Phytotherapy; Plants, Medicinal; Ginkgo biloba [therapeutic use];
   Macular Degeneration [therapy]; Humans
ID DOUBLE-BLIND; EGB-761; TRIALS
AB Background
   Ginkgo is used in the treatment of peripheral vascular disease and 'cerebral insufficiency'. It is thought to have several potential mechanisms of action including increased blood flow, platelet activating factor antagonism, and prevention of membrane damage caused by free radicals. Vascular factors and oxidative damage are thought to be two potential mechanisms in the pathology of age-related macular degeneration (AMD).
   Objectives
   The objective of this review was to determine the effect of Ginkgo biloba extract on the progression of AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 10), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to October 2012), EMBASE (January 1980 to October 2012), Allied and Complementary Medicine Database (AMED) (January 1985 to October 2012), OpenGrey (System for Information on Grey Literature in Europe) (www.opengrey.eu/), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 5 October 2012. We searched the reference lists of identified reports and the Science Citation Index. We also contacted investigators of included studies for additional information.
   Selection criteria
   All randomised trials in people with AMD where Ginkgo biloba extract had been compared to control were included.
   Data collection and analysis
   The review author extracted data using a standardised form. The data were verified with the trial investigators. Trial quality was assessed.
   Main results
   Two published trials were identified that randomised a total of 119 people. In one study conducted in France, 20 people were randomly allocated to Gingko biloba extract EGb 761 80 mg twice daily or placebo. In the other study conducted in Germany, 99 people were randomly allocated to two different doses of Ginkgo biloba extract EGb 761 (240 mg per day and 60 mg per day). Treatment duration in both studies was six months. Both trials reported some positive effects of Ginkgo biloba on vision however their results could not be pooled. Adverse effects and quality of life for people with AMD were not reported.
   Authors' conclusions
   The question as to whether people with AMD should take Ginkgo biloba extract to prevent progression of the disease has not been answered by research to date. Two small trials have suggested possible benefit of Gingko biloba on vision and further trials are warranted. Ginkgo biloba is widely used in China, Germany, and France. Future trials should be larger, and last longer, in order to provide a more robust measure of the effect of Gingko biloba extract on AMD.
C1 Univ London London Sch Hyg & Trop Med, ICEH, Cochrane Eyes & Vis Grp, London WC1E 7HT, England.
C3 University of London; London School of Hygiene & Tropical Medicine
RP Evans, JR (通讯作者)，Univ London London Sch Hyg & Trop Med, ICEH, Cochrane Eyes & Vis Grp, Keppel St, London WC1E 7HT, England.
EM jennifer.evans@lshtm.ac.uk
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030
CR Birks J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003120.pub3
   DroyLefaix MT, 1995, INT J TISSUE REACT, V17, P93
   DROYLEFAIX MT, 1993, INT J TISSUE REACT, V15, P85
   Evans J., 1996, HEALTH TRENDS, V28, P5
   Evans JR, 1999, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001775, DOI 10.1002/14651858.CD001775]
   Fies P, 2002, Wien Med Wochenschr, V152, P423, DOI 10.1046/j.1563-258X.2002.02066.x
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Higgins J., 2011, COCHRANE HDB SYST RE
   Hilton M., 2004, COCHRANE DB SYST REV
   KLEIJNEN J, 1992, LANCET, V340, P1136, DOI 10.1016/0140-6736(92)93158-J
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Knipschild PG, 1998, ARZNEIMITTEL-FORSCH, V48, P1033
   LEBUISSON DA, 1986, PRESSE MED, V15, P1556
   PRITZHOHMEIER S, 1994, OPHTHALMIC RES, V26, P80, DOI 10.1159/000267396
   Rosenblatt M, 1997, NEW ENGL J MED, V336, P1108, DOI 10.1056/NEJM199704103361518
   Rowin J, 1996, NEUROLOGY, V46, P1775, DOI 10.1212/WNL.46.6.1775
   Zeng X, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003691.pub2
NR 17
TC 31
Z9 33
U1 0
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2013
IS 1
AR CD001775
DI 10.1002/14651858.CD001775.pub2
PG 18
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 081JQ
UT WOS:000314315800015
PM 23440785
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Eshtiaghi, A
   Popovic, MM
   Sothivannan, A
   Muni, RH
   Kertes, PJ
AF Eshtiaghi, Arshia
   Popovic, Marko M.
   Sothivannan, Amirthan
   Muni, Rajeev H.
   Kertes, Peter J.
TI STATIN USE AND THE INCIDENCE OF AGE-RELATED MACULAR DEGENERATION A
   Meta-Analysis
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   geographic atrophy; meta-analysis; statin
ID REDUCTASE INHIBITORS; RISK; PROGRESSION; ANTIOXIDANT; OUTCOMES; COHORT
AB Purpose: Age-related macular degeneration (AMD) shares many of the same risk factors with atherosclerosis. There is a postulated role of lipid-lowering agents in preventing AMD. This meta-analysis investigates the possible role of statins in the prevention of AMD onset and progression.
   Methods: MEDLINE, EMBASE, Cochrane CENTRAL, and the reference lists of included studies were systematically searched from inception to September 2020. Studies were included if they measured the risk of AMD development or progression with statin use. The primary outcomes assessed were AMD incidence and progression. Secondary outcomes were the incidence of early AMD, late AMD, choroidal neovascularization, and geographic atrophy.
   Results: Twenty-one articles (1 randomized control trial and 20 observational studies) collectively reporting on 1,460,989 participants were included. The pooled risk ratios (95% confidence interval) for statin use on any, early, and late AMD incidence were 1.05 (0.85-1.29) (P = 0.44), 0.99 (0.88-1.11) (P = 0.86), and 1.15 (0.90-1.47) (P = 0.27), respectively. In patients with existing AMD, the respective risk ratios for statin use on incidence of AMD progression, choroidal neovascularization, and geographic atrophy were 1.04 (0.70-1.53) (P = 0.85), 0.99 (0.66-1.48) (P = 0.95), and 0.84 (0.58-1.22) (P = 0.36).
   Conclusion: This meta-analysis found that there was no significant difference in the incidence or progression of AMD based on statin use.
C1 [Eshtiaghi, Arshia] Univ Toronto, Temerty Fac Med, Toronto, ON, Canada.
   [Popovic, Marko M.; Muni, Rajeev H.; Kertes, Peter J.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Sothivannan, Amirthan] McMaster Univ, Michael G DeGroote Fac Med, Hamilton, ON, Canada.
   [Muni, Rajeev H.] St Michaels Hosp, Unity Hlth Toronto, Dept Ophthalmol, Toronto, ON, Canada.
   [Kertes, Peter J.] Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, 2075 Bayview Ave,Room M1-202a, Toronto, ON M4N 3M5, Canada.
C3 University of Toronto; University of Toronto; McMaster University;
   University of Toronto; University Toronto Affiliates; Saint Michaels
   Hospital Toronto; University of Toronto; Sunnybrook Research Institute;
   University Toronto Affiliates; Sunnybrook Health Science Center
RP Kertes, PJ (通讯作者)，Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, 2075 Bayview Ave,Room M1-202a, Toronto, ON M4N 3M5, Canada.
EM peter.kertes@sunnybrook.ca
OI Popovic, Marko/0000-0002-0370-5968; Eshtiaghi,
   Arshia/0000-0002-0047-8157
CR Abramson JD., 2014, BRIT DENT J, V216, P23
   Bulbulia R, 2011, LANCET, V378, P2013, DOI 10.1016/S0140-6736(11)61125-2
   Chang BH, 2017, MED CARE, V55, P328, DOI 10.1097/MLR.0000000000000696
   Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.1136/bmj.l4898, 10.4084/MJHID.2010.005]
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Kossmeier M, 2019, Z PSYCHOL, V227, P83, DOI 10.1027/2151-2604/a000358
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moon GJ, 2014, J CLIN NEUROL, V10, P140, DOI 10.3988/jcn.2014.10.2.140
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   PAULE RC, 1989, J RES NATL INST STAN, V94, P197, DOI 10.6028/jres.094.020
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Services UD of H and H, 2014, QUALITY ASSESSMENT T
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Wells G., 2014, NEWCASTLE OTTAWA QUA, DOI DOI 10.2307/632432
   Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690
NR 32
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2022
VL 42
IS 4
BP 643
EP 652
DI 10.1097/IAE.0000000000003398
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0A8RN
UT WOS:000774215200008
PM 34983903
DA 2022-11-30
ER

PT J
AU Rajapakse, D
   Peterson, K
   Mishra, S
   Fan, JG
   Lerner, J
   Campos, M
   Wistow, G
AF Rajapakse, Dinusha
   Peterson, Katherine
   Mishra, Sanghamitra
   Fan, Jianguo
   Lerner, Joshua
   Campos, Maria
   Wistow, Graeme
TI Amelotin is expressed in retinal pigment epithelium and localizes to
   hydroxyapatite deposits in dry age-related macular degeneration
SO TRANSLATIONAL RESEARCH
LA English
DT Article
ID VASCULAR CALCIFICATION; PHOSPHATE; CHOLESTEROL; CALCIUM; IDENTIFICATION;
   CELLS; ZINC; EYES
AB Deposition of hydroxyapatite (HAP) basal to the retinal pigment epithelium (RPE) is linked to the progression of age-related macular degeneration (AMD). Serum-deprivation of RPE cells in culture mimics some features of AMD. We now show that serum-deprivation also leads to the induction of amelotin (AMTN), a protein involved in hydroxyapatite mineralization in enamel. HAP is formed in our culture model and is blocked by siRNA inhibition of AMTN expression. In situ hybridization and immunofluorescence imaging of human eye tissue show that AMTN is expressed in RPE of donor eyes with geographic atrophy ("dry" AMD) in regions with soft drusen containing HAP spherules or nodules. AMTN is not found in hard drusen, normal RPE, or donor eyes diagnosed with wet AMD. These findings suggest that AMTN is involved in formation of HAP spherules or nodules in AMD, and as such provides a new therapeutic target for slowing disease progression.
C1 [Rajapakse, Dinusha; Peterson, Katherine; Mishra, Sanghamitra; Fan, Jianguo; Lerner, Joshua; Wistow, Graeme] NEI, Sect Mol Struct & Funct Genom, NIH, Bethesda, MD 20892 USA.
   [Campos, Maria] NEI, Histopathol Core Facil, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Wistow, G (通讯作者)，NEI, Sect Mol Struct & Funct Genom, NIH, Bethesda, MD 20892 USA.
EM graeme@helix.nih.gov
OI Lerner, Joshua/0000-0001-5055-1247
FU Intramural Program of the National Eye Institute
FX This work was supported by the Intramural Program of the National Eye
   Institute.
CR Abbarin N, 2015, J BONE MINER RES, V30, P775, DOI 10.1002/jbmr.2411
   Anderson H Clarke, 2003, Curr Rheumatol Rep, V5, P222, DOI 10.1007/s11926-003-0071-z
   Asai-Coakwell M, 2009, HUM MOL GENET, V18, P1110, DOI 10.1093/hmg/ddp008
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boileau G, 2001, BIOCHEM J, V355, P707, DOI 10.1042/bj3550707
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chen JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097428
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Foroud T, 2008, OSTEOPOROSIS INT, V19, P637, DOI 10.1007/s00198-007-0484-z
   Golub EE, 2009, BBA-GEN SUBJECTS, V1790, P1592, DOI 10.1016/j.bbagen.2009.09.006
   Ioannidis JPA, 2004, JAMA-J AM MED ASSOC, V292, P2105, DOI 10.1001/jama.292.17.2105
   Iwasaki K, 2005, J DENT RES, V84, P1127, DOI 10.1177/154405910508401207
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kostik MM, 2013, EPMA J, V4, DOI 10.1186/1878-5085-4-15
   Kuro-o M, 2018, INT J NEPHROL, V2018, DOI 10.1155/2018/9679841
   La Fontaine A, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1601145
   Lee HK, 2015, J BIOL CHEM, V290, P14740, DOI 10.1074/jbc.M115.648022
   Li XW, 2006, CIRC RES, V98, P905, DOI 10.1161/01.RES.0000216409.20863.e7
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mazerbourg S, 2005, J BIOL CHEM, V280, P32122, DOI 10.1074/jbc.M504629200
   McManus Stephen, 2012, J Mol Signal, V7, P1, DOI 10.1186/1750-2187-7-1
   Mikhaylova L, 2007, CALCIFIED TISSUE INT, V81, P372, DOI 10.1007/s00223-007-9073-6
   Mishra S, 2016, MOL VIS, V22, P1387
   Moradian-Oldak J, 2012, FRONT BIOSCI-LANDMRK, V17, P1996, DOI 10.2741/4034
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peterson KM, 2019, USING INTERACTIVE VI
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Rajapakse D, 2017, EXP CELL RES, V361, P333, DOI 10.1016/j.yexcr.2017.10.036
   Reynolds JL, 2004, J AM SOC NEPHROL, V15, P2857, DOI 10.1097/01.ASN.0000141960.01035.28
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Runkle EA, 2011, METHODS MOL BIOL, V686, P133, DOI 10.1007/978-1-60761-938-3_5
   Samuel W, 2017, MOL VIS, V23, P60
   Son YO, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08035-7
   Sun K, 2007, MOL VIS, V13, P2310
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tan TW, 2012, J CELL PHYSIOL, V227, P2531, DOI 10.1002/jcp.22991
   Tas AC, 2000, BIOMATERIALS, V21, P1429
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, pE3971
   Tsukamoto S, 2014, SCI REP-UK, V4, DOI 10.1038/srep07596
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Yoo SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158481
   Yu MH, 2019, CRYST GROWTH DES, V19, P2104, DOI 10.1021/acs.cgd.8b01680
   Zimmer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035062
NR 55
TC 0
Z9 0
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1931-5244
EI 1878-1810
J9 TRANSL RES
JI Transl. Res.
PD MAY
PY 2020
VL 219
BP 45
EP 62
DI 10.1016/j.trsl.2020.02.007
PG 18
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology; General & Internal Medicine; Research &
   Experimental Medicine
GA LH4SN
UT WOS:000528776000004
PM 32160961
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kim, KT
   Chae, JB
   Lee, S
   Seo, EJ
   Kim, DY
AF Kim, Kyung Tae
   Chae, Ju Byung
   Lee, Seungheon
   Seo, Eoi Jong
   Kim, Dong Yoon
TI Analyses of the effects of persistent subretinal fluid on
   visual/anatomic outcomes according to the type of macular
   neovascularization during the relaxed treat-and-extend protocol in
   age-related macular degeneration patients
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor; Macular neovascularization;
   Exudative age-related macular degeneration; Subretinal fluid
ID PIGMENT EPITHELIAL DETACHMENT; VISUAL-ACUITY; RANIBIZUMAB; THERAPY;
   BEVACIZUMAB; RELEVANT; REGIMEN; NEED
AB Background To analyze the long-term effects of persistent subretinal fluid (SRF) on visual/anatomic outcomes according to the type of macular neovascularization (MNV) during relaxed treat-and-extend regimen with anti-vascular endothelial growth factor (anti-VEGF) agents in age-related macular degeneration (AMD) patients. Methods Patients with fovea-involving type 1 or type 2 MNV, treated with a relaxed treat-and-extend regimen for 2 years were retrospectively reviewed. Eyes with SRF observed more than three times per year were defined as the 'persistent SRF (+) group'. To exclude the effects of IRF as much as possible, the eyes with persistent IRF were excluded. The effects of persistent SRF on the best-corrected visual acuity (BCVA), central subfield retinal thickness (CST), and changes in the photoreceptor layer (PRL) thickness and outer retinal bands (external limiting membrane, ellipsoid zone, and cone outer segment tip line) after anti-VEGF injection were analyzed for each MNV type. Results Seventy-seven eyes with type 1 MNV (44 eyes with persistent SRF) and 53 eyes with type 2 MNV (18 eyes with persistent SRF) were enrolled. Following a relaxed treat-and-extend regimen with anti-VEGF agents, BCVA and CST improved for each MNV type. In comparison between persistent SRF (+) and persistent SRF (-) group, there were no differences in the amount of change in BCVA and CST between the two groups for each MNV type during 2-year follow-up periods. In addition, there were no differences in the amount of reduction in PRL thickness and state of the outer retinal bands between the two groups for each MNV type. Conclusions Using a relaxed treat-and-extend regimen with anti-VEGF agents, persistent SRF did not have additional effects on visual and anatomic outcomes by 2 years, regardless of the MNV type.
C1 [Kim, Kyung Tae; Chae, Ju Byung; Lee, Seungheon; Seo, Eoi Jong; Kim, Dong Yoon] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Dept Ophthalmol, 776,Sunhwan 1 Ro, Cheongju 28644, South Korea.
C3 Chungbuk National University; Chungbuk National University Hospital
RP Kim, DY (通讯作者)，Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Dept Ophthalmol, 776,Sunhwan 1 Ro, Cheongju 28644, South Korea.
EM umlover9@gmail.com
CR Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kim KT, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092692
   Kim KT, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061863
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   Odrobina D, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/361513
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Sato T, 2015, RETINA-J RET VIT DIS, V35, P1292, DOI 10.1097/IAE.0000000000000505
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 35
TC 2
Z9 2
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 10
PY 2021
VL 21
IS 1
AR 294
DI 10.1186/s12886-021-02063-6
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TY4BY
UT WOS:000683730000001
PM 34376158
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yip, JLY
   Khawaja, AP
   Chan, MPY
   Broadway, DC
   Peto, T
   Luben, R
   Hayat, S
   Bhaniani, A
   Wareham, N
   Foster, PJ
   Khaw, KT
AF Yip, Jennifer L. Y.
   Khawaja, Anthony P.
   Chan, Michelle P. Y.
   Broadway, David C.
   Peto, Tunde
   Luben, Robert
   Hayat, Shabina
   Bhaniani, Amit
   Wareham, Nick
   Foster, Paul J.
   Khaw, Kay-Tee
TI Area deprivation and age related macular degeneration in the
   EPIC-Norfolk Eye Study
SO PUBLIC HEALTH
LA English
DT Article
DE Area deprivation; Inequalities; Macular degeneration
ID SOCIOECONOMIC-STATUS; RISK-FACTORS; VISUAL IMPAIRMENT; POOLED FINDINGS;
   EQUITY PROFILE; POPULATION; EDUCATION; GLAUCOMA; DISEASE; QUESTIONNAIRE
AB Objectives: To investigate the relationship between area deprivation, individual socioeconomic status (SES) and age related macular degeneration (AMD).
   Study design: Cross sectional study nested within a longitudinal cohort study.
   Methods: Data were collected in the EPIC-Norfolk Eye Study by trained nurses, using standardized protocols and lifestyle questionnaires. The English Index of multiple deprivation 2010 (IMD) was derived from participants' postcodes. AMD was identified from standardized grading of fundus photographs. Logistic regression was used to examine associations between IMD, SES and AMD.
   Results: 5344 pairs (62.0% of total 8623) of fundus photographs were of sufficient quality for grading of AMD. Of 5182 participants with complete data, AMD was identified in 653 participants (12.60%, 95%CI = 11.7-13.5%). Multivariable logistic regression showed that people living in the most affluent 5% of areas had nearly half the odds of AMD compared to those living in comparatively more deprived areas (OR = 0.56, 95%CI = 0.36-0.89, P = 0.02), after adjusting for age, sex, education, social class and smoking.
   Conclusions: The authors found that living in the most affluent areas exerted a protective effect on AMD, independently of education and social class. Further investigation into underlying mechanisms will inform potential interventions to reduce health inequalities relating to AMD. (C) 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
C1 [Yip, Jennifer L. Y.; Khawaja, Anthony P.; Luben, Robert; Hayat, Shabina; Bhaniani, Amit; Khaw, Kay-Tee] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
   [Yip, Jennifer L. Y.; Khawaja, Anthony P.; Chan, Michelle P. Y.; Peto, Tunde; Foster, Paul J.] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Yip, Jennifer L. Y.; Khawaja, Anthony P.; Chan, Michelle P. Y.; Peto, Tunde; Foster, Paul J.] UCL Inst Ophthalmol, London, England.
   [Broadway, David C.] Norfolk & Norwich Univ Hosp, Dept Ophthalmol, Norwich, Norfolk, England.
   [Wareham, Nick] Univ Cambridge, Sch Clin Med, MRC Epidemiol Unit, Cambridge, England.
C3 University of Cambridge; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London; Norfolk & Norwich University
   Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital;
   University of Cambridge
RP Yip, JLY (通讯作者)，Strangeways Labs, Dept Publ Hlth & Primary Care, Worts Causeway, Cambridge, England.
EM jlyy2@medschl.cam.ac.uk
RI Luben, Robert N/H-5519-2015; Khaw, Kay-Tee/AAZ-3209-2021; Peto,
   Tunde/G-8812-2018; Foster, Paul/V-7288-2019
OI Luben, Robert N/0000-0002-5088-6343; Peto, Tunde/0000-0001-6265-0381;
   Foster, Paul/0000-0002-4755-177X; Yip, Jennifer Lai
   Yee/0000-0003-3788-7170; Khawaja, Anthony/0000-0001-6802-8585
FU Medical Research Council [G0401527, G9502233]; Cancer Research UK
   [C864/A8257, C864/A2883]; Age UK Research into Ageing grant [262];
   Department for Health through NIHR; Medical Research Council [G0500300,
   G0800603, G1001939, G0500300B, MC_UU_12015/1, MC_U106179471, G1000143]
   Funding Source: researchfish; National Institute for Health Research
   [NF-SI-0512-10114, CL-2010-14-004, NF-SI-0512-10135] Funding Source:
   researchfish; MRC [G0500300, G0800603, MC_UU_12015/1, G1001939] Funding
   Source: UKRI
FX EPIC-Norfolk infrastructure and core functions are supported by grants
   from the Medical Research Council (G0401527) and Cancer Research UK
   (C864/A8257). The clinic for the third health examination was funded by
   an Age UK Research into Ageing grant (262). The pilot phase was
   supported by Medical Research Council (G9502233) and Cancer Research UK
   (C864/A2883). Dr Yip is a National Institute for Health Research (NIHR)
   Clinical Lecturer. Dr Khawaja is a Wellcome Trust Clinical Research
   Fellow. Michelle Chan is an MRC/RCOphth Clinical Training Felllow and
   has received additional support from the International Glaucoma
   Association. Professor Foster has received additional support from the
   Richard Desmond Charitable Trust (via Fight for Sight). Professor Foster
   and Tunde Peto received funding from the Department for Health through
   the award made by the NIHR to Moorfields Eye Hospital and the UCL
   Institute of Ophthalmology for a specialist Biomedical Research Centre
   for Ophthalmology. None of the funding organizations had a role in the
   design or conduct of the research.
CR Acharya N, 2009, BRIT J OPHTHALMOL, V93, P627, DOI 10.1136/bjo.2008.147231
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Day F, 2010, EYE, V24, P1478, DOI 10.1038/eye.2010.73
   Department for Communities and Local Government, 2011, ENGL IND DEPR 2010
   Department of Health, 1998, INDEPENDENT INQUIRY
   Department of Health and Social Security, 1980, REP WORK GROUP IN HL
   Fraser S, 2001, BMJ-BRIT MED J, V322, P639, DOI 10.1136/bmj.322.7287.639
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Hayat SA, 2014, INT J EPIDEMIOL, V43, P1063, DOI 10.1093/ije/dyt086
   Khaw KT, 2006, INT J EPIDEMIOL, V35, P1034, DOI 10.1093/ije/dyl079
   Khawaja AP, 2013, BMJ OPEN, V3
   Kliner M, 2012, EYE, V26, P671, DOI 10.1038/eye.2012.3
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Malik ANJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001496
   Nessim M, 2008, BR J OPHTHALMOL, V94, P1304
   Ng WS, 2010, BRIT J OPHTHALMOL, V94, P85, DOI 10.1136/bjo.2008.153312
   Nicklett EJ, 2011, J NUTR, V141, P284, DOI 10.3945/jn.110.129684
   Office for National Statistics, 2014, DO SMOK RAT VAR MOR
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pascolini D, 2010, BR J OPHTHALMOL, V96, P614, DOI DOI 10.1136/BJ0PHTHALM0L-2011-300539
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   TAYLOR R, 1985, INT J HEALTH SERV, V15, P547, DOI 10.2190/XX9V-ACD4-KUXD-C0E5
   TIELSCH JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P637, DOI 10.1001/archopht.1991.01080050051027
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Varma R, 2004, OPHTHALMOLOGY, V111, P1132, DOI 10.1016/j.ophtha.2004.02.002
   Wareham NJ, 2003, PUBLIC HEALTH NUTR, V6, P407, DOI 10.1079/PHN2002439
   Wareham NJ, 2002, INT J EPIDEMIOL, V31, P168, DOI 10.1093/ije/31.1.168
   Wong TY, 2002, BRIT J OPHTHALMOL, V86, P963, DOI 10.1136/bjo.86.9.963
   World Health Organisation, 2008, COMM SOC DET HLTH FI
   Yip JLY, 2007, BRIT J OPHTHALMOL, V91, P56, DOI 10.1136/bjo.2006.099549
   Yip JLY, 2014, J EPIDEMIOL COMMUN H, V68, P204, DOI 10.1136/jech-2013-203265
   Yip JLY, 2011, OPHTHAL EPIDEMIOL, V18, P217, DOI 10.3109/09286586.2011.602507
   Zhang XZ, 2012, AM J OPHTHALMOL, V154, pS53, DOI 10.1016/j.ajo.2011.08.045
NR 38
TC 11
Z9 11
U1 1
U2 5
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0033-3506
EI 1476-5616
J9 PUBLIC HEALTH
JI Public Health
PD FEB
PY 2015
VL 129
IS 2
BP 103
EP 109
DI 10.1016/j.puhe.2014.10.012
PG 7
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA CD7UU
UT WOS:000351300500004
PM 25687711
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Pedrosa, AC
   Sousa, T
   Pinheiro-Costa, J
   Beato, J
   Falcao, MS
   Falcao-Reis, F
   Carneiro, A
AF Pedrosa, Ana Catarina
   Sousa, Tiago
   Pinheiro-Costa, Joao
   Beato, Joao
   Falcao, Manuel S.
   Falcao-Reis, Fernando
   Carneiro, Angela
TI Treatment of Neovascular Age-Related Macular Degeneration with Anti-VEGF
   Agents: Predictive Factors of Long-Term Visual Outcomes
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBGROUP ANALYSIS; RANIBIZUMAB
AB Purpose. To evaluate the predictive factors of long-term visual outcomes in neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor (anti-VEGF) agents. Methods. Unicentric retrospective review of patients with nAMD treated with anti-VEGF agents. Visual outcomes, 12 and 60 months after diagnosis, were evaluated. In an attempt to identify predictive factors of visual outcomes, multiple variables (demographic and epidemiological characteristics, angiographic and tomographic features) were analyzed, at baseline and during follow-up. Results. One hundred and seventeen patients were included. In multivariate analysis, baseline best-corrected visual acuity was associated with all visual endpoints at 12 and 60 months. Additionally, age, gender, number of injections, and development of subretinal fibrosis during follow-up were also significant predictors of visual outcomes at 60 months. Conclusions. Several factors can be useful in clinical practice as predictors of visual outcomes in response to anti-VEGF treatment of nAMD.
C1 [Pedrosa, Ana Catarina; Pinheiro-Costa, Joao; Beato, Joao; Falcao, Manuel S.; Falcao-Reis, Fernando; Carneiro, Angela] Ctr Hosp Sao Joao, Dept Ophthalmol, Oporto, Portugal.
   [Sousa, Tiago; Falcao, Manuel S.; Falcao-Reis, Fernando; Carneiro, Angela] Univ Porto, Dept Sense Organs, Fac Med, Oporto, Portugal.
   [Pinheiro-Costa, Joao] Univ Porto, Dept Anat, Fac Med, Oporto, Portugal.
C3 Sao Joao Hospital; Universidade do Porto; Universidade do Porto
RP Pedrosa, AC (通讯作者)，Ctr Hosp Sao Joao, Dept Ophthalmol, Oporto, Portugal.
EM catarina.c.pedrosa@gmail.com
RI Falcao/AAQ-8509-2020; Carneiro, Angela/N-9680-2013
OI Falcao/0000-0003-4718-0910; Carneiro, Angela/0000-0002-3370-7243;
   Falcao-Reis, Fernando/0000-0002-5995-9430
FU Novartis; Alimera; Allergan
FX Joao Pinheiro-Costa has participated in advisory boards for Bayer.
   Manuel S. Falcao has participated in advisory boards for Bayer and has
   received travel grants from Novartis, Alimera, and Allergan. Angela
   Carneiro has participated in advisory boards for Alcon, Bayer, Novartis,
   Alimera, and Allergan. The other authors declare no conflicts of
   interest regarding the publication of this paper.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calvo P, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/820605
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 12
TC 22
Z9 23
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2017
VL 2017
AR 4263017
DI 10.1155/2017/4263017
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX6OM
UT WOS:000403361600001
PM 28656102
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Chrapek, O
   Jarkovsky, J
   Studnicka, J
   Sin, M
   Kolar, P
   Jirkova, B
   Dusek, L
   Pitrova, S
   Rehak, J
AF Chrapek, Oldrich
   Jarkovsky, Jiri
   Studnicka, Jan
   Sin, Martin
   Kolar, Petr
   Jirkova, Barbora
   Dusek, Ladislav
   Pitrova, Sarka
   Rehak, Jiri
TI The efficacy of ranibizumab treatment in clinical practice in patients
   with the wet form of age-related macular degeneration. The results of
   the Czech National Registry
SO BIOMEDICAL PAPERS-OLOMOUC
LA English
DT Article
DE age-related macular degeneration; ranibizumab
ID EARLY CHOROIDAL NEOVASCULARIZATION; PEGAPTANIB
AB Aims. The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration.
   Methods. Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database. From 01/09/2008 to 25/10/2011, 671 patients/685 eyes treated with ranibizumab monotherapy were entered in the registry. 454 ranibizumab treated eyes and 444 patients were monitored for 12-months. The dependent variable used to monitor disease progression and treatment results was change in visual acuity in the ETDRS (Early Treatment Diabetic Retinopathy Study) chart over time.
   Results. After 12 months of treatment, a loss of < 15 letters in the ETDRS chart was found in 81.5% of eyes treated with ranibizumab. A gain of >= 15 letters was found in 9.7% of eyes on ranibizumab. The results for our patients treated in clinical practice with ranibizumab were poorer than those in the SUSTAIN (Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration) study. A rationale for this was sought in a sub-analysis.
   Conclusions. Sub-analysis demonstrated that treatment naive CNV (choroidal neovascularization), occult CNV and lower height of the macular oedema at the outset of the disease may be positive prognostic factors for final visual acuity in anti-VEGF (vascular endothelial growth factor) treated patients.
C1 [Chrapek, Oldrich; Sin, Martin; Jirkova, Barbora; Rehak, Jiri] Palacky Univ Olomouc, Fac Med & Dent, Dept Ophthalmol, Olomouc, Czech Republic.
   [Jarkovsky, Jiri; Dusek, Ladislav] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic.
   [Jarkovsky, Jiri; Dusek, Ladislav] Masaryk Univ, Fac Sci, CS-61137 Brno, Czech Republic.
   [Studnicka, Jan] Charles Univ Prague, Fac Med Hradec Kralove, Dept Ophthalmol, Prague, Czech Republic.
   [Studnicka, Jan] Univ Hosp, Hradec Kralove, Czech Republic.
   [Kolar, Petr] Masaryk Univ, Fac Med, Dept Ophthalmol, Brno, Czech Republic.
   [Kolar, Petr] Univ Hosp Brno, Brno, Czech Republic.
   [Pitrova, Sarka] Private Eye Clin, Prague, Czech Republic.
C3 Palacky University Olomouc; Institute of Biostatistics & Analyses;
   Masaryk University Brno; Masaryk University Brno; Charles University
   Prague; Masaryk University Brno; University Hospital Brno
RP Kolar, P (通讯作者)，Masaryk Univ, Fac Med, Dept Ophthalmol, Brno, Czech Republic.
EM pe.kolar@gmail.com
RI Studnička, Jan/AAC-4127-2022; Studnicka, Jan/K-2875-2017; Jarkovsky,
   Jiri/G-5494-2017; Chrapek, Oldrich/ABD-9894-2020; Dušek,
   Ladislav/G-8794-2013; Sin, Martin/AAJ-6818-2021
OI Studnicka, Jan/0000-0002-9911-4379; Chrapek,
   Oldrich/0000-0002-1403-4936; Kolar, Petr/0000-0003-3709-4648; Sin,
   Martin/0000-0002-5073-9482; Dusek, Ladislav/0000-0002-8589-4378
FU Novartis Pharma AG
FX Financial support: A grant from Novartis Pharma AG was received for the
   national registry AMADEUS.
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Pagliarini S, J OPHTHALMOLOGY, V2014
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P851, DOI 10.1097/IAE.0b013e31806458f0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
NR 12
TC 1
Z9 1
U1 0
U2 4
PU PALACKY UNIV, MEDICAL FAC
PI OLOMOUC
PA CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC
SN 1213-8118
EI 1804-7521
J9 BIOMED PAP
JI Biomed. Pap-Olomouc
PY 2015
VL 159
IS 3
BP 407
EP 412
DI 10.5507/bp.2015.017
PG 6
WC Engineering, Biomedical; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Research & Experimental Medicine
GA CW4FZ
UT WOS:000364948100012
PM 25916281
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Volz, C
   Pauly, D
AF Volz, Cornelia
   Pauly, Diana
TI Antibody therapies and their challenges in the treatment of age-related
   macular degeneration
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Age-related macular degeneration; Therapeutic antibody; Intravitreal;
   Anti-angiogenic; Anti-complement system; Anti-inflammatory; Anti-amyloid
   beta; Clinical studies
ID ENDOTHELIAL GROWTH-FACTOR; ALTERNATIVE COMPLEMENT PATHWAY;
   ANTI-ALPHA-5-BETA-1 INTEGRIN ANTIBODY; BEVACIZUMAB AVASTIN THERAPY; D
   MONOCLONAL-ANTIBODY; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   INFLIXIMAB; AMYLOID-BETA; AUTOIMMUNE-DISEASES; RETINAL DISEASES
AB Age-related macular degeneration (AMD) is the leading cause of vision loss in the western world. This multifactorial disease results from the combined contributions of age, environment and genetic predisposition. Antibody-based treatment of late-stage neovascular AMD with inhibitors of vascular endothelial growth factor has had great success, which is now the goal for currently untreatable AMD manifestations. The existence of an immune-privileged environment in the eye supports the feasibility of localized antibody therapy. Many different antibodies against various targets are being developed for the treatment of AMD, which reflects the etiological complexity of the disease. This review provides an overview of 19 potential therapeutic antibodies targeting angiogenesis, the complement system, inflammation or amyloid beta deposition in the eye. It summarizes the immunoglobulin structure, the specific target and study outcomes for each approach. The latter include beneficial results or adverse effects in AMD models and patients. Finally, this article discusses the challenges in the development of antibody-based drugs to treat degenerative processes in the posterior eye. In spite of these difficulties, to date, the following four antibodies have overcome the technical and preclinical hurdles and are being tested in active clinical studies: Lampalizumab, Sonepcizumab, GSK933776 and LFG316. We conclude that, while there are some antibody-based drugs that have made it into clinical practice, a successful transfer from bench to beside is still pending for many promising approaches. (C) 2015 Published by Elsevier B.V.
C1 [Volz, Cornelia; Pauly, Diana] Univ Hosp Regensburg, Dept Ophthalmol, D-93042 Regensburg, Germany.
C3 University of Regensburg
RP Pauly, D (通讯作者)，Univ Hosp Regensburg, Dept Ophthalmol, Franz Josef Strauss Allee 11, D-93042 Regensburg, Germany.
EM diana.pauly@klinik.uni-regensburg.de
RI Volz, Cornelia/ABB-4451-2021
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Alexion, 2014, SOL EC PACK INS
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson OA, 2010, DRUG DISCOV TODAY, V15, P272, DOI 10.1016/j.drudis.2010.02.004
   Androudi S, 2010, OPHTHALMOLOGY, V117, P1612, DOI 10.1016/j.ophtha.2009.12.011
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arias L, 2010, RETINA-J RET VIT DIS, V30, P1601, DOI 10.1097/IAE.0b013e3181e9f942
   Atzeni F, 2005, AUTOIMMUN REV, V4, P144, DOI 10.1016/j.autrev.2004.08.004
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   de Freitas LGA, 2013, ARQ BRAS OFTALMOL, V76, P180, DOI 10.1590/S0004-27492013000300010
   Bansal R, 2009, WO, Patent No. [2009/ 029669A1, 2009029669]
   BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978
   Behring E., 1890, DEUT MED WOCHENSCHR, V16, P1113, DOI 10.1055/s-0029-1207589
   Bell-McGuinn KM, 2011, GYNECOL ONCOL, V121, P273, DOI 10.1016/j.ygyno.2010.12.362
   Berger B.B., 2013, ARVO ANN M, P4505
   Besse B, 2013, ANN ONCOL, V24, P90, DOI 10.1093/annonc/mds281
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bielekova B, 2006, P NATL ACAD SCI USA, V103, P5941, DOI 10.1073/pnas.0601335103
   BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0
   BREITLING F, 1991, GENE, V104, P147, DOI 10.1016/0378-1119(91)90244-6
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Carrion A., 2014, ARVO M
   Carswell CI, 2001, BIODRUGS, V15, P745, DOI 10.2165/00063030-200115110-00005
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Daha MR, 2013, J AM SOC NEPHROL, V24, P5, DOI 10.1681/ASN.2012111110
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Dentchev T, 2003, MOL VIS, V9, P184
   Diaz-Rubio E, 2010, HDB THERAPEUTIC ANTI, P779
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehrlich P., 1908, NOBEL LECT PHYSL MED, P304
   El Sanharawi M, 2010, PROG RETIN EYE RES, V29, P443, DOI 10.1016/j.preteyeres.2010.04.001
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277
   FREI Y, 1987, MOL CELL PROBE, V1, P141, DOI 10.1016/0890-8508(87)90022-3
   Fung M, 2001, J THORAC CARDIOV SUR, V122, P113, DOI 10.1067/mtc.2001.114777
   Gardell SE, 2006, TRENDS MOL MED, V12, P65, DOI 10.1016/j.molmed.2005.12.001
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Goebel J, 2000, TRANSPL IMMUNOL, V8, P153, DOI 10.1016/S0966-3274(00)00021-6
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Grishanin R.N., 2014, 4 INT C CLIN EXP OPH
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gupta-Bansal R, 2000, MOL IMMUNOL, V37, P191, DOI 10.1016/S0161-5890(00)00047-X
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Heyen JR, 2014, TOXICOL PATHOL, V42, P765, DOI 10.1177/0192623314522559
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz F.G., 2013, EUR M SEPT, P28
   Hu XZ, 2013, MOL IMMUNOL, V54, P302, DOI 10.1016/j.molimm.2012.12.018
   Hunter J., 2013, Humaneered Anti-factor B Antibody, Patent No. [WO2013/177035 A2, 2013177035]
   IDEC B., 2014, AVVVIE POST TOP LIN, P1
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   JAKOBOVITS A, 1995, CURR OPIN BIOTECH, V6, P561, DOI 10.1016/0958-1669(95)80093-X
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kaplan Mariana, 2002, Curr Opin Investig Drugs, V3, P1017
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kemper C, 2010, ANNU REV IMMUNOL, V28, P131, DOI 10.1146/annurev-immunol-030409-101250
   Kim H, 2013, BRAIN RES, V1502, P11, DOI 10.1016/j.brainres.2013.01.043
   Kim H, 2009, MOL VIS, V15
   Kim J., 2014, J OCUL PHARM THER
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Klettner A, 2014, BRIT J OPHTHALMOL, V98, P1448, DOI 10.1136/bjophthalmol-2014-305105
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Langer HF, 2010, BLOOD, V116, P4395, DOI 10.1182/blood-2010-01-261503
   Laude A, 2010, PROG RETIN EYE RES, V29, P466, DOI 10.1016/j.preteyeres.2010.04.003
   Lee SH, 2011, ARCH PHARM RES, V34, P1223, DOI 10.1007/s12272-011-0821-9
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13
   LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu J., 2012, ARVO ANN M, P1236
   Lonberg N, 1995, Int Rev Immunol, V13, P65, DOI 10.3109/08830189509061738
   Loyet K.M., 2014, J PHARM EXP THER
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Lukowski ZL, 2013, J GLAUCOMA, V22, P145, DOI 10.1097/IJG.0b013e31822e8c83
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Manzano RPA, 2011, J OCUL PHARMACOL TH, V27, P327, DOI 10.1089/jop.2010.0174
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Miao J, 2014, KIDNEY INT, V86, P726, DOI 10.1038/ki.2014.103
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Milner R, 2007, J IMMUNOL, V178, P8158, DOI 10.4049/jimmunol.178.12.8158
   Miwa T, 2013, J IMMUNOL, V190, P3552, DOI 10.4049/jimmunol.1202275
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Myers A.C., 2014, CURR EYE RES, P1
   Nakajima T, 2014, MOL VIS, V20, P864
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Nussbaum JM, 2013, PRION, V7, P14, DOI 10.4161/pri.22118
   Nussenblatt R.B., 2011, RETINA, V30, P1579
   O'Brien N, 2009, J LIPID RES, V50, P2245, DOI 10.1194/jlr.M900048-JLR200
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Ophthotech Corporation, 2013, OPHTH FORM 10 Q QUAR, P1
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pauly D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096371
   Petrou P.A., 2014, ARVO ANN M, P5892
   Presta LG, 1997, CANCER RES, V57, P4593
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029
   Ramakrishnan V, 2006, J EXP THER ONCOL, V5, P273
   Rao L.J., 2014, RETIN PHYS, V12, P23
   Ricklin D, 2013, J IMMUNOL, V190, P3839, DOI 10.4049/jimmunol.1203200
   Roche, 2014, INV UPD, P1
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roguska M., 2014, ARVO M
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sabbadini RA, 2011, BRIT J PHARMACOL, V162, P1225, DOI 10.1111/j.1476-5381.2010.01118.x
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schwaeble H.-W., 2011, Methods for Treating Disseminated Intravascular Coagulation by Inhibiting masp-2 dependent Complement Activation, Patent No. [WO 2011047346 A1, 2011047346]
   Schwaeble WJ, 2011, P NATL ACAD SCI USA, V108, P7523, DOI 10.1073/pnas.1101748108
   Schwalm S, 2014, BASIC CLIN PHARMACOL, V114, P44, DOI 10.1111/bcpt.12103
   Schweizer D, 2014, EUR J PHARM BIOPHARM, V88, P291, DOI 10.1016/j.ejpb.2014.08.001
   Semeraro F, 2013, INT J IMMUNOPATH PH, V26, P765, DOI 10.1177/039463201302600321
   Shah CP, 2011, AGE-RELATED MACULAR DEGENERATION DIAGNOSIS AND TREATMENT, P135, DOI 10.1007/978-1-4614-0125-4_9
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   SIEGEL SA, 1995, CYTOKINE, V7, P15, DOI 10.1006/cyto.1995.1003
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Thurman JM, 2005, MOL IMMUNOL, V42, P87, DOI 10.1016/j.molimm.2004.07.043
   Tolentino MJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P78
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   van Hagen P.M., 2014, ACTA OPHTHALMOL, P1
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VOLANAKIS JE, 1985, NEW ENGL J MED, V312, P395, DOI 10.1056/NEJM198502143120702
   Waldmann TA, 2007, J CLIN IMMUNOL, V27, P1, DOI 10.1007/s10875-006-9060-0
   Wang L, 2014, EXP EYE RES, V127, P117, DOI 10.1016/j.exer.2014.07.006
   Wiekowski M., 2010, HDB THER ANTIBODIES, V2, P885
   Wojciak JM, 2009, P NATL ACAD SCI USA, V106, P17717, DOI 10.1073/pnas.0906153106
   Wu L, 2013, J OCUL PHARMACOL TH, V29, P366, DOI 10.1089/jop.2012.0203
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161
NR 153
TC 41
Z9 42
U1 0
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD SEP
PY 2015
VL 95
BP 158
EP 172
DI 10.1016/j.ejpb.2015.02.020
PN B
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CU8WH
UT WOS:000363824300002
PM 25725263
DA 2022-11-30
ER

PT J
AU Qin, VL
   Young, J
   Silva, FQ
   Conti, FF
   Singh, RP
AF Qin, Vivian L.
   Young, Jason
   Silva, Fabiana Q.
   Conti, Felipe F.
   Singh, Rishi P.
TI OUTCOMES OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION
   TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR THREE OR
   MORE YEARS A Review of Current Outcomes
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; choroidal neovascularization; long-term outcomes; aflibercept;
   ranibizumab; bevacizumab; visual acuity; tachyphylaxis; geographic
   atrophy
ID LONG-TERM OUTCOMES; RANIBIZUMAB; TACHYPHYLAXIS; BEVACIZUMAB; DISEASE
AB Purpose: To summarize the findings of long-term outcomes of anti-vascular endothelial growth factor (VEGF) therapy (>= 36 months) in patients with exudative age-related macular degeneration.
   Methods: Studies reporting long-term outcomes (>= 36 months) of anti-VEGF therapy (n = 11) were identified and analyzed for changes in visual acuity (VA), optical coherence tomography, and safety findings.
   Results: Six prospective extension studies of Phase 3 clinical trials and five retrospective evaluation studies were identified. The largest improvements in VA with anti-VEGF treatment were found in Years 1 to 2 after treatment initiation. In five studies, VA ultimately declined below patients' pretreatment initial baseline; in three studies, VA ultimately returned to patients' baseline; in three studies, VA decreased but ultimately remained improved over patients' baseline. There was a trend demonstrating that a higher frequency of intravitreous injections showed a better maintenance in VA. Rates of adverse events were similar to previous registration studies of anti-VEGF drugs.
   Conclusion: The body of evidence to date regarding long-term anti-VEGF treatment indicates a variable course at greater than 36 months follow-up and seems to be dependent on the treatment protocol. Consistent dosing with fluid-free interval is suggested to maintain VA gains in patients with exudative age-related macular degeneration. There is no evidence suggesting that there are additional adverse events from long-term anti-VEGF use.
C1 [Qin, Vivian L.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Young, Jason; Silva, Fabiana Q.; Conti, Felipe F.; Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave,Desk I32, Cleveland, OH 44195 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation
RP Singh, RP (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave,Desk I32, Cleveland, OH 44195 USA.
EM SINGHR@ccf.org
RI Silva, Fabiana/GWU-9143-2022
FU Alcon; Regeneron; Genentech
FX R. P. Singh: Thrombogenics (consultant), Alcon (consultant, research
   grant), Regeneron (consultant, research grant); Shire (consultant),
   Genentech (consultant, research grant). The remaining authors have no
   financial/conflicting interests to disclose.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arevalo JF, 2015, RETINA, V36, P859
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1
   MARCUS DM, 2014, INVEST OPHTH VIS SCI, V55
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide Richard F, 2009, Retina, V29, pS5, DOI 10.1097/IAE.0b013e3181ad237a
   Sunness JS, 1999, MOL VIS, V5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 29
TC 18
Z9 18
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2018
VL 38
IS 8
BP 1500
EP 1508
DI 10.1097/IAE.0000000000001753
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VJ
UT WOS:000454002400018
PM 28671895
DA 2022-11-30
ER

PT J
AU Simader, C
   Ritter, M
   Bolz, M
   Deak, GG
   Mayr-Sponer, U
   Golbaz, I
   Kundi, M
   Schmidt-Erfurth, UM
AF Simader, Christian
   Ritter, Markus
   Bolz, Matthias
   Deak, Gabor G.
   Mayr-Sponer, Ulrike
   Golbaz, Isabelle
   Kundi, Michael
   Schmidt-Erfurth, Ursula M.
TI Morphologic Parameters Relevant for Visual Outcome During
   Anti-Angiogenic Therapy of Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB
   LUCENTIS; DOSING REGIMEN; EFFICACY; REPRODUCIBILITY; PREDICTORS; SAFETY;
   TRIAL
AB Purpose: To identify the effects of anti-angiogenic therapy in neovascular age-related macular degeneration (AMD) in respect to morphologic type and time course and to identify prognostic factors for visual outcome on the basis of standardized optical coherence tomography (OCT) analysis.
   Design: Subanalysis of a prospective, 12-month, multicenter, phase IIIb trial (Efficacy and Safety of Rani-bizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration [EXCITE]).
   Participants: A total of 353 treatment-naive patients with subfoveal choroidal neovascularization (CNV) receiving quarterly or monthly ranibizumab therapy.
   Methods: Patients were randomized to receive 0.3 mg quarterly, 0.5 mg quarterly, or 0.3 mg monthly doses of ranibizumab. Treatment comprised a loading phase of 3 consecutive monthly injections followed by a 9-month maintenance phase of monthly or quarterly injections. Best-corrected visual acuity (BCVA) was measured using the Early Treatment Diabetic Retinopathy Study protocol, and retinal morphology was assessed by Stratus OCT (Carl Zeiss Meditec, Dublin, CA). Imaging data were evaluated by certified examiners of the Vienna Reading Center using a standardized protocol.
   Main Outcome Measures: The BCVA was measured using ETDRS charts and retinal morphology was assessed by OCT.
   Results: During the loading phase, there was a significant correlation between a reduction in central retinal thickness and an increase in BCVA (P < 0.001), which decreased during the maintenance phase in all treatment arms. The proportion of patients showing retinal morphologic changes, such as intraretinal cysts (IRCs), subretinal fluid (SRF), and pigment epithelial detachments (PEDs), decreased significantly in all groups (P< 0.001), more intensively in the 0.5 mg quarterly than in both 0.3 mg groups. Intraretinal cysts resolved most rapidly followed by SRF, whereas PED decreased at a slower rate and intensity. Patients with IRC at baseline had lower BCVA levels that remained lower over the entire study period, whereas recurrence of IRC during follow-up showed no additional negative effect on function. Baseline SRF had no effect on visual recovery; however, recurrence of SRF during follow-up showed a tendency for an additional negative effect on function (P = 0.06). Baseline PED showed a negative influence on visual outcome only in combination with IRC and SRF.
   Conclusions: There is a distinct response pattern and time course of morphologic parameters associated with anti-vascular endothelial growth factor therapy in neovascular AMD. Specific alterations, such as IRC, SRF, and PED, as baseline or follow-up features are significantly influencing the potential for visual gain. (C) 2014 by the American Academy of Ophthalmology.
C1 [Simader, Christian; Ritter, Markus; Bolz, Matthias; Deak, Gabor G.; Mayr-Sponer, Ulrike; Golbaz, Isabelle; Schmidt-Erfurth, Ursula M.] Med Univ Vienna, Dept Ophthalmol, Vienna Reading Ctr, A-1090 Vienna, Austria.
   [Kundi, Michael] Med Univ Vienna, Ctr Publ Hlth, Inst Environm Hlth, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, UM (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI Bolz, Matthias/HCI-0622-2022
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Bolz,
   Matthias/0000-0001-8691-5276; Ritter, Markus/0000-0003-1406-8340
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Pelosini L, 2011, INVEST OPHTH VIS SCI, V52, P2741, DOI 10.1167/iovs.09-4493
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 32
TC 119
Z9 124
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2014
VL 121
IS 6
BP 1237
EP 1245
DI 10.1016/j.ophtha.2013.12.029
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ0KG
UT WOS:000337339100016
PM 24684838
DA 2022-11-30
ER

PT J
AU Li, J
   Zhang, H
   Sun, P
   Gu, F
   Liu, ZL
AF Li, Jun
   Zhang, Han
   Sun, Peng
   Gu, Feng
   Liu, Zhe-Li
TI Bevacizumab vs ranibizumab for neovascular age-related macular
   degeneration in Chinese patients
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   bevacizumab (avastin); ranibizumab (lucentis)
ID VEGF; EXPRESSION; MEMBRANES; AVASTIN; TRIAL
AB AIM: To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age -related macular degeneration (AMD).
   METHODS: Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1.25mg) and 32 received intravitreal ranibizumab injections (0.5mg), once a month for 3 months and were followed for a total of 6 months. Monthly optical coherence tomography (OCT) was used to determine whether the patients received additional treatments during the follow -up. We compared the baseline and 6-month follow-up values of mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in both groups of patients. We also compared the occurrence of adverse events.
   RESULTS: At the 6-month follow-up, the mean BCVA (logMAR) of the bevacizumab and ranibizumab treatment groups improved from the baseline measurements of 0.72 +/- 0.23 and 0.73 +/- 0.22 to 0.47 +/- 0.14 and 0.45 +/- 0.20, respectively (P <0.05 for both groups). However, the change was not significantly different between the two groups. As evaluated by OCT, CRT decreased from 366.71 +/- 34.72 mu m and 352 +/- 36.9 mu m at baseline to 250.86 +/- 41.51 mu m and 243.22 +/- 41.38 mu m in the bevacizumab and ranibizumab groups, respectively (P <0.05 for both groups). However, the change was not significantly different between the two groups. There were no severe local adverse reactions or systemic adverse events.
   CONCLUSION: Intravitreal bevacizumab and ranibizumab have equivalent effects on BCVA and CRT and appeare safe over the short-term.
C1 [Li, Jun; Zhang, Han; Sun, Peng; Gu, Feng; Liu, Zhe-Li] China Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Shenyang 110001, Liaoning Provin, Peoples R China.
C3 China Medical University
RP Liu, ZL (通讯作者)，China Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Shenyang 110001, Liaoning Provin, Peoples R China.
EM zheli_liu@yahoo.com.cn
OI Zhang, Han/0000-0002-9338-0051
CR Abeysiri P, 2010, CLIN EXP OPHTHALMOL, V38, P84, DOI 10.1111/j.1442-9071.2010.02196.x
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Hornig C, 1999, Angiogenesis, V3, P33, DOI 10.1023/A:1009033017809
   Joeres S, 2007, GRAEF ARCH CLIN EXP, V245, P1597, DOI 10.1007/s00417-007-0580-y
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lou ZL, 2008, OPHTHALMOL RES, V26, P822
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ni Z., 2002, PATHOLOGICAL ANATOMY, P281
   O'Shea JG, 2012, CLIN EXP OPTOM, V95, P541, DOI 10.1111/j.1444-0938.2012.00736.x
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960
   Sheng YJ., 2004, J CLIN OPHTHALMOL, V12, P471
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Zhang H, 2012, AM J OPHTHALMOL, V153, P300, DOI 10.1016/j.ajo.2011.07.019
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 20
TC 11
Z9 14
U1 0
U2 11
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2013
VL 6
IS 2
BP 169
EP 173
DI 10.3980/j.issn.2222-3959.2013.02.12
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 129VY
UT WOS:000317873300012
PM 23638418
DA 2022-11-30
ER

PT J
AU Yoganathan, P
   Deramo, VA
   Lai, JC
   Tibrewala, RK
   Fastenberg, DM
AF Yoganathan, Pradeepa
   Deramo, Vincent A.
   Lai, James C.
   Tibrewala, Rajen K.
   Fastenberg, David M.
TI Visual improvement following intravitreal bevacizumab (Avastin) in
   exudative age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; Avastin; bevacizumab; choroidal
   neovascularization; vascular endothelial growth factor
ID ANTIBODY
AB Purpose: To study the visual and anatomic outcome of intravitreal bevacizumab injection in the treatment of exudative age-related macular degeneration (AMD).
   Methods: Retrospective review of patients who received one or more intravitreal bevacizumab injections for exudative AMD. Outcome measures include standardized visual acuity, optical coherence tomography (OCT), macular thickness and volume, intraocular pressure, and blood pressure at 24 or more weeks follow-up.
   Results: Fifty eyes of 48 patients were identified. Patients were observed for a median length of follow-up of 34 weeks (range, 24-50 weeks). Thirty-six eyes (72%) had prior treatment with pegaptanib (Macugen) and/or photodynamic therapy (PDT) and 14 eyes (28%) were treatment-naive. Mean visual acuity increased by 6.5 letters (P < 0.01) at 4 weeks and 5.3 letters (P < 0.01) at 24 weeks after initial bevacizumab injection. At 24 weeks, naive eyes had a mean increase of 14.2 letters (P < 0.001) and previously treated eyes had a mean increase of 2.8 letters (P = 0.06). Overall, mean OCT macular thickness and volume decreased by 73 mu m (P < 0.001) and 1.0 mm(3) (P < 0.001) respectively at last follow-up. At last follow-up, all eyes received an average of 3.5 injections and experienced an average of 1.08 recurrences. There was no incidence of severe vision loss or adverse effect.
   Conclusion: Intravitreal bevacizurnab has the potential for improvement in vision in both naive and previously treated eyes for at least 6 months. The benefit is more pronounced in eyes without prior pegaptanib and/or PDT.
C1 Long Isl Vitreoretinal Consultants, Great Neck, NY 11021 USA.
   N Shore Long Isl Jewish Hlth Syst, Dept Ophthalmol, Great Neck, NY USA.
   New York Inst Technol, Sch Management, Old Westbury, NY 11568 USA.
C3 Northwell Health; New York Institute Technology
RP Deramo, VA (通讯作者)，Long Isl Vitreoretinal Consultants, 600 No Blvd,Suite 216, Great Neck, NY 11021 USA.
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosiak Jean, 2005, Clin J Oncol Nurs, V9, P407
NR 12
TC 94
Z9 99
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2006
VL 26
IS 9
BP 994
EP 998
DI 10.1097/01.iae.0000244380.34082.67
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 175AZ
UT WOS:000246985700003
PM 17151485
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Marino, EK
   Kuller, LH
   Furberg, C
   Burke, GL
   Hubbard, LD
AF Klein, R
   Klein, BEK
   Marino, EK
   Kuller, LH
   Furberg, C
   Burke, GL
   Hubbard, LD
TI Early age-related maculopathy in the cardiovascular health study
SO OPHTHALMOLOGY
LA English
DT Article
ID SENILE MACULAR DEGENERATION; RISK-FACTORS; ATHEROSCLEROSIS RISK;
   GEOGRAPHIC REGION; NATIONAL-HEALTH; PREVALENCE; DISEASE; ASSOCIATION;
   ABNORMALITIES; OLDER
AB Objective: To describe the prevalence of early age-related maculopathy (ARM) and its relation to atherosclerosis, lipids, hypertension, and inflammatory factors in a population studied for cardiovascular disease risk factors and outcomes.
   Design: Population-based cohort study.
   Participants: A biracial population of 2361 adults (ranging from 69-97 years of age; 1998 whites and 363 blacks) living in four US counties (Allegheny County, Pennsylvania; Forsyth County, North Carolina; Sacramento County, California; and Washington County, Maryland) were examined during the interval from 1997 to 1998.
   Methods: Drusen and other lesions typical of ARM were identified by examining a 45degrees color fundus photograph of one eye of each participant and classified by means of a modification of the Wisconsin Age-Related Maculopathy Grading System.
   Main Outcome Measures: Early ARM.
   Results: Early ARM was present in 15.5% and late ARM in 1.3% of the cohort. The overall prevalence of any ARM was lower in blacks (9.1%) compared with whites (18.2%). While controlling for age, race, gender, and total calories consumed in the diet, factors associated with ARM were cerebral white matter disease as detected by magnetic resonance imaging (odds ratio [OR], 1.50; 95% confidence interval [CI], 1.05, 2.16, P = 0.027), and lower serum total cholesterol (OR, per 10 mg/dl increase 0.95; 95% CI, 0.91, 0.98, P = 0.02). There were no associations between hypertension, blood pressure, common carotid artery plaque, or any systemic inflammatory factors studied and early ARM.
   Conclusions: This population-based study documents the higher prevalence of ARM in whites compared with blacks. Although an association was found between signs of white matter disease and early ARM, there was no evidence of an association of ARM with either hypertension or inflammatory factors.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
   Univ Washington, Dept Biostat, CHS Coordinating Ctr, Seattle, WA 98195 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.
   Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Washington; University of Washington Seattle; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Wake Forest University
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,405 WARF, Madison, WI 53706 USA.
OI Klein, Ronald/0000-0002-4428-6237
FU NHLBI NIH HHS [NHLBI HC-97-06] Funding Source: Medline
CR ALBRINK MJ, 1963, AM J OPHTHALMOL, V55, P709, DOI 10.1016/0002-9394(63)92428-0
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], [No title captured]
   *ARIC STUD RES GRO, ARIC RET PHOT PROT M
   BISCHOFF PM, 1983, AM J OPHTHALMOL, V96, P398, DOI 10.1016/S0002-9394(14)77839-0
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DELANEY WV, 1982, ANN OPHTHALMOL, V14, P21
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   FRIEDMAN E, 1999, AGE RELATED MACULAR, P173
   FURBERG CD, 1992, AM J CARDIOL, V69, P1329, DOI 10.1016/0002-9149(92)91231-R
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   HYMAN L, 2000, ARCH OPHTHALMOL-CHIC, V35, P1
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JAMPOL LM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1699, DOI 10.1001/archopht.1992.01080240039024
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   KULLER L, 1994, AM J EPIDEMIOL, V139, P1164, DOI 10.1093/oxfordjournals.aje.a116963
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   MANOLIO TA, 1994, STROKE, V25, P318, DOI 10.1161/01.STR.25.2.318
   Mares-Perlman J.A., 1999, CRC MOD NUT, P181
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   National Society to Prevent Blindness, 1980, VIS PROBL US DAT AN, P1
   OLEARY DH, 1991, STROKE, V22, P1155, DOI 10.1161/01.STR.22.9.1155
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   Potts A M, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P1058
   RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211
   Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871
   SARKS SH, 1985, PATTERNS MACULAR DEG, P87
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9
   VIDAURRI JS, 1984, OPHTHALMOLOGICA, V188, P243, DOI 10.1159/000309370
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 58
TC 136
Z9 143
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2003
VL 110
IS 1
BP 25
EP 33
AR PII S0161-6420(02)01565-8
DI 10.1016/S0161-6420(02)01565-8
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 633PT
UT WOS:000180292200016
PM 12511342
DA 2022-11-30
ER

PT J
AU Zarbin, M
   Sugino, I
   Townes-Anderson, E
AF Zarbin, Marco
   Sugino, Ilene
   Townes-Anderson, Ellen
TI Concise Review: Update on Retinal Pigment Epithelium Transplantation for
   Age-Related Macular Degeneration
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Review
DE Autologous stem cell transplantation; Cell transplantation; Clinical
   trials; Experimental models; Induced pluripotent stem cells; Embryonic
   stem cells; Retina
ID GEOGRAPHIC ATROPHY; BRUCHS MEMBRANE; STEM-CELLS; SUBRETINAL
   IMPLANTATION; OUTER NUCLEAR; DETACHMENT; RECOVERY; SURVIVAL; THERAPY;
   EYES
AB Retinal cell therapy can have the objectives of rescue (i.e., modulation of metabolic abnormalities primarily for sight preservation) as well as replacement (i.e., replace cells lost due to injury or disease for sight restoration as well as preservation). The first clinical trials of retinal pigment epithelium (RPE) transplantation for vision-threatening complications of age-related macular degeneration (AMD) have begun with some preliminary signs of success (e.g., improvement in vision in some patients, anatomic evidence of transplant-host integration with some evidence of host photoreceptor recovery, long-term survival of autologous induced pluripotent stem cell-derived RPE transplants without immune suppression) as well as limitations (e.g., limited RPE suspension survival in the AMD eye, limited tolerance for long-term systemic immune suppression in elderly patients, suggestion of uncontrolled cell proliferation in the vitreous cavity). RPE survival on aged and AMD Bruch's membrane can be improved with chemical treatment, which may enhance the efficacy of RPE suspension transplants in AMD patients. Retinal detachment, currently used to deliver transplanted RPE cells to the subretinal space, induces disjunction of the first synapse in the visual pathway: the photoreceptor-bipolar synapse. This synaptic change occurs even in areas of attached retina near the locus of detachment. Synaptic disjunction and photoreceptor apoptosis associated with retinal detachment can be reduced with Rho kinase inhibitors. Addition of Rho kinase inhibitors may improve retinal function and photoreceptor survival after subretinal delivery of cells either in suspension or on scaffolds.
C1 [Zarbin, Marco; Sugino, Ilene] Rutgers State Univ, Rutgers New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ USA.
   [Townes-Anderson, Ellen] Rutgers New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ USA.
C3 Rutgers State University Newark; Rutgers State University New Brunswick;
   Rutgers State University Medical Center; Rutgers State University New
   Brunswick; Rutgers State University Medical Center
RP Zarbin, M (通讯作者)，Room 6156,90 Bergen St, Newark, NJ 07103 USA.
EM zarbin@earthlink.net
OI Zarbin, Marco/0000-0002-7811-7132
FU New Jersey Lions Eye Research Foundation; Joseph J. and Marguerite
   DiSepio Retina Research Fund; Edward N. & Della L. Thome Memorial
   Foundation Awards Program in Age-Related Macular Degeneration Research;
   Eng Family Foundation; F.M. Kirby Foundation; NIH [EY021542]
FX This work was supported in part by the New Jersey Lions Eye Research
   Foundation (M.Z., I.S.), the Joseph J. and Marguerite DiSepio Retina
   Research Fund (M.Z., I.S.), the Edward N. & Della L. Thome Memorial
   Foundation Awards Program in Age-Related Macular Degeneration Research
   (M.Z., I.S.), the Eng Family Foundation (M.Z., I.S.), the F.M. Kirby
   Foundation (E.T.-A.), and NIH grant EY021542 (E.T.-A., M.Z., I.S.).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bottoni F, 2011, INVEST OPHTH VIS SCI, V52, P4439, DOI 10.1167/iovs.10-6732
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   ERICKSON PA, 1983, INVEST OPHTH VIS SCI, V24, P927
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Fisher SK, 2003, VISION RES, V43, P887, DOI 10.1016/S0042-6989(02)00680-6
   Fisher SK, 2005, PROG RETIN EYE RES, V24, P395, DOI 10.1016/j.preteyeres.2004.10.004
   Fontainhas AM, 2011, INVEST OPHTH VIS SCI, V52, P579, DOI 10.1167/iovs.10-5744
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   GELLER AM, 1993, RETINAL DEGENERATION, P25
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GUERIN CJ, 1993, INVEST OPHTH VIS SCI, V34, P175
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   GULLAPALLI VK, 2004, T AM OPHTHAL SOC, V102, P137
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Lewis GP, 1998, INVEST OPHTH VIS SCI, V39, P424
   Linberg KA, 2009, MOL VIS, V15, P10
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Lu B, 2014, DEV OPHTHALMOL, V53, P155, DOI 10.1159/000357375
   Lu Y, 2017, ACTA OPHTHALMOL, V95, pE443, DOI 10.1111/aos.13054
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Menghini M, 2015, INVEST OPHTH VIS SCI, V56, P372, DOI 10.1167/iovs.14-15521
   Menghini M, 2014, DEV OPHTHALMOL, V53, P53, DOI 10.1159/000357324
   Mitamura Y, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/518170
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI DOI 10.1167/I0VS.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sethi CS, 2005, INVEST OPHTH VIS SCI, V46, P329, DOI 10.1167/iovs.03-0518
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Sugino IK, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.1.8
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P9598, DOI 10.1167/iovs.11-8400
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2015, LANCET, V386, P29, DOI 10.1016/S0140-6736(15)61201-6
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Tezel TH, 1997, CURR EYE RES, V16, P802, DOI 10.1076/ceyr.16.8.802.8981
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Townes-Anderson E, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.22
   Wang JF, 2016, INVEST OPHTH VIS SCI, V57, P3892, DOI 10.1167/iovs.16-19447
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
NR 72
TC 41
Z9 43
U1 4
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD MAY
PY 2019
VL 8
IS 5
BP 466
EP 477
DI 10.1002/sctm.18-0282
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HU5RR
UT WOS:000465337000007
PM 30748126
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yu, JM
   Wiita, P
   Kawaguchi, R
   Honda, J
   Jorgensen, A
   Zhang, K
   Fischetti, VA
   Sun, H
AF Yu, Jiamei
   Wiita, Patrick
   Kawaguchi, Riki
   Honda, Jane
   Jorgensen, Adam
   Zhang, Kang
   Fischetti, Vincent A.
   Sun, Hui
TI Biochemical analysis of a common human polymorphism associated with
   age-related macular degeneration
SO BIOCHEMISTRY
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; REGULATOR FACTOR-H;
   STREPTOCOCCAL-M-PROTEIN; DISEASE-ASSOCIATED FORM; SHORT CONSENSUS
   REPEAT; HEPARIN-BINDING; APOPTOTIC CELLS; SURFACE PROTEIN; Y402H VARIANT
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in developed countries. A large number of human genetic studies have associated a common variant (Y402H) of complement factor H (CFH) with a highly significant increase in AMD risk. CFH is a modular protein with 20 homologous short consensus repeats (SCRs). The Y402H variant is located in SCR7 of both CFH and factor H-like protein 1 (FHL-1), a splice variant of CFH (containing SCR1-7) with unique biochemical properties. Because SCR7 is known to bind to heparin, C-reactive protein (CRP), and M protein from Streptococcus pyogenes, it has been hypothesized that the AMD-associated polymorphism may affect interactions with these CFH ligands. In this study, we tested this hypothesis in the context of full-length CFH (SCR1-20) and FHL-1. We systematically analyzed the interactions of the Y402 and H402 variants of CFH and FHL-1 with heparin, CRP, and several bacterial ligands: M6 protein of Streptococcus pyogenes, PspC of Streptococcus pneumoniea, and BbCRASP-1 of Borrelia burgdorferi. In comparing the Y and H variants of CFH and FHL-1, we found no significant difference in their protein secretion, cofactor activity, or interactions with heparin, BbCRASP-1, or PspC, but a significant difference in binding to CRP and M6 protein. This study reveals the fundamental properties of a common polymorphism of CFH and lays the groundwork for elucidating the role of CFH in AMD pathogenesis.
C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   Univ Utah, Sch Med, Moran Eye Ctr, Eccles Inst Human Genet, Salt Lake City, UT 84132 USA.
   Univ Utah, Sch Med, Program Human Mol Biol & Genet, Eccles Inst Human Genet, Salt Lake City, UT 84132 USA.
   Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Utah System of Higher
   Education; University of Utah; Utah System of Higher Education;
   University of Utah; Rockefeller University
RP Sun, H (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, 53-231 CHS,650 Charles E Young Dr S, Los Angeles, CA 90095 USA.
EM hsun@mednet.ucla.edu
RI Kawaguchi, Riki/AAV-6090-2020; Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
FU NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NEI NIH HHS
   [R01EY14428, P30EY014800, R01EY14448] Funding Source: Medline; NIAID NIH
   HHS [AI11822] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH
   RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R01EY014448, P30EY014800, R01EY014428] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
   [R37AI011822, R01AI011822] Funding Source: NIH RePORTER
CR Agrawal A, 2005, MOL IMMUNOL, V42, P927, DOI 10.1016/j.molimm.2004.09.028
   ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389
   Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381
   BIRO A, 2007, IMMUNOLOGY
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Bridson EY, 1996, BRIT J BIOMED SCI, V53, P134
   Burnet M., 1972, NATURAL HIST INFECT
   Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
   CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1
   CHINA B, 1993, INFECT IMMUN, V61, P3129, DOI 10.1128/IAI.61.8.3129-3136.1993
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dimitrellos V, 2003, BIOMED CHROMATOGR, V17, P42, DOI 10.1002/bmc.208
   DISCIPIO RG, 1992, J IMMUNOL, V149, P2592
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   FISCHETTI VA, 1995, INFECT IMMUN, V63, P149, DOI 10.1128/IAI.63.1.149-153.1995
   FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989
   FISCHETTI VA, 1984, J EXP MED, V159, P1083, DOI 10.1084/jem.159.4.1083
   Flanagan JG, 2000, METHOD ENZYMOL, V327, P198, DOI 10.1016/S0076-6879(00)27277-7
   FORSGREN A, 1975, J LAB CLIN MED, V85, P904
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Giannakis E, 2001, INT IMMUNOPHARMACOL, V1, P433, DOI 10.1016/S1567-5769(00)00040-0
   Hack CE, 1997, IMMUNOL TODAY, V18, P111, DOI 10.1016/S0167-5699(97)01002-5
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hegasy GA, 2003, IMMUNOGENETICS, V55, P462, DOI 10.1007/s00251-003-0605-6
   Hellwage J, 1997, BIOCHEM J, V326, P321, DOI 10.1042/bj3260321
   Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jarva H, 2002, J IMMUNOL, V168, P1886, DOI 10.4049/jimmunol.168.4.1886
   Jozsi M, 2004, HISTOL HISTOPATHOL, V19, P251, DOI 10.14670/HH-19.251
   KATZ AR, 1992, CLIN INFECT DIS, V14, P298, DOI 10.1093/clinids/14.1.298
   KAZATCHKINE MD, 1979, J EXP MED, V150, P1202, DOI 10.1084/jem.150.5.1202
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kotarsky H, 1998, J IMMUNOL, V160, P3349
   Kraiczy P, 2004, J BIOL CHEM, V279, P2421, DOI 10.1074/jbc.M308343200
   Kraiczy P, 2001, INFECT IMMUN, V69, P7800, DOI 10.1128/IAI.69.12.7800-7809.2001
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   MAGNUSSON KP, 2006, PLOSMED, V3, P109
   Marnell L, 2005, CLIN IMMUNOL, V117, P104, DOI 10.1016/j.clim.2005.08.004
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Nesse RM, 1998, SCI AM, V279, P86, DOI 10.1038/scientificamerican1198-86
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012
   Pandiripally V, 2003, INFECT IMMUN, V71, P7119, DOI 10.1128/IAI.71.12.7119-7128.2003
   PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   Pier GB, 1998, NATURE, V393, P79, DOI 10.1038/30006
   Prodinger WM, 1998, BIOCHEM J, V331, P41, DOI 10.1042/bj3310041
   Quin LR, 2005, J INFECT DIS, V192, P1996, DOI 10.1086/497605
   Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sharma AK, 1997, INFECT IMMUN, V65, P484, DOI 10.1128/IAI.65.2.484-487.1997
   SIMONELLI F, 2006, BR J OPHTHALMOL
   Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Souied EH, 2005, MOL VIS, V11, P1135
   SPENCER RC, 1995, EUR J CLIN MICROB S1, V14, P26
   Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9
   VOLANAKIS JE, 1979, NATURE, V281, P155, DOI 10.1038/281155a0
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
   Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
NR 78
TC 50
Z9 50
U1 1
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JUL 17
PY 2007
VL 46
IS 28
BP 8451
EP 8461
DI 10.1021/bi700459a
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 188BI
UT WOS:000247893000024
PM 17580967
DA 2022-11-30
ER

PT J
AU Fisher, SA
   Rivera, A
   Fritsche, LG
   Keilhauer, CN
   Lichtner, P
   Meitinger, T
   Rudolph, G
   Weber, BHE
AF Fisher, Sheila A.
   Rivera, Andrea
   Fritsche, Lars G.
   Keilhauer, Claudia N.
   Lichtner, Peter
   Meitinger, Thomas
   Rudolph, Guenther
   Weber, Bernhard H. E.
TI Case-control genetic association study of fibullin-6 (FBLN6 or HMCN1)
   variants in age-related macular degeneration (AMD)
SO HUMAN MUTATION
LA English
DT Article
DE age-related macular degeneration; fibulin-6; hemicentin-1; association;
   linkage disequilibrium; mutation; FBLN6; HMCN1
ID COMPLEMENT FACTOR-H; SUSCEPTIBILITY LOCI; GENOMEWIDE-SCAN; MACULOPATHY;
   POLYMORPHISM; LOC387715; LINKAGE; RISK; HEMICENTIN-1; INCREASES
AB This article reports a well-powered age,related macular degeneration (AMD) case-control association study in the HMCN1 gene, showing that common variants do not account for a substantial proportion of AMD cases. Thus, the consistent linkage peak observed by several genome-wide linkage scans within the 1q32 region is unlikely to be attributed to polymorphisms at the HMCN1 locus. In addition, the analysis provides comprehensive data suggesting that low-frequency variants encoding possible functional amino acid polymorphisms in the HMCN1 gene may not contribute substantially to disease, although HMCN1 mutations may still confer disease susceptibility in a small subset of patients. Interestingly, the HMCN1 p.Gln5346Arg mutation, which is thought to be a causal mutation in a large AMD pedigree segregating the disease as a single-gene trait, appears to occur in our control cohort as a low-frequency polymorphism with an allele frequency of approximately 0.0026.
C1 Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Mol & Med Genet, London WC2R 2LS, England.
   Univ Wurzburg, Eye Clin, Dept Ophthalmol, Wurzburg, Germany.
   GSF Munich, Res Ctr Environm & Hlth, Inst Human Genet, Munich, Germany.
   Univ Munich, Hosp Eye, Munich, Germany.
C3 University of Regensburg; University of London; King's College London;
   University of Wurzburg; Helmholtz Association; Helmholtz-Center Munich -
   German Research Center for Environmental Health; University of Munich
RP Weber, BHE (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Fritsche, Lars G/AAF-9387-2019; Meitinger, Thomas/O-1318-2015
OI Fritsche, Lars G/0000-0002-2110-1690; Meitinger,
   Thomas/0000-0002-8838-8403; Weber, Bernhard H.F./0000-0002-8808-7723
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dudbridge Frank, 2003, Human Genomics, V1, P63
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069
   McKay GJ, 2004, MOL VIS, V10, P682
   Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6
   RISCH N, 1990, AM J HUM GENET, V46, P222
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097
   Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seitsonen S, 2006, MOL VIS, V12, P796
   Smith DJ, 2002, HUM MOL GENET, V11, P2455, DOI 10.1093/hmg/11.20.2455
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 47
TC 26
Z9 28
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD APR
PY 2007
VL 28
IS 4
BP 406
EP 413
DI 10.1002/humu.20464
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 148XL
UT WOS:000245110600011
PM 17216616
DA 2022-11-30
ER

PT J
AU Kim, CG
   Park, S
   Kim, Y
AF Kim, Chul-Gyu
   Park, Seungmi
   Kim, Youngji
TI Age-related macular degeneration among the elderly: The 5th National
   Health and Nutrition Examination Survey, 2010 through 2012
SO JAPAN JOURNAL OF NURSING SCIENCE
LA English
DT Article
DE age-related macular degeneration; elderly; risk
ID RISK-FACTORS; VISUAL IMPAIRMENT; GLOBAL PREVALENCE; TERM INCIDENCE;
   ASSOCIATION; DISEASE; POPULATION; EYE; MACULOPATHY; GENDER
AB Aim This study was conducted to identify the prevalence and factors associated with age-related macular degeneration (AMD) in Korean elderly. Methods The study population of this cross-sectional survey was the Korean Health and Nutrition Examination Survey (KHANES) 2010 through 2012, the fifth population-based study. Results Analysis of 2,767 elderly (above age 65) from 23,376 participants showed the prevalence of any AMD to be 17.6% in the Korean elderly. Factors that were significantly positively associated with AMD included age, sex, occupation, low socioeconomic status, liver cirrhosis and physical activity (p < .01). Significantly negatively associated with AMD were cardiovascular disease, obesity, and beta-carotene intake (p < .05). Conclusions This study estimated the prevalence rate and assessed factors associated with AMD in the elderly. This can be used to build a strategy for elderly eye health, and provides valuable information for screening for putative risks in the elderly.
C1 [Kim, Chul-Gyu] Chungbuk Natl Univ, Dept Nursing, Cheongju, South Korea.
   [Park, Seungmi] Hoseo Univ, Dept Nursing, Asan, South Korea.
   [Park, Seungmi] Hoseo Univ, Res Inst Basic Sci, 79-20 Hoseo Ro, Asan 336795, Chungcheongnam, South Korea.
   [Kim, Youngji] Kongju Natl Univ, Coll Nursing & Hlth, Dept Nursing, Gongju Si, South Korea.
C3 Chungbuk National University; Hoseo University; Hoseo University; Kongju
   National University
RP Park, S (通讯作者)，Hoseo Univ, Res Inst Basic Sci, 79-20 Hoseo Ro, Asan 336795, Chungcheongnam, South Korea.
EM seungmipark@hoseo.edu
OI Kim, Chul-Gyu/0000-0002-2512-139X; PARK, SEUNGMI/0000-0001-6156-1336
FU Chungbuk National University [2015115004] Funding Source: Medline
CR An H., 2016, KOREAN J VISION SCI, V18, P7
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P4430, DOI 10.1167/iovs.14-14379
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Gyu Kim Chul, 2013, [Journal of Korean Academy of Community Health Nursing, 지역사회간호학회지], V24, P1, DOI 10.12799/jkachn.2013.24.1.1
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jacobson TA, 2015, J CLIN LIPIDOL, V9, P129, DOI 10.1016/j.jacl.2015.02.003
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Korea Centers for Disease Control and Prevention, 2009, KOR HLTH STAT 2009 K
   Korea Centers for Disease Control and Prevention, 2012, GUID UT DAT 5 KOR NA
   KyuHyung Park，, 2010, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V51, P516
   Lee J., 2015, J KOREA ACAD IND COO, V16, P7978
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Ngai LY, 2011, EYE, V25, P784, DOI 10.1038/eye.2011.56
   Olea JL, 2012, EUR J OPHTHALMOL, V22, P404, DOI 10.5301/ejo.5000023
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P141
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
NR 37
TC 2
Z9 2
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-7932
EI 1742-7924
J9 JPN J NURS SCI
JI Jpn. J. Nurs. Sci.
PD JAN
PY 2020
VL 17
IS 1
AR e12257
DI 10.1111/jjns.12257
PG 11
WC Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Nursing
GA KA1AF
UT WOS:000505531000015
PM 31161727
DA 2022-11-30
ER

PT J
AU Motozawa, N
   An, GZ
   Takagi, S
   Kitahata, S
   Mandai, M
   Hirami, Y
   Yokota, H
   Akiba, M
   Tsujikawa, A
   Takahashi, M
   Kurimoto, Y
AF Motozawa, Naohiro
   An, Guangzhou
   Takagi, Seiji
   Kitahata, Shohei
   Mandai, Michiko
   Hirami, Yasuhiko
   Yokota, Hideo
   Akiba, Masahiro
   Tsujikawa, Akitaka
   Takahashi, Masayo
   Kurimoto, Yasuo
TI Optical Coherence Tomography-Based Deep-Learning Models for Classifying
   Normal and Age-Related Macular Degeneration and Exudative and
   Non-Exudative Age-Related Macular Degeneration Changes
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Age-related macular degeneration; Artificial intelligence; Class
   activation mapping; Convolution neural network; Deep learning; Machine
   learning; Optical coherence tomography; Transfer learning
ID AUTOMATED DETECTION; 10-YEAR INCIDENCE; RANIBIZUMAB; PROGRESSION;
   VERTEPORFIN; MACULOPATHY; DISEASES; FLUID; AMD
AB Introduction The use of optical coherence tomography (OCT) images is increasing in the medical treatment of age-related macular degeneration (AMD), and thus, the amount of data requiring analysis is increasing. Advances in machine-learning techniques may facilitate processing of large amounts of medical image data. Among deep-learning methods, convolution neural networks (CNNs) show superior image recognition ability. This study aimed to build deep-learning models that could distinguish AMD from healthy OCT scans and to distinguish AMD with and without exudative changes without using a segmentation algorithm. Methods This was a cross-sectional observational clinical study. A total of 1621 spectral domain (SD)-OCT images of patients with AMD and a healthy control group were studied. The first CNN model was trained and validated using 1382 AMD images and 239 normal images. The second transfer-learning model was trained and validated with 721 AMD images with exudative changes and 661 AMD images without any exudate. The attention area of the CNN was described as a heat map by class activation mapping (CAM). In the second model, which classified images into AMD with or without exudative changes, we compared the learning stabilization of models using or not using transfer learning. ResultsUsing the first CNN model, we could classify AMD and normal OCT images with 100% sensitivity, 91.8% specificity, and 99.0% accuracy. In the second, transfer-learning model, we could classify AMD as having or not having exudative changes, with 98.4% sensitivity, 88.3% specificity, and 93.9% accuracy. CAM successfully described the heat-map area on the OCT images. Including the transfer-learning model in the second model resulted in faster stabilization than when the transfer-learning model was not included. Conclusion Two computational deep-learning models were developed and evaluated here; both models showed good performance. Automation of the interpretation process by using deep-learning models can save time and improve efficiency.
C1 [Motozawa, Naohiro; Takagi, Seiji; Kitahata, Shohei; Mandai, Michiko; Hirami, Yasuhiko; Takahashi, Masayo; Kurimoto, Yasuo] Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Motozawa, Naohiro; Kitahata, Shohei; Mandai, Michiko; Hirami, Yasuhiko; Takahashi, Masayo; Kurimoto, Yasuo] RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo, Japan.
   [Motozawa, Naohiro; Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [An, Guangzhou; Akiba, Masahiro] Topcon Corp, R&D Div, Tokyo, Japan.
   [An, Guangzhou; Yokota, Hideo; Akiba, Masahiro] RIKEN Ctr Adv Photon, Cloud Based Eye Dis Diag Joint Res Team, Saitama, Japan.
   [An, Guangzhou] Kobe Univ, Grad Sch Syst Informat, Kobe, Hyogo, Japan.
   [Takagi, Seiji] Toho Univ, Omori Med Ctr, Dept Ophthalmol, Tokyo, Japan.
   [Yokota, Hideo] RIKEN Ctr Adv Photon, Image Proc Res Team, Saitama, Japan.
C3 RIKEN; Kyoto University; Topcon Corporation; RIKEN; Kobe University;
   Toho University; RIKEN
RP Takagi, S (通讯作者)，Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
EM tigerseiji@gmail.com
RI An, Guangzhou/O-5202-2018; An, Guangzhou/AAR-8850-2021; An,
   Guangzhou/P-5406-2019
OI An, Guangzhou/0000-0002-0875-4494; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR Agarwal A, 2016, MIDDLE EAST AFR J OP, V23, P27, DOI 10.4103/0974-9233.173133
   Alexandru Malciolu Radu, 2016, Rom J Ophthalmol, V60, P9
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Glorot X, 2010, P 13 INT C ART INT S, P249, DOI DOI 10.1177/1753193409103364.
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ioffe S., 2015, PR MACH LEARN RES, P448, DOI DOI 10.1007/S13398-014-0173-7.2
   Jiang F, 2017, STROKE VASC NEUROL, V2, P230, DOI 10.1136/svn-2017-000101
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee H, 2018, AM J OPHTHALMOL, V191, P64, DOI 10.1016/j.ajo.2018.04.007
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168606
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yousefi S, 2018, AM J OPHTHALMOL, V193, P71, DOI 10.1016/j.ajo.2018.06.007
   ZHOU B, 2016, PROC CVPR IEEE, P2921, DOI DOI 10.1109/CVPR.2016.319
NR 36
TC 44
Z9 45
U1 3
U2 18
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD DEC
PY 2019
VL 8
IS 4
BP 527
EP 539
DI 10.1007/s40123-019-00207-y
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JN1JJ
UT WOS:000496659000004
PM 31407214
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhu, W
   Meng, YF
   Xing, Q
   Tao, JJ
   Lu, J
   Wu, Y
AF Zhu, Wei
   Meng, Yi-Fang
   Xing, Qian
   Tao, Jian-Jun
   Lu, Jiong
   Wu, Yan
TI Identification of lncRNAs involved in biological regulation in early
   age-related macular degeneration
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE age-related macular degeneration; lncRNAs; microarray; bioinformatics
   analyses
ID LONG NONCODING RNAS; GENE-EXPRESSION; BIOMARKERS; PACKAGE
AB Background: Age-related macular degeneration (AMD) is one of the most common causes of adult blindness in developed countries. However, the role of long noncoding RNAs (lncRNAs) in the development and progression of early AMD is unclear.
   Methods: We established the lncRNA profile of early AMD by reannotation of microarrays from the gene expression omnibus database. Quantitative real-time polymerase chain reaction was used to determine the expression of selected lncRNAs.
   Results: The expression profiles of 9 cases of AMD and 7 controls were studied. A total of 266 differentially expressed genes (DEGs) were detected (94 upregulated and 172 downregulated). Among all the DEGs, 64 were lncRNAs. Advanced bioinformatics analyses demonstrated that differentially expressed lncRNAs could play significant roles in visual perception, sensory perception of light stimulus, and cognition. The pathway analyses showed that the two most significantly influenced Kyoto Encyclopedia of Genes and Genomes pathways were those of phototransduction and purine metabolism. By the analyses of the key lncRNAs, it was found that RP11-234O6.2 was downregulated in the aging retinal pigment epithelium (RPE) cellular model. Exogenous RP11-234O6.2 treatment led to increased cell viability and improved apoptosis but it did not affect the cell migration ability of aging RPE cells.
   Conclusion: This study indicated that lncRNAs are differentially expressed in early AMD and may produce important regulative effects. An lncRNA, RP11-234O6.2, might be involved in the biological regulation of early AMD and have therapeutic potential.
C1 [Zhu, Wei; Meng, Yi-Fang; Xing, Qian; Tao, Jian-Jun; Lu, Jiong] Changshu 2 Peoples Hosp, Dept Ophthalmol, 99 Xiannan St, Changshu 215000, Jiangsu, Peoples R China.
   [Wu, Yan] Soochow Univ, Hosp Affiliated 1, Dept Ophthalmol, 188 Shizi St, Suzhou 215000, Jiangsu, Peoples R China.
C3 Soochow University - China
RP Lu, J (通讯作者)，Changshu 2 Peoples Hosp, Dept Ophthalmol, 99 Xiannan St, Changshu 215000, Jiangsu, Peoples R China.; Wu, Y (通讯作者)，Soochow Univ, Hosp Affiliated 1, Dept Ophthalmol, 188 Shizi St, Suzhou 215000, Jiangsu, Peoples R China.
EM cslujiong@163.com; txwuyan@suda.edu.cn
FU Foundation for Young Scholars of Suzhou, China [kjxw2015044]; Foundation
   for Young Medical Talents of Jiangsu Province [QNRC2016211]
FX This work was supported in whole or in part by the Foundation for Young
   Scholars of Suzhou, China (grant number kjxw2015044) and the Foundation
   for Young Medical Talents of Jiangsu Province, 2016 (grant number
   QNRC2016211). The sponsor and funding organizations had no role in the
   design or conduct of this research.
CR Balaiya S, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3187594
   Calzia D, 2016, BIOCHIMIE, V125, P171, DOI 10.1016/j.biochi.2016.03.016
   Cao MX, 2017, ONCOTARGET, V8, P12472, DOI 10.18632/oncotarget.13957
   Deemer AD, 2017, INVEST OPHTH VIS SCI, V58, P1514, DOI 10.1167/iovs.16-20001
   Degirmenci U, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00151
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Diboun I, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-252
   Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149
   Garg A, 2017, CELLS-BASEL, V6, DOI 10.3390/cells6010004
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Krol J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8305
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Reichenbach A, 2016, NEUROPHARMACOLOGY, V104, P194, DOI 10.1016/j.neuropharm.2015.05.005
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen YF, 2016, GENES-BASEL, V7, DOI 10.3390/genes7070034
   Sun CY, 2016, ONCOTARGET, V7, P73541, DOI 10.18632/oncotarget.11999
   Wan PX, 2017, J MED GENET, V54, P450, DOI 10.1136/jmedgenet-2016-104266
   Wang WT, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0348-0
   Wenzel A, 2012, BIOINFORMATICS, V28, P2738, DOI 10.1093/bioinformatics/bts519
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Xu XD, 2014, MOL BIOL REP, V41, P4493, DOI 10.1007/s11033-014-3320-5
   Yan BA, 2015, CIRC RES, V116, P1143, DOI 10.1161/CIRCRESAHA.116.305510
   Yang T, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0166177, 10.1371/journal.pone.0152687]
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang J., 2017, BIOSCI REP, V37
   Zhang Q, 2015, INT J EXP PATHOL, V96, P387, DOI 10.1111/iep.12158
   Zhu W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110743
   Zhu W, 2015, DRUG DES DEV THER, V9, P5337, DOI 10.2147/DDDT.S84979
NR 33
TC 23
Z9 23
U1 1
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2017
VL 12
BP 7589
EP 7602
DI 10.2147/IJN.S140275
PG 14
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA FJ9TN
UT WOS:000413124000001
PM 29089757
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Fernandez, AB
   Panza, GA
   Cramer, B
   Chatterjee, S
   Jayaraman, R
   Wu, WC
AF Fernandez, Antonio B.
   Panza, Gregory A.
   Cramer, Benjamin
   Chatterjee, Saurav
   Jayaraman, Ramya
   Wu, Wen-Chih
TI Age-Related Macular Degeneration and Incident Stroke: A Systematic
   Review and Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; ENDOTHELIAL GROWTH-FACTOR; BEAVER DAM
   EYE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PREVALENCE;
   EPIDEMIOLOGY; THERAPIES; MORTALITY; MODEL
AB Background
   Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness in people over 65 years old in the United States and has been associated with cardiovascular risk and decreased survival. There is conflicting data, however, regarding the contribution of AMD to the prediction of stroke.
   Aim
   To determine whether AMD is a risk indicator for incident stroke in a meta-analysis of available prospective and retrospective cohort studies published in the English literature.
   Methods
   We performed a systematic literature search of all studies published in English with Pub Med and other databases from 1966 to August 2014, reporting stroke incidence in patients with macular degeneration. Two investigators independently extracted the data. A random effects model was used to report Odds ratios (OR), with corresponding 95% confidence intervals (CI). Meta-regression using a mixed linear model was used to understand potential heterogeneity amongst studies.
   Results
   We identified 9 studies that reported stroke incidence in patients with and without early AMD (N = 1,420,978). No significant association was found between early AMD with incident stroke. Combined, these 9 studies demonstrated random effects (OR, 1.12; CI, 0.86-1.47; I-2 = 96%). Meta-regression on baseline covariates of age, sex, and year of publication did not significantly relate to heterogeneity.
   Conclusions
   We found no significant relationship between AMD and incident stroke. Further studies are needed to clarify other causes of decreased survival in patients with AMD.
C1 [Fernandez, Antonio B.; Panza, Gregory A.] Hartford Hosp, Div Cardiol, Hartford, CT 06115 USA.
   [Fernandez, Antonio B.] Univ Connecticut, Sch Med, Farmington, CT USA.
   [Panza, Gregory A.] Univ Connecticut, Dept Kinesiol, Storrs, CT USA.
   [Cramer, Benjamin] Quinnipiac Univ, Frank H Netter Sch Med, Hamden, CT USA.
   [Chatterjee, Saurav] Mt Sinai Hlth Syst, St Lukes Roosevelt Hosp, New York, NY USA.
   [Jayaraman, Ramya] St Vincents Med Ctr, Dept Med, Bridgeport, CT USA.
   [Wu, Wen-Chih] Brown Univ, Alpert Med Sch, Med Serv, Providence VA Med Ctr, Providence, RI 02912 USA.
   [Wu, Wen-Chih] Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912 USA.
C3 Hartford Hospital; University of Connecticut; University of Connecticut;
   Quinnipiac University; Icahn School of Medicine at Mount Sinai; Mount
   Sinai St. Luke's; Mount Sinai West; St. Vincent's Medical Center; Brown
   University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Providence VA Medical Center; Brown University
RP Fernandez, AB (通讯作者)，Hartford Hosp, Div Cardiol, Hartford, CT 06115 USA.
EM antoinefemandezt@hotmail.com
RI Jayaraman, Ramya/AAM-1518-2021
CR A Martillo Miguel, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P37
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Hogg RE, 2007, OPHTHALMOLOGY, V115
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Voutilainen-Kaunisto RM, 2002, DIABETES CARE, V20, P1672
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wong TY, 2009, AM J OPHTHALMOL, V148, P327, DOI 10.1016/j.ajo.2009.05.012
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 35
TC 11
Z9 11
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 18
PY 2015
VL 10
IS 11
AR e0142968
DI 10.1371/journal.pone.0142968
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CW7CD
UT WOS:000365154600071
PM 26580396
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Morohoshi, K
   Patel, N
   Ohbayashi, M
   Chong, V
   Grossniklaus, HE
   Bird, AC
   Ono, SJ
AF Morohoshi, Kei
   Patel, Nishal
   Ohbayashi, Masaharu
   Chong, Victor
   Grossniklaus, Hans E.
   Bird, Alan C.
   Ono, Santa J.
TI Serum autoantibody biomarkers for age-related macular degeneration and
   possible regulators of neovascularization
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-retinal antibody; Autoantibody
   profile; Phosphatidylserine; ROC analysis
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrial counties. Its pathogenesis is at least partially mediated by immunological factors, including a possible autoimmune response. To date, only a few antibodies have been identified in sera from patients with AMD. In order to reveal an autoantibody profile for AMD and identify biomarkers for progression of this disease, we have performed an antigen microarray analysis of serum samples from patients with AMD and healthy controls. Sera from the AMD groups contained high levels of IgG and IgM autoantibodies to some systemic antigens when compared to the normal group. Targeted antigens included cyclic nucleotide phosphodiesterase, phosphatidylserine (PS) and proliferating cell nuclear antigen. The IgG/IgM ratio for antibodies to PS was notably elevated in the AMD group compared to the normal group, and this ratio correlated best with the stage of AMD patients with an anti-PS ratio greater than the cut-off value had a 44-fold risk for advanced AMD with choroidal neovascularization. PS immunoreactivity was also elevated in AMD retina. Moreover, IgG autoantibodies purified from sera of AMD patients induced more tube formation on choroidal-retinal endothelial cells compared to those of healthy donors. Hence, sera from patients with AMD contain specific autoantibodies which may be used as biomarkers for AMD, and the IgG/M ratio for autoantibodies to PS might allow better monitoring of AMD progression. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Morohoshi, Kei; Ohbayashi, Masaharu; Ono, Santa J.] Univ Cincinnati, Cincinnati Childrens Hosp, Div Allergy & Immunol, Dept Pediat,Med Ctr,Coll Med, Cincinnati, OH 45267 USA.
   [Morohoshi, Kei; Ohbayashi, Masaharu; Grossniklaus, Hans E.; Ono, Santa J.] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Morohoshi, Kei; Ohbayashi, Masaharu; Grossniklaus, Hans E.; Ono, Santa J.] Emory Eye Ctr, Dobbs Ocular Immunol Labs, Atlanta, GA USA.
   [Patel, Nishal] UCL, Inst Ophthalmol, London, England.
   [Chong, Victor] Kings Coll Hosp London, Laser & Retinal Res Unit, London, England.
   [Bird, Alan C.] Moorfields Eye Hosp, Med Retina Serv, London, England.
C3 Cincinnati Children's Hospital Medical Center; University System of
   Ohio; University of Cincinnati; Emory University; University of London;
   University College London; King's College Hospital NHS Foundation Trust;
   King's College Hospital; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Ono, SJ (通讯作者)，Univ Cincinnati, 2614 McMicken Circle,210 Van Wormer Hall, Cincinnati, OH 45221 USA.
EM santa.ono@uc.edu
RI Chong, Victor/Q-6565-2018
OI Chong, Victor/0000-0002-7693-522X; Morohoshi, Kei/0000-0002-2891-9073
FU R. Howard Dobbs, Jr. Foundation; Special Trustees of Moorfields Eye
   Hospital
FX This work was supported by the R. Howard Dobbs, Jr. Foundation and the
   Special Trustees of Moorfields Eye Hospital.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Aprahamian T, 2004, J EXP MED, V199, P1121, DOI 10.1084/jem.20031557
   Asano K, 2004, J EXP MED, V200, P459, DOI 10.1084/jem.20040342
   Aslanian AM, 2006, CIRCULATION, V114, P583, DOI 10.1161/CIRCULATIONAHA.105.540583
   BROWN SS, 1980, DIFFERENTIATION, V16, P173, DOI 10.1111/j.1432-0436.1980.tb01073.x
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cuadrado MJ, 2006, J THROMB HAEMOST, V4, P2461, DOI 10.1111/j.1538-7836.2006.02193.x
   Dineen B, 2006, OPHTHAL EPIDEMIOL, V13, P31, DOI 10.1080/09286580500473787
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dot C, 2005, AM J OPHTHALMOL, V139, P746, DOI 10.1016/j.ajo.2004.10.044
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Forger F, 2004, LUPUS, V13, P36, DOI 10.1191/0961203304lu485oa
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hoffmann PR, 2005, J IMMUNOL, V174, P1393, DOI 10.4049/jimmunol.174.3.1393
   Jo N, 2006, MOL VIS, V12, P1243
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kremmer S, 2001, CLIN EXP IMMUNOL, V125, P211, DOI 10.1046/j.1365-2249.2001.01578.x
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Li QZ, 2007, CLIN EXP IMMUNOL, V147, P60, DOI 10.1111/j.1365-2249.2006.03251.x
   Mantel I, 2008, EXP MOL PATHOL, V84, P90, DOI 10.1016/j.yexmp.2007.10.006
   MATSUDA J, 1994, AM J HEMATOL, V47, P56, DOI 10.1002/ajh.2830470112
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Muraro PA, 2002, J NEUROIMMUNOL, V130, P233, DOI 10.1016/S0165-5728(02)00229-1
   Norgren N, 2004, NEUROLOGY, V63, P1586, DOI 10.1212/01.WNL.0000142988.49341.D1
   Otsuka M, 2005, BIOL PHARM BULL, V28, P1707, DOI 10.1248/bpb.28.1707
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Pierangeli SS, 1999, CIRCULATION, V99, P1997, DOI 10.1161/01.CIR.99.15.1997
   Rampazzo P, 2001, THROMB HAEMOSTASIS, V85, P57, DOI 10.1055/s-0037-1612904
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   Sanna G, 2000, LUPUS, V9, P573, DOI 10.1191/096120300678828695
   SIMANTOV R, 1995, J CLIN INVEST, V96, P2211, DOI 10.1172/JCI118276
   Sivaprasad S, 2005, INVEST OPHTH VIS SCI, V46, P3046, DOI 10.1167/iovs.04-1277
   Suvajac G, 2007, AUTOIMMUN REV, V6, P409, DOI 10.1016/j.autrev.2006.11.005
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Vega-Ostertag ME, 2007, J THROMB HAEMOST, V5, P1828, DOI 10.1111/j.1538-7836.2007.02680.x
   VOGEL US, 1988, J NEUROCHEM, V50, P1667, DOI 10.1111/j.1471-4159.1988.tb02461.x
   Walsh MJ, 1998, J CLIN INVEST, V101, P1923, DOI 10.1172/JCI1983
NR 45
TC 40
Z9 41
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
EI 1096-0945
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD FEB
PY 2012
VL 92
IS 1
BP 64
EP 73
DI 10.1016/j.yexmp.2011.09.017
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA V38LV
UT WOS:000209345800012
PM 22001380
DA 2022-11-30
ER

PT J
AU Ramanoel, S
   Chokron, S
   Hera, R
   Kauffmann, L
   Chiquet, C
   Krainik, A
   Peyrin, C
AF Ramanoel, Stephen
   Chokron, Sylvie
   Hera, Ruxandra
   Kauffmann, Louise
   Chiquet, Christophe
   Krainik, Alexandre
   Peyrin, Carole
TI Age-related macular degeneration changes the processing of visual scenes
   in the brain
SO VISUAL NEUROSCIENCE
LA English
DT Article
DE Retina; Occipital cortex; Parahippocampal place area; Spatial frequency;
   Contrast
ID CENTRAL VISION LOSS; CONTRAST SENSITIVITY DECLINE; CORTICAL
   REORGANIZATION; SPATIAL-FREQUENCIES; FACE RECOGNITION; RETINAL LESIONS;
   TOPOGRAPHIC MAP; FOVEAL LOSS; CORTEX; CATEGORIZATION
AB In age-related macular degeneration (AMD), the processing of fine details in a visual scene, based on a high spatial frequency processing, is impaired, while the processing of global shapes, based on a low spatial frequency processing, is relatively well preserved. The present fMRI study aimed to investigate the residual abilities and functional brain changes of spatial frequency processing in visual scenes in AMD patients. AMD patients and normally sighted elderly participants performed a categorization task using large black and white photographs of scenes (indoors vs. outdoors) filtered in low and high spatial frequencies, and nonfiltered. The study also explored the effect of luminance contrast on the processing of high spatial frequencies. The contrast across scenes was either unmodified or equalized using a root-mean-square contrast normalization in order to increase contrast in high-pass filtered scenes. Performance was lower for high-pass filtered scenes than for low-pass and nonfiltered scenes, for both AMD patients and controls. The deficit for processing high spatial frequencies was more pronounced in AMD patients than in controls and was associated with lower activity for patients than controls not only in the occipital areas dedicated to central and peripheral visual fields but also in a distant cerebral region specialized for scene perception, the parahippocampal place area. Increasing the contrast improved the processing of high spatial frequency content and spurred activation of the occipital cortex for AMD patients. These findings may lead to new perspectives for rehabilitation procedures for AMD patients.
C1 [Ramanoel, Stephen; Kauffmann, Louise; Peyrin, Carole] Univ Grenoble Alpes, CNRS, LPNC, F-38000 Grenoble, France.
   [Ramanoel, Stephen; Krainik, Alexandre] Univ Grenoble Alpes, INSERM, CHU Grenoble, GIN, F-38000 Grenoble, France.
   [Chokron, Sylvie] Univ Paris 05, UMR 8242, Lab Psychol Percept, Paris, France.
   [Chokron, Sylvie] CNRS, Paris, France.
   [Chokron, Sylvie] Fdn Ophtalmol Rothschild, Unite Vis & Cognit, Paris, France.
   [Hera, Ruxandra] Alpes Retine, Montbonnot St Martin, France.
   [Chiquet, Christophe] Univ Hosp, Dept Ophthalmol, Grenoble, France.
   [Krainik, Alexandre] CHU Grenoble Alpes, Dept Neuroradiol, Grenoble, France.
   [Krainik, Alexandre] CHU Grenoble Alpes, MRI, Grenoble, France.
   [Krainik, Alexandre] Univ Grenoble Alpes, CNRS UMS 3552, CHU Grenoble Alpes, Inserm US17,IRMaGe, Grenoble, France.
C3 Centre National de la Recherche Scientifique (CNRS); Communaute
   Universite Grenoble Alpes; UDICE-French Research Universities;
   Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche
   Scientifique (CNRS); CHU Grenoble Alpes; Communaute Universite Grenoble
   Alpes; UDICE-French Research Universities; Universite Grenoble Alpes
   (UGA); Institut National de la Sante et de la Recherche Medicale
   (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); UDICE-French Research
   Universities; Universite Paris Cite; Centre National de la Recherche
   Scientifique (CNRS); UDICE-French Research Universities; Universite
   Paris Cite; CHU Grenoble Alpes; CHU Grenoble Alpes; CHU Grenoble Alpes;
   Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); CHU Grenoble Alpes; Communaute Universite
   Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble
   Alpes (UGA)
RP Peyrin, C (通讯作者)，Univ Grenoble Alpes, LPNC, BSHM 1251 Av Cent CS40700, F-38058 Grenoble 9, France.
EM carole.peyrin@univ-grenoble-alpes.fr
RI Ramanoel, Stephen/AAB-5080-2022; KRAINIK, Alexandre/L-5874-2014
OI Ramanoel, Stephen/0000-0003-4735-1097; 
FU SFR "Sante et Societe" (Universite Grenoble Alpes, France); RECOR
   "Agence Nationale pour la Recherche" [ANR-12-JHS2-0002-01 RECOR]; French
   program "Investissement d'Avenir" [ANR-11-INBS-0006]
FX This work was supported by the SFR "Sante et Societe" (Universite
   Grenoble Alpes, France) and the RECOR "Agence Nationale pour la
   Recherche" Grant (ANR-12-JHS2-0002-01 RECOR). Grenoble MRI facility
   IRMaGE was partly funded by the French program "Investissement d'Avenir"
   run by the "Agence Nationale pour la Recherche": Grant "Infrastructure
   d'Avenir en Biologie Sante" (ANR-11-INBS-0006). We thank Catherine Dal
   Molin for the English revision of the manuscript.
CR Aminoff E, 2007, CEREB CORTEX, V17, P1493, DOI 10.1093/cercor/bhl078
   Baker CI, 2008, VISION RES, V48, P1910, DOI 10.1016/j.visres.2008.05.020
   Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   Botelho EP, 2014, CEREB CORTEX, V24, P1, DOI 10.1093/cercor/bhs208
   Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119
   Boucart M, 2008, VISUAL NEUROSCI, V25, P603, DOI 10.1017/S0952523808080656
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   BROWN B, 1993, OPTOMETRY VISION SCI, V70, P45, DOI 10.1097/00006324-199301000-00009
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Burge WK, 2016, SCI REP-UK, V6, DOI 10.1038/srep23268
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   CHINO YM, 1995, J NEUROSCI, V15, P2417, DOI 10.1523/JNEUROSCI.15-03-02417.1995
   Crawford JR, 2010, COGN NEUROPSYCHOL, V27, P245, DOI 10.1080/02643294.2010.513967
   Crawford JR, 1998, J CLIN EXP NEUROPSYC, V20, P755, DOI 10.1076/jcen.20.5.755.1132
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Dilks DD, 2014, OPTOMETRY VISION SCI, V91, pE199, DOI 10.1097/OPX.0000000000000325
   ELLIOTT D, 1990, VISION RES, V30, P541, DOI 10.1016/0042-6989(90)90066-T
   ELLIOTT DB, 1987, OPHTHAL PHYSL OPT, V7, P415, DOI 10.1111/j.1475-1313.1987.tb00771.x
   ELLIOTT DB, 1995, OPTOMETRY VISION SCI, V72, P186, DOI 10.1097/00006324-199503000-00006
   Elliott SL, 2010, J VISION, V10, DOI 10.1167/10.4.4
   Epstein R, 1999, NEURON, V23, P115, DOI 10.1016/S0896-6273(00)80758-8
   Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402
   FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379
   FINE EM, 1995, J OPT SOC AM A, V12, P2286, DOI 10.1364/JOSAA.12.002286
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Frezzotti P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105931
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007
   GITTINGS NS, 1986, EXP GERONTOL, V21, P423, DOI 10.1016/0531-5565(86)90047-1
   Grill-Spector K, 2004, ANNU REV NEUROSCI, V27, P649, DOI 10.1146/annurev.neuro.27.070203.144220
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   HEINEN SJ, 1991, EXP BRAIN RES, V83, P670
   Henriksson L, 2008, J VISION, V8, DOI 10.1167/8.10.5
   HIGGINS KE, 1988, J OPT SOC AM A, V5, P2173, DOI 10.1364/JOSAA.5.002173
   Horton JC, 1998, J NEUROSCI, V18, P5433, DOI 10.1523/JNEUROSCI.18-14-05433.1998
   KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637
   Kauffmann L, 2015, NEUROIMAGE, V112, P86, DOI 10.1016/j.neuroimage.2015.02.058
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Liu TT, 2010, INVEST OPHTH VIS SCI, V51, P6826, DOI 10.1167/iovs.09-4926
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   Moshtael H, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.4.6
   Murakami I, 1997, VISUAL NEUROSCI, V14, P89, DOI 10.1017/S0952523800008798
   Musel B, 2013, J COGNITIVE NEUROSCI, V25, P1315, DOI 10.1162/jocn_a_00397
   Musel B, 2011, VISUAL NEUROSCI, V28, P529, DOI 10.1017/S0952523811000435
   Osterberg G, 1935, Acta Ophthalmol., V13, P11
   OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9
   Owsley C, 2011, VISION RES, V51, P1610, DOI 10.1016/j.visres.2010.10.020
   PELI E, 1994, J OPT SOC AM A, V11, P1929, DOI 10.1364/JOSAA.11.001929
   Peyrin C, 2017, VISION RES, V130, P36, DOI 10.1016/j.visres.2016.11.004
   Prins D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146684
   Rajimehr R, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000608
   Ramanoel S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134554
   Rosa AM, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/568354
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   SALIVE ME, 1994, J AM GERIATR SOC, V42, P287, DOI 10.1111/j.1532-5415.1994.tb01753.x
   Sasaki Y, 2001, P NATL ACAD SCI USA, V98, P2077, DOI 10.1073/pnas.98.4.2077
   Schumacher EH, 2008, RESTOR NEUROL NEUROS, V26, P391
   SEKULER R, 1980, SCIENCE, V209, P1255, DOI 10.1126/science.7403884
   Smirnakis SM, 2005, NATURE, V435, P300, DOI 10.1038/nature03495
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Thi HCT, 2012, OPTOMETRY VISION SCI, V89, P419, DOI 10.1097/OPX.0b013e31824c3a21
   Thi HCT, 2011, INVEST OPHTH VIS SCI, V52, P1655, DOI 10.1167/iovs.10-6003
   Thibaut M, 2014, VISION RES, V98, P46, DOI 10.1016/j.visres.2014.03.004
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wandell BA, 2007, NEURON, V56, P366, DOI 10.1016/j.neuron.2007.10.012
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 70
TC 3
Z9 4
U1 1
U2 10
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0952-5238
EI 1469-8714
J9 VISUAL NEUROSCI
JI Visual Neurosci.
PD MAR 19
PY 2018
VL 35
AR e006
DI 10.1017/S0952523817000372
PG 12
WC Neurosciences; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology
GA GH5QZ
UT WOS:000433489700001
PM 29905126
DA 2022-11-30
ER

PT J
AU Wang, GF
   Spencer, KL
   Court, BL
   Olson, LM
   Scott, WK
   Haines, JL
   Pericak-Vance, MA
AF Wang, Gaofeng
   Spencer, Kylee L.
   Court, Brenda L.
   Olson, Lana M.
   Scott, William K.
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
TI Localization of Age-Related Macular Degeneration-Associated ARMS2 in
   Cytosol, Not Mitochondria
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOMEWIDE-SCAN; CIGARETTE-SMOKING; EXTENDED
   FAMILIES; CHROMOSOME 10Q26; SUSCEPTIBILITY; RISK; GENE; POLYMORPHISM;
   VARIANT
AB PURPOSE. To analyze the relationship between ARMS2 and HTRA1 in the association with age-related macular degeneration (AMD) in an independent case-control dataset and to investigate the subcellular localization of the ARMS2 protein in an in vitro system.
   METHODS. Two SNPs in ARMS2 and HTRA1 were genotyped in 685 cases and 269 controls by a genotyping assay. Allelic association was tested by a chi(2) test. A likelihood ratio test (LRT) of full versus reduced models was used to analyze the interaction between ARMS2 and smoking and HTRA1 and smoking, after adjustment for CFH and age. Immunofluorescence and immunoblot were applied to localize ARMS2 in retinal epithelial ARPE-19 cells and COS7 cell transfected by ARMS2 constructs.
   RESULTS. Both significantly associated SNP rs10490924 and rs11200638 (P < 0.0001) are in strong linkage disequilibrium (LD; D' = 0.97, r(2) = 0.93) that generates virtually identical association test and odds ratios. In separate logistic regression models, the interaction effect for both smoking with ARMS2 and with HTRA1 was not statistically significant. Immunofluorescence and immunoblot show that both endogenous and exogenous ARMS2 are mainly distributed in the cytosol, not the mitochondria. Compared with the wild-type, ARMS2 A69S is more likely to be associated with the cytoskeleton in COS7 cells.
   CONCLUSIONS. The significant associations in ARMS2 and HTRA1 are with polymorphisms in strong LD that confer virtually identical risks, preventing differentiation at the statistical level. ARMS2 was mainly distributed in the cytosol, not in the mitochondrial outer membrane as previously reported, suggesting that ARMS2 may not confer risk to AMD through the mitochondrial pathway. (Invest Ophthalmol Vis Sci. 2009;50:3084-3090) DOI:10.1167/iovs.08-3240
C1 [Wang, Gaofeng] Univ Miami, Miller Sch Med, Miami Inst Human Gen, Miami, FL 33136 USA.
   [Spencer, Kylee L.; Olson, Lana M.; Haines, Jonathan L.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN USA.
C3 University of Miami; Vanderbilt University
RP Wang, GF (通讯作者)，Univ Miami, Miller Sch Med, Miami Inst Human Gen, Miami, FL 33136 USA.
EM gwang@med.miami.edu
RI Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU National Institutes of Health [EY12118]; NATIONAL EYE INSTITUTE
   [U10EY012118, R01EY012118] Funding Source: NIH RePORTER
FX Supported by National Institutes of Health Grant EY12118 (MAP-V, JLH).
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Horton P, 2007, NUCLEIC ACIDS RES, V35, pW585, DOI 10.1093/nar/gkm259
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 28
TC 66
Z9 70
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2009
VL 50
IS 7
BP 3084
EP 3090
DI 10.1167/iovs.08-3240
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 461SP
UT WOS:000267292100006
PM 19255159
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kersten, E
   Paun, CC
   Schellevis, RL
   Hoyng, CB
   Delcourt, C
   Lengyel, I
   Peto, T
   Ueffing, M
   Klaver, CCW
   Dammeier, S
   den Hollander, AI
   de Jong, EK
AF Kersten, Eveline
   Paun, Constantin C.
   Schellevis, Rosa L.
   Hoyng, Carel. B.
   Delcourt, Cecile
   Lengyel, Imre
   Peto, Tunde
   Ueffing, Marius
   Klaver, Caroline C. W.
   Dammeier, Sascha
   den Hollander, Anneke I.
   de Jong, Eiko K.
TI Systemic and ocular fluid compounds as potential biomarkers in
   age-related macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; biomarkers; serum; plasma; vitreous;
   aqueous
ID C-REACTIVE PROTEIN; ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H;
   POLYPOIDAL CHOROIDAL VASCULOPATHY; NUTRITION EXAMINATION SURVEY;
   CARDIOVASCULAR RISK-FACTORS; LONG-TERM INCIDENCE; ANTI-RETINAL
   ANTIBODIES; LOW-DENSITY-LIPOPROTEIN; CHLAMYDIA-PNEUMONIAE INFECTION
AB Biomarkers can help unravel mechanisms of disease and identify new targets for therapy. They can also be useful in clinical practice for monitoring disease progression, evaluation of treatment efficacy, and risk assessment in multifactorial diseases, such as age-related macular degeneration (AMD). AMD is a highly prevalent progressive retinal disorder for which multiple genetic and environmental risk factors have been described, but the exact etiology is not yet fully understood. Many compounds have been evaluated for their association with AMD. We performed an extensive literature review of all compounds measured in serum, plasma, vitreous, aqueous humor, and urine of AMD patients. Over 3600 articles were screened, resulting in more than 100 different compounds analyzed in AMD studies, involved in neovascularization, immunity, lipid metabolism, extracellular matrix, oxidative stress, diet, hormones, and comorbidities (such as kidney disease). For each compound, we provide a short description of its function and discuss the results of the studies in relation to its usefulness as AMD biomarker. In addition, biomarkers identified by hypothesis-free techniques, including metabolomics, proteomics, and epigenomics, are covered. In summary, compounds belonging to the oxidative stress pathway, the complement system, and lipid metabolism are the most promising biomarker candidates for AMD. We hope that this comprehensive survey of the literature on systemic and ocular fluid compounds as potential biomarkers in AMD will provide a stepping stone for future research and possible implementation in clinical practice. (C) 2017 The Authors. Published by Elsevier Inc.
C1 [Kersten, Eveline; Paun, Constantin C.; Schellevis, Rosa L.; Hoyng, Carel. B.; Klaver, Caroline C. W.; den Hollander, Anneke I.; de Jong, Eiko K.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Delcourt, Cecile] Univ Bordeaux, ISPED, Bordeaux, France.
   [Delcourt, Cecile] INSERM, Bordeaux Populat Hlth Res Ctr U1219, Bordeaux, France.
   [Lengyel, Imre] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Expt Med, Belfast, Antrim, North Ireland.
   [Peto, Tunde] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Ueffing, Marius; Dammeier, Sascha] Univ Tubingen, Inst Ophthalm Res, Dept Ophthalmol, Tubingen, Germany.
   [Ueffing, Marius; Dammeier, Sascha] Univ Tubingen, Inst Ophthalm Res, Med Bioanalyt Ctr Tubingen, Tubingen, Germany.
   [Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; UDICE-French Research Universities;
   Universite de Bordeaux; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Queens University Belfast; Queens University Belfast;
   Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus
   University Rotterdam; Erasmus MC; Radboud University Nijmegen
RP de Jong, EK (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.; de Jong, EK (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM eiko.dejong@radboudumc.nl
RI Peto, Tunde/G-8812-2018; Hollander, Anneke den/N-4911-2014; Klaver,
   Caroline C.W./A-2013-2016; Delcourt, Cecile/I-2627-2013; Schellevis,
   Rosa/I-9371-2016; Kersten, Eveline/P-8173-2015; Lengyel,
   Imre/B-5217-2009
OI Peto, Tunde/0000-0001-6265-0381; Delcourt, Cecile/0000-0002-2099-0481;
   Schellevis, Rosa/0000-0002-6939-8358; Lengyel, Imre/0000-0001-7467-2174;
   Klaver, Caroline/0000-0002-2355-5258
FU EYE-RISK Consortium; European Union's Horizon research and innovation
   programme [634479]
FX The authors wish to acknowledge the support of the EYE-RISK Consortium.
   This project has received funding from the European Union's Horizon 2020
   research and innovation programme under grant agreement No 634479.
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Ambreen F, 2015, MOL VIS, V21, P985
   Ambreen F, 2014, J PAK MED ASSOC, V64, P664
   Anand A, 2013, OXID MED CELL LONGEV, V2013, DOI DOI 10.1155/2013/365046
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Arbor Sage C., 2016, Yale Journal of Biology and Medicine, V89, P5
   Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Bai YJ, 2014, MOL VIS, V20, P1258
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Baulieu EE, 2000, P NATL ACAD SCI USA, V97, P4279, DOI 10.1073/pnas.97.8.4279
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Belda JI, 1999, MECH AGEING DEV, V107, P159, DOI 10.1016/S0047-6374(98)00144-4
   Bertelmann T, 2013, GRAEF ARCH CLIN EXP, V251, P2697, DOI 10.1007/s00417-013-2374-8
   Bhattacharya PT, 2016, SCIENTIFICA, V2016, DOI 10.1155/2016/5464373
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Binder BR, 2002, NEWS PHYSIOL SCI, V17, P56, DOI 10.1152/nips.01369.2001
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Bosevski M, 2007, BRATISL MED J, V108, P297
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chelikani P, 2004, CELL MOL LIFE SCI, V61, P192, DOI 10.1007/s00018-003-3206-5
   Chen H, 2001, J Tongji Med Univ, V21, P68
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Chong EW, 2014, OPTOMETRY VISION SCI, V91, P860, DOI 10.1097/OPX.0000000000000288
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Chou MY, 2009, J CLIN INVEST, V119, P1335, DOI 10.1172/JCI36800
   Christen WG, 2015, OPHTHAL EPIDEMIOL, V22, P85, DOI 10.3109/09286586.2015.1012272
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Cohn AC, 2013, AM J EPIDEMIOL, V177, P933, DOI 10.1093/aje/kws332
   Colak E, 2012, AGING CLIN EXP RES, V24, P588, DOI 10.3275/8593
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dalle-Donne I, 2003, CLIN CHIM ACTA, V329, P23, DOI 10.1016/S0009-8981(03)00003-2
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Davari MH, 2013, J RES HEALTH SCI, V13, P98
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   DelaPaz MA, 1996, BRIT J OPHTHALMOL, V80, P445, DOI 10.1136/bjo.80.5.445
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Dentchev T, 2003, MOL VIS, V9, P184
   Doni A, 2012, IMMUNOBIOLOGY, V217, P1122, DOI 10.1016/j.imbio.2012.07.004
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Enders P, 2015, RETINA-J RET VIT DIS, V35, P454, DOI 10.1097/IAE.0000000000000320
   Erie JC, 2007, AM J OPHTHALMOL, V144, P414, DOI 10.1016/j.ajo.2007.05.020
   Erqou S, 2009, JAMA-J AM MED ASSOC, V302, P412, DOI 10.1001/jama.2009.1063
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Ertekin S, 2014, MOL VIS, V20, P1057
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Evereklioglu C, 2003, EYE, V17, P350, DOI 10.1038/sj.eye.6700345
   Faber C, 2015, ACTA OPHTHALMOL, V93, P242, DOI 10.1111/aos.12581
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Falk MK, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-22
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Fiedor J, 2014, NUTRIENTS, V6, P466, DOI 10.3390/nu6020466
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Fourgeux C, 2012, INVEST OPHTH VIS SCI, V53, P7026, DOI 10.1167/iovs.12-9652
   FRIEDEWA WT, 1972, CLIN CHEM, V18, P499, DOI [DOI 10.1093/clinchem/18.6.499, 10.1093/clinchem/18.6.499]
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gajowik Aneta, 2014, Rocz Panstw Zakl Hig, V65, P263
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Garcia A, 2004, CAN MED ASSOC J, V171, P897, DOI 10.1503/cmaj.1031586
   Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Geyer PE, 2016, CELL SYST, V2, P185, DOI 10.1016/j.cels.2016.02.015
   Ghorbanihaghjo Amir, 2014, Acta Med Iran, V52, P265
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Grierson R, 2013, J OCUL PHARMACOL TH, V29, P530, DOI 10.1089/jop.2012.0013
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XY, 2014, CURR EYE RES, V39, P518, DOI 10.3109/02713683.2013.848899
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602, DOI 10.1016/s0161-6420(91)32252-8
   Guymer R, 2015, GRAEF ARCH CLIN EXP, V253, P1347, DOI 10.1007/s00417-015-2970-x
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Haas P, 2011, CURR EYE RES, V36, P143, DOI 10.3109/02713683.2010.533808
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hegele RA, 2009, NAT REV GENET, V10, P109, DOI 10.1038/nrg2481
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Ho L, 2009, ARCH OPHTHALMOL-CHIC, V127, P340, DOI 10.1001/archophthalmol.2009.8
   Hogan M J, 1967, Trans Ophthalmol Soc U K, V87, P113
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Honarmand Hamidreza, 2013, Interdiscip Perspect Infect Dis, V2013, P941392, DOI 10.1155/2013/941392
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hou HY, 2010, MOL THER, V18, P1837, DOI 10.1038/mt.2010.144
   Houston MC, 2011, J CLIN HYPERTENS, V13, P621, DOI 10.1111/j.1751-7176.2011.00489.x
   Huber M, 2012, OPHTHALMOLOGICA, V228, P188, DOI 10.1159/000339952
   Hwang HS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134338
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Gonalves FTI, 2015, ARQ BRAS OFTALMOL, V78, P290, DOI 10.5935/0004-2749.20150077
   Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Ilhan N, 2015, OCUL IMMUNOL INFLAMM, V23, P287, DOI 10.3109/09273948.2014.921715
   INHOFFEN W, 1990, GRAEF ARCH CLIN EXP, V228, P316, DOI 10.1007/BF00920054
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javadzadeh A, 2007, SAUDI MED J, V28, P221
   Javadzadeh A, 2012, RETINA-J RET VIT DIS, V32, P658, DOI 10.1097/IAE.0b013e31822529b1
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Jia LH, 2011, AGING CLIN EXP RES, V23, P264, DOI 10.1007/BF03324965
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Johnson LV, 2004, NEW ENGL J MED, V351, P320, DOI 10.1056/NEJMp048131
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Juel HB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132800
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kakafika AI, 2007, CURR PHARM DESIGN, V13, P1647, DOI 10.2174/138161207780831310
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Kassner U, 2015, ATHEROSCLEROSIS SUPP, V18, P263, DOI 10.1016/j.atherosclerosissup.2015.02.039
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Kennaway DJ, 1999, J PINEAL RES, V27, P210, DOI 10.1111/j.1600-079X.1999.tb00617.x
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P5702, DOI 10.1167/iovs.14-14774
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Kim HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32548
   Kim HJ, 2014, INVEST OPHTH VIS SCI, V55, P7166, DOI 10.1167/iovs.14-15168
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kubicka-Trzaska A, 2014, ACTA OPHTHALMOL, V92, pe610, DOI 10.1111/aos.12435
   Kubicka-Trzaska A, 2012, ACTA OPHTHALMOL, V90, pE21, DOI 10.1111/j.1755-3768.2011.02237.x
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   La Thangue NB, 2011, NAT REV CLIN ONCOL, V8, P587, DOI 10.1038/nrclinonc.2011.121
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lee H, 2014, BMB REP, V47, P292, DOI 10.5483/BMBRep.2014.47.5.193
   Levitt DG, 2016, INT J GEN MED, V9, P229, DOI 10.2147/IJGM.S102819
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lorenzo Y, 2009, CARCINOGENESIS, V30, P308, DOI 10.1093/carcin/bgn270
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   Lusis AJ, 2008, NAT GENET, V40, P129, DOI 10.1038/ng0208-129
   Lyngholm M, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-3
   Machalinska A, 2011, GRAEF ARCH CLIN EXP, V249, P1785, DOI 10.1007/s00417-011-1767-9
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Maninger N, 2009, FRONT NEUROENDOCRIN, V30, P65, DOI 10.1016/j.yfrne.2008.11.002
   Manresa N, 2015, RETINA-J RET VIT DIS, V35, P1765, DOI 10.1097/IAE.0000000000000552
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Mauer J, 2015, TRENDS IMMUNOL, V36, P92, DOI 10.1016/j.it.2014.12.008
   Mayer MJ, 1998, ACTA OPHTHALMOL SCAN, V76, P62, DOI 10.1034/j.1600-0420.1998.760111.x
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   MEISTER A, 1988, J BIOL CHEM, V263, P17205
   Merle BMJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130816
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Michalska-Malecka K, 2008, CLIN HEMORHEOL MICRO, V38, P209
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Min JK, 2015, OCUL IMMUNOL INFLAMM, V23, P205, DOI 10.3109/09273948.2014.891755
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nobl M, 2016, EXP EYE RES, V146, P107, DOI 10.1016/j.exer.2016.01.001
   Norman AW, 2008, AM J CLIN NUTR, V88, p491S, DOI 10.1093/ajcn/88.2.491S
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Obeid R, 2013, CLIN CHEM LAB MED, V51, P657, DOI 10.1515/cclm-2012-0402
   Okamoto T, 2002, MICROVASC RES, V63, P186, DOI 10.1006/mvre.2001.2371
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Orban T, 2015, FASEB J, V29, P4579, DOI 10.1096/fj.15-275289
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Ouchi M, 2002, OPHTHALMOLOGICA, V216, P363, DOI 10.1159/000066178
   Ouweneel AB, 2016, VASC PHARMACOL, V82, P1, DOI 10.1016/j.vph.2015.10.009
   Owen LA, 2014, INVEST OPHTH VIS SCI, V55, P3543, DOI 10.1167/iovs.14-14047
   Ozkan B, 2012, CAN J OPHTHALMOL, V47, P264, DOI 10.1016/j.jcjo.2012.03.016
   Packer L, 2001, J NUTR, V131, p369S, DOI 10.1093/jn/131.2.369S
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Park DH, 2014, RETINA-J RET VIT DIS, V34, P1167, DOI 10.1097/IAE.0000000000000047
   Park KH, 2014, INVEST OPHTH VIS SCI, V55, P5522, DOI 10.1167/iovs.14-14566
   Park SJ, 2015, OPHTHALMOLOGY, V122, P129, DOI 10.1016/j.ophtha.2014.07.039
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Paun CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26568
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Peiretti E, 2014, EXP EYE RES, V124, P11, DOI 10.1016/j.exer.2014.04.017
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Plestina-Borjan I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/804054
   Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200
   Poletaev A B, 2012, Pathophysiology, V19, P221, DOI 10.1016/j.pathophys.2012.07.003
   PRASHAR S, 1993, ACTA OPHTHALMOL, V71, P214
   Qin L, 2014, GRAEF ARCH CLIN EXP, V252, P23, DOI 10.1007/s00417-013-2418-0
   Raghavan S, 2012, J LEUKOCYTE BIOL, V92, P1055, DOI 10.1189/jlb.1211617
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480
   Reiter RJ, 2003, ACTA BIOCHIM POL, V50, P1129
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Rosen R, 2009, MOL VIS, V15, P1673
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Rudnicka AR, 2010, EYE, V24, P1199, DOI 10.1038/eye.2010.8
   Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   Satarug S, 2008, EXP EYE RES, V87, P587, DOI 10.1016/j.exer.2008.09.014
   Schalinske KL, 2012, ADV NUTR, V3, P755, DOI 10.3945/an.112.002758
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schmid-Kubista KE, 2009, ACTA OPHTHALMOL, V87, P89, DOI 10.1111/j.1755-3768.2008.01173.x
   Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scotti F, 2014, RETINA-J RET VIT DIS, V34, P1802, DOI 10.1097/IAE.0000000000000147
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Semba RD, 2014, JAMA OPHTHALMOL, V132, P464, DOI 10.1001/jamaophthalmol.2013.7664
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Seshasai S, 2015, INVEST OPHTH VIS SCI, V56, P1880, DOI 10.1167/iovs.14-15933
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Sharma NK, 2013, DNA CELL BIOL, V32, P549, DOI 10.1089/dna.2013.2072
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Shen XL, 2012, J NUTR HEALTH AGING, V16, P201, DOI 10.1007/s12603-011-0350-8
   Silva AS, 2012, MOL VIS, V18, P2288
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Sivaprasad S, 2005, INVEST OPHTH VIS SCI, V46, P3046, DOI 10.1167/iovs.04-1277
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Song D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00024
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Stahl W, 2003, MOL ASPECTS MED, V24, P345, DOI 10.1016/S0098-2997(03)00030-X
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Subramani S, 2010, Med J Malaysia, V65, P36
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tamer C, 2007, AM J OPHTHALMOL, V143, P212, DOI 10.1016/j.ajo.2006.09.054
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   TSANG NCK, 1992, DOC OPHTHALMOL, V81, P387
   Uehara H, 2015, AM J OPHTHALMOL, V159, P92, DOI 10.1016/j.ajo.2014.09.036
   Ugurlu N, 2013, CURR EYE RES, V38, P497, DOI 10.3109/02713683.2013.774023
   Ulas F, 2013, INT OPHTHALMOL, V33, P485, DOI 10.1007/s10792-013-9728-4
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Venza I, 2012, AGING CLIN EXP RES, V24, P530, DOI 10.3275/8477
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wagenseil Jessica E., 2007, Birth Defects Research, V81, P229, DOI 10.1002/bdrc.20111
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wang H, 2014, CHEM RES TOXICOL, V27, P2015, DOI 10.1021/tx500216a
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026871
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Weismann D, 2012, BBA-BIOMEMBRANES, V1818, P2465, DOI 10.1016/j.bbamem.2012.01.018
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu EW, 2014, ENVIRON RES, V133, P178, DOI 10.1016/j.envres.2014.05.023
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Wysokinski D, 2013, EXP EYE RES, V106, P14, DOI 10.1016/j.exer.2012.10.003
   Xu XR, 2014, INT J OPHTHALMOL-CHI, V7, P256, DOI 10.3980/j.issn.2222-3959.2014.02.12
   Yang K, 2014, RETINA-J RET VIT DIS, V34, P1539, DOI 10.1097/IAE.0000000000000118
   Yao JQ, 2013, PROTEOM CLIN APPL, V7, P550, DOI 10.1002/prca.201200012
   Yating Q, 2014, CURR EYE RES, V40, P1
   Yildirim O, 2004, OPHTHALMOLOGICA, V218, P202, DOI 10.1159/000076845
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zafrilla P, 2013, J NUTR HEALTH AGING, V17, P219, DOI 10.1007/s12603-012-0095-z
   Zehetner C, 2014, INVEST OPHTH VIS SCI, V55, P337, DOI 10.1167/iovs.13-12978
   Zeng RP, 2013, MOL VIS, V19, P729
   Zhang RZ, 2006, J NEUROIMMUNOL, V179, P87, DOI 10.1016/j.jneuroim.2006.06.008
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
   Zhou HY, 2011, INVEST OPHTH VIS SCI, V52, P4338, DOI 10.1167/iovs.10-6519
   Zolg JW, 2004, MOL CELL PROTEOMICS, V3, P345, DOI 10.1074/mcp.M400007-MCP200
NR 384
TC 73
Z9 76
U1 1
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN-FEB
PY 2018
VL 63
IS 1
BP 9
EP 39
DI 10.1016/j.survophthal.2017.05.003
PG 31
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP5QF
UT WOS:000417673300002
PM 28522341
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Burlina, PM
   Joshi, N
   Pekala, M
   Pacheco, KD
   Freund, DE
   Bressler, NM
AF Burlina, Philippe M.
   Joshi, Neil
   Pekala, Michael
   Pacheco, Katia D.
   Freund, David E.
   Bressler, Neil M.
TI Automated Grading of Age-Related Macular Degeneration From Color Fundus
   Images Using Deep Convolutional Neural Networks
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; DIABETIC-RETINOPATHY; EYE DISEASE; FEATURES; DRUSEN;
   SYSTEM
AB IMPORTANCE Age-related macular degeneration (AMD) affects millions of people throughout the world. The intermediate stage may go undetected, as it typically is asymptomatic. However, the preferred practice patterns for AMD recommend identifying individuals with this stage of the disease to educate how to monitor for the early detection of the choroidal neovascular stage before substantial vision loss has occurred and to consider dietary supplements that might reduce the risk of the disease progressing from the intermediate to the advanced stage. Identification, though, can be time-intensive and requires expertly trained individuals.
   OBJECTIVE To develop methods for automatically detecting AMD from fundus images using a novel application of deep learning methods to the automated assessment of these images and to leverage artificial intelligence advances.
   DESIGN, SETTING, AND PARTICIPANTS Deep convolutional neural networks that are explicitly trained for performing automated AMD grading were compared with an alternate deep learning method that used transfer learning and universal features and with a trained clinical grader. Age-related macular degeneration automated detection was applied to a 2-class classification problem in which the task was to distinguish the disease-free/early stages from the referable intermediate/advanced stages. Using several experiments that entailed different data partitioning, the performance of the machine algorithms and human graders in evaluating more than 130 000 images that were deidentified with respect to age, sex, and race/ethnicity from 4613 patients against a gold standard included in the National Institutes of Health Age-Related Eye Disease Study data set was evaluated.
   MAIN OUTCOMES AND MEASURES Accuracy, receiver operating characteristics and area under the curve, and. score.
   RESULTS The deep convolutional neural network method yielded accuracy that ranged between 88.4%(SD, 0.5%) and 91.6%(SD, 0.1%), the area under the receiver operating characteristic curve was between 0.94 and 0.96, and. (SD) between 0.764 (0.010) and 0.829 (0.003), which indicated a substantial agreement with the gold standard Age-Related Eye Disease Study data set.
   CONCLUSIONS AND RELEVANCE Applying a deep learning-based automated assessment of AMD from fundus images can produce results that are similar to human performance levels. This study demonstrates that automated algorithms could play a role that is independent of expert human graders in the current management of AMD and could address the costs of screening or monitoring, access to health care, and the assessment of novel treatments that address the development or progression of AMD.
C1 [Burlina, Philippe M.; Joshi, Neil; Pekala, Michael; Freund, David E.] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD USA.
   [Pacheco, Katia D.] Vis Eye Hosp, Brazilian Ctr, Retina Div, Basilia, DF, Brazil.
   [Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins University Applied Physics
   Laboratory; Johns Hopkins University; Johns Hopkins Medicine
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, 600 N Wolfe St,Maumenee 752, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
RI Freund, D.E./AAW-9401-2020
FU National Eye Institute [R21EY024310]; James P. Gills Professorship
FX This work was supported by award R21EY024310 from the National Eye
   Institute, the James P. Gills Professorship, and unrestricted research
   funds to the Johns Hopkins University School of Medicine Retina Division
   for Macular Degeneration and Related Diseases Research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Burlina P, 2011, IEEE ENG MED BIO, P3962, DOI 10.1109/IEMBS.2011.6090984
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Freund DE, 2009, I S BIOMED IMAGING, P61, DOI 10.1109/ISBI.2009.5192983
   Girshick R., RICH FEATURE HIERARC
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Krizhevsky A., IMAGENET CLASSIFICAT
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94
   Pacheco KD, 2016, INVEST OPHTH VIS SCI, V57
   Quellec G, 2017, MED IMAGE ANAL, V39, P178, DOI 10.1016/j.media.2017.04.012
   Rajagopalan AN, 1999, INT JOINT C NEUR NET
   Razavian AS, 2014, I EL EL ENG C COMP V
   Sermanet P., OVERFEAT INTEGRATED
   Simonyan K., VERY DEEP CONVOLUTIO, DOI DOI 10.48550/ARXIV.1409.1556
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Szegedy C, 2015, I EL EL ENG C COMP V
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Trucco E, 2013, INVEST OPHTH VIS SCI, V54, P3546, DOI 10.1167/iovs.12-10347
   Vapnik V., 1998, STAT LEARNING THEORY
   Zeiler MD, 2014, LECT NOTES COMPUT SC, V8689, P818, DOI 10.1007/978-3-319-10590-1_53
NR 31
TC 278
Z9 293
U1 5
U2 80
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV
PY 2017
VL 135
IS 11
BP 1170
EP 1176
DI 10.1001/jamaophthalmol.2017.3782
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM2ER
UT WOS:000414798100009
PM 28973096
OA Green Published, Bronze
HC Y
HP N
DA 2022-11-30
ER

PT J
AU von der Emde, L
   Pfau, M
   Dysli, C
   Thiele, S
   Moller, PT
   Lindner, M
   Schmid, M
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF von der Emde, Leon
   Pfau, Maximilian
   Dysli, Chantal
   Thiele, Sarah
   Moeller, Philipp T.
   Lindner, Moritz
   Schmid, Matthias
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Artificial intelligence for morphology-based function prediction in
   neovascular age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GEOGRAPHIC ATROPHY; FUNDUS PERIMETRY; VISUAL FUNCTION; MICROPERIMETRY;
   AUTOFLUORESCENCE; RANIBIZUMAB; LAYER
AB Spatially-resolved mapping of rod- and cone-function may facilitate monitoring of macular diseases and serve as a functional outcome parameter. However, mesopic and dark-adapted two-color fundus-controlled perimetry (FCP, also called "microperimetry") constitute laborious examinations. We have devised a machine-learning-based approach to predict mesopic and dark-adapted (DA) retinal sensitivity in eyes with neovascular age-related macular degeneration (nAMD). Extensive psychophysical testing and volumetric multimodal retinal imaging data were acquired including mesopic, DA red and DA cyan FCP, spectral-domain optical coherence tomography and confocal scanning laser ophthalmoscopy infrared reflectance and fundus autofluorescence imaging. With patient-wise leave-one-out cross-validation, we have been able to achieve prediction accuracies of (mean absolute error, MAE [95%CI]) 3.94 dB [3.38, 4.5] for mesopic, 4.93 dB [4.59, 5.27] for DA cyan and 4.02 dB [3.63, 4.42] for DA red testing. Partial addition of patient-specific sensitivity data decreased the cross-validated MAE to 2.8 dB [2.51, 3.09], 3.71dB [3.46, 3.96], and 2.85 dB [2.62, 3.08]. The most important predictive feature was outer nuclear layer thickness. This artificial intelligence-based analysis strategy, termed "inferred sensitivity", herein, enables to estimate differential effects of retinal structural abnormalities on cone- and rod-function in nAMD, and may be used as quasi-functional surrogate endpoint in future clinical trials.
C1 [von der Emde, Leon; Pfau, Maximilian; Dysli, Chantal; Thiele, Sarah; Moeller, Philipp T.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, Bonn, Germany.
   [Pfau, Maximilian; Thiele, Sarah; Moeller, Philipp T.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] GRADE Reading Ctr, Ernst Abbe Str 2, Bonn, Germany.
   [Dysli, Chantal] Bern Univ Hosp, Inselspital, Dept Ophthalmol, Bern, Switzerland.
   [Dysli, Chantal] Bern Univ Hosp, Inselspital, Dept Clin Res, Bern, Switzerland.
   [Dysli, Chantal] Univ Bern, Bern, Switzerland.
   [Lindner, Moritz] Univ Oxford, Nuffield Lab Ophthalmol, Sleep & Circadian Neurosci Inst, Nuffield Dept Clin Neurosci, Oxford, England.
   [Schmid, Matthias] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
C3 University of Bonn; University of Bern; University Hospital of Bern;
   University of Bern; University Hospital of Bern; University of Bern;
   University of Oxford; University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, Bonn, Germany.; Schmitz-Valckenberg, S (通讯作者)，GRADE Reading Ctr, Ernst Abbe Str 2, Bonn, Germany.
EM steffen.schmitz-valckenberg@ukbonn.de
RI Lindner, Moritz/AAC-8639-2021; ARSLAN, Okan/AAA-3232-2020; Pfau,
   Maximilian/N-1888-2019
OI Lindner, Moritz/0000-0002-4416-3421; Pfau,
   Maximilian/0000-0001-9761-9640; Schmid, Matthias/0000-0002-0788-0317
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chiu SJ, 2017, INVEST OPHTH VIS SCI, V53, P53
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Hussnain SA, 2019, RETINA-J RET VIT DIS, V39, P1925, DOI 10.1097/IAE.0000000000002367
   Jolly JK, 2017, INVEST OPHTH VIS SCI, V58, P5575, DOI 10.1167/iovs.17-22486
   Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05
   Lewis JA, 1999, STAT MED, V18, P1903, DOI 10.1002/(SICI)1097-0258(19990815)18:15<1903::AID-SIM188>3.3.CO;2-6
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Olsson J, 1997, ACTA OPHTHALMOL SCAN, V75, P181
   Pfau M., 2018, EYE LOND
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, P158, DOI 10.1167/iovs.17-21454
   Pfau M, 2020, RETINA-J RET VIT DIS, V40, P169, DOI 10.1097/IAE.0000000000002337
   Pfau M, 2018, BRIT J OPHTHALMOL, V102, P1054, DOI 10.1136/bjophthalmol-2017-311012
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Pfau M, 2017, OPHTHALMOLOGICA, V237, P42, DOI 10.1159/000453079
   Rohm M, 2018, OPHTHALMOLOGY, V125, P1028, DOI 10.1016/j.ophtha.2017.12.034
   Rohrschneider K, 2012, OPHTHALMOLOGE, V109, P345, DOI 10.1007/s00347-012-2545-8
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Sassmannshausen M, 2018, INVEST OPHTH VIS SCI, V59, P1599, DOI 10.1167/iovs.17-22712
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Springer C, 2007, OPHTHALMOLOGE, V104, P474, DOI 10.1007/s00347-007-1538-5
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   Team RC, 2013, R LANG ENV STAT COMP
   von der Emde L, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.7
   Vujosevic S., 2016, GRAEFES ARCH CLIN EX, P1, DOI [10.1007/s00417-016-3466-z, DOI 10.1007/S00417-016-3466-Z]
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Welling S.H., 2016, FOREST FLOOR VISUALI
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
NR 44
TC 30
Z9 31
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 31
PY 2019
VL 9
AR 11132
DI 10.1038/s41598-019-47565-y
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IM4FT
UT WOS:000477950800055
PM 31366903
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kaiser, RS
   Berger, JW
   Williams, GA
   Tolentino, MJ
   Maguire, AM
   Alexander, J
   Madjarov, B
   Margherio, RM
AF Kaiser, RS
   Berger, JW
   Williams, GA
   Tolentino, MJ
   Maguire, AM
   Alexander, J
   Madjarov, B
   Margherio, RM
TI Variability in fluorescein angiography interpretation for photodynamic
   therapy in age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE photodynamic therapy (PDT); age-related macular degeneration (AMD);
   fluorescein angiography (FA); choroidal neovascularization (CNV)
ID MACULOPATHY; PREVALENCE
AB Objectives: To investigate the variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration.
   Methods: Eight graders, who included two TAP-certified ophthalmologists, three other retinal specialists, two fellows in vitreoretinal diseases, and a senior fundus photograph grader, evaluated fluorescein angiograms of six patients treated according to the Treatment for ARMD With Verteporfin (TAP) protocol at a single center. Each patient's baseline angiogram was evaluated to determine whether the CNV lesion was predominantly (greater than or equal to50%) classic. For each follow-up angiogram, at 3,6,12, and 24 months, the grader was required to determine whether fluorescein leakage was present. Six months after the initial gradings, each reader was again presented with the baseline angiogram for each patient and once again asked to determine whether the CNV lesion was predominantly classic without knowledge of the previous grading. All gradings were performed without knowledge of the clinical course.
   Results: In grading initial visit and follow-up visit angiograms, the overall concordance rates were 81% and 82%, respectively. Concordance rates were not statistically different between the group as a whole when compared with the gradings of the two TAP-certified ophthalmologists. When initial visit angiograms were regraded, an intraobserver variability of 17% was noted. Overall, gradings were discordant with the majority opinion in approximately 19% of decisions.
   Conclusions: Considerable variability can be expected in fluorescein angiography interpretation as the results of the TAP investigation are applied to clinical practice.
C1 Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA 19107 USA.
   Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   William Beaumont Hosp, Royal Oak, MI 48072 USA.
C3 Jefferson University; University of Pennsylvania; Pennsylvania Medicine;
   Beaumont Health
RP Kaiser, RS (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, 9th & Walnut St, Philadelphia, PA 19107 USA.
FU PHS HHS [NIH K08 00374] Funding Source: Medline
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SHROUT P, 1979, INTRACLASS CORRELATI, P420
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   *TREATM AG REL MAC, 2000, INV OPHTHALMOL VIS S, V41, pS532
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WINER BJ, STAT PRINCIPLES EXPT, P1011
NR 13
TC 29
Z9 29
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2002
VL 22
IS 6
BP 683
EP 690
DI 10.1097/00006982-200212000-00001
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 627UQ
UT WOS:000179954900001
PM 12476092
DA 2022-11-30
ER

PT J
AU Bertram, KM
   Baglole, CJ
   Phipps, RP
   Libby, RT
AF Bertram, Kurt M.
   Baglole, Carolyn J.
   Phipps, Richard P.
   Libby, Richard T.
TI Molecular regulation of cigarette smoke induced-oxidative stress in
   human retinal pigment epithelial cells: implications for age-related
   macular degeneration
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE glutathione; heme oxygenase-1; vascular endothelial growth factor;
   nuclear factor erythroid-derived 2, like 2; apoptosis
ID ENDOTHELIAL GROWTH-FACTOR; NRF2 ENHANCES SUSCEPTIBILITY; HUMAN LUNG
   FIBROBLASTS; HEME OXYGENASE-1; GLUTATHIONE SYNTHESIS;
   LIPID-PEROXIDATION; CULTURED RPE; APOPTOSIS; EXPRESSION; INDUCTION
AB Bertram KM, Baglole CJ, Phipps RP, Libby RT. Molecular regulation of cigarette smoke induced-oxidative stress in human retinal pigment epithelial cells: implications for age-related macular degeneration. Am J Physiol Cell Physiol 297: C1200-C1210, 2009. First published September 16, 2009; doi:10.1152/ajpcell.00126.2009.-Cigarette smoke is the most important environmental risk factor for developing age-related macular degeneration (AMD). Damage to the retinal pigment epithelium (RPE) caused by cigarette smoke may underlie the etiology of AMD. This study investigated the molecular and cellular effects of cigarette smoke exposure on human RPE cells. ARPE-19 or primary human RPE cells were exposed to cigarette smoke extract (CSE) or hydroquinone (HQ), a component of cigarette smoke. The effect of this exposure on key aspects of RPE vitality including viability, cell size, mitochondrial membrane potential (Delta Psi(m)), superoxide production, 4-hydroxy-2-nonenal (4-HNE), vascular endothelial growth factor (VEGF), and heme oxygenase-1 (HO-1) expression was determined. Exposure of RPE cells to CSE or HQ caused oxidative damage and apoptosis, characterized by a reduction in cell size and nuclear condensation. Evidence of oxidative damage also included increased lipid peroxidation (4-HNE) and mitochondrial superoxide production, as well as a decrease in intracellular glutathione (GSH). Exogenous administration of antioxidants (GSH and N-acetyl-cysteine) prevented oxidative damage to the RPE cells caused by CSE. Cigarette smoke also induced expression of VEGF, HO-1, and the transcription factor nuclear factor erythroid-derived 2, like 2 (NRF2). However, NRF2 was only modestly involved in CSE-induced HO-1 expression, as shown by the NRF2 small interfering RNA studies. These new findings demonstrate that cigarette smoke is a potent inducer of oxidative damage and cell death in human RPE cells. These data support the hypothesis that cigarette smoke contributes to AMD pathogenesis by causing oxidative damage and cell death to RPE cells.
C1 [Libby, Richard T.] Univ Rochester, Sch Med & Dent, Dept Ophthalmol, Rochester, NY 14642 USA.
   [Bertram, Kurt M.; Baglole, Carolyn J.; Phipps, Richard P.] Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA.
   [Bertram, Kurt M.; Baglole, Carolyn J.; Phipps, Richard P.] Univ Rochester, Sch Med & Dent, Lung Biol & Dis Program, Rochester, NY 14642 USA.
   [Libby, Richard T.] Univ Rochester, Sch Med & Dent, Dept Biomed Genet, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester; University of
   Rochester; University of Rochester
RP Libby, RT (通讯作者)，Univ Rochester, Sch Med & Dent, Dept Ophthalmol, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM richard_libby@urmc.rochester.edu
RI Libby, Richard/Q-6720-2019
OI Libby, Richard/0000-0003-2844-7632
FU Parker B. Francis Fellowship; American Thoracic Society Research Grant;
   Research to Prevent Blindness Career Development Award; University of
   Rochester Department of Environmental Medicine Pilot; Toxicology
   Training [T32ES07026]; National Institutes of Health [ES01247, HL075432,
   EY017123]; NATIONAL EYE INSTITUTE [R01EY017123] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075432]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH
   SCIENCES [T32ES007026, P30ES001247] Funding Source: NIH RePORTER
FX This research was supported by a Parker B. Francis Fellowship and
   American Thoracic Society Research Grant (to C. J. Baglole); Research to
   Prevent Blindness Career Development Award (to R. T. Libby); University
   of Rochester Department of Environmental Medicine Pilot Project Grant
   (to R. T. Libby); Toxicology Training Grant T32ES07026 (to K. M.
   Bertram); National Institutes of Health Grants ES01247, HL075432, and
   EY017123; and a Challenge Grant from The Research to Prevent Blindness
   (Department of Ophthalmology at University of Rochester).
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Adenuga D, 2009, AM J RESP CELL MOL, V40, P464, DOI 10.1165/rcmb.2008-0255OC
   Alcazar O, 2007, INVEST OPHTH VIS SCI, V48, P5662, DOI 10.1167/iovs.07-0392
   Arroyo JG, 2006, JAMA-J AM MED ASSOC, V295, P2394, DOI 10.1001/jama.295.20.2394
   Ayalasomayajula SP, 2002, EUR J PHARMACOL, V449, P213, DOI 10.1016/S0014-2999(02)02043-5
   Baglole CJ, 2008, AM J PHYSIOL-LUNG C, V295, pL624, DOI 10.1152/ajplung.90215.2008
   Baglole CJ, 2006, AM J PHYSIOL-LUNG C, V291, pL19, DOI 10.1152/ajplung.00306.2005
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CARP H, 1978, AM REV RESPIR DIS, V118, P617
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Comporti MM, 1998, FREE RADICAL RES, V28, P623, DOI 10.3109/10715769809065818
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   DRUMMOND GS, 1981, P NATL ACAD SCI-BIOL, V78, P6466, DOI 10.1073/pnas.78.10.6466
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Eichler W, 2008, EXP EYE RES, V87, P342, DOI 10.1016/j.exer.2008.06.017
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Kannan R, 2006, MOL VIS, V12, P1649
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Knorr-Wittmann C, 2005, FREE RADICAL BIO MED, V39, P1438, DOI 10.1016/j.freeradbiomed.2005.07.003
   Kode A, 2008, AM J PHYSIOL-LUNG C, V294, pL478, DOI 10.1152/ajplung.00361.2007
   Kode A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-132
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Kroemer G, 2003, BIOCHEM BIOPH RES CO, V304, P433, DOI 10.1016/S0006-291X(03)00614-4
   KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177
   Lee DW, 2006, TOXICOL SCI, V90, P159, DOI 10.1093/toxsci/kfj052
   Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   Martey CA, 2004, AM J PHYSIOL-LUNG C, V287, pL981, DOI 10.1152/ajplung.00239.2003
   O'Brien JJ, 2009, J THROMB HAEMOST, V7, P182, DOI 10.1111/j.1538-7836.2008.03191.x
   Odaka C, 1996, MICROSC RES TECHNIQ, V34, P267, DOI 10.1002/(SICI)1097-0029(19960615)34:3<267::AID-JEMT9>3.0.CO;2-M
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Orosz Z, 2007, AM J PHYSIOL-HEART C, V292, pH130, DOI 10.1152/ajpheart.00599.2006
   Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029
   Ozgen U, 2000, CYTOMETRY, V42, P74, DOI 10.1002/(SICI)1097-0320(20000215)42:1<74::AID-CYTO11>3.0.CO;2-6
   Rahman I, 2006, NAT PROTOC, V1, P3159, DOI 10.1038/nprot.2006.378
   Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146
   Raza H, 2008, TOXICOL APPL PHARM, V226, P161, DOI 10.1016/j.taap.2007.09.002
   Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Shapiro SD, 2004, AM J RESP CELL MOL, V31, P481, DOI 10.1165/rcmb.F285
   Sharma A, 2008, INVEST OPHTH VIS SCI, V49, P5111, DOI 10.1167/iovs.08-2060
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   TENHUNEN R, 1969, J BIOL CHEM, V244, P6388
   Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Trimborn M, 2004, AM J HUM GENET, V75, P261, DOI 10.1086/422855
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 72
TC 92
Z9 94
U1 0
U2 13
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD NOV
PY 2009
VL 297
IS 5
BP C1200
EP C1210
DI 10.1152/ajpcell.00126.2009
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 512PY
UT WOS:000271263500015
PM 19759330
OA Green Published
DA 2022-11-30
ER

PT J
AU Lains, I
   Chung, W
   Kelly, RS
   Gil, J
   Marques, M
   Barreto, P
   Murta, JN
   Kim, IK
   Vavvas, DG
   Miller, JB
   Silva, R
   Lasky-Su, J
   Liang, LM
   Miller, JW
   Husain, D
AF Lains, Ines
   Chung, Wonil
   Kelly, Rachel S.
   Gil, Joao
   Marques, Marco
   Barreto, Patricia
   Murta, Joaquim N.
   Kim, Ivana K.
   Vavvas, Demetrios G.
   Miller, John B.
   Silva, Rufino
   Lasky-Su, Jessica
   Liang, Liming
   Miller, Joan W.
   Husain, Deeba
TI Human Plasma Metabolomics in Age-Related Macular Degeneration:
   Meta-Analysis of Two Cohorts
SO METABOLITES
LA English
DT Article
DE age-related macular degeneration; metabolomics; mass spectrometry
ID OXIDATIVE STRESS; CONE PHOTORECEPTORS; ALZHEIMERS-DISEASE; TAURINE
   TRANSPORT; EYE DISEASE; CELLS; GLYCEROPHOSPHOLIPIDS; IDENTIFICATION;
   RANIBIZUMAB; ASSOCIATION
AB The pathogenesis of age-related macular degeneration (AMD), a leading cause of blindness worldwide, remains only partially understood. This has led to the current lack of accessible and reliable biofluid biomarkers for diagnosis and prognosis, and absence of treatments for dry AMD. This study aimed to assess the plasma metabolomic profiles of AMD and its severity stages with the ultimate goal of contributing to addressing these needs. We recruited two cohorts: Boston, United States (n = 196) and Coimbra, Portugal (n = 295). Fasting blood samples were analyzed using ultra-high performance liquid chromatography mass spectrometry. For each cohort, we compared plasma metabolites of AMD patients versus controls (logistic regression), and across disease stages (permutation-based cumulative logistic regression considering both eyes). Meta-analyses were then used to combine results from the two cohorts. Our results revealed that 28 metabolites di ff ered significantly between AMDpatients versus controls (false discovery rate (FDR) q-value: 4.1 x 10 2-1.8 x 10 5), and 67 across disease stages (FDR q-value: 4.5 x 10 2-1.7 x 10 4). Pathway analysis showed significant enrichment of glycerophospholipid, purine, taurine and hypotaurine, and nitrogen metabolism (p-value x 0.04). In conclusion, our findings support that AMD patients present distinct plasma metabolomic profiles, which vary with disease severity. This work contributes to the understanding ofAMDpathophysiology, and can be the basis of future biomarkers and precision medicine for this blinding condition.
C1 [Lains, Ines; Kim, Ivana K.; Vavvas, Demetrios G.; Miller, John B.; Miller, Joan W.; Husain, Deeba] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
   [Lains, Ines; Gil, Joao; Marques, Marco; Murta, Joaquim N.; Silva, Rufino] Univ Coimbra, Fac Med, P-3000 Coimbra, Portugal.
   [Lains, Ines; Murta, Joaquim N.; Silva, Rufino] Ctr Hosp & Univ Coimbra, P-3000 Coimbra, Portugal.
   [Lains, Ines; Barreto, Patricia; Murta, Joaquim N.; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image, P-3000 Coimbra, Portugal.
   [Chung, Wonil; Liang, Liming] Harvard TH Chan Sch Publ Hlth, Program Genet Epidemiol & Stat Genet, Boston, MA 02115 USA.
   [Chung, Wonil; Liang, Liming] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Kelly, Rachel S.; Lasky-Su, Jessica] Brigham & Womens Hosp, Channing Div Network Med, Syst Genet & Genom Unit, 75 Francis St, Boston, MA 02115 USA.
   [Kelly, Rachel S.; Lasky-Su, Jessica] Harvard Med Sch, Boston, MA 02115 USA.
   [Liang, Liming] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Universidade de Coimbra; Universidade de Coimbra; Centro
   Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra;
   Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Brigham & Women's Hospital; Harvard University; Harvard
   Medical School; Harvard University; Harvard T.H. Chan School of Public
   Health
RP Husain, D (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
EM Deeba_Husain@meei.harvard.edu
RI Silva, Rufino M/J-2817-2012; kelly, rachel/H-4505-2017; Miller, John
   J/GZG-5663-2022; Murta, Joaquim/V-5494-2017
OI Silva, Rufino M/0000-0001-8676-0833; kelly, rachel/0000-0003-3023-1822;
   Murta, Joaquim/0000-0001-8926-5176; Miller, Joan/0000-0003-2046-3996;
   Quadrado Gil, Joao/0000-0001-9032-1008; Chung, Wonil/0000-0002-5766-6247
FU Miller Retina Research Fund (Mass. Eye and Ear); Champalimaud Vision
   Award; Research to Prevent Blindness; Portuguese Foundation for Science
   and Technology/Harvard Medical School Portugal Program
   [HMSP-ICJ/006/2013]; Commonwealth Unrestricted Grant for Eye Research;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL146980] Funding Source:
   NIH RePORTER
FX Miller Retina Research Fund (Mass. Eye and Ear), Champalimaud Vision
   Award (JWM), unrestricted departmental Grant from Research to Prevent
   Blindness, Portuguese Foundation for Science and Technology/Harvard
   Medical School Portugal Program (HMSP-ICJ/006/2013), Commonwealth
   Unrestricted Grant for Eye Research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ahsan H, 2015, DIABETES METAB SYND, V9, P51, DOI 10.1016/j.dsx.2014.09.011
   Ando D, 2012, NEUROCHEM INT, V60, P597, DOI 10.1016/j.neuint.2012.02.018
   Barnes S, 2016, J MASS SPECTROM, V51, P535, DOI 10.1002/jms.3780
   Barnes S, 2016, J MASS SPECTROM, V51, P461, DOI 10.1002/jms.3782
   Boldyrev A, 2004, NEUROTOX RES, V6, P581, DOI 10.1007/BF03033454
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Carver KA, 2017, BIOCHEM BIOPH RES CO, V482, P81, DOI 10.1016/j.bbrc.2016.10.140
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong J, 2018, NUCL ACIDS RES
   COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Do KT, 2015, J PROTEOME RES, V14, P1183, DOI 10.1021/pr501130a
   Farooqui AA, 2000, CHEM PHYS LIPIDS, V106, P1, DOI 10.1016/S0009-3084(00)00128-6
   Farooqui AA, 2007, J NEUROSCI RES, V85, P1834, DOI 10.1002/jnr.21268
   Farooqui AA, 2012, J ALZHEIMERS DIS, V30, pS163, DOI 10.3233/JAD-2011-111085
   Feng Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep22525
   Frisardi V, 2011, PROG LIPID RES, V50, P313, DOI 10.1016/j.plipres.2011.06.001
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gaucher D, 2012, AMINO ACIDS, V43, P1979, DOI 10.1007/s00726-012-1273-3
   George AK, 2018, INT J OPHTHALMOL-CHI, V11, P881, DOI 10.18240/ijo.2018.05.26
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Guha S, 2013, FASEB J, V27, P4500, DOI 10.1096/fj.13-236166
   Hadj-Said W, 2016, INVEST OPHTH VIS SCI, V57, P4692, DOI 10.1167/iovs.16-19535
   Hopiavuori BR, 2017, J LIPID RES, V58, P668, DOI 10.1194/jlr.M070714
   Ishikawa M, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/528940
   Jove M, 2014, J NEUROPATH EXP NEUR, V73, P640, DOI 10.1097/NEN.0000000000000091
   Kaddurah-Daouk R, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.18
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Do KT, 2017, NPJ SYST BIOL APPL, V3, DOI 10.1038/s41540-017-0029-9
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Kori M, 2016, OMICS, V20, P645, DOI 10.1089/omi.2016.0106
   Kraus WE, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005553
   Lains I, 2017, OPHTHALMOLOGY
   Lains I., 2018, PROG RETIN EYE RES
   Lains I, 2017, RETINA
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Li B, 2016, SCI REP-UK, V6, DOI 10.1038/srep38881
   Mapstone M, 2014, NAT MED, V20, P415, DOI 10.1038/nm.3466
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Nicholson JK, 2012, NATURE, V491, P384, DOI 10.1038/nature11708
   Pasantes-Morales H, 1985, Prog Clin Biol Res, V179, P371
   PASANTESMORALES H, 1985, BRAIN RES, V330, P154, DOI 10.1016/0006-8993(85)90018-6
   Patti GJ, 2012, NAT REV MOL CELL BIO, V13, P263, DOI 10.1038/nrm3314
   Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957
   Reichenbach A, 2016, NEUROPHARMACOLOGY, V104, P194, DOI 10.1016/j.neuropharm.2015.05.005
   Ripps H, 2012, MOL VIS, V18, P2673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sobrin L, 2013, PROG RETIN EYE RES
   Spaide R. F., 2018, RETINA
   Spaide R. F., 2017, RETINA
   Suhre K, 2012, NAT REV GENET, V13, P759, DOI 10.1038/nrg3314
   Takahashi H, 2015, RETINA-J RET VIT DIS, V35, P1331, DOI 10.1097/IAE.0000000000000513
   Tomi M, 2007, MICROVASC RES, V73, P100, DOI 10.1016/j.mvr.2006.10.003
   Trushina E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063644
   Tsikata E, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.3
   van Leeuwen E.M., 2018, PROG RETIN EYE RES
   Whitlock MC, 2005, J EVOLUTION BIOL, V18, P1368, DOI 10.1111/j.1420-9101.2005.00917.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia JG, 2010, NUCLEIC ACIDS RES, V38, pW71, DOI 10.1093/nar/gkq329
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P1522, DOI 10.1167/iovs.10-6172
   Yin PY, 2013, CLIN CHEM, V59, P833, DOI 10.1373/clinchem.2012.199257
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zaykin DV, 2011, J EVOLUTION BIOL, V24, P1836, DOI 10.1111/j.1420-9101.2011.02297.x
   Zhu W, 2017, INT J NANOMED, V12, P7589, DOI 10.2147/IJN.S140275
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 69
TC 19
Z9 19
U1 1
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-1989
J9 METABOLITES
JI Metabolites
PD JUL
PY 2019
VL 9
IS 7
AR 127
DI 10.3390/metabo9070127
PG 22
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA IR5VL
UT WOS:000481505900008
PM 31269701
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Virgili, G
   Bini, A
AF Virgili, G.
   Bini, A.
TI Laser photocoagulation for neovascular age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; ARGON-LASER; OPHTHALMIC
   FINDINGS; ADULT-POPULATION; RED KRYPTON; MACULOPATHY; PREVALENCE;
   SURGERY; GREEN; RANIBIZUMAB
AB Background
   Laser photocoagulation was the first treatment introduced to try to halt the progression of neovascular age-related macular degeneration (AMD), in which newly formed vessels or choroidal neovascularisation ( CNV) grow under the macula leading to the occurrence of a scotoma or blind spot in the central visual field.
   Objectives
   The aim of this review was to examine the effects of laser photocoagulation for neovascular AMD.
   Search strategy
   We searched the CENTRAL, MEDLINE, EMBASE, LILACS, NRR and ZETOC in March 2007.
   Selection criteria
   We included randomised trials of laser photocoagulation in people with CNV due to AMD.
   Data collection and analysis
   Two authors independently extracted the data. The risk ratio ( RR) of severe visual loss ( loss of six or more lines of visual acuity) was estimated at three months and two years after treatment.
   Main results
   Fifteen trials were included in the review ( 2064 participants). Three types of photocoagulation were used in the trials: direct photocoagulation of the entire CNV ( 11 trials), perifoveal photocoagulation ( one trial) and grid photocoagulation ( three trials). In 12 trials the control group was observation only. One trial compared photocoagulation to submacular surgery and two trials compared different lasers. Data on the progression of visual loss could be extracted from five of the eight trials of direct photocoagulation of the CNV versus observation. The treatment effect was in the direction of harm in all studies at three months follow up ( RR 1.41, 95% confidence intervals ( CI) 1.08 to 1.82). After two years the treatment effect was in the direction of benefit ( RR 0.67, 95% CI 0.53 to 0.83). These studies were clinically heterogenous with participants having CNV lesions in different locations and different baseline visual acuities. There was little evidence of statistical heterogeneity at three months but substantial statistical heterogeneity at two years. However, all treatment effects in the individual trials were in the direction of benefit. One study comparing perifoveal photocoagulation or observation of subfoveal CNV found benefits that were statistically significant only at two years ( RR 0.36, 95% CI 0.18 to 0.72). Other comparisons did not demonstrate differences.
   Authors' conclusions
   In the medium to long term laser photocoagulation of CNV slows the progression of visual loss in people with neovascular AMD. However, it is associated with an increased risk of visual loss immediately after treatment and this period may be longer in people with subfoveal AMD. With the advent of modern pharmacological therapies, and concern for the impact of iatrogenic scotoma in subfoveal CNV, laser photocoagulation of subfoveal CNV is not recommended. No studies have compared photocoagulation with modern pharmacological agents for AMD for non-subfoveal CNV.
C1 Univ Florence, Dept Ophthalmol, I-50134 Florence, Italy.
C3 University of Florence
RP Virgili, G (通讯作者)，Univ Florence, Dept Ophthalmol, Via Morgagni 85, I-50134 Florence, Italy.
EM gianni.virgili@unifi.it
RI Virgili, Gianni/P-6607-2014
OI Virgili, Gianni/0000-0002-9960-2989
CR [Anonymous], 1982, Br J Ophthalmol, V66, P745
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arnold J, 1997, GRAEF ARCH CLIN EXP, V235, P208, DOI 10.1007/BF00941761
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1996, ARCH OPHTHALMOL-CHIC, V114, P1456, DOI 10.1001/archopht.1996.01100140654002
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1994, ARCH OPHTHALMOL-CHIC, V112, P1176
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   *CAN OPHTH STUD GR, 1993, ARCH OPTHALMOLOGY, V111, P177
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   COSCAS G, 1983, OPHTHALMOLOGY, V90, P1013
   Coscas G, 1982, Bull Mem Soc Fr Ophtalmol, V94, P149
   COSCAS G, 1984, J FR OPHTALMOL, V7, P99
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fujii Gildo Y, 2002, Ophthalmol Clin North Am, V15, P425, DOI 10.1016/S0896-1549(02)00046-9
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gustavsson C, 2005, ACTA OPHTHALMOL SCAN, V83, P148, DOI 10.1111/j.1600-0420.2005.00427.x
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lambert H M, 2000, Semin Ophthalmol, V15, P92
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   MESTRES FD, 1993, LASER LIGHT OPHTHALM, V6, P27
   PICCOLINO FC, 1993, INT OPHTHALMOL, V17, P77, DOI 10.1007/BF00942779
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Soubrane G, 1987, Bull Soc Ophtalmol Fr, V87, P249
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   *SUB MAC SURG TRIA, 2000, AM J OPHTHALMOL, V130, P408
   Vander J F, 2000, Curr Opin Ophthalmol, V11, P159, DOI 10.1097/00055735-200006000-00001
   VERSTEEGTIJMES NT, 1982, GRAEF ARCH CLIN EXP, V218, P271, DOI 10.1007/BF02175896
   Willan AR, 1996, CAN J OPHTHALMOL, V31, P11
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
   YASSUR Y, 1982, RETINA-J RET VIT DIS, V2, P127, DOI 10.1097/00006982-198200230-00001
NR 65
TC 47
Z9 47
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2007
IS 3
AR CD004763
DI 10.1002/14651858.CD004763.pub2
PG 41
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 191FZ
UT WOS:000248118000032
PM 17636773
DA 2022-11-30
ER

PT J
AU Gourgouli, K
   Gourgouli, I
   Tsaousis, G
   Spai, S
   Niskopoulou, M
   Efthimiopoulos, S
   Lamnissou, K
AF Gourgouli, Kalliopi
   Gourgouli, Ioanna
   Tsaousis, Georgios
   Spai, Sofia
   Niskopoulou, Maria
   Efthimiopoulos, Spiros
   Lamnissou, Klea
TI Investigation of genetic base in the treatment of age-related macular
   degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Antioxidants; Ranibizumab; Single
   nucleotide polymorphisms; Treatment response
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF THERAPY;
   FACTOR-B; VISION LOSS; RISK; CFH; ASSOCIATION; ZINC; POLYMORPHISMS
AB Purpose To determine whether gene polymorphisms which are associated with age-related macular degeneration (AMD) influence treatments' response and specifically the antioxidant supplementation in dry AMD patients, as well as the anti-vascular endothelial growth factor (anti-VEGF) therapy in neovascular AMD patients. Methods A total of 170 patients with dry AMD and 52 neovascular AMD patients were genotyped for the following single nucleotide polymorphisms (SNPs): rs1061170/Y402H in CFH gene, rs10490924/A69S in ARMS2 gene, rs9332739/E318D and rs547154/IVS10 in C2 gene, and rs4151667/L9H and rs2072633/IVS17 in CFB gene. Treatment response was evaluated by comparing visual acuity and optical coherence tomography between baseline and at the end of the treatment. Results tau he CFH/Y402H variant was associated with the response to antioxidants in dry AMD patients. Carriers of one or two CFH risk alleles displayed a lower chance of responding compared to those with no risk allele. No association of antioxidants' response and ARMS2/A69S genotype was identified. The analysis of the C2 and CFB genetic variants (protective SNPs) revealed that antioxidant supplementation was much more effective in protective SNP carriers. In neovascular AMD patients, the analysis indicated that Y402H homozygous patients were less likely to respond to anti-VEGF therapy compared to heterozygous. Regarding the ARMS2/A69S genotype, carriers of the risk variant experienced significantly worse treatment outcome compared to wild-type patients. Conclusion In AMD patients, the efficacy of the antioxidant supplementation and the anti-VEGF therapy appears to differ by genotype. The detection of genetic variants, associated with treatment responsiveness, could lead to improved visual outcomes through genotype-directed therapy.
C1 [Gourgouli, Kalliopi; Lamnissou, Klea] Natl & Kapodistrian Univ Athens, Dept Biol, Div Genet & Biotechnol, Athens 15701, Greece.
   [Gourgouli, Ioanna; Spai, Sofia] Sismanoglio Gen Hosp Attica, Dept Ophthalmol, Athens, Greece.
   [Tsaousis, Georgios] Natl & Kapodistrian Univ Athens, Dept Biol, Div Cell Biol & Biophys, Athens, Greece.
   [Niskopoulou, Maria] Consultant Ophthalm Surg, Agias Paraskevis 118, Athens 15232, Greece.
   [Efthimiopoulos, Spiros] Natl & Kapodistrian Univ Athens, Dept Biol, Div Anim & Human Physiol, Athens, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens; National & Kapodistrian University of Athens
RP Gourgouli, K (通讯作者)，Natl & Kapodistrian Univ Athens, Dept Biol, Div Genet & Biotechnol, Athens 15701, Greece.
EM kgourgouli@gmail.com
RI Tsaousis, Georgios/L-5504-2013
OI Tsaousis, Georgios/0000-0002-8975-8779
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bardak H, 2016, Genet Mol Res, V15, DOI 10.4238/gmr15049164
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campbell I, 2007, STAT MED, V26, P3661, DOI 10.1002/sim.2832
   Chaudhary V, 2016, OPHTHALMOLOGICA, V236, P88, DOI 10.1159/000446819
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Garcia M, 2015, ACTA OPHTHALMOL, V93, pE658, DOI 10.1111/aos.12790
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Teper SJ, 2010, MOL VIS, V16, P2598
NR 44
TC 3
Z9 3
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD APR
PY 2020
VL 40
IS 4
BP 985
EP 997
DI 10.1007/s10792-019-01274-7
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LE2GL
UT WOS:000526541400023
PM 31916060
DA 2022-11-30
ER

PT J
AU Lains, I
   Park, DH
   Mukai, R
   Silverman, R
   Oellers, P
   Mach, S
   Kim, IK
   Vavvas, DG
   Miller, JW
   Miller, JB
   Husain, D
AF Lains, Ines
   Park, Dong Ho
   Mukai, Ryo
   Silverman, Rebecca
   Oellers, Patrick
   Mach, Steven
   Kim, Ivana K.
   Vavvas, Demetrios G.
   Miller, Joan W.
   Miller, John B.
   Husain, Deeba
TI Peripheral Changes Associated With Delayed Dark Adaptation in
   Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; RETICULAR PSEUDODRUSEN; VISUAL FUNCTION;
   OLDER EYES; FUNDUS; AUTOFLUORESCENCE; MACULOPATHY; DRUSEN; LIPOFUSCIN;
   GENOTYPES
AB PURPOSE: To study the association between peripheral changes in age-related macular degeneration (AMD) and dark adaptation (DA).
   DESIGN: Prospective, cross-sectional study.
   METHODS: We recruited patients with AMD and a control group (> 50 years) without any vitreoretinal disease. Ultra-widefield (UWF) pseudocolor and fundus autofluorescence (FAF) were obtained, and were assessed by 2 graders for the presence of several peripheral changes in perimacular, midperipheral, and far-peripheral zones. All participants were also imaged with 7-field color fundus photographs used for AMD staging (Age-Related Eye Disease Study classification system). Both eyes of study participants were tested with a dark adaptation (DA) extended protocol (20 minutes). Multilevel mixed-effect models (accounting for correlated outcomes between 2 eyes) were used for analyses.
   RESULTS: We included 128 eyes (n = 72 patients), 75% with AMD and the remainder controls. The presence of reticular pigmentary changes in the midperipheral (beta = 4.3, P = .012) and far-peripheral zones (beta = 8.4, P < .001) was associated with delayed rod-intercept times (RITs), even after adjusting for confounding factors. The presence, number, and extent of peripheral classic drusen did not show a similar association (P >= 148). The presence of a mottled decreased FAF pattern in the midperipheral zone was also associated with prolonged RITs (0 = 4.4, P = .031).
   CONCLUSION: Our results suggest an association between DA and the presence of peripheral reticular pigmentary changes, as well as the presence of a peripheral mottled decreased FAF pattern. This provides new insights on the clinical significance of peripheral changes in AMD, and their contribution to impairments on DA. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Lains, Ines; Park, Dong Ho; Mukai, Ryo; Silverman, Rebecca; Oellers, Patrick; Mach, Steven; Kim, Ivana K.; Vavvas, Demetrios G.; Miller, Joan W.; Miller, John B.; Husain, Deeba] Harvard Med Sch, Harvard Ophthalmol AMD Ctr Excellence, Massachusetts Eye & Ear, Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA.
   [Park, Dong Ho] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Daegu, South Korea.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Kyungpook National University
RP Husain, D (通讯作者)，Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear, 243 Charles St, Boston, MA 02114 USA.
EM Deeba_Husain@rneei.harvard.edu
RI Miller, John J/GZG-5663-2022
OI Husain, Deeba/0000-0002-8494-0950; Vavvas,
   Demetrios/0000-0002-8622-6478; Kim, Ivana/0000-0003-0310-6129
FU MILLER RETINA RESEARCH FUND (MASSACHUSETTS Eye and Ear); Champalimaud
   Vision Award; Research to Prevent Blindness, Inc, New York, New York;
   Portuguese Foundation for Science and Technology/Harvard Medical School
   Portugal Program [HMSP-ICJ/006/2013]; NATIONAL EYE INSTITUTE
   [R01EY030088, T32EY007145] Funding Source: NIH RePORTER
FX THIS STUDY WAS FINANCIALLY SUPPORTED BY THE MILLER RETINA RESEARCH FUND
   (MASSACHUSETTS Eye and Ear), the Champalimaud Vision Award (J.W.M.), an
   unrestricted departmental Grant from Research to Prevent Blindness, Inc,
   New York, New York, and the Portuguese Foundation for Science and
   Technology/Harvard Medical School Portugal Program (HMSP-ICJ/006/2013).
   J.W.M. served on the Scientific Advisory Board for Maculogix from 2013
   to 2015, but received no compensation. In kind, Massachusetts Eye and
   Ear received donation of an AdaptDx dark adaptometer. All the
   above-mentioned funding organizations had no role in the design or
   conduct of this research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bae K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170526
   BASTEK JV, 1982, OPHTHALMOLOGY, V89, P1455
   Bonate PL, 2011, PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION, SECOND EDITION, P189, DOI 10.1007/978-1-4419-9485-1_6
   Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   FRIEDMAN E, 1968, ARCH OPHTHALMOL-CHIC, V79, P315, DOI 10.1001/archopht.1968.03850040317017
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Heussen FM, 2012, INVEST OPHTH VIS SCI, V53, P6526, DOI 10.1167/iovs.12-9909
   HUMPHREY WT, 1984, AM J OPHTHALMOL, V98, P717, DOI 10.1016/0002-9394(84)90686-X
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   KANSKI JJ, 1975, T OPHTHAL SOC UK, V95, P173
   LaIns I, 2017, RETINA, DOI [10.1097/1AE.0000000000001659, DOI 10.1097/1AE.0000000000001659]
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   LEWIS H, 1985, OPHTHALMOLOGY, V92, P1485
   LEWIS H, 1985, ARCH OPHTHALMOL-CHIC, V103, P1631
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Nagiel A, 2016, RETINA-J RET VIT DIS, V36, P660, DOI 10.1097/IAE.0000000000000937
   Oellers P, 2017, CLIN OPHTHALMOL, V11, P1967, DOI 10.2147/OPTH.S143246
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Reznicek L, 2012, INVEST OPHTH VIS SCI, V53, P2193, DOI 10.1167/iovs.11-8483
   Schaal KB, 2017, OPHTHALMOLOGY, V124, P205, DOI 10.1016/j.ophtha.2016.10.009
   Schaal KB, 2015, OSLI RETINA, V46, P550, DOI 10.3928/23258160-20150521-06
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Tsikata E, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.3
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
NR 40
TC 11
Z9 11
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2018
VL 190
BP 113
EP 124
DI 10.1016/j.ajo.2018.03.035
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GI1AY
UT WOS:000434102800016
PM 29621510
DA 2022-11-30
ER

PT J
AU Dias, JRD
   Rodrigues, EB
   Maia, M
   Magalhaes, O
   Penha, FM
   Farah, ME
AF de Oliveira Dias, Joao Rafael
   Rodrigues, Eduardo Buechele
   Maia, Mauricio
   Magalhaes, Octaviano, Jr.
   Penha, Fernando Marcondes
   Farah, Michel Eid
TI Cytokines in neovascular age-related macular degeneration: fundamentals
   of targeted combination therapy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR;
   TUMOR-NECROSIS-FACTOR; COMPLEMENT FACTOR-H; EXPERIMENTAL CHOROIDAL
   NEOVASCULARIZATION; PHOTORECEPTOR OUTER SEGMENTS; FACTOR FAMILY;
   FACTOR-RECEPTOR; OCULAR NEOVASCULARIZATION; FACTOR-B
AB The neovascular form of age-related macular degeneration (AMD), called wet-AMD or choroidal neovascularisation, begins with damage to the outer retinal cells and retinal pigment epithelium (RPE), which elicits a cascade of inflammatory and angiogenic responses leading to neovascularisation under the macula. Studies showed that oxidative damage, chronic inflammation of the RPE and complement misregulation work at different steps of this disease. After established neovascularisation, several pro-and antiangiogenic agents start to play an important role. Vascular endothelial growth factors (VEGFs) are the most specific and potent regulators of angiogenesis, which are inhibited by intravitreal injections of ranibizumab, bevacizumab, VEGF Trap, pegaptanib sodium and other agents under investigation. Pigment epithelium-derived factor, on the other hand, shows neuroprotective and antiangiogenic activities. Hepatocyte growth factor (HGF) has a mitogenic effect on a wide range of epithelial and endothelial cells, and it is inhibited by an anti-HGF monoclonal antibody. Platelet-derived growth factor is a potent chemoattractant and mitogen for both fibroblasts and retinal RPE cells, which has been inhibited experimentally by VEGF Trap and human anti-platelet-derived growth factor-D monoclonal antibody. Fibroblast growth factor-2 has pleiotropic effects in different cell and organ systems, and it is blocked by anti-FGF antibodies, with a greater benefit regarding antiangiogenesis when combined treatment with anti-VEGF is performed. Tumour necrosis factor alpha is expressed in the retina and the choroid, and its blockade in choroidal neovascularisation includes the use of monoclonals such as infliximab. This paper reviews the most important cytokines involved in the pathogenesis of wet-AMD, with emphasis on potential combined therapies for disease control.
C1 [de Oliveira Dias, Joao Rafael; Rodrigues, Eduardo Buechele; Maia, Mauricio; Magalhaes, Octaviano, Jr.; Penha, Fernando Marcondes; Farah, Michel Eid] Univ Fed Sao Paulo, Dept Ophthalmol, Vis Inst IPEPO, Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Dias, JRD (通讯作者)，Rua Napoleao de Barros 1098,Ap 74, BR-04024003 Sao Paulo, Brazil.
EM dias_joaor@yahoo.com.br
RI Maia, Mauricio/I-5892-2015; Rodrigues, Eduardo Büchele/C-6852-2015;
   Penha, Fernando M/G-1784-2012; de Oliveira Dias, João/J-6735-2016;
   Farah, Michel Eid E/F-3285-2012; Maia, Mauricio/Z-1042-2019
OI Maia, Mauricio/0000-0002-7034-8091; Farah, Michel Eid
   E/0000-0001-5951-0193; Maia, Mauricio/0000-0002-7034-8091; Buchele
   Rodrigues, Eduardo/0000-0002-4224-0921
CR Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x
   Adamis AP, 2009, RETINA-J RET VIT DIS, V29, pS42, DOI 10.1097/IAE.0b013e3181ad2500
   Allavena P, 2008, IMMUNOL REV, V222, P155, DOI 10.1111/j.1600-065X.2008.00607.x
   Amaral J, 2010, INVEST OPHTH VIS SCI, V51, P1318, DOI 10.1167/iovs.09-4455
   Apte RS, 2004, INVEST OPHTH VIS SCI, V45, P4491, DOI 10.1167/iovs.04-0172
   Ashok D, 2005, RHEUMATOLOGY, V44, P950, DOI 10.1093/rheumatology/keh635
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X
   Baughman RR, 2005, INT J CLIN PHARM TH, V43, P7
   Benitez-del-Castillo JM, 2005, EYE, V19, P841, DOI 10.1038/sj.eye.6701689
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039
   BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CAMPOCHIARO PA, 1985, ARCH OPHTHALMOL-CHIC, V103, P576
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Cazabon S, 2005, EYE, V19, P222, DOI 10.1038/sj.eye.6701457
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Choudhury P, 1997, INVEST OPHTH VIS SCI, V38, P824
   CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Díaz-Valle D, 2004, Arch Soc Esp Oftalmol, V79, P405
   Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Do DV Investigators C-I, 2009, INVEST OPHTHALMOL VI, V50
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Feucht N, 2008, CLIN OPHTHALMOL, V2, P253
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   GABRIELIAN K, 1994, INVEST OPHTH VIS SCI, V35, P4253
   Garcia M, 2003, HISTOL HISTOPATHOL, V18, P1205, DOI 10.14670/HH-18.1205
   Gerritsen ME, 2005, CIRC RES, V96, P272, DOI 10.1161/01.RES.0000157575.66295.e0
   Giganti M, 2010, SAFETY TOLERABILITY
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Gupta K, 2005, POSTGRAD MED J, V81, P236, DOI 10.1136/pgmj.2004.023309
   Hawthorne T, 2008, INT J CLIN PHARM TH, V46, P236
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hollborn M, 2004, GRAEF ARCH CLIN EXP, V242, P414, DOI 10.1007/s00417-004-0879-x
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   Hu WZ, 2009, EXP EYE RES, V88, P79, DOI 10.1016/j.exer.2008.10.014
   Hull J, 2001, AM J HUM GENET, V69, P413, DOI 10.1086/321291
   Im E, 2006, EMBO J, V25, P2075, DOI 10.1038/sj.emboj.7601100
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Karakousis PC, 2001, MOL VIS, V7, P154
   Kim K, 2007, BIOCHEM BIOPH RES CO, V354, P115, DOI 10.1016/j.bbrc.2006.12.164
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kobayashi S, 2005, BIOL PHARM BULL, V28, P242, DOI 10.1248/bpb.28.242
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579
   Li X, 2008, ARTERIOSCL THROM VAS, V28, P1614, DOI 10.1161/ATVBAHA.107.158725
   Majka S, 2002, INVEST OPHTH VIS SCI, V43, P260
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Martin TA, 2001, CLIN CANCER RES, V7, P734
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1
   Nakamura Y, 1996, J HYPERTENS, V14, P1067, DOI 10.1097/00004872-199609000-00004
   Nishimura M, 1999, J CLIN ENDOCR METAB, V84, P659, DOI 10.1210/jc.84.2.659
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regatieri CV, 2009, INVEST OPHTH VIS SCI, V50, P5487, DOI 10.1167/iovs.08-3171
   Reiff A, 2001, ARTHRITIS RHEUM, V44, P1411, DOI 10.1002/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenthal R, 2005, BIOCHEM BIOPH RES CO, V337, P241, DOI 10.1016/j.bbrc.2005.09.028
   RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schmid MC, 2008, METHOD ENZYMOL, V445, P343, DOI 10.1016/S0076-6879(08)03015-2
   Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Smith JR, 2001, ARTHRIT RHEUM-ARTHR, V45, P252, DOI 10.1002/1529-0131(200106)45:3<252::AID-ART257>3.3.CO;2-X
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Stahl A, 2009, GRAEF ARCH CLIN EXP, V247, P767, DOI 10.1007/s00417-009-1058-x
   STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11
   Stock P, 2007, MOL CANCER THER, V6, P1932, DOI 10.1158/1535-7163.MCT-06-0720
   Suto K, 2005, J BIOL CHEM, V280, P2126, DOI 10.1074/jbc.M411395200
   Symons A, 2010, RETINAL PHARMACOTHER, P364
   Takahashi H, 2008, CURR EYE RES, V33, P1002, DOI 10.1080/02713680802492440
   Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5
   Taub D D, 1994, Ther Immunol, V1, P229
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tombran-Tink J, 2003, TRENDS MOL MED, V9, P244, DOI 10.1016/S1471-4914(03)00074-1
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yamazaki Y, 2005, BIOCHEMISTRY-US, V44, P8858, DOI 10.1021/bi050197d
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou HH, 2005, J CLIN PHARMACOL, V45, P490, DOI 10.1177/0091270004273321
   Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231
NR 119
TC 77
Z9 78
U1 1
U2 16
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2011
VL 95
IS 12
BP 1631
EP 1637
DI 10.1136/bjo.2010.186361
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 851IM
UT WOS:000297261700004
PM 21546514
DA 2022-11-30
ER

PT J
AU More, P
   Almuhtaseb, H
   Smith, D
   Fraser, S
   Lotery, AJ
AF More, Pradnya
   Almuhtaseb, Hussein
   Smith, Dianna
   Fraser, Simon
   Lotery, Andrew J.
TI Socio-economic status and outcomes for patients with age-related macular
   degeneration
SO EYE
LA English
DT Article
ID HEALTH LITERACY; VISUAL-ACUITY; FOLLOW-UP; DEPRIVATION; PREVALENCE;
   THERAPY; BURDEN; RANIBIZUMAB; SERVICE; RISK
AB Objectives To explore disparities in severity of baseline disease, treatment completion, and treatment outcomes among patients with wet age-related macular degeneration (AMD) receiving anti-vascular endothelial growth factor therapy by socio-economic status (SES) and distance from home to hospital.
   Study design Retrospective cohort study.
   Methods Data from clinic records of 756 wet AMD patients receiving treatment for wet AMD with aflibercept between May 2013 and Jan 2017 were obtained. Area SES (using Index of Multiple Deprivation (IMD) 2015) and distance from hospital (dichotomized > = 10 vs. <10 km) were derived from anonymized postcodes. Univariate and multivariable logistic regression models were used to identify associations of area deprivation and distance from hospital at baseline-with visual acuity (VA) at baseline-treatment completion, and treatment outcome.
   Results Living in the most deprived compared with less deprived areas was associated with a significantly higher risk of presenting with severe reduction in VA (OR = 3.59; 95% CI = 1.39-9.27; P = .01). This association was maintained after adjustment for age, gender, and distance from hospital. On univariate analysis, delayed treatment completion was more likely in those living in most deprived areas (OR = 2.80; 95% CI = 1.21-6.47; P = .04), though this association was attenuated after adjustment for age, gender, and distance from hospital. No association was observed between SES and treatment outcomes or between distance from hospital and baseline VA, treatment completion or treatment outcome.
   Conclusion This study found poorer baseline VA among people with wet AMD from more deprived areas. This work suggests a need for earlier identification of AMD among more deprived populations.
C1 [More, Pradnya; Lotery, Andrew J.] Univ Southampton, Fac Med, Southampton, Hants, England.
   [Almuhtaseb, Hussein] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England.
   [Smith, Dianna] Univ Southampton, Dept Geog, Southampton, Hants, England.
   [Fraser, Simon] Univ Southampton, Southampton Gen Hosp, Acad Unit Primary Care & Populat Sci, Fac Med, Southampton, Hants, England.
C3 University of Southampton; University of Southampton; University
   Hospital Southampton NHS Foundation Trust; University of Southampton;
   University of Southampton
RP Lotery, AJ (通讯作者)，Univ Southampton, Fac Med, Southampton, Hants, England.
EM A.J.LOTERY@SOTON.AC.UK
RI Fraser, Simon DS/HCH-3208-2022
OI Lotery, Andrew/0000-0001-5541-4305; Fraser, Simon D/0000-0002-4172-4406;
   Smith, Dianna/0000-0002-0650-6606
CR Access Economics, 2009, FUT COST SIGHT LOSS
   Acharya N, 2009, BRIT J OPHTHALMOL, V93, P627, DOI 10.1136/bjo.2008.147231
   Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   Ashton JR, 2009, SIGHT LOSS PUBLIC HL
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bachmann MO, 2003, DIABETIC MED, V20, P921, DOI 10.1046/j.1464-5491.2003.01050.x
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1312, DOI 10.1136/bjo.2007.136077
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew H, 2005, CAN J OPHTHALMOL, V40, P384, DOI 10.1016/S0008-4182(05)80081-X
   Chua PY, 2013, EUR J OPHTHALMOL, V23, P831, DOI 10.5301/ejo.5000302
   Cross V, 2007, EYE, V21, P912, DOI 10.1038/sj.eye.6702461
   Dandona L, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-7
   Hamano T, 2015, OPHTHAL EPIDEMIOL, V22, P308, DOI 10.3109/09286586.2015.1056537
   Hiscock R, 2012, ANN NY ACAD SCI, V1248, P107, DOI 10.1111/j.1749-6632.2011.06202.x
   Hykin P, 2016, CLIN OPHTHALMOL, V10, P87, DOI 10.2147/OPTH.S92627
   Kelly C, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013059
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   Latalska M, 2013, ANN AGR ENV MED, V20, P726
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Macular Society, 2016, AG REL MAC DEG COLL
   McManus S., 2012, CIRCUMSTANCES PEOPLE
   Ng WS, 2010, BRIT J OPHTHALMOL, V94, P85, DOI 10.1136/bjo.2008.153312
   NICE, 2018, AFL SOL INJ TREAT WE
   Nicklett EJ, 2011, J NUTR, V141, P284, DOI 10.3945/jn.110.129684
   O'Connor PM, 2008, CLIN EXP OPHTHALMOL, V36, P547, DOI 10.1111/j.1442-9071.2008.01830.x
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Protheroe J, 2017, HEALTH EXPECT, V20, P112, DOI 10.1111/hex.12440
   Protheroe J, 2009, BRIT J GEN PRACT, V59, P721, DOI 10.3399/bjgp09X472584
   Royal National Institute of Blind People, 2018, CRIT CERT
   Scuffham P.A., 2002, VISUAL IMPAIRMENT RE, V4, P1, DOI [10. 1076/vimr. 4. 1. 1. 15635, DOI 10.1076/VIMR.4.1.1.15635, 10.1076/vimr.4.1.1.15635]
   Sharma HE, 2014, BRIT J OPHTHALMOL, V98, P1625, DOI 10.1136/bjophthalmol-2014-304959
   Sloan FA, 2014, OPHTHALMOLOGY, V121, P2452, DOI 10.1016/j.ophtha.2014.07.020
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yip JLY, 2015, PUBLIC HEALTH, V129, P103, DOI 10.1016/j.puhe.2014.10.012
NR 39
TC 7
Z9 7
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2019
VL 33
IS 8
BP 1224
EP 1231
DI 10.1038/s41433-019-0393-3
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IP8ZQ
UT WOS:000480336800007
PM 30858565
OA Green Published, Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Ozdemir, H
   Karacorlu, M
   Senturk, F
   Karacorlu, SA
   Uysal, O
AF Ozdemir, Hakan
   Karacorlu, Murat
   Senturk, Fevzi
   Karacorlu, Serra Arf
   Uysal, Omer
TI Microperimetric changes after intravitreal bevacizumab injection for
   exudative age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE exudative age-related macular degeneration; intravitreal bevacizumab;
   microperimetry; retinal sensitivity
ID OCCULT CHOROIDAL NEOVASCULARIZATION; AVASTIN THERAPY; VISUAL FUNCTION
AB Purpose: To evaluate the effect of intravitreal bevacizumab on macular function in the cases of exudative age-related macular degeneration (AMD).
   Methods: A total of 21 eyes of 21 patients with exudative AMD were included in this study. In each eye, at baseline and 1, 3 and 6 months after intravitreal bevacizumab injection, logMAR visual acuity, central 4 degrees macular sensitivity, absolute scotoma size, fixation stability and fixation location by MP-1 microperimetry and optical coherence tomography (OCT) foveal morphologic changes were assessed. After the initial treatment phase which included three consecutive injections, the decision to re-treat was based on OCT and clinical findings. Subsequent injections could be administered at least 1 month after the previous injection period according to the OCT-guided treatment regimen.
   Results: Mean retinal sensitivity within central 4 degrees (12 points) area had increased from 3.69 +/- 3.44 dB at baseline to 7.16 +/- 3.27 dB at month 6. In all controls after the treatment, there was significant increase in logMAR visual acuity (p < 0.001) and MP-1 retinal sensitivity (p < 0.001). Mean absolute scotoma in test point location had decreased significantly from 12 of the 76 applied test point locations measured at baseline to five test point locations () 7 test point locations; p < 0.001) at month 6 showing statistical significance. Fixation properties had preserved in all patients 6 months after intravitreal bevacizumab treatment.
   Conclusion: Intravitreal bevacizumab therapy induced a significant increase in mean retinal sensitivity and significant decrease in mean absolute scotoma size during 6 months. The MP1 microperimetry proved to be a valuable tool in the evaluation of functional benefit of exudative AMD therapy with intravitreal bevacizumab.
C1 [Ozdemir, Hakan; Karacorlu, Murat; Senturk, Fevzi; Karacorlu, Serra Arf] Istanbul Retina Inst, TR-34349 Istanbul, Turkey.
   [Uysal, Omer] Istanbul Univ, Dept Biostat, Cerrahpasa Med Sch, Istanbul, Turkey.
C3 Istanbul Retina Enstitusu; Istanbul University; Istanbul University -
   Cerrahpasa
RP Karacorlu, M (通讯作者)，Istanbul Retina Inst, Hakki Yeten Cad,19-7 Sisli, TR-34349 Istanbul, Turkey.
EM retina@pobox.com
RI Karaçorlu, Murat/AAF-7763-2022; Karaçorlu, Murat/AFK-0782-2022; Uysal,
   Ömer/AAR-4220-2020
OI Uysal, Ömer/0000-0002-8833-697X
CR Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Pedersen KB, 2009, ACTA OPHTHALMOL, V87, P714, DOI 10.1111/j.1755-3768.2008.01346.x
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Schneider U, 1996, GRAEF ARCH CLIN EXP, V234, P612, DOI 10.1007/BF00185293
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   Varano M, 1998, Semin Ophthalmol, V13, P203, DOI 10.3109/08820539809056054
NR 21
TC 22
Z9 23
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2012
VL 90
IS 1
BP 71
EP 75
DI 10.1111/j.1755-3768.2009.01838.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 883HK
UT WOS:000299624600034
PM 20163371
OA Bronze
DA 2022-11-30
ER

PT J
AU Spaide, RF
AF Spaide, Richard F.
TI DISEASE EXPRESSION IN NONEXUDATIVE AGE-RELATED MACULAR DEGENERATION
   VARIES WITH CHOROIDAL THICKNESS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; drusen; optical coherence tomography;
   pachydrusen; pachychoroid; pseudodrusen; subretinal drusenoid deposits
ID CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY;
   SUBRETINAL DRUSENOID DEPOSITS; PACHYCHOROID PIGMENT EPITHELIOPATHY;
   RETICULAR PSEUDODRUSEN; REFRACTIVE ERROR; AXIAL LENGTH; PREVALENCE;
   NEOVASCULARIZATION; EYES
AB Purpose: To investigate the relationship between subfoveal choroidal thickness and disease manifestation in a series of eyes with nonexudative age-related macular degeneration (AMD).
   Methods: Retrospective study of eyes with nonexudative AMD. The extracellular deposits present, drusen and subretinal drusenoid deposits (SDD, pseudodrusen) along with a newly recognized form of drusen, pachydrusen, were graded and compared with choroidal thickness as determined by optical coherence tomography. Demographic and imaging information was evaluated with descriptive statistics and generalized estimating equations.
   Results: There were 94 eyes of 71 patients, who had a mean age of 78.1 years. Soft drusen alone were found in 45 eyes (47.9%) and subretinal drusenoid deposit with or without drusen in 38 (40.4%). Pachydrusen, which were typically larger than 125 1.1,m, often had an irregular outer contour, showed a scattered distribution over the posterior pole and occurred in isolation or in groups of only a few drusen were found in 11 (11.7%). The mean subfoveal choroidal thickness in the soft drusen group was 227.9 mu m, in the subretinal drusenoid deposit group 167.3 mu m, and in the pachydrusen group 419 mu m. The differences between the groups were highly significant.
   Conclusion: Extracellular deposits, subretinal drusenoid deposits and drusen, which are on either side of the retinal pigment epithelium, respectively, are common in nonexudative AMD. A new form of drusen presentation could be differentiated from typical soft drusen and was associated with thicker choroids. Disease manifestation in nonexudative AMD seems to be associated with choroidal thickness. Each of these has potential to lead to specific forms of late AMD.
C1 [Spaide, Richard F.] Macula Consultants New York, Retina, Vitreous, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
   [Spaide, Richard F.] LuEster T Mertz Retina Res Lab, New York, NY USA.
C3 Vitreous Retina Macula Consultants of New York
RP Spaide, RF (通讯作者)，Macula Consultants New York, Retina, Vitreous, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rickspaide@gmail.com
RI Spaide, Richard/ABD-7368-2020
FU Macula Foundation, New York, NY; Topcon Medical Systems; Heidelberg
   Engineering
FX Supported in part by the Macula Foundation, New York, NY.; The author
   has received consulting and royalty fees from Topcon Medical Systems,
   royalties from DORC, and consulting fees from Heidelberg Engineering.
CR Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   Azar G, 2017, ACTA OPHTHALMOL, V95, P421, DOI 10.1111/aos.13221
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Chung H, 2016, RETINA
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kim M, 2014, OPTOMETRY VISION SCI, V91, P491, DOI 10.1097/OPX.0000000000000229
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, INVEST OPHTH VIS SCI, V55, P5252, DOI 10.1167/iovs.14-14959
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Sardell RJ, 2016, OPHTHALMOLOGY, V123, P2537, DOI 10.1016/j.ophtha.2016.09.001
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Tuncer I, 2015, INT OPHTHALMOL, V35, P403, DOI 10.1007/s10792-014-9962-4
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 45
TC 96
Z9 97
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2018
VL 38
IS 4
BP 708
EP 716
DI 10.1097/IAE.0000000000001689
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2BD
UT WOS:000440623400015
PM 28505013
DA 2022-11-30
ER

PT J
AU Minnella, AM
   Federici, M
   Falsini, B
   Barbano, L
   Gambini, G
   Lanza, A
   Caporossi, A
   Savastano, MC
AF Minnella, Angelo Maria
   Federici, Matteo
   Falsini, Benedetto
   Barbano, Lucilla
   Gambini, Gloria
   Lanza, Angela
   Caporossi, Aldo
   Savastano, Maria Cristina
TI Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative
   Age-Related Macular Degeneration
SO BIODRUGS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; THERAPY; PHARMACOKINETICS; FRAGMENT
AB Background The results regarding changes of choroidal thickness following intravitreal ranibizumab injections in the literature are controversial. Vascular endothelial growth factor A is implicated in pathogenesis of neovascular age-related macular degeneration (AMD). The suspected unchanged choroidal layer thickness after intravitreal injections of ranibizumab suggests a possible protection of the outer blood-retinal barrier in the human eye.
   Objective The aim was to evaluate choroidal thickness following the first administration of the study drug ranibizumab into the eyes of naive wet AMD patients (nAMD).
   Methods In this open label, 3-month, prospective, single-center, interventional, single-arm pilot study, 20 nAMD eyes were included and underwent three consecutive monthly injections of ranibizumab (0.5 mg/0.05 ml). Vital signs (i.e., blood pressure and pulse), ophthalmic examinations, intraocular pressure, best correct visual acuity and subfoveal choroidal thickness as examined with optical coherence tomography using enhanced depth imaging (OCT-EDI) were assessed at each visit. All patients were evaluated at baseline and at 15, 30 60 and 90 days after intravitreal injection. Ten eyes with fibrotic AMD lesions were evaluated as the control group.
   Results In all eyes, the choroidal thicknesses (mu m) exhibited no significant changes from the baseline visit to the visits at 15, 30, 60 and 90 days post-injection (P > 0.05). The intravitreal treatment with ranibizumab was well tolerated, and no adverse events were registered.
   Conclusion Choroidal thickness appeared to be unmodified following the intravitreal injection of ranibizumab into nAMD eyes. Intravitreal ranibizumab injections probably elicit a pharmacologic effect only in the choroidal neovascularization and not in the choroid circulation under neovascular lesions.
C1 [Minnella, Angelo Maria; Federici, Matteo; Falsini, Benedetto; Barbano, Lucilla; Gambini, Gloria; Lanza, Angela; Caporossi, Aldo; Savastano, Maria Cristina] Univ Cattolica Sacro Cuore, A Gemelli Fdn, I-00168 Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Minnella, AM (通讯作者)，Univ Cattolica Sacro Cuore, A Gemelli Fdn, I-00168 Rome, Italy.
EM aminnella59@gmail.com
RI Gambini, Gloria/AAE-9479-2021; Falsini, Benedetto/AAC-5907-2022;
   Barbano, Lucilla/Y-6291-2019; Barbano, Lucilla/AAL-6652-2020; Savastano,
   Maria Cristina/I-5355-2015; minnella, angelo maria/AAQ-6250-2020;
   Falsini, Benedetto/V-1070-2019
OI Barbano, Lucilla/0000-0001-5120-8635; Savastano, Maria
   Cristina/0000-0003-1397-4333; minnella, angelo
   maria/0000-0001-5896-5313; Falsini, Benedetto/0000-0002-1694-1062;
   Falsini, Benedetto/0000-0002-3569-4968
FU Novartis
FX No sources of funding were used to assist in the preparation of this
   manuscript. Drug and partial financial support for the study were
   provided by Novartis.
CR Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2012, EUR J OPHTHALMOL, V22, P992, DOI 10.5301/ejo.5000189
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kim JH, 2013, EYE, V27, P809, DOI 10.1038/eye.2013.78
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Walsh MP, 2006, J PHYSIOL-LONDON, V575, P263, DOI 10.1113/jphysiol.2006.108753
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yun C, 2016, GRAEFES ARCH CLIN EX
NR 20
TC 8
Z9 8
U1 0
U2 3
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-8804
EI 1179-190X
J9 BIODRUGS
JI Biodrugs
PD AUG
PY 2016
VL 30
IS 4
BP 353
EP 359
DI 10.1007/s40259-016-0179-0
PG 7
WC Oncology; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology; Pharmacology & Pharmacy
GA DT1EP
UT WOS:000381224800008
PM 27189458
DA 2022-11-30
ER

PT J
AU Mookiah, MRK
   Acharya, UR
   Koh, JEW
   Chua, CK
   Tan, JH
   Chandran, V
   Lim, CM
   Noronha, K
   Laude, A
   Tong, L
AF Mookiah, Muthu Rama Krishnan
   Acharya, U. Rajendra
   Koh, Joel E. W.
   Chua, Chua Kuang
   Tan, Jen Hong
   Chandran, Vinod
   Lim, Choo Min
   Noronha, Kevin
   Laude, Augustinus
   Tong, Louis
TI Decision support system for age-related macular degeneration using
   discrete wavelet transform
SO MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING
LA English
DT Article
DE Age-related macular degeneration; Energy; Entropy; Gini index; Feature
   ranking; Classifier tuning; Computer-aided diagnosis
ID DIABETIC-RETINOPATHY; AUTOMATIC DETECTION; SEGMENTATION; DIAGNOSIS;
   FEATURES; DISEASE
AB Age-related macular degeneration (AMD) affects the central vision and subsequently may lead to visual loss in people over 60 years of age. There is no permanent cure for AMD, but early detection and successive treatment may improve the visual acuity. AMD is mainly classified into dry and wet type; however, dry AMD is more common in aging population. AMD is characterized by drusen, yellow pigmentation, and neovascularization. These lesions are examined through visual inspection of retinal fundus images by ophthalmologists. It is laborious, time-consuming, and resource-intensive. Hence, in this study, we have proposed an automated AMD detection system using discrete wavelet transform (DWT) and feature ranking strategies. The first four-order statistical moments (mean, variance, skewness, and kurtosis), energy, entropy, and Gini index-based features are extracted from DWT coefficients. We have used five (t test, Kullback-Lieber Divergence (KLD), Chernoff Bound and Bhattacharyya Distance, receiver operating characteristics curve-based, and Wilcoxon) feature ranking strategies to identify optimal feature set. A set of supervised classifiers namely support vector machine (SVM), decision tree, -nearest neighbor (-NN), Naive Bayes, and probabilistic neural network were used to evaluate the highest performance measure using minimum number of features in classifying normal and dry AMD classes. The proposed framework obtained an average accuracy of 93.70 %, sensitivity of 91.11 %, and specificity of 96.30 % using KLD ranking and SVM classifier. We have also formulated an AMD Risk Index using selected features to classify the normal and dry AMD classes using one number. The proposed system can be used to assist the clinicians and also for mass AMD screening programs.
C1 [Mookiah, Muthu Rama Krishnan; Acharya, U. Rajendra; Koh, Joel E. W.; Chua, Chua Kuang; Tan, Jen Hong; Lim, Choo Min] Ngee Ann Polytech, Dept Elect & Comp Engn, Clementi 599489, Singapore.
   [Acharya, U. Rajendra] Univ Malaya, Dept Biomed Engn, Fac Engn, Kuala Lumpur 50603, Malaysia.
   [Chandran, Vinod] Queensland Univ Technol, Sch Elect Engn & Comp Sci, Brisbane, Qld 4000, Australia.
   [Noronha, Kevin] St Francis Inst Technol, Dept Elect & TeleCommun, Mumbai 400103, Maharashtra, India.
   [Laude, Augustinus] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Novena 308433, Singapore.
   [Tong, Louis] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Tong, Louis] Singapore Eye Res Inst, Ocular Surface Res Grp, Singapore 168751, Singapore.
   [Tong, Louis] Duke NUS Grad Med Sch, Singapore 169857, Singapore.
   [Tong, Louis] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117597, Singapore.
C3 Universiti Malaya; Queensland University of Technology (QUT); Tan Tock
   Seng Hospital; Singapore National Eye Center; National University of
   Singapore; Singapore National Eye Center; National University of
   Singapore; National University of Singapore
RP Mookiah, MRK (通讯作者)，Ngee Ann Polytech, Dept Elect & Comp Engn, Clementi 599489, Singapore.
EM mkm2@np.edu.sg; aru@np.edu.sg; kje2@np.edu.sg; ckc@np.edu.sg;
   tjh6@np.edu.sg; v.chandran@qut.edu.au; lcm@np.edu.sg;
   kevinkurkal@yahoo.co.in; draugustinuslaude@yahoo.com.sg;
   louis.tong.h.t@snec.com.sg
RI Mookiah, Muthu Rama Krishnan/G-4033-2011; NORONHA, KEVIN/AAV-1433-2020;
   Chandran, Vinod/N-3053-2019; Tan, Jenhong/AAD-3664-2020; Acharya,
   Rajendra U/E-3791-2010; Tan, Jen Hong/ABE-6525-2020
OI Mookiah, Muthu Rama Krishnan/0000-0001-6437-1482; NORONHA,
   KEVIN/0000-0002-8753-5918; Chandran, Vinod/0000-0003-3185-0852; Acharya,
   Rajendra U/0000-0003-2689-8552; Tong, Louis/0000-0002-3986-6552
FU Social Innovation Research Fund (SIRF), Singapore [T1202]; National
   medical research council [NMRC/CSA/045/2012]
FX Authors thank Social Innovation Research Fund (SIRF/Project Code:
   T1202), Singapore, for providing grant for this research. Also, authors
   would like to thank National medical research council
   (NMRC/CSA/045/2012).
CR Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Albregtsen F, 1995, STAT TEXTURE MEASURE
   Barriga E, 2009, IEEE INT S COMP BAS, P1
   Ben Sbeh Z, 2001, IEEE T MED IMAGING, V20, P1321, DOI 10.1109/42.974927
   Bossu J, 2009, COMPUT ELECTRON AGR, V65, P133, DOI 10.1016/j.compag.2008.08.004
   Brandon Lee, 2003, THESIS CLEMSON U
   Bressan M, 2003, IEEE T PATTERN ANAL, V25, P1312, DOI 10.1109/TPAMI.2003.1233904
   Cheng J, 2012, IEEE IMAGE PROC, P2805, DOI 10.1109/ICIP.2012.6467482
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dua S, 2012, IEEE T INF TECHNOL B, V16, P80, DOI 10.1109/TITB.2011.2176540
   Duda R.O., 2000, PATTERN CLASSIFICATI, DOI https://doi.org/10.1007/978-3-319-57027-3_4
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Freund DE, 2009, I S BIOMED IMAGING, P61, DOI 10.1109/ISBI.2009.5192983
   Giannakakis GA, 2008, IEEE INT C BIOINF BI, P1098
   HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314
   Hijazi MHA, 2010, P INT JOINT C NEUR N, P3501
   Hijazi MHA, 2012, KNOWL-BASED SYST, V29, P83, DOI 10.1016/j.knosys.2011.07.002
   Hurley N, 2009, IEEE T INFORM THEORY, V55, P4723, DOI 10.1109/TIT.2009.2027527
   Khadra L, 1997, MED BIOL ENG COMPUT, V35, P626, DOI 10.1007/BF02510970
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kohavi R, 1997, ARTIF INTELL, V97, P273, DOI 10.1016/S0004-3702(97)00043-X
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Liang ZY, 2010, IEEE ENG MED BIO, P4100, DOI 10.1109/IEMBS.2010.5627289
   Ma WY, 1996, PROC CVPR IEEE, P425, DOI 10.1109/CVPR.1996.517107
   Mallat S., 1999, WAVELET TOUR SIGNAL, DOI [10.1016/B978-012466606-1/50008-8, 10.1016/B978-0-12-466606-1.X5000-4]
   Mohan GA, 1973, OUTLINE STAT THEORY
   Mookiah MRK, 2013, KNOWL-BASED SYST, V39, P9, DOI 10.1016/j.knosys.2012.09.008
   Mookiah MRK, 2013, COMPUT BIOL MED, V43, P2136, DOI 10.1016/j.compbiomed.2013.10.007
   Mookiah MRK, 2012, KNOWL-BASED SYST, V33, P73, DOI 10.1016/j.knosys.2012.02.010
   Murray V, 2008, CONF REC ASILOMAR C, P664, DOI 10.1109/ACSSC.2008.5074490
   Pharwaha A.P.S., 2009, P WORLD C ENG COMP S, V2, P20
   Pisano ED, 1998, J DIGIT IMAGING, V11, P193, DOI 10.1007/BF03178082
   Puri M, 2005, MED BIOL ENG COMPUT, V43, P756, DOI 10.1007/BF02430954
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Rosso OA, 2004, MED BIOL ENG COMPUT, V42, P516, DOI 10.1007/BF02350993
   SAFAVIAN SR, 1991, IEEE T SYST MAN CYB, V21, P660, DOI 10.1109/21.97458
   Santos-Villalobos H, 2011, IEEE ENG MED BIO, P6236, DOI 10.1109/IEMBS.2011.6091540
   Shawe-Taylor J., 2000, INTRO SUPPORT VECTOR, V204
   Singh K., 2008, BOOTSTRAP STAT METHO
   Soliz P, 2008, 2008 IEEE SOUTHWEST SYMPOSIUM ON IMAGE ANALYSIS & INTERPRETATION, P65, DOI 10.1109/SSIAI.2008.4512286
   SPECHT DF, 1990, NEURAL NETWORKS, V3, P109, DOI 10.1016/0893-6080(90)90049-Q
   Teng T, 2002, MED BIOL ENG COMPUT, V40, P2, DOI 10.1007/BF02347689
   Vapnik V., 1998, STAT LEARNING THEORY
   Yuanjie Z, 2013, IEEE 10 INT S BIOM I, P1440
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
NR 46
TC 35
Z9 36
U1 0
U2 15
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0140-0118
EI 1741-0444
J9 MED BIOL ENG COMPUT
JI Med. Biol. Eng. Comput.
PD SEP
PY 2014
VL 52
IS 9
BP 781
EP 796
DI 10.1007/s11517-014-1180-8
PG 16
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Mathematical & Computational Biology;
   Medical Informatics
GA AN6DJ
UT WOS:000340683800007
PM 25112273
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Wang, WS
   Li, XR
   Xu, ZY
   Yu, WH
   Zhao, JC
   Ding, DY
   Chen, YX
AF Wang, Weisen
   Li, Xirong
   Xu, Zhiyan
   Yu, Weihong
   Zhao, Jianchun
   Ding, Dayong
   Chen, Youxin
TI Learning Two-Stream CNN for Multi-Modal Age-Related Macular Degeneration
   Categorization
SO IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS
LA English
DT Article
DE Training; Feature extraction; Retina; Image synthesis; Convolutional
   neural networks; Image color analysis; Diseases; Multi-modal AMD
   categorization; multi- modal fundus imaging; two-stream CNN; data
   augmen- tation; loose pairing training; image synthesis
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; AMD
AB This paper tackles automated categorization of Age-related Macular Degeneration (AMD), a common macular disease among people over 50. Previous research efforts mainly focus on AMD categorization with a single-modal input, let it be a color fundus photograph (CFP) or an OCT B-scan image. By contrast, we consider AMD categorization given a multi-modal input, a direction that is clinically meaningful yet mostly unexplored. Contrary to the prior art that takes a traditional approach of feature extraction plus classifier training that cannot be jointly optimized, we opt for end-to-end multi-modal Convolutional Neural Networks (MM-CNN). Our MM-CNN is instantiated by a two-stream CNN, with spatially-invariant fusion to combine information from the CFP and OCT streams. In order to visually interpret the contribution of the individual modalities to the final prediction, we extend the class activation mapping (CAM) technique to the multi-modal scenario. For effective training of MM-CNN, we develop two data augmentation methods. One is GAN-based CFP/OCT image synthesis, with our novel use of CAMs as conditional input of a high-resolution image-to-image translation GAN. The other method is Loose Pairing, which pairs a CFP image and an OCT image on the basis of their classes instead of eye identities. Experiments on a clinical dataset consisting of 1,094 CFP images and 1,289 OCT images acquired from 1,093 distinct eyes show that the proposed solution obtains better F1 and Accuracy than multiple baselines for multi-modal AMD categorization. Code and data are available at https://github.com/li-xirong/mmc-amd.
C1 [Wang, Weisen; Li, Xirong] Renmin Univ China, MoE Key Lab Data Engn & Knowledge Engn, Beijing 100872, Peoples R China.
   [Wang, Weisen; Li, Xirong] Renmin Univ China, Sch Informat, AIMC Lab, Beijing 100872, Peoples R China.
   [Xu, Zhiyan; Yu, Weihong; Chen, Youxin] Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China.
   [Xu, Zhiyan; Yu, Weihong; Chen, Youxin] Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Zhao, Jianchun; Ding, Dayong] Visionary Intelligence Ltd, Vistel AI Lab, Beijing 100872, Peoples R China.
C3 Renmin University of China; Renmin University of China; Chinese Academy
   of Medical Sciences - Peking Union Medical College; Chinese Academy of
   Medical Sciences - Peking Union Medical College; Peking Union Medical
   College Hospital
RP Li, XR (通讯作者)，Renmin Univ China, MoE Key Lab Data Engn & Knowledge Engn, Beijing 100872, Peoples R China.; Li, XR (通讯作者)，Renmin Univ China, Sch Informat, AIMC Lab, Beijing 100872, Peoples R China.
EM musan1212@qq.com; xirong@ruc.edu.cn; xuzythu@163.com; 536273640@qq.com;
   jianchun.zhao@vistel.cn; dayong.ding@vistel.cn; chenyouxinpumch@163.com
RI Li, Xirong/AAD-3347-2019
OI Li, Xirong/0000-0002-0220-8310
FU NSFC [62172420, 61672523]; BJNSF [4202033]; BJNSF-Haidian Original
   Innovation Joint Fund [19L2062]; Non-Profit Central Research Institute
   Fund of Chinese Academy of Medical Sciences [2018PT32029]; CAMS
   Initiative for Innovative Medicine [CAMS-I2M, 2018-I2M-AI-001];
   Pharmaceutical Collaborative Innovation Research Project of Beijing
   Science and Technology Commission [Z191100007719002]
FX This work was supported in part by NSFC under Grants 62172420 and
   61672523, in part by BJNSF under Grant 4202033, in part by BJNSF-Haidian
   Original Innovation Joint Fund under Grant 19L2062, in part by the
   Non-Profit Central Research Institute Fund of Chinese Academy of Medical
   Sciences under Grant 2018PT32029, in part by the CAMS Initiative for
   Innovative Medicine under Grants CAMS-I2M and 2018-I2M-AI-001, and in
   part by the Pharmaceutical Collaborative Innovation Research Project of
   Beijing Science and Technology Commission under Grant Z191100007719002.
CR Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2019, JAMA OPHTHALMOL, V137, P258, DOI 10.1001/jamaophthalmol.2018.6156
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Deng J., 2009, P IEEE COMP SOC C CO, P248, DOI DOI 10.1109/CVPR.2009.5206848
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Feichtenhofer C, 2016, PROC CVPR IEEE, P1933, DOI 10.1109/CVPR.2016.213
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Isola P, 2017, PROC CVPR IEEE, P5967, DOI 10.1109/CVPR.2017.632
   Jintasuttisak T, 2014, INT C CONTR AUTOMAT, P692, DOI 10.1109/ICCAS.2014.6987868
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Karras T., 2018, INT C LEARNING REPRE
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Krizhevsky Alex, 2017, Communications of the ACM, V60, P84, DOI 10.1145/3065386
   Lai X, 2019, LECT NOTES COMPUT SC, V11295, P507, DOI 10.1007/978-3-030-05710-7_42
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Paszke A, 2019, ADV NEUR IN, V32
   Radford A., 2015, ARXIV PREPRINT ARXIV
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Shin HC, 2018, LECT NOTES COMPUT SC, V11037, P1, DOI 10.1007/978-3-030-00536-8_1
   Simonyan K., 2015, 3 INT C LEARN REPR I
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   van der Maaten L, 2008, J MACH LEARN RES, V9, P2579
   Wang TC, 2018, PROC CVPR IEEE, P8798, DOI 10.1109/CVPR.2018.00917
   Wang WS, 2019, LECT NOTES COMPUT SC, V11764, P156, DOI 10.1007/978-3-030-32239-7_18
   Wei Q., 2018, PROC ASIAN C COMPUT, P191
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xing Y., 2019, PROC INT C MED IMAGE
   Yang ZY, 2019, LECT NOTES COMPUT SC, V11861, P453, DOI 10.1007/978-3-030-32692-0_52
   Yi X, 2019, MED IMAGE ANAL, V58, DOI 10.1016/j.media.2019.101552
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
   Yu J, 2020, IEEE T CIRC SYST VID, V30, P4467, DOI 10.1109/TCSVT.2019.2947482
   Zheng R, 2018, BIOMED OPT EXPRESS, V9, P4863, DOI 10.1364/BOE.9.004863
   Zhou B, 2016, PROC CVPR IEEE, P2921, DOI 10.1109/CVPR.2016.319
   Zhou Y, 2019, LECT NOTES COMPUT SC, V11764, P505, DOI 10.1007/978-3-030-32239-7_56
NR 41
TC 0
Z9 0
U1 7
U2 7
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2168-2194
EI 2168-2208
J9 IEEE J BIOMED HEALTH
JI IEEE J. Biomed. Health Inform.
PD AUG
PY 2022
VL 26
IS 8
BP 4111
EP 4122
DI 10.1109/JBHI.2022.3171523
PG 12
WC Computer Science, Information Systems; Computer Science,
   Interdisciplinary Applications; Mathematical & Computational Biology;
   Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Mathematical & Computational Biology; Medical
   Informatics
GA 3V7PB
UT WOS:000841851000050
PM 35503853
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Montgomery, MP
   Postel, E
   Umbach, DM
   Richards, M
   Watson, M
   Blair, A
   Chen, HL
   Sandler, DP
   Schmidt, S
   Kamel, F
AF Montgomery, Martha P.
   Postel, Eric
   Umbach, David M.
   Richards, Marie
   Watson, Mary
   Blair, Aaron
   Chen, Honglei
   Sandler, Dale P.
   Schmidt, Silke
   Kamel, Freya
TI Pesticide Use and Age-Related Macular Degeneration in the Agricultural
   Health Study
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
ID RETINAL DEGENERATION; OXIDATIVE STRESS; COMPLEMENT-SYSTEM; MOUSE RETINA;
   RISK-FACTORS; IN-VIVO; SMOKING; SERUM; ASSOCIATION; EXPOSURE
AB BACKGROUND: Age-related macular degeneration (AMD) is a leading cause of blindness in developed countries. Few studies have investigated its relationship to environmental ncurotoxicants. In previous cross-sectional studies, we found an association between pesticide use and self-reported retinal degeneration.
   OBJECTIVE: We evaluated the association of pesticide use with physician-confirmed incident AWL.
   METHODS: The Agricultural Health Study (AHS) is a prospective cohort of pesticide applicators and their spouses enrolled from 1993-1997 in Iowa and North Carolina. Cohort members reported lifetime use of 50 specific pesticides at enrollment. Self-reports of incident AMD during follow-up through 2007 were confirmed by reports from participants' physicians and by independent evaluation of retinal photographs provided by the physicians. Confirmed cases (n = 161) were compared with AHS cohort members without AMD in = 39,108). We estimated odds ratios (ORS) and 95% confidence intervals (Cis) by logistic regression with adjustment for age, gender, and smoking.
   RESULTS: AMD was associated with ever use of organochlorine [OR = 2.7 (95% CI: 1.8,4.0)1 and organophosphate [OR =2.0 (95% CI: 1.3, 3.0)1 insecticides and phenoxyacetate herbicides [OR = 1.9 (95% CL 1.2, 2.8)]. Specific pesticides consistently associated with AMD included chlordane, dichlorodiphenyltrichloroethane (DDT), malathion, and captan; others with notable but slightly less consistent associations were heptachlor, diazinon, phorate, 2,4,5-aichlorophenoxyacetic acid (2,4,5-T), and 2,4-dichlorophenoxyacetic acid (2,4-D). Results were similar for men and women. Some specific pesticides were associated with both early- and late-stage AMD, but others were associated with only one stage.
   CONCLUSIONS: Exposures to specilic pesticides may be modifiable risk factors for AMD.
C1 [Montgomery, Martha P.; Chen, Honglei; Sandler, Dale P.; Kamel, Freya] NIEHS, Epidemiol Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA.
   [Postel, Eric] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC USA.
   [Umbach, David M.] NIEHS, Biostat & Computat Biol Branch, NIH, DHHS, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Richards, Marie] Westat Corp, Durham, NC USA.
   [Watson, Mary] Social & Sci Syst Inc, Durham, NC USA.
   [Blair, Aaron] NCI, Occupat & Environm Epidemiol Branch, NIH, DHHS, Rockville, MD USA.
   [Schmidt, Silke] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); Duke University; National
   Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); Westat; Social & Scientific
   Systems; National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); Duke University
RP Kamel, F (通讯作者)，NIEHS, Epidemiol Branch, 111 TW Alexander Dr,Bldg 101,Room 327,POB 1223, Res Triangle Pk, NC 27709 USA.
EM kamel@niehs.nih.gov
OI Chen, Honglei/0000-0003-3446-7779
FU Intramural Research Program of the National Institutes of
   Health/National Institute of Environmental Health Sciences
   [Z01-ES049030]; National Cancer Institute [Z01-CP-1-119]; NATIONAL
   INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES049030, ZIAES049030]
   Funding Source: NIH RePORTER
FX B. Wujciak evaluated medical records provided by physicians. This work
   was supported in part by the Intramural Research Program of the National
   Institutes of Health/National Institute of Environmental Health Sciences
   (Z01-ES049030) and the National Cancer Institute (Z01-CP-1-119).
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Ayub S, 2001, CURR SCI INDIA, V80, P1592
   Bagchi D, 1995, TOXICOLOGY, V104, P129, DOI 10.1016/0300-483X(95)03156-A
   Blair A, 2002, EPIDEMIOLOGY, V13, P94, DOI 10.1097/00001648-200201000-00015
   Blair A, 2011, OCCUP ENVIRON MED, V68, P537, DOI 10.1136/oem.2010.059469
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cingolani C, 2006, FREE RADICAL BIO MED, V40, P660, DOI 10.1016/j.freeradbiomed.2005.09.032
   DEMENTI B, 1994, J APPL TOXICOL, V14, P119, DOI 10.1002/jat.2550140214
   Dutta R, 2008, TOXICOLOGY, V252, P78, DOI 10.1016/j.tox.2008.07.063
   Dutta R, 2011, TOXICOLOGY, V285, P126, DOI 10.1016/j.tox.2011.04.012
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hayley S, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-65
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   IMAI H, 1983, ENVIRON RES, V30, P453, DOI 10.1016/0013-9351(83)90231-1
   Kamel F, 2000, AM J IND MED, V37, P618, DOI 10.1002/(SICI)1097-0274(200006)37:6&lt;618::AID-AJIM6&gt;3.0.CO;2-E
   Kim Ki-Su, 2012, J Prev Med Public Health, V45, P62, DOI 10.3961/jpmph.2012.45.2.62
   Kim YS, 2012, INT J MOL MED, V30, P1521, DOI 10.3892/ijmm.2012.1143
   Kirrane EF, 2005, AM J EPIDEMIOL, V161, P1020, DOI 10.1093/aje/kwi140
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Kumar J, 2014, ENVIRON INT, V71, P94, DOI 10.1016/j.envint.2014.06.009
   Lash T.L, 2009, APPL QUANTITATIVE BI, P43, DOI [DOI 10.1007/978-0-387-87959-8_4, 10.1007/978-0-387-87959-8_4]
   Lee DW, 2004, NEUROTOXICOLOGY, V25, P925, DOI 10.1016/j.neuro.2004.05.005
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   MISRA UK, 1985, HUM TOXICOL, V4, P135, DOI 10.1177/096032718500400204
   Montgomery MP, 2010, AM J IND MED, V53, P486, DOI 10.1002/ajim.20789
   Rinsky JL, 2016, AM J EPIDEMIOL
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tong Y, 2010, MOL VIS, V16, P1958
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wielgus AR, 2012, PHOTOCHEM PHOTOBIOL, V88, P1320, DOI 10.1111/j.1751-1097.2012.01174.x
   Yu F, 2008, EXP TOXICOL PATHOL, V59, P415, DOI 10.1016/j.etp.2007.11.007
   Zafrilla P, 2013, J NUTR HEALTH AGING, V17, P219, DOI 10.1007/s12603-012-0095-z
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zhang X, 2006, J TOXICOL ENV HEAL A, V69, P1681, DOI 10.1080/15287390600630203
NR 46
TC 10
Z9 10
U1 0
U2 9
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD JUL
PY 2017
VL 125
IS 7
AR 077013
DI 10.1289/EHP793
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA FK8WB
UT WOS:000413791300021
PM 28886597
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Savastano, MC
   Rizzo, C
   Gambini, G
   Savastano, A
   Falsini, B
   Bacherini, D
   Caputo, CG
   Kilian, R
   Faraldi, F
   De Vico, U
   Rizzo, S
AF Savastano, Maria Cristina
   Rizzo, Clara
   Gambini, Gloria
   Savastano, Alfonso
   Falsini, Benedetto
   Bacherini, Daniela
   Caputo, Carmela Grazia
   Kilian, Raphael
   Faraldi, Francesco
   De Vico, Umberto
   Rizzo, Stanislao
TI Choriocapillaris Vascular Density Changes: Healthy vs. Advanced
   Exudative Age-Related Macular Degeneration Previously Treated with
   Multiple Anti-VEGF Intravitreal Injections
SO DIAGNOSTICS
LA English
DT Article
DE advanced exudative AMD; age-related macular degeneration; innovative
   biotechnologies; macular neovascularization; OCT angiography;
   personalized medicine; biomarkers
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; CHOROIDAL THICKNESS; GEOGRAPHIC
   ATROPHY; FELLOW EYE; FLOW; RANIBIZUMAB; PROGRESSION; THERAPY
AB Purpose: To assess choriocapillaris vascular density (VD) in healthy and advanced exudative age-related macular degeneration (ae-AMD) patients by new full-range optical coherence tomography angiography (OCT-A). Method: In this observational, cross-sectional study, 21 healthy and 21 ae-AMD eyes, already treated with anti-VEGF, were enrolled. Angio-View retina patterns centered on fovea (6.4 x 6.4 mm) were acquired for all participants using Solix full-range OCT (Optovue Inc., Freemont, CA, USA). The main outcome was to compare choriocapillaris VD between healthy and ae-AMD eyes. Automated measurements of whole image choriocapillaris VD (%) and fovea grid-based (%) were collected for the analysis. Angio-View patterns were used to assess the flow area (mm(2)) of macular neovascularization (MNV) by contour flow measure algorithm. Best-corrected visual acuity (BCVA) of both groups was also used for the statistical analysis. Results: The mean age was 60.9 (& PLUSMN;8.3) in healthy and 73.33 (& PLUSMN;15.05) in ae-AMD eyes. The mean BCVA (ETDRS letters) was 98.47 (& PLUSMN;1.50) in healthy and 7.04 (& PLUSMN;5.96) in ae-AMD eyes. The Mann-Whitney test comparing choriocapillaries VD for whole and fovea healthy and ae-AMD eyes showed statistical significance (p < 0.0001 (t = 4.91; df = 40) and p < 0.0001 (t = 6.84; df = 40), respectively). Regarding, the correlation between MNV and VD of choriocapillaries, neither whole nor fovea areas were statistically significant (F = 0.38 (R-2 = 0.01) and 1.68 (R-2 = 0.08), respectively). Conclusions: Choriocapillaris VD showed a statistically significant reduction in comparison to healthy eyes in ae-AMD eyes. Choriocapillaris impairment can be seen in the early phase of MNV pathogenesis.
C1 [Savastano, Maria Cristina; Gambini, Gloria; Savastano, Alfonso; Falsini, Benedetto; Caputo, Carmela Grazia; De Vico, Umberto; Rizzo, Stanislao] IRCCS, Unit Ophthalmol, Fdn Policlin A Gemelli, I-00191 Rome, Italy.
   [Savastano, Maria Cristina; Gambini, Gloria; Savastano, Alfonso; Falsini, Benedetto; Caputo, Carmela Grazia; Rizzo, Stanislao] Univ Cattolica Sacro Cuore, Unit Ophthalmol, I-00168 Rome, Italy.
   [Rizzo, Clara] Univ Pisa, Dept Surg Med & Mol Pathol & Crit Care Med, Ophthalmol, I-56126 Pisa, Italy.
   [Bacherini, Daniela] Univ Florence, Dept Surg & Translat Med, AOU Careggi, I-50139 Florence, Italy.
   [Kilian, Raphael] Univ Verona, Ophthalmol Unit, I-37134 Verona, Italy.
   [Faraldi, Francesco] ASL Torino 5, Torino Eye Clin, Turin, Italy.
   [Rizzo, Stanislao] Consiglio Nazl Ric CNR, Ist Neurosci, I-56124 Pisa, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   University of Pisa; University of Florence; Azienda Ospedaliero
   Universitaria Careggi; University of Verona; Consiglio Nazionale delle
   Ricerche (CNR); Istituto di Neuroscienze (IN-CNR)
RP Savastano, MC (通讯作者)，IRCCS, Unit Ophthalmol, Fdn Policlin A Gemelli, I-00191 Rome, Italy.; Savastano, MC (通讯作者)，Univ Cattolica Sacro Cuore, Unit Ophthalmol, I-00168 Rome, Italy.; Rizzo, C (通讯作者)，Univ Pisa, Dept Surg Med & Mol Pathol & Crit Care Med, Ophthalmol, I-56126 Pisa, Italy.
EM mariacristina.savastano@gmail.com; clararizzo2@gmai.com;
   gambini.gloria@gmail.com; asavastano21@gmail.com; bfalsini@gmail.com;
   daniela.bacherini@gmail.com; carmelagrazia.caputo@gmail.com;
   raphaelkilian8@yahoo.it; faraldi@retinatorino.it;
   umbertodevico@gmail.com; stanislao.rizzo@gmail.com
RI Savastano, Maria Cristina/I-5355-2015; Savastano, Alfonso/AAJ-4173-2021;
   Falsini, Benedetto/AAC-5907-2022
OI Savastano, Maria Cristina/0000-0003-1397-4333; Savastano,
   Alfonso/0000-0003-1575-6567; De Vico, Umberto/0000-0001-8557-3964
CR Alagorie AR, 2020, RETINA-J RET VIT DIS, V40, P2106, DOI 10.1097/IAE.0000000000002878
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-23943
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Chatziralli I, 2018, INT OPHTHALMOL, V38, P1887, DOI 10.1007/s10792-017-0671-7
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Di Antonio L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243074
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Gharbiya M, 1999, EYE, V13, P621, DOI 10.1038/eye.1999.170
   Govetto A, 2017, BRIT J OPHTHALMOL, V101, P764, DOI 10.1136/bjophthalmol-2016-309281
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Invernizzi A, 2018, INVEST OPHTH VIS SCI, V59, P3836, DOI 10.1167/iovs.18-23960
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Luo MY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01386-0
   Manian KV, 2021, CELL STEM CELL, V28, P846, DOI 10.1016/j.stem.2021.02.006
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Minnella AM, 2016, BIODRUGS, V30, P353, DOI 10.1007/s40259-016-0179-0
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   Rocholz R., 2019, HIGH RESOLUTION IMAG
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Scharf J, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040751
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Tey KY, 2019, EYE VISION, V6, DOI 10.1186/s40662-019-0160-3
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Vogl WD, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85110-y
   Vujosevic S, 2019, ACTA OPHTHALMOL, V97, pE919, DOI 10.1111/aos.14088
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 48
TC 1
Z9 1
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD NOV
PY 2021
VL 11
IS 11
AR 1958
DI 10.3390/diagnostics11111958
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XG7QY
UT WOS:000724944800001
PM 34829305
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sivagurunathan, S
   Selvan, LDN
   Khan, AA
   Parameswaran, S
   Bhattacharjee, H
   Gogoi, K
   Gowda, H
   Prasad, TSK
   Pandey, A
   Kumar, SA
   Rishi, P
   Rishi, E
   Ratra, D
   Bhende, M
   Janakiraman, N
   Biswas, J
   Krishnakumar, S
AF Sivagurunathan, Sivapriya
   Selvan, Lakshmi Dhevi N.
   Khan, Aafaque Ahmad
   Parameswaran, Sowmya
   Bhattacharjee, Harsha
   Gogoi, Krishna
   Gowda, Harsha
   Prasad, T. S. Keshava
   Pandey, Akhilesh
   Kumar, Ashok S.
   Rishi, Pukhraj
   Rishi, Ekta
   Ratra, Dhanashree
   Bhende, Muna
   Janakiraman, Narayanan
   Biswas, Jyotirmay
   Krishnakumar, Subramanian
TI Proteomics-based approach for differentiation of age-related macular
   degeneration sub-types
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; biomarkers; proteomics; subtypes;
   urine
ID COMPLEMENT-FACTOR-H; C-REACTIVE PROTEIN; IDENTIFICATION; BIOMARKERS;
   PIGMENT; RISK
AB Purpose: Age-related macular degeneration (AMD) is one of the leading causes of irreversible central vision loss in the elderly population. The current study aims to find non-invasive prognostic biomarkers in the urine specimens of the AMD patients. Methods: Peripheral blood and urine samples were collected from 23 controls and 61 AMD patients. Genomic DNA was extracted from the buffy coat of peripheral blood. Allele specific PCR was used to assay SNPs in complement factor H (CFH), complement component 3 (C3). Comparative proteomic analysis of urine samples from early AMD, choroidal neovascular membrane ( CNVM), geographic atrophy (GA), and healthy controls was performed using isobaric labelling followed by mass spectrometry. Validation was performed using enzyme-linked immunosorbent assay (ELISA). Results: Comparative proteomic analysis of urine samples identified 751 proteins, of which 383 proteins were found to be differentially expressed in various groups of AMD patients. Gene ontology classification of differentially expressed proteins revealed the majority of them were involved in catalytic functions and binding activities. Pathway analysis showed cell adhesion molecule pathways (CAMs), Complement and coagulation cascades, to be significantly deregulated in AMD. Upon validation by ELISA, SERPINA-1 (Alpha1 antitrypsin), TIMP-1 ( Tissue inhibitor of matrix metaloprotease-1), APOA-1 (Apolipoprotein A-1) were significantly over-expressed in AMD (n = 61) patients compared to controls (n = 23). A logistic model of APOA-1 in combination with CFH and C3 polymorphisms predicted the risk of developing AMD with 82% accuracy. Conclusion: This study gives us a preliminary data on non-invasive predictive biomarkers for AMD, which can be further validated in a large cohort and translated for diagnostic use.
C1 [Sivagurunathan, Sivapriya; Selvan, Lakshmi Dhevi N.; Biswas, Jyotirmay; Krishnakumar, Subramanian] Sankara Nethralaya, Vis Res Fdn, L&T Opthalm Pathol, Chennai, Tamil Nadu, India.
   [Sivagurunathan, Sivapriya; Kumar, Ashok S.] Anna Univ, Ctr Biotechnol, Chennai, Tamil Nadu, India.
   [Khan, Aafaque Ahmad; Gowda, Harsha; Pandey, Akhilesh] Inst Bioinformat, Int Technol Pk, Bangalore, Karnataka, India.
   [Parameswaran, Sowmya] Sankara Nethralaya, Radheshyam Kanoi Stem Cell Lab, Vis Res Fdn, Chennai, Tamil Nadu, India.
   [Bhattacharjee, Harsha; Gogoi, Krishna] Sri Sankaradeva Nethralaya, Gauhati, Assam, India.
   [Prasad, T. S. Keshava] Yenepoya Deemed Be Univ, Yenepoya Res Ctr, Ctr Syst Biol & Mol Med, Mangalore, Karnataka, India.
   [Rishi, Pukhraj; Rishi, Ekta; Ratra, Dhanashree; Bhende, Muna] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Chennai, Tamil Nadu, India.
   [Janakiraman, Narayanan] Sankara Nethralaya, Dept Nanobiotechnol, Vis Res Fdn, Chennai, Tamil Nadu, India.
   [Biswas, Jyotirmay] Sankara Nethralaya, Dept Uvea, Chennai, Tamil Nadu, India.
C3 Anna University; Anna University Chennai; Yenepoya (Deemed to be
   University)
RP Krishnakumar, S (通讯作者)，Sankara Nethralaya, Vis Res Fdn, L&T Opthalm Pathol, Chennai, Tamil Nadu, India.
EM drkk@snmail.org
RI Sowmya, Parameswaran/GZK-8635-2022; Gowda, Harsha/A-8526-2011; Ratra,
   Dhanashree/AAE-2517-2020; J, Narayanan/S-6869-2019; Khan,
   Aafaque/AFA-0670-2022; Prasad, Keshava/F-7631-2010; Pandey,
   Akhilesh/CAI-9458-2022
OI Gowda, Harsha/0000-0002-4118-6855; Ratra,
   Dhanashree/0000-0001-5687-6384; J, Narayanan/0000-0003-0866-9828;
   Prasad, Keshava/0000-0002-6206-2384; Pandey,
   Akhilesh/0000-0001-9943-6127; Khan, Aafaque Ahmad/0000-0002-8127-9677
FU DBT's Twinning programme for the North Eastern Region
   [BT/268/NE/TBP/2011]
FX This work was supported by DBT's Twinning programme for the North
   Eastern Region (ProjectNo:BT/268/NE/TBP/2011).
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Decramer S, 2008, MOL CELL PROTEOMICS, V7, P1850, DOI 10.1074/mcp.R800001-MCP200
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Kim HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32548
   Kim HJ, 2014, INVEST OPHTH VIS SCI, V55, P7166, DOI 10.1167/iovs.14-15168
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Miravitlles M, 2012, CURR OPIN PHARMACOL, V12, P309, DOI 10.1016/j.coph.2012.02.004
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Sathe G, 2019, PROTEOM CLIN APPL, V13, DOI 10.1002/prca.201800105
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sniderman AD, 2006, CLIN LAB MED, V26, P733, DOI 10.1016/j.cll.2006.07.007
   Wong CW, 2014, KIDNEY INT, V85, P1290, DOI 10.1038/ki.2013.491
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Xu XR, 2014, INT J OPHTHALMOL-CHI, V7, P256, DOI 10.3980/j.issn.2222-3959.2014.02.12
   Yokosako K, 2014, OPEN OPHTHALMOL J, V8, P39, DOI 10.2174/1874364101408010039
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
NR 33
TC 3
Z9 3
U1 1
U2 4
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAR
PY 2021
VL 69
IS 3
BP 647
EP 654
DI 10.4103/ijo.IJO_470_20
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QQ3ZW
UT WOS:000624463600039
PM 33595494
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Querques, G
   Sacconi, R
   Gelormini, F
   Borrelli, E
   Prascina, F
   Zucchiatti, I
   Querques, L
   Bandello, F
AF Querques, Giuseppe
   Sacconi, Riccardo
   Gelormini, Francesco
   Borrelli, Enrico
   Prascina, Francesco
   Zucchiatti, Ilaria
   Querques, Lea
   Bandello, Francesco
TI Subthreshold laser treatment for reticular pseudodrusen secondary to
   age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DIODE MICROPULSE PHOTOCOAGULATION; CENTRAL SEROUS CHORIORETINOPATHY;
   SUBRETINAL DRUSENOID DEPOSITS; OUTER RETINAL ATROPHY; EDEMA; SAFETY;
   PREVALENCE; EYES
AB There is a lack of treatment aimed at the regression of reticular pseudodrusen (RPD) secondary to age-related macular degeneration (AMD). The aim of this prospective, pilot study is to evaluate the safety and short-term efficacy of subthreshold laser treatment (SLT) in patients affected by RPD secondary to dry AMD (dAMD). Twenty eyes of 20 patients (mean age 78.4 +/- 6.8 years) with RPD secondary to dAMD were prospectively enrolled. All patients were treated in an extrafoveal area of 1.27 mm(2) using end-point management yellow subthreshold laser and followed for 3 months. Best-corrected visual acuity was 0.140 +/- 0.09 LogMAR at the baseline and no changes were observed during the follow-up (p=0.232). No significant worsening was disclosed before and after the treatment analyzing the macular sensitivity of the treated area (p=0.152). No topical and/or systemic side effects were disclosed during the 3-month follow-up. The distribution among the RPD stages changed after the treatment (p<0.001). In detail, in the treated area, we observed a significant increase in the number of Stage 1 RPD during the follow-up (p=0.002), associated with a significant decrease of Stage 3 RPD (p=0.020). Outer nuclear layer (ONL) thickness analysis showed a significant increase after the treatment associated with RPD regression (p=0.001). End-point management SLT appears a safe treatment for RPD secondary to dAMD, showing short-term safety outcomes. Our results suggest that SLT could be effective in inducing a RPD regression in terms of RPD stage and ONL thickening.
C1 [Querques, Giuseppe; Sacconi, Riccardo; Gelormini, Francesco; Borrelli, Enrico; Bandello, Francesco] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Querques, Giuseppe; Sacconi, Riccardo; Gelormini, Francesco; Borrelli, Enrico; Prascina, Francesco; Zucchiatti, Ilaria; Querques, Lea; Bandello, Francesco] IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.
   [Querques, Giuseppe] Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.; Querques, G (通讯作者)，IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.; Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM querques.giuseppe@hsr.it
OI Sacconi, Riccardo/0000-0003-2891-2012
FU Topcon Medical Laser System, Inc. (California, USA)
FX Topcon Medical Laser System, Inc. (California, USA) supported the study
   with a grant.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Borrelli E, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.5
   Chen SN, 2008, OPHTHALMOLOGY, V115, P2229, DOI 10.1016/j.ophtha.2008.08.026
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Luttrull JK, 2015, RETINA-J RET VIT DIS, V35, P1184, DOI 10.1097/IAE.0000000000000458
   Luttrull JK, 2014, RETINA-J RET VIT DIS, V34, P2010, DOI 10.1097/IAE.0000000000000177
   Luttrull JK, 2012, CURR DIABETES REV, V8, P274, DOI 10.2174/157339912800840523
   Luttrull JK, 2012, RETINA-J RET VIT DIS, V32, P375, DOI 10.1097/IAE.0b013e3182206f6c
   Luttrull JK, 2005, BRIT J OPHTHALMOL, V89, P74, DOI 10.1136/bjo.2004.051540
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Parodi MB, 2006, OPHTHALMOLOGY, V113, P2237, DOI 10.1016/j.ophtha.2006.05.056
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Rabiolo A, 2019, RETINA-J RET VIT DIS, V39, P2205, DOI 10.1097/IAE.0000000000002283
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacconi R, 2018, EYE, V32, P734, DOI 10.1038/eye.2017.295
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P97, DOI 10.1136/bjophthalmol-2019-315800
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Theodore Smith R, 2019, Ann Eye Sci, V4, DOI 10.21037/aes.2018.12.04
   van Dijk EHC, 2018, OPHTHALMOLOGY, V125, P1547, DOI 10.1016/j.ophtha.2018.04.021
   Vujosevic S, 2015, RETINA-J RET VIT DIS, V35, P1594, DOI 10.1097/IAE.0000000000000521
   Vujosevic S, 2013, CURR MED CHEM, V20, P3267, DOI 10.2174/09298673113209990030
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 35
TC 2
Z9 2
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 26
PY 2021
VL 11
IS 1
AR 2193
DI 10.1038/s41598-021-81810-7
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TA8OP
UT WOS:000667505700015
PM 33500505
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Karunadharma, PP
   Nordgaard, CL
   Olsen, TW
   Ferrington, DA
AF Karunadharma, Pabalu P.
   Nordgaard, Curtis L.
   Olsen, Timothy W.
   Ferrington, Deborah A.
TI Mitochondrial DNA Damage as a Potential Mechanism for Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; HYDROGEN-PEROXIDE; OXIDATIVE STRESS;
   SKELETAL-MUSCLE; PROGRESSIVE STAGES; COMMON DELETION; NUCLEAR-DNA;
   REPAIR; CELLS; PROTEOMICS
AB PURPOSE. Increasing evidence suggests a central role for mitochondrial (mt) dysfunction in age-related macular degeneration (AMD). Previous proteomic data from the retinal pigment epithelium (RPE) revealed significant changes to mt proteins, suggesting potential functional defects and damage to mitochondrial DNA (mtDNA) with AMD progression. The present study tests the hypothesis that mtDNA damage increases with aging and AMD.
   METHODS. Genomic DNA was isolated from the macular region of human donor RPE graded for stages of AMD (Minnesota Grading System [MGS] 1-4). Region-specific mtDNA damage with normal aging was evaluated in 45 control subjects (ages 34-88 years, MGS 1) and AMD-associated damage in diseased subjects (n = 46), compared with that in age-matched control subjects (n = 26). Lesions per 10 kb per genome in the mtDNA and nuclear DNA were measured with long-extension polymerase chain reaction (LX PCR). The level of deleted mtDNA in each donor was measured with quantitative real-time PCR (qPCR).
   RESULTS. With aging, an increase in mtDNA damage was observed only in the common deletion region of the mt genome. In contrast, with AMD, mtDNA lesions increased significantly in all regions of the mt genome beyond levels found in age-matched control subjects. mtDNA accumulated more lesions than did two nuclear genes, with total damage of the mt genome estimated to be eight times higher.
   CONCLUSIONS. Collectively, the data indicate that mtDNA is preferentially damaged with AMD progression. These results suggest a potential link between mt dysfunction due to increased mtDNA lesions and AMD. (Invest Ophthalmol Vis Sci. 2010; 51: 5470-5479) DOI: 10.1167/iovs.10-5429
C1 [Olsen, Timothy W.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Karunadharma, Pabalu P.; Nordgaard, Curtis L.; Ferrington, Deborah A.] Univ Minnesota Twin Cities, Dept Ophthalmol, Minneapolis, MN USA.
   [Karunadharma, Pabalu P.; Ferrington, Deborah A.] Univ Minnesota Twin Cities, Grad Program Biochem Mol Biol & Biophys, Minneapolis, MN USA.
C3 Emory University; University of Minnesota System; University of
   Minnesota Twin Cities; University of Minnesota System; University of
   Minnesota Twin Cities
RP Ferrington, DA (通讯作者)，Univ Minnesota, 380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU National Institute on Aging [AG025392]; Research to Prevent Blindness;
   Emory University; NATIONAL EYE INSTITUTE [P30EY006360] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025392] Funding Source:
   NIH RePORTER
FX Supported in part by National Institute on Aging Grant AG025392, an
   unrestricted grant from Research to Prevent Blindness to the Departments
   of Ophthalmology at the University of Minnesota and Emory University,
   and a generous donation from the Daniel and Helen Lindsay Family.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ayala-Torres S, 2000, METHODS, V22, P135, DOI 10.1006/meth.2000.1054
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960
   Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Barrientos A, 1997, MOL BRAIN RES, V52, P284, DOI 10.1016/S0169-328X(97)00278-7
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Blokhin A, 2008, J MOL NEUROSCI, V35, P283, DOI 10.1007/s12031-008-9115-1
   BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Canter JA, 2008, PHARMACOGENOMICS J, V8, P71, DOI 10.1038/sj.tpj.6500470
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Ethen CM, 2005, INVEST OPHTH VIS SCI, V46, P769, DOI 10.1167/iovs.04-0810
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GRAMAJO AL, 2007, INVEST OPHTH VIS SCI, V51, P1164
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   KALINOWSKI DP, 1992, NUCLEIC ACIDS RES, V20, P3485, DOI 10.1093/nar/20.13.3485
   Kovalenko Olga A, 2009, Curr Protoc Hum Genet, VChapter 19, DOI 10.1002/0471142905.hg1901s62
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Markaryan A, 2009, LARYNGOSCOPE, V119, P1184, DOI 10.1002/lary.20218
   Masuyama M, 2005, BBA-GEN SUBJECTS, V1723, P302, DOI 10.1016/j.bbagen.2005.03.001
   Meissner C, 2008, EXP GERONTOL, V43, P645, DOI 10.1016/j.exger.2008.03.004
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Poe BG, 2007, ANAL BIOCHEM, V362, P193, DOI 10.1016/j.ab.2006.12.035
   RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Santos Janine H, 2006, Methods Mol Biol, V314, P183
   Santos Janine H, 2002, Methods Mol Biol, V197, P159, DOI 10.1385/1-59259-284-8:159
   Sawyer DE, 2001, REDOX REP, V6, P182, DOI 10.1179/135100001101536157
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Terman A, 2004, ANN NY ACAD SCI, V1019, P70, DOI 10.1196/annals.1297.015
   Wang AL, 2008, MOL VIS, V14, P644
   Xie L, 2008, INVEST OPHTH VIS SCI, V49, P4203, DOI 10.1167/iovs.07-1364
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
NR 49
TC 156
Z9 160
U1 0
U2 11
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2010
VL 51
IS 11
BP 5470
EP 5479
DI 10.1167/iovs.10-5429
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672BQ
UT WOS:000283558400009
PM 20505194
OA Green Published
DA 2022-11-30
ER

PT J
AU Park, UC
   Shin, JY
   Chung, H
   Yu, HG
AF Park, Un Chul
   Shin, Joo Young
   Chung, Hum
   Yu, Hyeong Gon
TI Association of ARMS2 genotype with response to anti-vascular endothelial
   growth factor treatment in polypoidal choroidal vasculopathy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Anti-vascular endothelial growth
   factor; Single nucleotide polymorphism; Pharmacogenetics
ID PIGMENT EPITHELIAL DETACHMENT; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; PHARMACOGENETIC ASSOCIATIONS; INTRAVITREAL RANIBIZUMAB;
   GENETIC-VARIANTS; VERTEPORFIN; INJECTION; MONOTHERAPY; EFFICACY
AB Background: To investigate whether genetic risk variants for age-related macular degeneration (AMD) are associated with response to intravitreal anti-vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV) patients.
   Methods: This prospective cohort study included 95 treatment-naive patients that underwent anti-VEGF treatment for PCV for 12 months. Patients were genotyped for 10 single nucleotide polymorphisms in eight AMD-relevant genes. Genotypic association with visual and anatomic outcome measures at 12 months after initial treatment, including mean change in best-corrected visual acuity (BCVA) and total foveal thickness, visual gain of >= 15 letters, dry status on optical coherence tomography (OCT), pigment epithelial detachment (PED) regression on OCT, polyp regression on indocyanine green angiography, and injection numbers, were investigated using regression models with adjustment for non-genetic covariates under additive genetic model.
   Results: In 81 patients who completed 12-month anti-VEGF monotherapy without photodynamic therapy, significant pharmacogenetic association was found between ARMS2 rs10490924 and PED regression on OCT. Proportions of PED regression were 26.4% for TT, 45.7% for TG, and 63.6% for GG genotype, showing additive effect of G allele for higher chance of PED regression (OR, 2.96; 95% CI, 1.38-6.36; corrected P = 0.043). For entire 95 patients, no significant association was found between candidate polymorphisms and receiving photodynamic therapy within 12 months.
   Conclusions: In PCV patients, ARMS2 rs10490924 showed association with anatomic therapeutic response to anti-VEGF, suggesting pharmacogenetic relationship.
C1 [Park, Un Chul; Shin, Joo Young; Chung, Hum; Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, 103 Daehak Ro, Seoul 110799, South Korea.
   [Chung, Hum] Chung Ang Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Park, Un Chul; Shin, Joo Young; Yu, Hyeong Gon] Seoul Natl Univ Hosp, Biomed Res Inst, Retinal Degenerat Res Lab, Seoul, South Korea.
C3 Seoul National University (SNU); Chung Ang University; Chung Ang
   University Hospital; Seoul National University (SNU); Seoul National
   University Hospital
RP Yu, HG (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, 103 Daehak Ro, Seoul 110799, South Korea.; Yu, HG (通讯作者)，Seoul Natl Univ Hosp, Biomed Res Inst, Retinal Degenerat Res Lab, Seoul, South Korea.
EM hgonyu@snu.ac.kr
FU SNUH Research Fund [04-2011-1160]
FX This study was supported by grant No 04-2011-1160 from the SNUH Research
   Fund. The funding body had no role in the design of the study and
   collection, analysis, and interpretation of data and in writing the
   manuscript.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen HY, 2012, MOL VIS, V18, P816
   Cheng Y, 2016, CHINESE MED J-PEKING, V129, P2610, DOI 10.4103/0366-6999.192779
   Chevreaud O, 2017, GRAEF ARCH CLIN EXP, V255, P743, DOI 10.1007/s00417-016-3564-y
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Honda S, 2012, MOL VIS, V18, P2796
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Park UC, 2014, MOL VIS, V20, P1680
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yanagisawa S, 2011, MOL VIS, V17, P3574
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zhang XZ, 2011, INVEST OPHTH VIS SCI, V52, P8063, DOI 10.1167/iovs.11-7820
NR 39
TC 6
Z9 6
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 7
PY 2017
VL 17
AR 241
DI 10.1186/s12886-017-0631-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP3HD
UT WOS:000417508400002
PM 29212537
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lambiase, A
   Coassin, M
   Tirassa, P
   Mantelli, F
   Aloe, L
AF Lambiase, Alessandro
   Coassin, Marco
   Tirassa, Paola
   Mantelli, Flavio
   Aloe, Luigi
TI Nerve growth factor eye drops improve visual acuity and
   electrofunctional activity in age-related macular degeneration: a case
   report
SO ANNALI DELL ISTITUTO SUPERIORE DI SANITA
LA English
DT Article
DE macular degeneration; nerve growth factor; visual pathways; retina; eye
   drops
ID RETINAL GANGLION-CELLS; OPTIC-NERVE; CLINICAL-APPLICATION; TOPICAL
   APPLICATION; NGF; ULCERS; RANIBIZUMAB; VERTEPORFIN; PROMOTES; RECOVERY
AB Age-related macular degeneration (ARMD) is a severe disease affecting visual function in the elderly. Currently available surgical and medical options do not guarantee a significant impact on the outcome of the disease. We describe the effects of nerve growth factor eye drop treatment in a 94 years old female with ARMD, whose visual acuity was progressively worsening in spite of previous surgical and medical treatments. NGF eye drops improved visual acuity and electrofunctional parameters as early as 3 months after initiation of treatment. These results are in line with previous reports on a neuroprotective effect of NGF on retinal cells and on NGF eye drops bioavailability in the retina and optic nerve. No side effects were observed after five years of follow-up, suggesting that topical NGF treatment may be a safe and effective therapy for ARMD.
C1 [Tirassa, Paola; Aloe, Luigi] CNR, Ist Neurobiol & Med Mol, I-00143 Rome, Italy.
   [Lambiase, Alessandro; Coassin, Marco; Mantelli, Flavio] Univ Campus Biomed, Dipartimento Oftalmol, Rome, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); University Campus Bio-Medico -
   Rome Italy
RP Aloe, L (通讯作者)，CNR, Ist Neurobiol & Med Mol, Via Fosso del Fiorano 64-65, I-00143 Rome, Italy.
EM luigi.aloe@inmm.cnr.it
RI Tirassa, Paola/F-7911-2015; Lambiase, Alessandro/K-3902-2016
OI Lambiase, Alessandro/0000-0002-8974-991X; TIRASSA,
   PAOLA/0000-0002-8791-4424
CR Aloe L, 2004, PROG BRAIN RES, V146, P515
   Aloe L, 1997, CLIN EXP RHEUMATOL, V15, P433
   Apfel SC, 1998, NEUROLOGY, V51, P695, DOI 10.1212/WNL.51.3.695
   Bernabei R, 1999, LANCET, V354, P307, DOI 10.1016/S0140-6736(99)02784-1
   BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CARMIGNOTO G, 1989, J NEUROSCI, V9, P1263
   Chiaretti A, 2002, ARCH DIS CHILD, V87, P446, DOI 10.1136/adc.87.5.446
   Coassin M, 2008, GRAEF ARCH CLIN EXP, V246, P1743, DOI 10.1007/s00417-008-0913-5
   Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6
   Di Fausto V, 2007, EUR J NEUROSCI, V26, P2473, DOI 10.1111/j.1460-9568.2007.05883.x
   Generini S, 2004, EXP CLIN ENDOCR DIAB, V112, P542, DOI 10.1055/s-2004-821313
   Ho A C, 1999, Curr Opin Ophthalmol, V10, P204, DOI 10.1097/00055735-199906000-00009
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Lambiase A, 2005, INVEST OPHTH VIS SCI, V46, P3800, DOI 10.1167/iovs.05-0301
   Lambiase A, 2003, ARCH ITAL BIOL, V141, P141
   Lambiase A, 1998, NEW ENGL J MED, V338, P1174, DOI 10.1056/NEJM199804233381702
   Lambiase A, 1997, GRAEF ARCH CLIN EXP, V235, P780, DOI 10.1007/BF02332863
   Lambiase A, 2007, PHARMACOL RES, V56, P65, DOI 10.1016/j.phrs.2007.03.007
   Lambiase A, 2007, BRAIN RES, V1127, P45, DOI 10.1016/j.brainres.2006.09.102
   Lambiase A, 2009, P NATL ACAD SCI USA, V106, P13469, DOI 10.1073/pnas.0906678106
   Micera A, 2007, CYTOKINE GROWTH F R, V18, P245, DOI 10.1016/j.cytogfr.2007.04.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SHIMOHAMA S, 1993, BRAIN RES, V632, P296, DOI 10.1016/0006-8993(93)91164-N
   SILIPRANDI R, 1993, INVEST OPHTH VIS SCI, V34, P3232
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   Sposato V, 2008, NEUROSCI LETT, V446, P20, DOI 10.1016/j.neulet.2008.09.024
   Taylor HR, 2001, BRIT J OPHTHALMOL, V85, P261, DOI 10.1136/bjo.85.3.261
   Tuveri M, 2000, LANCET, V356, P1739, DOI 10.1016/S0140-6736(00)03212-8
   VERGE VMK, 1992, J NEUROSCI, V12, P4011
   Williams BJ, 2006, PROG NEUROBIOL, V80, P114, DOI 10.1016/j.pneurobio.2006.09.001
NR 31
TC 38
Z9 39
U1 0
U2 6
PU PENSIERO SCIENTIFICO
PI ROME
PA VIA SAN GIOVANNI VALDARNO 8, ROME, 00198, ITALY
SN 0021-2571
J9 ANN I SUPER SANITA
JI Ann. Ist. Super. Sanita
PY 2009
VL 45
IS 4
BP 439
EP 442
PG 4
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA V15SQ
UT WOS:000207822100014
PM 20061666
DA 2022-11-30
ER

PT J
AU Shen, L
   Hoffmann, TJ
   Melles, RB
   Sakoda, LC
   Kvale, MN
   Banda, Y
   Schaefer, C
   Risch, N
   Jorgenson, E
AF Shen, Ling
   Hoffmann, Thomas J.
   Melles, Ronald B.
   Sakoda, Lori C.
   Kvale, Mark N.
   Banda, Yambazi
   Schaefer, Catherine
   Risch, Neil
   Jorgenson, Eric
TI Differences in the Genetic Susceptibility to Age-Related Macular
   Degeneration Clinical Subtypes
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; prevalence; heritability; ApoE
ID GENOME-WIDE ASSOCIATION; APOLIPOPROTEIN-E POLYMORPHISMS; FACTOR-H
   POLYMORPHISM; GENOTYPE IMPUTATION; PROGRESSION; RISK; MACULOPATHY;
   PREVALENCE; VARIANTS; INCREASES
AB PURPOSE. We compared across age-related macular degeneration (AMD) subtypes the effect of AMD risk variants, their predictive power, and heritability.
   METHODS. The prevalence of AMD was estimated among active non-Hispanic white Kaiser Permanente Northern California members who were at least 65 years of age as of June 2013. The genetic analysis included 5,170 overall AMD cases ascertained from electronic health records (EHR), including 1,239 choroidal neovascularization (CNV) cases and 1,060 nonexudative AMD cases without CNV, and 23,130 controls of non-Hispanic white ancestry from the Kaiser Permanente Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort. Imputation was based on the 1000 Genomes Project reference panel.
   RESULTS. The narrow-sense heritability due to common autosomal single nucleotide polymorphisms (SNPs) was 0.37 for overall AMD, 0.19 for AMD unspecified, 0.20 for nonexudative AMD, and 0.60 for CNV. For the 19 previously reported AMD risk loci, the area under the receiver operating characteristic (ROC) curve was 0.675 for overall AMD, 0.640 for AMD unspecified, 0.678 for nonexudative AMD, and 0.766 for CNV. The individual effects on the risk of AMD for 18 of the 19 SNPs were in a consistent direction with those previously reported, including a protective effect of the APOE epsilon 4 allele. Conversely, the risk of AMD was significantly increased in carriers of the epsilon 2 allele.
   CONCLUSIONS. These findings provide an independent confirmation of many of the previously identified AMD risk loci, and support a potentially greater role of genetic factors in the development of CNV. The replication of established associations validates the use of EHR in genetic studies of ophthalmologic traits.
C1 [Shen, Ling; Sakoda, Lori C.; Schaefer, Catherine; Risch, Neil; Jorgenson, Eric] Kaiser Permanente Div Res, Oakland, CA 94612 USA.
   [Hoffmann, Thomas J.] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA.
   [Hoffmann, Thomas J.; Kvale, Mark N.; Banda, Yambazi; Risch, Neil] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Melles, Ronald B.; Risch, Neil] Kaiser Permanente No Calif, Redwood City Med Ctr, Dept Ophthalmol, Redwood City, CA USA.
C3 Kaiser Permanente; University of California System; University of
   California San Francisco; University of California System; University of
   California San Francisco; Kaiser Permanente
RP Jorgenson, E (通讯作者)，Kaiser Permanente Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM eric.jorgenson@kp.org
RI Sakoda, Lori/ABD-6828-2020
OI Sakoda, Lori/0000-0002-0900-5735; Melles, Ronald/0000-0003-1027-4083
FU NIA NIH HHS [R21 AG046616, RC2 AG036607] Funding Source: Medline;
   NATIONAL INSTITUTE ON AGING [R21AG046616, RC2AG036607] Funding Source:
   NIH RePORTER
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Ang LS, 2008, EXP GERONTOL, V43, P615, DOI 10.1016/j.exger.2008.03.010
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hoffmann TJ, 2011, GENOMICS, V98, P422, DOI 10.1016/j.ygeno.2011.08.007
   Hoffmann TJ, 2011, GENOMICS, V98, P79, DOI 10.1016/j.ygeno.2011.04.005
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354
   Howie B, 2011, G3-GENES GENOM GENET, V1, P457, DOI 10.1534/g3.111.001198
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703
   Lee SH, 2011, AM J HUM GENET, V88, P294, DOI 10.1016/j.ajhg.2011.02.002
   Marchini J, 2010, NAT REV GENET, V11, P499, DOI 10.1038/nrg2796
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   van den Elzen P, 2005, NATURE, V437, P906, DOI 10.1038/nature04001
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang HL, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/357412
NR 50
TC 12
Z9 13
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2015
VL 56
IS 8
BP 4290
EP 4299
DI 10.1167/iovs.15-16533
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT5WV
UT WOS:000362882700014
PM 26176866
OA Green Published
DA 2022-11-30
ER

PT J
AU Barkana, Y
   Pondorfer, SG
   Schmitz-Valckenberg, S
   Russ, H
   Finger, RP
AF Barkana, Yaniv
   Pondorfer, Susanne G.
   Schmitz-Valckenberg, Steffen
   Russ, Hermann
   Finger, Robert P.
TI Improved sensitivity of microperimetric outcomes for clinical studies in
   age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DRY AMD
AB To investigate sensitive outcome measures based exclusively on abnormal points in microperimetry testing of eyes with intermediate age-related macular degeneration (iAMD). 25 eyes of 25 subjects with iAMD had undergone 2 successive tests of mesopic microperimetry with the Macular Integrity Assessment Microperimeter (MAIA), using a custom grid of 33 points spanning the central 14 degrees of the macula. Each point was defined as abnormal if its threshold sensitivity was lower than 1.65 standard deviations (SD) (5%) or 2 SD (2.5%) than the expected threshold in healthy eyes according to the MAIA internal database. Among the 25 eyes there were 11.8 +/- 9 and 8.4 +/- 8.2 abnormal points at<5% and<2.5%, with mean deviation of thresholds from normal -4.9 +/- 1.2 dB and -5.8 +/- 1.5 dB, respectively. These deviations were greater, and their SD smaller, compared with the complete microperimetry grid, -2.3 +/- 2.0 dB. The 95% limits of agreement for average threshold between the 2 successive tests were smaller when only abnormal points were included. Analyzing only abnormal grid points yields an outcome parameter with a greater deviation from normal, a more homogenous dataset, and better test-retest variability, compared with analysis of all grid points. This parameter may thus be more sensitive to change, while moderately limiting the number of potential recruits. The proposed outcome measures should be further investigated as potential endpoints in clinical trials in iAMD.
C1 [Barkana, Yaniv; Russ, Hermann] Galimedix Therapeut, 3704 Calvend Lane, Kensington, MD 20895, Australia.
   [Barkana, Yaniv] Sheba Med Ctr, Sam Rothberg Glaucoma Ctr, Glaucoma Innovat & Res Lab, Ramat Gan, Israel.
   [Pondorfer, Susanne G.; Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
C3 Chaim Sheba Medical Center; University of Bonn; Utah System of Higher
   Education; University of Utah
RP Barkana, Y (通讯作者)，Galimedix Therapeut, 3704 Calvend Lane, Kensington, MD 20895, Australia.; Barkana, Y (通讯作者)，Sheba Med Ctr, Sam Rothberg Glaucoma Ctr, Glaucoma Innovat & Res Lab, Ramat Gan, Israel.
EM yanivbarkana@gmail.com
FU Research to Prevent Blindness, New York, NY
FX Supported in part by an Unrestricted Grant from Research to Prevent
   Blindness, New York, NY, to the Department of Ophthalmology & Visual
   Sciences, University of Utah.
CR Allingham MJ, 2019, INVEST OPHTH VIS SCI, V60
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Heijl A, 2012, FIELD ANAL PRIMER EF, V4th
   Hsu WY, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00091
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Munk MR, 2018, INVEST OPHTH VIS SCI, V59
   Roh M, 2019, BRIT J OPHTHALMOL, V103, P1769, DOI 10.1136/bjophthalmol-2018-313316
   Russ H, 2019, INVEST OPHTH VIS SCI, V60
   Sassmannshausen M, 2018, INVEST OPHTH VIS SCI, V59, P1599, DOI 10.1167/iovs.17-22712
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Welker Susanne G, 2018, Invest Ophthalmol Vis Sci, V59, pAMD152, DOI 10.1167/iovs.18-23878
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
NR 16
TC 0
Z9 0
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 26
PY 2021
VL 11
IS 1
AR 4764
DI 10.1038/s41598-021-83716-w
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QT5KT
UT WOS:000626627100002
PM 33637858
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ioanna, Z
   Christian, S
   Christian, G
   Daniel, B
AF Ioanna, Zygoula
   Christian, Schori
   Christian, Grimm
   Daniel, Barthelmes
TI Plasma levels of hypoxia-regulated factors in patients with age-related
   macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Vascular endothelial growth factor;
   Cytokines; Plasma
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; PROLIFERATIVE
   DIABETIC-RETINOPATHY; INDUCIBLE FACTOR-I; CHOROIDAL NEOVASCULARIZATION;
   UP-REGULATION; RETINAL NEOVASCULARIZATION; LASER PHOTOCOAGULATION;
   ERYTHROPOIETIN LEVELS; GLYCEMIC CONTROL
AB Various hypoxia-related proteins are differentially expressed in the retina and secreted to the vitreous and/or aqueous humor of patients affected by dry or neovascular age-related macular degeneration (nAMD). To determine whether these conditions alter concentrations of cytokines also in the systemic circulation, we measured plasma levels of six hypoxia-related proteins.
   Plasma was prepared from EDTA blood that was collected from patients affected by dry AMD (n = 5), nAMD (n = 11), proliferative diabetic retinopathy (PDR; n = 9), and patients with an epiretinal membrane (ERM; n = 11). ERM samples served as negative controls, PDR samples as positive controls. Protein concentrations of vascular endothelial growth factor (VEGF), erythropoietin (EPO), angiopoietin-like 4 (ANGPTL4), placental growth factor (PlGF), tumor necrosis factor alpha (TNF-alpha), and pigment epithelium-derived factor (PEDF) were determined by enzyme-linked immunosorbent assay (ELISA).
   The concentration of PlGF was significantly increased in plasma of patients affected by nAMD. Although no statistically significant differences were found for EPO, ANGPTL4, PlGF, TNF-alpha, and PEDF, the mean concentration of VEGF was lowest in the nAMD group. Plasma concentrations of the six factors did not correlate with gender or age of patients.
   nAMD may increase plasma concentrations of PlGF, making it a candidate as a biomarker for the neovascular form of AMD. Other factors, however, were not differentially regulated, suggesting that their systemic concentrations are not generally increased in hypoxia-related retinal diseases.
C1 [Ioanna, Zygoula; Daniel, Barthelmes] Univ Hosp Zurich, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
   [Christian, Schori; Christian, Grimm] Univ Zurich, Lab Retinal Cell Biol, Dept Ophthalmol, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland.
   [Christian, Schori; Christian, Grimm] Univ Zurich, Neurosci Ctr ZNZ, Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   Zurich Center Integrative Human Physiology (ZIHP); University of Zurich
RP Daniel, B (通讯作者)，Univ Hosp Zurich, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM dbar8165@uni.sydney.edu.au
FU Novartis [-] Funding Source: Medline
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Babapoor-Farrokhran S, 2015, P NATL ACAD SCI USA, V112, pE3030, DOI 10.1073/pnas.1423765112
   Boeri D, 2001, DIABETES, V50, P1432, DOI 10.2337/diabetes.50.6.1432
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bruno CM, 2004, WORLD J GASTROENTERO, V10, P1353
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Carnevale D, 2015, ONCOTARGET, V6, P18246, DOI 10.18632/oncotarget.4914
   DaCosta J, 2013, ARVO M ABSTR, V54, P4108
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   Doganay S, 2002, EYE, V16, P163, DOI 10.1038/sj/eye/6700095
   Fong Siew Wai, 2015, BMC Res Notes, V8, P679, DOI 10.1186/s13104-015-1677-8
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gholamhossein Yaghoobi, 2014, Korean J Ophthalmol, V28, P373, DOI 10.3341/kjo.2014.28.5.373
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   He XM, 2015, CLIN SCI, V128, P805, DOI 10.1042/CS20130463
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hempel SL, 1996, AM J RESP CELL MOL, V14, P170, DOI 10.1165/ajrcmb.14.2.8630267
   Himmerich H, 2006, EUR CYTOKINE NETW, V17, P196, DOI 10.1684/ecn.2006.0037
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Jeevaratnam K, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-58
   Jiang F, 2013, ANN CLIN LAB SCI, V43, P37
   Jonker JT, 2013, AM J CLIN NUTR, V97, P255, DOI 10.3945/ajcn.112.043687
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Kaiser A, 2012, DIABETIC MED, V29, P190, DOI 10.1111/j.1464-5491.2011.03422.x
   Kakizawa H, 2004, METABOLISM, V53, P550, DOI 10.1016/j.metabol.2003.12.002
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khurana R, 2005, CIRCULATION, V111, P2828, DOI 10.1161/CIRCULATIONAHA.104.495887
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krauss T, 2004, HYPERTENS PREGNANCY, V23, P101, DOI 10.1081/PRG-120028286
   Larsson A., 2002, Angiogenesis, V5, P107, DOI 10.1023/A:1021588227705
   Li S, 2012, INT J OPHTHALMOL-CHI, V5, P726, DOI 10.3980/j.issn.2222-3959.2012.06.14
   Li XO, 2015, INT J CHRONIC OBSTR, V10, P587, DOI 10.2147/COPD.S78546
   Lim JI, 2010, RETINA-J RET VIT DIS, V30, P1472, DOI 10.1097/IAE.0b013e3181d6df09
   Lip PL, 2000, INVEST OPHTH VIS SCI, V41, P2115
   Lip PL, 2004, BRIT J OPHTHALMOL, V88, P1543, DOI 10.1136/bjo.2004.048587
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Ma Y, 2012, AM J OPHTHALMOL, V153, P307, DOI 10.1016/j.ajo.2011.08.006
   Machalinska Anna, 2012, Klin Oczna, V114, P115
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mirshahi Alireza, 2012, J Ophthalmic Vis Res, V7, P39
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mohan N, 2012, J DIABETES COMPLICAT, V26, P435, DOI 10.1016/j.jdiacomp.2012.05.005
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Ogata N, 2007, J CLIN ENDOCR METAB, V92, P1176, DOI 10.1210/jc.2006-2249
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Petersen SV, 2003, BIOCHEM J, V374, P199, DOI 10.1042/BJ20030313
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   STITT AW, 1995, BRIT J OPHTHALMOL, V79, P362, DOI 10.1136/bjo.79.4.362
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Tudisco L, 2014, EPIGENETICS-US, V9, P600, DOI 10.4161/epi.27835
   Vadlapatla RK, 2013, ARVO M ABSTR, V54, P3275
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang J, 2014, PLOS ONE, V9
   Wang XQ, 2009, AM J OPHTHALMOL, V148, P883, DOI 10.1016/j.ajo.2009.07.007
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   WOGNUM AW, 1990, BLOOD, V76, P1323
   Xin XB, 2013, P NATL ACAD SCI USA, V110, pE3425, DOI 10.1073/pnas.1217091110
   Yang XM, 2012, J NEUROSCI RES, V90, P257, DOI 10.1002/jnr.22732
   Yao YG, 2005, FEBS LETT, V579, P1227, DOI 10.1016/j.febslet.2005.01.017
   Zehetner C, 2013, ACTA OPHTHALMOL, V91, pe470, DOI 10.1111/aos.12081
   Zhang SX, 2006, J MOL ENDOCRINOL, V37, P1, DOI 10.1677/jme.1.02008
   Zheng L, 2007, INVEST OPHTH VIS SCI, V48, P361, DOI 10.1167/iovs.06-0510
   Zhou JZ, 2012, CURR EYE RES, V37, P416, DOI 10.3109/02713683.2012.661114
NR 76
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2018
VL 256
IS 2
BP 325
EP 332
DI 10.1007/s00417-017-3846-z
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FU2WB
UT WOS:000423709600011
PM 29177891
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Logan, AJ
   Gordon, GE
   Loffler, G
AF Logan, Andrew J.
   Gordon, Gael E.
   Loffler, Gunter
TI The Effect of Age-Related Macular Degeneration on Components of Face
   Perception
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE face perception; psychophysics; age-related macular degeneration; face
   features
ID PREFERRED RETINAL LOCUS; VISUAL FUNCTION; CONTRAST SENSITIVITY;
   SHAPE-DISCRIMINATION; OBJECT RECOGNITION; UNFAMILIAR FACES; DISABILITY;
   FAMILIAR; FEATURES; LIFE
AB PURPOSE. Patients with age-related macular degeneration (AMD) experience difficulty with discriminating between faces. We aimed to use a new clinical test to quantify the impact of AMD on face perception and to determine the specific aspects that are affected.
   METHODS. The Caledonian face test uses an adaptive procedure to measure face discrimination thresholds: the minimum difference required between faces for reliable discrimination. Discrimination thresholds were measured for full-faces, external features (headshape and hairline), internal features (nose, mouth, eyes, and eyebrows) and shapes (non-face task). Participants were 20 patients with dry AMD (logMAR VA = 0.14 to 0.62), 20 patients with wet AMD (0.10 to 0.60), and 20 age-matched control subjects (-0.18 to +0.06).
   RESULTS. Relative to controls, full-face discrimination thresholds were, on average, 1.76 and 1.73 times poorer in participants with dry and wet AMD, respectively. AMD also reduced sensitivity to face features, but discrimination of the internal, relative to external, features was disproportionately impaired. Both distance VA and contrast sensitivity were significant independent predictors of full-face discrimination thresholds (R-2 = 0.66). Sensitivity to full-faces declined by a factor of approximately 1.19 per 0.1 logMAR reduction in VA.
   CONCLUSIONS. Both dry and wet AMD significantly reduce sensitivity to full-faces and their component parts to similar extents. Distance VA and contrast sensitivity are closely associated with face discrimination sensitivity. These results quantify the extent of sensitivity impairment in patients with AMD and predict particular difficulty in everyday tasks that rely on internal feature information, including recognition of familiar faces and facial expressions.
C1 [Logan, Andrew J.; Gordon, Gael E.; Loffler, Gunter] Glasgow Caledonian Univ, Dept Vis Sci, Glasgow, Lanark, Scotland.
   [Logan, Andrew J.] Univ Bradford, Sch Optometry & Vis Sci, Bradford, W Yorkshire, England.
C3 Glasgow Caledonian University; University of Bradford
RP Logan, AJ (通讯作者)，Glasgow Caledonian Univ, Cowcaddens Rd, Glasgow G4 0BA, Lanark, Scotland.
EM Andrew.Logan@gcu.ac.uk
OI Loffler, Gunter/0000-0002-8359-9033; Logan, Andrew/0000-0001-9140-5545
FU College of Optometrists
FX Supported by a Research Fellowship awarded by the College of
   Optometrists to AJL.
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Barnes CS, 2011, OPTOMETRY VISION SCI, V88, P188, DOI 10.1097/OPX.0b013e318205a17c
   Barteselli G, 2014, EYE, V28, P1231, DOI 10.1038/eye.2014.189
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Bruce V, 1999, J EXP PSYCHOL-APPL, V5, P339, DOI 10.1037/1076-898X.5.4.339
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   Caldara R, 2005, J COGNITIVE NEUROSCI, V17, P1652, DOI 10.1162/089892905774597254
   Campbell R, 1999, VIS COGN, V6, P197, DOI 10.1080/713756807
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Dulin D, 2011, Q J EXP PSYCHOL, V64, P1955, DOI 10.1080/17470218.2011.608852
   ELLIS HD, 1979, PERCEPTION, V8, P431, DOI 10.1068/p080431
   FRASER IH, 1990, PERCEPTION, V19, P661, DOI 10.1068/p190661
   Goffaux V, 2006, J EXP PSYCHOL HUMAN, V32, P1023, DOI 10.1037/0096-1523.32.4.1023
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Haymes SA, 2002, OPHTHAL PHYSL OPT, V22, P79, DOI 10.1046/j.1475-1313.2002.00016.x
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Lee Y, 2010, CORTEX, V46, P949, DOI 10.1016/j.cortex.2009.07.012
   Lehky SR, 2000, J COGNITIVE NEUROSCI, V12, P848, DOI 10.1162/089892900562453
   Levi DM, 2008, VISION RES, V48, P635, DOI 10.1016/j.visres.2007.12.009
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu P, 2014, VISION RES, V105, P189, DOI 10.1016/j.visres.2014.10.014
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Loffler G, 2005, NAT NEUROSCI, V8, P1386, DOI 10.1038/nn1538
   Loffler G, 2015, J VISION, V15, DOI 10.1167/15.7.1
   Logan AJ, 2019, J VISION, V19, DOI 10.1167/19.4.23
   Logan AJ, 2017, VISION RES, V137, P29, DOI 10.1016/j.visres.2017.05.011
   Logan AJ, 2016, VISION RES, V119, P29, DOI 10.1016/j.visres.2015.11.003
   Longmore CA, 2015, Q J EXP PSYCHOL, V68, P249, DOI 10.1080/17470218.2014.939666
   Lott LA, 2005, OPTOMETRY VISION SCI, V82, P874, DOI 10.1097/01.opx.0000180764.68737.91
   Martelli M, 2005, J VISION, V5, P58, DOI 10.1167/5.1.6
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   McCulloch DL, 2011, OPHTHAL PHYSL OPT, V31, P240, DOI 10.1111/j.1475-1313.2011.00828.x
   Nasanen R, 1999, VISION RES, V39, P3824, DOI 10.1016/S0042-6989(99)00096-6
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Robison CD, 2011, BRIT J OPHTHALMOL, V95, P1419, DOI 10.1136/bjo.2010.194886
   Rossion B, 2009, ACTA PSYCHOL, V132, P300, DOI 10.1016/j.actpsy.2009.08.002
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Schmidtmann G, 2015, J VISION, V15, DOI 10.1167/15.5.18
   Schmier JK, 2006, OPHTHAL EPIDEMIOL, V13, P137, DOI 10.1080/09286580600573049
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Seiple W, 2013, OPTOMETRY VISION SCI, V90, P45, DOI 10.1097/OPX.0b013e3182794775
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   TANAKA JW, 1993, Q J EXP PSYCHOL-A, V46, P225, DOI 10.1080/14640749308401045
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Wallace JM, 2017, J VISION, V17, DOI 10.1167/17.1.33
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828
   Watson GR, 1997, OPTOMETRY VISION SCI, V74, P249, DOI 10.1097/00006324-199705000-00019
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   Whitney D, 2011, TRENDS COGN SCI, V15, P160, DOI 10.1016/j.tics.2011.02.005
   Wilkinson F, 1998, VISION RES, V38, P3555, DOI 10.1016/S0042-6989(98)00039-X
   Wilson HR, 2002, VISION RES, V42, P2909, DOI 10.1016/S0042-6989(02)00362-0
   Wilson HR, 2002, VISION RES, V42, P589, DOI 10.1016/S0042-6989(01)00299-1
   YOUNG AW, 1985, PERCEPTION, V14, P737, DOI 10.1068/p140737
NR 69
TC 3
Z9 3
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2020
VL 61
IS 6
AR 38
DI 10.1167/iovs.61.6.38
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA MD7MJ
UT WOS:000544154500039
PM 32543666
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Singh, JA
   Cleveland, JD
AF Singh, Jasvinder A.
   Cleveland, John D.
TI Gout and the risk of age-related macular degeneration in the elderly
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE STRESS; EYE DISEASE; CARDIOVASCULAR-DISEASE; URIC-ACID;
   INFLAMMATION; PATHOGENESIS; HYPERTENSION; MACULOPATHY; ATHEROSCLEROSIS;
   ANTIOXIDANTS
AB Objective
   To assess whether gout is associated with incident age-related macular degeneration (AMD).
   Methods
   We used the 5% Medicare claims data from 2006-12 for all beneficiaries who were enrolled in Medicare fee-for-service (Parts A, B) and not enrolled in a Medicare Advantage Plan, and resided in the U.S. People were censored at the occurrence of new diagnosis of AMD, death or the end of study (12/31/2012), whichever occurred first. We used multivariable-adjusted Cox regression analyses to assess the association of gout with incident AMD, adjusted for demographics, comorbidity, and use of medications for cardiovascular disease and gout. Hazard ratios and 95% confidence intervals were calculated.
   Results
   In this observational cohort study, of the 1,684,314 eligible people, 116,097 developed incident AMD (6.9%). Incidence rates of AMD per 1,000 person-years were 20.1 for people with gout and 11.7 for people without gout. In multivariable-adjusted analyses, a diagnosis of gout was significantly associated with a higher risk of incident AMD with a hazard ratio of 1.39 (95% CI, 1.35, 1.43). This association was confirmed in sensitivity analyses that substituted Charlson-Romano comorbidity index continuous score with either a categorical Charlson-Romano comorbidity index score or individual Charlson-Romano index comorbidities plus hypertension, hyperlipidemia and coronary artery disease. Other covariates significantly associated with higher hazards of incident AMD were older age, female gender, White race/ethnicity, and higher Charlson-Romano comorbidity index score.
   Conclusions
   We noted a novel association of gout with AMD in the elderly. Future studies should investigate the pathways that mediate this association.
C1 [Singh, Jasvinder A.] VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.
   [Singh, Jasvinder A.; Cleveland, John D.] UAB, Dept Med, Sch Med, Birmingham, AL 35294 USA.
   [Singh, Jasvinder A.] UAB, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Singh, JA (通讯作者)，VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.; Singh, JA (通讯作者)，UAB, Dept Med, Sch Med, Birmingham, AL 35294 USA.; Singh, JA (通讯作者)，UAB, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
EM Jasvinder.md@gmail.com
RI Singh, Jasvinder/R-6172-2019
OI Singh, Jasvinder/0000-0003-3485-0006
FU Division of Rheumatology at the University of Alabama at Birmingham
FX This material is the result of work supported by research funds from the
   Division of Rheumatology at the University of Alabama at Birmingham and
   the resources and use of facilities at the Birmingham VA Medical Center,
   Birmingham, Alabama, USA to JAS. The funding body did not play any role
   in design, in the collection, analysis, and interpretation of data; in
   the writing of the manuscript; and in the decision to submit the
   manuscript for publication.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2015, FACTS AG REL MAC DEG
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beltowski J, 2005, TOXICOL MECH METHOD, V15, P61, DOI 10.1080/15376520590918766
   Berry SD, 2010, J AM GERIATR SOC, V58, P783, DOI 10.1111/j.1532-5415.2010.02767.x
   Betteridge DJ, 2000, METABOLISM, V49, P3, DOI 10.1016/S0026-0495(00)80077-3
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curcio CA, 2017, JAMA OPHTHALMOL, V135, P843, DOI 10.1001/jamaophthalmol.2017.2008
   Danulescu R, 2013, MED-SURG J, V117, P328
   Doherty M, 2009, RHEUMATOLOGY, V48, P2, DOI 10.1093/rheumatology/kep086
   Fauser S, 2015, ACTA OPHTHALMOL, V93, P734, DOI 10.1111/aos.12770
   George J, 2006, CIRCULATION, V114, P2508, DOI 10.1161/CIRCULATIONAHA.106.651117
   George Jacob, 2009, Ther Clin Risk Manag, V5, P799
   George J, 2009, VASC HEALTH RISK MAN, V5, P265, DOI 10.2147/VHRM.S4265
   Glantzounis GK, 2005, CURR PHARM DESIGN, V11, P4145, DOI 10.2174/138161205774913255
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kalayoglu MV, 2007, CLIN EXP OPHTHALMOL, V35, P3, DOI 10.1111/j.1442-9071.2007.01432.x
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katsi VK, 2015, J HYPERTENS, V33, P2382, DOI 10.1097/HJH.0000000000000766
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Keenan TDL, 2015, RETINA-J RET VIT DIS, V35, P2613, DOI 10.1097/IAE.0000000000000651
   Kim SK, 2016, INFLAMMATION, V39, P473, DOI 10.1007/s10753-015-0271-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Krishnan E, 2010, RHEUMATOLOGY, V49, P1229, DOI 10.1093/rheumatology/keq037
   Latkany Paul, 2010, J Ocul Biol Dis Infor, V3, P30, DOI 10.1007/s12177-010-9052-4
   Liote Frederic, 2003, Curr Rheumatol Rep, V5, P227, DOI 10.1007/s11926-003-0072-y
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Neogi T, 2011, NEW ENGL J MED, V364, P443, DOI 10.1056/NEJMcp1001124
   Pham-Huy Lien Ai, 2008, Int J Biomed Sci, V4, P89
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Singh JA, 2007, ARTHRIT RHEUM-ARTHR, V57, P822, DOI 10.1002/art.22767
   Singh JA, 2015, JCR-J CLIN RHEUMATOL, V21, P225, DOI 10.1097/RHU.0000000000000246
   Singh JA, 2014, J RHEUMATOL, V41, P615, DOI 10.3899/jrheum.131258
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Taylor H R, 2000, Trans Am Ophthalmol Soc, V98, P91
   Taylor HR, 2000, T AM OPHTHAL SOC, V98, P6
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   U. S. Census Bureau, NAT POP PROJ 1 SUMM
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   Wortmann RL, 2002, CURR OPIN RHEUMATOL, V14, P281, DOI 10.1097/00002281-200205000-00015
   Zamudio-Cuevas Y, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1012-3
   Zhang JX, 2015, ENDOCRINE, V48, P135, DOI 10.1007/s12020-014-0239-5
NR 60
TC 10
Z9 10
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 12
PY 2018
VL 13
IS 7
AR e0199562
DI 10.1371/journal.pone.0199562
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GM8FT
UT WOS:000438457400012
PM 30001351
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Brion, M
   Sanchez-Salorio, M
   Corton, M
   de la Fuente, M
   Pazos, B
   Othman, M
   Swaroop, A
   Abecasis, G
   Sobrino, B
   Carracedo, A
AF Brion, Maria
   Sanchez-Salorio, Manuel
   Corton, Marta
   de la Fuente, Maria
   Pazos, Belen
   Othman, Mohammad
   Swaroop, Anand
   Abecasis, Goncalo
   Sobrino, Beatriz
   Carracedo, Angel
CA Spanish Multi-Ctr Grp AMD
TI Genetic association study of age-related macular degeneration in the
   Spanish population
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE ABCA4; age-related macular degeneration; ARMS2; case-control study; CFH;
   FGF2; genetic association
ID COMPLEMENT-FACTOR-H; STARGARDT DISEASE GENE; GENOME SCAN; SUSCEPTIBILITY
   LOCI; HEMICENTIN-1 GENES; GROWTH-FACTORS; ABCR GENE; POLYMORPHISM; RISK;
   VARIANT
AB Purpose: To investigate new genetic risk factors and replicate reported associations with advanced age-related macular degeneration (AMD) in a prospective case-control study developed with a Spanish cohort.
   Methods: Three hundred and fifty-three unrelated patients with advanced AMD (225 with atrophic AMD, 57 with neovascular AMD, and 71 with mixed AMD) and 282 age-matched controls were included. Functional and tagging SNPs in 55 candidate genes were genotyped using the SNPlex (TM) genotyping system. Single SNP and haplotype association analysis were performed to determine possible genetic associations; interaction effects between SNPs were also investigated.
   Results: In agreement with previous reports, ARMS2 and CFH genes were strongly associated with AMD in the studied Spanish population. Moreover, both loci influenced risk independently giving support to different pathways implicated in AMD pathogenesis. No evidence for association of advanced AMD with other previous reported susceptibility genes, such as CST3, CX3CR1, FBLN5, HMCN1, PON1, SOD2, TLR4, VEGF and VLDLR, was detected. However, two additional genes appear to be candidate markers for the development of advanced AMD. A variant located at the 3' UTR of the FGF2 gene (rs6820411) was highly associated with atrophic AMD, and the functional SNP rs3112831 at ABCA4 showed a marginal association with the disease.
   Conclusion: We performed a large gene association study in advanced AMD in a Spanish population. Our findings show that CFH and ARMS2 genes seem to be the principal risk loci contributing independently to AMD in our cohort. We report new significant associations that could also influence the development of advanced AMD. These findings should be confirmed in further studies with larger cohorts.
C1 [Brion, Maria] Hospital Univ Complex Santiago CHUS, Santiago De Compostela, Spain.
   [Brion, Maria; Corton, Marta; Sobrino, Beatriz; Carracedo, Angel] Univ Santiago de Compostela, CIBERER, Genom Med Grp, Santiago De Compostela, Spain.
   [Sanchez-Salorio, Manuel; de la Fuente, Maria; Pazos, Belen] Inst Gallego Oftalmol INGO, Santiago De Compostela, Spain.
   [Othman, Mohammad; Swaroop, Anand] Univ Michigan, Dept Ophthalmol, Ann Arbor, MI USA.
   [Othman, Mohammad; Swaroop, Anand] Univ Michigan, Dept Visual Sci & Human Genet, Ann Arbor, MI USA.
   [Swaroop, Anand] NEI, Natl Inst Hlth, Neurobiol Neurodegenerat & Repair Lab, Bethesda, MD USA.
   [Abecasis, Goncalo] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Sobrino, Beatriz; Carracedo, Angel] Univ Santiago de Compostela, Natl Genotyping Ctr CEGEN, Santiago De Compostela, Spain.
C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Universidade
   de Santiago de Compostela; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Michigan System; University of Michigan;
   Universidade de Santiago de Compostela
RP Brion, M (通讯作者)，Univ Santiago de Compostela, Fac Med, San Francisco S-N, Santiago De Compostela 5782, Spain.
EM maria.brion@usc.es
RI Carracedo, Angel/D-4257-2012; Rey, Beatriz Sobrino/ABB-8518-2020;
   Martin, Rosa Maria Coco/H-4511-2015; DE LA FUENTE, MARIA/R-9993-2018;
   Brion, Maria/J-8059-2014
OI Carracedo, Angel/0000-0003-1085-8986; Martin, Rosa Maria
   Coco/0000-0002-1811-1417; DE LA FUENTE, MARIA/0000-0002-3688-3808;
   Brion, Maria/0000-0001-7463-2148; Corton, Marta/0000-0003-0087-1626;
   Abecasis, Goncalo/0000-0003-1509-1825; Sobrino Rey,
   Beatriz/0000-0002-6605-9377; Swaroop, Anand/0000-0002-1975-1141
FU Xunta de Galicia [PGI-DIT06PXIB208204PR]; Instituto de Salud Carlos III
   [EMER07/018]; National Institutes of Health, USA; NATIONAL EYE INSTITUTE
   [ZIAEY000475] Funding Source: NIH RePORTER
FX This study was supported by grants from the Xunta de Galicia
   (PGI-DIT06PXIB208204PR), the Instituto de Salud Carlos III (EMER07/018),
   and National Institutes of Health, USA. The sponsor or funding
   organization had no role in the design or conduct of this research.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baguma-Nibasheka M, 2007, MOL CELL ENDOCRINOL, V267, P127, DOI 10.1016/j.mce.2007.01.008
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Barral S, 2006, INVEST OPHTH VIS SCI, V47, P5453, DOI 10.1167/iovs.06-0655
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bojanowski Christine M, 2005, Trans Am Ophthalmol Soc, V103, P37
   BOJANOWSKI CM, 2005, T AM OPHTHAL SOC, V103, P44
   Browning AC, 2008, BRIT J OPHTHALMOL, V92, P1003, DOI 10.1136/bjo.2007.127670
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   De la Fuente M, 2007, OPHTHALMOLOGY, V114, P193
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jun G, 2005, INVEST OPHTH VIS SCI, V46, P3081, DOI 10.1167/iovs.04-1360
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kang HJ, 2005, NUCLEIC ACIDS RES, V33, pD518
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Morcillo-Suarez C, 2008, BIOINFORMATICS, V24, P1643, DOI 10.1093/bioinformatics/btn241
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ogata N, 1996, CURR EYE RES, V15, P1008, DOI 10.3109/02713689609017649
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Recalde S, 2008, OPHTHALMOLOGY, V115, P916, DOI 10.1016/j.ophtha.2007.12.012
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seitsonen S, 2006, MOL VIS, V12, P796
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tobler Andreas R, 2005, J Biomol Tech, V16, P398
   Utheim OA, 2008, ACTA OPHTHALMOL, V86, P401, DOI 10.1111/j.1600-0420.2007.01070.x
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weger M, 2007, MOL VIS, V13, P1274
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
NR 74
TC 33
Z9 37
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2011
VL 89
IS 1
BP E12
EP E22
DI 10.1111/j.1755-3768.2010.02040.x
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 711YL
UT WOS:000286628100002
PM 21106043
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Mansour, AM
   Chhablani, J
   Antonios, RS
   Yogi, R
   Younis, MH
   Dakroub, R
   Chahine, H
AF Mansour, Ahmad M.
   Chhablani, Jay
   Antonios, Rafic S.
   Yogi, Rohit
   Younis, Muhammad H.
   Dakroub, Rola
   Chahine, Hasan
TI Three-month outcome of ziv-aflibercept for exudative age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; SUBMACULAR HEMORRHAGE; COST-EFFECTIVENESS;
   RANIBIZUMAB; BEVACIZUMAB; SECONDARY; INJECTION
AB Purpose In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using intravitreal ziv-aflibercept. Our purpose is to ascertain the 3-month safety and efficacy in wet age-related macular degeneration (AMD) treated with intravitreal ziv-aflibercept.
   Methods Prospectively, consecutive patients with wet AMD underwent ziv-aflibercept intravitreal injection (1.25 mg/0.05 mL) from March 2015 to November 2015. Monitoring of best-corrected visual acuity, intraocular inflammation, cataract progression and by spectral domain optical coherence tomography were carried out at baseline day 1, 1 week, 1 month, 2 months and 3 months after injections.
   Results 30 eyes were treated (22 Caucasians, 8 Indians; 16 men, 14 women; 14 right eyes and 16 left eyes) with mean age of 74.3 years with 11 treatment-naive cases and 19 having had treatment-non-naive. Best-corrected visual acuity improved from baseline logMAR 1.08-0.74 at 1 week, 0.72 at 1 month, 0.67 at 2 months and 0.71 at 3 months (p<0.001 for all time periods). Central macular thickness in microns decreased from 332.8 to 302.0 at 1 week, 244.8 at 1 month, 229.0 at 2 months and 208.2 at 3 months (p<0.001 for all time periods). There were no signs of intraocular inflammation, or change in lens status or increase in intraocular pressure throughout the study.
   Conclusions Off label use of ziv-aflibercept improves visual acuity, without detectable ocular toxicity and offers a cheaper alternative to the same molecule aflibercept, especially in low/middle-income countries and in countries where aflibercept (Eylea) is not available.
C1 [Mansour, Ahmad M.; Antonios, Rafic S.; Younis, Muhammad H.; Dakroub, Rola; Chahine, Hasan] Amer Univ Beirut, Dept Ophthalmol, Beirut, Lebanon.
   [Mansour, Ahmad M.; Younis, Muhammad H.; Dakroub, Rola] Rafik Hariri Univ Hosp, Dept Ophthalmol, Beirut, Lebanon.
   [Chhablani, Jay; Yogi, Rohit] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad 500034, Andhra Pradesh, India.
C3 American University of Beirut; American University of Beirut; L. V.
   Prasad Eye Institute
RP Chhablani, J (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad 500034, Andhra Pradesh, India.
EM jay.chhablani@gmail.com
CR Bailey Caroline, 2009, Int J Pharm Compd, V13, P564
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P1126, DOI 10.1097/IAE.0000000000000913
   Chhablani J, 2015, INDIAN J OPHTHALMOL, V63, P469, DOI 10.4103/0301-4738.159909
   Chung C, 2013, AM J HEALTH-SYST PH, V70, P1887, DOI 10.2146/ajhp130143
   Dias JRD, 2015, OSLI RETINA, V46, P91, DOI 10.3928/23258160-20150101-17
   Dias JRD, 2014, OSLI RETINA, V45, P577, DOI 10.3928/23258160-20141118-15
   Jain S, 2013, INDIAN J OPHTHALMOL, V61, P490, DOI 10.4103/0301-4738.119432
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   Nagiel Aaron, 2015, Retin Cases Brief Rep, V9, P269, DOI 10.1097/ICB.0000000000000184
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silver J, 2014, JAMA-J AM MED ASSOC, V312, P23, DOI 10.1001/jama.2014.6672
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Videkar Chetan, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-212988
   Ziemssen F, 2016, OPHTHALMOLOGE, V113, P143, DOI 10.1007/s00347-015-0099-2
NR 19
TC 22
Z9 22
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2016
VL 100
IS 12
BP 1629
EP 1633
DI 10.1136/bjophthalmol-2015-308319
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EC7XD
UT WOS:000388353500008
PM 27030277
OA Bronze
DA 2022-11-30
ER

PT J
AU Nguyen, CT
   Fraser, RG
   Tan, R
   Caruso, E
   Lek, JJ
   Guymer, RH
   Luu, CD
AF Nguyen, Chinh T.
   Fraser, Rogan G.
   Tan, Rose
   Caruso, Emily
   Lek, Jia Jia
   Guymer, Robyn H.
   Luu, Chi D.
TI Longitudinal Changes in Retinotopic Rod Function in Intermediate
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age related macular degeneration; dark adaptation; rod function
ID RETICULAR PSEUDODRUSEN; DARK-ADAPTATION; MACULOPATHY; PROGRESSION;
   PREVALENCE
AB PURPOSE. Although impairment of rod function in the early stages of age-related macular degeneration (AMD) has been well recognized, data on longitudinal changes in rod function at multiple retinal locations remain limited. This study investigated the longitudinal changes in retinotopic rod function in eyes with intermediate AMD (iAMD).
   METHODS. Complete ophthalmic examination, multimodal imaging, and scotopic perimetry were performed at baseline and at 12-month follow-up. Perimetric scotopic retinal sensitivities for the 505-nm stimulus were repeatedly measured for 20 minutes after exposing to a single photobleach (similar to 30%). The rod intercept time (RIT) and retinal sensitivity at seven retinal loci within the central 12 degrees were ascertained. Using the 95% limit of measurement variability derived from the control eyes as a reference, the proportion of test points with a significant change in retinal sensitivity or RIT at follow-up was determined.
   RESULTS. Twenty iAMD and 6 control eyes were included. Decline in rod function was detected at 12-month follow-up in eyes with iAMD, but not in control eyes. Approximately 25% of test points in iAMD eyes showed a significant increase in RIT compared to 6% of test points with a decrease in RIT over the 12-month period (P < 0.001). Similarly, 40% of test points demonstrated a reduction in retinal sensitivity compared to the 7% of test points with an increase in retinal sensitivity at follow-up (P < 0.001).
   CONCLUSIONS. There are detectable retinotopic changes in rod function over 12 months in iAMD eyes, indicating an ongoing disease progression in rod impairment or loss with time.
C1 [Nguyen, Chinh T.; Fraser, Rogan G.; Tan, Rose; Caruso, Emily; Lek, Jia Jia; Guymer, Robyn H.; Luu, Chi D.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Nguyen, Chinh T.; Fraser, Rogan G.; Tan, Rose; Caruso, Emily; Lek, Jia Jia; Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Dept Surg Ophthalmol, East Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Level 8,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; Rose, Rose/0000-0002-7351-2774
FU Macular Disease Foundation Australia grant; National Health and Medical
   Research Council Practitioner Fellowship [1103013]; Ophthalmic Research
   Institute of Australia
FX Supported by a Macular Disease Foundation Australia grant (CDL), a
   National Health and Medical Research Council Practitioner Fellowship
   (#1103013, RHG), and Ophthalmic Research Institute of Australia (JJL).
   The Centre for Eye Research Australia (CERA) receives Operational
   Infrastructure Support from the Victorian Government.
CR Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 14
TC 20
Z9 20
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
DI 10.1167/iovs.17-23084
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF2VH
UT WOS:000431797500001
PM 29860308
OA gold
DA 2022-11-30
ER

PT J
AU Sharma, NK
   Sharma, SK
   Gupta, A
   Prabhakar, S
   Singh, R
   Anand, A
AF Sharma, Neel Kamal
   Sharma, Suresh Kumar
   Gupta, Amod
   Prabhakar, Sudesh
   Singh, Ramandeep
   Anand, Akshay
TI Predictive Model for Earlier Diagnosis of Suspected Age-Related Macular
   Degeneration Patients
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID GENE; COMPLEMENT; SUSCEPTIBILITY; POLYMORPHISM; ASSOCIATION; RISK;
   VARIANT
AB The primary goal of tailored medicine is to presymptomatically identify individuals at high risk for disease using information of each individual's genetic profile and collection of environmental risk factors. Recently, algorithms were given the strong recognition of several replicated risk factors for age-related macular degeneration (AMD), this distant goal is beginning to seem less mysterious. The purpose of the study was to develop a statistical model for AMD. This study includes total 106 subjects. To identify the risk of earlier diagnosis of suspected AMD patients, 22 independent variables were included in the study. Forward stepwise (likelihood ratio) binary logistic regression has been used to find significant variables associated with the risk of AMD. Prediction equation, based on significant risk factors, and model authenticity have been developed. Hosmer-Lemeshow goodness of fit statistic (chi(2) = 0.143, df = 8, p = 1.0), which is nonsignificant, indicates the appropriateness of the logistic regression model to predict AMD. After going through stepwise logistic regression, only 6 variables out of the 22 independent variables, namely, serum complement factor H (CFH), serum chemokine (C-C motif) ligand 2 (CCL2), serum superoxide dismutase 1 (SOD1), polymorphism in CCL2 (rs4586), stress, and comorbidity were found to be significant (p < 0.05). The binary logistic regression model is an appropriate tool to predict AMD in the presence of serum CFH, serum CCL2, serum SOD1, polymorphism in CCL2 (rs4586), stress, and comorbidity with high specificity and sensitivity. The area under the receiver operating characteristic curve (0.909, p = 0.001) with less standard error of 0.034 and close 95% confidence intervals (0.842-0.976) further validates the model.
C1 [Sharma, Neel Kamal; Prabhakar, Sudesh; Anand, Akshay] Postgrad Inst Med Educ & Res, Dept Neurol, Chandigarh 160012, India.
   [Sharma, Suresh Kumar] Panjab Univ, Dept Stat, Chandigarh 160014, India.
   [Gupta, Amod; Singh, Ramandeep] Postgrad Inst Med Educ & Res, Dept Ophthalmol, Chandigarh 160012, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Panjab University; Post Graduate Institute of Medical
   Education & Research (PGIMER), Chandigarh
RP Anand, A (通讯作者)，Postgrad Inst Med Educ & Res, Dept Neurol, Chandigarh 160012, India.
EM akshay1anand@rediffmail.com
RI Gupta, Amod/V-7633-2017; anand, Akshay/AAI-1586-2019
OI Gupta, Amod/0000-0001-8427-5738; 
FU Indian Council of Medical research, India [45/11/2010-HUM/BMS]
FX The study was carried out at the Department of Neurology, PGIMER,
   Chandigarh, India. We acknowledge the Indian Council of Medical
   research, India for providing funds (45/11/2010-HUM/BMS). The funders
   (45/11/2010-HUM/BMS) had no role in the study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Jia LH, 2011, AGING CLIN EXP RES, V23, P264, DOI 10.1007/BF03324965
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sharma NK, 2012, CURR NEUROVASC RES, V9, P256
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 26
TC 15
Z9 15
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD SEP
PY 2013
VL 32
IS 9
BP 549
EP 555
DI 10.1089/dna.2013.2072
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 205DC
UT WOS:000323420600010
PM 23848218
DA 2022-11-30
ER

PT J
AU Kim, HS
   Kim, YH
   Mok, JW
   Joo, CK
AF Kim, Hyun-Seok
   Kim, Yeong Hoon
   Mok, Jee Won
   Joo, Choun-Ki
TI Genetic association of VEGF and PEDF polymorphisms with age-related
   macular degeneration in Korean
SO GENES & GENOMICS
LA English
DT Article
DE Vascular endothelial growth factor (VEGF); Pigment epithelium-derived
   factor (PEDF); Age-related macular degeneration (AMD); Korean;
   Polymorphism
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR;
   DIABETIC-RETINOPATHY; NEOVASCULARIZATION; EXPRESSION; IDENTIFICATION;
   MIGRATION; EDEMA
AB Age-related macular degeneration (AMD) causes progressive impairment of central vision and is the leading cause of vision loss in older individuals. Although the etiology of AMD has not been clearly elucidated, genetic and environmental factors have been implicated. Vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF), a major regulator of vascular permeability and angiogenesis, have been suggested to play an important role in the pathogenesis of AMD. This study was performed to determine whether VEGF and PEDF variations are associated with AMD in the Korean population. Four SNPs of both the VEGF gene the PEDF gene were used to screen for genetic variation. This analysis was performed using polymerase chain reaction-restriction fragment length polymorphism, direct sequencing and an allele-specific oligonucleotide analysis. The study investigated four SNPs in VEGF and PEDF in Korean patients with AMD. The frequency of the TT genotype of rs1413711 and the recessive VEGF allele significantly differed between the patient and control groups. The TT genotype of rs1136287 (M72T) in PEDF significantly differed between the patient and control groups. Six haplotypes in the VEGF gene and two haplotypes in the PEDF gene were significantly associated with AMD. In this study, rs1413711 of VEGF, rs1136287 of PEDF and haplotypes were identified as candidate variants associated with AMD in Korean patients.
C1 [Kim, Hyun-Seok; Kim, Yeong Hoon; Mok, Jee Won; Joo, Choun-Ki] Catholic Univ Korea, Catholic Inst Visual Sci, Coll Med, Seoul 137701, South Korea.
   [Kim, Yeong Hoon; Joo, Choun-Ki] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Seoul 137701, South Korea.
   [Joo, Choun-Ki] Seoul St Marys Hosp Eye Inst SSEI, Seoul, South Korea.
C3 Catholic University of Korea; Catholic University of Korea; Seoul St.
   Mary's Hospital
RP Joo, CK (通讯作者)，Catholic Univ Korea, Catholic Inst Visual Sci, Coll Med, 505 Banpo Dong, Seoul 137701, South Korea.
EM ckjoo@catholic.ac.kr
FU Ministry for Health & Welfare Affairs, Republic of Korea [A092258]
FX This study was supported by a Grant of the Korea Healthcare Technology
   R&D project, Ministry for Health & Welfare Affairs, Republic of Korea
   (A092258).
CR Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Awata T, 2005, BIOCHEM BIOPH RES CO, V333, P679, DOI 10.1016/j.bbrc.2005.05.167
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Chung YS, 2010, GENES GENOM, V32, P499, DOI 10.1007/s13258-010-0013-x
   Churchill AJ, 2008, INVEST OPHTH VIS SCI, V49, P3611, DOI 10.1167/iovs.07-1383
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   Darrington E, 2012, ASIAN J ANDROL, V14, P745, DOI 10.1038/aja.2011.197
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Houenou LJ, 1999, J COMP NEUROL, V412, P506
   Iizuka H, 2007, BIOCHEM BIOPH RES CO, V361, P421, DOI 10.1016/j.bbrc.2007.07.025
   Imai D, 2005, J CELL PHYSIOL, V202, P570, DOI 10.1002/jcp.20155
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Kimura R, 2005, STROKE, V36, P1259, DOI 10.1161/01.STR.0000165925.20413.14
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lee SE, 2010, DERMATOL SIN, V28, P1
   Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101
   Mohan N, 2012, J DIABETES COMPLICAT, V26, P435, DOI 10.1016/j.jdiacomp.2012.05.005
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Murugeswari P, 2008, RETINA-J RET VIT DIS, V28, P817, DOI 10.1097/IAE.0b013e31816576d5
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Rosenbaum-Dekel Y, 2005, BIOCHEM BIOPH RES CO, V332, P271, DOI 10.1016/j.bbrc.2005.04.123
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Takenaka K, 2005, LIFE SCI, V77, P3231, DOI 10.1016/j.lfs.2005.05.048
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
   Wu KF, 2012, CURR EYE RES, V37, P68, DOI 10.3109/02713683.2011.618289
   Xu YL, 2008, MOL VIS, V14, P1373
   Xu ZM, 2011, CANCER SCI, V102, P1789, DOI 10.1111/j.1349-7006.2011.02013.x
   Yamagishi S, 2002, INT J CLIN PHARM RES, V22, P67
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
NR 42
TC 1
Z9 1
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1976-9571
EI 2092-9293
J9 GENES GENOM
JI Genes Genom.
PD JUN
PY 2013
VL 35
IS 3
BP 335
EP 342
DI 10.1007/s13258-013-0090-8
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 153PI
UT WOS:000319614200007
DA 2022-11-30
ER

PT J
AU Kaur, I
   Ghanekar, Y
   Chakrabarti, S
AF Kaur, Inderjeet
   Ghanekar, Yashoda
   Chakrabarti, Subhabrata
TI Understanding the genetics of age-related macular degeneration: Some
   insights into the disease pathogenesis
SO INTERNATIONAL JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE AMD; genes; SNP; genotype; association; CFH
ID COMPLEMENT FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; APOLIPOPROTEIN-E;
   GEOGRAPHIC ATROPHY; GENOMEWIDE SCAN; Y402H VARIANT; RISK-FACTORS;
   ASSOCIATION; SUSCEPTIBILITY; MACULOPATHY
AB Age-related macular degeneration (AMD) is a late-onset complex disorder with multifactorial etiologies. Both genetic and environmental factors play a role in the disease pathogenesis. AMD is the third leading cause of blindness in the elderly. Familial aggregation, segregation studies and linkage analysis have provided both qualitative and quantitative evidence on the genetic basis in AMD. Several candidate loci have been earlier mapped in AMD but variants in genes viz. APOE, ABCA4, FBLN6 and EFEMP1 harboring these loci have accounted for only a small proportion of cases. Recent screening of two major loci has led to the identification of the Complement Factor H (CFH) on 1q32 and LOC387715 and HTRA1 on the 10q26 gene cluster. Single nucleotide polymorphisms (SNPs) in CFH (Y402H), LOC387715 (A69S) and a promoter variant in HTRA1 have been associated with AMD in large case-control cohorts. These SNPs exhibited large effect sizes and high disease odds for the risk genotypes across different populations. Interestingly, these associations have been widely replicated across multiple ethnic groups worldwide indicating their potential role in the disease pathogenesis. In this review, we would outline the genetics of AMD with special emphasis on CFH followed by other genetic variants based on studies done by our group and colleagues worldwide. We would also provide a brief overview on the possible molecular mechanisms leading to AMD.
C1 [Kaur, Inderjeet; Chakrabarti, Subhabrata] LV Prasad Eye Inst, Brien Holden Eye Res Ctr, Mol Genet Lab, Hyderabad 500034, Andhra Pradesh, India.
   [Ghanekar, Yashoda] LV Prasad Eye Inst, Sudhakar & Sreekanth Ravi Stem Cell Biol Lab, Hyderabad 500034, Andhra Pradesh, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute
RP Chakrabarti, S (通讯作者)，LV Prasad Eye Inst, Brien Holden Eye Res Ctr, Mol Genet Lab, Rd 2 Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.
EM subho@lvpei.org
RI Chakrabarti, Subhabrata/F-2468-2015; Kaur, Inderjeet/ABD-1833-2021
OI Chakrabarti, Subhabrata/0000-0003-3717-4963; 
CR *AGE REL EY DIS ST, 2005, OPHTHALMOLOGY, V11, P532
   Akimoto A, 2001, GRAEF ARCH CLIN EXP, V239, P66, DOI 10.1007/PL00007900
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Balasubramanian D, 2002, CURR SCI INDIA, V82, P948
   Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEDDON JM, 1995, JAMA-J AM MED ASSOC, V273, P622
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Todd JA, 2006, NAT GENET, V38, P731, DOI 10.1038/ng0706-731
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Tomany SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P362
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   *WHO, 2004, 282 WHO
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 82
TC 3
Z9 3
U1 0
U2 2
PU KAMLA-RAJ ENTERPRISES
PI GURGAON
PA B2-GROUND FLR, SOUTH CITY II, GURGAON, HARYANA 122 018, INDIA
SN 0972-3757
EI 2456-6330
J9 INT J HUM GENET
JI Int. J. Hum. Genet.
PD MAR-JUN
PY 2008
VL 8
IS 1-2
BP 161
EP 169
DI 10.1080/09723757.2008.11886028
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 298BM
UT WOS:000255661300015
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Tano, Y
   Ohji, M
   Kusaka, S
   Gomi, F
   Sawa, M
   Nishimaki, A
   Okai, K
   Sekimoto, N
   Kurano, M
   Takami, Y
   Akaike, A
   Hatazaki, T
   Yuzawa, M
   Ishihara, N
   Nagata, T
   Kikuchi, Y
   Orito, C
   Tanabe, M
   Matsumura, M
   Takahashi, K
   Yamazaki, Y
   Seo, J
   Sawatani, Y
   Fukunaga, C
   Nakamura, K
   Nakamura, N
   Fushimi, C
   Shiraga, F
   Takasu, I
   Katoh, M
   Okanouchi, T
   Terada, Y
   Munemiya, M
   Takesue, N
   Nishihara, S
   Horikawa, A
   Hirai, Y
   Itami, M
   Ishibashi, T
   Sonoda, K
   Murata, Y
   Tahara, Y
   Enaida, H
   Baba, K
   Koda, K
   Kikutake, K
   Kusaki, W
   Seto, H
   Tsutsumi, C
   Sasa, Y
   Shiose, S
   Bressler, SB
   Bressler, NM
   Manos, KS
   Phillips, DA
   Denbow, RL
   Lowery, ER
   Hartnett, MM
   Hawse, PL
   Orr, PR
   Yamaguchi, N
   Katashiro, T
   Furui, Y
   Yokota, N
   Arai, K
   Pandya, M
   Ueno, M
   Shimbo, Y
   Masamura, K
   Fujisawa, Y
   Ohyama, K
   Murata, Y
   Yagi, T
   Okuyama, T
   Sumiya, K
   Ishibashi, Y
   Kleinermans, D
   Deslandes, JY
   Basch, V
   Truett, K
   Mitchko, M
   Koester, J
   Viswanathan, B
   Burdan, A
   Strong, A
   Bressler, NM
   Ishibashi, T
   Shiraga, F
   Takahashi, K
   Tano, Y
   Yuzawa, M
   Kleinermans, D
   Mitchko, M
   Haynes, L
   Tano, Y
   Bressler, NM
   Okuyama, T
   Deslandes, JY
   Arai, K
   Strong, A
AF Tano, Y
   Ohji, M
   Kusaka, S
   Gomi, F
   Sawa, M
   Nishimaki, A
   Okai, K
   Sekimoto, N
   Kurano, M
   Takami, Y
   Akaike, A
   Hatazaki, T
   Yuzawa, M
   Ishihara, N
   Nagata, T
   Kikuchi, Y
   Orito, C
   Tanabe, M
   Matsumura, M
   Takahashi, K
   Yamazaki, Y
   Seo, J
   Sawatani, Y
   Fukunaga, C
   Nakamura, K
   Nakamura, N
   Fushimi, C
   Shiraga, F
   Takasu, I
   Katoh, M
   Okanouchi, T
   Terada, Y
   Munemiya, M
   Takesue, N
   Nishihara, S
   Horikawa, A
   Hirai, Y
   Itami, M
   Ishibashi, T
   Sonoda, K
   Murata, Y
   Tahara, Y
   Enaida, H
   Baba, K
   Koda, K
   Kikutake, K
   Kusaki, W
   Seto, H
   Tsutsumi, C
   Sasa, Y
   Shiose, S
   Bressler, SB
   Bressler, NM
   Manos, KS
   Phillips, DA
   Denbow, RL
   Lowery, ER
   Hartnett, MM
   Hawse, PL
   Orr, PR
   Yamaguchi, N
   Katashiro, T
   Furui, Y
   Yokota, N
   Arai, K
   Pandya, M
   Ueno, M
   Shimbo, Y
   Masamura, K
   Fujisawa, Y
   Ohyama, K
   Murata, Y
   Yagi, T
   Okuyama, T
   Sumiya, K
   Ishibashi, Y
   Kleinermans, D
   Deslandes, JY
   Basch, V
   Truett, K
   Mitchko, M
   Koester, J
   Viswanathan, B
   Burdan, A
   Strong, A
   Bressler, NM
   Ishibashi, T
   Shiraga, F
   Takahashi, K
   Tano, Y
   Yuzawa, M
   Kleinermans, D
   Mitchko, M
   Haynes, L
   Tano, Y
   Bressler, NM
   Okuyama, T
   Deslandes, JY
   Arai, K
   Strong, A
CA JAT Study Grp
TI Japanese age-related macular degeneration trial: 1-year results of
   photodynamic therapy with verteporfin in Japanese patients with
   subfoveal choroidal neovascularization secondary to age-related macular
   degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; LASER PHOTOCOAGULATION; PATHOLOGICAL MYOPIA;
   LESIONS; IMPACT
AB PURPOSE: To determine the effect and safety of verteporfin therapy (Visudyne) in Japanese age related macular degeneration (AMD) patients.
   DESIGN: Open-label, multicenter, prospective, noncontrolled study.
   METHODS: The setting was five university hospitals in Japan. The study population was patients at least 50 years old, with best,corrected visual acuity of 20/40 to 20/200 inclusive and fluorescein angiography documenting subfoveal, classic-containing choroidal neovascularization (CNV) secondary to AMD and a lesion of greatest linear dimension less than or equal to 5 5,400 mum. For the intervention, patients received verteporfin intravenously followed by light administration 15 minutes after the infusion start. Additional treatment was given every 3 months through month 9 if leakage from CNV was observed on angiogram. The main outcome measure was percentage of lesions with progression of classic CNV beyond the area of the baseline lesion.
   RESULTS: Sixty,four patients were enrolled at five centers, and 61 patients completed the study. The methan number of treatments given during the trial was three. At the 12-month examination, 12 patients (19%; 95% confidence interval: 11%-31%) had progression of classic CNV whereas 32 (50%) and 49 (77%) patients had no leakage from classic or occult CNV, respectively. The median visual acuity score (approximate Snellen equivalent) from baseline to month 12 increased from 50.0 (20/100)-56.5 (20/80(+2)) letters. Fourteen patients (22%) had visual disturbances, including two patients (3%) with acute vision decrease considered as serious adverse events and one patient (2%) with infusion. related back pain. No photosensitivity reactions were reported.
   CONCLUSIONS: Verteporfin therapy for subfoveal CNV in these Japanese patients appeared to have a similar or better angiographic and vision effect as that observed in Caucasian patients, with the same safety profile, supporting its use in Japanese patients. (C) 2003 by Elsevier Inc. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
C3 Johns Hopkins University
RP Bressler, NM (通讯作者)，Suite 115,550 N Broadway, Baltimore, MD 21205 USA.
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   MANDAI M, 1996, NIPPON GANKA GAKKAI, V38, P1045
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Matsuhashi Hideaki, 1999, Nippon Ganka Gakkai Zasshi, V103, P456
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tano Y, 2002, AM J OPHTHALMOL, V134, P645, DOI 10.1016/S0002-9394(02)01883-4
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   2003, IN PRESS ARCH OPHTHA
   2001, AM ACAD OPHTHALMOLOG
   IN PRESS AM J OPHTHA
   2002, RETINA, V22, P6
NR 22
TC 74
Z9 97
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2003
VL 136
IS 6
BP 1049
EP 1061
DI 10.1016/S0002-9394(03)00576-2
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 749MF
UT WOS:000186924000010
PM 14644215
DA 2022-11-30
ER

PT J
AU Okamoto, H
   Umeda, S
   Obazawa, M
   Minami, M
   Noda, T
   Mizota, A
   Honda, M
   Tanaka, M
   Koyama, R
   Takagi, I
   Sakamoto, Y
   Saito, Y
   Miyake, Y
   Iwata, T
AF Okamoto, H
   Umeda, S
   Obazawa, M
   Minami, M
   Noda, T
   Mizota, A
   Honda, M
   Tanaka, M
   Koyama, R
   Takagi, I
   Sakamoto, Y
   Saito, Y
   Miyake, Y
   Iwata, T
TI Complement factor H polymorphisms in Japanese population with
   age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID RISK-FACTORS; MACULOPATHY; SUSCEPTIBILITY; PREVALENCE; ATHEROSCLEROSIS;
   DISEASE; VARIANT; COMMON; SCAN
AB PURPOSE: To study the frequency of five haplotypes previously reported in the complement factor H (CFH) gene for Japanese patients with age-related macular degeneration (AMD).
   METHODS: Genomic DNA was isolated from peripheral blood samples taken from 96 Japanese AMD patients and 89 age-matched controls. All patients were diagnosed as having exudative (wet-type) AMD. The amplified polymerase chain reaction (PCR) products of CFH exons 2, 9, and 13, and intron 6 were analyzed by temperature gradient capillary electrophoresis (TGCE) and by direct sequencing. The haplotypes were identified, and their frequencies were calculated and compared with reported results.
   RESULTS: Five haplotypes were identified in the Japanese population including four already reported in the American population. The frequencies of these haplotypes were significantly different between Japanese and American in both control and case groups. The haplotype containing Y402H, which was previously reported to be associated with AMD, was only 4% in the control and case population, with a p value of 0.802. However, two other haplotypes were found as risk factors, which gave an increased likelihood of AMD of 1.9 and 2.5 fold (95% CI 1.12-3.69 and 1.42-6.38). One protective haplotype that decreased the likelihood of AMD by 1.6 fold (95% CI 0.26-0.67) was identified.
   CONCLUSIONS: The frequencies for five haplotypes previously identified were analyzed in a Japanese population with AMD. Four previously found haplotypes were identified and one additional haplotype was found. The frequencies of each haplotype were significantly different from that in found Americans affected with AMD. Two of the haplotypes were identified as risk factors and one was considered protective.
C1 Natl Hosp Org Tokyo Med Ctr, Natl Inst Sensory Organs, Cellular & Mol Biol Lab, Meguro Ku, Tokyo, Japan.
   Juntendo Univ, Urayasu Hosp, Dept Ophthalmol, Chiba, Japan.
   Tokyo Coll Biotechnol, Tokyo, Japan.
   Natl Hosp Org Kyushu Med Ctr, Div Ophthalmol, Fukuoka, Japan.
   Natl Hosp Org Osaka Med Ctr, Div Ophthalmol, Osaka, Japan.
C3 Juntendo University
RP Iwata, T (通讯作者)，Natl Hosp Org Tokyo Med Ctr, Natl Inst Sensory Organs, Cellular & Mol Biol Lab, Meguro Ku, 2-5-1 Higashigaoka, Tokyo, Japan.
EM iwatatakeshi@kankakuki.go.jp
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 15
TC 98
Z9 104
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 6
PY 2006
VL 12
IS 17
BP 156
EP 158
PG 3
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 021RU
UT WOS:000236003500001
PM 16541016
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Luu, CD
   Ayton, LN
   Goh, JK
   Lucci, LM
   Hubbard, WC
   Hageman, JL
   Hageman, GS
   Guymer, RH
AF Wu, Zhichao
   Luu, Chi D.
   Ayton, Lauren N.
   Goh, Jonathan K.
   Lucci, Lucia M.
   Hubbard, William C.
   Hageman, Jill L.
   Hageman, Gregory S.
   Guymer, Robyn H.
TI Fundus Autofluorescence Characteristics of Nascent Geographic Atrophy in
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; fundus autofluorescence; geographic
   atrophy drusen; spectral-domain optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; HIGH-RISK; MICROPERIMETRY; EYES;
   PROGRESSION; PATTERNS
AB PURPOSE. We examined the fundus autofluorescence (FAF) characteristics of nascent geographic atrophy (nGA), pathological features preceding the development of drusenassociated atrophy in eyes with age-related macular degeneration (AMD) that can be visualized using high-resolution optical coherence tomography (OCT).
   METHODS. Spectral-domain OCT (SD-OCT) and FAF imaging were performed longitudinally in 221 eyes with intermediate AMD (having at least drusen > 125 mu m), and seven areas that developed drusen-associated atrophy in five eyes were examined and categorized with respect to FAF characteristics. These categories then were used to characterize 49 areas of nGA or drusen-associated atrophy on SD-OCT identified in a cross-sectional study with 230 participants with bilateral intermediate AMD.
   RESULTS. Sequential imaging revealed that FAF characteristics in the atrophic areas could be grouped into three categories: predominantly hyperautofluorescent (hyperAF), presence of both hyper-and hypoautofluorescence (mixed AF), or predominantly hypoautofluorescent (hypoAF). In the cross-sectional study, the FAF characteristics were significantly dependent on the type of atrophic area (P = 0.002), where areas of nGA appeared most commonly as being mixed AF (63%), while areas of drusen-associated atrophy most commonly as hypoAF (86%).
   CONCLUSIONS. Fundus autofluorescence imaging revealed that areas of nGA were most commonly characterized by both hyper-and hypoautofluorescent changes, which differs from areas of drusen-associated atrophy that most often appeared hypoautofluorescent. These findings provide important insights into the FAF characteristics of areas undergoing atrophic changes in eyes still considered to be in the early stages of AMD by current methods, and thus assist in the characterization of disease severity in these early stages.
C1 [Wu, Zhichao; Luu, Chi D.; Ayton, Lauren N.; Goh, Jonathan K.; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3010, Australia.
   [Lucci, Lucia M.; Hubbard, William C.; Hageman, Jill L.; Hageman, Gregory S.] Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Ctr Translat Med, Salt Lake City, UT USA.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Utah System of Higher Education; University of
   Utah
RP Wu, ZC (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM wu.z@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Guymer, Robyn/0000-0002-9441-4356;
   Luu, Chi/0000-0002-7604-7097
FU National Health and Medical Research Council (NHMRC; Canberra,
   Australia) Project [1027624]; NHMRC practitioner fellowship [529905];
   Macular Degeneration Foundation research grant; BrightFocus Foundation;
   Menzies Foundation; National Institutes of Health (NIH) [R24 EY017404];
   Department of Ophthalmology and Visual Sciences from Research to Prevent
   Blindness, Inc.; NHMRC Centre for Clinical Research Excellence Award
   [529923]; NATIONAL EYE INSTITUTE [R24EY017404] Funding Source: NIH
   RePORTER
FX Supported by National Health and Medical Research Council (NHMRC;
   Canberra, Australia) Project Grant 1027624, NHMRC practitioner
   fellowship #529905 (RHG), a Macular Degeneration Foundation research
   grant (GSH and RHG), BrightFocus Foundation, The Menzies Foundation,
   National Institutes of Health (NIH; Bethesda, MD, USA) Grant R24
   EY017404 (GSH), and an unrestricted grant to the University of Utah John
   A. Moran Eye Center, and Department of Ophthalmology and Visual Sciences
   from Research to Prevent Blindness, Inc. Centre for Eye Research
   Australia receives Operational Infrastructure Support from the Victorian
   Government and is supported by an NHMRC Centre for Clinical Research
   Excellence Award (#529923).
CR Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Freund KB, 2013, JAMA OPHTHALMOL, V131, P1645, DOI 10.1001/jamaophthalmol.2013.5030
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jobling AI, 2014, FASEB J, V29, P696
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
NR 36
TC 47
Z9 47
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2015
VL 56
IS 3
BP 1546
EP 1552
DI 10.1167/iovs.14-16211
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE9BF
UT WOS:000352137600017
PM 25678689
OA Green Published
DA 2022-11-30
ER

PT J
AU Wieberdink, RG
   Ho, L
   Ikram, MK
   Koudstaal, PJ
   Hofman, A
   de Jong, PTVM
   Vingerling, JR
   Breteler, MMB
AF Wieberdink, Renske G.
   Ho, Lintje
   Ikram, M. Kamran
   Koudstaal, Peter J.
   Hofman, Albert
   de Jong, Paulus T. V. M.
   Vingerling, Johannes R.
   Breteler, Monique M. B.
TI Age-Related Macular Degeneration and the Risk of Stroke The Rotterdam
   Study
SO STROKE
LA English
DT Article
DE age-related macular degeneration; cerebral infarction; epidemiology;
   intracerebral hemorrhage; risk factors
ID INTRACEREBRAL HEMORRHAGE; ATHEROSCLEROSIS; MACULOPATHY; POLYMORPHISM;
   POPULATION; DISEASE
AB Background and Purpose-Age-related macular degeneration (AMD) and stroke are both frequent diseases in the elderly. A link between AMD and stroke has been suggested, because both disorders have many risk factors in common. The aim of this study was to investigate the association between AMD and stroke and the subtypes cerebral infarction and intracerebral hemorrhage in the general elderly population.
   Methods-This study was part of the population-based Rotterdam Study and included 6207 participants aged >= 55 years who were stroke-free at baseline (1990 to 1993). Signs of AMD were assessed on fundus photographs at baseline and at regular follow-up examinations and were categorized in 5 stages (0 to 4) representing an increasing severity. Late AMD (Stage 4) was subdivided into dry and wet AMD. Follow-up for incident stroke was complete up to January 1, 2007. Data were analyzed using time-dependent Cox regression models adjusted for age, sex, and potential confounders.
   Results-During a median follow-up of 13.6 years, 726 participants developed a stroke (397 cerebral infarction, 59 intracerebral hemorrhage, 270 unspecified). Late AMD was associated with an increased risk of any stroke (hazard ratio, 1.56; 95% CI, 1.08 to 2.26) due to a strong association with intracerebral hemorrhage (hazard ratio, 6.11; 95% CI, 2.34 to 15.98). In contrast, late AMD was not associated with cerebral infarction. Earlier AMD stages were not associated with risk of stroke or any of its subtypes.
   Conclusions-We found that late AMD is strongly associated with intracerebral hemorrhage, but not with cerebral infarction, in the general elderly population. (Stroke. 2011;42:2138-2142.)
C1 [Wieberdink, Renske G.; Ho, Lintje; Ikram, M. Kamran; Hofman, Albert; Vingerling, Johannes R.; Breteler, Monique M. B.] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands.
   [Wieberdink, Renske G.; Ikram, M. Kamran; Koudstaal, Peter J.] Erasmus MC, Dept Neurol, NL-3000 CA Rotterdam, Netherlands.
   [Ho, Lintje; Ikram, M. Kamran; Vingerling, Johannes R.] Erasmus MC, Dept Ophthalmol, NL-3000 CA Rotterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Amsterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of
   Amsterdam; Academic Medical Center Amsterdam; Royal Netherlands Academy
   of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)
RP Breteler, MMB (通讯作者)，Erasmus MC, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM m.breteler@erasmusmc.nl
RI Breteler, Monique M.B./J-5058-2014
OI Breteler, Monique M.B./0000-0002-0626-9305; Ikram, Mohammad
   Kamran/0000-0003-0173-9571
FU Erasmus Medical Center Rotterdam; Erasmus University Rotterdam;
   Netherlands Organization for Scientific Research (NWO); Netherlands
   Organization for Health Research and Development (ZonMW); Research
   Institute for Diseases in the Elderly (RIDE); Ministry of Education,
   Culture and Science; Ministry of Health, Welfare and Sports; European
   Commission; Municipality of Rotterdam; Stichting Lijf en Leven, Krimpen
   aan de Lek; MD Fonds, Utrecht; Rotterdamse Vereniging Blindenbelangen,
   Rotterdam; Stichting Oogfonds Nederland, Utrecht; Blindenpenning,
   Amsterdam; Blindenhulp, The Hague; Algemene Nederlandse Vereniging ter
   Voorkoming van Blindheid, Doorn; Landelijke Stichting voor Blinden en
   Slechtzienden, Utrecht; Swart van Essen, Rotterdam; Stichting
   Winckel-Sweep, Utrecht; Henkes Stichting, Rotterdam; Lameris Ootech BV,
   Nieuwegein; Medical Workshop, de Meern; Topcon Europe BV, Capelle aan de
   IJssel
FX The Rotterdam Study is supported by the Erasmus Medical Center
   Rotterdam, the Erasmus University Rotterdam, The Netherlands
   Organization for Scientific Research (NWO), The Netherlands Organization
   for Health Research and Development (ZonMW), the Research Institute for
   Diseases in the Elderly (RIDE), the Ministry of Education, Culture and
   Science, the Ministry of Health, Welfare and Sports, the European
   Commission (DG XII), and the Municipality of Rotterdam. This study was
   supported by grants from the following institutions: Stichting Lijf en
   Leven, Krimpen aan de Lek; MD Fonds, Utrecht; Rotterdamse Vereniging
   Blindenbelangen, Rotterdam; Stichting Oogfonds Nederland, Utrecht;
   Blindenpenning, Amsterdam; Blindenhulp, The Hague; Algemene Nederlandse
   Vereniging ter Voorkoming van Blindheid, Doorn; Landelijke Stichting
   voor Blinden en Slechtzienden, Utrecht; Swart van Essen, Rotterdam;
   Stichting Winckel-Sweep, Utrecht; Henkes Stichting, Rotterdam; Lameris
   Ootech BV, Nieuwegein; Medical Workshop, de Meern; and Topcon Europe BV,
   Capelle aan de IJssel, all in the Netherlands. The sponsors or funding
   organizations had no role in the design, conduct, analysis or
   publication of this research.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bots ML, 1996, ANN EPIDEMIOL, V6, P147, DOI 10.1016/1047-2797(96)00001-4
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hofman A, 2009, EUR J EPIDEMIOL, V24, P553, DOI 10.1007/s10654-009-9386-z
   Hollander M, 2003, J NEUROL NEUROSUR PS, V74, P317, DOI 10.1136/jnnp.74.3.317
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sturgeon JD, 2008, STROKE, V39, P2268, DOI 10.1161/STROKEAHA.107.505800
   Sudlow C, 2006, STROKE, V37, P364, DOI 10.1161/01.STR.0000199065.12908.62
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vliegenthart R, 2002, AM J EPIDEMIOL, V155, P332, DOI 10.1093/aje/155.4.332
   WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0
NR 27
TC 22
Z9 22
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
J9 STROKE
JI Stroke
PD AUG
PY 2011
VL 42
IS 8
BP 2138
EP 2142
DI 10.1161/STROKEAHA.111.616359
PG 5
WC Clinical Neurology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 796UE
UT WOS:000293077400012
PM 21680903
OA Bronze
DA 2022-11-30
ER

PT J
AU Dinc, UA
   Yenerel, M
   Gorgun, E
   Oncel, M
AF Dinc, U. A.
   Yenerel, M.
   Gorgun, E.
   Oncel, M.
TI Assessment of macular function by microperimetry in intermediate
   age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Intermediate age-related macular degeneration; Microperimetry
AB PURPOSE. To evaluate retrospectively macular function by microperimetry (MP) in intermediate age-related macular degeneration (AMD).
   METHODS. Thirty eyes of 30 patients with intermediate AMD and a visual acuity of 20/32 or better were enrolled in the study. Macular function in patients with intermediate AMD and age-matched control group were carried out with MP1 microperimeter. Mean sensitivity (MS), mean defect (MD) parameters, fixation patterns, and localizations were evaluated. Mann-Whitney U test was used for the comparison of macular function parameters between the intermediate AMD group and the control group.
   RESULTS. MS was 12.7 +/- 2.8 dB and MD was detected as -6.2 +/- 2.2 dB in the intermediate AMD group by MP. Fixation patterns were stable in 22 eyes, relatively unstable in 7 eyes, and unstable in 1 eye. Fixation location was predominantly central in 19 eyes, poor central in 5 eyes, and predominantly eccentric in 6 eyes. In the control group MS was 18.0 +/- 0.6 dB and MD was -1.9 +/- 0.6 dB. When compared with control group, the decrease in MS and the increase in MD were statistically significant in the intermediate AMD group (p=0.001 and p=0.001, respectively).
   CONCLUSIONS. Assessment of retinal sensitivity with MP1 microperimeter is a rapid, safe and noninvasive diagnostic method. Early macular function loss in intermediate AMD can be precisely detected by MP1 microperimeter before significant visual impairment is established and it is also useful for demonstrating the shift in the localization and the stability of fixation prior to progression of intermediate AMD to advanced and exudative stage. (Eur J Ophthalmol 2008; 18: 595-600)
C1 [Dinc, U. A.; Yenerel, M.; Gorgun, E.; Oncel, M.] Yeditepe Univ, Hosp Eye, TR-34349 Istanbul, Turkey.
C3 Yeditepe University
RP Dinc, UA (通讯作者)，Yeditepe Univ, Hosp Eye, Sakir Kesebir Sokak 28, TR-34349 Istanbul, Turkey.
EM umutdinc@yahoo.com
CR Age-Related Eye Disease Study Research Group, 2000, J NUTR, V130, p1516S
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hikichi T, 2000, ARCH OPHTHALMOL-CHIC, V118, P193
   Jarc-Vidmar M, 2006, EYE, V20, P688, DOI 10.1038/sj.eye.6701949
   JOHNSON CA, 1988, J OPT SOC AM A, V5, P2131, DOI 10.1364/JOSAA.5.002131
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P84, DOI 10.1136/bjo.2007.124016
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Midena E, 2006, Arch Soc Esp Oftalmol, V81, P183
   Midena E, 2007, PERIMETRY FUNDUS INT, P15
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Mori F, 2001, AM J OPHTHALMOL, V132, P897, DOI 10.1016/S0002-9394(01)01216-8
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   Richter-Mueksch S, 2007, AM J OPHTHALMOL, V144, P23, DOI 10.1016/j.ajo.2007.03.045
   SJAARDA RN, 1993, AM J OPHTHALMOL, V116, P129, DOI 10.1016/S0002-9394(14)71276-0
   Springer C, 2006, OPHTHALMOLOGE, V103, P791, DOI 10.1007/s00347-006-1396-6
   Uusitalo MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P41
   Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141
   Yodoi Y, 2007, AM J OPHTHALMOL, V143, P984, DOI 10.1016/j.ajo.2007.01.026
NR 27
TC 22
Z9 24
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL-AUG
PY 2008
VL 18
IS 4
BP 595
EP 600
DI 10.1177/112067210801800416
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V20HH
UT WOS:000208130600016
PM 18609481
DA 2022-11-30
ER

PT J
AU Reibaldi, M
   Longo, A
   Pulvirenti, A
   Avitabile, T
   Russo, A
   Cillino, S
   Mariotti, C
   Casuccio, A
AF Reibaldi, Michele
   Longo, Antonio
   Pulvirenti, Alfredo
   Avitabile, Teresio
   Russo, Andrea
   Cillino, Salvatore
   Mariotti, Cesare
   Casuccio, Alessandra
TI Geo-Epidemiology of Age-Related Macular Degeneration: New Clues Into the
   Pathogenesis
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VITAMIN-D DEFICIENCY; RISK-FACTORS; JAPANESE POPULATION; SUNLIGHT
   EXPOSURE; HYPOVITAMINOSIS D; 10-YEAR INCIDENCE; ADULT-POPULATION; SUN
   EXPOSURE; PREVALENCE; MACULOPATHY
AB PURPOSE: To evaluate the demographic, geographic, and race-related variables that account for geographic variability in prevalence rates of age-related macular degeneration (AMD).
   DESIGN: Systematic review, meta-regression, and decision-tree analysis.
   METHODS: A systematic literature review of PubMed, Medline, Web of Science, and Embase databases identified population-based studies on the prevalence of AMD published before May 2014. Only population-based studies that took place in a spatially explicit geographic area that could be geolocalized, and used retinal photographs and standardized grading classifications, were included. Latitude and longitude data (geolocalization) and the mean annual insolation for the area where survey took place were obtained. Age-standardized prevalence rates across studies were estimated using the direct standardization method. Correlations between the prevalence of AMD and longitude and latitude were obtained by regression analysis. A hierarchical Bayesian metaregression approach was used to assess the association between the prevalence of AMD and other relevant factors. We further investigated the interplay between location and these factors on the prevalence of AMD using regression based on conditional-inference decision trees.
   RESULTS: We observed significant inverse correlations between latitude or longitude, and crude or age-standardized prevalence rates, of early and late AMD (P < .001). Metaregression analysis showed that insolation, latitude, longitude, age, and race have a significant effect on the prevalence rates of early and late, AMD (P < .001). Decision-tree analysis identified that the most important predictive variable was race for early AMP (P =.002) and insolation for late AMD (P = .001).
   CONCLUSIONS: Geographic position and insolation are key factors in the prevalence of AMD. (C) 2016 by Elsevier Inc. All rights reserved.
C1 [Reibaldi, Michele; Longo, Antonio; Avitabile, Teresio; Russo, Andrea] Univ Catania, Dept Ophthalmol, I-95124 Catania, Italy.
   [Pulvirenti, Alfredo] Univ Catania, Dept Clin & Expt Med, I-95124 Catania, Italy.
   [Cillino, Salvatore] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Palermo, Italy.
   [Casuccio, Alessandra] Univ Palermo, Dept Sci Hlth Promot & Mother Child Care, Palermo, Italy.
   [Mariotti, Cesare] Univ Ancona, Dept Ophthalmol, Ancona, Italy.
C3 University of Catania; University of Catania; University of Palermo;
   University of Palermo; Marche Polytechnic University
RP Reibaldi, M (通讯作者)，Univ Catania, Dept Ophthalmol, Via S Sofia 78, I-95124 Catania, Italy.
EM mreibaldi@libero.it
RI Longo, Antonio/AAC-6092-2022; casuccio, alessandra/B-1730-2013;
   Reibaldi, Michele/AAL-1113-2021; Pulvirenti, Alfredo/I-7272-2018;
   Avitabile, Teresio/AAC-6076-2022; Russo, Andrea/AAC-5349-2022
OI casuccio, alessandra/0000-0002-5676-9535; Pulvirenti,
   Alfredo/0000-0002-9764-0295; Russo, Andrea/0000-0002-7725-5971;
   Reibaldi, Michele/0000-0003-1368-6729; LONGO,
   Antonio/0000-0002-9525-1800
CR Andersen MVN, 2008, OPHTHALMOLOGY, V115, P700, DOI 10.1016/j.ophtha.2007.12.013
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   Arabi A, 2010, NAT REV ENDOCRINOL, V6, P550, DOI 10.1038/nrendo.2010.146
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Cantorna MT, 2006, PROG BIOPHYS MOL BIO, V92, P60, DOI 10.1016/j.pbiomolbio.2006.02.020
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cochrane Consumers and Communication Review Group, 2011, DAT EXTR TEMPL COCHR
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Fowkes FGR, 2013, LANCET, V382, P1329, DOI 10.1016/S0140-6736(13)61249-0
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Graffe A, 2012, J AM GERIATR SOC, V60, P1367, DOI 10.1111/j.1532-5415.2012.04015.x
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Jenchitr W, 2011, OPHTHAL EPIDEMIOL, V18, P48, DOI 10.3109/09286586.2010.545502
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kozobolis VP, 1999, ARCH OPHTHALMOL-CHIC, V117, P664
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Krishnaiah S, 2009, BRIT J OPHTHALMOL, V93, P1146, DOI 10.1136/bjo.2009.159723
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lionetti E, 2014, NEW ENGL J MED, V371, P1295, DOI 10.1056/NEJMoa1400697
   Mathenge W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001393
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Mullin GE, 2007, NUTR CLIN PRACT, V22, P305, DOI 10.1177/0115426507022003305
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   National Aeronautics and Space Administration (NASA) Atmospheric Science Data Center, SURF MET SOL EN INT
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Pham TQ, 2009, OPHTHAL EPIDEMIOL, V16, P136, DOI 10.1080/09286580701299395
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Shapira Y, 2010, J AUTOIMMUN, V34, pJ168, DOI 10.1016/j.jaut.2009.11.018
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   South A, 2011, R J, V3, P35
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   United States Census Bureau, WORLD POP AG SEX
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vinding T, 1995, Acta Ophthalmol Scand Suppl, P1
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood S., 2006, GEN ADDITIVE MODELS, P1
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
NR 79
TC 26
Z9 27
U1 2
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2016
VL 161
BP 78
EP 93
DI 10.1016/j.ajo.2015.09.031
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA2NG
UT WOS:000367632300012
PM 26432929
DA 2022-11-30
ER

PT J
AU Mookiah, MRK
   Acharya, UR
   Fujita, H
   Koh, JEW
   Tan, JH
   Noronha, K
   Bhandary, SV
   Chua, CK
   Lim, CM
   Laude, A
   Tong, L
AF Mookiah, Muthu Rama Krishnan
   Acharya, U. Rajendra
   Fujita, Hamido
   Koh, Joel E. W.
   Tan, Jen Hong
   Noronha, Kevin
   Bhandary, Sulatha V.
   Chua, Chua Kuang
   Lim, Choo Min
   Laude, Augustinus
   Tong, Louis
TI Local configuration pattern features for age-related macular
   degeneration characterization and classification
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Retina; Age-related macular degeneration; Fundus imaging; Local
   configuration pattern; Support vector machine
ID DIABETIC-RETINOPATHY; AUTOMATIC DETECTION; DRUSEN DETECTION; RETINAL
   IMAGES; SEGMENTATION; EXTRACTION; DIAGNOSIS; DISEASE; RECOGNITION;
   SYSTEM
AB Age-related Macular Degeneration (AMD) is an irreversible and chronic medical condition characterized by drusen, Choroidal Neovascularization (CNV) and Geographic Atrophy (GA). AMD is one of the major causes of visual loss among elderly people. It is caused by the degeneration of cells in the macula which is responsible for central vision. AMD can be dry or wet type, however dry AMD is most common. It is classified into early, intermediate and late AMD. The early detection and treatment may help one to stop the progression of the disease. Automated AMD diagnosis may reduce the screening time of the clinicians. In this work, we have introduced LCP to characterize normal and AMD classes using fundus images. Linear Configuration Coefficients (CC) and Pattern Occurrence (PO) features are extracted from fundus images. These extracted features are ranked using p-value of the t-test and fed to various supervised classifiers viz. Decision Tree (DT), Nearest Neighbour (k-NN), Naive Bayes (NB), Probabilistic Neural Network (PNN) and Support Vector Machine (SVM) to classify normal and AMD classes. The performance of the system is evaluated using both private (Kasturba Medical Hospital, Manipal, India) and public domain datasets viz. Automated Retinal Image Analysis (ARIA) and STructured Analysis of the Retina (STARE) using ten-fold cross validation. The proposed approach yielded best performance with a highest average accuracy of 97.78%, sensitivity of 98.00% and specificity of 97.50% for STARE dataset using 22 significant features. Hence, this system can be used as an aiding tool to the clinicians during mass eye screening programs to diagnose AMD. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Mookiah, Muthu Rama Krishnan; Acharya, U. Rajendra; Koh, Joel E. W.; Tan, Jen Hong; Chua, Chua Kuang] Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
   [Acharya, U. Rajendra] SIM Univ, Sch Sci & Technol, Dept Biomed Engn, Singapore 599491, Singapore.
   [Acharya, U. Rajendra] Univ Malaya, Fac Engn, Dept Biomed Engn, Kuala Lumpur 50603, Malaysia.
   [Fujita, Hamido] Iwate Prefectural Univ, Fac Software & Informat Sci, Takizawa, Iwate 0200693, Japan.
   [Noronha, Kevin] St Francis Inst Technol, Dept Elect & Telecommun, Bombay 400103, Maharashtra, India.
   [Bhandary, Sulatha V.] Kasturba Med Coll & Hosp, Dept Ophthalmol, Manipal 576104, Karnataka, India.
   [Lim, Choo Min] Ngee Ann Polytech, Sch Engn, Singapore 599489, Singapore.
   [Laude, Augustinus] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.
   [Tong, Louis] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Tong, Louis] Singapore Eye Res Inst, Ocular Surface Res Grp, Singapore 168751, Singapore.
   [Tong, Louis] Duke NUS Grad Med Sch, Singapore 169857, Singapore.
   [Tong, Louis] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117597, Singapore.
C3 Singapore University of Social Sciences (SUSS); Universiti Malaya; Iwate
   Prefectural University; Manipal Academy of Higher Education (MAHE);
   Kasturba Medical College, Manipal; Tan Tock Seng Hospital; Singapore
   National Eye Center; National University of Singapore; Singapore
   National Eye Center; National University of Singapore; National
   University of Singapore
RP Mookiah, MRK (通讯作者)，Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
EM mkm2@np.edu.sg
RI NORONHA, KEVIN/AAV-1433-2020; Mookiah, Muthu Rama Krishnan/G-4033-2011;
   Fujita, Hamido/D-6249-2012; Tan, Jenhong/AAD-3664-2020; Acharya,
   Rajendra U/E-3791-2010; Tan, Jen Hong/ABE-6525-2020
OI NORONHA, KEVIN/0000-0002-8753-5918; Mookiah, Muthu Rama
   Krishnan/0000-0001-6437-1482; Fujita, Hamido/0000-0001-5256-210X;
   Acharya, Rajendra U/0000-0003-2689-8552; Tong,
   Louis/0000-0002-3986-6552; Bhandary, Sulatha/0000-0002-3150-707X
FU Social Innovation Research Fund (SIRF) [T1202]
FX Authors thank Social Innovation Research Fund (SIRF/Project Code:
   T1202), Singapore for providing grant for this research. Also authors
   would like to acknowledge Head of Department and all staff members of
   Department of Ophthalmology, Kasturba Medical College, Manipal, India
   for sharing the images for this study.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   [Anonymous], 1998, STAT LEARNING THEORY
   Antal B, 2012, IEEE T BIO-MED ENG, V59, P1720, DOI 10.1109/TBME.2012.2193126
   Barriga E, 2009, IEEE INT S COMP BAS, P1
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Ben Sbeh Z, 2001, IEEE T MED IMAGING, V20, P1321, DOI 10.1109/42.974927
   Bhuiyan A., 2014, J COMPUT SCI SYST BI, V7
   Bock R, 2010, MED IMAGE ANAL, V14, P471, DOI 10.1016/j.media.2009.12.006
   Brandon L, 2003, LECT NOTES COMPUT SC, V2878, P618
   Burlina P, 2011, IEEE ENG MED BIO, P3962, DOI 10.1109/IEMBS.2011.6090984
   Cheng J, 2012, IEEE IMAGE PROC, P2805, DOI 10.1109/ICIP.2012.6467482
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Chowriappa P, 2013, COMPUT BIOL MED, V43, P2156, DOI 10.1016/j.compbiomed.2013.10.003
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delany P, 2007, MULTIPLE CLASSIFIER, P1, DOI [10.1016/S0031-3203(00)00099-6, DOI 10.1145/3459665]
   Duda R.O., 2000, PATTERN CLASSIFICATI, DOI https://doi.org/10.1007/978-3-319-57027-3_4
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Freund DE, 2009, I S BIOMED IMAGING, P61, DOI 10.1109/ISBI.2009.5192983
   Galar M, 2015, KNOWL-BASED SYST, V81, P76, DOI 10.1016/j.knosys.2015.02.008
   Gun A., 2008, FUNDAMENTALS STAT, VI
   Guo Y, 2011, BMVC, P1, DOI DOI 10.5244/C.25.119.PP.199.1-199.10
   Gutierrez-Rodriguez AE, 2015, KNOWL-BASED SYST, V82, P70, DOI 10.1016/j.knosys.2015.02.019
   Haleem MS, 2013, COMPUT MED IMAG GRAP, V37, P581, DOI 10.1016/j.compmedimag.2013.09.005
   Hijazi M. H. A., 2015, INT J SIMUL SYST SCI, P57
   Hijazi MHA, 2010, P INT JOINT C NEUR N, P3501
   Hijazi MHA, 2012, KNOWL-BASED SYST, V29, P83, DOI 10.1016/j.knosys.2011.07.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kohavi R., 1995, IJCAI-95. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence, P1137
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Kwak JT, 2015, EXPERT SYST APPL, V42, P4529, DOI 10.1016/j.eswa.2015.01.055
   Lam L, 1997, IEEE T SYST MAN CY A, V27, P553, DOI 10.1109/3468.618255
   Liang ZY, 2010, IEEE ENG MED BIO, P4100, DOI 10.1109/IEMBS.2010.5627289
   Mookiah MRK, 2013, KNOWL-BASED SYST, V39, P9, DOI 10.1016/j.knosys.2012.09.008
   Mookiah M. R. K., 2013, J MECH MED BIOL, V13
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   Mookiah MRK, 2013, COMPUT BIOL MED, V43, P2136, DOI 10.1016/j.compbiomed.2013.10.007
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   NORMANDO EM, 2013, DRUG DISCOV TODAY TH, V10, pe35
   Ojala T, 2002, IEEE T PATTERN ANAL, V24, P971, DOI 10.1109/TPAMI.2002.1017623
   PIZER SM, 1987, COMPUT VISION GRAPH, V39, P355, DOI 10.1016/S0734-189X(87)80186-X
   Quellec G, 2011, IEEE T MED IMAGING, V30, P523, DOI 10.1109/TMI.2010.2089383
   Raffei AFM, 2015, KNOWL-BASED SYST, V74, P40, DOI 10.1016/j.knosys.2014.11.002
   Ramlugun GS, 2012, EXPERT SYST APPL, V39, P1141, DOI 10.1016/j.eswa.2011.07.115
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Roweis ST, 2000, SCIENCE, V290, P2323, DOI 10.1126/science.290.5500.2323
   SAFAVIAN SR, 1991, IEEE T SYST MAN CYB, V21, P660, DOI 10.1109/21.97458
   Santos-Villalobos H, 2011, IEEE ENG MED BIO, P6236, DOI 10.1109/IEMBS.2011.6091540
   Singh K., BOOTSTRAP STAT UNPUB
   Soliz P, 2008, 2008 IEEE SOUTHWEST SYMPOSIUM ON IMAGE ANALYSIS & INTERPRETATION, P65, DOI 10.1109/SSIAI.2008.4512286
   SPECHT DF, 1990, NEURAL NETWORKS, V3, P109, DOI 10.1016/0893-6080(90)90049-Q
   Tomar D, 2015, KNOWL-BASED SYST, V81, P131, DOI 10.1016/j.knosys.2015.02.009
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   You WJ, 2014, KNOWL-BASED SYST, V55, P15, DOI 10.1016/j.knosys.2013.10.004
   Zarbin M., 2008, SURV OPHTHALMOL, V53
   Zhao MB, 2015, KNOWL-BASED SYST, V76, P148, DOI 10.1016/j.knosys.2014.12.014
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
   Zuiderveld K., 1994, GRAPHICS GEMS, VIV, P474, DOI [10.1016/b978-0-12-336156-1.50061-6, DOI 10.1016/B978-0-12-336156-1.50061-6]
NR 61
TC 31
Z9 31
U1 0
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD AUG 1
PY 2015
VL 63
BP 208
EP 218
DI 10.1016/j.compbiomed.2015.05.019
PG 11
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA CN2RJ
UT WOS:000358269300023
PM 26093788
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Glowacki, S
   Kauppinen, A
   Kaarniranta, K
AF Blasiak, Janusz
   Glowacki, Sylwester
   Kauppinen, Anu
   Kaarniranta, Kai
TI Mitochondrial and Nuclear DNA Damage and Repair in Age-Related Macular
   Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; DNA damage; DNA repair; mitochondrial
   DNA; oxidative stress
ID BASE EXCISION-REPAIR; RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS;
   HYDROGEN-PEROXIDE; SMOKE EXPOSURE; DISEASE; INDUCTION; PATHWAYS; URACIL;
   RECOMBINATION
AB Aging and oxidative stress seem to be the most important factors in the pathogenesis of age-related macular degeneration (AMD), a condition affecting many elderly people in the developed world. However, aging is associated with the accumulation of oxidative damage in many biomolecules, including DNA. Furthermore, mitochondria may be especially important in this process because the reactive oxygen species produced in their electron transport chain can damage cellular components. Therefore, the cellular response to DNA damage, expressed mainly through DNA repair, may play an important role in AMD etiology. In several studies the increase in mitochondrial DNA (mtDNA) damage and mutations, and the decrease in the efficacy of DNA repair have been correlated with the occurrence and the stage of AMD. It has also been shown that mitochondrial DNA accumulates more DNA lesions than nuclear DNA in AMD. However, the DNA damage response in mitochondria is executed by nucleus-encoded proteins, and thus mutagenesis in nuclear DNA (nDNA) may affect the ability to respond to mutagenesis in its mitochondrial counterpart. We reported that lymphocytes from AMD patients displayed a higher amount of total endogenous basal and oxidative DNA damage, exhibited a higher sensitivity to hydrogen peroxide and UV radiation, and repaired the lesions induced by these factors less effectively than did cells from control individuals. We postulate that poor efficacy of DNA repair (i.e., is impaired above average for a particular age) when combined with the enhanced sensitivity of retinal pigment epithelium cells to environmental stress factors, contributes to the pathogenesis of AMD. Collectively, these data suggest that the cellular response to both mitochondrial and nuclear DNA damage may play an important role in AMD pathogenesis.
C1 [Blasiak, Janusz; Glowacki, Sylwester] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90236 Lodz, Poland.
   [Kauppinen, Anu; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70211, Finland.
C3 University of Lodz; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland
RP Blasiak, J (通讯作者)，Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
EM jblasiak@biol.uni.lodz.pl; sglowa@biol.uni.lodz.pl;
   anu.kauppinen@uef.fi; Kai.Kaarniranta@kuh.fi
OI Kaarniranta, Kai/0000-0003-2600-8679; Blasiak,
   Janusz/0000-0001-9539-9584
CR Akbari M, 2008, DNA REPAIR, V7, P605, DOI 10.1016/j.dnarep.2008.01.002
   Alexandrov K, 2010, TOXICOL LETT, V198, P63, DOI 10.1016/j.toxlet.2010.04.009
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bacman SR, 2009, NUCLEIC ACIDS RES, V37, P4218, DOI 10.1093/nar/gkp348
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Ballinger SW, 2002, CIRCULATION, V106, P544, DOI 10.1161/01.CIR.0000023921.93743.89
   Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Beard WA, 2010, MUTAT RES-GEN TOX EN, V703, P18, DOI 10.1016/j.mrgentox.2010.07.013
   Bharati S, 1998, NUCLEIC ACIDS RES, V26, P4953, DOI 10.1093/nar/26.21.4953
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Boesch P, 2011, BBA-MOL CELL RES, V1813, P186, DOI 10.1016/j.bbamcr.2010.10.002
   Boesch P, 2010, NUCLEIC ACIDS RES, V38, P1478, DOI 10.1093/nar/gkp1143
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Copeland WC, 2008, MOL CELL, V32, P457, DOI 10.1016/j.molcel.2008.11.007
   Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354
   de Souza-Pinto NC, 2009, DNA REPAIR, V8, P704, DOI 10.1016/j.dnarep.2009.01.021
   Delaney S, 2012, FREE RADICAL RES, V46, P420, DOI 10.3109/10715762.2011.653968
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Durik M, 2012, CIRCULATION, V126, P468, DOI 10.1161/CIRCULATIONAHA.112.104380
   Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978-94-007-2869-1_7
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fischer F, 2012, TRENDS BIOCHEM SCI, V37, P284, DOI 10.1016/j.tibs.2012.02.004
   Garinis GA, 2008, NAT CELL BIOL, V10, P1241, DOI 10.1038/ncb1108-1241
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Harman D, 2006, ANN NY ACAD SCI, V1067, P10, DOI 10.1196/annals.1354.003
   Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015
   Hecht SS, 2008, CHEM RES TOXICOL, V21, P160, DOI 10.1021/tx7002068
   Hu JP, 2005, J BIOL CHEM, V280, P40544, DOI 10.1074/jbc.M508772200
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003
   Jarrett SG, 2007, OPHTHALMIC RES, V39, P213, DOI 10.1159/000104683
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kalariya NM, 2009, CURR EYE RES, V34, P737, DOI 10.1080/02713680903046855
   Kalifa L, 2009, DNA REPAIR, V8, P1242, DOI 10.1016/j.dnarep.2009.07.008
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kazak L, 2012, NAT REV MOL CELL BIO, V13, P659, DOI 10.1038/nrm3439
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Knight-Lozano CA, 2002, CIRCULATION, V105, P849, DOI 10.1161/hc0702.103977
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Lakshmipathy U, 1999, NUCLEIC ACIDS RES, V27, P1198, DOI 10.1093/nar/27.4.1198
   LeDoux SP, 2001, PROG NUCLEIC ACID RE, V68, P273
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liu P, 2008, MOL CELL BIOL, V28, P4975, DOI 10.1128/MCB.00457-08
   Liu PF, 2010, ENVIRON MOL MUTAGEN, V51, P417, DOI 10.1002/em.20576
   Mason PA, 2003, NUCLEIC ACIDS RES, V31, P1052, DOI 10.1093/nar/gkg167
   McCall MR, 1999, FREE RADICAL BIO MED, V26, P1034, DOI 10.1016/S0891-5849(98)00302-5
   Nair J, 2005, CARCINOGENESIS, V26, P1307, DOI 10.1093/carcin/bgi073
   Naviaux RK, 2012, J PHARMACOL EXP THER, V342, P608, DOI 10.1124/jpet.112.192120
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Park MJ, 2009, DNA REPAIR, V8, P1190, DOI 10.1016/j.dnarep.2009.06.004
   Pitceathly RDS, 2012, NEUROMUSCULAR DISORD, V22, P577, DOI 10.1016/j.nmd.2012.03.009
   Poe BG, 2007, ANAL BIOCHEM, V362, P193, DOI 10.1016/j.ab.2006.12.035
   Ralph SJ, 2010, MOL ASPECTS MED, V31, P145, DOI 10.1016/j.mam.2010.02.008
   Rasmussen AK, 2005, MITOCHONDRION, V5, P411, DOI 10.1016/j.mito.2005.08.003
   Ruchko MV, 2011, FREE RADICAL BIO MED, V50, P1107, DOI 10.1016/j.freeradbiomed.2010.10.692
   Sage JM, 2010, J BIOL CHEM, V285, P18984, DOI 10.1074/jbc.M109.099846
   Shabalina IG, 2011, BIOCHEM SOC T, V39, P1305, DOI 10.1042/BST0391305
   Stierum RH, 1999, NUCLEIC ACIDS RES, V27, P3712, DOI 10.1093/nar/27.18.3712
   Strunnikova N, 2005, FREE RADICAL BIO MED, V39, P781, DOI 10.1016/j.freeradbiomed.2005.04.029
   Synowiec E, 2012, EXP EYE RES, V98, P58, DOI 10.1016/j.exer.2012.02.008
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Valavanidis A, 2009, INT J ENV RES PUB HE, V6, P445, DOI 10.3390/ijerph6020445
   Vegh MJ, 2012, J PROTEOME RES, V11, P1855, DOI 10.1021/pr201203m
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wang AL, 2008, MOL VIS, V14, P644
   WATERS R, 1975, J BACTERIOL, V121, P901, DOI 10.1128/JB.121.3.901-906.1975
   Yang Z, 2004, CIRCULATION, V110, P3715, DOI 10.1161/01.CIR.0000149747.82157.01
   Yang Z, 2007, MUTAT RES-FUND MOL M, V621, P61, DOI 10.1016/j.mrfmmm.2007.02.010
   Zhang HS, 2011, ADV EXP MED BIOL, V701, P201, DOI 10.1007/978-1-4419-7756-4_27
NR 80
TC 64
Z9 66
U1 2
U2 36
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1661-6596
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2013
VL 14
IS 2
BP 2996
EP 3010
DI 10.3390/ijms14022996
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 096IR
UT WOS:000315397900043
PM 23434654
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Sun, E
   Lim, A
   Liu, XP
   Snellingen, T
   Wang, NL
   Liu, NP
AF Sun, Erdan
   Lim, Apiradee
   Liu, Xipu
   Snellingen, Torkel
   Wang, Ningli
   Liu, Ningpu
TI Apolipoprotein E gene and age-related macular degeneration in a Chinese
   population
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; LONG-TERM INCIDENCE; CHOLESTEROL TRANSPORT;
   EPSILON-4 ALLELE; E POLYMORPHISMS; RISK; ASSOCIATION; MACULOPATHY;
   EXPRESSION; SMOKING
AB Purpose: To examine the association between apolipoprotein E (APOE) polymorphisms and age-related macular degeneration (AMD) in a Chinese population.
   Methods: The study consisted of 712 subjects, including 201 controls, 363 cases with early AMD, and 148 cases with exudative AMD. Genomic DNA was extracted from venous blood leukocytes. Common allelic variants of APOE (epsilon 2, epsilon 3, and epsilon 4) were analyzed by PCR and direct sequencing.
   Results: APOE epsilon 3 epsilon 3 was the most frequent genotype, with a frequency of 72.6% in controls, 72.5% in early AMD, and 70.3% in exudative AMD. Frequency of the epsilon 2 allele was 6.7% in controls, 7.4% in early AMD, and 8.8% in exudative AMD. Frequency of the epsilon 4 allele was 8.7% in controls, 7.7% in early AMD, and 7.8% in exudative AMD. No statistically significant difference in APOE genotype and allele frequency distribution was observed among controls, cases with early AMD, and cases with exudative AMD. For epsilon 2 allele carriers, the odds ratio was 1.12 (95% confidence interval [CI], 0.65-1.93) for early AMD and 1.06 (95% CI, 0.53-2.10) for exudative AMD. For epsilon 4 allele carriers, the odds ratio was 1.04 (95% CI, 0.61-1.75) for early AMD and 0.83 (95% CI, 0.42-1.62) for exudative AMD.
   Conclusions: Our data provide no evidence to support an association of APOE polymorphisms with early or exudative AMD, suggesting that APOE is less likely to be a major AMD susceptibility gene in the Chinese population.
C1 [Sun, Erdan; Wang, Ningli; Liu, Ningpu] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China.
   [Lim, Apiradee] Prince Songkla Univ, Fac Sci & Technol, Dept Math & Comp Sci, Pattani, Thailand.
   [Liu, Xipu; Snellingen, Torkel] Sekwa Eye Hosp, Beijing, Peoples R China.
C3 Capital Medical University; Prince of Songkla University
RP Liu, NP (通讯作者)，Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM nliu001@gmail.com
FU National Basic Research Program of China (973 Program) [2007CB512201];
   Beijing Municipal Health Bureau [2009208]; National Natural Science
   Foundation of China [81070734]
FX This work was supported by the National Basic Research Program of China
   (973 Program) Grant 2007CB512201, the Beijing Municipal Health Bureau
   Grant 2009208, and the National Natural Science Foundation of China
   Grant 81070734.
CR Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Friedman DA, 2007, MED HYPOTHESES, V68, P1047, DOI 10.1016/j.mehy.2006.09.049
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Kovacs Katalin A, 2007, Ideggyogy Sz, V60, P169
   Lee SJ, 2007, J MICROBIOL BIOTECHN, V17, P1024
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   OLAISEN B, 1982, HUM GENET, V62, P233, DOI 10.1007/BF00333526
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   PITAS RE, 1987, J BIOL CHEM, V262, P14352
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tikellis G, 2007, ARCH OPHTHALMOL-CHIC, V125, P68, DOI 10.1001/archopht.125.1.68
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Utheim OA, 2008, ACTA OPHTHALMOL, V86, P401, DOI 10.1111/j.1600-0420.2007.01070.x
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 38
TC 14
Z9 17
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 20
PY 2011
VL 17
IS 111
BP 997
EP 1002
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 755OX
UT WOS:000289944100001
PM 21541275
DA 2022-11-30
ER

PT J
AU Maynard, ML
   Zele, AJ
   Feigl, B
AF Maynard, Michelle L.
   Zele, Andrew J.
   Feigl, Beatrix
TI Melanopsin-Mediated Post-Illumination Pupil Response in Early
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE intrinsically photosensitive retinal ganglion cells; ipRGCs; melanopsin;
   post-illumination pupil response; pupil light reflex
ID RETINAL GANGLION-CELLS; MULTIFOCAL ELECTRORETINOGRAM; INJURY-RESISTANT;
   ASSESSING ROD; LIGHT REFLEX; CONE; MACULOPATHY; PUPILLOGRAPHY;
   PRESERVATION; ADAPTATION
AB PURPOSE. To determine whether melanopsin-expressing intrinsically photosensitive retinal ganglion cell (ipRGC) inputs to the pupil light reflex (PLR) are affected in early age-related macular degeneration (AMD).
   METHODS. The PLR was measured in 40 participants (20 early AMD and 20 age-matched controls) using a custom-built Maxwellian view pupillometer. Sinusoidal stimuli (0.5 Hz, 11.9 seconds duration, 35.6 degrees diameter) were presented to the study eye and the consensual pupil response was measured to lights with high melanopsin excitation (464 nm [blue]) and with low melanopsin excitation (638 nm [red]) that biased activation to the outer retina. Two melanopsin PLR metrics were quantified: the phase amplitude percentage (PAP) during the sinusoidal stimulus presentation and the post-illumination pupil response (PIPR). The PLR during stimulus presentation was analyzed using latency to constriction, the transient pupil response and maximum pupil constriction metrics. Diagnostic accuracy was evaluated using receiver operating characteristic (ROC) curves.
   RESULTS. The blue PIPR was significantly less sustained in the early AMD group (P < 0.001). The red PIPR was not significantly different between groups (P > 0.05). The PAP and blue stimulus constriction amplitude were significantly lower in the early AMD group (P < 0.05). There was no significant difference between groups in the latency or transient amplitude for both stimuli (P > 0.05). ROC analysis showed excellent diagnostic accuracy for the blue PIPR metrics (area under the curve > 0.9).
   CONCLUSIONS. This is the initial report that the melanopsin-controlled PIPR is dysfunctional in early AMD. The noninvasive, objective measurement of the ipRGC controlled PIPR has excellent diagnostic accuracy for early AMD.
C1 [Maynard, Michelle L.; Zele, Andrew J.; Feigl, Beatrix] Queensland Univ Technol, Med Retina & Visual Sci Labs, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Maynard, Michelle L.; Feigl, Beatrix] Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld 4059, Australia.
   [Zele, Andrew J.] Queensland Univ Technol, Sch Optometry & Vis Sci, Brisbane, Qld 4059, Australia.
   [Feigl, Beatrix] Queensland Eye Inst, South Brisbane, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); Queensland University of Technology (QUT); Queensland
   Eye Institute
RP Feigl, B (通讯作者)，Queensland Univ Technol, Sch Biomed Sci, Inst Hlth & Biomed Innovat, 60 Musk Ave, Brisbane, Qld 4059, Australia.
EM andrew.zele@qut.edu.au; b.feigl@qut.edu.au
OI Zele, Andrew/0000-0003-0291-9929; Feigl, Beatrix/0000-0001-7198-7373;
   Maynard, Michelle/0000-0002-7678-3414
CR Adhikari P, 2015, INVEST OPHTH VIS SCI, V56, P3838, DOI 10.1167/iovs.14-16233
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Asakawa K, 2014, KITASATO MED J, V44, P195
   Barrionuevo PA, 2014, INVEST OPHTH VIS SCI, V55, P719, DOI 10.1167/iovs.13-13252
   Belenky MA, 2003, J COMP NEUROL, V460, P380, DOI 10.1002/cne.10652
   Berson DM, 2010, J COMP NEUROL, V518, P2405, DOI 10.1002/cne.22381
   Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262
   Brozou CG, 2009, EUR J OPHTHALMOL, V19, P254, DOI 10.1177/112067210901900213
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Cui Q, 2015, NEUROSCIENCE, V284, P845, DOI 10.1016/j.neuroscience.2014.11.002
   Dacey DM, 2005, NATURE, V433, P749, DOI 10.1038/nature03387
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Do MTH, 2009, NATURE, V457, P281, DOI 10.1038/nature07682
   Do MTH, 2010, PHYSIOL REV, V90, P1547, DOI 10.1152/physrev.00013.2010
   Esquiva G, 2013, INVEST OPHTH VIS SCI, V54, P4605, DOI 10.1167/iovs.13-12120
   Feigl B, 2005, INVEST OPHTH VIS SCI, V46, P4722, DOI 10.1167/iovs.05-0795
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Feigl B, 2014, OPTOMETRY VISION SCI, V91, P894, DOI 10.1097/OPX.0000000000000284
   Feigl B, 2012, ACTA OPHTHALMOL, V90, pe230, DOI 10.1111/j.1755-3768.2011.02226.x
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P4362, DOI 10.1167/iovs.10-7069
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Gamlin PDR, 2007, VISION RES, V47, P946, DOI 10.1016/j.visres.2006.12.015
   Garcia-Ayuso D, 2015, INVEST OPHTH VIS SCI, V56, P4592, DOI 10.1167/iovs.15-16808
   Gracitelli CPB, 2014, INVEST OPHTH VIS SCI, V55, P7997, DOI 10.1167/iovs.14-15146
   Guler AD, 2008, NATURE, V453, P102, DOI 10.1038/nature06829
   Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609
   Herbst K., 2011, FRONT NEUROL, V2, P1
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Joyce DS, 2015, VISION RES, V107, P58, DOI 10.1016/j.visres.2014.12.001
   Jusuf PR, 2007, EUR J NEUROSCI, V26, P2906, DOI 10.1111/j.1460-9568.2007.05924.x
   Kankipati L, 2011, INVEST OPHTH VIS SCI, V52, P2287, DOI 10.1167/iovs.10-6023
   Kankipati L, 2010, INVEST OPHTH VIS SCI, V51, P2764, DOI 10.1167/iovs.09-4717
   Kardon R, 2011, OPHTHALMOLOGY, V118, P376, DOI 10.1016/j.ophtha.2010.06.033
   Kardon R, 2009, OPHTHALMOLOGY, V116, P1564, DOI 10.1016/j.ophtha.2009.02.007
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Kawasaki A, 2014, EXP EYE RES, V120, P161, DOI 10.1016/j.exer.2013.11.005
   Kawasaki A, 2012, INVEST OPHTH VIS SCI, V53, P5562, DOI 10.1167/iovs.12-10230
   Kawasaki A, 2010, CLIN EXP OPHTHALMOL, V38, P322, DOI 10.1111/j.1442-9071.2010.02212.x
   La Morgia C, 2010, BRAIN, V133, P2426, DOI 10.1093/brain/awq155
   Li RS, 2006, INVEST OPHTH VIS SCI, V47, P2951, DOI 10.1167/iovs.05-1295
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Lucas RJ, 2001, NAT NEUROSCI, V4, P621, DOI 10.1038/88443
   Markwell EL, 2010, CLIN EXP OPTOM, V93, P137, DOI 10.1111/j.1444-0938.2010.00479.x
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   McDougal DH, 2010, VISION RES, V50, P72, DOI 10.1016/j.visres.2009.10.012
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Moura ALA, 2013, INVEST OPHTH VIS SCI, V54, P4471, DOI 10.1167/iovs.12-11137
   Muller LPD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093274
   Mure LS, 2007, J BIOL RHYTHM, V22, P411, DOI 10.1177/0748730407306043
   Nakayama M, 2014, EURASIP J BIOINFORM, DOI 10.1186/s13637-014-0018-x
   Ostergaard J, 2007, INVEST OPHTH VIS SCI, V48, P3812, DOI 10.1167/iovs.06-1322
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Panda S, 2002, SCIENCE, V298, P2213, DOI 10.1126/science.1076848
   Park JC, 2011, INVEST OPHTH VIS SCI, V52, P6624, DOI 10.1167/iovs.11-7586
   Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000
   Robinson GA, 2004, VISION RES, V44, P2667, DOI 10.1016/j.visres.2004.06.010
   Rosli Y, 2012, VISION RES, V69, P42, DOI 10.1016/j.visres.2012.07.019
   Sabeti F, 2014, OPTOMETRY VISION SCI, V91, P904, DOI 10.1097/OPX.0000000000000319
   Sabeti F, 2013, GRAEF ARCH CLIN EXP, V251, P1707, DOI 10.1007/s00417-013-2273-z
   Sabeti F, 2011, OPTOMETRY VISION SCI, V88, P1477, DOI 10.1097/OPX.0b013e318235af61
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   van de Kraats J, 2007, J OPT SOC AM A, V24, P1842, DOI 10.1364/JOSAA.24.001842
   Vugler AA, 2008, VISUAL NEUROSCI, V25, P125, DOI 10.1017/S0952523808080309
   Zele AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017860
   Zhou Y, 2014, CAN J OPHTHALMOL, V49, pE20, DOI 10.1016/j.jcjo.2013.10.008
NR 68
TC 31
Z9 35
U1 2
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2015
VL 56
IS 11
BP 6906
EP 6913
DI 10.1167/iovs.15-17357
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB0YQ
UT WOS:000368235100094
PM 26505464
DA 2022-11-30
ER

PT J
AU Puell, MC
   Barrio, AR
   Palomo-Alvarez, C
   Gomez-Sanz, FJ
   Clement-Corral, A
   Perez-Carrasco, MJ
AF Puell, Maria C.
   Barrio, Ana R.
   Palomo-Alvarez, Catalina
   Gomez-Sanz, Fernando J.
   Clement-Corral, Amaya
   Perez-Carrasco, Maria J.
TI Impaired Mesopic Visual Acuity in Eyes with Early Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MEDIATED MULTIFOCAL ELECTRORETINOGRAM; GEOGRAPHIC ATROPHY;
   DARK-ADAPTATION; MACULOPATHY; LUMINANCE; VISION; CHART; CLASSIFICATION;
   DYSFUNCTION; SYSTEM
AB PURPOSE. To determine photopic and mesopic distance high-contrast visual acuity (HC-VA) and low-contrast visual acuity (LC-VA) in eyes with early age-related macular degeneration (AMD).
   METHODS. Measurements were made in 22 subjects with early AMD and 28 healthy control subjects. Inclusion criteria included a photopic HC-VA of 20/25 or better. Distance VA was measured using HC (96%) and LC (10%) Bailey-Lovie logMAR letter charts under photopic (85 cd/m(2)) and mesopic (0.1-0.2 cd/m(2)) luminance conditions.
   RESULTS. Mean mesopic distance HC-VA and LC-VA were significantly worse (0.1 logMAR and 0.28 logMAR, respectively) in the early AMD group than in the control group. Under mesopic conditions, the mean difference between LC-VA and HC-VA was significantly greater in the early AMD (0.45 logMAR) than the control group (0.27 logMAR). Mean differences between mesopic versus photopic HC-VA and mesopic versus photopic LC-VA were significantly greater in the early AMD than the control group (0.13 and 0.32 logMAR of difference between the means, respectively). Sensitivity and specificity were significantly greater for mesopic LC-VA than for mesopic HC-VA (Receiver Operating Characteristics, area under the curve [AUC], 0.94 +/- 0.030 and 0.76 +/- 0.067, respectively). AUC values for photopic HC-VA and LC-VA were below 0.70.
   CONCLUSIONS. Visual acuity testing under low luminance conditions emerged as an optimal quantitative measure of retinal function in early AMD. (Invest Ophthalmol Vis Sci. 2012; 53: 7310-7314) DOI: 10.1167/iovs.11-8649
C1 [Puell, Maria C.] Univ Complutense, Sch Opt & Optometry, Appl Vis Res Grp, Madrid 28037, Spain.
   [Gomez-Sanz, Fernando J.; Clement-Corral, Amaya] Hosp Henares, Madrid, Spain.
C3 Complutense University of Madrid
RP Puell, MC (通讯作者)，Univ Complutense, Sch Opt & Optometry, Appl Vis Res Grp, Ave Arcos de Jalon 118, Madrid 28037, Spain.
EM puellma@fis.ucm.es
RI Puell, MarÃa/ABE-2972-2021; Barrio, Ana/J-7246-2017
OI Palomo-Alvarez, Catalina/0000-0003-2110-678X
FU Fundacion Investigacion Medica Mutua Madrilena Grant [FMM-02538/2008];
   Banco Santander-Universidad Complutense de Madrid Grant [GR 58/08]
FX Supported by Fundacion Investigacion Medica Mutua Madrilena Grant
   FMM-02538/2008 and Banco Santander-Universidad Complutense de Madrid
   Grant GR 58/08.
CR Abadi RV, 1996, OPHTHAL PHYSL OPT, V16, P455, DOI 10.1046/j.1475-1313.1996.96000129.x
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Applegate RA, 2006, OPTOMETRY VISION SCI, V83, P635, DOI 10.1097/01.opx.0000232842.60932.af
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   Cho P, 2004, OPHTHAL PHYSL OPT, V24, P427, DOI 10.1111/j.1475-1313.2004.00216.x
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Feigl B, 2006, CURR EYE RES, V31, P635, DOI 10.1080/02713680600762739
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Haegerstrom-Portnoy G, 2005, OPTOMETRY VISION SCI, V82, P87, DOI 10.1097/01.OPX.0000153162.05903.4C
   HaegerstromPortnoy G, 1997, INVEST OPHTH VIS SCI, V38, P207
   Hazel CA, 2002, OPTOMETRY VISION SCI, V79, P788, DOI 10.1097/00006324-200212000-00011
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Leinonen J, 2005, ACTA OPHTHALMOL SCAN, V83, P328, DOI 10.1111/j.1600-0420.2005.00469.x
   Linden A, 2006, J EVAL CLIN PRACT, V12, P132, DOI 10.1111/j.1365-2753.2005.00598.x
   Lovie-Kitchin J, 1989, Ophthalmic Physiol Opt, V9, P456, DOI 10.1016/0275-5408(89)90268-8
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Lovie-Kitchin JE, 1989, CLIN EXP OPTOM, V72, P79
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Petzold A, 2006, OPHTHAL PHYSL OPT, V26, P326, DOI 10.1111/j.1475-1313.2006.00417.x
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schneck ME, 2004, VISION RES, V44, P2317, DOI 10.1016/j.visres.2004.04.018
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
NR 34
TC 44
Z9 45
U1 0
U2 18
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2012
VL 53
IS 11
BP 7310
EP 7314
DI 10.1167/iovs.11-8649
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030SH
UT WOS:000310589900077
PM 23033386
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Metelitsina, TI
   Grunwald, JE
   DuPont, JC
   Ying, GS
AF Metelitsina, TI
   Grunwald, JE
   DuPont, JC
   Ying, GS
TI Effect of niacin on the choroidal circulation of patients with age
   related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLOOD-FLOW; REGION
AB Aim: To investigate the effects of niacin on choroidal blood flow in age related macular degeneration (AMD).
   Methods: 12 AMD patients with bilateral drusen and visual acuity of 20/40 or better in the study eye received a single oral dose of niacin (six subjects received 500 mg and six received 250 mg) or matching placebo on two separate occasions. Laser Doppler flowmetry was used to assess relative choroidal blood velocity (ChB(Vel)), volume (ChB(Vol)), and flow (ChB(Flow)) in the foveola of the study eye at baseline, 30, and 90 minutes after dosing.
   Results: In comparison with placebo, a statistically significant 24% increase in ChB(Vol) was observed 30 minutes after niacin administration (ANOVA, p=0.01). In comparison with placebo, a significant decrease in ChB(Vel) of 23% was observed in the 500 mg group (p=0.04) and no significant change in ChB(Vel) was seen in the 250 mg group at 30 minutes. No significant changes in ChB(Flow) were detected at 30 or 90 minutes. Also, there were no statistically significant changes in ChB(Vol) or ChB(Vel) at 90 minutes.
   Conclusion: In comparison with placebo, a significant 24% increase in ChB(Vol) was observed 30 minutes after niacin administration. Owing to simultaneous decrease in ChB(Vel), however, no significant change in ChB(Flow) was detected.
C1 Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Grunwald, JE (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM juangrun@mail.med.upenn.edu
FU NEI NIH HHS [EY 12769] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY012769] Funding Source: NIH RePORTER
CR [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Callanan D, 1998, JAMA-J AM MED ASSOC, V279, P1702, DOI 10.1001/jama.279.21.1702-b
   CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5
   CHANDRA SR, 1979, ARCH OPHTHALMOL-CHIC, V97, P1331, DOI 10.1001/archopht.1979.01020020073017
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Clark AB, 1997, AM J MANAG CARE, V3, P1211
   CRAIG CR, 1986, MODERN PHARM, P1
   DUKEELDER S, 1966, SYSTEM OPHTHALMOLOGY, V9, P609
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Gadegbeku CA, 2003, AM J HYPERTENS, V16, P67, DOI 10.1016/S0895-7061(02)03196-5
   GASS JDM, 1973, AM J OPHTHALMOL, V76, P500, DOI 10.1016/0002-9394(73)90738-1
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Knopp RH, 1999, NEW ENGL J MED, V341, P498, DOI 10.1056/NEJM199908123410707
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   MARROW JD, 1989, PROSTAGLANDINS, V28, P263
   MILLAY RH, 1988, OPHTHALMOLOGY, V95, P930
   MORROW JD, 1992, J INVEST DERMATOL, V98, P812, DOI 10.1111/1523-1747.ep12499963
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Petrig BL, 1996, OCULAR BLOOD FLOW, P120
   PRUNTE C, 1988, GRAEF ARCH CLIN EXP, V226, P55, DOI 10.1007/BF02172719
   RIVA CE, 1992, EXP EYE RES, V55, P499, DOI 10.1016/0014-4835(92)90123-A
   Riva CE, 1996, OCULAR BLOOD FLOW, P128
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Spirn MJ, 2003, AM J OPHTHALMOL, V135, P913, DOI 10.1016/S0002-9394(02)02296-1
   WILKIN JK, 1982, CLIN PHARMACOL THER, V31, P478, DOI 10.1038/clpt.1982.63
NR 30
TC 9
Z9 10
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2004
VL 88
IS 12
BP 1568
EP 1572
DI 10.1136/bjo.2004.046607
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 871VP
UT WOS:000225165000023
PM 15548814
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Gehlbach, P
   Li, TJ
   Hatef, E
AF Gehlbach, Peter
   Li, Tianjing
   Hatef, Elham
TI Statins for age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Hydroxymethylglutaryl-CoA Reductase Inhibitors [therapeutic use];
   Macular Degeneration [prevention & control]; Randomized Controlled
   Trials as Topic; Simvastatin [therapeutic use]; Humans; Middle Aged
ID REDUCTASE INHIBITORS STATINS; 5-YEAR INCIDENCE; MACULOPATHY;
   PROGRESSION; RISK; PREVALENCE; COHORT; SERUM
AB Background
   Age-related macular degeneration (AMD) is a progressive, late-onset disorder of the macula affecting central vision. It is the leading cause of blindness in people over 65 years in industrialized countries. Recent epidemiologic, genetic, and pathological evidence has shown that AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective effects in AMD.
   Objectives
   The objective of this review was to examine the effectiveness of statins compared with other treatments, no treatment, or placebo in delaying the onset and progression of AMD.
   Search methods
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 3), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLD MEDLINE (January 1946 to March 2016), EMBASE (January 1980 toMarch 2016), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to March 2016), PubMed (January 1946 to March 2016), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com) (last searched 5 June 2014), ClinicalTrials.gov (www.clinicaltrials.gov), and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 31 March 2016.
   Selection criteria
   We included randomized controlled trials (RCTs) and quasi-randomized trials that compared statins with other treatments, no treatment, or placebo in people who were diagnosed as having the early stages of AMD.
   Data collection and analysis
   We used standard methodological procedures expected by Cochrane. Two review authors independently evaluated the search results against the selection criteria, abstracted data, and assessed risk of bias. We did not perform meta-analysis due to heterogeneity in the interventions and outcomes between the included studies.
   Main results
   Two RCTs with a total of 144 participants met the selection criteria. Both trials compared simvastatin versus placebo in older people (older than 50 or 60 years) with high risk of developing AMD (drusen present on examination). Overall, we judged the quality of the evidence to be low, as we downgraded all outcomes due to limitations in the designs of the trials and insufficient outcome reporting. The larger trial, with 114 participants, was conducted in Australia and used a higher dose (40 mg daily) of simvastatin for three years. Participants and study personnel in this trial were adequately masked, however data were missing for 30% of participants at three years' follow-up. The smaller trial, with 30 participants, was conducted in Italy and used a lower dose (20 mg) of simvastatin for three months. This trial reported insufficient details to assess the risk of bias.
   Neither trial reported data for change in visual acuity. Low-quality evidence from the smaller trial, with 30 participants, did not show a statistically significant difference between the simvastatin and placebo groups in visual acuity values at three months of treatment (decimal visual acuity 0.21 +/- 0.56 in simvastatin group and 0.19 +/- 0.40 in placebo group) or 45 days after the completion of treatment (decimal visual acuity 0.20 +/- 0.50 in simvastatin group and 0.19 +/- 0.48 in placebo group). The lack of a difference in visual acuity was not explained by lens or retina status, which remained unchanged during and after the treatment period for both groups.
   Preliminary analyses of 42 participants who had completed 12 months' follow-up in the larger trial did not show a statistically significant difference between simvastatin and the placebo groups for visual acuity, drusen score, or visual function (effect estimates and confidence intervals were not available). Complete data for these outcomes at three years' follow-up were not reported. At three years, low-quality evidence showed an effect of simvastatin in slowing progression of AMD compared with placebo to be uncertain (odds ratio 0.51, 95% confidence interval 0.23 to 1.09).
   One trial did not report adverse outcomes. The second trial reported no difference between groups in terms of adverse events such as death, muscle aches, and acute hepatitis.
   Authors' conclusions
   Evidence from currently available RCTs is insufficient to conclude that statins have a role in preventing or delaying the onset or progression of AMD.
C1 [Gehlbach, Peter] Johns Hopkins Univ, Sch Med, Retina Div, Wilmer Eye Inst, 1550 Orleans St,Canc Res Bldg 2, Baltimore, MD 21231 USA.
   [Li, Tianjing] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Hatef, Elham] Johns Hopkins Bloomberg Sch Publ Hlth JHBSPH, Dept Hlth Policy & Management, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health; Johns
   Hopkins University; Johns Hopkins Bloomberg School of Public Health
RP Gehlbach, P (通讯作者)，Johns Hopkins Univ, Sch Med, Retina Div, Wilmer Eye Inst, 1550 Orleans St,Canc Res Bldg 2, Baltimore, MD 21231 USA.
EM pgelbach@jhmi.edu
FU Johns Hopkins Bloomberg School of Public Health, USA; National Eye
   Institute, National Institutes of Health, USA [1 U01 EY020522]; National
   Institute for Health Research, UK; Department of Health through National
   Institute for Health Research; NIHR; NATIONAL EYE INSTITUTE
   [U01EY020522] Funding Source: NIH RePORTER
FX Internal sources; Johns Hopkins Bloomberg School of Public Health, USA.;
   External sources; Grant 1 U01 EY020522, National Eye Institute, National
   Institutes of Health, USA.; National Institute for Health Research, UK.;
   Richard Wormald, Co-ordinating Editor for Cochrane Eyes and Vision (CEV)
   acknowledges financial support for his CEV research sessions from the
   Department of Health through the award made by the National Institute
   for Health Research to Moorfields Eye Hospital NHS Foundation Trust and
   UCL Institute of Ophthalmology for a Specialist Biomedical Research
   Centre for Ophthalmology.; The NIHR also funds the CEV Editorial Base in
   London.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   [Anonymous], 1994, Arch Ophthalmol, V112, P500
   Berendschot TTJM, 2009, BRIT J NUTR, V101, P1607, DOI 10.1017/S0007114508111448
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Della Valle V, 2000, ANN OTTALMOLOGIA CLI, V126, P89
   Della Valle V, 2000, ANN OTTALMOLOGIA CLI, V126, P249
   Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20
   Drobek-Slowik Monika, 2008, Klin Oczna, V110, P50
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Gehlbach P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub2
   Gehlbach P, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006927, DOI 10.1002/14651858.CD006927]
   Gehlbach P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub4
   Gehlbach P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub3
   Geltzer A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub3
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011
   Guymer RH, 2005, INVEST OPHTH VIS SCI, V46
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2003, INVESTIGATIVE OPHTHA, V44
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Li TJ, 2014, J CLIN EPIDEMIOL, V67, P15, DOI 10.1016/j.jclinepi.2013.08.013
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Mao YQ, 2009, INT J OPHTHALMOLOGY, V9, P1521
   MARTINI E, 1991, Annali di Ottalmologia e Clinica Oculistica, V117, P1121
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nordic Cochrane Centre, 2014, REV MAN REVMAN COMP
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Sagara N, 2007, EXP EYE RES, V84, P1074, DOI 10.1016/j.exer.2007.02.005
   Sen K, 2002, DIABETES RES CLIN PR, V56, P1, DOI 10.1016/S0168-8227(01)00341-2
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smeeth L, 2009, BRIT J CLIN PHARMACO, V67, P99, DOI 10.1111/j.1365-2125.2008.03308.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
NR 54
TC 28
Z9 28
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2016
IS 8
AR CD006927
DI 10.1002/14651858.CD006927.pub5
PG 35
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EE4TK
UT WOS:000389598000025
PM 27490232
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Baumal, CR
AF Baumal, Caroline R.
TI Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the
   Injection Burden
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID ANTI-VEGF THERAPY; GEOGRAPHIC ATROPHY; ABICIPAR-PEGOL; VISUAL-ACUITY;
   RANIBIZUMAB; BEVACIZUMAB; DISEASE; GROWTH; OUTCOMES; IMPACT
AB The burden of age-related macular degeneration (AMD), a leading cause of vision loss in the elderly population, is poised to increase dramatically as the baby boomer generation ages. Fortunately, the prognosis of neovascular AMD has improved dramatically since anti-vascular endothelial growth factor (VEGF) agents reached the market 15 years ago. In large-scale clinical trials, anti-VEGF utilization maintained visual acuity in more than 90% of patients. However, providing anti-VEGF treatment requires the specialized expertise of retina specialists and is labor intensive and costly. Further, results in clinical practice do not always measure up to those obtained in rigorous phase 3 trials. Undertreatment and the burden on patients and caregivers from frequent anti-VEGF injections contribute to suboptimal visual acuity results in the real world. As a consequence, retinal specialists are focused on finding effective strategies to extend the dosing interval. These include individualized optical coherence tomography-guided dosing regimens, longer acting new agents with similar or new mechanisms of action, and sustained release delivery devices. With the recent approval of brolucizumab, the neovascular AMD armamentarium has expanded to 4 anti-VEGF agents, and more are in development. Understanding the treatment landscape is a key issue in managed care due to the substantial cost of anti-VEGF medications. The goal of this article is to provide managed care clinicians with an up-to-date assessment of currently available agents, followed by a preview of some investigational agents that could alter the future treatment landscape. These agents include abicipar pegol, faricimab, the ranibizumab port delivery system, an intravitreal bevacizumab formulation, and anti-VEGF biosimilars.
C1 [Baumal, Caroline R.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Baumal, Caroline R.] New England Eye Ctr, Boston, MA 02116 USA.
C3 Tufts University
RP Baumal, CR (通讯作者)，Tufts Univ, Sch Med, Boston, MA 02111 USA.; Baumal, CR (通讯作者)，New England Eye Ctr, Boston, MA 02116 USA.
EM cbaumal@tuftsmedicalcenter.org
FU Genentech
FX This activity is supported by an educational grant from Genentech.
CR Andersen DJ, 2019, J VITREORETINAL DIS, V3, P354, DOI [10.1177/2474126419858462, DOI 10.1177/2474126419858462]
   Angermann R, 2019, GRAEF ARCH CLIN EXP, V257, P2119, DOI 10.1007/s00417-019-04414-y
   [Anonymous], 2019, WORLD REP VIS
   [Anonymous], 2018, PRESCRIBING INFORM
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Bhandari S, 2020, OPHTHALMOLOGY, V127, P369, DOI 10.1016/j.ophtha.2019.10.006
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown D., 2017, J VITREORETINAL DIS, V1, P294, DOI [10.1177/2474126417725946, DOI 10.1177/2474126417725946]
   Callum D, 2018, J OCUL PHARMACOL TH, DOI [10.1089/jop.2018.006, DOI 10.1089/JOP.2018.006]
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Corporate presentation, 2019, OUTL THER
   Danzig C, 2019, ASS RES VIS OPTH M A
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Freund K.B., 2019, J VITR DIS, V3, P167, DOI [10.1177/2474126419834702, DOI 10.1177/2474126419834702]
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garratt S., 2019, AGE RELATED MACULAR
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Isaac David Leonardo Cruvinel, 2007, Arq. Bras. Oftalmol., V70, P771, DOI 10.1590/S0004-27492007000500009
   IVAN STUD INV, 2012, OPHTHALMOLOGY, V119, P1399, DOI DOI 10.1016/J.0PHTHA.2012.04.015
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Keenan TD, 2019, OPHTHALMOLOGY, V126, P1647, DOI 10.1016/j.ophtha.2019.06.023
   Khurana RN, 2017, JAMA OPHTHALMOL, V135, P800, DOI 10.1001/jamaophthalmol.2017.1815
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein C, 2019, METHODS, V154, P21, DOI 10.1016/j.ymeth.2018.11.008
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kunzmann K., 2018, MD MAGAZINE
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   MAGUIRE S, 2012, ISSUE BRIEF, V17, DOI DOI 10.5153/SRO.2517
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massamba N, 2015, EYE, V29, P1453, DOI 10.1038/eye.2015.128
   McLaughlin MD, 2017, OPHTHALMOLOGY, V124, P667, DOI 10.1016/j.ophtha.2017.01.001
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moisseiev E, 2020, EYE, V34, P605, DOI 10.1038/s41433-019-0584-y
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Olson D., 2019, J VITREORETIN DIS, V3, P211, DOI [10.1177/2474126419849199, DOI 10.1177/2474126419849199]
   Parikh R, 2019, JAMA OPHTHALMOL, V137, P914, DOI 10.1001/jamaophthalmol.2019.1947
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rajan K., UPDATE BROLUCIZUMABS
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmid MK, 2019, EYE, V33, P1584, DOI 10.1038/s41433-019-0455-6
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Sharma A, 2020, EYE, V34, P797, DOI 10.1038/s41433-019-0607-8
   Sharma A, 2020, EYE, V34, P424, DOI 10.1038/s41433-019-0582-0
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Soares RR, 2020, OPHTHALMOL RETINA, V4, P134, DOI 10.1016/j.oret.2019.07.010
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Staes C, 2013, AM J HEALTH-SYST PH, V70, P1301, DOI 10.2146/ajhp130049
   Stewart MW, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010021
   Stone TW, 2019, ASRS 2019 PREFERENCE
   Tomkins-Netzer O, 2019, 2019 ASS RES VIS OPT
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   Vraylar, 2019, PRESCRIBING INFORM, DOI [Accessed May 20, 2020, ZYVOX&REG; (Linezolid) .]
   Weiss M, 2018, RETINA-J RET VIT DIS, V38, P2293, DOI 10.1097/IAE.0000000000001892
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yannuzzi NA, 2015, JAMA OPHTHALMOL, V133, P32, DOI 10.1001/jamaophthalmol.2014.3591
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 82
TC 9
Z9 10
U1 0
U2 3
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAY
PY 2020
VL 26
IS 5
SU S
BP S103
EP S111
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; General & Internal Medicine
GA PW7VJ
UT WOS:000610877700001
PM 32479026
DA 2022-11-30
ER

PT J
AU Rogers, AH
   Greenberg, PB
   Martidis, A
   Puliafito, CA
AF Rogers, AH
   Greenberg, PB
   Martidis, A
   Puliafito, CA
TI Photodynamic therapy of polypoidal choroidal vasculopathy
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
AB Polypoidal choroidal vasculopathy is an abnormality of the choroidal vasculature characterized by aneurysmal-like budding of the vessels with exudation and recurrent serosanguinous detachments of the retinal pigment epithelium. Treatment is limited to laser photocoagulation of leaking vessels, which is used when vision is decreased, or exudate and hemorrhage threaten or involve the fovea. This article describes a patient with polypoidal choroidal vasculopathy successfully treated with photodynamic therapy using verteporfin.
C1 Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA.
C3 Tufts University
RP Puliafito, CA (通讯作者)，900 NW 17th St, Miami, FL 33136 USA.
CR Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 6
TC 18
Z9 18
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1082-3069
J9 OPHTHALMIC SUR LA IM
JI Ophthalmic Surg. Lasers Imaging
PD JAN-FEB
PY 2003
VL 34
IS 1
BP 60
EP 63
DI 10.3928/1542-8877-20030101-14
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 709KF
UT WOS:000184623800011
PM 12570008
DA 2022-11-30
ER

PT J
AU Hytti, M
   Korhonen, E
   Hongisto, H
   Kaarniranta, K
   Skottman, H
   Kauppinen, A
AF Hytti, Maria
   Korhonen, Eveliina
   Hongisto, Heidi
   Kaarniranta, Kai
   Skottman, Heli
   Kauppinen, Anu
TI Differential Expression of Inflammasome-Related Genes in Induced
   Pluripotent Stem-Cell-Derived Retinal Pigment Epithelial Cells with or
   without History of Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE induced pluripotent stem cells; retinal pigment epithelium; age-related
   macular degeneration; inflammation; inflammasomes
ID H Y402H POLYMORPHISM; NLRP3 INFLAMMASOME; OXIDATIVE STRESS; DISEASE;
   MODEL; ACTIVATION; CYTOKINES; THERAPY; PROTEIN; IL-8
AB Inflammation is a key underlying factor of age-related macular degeneration (AMD) and inflammasome activation has been linked to disease development. Induced pluripotent stem-cell-derived retinal pigment epithelial cells (iPSC-RPE) are an attractive novel model system that can help to further elucidate disease pathways of this complex disease. Here, we analyzed the effect of dysfunctional protein clearance on inflammation and inflammasome activation in iPSC-RPE cells generated from a patient suffering from age-related macular degeneration (AMD) and an age-matched control. We primed iPSC-RPE cells with IL-1 alpha and then inhibited both proteasomal degradation and autophagic clearance using MG-132 and bafilomycin A1, respectively, causing inflammasome activation. Subsequently, we determined cell viability, analyzed the expression levels of inflammasome-related genes using a PCR array, and measured the levels of pro-inflammatory cytokines IL-1 beta, IL-6, IL-8, and MCP-1 secreted into the medium. Cell treatments modified the expression of 48 inflammasome-related genes and increased the secretion of mature IL-1 beta, while reducing the levels of IL-6 and MCP-1. Interestingly, iPSC-RPE from an AMD donor secreted more IL-1 beta and expressed more Hsp90 prior to the inhibition of protein clearance, while MCP-1 and IL-6 were reduced at both protein and mRNA levels. Overall, our results suggest that cellular clearance mechanisms might already be dysfunctional, and the inflammasome activated, in cells with a disease origin.
C1 [Hytti, Maria; Korhonen, Eveliina; Kauppinen, Anu] Univ Eastern Finland, Sch Pharm, Immunoophthalmol, Kuopio 70210, Finland.
   [Korhonen, Eveliina] Helsinki Univ Hosp, HUSLAB, Dept Clin Chem, Helsinki 00029, Finland.
   [Hongisto, Heidi; Skottman, Heli] Tampere Univ, Fac Med & Hlth Technol, Tampere 33014, Finland.
   [Hongisto, Heidi; Kaarniranta, Kai] Univ Eastern Finland, Sch Med, Ophthalmol, Kuopio 70210, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
C3 University of Eastern Finland; University of Helsinki; Helsinki
   University Central Hospital; Tampere University; University of Eastern
   Finland; Kuopio University Hospital; University of Eastern Finland
RP Hytti, M; Kauppinen, A (通讯作者)，Univ Eastern Finland, Sch Pharm, Immunoophthalmol, Kuopio 70210, Finland.
EM maria.hytti@uef.fi; eveliina.korhonen@uef.fi; heidi.m.hongisto@tuni.fi;
   kai.kaarniranta@uef.fi; heli.skottman@tuni.fi; anu.kauppinen@uef.fi
RI Hytti, Maria/AAE-4016-2019
OI Hytti, Maria/0000-0003-2150-6847; Hongisto, Heidi/0000-0002-2416-5673;
   Korhonen, Eveliina/0000-0002-5360-7258; Skottman,
   Heli/0000-0002-4127-8792
FU Academy of Finland [315085, 296840, 297267, 328443]; Emil Aaltonen
   Foundation; Sigrid Juselius Foundation; Mary and Georg C. Ehrnrooth
   Foundation; Kuopio University Hospital [5503743]; Finnish Eye
   Foundation; Paivikki and Sakari Sohlberg Foundation
FX This research was funded by the Academy of Finland (HS and HH (315085),
   KK (296840), AK (297267, 328443)), the Emil Aaltonen Foundation, the
   Sigrid Juselius Foundation, the Mary and Georg C. Ehrnrooth Foundation,
   the Kuopio University Hospital (Grant Number 5503743), the Finnish Eye
   Foundation, and the Paivikki and Sakari Sohlberg Foundation.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Afarid M, 2019, J RES MED SCI, V24, DOI 10.4103/jrms.JRMS_363_18
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dang EV, 2017, CELL, V171, P1057, DOI 10.1016/j.cell.2017.09.029
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2020, TRENDS MOL MED, V26, P105, DOI 10.1016/j.molmed.2019.10.008
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fodor M, 2006, OPHTHALMIC RES, V38, P182, DOI 10.1159/000093068
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Greene WA, 2019, ADV EXP MED BIOL, V1186, P33, DOI 10.1007/978-3-030-28471-8_2
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Hongisto H, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0738-4
   Hytti M, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1583656
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Juuti-Uusitalo K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051089
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kauppinen A, 2020, CELL MOL LIFE SCI, V77, P779, DOI 10.1007/s00018-019-03418-5
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kiamehr M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153773
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Li Y, 2016, ADV EXP MED BIOL, V854, P549, DOI 10.1007/978-3-319-17121-0_73
   Li Y, 2014, MOL THER, V22, P1688, DOI 10.1038/mt.2014.100
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Lukovic D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12910
   May-Simera HL, 2018, CELL REP, V22, P189, DOI 10.1016/j.celrep.2017.12.038
   Miller JD, 2013, CELL STEM CELL, V13, P691, DOI 10.1016/j.stem.2013.11.006
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Piippo N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25123-2
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Polinati PP, 2015, INVEST OPHTH VIS SCI, V56, P3371, DOI 10.1167/iovs.14-14007
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Singh R, 2015, MOL THER, V23, P1700, DOI 10.1038/mt.2015.141
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Viiri J, 2010, MOL VIS, V16, P1399
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Zuo YC, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00401
NR 57
TC 6
Z9 6
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2021
VL 22
IS 13
AR 6800
DI 10.3390/ijms22136800
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TF7WI
UT WOS:000670927300001
PM 34202702
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fisher, CR
   Ebeling, MC
   Geng, ZH
   Kapphahn, RJ
   Roehrich, H
   Montezuma, SR
   Dutton, JR
   Ferrington, DA
AF Fisher, Cody R.
   Ebeling, Mara C.
   Geng, Zhaohui
   Kapphahn, Rebecca J.
   Roehrich, Heidi
   Montezuma, Sandra R.
   Dutton, James R.
   Ferrington, Deborah A.
TI Human iPSC- and Primary-Retinal Pigment Epithelial Cells for Modeling
   Age-Related Macular Degeneration
SO ANTIOXIDANTS
LA English
DT Article
DE retinal pigment epithelium; age-related macular degeneration;
   mitochondria; oxidative stress
ID OXIDATIVE STRESS; DISEASE; DEATH; RPE; EXPRESSION; RESISTANCE
AB Primary cultures of retinal pigment epithelium (RPE) from human adult donors (haRPE) and induced pluripotent stem cell derived-RPE (iPSC-RPE) are valuable model systems for gaining mechanistic insight and for testing potential therapies for age-related macular degeneration (AMD). This study evaluated the treatment response of haRPE and iPSC-RPE to oxidative stress and potential therapeutics addressing mitochondrial defects. haRPE and iSPC-RPE were derived from donors with or without AMD. Mitochondrial function was measured after treatment with menadione, AICAR, or trehalose and the response to treatment was compared between cell models and by disease status. In a subset of samples, haRPE and iPSC-RPE were generated from the same human donor to make a side-by-side comparison of the two cell models' response to treatment. Disease-specific responses to all three treatments was observed in the haRPE. In contrast, iPSC-RPE had a similar response to all treatments irrespective of disease status. Analysis of haRPE and iPSC-RPE generated from the same human donor showed a similar response for donors without AMD, but there were significant differences in treatment response between cell models generated from AMD donors. These results support the use of iPSC-RPE and haRPE when investigating AMD mechanisms and new therapeutics but indicates that attention to experimental conditions is required.
C1 [Fisher, Cody R.; Ebeling, Mara C.; Kapphahn, Rebecca J.; Montezuma, Sandra R.; Dutton, James R.; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Fisher, Cody R.; Ferrington, Deborah A.] Univ Minnesota, Coll Biol Sci, Grad Program Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
   [Geng, Zhaohui; Dutton, James R.; Ferrington, Deborah A.] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.
   [Geng, Zhaohui; Dutton, James R.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
   [Roehrich, Heidi] Univ Minnesota, Histol Core Vis Res, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Dutton, JR; Ferrington, DA (通讯作者)，Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.; Ferrington, DA (通讯作者)，Univ Minnesota, Coll Biol Sci, Grad Program Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.; Dutton, JR; Ferrington, DA (通讯作者)，Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.; Dutton, JR (通讯作者)，Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
EM fishe765@umn.edu; ebeli017@umn.edu; gengx027@umn.edu; kapph001@umn.edu;
   rohri002@umn.edu; smontezu@umn.edu; dutto015@umn.edu; ferri013@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464; , Heidi/0000-0002-2232-9494
FU National Institutes of Health (NIH) National Eye Institute (NEI)
   [F31-EY031558, T32-EY025187, R01EY026012, R01EY028554]; NIH National
   Institute of Aging (NIA) [T32-AG029796]; Diana Jacobs Kalman/AFAR
   Scholarships for Research in the Biology of Aging; VitreoRetinal Surgery
   Foundation Fellowship; Elaine and Robert Larson Endowed Vision Chair;
   Lindsay Family Foundation
FX This work was supported in part by the National Institutes of Health
   (NIH) National Eye Institute (NEI) F31-EY031558 (to CRF), T32-EY025187
   (to CRF), R01EY026012 (to DAF), and R01EY028554 (to DAF and JRD), NIH
   National Institute of Aging (NIA) T32-AG029796 (to CRF), Diana Jacobs
   Kalman/AFAR Scholarships for Research in the Biology of Aging (to CRF),
   VitreoRetinal Surgery Foundation Fellowship (to CRF), the Elaine and
   Robert Larson Endowed Vision Chair, the Lindsay Family Foundation, and
   an anonymous benefactor for AMD research.
CR Andreux PA, 2013, NAT REV DRUG DISCOV, V12, P465, DOI 10.1038/nrd4023
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Cai H, 2021, EXP EYE RES, V207, DOI 10.1016/j.exer.2021.108576
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Comitato A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0613-y
   Durham JT, 2015, INVEST OPHTH VIS SCI, V56, P3441, DOI 10.1167/iovs.14-13945
   Ebeling MC, 2022, PHARMACEUTICALS-BASE, V15, DOI 10.3390/ph15010062
   Ebeling MC, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040789
   Ebeling MC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101552
   Ferrer M, 2014, STEM CELL TRANSL MED, V3, P911, DOI 10.5966/sctm.2013-0192
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fisher CRR, 2022, EXP EYE RES, V217, DOI 10.1016/j.exer.2022.108981
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Geng ZH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173575
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Hongisto H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06233-9
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Jabbehdari S, 2021, SURV OPHTHALMOL, V66, P423, DOI 10.1016/j.survophthal.2020.09.002
   Jablonski MM, 2000, J NEUROSCI, V20, P7149
   Karim MR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231212
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kim DP, 2012, WOUND REPAIR REGEN, V20, P74, DOI 10.1111/j.1524-475X.2011.00746.x
   Kumar S, 2016, MOL CELL ENDOCRINOL, V422, P233, DOI 10.1016/j.mce.2015.12.019
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lin TC, 2019, CELL TRANSPLANT, V28, P1345, DOI 10.1177/0963689719860130
   Loor G, 2010, FREE RADICAL BIO MED, V49, P1925, DOI 10.1016/j.freeradbiomed.2010.09.021
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Miyagishima K.J., 2017, STEM CELL TRANSL INV, V4, P1497
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Reddy MA, 2016, ARTERIOSCL THROM VAS, V36, P864, DOI 10.1161/ATVBAHA.115.306770
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Schafer N, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090793
   Schreiter S, 2020, STEM CELL REP, V15, P1347, DOI 10.1016/j.stemcr.2020.10.013
   Sharma R, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27488-x
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Truong V, 2021, SLAS TECHNOL, V26, P287, DOI 10.1177/2472630320972110
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
NR 44
TC 1
Z9 1
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD APR
PY 2022
VL 11
IS 4
AR 605
DI 10.3390/antiox11040605
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 0R4ZP
UT WOS:000785605300001
PM 35453289
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, JJ
   Wang, WZ
   Li, QM
AF Chen, Jiajia
   Wang, Wenzhan
   Li, Qiuming
TI Increased Th1/Th17 Responses Contribute to Low-Grade Inflammation in
   Age-Related Macular Degeneration
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Age-related macular degeneration; Th1; Th17
ID ADAPTIVE IMMUNITY; EPITHELIAL-CELLS; EXPRESSION; MONOCYTES; MACROPHAGES;
   INDUCTION; UVEITIS
AB Background/Aims: Age-related macular degeneration (AMD) is the primary cause of senior blindness in developed countries. Mechanisms underlying initiation and development of AMD remained known. Methods: We examined the CD4(+) T cell compartments and their functions in AMD patients. Results: AMD patients presented significantly higher frequencies of interferon (IFN)-gamma-expressing and interleukin (IL)-17-expressing CD4(+) T cells than healthy controls. The levels of IFN-gamma and IL-17 expression by CD4(+) T cells were significantly higher in AMD patients. These IFN-gamma-expressing Th1 cells and IL-17-expressing Th17 cells could be selectively enriched by surface CCR3(+) and CCR4(+) CCR6(+) expression, respectively. Th1 and Th17 cells from AMD patients promoted the differentiation of monocytes toward M1 macrophages, which were previously associated with retinal damage. Th1 and Th17 cells also increased the level of MHC class I expression in human retinal pigment epithelial (RPE)-1 cells, while Th1 cells increased the frequency of MHC class II-expressing RPE-1 cells. These proinflammatory effects were partly, but not entirely, induced by the secretion of IFN-gamma and IL-17. Conclusions: This study demonstrated an enrichment of Th1 cells and Th17 cells in AMD patients. These Th1 and Th17 cells possessed proinflammatory roles in an IFN-gamma- and IL-17-dependent fashion, and could potentially serve as therapeutic targets. (c) 2017 The Author(s) Published by S. Karger AG, Basel
C1 [Chen, Jiajia; Wang, Wenzhan] Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol 1, Zhengzhou, Henan, Peoples R China.
   [Li, Qiuming] Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol 2, 1 Jianshe East Rd, Zhengzhou, Henan, Peoples R China.
C3 Zhengzhou University; Zhengzhou University
RP Li, QM (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol 2, 1 Jianshe East Rd, Zhengzhou, Henan, Peoples R China.
EM drqiumingli@126.com
CR Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Foxman EF, 2002, J IMMUNOL, V168, P2483, DOI 10.4049/jimmunol.168.5.2483
   Grunin M, 2014, ADV EXP MED BIOL, V801, P199, DOI 10.1007/978-1-4614-3209-8_26
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397
   Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514
   Lahoute C, 2011, NAT REV CARDIOL, V8, P348, DOI 10.1038/nrcardio.2011.62
   Li C, 2016, CELL PHYSIOL BIOCHEM, V40, P245, DOI 10.1159/000452541
   Liu YB, 2015, CELL PHYSIOL BIOCHEM, V36, P1274, DOI 10.1159/000430296
   Liu YZ, 2015, CELL PHYSIOL BIOCHEM, V35, P553, DOI 10.1159/000369719
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nassar K., 2014, GRAEFES ARCH CLIN EX, P1
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Rocha VZ, 2008, CIRC RES, V103, P467, DOI 10.1161/CIRCRESAHA.108.177105
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Wang LL, 2015, CELL PHYSIOL BIOCHEM, V37, P2012, DOI 10.1159/000438561
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 28
TC 21
Z9 23
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 44
IS 1
BP 357
EP 367
DI 10.1159/000484907
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA FT3YR
UT WOS:000423087200027
PM 29132135
OA gold
DA 2022-11-30
ER

PT J
AU Chang, LK
   Spaide, RF
   Brue, C
   Freund, KB
   Klancnik, JM
   Slakter, JS
AF Chang, Louis K.
   Spaide, Richard F.
   Brue, Claudia
   Freund, K. Bailey
   Klancnik, James M., Jr.
   Slakter, Jason S.
TI Bevacizumab treatment for subfoveal choroidal neovascularization from
   causes other than age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB LUCENTIS; RANDOMIZED CLINICAL-TRIAL;
   PHOTODYNAMIC THERAPY; PATHOLOGICAL MYOPIA; ANGIOID STREAKS; MULTIFOCAL
   CHOROIDITIS; VERTEPORFIN; AVASTIN; SECONDARY; PANUVEITIS
AB Objective: To report the results of intravitreous bevacizumab (Avastin) treatment for choroidal neovascularization (CNV) from causes other than age-related macular degeneration (AMD).
   Methods: We performed a retrospective analysis of eyes that received intravitreous bevacizumab, 1.25 mg, for sub-foveal non-AMD CNV at a referral-based retinal practice. Repeated treatment with intravitreous bevacizumab occurred if there were signs of persistent or recurrent exudation. The main outcome measure was visual acuity (VA).
   Results: The study included 39 eyes of 36 patients with subfoveal CNV secondary to multifocal choroiditis (n = 12), angioid streaks (n = 11), myopic degeneration (n = 10), idiopathic disease (n = 4), or other disease (n = 2). The median baseline VA was 20/60 (logMAR, 0.48). The mean follow-up was 58.8 weeks, and the mean number of injections per eye was 3.4. After 3-month follow-up, the median VA was 20/30 (logMAR, 0.18) (P = .004 vs baseline). At last follow-up, the median VA was 20/40 (logMAR, 0.30). This remained an improvement compared with baseline (P < .02) but was worse than 3-month follow-up (P < .03). There was no correlation between underlying diagnosis and VA change during follow-up.
   Conclusion: Subfoveal CNV secondary to non-AMD causes treated with intravitreous bevacizumab responded favorably and similarly, despite varying underlying etiologies.
C1 [Chang, Louis K.; Spaide, Richard F.; Brue, Claudia; Freund, K. Bailey; Klancnik, James M., Jr.; Slakter, Jason S.] Macula Consultants New York, New York, NY 10022 USA.
RP Spaide, RF (通讯作者)，Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM rickspaide@yahoo.com
RI Spaide, Richard/ABD-7368-2020; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Arias L, 2006, GRAEF ARCH CLIN EXP, V244, P753, DOI 10.1007/s00417-005-0131-3
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P897, DOI 10.1097/IAE.0b013e31809ff5df
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bottoni Ferdinando, 2001, International Ophthalmology, V24, P249, DOI 10.1023/A:1025488429802
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning AC, 2005, OPHTHALMOLOGY, V112, P1227, DOI 10.1016/j.ophtha.2005.02.011
   Chan WM, 2007, OPHTHALMOLOGY, V114, P2190, DOI 10.1016/j.ophtha.2007.03.043
   Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gerth C, 2006, EUR J OPHTHALMOL, V16, P111, DOI 10.1177/112067210601600118
   Gomi F, 2007, AM J OPHTHALMOL, V143, P507, DOI 10.1016/j.ajo.2006.10.050
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Heimann H, 2005, GRAEF ARCH CLIN EXP, V243, P1115, DOI 10.1007/s00417-005-1193-y
   Hernandez-Rojas ML, 2007, RETINA-J RET VIT DIS, V27, P707
   Jurklies B, 2006, OPHTHALMIC RES, V38, P209, DOI 10.1159/000093071
   Laud K, 2006, RETINA-J RET VIT DIS, V26, P960, DOI 10.1097/01.iae.0000240121.28034.c3
   Mandal S, 2007, EUR J OPHTHALMOL, V17, P620, DOI 10.1177/112067210701700422
   Parodi MB, 2004, AM J OPHTHALMOL, V138, P263, DOI 10.1016/j.ajo.2004.03.029
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P545, DOI 10.1097/00006982-200210000-00003
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Teixeira A, 2006, ACTA OPHTHALMOL SCAN, V84, P835, DOI 10.1111/j.1600-0420.2006.00762.x
   Tewari A, 2006, RETINA-J RET VIT DIS, V26, P1093, DOI 10.1097/01.iae.0000254896.78766.74
   Thorne JE, 2006, OPHTHALMOLOGY, V113, P2310, DOI 10.1016/j.ophtha.2006.05.067
   Yamamoto I, 2007, BRIT J OPHTHALMOL, V91, P157, DOI 10.1136/bjo.2006.096776
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 35
TC 49
Z9 50
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2008
VL 126
IS 7
BP 941
EP 945
DI 10.1001/archopht.126.7.941
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 324IC
UT WOS:000257511300008
PM 18625940
OA Bronze
DA 2022-11-30
ER

PT J
AU Lin, P
   McClintic, SM
   Nadeem, U
   Skondra, D
AF Lin, Phoebe
   McClintic, Scott M.
   Nadeem, Urooba
   Skondra, Dimitra
TI A Review of the Role of the Intestinal Microbiota in Age-Related Macular
   Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE intestinal microbiota; microbiome; age-related macular degeneration;
   AREDS; complement; diet
ID GUT MICROBIOTA; MICROGLIA; OMEGA-3-FATTY-ACIDS; ASSOCIATION; ACTIVATION;
   PROTECTION; FEATURES; OBESITY; IMPACT; NLRP3
AB Blindness from age-related macular degeneration (AMD) is an escalating problem, yet AMD pathogenesis is incompletely understood and treatments are limited. The intestinal microbiota is highly influential in ocular and extraocular diseases with inflammatory components, such as AMD. This article reviews data supporting the role of the intestinal microbiota in AMD pathogenesis. Multiple groups have found an intestinal dysbiosis in advanced AMD. There is growing evidence that environmental factors associated with AMD progression potentially work through the intestinal microbiota. A high-fat diet in apo-E-/- mice exacerbated wet and dry AMD features, presumably through changes in the intestinal microbiome, though other independent mechanisms related to lipid metabolism are also likely at play. AREDS supplementation reversed some adverse intestinal microbial changes in AMD patients. Part of the mechanism of intestinal microbial effects on retinal disease progression is via microbiota-induced microglial activation. The microbiota are at the intersection of genetics and AMD. Higher genetic risk was associated with lower intestinal bacterial diversity in AMD. Microbiota-induced metabolite production and gene expression occur in pathways important in AMD pathogenesis. These studies suggest a crucial link between the intestinal microbiota and AMD pathogenesis, thus providing a novel potential therapeutic target. Thus, the need for large longitudinal studies in patients and germ-free or gnotobiotic animal models has never been more pressing.
C1 [Lin, Phoebe] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [McClintic, Scott M.] Retina Consultants LLC, Salem, OR 97302 USA.
   [Nadeem, Urooba] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA.
   [Skondra, Dimitra] Univ Chicago, Dept Ophthalmol, Chicago, IL 60637 USA.
C3 Oregon Health & Science University; University of Chicago; University of
   Chicago
RP Lin, P (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
EM linp@ohsu.edu; smcclint@gmail.com; Urooba.Nadeem@uchospitals.edu;
   dimitraskondra@gmail.com
FU Bright Focus Foundation; Illinois Society of Prevention Blindness (ISPB)
   grant; University of Chicago Women's Board grant; National Eye Institute
   [K08 EY022948]; Collins Medical Trust; Research to Prevent Blindness
   Career Development Award; National Institute of Health (Bethesda, MD)
   [P30 EY010572]; Research to Prevent Blindness (New York, NY); Alcon
   Research Institute Young Investigator Award; OHSU Physician-Scientist
   award; Thome Foundation
FX D.S. has been supported by a Bright Focus Foundation grant, an Illinois
   Society of Prevention Blindness (ISPB) grant, and University of Chicago
   Women's Board grant; P.L. has been supported by a National Eye Institute
   Grant K08 EY022948, a Collins Medical Trust Grant, and a Research to
   Prevent Blindness Career Development Award (P.L.). This study was also
   supported by Core grant P30 EY010572 from the National Institute of
   Health (Bethesda, MD) and by unrestricted departmental funding from
   Research to Prevent Blindness (New York, NY). P.L. is also the recipient
   of an Alcon Research Institute Young Investigator Award, the OHSU
   Physician-Scientist award, and is the recipient of a Thome Foundation
   award.
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Ahrazem O, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111781
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Beli E, 2018, DIABETES, V67, P1867, DOI 10.2337/db18-0158
   Berry D, 2013, BEST PRACT RES CL GA, V27, P47, DOI 10.1016/j.bpg.2013.03.005
   Bohn T, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600685
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chen HH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05681-9
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Costantini L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122645
   Costello ME, 2015, ARTHRITIS RHEUMATOL, V67, P686, DOI 10.1002/art.38967
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dimitra Skondra M.D., 2019, INVESTIG OPHTHALMOL, V60, P3273
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ericsson AC, 2015, ILAR J, V56, P205, DOI 10.1093/ilar/ilv021
   Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Huang XY, 2018, INVEST OPHTH VIS SCI, V59, P1523, DOI 10.1167/iovs.17-22677
   Janowitz C, 2019, INVEST OPHTH VIS SCI, V60, P420, DOI 10.1167/iovs.18-24813
   Kiang L, 2017, INVEST OPHTH VIS SCI, V58
   Liang MH, 2018, CRIT REV FOOD SCI, V58, P2314, DOI 10.1080/10408398.2017.1322552
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Lin P., AREDS SUPPLEMENTATIO
   Lin P, 2019, CLIN EXP OPHTHALMOL, V47, P418, DOI 10.1111/ceo.13493
   Lin P, 2018, CURR OPIN OPHTHALMOL, V29, P261, DOI 10.1097/ICU.0000000000000465
   Luckoff A, 2017, NAT PROTOC, V12, P1136, DOI 10.1038/nprot.2017.032
   Manasson J, 2018, ARTHRITIS RHEUMATOL, V70, P242, DOI 10.1002/art.40359
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Miyake S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137429
   Miyoshi J, 2017, TRANSL RES, V179, P38, DOI 10.1016/j.trsl.2016.06.002
   Morita Y, 2018, AGING-US, V10, P2723, DOI 10.18632/aging.101583
   Mosher KI, 2015, NAT NEUROSCI, V18, P930, DOI 10.1038/nn.4051
   Nadeem U., 2020, HIGH THROUGHPUT RNA, DOI [10.1101/2020.10.01.318949, DOI 10.1101/2020.10.01.318949]
   Nakamura YK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12163-3
   Nakamura YK, 2016, INVEST OPHTH VIS SCI, V57, P3747, DOI 10.1167/iovs.16-19733
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Savin Z, 2018, ARCH MICROBIOL, V200, P677, DOI 10.1007/s00203-018-1506-2
   Scher JU, 2013, ELIFE, V2, DOI 10.7554/eLife.01202
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Skondra D., 2007, INVESTIG OPHTHALMOL, V48, P1768
   Skondra D., USING INTEGRATED MUL
   Skondra D, 2020, J AAPOS, V24, P236, DOI 10.1016/j.jaapos.2020.03.010
   Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165
   Sudo N, 2004, J PHYSIOL-LONDON, V558, P263, DOI 10.1113/jphysiol.2004.063388
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Vaarala Outi, 2012, Rev Diabet Stud, V9, P251, DOI 10.1900/RDS.2012.9.251
   Vainshtein A, 2015, AM J PHYSIOL-CELL PH, V308, pC710, DOI 10.1152/ajpcell.00380.2014
   Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zysset-Burri DC, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-020-00141-0
NR 66
TC 8
Z9 8
U1 3
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2021
VL 10
IS 10
AR 2072
DI 10.3390/jcm10102072
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SI5HN
UT WOS:000654855300001
PM 34065988
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Arnarsson, A
   Sverrisson, T
   Stefansson, E
   Sigurdsson, H
   Sasaki, H
   Sasaki, K
   Jonasson, F
AF Arnarsson, Arsaell
   Sverrisson, Thordur
   Stefansson, Einar
   Sigurdsson, Haraldur
   Sasaki, Hiroshi
   Sasaki, Kazuyuki
   Jonasson, Fridbert
TI Risk factors for five-year incident age-related macular degeneration:
   The Reykjavik Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; COPENHAGEN CITY EYE; BLUE-MOUNTAINS-EYE;
   CARDIOVASCULAR-DISEASE; GEOGRAPHIC ATROPHY; LENS OPACIFICATION;
   CATARACT-SURGERY; POOLED FINDINGS; GRADING SYSTEM; TERM INCIDENCE
AB center dot PURPOSE: To establish risk factors for five,year incidence of age-related macular degeneration (AMD).
   center dot DESIGN: Population,based, prospective cohort study, and risk analysis.
   center dot METHODS: A random sample from the Reykjavik Population Census for individuals 50 years and older was selected. We took fundus stereo color photographs and used standard grading system to study the five,year incidence of drusen, pigmentary abnormalities, and AMD and to examine possible risk factors. A questionnaire including information on disease, medication, diet, and lifestyle from the Reykjavik Eye Study database provided additional information.
   center dot RESULTS: Current alcohol consumption decreased the risk for drusen. Being married rather than divorced or widowed decreased the risk for soft drusen; being single decreased the risk of hypopigmentation as compared with being divorced or married. Both consuming dietary fiber-rich vegetables and meat and meat products once a week or less frequently was a risk factor for developing soft drusen and decreased the risk of pigmentary abnormalities. Those who had smoked 20 pack-years or more as compared with nonsmokers had decreased survival rate over the five years (odds ratio (OR) 0.46, 95% confidence interval (CI) 0.27 to 0.80; P = .006).
   center dot CONCLUSIONS: Risk factors for drusen appear to differ from risk factors for pigmentary abnormalities. The effect of smoking on developing AMD is partly masked by selective mortality.
C1 Univ Iceland, Landspitalinn, Dept Ophthalmol, IS-101 Reykjavik, Iceland.
   Kanazawa Med Univ, Uchinada, Ishikawa 92002, Japan.
C3 University of Iceland; Kanazawa Medical University
RP Jonasson, F (通讯作者)，Univ Iceland, Landspitalinn, Dept Ophthalmol, IS-101 Reykjavik, Iceland.
EM fridbert@landspitali.is
RI Jonasson, Fridbert/ABA-9889-2021
CR Agarwal S, 2000, CAN MED ASSOC J, V163, P739
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   EDWARDS AO, SCIENCE, V30, P421
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   *FOOD AGR ORG UN N, 1988, FAO FISH STAT 1986
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Jonasson F, 2003, EYE, V17, P747, DOI 10.1038/sj.eye.6700374
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Katoh N, 2001, ACTA OPHTHALMOL SCAN, V79, P154, DOI 10.1034/j.1600-0420.2001.079002154.x
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Sasaki H, 2000, OPHTHALMOLOGICA, V214, P412, DOI 10.1159/000027535
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
NR 45
TC 65
Z9 66
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2006
VL 142
IS 3
BP 419
EP 428
DI 10.1016/j.ajo.2006.04.015
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 082MJ
UT WOS:000240390600008
PM 16935586
DA 2022-11-30
ER

PT J
AU Ding, Y
   Liu, Y
   Yan, Q
   Fritsche, LG
   Cook, RJ
   Clemons, T
   Ratnapriya, R
   Klein, ML
   Abecasis, GR
   Swaroop, A
   Chew, EY
   Weeks, DE
   Chen, W
AF Ding, Ying
   Liu, Yi
   Yan, Qi
   Fritsche, Lars G.
   Cook, Richard J.
   Clemons, Traci
   Ratnapriya, Rinki
   Klein, Michael L.
   Abecasis, Goncalo R.
   Swaroop, Anand
   Chew, Emily Y.
   Weeks, Daniel E.
   Chen, Wei
TI Bivariate Analysis of Age-Related Macular Degeneration Progression Using
   Genetic Risk Scores
SO GENETICS
LA English
DT Article
DE AMD progression; AREDS; bivariate time-to-event; genetic risk score;
   risk prediction
ID CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC ATROPHY; PREDICTION MODEL; EYE
   DISEASE; SUSCEPTIBILITY; ASSOCIATION; PREVALENCE
AB Age-related macular degeneration (AMD) is a leading cause of blindness in the developed world. While many AMD susceptibility variants have been identified, their influence on AMD progression has not been elucidated. Using data from two large clinical trials, Age-Related Eye Disease Study (AREDS) and AREDS2, we evaluated the effects of 34 known risk variants on disease progression. In doing so, we calculated the eye-level time-to-late AMD and modeled them using a bivariate survival analysis approach, appropriately accounting for between-eye correlation. We then derived a genetic risk score (GRS) based on these 34 risk variants, and analyzed its effect on AMD progression. Finally, we used the AREDS data to fit prediction models of progression based on demographic and environmental factors, eye-level AMD severity scores and the GRS and tested the models using the AREDS2 cohort. We observed that GRS was significantly associated with AMD progression in both cohorts, with a stronger effect in AREDS than in AREDS2 (AREDS: hazard ratio (HR) = 1.34, p = 1.6 x 10(-22); AREDS2: HR = 1.11, P = 2.1 x 10(-4)). For prediction of AMD progression, addition of GRS to the demographic/environmental risk factors considerably improved the prediction performance. However, when the baseline eye-level severity scores were included as the predictors, any other risk factors including the GRS only provided small additional predictive power. Our model for predicting the disease progression risk demonstrated satisfactory performance in both cohorts, and we recommend its use with baseline AMD severity scores plus baseline age, education level, and smoking status, either with or without GRS.
C1 [Ding, Ying; Liu, Yi; Weeks, Daniel E.; Chen, Wei] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Weeks, Daniel E.; Chen, Wei] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Liu, Yi; Yan, Qi; Chen, Wei] Univ Pittsburgh, UPMC, Childrens Hosp Pittsburgh, Div Pulm Med Allergy & Immunol,Dept Pediat, Pittsburgh, PA 15224 USA.
   [Fritsche, Lars G.; Abecasis, Goncalo R.] Univ Michigan, Ctr Stat Genet, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Cook, Richard J.] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada.
   [Clemons, Traci] EMMES Corp, Rockville, MD USA.
   [Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; University of
   Michigan System; University of Michigan; University of Waterloo; Emmes
   Corporation; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); Oregon Health & Science University
RP Weeks, DE (通讯作者)，Univ Pittsburgh, Crabtree Hall,Room A303, Pittsburgh, PA 15261 USA.; Chen, W (通讯作者)，Univ Pittsburgh, UPMC, Childrens Hosp Pittsburgh, 4401 Penn Ave,Rangos Res Bldg 9125, Pittsburgh, PA 15224 USA.
EM weeks@pitt.edu; wei.chen@chp.edu
RI Fritsche, Lars G/AAF-9387-2019; Weeks, Daniel E/B-2995-2012; Chen,
   Wei/AAX-5994-2020
OI Fritsche, Lars G/0000-0002-2110-1690; Weeks, Daniel
   E/0000-0001-9410-7228; Chen, Wei/0000-0001-7196-8703; Ratnapriya,
   Rinki/0000-0002-0469-4631; Cook, Richard/0000-0002-1414-4908
FU National Institutes of Health [EY024226, EY022005, EY021532]; Intramural
   Research Program of the National Eye Institute; RPB (Research to Prevent
   Blindness); NATIONAL EYE INSTITUTE [R01EY022005, ZIAEY000546,
   R01EY024226, R01EY021532, ZIAEY000489] Funding Source: NIH RePORTER
FX We thank the participants in the AREDS and AREDS2 studies, who made this
   study possible, and the International Age-Related Macular Degeneration
   (AMD) Genomics Consortium for generating the genetic data and performing
   the quality check. This research was supported by the National
   Institutes of Health (EY024226 to W.C., Y.D., D.E.W., and Q.Y., EY022005
   to G.R.A. and L.G.F., and EY021532 to M.L.K.), Intramural Research
   Program of the National Eye Institute (to A.S., E.Y.C., and R.P.), and
   RPB (Research to Prevent Blindness) unrestricted departmental grant (to
   M.L.K.). D.E.W. is a coinventor on licensed patents held by the
   University of Pittsburgh for the chromosome 10q26 PLEHA1 and ARMS2 loci
   for AMD.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Age- Related Eye Disease Study 2 Research Group, 2013, JAMA-J AM MED ASSOC, V309, P208
   BARBEITO R, 1991, OPTOMETRY VISION SCI, V68, P73, DOI 10.1097/00006324-199101000-00011
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gerds TA, 2006, BIOMETRICAL J, V48, P1029, DOI 10.1002/bimj.200610301
   Graf E, 1999, STAT MED, V18, P2529
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Lee EW, 1992, SURVIVAL ANAL STATE, P237, DOI [DOI 10.1007/978-94-015-7983-4_14, 10.1007/978-94-015-7983-4_14]
   Murdoch IE, 1998, BRIT J OPHTHALMOL, V82, P971, DOI 10.1136/bjo.82.8.971
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Pepe M, 2013, RISK ASSESSMENT EVAL, P107
   Pepe MS, 2011, AM J EPIDEMIOL, V173, P1327, DOI 10.1093/aje/kwr013
   Pepe MS, 2013, STAT MED, V32, P1467, DOI 10.1002/sim.5727
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
NR 30
TC 33
Z9 33
U1 0
U2 5
PU GENETICS SOCIETY AMERICA
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 0016-6731
EI 1943-2631
J9 GENETICS
JI Genetics
PD MAY
PY 2017
VL 206
IS 1
BP 119
EP 133
DI 10.1534/genetics.116.196998
PG 15
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EU6EW
UT WOS:000401127800008
PM 28341650
OA Green Published
DA 2022-11-30
ER

PT J
AU Lindekleiv, H
   Erke, MG
   Bertelsen, G
   Peto, T
   Arntzen, KA
   Schirmer, H
   Wilsgaard, T
   Mathiesen, EB
   Njolstad, I
AF Lindekleiv, H.
   Erke, M. G.
   Bertelsen, G.
   Peto, T.
   Arntzen, K. A.
   Schirmer, H.
   Wilsgaard, T.
   Mathiesen, E. B.
   Njolstad, I.
TI Cognitive function, drusen, and age-related macular degeneration: a
   cross-sectional study
SO EYE
LA English
DT Article
DE drusen; AMD; cognitive function
ID MACULOPATHY; IMPAIRMENT; ATHEROSCLEROSIS; PREVALENCE
AB Purpose To examine the cross-sectional relationship between drusen, late age-related macular degeneration (AMD), and cognitive function.
   Methods We included 2149 stroke-free participants from the population-based Tromso Study in Norway. Retinal photographs were graded for presence of drusen and AMD. Cognitive function was assessed using the verbal memory test (short verbal memory), digit-symbol coding test (processing speed), and the tapping test (psychomotor tempo). We assessed the relationship between drusen, late AMD, and cognitive test scores, adjusted for potential confounders.
   Results Late AMD was associated with decreased performance in the verbal memory test (standardized beta = -0.23, 95% confidence interval (CI): -0.51 to - 0.01). Intermediate and large drusen were associated with decreased performance in the digit-symbol coding test (standardized beta - 0.14 and -0.19, 95% CIs: - 0.23 to - 0.05 and - 0.29 to - 0.09, respectively). Participants with large drusen were more likely to have test scores in the lowest quartile of the digit-symbol coding test (odds ratio (OR) 1.9, 95% CI: 1.1-3.5) and the tapping test (OR 1.6, 95% CI: 1.0-2.6), but not in the verbal memory test (OR 1.0, 95% CI: 0.6-1.6).
   Conclusions The findings suggest a relationship between drusen deposition and reduced cognitive function. Although the relationships between drusen, late AMD, and the cognitive test results varied in strength and significance across the types of cognitive test, and may partly have been caused by residual confounding, it is not unlikely that a genuine but weaker relationship exists between drusen deposition and cognitive decline.
C1 [Lindekleiv, H.; Erke, M. G.; Bertelsen, G.; Arntzen, K. A.; Schirmer, H.; Wilsgaard, T.; Mathiesen, E. B.; Njolstad, I.] Univ Tromso, Fac Hlth Sci, N-9037 Tromso, Norway.
   [Erke, M. G.; Bertelsen, G.; Arntzen, K. A.; Schirmer, H.; Mathiesen, E. B.] Univ Hosp North Norway, Tromso, Norway.
   [Peto, T.] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Peto, T.] UCL, Inst Ophthalmol, London, England.
C3 UiT The Arctic University of Tromso; UiT The Arctic University of
   Tromso; University Hospital of North Norway; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London
RP Lindekleiv, H (通讯作者)，Univ Tromso, Fac Hlth Sci, Dept Community Med, N-9037 Tromso, Norway.
EM haakon.lindekleiv@gmail.com
RI Peto, Tunde/G-8812-2018; Njolstad, Inger/X-3784-2019; Bertelsen,
   Geir/ABB-9865-2021
OI Peto, Tunde/0000-0001-6265-0381; Schirmer, Henrik/0000-0002-9348-3149
FU Simon Fougner Hartmanns familiefond; Northern Norway Regional Health
   Authority [SFP897-09]; Norwegian Research Council [176939/V40]; NIHR, UK
FX This study was supported by Grants from Simon Fougner Hartmanns
   familiefond, the Northern Norway Regional Health Authority (SFP897-09),
   the Norwegian Research Council (176939/V40). Tunde Peto was supported by
   grants from the NIHR, UK.
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Arntzen KA, 2010, ACTA NEUROL SCAND, V122, P23, DOI 10.1111/j.1600-0404.2010.01371.x
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Bertelsen G, 2013, ACTA OPHTHALMOL, V91, P635, DOI 10.1111/j.1755-3768.2012.02511.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Fabrigoule C, 1998, BRAIN, V121, P135, DOI 10.1093/brain/121.1.135
   Jacobsen BK, 2012, INT J EPIDEMIOL, V41, P961, DOI 10.1093/ije/dyr049
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 18
TC 12
Z9 12
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD NOV
PY 2013
VL 27
IS 11
BP 1281
EP 1287
DI 10.1038/eye.2013.181
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 251VA
UT WOS:000326957700008
PM 23970030
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Fenwick, EK
   Cheung, CMG
   Ong, PG
   Tan, G
   Lee, SY
   Yeo, I
   Cheng, CY
   Wong, TY
   Lamoureux, EL
AF Fenwick, Eva K.
   Cheung, Chui Ming Gemmy
   Ong, Peng Guan
   Tan, Gavin
   Lee, Shu Yen
   Yeo, Ian
   Cheng, Ching Yu
   Wong, Tien Y.
   Lamoureux, Ecosse L.
TI The impact of typical neovascular age-related macular degeneration and
   polypoidal choroidal vasculopathy on vision-related quality of life in
   Asian patients
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID IMPAIRMENT QUESTIONNAIRE; CLINICAL-TRIAL; RASCH ANALYSIS; EYE; COHORT
AB Aims To determine the impact of neovascular agerelated macular degeneration (nAMD) on vision-related quality of life (VRQoL) in an Asian population.
   Methods In this cross-sectional study, 162 subjects with nAMD from the Asian AMD Phenotyping Study and 105 randomly sampled age-matched and gender-matched controls from the population-based Singapore Chinese Eye Study were recruited. nAMD was categorised as either polypoidal choroidal vasculopathy (PCV) or 'typical' AMD (tAMD). The reading, mobility and emotional well-being subscales of the impact of vision impairment (IVI) scale were validated using Rasch analysis and used as the main outcome measures and collectively referred to as VRQoL. Multivariate linear regression analyses were performed to assess the impact of nAMD overall, and PCV and tAMD subtypes, on the three IVI domains.
   Results Of the 162 with nAMD, 103 (63.6%) had PCV and 59 (36.4%) had tAMD. In multivariate models, nAMD overall was independently associated with a 21% reduction in reading (beta=-1.08; CI - 1.58 to - 0.57); 16% reduction in mobility (beta=-0.74; -1.14 to -0.33) and 44% reduction in emotional well-being (beta=-2.15; -2.83 to -1.47) compared with controls. There were significant VRQoL deficits (p<0.05) associated with both PCV and tAMD; these deficits were similar and not statistically different between the two nAMD subtypes (p>0.05).
   Conclusions Neovascular AMD, including both PCV and tAMD subtypes, has a detrimental impact on VRQoL in Asian subjects independent of level of vision impairment. Interventions to increase reading capacity, enhance mobility and independence and improve mental health outcomes for subjects with neovascular AMD further address the impact of the condition on VRQoL in addition to pharmacological therapies.
C1 [Fenwick, Eva K.; Wong, Tien Y.; Lamoureux, Ecosse L.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Fenwick, Eva K.; Cheung, Chui Ming Gemmy; Ong, Peng Guan; Tan, Gavin; Lee, Shu Yen; Yeo, Ian; Cheng, Ching Yu; Wong, Tien Y.; Lamoureux, Ecosse L.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Tan, Gavin; Lee, Shu Yen; Yeo, Ian; Cheng, Ching Yu; Wong, Tien Y.; Lamoureux, Ecosse L.] Natl Univ Singapore, Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore, Singapore.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; National University of Singapore; Singapore
   National Eye Center; National University of Singapore
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Lamoureux, Ecosse/Z-5482-2019; Cheng,
   Ching-Yu/Y-2229-2019
OI Wong, Tien Yin/0000-0002-8448-1264; Cheng, Ching-Yu/0000-0003-0655-885X;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU National Medical Research Council [STaR/0003/2008, NIG/1003/2009];
   National Medical Research Council grant [NMRC/NIG/1003/2009]; Singapore
   Bio Imaging Consortium [C-011/2006]; Biomedical Research Council
   [08/1/35/19/550]; National Health and Medical Research Council (NHMRC)
   [1072987]
FX This study was supported by grants from the National Medical Research
   Council (STaR/0003/2008 and NIG/1003/2009), National Medical Research
   Council grant NMRC/NIG/1003/2009; the Singapore Bio Imaging Consortium
   (C-011/2006) and the Biomedical Research Council (08/1/35/19/550). EF is
   funded by a National Health and Medical Research Council (NHMRC) Early
   Career Fellowship (# 1072987). The Centre for Eye Research Australia
   receives Operational Infrastructure Support from the Victorian
   Government.
CR ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Fenwick EK, 2016, QUAL LIFE RES, V25, P871, DOI 10.1007/s11136-015-1141-1
   Finger RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081042
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Khadka J, 2014, INVEST OPHTH VIS SCI, V55, P4413, DOI 10.1167/iovs.14-14017
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Lamoureux EL, 2010, OPHTHALMOLOGY, V117, P757, DOI 10.1016/j.ophtha.2009.09.035
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Linacre J., 2002, USERS GUIDE WINSTEPS
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Macular Photocoagulation Study Group, 1991, ARCH OPHTHALMOL-CHIC, V251, P19
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Rovner BW, 2013, OPHTHALMOLOGY, V120, P1649, DOI 10.1016/j.ophtha.2013.01.022
   Siaudvytyte L, 2012, MEDICINA-LITHUANIA, V48, P109, DOI 10.3390/medicina48020015
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 27
TC 17
Z9 17
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2017
VL 101
IS 5
BP 591
EP 596
DI 10.1136/bjophthalmol-2016-308541
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW2MQ
UT WOS:000402331100010
PM 27485722
DA 2022-11-30
ER

PT J
AU Wolf-Schnurrbusch, UEK
   Stuck, AK
   Hess, R
   Wolf, S
   Enzmann, V
AF Wolf-Schnurrbusch, Ute E. K.
   Stuck, Anna K.
   Hess, Roberto
   Wolf, Sebastian
   Enzmann, Volker
TI COMPLEMENT FACTOR P IN CHOROIDAL NEOVASCULAR MEMBRANES OF PATIENTS WITH
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE complement; Factor P; AMD; CNV; immunocytochemistry; alternative pathway
ID FACTOR-H POLYMORPHISM; RISK; PATHOGENESIS; INFLAMMATION; PROPERDIN;
   VARIANT; INDIVIDUALS; PATHWAY; DISEASE
AB Purpose: To evaluate whether complement Factor P (properdin) was present in surgically removed choroidal neovascular membranes of patients with age-related macular degeneration (AMD) and to investigate whether associated pre- and postoperative clinical characteristics can be correlated.
   Methods: The study population consisted of 26 AMD patients (26 eyes) with the exclusion criterion of prior treatment of the choroidal neovascular membranes. Factor P was detected immunocytochemically on paraffin sections (7 mu m) by a polyclonal rabbit antihuman antibody.
   Results: Eleven of 22 assessable membranes showed a positive reaction for Factor P. The average percentage of Factor P-positive cells per membrane ranged from 0.65% to 4.09%. The duration of visual loss was significantly longer (8.6 +/- 2.7 vs. 3.9 +/- 0.8 months), and the size of postoperative measured area of atrophic retinal pigment epithelium was larger (27.6 +/- 7.6 vs. 15.0 +/- 6.9 mm(2)) in patients with Factor P-positive membranes compared with Factor P-negative ones.
   Conclusion: Factor P was expressed in 50% of choroidal neovascular membranes of patients with AMD. The group with Factor P-positive membranes differed significantly from the Factor P-negative group in key clinical outcomes. Additional studies need to investigate the role of Factor P in the development of AMD for potential therapeutic intervention.
C1 [Wolf-Schnurrbusch, Ute E. K.; Stuck, Anna K.; Hess, Roberto; Wolf, Sebastian; Enzmann, Volker] Univ Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
   [Wolf, Sebastian] Univ Bern, Sch Med, Dept Pathol, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern
RP Enzmann, V (通讯作者)，Univ Bern, Inselspital, Dept Ophthalmol, Freiburgstr 14, CH-3010 Bern, Switzerland.
EM volker.enzmann@insel.ch
RI Mohammed, Imran/J-8271-2012; Wolf, Sebastian/B-8782-2008
OI Mohammed, Imran/0000-0002-8412-0768; Wolf,
   Sebastian/0000-0002-7467-7028; Stuck, Anna K./0000-0001-8322-5501;
   Enzmann, Volker/0000-0003-4384-4855
FU Berne University Research Foundation
FX Supported in part by a grant from the Berne University Research
   Foundation.
CR Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Colten H R, 1979, Ann N Y Acad Sci, V332, P482, DOI 10.1111/j.1749-6632.1979.tb47142.x
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1991, RETINA-J RET VIT DIS, V11, P328, DOI 10.1097/00006982-199111030-00010
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hourcade DE, 2006, J BIOL CHEM, V281, P2128, DOI 10.1074/jbc.M508928200
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kemper C, 2008, P NATL ACAD SCI USA, V105, P9023, DOI 10.1073/pnas.0801015105
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   MINTA JO, 1988, MOL IMMUNOL, V25, P1363, DOI 10.1016/0161-5890(88)90052-1
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 32
TC 9
Z9 11
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2009
VL 29
IS 7
BP 966
EP 973
DI 10.1097/IAE.0b013e3181a2f40f
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 470DT
UT WOS:000267955400010
PM 19584655
DA 2022-11-30
ER

PT J
AU Yoshida, T
   Ohno-Matsui, K
   Ichinose, S
   Sato, T
   Iwata, N
   Saido, TC
   Hisatomi, T
   Mochizuki, M
   Morita, I
AF Yoshida, T
   Ohno-Matsui, K
   Ichinose, S
   Sato, T
   Iwata, N
   Saido, TC
   Hisatomi, T
   Mochizuki, M
   Morita, I
TI The potential role of amyloid beta in the pathogenesis of age-related
   macular degeneration
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; CAUSE-SPECIFIC
   PREVALENCE; FACTOR-H POLYMORPHISM; PIGMENT EPITHELIUM; OXIDATIVE STRESS;
   A-BETA; INCREASED EXPRESSION; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN
AB Drusen are extracellular deposits that lie beneath the retinal pigment epithelium (RPE) and are the. earliest signs of age-related macular degeneration (AMD). Recent proteome analysis demonstrated that amyloid beta (A beta) deposition was specific to drusen from eyes with AMD. To work toward a molecular understanding of the development of AMD from drusen, we investigated the effect of A beta on cultured human RPE cells as well as ocular findings in neprilysin gene-disrupted mice, which leads to an increased deposition A beta. The results showed that A beta treatment induced a marked increase in VEGF as well as a marked decrease in pigment epithelium-derived factor (PEDF). Conditioned media from A beta-exposed RPE cells caused a dramatic increase in tubular formation by human umbilical vein endothelial cells. Light microscopy of senescent neprilysin gene-disrupted mice showed an increased number of degenerated RPE cells with vacuoles. Electron microscopy revealed basal laminar and linear deposits beneath the RPE layer, but we did not observe choroidal neovascularization (CNV). The present study demonstrates that A beta accumulation affects the balance between VEGF and PEDF in the RPE, and an accumulation of A beta reproduces features characteristic of human AMD, such as RPE atrophy and basal deposit formation. Some other factors, such as breakdown of integrity of Bruch membrane, might be necessary to induce CNV of AMD.
C1 Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, Tokyo 1138519, Japan.
   Tokyo Med & Dent Univ, Instrumental Anal Res Ctr, Tokyo 1138519, Japan.
   Tsurumi Univ, Sch Dent Med, Dept Anat, Yokohama, Kanagawa, Japan.
   RIKEN, Brain Sci Inst, Inst Phys & Chem Res, Lab Proteolyt Neurosci, Wako, Saitama 35101, Japan.
   Kyushu Univ, Dept Ophthalmol, Higashi Ku, Fukuoka 812, Japan.
   Tokyo Med & Dent Univ, Sect Cellular Physiol Chem, Tokyo, Japan.
C3 Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental
   University (TMDU); Tsurumi University; RIKEN; Kyushu University; Tokyo
   Medical & Dental University (TMDU)
RP Ohno-Matsui, K (通讯作者)，Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.
EM k.ohno.oph@tmd.ac.jp
RI Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021
OI Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903;
   Hisatomi, Toshio/0000-0003-2552-9595
CR Abramovici M, 2004, SERV IND J, V24, P56, DOI 10.1080/02642060412331301132
   Alizadeh M, 2001, INVEST OPHTH VIS SCI, V42, P2706
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Butterfield DA, 2004, BRAIN PATHOL, V14, P426
   CAMPOCHIARO PA, 1993, EXP EYE RES, V57, P539, DOI 10.1006/exer.1993.1158
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dentchev T, 2003, MOL VIS, V9, P184
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fernandez-Robredo P, 2005, INVEST OPHTH VIS SCI, V46, P1140, DOI 10.1167/iovs.04-0516
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Frederikse PH, 1996, J BIOL CHEM, V271, P10169, DOI 10.1074/jbc.271.17.10169
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Goldstein LE, 2003, LANCET, V361, P1258, DOI 10.1016/S0140-6736(03)12981-9
   GREEN RG, 1999, AGE RELATED MACULAR, P81
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2
   Hock C, 2002, NAT MED, V8, P1270, DOI 10.1038/nm783
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE, P393
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265
   Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004
   Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390
   Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Lombardo JA, 2003, J NEUROSCI, V23, P10879, DOI 10.1523/jneurosci.23-34-10879.2003
   MaatSchieman MLC, 1997, J NEUROPATH EXP NEUR, V56, P273, DOI 10.1097/00005072-199703000-00006
   Marmor M, 1998, RETINAL PIGMENT EPIT, P3
   Matsuda S, 2005, INVEST OPHTH VIS SCI, V46, P1062, DOI 10.1167/iovs.04-0761
   Meehan S, 2004, J BIOL CHEM, V279, P3413, DOI 10.1074/jbc.M308203200
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pereira C, 2004, J MOL NEUROSCI, V23, P97, DOI 10.1385/JMN:23:1-2:097
   Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3
   Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5
   Sandilands A, 2002, EMBO J, V21, P6005, DOI 10.1093/emboj/cdf609
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741
   Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Uchihara T, 1997, STROKE, V28, P1948, DOI 10.1161/01.STR.28.10.1948
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147
   Yamada M, 1996, STROKE, V27, P1155, DOI 10.1161/01.STR.27.7.1155
NR 63
TC 167
Z9 189
U1 0
U2 7
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD OCT
PY 2005
VL 115
IS 10
BP 2793
EP 2800
DI 10.1172/JCI24635
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 971IE
UT WOS:000232376600030
PM 16167083
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Nguyen, V
   Leung, KFC
   Nguyen, CL
   Squirrell, D
   Essex, R
   Arnold, J
   Young, S
   Barthelmes, D
   Gillies, M
AF Nguyen, Vuong
   Leung, King Fai Calvin
   Nguyen, Chu Luan
   Squirrell, David
   Essex, Rohan
   Arnold, Jennifer
   Young, Stephanie
   Barthelmes, Daniel
   Gillies, Mark
CA Fight Retinal Blindness Study Grp
TI ASSESSING THE ACCURACY OF A LARGE OBSERVATIONAL REGISTRY OF NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE observational data; registry; data quality; audit
ID DATA QUALITY; INTRAVITREAL THERAPY; 12-MONTH OUTCOMES; RELIABILITY;
   GUIDELINES; EPITHELIUM; CATARACT; PROGRAM; AUDIT
AB Purpose: To evaluate the accuracy of an observational database that tracks real-world treatment outcomes for neovascular age-related macular degeneration. Methods: We audited 245 randomly sampled eyes from 189 patients with 3,356 visits from 11 doctors in the Fight Retinal Blindness! database. Sex, birth year, previous treatments received, treatment, and visual acuity were validated against the clinical notes. Error rates, the proportion of missed visits (the number of visits present in the patient record but not entered into Fight Retinal Blindness!), the level of agreement using Cohen's kappa (kappa) and intraclass correlation coefficients, and positive and negative predictive values were calculated. A visual acuity error was defined as an absolute difference of >= 5 letters. Results: The overall error rate was 3.5% (95% confidence interval: 3.1-3.9). The error rate for visual acuity was 5.1% (95% confidence interval: 4.2-5.9) and <5% for the remaining fields. The level of agreement for each field ranged from good to excellent (kappa or intraclass correlation >= 0.75). The positive predictive value and negative predictive value for visits were 99% and 89%, respectively. The proportion of missed visits was 10.2%. Conclusion: Accuracy of the Fight Retinal Blindness! database was good (>95%). The rate of missed visits was high, possibly due to the high burden of retrospective data entry or patients switching practitioners during treatment.
C1 [Nguyen, Vuong; Leung, King Fai Calvin; Nguyen, Chu Luan; Barthelmes, Daniel; Gillies, Mark] Univ Sydney, Save Sight Inst, Sydney Med Sch, Discipline Ophthalmol, Sydney, NSW, Australia.
   [Squirrell, David] Univ Auckland, Dept Ophthalmol, Auckland, New Zealand.
   [Essex, Rohan] Australian Natl Univ, Acad Unit Ophthalmol, Acton, ACT, Australia.
   [Arnold, Jennifer] Marsden Eye Specialists, Parramatta, NSW, Australia.
   [Young, Stephanie] Gladesville Retina, Gladesville, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; University of Auckland; Australian National
   University; University of Zurich; University Zurich Hospital
RP Nguyen, V (通讯作者)，Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
EM phuc.nguyen@sydney.edu.au
OI Nguyen, Chu Luan/0000-0002-4630-6182; Essex, Rohan/0000-0001-5323-0334
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Arts DGT, 2002, J AM MED INFORM ASSN, V9, P600, DOI 10.1197/jamia.M1087
   Barthelmes D, 2015, BRIT J OPHTHALMOL, V99, P359, DOI 10.1136/bjophthalmol-2014-305514
   Barthelmes D, 2014, OPHTHALMOLOGY, V121, P2073, DOI 10.1016/j.ophtha.2014.05.007
   Behndig A, 2011, J CATARACT REFR SURG, V37, P1539, DOI 10.1016/j.jcrs.2011.05.021
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Daien V, 2018, AM J OPHTHALMOL, V190, P50, DOI 10.1016/j.ajo.2018.03.012
   Daien V, 2018, OPHTHALMOLOGY, V125, P66, DOI 10.1016/j.ophtha.2017.07.005
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Finger RP, 2012, OPHTHALMOLOGE, V109, P474, DOI 10.1007/s00347-012-2554-7
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P589, DOI 10.1016/j.ophtha.2014.10.001
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Invernizzi A, 2018, OPHTHALMOLOGY, V125, P237, DOI 10.1016/j.ophtha.2017.08.039
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Lundstrom M, 2012, J CATARACT REFR SURG, V38, P1086, DOI 10.1016/j.jcrs.2012.03.006
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   Messenger JC, 2012, J AM COLL CARDIOL, V60, P1484, DOI 10.1016/j.jacc.2012.07.020
   Parke DW, 2017, OPHTHALMOLOGY, V124, P1572, DOI 10.1016/j.ophtha.2017.08.035
   R Core Team, 2018, R LANG ENV STAT COMP
   Revelle W., 2018, R PACKAGE VERSION, V1, P4
   RICKETTS D, 1993, ANN ROY COLL SURG, V75, P393
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Seddon DJ, 1997, BRIT J CANCER, V76, P667, DOI 10.1038/bjc.1997.443
   Thoburn KK, 2007, CANCER-AM CANCER SOC, V109, P1607, DOI 10.1002/cncr.22566
   van der Veer SN, 2010, INT J MED INFORM, V79, P305, DOI 10.1016/j.ijmedinf.2010.01.011
   Williams KA, 2008, TRANSPLANTATION, V86, P1720, DOI 10.1097/TP.0b013e3181903b0a
   Wyatt J, 1995, J Eval Clin Pract, V1, P15
   Xian Y, 2012, AM HEART J, V163, P392, DOI 10.1016/j.ahj.2011.12.012
NR 32
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2020
VL 40
IS 5
BP 866
EP 872
DI 10.1097/IAE.0000000000002485
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LL2HK
UT WOS:000531376000010
PM 30821728
DA 2022-11-30
ER

PT J
AU Singh, A
   Faber, C
   Falk, M
   Nissen, MH
   Hviid, TVF
   Sorensen, TL
AF Singh, Amardeep
   Faber, Carsten
   Falk, Mads
   Nissen, Mogens H.
   Hviid, Thomas V. F.
   Sorensen, Torben L.
TI Altered Expression of CD46 and CD59 on Leukocytes in Neovascular
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; SUBRETINAL FIBROSIS; ACTIVATION; RISK; VARIANT;
   POLYMORPHISM; INDIVIDUALS; COMPONENT; RECEPTOR; SMOKING
AB PURPOSE: To investigate the expression of the complement regulatory proteins CD46, CD55, and CD59 on peripheral leukocytes in neovascular age-related macular degeneration (AMD).
   DESIGN: Prospective, case-control study.
   METHODS: Thirty-five unrelated patients with neovascular AMD and 30 control individuals were included in this case-control study. All participants were subjected to a structured interview and detailed imaging (autofluorescence, digital funduscopy, spectral-domain optical coherence tomography, and fluorescein and indocyanine green angiography in patients suspected of having neovascular AMD) was performed. Fresh ethylenediamine-tetraacetic acid blood was obtained and stained with monoclonal antibodies. Using flow cytometry, the percentage of CD14(+) monocytes, CD45(+) lymphocytes, and CD45(+) granulocytes positive for CD46, CD55, and CD59 was determined in patients with neovascular AMD and was compared with that of controls.
   RESULTS: We found that the expression of CD46 and CD59 was significantly lower on CD14(+) monocytes in patients with neovascular AMD compared with controls (P = .0070). A significantly lower expression of CD46 on lymphocytes was observed in patients with fibrosis compared with patients without fibrosis (P = .010).
   CONCLUSIONS: Our study suggests that neovascular AMD is associated with an inadequate regulation of the complement system, supporting current evidence on the role of complement dysregulation in the pathogenesis of AMD. (Am J Ophthalmol 2012;154:193-199. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Singh, Amardeep; Falk, Mads; Sorensen, Torben L.] Copenhagen Univ Hosp, Dept Ophthalmol, DK-4000 Roskilde, Denmark.
   [Faber, Carsten; Nissen, Mogens H.] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Eye Res Unit, Copenhagen, Denmark.
   [Hviid, Thomas V. F.] Copenhagen Univ Hosp, Dept Clin Biochem, DK-4000 Roskilde, Denmark.
   [Hviid, Thomas V. F.] CIRRI, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen; University of
   Copenhagen
RP Singh, A (通讯作者)，Copenhagen Univ Hosp, Dept Ophthalmol, Kogevej 7-13, DK-4000 Roskilde, Denmark.
EM asingh@dadlnet.dk
RI Sørensen, Torben Lykke L/N-1417-2014; Faber, Carsten/I-4150-2013; Faber,
   Carsten/N-3210-2019; Nissen, Mogens/B-4825-2008; Singh,
   Amardeep/ABI-4544-2020
OI Sørensen, Torben Lykke L/0000-0002-6790-0199; Faber,
   Carsten/0000-0002-2517-7270; Faber, Carsten/0000-0002-2517-7270; Nissen,
   Mogens/0000-0001-7729-8667; 
FU Region Zealand's Research Fund (Soro, Denmark); Velux Foundation
   (Horsholm, Denmark); Danish Research Eye Foundation (Copenhagen,
   Denmark); Danish Eye Health Society (Vaern om Synet; Copenhagen,
   Denmark); Beckett Foundation (Copenhagen, Denmark); Synoptik Foundation
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF Interest and none were reported. Publication
   of this article was supported by Region Zealand's Research Fund (Soro,
   Denmark), the Velux Foundation (Horsholm, Denmark), the Danish Research
   Eye Foundation (Copenhagen, Denmark), the Danish Eye Health Society
   (Vaern om Synet; Copenhagen, Denmark), the Beckett Foundation
   (Copenhagen, Denmark), and the Synoptik Foundation. All authors have
   completed and submitted the ICMJE Form for Disclosure of Potential
   Conflicts of Interest and none were reported. Involved in Design and
   conduct of study (A.S., T.V.F.H., T.L.S.); Data collection (A.S., M.F.);
   Management, analysis, and interpretation of data (A.S., C.F., T.V.F.H.,
   M.H.N., T.L.S.); and Preparation, review, or approval of manuscript
   (A.S., C.F., M.F., M.H.N., T.V.F.H., T.L.S.). The study was approved by
   the Regional Committee on Biomedical Research and followed the tenets of
   the Declaration of Helsinki. Informed written and oral consent was
   obtained from all participants to participate in this research after
   explanation of the nature and possible consequences of the study.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bohana-Kashtan O, 2004, MOL IMMUNOL, V41, P583, DOI 10.1016/j.molimm.2004.04.007
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Burgisser P, 2007, CYTOM PART A, V71A, P632, DOI 10.1002/cyto.a.20414
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2
   Giddings KS, 2004, NAT STRUCT MOL BIOL, V11, P1173, DOI 10.1038/nsmb862
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harkness KA, 2003, J NEUROIMMUNOL, V142, P1, DOI 10.1016/S0165-5728(03)00251-0
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Iyer A, 2011, J CARDIOVASC PHARM, V58, P479, DOI 10.1097/FJC.0b013e31822a7a09
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Koch N, 2009, J LEUKOCYTE BIOL, V86, P155, DOI [10.1189/JLB.0708443, 10.1189/jlb.0708443]
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lim WK, 2004, AM J OPHTHALMOL, V138, P475, DOI 10.1016/j.ajo.2004.04.013
   Loeffler KU, 1997, GRAEF ARCH CLIN EXP, V235, P248, DOI 10.1007/BF00941767
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   PALESTINE AG, 1985, OPHTHALMOLOGY, V92, P838
   Riley-Vargas RC, 2004, TRENDS IMMUNOL, V25, P496, DOI 10.1016/j.it.2004.07.004
   ROBBINS RA, 1991, AM J PHYSIOL, V260, pL254, DOI 10.1152/ajplung.1991.260.4.L254
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 43
TC 43
Z9 45
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2012
VL 154
IS 1
BP 193
EP 199
DI 10.1016/j.ajo.2012.01.036
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 966XX
UT WOS:000305871800025
PM 22541656
DA 2022-11-30
ER

PT J
AU Cherepanoff, S
   McMenamin, P
   Gillies, MC
   Kettle, E
   Sarks, SH
AF Cherepanoff, S.
   McMenamin, P.
   Gillies, M. C.
   Kettle, E.
   Sarks, S. H.
TI Bruch's membrane and choroidal macrophages in early and advanced
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; NITRIC-OXIDE SYNTHASE; ENDOTHELIAL
   GROWTH-FACTOR; COMPLEMENT FACTOR-H; II-POSITIVE CELLS;
   MORPHOMETRIC-ANALYSIS; AUTOIMMUNE UVEORETINITIS; NEOVASCULAR MEMBRANES;
   UVEAL TRACT; DRUSEN
AB Aim To determine the sub-macular Bruch's membrane (BrM) macrophage count and the choroidal and BrM macrophage immunophenotype in normal eyes and in eyes with early and advanced age-related macular degeneration (AMD).
   Methods BrM macrophages were counted in 125 human eyes (normal, normal aged, early AMD and geographical atrophy), and CD68 and inducible nitric oxide synthase (iNOS) immunohistochemistry was performed on 16 human eyes (normal, normal aged, early AMD, geographical atrophy and disciform scarring). All eyes were examined clinically ante mortem. Results were correlated with histopathological features, including basal laminar deposit and membranous debris, and with clinical fundus appearance.
   Results CD68(+) macrophages were found in the choroid of normal human eyes, and did not express iNOS. Expression of iNOS by choroidal macrophages (as well as endothelial cells and pericytes) was associated with: (1) recruitment of macrophages to BrM in early AMD eyes with soft drusen or thick continuous basal laminar deposit, corresponding to clinically detectable soft drusen or pigment changes; and (2) active disciform scarring. iNOS expression was absent in BrM macrophages, suggesting immunomodulatory differences between the choroid and BrM. The highest BrM macrophage counts were found in eyes with subclinical choroidal neovascularisation.
   Conclusion The presence of extracellular deposits (soft drusen and thick continuous basal laminar deposit) is associated with macrophage recruitment to BrM and alteration in the immunophenotype of resident choroidal macrophages.
C1 [Cherepanoff, S.] Prince Wales Hosp, SEALS, Randwick, NSW 2031, Australia.
   [Cherepanoff, S.] Univ New S Wales, Sch Med Sci, Dept Pathol, Sydney, NSW, Australia.
   [McMenamin, P.] Univ Western Australia, Dept Anat & Human Biol, Crawley, WA, Australia.
   [McMenamin, P.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Crawley, WA, Australia.
   [Gillies, M. C.] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Kettle, E.] Childrens Med Res Inst, Westmead, NSW, Australia.
C3 University of New South Wales Sydney; University of Western Australia;
   Lions Eye Institute; University of Western Australia; University of
   Sydney; Children's Medical Research Institute - Australia
RP Cherepanoff, S (通讯作者)，Prince Wales Hosp, SEALS, Level 4,Campus Ctr,Barker St, Randwick, NSW 2031, Australia.
EM svetlana.cherepanoff@sesiahs.health.nsw.gov.au
RI gillies, mark c/B-3242-2012
OI McMenamin, Paul/0000-0002-7141-1283
FU National Health and Medical Research Council (Canberra ACT, Australia)
   [008103]
FX We thank Adeline Akkari for assistance with immunohistochemistry. SC was
   supported by a National Health and Medical Research Council (Canberra
   ACT, Australia) PhD Scholarship (No. 008103).
CR Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083
   Blaise GA, 2005, TOXICOLOGY, V208, P177, DOI 10.1016/j.tox.2004.11.032
   Butler TL, 1996, INVEST OPHTH VIS SCI, V37, P2195
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   FORRESTER JV, 1994, INVEST OPHTH VIS SCI, V35, P64
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hangai M, 1996, EXP EYE RES, V63, P501, DOI 10.1006/exer.1996.0140
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Hollborn M, 2000, CURR EYE RES, V20, P488, DOI 10.1076/0271-3683(200006)20:6;1-Y;FT488
   HOLNESS CL, 1993, BLOOD, V81, P1607
   Holtkamp GM, 1999, CLIN EXP IMMUNOL, V118, P35
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   KEZIC J, 2008, J LEUKOCYTE BIOL
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Lommatzsch A, 2007, GRAEF ARCH CLIN EXP, V245, P1713, DOI 10.1007/s00417-007-0649-7
   McMenamin PG, 1999, BRIT J OPHTHALMOL, V83, P598, DOI 10.1136/bjo.83.5.598
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   SARKS SH, 1978, 23 CONC OPHTH KYOT, P228
   SARKS SH, 1985, OPHTHALMOLOGY
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schroedl F, 2008, INVEST OPHTH VIS SCI, V49, P5222, DOI 10.1167/iovs.08-1721
   Sennlaub F, 2001, J CLIN INVEST, V107, P717, DOI 10.1172/JCI10874
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Xiong M, 1998, AM J PATHOL, V153, P587, DOI 10.1016/S0002-9440(10)65601-5
   Yang PZ, 1997, BRIT J OPHTHALMOL, V81, P396, DOI 10.1136/bjo.81.5.396
   Zamiri P, 2006, INVEST OPHTH VIS SCI, V47, P3912, DOI 10.1167/iovs.05-1267
NR 52
TC 161
Z9 165
U1 0
U2 7
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2010
VL 94
IS 7
BP 918
EP 925
DI 10.1136/bjo.2009.165563
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 621GR
UT WOS:000279564400022
PM 19965817
DA 2022-11-30
ER

PT J
AU Torrini, M
   Marchese, C
   Vanzetti, M
   Marini, V
   Origone, P
   Garre, C
   Mareni, C
AF Torrini, Margherita
   Marchese, Cristiana
   Vanzetti, Mario
   Marini, Valeria
   Origone, Paola
   Garre, Cecilia
   Mareni, Cristina
TI Mutation analysis of oxisterol-binding-protein gene in patients with
   age-related macular degeneration
SO GENETIC TESTING
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MACULOPATHY; FAMILY; 10Q26
AB Allelic variants of several genes are increasingly recognized as susceptibility factors in age-related macular degeneration (AMD). Because of its metabolic characteristics the macula is sensitive to oxidative damage, and supplementation with antioxidants has been shown to be effective in slowing the progression of disease in AMD patients. The oxisterol-binding-protein (OSBP2) gene is expressed mainly in the retinal pigmented epithelium underlying the macular region. Its product specifically binds and transports oxisterols, the cytotoxic effects of which may be involved in macular damage. The aim of this study was to search for allelic variants of OSBP2 gene, as well as to evaluate several risk factors in 24 patients with AMD; 17 with nonexudative (NE) and 7 with neovascular (NV) form. Total cholesterol was elevated in 66% of the patients, high-density lipoprotein (HDL) cholesterol was reduced in 12%; vitamin A or vitamin E deficiency was not observed. OSBP2 gene analysis was performed in AMD patients and in 110 control subjects by single-stranded conformational polymorphism (SSCP) analysis followed by direct sequencing. Six allelic variants were detected: 2 nonpolymorphic unique exonic variants in 2 AMD subjects and 4 polymorphic variants (2 exonic and 2 intronic). These data indicate a possible role of OSBP2 gene in the pathogenesis of oxidative damage to the macula induced by oxysterols in AMD patients.
C1 [Marini, Valeria; Origone, Paola; Garre, Cecilia] Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy.
   [Torrini, Margherita; Mareni, Cristina] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy.
   [Marchese, Cristiana] ASO Ordine Mauriziano, Dept Clin Pathol, Turin, Italy.
   [Vanzetti, Mario] ASO Ordine Mauriziano, Dept Ophthalmol, Turin, Italy.
C3 University of Genoa; University of Genoa; A.O.U. Citta della Salute e
   della Scienza di Torino; AOU San Giovanni Battista-Molinette; A.O.U.
   Citta della Salute e della Scienza di Torino; AOU San Giovanni
   Battista-Molinette
RP Garre, C (通讯作者)，Univ Genoa, Dept Oncol Biol & Genet, Viale Benedetto 15-6, I-16132 Genoa, Italy.
EM regar@unige.it
RI Marchese, Cristiana/HCI-3501-2022
CR Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fournier MV, 1999, CANCER RES, V59, P3748
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jaworski CJ, 2001, GENOMICS, V78, P185, DOI 10.1006/geno.2001.6663
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lehto M, 2001, J LIPID RES, V42, P1203
   Moreira EF, 2001, J BIOL CHEM, V276, P18570, DOI 10.1074/jbc.M011259200
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Silva NH, 2003, INT J MOL MED, V12, P663
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang C, 2002, BIOCHEM J, V361, P461, DOI 10.1042/0264-6021:3610461
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
NR 19
TC 7
Z9 7
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1090-6576
J9 GENET TEST
JI Genet. Test.
PD DEC
PY 2007
VL 11
IS 4
BP 421
EP 426
DI 10.1089/gte.2007.0021
PG 6
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA 254AR
UT WOS:000252559200013
PM 18294060
DA 2022-11-30
ER

PT J
AU Takeda, AL
   Colquitt, J
   Clegg, AJ
   Jones, J
AF Takeda, A. L.
   Colquitt, J.
   Clegg, A. J.
   Jones, J.
TI Pegaptanib and ranibizumab for neovascular age-related macular
   degeneration: a systematic review
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CONTROLLED CLINICAL-TRIALS; VERTEPORFIN
AB Aims: To assess the clinical effectiveness of pegaptanib sodium and ranibizumab for neovascular age-related macular degeneration (AMD).
   Methods: A systematic review of randomised controlled trials (RCTs) identified through searching 12 electronic databases, bibliographies and consultation with experts and manufacturers. RCTs were eligible if they assessed the effects of pegaptanib or ranibizumab with best supportive care, sham injection or photodynamic therapy (PDT) on patients with subfoveal choroidal neovascularisation associated with wet AMD and examined outcomes including visual acuity and adverse events.
   Results: Three RCTs of ranibizumab (MARINA, ANCHOR, FOCUS) and two of pegaptanib (VISION study) met the inclusion criteria. The RCTs included patients with different lesion types. The studies showed statistically significant benefit on different measures of visual acuity for patients receiving pegaptanib, ranibizumab or ranibizumab with PDT compared to control (sham injection, PDT or sham injection with PDT) after 12 months. These differences appeared to be clinically significant. Although adverse events were common among those receiving pegaptanib or ranibizumab, they were considered mild to moderate in nature. Meta-analysis of ranibizumab trials and indirect comparison of the two drugs were not possible due to differences in the study populations' lesion types. However, results from the RCTs of ranibizumab tended to show a greater effect on visual acuity than results from the RCT of pegaptanib.
   Conclusions: Pegaptanib and ranibizumab appear to slow or stop the progression of neovascular AMD. Uncertainty remains over the relative benefits of pegaptanib compared with ranibizumab and other unlicensed drugs (eg, Avastin), due to the nature of the evidence. Head-to-head RCTs and economic evaluations comparing these alternatives are needed.
C1 Univ Southampton, Southampton Hlth Technol Assessments Ctr, Wessex Inst Hlth Res & Dev, Southampton SO16 7PX, Hants, England.
C3 University of Southampton
RP Takeda, AL (通讯作者)，Univ Southampton, Southampton Hlth Technol Assessments Ctr, Wessex Inst Hlth Res & Dev, Mailpoint 728, Southampton SO16 7PX, Hants, England.
EM takeda@soton.ac.uk
OI Colquitt, Jillian Leigh/0000-0001-5962-2689
CR ABRAHAM P, 2006, PROGR ABSTR 24 ANN A
   BOSELEY S, 2007, GAURDIAN        0215
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Canning C, 2006, EYE, V20, P985, DOI 10.1038/sj.eye.6702501
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Egger M, 2001, SYSTEMATIC REV HLTH, P487
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   MIELER WF, 2006, PROGR ABSTR 24 ANN A
   *NAT EL LIB MED, NOV LAUNCH RAN LUC 1
   *NHS CTR REV DISS, 2001, UND SYST REV RES EFF
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   ROSENFELD P, 2006, PROGR ABSTR 24 ANN A
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   WONG D, ROYAL COLLEGE OPHTHA
NR 17
TC 60
Z9 68
U1 0
U2 13
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2007
VL 91
IS 9
BP 1177
EP 1182
DI 10.1136/bjo.2007.118562
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 202EN
UT WOS:000248884900024
PM 17475698
OA Green Published
DA 2022-11-30
ER

PT J
AU Fiotti, N
   Pedio, M
   Parodi, MB
   Altamura, N
   Uxa, L
   Guarnieri, G
   Giansante, C
   Ravalico, G
AF Fiotti, N
   Pedio, M
   Parodi, MB
   Altamura, N
   Uxa, L
   Guarnieri, G
   Giansante, C
   Ravalico, G
TI MMP-9 microsatellite polymorphism and susceptibility to exudative form
   of age-related macular degeneration
SO GENETICS IN MEDICINE
LA English
DT Article
DE MMP-9; age-related macular degeneration; choroidal neovascularization;
   weight; body mass index
ID BODY-MASS INDEX; MATRIX METALLOPROTEINASES; MATRIX-METALLOPROTEINASE-9;
   ASSOCIATION; MACULOPATHY; EXPRESSION; DISEASE; GENE; MICE; EYE
AB Purpose: To assess if a polymorphism (PM) of the microsatellite (CA(13-27)) in the promoter region of Matrix Metalloproteinase 9 (MMP-9) was associated with the exudative form of age-related macular degeneration (AMD) and to its risk factors. Methods: In 107 patients with AMD (AMD Group) and 223 age- and gender-matched controls (Control Group) with cataract, demographic, clinical data, and MMP-9 PM have been compared. Results: The comparison of allelic frequencies showed a different pattern of CA repeats between AMD and Control Group (P < 0.00005), in particular the prevalence of longer microsatellites (>= 22 CA repeats) was higher in AMD than in Control Group (O.R. 2.49, 95% CI 1.71 - 3.37, P < 0.001). Analyses of genetic frequencies gave similar results. Logistic regression confirmed that 22 or more CA repeats are associated to AMD. The only association between MMP-9 PM and other risk factors for AMD was with BMI (Spearman's R = 0.298, P < 0.00005): all patients with both microsatellites >= 22 CA repeats were overweight or obese (chi(2) test P < 0.0005, compared to other genotypes). Conclusions: Longer microsatellites in the promoter of MMP-9 are associated to the exudative form of AMD and to body mass index, a well-known risk factor for the disease.
C1 ASS I Triestina, Ctr Blood Transfus, Trieste, Italy.
   Univ Trieste, Dept Clin Morphol & Technol Sci, Trieste, Italy.
   Univ Trieste, Dept Surg Specialities Sci, Trieste, Italy.
C3 University of Trieste; University of Trieste
RP Fiotti, N (通讯作者)，Osped Cattinara, UCO Clin Med Gen, Str Fiunie 447, I-34149 Cattimara Trieste, Italy.
EM fiotti@units.it
RI Fiotti, Nicola/AEM-3887-2022; Parodi, Maurizio Battaglia/K-7876-2016
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961; FIOTTI,
   NICOLA/0000-0001-8918-7622
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Bouloumie A, 2001, DIABETES, V50, P2080, DOI 10.2337/diabetes.50.9.2080
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Croissandeau G, 2002, BIOCHEM J, V364, P739, DOI 10.1042/BJ20011158
   De la Paz MA, 1998, INVEST OPHTH VIS SCI, V39, P1256
   Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768
   Fiotti N, 2004, J NEUROIMMUNOL, V152, P147, DOI 10.1016/j.jneuroim.2004.03.009
   Fornoni A, 2002, J AM SOC NEPHROL, V13, P2068, DOI 10.1097/01.ASN.0000022421.86757.8D
   GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643
   Kaneko M, 2001, RHEUMATOLOGY, V40, P247, DOI 10.1093/rheumatology/40.3.247
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lijnen HR, 2002, ARTERIOSCL THROM VAS, V22, P374, DOI 10.1161/hq0302.104522
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Shimajiri S, 1999, FEBS LETT, V455, P70, DOI 10.1016/S0014-5793(99)00863-7
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   STJEAN PL, 1995, ANN HUM GENET, V59, P17
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   West SK, 2000, ARCH OPHTHALMOL-CHIC, V118, P393, DOI 10.1001/archopht.118.3.393
   Ye S, 2000, MATRIX BIOL, V19, P623, DOI 10.1016/S0945-053X(00)00102-5
   Yoon S, 1999, BIOCHEM BIOPH RES CO, V265, P563, DOI 10.1006/bbrc.1999.1721
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 33
TC 34
Z9 35
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD APR
PY 2005
VL 7
IS 4
BP 272
EP 277
DI 10.1097/01.GIM.0000159903.69597.73
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 917AQ
UT WOS:000228428600007
PM 15834245
OA Bronze
DA 2022-11-30
ER

PT J
AU Edo, A
   Pertiwi, YD
   Hirooka, K
   Masuda, S
   Kamaruddin, MI
   Yanagi, M
   Nagao, A
   Ohno, H
   Yoneda, M
   Kiuchi, Y
AF Edo, Ayaka
   Pertiwi, Yunialthy Dwia
   Hirooka, Kazuyuki
   Masuda, Shun
   Kamaruddin, Muhammad Irfan
   Yanagi, Masahide
   Nagao, Akiko
   Ohno, Haruya
   Yoneda, Masayasu
   Kiuchi, Yoshiaki
TI Association of Dietary Nutrient Intake with Early Age-Related Macular
   Degeneration in Japanese-Americans
SO METABOLITES
LA English
DT Article
DE age-related macular degeneration; saturated fatty acids; animal fat;
   nutrient intake
ID COMPLEMENT-FACTOR-H; GLYCEMIC INDEX; DOCOSAHEXAENOIC ACID; FISH
   CONSUMPTION; FATTY-ACIDS; RISK; MACULOPATHY; ANTIOXIDANTS; POLYMORPHISM;
   POPULATION
AB Lifestyle factors may be associated with the development of age-related macular degeneration (AMD), in addition to demographic and genetic factors. The purpose of this cross-sectional study is to elucidate the association between nutrient intake and AMD in the Japanese-American population living in Los Angeles. We conducted a medical survey of Japanese immigrants and their descendants living in Los Angeles, including interviews on dietary habits, fundus photography, and physical examinations. Participants were classified into early AMD and control groups on the basis of fundus photographic findings. Consequently, among the 555 participants, 111 (20.0%) were diagnosed with early AMD. There were no late-stage AMD participants. Multivariate logistic regression analysis showed that the intake of animal fat and saturated fatty acids (SFA) was positively associated with early AMD (p for trend = 0.01 for animal fat, p for trend = 0.02 for SFA), and the intake of vegetable fat, total carbohydrate, simple carbohydrate, sugar, and fructose was inversely associated with early AMD (p for trend = 0.04 for vegetable fat, p for trend = 0.046 for carbohydrate, p for trend = 0.03 for simple carbohydrate, p for trend = 0.046 for sugar, p for trend = 0.02). Our findings suggest that excessive animal fat and SFA intake increases the risk for early AMD in Japanese-Americans whose lifestyles have been westernized.
C1 [Edo, Ayaka; Hirooka, Kazuyuki; Masuda, Shun; Kiuchi, Yoshiaki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Ophthalmol & Visual Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
   [Pertiwi, Yunialthy Dwia] Hasanuddin Univ, Fac Med, Dept Microbiol, Jl Perintis Kemerdekaan KM 10, Kota Makassar 90245, Sulawesi Selata, Indonesia.
   [Kamaruddin, Muhammad Irfan] Hasanuddin Univ, Hasanuddin Univ Hosp, Dept Ophthalmol, Fac Med, Bldg 4th Floor,Perintis Kemerdekaan St Km 11, Makassar 90245, Sulawesi Selata, Indonesia.
   [Yanagi, Masahide] Hiroshima Nomura Eye Clin, Minami Ku, 3-1-202,Matsubara Cho, Hiroshima 7320822, Japan.
   [Nagao, Akiko] Hiroshima Univ Hosp, Div Nutrient Management, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
   [Ohno, Haruya; Yoneda, Masayasu] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol & Internal Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
C3 Hiroshima University; Universitas Hasanuddin; Universitas Hasanuddin;
   Hiroshima University; Hiroshima University
RP Edo, A (通讯作者)，Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Ophthalmol & Visual Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
EM ayakae@hiroshima-u.ac.jp; dwiapertiwi@gmail.com;
   kazuyk@hiroshima-u.ac.jp; masudash@hiroshima-u.ac.jp;
   iphenk_tampo@yahoo.com; myaja111@yahoo.co.jp; anagao@hiroshima-u.ac.jp;
   haruya-ohno@hiroshima-u.ac.jp; masayone17@hiroshima-u.ac.jp;
   ykiuchi@hiroshima-u.ac.jp
RI Pertiwi, Yunialthy Dwia/AAZ-5441-2020
OI Pertiwi, Yunialthy Dwia/0000-0002-1050-3280
FU Japan Society for the Promotion of Science KAKENHI [JP16K09035]
FX This study was financially supported by Japan Society for the Promotion
   of Science KAKENHI Grant (No. JP16K09035) to M. Yoneda.
CR Adams C.F., 1975, AGR RES SERVICE NUTR
   Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS13, DOI 10.2337/dc18-S002
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Augustin LSA, 2015, NUTR METAB CARDIOVAS, V25, P795, DOI 10.1016/j.numecd.2015.05.005
   Bantle JP, 2006, NES NUTR WS, V11, P83, DOI 10.1159/000094427
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Cougnard-Gregoire A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160240
   De Lorgeril Michel, 2007, Subcell Biochem, V42, P283
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Forouhi NG, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2139
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gopinath B, 2017, BRIT J OPHTHALMOL, V101, P1027, DOI 10.1136/bjophthalmol-2016-309490
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hu YQ, 2006, AM J CLIN NUTR, V84, P70, DOI 10.1093/ajcn/84.1.70
   Itakura K, 2015, INVEST OPHTH VIS SCI, V56, P5401, DOI 10.1167/iovs.15-16680
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jeffrey BG, 2001, LIPIDS, V36, P859, DOI 10.1007/s11745-001-0796-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kundu R, 2017, CARDIOLOGY ANGIOLOGY, V6, P1, DOI DOI 10.9734/CA/2017
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee JE, 2013, AM J CLIN NUTR, V98, P1032, DOI 10.3945/ajcn.113.062638
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Montserrat-de la Paz S, 2016, FOOD FUNCT, V7, P1345, DOI [10.1039/c6fo00136j, 10.1039/C6FO00136J]
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nagai N, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01483-2
   Okamoto H, 2006, MOL VIS, V12, P156
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sasaki M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.23
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sugihiro T, 2019, J DIABETES INVEST, V10, P1229, DOI 10.1111/jdi.13010
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   Yanagi Y, 2019, EYE, V33, P34, DOI 10.1038/s41433-018-0225-x
   Yoneda M, 2021, J ATHEROSCLER THROMB, V28, P214, DOI 10.5551/jat.RV17046
   Yoneda M, 2020, J DIABETES INVEST, V11, P1382, DOI 10.1111/jdi.13278
   Yoserizal M, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018314
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zhou BF, 2003, J HUM HYPERTENS, V17, P623, DOI 10.1038/sj.jhh.1001605
NR 61
TC 2
Z9 2
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-1989
J9 METABOLITES
JI Metabolites
PD OCT
PY 2021
VL 11
IS 10
AR 673
DI 10.3390/metabo11100673
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA WO9JI
UT WOS:000712760900001
PM 34677388
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wolffsohn, JS
   Anderson, SJ
   Mitchell, J
   Woodcock, A
   Rubinstein, M
   Ffytche, T
   Browning, A
   Willbond, K
   Amoaku, WM
   Bradley, C
AF Wolffsohn, JS
   Anderson, SJ
   Mitchell, J
   Woodcock, A
   Rubinstein, M
   Ffytche, T
   Browning, A
   Willbond, K
   Amoaku, WM
   Bradley, C
TI Effect of age related macular degeneration on the Eger macular
   stressometer photostress recovery time
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GLARE RECOVERY; MACULOPATHY; ADAPTATION; EYES
AB Aim: To assess the repeatability of Eger macular stressometer ( EMS) measures of photostress recovery and determine their association with other measures of visual function.
   Methods: EMS photostress recovery time was measured in 90 patients with bilateral exudative age related macular degeneration (AMD), 19 with bilateral atrophic AMD and 47 with both forms of the condition (mean age 79 (SD 13) years). Measurements were made on two occasions separated by 1 year. Intrasession repeatability was assessed by repeating the measures after a 10 minute recovery period at the first visit. Distance visual acuity was measured with a logMAR chart, near visual acuity with a MNRead chart at 25 cm, contrast sensitivity with a Pelli-Robson chart, and the presence of central visual disturbance assessed with an Amsler grid. A questionnaire was used to assess self reported difficulties with glare recovery.
   Results: The average EMS recovery time was 11.0 (SD 8.9) seconds, decreasing by 1.6 (5.2) seconds on repeated measurement (p < 0.05). EMS photostress recovery was not correlated with visual function measures or subjective difficulties with lights (p < 0.05). EMS photostress recovery time did not predict those whose vision decreased over the following year compared with those among whom it remained stable.
   Conclusions: The EMS test is not a useful tool in determining the severity or progression of AMD.
C1 Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
   Univ London, Royal Holloway & Bedford New Coll, Dept Psychol, Egham TW20 0EX, Surrey, England.
   Queens Med Ctr, Eye & ENT Ctr, Div Ophthalmol & Visual Sci, Nottingham NG7 2UH, England.
   Hosp Trop Dis, London NW1 0PE, England.
C3 Aston University; University of London; Royal Holloway University
   London; University of Nottingham; University College London Hospitals
   NHS Foundation Trust; University of London; London School of Hygiene &
   Tropical Medicine
RP Wolffsohn, JS (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
EM j.s.w.wolffsohn@aston.ac.uk
OI Bradley, Clare/0000-0002-4079-0364; Amoaku,
   Winfried/0000-0001-5028-7984; Wolffsohn, James/0000-0003-4673-8927
CR BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   BARLETT H, 2004, OPHTHAL PHYSL OPT, V24, P594
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   COLLINS M, 1989, OPHTHAL PHYSL OPT, V9, P368
   COLLINS M, 1989, CLIN VISION SCI, V4, P145
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   FORSIUS H, 1963, ARCH OPHTHALMOL-CHIC, V42, P55
   GLASER JS, 1977, AM J OPHTHALMOL, V83, P255, DOI 10.1016/0002-9394(77)90624-9
   GOMEZULLA F, 1986, BRIT J OPHTHALMOL, V70, P209, DOI 10.1136/bjo.70.3.209
   HOLLINS M, 1973, J GEN PHYSIOL, V62, P430, DOI 10.1085/jgp.62.4.430
   Ito Y, 1997, JPN J OPHTHALMOL, V41, P255, DOI 10.1016/S0021-5155(97)00044-0
   LOVASIK JV, 1983, INVEST OPHTH VIS SCI, V24, P437
   Margrain TH, 2002, OPHTHAL PHYSL OPT, V22, P61, DOI 10.1046/j.1475-1313.2002.00005.x
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Schmitt NJ, 2003, AM J OPHTHALMOL, V136, P314, DOI 10.1016/S0002-9394(03)00208-3
   WU G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1556, DOI 10.1001/archopht.1990.01070130058030
   ZABRISKIE NA, 1994, OPHTHALMOLOGY, V101, P1122
NR 19
TC 15
Z9 15
U1 0
U2 6
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2006
VL 90
IS 4
BP 432
EP 434
DI 10.1136/bjo.2005.085787
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 023CH
UT WOS:000236102400015
PM 16547321
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Bulik, A
   Tadayoni, R
   Quentel, G
AF Cohen, SY
   Bulik, A
   Tadayoni, R
   Quentel, G
TI Visual hallucinations and Charles Bonnet syndrome after photodynamic
   therapy for age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   BONNET,CHARLES SYNDROME; VERTEPORFIN
AB Aims: To report on visual hallucinations and Charles Bonnet syndrome (CBS) that may occur in patients with age related macular degeneration (AMD) treated by photodynamic therapy (PDT) with verteporfin for choroidal neovascularisation (CNV).
   Methods: 100 consecutive patients were asked to respond to an orally administered questionnaire on visual hallucinations following PDT. Three groups of patients, respectively without visual hallucinations, with unstructured visual hallucinations, and with structured hallucinations that is, CBS, were compared by ANOVA, Scheffe's test, or the c 2 test, to establish whether age, sex, or visual acuity, as scored on ETDRS charts, are risk factors for the occurrence of visual hallucinations.
   Results: Five patients (5%) described transient structured visual hallucinations, including known or unknown faces and geometric patterns. Fifteen patients (15%) reported photopsias and flashing lights of various colours. These symptoms usually occurred a few days after PDT. There was no significant difference between the group of patients with structured visual hallucinations and the two other groups, with regard to age ( p = 0.435), sex ( p = 0.406), or visual acuity ( p = 0.835).
   Conclusions: Visual hallucinations and CBS appear to be a possible, although unrecognised, side effect of PDT for CNV, which occur just after treatment. These results suggest the need to include the possibility of visual hallucinations in the information given to patients before PDT.
C1 Ctr Ophtalmol Imagerie & Laser, Paris, France.
RP Cohen, SY (通讯作者)，11 Rue Antoine Bourdelle Paris, F-75015 Paris, France.
EM sycohen@club-internet.fr
RI Tadayoni, Ramin/D-1165-2010
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BERRIOS GE, 1982, AGE AGEING, V11, P17, DOI 10.1093/ageing/11.1.17
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BONNET C, 1769, ESSAI ANAL FACULTES, V2, P176
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   COGAN DG, 1973, A GRAEF ARCH KLIN EX, V188, P139, DOI 10.1007/BF00407835
   Cohen SY, 2000, AM J OPHTHALMOL, V129, P815, DOI 10.1016/S0002-9394(00)00374-3
   CRANE WG, 1994, OPHTHALMOL CLIN N AM, V7, P143
   de Morsier G, 1967, ANN MED PSYCHOL, V125, P677
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P664
   Fernandez A, 1997, J NERV MENT DIS, V185, P195, DOI 10.1097/00005053-199703000-00009
   FITZGERALD RG, 1971, AM J PSYCHIAT, V127, P1533, DOI 10.1176/ajp.127.11.1533
   Karacorlu M, 2002, AM J OPHTHALMOL, V134, P360, DOI 10.1016/S0002-9394(02)01626-4
   Pfeiffer RF, 1996, J AM GERIATR SOC, V44, P1128, DOI 10.1111/j.1532-5415.1996.tb02955.x
   Pliskin NH, 1996, J AM GERIATR SOC, V44, P1055, DOI 10.1111/j.1532-5415.1996.tb02937.x
   Saperstein DA, 2002, OPHTHALMOLOGY, V109, P1499, DOI 10.1016/S0161-6420(02)01103-X
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SIATKOWSKI RM, 1990, J CLIN NEURO-OPHTHAL, V10, P215
   TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   ZISKIND E, 1966, AM J PSYCHIAT, V122, P893
NR 23
TC 26
Z9 28
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2003
VL 87
IS 8
BP 977
EP 979
DI 10.1136/bjo.87.8.977
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 704NU
UT WOS:000184346400015
PM 12881339
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Honda, S
   Yanagi, Y
   Koizumi, H
   Chen, Y
   Tanaka, S
   Arimoto, M
   Imai, K
AF Honda, Shigeru
   Yanagi, Yasuo
   Koizumi, Hideki
   Chen, Yirong
   Tanaka, Satoru
   Arimoto, Manami
   Imai, Kota
TI Impact of neovascular age-related macular degeneration: burden of
   patients receiving therapies in Japan
SO SCIENTIFIC REPORTS
LA English
DT Article
ID QUALITY-OF-LIFE; HEALTH RESOURCE UTILIZATION; CHARLSON COMORBIDITY
   INDEX; VISUAL IMPAIRMENT; ECONOMIC BURDEN; PREVALENCE; DISEASE; COSTS
AB The chronic eye disorder, neovascular age-related macular degeneration (nAMD), is a common cause of permanent vision impairment and blindness among the elderly in developed countries, including Japan. This study aimed to investigate the disease burden of nAMD patients under treatment, using data from the Japan National Health and Wellness surveys 2009-2014. Out of 147,272 respondents, 100 nAMD patients reported currently receiving treatment. Controls without nAMD were selected by 1:4 propensity score matching. Healthcare Resource Utilisation (HRU), Health-Related Quality of Life (HRQoL), and work productivity loss were compared between the groups. Regarding HRU, nAMD patients had significantly increased number of visits to any healthcare provider (HCP) (13.8 vs. 8.2), ophthalmologist (5.6 vs. 0.8), and other HCP (9.5 vs. 7.1) compared to controls after adjusting for confounding factors. Additionally, nAMD patients had reduced HRQoL and work productivity, i.e., reduced physical component summary (PCS) score (46.3 vs. 47.9), increased absenteeism (18.14% vs. 0.24%), presenteeism (23.89% vs. 12.44%), and total work productivity impairment (33.57% vs. 16.24%). The increased number of ophthalmologist visits were associated with decreased PCS score, increased presenteeism and total work productivity impairment. The current study highlighted substantial burden for nAMD patients, requiring further attention for future healthcare planning and treatment development.
C1 [Honda, Shigeru] Osaka City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Osaka, Japan.
   [Yanagi, Yasuo] Asahikawa Med Univ, Dept Ophthalmol, Asahikawa, Hokkaido, Japan.
   [Koizumi, Hideki] Univ Ryukyus, Dept Ophthalmol, Grad Sch Med, Nishihara, Okinawa, Japan.
   [Chen, Yirong] Kantar Hlth, Singapore, Singapore.
   [Tanaka, Satoru; Arimoto, Manami; Imai, Kota] Novartis Pharma KK, Tokyo, Japan.
C3 Osaka Metropolitan University; Asahikawa Medical College; University of
   Ryukyus; Novartis
RP Arimoto, M (通讯作者)，Novartis Pharma KK, Tokyo, Japan.
EM manami.arimoto@novartis.com
RI Yanagi, Yasuo/AAA-5441-2022
FU Novartis Pharma K.K., Japan
FX The authors would like to thank Dina Graae Kristensen at Kantar Health,
   Singapore, for providing medical writing support, which was funded by
   Novartis Pharma K.K., Japan.
CR [Anonymous], 2019, JAPAN TIMES ONLINE
   [Anonymous], 2013, IBM SPSS STAT WINDOW
   [Anonymous], 2007, USERS MANUAL SF 12V2
   Charlson ME, 2008, J CLIN EPIDEMIOL, V61, P1234, DOI 10.1016/j.jclinepi.2008.01.006
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Dilokthornsakul P, 2014, INT J OPHTHALMOL-CHI, V7, P145, DOI 10.3980/j.issn.2222-3959.2014.01.27
   Fenwick EK, 2018, BRIT J OPHTHALMOL, V102, P377, DOI 10.1136/bjophthalmol-2017-310532
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Hanemoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189035
   Ito A, 2017, OPHTHALMOLOGICA, V238, P236, DOI 10.1159/000479937
   Jaffe DH, 2018, J COMP EFFECT RES, V7, P1125, DOI 10.2217/cer-2018-0058
   Kodjikian L, 2021, EYE, V35, P2119, DOI 10.1038/s41433-021-01487-0
   Kume A, 2016, OPHTHALMOLOGY, V123, P1263, DOI 10.1016/j.ophtha.2016.01.042
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Maruish, 2011, USERS MANUAL SF 36V2
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Nakata K, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0896-9
   Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433
   RCoreTeam, 2021, R LANG ENV STAT COMP
   Reilly MC, 2010, RHEUMATOLOGY, V49, P812, DOI 10.1093/rheumatology/kep457
   Reuters Doxorubicin Market, 2019, REUTERS
   Rim TH, 2020, OPHTHALMOLOGY, V127, P1371, DOI 10.1016/j.ophtha.2020.04.019
   Roberts CB, 2010, ARCH OPHTHALMOL-CHIC, V128, P766, DOI 10.1001/archophthalmol.2010.86
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Sruamsiri R, 2018, MOD RHEUMATOL, V28, P482, DOI 10.1080/14397595.2017.1361893
   Takahashi Kanji, 2012, Nippon Ganka Gakkai Zasshi, V116, P1150
   Tsuji T, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021160
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanagisawa M, 2011, OPHTHALMIC RES, V45, P47, DOI 10.1159/000316135
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 35
TC 2
Z9 2
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 23
PY 2021
VL 11
IS 1
AR 13152
DI 10.1038/s41598-021-92567-4
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TE4QR
UT WOS:000669996400020
PM 34162934
OA Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Quaranta-El Maftouhi, M
   Mauget-Faysse, M
AF Quaranta-El Maftouhi, M
   Mauget-Faysse, M
TI Anomalous vitreoretinal adhesions in patients with exudative age-related
   macular degeneration: An OCT study
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; vitreoretinal adhesions
ID DRUSEN
AB PURPOSE. To analyze the relationship between the retina and the vitreous in patients with exudative age-related macular degeneration (ARMD).
   METHODS. Consecutive patients with exudative ARMD, proven by fluorescein angiography, were recruited. Fundus biomicroscopic examination, color and red-free fundus photographs, and serial scans of the macular region using optical coherence tomography (OCT3, Carl Zeiss) were performed before and after photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Ophthalmics). Vitreoretinal relationships have been described and compared with fundus photographs and data of fundus biomicroscopy examination.
   RESULTS. Sixty-six eyes of 52 consecutive patients (33 women, 19 men; mean age 75 years, range 64 to 89 years) with exudative ARMD were studied. Analysis of serial OCT scans showed that 13 eyes (20%) did not present any visible vitreous structures. Two eyes (3%) had the appearance of a complete posterior vitreous detachment (PVD). Fifty-one eyes (77%) exhibited some abnormalities of the vitreoretinal interface including 12 eyes with epiretinal membrane and retinal thickening and distortion. Among the 39 eyes examined before and after PDT with Visudyne, only 3 eyes developed a partial vitreous detachment and 1 eye progressed to a complete PVD.
   CONCLUSiONS. Eyes with exudative ARMD exhibit a high prevalence of abnormalities of the vitreoretinal interface similar to that observed in many chronic inflammatory diseases. PDT with verteporfin does not modify the observed vitreoretinal adhesions.
C1 Ctr Ophtalmol Rabelais, F-69003 Lyon, France.
RP Quaranta-El Maftouhi, M (通讯作者)，Ctr Ophtalmol Rabelais, 12-14 Rue Rabelais, F-69003 Lyon, France.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Sebag J, 2000, EUR J OPHTHALMOL, V10, P1
   Weber-Krause B, 1997, OPHTHALMOLOGE, V94, P619, DOI 10.1007/s003470050170
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
NR 5
TC 29
Z9 29
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2006
VL 16
IS 1
BP 134
EP 137
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 017YG
UT WOS:000235728600021
PM 16496257
DA 2022-11-30
ER

PT J
AU Sun, S
   Cai, BC
   Li, Y
   Su, WQ
   Zhao, XZ
   Gong, BT
   Li, ZQ
   Zhang, XM
   Wu, YL
   Chen, C
   Tsang, ST
   Yang, J
   Li, XR
AF Sun, Shuo
   Cai, Bincui
   Li, Yao
   Su, Wenqi
   Zhao, Xuzheng
   Gong, Boteng
   Li, Zhiqing
   Zhang, Xiaomin
   Wu, Yalin
   Chen, Chao
   Tsang, Stephen H.
   Yang, Jin
   Li, Xiaorong
TI HMGB1 and Caveolin-1 related to RPE cell senescence in age-related
   macular degeneration
SO AGING-US
LA English
DT Article
DE A2E; HMGB1; Caveolin-1; RPE cell senescence; AMD
ID OXIDATIVE STRESS; GENE-EXPRESSION; A2E; PHOTOOXIDATION; ACTIVATION;
   LIPOFUSCIN; QUERCETIN; PROTECT; BINDING
AB Accumulation of lipofuscin in the retinal pigment epithelium (RPE) is considered a major cause of RPE dysfunction and senescence in age-related macular degeneration (AMD), and N-retinylidene-N-retinyle-thanolamine (A2E) is the main fluorophore identified in lipofuscin from aged human eyes. Here, human induced pluripotent stem cell (iPSC)-RPE was generated from healthy individuals to reveal proteomic changes associated with A2E-related RPE cell senescence. A novel RPE cell senescence-related protein, high-mobility group box 1 (HMGB1), was identified based on proteomic mass spectrometry measurements on iPSC-RPE with A2E treatment. Furthermore, HMGB1 upregulated Caveolin-1, which also was related RPE cell senescence. To investigate whether changes in HMGB1 and Caveolin-1 expression under A2E exposure contribute to RPE cell senescence, human ARPE-19 cells were stimulated with A2E; expression of HMGB1, Caveolin-1, tight junction proteins and senescent phenotypes were verified. HMGB1 inhibition alleviated A2E induced cell senescence. Migration of RPE cells was evaluated. Notably, A2E less than or equal to 10 mu M induced both HMGB1 and Caveolin-1 protein upregulation and HMGB1 translocation, while Caveolin-1 expression was downregulated when there was more than 10 mu M A2E. Our data indicate that A2E-induced upregulation of HMGB1. Caveolin-1 and HMGB1 release may relate to RPE cell senescence and play a role in the pathogenesis of AMD.
C1 [Sun, Shuo; Cai, Bincui; Su, Wenqi; Gong, Boteng; Li, Zhiqing; Zhang, Xiaomin; Yang, Jin; Li, Xiaorong] Tianjin Med Univ Eye Hosp, Eye Inst, Tianjin Key Lab Retinal Funct & Dis, Tianjin, Peoples R China.
   [Sun, Shuo; Cai, Bincui; Su, Wenqi; Gong, Boteng; Li, Zhiqing; Zhang, Xiaomin; Yang, Jin; Li, Xiaorong] Tianjin Med Univ Eye Hosp, Sch Optometry, Tianjin, Peoples R China.
   [Li, Yao; Tsang, Stephen H.] New York Presbyterian Hosp, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Li, Yao; Tsang, Stephen H.] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Zhao, Xuzheng] Tangshan Eye Hosp, Tangshan, Peoples R China.
   [Wu, Yalin; Chen, Chao] Xiamen Univ, Coll Med, Eye Inst, Fujian Prov Key Lab Ophthalmol & Visual Sci, Xiamen, Fujian, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University;
   NewYork-Presbyterian Hospital; Columbia University; Xiamen University
RP Yang, J; Li, XR (通讯作者)，Tianjin Med Univ Eye Hosp, Eye Inst, Tianjin Key Lab Retinal Funct & Dis, Tianjin, Peoples R China.; Yang, J; Li, XR (通讯作者)，Tianjin Med Univ Eye Hosp, Sch Optometry, Tianjin, Peoples R China.
EM yangjinchina324@gmail.com; lixiaorong@tmu.edu.cn
OI Zhang, Xiaomin/0000-0003-4898-4152
FU Natural Science Foundation of Tianjin City [17JCYBJC27200,
   BJ-LM2015008L]; National Natural Science Funds [81400412]
FX This study was supported by Natural Science Foundation of Tianjin City
   (18JCQNJC10700); National Natural Science Funds (81670875); Natural
   Science Foundation of Tianjin City (17JCYBJC27200); a grant of the Dr.
   Henry Norman Bethune: LangMu Young Scientist scholarship
   (BJ-LM2015008L); the National Natural Science Funds (81400412).
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Baker N, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt276
   Bauer EM, 2012, MOL MED, V18, P1509, DOI 10.2119/molmed.2012.00283
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Chen QM, 2000, J CELL SCI, V113, P4087
   Chen ZL, 2012, MOL BIOL CELL, V23, P1388, DOI 10.1091/mbc.E11-09-0811
   Cho KA, 2005, MECH AGEING DEV, V126, P105, DOI 10.1016/j.mad.2004.09.029
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Crouch RK, 2015, PROG MOL BIOL TRANSL, V134, P449, DOI 10.1016/bs.pmbts.2015.06.005
   Davalos AR, 2013, J CELL BIOL, V201, P613, DOI 10.1083/jcb.201206006
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200
   Girard JP, 2007, CHEM BIOL, V14, P345, DOI 10.1016/j.chembiol.2007.04.001
   Grey AC, 2011, INVEST OPHTH VIS SCI, V52, P3926, DOI 10.1167/iovs.10-7020
   Haines P, 2011, J DERMATOL SCI, V64, P210, DOI 10.1016/j.jdermsci.2011.08.005
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hardyman MA, 2013, J ALLERGY CLIN IMMUN, V132, P665, DOI 10.1016/j.jaci.2013.03.005
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Jiang RZ, 2014, J IMMUNOL, V193, P5000, DOI 10.4049/jimmunol.1303445
   Kikuchi T, 2017, NATURE, V548, P592, DOI 10.1038/nature23664
   Kimura J, 2018, BIOL PHARM BULL, V41, P451, DOI 10.1248/bpb.b17-00364
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Lei C, 2013, NEUROSCIENCE, V229, P12, DOI 10.1016/j.neuroscience.2012.10.054
   Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182
   Li Z, 2016, CELL DEATH DIFFER, V23, P1428, DOI 10.1038/cdd.2016.21
   Lin F, 2018, J CELL PHYSIOL, V233, P6683, DOI 10.1002/jcp.26468
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Ma JB, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.281
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Nagasaka Y, 2017, INVEST OPHTH VIS SCI, V58, P221, DOI 10.1167/iovs.16-20513
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Shang D, 2016, SCI REP-UK, V6, DOI 10.1038/srep32180
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Tang DL, 2011, ANTIOXID REDOX SIGN, V14, P1315, DOI 10.1089/ars.2010.3356
   Tundis R, 2015, CURR MED CHEM, V22, P1515, DOI 10.2174/0929867322666150227151809
   Vermeer PD, 2009, AM J PHYSIOL-LUNG C, V296, pL751, DOI 10.1152/ajplung.90578.2008
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   Wang Y, 2017, EXP EYE RES, V160, P45, DOI 10.1016/j.exer.2017.04.010
   Xu SY, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0364-1
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yeo EJ, 2002, EXP GERONTOL, V37, P871, DOI 10.1016/S0531-5565(02)00027-X
   Yu DM, 2017, AGING CELL, V16, P773, DOI 10.1111/acel.12606
   Zhang GH, 2018, EUR J PHARMACOL, V828, P97, DOI 10.1016/j.ejphar.2018.03.041
   Zou HF, 2011, MECH AGEING DEV, V132, P533, DOI 10.1016/j.mad.2011.11.001
NR 47
TC 16
Z9 16
U1 0
U2 13
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JUL 15
PY 2019
VL 11
IS 13
BP 4323
EP 4337
DI 10.18632/aging.102039
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA IJ4BI
UT WOS:000475849100006
PM 31284269
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Suzuki, M
   Gomi, F
   Sawa, M
   Tsujikawa, M
   Sakaguchi, H
AF Suzuki, Mihoko
   Gomi, Fumi
   Sawa, Miki
   Tsujikawa, Motokazu
   Sakaguchi, Hirokazu
TI Bevacizumab treatment for choroidal neovascularization due to
   age-related macular degeneration in Japanese patients
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization
ID INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY; RANIBIZUMAB; SECONDARY;
   EFFICACY; AVASTIN; TRIAL; VASCULOPATHY; VERTEPORFIN; MACULOPATHY
AB To assess intravitreal bevacizumab (IVB) for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in Japanese patients.
   Forty-seven patients treated with IVB for newly diagnosed subfoveal or juxtafoveal CNV (predominantly classic CNV, 15 eyes; minimally classic CNV, 11 eyes; occult CNV, 21 eyes) secondary to AMD and followed for more than 12 months were reviewed retrospectively. IVB (1 mg) was injected via the pars plana. Additional IVB or photodynamic therapy was administered for either persistent or recurrent exudation. The main outcome measurements were best-corrected visual acuity (BCVA), number of injections, and treatment other than bevacizumab.
   The mean baseline visual acuity (VA) was 0.38 [logarithm of the minimum angle of resolution (logMAR), 0.42] and final VA was 0.42 (logMAR, 0.38). During 12 months, bevacizumab was injected a mean of 3.4 times. Eight eyes received additional treatment. Up until 12 months, the mean BCVA with predominantly classic CNV increased, whereas the BCVA with minimally classic or occult with no classic CNV stabilized. The mean number of injections for predominantly classic CNV was 2.5, that for minimally classic CNV was 4.9, and that for occult with no classic CNV was 3.3.
   IVB was especially effective for predominantly classic CNV, but CNV with subretinal pigment epithelial lesions might recur or enlarge despite additional IVB.
C1 [Suzuki, Mihoko; Gomi, Fumi; Sawa, Miki; Tsujikawa, Motokazu; Sakaguchi, Hirokazu] Osaka Univ, Dept Ophthalmol, Sch Med, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Dept Ophthalmol, Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Gomi, Fumi/0000-0003-0807-8817
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2008, JPN J OPHTHALMOL, V52, P99, DOI 10.1007/s10384-008-0512-3
NR 22
TC 8
Z9 8
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR
PY 2010
VL 54
IS 2
BP 124
EP 128
DI 10.1007/s10384-009-0775-3
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 584RJ
UT WOS:000276769900002
PM 20401560
DA 2022-11-30
ER

PT J
AU Kim, EJ
   Grant, GR
   Bowman, AS
   Haider, N
   Gudiseva, HV
   Chavali, VRM
AF Kim, Eun Ji
   Grant, Gregory R.
   Bowman, Anita S.
   Haider, Naqi
   Gudiseva, Harini V.
   Chavali, Venkata Ramana Murthy
TI Complete Transcriptome Profiling of Normal and Age-Related Macular
   Degeneration Eye Tissues Reveals Dysregulation of Anti-Sense
   Transcription
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENE-EXPRESSION; ASSOCIATION; BIOMARKERS; REGIONS; STRESS; RETINA;
   DRUSEN; RISK
AB Age-related macular degeneration (AMD) predominantly affects the retina and retinal pigment epithelium in the posterior eye. While there are numerous studies investigating the non-coding transcriptome of retina and RPE, few significant differences between AMD and normal tissues have been reported. Strand specific RNA sequencing of both peripheral retina (PR) and RPE-Choroid-Sclera (PRCS), in both AMD and matched normal controls were generated. The transcriptome analysis reveals a highly significant and consistent impact on anti-sense transcription as well as moderate changes in the regulation of non-coding (sense) RNA. Hundreds of genes that do not express anti-sense transcripts in normal PR and PRCS demonstrate significant anti-sense expression in AMD in all patient samples. Several pathways are highly enriched in the upregulated anti-sense transcripts-in particular the EIF2 signaling pathway. These results call for a deeper exploration into anti-sense and noncoding RNA regulation in AMD and their potential as therapeutic targets.
C1 [Kim, Eun Ji; Grant, Gregory R.] Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA.
   [Grant, Gregory R.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA.
   [Bowman, Anita S.; Haider, Naqi; Gudiseva, Harini V.; Chavali, Venkata Ramana Murthy] Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Bowman, Anita S.; Haider, Naqi; Chavali, Venkata Ramana Murthy] Univ Penn, Funct Genom Lab, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; University of Pennsylvania; University of Pennsylvania
RP Chavali, VRM (通讯作者)，Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.; Chavali, VRM (通讯作者)，Univ Penn, Funct Genom Lab, Philadelphia, PA 19104 USA.
EM vchavali@pennmedicine.upenn.edu
RI Grant, Gregory Robert/I-3599-2019
OI Grant, Gregory Robert/0000-0002-0139-7658
FU BrightFocus Foundation; Research to Prevent Blindness Unrestricted Grant
   Funds; F.M. Kirby Foundation; Paul and Evanina Bell Mackall Foundation
   Trust; National Center for Advancing Translational Sciences
   [5UL1TR000003]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
   [UL1TR000003] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [P30EY022589] Funding Source: NIH RePORTER
FX The authors thank Ms. Stephanie Yee for her help with the eye
   dissections and tissue banking. The authors also thank the financial
   support received from BrightFocus Foundation grant (VRMC), Research to
   Prevent Blindness Unrestricted Grant Funds to Scheie Eye Institute
   (VRMC), F.M. Kirby Foundation, and The Paul and Evanina Bell Mackall
   Foundation Trust, The National Center for Advancing Translational
   Sciences (5UL1TR000003, Garret A. FitzGerald).
CR Acharya S, 1998, GLYCOBIOLOGY, V8, P997, DOI 10.1093/glycob/8.10.997
   Alexander RP, 2010, NAT REV GENET, V11, P559, DOI 10.1038/nrg2814
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Ayyagari R, 2002, GENOMICS, V80, P166, DOI 10.1006/geno.2002.6815
   Ayyagari R, 2004, ANN M RES VIS OPHTH
   Cai H, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00008
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Downs C. A., 2004, ANN M RES VIS OPHTH
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Farkas MH, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-486
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hoozemans JJM, 2005, ACTA NEUROPATHOL, V110, P165, DOI 10.1007/s00401-005-1038-0
   Hornan DM, 2007, INVEST OPHTH VIS SCI, V48, P5388, DOI 10.1167/iovs.07-0355
   Kapranov P, 2005, GENOME RES, V15, P987, DOI 10.1101/gr.3455305
   Kapranov P, 2007, NAT REV GENET, V8, P413, DOI 10.1038/nrg2083
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee DY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010489
   Lev S, 2001, CELL MOL NEUROBIOL, V21, P575, DOI 10.1023/A:1015183500719
   Levine EM, 1997, J COMP NEUROL, V387, P439
   Li M, 2014, HUM MOL GENET
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lutty G, 1999, MOL VIS, V5
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Meng QJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164845
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Michaelides M, 2003, INVEST OPHTH VIS SCI, V44, P1657, DOI 10.1167/iovs.02-0941
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ohno M, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00022
   Pelechano V, 2013, NAT REV GENET, V14, P880, DOI 10.1038/nrg3594
   Pierce EA, 2001, BIOESSAYS, V23, P605, DOI 10.1002/bies.1086
   QIAGEN, ING PATHW AN
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rosenbluh J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026270
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Salminen A, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-41
   Sekine Y, 2006, CURR MOL MED, V6, P87, DOI 10.2174/156652406775574541
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Whitmore SS, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-21
   Xu ZY, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.1
   Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554
   Yoshida T., 2014, NEUROPROTECTION NEUR, P255
   Young TL, 2013, EXP EYE RES, V116, P265, DOI 10.1016/j.exer.2013.08.009
NR 53
TC 27
Z9 27
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 14
PY 2018
VL 8
AR 3040
DI 10.1038/s41598-018-21104-7
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FW0LE
UT WOS:000424985800078
PM 29445097
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Woo, SJ
   Park, KH
   Ahn, J
   Choe, JY
   Jeong, H
   Han, JW
   Kim, TH
   Kim, KW
AF Woo, Se Joon
   Park, Kyu Hyung
   Ahn, Jeeyun
   Choe, Jin Yeong
   Jeong, Hyeon
   Han, Ji Won
   Kim, Tae Hui
   Kim, Ki Woong
TI Cognitive Impairment in Age-related Macular Degeneration and Geographic
   Atrophy
SO OPHTHALMOLOGY
LA English
DT Article
ID ALZHEIMERS-DISEASE; VISUAL IMPAIRMENT; KOREAN VERSION; AMYLOID-BETA; EYE
   DISEASE; DRUSEN; MACULOPATHY; POPULATION; DEMENTIA; HEALTH
AB Purpose: To investigate cognitive function in patients with early and late age-related macular degeneration (AMD) compared with an elderly, community-dwelling Korean population without AMD.
   Design: Case-control study.
   Participants: We enrolled 170 AMD patients and 190 non-AMD community-based controls.
   Methods: A comprehensive battery for cognitive function evaluation consisting of 15 psychological tests, including a depression evaluation test, was used. Cognitive function scores were adjusted for age, gender, education, and visual acuity (VA). We categorized AMD as early AMD, exudative AMD, or geographic atrophy.
   Main Outcome Measures: The primary outcome measure was the degree of cognitive impairment, as assessed by the Korean versions of the Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Assessment Battery, Benton Visual Retention Test, and Digit Span Test Forward and Backward.
   Results: Patients with AMD showed lower global cognition scores than did normal controls (mean Mini-Mental State Examination [MMSE] score, 24.97 vs 25.99; P<0.001). Among cognitive functions, visuospatial function, verbal memory, visual memory, and frontal function were impaired in AMD patients relative to normal controls. The rate of mild cognitive impairment (MCI) was higher in AMD patients than in controls (52.4% vs 26.8%; P<0.001), with an odds ratio (OR) of 3.127 (95% confidence interval, 1.855-5.271) after adjustment for age, education, and VA. Geographic atrophy was associated with the highest risk of MCI (OR, 4.431; 95% confidence interval, 1.413-13.898) and a clinically significant reduction in MMSE scores (23.42) relative to the controls. There was a trend of worsening cognitive function test scores from the controls to the early AMD, then the exudative AMD, and finally the geographic atrophy patients, after adjustment for covariates. AMD patients with poor VA (<= 20/100) had 6 times the risk of MCI as AMD patients with good or moderate VA (>20/100).
   Conclusions: Patients with AMD, especially those with the geographic atrophy subtype, are at greater risk for cognitive impairment than are non-AMD control subjects. In the visual rehabilitation of AMD patients, potential cognitive impairment should be taken into consideration.
C1 [Woo, Se Joon; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Songnam, South Korea.
   [Woo, Se Joon; Park, Kyu Hyung; Ahn, Jeeyun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Ahn, Jeeyun] Seoul Metropolitan Govt Seoul Natl Univ Boramae M, Dept Ophthalmol, Seoul, South Korea.
   [Choe, Jin Yeong; Jeong, Hyeon; Han, Ji Won; Kim, Tae Hui; Kim, Ki Woong] Seoul Natl Univ, Bundang Hosp, Dept Neuropsychiat, Songnam, South Korea.
   [Kim, Ki Woong] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University Hospital; Seoul
   National University (SNU); Seoul National University (SNU)
RP Kim, KW (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Neuropsychiat, 300 Gumi Dong, Songnam 463707, Gyeonggi Do, South Korea.
EM kwkimmd@snu.ac.kr
RI Woo, Joon/I-7357-2013; Kim, Tae Hui/AAR-9213-2020; Kim, Ki
   Woong/D-5801-2012; Park, Kyu Hyung/J-5481-2012
OI Woo, Joon/0000-0003-3692-7169; Kim, Ki Woong/0000-0002-1103-3858; Ahn,
   Jeeyun/0000-0001-9017-1652; Kim, Tae Hui/0000-0003-0133-5227
FU Seoul National University Bundang Hospital Research Funds [03-2009-008,
   11-2008-002, 11-2009-037, 11-2010-037]; National Research Foundation of
   Korea (NRF); Ministry of Education, Science, and Technology
   [2009-0072603]; Korea Health Technology R&D Project, Ministry of Health
   & Welfare, Republic of Korea [A092077, A111161]
FX Supported by Seoul National University Bundang Hospital Research Funds
   (grant nos. 03-2009-008, 11-2008-002, 11-2009-037, and 11-2010-037), a
   National Research Foundation of Korea (NRF) grant funded by the Ministry
   of Education, Science, and Technology (2009-0072603), and grants from
   the Korea Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea (grant nos. A092077 and A111161).
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   APA, 1994, DIAGNOSTIC STAT MANU
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Dentchev T, 2003, MOL VIS, V9, P184
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jhoo JH, 2008, DEMENT GERIATR COGN, V26, P270, DOI 10.1159/000160960
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kim JY, 2008, PSYCHIAT INVEST, V5, P232, DOI 10.4306/pi.2008.5.4.232
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Lee DY, 2004, J INT NEUROPSYCH SOC, V10, P72, DOI 10.1017/s1355617704101094
   Lee JH, 2002, J GERONTOL B-PSYCHOL, V57, pP47, DOI 10.1093/geronb/57.1.P47
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Simon-Dack SL, 2008, BEHAV NEUROL, V20, P71, DOI [10.1155/2008/917492, 10.3233/BEN-2008-0217]
   Sivan AB., 1992, BENTON VISUAL RETENT
   Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813
   UHLMANN RF, 1991, J GEN INTERN MED, V6, P126, DOI 10.1007/BF02598307
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wechsler D, 1984, WMS R WECHSLER MEMOR
   Whitson HE, 2007, J AM GERIATR SOC, V55, P885, DOI 10.1111/j.1532-5415.2007.01093.x
   Whitson HE, 2010, ARCH GERONTOL GERIAT, V50, P209, DOI 10.1016/j.archger.2009.03.010
   Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
NR 26
TC 66
Z9 66
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2012
VL 119
IS 10
BP 2094
EP 2101
DI 10.1016/j.ophtha.2012.04.026
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030PF
UT WOS:000310581900024
PM 22705343
DA 2022-11-30
ER

PT J
AU Qiu, FF
   Liu, Z
   Zhou, YP
   He, J
   Gong, SJ
   Bai, X
   Zeng, YX
   Liu, ZG
   Ma, JX
AF Qiu, Fangfang
   Liu, Zhen
   Zhou, Yueping
   He, Jia
   Gong, Songjian
   Bai, Xue
   Zeng, Yingxia
   Liu, Zuguo
   Ma, Jian-Xing
TI Decreased Circulating Levels of Dickkopf-1 in Patients with Exudative
   Age-related Macular Degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; WNT SIGNALING PATHWAY; SERUM DICKKOPF-1;
   BIOMARKER; CANCER; DISEASE; MACULOPATHY; PROGRESSION; REGULATOR;
   DIAGNOSIS
AB Aberrant activation of the Wnt/beta-catenin signaling pathway plays a pathogenic role in retinal inflammation and neovascularization. Here, we investigated whether circulating levels of Dickkopf-1 (DKK-1), a specific inhibitor of this pathway, are altered in patients with exudative age-related macular degeneration (AMD). Plasma was obtained from 128 patients with exudative AMD, 46 patients with atrophic AMD and 111 healthy controls. DKK-1 levels in plasma were measured using ELISA, and data analyzed with one-way ANOVA, logistic regression analysis and receiver-operating characteristic analysis (ROC). We found that DKK-1 levels were decreased in exudative AMD patients, compared with healthy controls (P < 0.001) and atrophic AMD patients (P < 0.001). The decrease was more prominent in patients with classic choroidal neovascularization (CNV) than those with occult CNV (P < 0.001). The odds ratio (OR) of exudative AMD was 11.71 (95% CI; 5.24-6.13) for lowest versus upper quartile of DKK-1 levels. For discriminating exudative AMD patients, the optimum diagnostic cutoff of DKK-1 was 583.1 pg/mL with the area under curve (AUC) 0.76 (95% CI, 0.70-0.82; P < 0.001), sensitivity 78.1% and specificity 63.1%. These findings suggested that decreased circulating DKK-1 levels are associated with the development and severity of exudative AMD, and have potential to become a biomarker for exudative AMD.
C1 [Qiu, Fangfang; Liu, Zhen; Zhou, Yueping; He, Jia; Liu, Zuguo] Xiamen Univ, Fujian Prov Key Lab Ophthalmol & Visual Sci, Eye Inst, 4th Floor,Chengyi Bldg,Xiangan Campus Xiamen Univ, Xiamen 361102, Fujian, Peoples R China.
   [Qiu, Fangfang; Liu, Zuguo; Ma, Jian-Xing] Univ Oklahoma, Dept Physiol, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.
   [Gong, Songjian; Bai, Xue; Zeng, Yingxia] Xiamen Univ, Affiliated Xiamen Eye Ctr, Xiamen, Fujian, Peoples R China.
   [Bai, Xue] Xiamen Univ, Dept Ophthalmol, Affiliated Zhongshan Hosp, Xiamen, Fujian, Peoples R China.
C3 Xiamen University; University of Oklahoma System; University of Oklahoma
   Health Sciences Center; Xiamen University; Xiamen University
RP Liu, ZG (通讯作者)，Xiamen Univ, Fujian Prov Key Lab Ophthalmol & Visual Sci, Eye Inst, 4th Floor,Chengyi Bldg,Xiangan Campus Xiamen Univ, Xiamen 361102, Fujian, Peoples R China.; Liu, ZG; Ma, JX (通讯作者)，Univ Oklahoma, Dept Physiol, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.
EM zuguol@xmu.edu.cn; Jian-xing-ma@ouhsc.edu
RI Qiu, Fangfang/GLT-3151-2022; Qiu, Fangfang/GLT-3181-2022
OI Qiu, Fangfang/0000-0002-3584-0275; Qiu, Fangfang/0000-0002-3584-0275
FU National Institutes of Health (NIH) [EY018659, EY012231, EY019309,
   P20GM104934]; Chinese National key Scientific Researh Project
   [2013CB967003]; Juvenile Diabetes Research Foundation Innovative (JDRF)
   [2-SRA-2014-147-Q-R]; Oklahoma Center for the Advancement of Science and
   Technology (OCAST) [HR13-076]; NATIONAL EYE INSTITUTE [R01EY019309,
   R01EY012231, R01EY018659] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104934, P30GM122744] Funding
   Source: NIH RePORTER
FX This study was supported by grants from National Institutes of Health
   (NIH) grants (EY018659, EY012231, EY019309, P20GM104934), a Chinese
   National key Scientific Researh Project (No. 2013CB967003), a Juvenile
   Diabetes Research Foundation Innovative (JDRF) grant
   (2-SRA-2014-147-Q-R), and an Oklahoma Center for the Advancement of
   Science and Technology (OCAST) grant (HR13-076).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chen Y, 2009, AM J PATHOL, V175, P2676, DOI 10.2353/ajpath.2009.080945
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   De Ferrari GV, 2007, P NATL ACAD SCI USA, V104, P9434, DOI 10.1073/pnas.0603523104
   DUGUID IGM, 1992, CURR EYE RES, V11, P153, DOI 10.3109/02713689208999526
   ELNER SG, 1992, LAB INVEST, V66, P200
   Forget MA, 2007, BRIT J CANCER, V96, P646, DOI 10.1038/sj.bjc.6603579
   Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   Han SX, 2015, ONCOTARGET, V6, P19907, DOI 10.18632/oncotarget.4529
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Johnson ML, 2007, CURR OPIN RHEUMATOL, V19, P376, DOI 10.1097/BOR.0b013e32816e06f9
   Kim KI, 2006, ARTERIOSCL THROM VAS, V26, P91, DOI 10.1161/01.ATV.0000193569.12490.4b
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lane NE, 2007, ARTHRITIS RHEUM-US, V56, P3319, DOI 10.1002/art.22867
   Park KH, 2014, INVEST OPHTH VIS SCI, V55, P5522, DOI 10.1167/iovs.14-14566
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood-2008-03-145169
   Qiu F, 2014, EYE, V28, P402, DOI 10.1038/eye.2013.229
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Seshasai S, 2015, INVEST OPHTH VIS SCI, V56, P1880, DOI 10.1167/iovs.14-15933
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Shen QJ, 2012, LANCET ONCOL, V13, P817, DOI 10.1016/S1470-2045(12)70233-4
   Sheng SL, 2009, CLIN CHEM, V55, P1656, DOI 10.1373/clinchem.2009.125641
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Uehara H, 2015, AM J OPHTHALMOL, V159, P92, DOI 10.1016/j.ajo.2014.09.036
   Voorzanger-Rousselot N, 2009, CALCIFIED TISSUE INT, V84, P348, DOI 10.1007/s00223-009-9225-y
   Voorzanger-Rousselot N, 2009, BRIT J HAEMATOL, V145, P264, DOI 10.1111/j.1365-2141.2009.07587.x
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wylegala Edward, 2007, Klin Oczna, V109, P97
   Yamabuki T, 2007, CANCER RES, V67, P2517, DOI 10.1158/0008-5472.CAN-06-3369
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 38
TC 9
Z9 9
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 28
PY 2017
VL 7
AR 1263
DI 10.1038/s41598-017-01119-2
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ET4KA
UT WOS:000400247600022
PM 28455497
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU She, KQ
   Su, J
   Wang, QN
   Liu, Y
   Zhong, XM
   Jin, X
   Zhao, QY
   Xiao, JL
   Li, RT
   Deng, HX
   Lu, F
   Yang, Y
   Wei, YQ
AF She, Kaiqin
   Su, Jing
   Wang, Qingnan
   Liu, Yi
   Zhong, Xiaomei
   Jin, Xiu
   Zhao, Qinyu
   Xiao, Jianlu
   Li, Ruiting
   Deng, Hongxin
   Lu, Fang
   Yang, Yang
   Wei, Yuquan
TI Delivery of nVEGFi using AAV8 for the treatment of neovascular
   age-related macular degeneration
SO MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
LA English
DT Article
ID MULTIGENIC LENTIVIRAL VECTORS; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; GENE-TRANSFER; OPEN-LABEL; VEGF; THERAPY; SAFETY;
   INJECTION; PHASE-1
AB Inhibition of vascular endothelial growth factor (VEGF) is the standard therapy for neovascular age-related macular degeneration (nAMD). However, anti-VEGF agents used in the clinic require repeated injections, causing adverse effects. Gene therapy could provide sustained anti-VEGF levels after a single injection, thereby drastically decreasing the treatment burden and improving visual outcomes. In this study, we developed a novel VEGF Trap, nVEGFi, containing domains 1 and 2 of VEGFR1 and domain 3 of VEGFR2 fused to the Fc portion of human IgG. The nVEGFi had a higher expression level than aflibercept under the same expression cassettes of adeno-associated virus (AAV)8 in vitro and in vivo. nVEGFi was found to be noninferior to aflibercept in binding and blocking VEGF in vitro. AAV8-mediated expression of nVEGFi was maintained for at least 12 weeks by subretinal delivery in C57BL/6J mice. In a mouse laser-induced choroidal neovascularization (CNV) model, 4 x 10(8) genome copies of AAV8-nVEGFi exhibited a significantly increased reduction in the CNV area compared with AAV8-aflibercept (78.1% vs. 63.9%, p < 0.05), while causing no structural or functional changes to the retina. In conclusion, this preclinical study showed that subretinal injection of AAV8-nVEGFi was long lasting, well tolerated, and effective for nAMD treatment, supporting future translation to the clinic.
C1 [She, Kaiqin; Lu, Fang] Sichuan Univ, West China Hosp, Dept Ophthalmol, 37 Guoxue Xiang, Chengdu 610041, Sichuan, Peoples R China.
   [She, Kaiqin; Su, Jing; Wang, Qingnan; Liu, Yi; Zhong, Xiaomei; Jin, Xiu; Zhao, Qinyu; Xiao, Jianlu; Li, Ruiting; Deng, Hongxin; Yang, Yang; Wei, Yuquan] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 1,Ke Yuan Rd 4,Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.
   [She, Kaiqin; Su, Jing; Wang, Qingnan; Liu, Yi; Zhong, Xiaomei; Jin, Xiu; Zhao, Qinyu; Xiao, Jianlu; Li, Ruiting; Deng, Hongxin; Yang, Yang; Wei, Yuquan] Sichuan Univ, West China Hosp, Canc Ctr, 1,Ke Yuan Rd 4,Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.
   [She, Kaiqin; Su, Jing; Wang, Qingnan; Liu, Yi; Zhong, Xiaomei; Jin, Xiu; Zhao, Qinyu; Xiao, Jianlu; Li, Ruiting; Deng, Hongxin; Yang, Yang; Wei, Yuquan] Collaborat Innovat Ctr, 1,Ke Yuan Rd 4,Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Qingnan] Chengdu Genevector Therapeut Inc, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP Lu, F (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, 37 Guoxue Xiang, Chengdu 610041, Sichuan, Peoples R China.; Yang, Y (通讯作者)，Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 1,Ke Yuan Rd 4,Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.; Yang, Y (通讯作者)，Sichuan Univ, West China Hosp, Canc Ctr, 1,Ke Yuan Rd 4,Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.; Yang, Y (通讯作者)，Collaborat Innovat Ctr, 1,Ke Yuan Rd 4,Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.
EM lufang@wchscu.cn; yang2012@scu.edu.cn
OI YANG, YANG/0000-0002-8190-1825
FU Joint Funds of the National Natural Science Foundation of China
   [U19A2002]; National Major Scientific and Technological Special Project
   for "Significant New Drugs Development" [2018ZX09733001-005-002];
   Science and Technology Major Project of Sichuan Province [2017SZDZX0011]
FX This work was supported by the Joint Funds of the National Natural
   Science Foundation of China (grant no. U19A2002), National Major
   Scientific and Technological Special Project for "Significant New Drugs
   Development" (no. 2018ZX09733001-005-002), and the Science and
   Technology Major Project of Sichuan Province (no. 2017SZDZX0011).
CR ADVERUM, 2021, ADV PROV UPD ADVM 02
   Askou AL, 2018, METHODS MOL BIOL, V1715, P47, DOI 10.1007/978-1-4939-7522-8_4
   Askou AL, 2017, HUM GENE THER METHOD, V28, P222, DOI 10.1089/hgtb.2017.079
   Askou AL, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2014.64
   Askou AL, 2012, J GENE MED, V14, P632, DOI 10.1002/jgm.2678
   Biswal MR, 2018, J MOL MED, V96, P1107, DOI 10.1007/s00109-018-1683-0
   Bucher K, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100915
   Buck TM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124197
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Cao YH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.259re1
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x
   Dias MS, 2019, GENE THER, V26, P479, DOI 10.1038/s41434-019-0100-9
   Dinculescu A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148874
   Ding K, 2019, J CLIN INVEST, V129, P4901, DOI 10.1172/JCI129085
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Herley MT, 1999, BIOCHEM BIOPH RES CO, V262, P731, DOI 10.1006/bbrc.1999.1282
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holmgaard A, 2017, MOL THER-NUCL ACIDS, V9, P89, DOI 10.1016/j.omtn.2017.08.016
   Hori T, 2019, BIOCHEM BIOPH RES CO, V515, P222, DOI 10.1016/j.bbrc.2019.05.117
   Jacobson SG, 2006, MOL THER, V13, P1074, DOI 10.1016/j.ymthe.2006.03.005
   Khabou H, 2018, HUM GENE THER, V29, P1235, DOI 10.1089/hum.2018.144
   Khanani AM, 2021, ADVM 022 INTRAVITREA
   Kim E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14500
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Koo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04175-y
   Kotterman MA, 2015, GENE THER, V22, P116, DOI 10.1038/gt.2014.115
   Lee JE, 2015, MOL CANCER THER, V14, P470, DOI 10.1158/1535-7163.MCT-14-0968-T
   Lin FL, 2020, MOL THER, V28, P2120, DOI 10.1016/j.ymthe.2020.06.029
   Liu YY, 2018, MOL THER, V26, P542, DOI 10.1016/j.ymthe.2017.12.002
   Lock M, 2014, HUM GENE THER METHOD, V25, P115, DOI 10.1089/hgtb.2013.131
   Lock M, 2010, HUM GENE THER, V21, P1259, DOI 10.1089/hum.2010.055
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MacLachlan TK, 2018, MOL THER-METH CLIN D, V8, P105, DOI 10.1016/j.omtm.2017.12.001
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Ong T, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-018-2564-5
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   REGENXBIO, 2019, REGENXBIO ANN ADD PO
   Reid CA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29726-7
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Seitz IP, 2017, INVEST OPHTH VIS SCI, V58, P5784, DOI 10.1167/iovs.17-22473
   Vandenberghe LH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002103
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiong WJ, 2019, P NATL ACAD SCI USA, V116, P5785, DOI 10.1073/pnas.1821000116
   Ye GJ, 2016, HUM GENE THER, V27, P72, DOI 10.1089/hum.2015.130
   Yiu G, 2020, MOL THER-METH CLIN D, V16, P179, DOI 10.1016/j.omtm.2020.01.002
NR 55
TC 1
Z9 1
U1 2
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2329-0501
J9 MOL THER-METH CLIN D
JI Mol.Ther.-Methods Clin. Dev.
PD MAR 10
PY 2022
VL 24
BP 210
EP 221
DI 10.1016/j.omtm.2022.01.002
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 2P5XC
UT WOS:000819812600008
PM 35141350
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mozaffarieh, M
   Sacu, S
   Banesch, T
   Wedrich, A
AF Mozaffarieh, Maneli
   Sacu, Stefan
   Banesch, Thomas
   Wedrich, Andreas
TI Subretinal hemorrhages secondary to age-related macular degeneration:
   Psychological and vision-related functional perspectives
SO OPHTHALMOLOGICA
LA English
DT Article
DE psychological distress; vision-related functioning; subretinal
   hemorrhage; age-related macular degeneration
ID TISSUE-PLASMINOGEN ACTIVATOR; QUALITY-OF-LIFE; SUBMACULAR HEMORRHAGE;
   VISUAL FUNCTION; HOSPITAL ANXIETY; DEPRESSION SCALE; NATURAL-HISTORY;
   INJECTION; MANAGEMENT; GAS
AB Purpose: To assess psychological, visual and functional aspects associated with subretinal hemorrhages secondary to age-related macular degeneration (AMD). Method: In this prospective, comparative, longitudinal study, 90 eyes of 90 patients with a subretinal hemorrhage, secondary to AMD, of at least 1 disk diameter were treated with recombinant tissue plasminogen activator (rTPA) and gas, and compared to 25 eyes of 25 controls. Outcome measures were: (1) visual acuity, (2) self-reported vision-related quality of life (Visual Function 14-item questionnaire) and (3) Hospital Anxiety and Depression (HAD) scores. Visual acuity and questionnaire responses were recorded prior to as well as 2 weeks and 4 months after treatment. Results: Improvements across objective visual acuity and vision-related functional measures, assessed at 2 weeks and 4 months, were significantly higher in patients who had rTPA and gas injections than in controls (p < 0.01). Patients were significantly more distressed at their 2-week follow-up in comparison to controls (HAD scores p < 0.01). Comparisons to controls showed no significant difference in psychological scores at the 4-month follow-up (p > 0.32). Conclusions: Patients with subretinal hemorrhages secondary to AMD are psychologically distressed as a result of acute loss of vision. More attention should be given to strategies that teach patients to cope with acute vision loss and thereby psychological disorder. Copyright (C) 2008 S. Karger AG, Basel.
C1 [Mozaffarieh, Maneli; Sacu, Stefan] Med Univ Graz, Dept Ophthalmol, AT-8036 Graz, Austria.
   [Banesch, Thomas] Med Univ Graz, Inst Med Stat, AT-8036 Graz, Austria.
   [Wedrich, Andreas] Med Univ Graz, Dept Ophthalmol, Graz, Austria.
C3 Medical University of Graz; Medical University of Graz; Medical
   University of Graz
RP Wedrich, A (通讯作者)，Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 4, AT-8036 Graz, Austria.
EM andreas.wedrich@meduni-graz.at
RI Wedrich, Andreas/AAE-9171-2020
CR Adams G L, 1971, Ann Ophthalmol, V3, P72
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Campbell A, 1976, QUALITY AM LIFE
   CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104
   Chakravarthy Usha, 2005, Curr Opin Ophthalmol, V16, P179, DOI 10.1097/01.icu.0000163035.37957.c2
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Goldberg DP, 1979, MANUAL GEN HLTH QUES
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hay S R, 2000, Optometry, V71, P715
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   HERRIOT W, VITR M VAIL OCT 1996
   Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Leguay JM, 2000, J FR OPHTALMOL, V23, P797
   Mozaffarieh M, 2006, GRAEF ARCH CLIN EXP, V244, P1421, DOI 10.1007/s00417-005-0232-z
   RIESENBERG D, 1989, JAMA-J AM MED ASSOC, V262, P943, DOI 10.1001/jama.262.7.943
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   Rovner BW, 2007, INT J GERIATR PSYCH, V22, P789, DOI 10.1002/gps.1742
   Rovner BW, 2006, OPHTHALMOLOGY, V113, P1743, DOI 10.1016/j.ophtha.2006.05.033
   Schmidt JC, 2004, OPHTHALMOLOGE, V101, P584, DOI 10.1007/s00347-003-0912-1
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Tasman W, 2005, CAN J OPHTHALMOL, V40, P389, DOI 10.1016/S0008-4182(05)80082-1
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 33
TC 6
Z9 6
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2008
VL 222
IS 3
BP 199
EP 204
DI 10.1159/000126084
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 307XS
UT WOS:000256353500011
PM 18497530
DA 2022-11-30
ER

PT J
AU Goverdhan, SV
   Howell, MW
   Mullins, RF
   Osmond, C
   Hodgkins, PR
   Self, J
   Avery, K
   Lotery, AJ
AF Goverdhan, SV
   Howell, MW
   Mullins, RF
   Osmond, C
   Hodgkins, PR
   Self, J
   Avery, K
   Lotery, AJ
TI Association of HLA class I and class II polymorphisms with age-related
   macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SEQUENCE-SPECIFIC PRIMERS; INTRAVITREAL TRIAMCINOLONE ACETONIDE;
   POLYMERASE-CHAIN-REACTION; ANTIGEN-PRESENTING CELLS; ACUTE ANTERIOR
   UVEITIS; PCR-SSP; BRUCHS MEMBRANE; BIRDSHOT RETINOCHOROIDOPATHY; HUMAN
   UVEA; GENE
AB PURPOSE. To evaluate whether HLA genotypes are associated with age-related macular degeneration (AMD).
   METHODS. HLA class I-A, - B, and - Cw and class II DRB1 and DQB1 principal allele groups were genotyped in two stages: initially for principal allele groups in a cohort of 100 AMD cases and 92 control subjects, and then, in the next 100 cases and controls from the same cohort, for alleles or allele groups with P < 0.1 on initial typing. Genotype frequencies were compared by 2 x 2 contingency tables. The strongest associations for individual HLA alleles were calculated with two-locus stratification analysis and logistic regression for all possible pairwise HLA combinations. Bonferroni corrections were applied for multiple measurements (P-c). Each HLA allele was subjected to logistic regression for known AMD covariates. HLA immunohistochemistry for class I antigens was performed on elderly donor eyes.
   RESULTS. Allele Cw*0701 ( P = 0.004, P-c = 0.036) correlated positively with AMD, whereas alleles B*4001 (P = 0.003, P-c = 0.027) and DRB1*1301( P = 0.001, P-c = 0.009) were negatively associated. These HLA associations were independent of any linkage disequilibrium. Immunohistochemistry demonstrated differential HLA class I expression in choriocapillary endothelial cells.
   CONCLUSIONS. Significant positive and negative associations exist between HLA alleles and AMD. HLA polymorphisms influence the development of AMD, possibly via modulating choroidal immune function.
C1 Univ Southampton, Div Human Genet, Southampton SO16 6YD, Hants, England.
   Univ Southampton, MRC, Epidemiol Resource Ctr, Southampton SO16 6YD, Hants, England.
   Southampton Univ Hosp, Mol Pathol Lab, Southampton, Hants, England.
   Southampton Univ Hosp, Southampton Eye Unit, Southampton, Hants, England.
   Univ Iowa, Dept Ophthalmol & Visual Sci, Ctr Macular Degenerat, Iowa City, IA USA.
C3 University of Southampton; University of Southampton; University of
   Southampton; University of Southampton; University of Iowa
RP Lotery, AJ (通讯作者)，Univ Southampton, Southampton Gen Hosp, Div Human Genet, Duthie Bldg,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
RI self, james/F-8592-2013; Mullins, Robert F/I-6717-2013
OI self, james/0000-0002-1030-9963; Lotery, Andrew/0000-0001-5541-4305;
   Mullins, Robert/0000-0002-5006-0891; Osmond, Clive/0000-0002-9054-4655
FU NATIONAL EYE INSTITUTE [R03EY014563] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY 014563] Funding Source: Medline
CR ABIHANNA D, 1988, TRANSPLANTATION, V45, P610, DOI 10.1097/00007890-198803000-00021
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   BAARSMA GS, 1990, CURR EYE RES, V9, P63, DOI 10.3109/02713689008999422
   BAKKER M, 1986, DOC OPHTHALMOL, V61, P271, DOI 10.1007/BF00142353
   Bateman AC, 1996, HISTOPATHOLOGY, V28, P169, DOI 10.1046/j.1365-2559.1996.277323.x
   BLOCHMICHEL E, 1991, CAN J OPHTHALMOL, V26, P361
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   BUNCE M, 1993, HUM IMMUNOL, V37, P201, DOI 10.1016/0198-8859(93)90502-R
   CAVAN DA, 1993, DIABETOLOGIA, V36, P252, DOI 10.1007/BF00399959
   Chang JH, 2004, INVEST OPHTH VIS SCI, V45, P1871, DOI 10.1167/iovs.03-1113
   Dabil H, 2003, HUM IMMUNOL, V64, P960, DOI 10.1016/S0198-8859(03)00175-7
   Darke C, 1998, EXP CLIN IMMUNOGENET, V15, P69, DOI 10.1159/000019057
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   DERHAAG PJFM, 1988, AM J OPHTHALMOL, V105, P603, DOI 10.1016/0002-9394(88)90051-7
   DERHAAG PJFM, 1988, INVEST OPHTH VIS SCI, V29, P1137
   Donaldson PT, 2002, AUTOIMMUNITY, V35, P555, DOI 10.1080/0891693021000054093
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Enzmann V, 2001, GRAEF ARCH CLIN EXP, V239, P445, DOI 10.1007/s004170100297
   EVANS J, 1995, CAUSES BLINDNESS PAR, P57
   Finch T, 1997, EXP CLIN IMMUNOGENET, V14, P250
   Follmann DA, 2003, STAT MED, V22, P1999, DOI 10.1002/sim.1426
   Gandon G, 1996, HUM GENET, V97, P103, DOI 10.1007/BF00218843
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Howell WM, 2002, P NUTR SOC, V61, P447, DOI 10.1079/PNS2002186
   *IMGT, 2004, IMGT HLA SEQ DAT
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kilmartin DJ, 2001, BRIT J OPHTHALMOL, V85, P281, DOI 10.1136/bjo.85.3.281
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Lancaster Alex, 2003, Pac Symp Biocomput, P514
   Lopez-Vazquez A, 2002, GUT, V50, P336, DOI 10.1136/gut.50.3.336
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   OLERUP O, 1993, TISSUE ANTIGENS, V41, P55
   Oruc S, 2001, AM J OPHTHALMOL, V131, P657, DOI 10.1016/S0002-9394(00)00863-1
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1993, J NEUROIMMUNOL, V45, P183, DOI 10.1016/0165-5728(93)90179-3
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   *ROYAL COLL OPHTH, 2002, NAT RES STRAT OPHTH, P5
   Schaffer M, 2001, TISSUE ANTIGENS, V58, P299, DOI 10.1034/j.1399-0039.2001.580503.x
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   STREILEIN JW, 1992, J NEUROIMMUNOL, V39, P185, DOI 10.1016/0165-5728(92)90253-H
   SVEJGAARD A, 1994, TISSUE ANTIGENS, V43, P18, DOI 10.1111/j.1399-0039.1994.tb02291.x
   Szpak Y, 2001, P NATL ACAD SCI USA, V98, P2572, DOI 10.1073/pnas.051595998
   Thomson W, 2002, RHEUMATOLOGY, V41, P1183, DOI 10.1093/rheumatology/41.10.1183
   Thorsby E, 1997, HUM IMMUNOL, V53, P1, DOI 10.1016/S0198-8859(97)00024-4
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   2004, ALLELE FREQUENCIES W
NR 61
TC 52
Z9 54
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2005
VL 46
IS 5
BP 1726
EP 1734
DI 10.1167/iovs.04-0928
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 920RO
UT WOS:000228708000029
PM 15851575
DA 2022-11-30
ER

PT J
AU Ladewig, M
   Kraus, H
   Foerster, MH
   Kellner, U
AF Ladewig, M
   Kraus, H
   Foerster, MH
   Kellner, U
TI Cone dysfunction in patients with late-onset cone dystrophy and
   age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTORECEPTOR DYSFUNCTION
AB Objectives: To determine the clinical and functional findings in patients with late-onset cone dystrophy (LOCD) (after the age of 50 years), which is rare; and to compare them with those of patients with age-related macular degeneration (AMD).
   Methods: Eleven LOCD patients underwent ophthalmologic and electroretinographic examinations. Fullfield electroretinograms were recorded according to the International Society for Clinical Electrophysiology of Vision standard. The results were compared with those of a group of 20 AMD patients and a group of 23 age-related control subjects.
   Results: There was no difference between LOCD and AMD patients regarding the severity of visual acuity loss, color vision deficiencies, and central visual field defects. Alterations of the posterior pole were present in all LOCD and AMD patients. In contrast to the AMD group, all LOCD patients did not show drusen and 6 of the 11 LOCD patients displayed temporal optic disc pallor. The electroretinogram revealed the major functional difference, with severe reduction of cone-mediated responses and moderate reduction of rod-mediated responses in LOCD patients. Unexpectedly, the 30-Hz flicker amplitude was reduced in AMD patients compared with healthy controls.
   Conclusions: Late-onset cone dystrophy and AMD have several features in common. In elderly patients with progressive visual loss and without drusen, LOCD should be considered. The electroretinographic results in a small group of AMD patients indicate a generalized cone dysfunction.
C1 Free Univ Berlin, Klinikum Benjamin Franklin, Dept Ophthalmol, D-12200 Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin
RP Kellner, U (通讯作者)，Free Univ Berlin, Klinikum Benjamin Franklin, Dept Ophthalmol, Hindenburgdamm 30, D-12200 Berlin, Germany.
CR COGAN DG, 1990, KLIN MONATSBL AUGENH, V197, P156, DOI 10.1055/s-2008-1046260
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   FRANCOIS J, 1974, OPHTHALMOLOGICA, V169, P255, DOI 10.1159/000307127
   JACOBSON DM, 1989, OPHTHALMOLOGY, V96, P885
   Kellner U, 1998, BRIT J OPHTHALMOL, V82, P650, DOI 10.1136/bjo.82.6.650
   Kellner U, 1992, Ger J Ophthalmol, V1, P105
   Kellner U., 2000, HEREDITARY RETINAL D
   KELLNER U, 1996, BUCHEREI AUGENSRZTES, V135
   KRILL AE, 1973, DOC OPHTHALMOL, V35, P1
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   MADREPERLA SA, 1994, ARCH OPHTHALMOL-CHIC, V112, P807, DOI 10.1001/archopht.1994.01090180105044
   MARMOR MF, 1995, ARCH OPHTHALMOL-CHIC, V113, P1375, DOI 10.1001/archopht.1995.01100110035021
   *RETN, GEN CAUS RET DIS
   Ripps H, 1987, Trans Am Ophthalmol Soc, V85, P82
   ROWE SE, 1990, OPHTHALMOLOGY, V97, P1632
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   SZLYK JP, 1993, ARCH OPHTHALMOL-CHIC, V111, P781, DOI 10.1001/archopht.1993.01090060069025
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Weleber RG, 1988, RETINAL DYSTROPHIES, P233
NR 20
TC 10
Z9 12
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2003
VL 121
IS 11
BP 1557
EP 1561
DI 10.1001/archopht.121.11.1557
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 741QC
UT WOS:000186467900005
PM 14609911
OA Bronze
DA 2022-11-30
ER

PT J
AU Algvere, PV
   Seregard, S
AF Algvere, PV
   Seregard, S
TI Age-related maculopathy: pathogenetic features and new treatment
   modalities
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE age-related maculopathy; age-related macular degeneration; pathogenesis;
   lipofuscin; oxidative stress; free radicals; antioxidants; photodynamic
   therapy (PDT); transpupillary thermotherapy (TTT)
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; EPITHELIUM-DERIVED FACTOR;
   LIGHT-INDUCED APOPTOSIS; MACULAR DEGENERATION; PIGMENT-EPITHELIUM;
   TRANSPUPILLARY THERMOTHERAPY; SPATIAL-DISTRIBUTION; RETINOID COMPONENT;
   RISK-FACTORS; BLOOD-FLOW
AB A considerable amount of new information on putative pathogenetic mechanisms in age-related maculopathy and degeneration has emerged in recent years. This comprises experimental studies on retinal pigment epithelium (RPE) and rod photoreceptor ageing, lipofuscin accumulation, the roles of oxidative stress and free radical formation, as well as antioxidants and other defensive mechanisms operating against environmental factors and ageing.
   The current application of photodynamic therapy (PDT) using verteporfin marks a new era in the treatment of subfoveal classical choroidal neovascularization. Several new treatment modalities, such as transpupillary thermotherapy (TTT) and anti-vascular endothelial growth factor (VEGF) agents for inhibition of neovascularization, have emerged and are undergoing multicentre clinical trials. A period of dynamic development in this field has commenced.
C1 St Eriks Eye Hosp, Karolinska Inst, Dept Ophthalmol, SE-11282 Stockholm, Sweden.
C3 Karolinska Institutet
RP Algvere, PV (通讯作者)，St Eriks Eye Hosp, Karolinska Inst, Dept Ophthalmol, Polhemsgatan 50, SE-11282 Stockholm, Sweden.
EM peep.algvere@sankterik.se
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   ALGVERE PV, 2001, IN PRESS SEMIN OPHTH, V16, P90
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   [Anonymous], 1998, Ophthalmology, V105, P11
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BARRON MJ, 2001, INVEST OPHTH VIS SCI, V42, P306
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Connolly BP, 2001, INVEST OPHTH VIS SCI, V42, pS513
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELPRIORE L, 2000, 33 ANN M COR GABL FL
   DUKEELDER WS, 1940, TXB OPHTHALMOLOGY, P2116
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P244, DOI 10.1016/S0002-9394(00)00788-1
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Fine SL, 2001, INVEST OPHTH VIS SCI, V42, pS127
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Guyer DR, 2001, INVEST OPHTH VIS SCI, V42, pS522
   HALLER JA, 2000, SEMIN OPHTHALMOL, V5, P81
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   LAVAIL MM, 1976, INVEST OPHTH VISUAL, V15, P64
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Ogata N, 2001, AM J OPHTHALMOL, V132, P427, DOI 10.1016/S0002-9394(01)01021-2
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653
   Wu JM, 1999, EYE, V13, P577, DOI 10.1038/eye.1999.142
NR 64
TC 55
Z9 58
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD APR
PY 2002
VL 80
IS 2
BP 136
EP 143
DI 10.1034/j.1600-0420.2002.800204.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 543GJ
UT WOS:000175092800004
PM 11952478
DA 2022-11-30
ER

PT J
AU Deng, H
   Li, TH
   Xie, J
   Huang, NY
   Gu, Y
   Zhao, JQ
AF Deng, Hong
   Li, Tinghui
   Xie, Jie
   Huang, Naiyan
   Gu, Ying
   Zhao, Jingquan
TI Synthesis and bio-evaluation of novel hypocrellin derivatives: Potential
   photosensitizers for photodynamic therapy of age-related macular
   degeneration
SO DYES AND PIGMENTS
LA English
DT Article
DE Hypocrellin derivatives; Age-related macular degeneration; Target
   characters; Phototherapeutic window; Drug-delivery; Biological activity
ID DRUG-DELIVERY; IN-VIVO; EXTRAVASATION; LIPOPHILICITY; WAVELENGTH;
   PORPHYRINS; DIAGNOSIS; EFFICACY; TAURINE; PDT
AB The phototherapeutic window from 600 to 900 nm is necessary for photodynamic therapy (PDT) of solid tumors, but may not suitable for PDT of some microvascular diseases, like age-related macular degeneration (AMD), because of its deep penetration. Moreover, absorption of some neighboring photoreceptors should be avoided for PDT of AMD. Considering these, yellow-orange light may be a proper phototherapeutic window of AMD. Herein, two novel amino-alkyl-sulfonic acid-substituted hypocrellin B derivatives, 3 and 4 were designed and synthesized. They exhibited the maximal absorption at yellow-orange light, and possessed higher PDT activity than 2, proved by the in vitro or in vivo experiments. Besides, 4 showed much higher PDT activity than 3, ascribed to its higher cellular uptake suggested by its optimized amphiphilicity and liposome mimic results. And the vascular leakage of 4 was close to 2. Consequently, 4 has great potential for PDT of AMD or other superficial diseases. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Deng, Hong; Xie, Jie; Zhao, Jingquan] Chinese Acad Sci, Inst Chem, Key Lab Photochem, Beijing Natl Lab Mol Sci BNLMS, Beijing 100190, Peoples R China.
   [Li, Tinghui] PLA, Hosp 309, Dept Dermatol, Beijing 100091, Peoples R China.
   [Huang, Naiyan; Gu, Ying] Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, Beijing 100853, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Chemistry, CAS; Chinese
   People's Liberation Army General Hospital
RP Zhao, JQ (通讯作者)，Chinese Acad Sci, Inst Chem, Key Lab Photochem, Beijing Natl Lab Mol Sci BNLMS, POB 101,2,1st North St, Beijing 100190, Peoples R China.
EM drlitinghui@163.com; xicjie@iccas.ac.cn; guyinglaser@sina.com;
   zhaojq@iccas.ac.cn
RI zhao, jing/B-3868-2019
FU National Natural Science Foundation of China [20872144, 31170614,
   21303223]
FX Project supported by the National Natural Science Foundation of China
   (No. 20872144, 31170614 and 21303223).
CR Abramkin SA, 2010, J MED CHEM, V53, P7356, DOI 10.1021/jm100953c
   Ali SM, 2002, INT J ONCOL, V21, P1229
   AVELINE B, 1994, PHOTOCHEM PHOTOBIOL, V59, P328, DOI 10.1111/j.1751-1097.1994.tb05042.x
   Balaz M, 2009, ORG BIOMOL CHEM, V7, P874, DOI 10.1039/b814789b
   Beck TJ, 2003, P SOC PHOTO-OPT INS, V5138, P96, DOI 10.1117/12.508664
   Bourre L, 2003, J PHOTOCH PHOTOBIO B, V69, P179, DOI 10.1016/S1011-1344(03)00020-4
   Cetiner M, 2005, TOXICOL APPL PHARM, V209, P39, DOI 10.1016/j.taap.2005.03.009
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Deng H, 2012, J MED CHEM, V55, P1910, DOI 10.1021/jm2017368
   DIWU ZJ, 1992, J PHOTOCH PHOTOBIO A, V64, P273, DOI 10.1016/1010-6030(92)85002-C
   Fahr A, 2006, J LIPOSOME RES, V16, P281, DOI 10.1080/08982100600848702
   FOMIN GV, 1964, DOKL AKAD NAUK SSSR+, V157, P1199
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Gao L, 2012, ACS NANO, V6, P8030, DOI 10.1021/nn302634m
   Hanna J, 2004, EXP TOXICOL PATHOL, V56, P189, DOI 10.1016/j.etp.2004.08.004
   He C, 2008, PHARM RES-DORDR, V25, P1873, DOI 10.1007/s11095-008-9604-5
   He YY, 1999, DYES PIGMENTS, V44, P63, DOI 10.1016/S0143-7208(99)00074-1
   Hopper C, 2000, Lancet Oncol, V1, P212
   HU YZ, 1993, J PHOTOCH PHOTOBIO B, V17, P195, DOI 10.1016/1011-1344(93)80013-Y
   Hu YZ, 1993, CHINESE J ORG CHEM, V13, P597
   Hudson JB, 1997, PHOTOCHEM PHOTOBIOL, V65, P352, DOI 10.1111/j.1751-1097.1997.tb08570.x
   Ivanov VL, 2009, HIGH ENERG CHEM+, V43, P284, DOI 10.1134/S0018143909040079
   Jori G, 2006, LASER SURG MED, V38, P468, DOI 10.1002/lsm.20361
   Kaihong Z., 1989, CHINESE J ORG CHEM, V9, P252
   Kojima C, 2007, BIOCONJUGATE CHEM, V18, P663, DOI 10.1021/bc060244u
   Lange N, 2001, INVEST OPHTH VIS SCI, V42, P38
   Lee W, 2012, DYES PIGMENTS, V92, P942, DOI 10.1016/j.dyepig.2011.08.001
   Liu X, 2009, J PHOTOCH PHOTOBIO B, V94, P171, DOI 10.1016/j.jphotobiol.2008.11.008
   Liu YY, 2008, PROG CHEM, V20, P1345
   Liu YY, 2008, J PHYS CHEM B, V112, P9959, DOI 10.1021/jp7121467
   Lock JHJ, 2011, CLIN EXP OPTOM, V94, P43, DOI 10.1111/j.1444-0938.2010.00529.x
   MAINSTER MA, 1986, OPHTHALMOLOGY, V93, P952
   McKeage MJ, 2000, CANCER CHEMOTH PHARM, V46, P343, DOI 10.1007/s002800000166
   Morkved EH, 2009, POLYHEDRON, V28, P2635, DOI 10.1016/j.poly.2009.05.060
   Paul BT, 2009, J PHOTOCH PHOTOBIO B, V94, P38, DOI 10.1016/j.jphotobiol.2008.09.007
   Pegaz B, 2005, J PHOTOCH PHOTOBIO B, V80, P19, DOI 10.1016/j.jphotobiol.2005.02.003
   Qiu HX, 2011, DERMATOL SURG, V37, P1603, DOI 10.1111/j.1524-4725.2011.02129.x
   Robertson CA, 2009, J PHOTOCH PHOTOBIO B, V96, P1, DOI 10.1016/j.jphotobiol.2009.04.001
   Rogers JE, 2003, J PHYS CHEM A, V107, P11331, DOI 10.1021/jp0354705
   Siddiqui AQ, 1999, J MED CHEM, V42, P393, DOI 10.1021/jm9803931
   Song LM, 2007, PHOTOCH PHOTOBIO SCI, V6, P683, DOI 10.1039/b618678e
   Song YZ, 1999, J PHOTOCH PHOTOBIO A, V123, P39, DOI 10.1016/S1010-6030(99)00036-2
   Sun Y, 2012, DALTON T, V41, P651, DOI 10.1039/c1dt11401h
   Sun Y, 2011, J INORG BIOCHEM, V105, P978, DOI 10.1016/j.jinorgbio.2011.03.021
   SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Xia SQ, 2003, CHEM COMMUN, P2900, DOI 10.1039/b309024h
   Xu SJ, 2003, J ORG CHEM, V68, P2048, DOI 10.1021/jo026554x
   Zhang Y, 2010, PHOTOCHEM PHOTOBIOL, V86, P667, DOI 10.1111/j.1751-1097.2010.00711.x
   Zhao YW, 2004, DYES PIGMENTS, V63, P175, DOI 10.1016/j.dyepig.2004.02.010
   Zhao YW, 2003, NEW J CHEM, V27, P880, DOI 10.1039/b211388k
NR 52
TC 20
Z9 20
U1 4
U2 63
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0143-7208
EI 1873-3743
J9 DYES PIGMENTS
JI Dyes Pigment.
PD DEC
PY 2013
VL 99
IS 3
BP 930
EP 939
DI 10.1016/j.dyepig.2013.06.037
PG 10
WC Chemistry, Applied; Engineering, Chemical; Materials Science, Textiles
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Materials Science
GA 259XS
UT WOS:000327560200055
DA 2022-11-30
ER

PT J
AU George, PP
   Molina, JAD
   Heng, BH
AF George, Pradeep Paul
   Molina, Joseph Antonio DeCastro
   Heng, Bee Hoon
TI The methodological quality of systematic reviews comparing intravitreal
   bevacizumab and alternates for neovascular age related macular
   degeneration: A systematic review of reviews
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Bevacizumab; intravitreal; neovascular age related macular degeneration;
   systemic; systematic review; systematic review of reviews
ID RANIBIZUMAB; PREVALENCE; DISEASES
AB Objective: To systematically collate and evaluate the evidence from recent SRs of bevacizumab for neo-vascular age related macular degeneration. Materials and Methods: Literature searches were carried out in Medline, Embase, Cochrane databases for all systematic reviews (SRs) on the effectiveness of bevacizumab for neo-vascular age related macular degeneration, published between 2000 and 2013. Titles and abstracts were assessed against the inclusion/exclusion criteria using Joanna Briggs Institute (JBI) study eligibility form. Data was extracted using the JBI data extraction form. The quality of the SRs was assessed using JBI critical appraisal checklist for SRs. Decisions on study eligibility and quality were made by two reviewers; any disagreements were resolved by discussion. Results: Nine relevant reviews were identified from 30 citations, of which 5 reviews fulfilled the review's inclusion criteria. All 5 reviews showed bevacizumab to be effective for neovascular AMD in the short-term when used alone or in combination with PDT or Pegaptanib. The average quality score of the reviews was 7; 95% confidence interval 6.2 to 7.8 (maximum possible quality score is 10). The selection and publication bias were not addressed in all included reviews. Three-fifth of the reviews had a quality score of 7 or lower, these reviews had some methodological limitations, search strategies were only identified in 2 (40%) reviews, independent study selection and quality assessment of included studies (4 (80%)) were infrequently performed. Conclusion: Overall, the reviews on the effectiveness of intravitreal/systemic bevacizumab for neovascular age-related macular generation (AMD) received good JBI quality scores (mean score = 7.0 points), with a few exceptions. The study also highlights the suboptimal reporting of SRs on this topic. Reviews with poor methodology may limit the validity of the reported results; hence efforts should be made to improve the design, reporting and publication of SRs across all journals.
C1 [George, Pradeep Paul; Molina, Joseph Antonio DeCastro; Heng, Bee Hoon] Natl Healthcare Grp, HQ, Singapore 149547, Singapore.
RP George, PP (通讯作者)，Natl Healthcare Grp, 6 Commonwealth Lane,04-01-02 GMTI Bldg, Singapore 149547, Singapore.
EM Pradeep_Paul_G_Gunapal@nhg.com.sg
RI George, Pradeep Paul/ABE-9925-2020; Molina, Joseph Antonio/S-6181-2019
OI George, Pradeep Paul/0000-0003-4743-1425; 
CR Andriolo RB, 2009, SAO PAULO MED J, V127, P84, DOI 10.1590/S1516-31802009000200006
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen HY, 2012, BRIT J OPHTHALMOL, V96, P896, DOI 10.1136/bjophthalmol-2012-301589
   Ellis S, 2003, HIV PREVENTION AREVI
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kelly MP, 2002, METHODOLOGICAL PROBL
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Palmateer N, 2010, ADDICTION, V105, P844, DOI 10.1111/j.1360-0443.2009.02888.x
   Pitlick JM, 2012, ANN PHARMACOTHER, V46, P290, DOI 10.1345/aph.1Q471
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Smit DP, 2007, CLIN OPHTHALMOL, V1, P273
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]
   Weed DL, 2011, AM J CLIN NUTR, V94, P1340, DOI 10.3945/ajcn.111.015875
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Ziemssen F, 2009, DRUG AGING, V26, P295, DOI 10.2165/00002512-200926040-00002
NR 23
TC 6
Z9 6
U1 0
U2 4
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUL
PY 2014
VL 62
IS 7
BP 761
EP 767
DI 10.4103/0301-4738.138615
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ9WW
UT WOS:000348565900002
PM 25116765
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jemni-Damer, N
   Guedan-Duran, A
   Cichy, J
   Lozano-Picazo, P
   Gonzalez-Nieto, D
   Perez-Rigueiro, J
   Rojo, F
   Guinea, GV
   Virtuoso, A
   Cirillo, G
   Papa, M
   Armada-Maresca, F
   Largo-Aramburu, C
   Aznar-Cervantes, SD
   Cenis, JL
   Panetsos, F
AF Jemni-Damer, Nahla
   Guedan-Duran, Atocha
   Cichy, Jasmin
   Lozano-Picazo, Paloma
   Gonzalez-Nieto, Daniel
   Perez-Rigueiro, Jose
   Rojo, Francisco
   V. Guinea, Gustavo
   Virtuoso, Assunta
   Cirillo, Giovanni
   Papa, Michele
   Armada-Maresca, Felix
   Largo-Aramburu, Carlota
   Aznar-Cervantes, Salvador D.
   Cenis, Jose L.
   Panetsos, Fivos
TI First steps for the development of silk fibroin-based 3D biohybrid
   retina for age-related macular degeneration (AMD)
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article
DE scaffolds; retinal pigment epithelium; neurons; cultured cells; in
   vitro; macular degeneration
ID PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS; BRUCHS MEMBRANE;
   GANGLION-CELLS; TRANSPLANTATION; SURVIVAL; RPE; SCAFFOLDS; DISEASE;
   GROWTH
AB Age-related macular degeneration is an incurable chronic neurodegenerative disease, causing progressive loss of the central vision and even blindness. Up-to-date therapeutic approaches can only slow down he progression of the disease. Objective. Feasibility study for a multilayered, silk fibroin-based, 3D biohybrid retina. Approach. Fabrication of silk fibroin-based biofilms; culture of different types of cells: retinal pigment epithelium, retinal neurons, Muller and mesenchymal stem cells ; creation of a layered structure glued with silk fibroin hydrogel. Main results. In vitro evidence for the feasibility of layered 3D biohybrid retinas; primary culture neurons grow and develop neurites on silk fibroin biofilms, either alone or in presence of other cells cultivated on the same biomaterial; cell organization and cellular phenotypes are maintained in vitro for the seven days of the experiment. Significance. 3D biohybrid retina can be built using silk silkworm fibroin films and hydrogels to be used in cell replacement therapy for AMD and similar retinal neurodegenerative diseases.
C1 [Jemni-Damer, Nahla; Guedan-Duran, Atocha; Cichy, Jasmin; Panetsos, Fivos] Univ Complutense Madrid, Neurocomp & Neurorobot Res Grp, Madrid, Spain.
   [Jemni-Damer, Nahla; Guedan-Duran, Atocha; Panetsos, Fivos] Inst Hlth Res San Carlos Clin Hosp IdISSC, Innovat Res Grp, Madrid, Spain.
   [Guedan-Duran, Atocha] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.
   [Cichy, Jasmin] Univ Kiel, Fac Biol, Kiel, Germany.
   [Lozano-Picazo, Paloma; Gonzalez-Nieto, Daniel; Perez-Rigueiro, Jose; Rojo, Francisco; V. Guinea, Gustavo] Univ Politecn Madrid, Ctr Biomed Technol, Madrid, Spain.
   [Gonzalez-Nieto, Daniel; Perez-Rigueiro, Jose; Rojo, Francisco; V. Guinea, Gustavo] Biomed Res Networking Ctr Bioengn Biomat & Nanome, Madrid, Spain.
   [Gonzalez-Nieto, Daniel; Perez-Rigueiro, Jose; Rojo, Francisco; V. Guinea, Gustavo; Panetsos, Fivos] Silk Biomed SL, Madrid, Spain.
   [Gonzalez-Nieto, Daniel] Univ Politecn Madrid, Dept Photon Technol & Bioengn, ETSI Telecomunicat, Madrid, Spain.
   [Perez-Rigueiro, Jose; Rojo, Francisco; V. Guinea, Gustavo] Univ Politecn Madrid, Dept Mat Sci, ETSI Caminos Canales & Puertos, Madrid, Spain.
   [Virtuoso, Assunta; Cirillo, Giovanni; Papa, Michele] Univ Campania Luigi Vanvitelli, Div Human Anat, Dept Mental Phys Hlth & Prevent Med, Neuronal Networks Morphol Lab, Naples, Italy.
   [Armada-Maresca, Felix] La Paz Univ Hosp, Ophthalmol Serv, Madrid, Spain.
   [Largo-Aramburu, Carlota] Univ Hosp, Expt Surg, La Paz IdiPAZ, Madrid, Spain.
   [Aznar-Cervantes, Salvador D.; Cenis, Jose L.] Inst Murciano Invest & Desarrollo Agr & Alimentar, Dept Biotechnol La Alberca Murcia, E-30150 Murcia, Spain.
C3 Complutense University of Madrid; Tufts University; University of Kiel;
   Universidad Politecnica de Madrid; Centro de Tecnologia Biomedica (CTB);
   CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Universidad
   Politecnica de Madrid; Universidad Politecnica de Madrid; Universita
   della Campania Vanvitelli; Hospital Universitario La Paz
RP Panetsos, F (通讯作者)，Univ Complutense Madrid, Neurocomp & Neurorobot Res Grp, Madrid, Spain.; Panetsos, F (通讯作者)，Inst Hlth Res San Carlos Clin Hosp IdISSC, Innovat Res Grp, Madrid, Spain.; Panetsos, F (通讯作者)，Silk Biomed SL, Madrid, Spain.
EM fivos@ucm.es
RI Papa, Michele/AAB-1759-2021
OI Papa, Michele/0000-0002-6609-7453; Guedan Duran,
   Atocha/0000-0002-0544-9574; Virtuoso, Assunta/0000-0002-5304-247X;
   Panetsos, Fivos/0000-0003-0897-411X; AZNAR CERVANTES,
   SALVADOR/0000-0001-9809-7215; Perez-Rigueiro, Jose/0000-0001-8298-8398;
   GONZALEZ NIETO, DANIEL/0000-0003-2972-729X
FU Spanish Ministerio de Economia y Competitividad Spain [MAT2016-76847-R,
   MAT2016-79832-R, MAT2015-66666-C3-3-R]; National Institute for
   Agricultural and Food Research and Technology (INIA); Spanish State
   Research Agency (AEI) program INIA-CCAA; Comunidad de Madrid
   [Neurocentro-B2017/BMD-3760, IND2018/BMD-9804]; ERDF/FEDER Operative
   Program of the Region of Murcia [14-20/20]; predoctoral FPI grant
FX The authors gratefully acknowledge financial support received from the
   Spanish Ministerio de Economia y Competitividad Spain through grants
   MAT2016-76847-R, MAT2016-79832-R and MAT2015-66666-C3-3-R and
   predoctoral FPI grant (AGD) as well as research contract (ADAC) from the
   National Institute for Agricultural and Food Research and Technology
   (INIA) and the Spanish State Research Agency (AEI) program INIA-CCAA,
   from the Comunidad de Madrid through grants Neurocentro-B2017/BMD-3760
   and IND2018/BMD-9804, ERDF/FEDER Operative Program of the Region of
   Murcia (Project No. 14-20/20). Authors also acknowledge preliminary work
   of Rocio Fernandez Sierra (Silk Biomed, CTB-UPM) and Rebeca Gallego Ruiz
   (CTB-UPM, UCM), help in experimental work of Nuria Alfageme Lopez, Nora
   Serrano Bengoechea, Cristina Castro Dominguez, Paula alvarez Montoya y
   Miguel Terriza Roberto (UCM, IdISSC) and the invaluable technical
   support of Soledad Martinez (CTB-UPM).
CR Achberger K, 2019, ELIFE, V8, DOI 10.7554/eLife.46188
   Al-Nawaiseh S, 2016, JOVE-J VIS EXP, DOI 10.3791/53927
   Altman GH, 2003, BIOMATERIALS, V24, P401, DOI 10.1016/S0142-9612(02)00353-8
   Altman GH, 2002, BIOMATERIALS, V23, P4131, DOI 10.1016/S0142-9612(02)00156-4
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Barnea-Cramer AO, 2016, SCI REP-UK, V6, DOI 10.1038/srep29784
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behtaj S, 2020, TISSUE ENG REGEN MED, V17, P253, DOI 10.1007/s13770-020-00254-8
   Ben M'Barek K, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4568979
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Bhattacharya Sujoy, 2017, Curr Mol Biol Rep, V3, P172, DOI 10.1007/s40610-017-0069-3
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brooks MJ, 2019, STEM CELL REP, V13, P891, DOI 10.1016/j.stemcr.2019.09.009
   Calejo MT, 2017, ACTA BIOMATER, V54, P138, DOI 10.1016/j.actbio.2017.02.035
   Cao Y, 2009, INT J MOL SCI, V10, P1514, DOI 10.3390/ijms10041514
   Cha Y, 2017, TOXICOL APPL PHARM, V314, P48, DOI 10.1016/j.taap.2016.11.008
   Chen GP, 2001, BIOMATERIALS, V22, P2453, DOI 10.1016/S0142-9612(00)00432-4
   Chen MW, 2011, ACTA BIOMATER, V7, P2244, DOI 10.1016/j.actbio.2010.12.031
   Chen TC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010178
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   Collins MN, 2013, CARBOHYD POLYM, V92, P1262, DOI 10.1016/j.carbpol.2012.10.028
   Cotrim CC, 2017, CLIN OPHTHALMOL, V11, P931, DOI 10.2147/OPTH.S133502
   Crafoord S, 2002, ACTA OPHTHALMOL SCAN, V80, P387, DOI 10.1034/j.1600-0420.2002.800408.x
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Damian Javier, 2006, Aten Primaria, V38, P51, DOI 10.1157/13090016
   Daneault V, 2016, J PHYSIOL ANTHROPOL, V35, DOI 10.1186/s40101-016-0091-9
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   Ding SLS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081406
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fernandez-Garcia L, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00296
   Fernandez-Garcia L, 2016, ACTA BIOMATER, V45, P262, DOI 10.1016/j.actbio.2016.09.003
   Fligor CM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32871-8
   Gagliardi G, 2019, PROG RETIN EYE RES, V71, P1, DOI 10.1016/j.preteyeres.2019.03.001
   Galloway CA, 2018, INVEST OPHTH VIS SCI, V59, P2792, DOI 10.1167/iovs.17-23157
   Garita-Hernandez M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12330-2
   Gasparini SJ, 2019, PROG RETIN EYE RES, V69, P1, DOI 10.1016/j.preteyeres.2018.11.001
   Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428
   Gonzalez-Nieto D, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051074
   Gorenkova N, 2019, ACS BIOMATER SCI ENG, V5, P859, DOI 10.1021/acsbiomaterials.8b01024
   Guenther E, 1999, VISION RES, V39, P3988, DOI 10.1016/S0042-6989(99)00128-5
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hertz J, 2013, ACTA BIOMATER, V9, P7622, DOI 10.1016/j.actbio.2013.04.048
   Hogan M J, 1971, HISTOLOGY HUMAN EYE, P687
   Horn-Ranney EL, 2013, BIOMED MICRODEVICES, V15, P49, DOI 10.1007/s10544-012-9687-y
   Huang D, 2014, EUR J PHARM BIOPHARM, V88, P104, DOI 10.1016/j.ejpb.2014.04.011
   Ilmarinen T, 2019, ACTA OPHTHALMOL, V97, pE688, DOI 10.1111/aos.14004
   Imai H, 2007, CURR EYE RES, V32, P903, DOI 10.1080/02713680701604749
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jiang JP, 2020, NEURAL REGEN RES, V15, P959, DOI 10.4103/1673-5374.268974
   Jin ZB, 2019, PROG RETIN EYE RES, V69, P38, DOI 10.1016/j.preteyeres.2018.11.003
   Kador KE, 2016, TISSUE ENG PT A, V22, P286, DOI [10.1089/ten.tea.2015.0373, 10.1089/ten.TEA.2015.0373]
   Kador KE, 2014, ACTA BIOMATER, V10, P4939, DOI 10.1016/j.actbio.2014.08.032
   Kador KE, 2012, EXPERT REV OPHTHALMO, V7, P459, DOI 10.1586/EOP.12.56
   Kador KE, 2013, BIOMATERIALS, V34, P4242, DOI 10.1016/j.biomaterials.2013.02.027
   KAPLAN D, 1994, ACS SYM SER, V544, P2
   Kaplan DL, 1998, POLYM DEGRAD STABIL, V59, P25, DOI 10.1016/S0141-3910(97)00000-1
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lai JY, 2013, J MATER SCI-MATER M, V24, P2201, DOI 10.1007/s10856-013-4961-y
   Laughter MR, 2016, ACS APPL MATER INTER, V8, P20540, DOI 10.1021/acsami.6b04679
   Li KJ, 2017, ACTA BIOMATER, V54, P117, DOI 10.1016/j.actbio.2017.02.032
   Li MZ, 2003, BIOMATERIALS, V24, P357, DOI 10.1016/S0142-9612(02)00326-5
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Liu X, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01651-5
   Llonch S, 2018, DEV BIOL, V433, P132, DOI 10.1016/j.ydbio.2017.09.028
   Lorach H, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.30
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu LC, 1998, J BIOMAT SCI-POLYM E, V9, P1187
   Lu LC, 2001, BIOMATERIALS, V22, P291, DOI 10.1016/S0142-9612(00)00179-4
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Madduri S, 2010, BIOMATERIALS, V31, P2323, DOI 10.1016/j.biomaterials.2009.11.073
   Marmor M F, 1998, RETINAL PIGMENT EPIT, P745
   Martin-Martin Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45238-4
   Mauney JR, 2005, BIOMATERIALS, V26, P6167, DOI 10.1016/j.biomaterials.2005.03.024
   Mauney JR, 2005, TISSUE ENG, V11, P787, DOI 10.1089/ten.2005.11.787
   Maya-Vetencourt JF, 2017, NAT MATER, V16, P681, DOI [10.1038/NMAT4874, 10.1038/nmat4874]
   McConnell V, 2005, Ulster Med J, V74, P82
   McCormick R, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00456
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   Meinel L, 2005, BONE, V37, P688, DOI 10.1016/j.bone.2005.06.010
   Meinel L, 2004, BIOTECHNOL BIOENG, V88, P379, DOI 10.1002/bit.20252
   Meinel L, 2004, J BIOMED MATER RES A, V71A, P25, DOI 10.1002/jbm.a.30117
   MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Peng CH, 2016, ONCOTARGET, V7, P64631, DOI 10.18632/oncotarget.11502
   Peter SJ, 1998, J BIOMED MATER RES, V43, P422, DOI 10.1002/(SICI)1097-4636(199824)43:4<422::AID-JBM9>3.3.CO;2-T
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Ramakrishna S, 2001, COMPOS SCI TECHNOL, V61, P1189, DOI 10.1016/S0266-3538(00)00241-4
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rocco ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124810
   Rose JB, 2014, MATERIALS, V7, P3106, DOI 10.3390/ma7043106
   Schubert C, 2014, BRIT J OPHTHALMOL, V98, P159, DOI 10.1136/bjophthalmol-2013-304446
   Sergejeva O, 2016, MEDICINA-LITHUANIA, V52, P79, DOI 10.1016/j.medici.2016.02.004
   Shadforth AMA, 2017, J TISSUE ENG REGEN M, V11, P1915, DOI 10.1002/term.2089
   Shadforth AMA, 2015, J FUNCT BIOMATER, V6, P946, DOI 10.3390/jfb6030946
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Shen JH, 2017, MED SCI MONITOR, V23, P6132, DOI 10.12659/MSM.905569
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Singh R, 2018, STEM CELL REV REP, V14, P463, DOI 10.1007/s12015-018-9802-4
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Stern JH, 2018, CELL STEM CELL, V22, P834, DOI 10.1016/j.stem.2018.05.013
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Suzuki S, 2019, MAT SCI ENG C-MATER, V105, DOI 10.1016/j.msec.2019.110131
   Szybala C, 2009, EXP NEUROL, V219, P126, DOI 10.1016/j.expneurol.2009.05.018
   Tang-Schomer MD, 2019, ACTA BIOMATER, V94, P306, DOI 10.1016/j.actbio.2019.02.052
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Ventola C Lee, 2014, P T, V39, P704
   Vepari C, 2007, PROG POLYM SCI, V32, P991, DOI 10.1016/j.progpolymsci.2007.05.013
   von Philipsborn AC, 2006, DEVELOPMENT, V133, P2487, DOI 10.1242/dev.02412
   Vozzi G, 2012, MOL BIOTECHNOL, V50, P99, DOI 10.1007/s12033-011-9411-9
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Weiss JN, 2015, NEURAL REGEN RES, V10, P982, DOI 10.4103/1673-5374.158365
   West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520
   White CE, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417720841
   Williams R, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701328
   Winkler BS, 1999, MOL VIS, V5
   Wittenborn J, 2014, PREVENT BLINDNESS FO, V60603, P312
   Wittmer CR, 2011, ADV FUNCT MATER, V21, P4232, DOI 10.1002/adfm.201100755
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu HJ, 2007, GRAEF ARCH CLIN EXP, V245, P135, DOI 10.1007/s00417-006-0296-4
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Yang PT, 2019, INT CONF WIREL OPT, P276, DOI 10.1080/10837450.2018.1545236
   Yang TC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18092013
   Yang Y, 2007, BIOMATERIALS, V28, P5526, DOI 10.1016/j.biomaterials.2007.09.001
   Yao J, 2015, TISSUE ENG PT A, V21, P1247, DOI [10.1089/ten.tea.2013.0720, 10.1089/ten.TEA.2013.0720]
   Yoon D M, 2006, POLYMERIC SCAFFOLDS, DOI 10.1201/9781420003871
   Young MJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P1725, DOI 10.1001/archopht.123.12.1725
   Yucel T, 2014, J CONTROL RELEASE, V190, P381, DOI 10.1016/j.jconrel.2014.05.059
   Zarbin M, 2019, STEM CELL TRANSL MED, V8, P466, DOI 10.1002/sctm.18-0282
   Zhang DD, 2015, SCI REP-UK, V5, DOI 10.1038/srep14326
NR 139
TC 3
Z9 3
U1 3
U2 18
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
EI 1741-2552
J9 J NEURAL ENG
JI J. Neural Eng.
PD OCT
PY 2020
VL 17
IS 5
AR 055003
DI 10.1088/1741-2552/abb9c0
PG 19
WC Engineering, Biomedical; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Neurosciences & Neurology
GA OI2XR
UT WOS:000583148500001
PM 32947273
DA 2022-11-30
ER

PT J
AU Liu, JH
   Tian, ZQ
   Li, JH
   Zhao, GM
AF Liu, Jianhui
   Tian, Zhiqing
   Li, Jinhui
   Zhao, Guangming
TI Associations ofIL-8gene polymorphisms and IL-8 levels with
   predisposition to age-related macular degeneration: a meta-analysis
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Review
DE Inflammation; Interleukin-8 (IL-8); Age-related macular degeneration
   (AMD); Meta-analysis
ID AQUEOUS-HUMOR; BEVACIZUMAB; RISK; CYTOKINES; CANCER; REGION
AB Purpose Interleukin-8 (IL-8) might influence predisposition to age-related macular degeneration (AMD), but the results of related studies were still controversial and ambiguous. The authors designed this meta-analysis to more precisely estimate the relationships betweenIL-8gene polymorphisms, IL-8 levels, and predisposition to AMD. Methods Meta-analyses of studies that investigatedIL-8gene polymorphisms and IL-8 levels in patients with AMD and controls were performed. Results The pooled meta-analyses result showed that IL-8 +781 C/T (rs2227306) polymorphism was significantly associated with predisposition to AMD and wet AMD, but no such significant association was detected for IL-8 -251 A/T (rs4073) polymorphism. In parallel, we also found that patients with AMD or wet AMD had elevated IL-8 levels compared to controls. Conclusions This meta-analysis suggests thatIL-8 +781 C/T polymorphism affects predisposition to AMD and wet AMD. Moreover, patients with AMD and wet AMD also have elevated IL-8 levels.
C1 [Liu, Jianhui; Tian, Zhiqing; Li, Jinhui] Changyi Peoples Hosp, Dept Ophthalmol, Changyi 261300, Shandong, Peoples R China.
   [Zhao, Guangming] Shaoxing Univ, Zhuji Affiliated Hosp, Dept Ophthalmol, Zhuji 311800, Zhejiang, Peoples R China.
C3 Shaoxing University
RP Zhao, GM (通讯作者)，Shaoxing Univ, Zhuji Affiliated Hosp, Dept Ophthalmol, Zhuji 311800, Zhejiang, Peoples R China.
EM zhaoguandidne@163.com
RI Li, Jin/GYQ-5363-2022
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Ambreen F, 2015, MOL VIS, V21, P985
   Andia DC, 2011, J PERIODONTOL, V82, P893, DOI 10.1902/jop.2010.100513
   Conedera FM, 2019, GLIA, V67, P1150, DOI 10.1002/glia.23601
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Hautamaki A, 2014, OPHTHALMOLOGY, V121, P973, DOI 10.1016/j.ophtha.2013.11.035
   Hozo S.P., 2005, BMC MED RES METHODOL, V5, DOI DOI 10.1186/1471-2288-5-13
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Iocono JA, 2000, WOUND REPAIR REGEN, V8, P216, DOI 10.1046/j.1524-475x.2000.00216.x
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Lazzeri S, 2016, PHARMACOGENOMICS, V17, P27, DOI 10.2217/pgs.15.153
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Linhartova PB, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/342351
   Mimura T, 2019, OPHTHALMOLOGICA, V241, P81, DOI 10.1159/000490153
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   Motohashi R, 2017, OPHTHALMIC RES, V58, P209, DOI 10.1159/000478705
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Schultheis AM, 2008, CLIN CANCER RES, V14, P7554, DOI 10.1158/1078-0432.CCR-08-0351
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Taguchi A, 2005, CANCER EPIDEM BIOMAR, V14, P2487, DOI 10.1158/1055-9965.EPI-05-0326
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Thapa R, 2017, CLIN OPHTHALMOL, V11, P963, DOI 10.2147/OPTH.S132338
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135
   Zhang M, 2016, ONCOTARGETS THER, V9, DOI 10.2147/OTT.S103159
NR 37
TC 2
Z9 2
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1594-0667
EI 1720-8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD DEC
PY 2020
VL 32
IS 12
BP 2703
EP 2703
DI 10.1007/s40520-020-01501-7
EA MAR 2020
PG 1
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA PD0WR
UT WOS:000562572300001
PM 32157592
OA Bronze
DA 2022-11-30
ER

PT J
AU Yu, HH
   Zou, XL
   Peng, LH
   Wang, Y
   Zhang, C
   Chen, B
   Zou, YP
AF Yu, Honghua
   Zou, Xiulan
   Peng, Lianghong
   Wang, Yong
   Zhang, Chu
   Chen, Bin
   Zou, Yuping
TI Effect of Soluble Inducible Costimulator Level and Its Polymorphisms on
   Age-Related Macular Degeneration
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID HELPER-CELLS; B-CELL; ICOS; EXPRESSION; MOLECULE; GENERATION; MEMORY;
   CTLA-4; CD28
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population. Evidence has shown that the human immune system may play critical roles in this disease. Inducible costimulator (ICOS) promotes T-cell activation, differentiation, and T:B-cell interactions. The aim of the study was to understand the effect of ICOS on the development of AMD from genetic polymorphism perspective and serum level perspective. Two ICOS polymorphisms, rs10183087A/C and rs10932037C/T, were tested in 223 AMD cases and 262 healthy controls. The serum level of soluble ICOS (sICOS) was compared among subjects with different genotypes, as well as between AMD patients and controls. Data showed that prevalence of rs10183087CC genotype was significantly increased in AMD than in controls (p=0.001). Function analysis revealed that subjects carrying rs10183087CC genotype had higher serum levels of sICOS than those with AA or AC genotypes (p < 0.05). When we compared serum levels of sICOS between cases and controls, results showed that AMD patients had significantly increased sICOS levels than healthy donors (p < 0.05). Also, wet type cases were observed to have higher sICOS levels than cases with dry type (p < 0.05). These data suggested ICOS polymorphism could affect the susceptibility to AMD by elevating protein expression, and serum levels of sICOS may be closed correlated with the development and progression of this disease.
C1 [Yu, Honghua; Zou, Xiulan; Peng, Lianghong; Wang, Yong; Zhang, Chu; Chen, Bin; Zou, Yuping] PLA, Guangzhou Mil Command, Gen Hosp, Dept Ophthalmol, Guangzhou 510010, Guangdong, Peoples R China.
C3 Southern Theater Command General Hospital
RP Chen, B (通讯作者)，PLA, Guangzhou Mil Command, Gen Hosp, Dept Ophthalmol, Guangzhou 510010, Guangdong, Peoples R China.
EM binchengz@126.com; yupingzougz@126.com
OI Yu, Honghua/0000-0002-0782-346X
FU State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun
   Yat-sen University, Guangzhou China [2011KF03]
FX This study was supported by Grant 2011KF03 from the State Key Laboratory
   of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University,
   Guangzhou 510060, China.
CR Bauquet AT, 2009, NAT IMMUNOL, V10, P167, DOI 10.1038/ni.1690
   Burmeister Y, 2008, J IMMUNOL, V180, P774, DOI 10.4049/jimmunol.180.2.774
   Castelli L, 2007, J NEUROIMMUNOL, V186, P193, DOI 10.1016/j.jneuroim.2007.03.022
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Coyle AJ, 2004, SPRINGER SEMIN IMMUN, V25, P349, DOI 10.1007/s00281-003-0154-y
   Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611
   Haimila KE, 2002, IMMUNOGENETICS, V53, P1028, DOI 10.1007/s00251-002-0431-2
   Hutloff A, 2004, ARTHRITIS RHEUM-US, V50, P3211, DOI 10.1002/art.20519
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain VV, 2008, PHARMACOL THERAPEUT, V117, P385, DOI 10.1016/j.pharmthera.2007.12.002
   Lohning M, 2003, J EXP MED, V197, P181, DOI 10.1084/jem.20020632
   McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009
   Okamoto T, 2003, J RHEUMATOL, V30, P1157
   Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x
   Sharpe AH, 2009, IMMUNOL REV, V229, P5, DOI 10.1111/j.1600-065X.2009.00784.x
   Shilling RA, 2006, CLIN IMMUNOL, V121, P13, DOI 10.1016/j.clim.2006.04.574
   Swallow MM, 1999, IMMUNITY, V11, P423, DOI 10.1016/S1074-7613(00)80117-X
   Wu J, 2009, CLIN CHIM ACTA, V403, P229, DOI 10.1016/j.cca.2009.03.037
NR 20
TC 7
Z9 7
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD DEC 1
PY 2013
VL 32
IS 12
BP 717
EP 721
DI 10.1089/dna.2013.2127
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 257KD
UT WOS:000327381400006
PM 24083358
OA Green Published
DA 2022-11-30
ER

PT J
AU Kersten, E
   Geerlings, MJ
   Pauper, M
   Corominas, J
   Bakker, B
   Altay, L
   Fauser, S
   de Jong, EK
   Hoyng, CB
   den Hollander, AI
AF Kersten, Eveline
   Geerlings, Maartje J.
   Pauper, Marc
   Corominas, Jordi
   Bakker, Bjorn
   Altay, Lebriz
   Fauser, Sascha
   de Jong, Eiko K.
   Hoyng, Carel B.
   den Hollander, Anneke I.
TI Genetic screening for macular dystrophies in patients clinically
   diagnosed with dry age-related macular degeneration
SO CLINICAL GENETICS
LA English
DT Article
DE age-related macular degeneration; AMD; CACD; central areolar choroidal
   dystrophy; genetic screening; macular dystrophies; PRPH2; WES;
   whole-exome sequencing
ID AREOLAR CHOROIDAL DYSTROPHY; VARIANTS
AB It can be clinically challenging to distinguish dry age-related macular degeneration (AMD) from AMD-mimicking dystrophies, and sometimes misdiagnosis occurs. With upcoming therapies for dry AMD it is important to exclude patients with a different retinal disease from clinical trials. In this study we evaluated the occurrence of AMD-mimicking dystrophies in an AMD cohort. Whole-exome sequencing (WES) was performed in 218 patients with intermediate AMD or geographic atrophy secondary to AMD and 133 control individuals. WES data was analyzed for rare variants in 19 genes associated with autosomal dominant and recessive macular dystrophies mimicking AMD. In three (1.4%) of 218 cases we identified a pathogenic heterozygous variant (PRPH2 c.424C > T; p.R142W) causal for autosomal dominant central areolar choroidal dystrophy (CACD). Phenotypically, these patients all presented with geographic atrophy. In 12 (5.5%) of 218 cases we identified a heterozygous variant of unknown clinical significance, but predicted to be highly deleterious, in genes previously associated with autosomal dominant macular dystrophies. The distinction between AMD and AMD-mimicking dystrophies, such as CACD, can be challenging based on fundus examination alone. Genetic screening for genes associated with macular dystrophies, especially PRPH2, can be beneficial to help identify AMD-mimicking dystrophies.
C1 [Kersten, Eveline; Geerlings, Maartje J.; Pauper, Marc; Corominas, Jordi; Bakker, Bjorn; de Jong, Eiko K.; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Dept Ophthalmol, Donders Inst Brain Cognit & Behav, Med Ctr, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
   [Pauper, Marc; Corominas, Jordi; den Hollander, Anneke I.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
   [Altay, Lebriz; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche & Cie AG, Global Head Ophthalmol, Basel, Switzerland.
C3 Philips; Radboud University Nijmegen; Radboud University Nijmegen;
   University of Cologne; Roche Holding
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Dept Ophthalmol, Donders Inst Brain Cognit & Behav, Med Ctr, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI Bakker, Bjorn/E-2842-2016; Pauper, Marc/AGZ-0438-2022; Kersten,
   Eveline/P-8173-2015; Geerlings, Maartje/P-3338-2019; Hollander, Anneke
   den/N-4911-2014
OI Pauper, Marc/0000-0001-6274-9891; Geerlings,
   Maartje/0000-0003-1164-3573; 
FU European Commission [634479]; H2020 European Research Council [310644]
FX European Commission, Grant/Award Number: 634479 (EYE-RISK); H2020
   European Research Council, Grant/Award Number: 310644 (MACULA)
CR Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   Fokkema IFAC, 2011, HUM MUTAT, V32, P557, DOI 10.1002/humu.21438
   Francioli LC, 2014, NAT GENET, V46, P818, DOI 10.1038/ng.3021
   Hoyng CB, 1996, GRAEF ARCH CLIN EXP, V234, P87, DOI 10.1007/BF00695246
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892
   Klevering BJ, 2002, BRIT J OPHTHALMOL, V86, P91, DOI 10.1136/bjo.86.1.91
   Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Li HL, 2017, EXPERT OPIN INV DRUG, V26, P1103, DOI 10.1080/13543784.2017.1369042
   Muller PL, 2015, INVEST OPHTH VIS SCI, V56, P8179, DOI 10.1167/iovs.15-17629
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Zhang K, 1999, GENOMICS, V60, P234, DOI 10.1006/geno.1999.5896
NR 20
TC 13
Z9 13
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9163
EI 1399-0004
J9 CLIN GENET
JI Clin. Genet.
PD DEC
PY 2018
VL 94
IS 6
BP 569
EP 574
DI 10.1111/cge.13447
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA HA1ZN
UT WOS:000450028600010
PM 30215852
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Tan, ACS
   Pilgrim, MG
   Fearn, S
   Bertazzo, S
   Tsolaki, E
   Morrell, AP
   Li, ML
   Messinger, JD
   Dolz-Marco, R
   Lei, JQ
   Nittala, MG
   Sadda, SR
   Lengyel, I
   Freund, KB
   Curcio, CA
AF Tan, Anna C. S.
   Pilgrim, Matthew G.
   Fearn, Sarah
   Bertazzo, Sergio
   Tsolaki, Elena
   Morrell, Alexander P.
   Li, Miaoling
   Messinger, Jeffrey D.
   Dolz-Marco, Rosa
   Lei, Jianqin
   Nittala, Muneeswar G.
   Sadda, Srinivas R.
   Lengyel, Imre
   Freund, K. Bailey
   Curcio, Christine A.
TI Calcified nodules in retinal drusen are associated with disease
   progression in age-related macular degeneration
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT-EPITHELIUM DETACHMENT; GEOGRAPHIC
   ATROPHY; MAGNESIUM WHITLOCKITE; CLINICOPATHOLOGICAL CORRELATION;
   HYDROXYAPATITE FORMATION; VASCULAR CALCIFICATION; ELECTRON-MICROSCOPY;
   REFRACTILE DRUSEN; CALCIUM-PHOSPHATE
AB Drusen are lipid-, mineral-, and protein-containing extracellular deposits that accumulate between the basal lamina of the retinal pigment epithelium (RPE) and Bruch's membrane (BrM) of the human eye. They are a defining feature of age-related macular degeneration (AMD), a common sight-threatening disease of older adults. The appearance of heterogeneous internal reflectivity within drusen (HIRD) on optical coherence tomography (OCT) images has been suggested to indicate an increased risk of progression to advanced AMD. Here, in a cohort of patients with AMD and drusen, we show that HIRD indicated an increased risk of developing advanced AMD within 1 year. Using multimodal imaging in an independent cohort, we demonstrate that progression to AMD was associated with increasing degeneration of the RPE overlying HIRD. Morphological analysis of clinically imaged cadaveric human eye samples revealed that HIRD was formed by multilobular nodules. Nanoanalytical methods showed that nodules were composed of hydroxyapatite and that they differed from spherules and BrM plaques, other refractile features also found in the retinas of patients with AMD. These findings suggest that hydroxyapatite nodules may be indicators of progression to advanced AMD and that using multimodal clinical imaging to determine the composition of macular calcifications may help to direct therapeutic strategies and outcome measures in AMD.
C1 [Tan, Anna C. S.; Dolz-Marco, Rosa; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Tan, Anna C. S.; Dolz-Marco, Rosa; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10075 USA.
   [Tan, Anna C. S.] Singapore Eye Res Inst Singapore, Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Tan, Anna C. S.] Duke NUS Singapore, Singapore 168751, Singapore.
   [Pilgrim, Matthew G.; Lengyel, Imre] UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
   [Pilgrim, Matthew G.] UCL, UCL Eastman Dent Inst, Div Biomat & Tissue Engn, London WC1X 8LD, England.
   [Fearn, Sarah] Imperial Coll London, Dept Mat, London SW7 2AZ, England.
   [Bertazzo, Sergio; Tsolaki, Elena] UCL, Dept Med Phys & Biomed Engn, Malet Pl Engn Bldg, London WC1E 6BT, England.
   [Morrell, Alexander P.] Aston Univ, Mat Phys, Aston Express Way, Birmingham B4 7ET, W Midlands, England.
   [Li, Miaoling; Messinger, Jeffrey D.; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 32594 USA.
   [Lei, Jianqin; Nittala, Muneeswar G.; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Lengyel, Imre] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Expt Med, Belfast BT9 7BL, Antrim, North Ireland.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Langone Sch Med, New York, NY 10016 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Singapore National Eye Center; University of London;
   University College London; University of London; University College
   London; Imperial College London; University of London; University
   College London; Aston University; University of Alabama System;
   University of Alabama Birmingham; Doheny Eye Institute; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; Queens University Belfast; New York University; NYU Langone
   Medical Center
RP Lengyel, I (通讯作者)，UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.; Lengyel, I (通讯作者)，Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Expt Med, Belfast BT9 7BL, Antrim, North Ireland.
EM i.lengyel@qub.ac.uk
RI Lengyel, Imre/B-5217-2009; Nittala, Muneeswar/AAT-7533-2020; Bertazzo,
   Sergio/J-7357-2016; Fearn, Sarah/N-7748-2017; Freund, K.
   Bailey/V-7488-2018
OI Lengyel, Imre/0000-0001-7467-2174; Bertazzo, Sergio/0000-0003-4889-8190;
   Fearn, Sarah/0000-0002-9798-8398; Freund, K. Bailey/0000-0002-7888-9773;
   Pilgrim, Matthew/0000-0001-8144-5631; Tsolaki, Elena/0000-0003-1436-7834
FU Bill Brown Charitable Trust Senior Research Fellowship; Moorfields Eye
   Hospital Special Trustees; European Union [634479]; National Institute
   for Health Research; National Institutes of Health [R01EY06019,
   P30EY003039]; EyeSight Foundation of Alabama; International Retinal
   Research Foundation; Edward N. and Della L. Thome Foundation; Arnold and
   Mabel Beckman Initiative for Macular Research; Research to Prevent
   Blindness Inc. (New York, NY); Engineering and Physical Sciences
   Research Council, UK [EP/H006060/1]; Natural Environment Research
   Council, UK [NE/J013382/1]; NATIONAL EYE INSTITUTE [P30EY003039] Funding
   Source: NIH RePORTER
FX The research was supported by the Bill Brown Charitable Trust Senior
   Research Fellowship, Moorfields Eye Hospital Special Trustees, and the
   European Union's Horizon 2020 research and innovation program under
   grant agreement no. 634479 for the "Eye-Risk" project (to I.L.). The
   tissue repository was supported by funding from the National Institute
   for Health Research. The Project MACULA website and the recovery of
   human donor eyes for research were supported by the National Institutes
   of Health (grant nos. R01EY06019 and P30EY003039), the EyeSight
   Foundation of Alabama, the International Retinal Research Foundation,
   the Edward N. and Della L. Thome Foundation, the Arnold and Mabel
   Beckman Initiative for Macular Research, and Research to Prevent
   Blindness Inc. (New York, NY). Diamond Light Source (Harwell Science and
   Innovation Campus, Didcot, Oxfordshire OX11 0DE, UK) provided access to
   Beamline I18. The TOF-SIMS analysis was supported by the Engineering and
   Physical Sciences Research Council, UK (grant EP/H006060/1) and by the
   Natural Environment Research Council, UK (grant NE/J013382/1).
CR Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Bertazzo S, 2013, NAT MATER, V12, P576, DOI [10.1038/NMAT3627, 10.1038/nmat3627]
   Bonnet C, 2014, RETINA-J RET VIT DIS, V34, P1524, DOI 10.1097/IAE.0000000000000165
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chan CY, 2014, AM J OPHTHALMOL, V158, P644, DOI 10.1016/j.ajo.2014.05.031
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cullity B.D., 2001, ELEMENTS XRAY DIFFRA, Vthird
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA., 2018, INVEST OPHTH VIS SCI, V59
   Curcio C, 2017, INVEST OPHTH VIS SCI, V58
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   DAVIS WL, 1981, J HISTOCHEM CYTOCHEM, V29, P601, DOI 10.1177/29.5.7252127
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Fischer DC, 2012, CALCIFIED TISSUE INT, V90, P465, DOI 10.1007/s00223-012-9594-5
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Fratzl P, 2007, PROG MATER SCI, V52, P1263, DOI 10.1016/j.pmatsci.2007.06.001
   Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665
   Garrity S. T., 2018, INVEST OPHTH VIS SCI, V59
   GASS JDM, 1967, AM J OPHTHALMOL, V64, P612
   Gomez NM, 2018, FASEB J, V32, P782, DOI 10.1096/fj.201700220RR
   Gong HQ, 2001, EXP EYE RES, V72, P23, DOI 10.1006/exer.2000.0928
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Heiferman MJ, 2016, RETINA-J RET VIT DIS, V36, pS137, DOI 10.1097/IAE.0000000000001254
   Hirata I, 2010, DENT MATER J, V29, P438, DOI 10.4012/dmj.2010-017
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   Hogan M. J., 1971, HISTOLOGY HUMAN EYE, P328
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Jahnen-Dechent W, 2012, CLIN KIDNEY J, V5, P3, DOI 10.1093/ndtplus/sfr163
   Jahnen-Dechent W, 2011, CIRC RES, V108, P1494, DOI 10.1161/CIRCRESAHA.110.234260
   JENSEN OA, 1977, A GRAEF ARCH KLIN EX, V203, P311, DOI 10.1007/BF00409836
   Kakigi CLM, 2015, JAMA OPHTHALMOL, V133, P746, DOI 10.1001/jamaophthalmol.2015.0514
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   KANI T, 1983, J DENT RES, V62, P92, DOI 10.1177/00220345830620021901
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Lagier R, 2003, PATHOL RES PRACT, V199, P329, DOI 10.1078/0344-0338-00425
   Lau WL, 2010, THROMB HAEMOSTASIS, V104, P464, DOI 10.1160/TH09-12-0814
   Lederer E, 2014, J PHYSIOL-LONDON, V592, P3985, DOI 10.1113/jphysiol.2014.273979
   LEHNINGER A L, 1970, Biochemical Journal, V119, P129
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Li M., 2018, OPHTHALMOL RETINA
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   LINDE A, 1989, CALCIFIED TISSUE INT, V44, P286, DOI 10.1007/BF02553763
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Malmberg P, 2008, PROTEOMICS, V8, P3755, DOI 10.1002/pmic.200800198
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   NANCOLLAS GH, 1989, ANAT RECORD, V224, P234, DOI 10.1002/ar.1092240213
   Nordgaard C. L., INVEST OPHTHALMOL VI, V49, P2848
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Ouyang YL, 2013, INVEST OPHTH VIS SCI, V54, P1144, DOI 10.1167/iovs.12-9903
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Pattnaik BR, 2009, AM J PHYSIOL-CELL PH, V297, pC1001, DOI 10.1152/ajpcell.00250.2009
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Pichi F, 2016, RETINA-J RET VIT DIS, V36, P1199, DOI 10.1097/IAE.0000000000000829
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   RAGGIO CL, 1986, J BONE MINER RES, V1, P409
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sato T, 2013, AM J OPHTHALMOL, V156, P275, DOI 10.1016/j.ajo.2013.03.039
   SCOTCHFORD CA, 1995, ANN RHEUM DIS, V54, P339, DOI 10.1136/ard.54.5.339
   Scotchford CA, 1997, OSTEOARTHR CARTILAGE, V5, P107, DOI 10.1016/S1063-4584(97)80004-0
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Tas AC, 2000, BIOMATERIALS, V21, P1429
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   ULSHAFER RJ, 1987, INVEST OPHTH VIS SCI, V28, P683
   VANDERSCHAFT TL, 1992, ARCH OPHTHALMOL-CHIC, V110, P389, DOI 10.1001/archopht.1992.01080150087034
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Verberckmoes SC, 2007, KIDNEY INT, V71, P298, DOI 10.1038/sj.ki.5002028
   Villa-Bellosta R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178872
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang XM, 2013, EXP EYE RES, V116, P424, DOI 10.1016/j.exer.2013.10.013
NR 91
TC 61
Z9 61
U1 2
U2 17
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD NOV 7
PY 2018
VL 10
IS 466
AR eaat4544
DI 10.1126/scitranslmed.aat4544
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GZ5MZ
UT WOS:000449468600001
PM 30404862
OA Green Published, Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Teixeira, AG
   Silva, AS
   Lin, FLH
   Velletri, R
   Bavia, L
   Belfort, R
   Isaac, L
AF Teixeira, Anderson G.
   Silva, Aldacilene S.
   Lin, Fabio L. H.
   Velletri, Roberta
   Bavia, Lorena
   Belfort, Rubens, Jr.
   Isaac, Lourdes
TI Association of complement factor H Y402H polymorphism and age-related
   macular degeneration in Brazilian patients
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; complement Factor H gene; complement
   system; Polymorphism
ID C-REACTIVE PROTEIN; FAMILIAL AGGREGATION; SUSCEPTIBILITY LOCI; VISUAL
   IMPAIRMENT; DRUSEN FORMATION; PLASMA-LEVELS; POPULATION; MACULOPATHY;
   DISEASE; RISK
AB Purpose:
   The aim of this study was investigate the association between complement Factor H polymorphism (Y402H) and age-related macular degeneration (AMD) in Brazilian patients.
   Methods:
   Patients with AMD aged 50 or more and age-matched healthy controls were enrolled in the study. Genomic DNA was isolated from leucocytes of patients and controls; the Y402H polymorphism of complement Factor H gene (CFH) was determined by polymerase chain reaction directed sequencing.
   Results:
   The frequency of 1277C allele of Factor H was 56.30% in patients with AMD compared with 36.51% in controls (p-value = 0.001). The genotypic distribution differed significantly between the two groups (1277CC 36.98%, 1277CT 38.65% and 1277TT 24.37% for AMD group; 1277CC 13.16%, 1277CT 46.71% and 1277TT 40.13% for controls, p-value = 0.001). The odds ratio for patients with AMD carrying only one 1277C allele was 1.36 and for those carrying two 1277C alleles was 4.63, when compared to the control group.
   Conclusions:
   These results suggest the Y402H polymorphism of CFH is a risk factor to the development of AMD in Brazilian patients. This is in accordance with findings from the majority of previous study population in Europe and North American.
C1 [Silva, Aldacilene S.; Lin, Fabio L. H.; Bavia, Lorena; Isaac, Lourdes] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508900 Sao Paulo, Brazil.
   [Teixeira, Anderson G.; Velletri, Roberta; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Dept Ophthalmol, BR-04023062 Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP)
RP Isaac, L (通讯作者)，Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, Av Prof Lineu Prestes 1730, BR-05508900 Sao Paulo, Brazil.
EM prof.rubens@clinicabelfort.com.br; louisaac@icb.usp.br
RI Isaac, Lourdes/I-7186-2012; Teixeira, Anderson/K-2320-2013; Belfort,
   Rubens/E-2252-2012; Bavia, Lorena/H-3750-2014
OI Belfort, Rubens/0000-0002-8422-3898; Isaac, Lourdes/0000-0002-7746-8942;
   Bavia, Lorena/0000-0003-1702-2284; Teixeira,
   Anderson/0000-0001-7585-712X
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2006/50990-3, 06/53296-0]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) [470069/2007-4]
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP - 2006/50990-3) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq - 470069/2007-4). A. S.
   Silva is in receipt of a fellowship from FAPESP (06/53296-0).
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chowers I, 2008, MOL VIS, V14, P1829
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Esparza-Gordillo J, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.010611
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   GASS J, 1997, STERIOSCOPUC ATLAS M, P321
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Greenfield JR, 2004, CIRCULATION, V109, P3022, DOI 10.1161/01.CIR.0000130640.77501.79
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   KAZATCHKINE MD, 1981, J CLIN INVEST, V67, P223, DOI 10.1172/JCI110017
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Santangelo Susan L, 2005, Ophthalmic Genet, V26, P61, DOI 10.1080/13816810490967944
   Santos Laura Patrícia Ferreira, 2005, Arq. Bras. Oftalmol., V68, P229, DOI 10.1590/S0004-27492005000200014
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1029, DOI 10.1007/s00347-005-1270-y
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Suarez-Kurtz G, 2007, PHARMACOGENOMICS, V8, P1299, DOI 10.2217/14622416.8.10.1299
   Suarez-Kurtz G, 2007, PHARMACOGENET GENOM, V17, P765, DOI 10.1097/FPC.0b013e3281c10e52
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Wener MH, 2000, J RHEUMATOL, V27, P2351
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 51
TC 12
Z9 12
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2010
VL 88
IS 5
BP E165
EP E169
DI 10.1111/j.1755-3768.2010.01932.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 625MA
UT WOS:000279898200003
PM 20626361
OA Bronze
DA 2022-11-30
ER

PT J
AU Selim, A
   Kocak, N
   Aslankara, H
   Kaynak, S
AF Selim, Ahmet
   Kocak, Nilufer
   Aslankara, Huseyin
   Kaynak, Suleyman
TI Comparative study of photodynamic therapy monotherapy versus triple
   management in age-related macular degeneration
SO TURKISH JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Age-related macular degeneration; bevacizumab; choroidal
   neovascularization; pegaptanib sodium; photodynamic therapy
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; VERTEPORFIN PLUS RANIBIZUMAB;
   CHOROIDAL NEOVASCULARIZATION; COMBINATION THERAPY; INJECTION; VEGF
AB Aim: To compare the effectiveness of photodynamic therapy (PDT) and PDT combined with intravitreal triamcinolone (IVTA) and vascular endothelial growth factor inhibition (anti-VEGF) in age-related macular degeneration (AMD).
   Materials and methods: Eighty eyes of 80 patients diagnosed with choroidal neovascularization (CNV) caused by AMD were included in the study. PDT was carried out on 40 eyes in group I, and PDT combined with 4 mg IVTA and anti-VEGF (1.25 mg bevacizumab in 20 eyes, 0.3 mg pegaptanib sodium in 20 eyes) was carried out in group II. The primary efficacy endpoint was the mean change from baseline visual acuity at month 12.
   Results: Mean follow-up was 14.2 +/- 2.18 months in group I and 12.45 +/- 2.82 months in group II. In group I there was a 2.88 logMAR line decrease and 1.95 logMAR line increase in group II in vision between pretreatment and 12th month measurements (P < 0.05). Mean PDT session was 2.00 in group I and the mean combined treatment session was 1.15 in group II in the 12th month.
   Conclusion: Combination of IVTA and anti-VEGF with PDT is more effective and safer than PDT monotherapy in the treatment of CNV secondary to AMD. Combination treatment decreases the frequency and number of treatment sessions for an improved visual prognosis.
C1 [Selim, Ahmet; Kocak, Nilufer; Aslankara, Huseyin; Kaynak, Suleyman] Dokuz Eylul Univ, Fac Med, Dept Ophthalmol, Izmir, Turkey.
C3 Dokuz Eylul University
RP Aslankara, H (通讯作者)，Dokuz Eylul Univ, Fac Med, Dept Ophthalmol, Izmir, Turkey.
EM aslankara@yahoo.com
CR Ahmadieh Hamid, 2007, BMC Ophthalmol, V7, P10, DOI 10.1186/1471-2415-7-10
   [Anonymous], 1986, Arch Ophthalmol, V104, P694
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2006, BUSINESS BRIEFING EU, P30
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Toklu Y, 2012, TURK J MED SCI, V42, P681, DOI 10.3906/sag-1101-1470
NR 26
TC 4
Z9 4
U1 0
U2 2
PU TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY
SN 1300-0144
EI 1303-6165
J9 TURK J MED SCI
JI Turk. J. Med. Sci.
PY 2014
VL 44
IS 5
BP 889
EP 895
DI 10.3906/sag-1104-54
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AQ8II
UT WOS:000343068800029
PM 25539563
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Baskol, G
   Karakucuk, S
   Oner, AO
   Baskol, M
   Kocer, D
   Mirza, E
   Saraymen, R
   Ustdal, M
AF Baskol, G
   Karakucuk, S
   Oner, AO
   Baskol, M
   Kocer, D
   Mirza, E
   Saraymen, R
   Ustdal, M
TI Serum paraoxonase 1 activity and lipid peroxidation levels in patients
   with age-related macular degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; paraoxonase 1; malondialdehyde
ID PIGMENT EPITHELIAL-CELLS; MITOCHONDRIAL-DNA DAMAGE;
   LOW-DENSITY-LIPOPROTEIN; ROD OUTER SEGMENTS; POSSIBLE MECHANISM;
   HUMAN-DISEASE; NITRIC-OXIDE; RISK-FACTORS; ANTIOXIDANTS; MALONDIALDEHYDE
AB Our objective was to investigate antioxidant paraoxonase 1 (PON1) activity together with malondialdehyde (MDA) levels to evaluate oxidative stress in patients with age-related macular degeneration (AMD), an important cause of blindness in the elderly population. Serum PON1 activity and MDA levels were analyzed in 37 patients with AMD and compared with 29 healthy controls using a spectrophotometric method. Serum MDA levels were significantly higher in the patient group (2.76 +/- 1.28 nmol/ml) than controls (1.00 +/- 0.36 nmol/ml; p < 0.001), whereas PON1 activity was lower in the patient group (132.27 +/- 63.39 U/I) than controls (312.13 +/- 136.23 U/I; p < 0.001). There was a negative correlation between MDA and PON1 levels (r = - 0.470, p < 0.001). We conclude that the observed increase in MDA levels may be related to decreased PON1 activity; the present data also demonstrated that an obvious negative correlation between PON1 activity and MDA levels exists in patients with AMD. PON1 is also an antioxidant agent, therefore effective antioxidant therapy to inhibit lipid peroxidation is necessary and agents to increase PON1 activity may be a therapeutic option in AMD. Copyright (c) 2006 S. Karger AG, Basel.
C1 Erciyes Univ, Fac Med, Dept Biochem & Clin Biochem, Kayseri, Turkey.
   Erciyes Univ, Fac Med, Dept Ophthalmol, Kayseri, Turkey.
   Erciyes Univ, Fac Med, Dept Internal Med, Kayseri, Turkey.
C3 Erciyes University; Erciyes University; Erciyes University
RP Baskol, G (通讯作者)，Erciyes Univ, Fac Med, Dept Biochem & Clin Biochem, Kayseri, Turkey.
EM gbaskol@yahoo.com
RI Kocer, Derya/AAQ-4011-2021; Başkol, Gülden/Y-5561-2018
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Aviram M, 1999, FREE RADICAL BIO MED, V26, P892, DOI 10.1016/S0891-5849(98)00272-X
   Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHRISTEN WG, 1994, AM J MED, V97, pS14, DOI 10.1016/0002-9343(94)90293-3
   Coudray C, 1997, BIOL TRACE ELEM RES, V57, P183, DOI 10.1007/BF02778201
   DELAPAZ MA, 1992, INVEST OPHTH VIS SCI, V33, P2091
   DRAPER HH, 1990, XENOBIOTICA, V20, P901, DOI 10.3109/00498259009046905
   ECKERSON HW, 1983, AM J HUM GENET, V35, P214
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   GERSTER H, 1991, AGE AGEING, V20, P60, DOI 10.1093/ageing/20.1.60
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X
   Harman D, 1998, ANN NY ACAD SCI, V854, P1, DOI 10.1111/j.1749-6632.1998.tb09886.x
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Ikeda Tsunehiko, 2003, Nippon Ganka Gakkai Zasshi, V107, P785
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   JAIN SK, 1988, BIOCHIM BIOPHYS ACTA, V937, P205, DOI 10.1016/0005-2736(88)90242-8
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   LADU BN, 1993, CHEM-BIOL INTERACT, V87, P25, DOI 10.1016/0009-2797(93)90022-Q
   LaDu BN, 1996, NAT MED, V2, P1186, DOI 10.1038/nm1196-1186
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Mackness MI, 1996, CURR OPIN LIPIDOL, V7, P69, DOI 10.1097/00041433-199604000-00004
   Nayak D U, 2001, Heart Dis, V3, P28
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   PRASHAR S, 1993, ACTA OPHTHALMOL, V71, P214
   Romero FJ, 1998, ENVIRON HEALTH PERSP, V106, P1229, DOI 10.2307/3433990
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Taylor H R, 1989, Trans Am Ophthalmol Soc, V87, P802
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   VINDERLING JR, 1995, AM J EPIDEMIOL, V142, P404
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Winkler B S, 1999, Mol Vis, V5, P32
   Yildirim O, 2004, OPHTHALMOLOGICA, V218, P202, DOI 10.1159/000076845
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 47
TC 49
Z9 50
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2006
VL 220
IS 1
BP 12
EP 16
DI 10.1159/000089269
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 996JN
UT WOS:000234170300003
PM 16374043
DA 2022-11-30
ER

PT J
AU Ethen, CM
   Feng, X
   Olsen, TW
   Ferrington, DA
AF Ethen, CM
   Feng, X
   Olsen, TW
   Ferrington, DA
TI Declines in arrestin and rhodopsin in the macula with progression of
   age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID GRADING SYSTEM; PREVALENCE; RETINA; CONES; RODS; VULNERABILITY;
   MACULOPATHY; TRANSDUCIN; CELLS; EYES
AB PURPOSE. Biochemical analysis of age-related macular degeneration (AMD) at distinct stages of the disease will help further understanding of the molecular events associated with disease progression. This study was conducted to determine the ability of a new grading system for eye bank eyes, the Minnesota Grading System (MGS), to discern distinct stages of AMD so that retinal region-specific changes in rod photoreceptor protein expression from donors could be determined.
   METHODS. Donor eyes were assigned to a specific level of AMD by using the MGS. Expression of the rod photoreceptor proteins rhodopsin and arrestin was evaluated by Western immunoblot analysis in the macular and peripheral regions of the neurosensory retina from donors at different stages of AMD.
   RESULTS. A significant linear decline in both arrestin and rhodopsin content correlated with progressive MGS levels in the macula. In contrast, the peripheral region showed no significant correlation between MGS level and the content of either protein.
   CONCLUSIONS. The statistically significant relationship between decreasing macular rod photoreceptor proteins and progressive MGS levels of AMD demonstrates the utility of the clinically based MGS to correspond with specific protein changes found at known, progressive stages of degeneration. Future biochemical analysis of clinically characterized donor eyes will further understanding of the pathobiochemistry of AMD.
C1 Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.
   Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Ferrington, DA (通讯作者)，Univ Minnesota, Dept Ophthalmol, 380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU NEI NIH HHS [EY014176, T32 EY07133-12] Funding Source: Medline; NIA NIH
   HHS [R01 AG025392, AG025392] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R03EY014176, T32EY007133] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [R01AG025392] Funding Source: NIH RePORTER
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BARNSTABLE CJ, 1980, NATURE, V286, P231, DOI 10.1038/286231a0
   BROEKHUYSE RM, 1989, JPN J OPHTHALMOL, V33, P243
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1987, SCIENCE, V236, P579, DOI 10.1126/science.3576186
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fulton AB, 1999, INVEST OPHTH VIS SCI, V40, P1878
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LIEM ATA, 1991, INVEST OPHTH VIS SCI, V32, P2676
   Malik KF, 2003, INVEST OPHTH VIS SCI, V44, P2730, DOI 10.1167/iovs.02-1120
   McGinnis JF, 2002, J NEUROSCI RES, V67, P290, DOI 10.1002/jnr.10120
   MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50
   NORK TM, 1993, INVEST OPHTH VIS SCI, V34, P2918
   NORK TM, 1990, INVEST OPHTH VIS SCI, V31, P1451
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PandaJonas S, 1995, OPHTHALMOLOGY, V102, P1853, DOI 10.1016/S0161-6420(95)30784-1
   PLANTNER JJ, 1988, CURR EYE RES, V7, P1125, DOI 10.3109/02713688809001883
   Sakuma H, 1996, FEBS LETT, V382, P105, DOI 10.1016/0014-5793(96)00163-9
   SCHMIDT SY, 1980, INVEST OPHTH VIS SCI, V19, P1274
   SCHMIDT SY, 1990, INVEST OPHTH VIS SCI, V31, P1023
   Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0
   VANKUIJK FJGM, 1991, INVEST OPHTH VIS SCI, V32, P1962
   Zhang HB, 2003, MOL VIS, V9, P231
NR 38
TC 18
Z9 18
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2005
VL 46
IS 3
BP 769
EP 775
DI 10.1167/iovs.04-0810
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 900LR
UT WOS:000227216900001
PM 15728529
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Sobczuk, P
   Pawlowska, E
   Kaarniranta, K
AF Blasiak, Janusz
   Sobczuk, Piotr
   Pawlowska, Elzbieta
   Kaarniranta, Kai
TI Interplay between aging and other factors of the pathogenesis of
   age-related macular degeneration
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE Age-related macular degeneration; Chronological aging; Biological aging;
   Neural retina; Microglia; Retinal pigment epithelium; Circadian rhythm;
   Metabolic aging; Cellular senescence
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR;
   AMYLOID-BETA-PEPTIDE; RPE CELL SENESCENCE; OXIDATIVE STRESS; BRUCHS
   MEMBRANE; DNA-DAMAGE; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; CHOROIDAL
   NEOVASCULARIZATION
AB Age-related macular degeneration (AMD) is a complex eye disease with the retina as the target tissue and aging as per definition the most serious risk factor. However, the retina contains over 60 kinds of cells that form different structures, including the neuroretina and retinal pigment epithelium (RPE) which can age at different rates. Other established or putative AMD risk factors can differentially affect the neuroretina and RPE and can differently interplay with aging of these structures. The occurrence of beta-amyloid plaques and increased levels of cholesterol in AMD retinas suggest that AMD may be a syndrome of accelerated brain aging. Therefore, the question about the real meaning of age in AMD is justified. In this review we present and update information on how aging may interplay with some aspects of AMD pathogenesis, such as oxidative stress, amyloid beta formation, circadian rhythm, metabolic aging and cellular senescence. Also, we show how this interplay can be specific for photoreceptors, microglia cells and RPE cells as well as in Bruch's membrane and the choroid. Therefore, the process of aging may differentially affect different retinal structures. As an accurate quantification of biological aging is important for risk stratification and early intervention for age-related diseases, the determination how photoreceptors, microglial and RPE cells age in AMD may be helpful for a precise diagnosis and treatment of this largely untreatable disease.
C1 [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Sobczuk, Piotr] Med Univ Lodz, Emergency Med & Disaster Med Dept, Pomorska 251, PL-92209 Lodz, Poland.
   [Sobczuk, Piotr] Polish Mothers Mem Hosp, Res Inst, Dept Orthopaed & Traumatol, Rzgowska 281, PL-93338 Lodz, Poland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Pediat Dent, Pomorska 251, PL-92216 Lodz, Poland.
   [Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, POB 100, FI-70029 Kys, Finland.
C3 University of Lodz; Medical University Lodz; Polish Mother's Memorial
   Hospital - Research Institute; Medical University Lodz; University of
   Eastern Finland; Kuopio University Hospital
RP Blasiak, J (通讯作者)，Univ Lodz, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
EM janusz.blasiak@biol.uni.lodz.pl
FU National Science Centre, Poland;  [2017/27/B/NZ3/00872]
FX Acknowledgements This work was supported by National Science Centre,
   Poland grant number 2017/27/B/NZ3/00872. The authors thank Monika
   Kicinska for her help in figure preparation.
CR Aarsland D, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00292-z
   Aarsland D, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00280-3
   Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Abrahan CE, 2009, J NEUROSCI RES, V87, P964, DOI 10.1002/jnr.21903
   Akiguchi I, 2017, NEUROPATHOLOGY, V37, P293, DOI 10.1111/neup.12373
   Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Alvarez-Barrios A, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010089
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Ashok A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197290
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Baba K, 2018, J BIOL RHYTHM, V33, P441, DOI 10.1177/0748730418783648
   Baba K, 2018, ADV EXP MED BIOL, V1074, P345, DOI 10.1007/978-3-319-75402-4_42
   Baba K, 2010, MOL VIS, V16, P2605
   Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Barzilai N, 2012, DIABETES, V61, P1315, DOI 10.2337/db11-1300
   Basta G, 2005, ARTERIOSCL THROM VAS, V25, P1401, DOI 10.1161/01.ATV.0000167522.48370.5e
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Berson DM, 2007, PFLUG ARCH EUR J PHY, V454, P849, DOI 10.1007/s00424-007-0242-2
   Berson DM, 2003, TRENDS NEUROSCI, V26, P314, DOI 10.1016/S0166-2236(03)00130-9
   Bery A, 2022, DEV BIOL, V484, P40, DOI 10.1016/j.ydbio.2022.02.001
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bjork V, 2021, REJUV RES, V24, P274, DOI 10.1089/rej.2020.2388
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P919, DOI 10.1001/jamaophthalmol.2021.2132
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Carreno G, 2021, NEUROPATH APPL NEURO, V47, P359, DOI 10.1111/nan.12689
   CARRILLO MC, 1992, MECH AGEING DEV, V65, P187, DOI 10.1016/0047-6374(92)90035-C
   Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156
   Cerf E, 2011, FASEB J, V25, P1585, DOI 10.1096/fj.10-175976
   Chen GF, 2017, ACTA PHARMACOL SIN, V38, P1205, DOI 10.1038/aps.2017.28
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen PYJ, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-02196-8
   Chen SD, 2014, EXPERT REV OPHTHALMO, V9, P285, DOI 10.1586/17469899.2014.939171
   Cheng KC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031338
   Cheng MY, 2021, EUR J CELL BIOL, V100, DOI 10.1016/j.ejcb.2020.151144
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chi-Castaneda D, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00088
   Chi-Castaneda D, 2016, ASN NEURO, V8, DOI 10.1177/1759091416670766
   Chung SD, 2014, AM J OPHTHALMOL, V157, P464, DOI 10.1016/j.ajo.2013.09.026
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   COMFORT A, 1969, LANCET, V2, P1411
   Corbelli E, 2022, GRAEF ARCH CLIN EXP, V260, P1525, DOI 10.1007/s00417-021-05337-3
   Courtie E, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00768-3
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crouch J, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11040672
   Cunea A, 2007, VISUAL NEUROSCI, V24, P151, DOI 10.1017/S0952523807070204
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
   Davari MH, 2013, J RES HEALTH SCI, V13, P98
   Deng YH, 2022, GENES DIS, V9, P62, DOI 10.1016/j.gendis.2021.02.009
   Dentchev T, 2003, MOL VIS, V9, P184
   Dewing JM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010039
   DOLMAN CL, 1980, ARCH OPHTHALMOL-CHIC, V98, P2053
   Dutt Kamla, 2010, J Ocul Biol Dis Infor, V3, P144, DOI 10.1007/s12177-011-9076-4
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Eliasieh K, 2007, INVEST OPHTH VIS SCI, V48, P2824, DOI 10.1167/iovs.06-1228
   Etminan M, 2018, J CURR OPHTHALMOL, V30, P365, DOI 10.1016/j.joco.2018.08.004
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fang CC, 2020, PARKINSONS DIS-US, V2020, DOI 10.1155/2020/2076942
   Fang Y, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.738686
   Farajnia S, 2012, J NEUROSCI, V32, P5891, DOI 10.1523/JNEUROSCI.0469-12.2012
   Feng L, 2016, DISCOV MED, V21, P149
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Ferrington DA, 2021, ADV EXP MED BIOL, V1256, P237, DOI 10.1007/978-3-030-66014-7_10
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fjell AM, 2014, CEREB CORTEX, V24, P919, DOI 10.1093/cercor/bhs379
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Fu YB, 2007, PFLUG ARCH EUR J PHY, V454, P805, DOI 10.1007/s00424-006-0194-y
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   George AK, 2018, INT J OPHTHALMOL-CHI, V11, P881, DOI 10.18240/ijo.2018.05.26
   Gokhale KM, 2022, BRIT J OPHTHALMOL, DOI 10.1136/bjophthalmol-2021-319641
   Goldman JG, 2018, NPJ PARKINSON DIS, V4, DOI 10.1038/s41531-018-0055-3
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grajauskas LA, 2019, AGEING RES REV, V49, P67, DOI 10.1016/j.arr.2018.11.004
   Gredilla R, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/282438
   Gu XR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038673
   Guo L, 2022, FRONT CELL NEUROSCI, V16, DOI 10.3389/fncel.2022.804782
   Guzman-Martinez L, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01008
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Herzog ED, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a027706
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Hou XW, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.13
   Hu ML, 2021, LIFE-BASEL, V11, DOI 10.3390/life11070635
   Hu WY, 2022, AGE AGEING, V51, DOI 10.1093/ageing/afac062
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Husain MA, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.630502
   Hyttinen J, 2021, EXPERT OPIN THER TAR, V25, P773, DOI 10.1080/14728222.2021.1991913
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Ida H, 2004, INVEST OPHTH VIS SCI, V45, P2348, DOI 10.1167/iovs.03-1337
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   JAUREGUILOZANO J, 2022, PLOS GENETICS, V0018
   Jeyapalan JC, 2008, MECH AGEING DEV, V129, P467, DOI 10.1016/j.mad.2008.04.001
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jorge L, 2020, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00360
   Josephs KA, 2020, BRAIN, V143, P3463, DOI 10.1093/brain/awaa299
   Kaarniranta K, 2022, AUTOPHAGY, DOI 10.1080/15548627.2022.2069437
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kananen F, 2021, ACTA OPHTHALMOL, V99, pE1063, DOI 10.1111/aos.14774
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keeling E, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7020016
   Khodadadi M, 2022, PHARMACOL REP, V74, P310, DOI 10.1007/s43440-021-00334-z
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klemera P, 2006, MECH AGEING DEV, V127, P240, DOI 10.1016/j.mad.2005.10.004
   Klionsky DJ, 2020, CELL DEATH DIFFER, V27, P831, DOI 10.1038/s41418-020-0511-6
   Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207
   Kobayashi S, 2007, BIOL PHARM BULL, V30, P133, DOI 10.1248/bpb.30.133
   Kozhevnikova OS, 2018, BIOGERONTOLOGY, V19, P223, DOI 10.1007/s10522-018-9751-y
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kroll J, 2000, BIOGERONTOLOGY, V1, P363, DOI 10.1023/A:1026594602252
   Kumari R, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.645593
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Kwon W, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.604205
   Lashkari K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195751
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Liets LC, 2006, P NATL ACAD SCI USA, V103, P12156, DOI 10.1073/pnas.0605211103
   Liguori I, 2018, CLIN INTERV AGING, V13, P757, DOI 10.2147/CIA.S158513
   Lindekleiv H, 2013, EYE, V27, P1281, DOI 10.1038/eye.2013.181
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu ZZ, 2014, ADV EXP MED BIOL, V801, P237, DOI 10.1007/978-1-4614-3209-8_31
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Ma WW, 2015, NEUROCHEM RES, V40, P758, DOI 10.1007/s11064-015-1524-2
   Mallik S, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.856853
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marchesi N, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092394
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Masuda T, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20539
   McCauley JP, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108255
   McKee CA, 2020, CELL MOL LIFE SCI, V77, P1049, DOI 10.1007/s00018-019-03314-y
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McMahon DG, 2014, PROG RETIN EYE RES, V39, P58, DOI 10.1016/j.preteyeres.2013.12.001
   Meri S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611830
   Milicevic N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48203-3
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Miller JW, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.9
   Miller JW, 2014, SURV OPHTHALMOL, V59, P361, DOI 10.1016/j.survophthal.2013.07.003
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Miller-Thomas MM, 2016, RADIOGRAPHICS, V36, P1147, DOI 10.1148/rg.2016150172
   Mirzaei M, 2020, NEURAL REGEN RES, V15, P257, DOI 10.4103/1673-5374.265550
   Mitina M, 2020, AGING-US, V12, P18765, DOI 10.18632/aging.103880
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Moreno-Blas D, 2019, AGING-US, V11, P6175, DOI 10.18632/aging.102181
   Muraleva NA, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8060177
   Nakamura E, 2007, J GERONTOL A-BIOL, V62, P1096, DOI 10.1093/gerona/62.10.1096
   Nakamura TJ, 2011, J NEUROSCI, V31, P10201, DOI 10.1523/JNEUROSCI.0451-11.2011
   Nashine S, 2022, AGING-US, V14, P4247, DOI 10.18632/aging.204074
   Nashine S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051102
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nie C, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2022.110459
   Nivison-Smith L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67829-2
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   O'Leary F, 2021, FEBS J, DOI 10.1111/febs.16330
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5
   Paul G, 2022, FRONT AGING NEUROSCI, V14, DOI 10.3389/fnagi.2022.853372
   Petersen SV, 2003, BIOCHEM J, V374, P199, DOI 10.1042/BJ20030313
   Phan LT, 2021, CLIN OPHTHALMOL, V15, P3351, DOI 10.2147/OPTH.S205147
   QUIGLEY HA, 1989, AM J OPHTHALMOL, V107, P453, DOI 10.1016/0002-9394(89)90488-1
   Ramkisoensing A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00128
   Rashid K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01975
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Reichenbach A, 2020, GLIA, V68, P768, DOI 10.1002/glia.23727
   Ritschka B, 2017, GENE DEV, V31, P172, DOI 10.1101/gad.290635.116
   Roddy GW, 2021, CURR OPIN OPHTHALMOL, V32, P280, DOI 10.1097/ICU.0000000000000747
   Rodier F, 2011, J CELL SCI, V124, P68, DOI 10.1242/jcs.071340
   Roggia M., 2013, VITRO INVEST OPHTHAL, V54, P1175
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Ruan GX, 2006, P NATL ACAD SCI USA, V103, P9703, DOI 10.1073/pnas.0601940103
   Sacca SC, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060668
   Salvi SM, 2006, POSTGRAD MED J, V82, P581, DOI 10.1136/pgmj.2005.040857
   Samuel MA, 2014, NAT NEUROSCI, V17, P1190, DOI 10.1038/nn.3772
   Samuel MA, 2011, J NEUROSCI, V31, P16033, DOI 10.1523/JNEUROSCI.3580-11.2011
   Schnabolk G, 2019, ADV EXP MED BIOL, V1185, P27, DOI 10.1007/978-3-030-27378-1_5
   Schultz NM, 2021, CLIN THER, V43, P1792, DOI 10.1016/j.clinthera.2021.08.011
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Shilovsky GA, 2022, BIOCHEMISTRY-MOSCOW+, V87, P70, DOI 10.1134/S0006297922010060
   Sjogren M, 2005, WORLD J BIOL PSYCHIA, V6, P85, DOI 10.1080/15622970510029795
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Stefanova NA, 2014, CELL CYCLE, V13, P898, DOI 10.4161/cc.28255
   STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098
   Taylor-Walker G, 2016, EXP EYE RES, V153, P110, DOI 10.1016/j.exer.2016.10.013
   Telegina DV, 2017, SCI REP-UK, V7, DOI 10.1038/srep41533
   TERMAN JS, 1993, BRAIN RES, V605, P256
   Toops KA, 2016, ADV EXP MED BIOL, V854, P3, DOI 10.1007/978-3-319-17121-0_1
   Ueta T, 2012, ARTERIOSCL THROM VAS, V32, P1366, DOI 10.1161/ATVBAHA.112.248021
   Vavvas Demetrios, 2006, Ophthalmol Clin North Am, V19, P353
   Volonte YA, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00334
   von Zglinicki T, 2021, ANTIOXID REDOX SIGN, V34, P308, DOI 10.1089/ars.2020.8048
   Waheed Nadia K., 2004, International Ophthalmology Clinics, V44, P11, DOI 10.1097/00004397-200404430-00004
   Wang JQ, 2011, ANAT REC, V294, P1401, DOI 10.1002/ar.21438
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V424, P704, DOI 10.1016/j.bbrc.2012.07.014
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Wang L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052360
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wolosowicz M, 2022, MEDICINA-LITHUANIA, V58, DOI 10.3390/medicina58040472
   Wrigglesworth J, 2021, BMC NEUROL, V21, DOI 10.1186/s12883-021-02331-4
   Wu Y, 2019, CLIN INTERV AGING, V14, P1277, DOI 10.2147/CIA.S200637
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yang S, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.727870
   Yang Y, 2020, CELL DEATH DIFFER, V27, P858, DOI 10.1038/s41418-019-0480-9
   Yen K, 2020, AGING-US, V12, P11185, DOI 10.18632/aging.103534
   Yoo HJ, 2022, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.766267
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Yu B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16312-7
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhu SP, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.823354
   Zhu ZT, 2022, BRIT J OPHTHALMOL, DOI 10.1136/bjophthalmol-2021-319807
NR 247
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD NOV
PY 2022
VL 81
AR 101735
DI 10.1016/j.arr.2022.101735
PG 17
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 4Z7ZS
UT WOS:000862422300008
PM 36113764
OA hybrid
DA 2022-11-30
ER

PT J
AU Vingopoulos, F
   Wai, KM
   Katz, R
   Vavvas, DG
   Kim, LA
   Miller, JB
AF Vingopoulos, Filippos
   Wai, Karen M.
   Katz, Raviv
   Vavvas, Demetrios G.
   Kim, Leo A.
   Miller, John B.
TI Measuring the Contrast Sensitivity Function in Non-Neovascular and
   Neovascular Age-Related Macular Degeneration: The Quantitative Contrast
   Sensitivity Function Test
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE contrast sensitivity function; visual function metrics; qCSF;
   age-related macular degeneration; contrast sensitivity
ID INTRAVITREAL BEVACIZUMAB INJECTION; RETINAL VEIN OCCLUSION;
   VISUAL-ACUITY LOSS; LOW-LUMINANCE; CLINICAL-ASSESSMENT; RELIABILITY;
   ASSOCIATION; DISABILITY; VISTECH; DISEASE
AB Age-related macular degeneration (AMD) affects various aspects of visual function compromising patients' functional vision and quality of life. Compared to visual acuity, contrast sensitivity correlates better with vision-related quality of life and subjectively perceived visual impairment. It may also be affected earlier in the course of AMD than visual acuity. However, lengthy testing times, coarse sampling and resolution, and poor test-retest reliability of the existing contrast testing methods have limited its widespread adoption into routine clinical practice. Using active learning principles, the qCSF can efficiently measure contrast sensitivity across multiple spatial frequencies with both high sensitivity in detecting subtle changes in visual function and robust test-retest reliability, emerging as a promising visual function endpoint in AMD both in clinical practice and future clinical trials.
C1 [Vingopoulos, Filippos; Katz, Raviv; Miller, John B.] Harvard Med Sch, Massachusetts Eye & Ear, Harvard Retinal Imaging Lab, 243 Charles St, Boston, MA 02114 USA.
   [Wai, Karen M.; Vavvas, Demetrios G.; Kim, Leo A.; Miller, John B.] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye
   & Ear Infirmary
RP Miller, JB (通讯作者)，Harvard Med Sch, Massachusetts Eye & Ear, Harvard Retinal Imaging Lab, 243 Charles St, Boston, MA 02114 USA.; Miller, JB (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM Filippos_Vingopoulos@meei.harvard.edu; Karen_Wai@meei.harvard.edu;
   Raviv_Katz@meei.harvard.edu; Demetrios_Vavvas@meei.harvard.edu;
   leo_kim@meei.harvard.edu; john_miller@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
CR American National Standards Institute Committee, 2007, AM NAT STAND OPTH MU
   Bangor A, 2009, J USABILITY STUD, V4, P114
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Buhren J, 2006, OPTOMETRY VISION SCI, V83, P290, DOI 10.1097/01.opx.0000216100.93302.2d
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3960, DOI 10.1167/iovs.17-22339a
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Dorr M, 2015, CURR DIR BIOMED ENG, V1, P131
   Dorr M, 2017, SCI REP-UK, V7, DOI 10.1038/srep46706
   ELLIOTT DB, 1993, INVEST OPHTH VIS SCI, V34, P108
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Faria BM, 2015, RETINA-J RET VIT DIS, V35, P1465, DOI 10.1097/IAE.0000000000000474
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P3613, DOI 10.1167/iovs.10-7127
   Gepshtein S, 2013, P NATL ACAD SCI USA, V110, P4368, DOI 10.1073/pnas.1204109110
   GINSBURG AP, 1984, AM J OPTOM PHYS OPT, V61, P403
   Ginsburg AP, 1996, FUNCTIONAL ASSESSMEN, P77
   Harvey LO, 1997, SPATIAL VISION, V11, P121, DOI 10.1163/156856897X00159
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hohberger B, 2007, GRAEF ARCH CLIN EXP, V245, P1805, DOI 10.1007/s00417-007-0662-x
   Hou F, 2016, J VISION, V16, DOI 10.1167/16.6.18
   Hou F, 2010, INVEST OPHTH VIS SCI, V51, P5365, DOI 10.1167/iovs.10-5468
   Ivers RQ, 2000, CLIN EXP OPHTHALMOL, V28, P41, DOI 10.1046/j.1442-9071.2000.00236.x
   Jia L, 2015, VISION RES, V114, P135, DOI 10.1016/j.visres.2015.02.003
   Joltikov KA, 2017, INVEST OPHTH VIS SCI, V58, P277, DOI 10.1167/iovs.17-21863
   Kalia A, 2014, P NATL ACAD SCI USA, V111, P2035, DOI 10.1073/pnas.1311041111
   KELLY DH, 1973, PERCEPT PSYCHOPHYS, V14, P313, DOI 10.3758/BF03212397
   Kelly SA, 2012, OPTOMETRY VISION SCI, V89, P1172, DOI 10.1097/OPX.0b013e318264097b
   KENNEDY RS, 1990, OPTOMETRY VISION SCI, V67, P248, DOI 10.1097/00006324-199004000-00003
   Kim YJ, 2017, INVEST OPHTH VIS SCI, V58, P3628, DOI 10.1167/iovs.17-21645
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   LENNERSTRAND G, 1989, ACTA OPHTHALMOL, V67, P225
   Lesmes LA, 2006, VISION RES, V46, P3160, DOI 10.1016/j.visres.2006.04.022
   Lesmes Luis Andres, 2013, Drug Discov Today Ther Strateg, V10, pe43, DOI 10.1016/j.ddstr.2012.11.002
   Lesmes LA, 2010, J VISION, V10, DOI 10.1167/10.3.17
   Lin S, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.22
   LONG GM, 1988, AM J OPTOM PHYS OPT, V65, P37
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Moschos MM, 2018, SEMIN OPHTHALMOL, V33, P461, DOI 10.1080/08820538.2017.1301496
   Murugappan M, 2016, INVEST OPHTH VIS SCI, V57
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Nixon DR, 2017, CLIN OPHTHALMOL, V11, P715, DOI 10.2147/OPTH.S131343
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley Cynthia, 2003, Ophthalmol Clin North Am, V16, P171, DOI 10.1016/S0896-1549(03)00003-8
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pesudovs K, 2004, BRIT J OPHTHALMOL, V88, P11, DOI 10.1136/bjo.88.1.11
   POMERANCE GN, 1994, INVEST OPHTH VIS SCI, V35, P3357
   Pondorfer SG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51769-7
   Preti RC, 2014, OPHTHALMIC RES, V51, P140, DOI 10.1159/000357737
   Preti RC, 2012, ARQ BRAS OFTALMOL, V75, P29, DOI 10.1590/S0004-27492012000100006
   RAMULU PY, 2015, INVEST OPHTH VIS SCI, V56
   REEVES BC, 1991, OPTOMETRY VISION SCI, V68, P728, DOI 10.1097/00006324-199109000-00010
   Richman J, 2015, BRIT J OPHTHALMOL, V99, P16, DOI 10.1136/bjophthalmol-2014-305223
   Richman J, 2013, J CATARACT REFR SURG, V39, P1100, DOI 10.1016/j.jcrs.2013.05.001
   Roh M, 2019, BRIT J OPHTHALMOL, V103, P1769, DOI 10.1136/bjophthalmol-2018-313316
   Roh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196481
   Rubin G.S., 1987, CLIN VIS SCI, V88, P177
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Shah N, 2016, BRIT J OPHTHALMOL, V100, P1346, DOI 10.1136/bjophthalmol-2015-307375
   Siderov J, 1999, ACTA OPHTHALMOL SCAN, V77, P673, DOI 10.1034/j.1600-0420.1999.770613.x
   Silverman RF, 2020, OSLI RETINA, V51, P392, DOI 10.3928/23258160-20200702-04
   SJOSTRAND J, 1977, ACTA OPHTHALMOL, V55, P507
   Stellmann J P, 2015, Mult Scler J Exp Transl Clin, V1, p2055217315596184, DOI 10.1177/2055217315596184
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Terheyden JH, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04595-6
   Thayaparan K, 2007, BRIT J OPHTHALMOL, V91, P749, DOI 10.1136/bjo.2006.109280
   Thomas Merina, 2021, J Vitreoretin Dis, V5, P313, DOI 10.1177/2474126420961957
   Tran BK, 2015, KLIN MONATSBL AUGENH, V232, P529, DOI 10.1055/s-0035-1545779
   van Gaalen KW, 2009, J CATARACT REFR SURG, V35, P47, DOI 10.1016/j.jcrs.2008.09.016
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Wai KM, 2022, BRIT J OPHTHALMOL, V106, P839, DOI 10.1136/bjophthalmol-2020-318494
   Wang J, 2022, BRIT J OPHTHALMOL, V106, P241, DOI 10.1136/bjophthalmol-2020-317615
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   Wolffsohn JS, 2006, BRIT J OPHTHALMOL, V90, P432, DOI 10.1136/bjo.2005.085787
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yan FF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05294-0
   Yu HJ, 2021, OPHTHALMOL RETINA, V5, P224, DOI 10.1016/j.oret.2020.04.011
NR 83
TC 4
Z9 4
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2021
VL 10
IS 13
AR 2768
DI 10.3390/jcm10132768
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TH2WI
UT WOS:000671954600001
PM 34202569
OA Green Published
DA 2022-11-30
ER

PT J
AU Rowan, S
   Jiang, SH
   Chang, ML
   Volkin, J
   Cassalman, C
   Smith, KM
   Streeter, MD
   Spiegel, DA
   Moreira-Neto, C
   Rabbani, N
   Thornalley, PJ
   Smith, DE
   Waheed, NK
   Taylor, A
AF Rowan, Sheldon
   Jiang, Shuhong
   Chang, Min-Lee
   Volkin, Jonathan
   Cassalman, Christa
   Smith, Kelsey M.
   Streeter, Matthew D.
   Spiegel, David A.
   Moreira-Neto, Carlos
   Rabbani, Naila
   Thornalley, Paul J.
   Smith, Donald E.
   Waheed, Nadia K.
   Taylor, Allen
TI A low glycemic diet protects disease-prone Nrf2-deficient mice against
   age-related macular degeneration
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Advanced glycation end-product; Geographic atrophy; Retinal pigmented
   epithelium; Glycemic index; Antioxidant
ID GLYCATION END-PRODUCTS; OPTICAL COHERENCE TOMOGRAPHY; TRANSCRIPTION
   FACTOR; OXIDATIVE STRESS; BRUCHS MEMBRANE; MITOCHONDRIAL BIOGENESIS;
   TRANSGENIC MICE; GLYOXALASE 1; NRF2; ASSOCIATION
AB Age-related macular degeneration (AMD) is a major blinding disease, affecting over 14% of the elderly. Risk for AMD is related to age, diet, environment, and genetics. Dietary modulation of AMD risk is a promising treatment modality, but requires appropriate animal models to demonstrate advantages of diet. Mice lacking the antioxidant transcription factor Nrf2 (Nfe2l2) develop age-related retinopathy relevant to human AMD. Here we evaluated the effect of consuming high glycemic (HG) or low glycemic (LG) diets until 18-months of age on development of features relevant to AMD in Nrf2-null mice. Nrf2-null mice that consumed HG diets developed atrophic AMD, characterized by photoreceptor degeneration, retinal pigment epithelium (RPE) atrophy and pigmentary abnormalities, basal laminar deposits, and loss of the choriocapillaris. In contrast, Nrf2-null-mice that consumed LG diets did not develop retinal disease phenotypes. Consumption of HG diets was associated with accumulation of advanced glycation end-products in the RPE and systemically, whereas consumption of the LG diet was associated with increased levels of anti-glycative and anti-oxidative detoxification machinery. Together our data indicate that the Nrf2-null HG mouse is a good model for atrophic AMD studies and that the LG diet can activate protective pathways to prevent AMD, even in a genetically predisposed animal.
C1 [Rowan, Sheldon; Jiang, Shuhong; Chang, Min-Lee; Volkin, Jonathan; Smith, Kelsey M.; Smith, Donald E.; Taylor, Allen] Tufts Univ, JM USDA Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, Boston, MA 02111 USA.
   [Rowan, Sheldon; Smith, Kelsey M.; Taylor, Allen] Tufts Univ, Friedman Sch Nutr & Sci Policy, Boston, MA 02111 USA.
   [Rowan, Sheldon; Moreira-Neto, Carlos; Waheed, Nadia K.; Taylor, Allen] Tufts Univ, Dept Ophthalmol, Sch Med, Boston, MA 02111 USA.
   [Jiang, Shuhong] Inner Mongolia Autonomous Reg Peoples Hosp, Hohhot 010017, Inner Mongolia, Peoples R China.
   [Cassalman, Christa] Tufts Univ, Dept Pathol & Lab Med, Sch Med, Boston, MA 02111 USA.
   [Streeter, Matthew D.; Spiegel, David A.] Yale Univ, Dept Chem, New Haven, CT 06520 USA.
   [Rabbani, Naila; Thornalley, Paul J.] Univ Warwick, Univ Hosp, Warwick Med Sch, Clin Sci Res Labs, Coventry CV2 2DX, W Midlands, England.
   [Rabbani, Naila] Qatar Univ, Coll Med, Dept Basic Med Sci, QU Hlth, POB 2713, Doha, Qatar.
   [Thornalley, Paul J.] Hamad Bin Khalifa Univ, Qatar Fdn, Diabet Res Ctr, Qatar Biomed Res Inst, POB 34110, Doha, Qatar.
C3 Tufts University; United States Department of Agriculture (USDA); Tufts
   University; Tufts University; Tufts University; Yale University;
   University of Warwick; Qatar University; Hamad Bin Khalifa
   University-Qatar; Qatar Foundation (QF)
RP Rowan, S; Taylor, A (通讯作者)，Tufts Univ, JM USDA Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, Boston, MA 02111 USA.
EM sheldon.rowan@tufts.edu; allen.taylor@tufts.edu
RI Jiang, Shuhong/C-1596-2019; Jiang, Shuhong/AAQ-7147-2021
OI Rabbani, Naila/0000-0002-5819-2506; Jiang, Shuhong/0000-0003-3659-5950;
   CHANG, MIN-LEE/0000-0001-9868-4030; Smith, Kelsey/0000-0003-4536-082X
FU Boston Nutrition Obesity Research Center (BNORC); NIH [RO1EY021212,
   RO1EY028559, RO1EY026979]; USDA NIFA [2016-08885]; USDA
   [8050-51000-089-01S]; Thome Memorial Foundation; BrightFocus Foundation;
   National Natural Science Foundation of China (NSFC) [81760177]; Stanley
   N. Gershoff scholarship; U.S. Department of Agriculture - Agricultural
   Research Service (ARS) [58-1950-4-003]
FX We are grateful to Jennifer Cho and Jonathan Morrison for assistance
   with animal feeding, Barbara Nagel for histological and electron
   microscopy, Maria Stewart of Ingredion Inc. for dietary starches,
   Michael Freeman and Swati Biswas for Nrf2-heterozygous mice, Ryoji Nagai
   and Casper Schalkwijk for antibodies, and Jasper Weinberg for critical
   reading of the manuscript. Use of the EchoMRI-700 was supported by the
   Boston Nutrition Obesity Research Center (BNORC). Funding was supported
   by NIH RO1EY021212, RO1EY028559, and RO1EY026979 (to AT), USDA NIFA
   2016-08885 (to AT and SR), USDA 8050-51000-089-01S (to AT), Thome
   Memorial Foundation (to AT), BrightFocus Foundation (to SR), the
   National Natural Science Foundation of China (NSFC) 81760177 (to SJ),
   and the Stanley N. Gershoff scholarship (to KMS). This material is based
   upon work supported by the U.S. Department of Agriculture - Agricultural
   Research Service (ARS), under Agreement No. 58-1950-4-003. The authors
   declare that they have no conflict of interest.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Akiyama K, 2018, EXP ANIM TOKYO, V67, P201, DOI 10.1538/expanim.17-0112
   Aleksunes LM, 2010, J PHARMACOL EXP THER, V333, P140, DOI 10.1124/jpet.109.162271
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Axelsson AS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4477
   Beyer TA, 2008, EMBO J, V27, P212, DOI 10.1038/sj.emboj.7601950
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blander JM, 2017, NAT IMMUNOL, V18, P851, DOI 10.1038/ni.3780
   Bonilha VL, 2017, FREE RADICAL BIO MED, V104, P226, DOI 10.1016/j.freeradbiomed.2017.01.018
   Brouwers O, 2011, J BIOL CHEM, V286, P1374, DOI 10.1074/jbc.M110.144097
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ebrahimi KB, 2018, ANTIOXID REDOX SIGN, V29, P389, DOI 10.1089/ars.2017.7084
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Giacco F, 2014, DIABETES, V63, P291, DOI 10.2337/db13-0316
   Gureev AP, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00435
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002
   He CX, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201800427
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holmstrom KM, 2013, BIOL OPEN, V2, P761, DOI 10.1242/bio.20134853
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Huang JC, 2019, THERANOSTICS, V9, P1170, DOI 10.7150/thno.26281
   Hubbs AF, 2007, AM J PATHOL, V170, P2068, DOI 10.2353/ajpath.2007.060898
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Isken F, 2010, AM J PHYSIOL-ENDOC M, V298, pE287, DOI 10.1152/ajpendo.00515.2009
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   McGill TJ, 2016, INVEST OPHTH VIS SCI, V57, P1361, DOI 10.1167/iovs.15-18596
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   O'Mealey GB, 2017, J CELL SCI, V130, P3467, DOI 10.1242/jcs.203216
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889
   Pawlak DB, 2004, LANCET, V364, P778, DOI 10.1016/S0140-6736(04)16937-7
   Pi JB, 2010, J BIOL CHEM, V285, P9292, DOI 10.1074/jbc.M109.093955
   Piantadosi CA, 2008, CIRC RES, V103, P1232, DOI 10.1161/01.RES.0000338597.71702.ad
   Queisser MA, 2010, DIABETES, V59, P670, DOI 10.2337/db08-1565
   Rabbani N, 2014, BIOCHEM SOC T, V42, P511, DOI 10.1042/BST20140019
   Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798
   Rowan S., 2014, INVEST OPHTHALMOL VI, V55
   Rowan S, 2018, BBA-MOL BASIS DIS, V1864, P3631, DOI 10.1016/j.bbadis.2018.08.036
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sanghvi VR, 2019, CELL, V178, P807, DOI 10.1016/j.cell.2019.07.031
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Satish S, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9248640
   Scribner KB, 2007, OBESITY, V15, P2190, DOI 10.1038/oby.2007.260
   Singh R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07859-7
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Takahashi A, 2017, DIABETES, V66, P1359, DOI 10.2337/db16-0397
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thaiss CA, 2018, SCIENCE, V359, P1376, DOI 10.1126/science.aar3318
   Tonelli C, 2018, ANTIOXID REDOX SIGN, V29, P1727, DOI 10.1089/ars.2017.7342
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Wang J, 2019, FREE RADICAL BIO MED, V134, P604, DOI 10.1016/j.freeradbiomed.2019.02.001
   Wei YH, 2011, FREE RADICAL BIO MED, V51, P216, DOI 10.1016/j.freeradbiomed.2011.04.026
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Xiong WJ, 2015, J CLIN INVEST, V125, P1433, DOI 10.1172/JCI79735
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Xue MZ, 2015, ANTIOXID REDOX SIGN, V23, P613, DOI 10.1089/ars.2014.5962
   Xue MZ, 2012, BIOCHEM J, V443, P213, DOI 10.1042/BJ20111648
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhang Y, 2017, MOL VIS, V23, P228
   Zhao ZY, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15166
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 97
TC 12
Z9 12
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD APR
PY 2020
VL 150
BP 75
EP 86
DI 10.1016/j.freeradbiomed.2020.02.010
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA NO9DS
UT WOS:000569787100008
PM 32068111
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Schmid-Kubista, KE
   Krebs, I
   Gruenberger, B
   Zeiler, F
   Schueller, J
   Binder, S
AF Schmid-Kubista, K. E.
   Krebs, I.
   Gruenberger, B.
   Zeiler, F.
   Schueller, J.
   Binder, S.
TI Systemic bevacizumab (Avastin) therapy for exudative neovascular
   age-related macular degeneration. The BEAT-AMD-Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; INTRAVITREAL BEVACIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; TRANSPLANTATION;
   TRIAMCINOLONE; FLUOROURACIL; LEUCOVORIN; EYES
AB Background: Double-blinded, randomised, prospective, pilot-study to determine the effect of systemic bevacizumab therapy.
   Methods: Subjects with fibrovascular pigment epithelial detachment, subfoveal choroidal neovascularisation extending under the geometric centre of the foveal avascular zone and/or macular thickness of at least 300 mm in both eyes were included. Sixteen eyes were included and randomised equally to receive either three infusions of 5 mg/kg Avastin or 100 ml of 0.9% sodium chloride every 2 weeks. The main outcome measure was the lesion size. The follow-up time was 24 weeks.
   Results: Throughout the 24-week follow-up, the lesion size and macular thickness decreased in the Avastin group by 0.5 (SD 0.08) mm and 103.6 (14.9) mu l respectively. In both groups, visual acuity remained stable in seven eyes and decreased in one eye. At the end of follow-up, 50% of the eyes in the Avastin group became fibrotic, 37.5% remained unchanged, and 12.5% developed a subretinal bleeding. There was a treatable rise in blood pressure after Avastin treatment.
   Conclusion: Systemic Avastin could be offered to patients with exudative age-related macular degeneration in both eyes and/or patients who refuse intravitreal injections if blood pressure is normal and there is no history of thrombosis.
C1 [Schmid-Kubista, K. E.; Krebs, I.; Zeiler, F.; Binder, S.] Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Gruenberger, B.; Schueller, J.] Rudolf Fdn Clin, Dept Internal Med, A-1030 Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Schmid-Kubista, KE (通讯作者)，Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM schmid-kubista@wienkav.at
FU Scientific Grant of the Mayor of Vienna
FX There was financial support by the "Scientific Grant of the Mayor of
   Vienna,'' received in June 2006.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krebs I, 2004, OPHTHALMOLOGICA, V218, P185, DOI 10.1159/000076843
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Radner W, 2002, GRAEF ARCH CLIN EXP, V240, P461, DOI 10.1007/s00417-002-0443-5
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
NR 24
TC 13
Z9 13
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2009
VL 93
IS 7
BP 914
EP 919
DI 10.1136/bjo.2008.144410
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 462HO
UT WOS:000267341900017
PM 19406737
OA Bronze
DA 2022-11-30
ER

PT J
AU Dubey, SK
   Pradhan, R
   Hejmady, S
   Singhvi, G
   Choudhury, H
   Gorain, B
   Kesharwani, P
AF Dubey, Sunil Kumar
   Pradhan, Rajesh
   Hejmady, Siddhanth
   Singhvi, Gautam
   Choudhury, Hira
   Gorain, Bapi
   Kesharwani, Prashant
TI Emerging innovations in nano-enabled therapy against age-related macular
   degeneration: A paradigm shift
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Review
DE Age-related macular degeneration; Nanotherapies; Retina; Ocular
   delivery; Choroidal neovascularization; Targeted therapy
ID DRUG-DELIVERY SYSTEMS; HYALURONIC-ACID HYDROGELS; CHOROIDAL
   NEOVASCULARIZATION; REGULATORY ASPECTS; INORGANIC NANOPARTICLES;
   INTRAVITREAL INJECTION; PHYSIOLOGICAL BARRIERS; LIPID NANOPARTICLES;
   GOLD NANOPARTICLES; IMPLANT ILUVIEN(R)
AB Age-related macular degeneration (AMD), a degenerative eye disease, is the major cause of irreversible loss of vision among individuals aged 50 and older. Both genetic and environmental factors are responsible for the progressive damage to central vision. It is a multifactorial retinal disease with features such as drusen, hypopigmentation and/or hyperpigmentation of the retinal pigment epithelium, and even choroidal neovascularization in certain patients. AMD is of two major forms: exudative (wet) and atrophic (dry) with changes affecting the macula leading to impaired vision. Although the retina remains an accessible portion for delivering drugs, there are no current options to cure or treat AMD. The existing expensive therapeutics are unable to treat the underlying pathology but display several side effects. However, recent innovations in nanotherapeutics provide an optimal alternative of drug delivery to treat the neovascular condition. These new-age technologies in the nanometer scale would enhance bioactivity and improve the bioavailability of drugs at the site of action to treat AMD. The nanomedicine also provides sustained release of the drug with prolonged retention after penetrating across the ocular tissues. In this review, the insights into the cellular and molecular mechanisms associated with the pathophysiology of AMD are provided. It also serves to review the current progress in nanoparticle-based drug delivery systems that offer feasible treatments in AMD.
C1 [Dubey, Sunil Kumar; Pradhan, Rajesh; Hejmady, Siddhanth; Singhvi, Gautam] Birla Inst Technol & Sci, Dept Pharm, Pilani BITS PILANI, Pilani Campus, Pilani, Rajasthan, India.
   [Dubey, Sunil Kumar] Emami Ltd, R&D Healthcare Div, Med Res, BT Rd, Kolkata 700056, India.
   [Choudhury, Hira] Int Med Univ, Sch Pharm, Dept Pharmaceut Technol, Kuala Lumpur 57000, Malaysia.
   [Gorain, Bapi] Taylors Univ, Fac Hlth & Med Sci, Sch Pharm, Subang Jaya 47500, Selangor, Malaysia.
   [Gorain, Bapi] Taylors Univ, Fac Hlth & Med Sci, Ctr Drug Delivery & Mol Pharmacol, Subang Jaya 47500, Selangor, Malaysia.
   [Kesharwani, Prashant] Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India.
   [Dubey, Sunil Kumar] Emami Ltd, R&D Healthcare Div, Med Res, 13 BT Rd, Kolkata 700056, India.
C3 Birla Institute of Technology & Science Pilani (BITS Pilani);
   International Medical University Malaysia; Taylor's University; Taylor's
   University
RP Dubey, SK (通讯作者)，Birla Inst Technol & Sci, Dept Pharm, Pilani Campus, Pilani 333031, Rajasthan, India.; Kesharwani, P (通讯作者)，Jamia Hamdard, Sch Pharmaceut Educ & Res, New Delhi 110062, India.
EM sunilbit2014@gmail.com; prashantdops@gmail.com
OI kesharwani, prashant/0000-0002-0890-769X
FU University Grants Commission, New Delhi, India; Indian Council of
   Medical Research, New Delhi, India
FX The author (P. Kesharwani) acknowledge the financial support from the
   University Grants Commission, New Delhi, India, through Start-Up
   Research Grant and Indian Council of Medical Research, New Delhi, India,
   through Extramural Research Grant.
CR Abbasi E, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-247
   Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Agrawal M., 2020, J CONTROL RELEASE, V321, P372, DOI [10.1016/j.jconrel.2020.02.020, DOI 10.1016/J.JC0NREL.2020.02]
   Alshamrani M, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1404-1
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amjad MW, 2017, PROG POLYM SCI, V64, P154, DOI 10.1016/j.progpolymsci.2016.09.008
   Amjad MW, 2015, MOL PHARMACEUT, V12, P4247, DOI 10.1021/acs.molpharmaceut.5b00827
   Araujo J, 2009, NANOMED-NANOTECHNOL, V5, P394, DOI 10.1016/j.nano.2009.02.003
   Bachu RD, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010028
   Bailey C, 2017, EYE, V31, P1707, DOI 10.1038/eye.2017.125
   Balguri SP, 2016, EUR J PHARM BIOPHARM, V109, P224, DOI 10.1016/j.ejpb.2016.10.015
   Birch DG, 2007, INT J NANOMED, V2, P65, DOI 10.2147/nano.2007.2.1.65
   Bolla PK, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090798
   Bolla PK, 2020, J MICROENCAPSUL, V37, P502, DOI 10.1080/02652048.2020.1809724
   Booth BA, 2007, DRUG AGING, V24, P581, DOI 10.2165/00002512-200724070-00006
   Buscemi S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091321
   Butt AM, 2016, MOL PHARMACEUT, V13, P4179, DOI 10.1021/acs.molpharmaceut.6b00776
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766
   Chaplot SP, 2014, J PHARM PHARMACOL, V66, P542, DOI 10.1111/jphp.12104
   Chen CW, 2013, INT J NANOMED, V8, P2613, DOI 10.2147/IJN.S39622
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441
   Cho YW, 2014, INT J OPHTHALMOL-CHI, V7, P952, DOI 10.3980/j.issn.2222-3959.2014.06.07
   Cholkar K, 2015, AAPS PHARMSCITECH, V16, P610, DOI 10.1208/s12249-014-0244-2
   Choudhari M, 2021, INT J PHARMACEUT, V599, DOI 10.1016/j.ijpharm.2021.120351
   Choudhury H, 2017, INT J PHARMACEUT, V529, P506, DOI 10.1016/j.ijpharm.2017.07.018
   Choudhury H, 2017, CURR PHARM DESIGN, V23, P2504, DOI 10.2174/1381612822666161201143600
   Choudhury H, 2014, INT J PHARMACEUT, V460, P131, DOI 10.1016/j.ijpharm.2013.10.055
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Davis BM, 2014, SMALL, V10, P1575, DOI 10.1002/smll.201303433
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Dombi T, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-37
   Dong YD, 2019, J LIPOSOME RES, V29, P1, DOI 10.1080/08982104.2017.1391285
   Du JD, 2016, DRUG DELIV TRANSL RE, V6, P781, DOI 10.1007/s13346-016-0299-6
   Dubey SK, 2021, DRUG DISCOV TODAY, V26, P931, DOI 10.1016/j.drudis.2021.01.001
   Dubey SK, 2020, CURR DRUG TARGETS, V21, P528, DOI 10.2174/1389450120666191031092259
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   Egbu R, 2018, EUR J PHARM BIOPHARM, V124, P95, DOI 10.1016/j.ejpb.2017.12.019
   Ekladious I, 2019, NAT REV DRUG DISCOV, V18, P273, DOI 10.1038/s41573-018-0005-0
   Elvira C, 2005, MOLECULES, V10, P114, DOI 10.3390/10010114
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Fahr A, 2005, EUR J PHARM SCI, V26, P251, DOI 10.1016/j.ejps.2005.05.012
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fujisawa T, 2012, INT J PHARMACEUT, V436, P564, DOI 10.1016/j.ijpharm.2012.07.024
   Garrigue JS, 2017, J OCUL PHARMACOL TH, V33, P647, DOI 10.1089/jop.2017.0052
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Ge Y, 2020, EXPERT OPIN DRUG DEL, V17, P603, DOI 10.1080/17425247.2020.1735348
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gharib M, 2019, ACS SUSTAIN CHEM ENG, V7, P9834, DOI 10.1021/acssuschemeng.9b00295
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Gorain B., 2019, NANOTECHNOLOGY BASED, P161, DOI 10.1016/B978-0-12- 815720-6.00007-1
   Gorain B, 2020, DRUG DISCOV TODAY, V25, P1174, DOI 10.1016/j.drudis.2020.04.013
   Gorain B, 2017, DRUG DISCOV TODAY, V22, P652, DOI 10.1016/j.drudis.2016.12.007
   Gote V, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111072
   Gryziewicz L, 2005, ADV DRUG DELIVER REV, V57, P2092, DOI 10.1016/j.addr.2005.09.009
   Gupta A, 2021, J PHARM SCI-US, V110, P888, DOI 10.1016/j.xphs.2020.11.008
   Harding S, 2001, EYE, V15, P407, DOI 10.1038/eye.2001.145
   He HS, 2019, ACTA PHARM SIN B, V9, P36, DOI 10.1016/j.apsb.2018.06.005
   Hejmady S, 2020, THER DELIV, V11, P341, DOI 10.4155/tde-2020-0034
   Ho D, 2019, NANOSCALE HORIZ, V4, P365, DOI 10.1039/c8nh00233a
   Honda M, 2011, ARCH OPHTHALMOL-CHIC, V129, P317, DOI 10.1001/archophthalmol.2011.12
   Hua S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00790
   Ignatius AA, 1996, BIOMATERIALS, V17, P831, DOI 10.1016/0142-9612(96)81421-9
   Iyer S, 2019, J CONTROL RELEASE, V296, P140, DOI 10.1016/j.jconrel.2019.01.007
   Jain A, 2015, COLLOID SURFACE B, V134, P47, DOI 10.1016/j.colsurfb.2015.06.027
   Jeevanandam J, 2018, BEILSTEIN J NANOTECH, V9, P1050, DOI 10.3762/bjnano.9.98
   Jiang SB, 2018, INT J OPHTHALMOL-CHI, V11, P1038, DOI 10.18240/ijo.2018.06.23
   Juliana FR, 2019, MOLECULES, V24, DOI 10.3390/molecules24203805
   Kamaleddin MA, 2017, NANOMED-NANOTECHNOL, V13, P1459, DOI 10.1016/j.nano.2017.02.007
   Kambhampati SP, 2015, EUR J PHARM BIOPHARM, V95, P239, DOI 10.1016/j.ejpb.2015.02.013
   Kambhampati SP, 2013, J OCUL PHARMACOL TH, V29, P151, DOI 10.1089/jop.2012.0232
   Kesharwani P., 2014, DENDRIMER NANOCARRIE, V39, P268, DOI [10.1016/j.progpolymsci.2013.07.005, DOI 10.1016/J.PROGPOLYMSCI.2013.07.005]
   Kesharwani P, 2019, PROG MATER SCI, V103, P484, DOI 10.1016/j.pmatsci.2019.03.003
   Kesharwani P, 2018, DIABETES RES CLIN PR, V136, P52, DOI 10.1016/j.diabres.2017.11.018
   Kesharwani P, 2015, MATER TODAY, V18, P565, DOI 10.1016/j.mattod.2015.06.003
   Kesharwani P, 2015, BIOMACROMOLECULES, V16, P3042, DOI 10.1021/acs.biomac.5b00941
   Kesharwani P, 2015, COLLOID SURFACE B, V132, P138, DOI 10.1016/j.colsurfb.2015.05.007
   Kesharwani P, 2015, DRUG DISCOV TODAY, V20, P536, DOI 10.1016/j.drudis.2014.12.012
   Kesharwani P, 2015, PHARM RES-DORDR, V32, P1438, DOI 10.1007/s11095-014-1549-2
   Kesharwani P, 2014, PROG POLYM SCI, V39, P268, DOI 10.1016/j.progpolymsci.2013.07.005
   Kesharwani P, 2012, BIOMATERIALS, V33, P7138, DOI 10.1016/j.biomaterials.2012.06.068
   Kesharwani P, 2011, NANOMED-NANOTECHNOL, V7, P295, DOI 10.1016/j.nano.2010.10.010
   Khurana RK, 2018, DRUG DISCOV TODAY, V23, P763, DOI 10.1016/j.drudis.2018.01.021
   Khurana RK, 2017, EUR J PHARM BIOPHARM, V121, P42, DOI 10.1016/j.ejpb.2017.09.001
   Kim D, 2018, ACS CENTRAL SCI, V4, P324, DOI 10.1021/acscentsci.7b00574
   Kim TW, 2002, INVEST OPHTH VIS SCI, V43, P1809
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kojima C, 2011, NANOMED-NANOTECHNOL, V7, P1001, DOI 10.1016/j.nano.2011.03.007
   Koo H, 2012, BIOMATERIALS, V33, P3485, DOI 10.1016/j.biomaterials.2012.01.030
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Ladj R, 2013, J MATER CHEM B, V1, P1381, DOI 10.1039/c2tb00301e
   Lai SS, 2019, J NANOBIOTECHNOL, V17, DOI 10.1186/s12951-019-0498-7
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Laradji AM, 2021, ACS OMEGA, V6, P6172, DOI 10.1021/acsomega.0c05535
   Larson N, 2012, CHEM MATER, V24, P840, DOI 10.1021/cm2031569
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Li TH, 2015, PHOTOCH PHOTOBIO SCI, V14, P972, DOI 10.1039/c4pp00412d
   Liu Y, 2013, TISSUE ENG PT A, V19, P135, DOI [10.1089/ten.tea.2012.0209, 10.1089/ten.TEA.2012.0209]
   Luong D, 2016, ACTA BIOMATER, V43, P14, DOI 10.1016/j.actbio.2016.07.015
   Lynch C, 2019, POLYMERS-BASEL, V11, DOI 10.3390/polym11081371
   Lynch CR, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00228
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Maberley D, 2005, Issues Emerg Health Technol, P1
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Mandal A, 2017, J CONTROL RELEASE, V248, P96, DOI 10.1016/j.jconrel.2017.01.012
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   McCarthy CA, 2013, CLIN EXP PHARMACOL P, V40, P571, DOI 10.1111/1440-1681.12099
   Mishra MK, 2014, ACS NANO, V8, P2134, DOI 10.1021/nn404872e
   Morsi N, 2017, EUR J PHARM SCI, V104, P302, DOI 10.1016/j.ejps.2017.04.013
   Nakhlband A, 2012, BIOIMPACTS, V2, P69, DOI 10.5681/bi.2012.009
   Narvekar P, 2019, ASSAY DRUG DEV TECHN, V17, P167, DOI 10.1089/adt.2019.920
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Le NTT, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11110591
   Ngwa W, 2012, PHYS MED BIOL, V57, P6371, DOI 10.1088/0031-9155/57/20/6371
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okur N. O., 2015, INT J OPHTHAL RES, V1, P77, DOI DOI 10.17554/J.ISSN.2409-5680.2015.01.29
   Omerovic N, 2020, HEALTH TECHNOL-GER, V10, P61, DOI 10.1007/s12553-019-00381-w
   Pandey M, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010001
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Patel SP, 2016, J MICROENCAPSUL, V33, P103, DOI 10.3109/02652048.2015.1134685
   Patel SP, 2015, AAPS PHARMSCITECH, V16, P327, DOI 10.1208/s12249-014-0196-6
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0392-8
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pindrus M, 2015, MOL PHARMACEUT, V12, P3896, DOI 10.1021/acs.molpharmaceut.5b00336
   Purbrick RMJ, 2013, REV CLIN GERONTOL, V23, P234, DOI 10.1017/S0959259813000105
   Purvya Mahesh Chand, 2011, Ayu, V32, P20, DOI 10.4103/0974-8520.85719
   Qiu FF, 2019, MOL PHARMACEUT, V16, P1958, DOI 10.1021/acs.molpharmaceut.8b01319
   Ramos-Cabrer P, 2013, INT J NANOMED, V8, P951, DOI 10.2147/IJN.S30721
   Reeves BC, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16060
   Rowe-Rendleman CL, 2014, INVEST OPHTH VIS SCI, V55, P2714, DOI 10.1167/iovs.13-13707
   Sadekar S, 2011, BIOMACROMOLECULES, V12, P88, DOI 10.1021/bm101046d
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Sainz V, 2015, BIOCHEM BIOPH RES CO, V468, P504, DOI 10.1016/j.bbrc.2015.08.023
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   Sanchez-Lopez E, 2017, EUR J PHARM BIOPHARM, V110, P58, DOI 10.1016/j.ejpb.2016.10.013
   Sanchez-Lopez E, 2017, EUR J PHARM BIOPHARM, V110, P70, DOI 10.1016/j.ejpb.2016.10.009
   Sanford M, 2013, DRUGS, V73, P187, DOI 10.1007/s40265-013-0010-x
   Schmit-Eilenberger VK, 2015, CLIN OPHTHALMOL, V9, P801, DOI 10.2147/OPTH.S79785
   Schwartz SG, 2014, EXPERT OPIN DRUG DEL, V11, P61, DOI 10.1517/17425247.2013.859135
   Shah R, 2021, J BIOMAT SCI-POLYM E, V32, P833, DOI 10.1080/09205063.2020.1870378
   Sharma C.P., 2010, BIOINTEGRATION MED I, P1, DOI [10.1533/9781845699802, DOI 10.1533/9781845699802]
   Shembekar VR, 2007, BIOCHEMISTRY-US, V46, P5479, DOI 10.1021/bi700280e
   Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c
   Singh PK, 2020, MATER SCI ENG B-ADV, V258, DOI 10.1016/j.mseb.2020.114571
   Sk UH, 2013, BIOMACROMOLECULES, V14, P801, DOI 10.1021/bm3018615
   Soares S, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00360
   Soni N, 2016, J COLLOID INTERF SCI, V481, P107, DOI 10.1016/j.jcis.2016.07.020
   Souto EB, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11090460
   Srilatha B., 2012, J CLIN EXPT OPHTHALM, V02, DOI [10.4172/2155-9570.1000196, DOI 10.4172/2155-9570.1000196]
   Srinivasarao DA, 2019, WIRES NANOMED NANOBI, V11, DOI 10.1002/wnan.1548
   Tamaki Y, 2009, NANOMEDICINE-UK, V4, P341, DOI 10.2217/NNM.09.10
   Todorich B., 2014, CURR OPHTHALMOL REP, V2, P167, DOI 10.1007/s40135-014-0052-62-s2.0-84912073855
   Trabulo S, 2010, PHARMACEUTICALS, V3, P961, DOI 10.3390/ph3040961
   van Uden Sebastiao, 2017, Biomater Res, V21, P22, DOI 10.1186/s40824-017-0106-6
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wang YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08033-9
   Weng YH, 2017, ACTA PHARM SIN B, V7, P281, DOI 10.1016/j.apsb.2016.09.001
   Wilson BA, 2008, NEUROPSYCHOLOG REHAB, P53
   Xu Qingguo, 2013, Middle East Afr J Ophthalmol, V20, P26, DOI 10.4103/0974-9233.106384
   Yadav M, 2020, DRUG DELIV TRANSL RE, V10, P919, DOI 10.1007/s13346-020-00733-4
   Yavuz B, 2013, SCI WORLD J, DOI 10.1155/2013/732340
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Yu GP, 2014, BIOMACROMOLECULES, V15, P4570, DOI 10.1021/bm501352s
   Zafir-Lavie I, 2007, ONCOGENE, V26, P3714, DOI 10.1038/sj.onc.1210372
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhou HY, 2013, INT J OPHTHALMOL-CHI, V6, P390, DOI 10.3980/j.issn.2222-3959.2013.03.25
NR 177
TC 6
Z9 6
U1 4
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAY 1
PY 2021
VL 600
AR 120499
DI 10.1016/j.ijpharm.2021.120499
EA APR 2021
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA RY2JI
UT WOS:000647743200007
PM 33753164
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Gensler, G
   Milton, RC
   Klein, ML
   Rifai, N
AF Seddon, JM
   Gensler, G
   Milton, RC
   Klein, ML
   Rifai, N
TI Association between C-reactive protein and age-related macular
   degeneration
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID RISK-FACTORS; DIETARY-FAT; EYE DISEASE; VITAMIN-C; INFLAMMATION;
   PROGRESSION; MODEL; AREDS
AB Context C-reactive protein (CRP) is a systemic inflammatory marker associated with risk for cardiovascular disease (CVD). Some risk factors for CVD are associated with age-related macular degeneration (AMD), but the association between CRP and AMD is unknown.
   Objective To test the hypothesis that elevated CRP levels are associated with an increased risk for AMD.
   Design, Setting, and Participants A total of 930 (91%) of 1026 participants at 2 centers in the Age-Related Eye Disease Study (AREDS), a multicenter randomized trial of antioxidant vitamins and minerals, were enrolled in this case-control study. There were 183 individuals without any maculopathy, 200 with mild maculopathy, 325 with intermediate disease, and 222 with advanced AMD (geographic atrophy or neovascular AMD). The AMD status was assessed by standardized grading of fundus photographs, and stored fasting blood specimens drawn between January 1996 and April 1997 were analyzed for high-sensitivity CRP levels.
   Main Outcome Measure Association between CRP and AMD.
   Results The CRP levels were significantly higher among participants with advanced AMD (case patients) than among those with no AMD (controls; median values, 3.4 vs 2.7 mg/L; P=.02). After adjustment for age, sex, and other variables, including smoking and body mass index, CRP levels were significantly associated with the presence of intermediate and advanced stages of AMD. The odds ratio (OR) for the highest vs the lowest quartile of CRP was 1.65 (95% confidence interval [0], 1.07-2.55; P for trend =.02). The OR for CRP values at or above the 90th percentile (10.6 mg/L) was 1.92 (95% Cl, 1.20-3.06), and the OR for CRP values at or above the mean plus 2 SDs (16.8 mg/L) was 2.03 (95% Cl, 1.03-4.00). A trend for an increased risk for intermediate and advanced AMD with higher levels of CRP was seen for smokers (OR, 2.16; 95% Cl, 1.33-3.49) and those who never smoked (OR, 2.03; 95% Cl, 1.19-3.46) with the highest level of CRP.
   Conclusion Our results suggest that elevated CRP level is an independent risk factor for AMD and may implicate the role of inflammation in the pathogenesis of AMD.
C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Epidemiol Unit, Boston, MA 02114 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   EMMES Corp, Rockville, MD USA.
   Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   Harvard Univ, Sch Med, Childrens Hosp, Dept Lab Med, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard T.H. Chan School of Public
   Health; Emmes Corporation; Oregon Health & Science University; Harvard
   University; Boston Children's Hospital; Harvard Medical School
RP Seddon, JM (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Epidemiol Unit, 243 Charles St, Boston, MA 02114 USA.
EM Johanna_Seddon@meei.harvard.edu
FU NEI NIH HHS [N01EY02117, N01EY02126, R01EY13982] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [N01EY002126, R01EY013982, N01EY002117]
   Funding Source: NIH RePORTER
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Hawkins B, 2001, OCULAR HISTOPLASMOSI, V2, P1687
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C
   Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 21
TC 330
Z9 347
U1 1
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 11
PY 2004
VL 291
IS 6
BP 704
EP 710
DI 10.1001/jama.291.6.704
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 772AY
UT WOS:000188819200023
PM 14871913
OA Bronze
DA 2022-11-30
ER

PT J
AU Mohammad, F
   Wanek, J
   Zelkha, R
   Lim, JI
   Chen, J
   Shahidi, M
AF Mohammad, Fatimah
   Wanek, Justin
   Zelkha, Ruth
   Lim, Jennifer I.
   Chen, Judy
   Shahidi, Mahnaz
TI A Method for En Face OCT Imaging of Subretinal Fluid in Age-Related
   Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL SENSITIVITY; RANIBIZUMAB; IMAGES
AB Purpose. The purpose of the study is to report a method for en face imaging of subretinal fluid (SRF) due to age-related macular degeneration (AMD) based on spectral domain optical coherence tomography (SDOCT). Methods. High density SDOCT imaging was performed at two visits in 4 subjects with neovascular AMD and one healthy subject. En face OCT images of a retinal layer anterior to the retinal pigment epithelium were generated. Validity, repeatability, and utility of the method were established. Results. En face OCT images generated by manual and automatic segmentation were nearly indistinguishable and displayed similar regions of SRF. En face OCT images displayed uniform intensities and similar retinal vascular patterns in a healthy subject, while the size and appearance of a hypopigmented fibrotic scar in an AMD subject were similar at 2 visits. In AMD subjects, dark regions on en face OCT images corresponded to reduced or absent light reflectance due to SRF. On en face OCT images, a decrease in SRF areas with treatment was demonstrated and this corresponded with a reduction in the central subfield retinal thickness. Conclusion. En face OCT imaging is a promising tool for visualization and monitoring of SRF area due to disease progression and treatment.
C1 [Mohammad, Fatimah; Wanek, Justin; Zelkha, Ruth; Lim, Jennifer I.; Chen, Judy; Shahidi, Mahnaz] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Shahidi, M (通讯作者)，Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 W Taylor St, Chicago, IL 60612 USA.
EM mahnshah@uic.edu
FU NIH [EY014275, EY001792]; Department of VA, a Senior Scientific
   Investigator award; Research to Prevent Blindness, Inc.; Cless Family
   Foundation
FX This study was supported by NIH Grants EY014275 and EY001792, Department
   of VA, a Senior Scientific Investigator award to Mahnaz Shahidi, and an
   unrestricted departmental grant from Research to Prevent Blindness,
   Inc., and Cless Family Foundation.
CR A Sohrab Mahsa, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P69
   Alkabes M, 2011, INVEST OPHTH VIS SCI, V52, P8349, DOI 10.1167/iovs.11-8043
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Coscas F, 2012, INVEST OPHTH VIS SCI, V53, P4147, DOI 10.1167/iovs.12-9878
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Gorczynska I, 2009, BRIT J OPHTHALMOL, V93, P603, DOI 10.1136/bjo.2007.136101
   Hitzenberger CK, 2003, OPT EXPRESS, V11, P2753, DOI 10.1364/OE.11.002753
   Jiao SL, 2006, OPT EXPRESS, V14, P3368, DOI 10.1364/OE.14.003368
   Kaluzny JJ, 2009, OPHTHAL SURG LAS IM, V40, P102, DOI 10.3928/15428877-20090301-10
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Pircher M, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2358960
   Podoleanu AG, 2004, J BIOMED OPT, V9, P86, DOI 10.1117/1.1627778
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Rispoli M, 2012, RETINA-J RET VIT DIS, V32, P2070, DOI 10.1097/IAE.0b013e3182562076
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Wanek J, 2011, AM J OPHTHALMOL, V152, P807, DOI 10.1016/j.ajo.2011.04.027
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Wojtkowski M, 2009, OPT EXPRESS, V17, P4189, DOI 10.1364/OE.17.004189
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Zheng YL, 2013, AM J OPHTHALMOL, V155, P277, DOI 10.1016/j.ajo.2012.07.030
NR 25
TC 7
Z9 7
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 720243
DI 10.1155/2014/720243
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT5ZY
UT WOS:000345019600001
PM 25478209
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Gillies, MC
   Walton, R
   Simpson, JM
   Arnold, JJ
   Guymer, RH
   McAllister, IL
   Hunyor, AP
   Essex, RW
   Morlet, N
   Barthelmes, D
AF Gillies, Mark C.
   Walton, Richard
   Simpson, Judy M.
   Arnold, Jennifer J.
   Guymer, Robyn H.
   McAllister, Ian L.
   Hunyor, Alex P.
   Essex, Rohan W.
   Morlet, Nigel
   Barthelmes, Daniel
CA Fight Retinal Blindness Project In
TI Prospective Audit of Exudative Age-Related Macular Degeneration:
   12-Month Outcomes in Treatment-Naive Eyes
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE anti-VEGF; observational study; neovascular age-related macular
   degeneration
ID LOCALLY WEIGHTED REGRESSION; SMOOTHING SCATTERPLOTS; SUBGROUP ANALYSIS;
   VISUAL OUTCOMES; VEGF-TRAP; RANIBIZUMAB; BEVACIZUMAB; PREDICTORS
AB PURPOSE. We report the 12-month outcomes of 1140 treatment-naive eyes with exudative age-related macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice.
   METHODS. Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression.
   RESULTS. Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections.
   CONCLUSIONS. These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice.
C1 [Gillies, Mark C.; Walton, Richard; Hunyor, Alex P.; Barthelmes, Daniel] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Simpson, Judy M.] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [McAllister, Ian L.] Univ Western Australia, Ctr Ophthalmol & Vis Sci, Lions Eye Inst, Perth, WA 6009, Australia.
   [Hunyor, Alex P.] Retina Associates, Chatswood, NSW, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Acton, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA 6009, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; University of Sydney; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne;
   Lions Eye Institute; University of Western Australia; Australian
   National University; University of Western Australia; University of
   Zurich; University Zurich Hospital
RP Gillies, MC (通讯作者)，Save Sight Inst, South Block,8 Macquarie St, Sydney, NSW 2000, Australia.
EM mark.gillies@sydney.edu.au
RI Hunyor, Alex/AAT-8205-2021
OI Hunyor, Alex/0000-0002-8182-6167; Essex, Rohan/0000-0001-5323-0334;
   Fraser-Bell, Samantha/0000-0001-5646-9359; Simpson, Judy
   M/0000-0001-5172-3004; Guymer, Robyn/0000-0002-9441-4356
FU Eye Foundation; National Health and Medical Research Council, Australia
   [NHRMC 2010-1012]; NHMRC Clinical Research Fellowships; Walter and
   Gertrud Siegenthaler Foundation Zurich, Switzerland; Swiss National
   Foundation
FX Supported by a grant from the Eye Foundation (2007-2009) and a grant
   from the National Health and Medical Research Council, Australia (NHRMC
   2010-1012), in part by NHMRC Clinical Research Fellowships (MCG, a
   Sydney University Medical Foundation Fellow, and RHG), and by the Walter
   and Gertrud Siegenthaler Foundation Zurich, Switzerland and the Swiss
   National Foundation (DB). The authors alone are responsible for the
   content and writing of this paper.
CR [Anonymous], R LANG ENV STAT COMP
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407
   CLEVELAND WS, 1981, AM STAT, V35, P54, DOI 10.2307/2683591
   Cohen SY, 2012, RETINA, V33, P474
   DiCiccio TJ, 1996, STAT SCI, V11, P189
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   HAIMANN MH, 1982, ARCH OPHTHALMOL-CHIC, V100, P289
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kleinbaum DG, 2005, SURVIVAL ANAL SELF L, P45
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Traynor K, 2012, AM J HEALTH-SYST PH, V69, P6, DOI 10.2146/news120001
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 25
TC 30
Z9 30
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2013
VL 54
IS 8
BP 5754
EP 5760
DI 10.1167/iovs.13-11993
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 228EA
UT WOS:000325167200075
PM 23821201
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
   Hegel, MT
   Massof, RW
   Leiby, BE
   Tasman, WS
AF Rovner, Barry W.
   Casten, Robin J.
   Hegel, Mark T.
   Massof, Robert W.
   Leiby, Benjamin E.
   Tasman, William S.
TI Improving function in Age-Related Macular Degeneration: Design and
   methods of a randomized clinical trial
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Vision function; Age-Related Macular Degeneration; Clinical trial;
   Depression
ID COGNITIVE-BEHAVIORAL THERAPY; PROBLEM-SOLVING TREATMENT;
   QUALITY-OF-LIFE; VISION REHABILITATION; VISUAL IMPAIRMENT; MAJOR
   DEPRESSION; IMPACT; SYMPTOMS; RISK
AB Age-Related Macular Degeneration (AMD) is the leading cause of severe vision loss in older adults and impairs the ability to read, drive, and live independently and increases the risk for depression, falls, and earlier mortality. Although new medical treatments have improved AMD's prognosis, vision-related disability remains a major public health problem. Improving Function in AMD (IF-AMD) is a two-group randomized, parallel design, controlled clinical trial that compares the efficacy of Problem-Solving Therapy (PST) with Supportive Therapy (ST) (an attention control treatment) to improve vision function in 240 patients with AMD. PST and ST therapists deliver 6 one-hour respective treatment sessions to subjects in their homes over 2 months. Outcomes are assessed masked to treatment assignment at 3 months (main trial endpoint) and 6 months (maintenance effects). The primary outcome is targeted vision function (TVF), which refers to specific vision-dependent functional goals that subjects highly value but find difficult to achieve. TVF is an innovative outcome measure in that it is targeted and tailored to individual subjects yet is measured in a standardized way. This paper describes the research methods, theoretical and clinical aspects of the study treatments, and the measures used to evaluate functional and psychiatric outcomes in this population. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Rovner, Barry W.] Jefferson Hosp Neurosci, Jefferson Med Coll, Dept Psychiat & Neurol, Philadelphia, PA 19107 USA.
   [Casten, Robin J.] Jefferson Hosp Neurosci, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
   [Hegel, Mark T.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Lebanon, NH 03756 USA.
   [Hegel, Mark T.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Lebanon, NH 03756 USA.
   [Massof, Robert W.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, Baltimore, MD 21205 USA.
   [Leiby, Benjamin E.] Thomas Jefferson Univ, Jefferson Med Coll, Div Biostat, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA.
   [Tasman, William S.] Jefferson Med Coll, Wills Eye Inst, Dept Ophthalmol, Philadelphia, PA USA.
C3 Jefferson University; Jefferson University; Dartmouth College; Dartmouth
   College; Johns Hopkins University; Johns Hopkins Medicine; Jefferson
   University; Jefferson University
RP Rovner, BW (通讯作者)，Jefferson Hosp Neurosci, Jefferson Med Coll, Dept Psychiat & Neurol, 900 Walnut St,4th Floor, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu; robin.casten@jefferson.edu;
   Mark.T.Hegel@Dartmouth.edu; rmassof@lions.med.jhu.edu;
   bleiby@mail.jci.tju.edu; wst1@ureach.com
FU NEI [U01 EY 015839]; Farber Institute for Neurosciences of Thomas
   Jefferson University; NATIONAL EYE INSTITUTE [U01EY015839] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASES [T32DK060455] Funding Source: NIH RePORTER
FX This work was supported by NEI grant U01 EY 015839 and the Farber
   Institute for Neurosciences of Thomas Jefferson University.
CR Ahles TA, 2001, J PAIN SYMPTOM MANAG, V22, P584, DOI 10.1016/S0885-3924(01)00301-3
   Alexopoulos GS, 2003, AM J GERIAT PSYCHIAT, V11, P46, DOI 10.1176/appi.ajgp.11.1.46
   Arnold LE, 2003, J AM ACAD CHILD PSY, V42, P1443, DOI 10.1097/00004583-200312000-00011
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Barrowclough C, 2001, J CONSULT CLIN PSYCH, V69, P756, DOI 10.1037//0022-006X.69.5.756
   Bilsbury CD, 2002, ACTA PSYCHIAT SCAND, V106, P5, DOI 10.1046/j.0001-690x.2002.00052.x
   Borkovec TD, 2002, J CONSULT CLIN PSYCH, V70, P288, DOI 10.1037//0022-006X.70.2.288
   CARROLL KM, 1994, J CONSULT CLIN PSYCH, V62, P276, DOI 10.1037/0022-006X.62.2.276
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Cuijpers P, 2007, EUR PSYCHIAT, V22, P9, DOI 10.1016/j.eurpsy.2006.11.001
   DEVELLIS BM, 1988, PATIENT EDUC COUNS, V11, P29
   Evans JR, 2008, ARCH OPHTHALMOL-CHIC, V126, P1428, DOI 10.1001/archopht.126.10.1428
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Kanter JW, 2007, J PSYCHOPATHOL BEHAV, V29, P191, DOI 10.1007/s10862-006-9038-5
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Law M., 1996, CAN J OCCUP THER, V63, P9, DOI [10.1177/000841749906600304, DOI 10.1177/000841749606300103]
   LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, P763, DOI 10.1097/OPX.0b013e3181339efd
   Massof RW, 2005, ARCH PHYS MED REHAB, V86, P946, DOI 10.1016/j.apmr.2004.09.016
   Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1
   MASSOF RW, 1995, OPTOMETRY VISION SCI, V72, P725, DOI 10.1097/00006324-199510000-00005
   Massof RW, 2005, OPHTHAL EPIDEMIOL, V12, P103, DOI 10.1080/09286580590932789
   Massof RW., 2007, OPTOMETRY VISION SCI, V84, P690
   Mulsant BH, 1997, INT J GERIATR PSYCH, V12, P537, DOI 10.1002/(SICI)1099-1166(199705)12:5<537::AID-GPS542>3.0.CO;2-Z
   MynorsWallis L, 1997, BRIT J PSYCHIAT, V170, P113, DOI 10.1192/bjp.170.2.113
   MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441
   PERLIS RH, 2001, AM J PSYCHIAT, V167, P250
   Perri MG, 2001, J CONSULT CLIN PSYCH, V69, P722, DOI 10.1037/0022-006X.69.4.722
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reischies FM, 1997, BRIT J PSYCHIAT, V171, P449, DOI 10.1192/bjp.171.5.449
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Stelmack JA, 2006, INVEST OPHTH VIS SCI, V47, P3253, DOI 10.1167/iovs.05-1319
   Szabo SM, 2008, J AM GERIATR SOC, V56, P800, DOI 10.1111/j.1532-5415.2008.01666.x
   VERBRUGGE LM, 1989, MILBANK Q, V67, P450, DOI 10.2307/3350223
   VERBRUGGE LM, 2002, SOC SCI MED, V38, P114
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
   Ware J., 1992, MEASURING FUNCTIONIN
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
   Williams JW, 2000, JAMA-J AM MED ASSOC, V284, P1519, DOI 10.1001/jama.284.12.1519
   World Health Organization, 2001, ICF INTR
NR 47
TC 8
Z9 8
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD MAR
PY 2011
VL 32
IS 2
BP 196
EP 203
DI 10.1016/j.cct.2010.10.008
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 730TG
UT WOS:000288056700008
PM 20974293
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Serra, R
   Coscas, F
   Boulet, JF
   Cabral, D
   Lupidi, M
   Coscas, GJ
   Souied, EH
AF Serra, Rita
   Coscas, Florence
   Boulet, Jean Francois
   Cabral, Diogo
   Lupidi, Marco
   Coscas, Gabriel J.
   Souied, Eric H.
TI PREDICTIVE ACTIVATION BIOMARKERS OF TREATMENT-NAIVE ASYMPTOMATIC
   CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; multimodal imaging; pigment epithelium
   detachment; optical coherence tomography angiography; structural optical
   coherence tomography; predictive activation biomarkers; treatment-naive
   quiescent choroidal neovascularization
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; SPECTRAL-DOMAIN; SWEPT-SOURCE;
   SECONDARY
AB Purpose: To assess the long-term evolution of treatment-naive quiescent choroidal neovascularization (CNV), in age-related macular degeneration (AMD), to identify predictive activation biomarkers. Methods: Patients with quiescent CNV underwent a comprehensive ophthalmological examination, including fluorescein and indocyanine green angiographies, structural optical coherence tomography (OCT), and OCT angiography. Qualitative and quantitative analyses of structural OCT and OCT angiography images were performed during the study period. At the last follow-up evaluation, the enrolled eyes were divided into two groups: eyes with quiescent CNV converting to exudative AMD (eAMD) and those not progressing to eAMD. Results: Sixty-eight eyes of 68 patients were enrolled in the study. Mean follow-up duration was 40 +/- 28 months using multimodal imaging and 22 +/- 13 months using OCT angiography. On structural OCT, quiescent CNV not converting to eAMD showed a preferential growth of the pigment epithelium detachment greatest linear diameter (P= 0.009), whereas the eAMD group presented a preferential growth of the pigment epithelium detachment maximal height (P< 0.0001) during the study period. Quantitative analysis of choriocapillaris OCT angiograms confirmed the CNV area growth during follow-up (from 4.18 +/- 4.77 mm(2)at baseline to 5.10 +/- 5.06 mm(2)at the last follow-up visit;P= 0.02). Conclusion: A close follow-up is recommended to early identify predictive activation biomarkers of treatment-naive quiescent CNV.
C1 [Serra, Rita] Univ Sassari, Dept Surg & Biomed Sci, Sassari, Italy.
   [Serra, Rita] CNR, Ist Ric Genet & Biomed IRGB, Monserrato, CA, Italy.
   [Serra, Rita; Coscas, Florence; Coscas, Gabriel J.; Souied, Eric H.] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, Creteil, France.
   [Coscas, Florence; Coscas, Gabriel J.] Ctr Ophtalmol Odeon, 113 Bd St Germain, Paris, France.
   [Boulet, Jean Francois] Paris VI Univ, 361 Rue Clement Ader,Batiment C, Paris, France.
   [Cabral, Diogo] Inst Oftalmol Dr Gama Pinto, Lisbon, Portugal.
   [Lupidi, Marco] Univ Perugia, S Maria Misericordia Hosp, Sect Ophthalmol, Dept Surg & Biomed Sci, Perugia, Italy.
C3 University of Sassari; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; UDICE-French
   Research Universities; Sorbonne Universite; University of Perugia
RP Coscas, F (通讯作者)，Univ Paris Est, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94010 Creteil, France.
EM coscas.f@gmail.com
OI Reis Cabral, Diogo/0000-0003-1968-3561; SERRA, RITA/0000-0002-6341-1435
CR Andreanos KD, 2017, EUR J OPHTHALMOL, V27, pE140, DOI 10.5301/ejo.5000995
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Ichiyama Y, 2017, RETINA-J RET VIT DIS, V37, P724, DOI 10.1097/IAE.0000000000001576
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kang H, 2018, RETINA
   Lam D, 2018, RETINA-J RET VIT DIS, V38, P1100, DOI 10.1097/IAE.0000000000001698
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lindner M, 2016, INVEST OPHTH VIS SCI, V57, P6342, DOI 10.1167/iovs.16-19741
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Miotto S, 2018, J OCUL PHARMACOL TH, V34, P298, DOI 10.1089/jop.2017.0022
   Mouallem A, 2016, RETINA-J RET VIT DIS, V36, P2197, DOI 10.1097/IAE.0000000000001062
   Nehemy MB, 2015, OSLI RETINA, V46, P1056, DOI 10.3928/23258160-20151027-13
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P2433, DOI 10.1097/IAE.0000000000000761
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Ryan SJ, 2013, BASIC SCI TRASLATION, VI, P51
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Serra R, 2017, AM J OPHTHALMOL, V176, P108, DOI 10.1016/j.ajo.2016.12.027
   Souedan V, 2018, INT OPHTHALMOL, V38, P1051, DOI 10.1007/s10792-017-0559-6
   Souied EH, 2016, DEV OPHTHALMOL, V56, P52, DOI 10.1159/000442777
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P609, DOI 10.1097/IAE.0000000000001575
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 42
TC 13
Z9 13
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2020
VL 40
IS 7
BP 1224
EP 1233
DI 10.1097/IAE.0000000000002604
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MG9VH
UT WOS:000546379800003
PM 31259809
DA 2022-11-30
ER

PT J
AU Ahmadieh, H
   Taei, R
   Soheilian, M
   Riazi-Esfahani, M
   Ahadi, H
AF Ahmadieh, H.
   Taei, R.
   Soheilian, M.
   Riazi-Esfahani, M.
   Ahadi, H.
TI Single-session photodynamic therapy combined with intravitreal
   bevacizumab for neovascular age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; combination therapy;
   macular disease; photodynamic therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN THERAPY; AVASTIN
AB PURPOSE. To evaluate the efficacy of combined single-session photodynamic therapy (PDT) and intravitreal bevacizumab (IVB) for treatment of neovascular age-related macular degeneration (AMD).
   METHODS. In a prospective interventional case series, patients with subfoveal choroidal neovascularization (CNV) underwent PDT followed by 1.25 mg IVB injection. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) measurements were repeated at 6-week intervals and fluorescein angiography was performed after 12 weeks and when considered necessary thereafter. Repeat injections of IVB were performed based on fluorescein angiographic evidence of CNV leakage.
   RESULTS. Fourteen eyes were included in this study. Mean follow-up was 52.4+/-15.2 weeks (range: 26-74 weeks). Initially, mean BCVA was 0.80+/-0.42 logMAR and mean central macular thickness (CMT) was 308+/-88 mu m At week 12, BCVA improved to 0.62+/-0.47 logMAR (p= 0.006) and CMT reduced to 186+/-53 mu m (p= 0.003). Corresponding results were 0.53+/-0.52 logMAR (p= 0.02) and 193+/-78 mu m (p= 0.002) after 24 weeks. A second IVB injection was performed in 13 eyes with a mean interval of 16.3+/-5.9 weeks.
   CONCLUSIONS. Combination therapy with single-session PDT and IVB can improve vision and reduce CMT in neovascular AMD. Repeat IVB injections may maintain the visual gain from the initial combination therapy.
C1 [Ahmadieh, H.; Taei, R.; Soheilian, M.; Ahadi, H.] Shahid Beheshti Univ, Labbafinejad Med Ctr, Ophthalm Res Ctr, Tehran 16666, Iran.
   [Riazi-Esfahani, M.] Farabi Eye Hosp, Tehran, Iran.
C3 Shahid Beheshti University; Tehran University of Medical Sciences
RP Ahmadieh, H (通讯作者)，Shahid Beheshti Univ, Labbafinejad Med Ctr, Ophthalm Res Ctr, Pasdaran Ave,Boostan 9 St, Tehran 16666, Iran.
EM hahmadieh@hotmail.com
RI Soheilian, Masoud/AAW-4743-2020; Ahmadieh, Hamid/M-4853-2017
OI Ahmadieh, Hamid/0000-0002-8139-2661; Soheilian,
   Masoud/0000-0001-7508-426X
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
NR 9
TC 12
Z9 12
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2008
VL 18
IS 2
BP 297
EP 300
DI 10.1177/112067210801800222
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 268CX
UT WOS:000253557000022
PM 18320527
DA 2022-11-30
ER

PT J
AU Despriet, DDG
   van Duijn, CM
   Oostra, BA
   Uitterlinden, AG
   Hofman, A
   Wright, AF
   ten Brink, JB
   Bakker, A
   de Jong, PTVM
   Vingerling, JR
   Bergen, AAB
   Klaver, CCW
AF Despriet, Dominiek D. G.
   van Duijn, Cornelia M.
   Oostra, Ben A.
   Uitterlinden, Andre G.
   Hofman, Albert
   Wright, Alan F.
   ten Brink, Jacoline B.
   Bakker, Arne
   de Jong, Paulus T. V. M.
   Vingerling, Johannes R.
   Bergen, Arthur A. B.
   Klaver, Caroline C. W.
TI Complement Component C3 and Risk of Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MACULOPATHY; VARIANT; DRUSEN; METAANALYSIS;
   ACTIVATION; INCREASES
AB Objective: To explore the association between polymorphisms in the complement component 3 (C3) gene and age-related macular degeneration (AMD), and to investigate the modifying effect of complement factor H (CFH) Y402H, LOC387715 A69S and smoking.
   Design: Pooled data from the prospective, population-based Rotterdam Study (enrolment between 1990 and 1993, and 3 follow-up examinations between September 1, 1993, and December 31, 2004) and an independent case-control study from the Netherlands.
   Participants: The Rotterdam Study comprised a total of 6418 persons aged >= 55 years who had gradable fundus photographs. The case-control study consisted of 357 unrelated AMD patients and 173 control individuals aged >= 55 years.
   Methods: The variants R102G and P314L of the C3 gene, CFH Y402H and LOC387715 A69S, were genotyped in all study participants. Information on cigarette smoking was obtained by interview at baseline.
   Main Outcome Measures: Early and late stages of prevalent and incident AMD, graded according to the international classification and grading system for AMD.
   Results: We found a population frequency of 0.217 for R102G and 0.211 for P314L in the Rotterdam Study. Both alleles significantly increased the risk of early AMD and all subtypes of late AMD, and this risk seemed to be independent of CFH Y402H, LOC387715 A69S, and smoking. Detailed analysis showed that the haplotype carrying both alleles had the highest frequency difference between cases and controls (P = 0.006). We estimated a total population-attributable risk of 14.6%. A meta-analysis of all currently available data yielded a pooled odds ratio (OR) of 1.61 (95% confidence interval [CI], 1.46-1.78) for the R102G allele, and an OR of 1.50 (95% Cl, 1.31-1.71) for the P314L allele.
   Conclusions: Our study showed a significant association between variants in the C3 gene and AMD and further highlights the crucial role of the complement pathway in the etiology of AMD.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:474-480 (C) 2009 by the American Academy of Ophthalmology.
C1 [Despriet, Dominiek D. G.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, NL-3000 CA Rotterdam, Netherlands.
   [Despriet, Dominiek D. G.; van Duijn, Cornelia M.; Uitterlinden, Andre G.; Hofman, Albert; de Jong, Paulus T. V. M.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol & Biostat, NL-3000 CA Rotterdam, Netherlands.
   [Despriet, Dominiek D. G.; ten Brink, Jacoline B.; Bakker, Arne; de Jong, Paulus T. V. M.; Bergen, Arthur A. B.; Klaver, Caroline C. W.] Royal Netherlands Acad Arts & Sci KNAW, Netherlands Inst Neurosci, Dept Clin & Mol Ophthalmogenet, Amsterdam, Netherlands.
   [Oostra, Ben A.] Erasmus MC, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands.
   [Wright, Alan F.] MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Bergen, Arthur A. B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Royal Netherlands Academy of Arts & Sciences; Netherlands
   Institute for Neuroscience (NIN-KNAW); Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of
   Edinburgh; University of Amsterdam; Academic Medical Center Amsterdam;
   University of Amsterdam; Academic Medical Center Amsterdam; Vrije
   Universiteit Amsterdam
RP Vingerling, JR (通讯作者)，Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM j.vingerling@erasmusmc.nl
RI Klaver, Caroline C.W./A-2013-2016; Bergen, Arthur/J-3637-2013
OI Van Duijn, Cornelia/0000-0002-2374-9204; Klaver,
   Caroline/0000-0002-2355-5258; Bergen, Arthur/0000-0002-6333-9576
FU Erasmus University; Netherlands Organization for Scientific Research;
   Optimix; General Netherlands Society for the Prevention of Blindness;
   Neyenburgh; Physico Therapeutic Institute; Blindenpenning; Sint Laurens
   Institute; Bevordering van Volkskracht; Blindenhulp; Rotterdamse
   Blindenbelangen Association; OOG Foundation; Ooglijders; Prins Bernhard
   Cultuurfonds; Van Leeuwen Van Lignac; Verhagen; Netherlands Society for
   the Prevention of Blindness; Elise Mathilde; Topcon Europe BV; Medical
   Research Council [G0700704B, MC_U127584475] Funding Source:
   researchfish; MRC [MC_U127584475] Funding Source: UKRI
FX The Prof. Dr. Henkesstichting, (Rotterdam). Swart van Essen (Rotterdam).
   a fellowship grant of Erasmus University, the Netherlands Organization
   for Scientific Research (the Hague), Optimix (Amsterdam). General
   Netherlands Society for the Prevention of Blindness (Doorn), Neyenburgh
   (Bunnik). Physico Therapeutic Institute (Rotterdam), Blindenpenning
   (Amsterdam), Sint Laurens Institute (Rotterdam). Bevordering van
   Volkskracht (Rotterdam), Blindenhulp (the Hague). Rotterdamse
   Blindenbelangen Association (Rotterdam), OOG Foundation (the Hague),
   Ooglijders (Rotterdam). Prins Bernhard Cultuurfonds (Amsterdam), Van
   Leeuwen Van Lignac (Rotterdam), Verhagen (Rotterdam), the Netherlands
   Society for the Prevention of Blindness (Doorn), and Elise Mathilde
   (Maarn). All unrestricted grant was obtained from Topcon Europe BV
   (Capelle aan de Ussel). The sponsors or funding organizations had no
   role in the design or conduct of this research.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Despriet DDG, 2007, ARCH OPHTHALMOL-CHIC, V125, P1270, DOI 10.1001/archopht.125.9.1270
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Greenland S., 1998, MODERN EPIDEMIOLOGY, P329
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Hofman A, 2007, EUR J EPIDEMIOL, V22, P819, DOI 10.1007/s10654-007-9199-x
   HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Nishida N, 2006, P NATL ACAD SCI USA, V103, P19737, DOI 10.1073/pnas.0609791104
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 27
TC 78
Z9 99
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2009
VL 116
IS 3
BP 474
EP 480
DI 10.1016/j.ophtha.2008.09.055
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 416KQ
UT WOS:000264005400018
PM 19168221
DA 2022-11-30
ER

PT J
AU Schilling, OK
   Wahl, HW
AF Schilling, Oliver K.
   Wahl, Hans-Werner
TI Modeling late-life adaptation in affective well-being under a severe
   chronic health condition: The case of age-related macular degeneration
SO PSYCHOLOGY AND AGING
LA English
DT Article
DE adaptation; positive and negative affect; subjective well-being;
   age-related macular degeneration; nonlinear mixed models
ID OLDER-ADULTS; NEGATIVE AFFECT; SOCIAL SUPPORT; DEPRESSION; DISABILITY;
   REHABILITATION; PERSONALITY; STABILITY; ANXIETY; SATISFACTION
AB Age-related macular degeneration (AMD) was used as a case model to longitudinally study adaptation in affective well-being under a prevalent chronic health condition. Measures of positive and negative affect, obtained at 5 subsequent measurement occasions with 3-month intervals in between, were analyzed in 90 older adults diagnosed with AMD. The authors proposed a pattern of adaptation that shows initial decline in affective well-being after disease outbreak, followed by a turnaround into a restorative phase of increase, implying nonlinear intraindividual trajectories, with changes substantially related to disease duration. Analysis was conducted by means of a nonlinear mixed models approach. Results confirmed the hypothesized adaptation pattern for positive affect but not for negative affect, which was found more stable across measurement occasions.
C1 Heidelberg Univ, Dept Psychol Aging Res, Inst Psychol, D-69115 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Schilling, OK (通讯作者)，Heidelberg Univ, Dept Psychol Aging Res, Inst Psychol, Bergheimer Str 20, D-69115 Heidelberg, Germany.
EM oliver.schilling@psychologie.uni-heidelberg.de
CR BAKER LA, 1992, PSYCHOL AGING, V7, P158, DOI 10.1037/0882-7974.7.1.158
   Baltes MM, 1996, AGEING SOC, V16, P397, DOI 10.1017/S0144686X00003603
   BEVAN W, 1965, J PSYCHOL, V59, P73, DOI 10.1080/00223980.1965.9916779
   Boerner K, 2004, J GERONTOL B-PSYCHOL, V59, pP35, DOI 10.1093/geronb/59.1.P35
   BRANDTSTADTER J, 1994, DEV REV, V14, P52, DOI 10.1006/drev.1994.1003
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Burmedi D, 2002, VIS IMPAIR RES, V4, P15, DOI [10.1076/vimr.4.1.15.15633, DOI 10.1076/VIMR.4.1.15.15633]
   Charles ST, 2001, J PERS SOC PSYCHOL, V80, P136, DOI 10.1037//0022-3514.80.1.136
   CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   COSTA PT, 1987, BRIT J PSYCHOL, V78, P299, DOI 10.1111/j.2044-8295.1987.tb02248.x
   de Beurs E, 2005, J AFFECT DISORDERS, V84, P53, DOI 10.1016/j.jad.2004.09.006
   Diener E, 1999, PSYCHOL BULL, V125, P276, DOI 10.1037//0033-2909.125.2.276
   Diener E., 1998, ANN REV GERONTOLOGY, V17, P304, DOI [10.1891/0198-8794.17.1.304, DOI 10.1891/0198-8794.17.1.304]
   Eid M, 1999, J PERS SOC PSYCHOL, V76, P662, DOI 10.1037/0022-3514.76.4.662
   EVANS RL, 1983, PSYCHOL REP, V52, P603, DOI 10.2466/pr0.1983.52.2.603
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fleeson W, 2006, J RES PERS, V40, P5, DOI 10.1016/j.jrp.2005.08.004
   Folkman S, 2004, ANNU REV PSYCHOL, V55, P745, DOI 10.1146/annurev.psych.55.090902.141456
   Forsyth D.R., 1991, HDB SOCIAL CLIN PSYC, P221
   GEORGE LK, 2003, ENCY AGING, P13
   HELSON H, 1948, PSYCHOL REV, V55, P297, DOI 10.1037/h0056721
   HERSEN M, 1995, J VISUAL IMPAIR BLIN, V89, P524
   HERZOG AR, 1981, RES AGING, V3, P142, DOI 10.1177/016402758132002
   HOLZ FG, 2003, AGERELATED MACULAR D
   HORLEY J, 1995, SOC INDIC RES, V34, P275, DOI 10.1007/BF01079200
   Horowitz A, 2005, AGING MENT HEALTH, V9, P563, DOI 10.1080/13607860500193500
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Horowitz A, 2003, AGING MENT HEALTH, V7, P342, DOI 10.1080/1360786031000150739
   Hox J. J., 2018, MULTILEVEL ANAL TECH, V3rd
   KLEIN LE, 1985, J AM GERIATR SOC, V33, P483, DOI 10.1111/j.1532-5415.1985.tb05460.x
   Kunzmann U, 2000, PSYCHOL AGING, V15, P511, DOI 10.1037//0882-7974.15.3.511
   Lawton M.P., 1973, PSYCHOL ADULT DEV AG, P619, DOI DOI 10.1037/10044-020
   LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91
   Lazarus R.S., 1991, EMOTION ADAPTATION
   Lucas RE, 2003, J PERS SOC PSYCHOL, V84, P527, DOI 10.1037/0022-3514.84.3.527
   MICHALOS AC, 1985, SOC INDIC RES, V16, P347, DOI 10.1007/BF00333288
   Mroczek DK, 2005, J PERS SOC PSYCHOL, V88, P189, DOI 10.1037/0022-3514.88.1.189
   Mroczek DK, 2004, J PERS, V72, P355, DOI 10.1111/j.0022-3506.2004.00265.x
   Mroczek DK, 2006, HDB PSYCHOL AGING, P363
   ORR AL, 1992, VISION AGING CROSSRO, P3
   Pruchno RA, 2004, PSYCHOL AGING, V19, P394, DOI 10.1037/0882-7974.19.3.394
   REINHARDT JP, 2001, APPL DEV SCI, V5, P76, DOI DOI 10.1207/S1532480XADS0502_3
   Rothermund K, 2003, PSYCHOL AGING, V18, P80, DOI 10.1037/0882-7974.18.1.80
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   SAS, 1999, SAS STAT US GUID VER
   Schilling Oliver Karl, 2005, Eur J Ageing, V2, P254, DOI 10.1007/s10433-005-0016-7
   Shapiro AM, 1999, COGNITIVE THER RES, V23, P53, DOI 10.1023/A:1018710707960
   Smith J., 1999, BERLIN AGEING STUDY, P450, DOI DOI 10.1017/CBO9780511586545.018
   Snijders T., 2012, MULTILEVEL ANAL INTR, V2nd ed
   STACEY CA, 1991, J GERONTOL B-PSYCHOL, V46, P76
   Staudinger U.M., 1998, BERLIN AGING STUDY A, P302, DOI [10.1017/CBO9780511586545.012, DOI 10.1017/CBO9780511586545.012]
   Staudinger UM, 2000, PSYCHOL RUNDSCH, V51, P185, DOI 10.1026//0033-3042.51.4.185
   Tolman J, 2005, GERONTOLOGIST, V45, P747, DOI 10.1093/geront/45.6.747
   Travis LA, 2004, J VISUAL IMPAIR BLIN, V98, P534, DOI 10.1177/0145482X0409800905
   Wahl HW, 1999, J GERONTOL B-PSYCHOL, V54, pP304, DOI 10.1093/geronb/54B.5.P304
   Wahl HW, 2004, PSYCHOL AGING, V19, P235, DOI 10.1037/0882-7974.19.1.235
   WAHL HW, 2006, VISION 2005, P326
   Watson D, 1999, PSYCHOL BULL, V125, P601, DOI 10.1037/0033-2909.125.5.601
   WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063
   Watson D, 1994, PANAS 10 MANUAL POSI
   Wetherell JL, 2001, PSYCHOL AGING, V16, P187, DOI 10.1037//0882-7974.16.2.187
   WHITE EH, 1996, P 7 NAT BIOEN C, V1, P60
NR 64
TC 37
Z9 38
U1 0
U2 12
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0882-7974
EI 1939-1498
J9 PSYCHOL AGING
JI Psychol. Aging
PD DEC
PY 2006
VL 21
IS 4
BP 703
EP 714
DI 10.1037/0882-7974.21.4.703
PG 12
WC Gerontology; Psychology, Developmental
WE Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychology
GA 117MH
UT WOS:000242876800005
PM 17201491
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Konstantinidis, L
   Mantel, I
   Zografos, L
   Ambresin, A
AF Konstantinidis, L.
   Mantel, I.
   Zografos, L.
   Ambresin, A.
TI Intravitreal Ranibizumab in the Treatment of Predominantly Hemorrhagic
   Lesions in Exudative Age-Related Macular Degeneration
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE intravitreal ranibizumab; choroidal neovascularization; predominantly
   hemorrhagic age-related macular degeneration
ID TISSUE-PLASMINOGEN ACTIVATOR; CHOROIDAL NEOVASCULAR LESIONS; OPTICAL
   COHERENCE TOMOGRAPHY; SUBMACULAR HEMORRHAGE; SUBRETINAL HEMORRHAGE;
   PNEUMATIC DISPLACEMENT; PHOTODYNAMIC THERAPY; NATURAL-HISTORY; GAS
   INJECTION; EXPANSILE GAS
AB Background: Submacular hemorrhage is a manifestation of neovascular age-related macular degeneration (AMD) that has a very poor natural history leading to severe visual loss. We have evaluated the safety and efficacy of intravitreal ranibizumab in the treatment of predominantly hemorrhagic AMD.
   Patients and Methods: A retrospective study of patients with predominantly hemorrhagic AMD treated with intravitreal ranibizumab at the Jules Gonin Eye Hospital between December 2006 and December 2008 was undertaken. Baseline and monthly follow-up exams included visual acuity (VA), fundus exam and optical coherence tomography (OCT) while fluorescein and indocyanine green angiography were performed at least every three months.
   Results: The study included 8 eyes. The mean follow-up was 13 months (SD: 6.3). The mean number of intravitreal injections administered for each patient was 6.4 (SD: 2). 50% of the patients demonstrated stable or improved VA. The size of hemorrhage at baseline was inversely correlated to the final VA (two-tailed p value = 0.038) and positively correlated to the final central macular thickness (two-tailed p value = 0.021). Anticoagulation treatment was inversely correlated to the time of hemorrhage resolution (two-tailed p value = 0.039).
   Conclusions: Intravitreal ranibizumab may be an effective treatment for predominantly hemorrhagic lesions due to neovascular AMD.
C1 [Konstantinidis, L.; Mantel, I.; Zografos, L.; Ambresin, A.] Jules Gonin Univ, Hosp Eye, Lausanne, Switzerland.
RP Ambresin, A (通讯作者)，Hop Ophtalm Jules Gonin, 15 Av France, CH-1004 Lausanne, Switzerland.
EM aude.ambresin@fa2.ch
CR Ahmad S, 2008, AM J OPHTHALMOL, V145, P1052, DOI 10.1016/j.ajo.2008.02.008
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bakri SJ, 2006, OPHTHAL SURG LAS IM, V37, P278, DOI 10.3928/15428877-20060701-03
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Gibran S, 2009, GRAEF ARCH CLIN EXP, V247, P187, DOI 10.1007/s00417-008-0958-5
   Hasselbach HC, 2007, GRAEF ARCH CLIN EXP, V245, P1145, DOI 10.1007/s00417-006-0501-5
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Lincoff H, 2001, RETINA-J RET VIT DIS, V21, P191, DOI 10.1097/00006982-200104000-00021
   Lincoff H, 2008, RETINA-J RET VIT DIS, V28, P56, DOI 10.1097/IAE.0b013e31806e60db
   Ma ZZ, 2009, INVEST OPHTH VIS SCI, V50, P2975, DOI 10.1167/iovs.08-2573
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Ratanasukon M, 2005, EYE, V19, P1328, DOI 10.1038/sj.eye.6701769
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2006, EUR J OPHTHALMOL, V16, P426, DOI 10.1177/112067210601600311
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Steller A, 2004, OPHTHALMOLOGE, V101, P500, DOI 10.1007/s00347-003-0924-x
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
   THOMPSON JT, 2005, T AM OPHTHAL SOC, V103, P107
   Woo J. John, 2004, International Ophthalmology Clinics, V44, P43, DOI 10.1097/00004397-200404410-00006
NR 38
TC 3
Z9 3
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2011
VL 228
IS 4
BP 288
EP 292
DI 10.1055/s-0031-1273214
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 748RV
UT WOS:000289409600007
PM 21484631
DA 2022-11-30
ER

PT J
AU Hilal, A
   Bazarah, M
   Kapoula, Z
AF Hilal, Anis
   Bazarah, Mazen
   Kapoula, Zoi
TI Benefits of Implementing Eye-Movement Training in the Rehabilitation of
   Patients with Age-Related Macular Degeneration: A Review
SO BRAIN SCIENCES
LA English
DT Article
DE age-related macular degeneration; eye; central scotoma; macular
   degeneration; eye tracking quality of life; VFI tools; eye-movement
   training; neuroplasticity
ID QUALITY-OF-LIFE; CENTRAL SCOTOMA; VISUAL FUNCTION; PLASTICITY;
   EXPERIENCE; BLINDNESS
AB Age-related macular degeneration (ARMD) is one of the most debilitating eye-related illnesses worldwide. Eye-movement training is evolving to be a non-invasive, rapid, and effective method that is positively impacting vision and QoL (quality of life) in patients suffering from ARMD. This review aims to highlight why a greater adoption of eye-movement training in the clinical and research setting is of importance. A PubMed and ResearchGate search was performed for articles published between 1982 and 2020. Patients with advanced ARMD tend to experience a diminished QoL. Studies regarding eye-movement training for patients with central vision loss revealed overall significant improvements in reading speeds, fixation, and saccade performance. They also experienced less fatigue. In select studies, eye-movement training revealed an improvement in binocular vision, fixation, reading speed, and diminished reading exhaustion. The process of eye-movement training used in some of the studies was rather empirical. The latter requires standardization so that a uniform and applicable methodology can be adopted overall.
C1 [Hilal, Anis; Bazarah, Mazen] Skane Univ Hosp, Dept Ophthalmol, Kioskgatan 1, S-22285 Lund, Sweden.
   [Hilal, Anis; Kapoula, Zoi] Univ Paris, CNRS, Lab IRIS, UFR Biomed,FR2022,Physiopathol Vis & Motricite Bi, 45 Rue St Peres, F-75006 Paris, France.
C3 Lund University; Skane University Hospital; Centre National de la
   Recherche Scientifique (CNRS); UDICE-French Research Universities;
   Universite Paris Cite
RP Hilal, A; Bazarah, M (通讯作者)，Skane Univ Hosp, Dept Ophthalmol, Kioskgatan 1, S-22285 Lund, Sweden.; Hilal, A; Kapoula, Z (通讯作者)，Univ Paris, CNRS, Lab IRIS, UFR Biomed,FR2022,Physiopathol Vis & Motricite Bi, 45 Rue St Peres, F-75006 Paris, France.
EM anishilal13@gmail.com; mazen.b@live.com; zoi.kapoula@parisdescartes.fr
FU Lund University Hospital
FX I would like to acknowledge the guidance and counseling of Zoii Kappoula
   of the prestigious University of Paris. Her input has been priceless
   regarding a topic that has insurmountable potential for vision and
   healthcare. I would also like to acknowledge the time and care that
   Mazen Bazarah put into proofreading this project. Finally, I would like
   to thank Lund University Hospital for the time and support it granted me
   to put together this paper during my residency in ophthalmology.
CR Berdeaux G.H., 2007, AM J OPHTHALMOL, V125, P1460
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Coco-Martin MB, 2017, CURR EYE RES, V42, P1260, DOI 10.1080/02713683.2017.1315140
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Daniel F, 2016, FRONT INTEGR NEUROSC, V10, DOI 10.3389/fnint.2016.00033
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202
   Janssen CP, 2016, J VISION, V16, DOI 10.1167/16.15.29
   Kaltenegger K, 2019, GRAEF ARCH CLIN EXP, V257, P1499, DOI 10.1007/s00417-019-04328-9
   Karmarkar UR, 2006, NEURON, V52, P577, DOI 10.1016/j.neuron.2006.11.001
   Lene P, 2020, RESTOR NEUROL NEUROS, V38, P203, DOI 10.3233/RNN-190957
   Leonard R., STAT VISION IMPAIRME
   Li RW, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001135
   Liu R, 2016, J VISION, V16, DOI 10.1167/16.6.10
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Morales MU, 2020, INT OPHTHALMOL, V40, P305, DOI 10.1007/s10792-019-01180-y
   Murphy B.J., 1978, J NEUROSCI, V35, P10146
   Muzyka-Wozniak Maria, 2011, Klin Oczna, V113, P161
   National Eye Institute, AGE RELATED MACULAR
   Nelles G, 2010, J NEUROL, V257, P1832, DOI 10.1007/s00415-010-5617-1
   Nelson CA, 2000, DEVELOPMENTAL SCI, V3, P115, DOI 10.1111/1467-7687.00104
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Ord LM, 2015, J CLIN MED, V4, P1841, DOI 10.3390/jcm4091841
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Shima N, 2010, CAN J OPHTHALMOL, V45, P62, DOI 10.3129/i09-236
   Siaudvytyte L, 2012, MEDICINA-LITHUANIA, V48, P109, DOI 10.3390/medicina48020015
   Van der Stigchel S, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00579
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Walsh DV, 2014, VISION RES, V96, P75, DOI 10.1016/j.visres.2014.01.005
   World Health Organization, 2010, GLOB DAT WEBS POW TE
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
NR 38
TC 0
Z9 0
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3425
J9 BRAIN SCI
JI Brain Sci.
PD JAN
PY 2022
VL 12
IS 1
AR 36
DI 10.3390/brainsci12010036
PG 19
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA YS5PC
UT WOS:000750727600001
PM 35053780
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Samra, YA
   Kira, D
   Rajpurohit, P
   Mohamed, R
   Owen, LA
   Shakoor, A
   Kim, IK
   DeAngelis, MM
   Sheibani, N
   Al-Shabrawey, M
   Tawfik, A
AF Samra, Yara A.
   Kira, Dina
   Rajpurohit, Pragya
   Mohamed, Riyaz
   Owen, Leah A.
   Shakoor, Akbar
   Kim, Ivana K.
   DeAngelis, Margaret M.
   Sheibani, Nader
   Al-Shabrawey, Mohamed
   Tawfik, Amany
TI Implication of N-Methyl-D-Aspartate Receptor in Homocysteine-Induced
   Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE N-methyl-D-aspartate receptor; homocysteine; age-related macular
   degeneration; blood retinal barrier; cystathionine-beta-synthase; mouse
ID BLOOD-BRAIN-BARRIER; PLASMA HOMOCYSTEINE; RETINAL NEOVASCULARIZATION;
   NMDA RECEPTOR; VEGF; PHOSPHORYLATION; PROLIFERATION; VITAMIN-B12;
   ACTIVATION; EXPRESSION
AB Age-related macular degeneration (AMD) is a leading cause of vision loss. Elevated homocysteine (Hcy) (Hyperhomocysteinemia) (HHcy) has been reported in AMD. We previously reported that HHcy induces AMD-like features. This study suggests that N-Methyl-d-aspartate receptor (NMDAR) activation in the retinal pigment epithelium (RPE) is a mechanism for HHcy-induced AMD. Serum Hcy and cystathionine-beta-synthase (CBS) were assessed by ELISA. The involvement of NMDAR in Hcy-induced AMD features was evaluated (1) in vitro using ARPE-19 cells, primary RPE isolated from HHcy mice (CBS), and mouse choroidal endothelial cells (MCEC); (2) in vivo using wild-type mice and mice deficient in RPE NMDAR (NMDAR(R)(-/-)) with/without Hcy injection. Isolectin-B4, Ki67, HIF-1 alpha, VEGF, NMDAR1, and albumin were assessed by immunofluorescence (IF), Western blot (WB), Optical coherence tomography (OCT), and fluorescein angiography (FA) to evaluate retinal structure, fluorescein leakage, and choroidal neovascularization (CNV). A neovascular AMD patient's serum showed a significant increase in Hcy and a decrease in CBS. Hcy significantly increased HIF-1 alpha, VEGF, and NMDAR in RPE cells, and Ki67 in MCEC. Hcy-injected WT mice showed disrupted retina and CNV. Knocking down RPE NMDAR improved retinal structure and CNV. Our findings underscore the role of RPE NMDAR in Hcy-induced AMD features; thus, NMDAR inhibition could serve as a promising therapeutic target for AMD.
C1 [Samra, Yara A.; Kira, Dina; Rajpurohit, Pragya] Augusta Univ, Dent Coll Georgia, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA.
   [Samra, Yara A.; Kira, Dina; Rajpurohit, Pragya] Augusta Univ, James & Jean Culver Vis Discovery Inst, MCG, Augusta, GA 30912 USA.
   [Samra, Yara A.] Mansoura Univ, Fac Pharm, Dept Biochem, Mansoura 35516, Egypt.
   [Mohamed, Riyaz] Augusta Univ, Med Coll Georgia MCG, Dept Physiol, Augusta, GA 30912 USA.
   [Owen, Leah A.; DeAngelis, Margaret M.] SUNY Univ Buffalo, Jacobs Sch Med & Biomed Engn, Dept Ophthalmol, Buffalo, NY 14214 USA.
   [Owen, Leah A.; DeAngelis, Margaret M.] Univ Utah, Dept Populat Hlth Sci, Sch Med, Salt Lake City, UT 84108 USA.
   [Owen, Leah A.; Shakoor, Akbar; DeAngelis, Margaret M.] Univ Utah, Dept Ophthalmol & Visual Sci, Sch Med, Salt Lake City, UT 84132 USA.
   [Kim, Ivana K.] Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear, Boston, MA 02114 USA.
   [DeAngelis, Margaret M.] VA Western New York Healthcare Syst, Buffalo, NY 14215 USA.
   [Sheibani, Nader] Univ Wisconsin, Dept Ophthalmol Visual Sci & Biomed Engn, Sch Med & Publ Hlth, Madison, WI 53726 USA.
   [Al-Shabrawey, Mohamed; Tawfik, Amany] Oakland Univ, Dept Fdn Med Studies, William Beaumont Sch Med, Rochester, MI 48309 USA.
   [Al-Shabrawey, Mohamed; Tawfik, Amany] Oakland Univ, Eye Res Ctr, William Beaumont Sch Med, Rochester, MI 48309 USA.
   [Al-Shabrawey, Mohamed; Tawfik, Amany] Oakland Univ, Eye Res Inst, Rochester, MI 48309 USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; Egyptian Knowledge Bank (EKB); Mansoura
   University; University System of Georgia; Augusta University; State
   University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; Utah System of Higher Education; University of Utah;
   Utah System of Higher Education; University of Utah; Harvard University;
   Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of
   Wisconsin System; University of Wisconsin Madison; Oakland University;
   Oakland University; Oakland University
RP Tawfik, A (通讯作者)，Oakland Univ, Eye Res Ctr, William Beaumont Sch Med, Rochester, MI 48309 USA.; Tawfik, A (通讯作者)，Oakland Univ, Eye Res Inst, Rochester, MI 48309 USA.
EM yaraadel@mans.edu.eg; dkira@augusta.edu; prajpurohit@augusta.edu;
   rmohamed@augusta.edu; leah.owen@hsc.utah.edu;
   akbar.shakoor@hsc.utah.edu; Ivana_Kim@meei.harvard.edu;
   mmdeange@buffalo.edu; nsheibanikar@wisc.edu; malshabrawey@oakland.edu;
   amtawfik@oakland.edu
RI Samra, Yara/AGB-5593-2022; Samra, Yara A/AAD-1192-2022
OI adel, yara/0000-0002-0223-8683; Sheibani, Nader/0000-0003-2723-9217;
   Owen, Leah/0000-0003-3802-3868; DeAngelis, Margaret/0000-0003-3731-142X
FU NEI [R01 EY030054]; Macular Degeneration Foundation, Inc.; Carl Marshall
   and Mildred Almen Reeves Foundation
FX This research was funded by NEI grant award R01 EY029751-01-NEI00072,
   NEI grant award R01 EY030054, Macular Degeneration Foundation, Inc. Carl
   Marshall and Mildred Almen Reeves Foundation.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Andras IE, 2007, J CEREBR BLOOD F MET, V27, P1431, DOI 10.1038/sj.jcbfm.9600445
   Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   Beard RS, 2011, BLOOD, V118, P2007, DOI 10.1182/blood-2011-02-338269
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Diederen RMH, 2006, EXP EYE RES, V83, P45, DOI 10.1016/j.exer.2005.10.031
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Elmasry Khaled, 2018, Oncotarget, V9, P12562, DOI 10.18632/oncotarget.24333
   Elsherbiny NM, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030393
   Fei P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116423
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Forooghian F, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.123125
   Ganapathy PS, 2011, INVEST OPHTH VIS SCI, V52, P5551, DOI 10.1167/iovs.11-7256
   Garcia S, 2008, J CELL BIOCHEM, V104, P377, DOI 10.1002/jcb.21633
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Hardingham GE, 2009, BIOCHEM SOC T, V37, P1147, DOI 10.1042/BST0371147
   HENNEY CS, 1970, IMMUNOCHEMISTRY, V7, P275, DOI 10.1016/0019-2791(70)90166-7
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Ibrahim AS, 2016, ONCOTARGET, V7, P8532, DOI 10.18632/oncotarget.7384
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Kalani A, 2013, MOL NEUROBIOL, V48, P157, DOI 10.1007/s12035-013-8421-y
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1
   Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923
   Liu X, 2010, NEUROL SCI, V31, P699, DOI 10.1007/s10072-010-0241-5
   Martin PM, 2009, MOL VIS, V15, P362
   McCully KS, 2007, AM J CLIN NUTR, V86, p1563S, DOI 10.1093/ajcn/86.5.1563S
   Mohamed R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09731-y
   Mowat FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011103
   Murakami T, 2009, J BIOL CHEM, V284, P21036, DOI 10.1074/jbc.M109.016766
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Obeid R, 2013, CLIN CHEM LAB MED, V51, P657, DOI 10.1515/cclm-2012-0402
   Ola MS, 2011, NEUROCHEM INT, V59, P656, DOI 10.1016/j.neuint.2011.06.010
   Owen Leah A, 2019, Invest Ophthalmol Vis Sci, V60, P1204, DOI 10.1167/iovs.18-24254
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   Reigada D, 2006, J PHYSIOL-LONDON, V575, P707, DOI 10.1113/jphysiol.2006.114439
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Sawicki A, 1986, Pol Arch Med Wewn, V75, P417
   Schmidt KG, 2008, CURR NEUROPHARMACOL, V6, P164, DOI 10.2174/157015908784533851
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1
   Sharp CD, 2003, AM J PHYSIOL-HEART C, V285, pH2592, DOI 10.1152/ajpheart.00520.2003
   Tawfik A, 2021, J MOL MED, V99, P119, DOI 10.1007/s00109-020-02000-y
   Tawfik A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10081119
   Tawfik A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010121
   Tawfik Amany, 2014, Austin J Clin Ophthalmol, V1, P1023
   Tawfik A, 2014, AM J PATHOL, V184, P2573, DOI 10.1016/j.ajpath.2014.05.018
   Uchida N, 1998, EUR J PHARMACOL, V343, P265, DOI 10.1016/S0014-2999(97)01526-4
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu LX, 2016, J ALZHEIMERS DIS, V54, P297, DOI 10.3233/JAD-160329
   Yu XH, 2009, EXP EYE RES, V89, P967, DOI 10.1016/j.exer.2009.08.006
NR 59
TC 0
Z9 0
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2021
VL 22
IS 17
AR 9356
DI 10.3390/ijms22179356
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA UN9YG
UT WOS:000694361600001
PM 34502266
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Herbert, AP
   Deakin, JA
   Schmidt, CQ
   Blaum, BS
   Egan, C
   Ferreira, VP
   Pangburn, MK
   Lyon, M
   Uhrin, D
   Barlow, PN
AF Herbert, Andrew P.
   Deakin, Jon A.
   Schmidt, Christoph Q.
   Blaum, Barbel S.
   Egan, Claire
   Ferreira, Viviana P.
   Pangburn, Michael K.
   Lyon, Malcolm
   Uhrin, Dusan
   Barlow, Paul N.
TI Structure shows that a glycosaminoglycan and protein recognition site in
   factor H is perturbed by age-related macular degeneration-linked single
   nucleotide polymorphism
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; HEPARIN-BINDING DOMAIN; SHORT
   CONSENSUS REPEAT; ALTERNATIVE PATHWAY; STRONG ASSOCIATION;
   NMR-SPECTROSCOPY; VARIANT; COMMON; Y402H
AB A common single nucleotide polymorphism in the factor H gene predisposes to age-related macular degeneration. Factor H blocks the alternative pathway of complement on self-surfaces bearing specific polyanions, including the glycosaminoglycan chains of proteoglycans. Factor H also binds C-reactive protein, potentially contributing to noninflammatory apoptotic processes. The at risk sequence contains His ( rather than Tyr) at position 402 (384 in the mature protein), in the seventh of the 20 complement control protein (CCP) modules (CCP7) of factor H. We expressed both His402 and Tyr(402) variants of CCP7, CCP7,8, and CCP6-8. We determined structures of His(402) and Tyr(402) CCP7 and showed them to be nearly identical. The side chains of His/Tyr(402) have similar, solvent-exposed orientations far from interfaces with CCP6 and -8. Tyr(402) CCP7 bound significantly more tightly than His(402) CCP7 to a heparin affinity column as well as to defined-length sulfated heparin oligosaccharides employed in gel mobility shift assays. This observation is consistent with the position of the 402 side chain on the edge of one of two glycosaminoglycan-binding surface patches on CCP7 that we inferred on the basis of chemical shift perturbation studies with a sulfated heparin tetrasaccharide. According to surface plasmon resonance measurements, Tyr(402) CCP6-8 binds significantly more tightly than His(402) CCP6-8 to immobilized C-reactive protein. The data support a causal link between H402Y and age-related macular degeneration in which variation at position 402 modulates the response of factor H to age-related changes in the glycosaminoglycan composition and apoptotic activity of the macula.
C1 Univ Edinburgh, Sch Chem, Edinburgh Biomol NMR Unit, Edinburgh EH9 3JJ, Midlothian, Scotland.
   Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JJ, Midlothian, Scotland.
   Univ Manchester, Paterson Inst Canc Res, Canc Res Uk Glyco Oncol Grp, Manchester M20 4BX, Lancs, England.
   Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75703 USA.
C3 University of Edinburgh; University of Edinburgh; Paterson Institute for
   Cancer Research; University of Manchester; University of Texas System;
   University of Texas at Tyler; University of Texas-Health Sciences Center
   at Tyler (UTHSCT)
RP Barlow, PN (通讯作者)，Univ Edinburgh, Chem Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.
EM Paul.Barlow@ed.ac.uk
RI Barlow, Paul N/G-2853-2011; Herbert, Andrew P/C-4755-2008; Herbert, Andy
   P/F-6693-2010
OI Herbert, Andrew P/0000-0002-4549-6965; Herbert, Andy
   P/0000-0002-4549-6965; Blaum, Baerbel/0000-0003-4312-8912; Lyon,
   Malcolm/0000-0001-9575-6879; Ferreira, Viviana/0000-0001-8923-5671
FU Medical Research Council [G0001089] Funding Source: Medline; NIDDK NIH
   HHS [DK35081] Funding Source: Medline; Wellcome Trust Funding Source:
   Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [R37DK035081, R01DK035081] Funding Source: NIH RePORTER; MRC
   [G0001089] Funding Source: UKRI
CR Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Cordier F, 2003, J AM CHEM SOC, V125, P15750, DOI 10.1021/ja038616m
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Giannakis E, 2001, INT IMMUNOPHARMACOL, V1, P433, DOI 10.1016/S1567-5769(00)00040-0
   Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Habeck Michael, 2004, Methods Mol Biol, V278, P379
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9
   Kirkitadze MD, 1999, FEBS LETT, V459, P133, DOI 10.1016/S0014-5793(99)01205-3
   Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Lyon M, 2004, J BIOL CHEM, V279, P43560, DOI 10.1074/jbc.M408510200
   Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200
   Nabuurs SB, 2003, J AM CHEM SOC, V125, P12026, DOI 10.1021/ja035440f
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Nilges M, 1997, FOLD DES, V2, pS53, DOI 10.1016/S1359-0278(97)00064-3
   NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012
   ORMSBY RJ, 2007, MOL IMMUNOL, V44, P224
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   QUIOCHO FA, 1993, BIOCHEM SOC T, V21, P442, DOI 10.1042/bst0210442
   RIPOCHE J, 1986, BIOSCIENCE REP, V6, P65, DOI 10.1007/BF01145180
   Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285
   Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19
   Sue SC, 2004, J MOL BIOL, V343, P1365, DOI 10.1016/j.jmb.2004.09.014
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100
   Verdugo ME, 1997, EXP EYE RES, V65, P231, DOI 10.1006/exer.1997.0325
   Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2007, MOL IMMUNOL, V44, P3850, DOI 10.1016/j.molimm.2007.06.149
NR 62
TC 90
Z9 90
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 29
PY 2007
VL 282
IS 26
BP 18960
EP 18968
DI 10.1074/jbc.M609636200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 181ZQ
UT WOS:000247475300038
PM 17360715
OA hybrid
DA 2022-11-30
ER

PT J
AU Finger, RP
   Chong, E
   McGuinness, MB
   Robman, LD
   Aung, KZ
   Giles, G
   Baird, PN
   Guymer, RH
AF Finger, Robert P.
   Chong, Elaine
   McGuinness, Myra B.
   Robman, Luba D.
   Aung, Khin Zaw
   Giles, Graham
   Baird, Paul N.
   Guymer, Robyn H.
TI Reticular Pseudodrusen and Their Association with Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; RETINAL-PIGMENT EPITHELIUM; INCREASED
   EXPRESSION; GEOGRAPHIC-ATROPHY; SERINE-PROTEASE; RISK-FACTOR; HTRA1;
   EYES; MACULOPATHY; PROGRESSION
AB Purpose: To determine the prevalence of reticular pseudodrusen (RPD) and its association with age-related macular degeneration (AMD) and AMD risk factors in a large sample.
   Design: Community-based cohort study in Melbourne, Victoria, Australia.
   Participants: A total of 21 130 participants 48 to 86 years of age available for ophthalmic assessment at follow-up from 2003 through 2007.
   Methods: Lifestyle, diet, and anthropometric measurements were obtained at baseline and follow-up. At follow-up, digital macular color photographs were graded for early, intermediate, and late AMD as well as the presence of RPD. Data were analyzed using multinomial logistic regression controlling for age, gender, smoking, country of birth, and diet.
   Main Outcome Measures: Detection of RPD based on color fundus photographs.
   Results: Prevalence of RPD was 0.41% (87 of 21 130 participants), with 51% having bilateral RPD. Patients with RPD were older compared with patients with large drusen (> 125 mu m; 76 +/- 4 vs. 68 +/- 9 years; P < 0.001). Increasing age, female gender, being a current smoker, as well as focal pigmentary abnormalities and large drusen (> 125 mm) were associated with a higher prevalence of RPD. Presence of geographic atrophy (GA) was associated with the highest odds of having RPD (odds ratio [OR], 153; 95% confidence interval [CI], 53-442), followed by choroidal neovascularization (CNV; OR, 90; 95% CI, 26-310), intermediate AMD (OR, 33; 95% CI, 14-77), and early AMD (OR, 12; 95% CI, 5-31) compared with those with no AMD. The ARMS2 single nucleotide polymorphism (SNP) rs10490924, HTRA1 SNPs rs11200638 and rs3793917, and CFH SNPs rs393955, rs1061170, and rs2274700 were associated with increased prevalence of RPD (all P < 0.05).
   Conclusions: Reticular pseudodrusen are highly concurrent with AMD and have similar associations with known AMD risk factors such as age, gender, smoking, and genetic risk factors. Reticular pseudodrusen are associated more strongly with GA than with CNV. Although RPD are not specific to AMD, they are likely to be a strong risk factor for progression to late-stage AMD, similar to focal pigmentary abnormalities and large drusen. (C) 2016 by the American Academy of Ophthalmology.
C1 [Finger, Robert P.; Chong, Elaine; McGuinness, Myra B.; Robman, Luba D.; Aung, Khin Zaw; Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Giles, Graham] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Cancer Council Victoria
RP Finger, RP (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St,Level 1, East Melbourne, Vic 3002, Australia.
EM robertfinger@gmx.net
RI McGuinness, Myra/G-4900-2017
OI McGuinness, Myra/0000-0002-5422-040X; Baird, Paul/0000-0002-1305-3502;
   Finger, Robert P/0000-0003-4253-7597; Guymer, Robyn/0000-0002-9441-4356;
   Giles, Graham/0000-0003-4946-9099
FU National Health & Medical Research Council of Australia [209057, 251533,
   396414, 529923]; VicHealth and Cancer Council Victoria (cohort
   recruitment); Ophthalmic Research Institute of Australia; American
   Health Assistance Foundation [M2008-082]; Jack Brockhoff Foundation;
   John Reid Charitable Trust; Perpetual Trustees; Charles Viertel
   Charitable Foundation; Lloyd and Kathleen Ansell Ophthalmology
   Foundation; Mankiewicz-Zelkin Fellowship of the University of Melbourne,
   Melbourne, Australis; Victorian Centre for Biostatistics; National
   Health & Medical Research Council of Australia Centre of Research
   Excellence [1035261]; Victorian Government
FX Supported by the National Health & Medical Research Council of Australia
   (program grant no.: 209057, capacity building grant no.: 251533, and
   enabling grant no.: 396414); VicHealth and Cancer Council Victoria
   (cohort recruitment); Ophthalmic Research Institute of Australia;
   American Health Assistance Foundation (grant no.: M2008-082); Jack
   Brockhoff Foundation; John Reid Charitable Trust; Perpetual Trustees;
   the Charles Viertel Charitable Foundation; the Lloyd and Kathleen Ansell
   Ophthalmology Foundation; and the Mankiewicz-Zelkin Fellowship of the
   University of Melbourne, Melbourne, Australis (R.P.F.); the Victorian
   Centre for Biostatistics (Australian Postgraduate Award and studentship
   funded by National Health & Medical Research Council of Australia Centre
   of Research Excellence grant no.: 1035261 [M.B.M.]). The Centre for Eye
   Research Australia is supported by the National Health & Medical
   Research Council of Australia (Centre of Clinical Research Excellence
   grant no.: 529923) and the Victorian Government (operational
   infrastructure support). All sponsors are located in Australia except
   the American Health Assistance Foundation which is located in the United
   States. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Adams MKM, 2012, HUM MOL GENET, V21, P5229, DOI 10.1093/hmg/dds364
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Giles G G, 2002, IARC Sci Publ, V156, P69
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Ireland P, 1994, Asia Pac J Clin Nutr, V3, P19
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kumar S, 2014, INVEST OPHTH VIS SCI, V55, P3842, DOI 10.1167/iovs.13-13111
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Robman LD, 2015, OPHTHAL EPIDEMIOL, V22, P75, DOI 10.3109/09286586.2015.1010688
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 36
TC 75
Z9 78
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2016
VL 123
IS 3
BP 599
EP 608
DI 10.1016/j.ophtha.2015.10.029
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DE4UQ
UT WOS:000370626300035
PM 26681391
DA 2022-11-30
ER

PT J
AU Shen, YK
   Ge, QM
   Pan, YC
   Shu, HY
   Zhang, LJ
   Li, QY
   Liang, RB
   Shao, Y
   Yu, Y
AF Shen, Yan-Kun
   Ge, Qian-Min
   Pan, Yi-Cong
   Shu, Hui-Ye
   Zhang, Li-Juan
   Li, Qiu-Yu
   Liang, Rong-Bin
   Shao, Yi
   Yu, Yao
TI Decreased gray matter volume and increased white matter volume in
   patients with neovascular age-related macular degeneration: a
   voxel-based morphometry study
SO AGING-US
LA English
DT Article
DE neovascular age-related macular degeneration; choroidal
   neovascularization; mental disorder
ID ANTERIOR CINGULATE CORTEX; CONFLICT; NEUROSCIENCE; RANIBIZUMAB;
   GLAUCOMA; ATROPHY
AB Objective: To measure white and gray matter volume (WMV, GMV) in patients with neovascular age-related macular degeneration (nAMD) using voxel-based morphometry (VBM).
   Material: Eighteen patients (9 men, 9 women) with nAMD and 18 (9 men, 9 women) healthy controls (HCs) aligned were recruited. Functional magnetic resonance imaging (fMRI) and VBM of three-dimensional T1 brain images were analyzed. And we also apply t-tests to look for GMV and WMV differences between groups. Correlation analysis was utilized to probe the connection between observational GMV and WMV values of diverse brain areas and the severity of HADS (hospital anxiety and depression scale). Also, distinctions between nAMD and HCs in GMV can be presented with the help of a ROC (receiver operating characteristic) curve.
   Results: Compared with HCs, GMV values were significantly lower in patients with neovascular age-related macular degeneration in the right inferior frontal gyrus, temporal pole of left superior temporal gyrus, left superior temporal gyrus, left middle frontal gyrus, left anterior cingulate and para cingulate gyrus. While WMV was slightly increased in these areas. HADS (hospital anxiety and depression scale) scores portrayed a non-linear correlation with the GMV value of the right inferior frontal gyrus, left middle frontal gyrus, left anterior cingulate and paracingulate gyrus of the nAMD group (r=-0.6629, P=0.0027)(r=-0.9451, P<0.0001)(r=-0.6183, P=0.0062). Moreover, the ROC curve analysis of the mean VBM values for altered brain regions indicated high diagnostic accuracy.
   Conclusion: These results indicated that patients with nAMD have abnormal GMV and WMV and formed a basis for future research on pathological mechanisms in this disease. Moreover, decreased gray matter volume in particular brain regions might be associated with choroidal neovascularization and abnormal HADS score. It might help to explain the pathological mechanism of anxiety and depression in patients with nAMD.
C1 [Shen, Yan-Kun; Ge, Qian-Min; Pan, Yi-Cong; Shu, Hui-Ye; Zhang, Li-Juan; Li, Qiu-Yu; Liang, Rong-Bin; Shao, Yi; Yu, Yao] Nanchang Univ, Jiangxi Ctr Natl Ocular Dis Clin, Dept Endocrinol & Ophthalmol, Res Ctr,Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University
RP Shao, Y; Yu, Y (通讯作者)，Nanchang Univ, Jiangxi Ctr Natl Ocular Dis Clin, Dept Endocrinol & Ophthalmol, Res Ctr,Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.
EM freebee99@163.com; 375135747@qq.com
FU Central Government Guides Local Science and Technology Development
   Foundation [20211ZDG02003]; Key Research Foundation of Jiangxi Province
   [20181BBG70004, 20203BBG73059]; Excellent Talents Development Project of
   Jiangxi Province [20192BCBL23020]; Natural Science Foundation of Jiangxi
   Province [20181BAB205034]; Grassroots Health Appropriate Technology
   "Spark Promotion Plan" Project of Jiangxi Province [20188003]; Health
   Development Planning Commission Science Foundation of Jiangxi Province
   [20201032, 202130210]; Health Development Planning Commission Science
   TCM Foundation of Jiangxi Province [2018A060, 2020A0087]; Education
   Department Foundation of Jiangxi Province [GJJ200157, GJJ200159,
   GJJ200169]
FX The Central Government Guides Local Science and Technology Development
   Foundation (No: 20211ZDG02003) ; Key Research Foundation of Jiangxi
   Province (No: 20181BBG70004, 20203BBG73059) ; Excellent Talents
   Development Project of Jiangxi Province (No: 20192BCBL23020) ; Natural
   Science Foundation of Jiangxi Province (No: 20181BAB205034) ; Grassroots
   Health Appropriate Technology "Spark Promotion Plan" Project of Jiangxi
   Province (No: 20188003) ; Health Development Planning Commission Science
   Foundation of Jiangxi Province (No: 20201032,202130210) ; Health
   Development Planning Commission Science TCM Foundation of Jiangxi
   Province (No: 2018A060,2020A0087) ; Education Department Foundation of
   Jiangxi Province (No: GJJ200157, GJJ200159, GJJ200169) .
CR Aarts E, 2008, J NEUROSCI, V28, P4671, DOI 10.1523/JNEUROSCI.4400-07.2008
   Ahs F, 2014, NEUROPSYCHOLOGIA, V61, P291, DOI 10.1016/j.neuropsychologia.2014.06.030
   Binder JR, 2020, EPILEPSIA, V61, P1939, DOI 10.1111/epi.16643
   Bubb EJ, 2018, NEUROSCI BIOBEHAV R, V92, P104, DOI 10.1016/j.neubiorev.2018.05.008
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Caranci F, 2012, SEMIN ULTRASOUND CT, V33, P385, DOI 10.1053/j.sult.2012.06.007
   Chen WW, 2013, INVEST OPHTH VIS SCI, V54, P545, DOI 10.1167/iovs.12-9893
   Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134
   Elliott R, 2003, BRIT MED BULL, V65, P49, DOI 10.1093/bmb/65.1.49
   Gazzaniga MS, 2002, COGNITIVE NEUROSCIEN, P530
   Gehring WJ, 2002, SCIENCE, V295, P2279, DOI 10.1126/science.1066893
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Graves WW, 2008, J COGNITIVE NEUROSCI, V20, P1698, DOI 10.1162/jocn.2008.20113
   Hanson RLW, 2019, INVEST OPHTH VIS SCI, V60, P5045, DOI 10.1167/iovs.18-25823
   Hashimoto M, 2013, NEURO OPHTHALMOLOGY, V30, P30
   Herrmann KH, 2012, MAGN RESON MATER PHY, V25, P233, DOI 10.1007/s10334-011-0284-5
   Huang X, 2016, MED SCI MONITOR, V22, P1115, DOI 10.12659/MSM.897837
   Huo CD, 2018, INT EYE SCI, V12, P84
   Ito S, 2003, SCIENCE, V302, P120, DOI 10.1126/science.1087847
   Jayarajan RN, 2015, J CAN ACAD CHILD ADO, V24, P84
   Jia ZH, 2017, NEUROIMAGE-CLIN, V14, P130, DOI 10.1016/j.nicl.2017.01.019
   Kanske P, 2011, HUM BRAIN MAPP, V32, P198, DOI 10.1002/hbm.21012
   Kim KL, 2019, ARTERIOSCL THROM VAS, V39, P2120, DOI 10.1161/ATVBAHA.119.313179
   Lan DY, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.1
   Li B, 2020, ACTA RADIOL, V61, P395, DOI 10.1177/0284185119861898
   Li J, 2013, INT J OPHTHALMOL-CHI, V6, P169, DOI 10.3980/j.issn.2222-3959.2013.02.12
   Matsuda H, 2013, AGING DIS, V4, P29
   Michalski LJ, 2017, GENES BRAIN BEHAV, V16, P781, DOI 10.1111/gbb.12404
   Miller G, 2002, SCIENCE, V295, P2193
   Mummery CJ, 2000, ANN NEUROL, V47, P36
   Nemoto Kiyotaka, 2017, Brain Nerve, V69, P505, DOI 10.11477/mf.1416200776
   Niazi S, 2020, ACTA OPHTHALMOL, V98, P121, DOI 10.1111/aos.14287
   Peoples LL, 2002, SCIENCE, V296, P1623, DOI 10.1126/science.1072997
   Qi HJ, 2017, INT J OPHTHALMOL-CHI, V10, P91, DOI 10.18240/ijo.2017.01.15
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Samuraki M, 2015, J ALZHEIMERS DIS, V48, P517, DOI 10.3233/JAD-150274
   Sanz-Martin A, 2006, REV NEUROLOGIA, V42, P391, DOI 10.33588/rn.4207.2004572
   Shi WQ, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1421
   Shidara M, 2002, SCIENCE, V296, P1709, DOI 10.1126/science.1069504
   Smoski MJ, 2013, J AFFECT DISORDERS, V151, P171, DOI 10.1016/j.jad.2013.05.073
   Swick D, 2002, P NATL ACAD SCI USA, V99, P16354, DOI 10.1073/pnas.252521499
   Tianshuang Q, 2015, DATA ACQUISITION PRO, V30, P940, DOI [10.16337/j.1004-9037.2015.05.003, DOI 10.16337/J.1004-9037.2015.05.003]
   van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837
   Wang S, 2019, HUM BRAIN MAPP, V40, P4982, DOI 10.1002/hbm.24752
   Williams AL, 2013, INVEST OPHTH VIS SCI, V54, P5880, DOI 10.1167/iovs.13-11776
NR 45
TC 1
Z9 2
U1 5
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD OCT 15
PY 2021
VL 13
IS 19
BP 23182
EP 23192
PG 11
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Cell Biology; Geriatrics & Gerontology
GA WI5QP
UT WOS:000708414800010
PM 34623972
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lesniak, SP
   Fine, HF
   Prenner, JL
   Roth, DB
AF Lesniak, Sebastian P.
   Fine, Howard F.
   Prenner, Jonathan L.
   Roth, Daniel B.
TI Long-term follow-up of spontaneous retinal pigment epithelium tears in
   age-related macular degeneration treated with anti-VEGF therapy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF therapy; Retinal pigment
   epithelium tear
ID INTRAVITREAL BEVACIZUMAB INJECTION; RPE; AMD; RIP
AB PURPOSE. To describe the clinical response following anti-vascular endothelial growth factor (VEGF) therapy in patients with spontaneous retinal pigment epithelium (RPE) tears secondary to age-related macular degeneration (AMD).
   METHODS. Retrospective chart review of patients with AMD who developed a spontaneous RPE tear and were subsequently treated with anti-VEGF therapy at a single institution.
   RESULTS. In 5 patients included in the study, the median number (range) of injections received was 14.2 (5-18). The median baseline acuity was 20/200, which remained stable at 12 months and improved to 20/60 at 24 months. These changes were not statistically different.
   CONCLUSIONS. Anti-VEGF therapy appears safe in eyes with spontaneous RPE tear secondary to AMD and may help to stabilize or even improve acuity in some cases.
C1 [Lesniak, Sebastian P.; Fine, Howard F.; Prenner, Jonathan L.; Roth, Daniel B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08901 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center
RP Lesniak, SP (通讯作者)，Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, MEB 486, New Brunswick, NJ 08901 USA.
EM lesniasp@umdnj.edu
CR Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Gamulescu MA, 2007, GRAEF ARCH CLIN EXP, V245, P1037, DOI 10.1007/s00417-007-0551-3
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Peiretti E, 2006, RETINA-J RET VIT DIS, V26, P1097, DOI 10.1097/01.iae.0000233328.68999.5f
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
NR 10
TC 10
Z9 11
U1 0
U2 2
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2011
VL 21
IS 1
BP 73
EP 76
DI 10.5301/EJO.2010.2285
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 687MI
UT WOS:000284782200011
PM 20623466
DA 2022-11-30
ER

PT J
AU Dugel, PU
   Jhaveri, CD
   Chakravarthy, U
   Wykoff, CC
   Singh, RP
   Hamilton, R
   Weissgerber, G
   Mulyukov, Z
   Holz, FG
AF Dugel, Pravin U.
   Jhaveri, Chirag D.
   Chakravarthy, Usha
   Wykoff, Charles C.
   Singh, Rishi P.
   Hamilton, Robin
   Weissgerber, Georges
   Mulyukov, Zufar
   Holz, Frank G.
TI EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID
   PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Post Hoc
   Analysis of the HAWK and HARRIER Studies
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; anti-vascular endothelial
   growth factor therapy; central subfield thickness; variability
ID THERAPY; ACUITY; EYES
AB Purpose: To determine the association between central subfield thickness (CST) variability and visual outcomes in eyes with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapies. Methods: In this post hoc, treatment-agnostic analysis, patients (N = 1,752) were grouped into quartiles of increasing CST variation. The association between CST variability and best-corrected visual acuity was measured from baseline, or from the end of the loading phase, until the end of the study using a multilevel modeling for repeated-measures model. The association between CST variability and the presence of retinal fluid was also assessed. Results: Increased CST variability was associated with worse best-corrected visual acuity outcomes at the end of study, with a least-square mean difference in best-corrected visual acuity of 8.9 Early Treatment Diabetic Retinopathy Study letters between the quartiles with the lowest and highest CST variability at the final visit. Increased variability was also associated with a higher mean fraction of visits with the presence of fluid. Conclusion: More stable CST was associated with better visual outcomes at the end of treatment suggesting that CST variability may provide a more reliable prognostic marker of visual outcomes than the presence of fluid alone, with the potential to enhance the clinical care of neovascular age-related macular degeneration patients.
C1 [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Dugel, Pravin U.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA 90007 USA.
   [Dugel, Pravin U.] IVERIC Bio, New York, NY USA.
   [Jhaveri, Chirag D.] Retina Consultants Austin, Austin, TX USA.
   [Jhaveri, Chirag D.] Austin Res Ctr Retina, Austin, TX USA.
   [Jhaveri, Chirag D.] Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA.
   [Chakravarthy, Usha] Queens Univ Belfast, Inst Clin Sci, Belfast, Antrim, North Ireland.
   [Wykoff, Charles C.] Houston Methodist Hosp, Blanton Eye Inst, Retina Consultants Amer, Retina Consultants Houston, Houston, TX 77030 USA.
   [Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, Ctr Ophthalm Bioinformat, Cleveland, OH 44106 USA.
   [Hamilton, Robin] Moorfields Eye Hosp, Natl Inst Hlth, London, England.
   [Hamilton, Robin] Moorfields Eye Hosp, Res Biomed Ctr, London, England.
   [Weissgerber, Georges; Mulyukov, Zufar] Novartis Pharma AG, Basel, Switzerland.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
C3 University of Southern California; University of Texas System;
   University of Texas Austin; Queens University Belfast; The Methodist
   Hospital System; The Methodist Hospital - Houston; Cleveland Clinic
   Foundation; University of London; University College London; Moorfields
   Eye Hospital NHS Foundation Trust; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; Novartis;
   University of Bonn
RP Dugel, PU (通讯作者)，1249 South River Rd,Suite 107, Cranbury, NJ 08512 USA.
EM pdugel@gmail.com
FU Novartis Pharma AG (Basel, Switzerland)
FX Financial support: Financial support was provided by Novartis Pharma AG
   (Basel, Switzerland). The sponsor or funding organization participated
   in the design of the study; management, analysis, and interpretation of
   the data and preparation, review, and approval of the manuscript.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2021, R LANGUAGE ENV STAT
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
NR 19
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2022
VL 42
IS 3
BP 511
EP 518
DI 10.1097/IAE.0000000000003349
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZD6KA
UT WOS:000758305500019
PM 34923515
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Fernandez-Robredo, P
   Sancho, A
   Johnen, S
   Recalde, S
   Gama, N
   Thumann, G
   Groll, J
   Garcia-Layana, A
AF Fernandez-Robredo, P.
   Sancho, A.
   Johnen, S.
   Recalde, S.
   Gama, N.
   Thumann, G.
   Groll, J.
   Garcia-Layana, A.
TI Current Treatment Limitations in Age-Related Macular Degeneration and
   Future Approaches Based on Cell Therapy and Tissue Engineering
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; CILIARY NEUROTROPHIC FACTOR; PLURIPOTENT
   STEM-CELLS; BRUCHS MEMBRANE; SLEEPING-BEAUTY; IN-VITRO; AUTOLOGOUS
   TRANSPLANTATION; RPE TRANSPLANTATION
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world. With an ageing population, it is anticipated that the number of AMD cases will increase dramatically, making a solution to this debilitating disease an urgent requirement for the socioeconomic future of the European Union and worldwide. The present paper reviews the limitations of the current therapies as well as the socioeconomic impact of the AMD. There is currently no cure available for AMD, and even palliative treatments are rare. Treatment options show several side effects, are of high cost, and only treat the consequence, not the cause of the pathology. For that reason, many options involving cell therapy mainly based on retinal and iris pigment epithelium cells as well as stem cells are being tested. Moreover, tissue engineering strategies to design and manufacture scaffolds to mimic Bruch's membrane are very diverse and under investigation. Both alternative therapies are aimed to prevent and/or cure AMD and are reviewed herein.
C1 [Fernandez-Robredo, P.; Recalde, S.; Garcia-Layana, A.] Univ Navarra, Sch Med, Ophthalmol Expt Lab, Pamplona 31008, Spain.
   [Sancho, A.] Univ Navarra, CEIT & TECNUN, Tissue Engn & Biomat Unit, San Sebastian 20018, Spain.
   [Johnen, S.] RWTH Aachen Univ Hosp, Dept Ophthalmol, D-52074 Aachen, Germany.
   [Gama, N.; Thumann, G.] Univ Geneva, Fac Med, Univ Hosp Geneva, Dept Ophthalmol, CH-1211 Geneva 14, Switzerland.
   [Groll, J.] Univ Wurzburg, Dept Funct Mat Med & Dent, D-97070 Wurzburg, Germany.
   [Garcia-Layana, A.] Univ Navarra Clin, Sch Med, Dept Ophthalmol, Pamplona 31008, Spain.
C3 University of Navarra; University of Navarra; RWTH Aachen University;
   RWTH Aachen University Hospital; University of Geneva; University of
   Wurzburg; University of Navarra
RP Garcia-Layana, A (通讯作者)，Univ Navarra, Sch Med, Ophthalmol Expt Lab, C Irunlarrea 1, Pamplona 31008, Spain.
EM aglayana@unav.es
RI Recalde, Sergio/D-1815-2017; Johnen, Sandra/ABA-9955-2020; Groll,
   Jürgen/F-4202-2012; Sancho, Ana/J-6442-2019
OI Recalde, Sergio/0000-0002-9328-9725; Johnen, Sandra/0000-0003-0028-2557;
   Groll, Jürgen/0000-0003-3167-8466; Sancho, Ana/0000-0002-0560-9187
FU Basque Government
FX A. Sancho gratefully acknowledges the Research Mobility Program of the
   Basque Government for financial support.
CR Abe T, 1999, TOHOKU J EXP MED, V189, P295, DOI 10.1620/tjem.189.295
   Abe T, 2007, PROG RETIN EYE RES, V26, P302, DOI 10.1016/j.preteyeres.2007.01.003
   Adams J A, 1999, Med Dosim, V24, P233, DOI 10.1016/S0958-3947(99)00024-2
   Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Alamein MA, 2013, TISSUE ENG PART C-ME, V19, P458, DOI [10.1089/ten.tec.2012.0417, 10.1089/ten.TEC.2012.0417]
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1232
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arnhold S, 2004, EXP NEUROL, V187, P410, DOI 10.1016/j.expneurol.2004.02.015
   Arnhold S, 2006, INVEST OPHTH VIS SCI, V47, P4121, DOI 10.1167/iovs.04-1501
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Banerjee A, 2008, INDIAN J OPHTHALMOL, V56, P469
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Bartneck M, 2012, BIOMATERIALS, V33, P4136, DOI 10.1016/j.biomaterials.2012.02.050
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   BIRD AC, 1995, AM J OPHTHALMOL, V119, P543, DOI 10.1016/S0002-9394(14)70212-0
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown G, 2010, CURR OPIN OPHTHALMOL, V21, P169, DOI 10.1097/ICU.0b013e3283388605
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Brown TD, 2011, ADV MATER, V23, P5651, DOI 10.1002/adma.201103482
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Carwile ME, 1998, EXP EYE RES, V66, P791, DOI 10.1006/exer.1998.0488
   Castellarin AA, 1998, EXP EYE RES, V66, P49, DOI 10.1006/exer.1997.0404
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chong NHV, 1999, INVEST OPHTH VIS SCI, V40, P1298
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Crafoord S, 2002, ACTA OPHTHALMOL SCAN, V80, P387, DOI 10.1034/j.1600-0420.2002.800408.x
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   del Cerro M, 1989, J Neural Transplant, V1, P1
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Desai M, 2001, Aging Trends, P1
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Friberg T R, 1999, Semin Ophthalmol, V14, P45, DOI 10.3109/08820539909056062
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Fung A., 2002, INVESTIGATIVE OPHTHA, V43
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Geurts AM, 2006, NUCLEIC ACIDS RES, V34, P2803, DOI 10.1093/nar/gkl301
   Gias C, 2007, EUR J NEUROSCI, V25, P1940, DOI 10.1111/j.1460-9568.2007.05459.x
   Gouras P, 2002, INVEST OPHTH VIS SCI, V43, P3307
   Grabundzija I, 2013, NUCLEIC ACIDS RES, V41, P1829, DOI 10.1093/nar/gks1305
   Grafahrend D, 2011, NAT MATER, V10, P67, DOI 10.1038/NMAT2904
   Grafahrend D, 2010, MACROMOL BIOSCI, V10, P1022, DOI 10.1002/mabi.201000068
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hernandez-Pastor LJ, 2008, AM J HEALTH-SYST PH, V65, P1805, DOI 10.2146/ajhp070342
   Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142-9612(03)00343-0
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5
   Izsvak Z, 2010, BIOESSAYS, V32, P756, DOI 10.1002/bies.201000027
   Jager R. D., 2008, NEW ENGL J MED, V358, P2544
   Jin ZB, 2012, STEM CELL TRANSL MED, V1, P503, DOI 10.5966/sctm.2012-0005
   Joussen AM, 2003, GRAEF ARCH CLIN EXP, V241, P966, DOI 10.1007/s00417-003-0792-8
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kiilgaard JF, 2002, ACTA OPHTHALMOL SCAN, V80, P76
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Klingel R, 2002, THER APHER, V6, P271, DOI 10.1046/j.1526-0968.2002.00418.x
   Kociok N, 2007, GRAEF ARCH CLIN EXP, V245, P101, DOI 10.1007/s00417-006-0266-x
   Kozulin P, 2010, INVEST OPHTH VIS SCI, V51, P4298, DOI 10.1167/iovs.09-4905
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Kwan ASL, 1999, EXP NEUROL, V159, P21, DOI 10.1006/exnr.1999.7157
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Lee HKM, 2003, AGE AGEING, V32, P643, DOI 10.1093/ageing/afg110
   Lee S, 2013, J KOREAN MED SCI, V28, P769, DOI 10.3346/jkms.2013.28.5.769
   LOPEZ R, 1987, INVEST OPHTH VIS SCI, V28, P1131
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Ma ZZ, 2009, INVEST OPHTH VIS SCI, V50, P2975, DOI 10.1167/iovs.08-2573
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Mano JF, 2007, J R SOC INTERFACE, V4, P999, DOI 10.1098/rsif.2007.0220
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343
   McUsic AC, 2012, BIOMATERIALS, V33, P1396, DOI 10.1016/j.biomaterials.2011.10.083
   Mekala SR, 2013, J BIOSCIENCES, V38, P123, DOI 10.1007/s12038-012-9296-1
   Melville H, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-53
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Moviglia GA, 2012, OPHTHALMIC RES, V48, P1, DOI 10.1159/000339839
   Nadri S, 2013, NEUROSCI LETT, V541, P43, DOI 10.1016/j.neulet.2012.12.055
   Neeley WL, 2008, BIOMATERIALS, V29, P418, DOI 10.1016/j.biomaterials.2007.10.007
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ohno-Matsui Kyoko, 2003, Nippon Ganka Gakkai Zasshi, V107, P657
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Schraermeyer U, 2013, EXPERT OPIN BIOL TH, V13, P157, DOI 10.1517/14712598.2012.748741
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   Sharma Sanjay, 2004, Curr Opin Ophthalmol, V15, P227, DOI 10.1097/01.icu.0000124082.88389.cf
   Sheridan C, 2004, GRAEF ARCH CLIN EXP, V242, P68, DOI 10.1007/s00417-003-0800-z
   Silva RA, 2011, SEMIN OPHTHALMOL, V26, P121, DOI 10.3109/08820538.2011.554486
   Sistiabudi R, 2009, BIOTECHNOL BIOENG, V102, P1723, DOI 10.1002/bit.22215
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Stanzel BV, 2005, EXP EYE RES, V80, P103, DOI 10.1016/j.exer.2004.06.032
   Steedman MR, 2010, BIOMED MICRODEVICES, V12, P363, DOI 10.1007/s10544-009-9392-7
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thomson HAJ, 2011, BRIT J OPHTHALMOL, V95, P563, DOI 10.1136/bjo.2009.166728
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Thumann G, 1999, TRANSPLANTATION, V68, P195, DOI 10.1097/00007890-199907270-00006
   Thumann G, 1998, GRAEF ARCH CLIN EXP, V236, P753, DOI 10.1007/s004170050154
   Thumann G, 1999, GRAEF ARCH CLIN EXP, V237, P1046, DOI 10.1007/s004170050343
   Thumann G, 2009, GRAEF ARCH CLIN EXP, V247, P363, DOI 10.1007/s00417-008-0998-x
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Treharne AJ, 2012, J BIOMED MATER RES A, V100A, P2358, DOI 10.1002/jbm.a.34178
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P907
   Vaquette C, 2011, ACTA BIOMATER, V7, P2544, DOI 10.1016/j.actbio.2011.02.036
   Verma Lalit, 2000, Indian Journal of Ophthalmology, V48, P263
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P416, DOI 10.1167/iovs.07-0992
   Wei C, 2013, J MICROMECH MICROENG, V23, DOI 10.1088/0960-1317/23/2/025017
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Yao J, 2011, POLYMERS-BASEL, V3, P899, DOI 10.3390/polym3020899
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 170
TC 44
Z9 51
U1 0
U2 35
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 510285
DI 10.1155/2014/510285
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 301CB
UT WOS:000330509200001
PM 24672707
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Friberg, TR
   Bilonick, RA
   Brennen, PM
AF Friberg, Thomas R.
   Bilonick, Richard A.
   Brennen, Peter M.
TI Analysis of the Relationship Between Drusen Size and Drusen Area in Eyes
   With Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SEVERITY SCALE; MACULOPATHY; PREVALENCE; FUNDUS
AB BACKGROUND AND OBJECTIVE: To examine the relationship between drusen counts and drusen area in eyes with age-related macular degeneration, and to correlate drusen areas between fellow eyes.
   PATIENTS AND METHODS: Digital images from 378 patients (756 eyes) were analyzed using a validated drusen detection algorithm. Total drusen area and the number of drusen of various sizes (small: <62 microns, intermediate: 63-124 microns, large: 125-249 microns, etc) were recorded for the central 1,000- and 3,000-micron diameter macular regions. Correlations were assessed using structural equation models.
   RESULTS: For the 1,000-micron region, the number of intermediate drusen was more highly correlated to total drusen area than the number of large drusen (R = 0.91 vs 0.82); this difference was statistically significant. The correlation coefficients for drusen area between fellow eyes was 0.73.
   CONCLUSION: The number of large drusen does not correlate better with total drusen area than drusen of other sizes. The number of large drusen is not necessarily a good surrogate for total drusen area.
C1 [Friberg, Thomas R.; Bilonick, Richard A.; Brennen, Peter M.] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Friberg, TR (通讯作者)，Univ Pittsburgh, UPMC Eye Ctr, 203 Lothrop St,Suite 824, Pittsburgh, PA 15213 USA.
EM friberg@pitt.edu
FU Eye and Ear Foundation of Pittsburgh, Pittsburgh, Pennsylvania
FX Supported by the Eye and Ear Foundation of Pittsburgh, Pittsburgh,
   Pennsylvania, and an unrestricted grant from William J. McVay, MD,
   Pittsburgh, Pennsylvania.
CR Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Friberg TR, 2007, OPHTHAL SURG LAS IM, V38, P126, DOI 10.3928/15428877-20070301-07
   FRIBERG TR, 1987, RETINA-J RET VIT DIS, V7, P246, DOI 10.1097/00006982-198707040-00010
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pesce A, 2006, AGE RELATED MACULAR
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 18
TC 6
Z9 6
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2011
VL 42
IS 5
BP 369
EP 375
DI 10.3928/15428877-20110812-01
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 959UX
UT WOS:000305342100002
PM 21899243
DA 2022-11-30
ER

PT J
AU Rush, RB
   Rush, SW
   Aragon, AV
   Ysasaga, JE
AF Rush, Ryan B.
   Rush, Sloan W.
   Aragon, Antonio V., II
   Ysasaga, J. Edward
TI Predictability of Recurrent Exudation and Subretinal Hemorrhaging in
   Neovascular Age-Related Macular Degeneration With Indocyanine Green
   Angiography
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; BEVACIZUMAB; RANIBIZUMAB;
   VIDEOANGIOGRAPHY; THERAPY
AB BACKGROUND AND OBJECTIVE: To report the predictability of recurrent exudation and subretinal hemorrhaging after treatment extension in neovascular age-related macular degeneration (AMD) through assessment of interval changes in choroidal neovascularization (CNV) size on indocyanine green (ICG) angiography.
   PATIENTS AND METHODS: The charts of patients with neovascular AMD who underwent bevacizumab therapy using a treat-and-extend protocol were retrospectively reviewed over a 12-month period.
   RESULTS: An increase of 33% or more in CNV surface area on ICG angiography from 4 to 6 weeks, 6 to 8 weeks, and 8 to 10 weeks was observed in patients whose treatment interval could not be extended from 6 to 8 weeks, 8 to 10 weeks, and 10 to 12 weeks, respectively, and this was significant compared to patients whose treatment interval was successfully extended during those respective intervals (P < .0001, P = .0002, P = .0004, respectively).
   CONCLUSION: CNV size change on ICG angiography can predict which patients are likely to experience recurrent exudation and/or subretinal hemorrhaging after treatment extension using treat-and-extend bevacizumab.
C1 [Rush, Ryan B.; Aragon, Antonio V., II; Ysasaga, J. Edward] Southwest Retina Specialists, 7411 Wallace Blvd, Amarillo, TX 79106 USA.
   [Rush, Ryan B.; Rush, Sloan W.; Aragon, Antonio V., II; Ysasaga, J. Edward] Panhandle Eye Grp, Amarillo, TX USA.
   [Rush, Ryan B.; Rush, Sloan W.; Aragon, Antonio V., II; Ysasaga, J. Edward] Texas Tech Univ, Hlth Sci Ctr, Amarillo, TX USA.
C3 Texas Tech University System; Texas Tech University; Texas Tech
   University Health Science Center; Texas Tech University Health Sciences
   Center Amarillo
RP Rush, RB (通讯作者)，Southwest Retina Specialists, 7411 Wallace Blvd, Amarillo, TX 79106 USA.
EM ryanbradfordrush21@hotmail.com
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Jumper JM, 2012, PREFERENCES TRENDS S
   Kauffmann Y, 2014, J FR OPHTALMOL, V37, P195, DOI 10.1016/j.jfo.2013.08.005
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rush RB, 2014, AM J OPHTHALMOL, V158, P337, DOI 10.1016/j.ajo.2014.05.007
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Schneider U, 1996, GER J OPHTHALMOL, V5, P6
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Thi HCT, 2011, OPHTHAL SURG LAS IM, V42, P498, DOI 10.3928/15428877-20110804-04
   Watzke RC, 2000, OPHTHALMOLOGY, V107, P1601, DOI 10.1016/S0161-6420(00)00218-9
   Wolf S, 1996, GER J OPHTHALMOL, V5, P251
NR 17
TC 4
Z9 4
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUL
PY 2015
VL 46
IS 7
BP 718
EP 723
DI 10.3928/23258160-20150730-05
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9TW
UT WOS:000378841300006
PM 26247452
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
TI Difference Between the Incidence of Retinal Fluid Subtypes and Their
   Association with Visual Outcomes According to the Types of Macular
   Neovascularization in a Korean Population
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; macular
   neovascularization; subretinal fluid; intraretinal fluid
ID PIGMENT EPITHELIAL DETACHMENT; SUBRETINAL FLUID; DEGENERATION; ACUITY;
   RANIBIZUMAB; REGIMEN; TREAT
AB Purpose: To investigate differences in the incidence of retinal fluid subtypes among different subtypes of macular neovascularization (MNV) and evaluate the influence of the presence of retinal fluid subtypes on visual outcome in each subtype of MNV.Methods: This retrospective study included 248 patients (248 eyes) diagnosed with treatment-naive neovascular age-related macular degeneration and polypoidal choroidal vasculopathy (PCV). The incidence of retinal fluid subtypes at diagnosis and during the 24-month follow-up was compared among the different subtypes of MNV. In addition, visual acuity was compared between patients with and without the retinal fluid subtypes.Results: At diagnosis, there was a significant difference in the incidence of subretinal fluid (SRF), intraretinal fluid (IRF), and subretinal pigment epithelial fluid among type 1 MNV, type 2 MNV, type 3 MNV, and PCV (P < 0.001). The incidence of SRF (P < 0.001) during follow-up also differed among the 4 groups. In patients with type 1 MNV and IRF, the visual acuity at diagnosis (P = 0.004) and at 24 months (P < 0.001) were significantly worse. However, the presence of SRF was not associated with poor visual acuity. In type 3 MNV, there was no significant difference in visual acuity between patients with and without SRF/IRF.Conclusion: The results of this study indicate that the clinical significance of retinal fluid subtypes may differ in different subtypes of MNV, suggesting the need for analysis in isolation of each MNV subtype in fluid-based prognostication.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu] Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
C3 Konyang University; Konyang University Hospital
RP Kim, JH (通讯作者)，Konyang Univ, Coll Med, Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kims Eye Hospital Research Center
FX This study was supported by Kims Eye Hospital Research Center.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Chakravarthy U, 2020, EYE, V34, P2249, DOI 10.1038/s41433-020-0799-y
   Chen L, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.8
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Cho HJ, 2021, ACTA OPHTHALMOL, V99, pE540, DOI 10.1111/aos.14631
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Garweg JG, 2017, J OCUL PHARMACOL TH, V33, P567, DOI 10.1089/jop.2017.0031
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Hosseini H, 2021, GRAEF ARCH CLIN EXP, V259, P1153, DOI 10.1007/s00417-020-05024-9
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Kim JH, 2020, RETINA-J RET VIT DIS, V40, P1124, DOI 10.1097/IAE.0000000000002489
   Kodjikian L, 2021, EYE, V35, P2119, DOI 10.1038/s41433-021-01487-0
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Reiter GS, 2021, RETINA-J RET VIT DIS, V41, P1318, DOI 10.1097/IAE.0000000000003023
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Saenz-de-Viteri M, 2021, ACTA OPHTHALMOL, V99, P861, DOI 10.1111/aos.14786
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P259, DOI 10.1097/IAE.0000000000000690
   Sharma A, 2022, RETINA-J RET VIT DIS, V42, P107, DOI 10.1097/IAE.0000000000003261
   Sharma A, 2021, BRIT J OPHTHALMOL, V105, P297, DOI 10.1136/bjophthalmol-2020-318128
   Sharma A, 2021, OPHTHALMOL RETINA, V5, P105, DOI 10.1016/j.oret.2020.09.016
   Sharma A, 2021, BRIT J OPHTHALMOL, V105, P149, DOI 10.1136/bjophthalmol-2020-317933
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
NR 37
TC 1
Z9 1
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD APR 1
PY 2022
VL 38
IS 3
BP 261
EP 268
DI 10.1089/jop.2021.0103
EA FEB 2022
PG 8
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 1W0IR
UT WOS:000758875200001
PM 35119292
DA 2022-11-30
ER

PT J
AU Motozawa, N
   Miura, T
   Ochiai, K
   Yamamoto, M
   Horinouchi, T
   Tsuzuki, T
   Kanda, GN
   Ozawa, Y
   Tsujikawa, A
   Takahashi, K
   Takahashi, M
   Kurimoto, Y
   Maeda, T
   Mandai, M
AF Motozawa, Naohiro
   Miura, Takuya
   Ochiai, Koji
   Yamamoto, Midori
   Horinouchi, Takaaki
   Tsuzuki, Taku
   Kanda, Genki N.
   Ozawa, Yosuke
   Tsujikawa, Akitaka
   Takahashi, Koichi
   Takahashi, Masayo
   Kurimoto, Yasuo
   Maeda, Tadao
   Mandai, Michiko
TI Automated evaluation of retinal pigment epithelium disease area in eyes
   with age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IMAGES
AB The retinal pigment epithelium (RPE) is essential for the survival and function of retinal photoreceptor cells. RPE dysfunction causes various retinal diseases including age-related macular degeneration (AMD). Clinical studies on ES/iPS cell-derived RPE transplantation for RPE dysfunction-triggered diseases are currently underway. Quantification of the diseased RPE area is important to evaluate disease progression or the therapeutic effect of RPE transplantation. However, there are no standard protocols. To address this issue, we developed a 2-step software that enables objective and efficient quantification of RPE-disease area changes by analyzing the early-phase hyperfluorescent area in fluorescein angiography (FA) images. We extracted the Abnormal region. This extraction was based on deep learning-based discrimination. We scored the binarized extracted area using an automated program. Our program's performance for the same eye from the serial image captures was within 3.1 +/- 7.8% error. In progressive AMD, the trend was consistent with human assessment, even when FA images from two different visits were compared. This method was applicable to quantifying RPE-disease area changes over time, evaluating iPSC-RPE transplantation images, and a disease other than AMD. Our program may contribute to the assessment of the clinical course of RPE-disease areas in routine clinics and reduce the workload of researchers.
C1 [Motozawa, Naohiro; Yamamoto, Midori; Kanda, Genki N.; Takahashi, Masayo; Kurimoto, Yasuo; Maeda, Tadao; Mandai, Michiko] Kobe City Eye Hosp, Chuo Ku, 2-1-8 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
   [Motozawa, Naohiro; Tsujikawa, Akitaka] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
   [Miura, Takuya; Ochiai, Koji; Horinouchi, Takaaki; Kanda, Genki N.; Takahashi, Koichi] RIKEN Ctr Biosyst Dynam Res, Lab Biol Inspired Comp, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.
   [Tsuzuki, Taku; Ozawa, Yosuke] Epistra Inc, Minato Ku, 2-2-15 Hamamatsu Cho, Tokyo 1050013, Japan.
   [Takahashi, Masayo] VCCT Inc, Kobe Eye Ctr, Chuo Ku, 5F,2-1-8 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
C3 Kyoto University; RIKEN
RP Mandai, M (通讯作者)，Kobe City Eye Hosp, Chuo Ku, 2-1-8 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
EM e_lab.mandai@kcho.jp
RI Horinouchi, Takaaki/ADR-3136-2022
OI Horinouchi, Takaaki/0000-0001-9141-9103; Kanda,
   Genki/0000-0002-6372-241X
FU AMED
FX We would like to thank Editage (www.editage.com) for English language
   editing. We would like to thank K Sumi for his help in creating Fig. 1.
   This work was supported by a Grant from AMED (JP20bm0204002, AMED, to M.
   T.).
CR Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Calonder M, 2010, LECT NOTES COMPUT SC, V6314, P778, DOI 10.1007/978-3-642-15561-1_56
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   FISCHLER MA, 1981, COMMUN ACM, V24, P381, DOI 10.1145/358669.358692
   Gao Y, 2018, INVEST OPHTH VIS SCI, V59, P4307, DOI 10.1167/iovs.17-23747
   Gu H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75027-3
   Jin K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71622-6
   Kalatzis V, 2013, AM J OPHTHALMOL, V156, P433, DOI 10.1016/j.ajo.2013.05.009
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Rosten E, 2005, IEEE I CONF COMP VIS, P1508
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Sun G, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.6.065006
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Uyama H, 2021, DEV GROWTH DIFFER, V63, P59, DOI 10.1111/dgd.12704
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Wu HS, 2021, MED IMAGE ANAL, V70, DOI 10.1016/j.media.2021.102025
NR 24
TC 1
Z9 1
U1 3
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 18
PY 2022
VL 12
IS 1
AR 892
DI 10.1038/s41598-022-05006-3
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA YI8VH
UT WOS:000744120000011
PM 35042966
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lopez-Varela, E
   Vidal, PL
   Pascual, NO
   Novo, J
   Ortega, M
AF Lopez-Varela, Emilio
   Vidal, Placido L.
   Olivier Pascual, Nuria
   Novo, Jorge
   Ortega, Marcos
TI Fully-Automatic 3D Intuitive Visualization of Age-Related Macular
   Degeneration Fluid Accumulations in OCT Cubes
SO JOURNAL OF DIGITAL IMAGING
LA English
DT Article
DE Computer-aided diagnosis; 3D visualization; Optical Coherence
   Tomography; Age-related macular degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; DIABETIC-RETINOPATHY; SEGMENTATION;
   PREVALENCE; GLAUCOMA; IMAGES
AB Age-related macular degeneration is the leading cause of vision loss in developed countries, and wet-type AMD requires urgent treatment and rapid diagnosis because it causes rapid irreversible vision loss. Currently, AMD diagnosis is mainly carried out using images obtained by optical coherence tomography. This diagnostic process is performed by human clinicians, so human error may occur in some cases. Therefore, fully automatic methodologies are highly desirable adding a layer of robustness to the diagnosis. In this work, a novel computer-aided diagnosis and visualization methodology is proposed for the rapid identification and visualization of wet AMD. We adapted a convolutional neural network for segmentation of a similar domain of medical images to the problem of wet AMD segmentation, taking advantage of transfer learning, which allows us to work with and exploit a reduced number of samples. We generate a 3D intuitive visualization where the existence, position and severity of the fluid were represented in a clear and intuitive way to facilitate the analysis of the clinicians. The 3D visualization is robust and accurate, obtaining satisfactory 0.949 and 0.960 Dice coefficients in the different evaluated OCT cube configurations, allowing to quickly assess the presence and extension of the fluid associated to wet AMD.
C1 [Lopez-Varela, Emilio; Vidal, Placido L.; Novo, Jorge; Ortega, Marcos] Inst Invest Biomed A Coruna INIBIC, Grp VARPA, Xubias De Arriba 84, La Coruna 15006, Spain.
   [Lopez-Varela, Emilio; Vidal, Placido L.; Novo, Jorge; Ortega, Marcos] Univ A Coruna, Ctr Invest CITIC, Campus Elvina S-N, La Coruna 15071, Spain.
   [Olivier Pascual, Nuria] Complexo Hosp Univ Ferrol, Serv Oftalmoloxia, CHUF, Av Residencia S-N, Ferrol 15405, Spain.
C3 Universidade da Coruna; Instituto de Investigacion Biomedica de A Coruna
   (INIBIC); Universidade da Coruna; Complejo Hospitalario Universitario de
   Ferrol
RP Vidal, PL (通讯作者)，Inst Invest Biomed A Coruna INIBIC, Grp VARPA, Xubias De Arriba 84, La Coruna 15006, Spain.; Vidal, PL (通讯作者)，Univ A Coruna, Ctr Invest CITIC, Campus Elvina S-N, La Coruna 15071, Spain.
EM e.lopezv@udc.es; placido.francisco.lizancos.vidal@udc.es;
   nurolpa@gmail.com; jnovo@udc.es; mortega@udc.es
OI Olivier Pascual, Nuria/0000-0003-3178-7419; Lopez-Varela,
   Emilio/0000-0002-0764-1164; Lizancos Vidal, Placido
   Francisco/0000-0002-6009-4737
FU CRUE-CSIC; Springer Nature; Universidade da Coruna/CISUG; Instituto de
   Salud Carlos III, Government of Spain [PI17/00940, DTS18/00136];
   Ministerio de Ciencia e Innovacion y Universidades, Government of Spain
   [RTI2018-095894-B-I00]; Ayudas para la formacion de profesorado
   universitario (FPU) [FPU18/02271]; Ministerio de Ciencia e Innovacion,
   Government of Spain [PID2019-108435RB-I00]; Conselleria de Cultura,
   Educacion e Universidade, unta de Galicia, Grupos de Referencia
   Competitiva [ED431C 2020/24]; Conselleria de Cultura, Educacion e
   Universidade from Xunta de Galicia; ERDF Funds, ERDF Operational
   Programme Galicia 2014-2020; Secretaria Xeral de Universidades [ED431G
   2019/01]; FPI Grant Program [PID2019-108435RB-I00]
FX ~Open Access funding provided thanks to the CRUE-CSIC agreement with
   Springer Nature. Funding for open access charge: Universidade da
   Coruna/CISUG. The research was funded by Instituto de Salud Carlos III,
   Government of Spain through the PI17/00940 and DTS18/00136 research
   projects, Ministerio de Ciencia e Innovacion y Universidades, Government
   of Spain, RTI2018-095894-B-I00 research project, Ayudas para la
   formacion de profesorado universitario (FPU), grant ref. FPU18/02271;
   Ministerio de Ciencia e Innovacion, Government of Spain through the
   research project with reference PID2019-108435RB-I00; Conselleria de
   Cultura, Educacion e Universidade, unta de Galicia, Grupos de Referencia
   Competitiva, grant ref. ED431C 2020/24; CITIC, as Research Center
   accredited by Galician University System, is funded by "Conselleria de
   Cultura, Educacion e Universidade from Xunta de Galicia", supported in
   an 80% through ERDF Funds, ERDF Operational Programme Galicia 2014-2020,
   and the remaining 20% by "Secretaria Xeral de Universidades" (Grant
   ED431G 2019/01). Emilio Lopez Varela acknowledges its support under FPI
   Grant Program through the PID2019-108435RB-I00 project.
CR [Anonymous], 2020, VTK THE VISUALIZATIO
   Apostolopoulos S., MICCAI 2017, V10435
   Athanasiou LS, 2012, IEEE ENG MED BIO, P2647, DOI 10.1109/EMBC.2012.6346508
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bower BA, 2007, PROC SPIE, V6426, DOI 10.1117/12.704689
   Buda M, 2019, COMPUT BIOL MED, V109, P218, DOI 10.1016/j.compbiomed.2019.05.002
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Csaky K, 2003, OPHTHALMOLOGY, V110, P879
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x
   Gallego-Pinazo R., 2012, ARCHIVOS SOC ESPAOLA, V87
   Good I.J., 1956, Proceedings of the Institution of Electrical Engineers. C. Institution Monographs, V103, P200
   Harper RA., 2010, BASIC OPHTHALMOLOGY, P4771
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lu DH, 2019, MED IMAGE ANAL, V54, P100, DOI 10.1016/j.media.2019.02.011
   Mathenge W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001393
   Medeiros FA, 2005, AM J OPHTHALMOL, V139, P44, DOI 10.1016/j.ajo.2004.08.069
   Nesterov Y., 1983, SOVIET MATH DOKLADY, V27, P372
   Paszke A., PYTORCH IMPERATIVE S
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Rashno A., 2018, 2018 40 ANN INT C IE
   Ronneberger O., MEDICAL IMAGE COMPUT, Vvol9351
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P1200, DOI 10.1016/j.ajo.2015.09.010
   Taha AA, 2015, BMC MED IMAGING, V15, DOI 10.1186/s12880-015-0068-x
   Tan JH, 2016, INT C INTEL HUM MACH, P192, DOI 10.1109/IHMSC.2016.153
   Tennakoon R., 2018, 2018 IEEE 15 INT S B
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Visionimpairmentandblindness, 2020, VIS IMP BLINDN
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang J, 2020, IEEE T MED IMAGING, V39, P1335, DOI 10.1109/TMI.2019.2948867
   Zheng YL, 2013, AM J OPHTHALMOL, V155, P277, DOI 10.1016/j.ajo.2012.07.030
   Zou KH, 2004, ACAD RADIOL, V11, P178, DOI 10.1016/S1076-6332(03)00671-8
NR 34
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0897-1889
EI 1618-727X
J9 J DIGIT IMAGING
JI J. Digit. Imaging
PD OCT
PY 2022
VL 35
IS 5
BP 1271
EP 1282
DI 10.1007/s10278-022-00643-6
EA MAY 2022
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 5L3IQ
UT WOS:000791080900001
PM 35513586
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wu, B
   Li, J
   Lin, HW
   Wu, HX
AF Wu, Bin
   Li, Jin
   Lin, Houwen
   Wu, Haixiang
TI Different Strategies for the Treatment of Age-Related Macular
   Degeneration in China: An Economic Evaluation
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; COST-EFFECTIVENESS ANALYSIS;
   PHOTODYNAMIC THERAPY; PEGAPTANIB SODIUM; RISK-FACTORS; BEVACIZUMAB;
   RANIBIZUMAB; VERTEPORFIN; CARE; PREVALENCE
AB Purpose. To assess the cost-effectiveness of bevacizumab compared to ranibizumab, verteporfin photodynamic therapy (PDT), and usual care for the treatment of age-related macular degeneration (AMD) in China. Methods. A Markov model was developed according to patient visual acuity (VA) in the better-seeing eye (Snellen scale). Four cohorts of patients were treated with one of the following therapies: bevacizumab, ranibizumab, PDT, or usual care. Clinical data related to treatments were obtained from published randomized clinical trials. Direct medical costs and resource utilization in the Chinese health care setting were taken into account. Health and economic outcomes were evaluated over a lifetime horizon. Sensitivity analyses were performed. Results. Treatment with ranibizumab provided the greatest gains in quality-adjusted life-years (QALYs). The cost per marginal QALY gained with bevacizumab over usual care was $1,258, $3,803, and $2,066 for the predominantly classic, minimally classic, and occult lesions, respectively. One-way sensitivity analysis showed considerably influential factors, such as utility values and effectiveness data. Probabilistic sensitivity analysis indicated that, compared to usual care, PDT and ranibizumab most cases would be cost-effective in the bevacizumab arm at a threshold of $7,480/QALY. Conclusion. Bevacizumab can be a cost-effective option for the treatment of AMD in the Chinese setting.
C1 [Wu, Bin; Lin, Houwen] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Pharm,Med Decis & Econ Grp, South Campus, Shanghai 201114, Peoples R China.
   [Li, Jin] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Ophthalmol, Shanghai 200127, Peoples R China.
   [Wu, Haixiang] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200031, Peoples R China.
   [Wu, Haixiang] Fudan Univ, Eye & ENT Hosp, Shanghai Key Lab Visual Impairment & Restorat, Shanghai 200031, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan
   University; Fudan University
RP Wu, HX (通讯作者)，Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200031, Peoples R China.; Wu, HX (通讯作者)，Fudan Univ, Eye & ENT Hosp, Shanghai Key Lab Visual Impairment & Restorat, Shanghai 200031, Peoples R China.
EM whx577@163.com
OI Lin, Hou-Wen/0000-0002-7097-0876
FU National Natural Science Foundation of China [71373160, 81300781];
   Fourth Round of Three-Year Action Plan on Public Health Discipline and
   Talent Program (Evidence-Based Public Health and Health Economics)
   [15GWZK0901]
FX This study was supported by grants from the National Natural Science
   Foundation of China (nos. 71373160 and 81300781) and the Fourth Round of
   Three-Year Action Plan on Public Health Discipline and Talent Program
   (Evidence-Based Public Health and Health Economics, no. 15GWZK0901).
CR [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   [Anonymous], 2015, WORLD DEV INDICATORS
   [Anonymous], 2015, LIFE TABLES WHO MEMB
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown G. C., 2005, AM J OPHTHALMOL, V140
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Chen RL, 2004, INT J GERIATR PSYCH, V19, P407, DOI 10.1002/gps.1103
   Chen You-xin, 2007, Zhonghua Yan Ke Za Zhi, V43, P198
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   Eichler HG, 2004, VALUE HEALTH, V7, P518, DOI 10.1111/j.1524-4733.2004.75003.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Huang HB, 2013, CLIN EXP OPTOM, V96, P106, DOI 10.1111/j.1444-0938.2012.00812.x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li XX, 2012, OPHTHALMOLOGY, V119, P2087, DOI 10.1016/j.ophtha.2012.05.016
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MILLER DK, 1994, MED DECIS MAKING, V14, P52, DOI 10.1177/0272989X9401400107
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Murray CJL, 2000, HEALTH ECON, V9, P235, DOI 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Quellec G, 2011, INVEST OPHTH VIS SCI, V52, P9195, DOI 10.1167/iovs.10-6793
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sun XD, 2011, NEW ENGL J MED, V365, P378, DOI 10.1056/NEJMc1106415
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wang JT, 2010, AGEING RES REV, V9, pS13, DOI 10.1016/j.arr.2010.07.002
   World Health Organization, 2009, GLOB IN EL AV BLINDN
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
   Zong X., 2010, CHINA J PHARM EC, V15, P11
NR 44
TC 22
Z9 23
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2016
VL 2016
AR 7689862
DI 10.1155/2016/7689862
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DK9NX
UT WOS:000375258800001
PM 27200183
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fang, K
   Tian, J
   Qing, XY
   Li, S
   Hou, J
   Li, J
   Yu, WZ
   Chen, DF
   Hu, YH
   Li, XX
AF Fang, Kai
   Tian, Jun
   Qing, Xueying
   Li, Shuai
   Hou, Jing
   Li, Juan
   Yu, Wenzhen
   Chen, Dafang
   Hu, Yonghua
   Li, Xiaoxin
TI Predictors of Visual Response to Intravitreal Bevacizumab for Treatment
   of Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CIGARETTE-SMOKING; CHOROIDAL
   NEOVASCULARIZATION; SUBGROUP ANALYSIS; EPITHELIAL-CELLS; FACTOR VEGF;
   RANIBIZUMAB; ASSOCIATION; EXPRESSION; RISK
AB Purpose. To identify the predictors of visual response to the bevacizumab treatment of neovascular age-related macular degeneration (AMD). Design. A cohort study within the Neovascular AMD Treatment Trial Using Bevacizumab (NATTB). Methods. This was a multicenter trial including 144 participants from the NATTB study. Visual outcomes measured by change in visual acuity (VA) score, proportion gaining >= 15 letters, and change in central retinal thickness (CRT) were compared among groups according to the baseline, demographic, and ocular characteristics and genotypes. Results. Mean change in the VA score was 9.2 +/- 2.3 SD letters with a total of 46 participants (31.9%) gaining >= 15 letters. Change in median CRT was -81.5 mu m. Younger age, lower baseline VA score, shorter duration of neovascular AMD, and TT genotype in rs10490924 were significantly associated with greater VA score improvement (P = 0.028, P < 0.001, P = 0.02, and P = 0.039, resp.). Lower baseline VA score and TT genotype in rs10490924 were significantly associated with a higher likelihood of gaining >= 15 letters (P = 0.028, and P = 0.021, resp.). Conclusions. Baseline VA and genotype of rs10490924 were both important predictors for visual response to bevacizumab at 6 months. This trial is registered with the Registration no. NCT01306591.
C1 [Fang, Kai; Tian, Jun; Qing, Xueying; Li, Shuai; Chen, Dafang; Hu, Yonghua] Peking Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Hlth Sci Ctr, Beijing 100191, Peoples R China.
   [Hou, Jing; Yu, Wenzhen; Li, Xiaoxin] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100044, Peoples R China.
   [Hou, Jing; Yu, Wenzhen; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing 100044, Peoples R China.
   [Li, Juan] Beijing Ctr Dis Control & Prevent, Inst Immunoprophylaxis, Beijing 100013, Peoples R China.
C3 Peking University; Peking University
RP Hu, YH (通讯作者)，Peking Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Hlth Sci Ctr, Beijing 100191, Peoples R China.
EM yhhu@bjmu.edu.cn; dr_lixiaoxin@163.com
RI Li, Shuai/K-2164-2015
OI Li, Shuai/0000-0002-8696-8594
FU Ministry of Science and Technology of the People's Republic of China,
   Beijing, China [2006BAI02B05]
FX This paper was supported by the National Key Technology Research and
   Development Program in the 11th Five-Year Plan from The Ministry of
   Science and Technology of the People's Republic of China, Beijing, China
   (2006BAI02B05). Involved in conception and design of the study are Kai
   Fang, Wenzhen Yu, Dafang Chen, Yonghua Hu, and Xiaoxin Li; involved in
   the analysis and interpretation are Kai Fang and Jun Tian; involved in
   the writing of the paper are Kai Fang and Shuai Li; contributed to the
   critical revision of the paper are Jun Tian, Xueying Qing, Wenzhen Yu,
   Yonghua Hu, and Xiaoxin Li; assisted in the final approval of the paper
   are Kai Fang, Jun Tian, Xueying Qing, Shuai Li, Jing Hou, Juan Li,
   Wenzhen Yu, Dafang Chen, Yonghua Hu, and Xiaoxin Li; aided in the data
   collection Kai Fang, Jun Tian, Xueying Qing, Jing Hou, Juan Li, Wenzhen
   Yu, and Dafang Chen; facilitated the provision of materials, patients,
   or resources are Jing Hou, Wenzhen Yu, and Xiaoxin Li; supported with
   the obtaining funding (Yonghua Hu, Xiaoxin Li); literature search are
   Kai Fang, Jun Tian, and Juan Li; and provided the administrative,
   technical, or logistic support are Yonghua Hu, and Xiaoxin Li. The
   authors would like to thank the experts in the 13 clinical centers for
   their help in recruiting participants. Other group members are the
   following: Xiaodong Sun (Department of Ophthalmology, Shanghai First
   People's Hospital, Shanghai Jiao Tong University, Shanghai, China);
   Xiaohua Zhu (Department of Ophthalmology, The Second Xiangya Hospital,
   Central South University, Changsha, China); Xiaoguang Dong (Shandong Eye
   Institute, Qingdao, China); Zeli Liu (Department of Ophthalmology, The
   First Hospital, China Medical University, Shenyang, China); Yusheng Wang
   (Department of Ophthalmology, Xijing Hospital, The Fourth Military
   Medical University, Xi'an, China); Xiaoling Liu (Optometry Hospital,
   Wenzhou Medical College, Wenzhou, China); Xiaoling Liang (Zhongshan
   Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China); Qinghuai
   Liu (Department of Ophthalmology, The First Affiliated Hospital, Nanjing
   Medical University, Nanjing, China); Maonian Zhang (Department of
   Ophthalmology, General Hospital of PLA, Beijing, China); Junjun Zhang
   (Department of Ophthalmology, West China Hospital, Sichuan University,
   Chengdu, China); Youxing Chen (Department of Ophthalmology, Peking Union
   Medical College Hospital, Beijing, China); Yiqiao Xing (Department of
   Ophthalmology, Renmin Hospital, Wuhan University, Changsha, China).
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conklin BS, 2002, AM J PATHOL, V160, P413, DOI 10.1016/S0002-9440(10)64859-6
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Li XX, 2012, OPHTHALMOLOGY, V119, P2087, DOI 10.1016/j.ophtha.2012.05.016
   Lutty G, 1999, MOL VIS, V5
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Takeuchi A, 2009, INVEST OPHTH VIS SCI, V50, P3410, DOI 10.1167/iovs.08-2299
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 42
TC 19
Z9 19
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 676049
DI 10.1155/2013/676049
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 215HM
UT WOS:000324200500001
PM 24069533
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ayub, H
   Shafique, S
   Azam, A
   Muslim, I
   Qazi, NA
   Akhtar, F
   Khan, MA
   Ayub, A
   Bashir, S
   Bakker, B
   Ahmed, S
   Azam, M
   den Hollander, AI
   Qamar, R
AF Ayub, Humaira
   Shafique, Sobia
   Azam, Aisha
   Muslim, Irfan
   Qazi, Nauman A.
   Akhtar, Farah
   Khan, Muhammad Asim
   Ayub, Adil
   Bashir, Shaheena
   Bakker, Bjorn
   Ahmed, Shakil
   Azam, Maleeha
   den Hollander, Anneke I.
   Qamar, Raheel
TI Association of rs10490924 in ARMS2/HTRA1 with age-related macular
   degeneration in the Pakistani population
SO ANNALS OF HUMAN GENETICS
LA English
DT Article
DE AMD; ARMS2; HTRA1; CFH; genetic association study; Pakistani population
ID COMPLEMENT-FACTOR-H; GENE POLYMORPHISMS; VARIANT; RISK; SUSCEPTIBILITY;
   INCREASES; BF; C2
AB Age-related macular degeneration (AMD) is a disease of the elderly in which central vision is lost because of degenerative changes of the macula. The current study investigated the association of single-nucleotide polymorphisms (SNPs) with AMD in the Pakistani population. Four SNPs were analyzed in this study: rs1061170 in the CFH, rs429608 near CFB, rs2230199 in the C3, and rs10490924 in ARMS2/HTRA1. This case-control association study was conducted on 300 AMD patients (125 wet AMD and 175 dry AMD) and 200 unaffected age- and gender-matched control individuals. The association of the SNP genotypes and allele frequency distributions were compared between patients and healthy controls, keeping age, gender, and smoking status as covariates. A significant genotype and variant allele association was found of rs10490924 in ARMS2/HTRA1 with wet AMD, while the SNPs in CFH, CFB, and C3 were not associated with AMD in the current Pakistani cohort. The lack of association of CFH, CFB, and C3 may be attributed to limited sample size. This study demonstrates that genetic causative factors of AMD differ among populations and supports the need for genetic association studies among cohorts from various populations to increase our global understanding of the disease pathogenesis.
C1 [Ayub, Humaira; Bashir, Shaheena; Ahmed, Shakil; Azam, Maleeha; Qamar, Raheel] COMSATS Univ Islamabad, Dept Biosci, Transalat Genom Lab, Islamabad, Pakistan.
   [Ayub, Humaira] COMSATS Univ Islamabad, Dept Environm Sci, Abbottabad Campus, Abbottabad, Pakistan.
   [Shafique, Sobia] Inst Biomed & Genet Engn, G-9-1, Islamabad, Pakistan.
   [Azam, Aisha; Muslim, Irfan] Mayo Hosp, Inst Ophthalmol, Lahore, Pakistan.
   [Qazi, Nauman A.] Mumtaz Mem Hosp, Muzaffargarh, Pakistan.
   [Akhtar, Farah] Al Shifa Trust, Eye Hosp, Rawalpindi, Pakistan.
   [Khan, Muhammad Asim] Khyber Teaching Hosp, Dept Ophthalmol, Peshawar, Pakistan.
   [Ayub, Adil] Ayub Teaching Hosp, Abbottabad, Pakistan.
   [Bakker, Bjorn; den Hollander, Anneke I.] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
   [Qamar, Raheel] Pakistan Acad Sci, Islamabad, Pakistan.
C3 COMSATS University Islamabad (CUI); COMSATS University Islamabad (CUI);
   Radboud University Nijmegen; Radboud University Nijmegen
RP Qamar, R (通讯作者)，COMSATS Univ Islamabad, Islamabad 45600, Pakistan.; den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl; raheelqamar@hotmail.com
RI Khan, Muhammad Asim/AAN-4845-2021; Bakker, Bjorn/E-2842-2016; Azam,
   Maleeha/AAD-9924-2022; Azam, Maleeha/L-1721-2017
OI Khan, Muhammad Asim/0000-0001-6036-6264; Ayub,
   Humaira/0000-0002-4320-7242; Azam, Maleeha/0000-0003-0170-3325
FU Higher Education Commission of Pakistan [3738, 20-4885]; Pakistan
   Academy of Sciences [5-9/PAAS/1082]
FX This study is supported by Higher Education Commission of Pakistan
   (Grant Nos. 3738 and 20-4885) and Pakistan Academy of Sciences grants
   (Grant Nos. 5-9/PAAS/1082) to M.A. and R.Q.
CR Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Makarev E, 2014, AGING-US, V6, P1064, DOI 10.18632/aging.100711
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Naghza D, 2013, PAK J OPHTHALMOL, V29, P221
   Nazari Khanamiri Hossein, 2014, J Ophthalmic Vis Res, V9, P181
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schwartz SG, 2012, RETINA-J RET VIT DIS, V32, P1486, DOI 10.1097/IAE.0b013e318240a540
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 25
TC 4
Z9 4
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-4800
EI 1469-1809
J9 ANN HUM GENET
JI Ann. Hum. Genet.
PD JUL
PY 2019
VL 83
IS 4
BP 285
EP 290
DI 10.1111/ahg.12311
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA IB1IQ
UT WOS:000470019300011
PM 30895599
DA 2022-11-30
ER

PT J
AU Cao, K
   Sahebjada, S
   Richardson, AJ
   Baird, PN
AF Cao, Ke
   Sahebjada, Srujana
   Richardson, Andrea J.
   Baird, Paul N.
TI Do age-related macular degeneration genes show association with
   keratoconus?
SO EYE AND VISION
LA English
DT Article
DE Keratoconus; Gender; Genetic; Age-related macular degeneration
ID SINGLE NUCLEOTIDE POLYMORPHISMS; AUTOSOMAL-DOMINANT KERATOCONUS;
   GENOME-WIDE ASSOCIATION; CALPASTATIN CAST GENE; FINGER PROTEIN GENE;
   MUTATIONAL ANALYSIS; CORNEAL THICKNESS; CANDIDATE GENE; GREEK PATIENTS;
   SOD1 GENES
AB Background Keratoconus (KC) is a common corneal condition with an unknown gender predominance. Although numerous studies have investigated the genetic component of KC, no specific genes have yet been attributed to the condition. We recently reported posterior segment changes occurring in the eyes of KC patients. However, it is not clear whether these changes are part of KC pathogenesis or reflect changes in anatomical features of the eye manifested by changes at the cornea. Given retinal changes represent the main characteristics observed in age-related macular degeneration (AMD) and that pleiotropy has been demonstrated between different eye diseases, we wished to assess if known AMD associated genes were also associated with KC. Methods A total of 248 KC subjects and 366 non-KC (control) subjects were recruited from public and private clinics in Melbourne for this analysis. Nineteen single nucleotide polymorphisms (SNPs) previously associated with AMD, including rs10490924 (ARMS2/HTRA1), rs10737680 (CFH), rs13278062 (TNFRSF10A), rs1864163 (CETP), rs2230199 (C3), rs3130783 (IER3/DDR1), rs334353 (TGFBR1), rs3812111 (COL10A1), rs429608 (C2/CFB), rs4420638 (APOE), rs4698775 (CFI), rs5749482 (TIMP3), rs6795735 (ADAMTS9), rs8017304 (RAD51B), rs8135665 (SLC16A8), rs920915 (LIPC), rs943080 (VEGFA), rs9542236 (B3GALTL) and rs13081855 (COL8A1/FILIP1L), were genotyped in this cohort. Logistic regression was applied to evaluate the association between these SNPs and KC on both genders together, as well as each gender separately. Linear regression was also applied to assess the association between SNPs and corneal curvature. Bonferroni correction was applied to adjust for multiple testing. Results Genotyping data were available for 18 SNPs. The SNP, rs6795735 (ADAMTS9) was significantly associated with KC (p = 3.5 x 10(- 4)) when both genders were assessed, whereas rs5749482 (TIMP3) was only associated in males (p = 7.7 x 10(- 4)) following Bonferroni multiple correction. However, when the covariates of age and gender were included, the associations became non-significant. In addition, none of the SNPs appeared significant for corneal curvature. Conclusions Our study suggested a potential association of rs6795735 in the ADAMTS9 gene and rs5749482 in the TIMP3 gene in KC and that different associations may be gender specific. Overall, SNPs initially identified as associated with AMD following multiple correction may be further impacted by other factors such as age or gender and further studies are needed to resolve this issue.
C1 [Cao, Ke; Sahebjada, Srujana; Richardson, Andrea J.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Cao, Ke; Sahebjada, Srujana; Baird, Paul N.] Univ Melbourne, Dept Surg Ophthalmol, 32 Gisborne St, East Melbourne, Vic 3000, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Baird, PN (通讯作者)，Univ Melbourne, Dept Surg Ophthalmol, 32 Gisborne St, East Melbourne, Vic 3000, Australia.
EM pbaird@unimelb.edu.au
OI Baird, Paul/0000-0002-1305-3502
FU Australian National Health and Medical Research Council (NHMRC)
   [GNT1104700]; Angior Family Foundation; Lions Eye Foundation Fellowship;
    [1138585]
FX This study was supported by the Australian National Health and Medical
   Research Council (NHMRC) project grant GNT1104700 and Senior Research
   Fellowship (1138585 to PN Baird), the Angior Family Foundation and a
   Lions Eye Foundation Fellowship (SS). The Centre for Eye Research
   Australia (CERA) receives Operational Infrastructure Support from the
   Victorian Government.
CR Adams MKM, 2012, HUM MOL GENET, V21, P5229, DOI 10.1093/hmg/dds364
   Arbab M, 2017, INVEST OPHTH VIS SCI, V58, P3481, DOI 10.1167/iovs.16-21400
   Bardak H, 2016, Genet Mol Res, V15, DOI 10.4238/gmr15049024
   Bisceglia L, 2005, INVEST OPHTH VIS SCI, V46, P39, DOI 10.1167/iovs.04-0533
   Brancati F, 2004, J MED GENET, V41, P188, DOI 10.1136/jmg.2003.012872
   Burdon KP, 2013, CLIN EXP OPTOM, V96, P146, DOI 10.1111/cxo.12024
   Burdon KP, 2011, INVEST OPHTH VIS SCI, V52, P8514, DOI 10.1167/iovs.11-8261
   Bykhovskaya Yelena, 2016, Int J Keratoconus Ectatic Corneal Dis, V5, P63, DOI 10.5005/jp-journals-10025-1123
   Bykhovskaya Y, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0047-5
   Bykhovskaya Y, 2012, INVEST OPHTH VIS SCI, V53, P4152, DOI 10.1167/iovs.11-9268
   Chang HYP, 2013, SEMIN OPHTHALMOL, V28, P275, DOI 10.3109/08820538.2013.825295
   Cuellar-Partida G, 2015, HUM MOL GENET, V24, P5060, DOI 10.1093/hmg/ddv211
   Dash D, 2006, MOL VIS, V12, P499
   Davidson AE, 2014, EYE, V28, P189, DOI 10.1038/eye.2013.278
   De Bonis P, 2011, MOL VIS, V17, P2482
   Dudakova L, 2015, EUR J HUM GENET, V23, P1581, DOI 10.1038/ejhg.2015.28
   Fink BA, 2005, AM J OPHTHALMOL, V140, P459, DOI 10.1016/j.ajo.2005.03.078
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garoufalis P, 2005, OPHTHAL EPIDEMIOL, V12, P383, DOI 10.1080/09286580500281222
   Godefrooij DA, 2017, AM J OPHTHALMOL, V175, P169, DOI 10.1016/j.ajo.2016.12.015
   Gordon-Shaag A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/795738
   Guan T, 2018, Zhonghua Yan Ke Za Zhi, V54, P212, DOI 10.3760/cma.j.issn.0412-4081.2018.03.012
   Guan T, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0567-3
   Guan Tao, 2011, Zhonghua Yixue Yichuanxue Zazhi, V28, P152, DOI 10.3760/cma.j.issn.1003-9406.2011.02.007
   Bae HA, 2013, INVEST OPHTH VIS SCI, V54, P5132, DOI 10.1167/iovs.13-12377
   Hao XD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13162-0
   Hao XD, 2015, OPHTHALMIC GENET, V36, P132, DOI 10.3109/13816810.2015.1005317
   Hashemi H, 2013, CORNEA, V32, P1441, DOI 10.1097/ICO.0b013e3182a0d014
   Jhanji V, 2011, BRIT J OPHTHALMOL, V95, P1044, DOI 10.1136/bjo.2010.185868
   Jimenez JO, 1997, OPTOMETRY VISION SCI, V74, P147
   Jonas JB, 2009, AM J OPHTHALMOL, V148, P760, DOI 10.1016/j.ajo.2009.06.024
   Karolak JA, 2016, OPHTHALMIC GENET, V37, P37, DOI 10.3109/13816810.2014.926375
   KENNEDY RH, 1986, AM J OPHTHALMOL, V101, P267, DOI 10.1016/0002-9394(86)90817-2
   Kenney MC, 2005, INVEST OPHTH VIS SCI, V46, P823, DOI 10.1167/iovs.04-0549
   Kim SH, 2008, MOL VIS, V14, P2109
   Lechner J, 2014, HUM MOL GENET, V23, P5527, DOI 10.1093/hmg/ddu253
   Lechner J, 2013, INVEST OPHTH VIS SCI, V54, P5266, DOI 10.1167/iovs.13-12035
   Lee JE, 2009, MOL VIS, V15, P2480
   Li XH, 2004, OPHTHALMOLOGY, V111, P440, DOI 10.1016/j.ophtha.2003.06.020
   Li X, 2013, INVEST OPHTH VIS SCI, V54, P2696, DOI 10.1167/iovs.13-11601
   Li XH, 2013, CORNEA, V32, P696, DOI 10.1097/ICO.0b013e3182821c1c
   Liskova P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172365
   Lu Y, 2013, NAT GENET, V45, P155, DOI 10.1038/ng.2506
   Magalhaes OA, 2018, INT OPHTHALMOL, V38, P1627, DOI 10.1007/s10792-017-0634-z
   Mikami T, 2013, MOL VIS, V19, P845
   Millodot Michel, 2016, J Optom, V9, P72, DOI 10.1016/j.optom.2015.05.001
   Mok JW, 2008, J HUM GENET, V53, P842, DOI 10.1007/s10038-008-0319-6
   Moschos MM, 2016, CORNEA, V35, P631, DOI 10.1097/ICO.0000000000000769
   Moschos MM, 2015, OPHTHALMIC GENET, V36, P213, DOI 10.3109/13816810.2013.843712
   Nowak DM, 2013, INVEST OPHTH VIS SCI, V54, P2207, DOI 10.1167/iovs.13-11592
   Paliwal P, 2009, MOL VIS, V15, P2475
   Pathak D, 2011, MOL VIS, V17, P1514
   Sabti S, 2015, CORNEA, V34, P1157, DOI 10.1097/ICO.0000000000000491
   Saee-Rad S, 2011, MOL VIS, V17, P3128
   Sahebjada S, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/245953
   Sahebjada S, 2013, INVEST OPHTH VIS SCI, V54, P8224, DOI 10.1167/iovs.13-12982
   Sahebjada S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084067
   Saravani R, 2017, JPN J OPHTHALMOL, V61, P218, DOI 10.1007/s10384-017-0503-3
   Saravani R, 2015, CORNEA, V34, P318, DOI 10.1097/ICO.0000000000000356
   Sharif R, 2018, PROG RETIN EYE RES, V67, P150, DOI 10.1016/j.preteyeres.2018.05.002
   Shetty R, 2015, BMC MED GENET, V16, DOI 10.1186/s12881-015-0178-x
   Stabuc-Silih M, 2010, ACTA DERMATOVEN ALP, V19, P3
   Stabuc-Silih M, 2009, MOL VIS, V15, P2848
   Stabuc-Silih M, 2010, CORNEA, V29, P172, DOI 10.1097/ICO.0b013e3181aebf7a
   Synowiec E, 2015, CELL MOL BIOL, V61, P56
   Synowiec E, 2014, TOHOKU J EXP MED, V234, P17, DOI 10.1620/tjem.234.17
   Synowiec E, 2013, DIS MARKERS, V2013, P353, DOI 10.1155/2013/851817
   Tuft SJ, 2012, ACTA OPHTHALMOL, V90, pe482, DOI 10.1111/j.1755-3768.2012.02448.x
   Tyynismaa H, 2002, INVEST OPHTH VIS SCI, V43, P3160
   Udar N, 2006, INVEST OPHTH VIS SCI, V47, P3345, DOI 10.1167/iovs.05-1500
   Vincent AL, 2014, INVEST OPHTH VIS SCI, V55, P5629, DOI 10.1167/iovs.14-14532
   Vincent AL, 2013, MOL VIS, V19, P852
   Wagner H, 2007, Cont Lens Anterior Eye, V30, P223, DOI 10.1016/j.clae.2007.03.001
   Wang Y, 2016, CURR EYE RES, V41, P630, DOI 10.3109/02713683.2015.1045083
   Wang YN, 2013, OPHTHALMIC GENET, V34, P160, DOI 10.3109/13816810.2012.743569
   Williams KAKM., 2018, AUSTR CORNEAL GRAFT
   Wojcik KA, 2015, CELL MOL BIOL LETT, V20, P48, DOI 10.1515/cmble-2015-0001
   Wojcik KA, 2014, INT J MOL SCI, V15, P19682, DOI 10.3390/ijms151119682
   Wojcik KA, 2014, INT J MOL SCI, V15, P14786, DOI 10.3390/ijms150814786
   Wojcik KA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/247438
   Woodward MA, 2016, OPHTHALMOLOGY, V123, P457, DOI 10.1016/j.ophtha.2015.10.035
   Yildiz E, 2017, CURR EYE RES, V42, P1396, DOI 10.1080/02713683.2017.1325910
   Yildiz EH, 2009, EYE CONTACT LENS, V35, P309, DOI 10.1097/ICL.0b013e3181be5784
   Yu XN, 2017, MOL VIS, V23, P296
   Zhang J, 2018, GENE, V653, P10, DOI 10.1016/j.gene.2018.02.016
NR 86
TC 4
Z9 5
U1 1
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2326-0254
J9 EYE VISION
JI Eye Vis.
PD DEC 1
PY 2019
VL 6
IS 1
AR 38
DI 10.1186/s40662-019-0164-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JS0KZ
UT WOS:000500004500001
PM 31819893
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chang, AA
   Li, HT
   Broadhead, GK
   Hong, T
   Schlub, TE
   Wijeyakumar, W
   Zhu, MD
AF Chang, Andrew A.
   Li, Haitao
   Broadhead, Geoffrey K.
   Hong, Thomas
   Schlub, Timothy E.
   Wijeyakumar, Wijeyanthy
   Zhu, Meidong
TI Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related
   Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VEGF TRAP; VISUAL IMPAIRMENT; RANIBIZUMAB; BEVACIZUMAB; PREVALENCE;
   THERAPY; EYE
AB Objective: To assess the effectiveness of intravitreal aflibercept in patients with neovascular age-related macular degeneration (AMD) previously resistant to treatment with other anti-vascular endothelial growth factor agents.
   Design: Prospective, open-label, noncontrolled, registered clinical trial.
   Participants: Forty-nine patients with treatment-resistant neovascular AMD.
   Intervention: A dose of 2 mg intravitreal aflibercept was administered as 3 initial loading doses every 4 weeks (week 0, week 4, and week 8), followed by further injections every 8 weeks (weeks 16 and 24) across a 24-week period in total. All patients underwent a complete ophthalmic examination, including measurement of Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA), intraocular pressure assessment, adverse event monitoring, and spectral-domain optical coherence tomography at every visit. Baseline fluorescein angiography and indocyanine green angiography also were performed.
   Main Outcome Measures: Outcomes assessed included proportions of patients with a gain or loss of more than 5 ETDRS letters and a decrease or increase in central retinal thickness (CRT) of more than 150 mu m at week 24 compared with baseline, change in mean BCVA and CRT between baseline and week 24, and descriptive safety data.
   Results: The BCVA improved and CRT was reduced significantly at all follow-up visits compared with baseline (P < 0.001), with a mean improvement of 6.9 letters of BCVA and a decrease of 89.4 mu m in CRT at week 24. Spacing of injections from every 4 weeks to 8 weeks resulted in an increase of 37.4 mu m in CRT (P < 0.001); however, this was not correlated with a significant change in vision. There was 1 (2%) patient who lost more than 5 ETDRS letters, and 27 (55%) patients who gained more than 5 letters. Two (4%) patients had a more than 150 mu m increase in CRT at week 24, and 10 (20%) patients showed a decrease in CRT of more than 150 mu m.
   Conclusions: Intravitreal aflibercept is effective in previously treatment-resistant neovascular AMD. Further follow-up is required to determine whether these improvements can be maintained. (C) 2014 by the American Academy of Ophthalmology.
C1 [Chang, Andrew A.; Li, Haitao; Broadhead, Geoffrey K.; Hong, Thomas; Wijeyakumar, Wijeyanthy] Sydney Inst Vis Sci, Sydney, NSW, Australia.
   [Chang, Andrew A.; Broadhead, Geoffrey K.; Wijeyakumar, Wijeyanthy; Zhu, Meidong] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Schlub, Timothy E.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia.
C3 University of Sydney; University of Sydney
RP Chang, AA (通讯作者)，Sydney Retina Clin & Day Surg, Level 13,Pk House,187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
OI Schlub, Timothy/0000-0001-7746-9649
FU Bayer Corporation Global (Bayer Healthcare AG, Leverkusen, Germany)
FX Supported by Bayer Corporation Global (Bayer Healthcare AG, Leverkusen,
   Germany). The sponsor had no role in the design or conduct of this
   research.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 14
TC 103
Z9 110
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2014
VL 121
IS 1
BP 188
EP 192
DI 10.1016/j.ophtha.2013.08.035
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282KG
UT WOS:000329169500033
PM 24144450
DA 2022-11-30
ER

PT J
AU Lichtinger, A
   Caraza, M
   Galbinur, T
   Chowers, I
AF Lichtinger, Alejandro
   Caraza, Mauricio
   Galbinur, Tural
   Chowers, Itay
TI Factors Associated with Early Detection of Choroidal Neovascularization
   in Age-Related Macular Degeneration in the Clinic Setting
SO ISRAEL MEDICAL ASSOCIATION JOURNAL
LA English
DT Article
DE age-related macular degeneration (AMD); choroidal neovascularization
   (CNV); visual acuity (VA); follow-up; clinic setting
ID PREFERENTIAL HYPERACUITY PERIMETER; SUBGROUP ANALYSIS; PREVENTION TRIAL;
   RANIBIZUMAB; ISRAEL
AB Background: Delayed diagnosis of choroidal neovas cularization (CNV) in age-related macular degeneration (AMD) adversely affects visual outcome.
   Objectives: To identify factors associated with early detection of CNV in the clinic setting.
   Methods: Demographic and clinical data and lesion characteristics were retrospectively collected from 76 consecutive AMD patients who had a history of CNV in one eye and presented with CNV in the second eye. These data were evaluated for association with visual acuity (VA) at the time of presentation.
   Results: Better VA was associated with a history of CNV in the fellow eye (P < 0.0001), adherence to follow-up every 4 months (P = 0.015), younger age (P = 0.03), smaller lesion (P < 0.0001), and non-subfoveal location (P = 0.048). VA of the fellow eye did not correlate with VA at presentation with CNV.
   Conclusions: These data suggest that patients' experience of CNV, regardless of VA, facilitates early diagnosis in the fellow eye. Adherence to follow-up in the routine clinic setting also facilitates early detection of CNV.
C1 [Chowers, Itay] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
   Hadassah Hebrew Univ Med Sch, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
CR Abu Asleh S, 2007, ISRAEL MED ASSOC J, V9, P656
   Acharya N, 2009, BRIT J OPHTHALMOL, V93, P627, DOI 10.1136/bjo.2008.147231
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cervantes-Castaneda RA, 2008, EYE, V22, P777, DOI 10.1038/sj.eye.6702691
   Chowers I, 2008, MOL VIS, V14, P1829
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lai YH, 2011, RETINA-J RET VIT DIS, V31, P1620, DOI 10.1097/IAE.0b013e31820d3ed1
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   Niffenegger J, 1998, OPHTHALMOLOGY, V105, P1364
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Querques G, 2011, INVEST OPHTH VIS SCI, V52, P7012, DOI 10.1167/iovs.11-7517
   Querques G, 2011, BRIT J OPHTHALMOL, V95, P986, DOI 10.1136/bjo.2010.190942
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Waisbourd M, 2011, ISR MED ASSOC J, V13, P141
NR 22
TC 2
Z9 2
U1 0
U2 3
PU ISRAEL MEDICAL ASSOC JOURNAL
PI RAMAT GAN
PA 2 TWIN TOWERS, 11TH FL, 35 JABOTINSKY ST, PO BOX 3604, RAMAT GAN 52136,
   ISRAEL
SN 1565-1088
J9 ISR MED ASSOC J
JI Isr. Med. Assoc. J.
PD JUN
PY 2012
VL 14
IS 6
BP 363
EP 366
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 969EA
UT WOS:000306037300005
PM 22891397
DA 2022-11-30
ER

PT J
AU Bharathselvi, M
   Biswas, S
   Raman, R
   Selvi, R
   Coral, K
   Narayanansamy, A
   Ramakrishnan, S
   Sulochana, KN
AF Bharathselvi, Muthuvel
   Biswas, Sayantan
   Raman, Rajiv
   Selvi, Radhakrishnan
   Coral, Karunakaran
   Narayanansamy, Angayarkanni
   Ramakrishnan, Sivaramakrishnan
   Sulochana, Konerirajapuram N.
TI Homocysteine & its metabolite homocysteine-thiolactone & deficiency of
   copper in patients with age related macular degeneration - A pilot study
SO INDIAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article
DE Age; related macular degeneration; copper; glutathione; homocysteine;
   Homocysteine; thiolactone; oxidative stress
ID PROTEIN HOMOCYSTEINYLATION; SUPEROXIDE-DISMUTASE; PLASMA HOMOCYSTEINE;
   RISK-FACTORS; DISEASE; GLUTATHIONE; MACULOPATHY; SMOKING; CELLS
AB Background & objectives: Age related macular degeneration (ARMD) is a leading cause of blindness, particularly in persons above 60 yr of age. Homocysteine is implicated in many ocular diseases including ARMD. This study was undertaken to assess the status and relationship between plasma homocysteine, homocysteine-thiolactone, homocysteinylated protein and copper levels in patients with ARMD.
   Methods: A total of 16 patients with ARMD and 16 age-matched controls were recruited for the study. Plasma glutathione, homocysteine, homocysteine-thiolactone and extent of homocysteine conjugation with proteins, copper and thiobarbituric acid reactive substances were measured.
   Results: Homocysteine levels were elevated with increase in homocysteine-thiolactone, thiobarbituric acid reactive substances and a decrease of glutathione. The levels of homocysteinylated protein were elevated in ARMD. The elevated homocysteine, homocysteine-thiolactone correlated with the decrease in copper level.
   Interpretation & conclusions: Elevated homocysteine and its metabolite homocysteine-thiolactone and decreased levels of copper may play an important role in the pathogenesis of ARMD.
C1 [Sulochana, Konerirajapuram N.] Sankara Nethralaya, Vis Res Fdn, Dept Biochem & Cell Biol, 41 Coll Rd, Madras 600006, Tamil Nadu, India.
   Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Madras, Tamil Nadu, India.
RP Sulochana, KN (通讯作者)，Sankara Nethralaya, Vis Res Fdn, Dept Biochem & Cell Biol, 41 Coll Rd, Madras 600006, Tamil Nadu, India.
EM drkns@snmail.org
RI Biswas, Sayantan/AAQ-6183-2021; Coral, Karunakaran/AAK-2880-2021;
   Biswas, Sayantan/AAR-8256-2021; Raman, Rajiv/A-7234-2009
OI Biswas, Sayantan/0000-0001-6011-0365; Biswas,
   Sayantan/0000-0001-6011-0365; Raman, Rajiv/0000-0001-5842-0233
FU Indian Council of Medical Research (ICMR)
FX Authors acknowledge the Indian Council of Medical Research (ICMR) for
   financial support. The authors thank Dr S.R. Barathidevi, Shrimati R.
   Punitham for help, Shri Viswanathan (Biostatistician) for multiple
   testing corrections and Shriyut M. Arasu Kumar and T. Arokiaswamy
   (social workers) for recruiting patients and controls.
CR Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   Bharathselvi M, 2013, ANN CLIN BIOCHEM, V50, P330, DOI 10.1177/0004563213492146
   BROWN JCW, 1990, J NUTR, V120, P1068, DOI 10.1093/jn/120.9.1068
   BURTIS CA, 1986, TIETZ TXB CLIN CHEM
   Castro R, 2006, J INHERIT METAB DIS, V29, P3, DOI 10.1007/s10545-006-0106-5
   Chang HH, 2011, MOL VIS, V17, P1946
   Chwatko G, 2005, ANAL BIOCHEM, V337, P271, DOI 10.1016/j.ab.2004.11.035
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   DEVASAGAYAM TPA, 1987, BIOCHEM BIOPH RES CO, V145, P134, DOI 10.1016/0006-291X(87)91297-6
   Dionisio N, 2010, CURR MED CHEM, V17, P3109, DOI 10.2174/092986710791959783
   Dorota S, 2013, ANN AGR ENV MED, V20, P312
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HU ML, 1994, METHOD ENZYMOL, V233, P380
   Huesgen AG, 1999, SENSITIVE RELIABLE A, P1
   Hughes WM, 2008, CARDIOVASC TOXICOL, V8, P137, DOI 10.1007/s12012-008-9021-3
   Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45
   Jakubowski H, 2002, J BIOL CHEM, V277, P30425, DOI 10.1074/jbc.C200267200
   Jakubowski H, 2006, J NUTR, V136, p1741S, DOI 10.1093/jn/136.6.1741S
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Liu GM, 1997, J BIOL CHEM, V272, P32370, DOI 10.1074/jbc.272.51.32370
   Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006
   RAMAKRISHNAN S, 1995, BRIT J OPHTHALMOL, V79, P202, DOI 10.1136/bjo.79.3.202
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 32
TC 6
Z9 6
U1 0
U2 5
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0971-5916
J9 INDIAN J MED RES
JI Indian J. Med. Res.
PD JUN
PY 2016
VL 143
BP 756
EP 762
DI 10.4103/0971-5916.192026
PG 7
WC Immunology; Medicine, General & Internal; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; General & Internal Medicine; Research & Experimental
   Medicine
GA EA4VC
UT WOS:000386612600012
PM 27748300
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Enders, P
   Scholz, P
   Muether, PS
   Fauser, S
AF Enders, P.
   Scholz, P.
   Muether, P. S.
   Fauser, S.
TI Variability of disease activity in patients treated with ranibizumab for
   neovascular age-related macular degeneration
SO EYE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; AQUEOUS-HUMOR LEVELS; ANTI-VEGF TREATMENT;
   DIABETIC-RETINOPATHY; VITREOUS LEVELS; BEVACIZUMAB; DELAY
AB Purpose To analyze choroidal neovasularization (CNV) activity and recurrence patterns in patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab, and the correlation with individual intraocular vascular endothelial growth factor (VEGF) suppression time (VST).
   Methods Post-hoc analysis of data from a prospective, non-randomized clinical study. Patients with nAMD treated with ranibizumab on a pro re nata regimen. Disease activity was analyzed monthly by spectral-domain optical coherence tomography and correlated with VSTs.
   Results Overall, 73 eyes of 73 patients were included in the study with a mean follow-up of 717 days (range: 412-1239 days). Overall, the mean CNV-activity-free interval was 76.5 days (range: 0-829 days). The individual range of the length of dry intervals was high. A total of 42% of patients had a range of more than 90 days. Overall, 16% of patients showed persistent activity. And 12% stayed dry after the initial ranibizumab treatment. No significant correlation was found between the CNV-recurrence pattern and VST (P = 0.12).
   Conclusions CNV activity in nAMD is irregular, which is reflected in the range of the duration of dry intervals and late recurrences. The biomarker VST solely seems not to be sufficient to explain recurrence pattern of CNV in all AMD patients.
C1 [Enders, P.; Scholz, P.; Muether, P. S.; Fauser, S.] Univ Hosp Cologne, Dept Ophthalmol, Kerpener St 62, D-50924 Cologne, Germany.
C3 University of Cologne
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener St 62, D-50924 Cologne, Germany.
EM sascha.fauser@gmail.com
OI Enders, Philip/0000-0002-9527-4957
FU Novartis
FX This study was supported by a grant from the Novartis. The sponsor had
   no role in design, conduct, or analysis of the study.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Ecker SM, 2011, MOL VIS, V17, P2856
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Kiss S, 2014, OSLI RETINA, V45, P285, DOI 10.3928/23258160-20140709-04
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Noma H, 2010, EUR J OPHTHALMOL, V20, P402, DOI 10.1177/112067211002000222
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 15
TC 8
Z9 8
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2016
VL 30
IS 8
BP 1072
EP 1076
DI 10.1038/eye.2016.97
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DZ7EL
UT WOS:000386027400008
PM 27197870
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Christen, WG
   Cook, NR
   Ridker, PM
   Buring, JE
AF Christen, William G.
   Cook, Nancy R.
   Ridker, Paul M.
   Buring, Julie E.
TI Prospective Study of Plasma Homocysteine Level and Risk of Age-related
   Macular Degeneration in Women
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; homocysteine; prospective cohort; risk
   factor; Women's Health Study
ID RANDOMIZED CONTROLLED-TRIAL; LOW-DOSE ASPIRIN; CARDIOVASCULAR-DISEASE;
   FOLIC-ACID; PRIMARY PREVENTION; INFLAMMATORY MARKERS; SERUM
   HOMOCYSTEINE; FOLATE; VITAMIN-B12; MACULOPATHY
AB Purpose: Prospective data to examine the association of homocysteine with age-related macular degeneration (AMD) are limited. We examined the prospective relation of plasma homocysteine level and AMD in a large cohort of apparently healthy women.
   Methods: We evaluated the relationship between baseline levels of plasma homocysteine and incident AMD among 27,479 female health professionals aged 40 years or older. Main outcome measures were total AMD, defined as self-report documented by medical record evidence of an initial diagnosis after randomization, and visually significant AMD, defined as confirmed incident AMD with visual acuity 20/30 or worse attributable to this condition.
   Results: During an average 10 years of follow-up, a total of 452 cases of AMD, including 182 cases of visually significant AMD, were documented. Women in the highest versus lowest quartile of plasma homocysteine had modestly, but statistically non-significant, increased risks of total AMD (hazard ratio, HR, 1.24, 95% confidence interval, CI, 0.95-1.63; p for trend 0.07) and visually significant AMD (HR 1.41, 95% CI 0.92-2.17; p for trend 0.052) in age-and treatment-adjusted analyses.
   Conclusions: These prospective data from a large cohort of apparently healthy women do not support a strong role for homocysteine in AMD occurrence.
C1 [Christen, William G.; Cook, Nancy R.; Ridker, Paul M.; Buring, Julie E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, Boston, MA 02115 USA.
   [Ridker, Paul M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA.
   [Ridker, Paul M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Donald W Reynolds Ctr Cardiovasc Res, Boston, MA 02115 USA.
   [Ridker, Paul M.; Buring, Julie E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Harvard T.H. Chan School of Public Health
RP Christen, WG (通讯作者)，900 Commonwealth Ave East, Boston, MA 02215 USA.
EM wchristen@rics.bwh.harvard.edu
OI Venkatasubramanian, Siddharth/0000-0002-5860-0768
FU National Institutes of Health; Harvard University (Clinical Nutrition
   Research Center; DSM Nutritional Products Inc.; National Institutes of
   Health (Bethesda, MD) [EY 06633, EY 18820, HL 43851, HL 58755, CA
   47988]; Donald W. Reynolds Foundation, Las Vegas, NV; NATIONAL CANCER
   INSTITUTE [R01CA047988, UM1CA182913] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY018820, R01EY006633] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058755,
   R01HL043851] Funding Source: NIH RePORTER
FX W.G.C. investigator-initiated research funding from the National
   Institutes of Health, Harvard University (Clinical Nutrition Research
   Center), and DSM Nutritional Products Inc. (formerly Roche Vitamins).
   N.R.C. investigator-initiated research funding from the National
   Institutes of Health. P.M.R. investigator-initiated research funding
   from the National Institutes of Health. J.E.B. investigator-initiated
   research funding from the National Institutes of Health and assistance
   with study pills and packaging from Natural Source Vitamin E Association
   and Bayer Healthcare for the Women's Health Study.; This study was
   supported by Grants EY 06633, EY 18820, HL 43851, HL 58755, and CA 47988
   from the National Institutes of Health (Bethesda, MD) and the Donald W.
   Reynolds Foundation, Las Vegas, NV. The National Institutes of Health
   and the Donald W. Reynolds Foundation had no role in the design or
   conduct of this research.
CR Albert CM, 2008, JAMA-J AM MED ASSOC, V299, P2027, DOI 10.1001/jama.299.17.2027
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Clarke Robert, 2005, Semin Vasc Med, V5, P75, DOI 10.1055/s-2005-872393
   Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Domagala T B, 1998, J Cardiovasc Risk, V5, P239, DOI 10.1097/00043798-199808000-00006
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giovannucci E, 2006, JNCI-J NATL CANCER I, V98, P451, DOI 10.1093/jnci/djj101
   GLYNN RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P381, DOI 10.1001/archopht.1992.01080150079033
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Hennekens CH, 1987, EPIDEMIOLOGY MED
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
NR 32
TC 8
Z9 8
U1 0
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD APR
PY 2015
VL 22
IS 2
BP 85
EP 93
DI 10.3109/09286586.2015.1012272
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD9EO
UT WOS:000351400700002
PM 25777307
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wu, KHC
   Marmor, MF
AF Wu, KHC
   Marmor, MF
TI Alcohol- and light-induced electro-oculographic responses in age-related
   macular degeneration & central serous chorioretinopathy
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; alcohol response; central serous
   chorioretinopathy; electrophysiology; non-photic electro-oculogram;
   retinal pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; RETINITIS-PIGMENTOSA; MOUTH ALCOHOL;
   ABNORMALITIES; PATHOGENESIS; DISEASE; DRUSEN; SYSTEM; EOG
AB The non-photic electro-oculographic (EOG) response induced by alcohol has been proposed as an indicator of retinal pigment epithelial (RPE) integrity, and reported to be abnormal in age-related macular degeneration (ARMD). To evaluate this proposal, we have measured the alcohol-EOG as well as the ISCEV-standard EOG in patients with ARMD (n = 11 patients, 4 eyes with drusen, 8 eyes with 'dry' and 7 eyes with 'wet' lesions) and central serous chorioretinopathy (CSC, n = 11 patients, 7 eyes with active and 6 eyes with inactive lesions), compared with 29 normal controls. We recorded the alcohol-induced EOG response after a single oral administration of ethanol at 160 mg/kg, followed by an ISCEV-standard EOG. Blood alcohol levels were monitored with a breath analyzer. We found that neither the alcohol-EOG nor the light-induced EOG response showed any difference between either ARM D or CSC patients and normal controls. Nor was there difference among eyes of different ARM D or CSC subgroups. In addition, blood alcohol concentrations near the time of the alcohol-EOG peak showed no obvious relationship with peak/baseline ratios. These data suggest that neither the alcohol- nor the light-induced EOG is a sensitive indicator of these diseases.
C1 Stanford Univ, Med Ctr, Dept Ophthalmol, Stanford, CA 94305 USA.
C3 Stanford University
RP Marmor, MF (通讯作者)，Stanford Univ, Med Ctr, Dept Ophthalmol, 300 Pasteur Dr,Boswell A157, Stanford, CA 94305 USA.
EM marmor@stanford.edu
OI Marmor, Michael/0000-0001-6057-440X
CR Arden GB, 2000, INVEST OPHTH VIS SCI, V41, P2730
   Arden GB, 2000, INVEST OPHTH VIS SCI, V41, P2722
   Arden GB, 2003, INVEST OPHTH VIS SCI, V44, P3226, DOI 10.1167/iovs.02-0998
   Arden GB, 2000, BRIT J OPHTHALMOL, V84, P881, DOI 10.1136/bjo.84.8.881
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   DUBOWSKI KM, 1975, Z RECHTSMED, V76, P93
   GULLBERG RG, 1992, J FORENSIC SCI, V37, P1363
   GUPTA LY, 1994, DOC OPHTHALMOL, V88, P49, DOI 10.1007/BF01203701
   GUPTA LY, 1996, DOC OPHTHALMOL, V91, P101
   Harrison JM, 1999, OPHTHALMOLOGY, V106, P790, DOI 10.1016/S0161-6420(99)90168-9
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   MARCUS M, 1983, ANN OPHTHALMOL, V15, P235
   MARMOR MF, 1988, GRAEF ARCH CLIN EXP, V226, P548, DOI 10.1007/BF02169203
   MARMOR MF, 1991, DOC OPHTHALMOL, V76, P301, DOI 10.1007/BF00142668
   MARMOR MF, 2005, DOC OPHTHALMOL, P223
   MARMOR MF, 2002, INVEST OPHTHALMOL VI, V43
   Ozaki N, 1995, PSYCHIAT RES, V59, P151, DOI 10.1016/0165-1781(95)02788-2
   PAPAKOSTOPOULOS D, 1984, ELECTROEN CLIN NEURO, V59, P77, DOI 10.1016/0168-5597(84)90023-6
   Pinckers A, 1996, OPHTHALMIC GENET, V17, P103, DOI 10.3109/13816819609057112
   Shirao Y, 1997, JPN J OPHTHALMOL, V41, P174, DOI 10.1016/S0021-5155(97)00026-9
   Stavrou P, 1996, EYE, V10, P581, DOI 10.1038/eye.1996.134
   Steinberg RH, 1985, PROG RETIN RES, V4, P33, DOI [10.1016/0278-4327(85)90004-5, DOI 10.1016/0278-4327(85)90004-5]
   SUNNESS JS, 1986, AM J OPTOM PHYS OPT, V63, P7
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   WAKABAYASHI K, 1986, J JUZEN MED SOC, V95, P399
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wigmore JG, 2001, J ANAL TOXICOL, V25, P112, DOI 10.1093/jat/25.2.112
   YONEMURA D, 1979, DOC OPHTHALMOL, V48, P163, DOI 10.1007/BF00207350
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 30
TC 3
Z9 3
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD MAR-MAY
PY 2005
VL 110
IS 2-3
BP 237
EP 246
DI 10.1007/s10633-005-0649-z
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 031LM
UT WOS:000236706100012
PM 16328932
DA 2022-11-30
ER

PT J
AU MacLachlan, TK
   Lukason, M
   Collins, M
   Munger, R
   Isenberger, E
   Rogers, C
   Malatos, S
   DuFresne, E
   Morris, J
   Calcedo, R
   Veres, G
   Scaria, A
   Andrews, L
   Wadsworth, S
AF MacLachlan, Timothy K.
   Lukason, Michael
   Collins, Margaret
   Munger, Robert
   Isenberger, Elisabete
   Rogers, Cindy
   Malatos, Shana
   DuFresne, Elizabeth
   Morris, James
   Calcedo, Roberto
   Veres, Gabor
   Scaria, Abraham
   Andrews, Laura
   Wadsworth, Samuel
TI Preclinical Safety Evaluation of AAV2-sFLT01-A Gene Therapy for
   Age-related Macular Degeneration
SO MOLECULAR THERAPY
LA English
DT Article
ID PHASE-I TRIAL; LEBERS CONGENITAL AMAUROSIS; PARKINSONS-DISEASE;
   OPEN-LABEL; VECTOR; NEOVASCULARIZATION; RANIBIZUMAB; VEGF; TOLERABILITY;
   VERTEPORFIN
AB AAV2-sFLT01 is a vector that expresses a modified soluble Flt1 receptor designed to neutralize the proangiogenic activities of vascular endothelial growth factor (VEGF) for treatment of age-related macular degeneration (AMD) via an intravitreal injection. Owing to minimal data available for the intravitreal route of administration for adeno-associated virus (AAV), we initiated a 12-month safety study of AAV2-sFLT01 administered intravitreally at doses of 2.4 x 10(9) vector genomes (vg) and 2.4 x 10(10) vg to cynomolgus monkeys. Expression of sFlt01 protein peaked at similar to 1-month postadministration and remained relatively constant for the remainder of the study. Electroretinograms, fluorescein angiograms, and tonometry were assessed every 3 months, with no test article-related findings observed in any group. Indirect ophthalmoscopy and slit lamp exams performed monthly revealed a mild to moderate but self-resolving vitreal inflammation in the high-dose group only, which follow-up studies suggest was directed against the AAV2 capsid. Histological evaluation revealed no structural changes in any part of the eye and occasional inflammatory cells in the trabecular meshwork, vitreous and retina in the high-dose group. Biodistribution analysis in rats and monkeys found only trace amounts of vector outside the injected eye. In summary, these studies found AAV2-sFLT01 to be well-tolerated, localized, and capable of long-term expression.
C1 [MacLachlan, Timothy K.; Lukason, Michael; Isenberger, Elisabete; Rogers, Cindy; Malatos, Shana; DuFresne, Elizabeth; Morris, James; Scaria, Abraham; Andrews, Laura; Wadsworth, Samuel] Genzyme Corp, Framingham, MA 01701 USA.
   [Collins, Margaret] Charles River Labs Preclin Serv Nevada, Reno, NV USA.
   [Calcedo, Roberto] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Munger, Robert] Anim Ophthalmol Clin, Dallas, TX USA.
   [Veres, Gabor] Appl Genet Technol Corp, Alachua, FL USA.
C3 Sanofi-Aventis; Genzyme Corporation; University of Pennsylvania
RP Wadsworth, S (通讯作者)，Genzyme Corp, 49 New York Ave, Framingham, MA 01701 USA.
EM Sam.Wadsworth@genzyme.com
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Hackett RB, 1996, DERMATOTOXICOLOGY, P557
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Kang W, 2009, GENE THER, V16, P229, DOI 10.1038/gt.2008.158
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9
   Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Marks WJ, 2008, LANCET NEUROL, V7, P400, DOI 10.1016/S1474-4422(08)70065-6
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mueller C, 2008, GENE THER, V15, P858, DOI 10.1038/gt.2008.68
   NUSSENBLATT RB, 1985, OPHTHALMOLOGY, V92, P467
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   RASMUSSEN HS, 2003, PRECLINICA       MAR, P77
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Suburo A. M., 2006, V176, P71
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Van Vliet Kim M., 2008, V437, P51, DOI 10.1007/978-1-59745-210-6_2
NR 28
TC 119
Z9 129
U1 0
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD FEB
PY 2011
VL 19
IS 2
BP 326
EP 334
DI 10.1038/mt.2010.258
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 715WM
UT WOS:000286923000017
PM 21119620
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Bott, D
   Huntjens, B
   Binns, A
AF Bott, Deborah
   Huntjens, Byki
   Binns, Alison
TI Nutritional and smoking advice recalled by patients attending a UK
   age-related macular degeneration clinic
SO JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE age-related macular degeneration; lifestyle advice; nutrition
ID PRIMARY PREVENTION; UNITED-KINGDOM; BETA-CAROTENE; KNOWLEDGE;
   ANTIOXIDANTS; DEPRESSION; MORTALITY; DISEASE; TRIAL
AB Background Age-related macular degeneration (AMD) is responsible for half of registered visual impairment in the UK. The Royal College of Ophthalmologists recommends providing guidance to people with AMD regarding smoking, diet, and nutritional supplements. The aim of this study was to investigate lifestyle advice recalled by patients with neovascular AMD (nAMD).
   Methods The study took place at a UK hospital outpatients' clinic. Eligible patients with unilateral nAMD were presented with a survey about lifestyle advice provision.
   Results Of 248 respondents, only 39.9% remembered receiving advice regarding diet at the hospital. Only 24.2% of respondents recalled receiving advice regarding nutritional supplements, and only 19.8% of respondents started taking daily supplements as a result of their AMD. The most prevalent reason for not taking supplements amongst those advised to do so was lack of understanding of how it would help their eyes. Nearly 13% of the sample reported currently smoking, 53.1% of which reported that they were advised to stop smoking when diagnosed with AMD.
   Conclusion The findings suggest that it would be beneficial to review the provision of lifestyle advice to patients attending AMD outpatients' clinics, and to consider whether advice is being provided in an optimal format for later recall.
C1 [Bott, Deborah; Huntjens, Byki; Binns, Alison] City Univ London, Henry Wellcome Labs Vis Sci, Appl Vis Res Ctr, Northampton Sq, London EC1V 0HB, England.
C3 City University London
RP Binns, A (通讯作者)，City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, Northampton Sq, London EC1V 0HB, England.
EM Alison.Binns.1@city.ac.uk
OI Huntjens, Byki/0000-0002-4864-0723; Binns, Alison/0000-0001-8621-498X
CR Access Economics Pty Limited, 2009, FUT SIGHT LOSS UK 1
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Bunce C, 2015, PUBLIC HEALTH, V129, P138, DOI 10.1016/j.puhe.2014.12.018
   Carter BD, 2015, NEW ENGL J MED, V372, P631, DOI 10.1056/NEJMsa1407211
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Cimarolli VR, 2017, CLIN REHABIL, V31, P115, DOI 10.1177/0269215515624479
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Goodman GE, 2004, J NATL CANCER I, V96, P1743, DOI 10.1093/jnci/djh320
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy RD, 2011, OPTOMETRY, V82, P310, DOI 10.1016/j.optm.2010.10.014
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   National Institute for Health and Clinical Excellence, 2013, AFL SOL INJ TREAT WE
   National Institute for Health and Clinical Excellence, 2008, RAN PEG TREATM AG RE
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rovner BW, 2007, INT J GERIATR PSYCH, V22, P789, DOI 10.1002/gps.1742
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Sahu A, 2008, EYE, V22, P246, DOI 10.1038/sj.eye.6702592
   Sasaki M, 2012, ARCH OPHTHALMOL-CHIC, V130, P254, DOI 10.1001/archopthalmol.2011.1368
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Stevens R, 2014, BRIT J VISUAL IMPA, V32, P77, DOI 10.1177/0264619613519341
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
NR 33
TC 2
Z9 2
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1741-3842
EI 1741-3850
J9 J PUBLIC HEALTH-UK
JI J. Public Health
PD SEP
PY 2018
VL 40
IS 3
BP 614
EP 622
DI 10.1093/pubmed/fdx115
PG 9
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA HH9UJ
UT WOS:000456085500049
PM 28977430
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Akuffo, KO
   Nolan, JM
   Peto, T
   Stack, J
   Leung, I
   Corcoran, L
   Beatty, S
AF Akuffo, Kwadwo Owusu
   Nolan, John M.
   Peto, Tunde
   Stack, Jim
   Leung, Irene
   Corcoran, Laura
   Beatty, Stephen
TI Relationship between macular pigment and visual function in subjects
   with early age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; CAROTENOID FORMULATIONS; CONTRAST SENSITIVITY;
   PHOTOSTRESS RECOVERY; CHROMATIC CONTRAST; GLARE DISABILITY; ZEAXANTHIN;
   LUTEIN; ACUITY; SUPPLEMENTATION
AB Purpose To investigate the relationship between macular pigment (MP) and visual function in subjects with early age-related macular degeneration (AMD).
   Methods 121 subjects with early AMD enrolled as part of the Central Retinal Enrichment Supplementation Trial (CREST; ISRCTN13894787) were assessed using a range of psychophysical measures of visual function, including best corrected visual acuity (BCVA), letter contrast sensitivity (CS), mesopic and photopic CS, mesopic and photopic glare disability (GD), photostress recovery time (PRT), reading performance and subjective visual function, using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25). MP was measured using customised heterochromatic flicker photometry.
   Results Letter CS, mesopic and photopic CS, photopic GD and mean reading speed were each significantly (p<0.05) associated with MP across a range of retinal eccentricities, and these statistically significant relationships persisted after controlling for age, sex and cataract grade. BCVA, NEI VFQ-25 score, PRT and mesopic GD were unrelated to MP after controlling for age, sex and cataract grade (p>0.05, for all).
   Conclusions MP relates positively to many measures of visual function in unsupplemented subjects with early AMD. The CREST trial will investigate whether enrichment of MP influences visual function among those afflicted with this condition.
C1 [Akuffo, Kwadwo Owusu; Nolan, John M.; Stack, Jim; Corcoran, Laura; Beatty, Stephen] Waterford Inst Technol, Sch Hlth Sci, Macular Pigment Res Grp, Nutr Res Ctr Ireland, Waterford, Ireland.
   [Peto, Tunde; Leung, Irene] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Peto, Tunde; Leung, Irene] UCL, Inst Ophthalmol, London, England.
C3 South East Technological University (SETU); University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London
RP Akuffo, KO (通讯作者)，Waterford Inst Technol, Vis Res Ctr, Macular Pigment Res Grp, West Campus, Carriganore X91 K236, Waterford, Ireland.
EM kakuffo@wit.ie
RI Akuffo, Kwadwo Owusu/J-2036-2019; Peto, Tunde/G-8812-2018; Nolan,
   John/N-4921-2014
OI Akuffo, Kwadwo Owusu/0000-0001-6683-249X; Peto,
   Tunde/0000-0001-6265-0381; Nolan, John/0000-0002-5503-7084
FU European Research Council (ERC) [281096]; European Research Council;
   Howard Foundation, Cambridge, UK; NIHR BMRC at Moorfields Eye Hospital
   NHS Foundation Trust; UCL IoO, London, UK
FX This study was funded by the European Research Council (ERC); reference
   number: 281096. KOA, LC and JMN were funded by the European Research
   Council. JMN was also funded by the Howard Foundation, Cambridge, UK. TP
   and IL were funded by the NIHR BMRC at Moorfields Eye Hospital NHS
   Foundation Trust and UCL IoO, London, UK.
CR Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Akuffo KO, 2014, OPHTHAL EPIDEMIOL, V21, P111, DOI 10.3109/09286586.2014.888085
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Bovier ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108178
   Cheong AMY, 2007, VISION RES, V47, P2943, DOI 10.1016/j.visres.2007.07.010
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Craft N E, 2004, J Nutr Health Aging, V8, P156
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Engles M, 2007, INVEST OPHTH VIS SCI, V48, P2922, DOI 10.1167/iovs.06-0883
   Fletcher LM, 2014, OPTOMETRY VISION SCI, V91, P1089, DOI 10.1097/OPX.0000000000000355
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Hammond BR, 2013, INVEST OPHTH VIS SCI, V54, P476, DOI 10.1167/iovs.12-10411
   Hammond BR, 2012, VISION RES, V63, P58, DOI 10.1016/j.visres.2012.04.019
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Johnson EJ, 2012, AM J CLIN NUTR, V96, p1161S, DOI 10.3945/ajcn.112.034611
   Kelly D, 2015, J ALZHEIMERS DIS, V48, P261, DOI 10.3233/JAD-150199
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Mainster MA, 2012, AM J OPHTHALMOL, V153, P587, DOI 10.1016/j.ajo.2012.01.008
   Puell MC, 2013, ACTA OPHTHALMOL, V91, pE298, DOI 10.1111/aos.12067
   Putnam Christopher M, 2015, J Optom, V8, P258, DOI 10.1016/j.optom.2014.12.004
   READING VM, 1974, J OPT SOC AM, V64, P231, DOI 10.1364/JOSA.64.000231
   Renzi LM, 2013, NUTR NEUROSCI, V16, P262, DOI 10.1179/1476830513Y.0000000054
   Renzi LM, 2010, EXP EYE RES, V91, P896, DOI 10.1016/j.exer.2010.09.015
   Sabour-Pickett S, 2014, RETINA-J RET VIT DIS, V34, P1757, DOI 10.1097/IAE.0000000000000174
   Schultze M, 1866, UEBER GELBEN FLECK R
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2007, OPTOMETRY VISION SCI, V84, P859, DOI 10.1097/OPX.0b013e3181559c2b
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Vishwanathan R, 2013, NUTR NEUROSCI, V16, P21, DOI 10.1179/1476830512Y.0000000024
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
NR 36
TC 20
Z9 21
U1 1
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2017
VL 101
IS 2
BP 190
EP 197
DI 10.1136/bjophthalmol-2016-308418
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ6CO
UT WOS:000393306300020
PM 27091854
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Sorensen, MS
   Andersen, S
   Henningsen, GO
   Larsen, CT
   Sorensen, TL
AF Sorensen, Mette Sejer
   Andersen, Susanne
   Henningsen, Gitte Osterby
   Larsen, Charlotte Thornby
   Sorensen, Torben Lykke
TI Danish version of Visual Function Questionnaire-25 and its use in
   age-related macular degeneration
SO DANISH MEDICAL BULLETIN
LA English
DT Article
ID QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; NEI-VFQ; RELIABILITY;
   VALIDITY; VISION; RANIBIZUMAB; HEALTH
AB INTRODUCTION: Assessment of visual function can be a complex task and objective means of measurement of visual function do not always correlate with patients' self-perceived visual abilities. The purpose of this study was to translate the visual function questionnaire (VFQ)-25 into Danish with particular focus on its use in patients with late age-related macular degeneration (AMD).
   MATERIAL AND METHODS: The translation was done in accordance with standard internationally adopted methods. This includes forward translation, back translation, examination of translation quality, and adjudication by bilingual speakers. We presented the questionnaire to 120 consecutive patients with exudative AMD referred to our department and to 25 healthy individuals. We tested the reliability of the Danish version by measuring test-retest reliability, estimated the internal consistency of the questionnaire (Cronbach's a value) and analysed the discriminatory power (validity) of the questionnaire by comparing scores of patients with scores from control individuals without known eye disease.
   RESULTS: The translated questionnaire produced high test-retest correlations (range 0.8-0.9), had a relatively high level of internal consistency (range 0.4-0.9) and a high discriminatory power.
   CONCLUSION: The Danish version of VFQ-25 produces acceptable values of validity and reliability in patients with AMD.
C1 [Sorensen, Mette Sejer; Andersen, Susanne; Henningsen, Gitte Osterby; Larsen, Charlotte Thornby; Sorensen, Torben Lykke] Roskilde Hosp, Dept Ophthalmol, DK-4000 Roskilde, Denmark.
RP Sorensen, TL (通讯作者)，Roskilde Hosp, Dept Ophthalmol, DK-4000 Roskilde, Denmark.
EM torbenls@dadlnet.dk
RI Sørensen, Torben Lykke L/N-1417-2014
OI Sørensen, Torben Lykke L/0000-0002-6790-0199
FU Research Foundation of the Region Zealand
FX This study was supported by the Research Foundation of the Region
   Zealand.
CR ACQUDRO C, 1995, QUALITY LIFE PHARMAC, V2, P575
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Iyigun E, 2010, ACTA OPHTHALMOL, V88, pe115, DOI 10.1111/j.1755-3768.2009.01810.x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Nordmann JP, 2004, PHARMACOECONOMICS, V22, P197, DOI 10.2165/00019053-200422030-00005
   OLSSON H, 1998, MINDST RINGE SPORGES
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rossi GCM, 2003, J GLAUCOMA, V12, P213, DOI 10.1097/00061198-200306000-00006
   Sorensen Torben Lykke, 2010, Ugeskr Laeger, V172, P1685
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Wang CW, 2008, OPTOMETRY VISION SCI, V85, P1091, DOI 10.1097/OPX.0b013e31818b9f23
NR 20
TC 20
Z9 20
U1 0
U2 4
PU DANISH MEDICAL ASSOC
PI COPENHAGEN
PA TRONDHJEMSGADE 9, DK-2100 COPENHAGEN, DENMARK
SN 0907-8916
J9 DAN MED BULL
JI Dan. Med. Bull.
PD JUN
PY 2011
VL 58
IS 6
AR A4290
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 856FW
UT WOS:000297624800007
PM 21651879
DA 2022-11-30
ER

PT J
AU Karanjia, R
   Eng, KT
   Gale, J
   Sharma, S
   ten Hove, MW
AF Karanjia, R.
   Eng, K. T.
   Gale, J.
   Sharma, S.
   ten Hove, M. W.
TI Electrophysiological effects of intravitreal Avastin (bevacizumab) in
   the treatment of exudative age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; COHERENCE TOMOGRAPHY FINDINGS; RETINAL
   FUNCTION; RANIBIZUMAB; INJECTION; NEOVASCULARIZATION; THERAPY; DISEASE
AB Objective: To examine the sensitivity of the multifocal electroretinogram (mf-ERG) at measuring changes in retinal electrical activity in response to Avastin (bevacizumab) treatment for age-related macular degeneration (ARMD).
   Methods: Nine subjects with exudative ARMD, not previously treated with bevacizumab in the investigated eye, underwent pretreatment testing with mf-ERG and intravenous fluorescein angiography (IVFA). A second mf-ERG test was conducted post-treatment. The P1 response amplitudes were examined for the hexagons corresponding to areas of pathology on the IVFA. Intertest variability was accounted for by examining areas without pathology. Aggregate responses were also generated for central and lesion-associated responses.
   Results: Changes in P1 response amplitude correlated with changes in visual acuity (R(2) > 0.96). An improvement in Snellen visual acuity correlated with a significant improvement in P1 response amplitude from lesion associated recordings (p < 0.03). Changes in P1 response amplitudes were not observed when aggregate responses were generated.
   Conclusion: This study represents a novel method for assessing an improvement of mf-ERG responses. This is the first study to demonstrate a statistically significant change in retinal electrical activity postbevacizumab in patients with ARMD. This study demonstrates a method for utilising mf-ERG to assess changes in retinal electrical activity and to assess the effectiveness of treatments such as bevacizumab.
C1 [Karanjia, R.; Eng, K. T.; Gale, J.; Sharma, S.; ten Hove, M. W.] Queens Univ, Dept Ophthalmol, Hop Hotel Dieu, Kingston, ON K7L 5G2, Canada.
C3 Queens University - Canada
RP ten Hove, MW (通讯作者)，Queens Univ, Dept Ophthalmol, Hop Hotel Dieu, 166 Brock St, Kingston, ON K7L 5G2, Canada.
EM tenhove@queensu.ca
OI TEN HOVE, MARTIN/0000-0002-0781-9305
FU Department of Ophthalmology at Queen's University
FX Financial support for this study was provided internally by the
   Department of Ophthalmology at Queen's University.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hood DC, 1998, VISION RES, V38, P163, DOI 10.1016/S0042-6989(97)00143-0
   HOOD DC, 1997, OPT SOC AM TRENDS OP, V11, P33
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schneck ME, 2004, DOC OPHTHALMOL, V108, P223, DOI 10.1007/s10633-004-8745-z
NR 19
TC 12
Z9 12
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2008
VL 92
IS 9
BP 1248
EP 1252
DI 10.1136/bjo.2008.138800
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 340UA
UT WOS:000258669300020
PM 18617547
DA 2022-11-30
ER

PT J
AU Johnson, AP
   Woods-Fry, H
   Wittich-, W
AF Johnson, Aaron P.
   Woods-Fry, Heather
   Wittich, Walter
TI Effects of Magnification on Emotion Perception in Patients With
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE low vision; face perception; emotion perception; age-related macular
   degeneration; eye movements
ID FACE RECOGNITION; LOW-VISION; FACIAL EMOTION; VISUAL-ACUITY;
   INDIVIDUALS; ENHANCEMENT; MACULOPATHY; INFORMATION; SENSITIVITY;
   DISORDERS
AB PURPOSE. Individuals with low vision often experience difficulties in performing tasks of daily living, such as face perception. This leads them to having difficulties with social interactions, as they can no longer correctly perceive the emotion of others. The present study investigated the effects of magnification on face perception in participants with age-related macular degeneration (AMD), and their ability to detect and categorize emotions. It was hypothesized that patients with AMD would be less accurate in comparison to healthy controls, but that magnification would improve their performance to that of controls.
   METHODS. Faces containing happy, angry, or neutral emotion were both doubled (equivalent of arm's length distance) and decreased by half in size (equivalent of across the street). The ability to detect and to discriminate emotional content was compared between 20 AMD patients and 7 age-matched controls. Eye movements were recorded while conducting both tasks.
   RESULTS. Regardless of stimulus size, when compared to controls, we observed that individuals with AMD consistently performed with lower accuracy in both emotion detection and categorization tasks. Moreover, having images undergo a 2-fold increase in size did improve performance, but did not equate AMD participants' performance to that of the controls in either the emotion detection or categorization task. Eye movements in AMD participants were highly variable in position compared to controls.
   CONCLUSIONS. The data suggest that magnification alone does not appear to be the answer for improving emotion perception within individuals with low vision. Next steps should include an evaluation of the effects of viewing strategy.
C1 [Johnson, Aaron P.; Wittich, Walter] Concordia Univ, Dept Psychol, 7141 Sherbrooke West,PY-146, Montreal, PQ H4B 1R6, Canada.
   [Johnson, Aaron P.; Wittich, Walter] Ctr Ouest Ile de Montreal, CRIR Ctr Readaptat MAB Mackay CIUSSS, Montreal, PQ, Canada.
   [Woods-Fry, Heather; Wittich, Walter] Univ Ottawa, Dept Psychol, Ottawa, ON, Canada.
   [Wittich, Walter] Univ Montreal, Ecole Optometrie, Montreal, PQ, Canada.
   [Wittich, Walter] Monteregie Ctr, CRIR Inst Nazareth & Louis Braille CISSS, Longueuil, PQ, Canada.
C3 Concordia University - Canada; University of Ottawa; Universite de
   Montreal
RP Johnson, AP (通讯作者)，Concordia Univ, Dept Psychol, 7141 Sherbrooke West,PY-146, Montreal, PQ H4B 1R6, Canada.
EM aaron.johnson@concordia.ca
RI Wittich, Walter/AAH-2145-2020
OI Wittich, Walter/0000-0003-2184-6139; Johnson, Aaron/0000-0002-4428-7109
FU Centre de Recherche Interdisciplinaire en Readaptation de Montreal
   Metropolitaine; MAB-Mackay Foundation; FRQS Junior 1 career award
   [28881, 30620]
FX Supported by funds from the Centre de Recherche Interdisciplinaire en
   Readaptation de Montreal Metropolitaine, and the MAB-Mackay Foundation.
   WW is supported by an FRQS Junior 1 career award (28881 and 30620).
CR Al-Atabany WI, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-27
   Bach M, 1996, OPTOMETRY VISION SCI, V73, P49, DOI 10.1097/00006324-199601000-00008
   Barnes CS, 2011, OPTOMETRY VISION SCI, V88, P188, DOI 10.1097/OPX.0b013e318205a17c
   Binns AM, 2012, SURV OPHTHALMOL, V57, P34, DOI 10.1016/j.survophthal.2011.06.006
   Blais C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003022
   Boucart M, 2008, VISUAL NEUROSCI, V25, P603, DOI 10.1017/S0952523808080656
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890
   Costa AS, 2012, DEMENT GERIATR COGN, V33, P379, DOI 10.1159/000340006
   EBERT EM, 1986, ARCH OPHTHALMOL-CHIC, V104, P1009
   FIORENTINI A, 1983, PERCEPTION, V12, P195, DOI 10.1068/p120195
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gagne JP, 2010, PHON C HEAR CAR AD 2, P165
   Gold J, 1999, VISION RES, V39, P3537, DOI 10.1016/S0042-6989(99)00080-2
   Gold JM, 2012, PSYCHOL SCI, V23, P427, DOI 10.1177/0956797611427407
   Gosselin F, 2001, VISION RES, V41, P2261, DOI 10.1016/S0042-6989(01)00097-9
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Henderson JM, 2005, MEM COGNITION, V33, P98, DOI 10.3758/BF03195300
   Irons J, 2014, J VISION, V14, DOI 10.1167/14.2.12
   Johnson A, 2010, J VISION, V10, DOI 10.1167/10.12.18
   Levi DM, 2008, VISION RES, V48, P635, DOI 10.1016/j.visres.2007.12.009
   Martelli M, 2005, J VISION, V5, P58, DOI 10.1167/5.1.6
   McCulloch DL, 2011, OPHTHAL PHYSL OPT, V31, P240, DOI 10.1111/j.1475-1313.2011.00828.x
   Melmoth DR, 2000, INVEST OPHTH VIS SCI, V41, P2811
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Overbury O, 2011, INVEST OPHTH VIS SCI, V52, P8933, DOI 10.1167/iovs.11-8116
   PELI E, 1994, J OPT SOC AM A, V11, P1929, DOI 10.1364/JOSAA.11.001929
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Rubin GS, 2013, VISION RES, V90, P43, DOI 10.1016/j.visres.2013.02.015
   Schyns PG, 2002, PSYCHOL SCI, V13, P402, DOI 10.1111/1467-9280.00472
   Schyns PG, 1999, COGNITION, V69, P243, DOI 10.1016/S0010-0277(98)00069-9
   Seiple W, 2013, OPTOMETRY VISION SCI, V90, P45, DOI 10.1097/OPX.0b013e3182794775
   Sekuler AB, 2004, CURR BIOL, V14, P391, DOI 10.1016/j.cub.2004.02.028
   Smith ML, 2005, PSYCHOL SCI, V16, P184, DOI 10.1111/j.0956-7976.2005.00801.x
   Stewart S, 2012, CLIN GERONTOLOGIST, V35, P57, DOI 10.1080/07317115.2011.626515
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Wallis TSA, 2014, INVEST OPHTH VIS SCI, V55, P142, DOI 10.1167/iovs.13-12420
   Williams JR, 2008, B WORLD HEALTH ORGAN, V86, P650, DOI 10.2471/BLT.08.050955
   Wittich W, 2010, J VISUAL IMPAIR BLIN, V104, P360, DOI 10.1177/0145482X1010400606
NR 40
TC 9
Z9 9
U1 1
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2017
VL 58
IS 5
BP 2520
EP 2526
DI 10.1167/iovs.16-21349
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA EZ3DV
UT WOS:000404591500010
PM 28492869
OA gold
DA 2022-11-30
ER

PT J
AU Taniguchi, H
   Shiba, T
   Takahashi, M
   Kanai, H
   Hori, Y
   Shirai, K
   Maeno, T
AF Taniguchi, Hikari
   Shiba, Tomoaki
   Takahashi, Mao
   Kanai, Hidehito
   Hori, Yuichi
   Shirai, Kohji
   Maeno, Takatoshi
TI Cardio-Ankle Vascular Index Elevation in Patients with Exudative
   Age-Related Macular Degeneration
SO JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
LA English
DT Article
DE Age-related macular degeneration; Aging; Cardio-ankle vascular index;
   High-sensitivity C-reactive protein
ID C-REACTIVE PROTEIN; BLOOD-PRESSURE; RISK-FACTORS; CHOROIDAL
   NEOVASCULARIZATION; CARDIOVASCULAR-DISEASE; JAPANESE POPULATION;
   ARTERIAL STIFFNESS; MEDIA THICKNESS; MACULOPATHY; ASSOCIATION
AB Aim: To clarify whether the cardio-ankle vascular index (CAVI) independently contributes to the development of exudative age-related macular degeneration (AMD) compared with carotid arteriosclerosis parameters and other risk factors.
   Methods: Eighty-eight consecutive patients with exudative AMD were enrolled. A control group (40 age-matched men, 65 years of age or older) was also evaluated, and the parameters were compared between the two groups. A logistic regression analysis was used to determine independent factors for the diagnosis of AMD. In addition, simple linear and multiple regression analyses were used to determine the relationships between the CAVI and other parameters.
   Results: The carotid intima-media thickness and plaque scores in the AMD group did not differ significantly from those observed in the control group. The CAVI in the AMD group was significantly (p= 0.01) higher than that observed in the control group. A logistic regression analysis showed that the CAVI (odds ratio [OR], 1.91; 95% confidence interval [CI], 1.26-7.20; p= 0.007) and the use of lipid-lowering drugs (OR, 0.29; 95% CI, 0.10-0.86; p= 0.03) independently contributed to the diagnosis of AMD. Age, the high-sensitivity C-reactive protein level and the incidence of exudative AMD each independently contributed to the CAVI.
   Conclusions: The CAVI is more significantly associated with exudative AMD than carotid atherosclerosis parameters. The overall arterial stiffness is correlated with the pathogenesis of exudative AMD. The CAVI is a useful marker of exudative AMD in elderly patients with arteriosclerosis risk factors.
C1 [Taniguchi, Hikari; Shiba, Tomoaki; Kanai, Hidehito; Hori, Yuichi; Maeno, Takatoshi] Toho Univ, Sakura Med Ctr, Dept Ophthalmol, Sakura, Chiba 2858741, Japan.
   [Takahashi, Mao] Toho Univ, Sakura Med Ctr, Ctr Cardiovasc, Chiba 2748510, Japan.
   [Shirai, Kohji] Toho Univ, Sakura Med Ctr, Chiba 2748510, Japan.
C3 Toho University; Toho University; Toho University
RP Shiba, T (通讯作者)，Toho Univ, Sakura Med Ctr, Dept Ophthalmol, 564-1 Shimoshizu, Sakura, Chiba 2858741, Japan.
EM tomoaki-s@sakura.med.toho-u.ac.jp
CR Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   ASMAR R, 1995, HYPERTENSION, V26, P485, DOI 10.1161/01.HYP.26.3.485
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   HANDA N, 1990, STROKE, V21, P1567, DOI 10.1161/01.STR.21.11.1567
   Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2
   Higashiyama A, 2012, J ATHEROSCLER THROMB, V19, P1027, DOI 10.5551/jat.13599
   Hikichi T, 2001, AM J OPHTHALMOL, V132, P587, DOI 10.1016/S0002-9394(01)01139-4
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Lehmann ED, 1999, LANCET, V354, P528, DOI 10.1016/S0140-6736(99)00179-8
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nakamura K, 2008, CIRC J, V72, P598
   O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103
   Pinto E, 2007, POSTGRAD MED J, V83, P109, DOI 10.1136/pgmj.2006.048371
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Sato E, 2006, GRAEF ARCH CLIN EXP, V244, P963, DOI 10.1007/s00417-005-0201-6
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Shiba T, 2012, J ATHEROSCLER THROMB, V19, P999, DOI 10.5551/jat.13631
   Shirai K, 2006, J ATHEROSCLER THROMB, V13, P101, DOI 10.5551/jat.13.101
   Shirai K, 2011, J ATHEROSCLER THROMB, V18, P924
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Takiuchi S, 2004, J HUM HYPERTENS, V18, P17, DOI 10.1038/sj.jhh.1001628
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 36
TC 4
Z9 4
U1 0
U2 2
PU JAPAN ATHEROSCLEROSIS SOC
PI TOKYO
PA NICHINAI-KAIKAN B1, 3-28-8 HONGO BUNKYO-KU, TOKYO, 113-0033, JAPAN
SN 1340-3478
EI 1880-3873
J9 J ATHEROSCLER THROMB
JI J. Atheroscler. Thromb.
PY 2013
VL 20
IS 12
BP 903
EP 910
DI 10.5551/jat.18796
PG 8
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA AG5KS
UT WOS:000335458500006
PM 23903297
OA Bronze
DA 2022-11-30
ER

PT J
AU Cao, YQ
   Li, YL
   Gkerdi, A
   Reilly, J
   Tan, ZJ
   Shu, XH
AF Cao, Yanqun
   Li, Yuli
   Gkerdi, Antonia
   Reilly, James
   Tan, Zhoujin
   Shu, Xinhua
TI Association of Nutrients, Specific Dietary Patterns, and Probiotics with
   Age-related Macular Degeneration
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Retina; retinal pigment epithelium; dietary habits; nutrition; food
   intake; age-related macular degeneration
ID PIGMENT EPITHELIAL-CELLS; FATTY-ACID INTAKE; VITAMIN-D; EICOSAPENTAENOIC
   ACID; DOCOSAHEXAENOIC ACID; MEDITERRANEAN DIET; FISH CONSUMPTION; 5-YEAR
   INCIDENCE; RISK-FACTORS; BLUE-LIGHT
AB Age-related macular degeneration (AMD) is a complex disease that mainly affects people over 50 years of age. Even though management of the vascularisation associated with the "wet" form of AMD is effective using anti-VEGF drugs, there is currently no treatment for the "dry" form of AMD. Given this, it is imperative to develop methods for disease prevention and treatment. For this review, we searched scientific articles via PubMed and Google Scholar, and considered the impact of nutrients, specific dietary patterns, and probiotics on the incidence and progression of AMD. Many studies revealed that regular consumption of foods that contain omega-3 fatty acids is associated with a lower risk for late AMD. Particular dietary patterns, such as the Mediterranean diet that contains omega-3 FAs-rich foods (nuts, olive oil, and fish), seem to be protective against AMD progression compared to Western diets that are rich in fats and carbohydrates. Furthermore, randomized controlled trials that investigated the role of nutrient supplementation in AMD have shown that treatment with antioxidants, such as lutein/zeaxanthin, zinc, and carotenoids, may be effective against AMD progression. More recent studies have investigated the association of the antioxidant properties of gut bacteria, such as Bacteroides and Eysipelotrichi, with lower AMD risk in individuals whose microbiota is enriched with them. These are promising fields of research that may yield the capacity to improve the quality of life for millions of people, allowing them to live with a clear vision for longer and avoiding the high cost of vision-saving surgery.
C1 [Cao, Yanqun; Shu, Xinhua] Shaoyang Univ, Sch Basic Med Sci, Shaoyang 422000, Hunan, Peoples R China.
   [Li, Yuli; Tan, Zhoujin] Hunan Univ Chinese Med, Coll Chinese Med, Changsha 410208, Hunan, Peoples R China.
   [Gkerdi, Antonia; Reilly, James; Shu, Xinhua] Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Shu, Xinhua] Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
C3 Shaoyang University; Hunan University of Chinese Medicine; Glasgow
   Caledonian University; Glasgow Caledonian University
RP Shu, XH (通讯作者)，Shaoyang Univ, Sch Basic Med Sci, Shaoyang 422000, Hunan, Peoples R China.
EM Xinhua.Shu@gcu.ac.uk
RI Tan, Zhoujin/V-9258-2019
OI Tan, Zhoujin/0000-0003-3193-073X
FU Rosetrees Trust [M160-F2]; Sight Research UK [SAC037]; Tenovus Scotland
   [S20-02]; Lotus Scholarship Program of Hunan Province, China [2019-23]
FX This work was partially supported by the Rosetrees Trust (M160-F2),
   Sight Research UK (SAC037), the Tenovus Scotland (S20-02), and the Lotus
   Scholarship Program of Hunan Province, China (2019-23).
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Akimbekov NS, 2020, ACTA HISTOCHEM CYTOC, V53, P33, DOI 10.1267/ahc.20011
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Assa A, 2015, INFLAMM BOWEL DIS, V21, P297, DOI 10.1097/MIB.0000000000000282
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Braakhuis Andrea, 2017, Diseases, V5, DOI 10.3390/diseases5010003
   Cammalleri M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101079
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   Chang CH, 2017, PHARM BIOL, V55, P571, DOI 10.1080/13880209.2016.1263344
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cougnard-Gregoire A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160240
   Courtaut F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126590
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Gong Y, 2017, AM J CLIN NUTR, V106, P16, DOI 10.3945/ajcn.117.153825
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Jacobs L., 2017, J PEDIAT SURG NURS, V6, P53, DOI [10.1097/JPS.0000000000000140, DOI 10.1097/JPS.0000000000000140]
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   JOHNSON JA, 1995, CURR EYE RES, V14, P101, DOI 10.3109/02713689508999921
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kamen DL, 2010, J MOL MED, V88, P441, DOI 10.1007/s00109-010-0590-9
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Lee BL, 2016, NUTR RES, V36, P1402, DOI 10.1016/j.nutres.2016.11.008
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Li Z., 2019, XIANDAI SHIPIN KEJI, V35, P322
   Liu SW, 2021, J FOOD BIOCHEM, V45, DOI 10.1111/jfbc.13623
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Neuringer M., 2010, INVEST OPHTH VIS SCI, V51, P2786
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Perdices L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080718
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Querques G, 2009, EUR J OPHTHALMOL, V19, P100, DOI 10.1177/112067210901900115
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Rowan S, 2018, GUT MICROBES, V9, P452, DOI 10.1080/19490976.2018.1435247
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Schleicher M, 2013, NUTRIENTS, V5, P2405, DOI 10.3390/nu5072405
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Scripsema NK, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/865179
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tsao R, 2010, NUTRIENTS, V2, P1231, DOI 10.3390/nu2121231
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuzcu M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0524-1
   Uwitonze AM, 2018, J AM OSTEOPATH ASSOC, V118, P181, DOI 10.7556/jaoa.2018.037
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wang HB, 2016, MOL VIS, V22, P189
   Wang TT, 2010, J BIOL CHEM, V285, P2237, DOI 10.1074/jbc.C109.071225
   Wang TG, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5644
   Winkler BS, 1999, MOL VIS, V5
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Yanai R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196037
   Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhang YG, 2019, INFLAMM BOWEL DIS, V25, P97, DOI 10.1093/ibd/izy292
   Zhao Z., 2014, J SHANGHAI JIAOTONG
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zysset-Burri DC, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-020-00141-0
NR 89
TC 2
Z9 2
U1 2
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2022
VL 29
IS 40
BP 6141
EP 6158
DI 10.2174/0929867329666220511142817
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 5L1PP
UT WOS:000870188400004
PM 35546762
DA 2022-11-30
ER

PT J
AU Voelker, M
   Gelisken, F
   Ziemssen, F
   Wachtlin, J
   Grisanti, S
AF Voelker, M
   Gelisken, F
   Ziemssen, F
   Wachtlin, J
   Grisanti, S
TI Verteporfin photodynamic therapy for extrafoveal choroidal
   neovascularisation secondary to age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularisation;
   extrafoveal; treatment; photodynamic therapy
AB Purpose: To report the results of verteporfin photodynamic therapy (PDT) of extrafoveal predominantly classic choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD). Methods: In this retrospective study 20 consecutive patients (20 eyes) undergoing verteporfin PDT for extrafoveal predominantly classic CNV in AMD were examined. Colour photography of the fundus, fluorescein angiography and complete ophthalmic examination, including visual acuity assessment with ETDRS charts, were performed before treatment and at 3-month intervals thereafter. The primary outcome criterion was the change in visual acuity. The secondary outcome criterion was the extension of the CNV beneath the centre of the fovea during the follow-up period. Results: Mean follow-up time of the patients was 24.2 months (range 12 to 58 months). Visual acuity at baseline varied from 20/200 to 20/20 (mean 20/50 +/- 2.3 lines). Final visual acuity ranged from 20/1000 to 20/20 (mean 20/200 +/- 5.1 lines) (P < 0.001). In 85% (17/20) of the eyes visual acuity worsened. Visual acuity improved in 15% (3/20) of the eyes. During the course of the follow-up period, subfoveal extension of the CNV was detected in 80% (16/20) of the eyes. Conclusion: In 85% of the eyes with extrafoveal predominantly classic CNV secondary to AMD, visual acuity worsened after verteporfin PDT in an average follow-up time of 24 months. Subfoveal CNV was found in 80% of the eyes during follow-up. Even though verteporfin PDT can preserve visual acuity in selected cases, deterioration was seen in the majority of the patients.
C1 Univ Tubingen, Dept Ophthalmol 1, D-72076 Tubingen, Germany.
   Univ Med Berlin, Augenklin Charite, Berlin, Germany.
C3 Eberhard Karls University of Tubingen; Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin
RP Gelisken, F (通讯作者)，Univ Tubingen, Dept Ophthalmol 1, Schleichstr 12, D-72076 Tubingen, Germany.
EM Faik.Gelisken@med.unituebingen.de
RI , Ziemssen/B-9564-2009; Ziemssen, Focke/AAY-1686-2021
OI , Ziemssen/0000-0002-3873-0581; 
CR Anand R, 2003, ARCH OPHTHALMOL-CHIC, V121, P415
   [Anonymous], 1982, Br J Ophthalmol, V66, P745
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Blair MP, 2004, RETINA-J RET VIT DIS, V24, P501, DOI 10.1097/00006982-200408000-00001
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Coscas G, 1982, Bull Mem Soc Fr Ophtalmol, V94, P149
   Muller-Velten R, 2003, OPHTHALMOLOGE, V100, P384, DOI 10.1007/s00347-002-0723-9
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Wachtlin J, 2005, GRAEF ARCH CLIN EXP, V243, P438, DOI 10.1007/s00417-004-1071-z
NR 12
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2005
VL 243
IS 12
BP 1241
EP 1246
DI 10.1007/s00417-005-0021-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 988WS
UT WOS:000233632800009
PM 16010552
DA 2022-11-30
ER

PT J
AU Wang, K
   Zheng, M
   Lester, KL
   Han, ZC
AF Wang, Kai
   Zheng, Min
   Lester, Kaitlyn Lee
   Han, Zongchao
TI Light-induced Nrf2(-/-) mice as atrophic age-related macular
   degeneration model and treatment with nanoceria laden injectable
   hydrogel
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OXIDATIVE STRESS; VISUAL IMPAIRMENT; ANTIOXIDANT; PROGRESSION; CELLS;
   NEOVASCULARIZATION; ACTIVATION; ALGINATE
AB Elevated oxidative stress and associated reactive oxygen species (ROS) accumulation are hallmarks in the induction and progression of age-related macular degeneration (AMD). By exposing nuclear factor erythroid 2-related factor (Nrf2) knockout (Nrf2(-/-)) mice to mild white light, we were able to generate a new dry-AMD like murine model to the study. This animal model developed phenotypes of photoreceptor degeneration, retinal function impairment, ROS accumulation, and inflammation reaction in a relatively shorter time. In the treatment of this animal model we utilized an antioxidative and water soluble nanoparticle known as glycol chitosan coated cerium oxide nanoparticles (GCCNP). The delivery of GCCNP protected retina against progressive retinal oxidative damage. Further combination of GCCNP with alginate-gelatin based injectable hydrogel provided synergistic antioxidant effects and achieved a more rapid recovery of the retinal pigment epithelium and photoreceptor cells. This combined treatment technique has the potential to translate into a clinical intervention for the treatment of AMD.
C1 [Wang, Kai; Zheng, Min; Lester, Kaitlyn Lee; Han, Zongchao] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA.
   [Han, Zongchao] Univ N Carolina, Carolina Inst Nano Med, Chapel Hill, NC 27599 USA.
   [Han, Zongchao] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacoengn & Mol Pharmaceut, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill
RP Han, ZC (通讯作者)，Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA.; Han, ZC (通讯作者)，Univ N Carolina, Carolina Inst Nano Med, Chapel Hill, NC 27599 USA.; Han, ZC (通讯作者)，Univ N Carolina, Eshelman Sch Pharm, Div Pharmacoengn & Mol Pharmaceut, Chapel Hill, NC 27599 USA.
EM zongchao@med.unc.edu
RI Wang, Kai/GQI-1260-2022; Wang, Kai/AAE-4566-2021; Ariel,
   Pablo/AGJ-4118-2022
OI Wang, Kai/0000-0002-4419-9598; Wang, Kai/0000-0002-4419-9598; 
FU Edward N. & Della L. Thome Memorial Foundation; BrightFocus Foundation
   [M2019063]; Carolina Center of Cancer Nanotechnology Excellence; U.S.
   National Eye Institute [R01EY026564]; NATIONAL EYE INSTITUTE
   [R01EY026564] Funding Source: NIH RePORTER
FX The authors thank Ellen R. Weiss for allowing generous access to her ERG
   instrumentation and Microscopy Services Laboratory at UNC Chapel Hill
   for TEM samples processing. This work was supported by the Edward N. &
   Della L. Thome Memorial Foundation (Z.H.), the BrightFocus Foundation
   (M2019063, Z.H.), the Carolina Center of Cancer Nanotechnology
   Excellence (Z.H.), and the U.S. National Eye Institute (R01EY026564,
   Z.H.).
CR Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Cai X, 2016, ADV EXP MED BIOL, V854, P111, DOI 10.1007/978-3-319-17121-0_16
   Cai X, 2014, BIOMATERIALS, V35, P249, DOI 10.1016/j.biomaterials.2013.10.022
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Fang IM, 2013, EXP EYE RES, V113, P49, DOI 10.1016/j.exer.2013.05.007
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Grulke E, 2014, ENVIRON SCI-NANO, V1, P429, DOI 10.1039/c4en00105b
   Hirst SM, 2009, SMALL, V5, P2848, DOI 10.1002/smll.200901048
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kasdorf BT, 2015, BIOPHYS J, V109, P2171, DOI 10.1016/j.bpj.2015.10.002
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Karakoti AS, 2008, JOM-US, V60, P33, DOI 10.1007/s11837-008-0029-8
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Liang KJ, 2017, MOL THER, V25, P765, DOI 10.1016/j.ymthe.2016.12.016
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   Nagar S, 2017, P NATL ACAD SCI USA, V114, pE4048, DOI 10.1073/pnas.1613067114
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pujol-Lereis LM, 2016, ADV EXP MED BIOL, V854, P87, DOI 10.1007/978-3-319-17121-0_13
   Reme, 2012, METHOD MOL BIOL, V935, P87
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rozanowska MB, 2012, PHOTOCHEM PHOTOBIOL, V88, P1303, DOI 10.1111/j.1751-1097.2012.01240.x
   Saether HV, 2008, CARBOHYD POLYM, V74, P813, DOI 10.1016/j.carbpol.2008.04.048
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   Tomida H, 2010, CARBOHYD RES, V345, P82, DOI 10.1016/j.carres.2009.10.015
   Wang K, 2016, ACTA BIOMATER, V36, P143, DOI 10.1016/j.actbio.2016.03.016
   Wang K, 2018, J BIOMED MATER RES A, V106, P2795, DOI 10.1002/jbm.a.36450
   Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 40
TC 19
Z9 20
U1 2
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 10
PY 2019
VL 9
AR 14573
DI 10.1038/s41598-019-51151-7
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JC8VW
UT WOS:000489555200085
PM 31601909
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Oliver, VF
   Franchina, M
   Jaffe, AE
   Branham, KE
   Othman, M
   Heckenlively, JR
   Swaroop, A
   Campochiaro, B
   Vote, BJ
   Craig, JE
   Saffery, R
   Mackey, DA
   Qian, J
   Zack, DJ
   Hewitt, AW
   Merbs, SL
AF Oliver, Verity F.
   Franchina, Maria
   Jaffe, Andrew E.
   Branham, Kari E.
   Othman, Mohammad
   Heckenlively, John R.
   Swaroop, Anand
   Campochiaro, Betsy
   Vote, Brendan J.
   Craig, Jamie E.
   Saffery, Richard
   Mackey, David A.
   Qian, Jiang
   Zack, Donald J.
   Hewitt, Alex W.
   Merbs, Shannath L.
TI Hypomethylation of the IL17RC Promoter in Peripheral Blood Leukocytes Is
   Not A Hallmark of Age-Related Macular Degeneration
SO CELL REPORTS
LA English
DT Article
ID DNA METHYLATION; EXPRESSION; SMOKING; METHYLTRANSFERASE;
   HYPERMETHYLATION; REVEALS; ISLANDS; PROTEIN; RISK
AB Age-related macular degeneration (AMD) is a leading cause of visual impairment worldwide. Aberrant DNA methylation within the promoter of IL17RC in peripheral blood mononuclear cells has recently been reported in AMD. To validate this association, we examined DNA methylation of the IL17RC promoter in peripheral blood. First, we used Illumina Human Methylation450 Bead Arrays, a widely accepted platform for measuring global DNA methylation. Second, methylation status at multiple sites within the IL17RC promoter was determined by bisulfite pyrosequencing in two cohorts. Third, a methylation-sensitive quantitative PCR-based assay was performed on a subset of samples. In contrast to previous findings, we did not find evidence of differential methylation between AMD cases and age-matched controls. We conclude that hypomethylation within the IL17RC gene promoter in peripheral blood is not suitable for use as a clinical biomarker of AMD. This study highlights the need for considerable replication of epigenetic association studies prior to clinical application.
C1 [Oliver, Verity F.; Campochiaro, Betsy; Qian, Jiang; Zack, Donald J.; Merbs, Shannath L.] Johns Hopkins Univ, Sch Med, Wilmer Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Franchina, Maria; Mackey, David A.; Hewitt, Alex W.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
   [Jaffe, Andrew E.] Lieber Inst Brain Dev, Baltimore, MD 21287 USA.
   [Branham, Kari E.; Othman, Mohammad; Heckenlively, John R.] Univ Michigan, Dept Ophthalmol & Visual Sci, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
   [Swaroop, Anand] NEI, NIH, Bethesda, MD 20892 USA.
   [Vote, Brendan J.] Univ Tasmania, Launceston Eye Inst, Launceston, Tas 7249, Australia.
   [Craig, Jamie E.] Flinders Univ S Australia, Flinders Med Ctr, Dept Ophthalmol, Adelaide, SA 5042, Australia.
   [Saffery, Richard] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Canc & Dis Epigenet, Melbourne, Vic 3052, Australia.
   [Zack, Donald J.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Dept Mol Biol & Genet, Baltimore, MD 21287 USA.
   [Zack, Donald J.] Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21287 USA.
   [Zack, Donald J.] Univ Paris 06, Inst Vis, F-75012 Paris, France.
   [Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
C3 Johns Hopkins University; Lions Eye Institute; University of Western
   Australia; University of Michigan System; University of Michigan;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Tasmania; Flinders Medical Centre; Flinders
   University South Australia; Murdoch Children's Research Institute; Royal
   Children's Hospital Melbourne; University of Melbourne; Johns Hopkins
   University; Johns Hopkins University; UDICE-French Research
   Universities; Sorbonne Universite; Centre for Eye Research Australia;
   Royal Victorian Eye & Ear Hospital; University of Melbourne
RP Hewitt, AW (通讯作者)，Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
EM hewitt.alex@gmail.com; smerbs@jhmi.edu
RI Mackey, David A/H-5340-2014; Todd, Verity/K-7336-2012; Jaffe,
   Andrew/GPF-5693-2022; Hewitt, Alex W/D-1936-2013; Branham,
   Kari/AAA-8336-2022; Jaffe, Andrew/L-3089-2016
OI Mackey, David A/0000-0001-7914-4709; Todd, Verity/0000-0003-4786-8272;
   Jaffe, Andrew/0000-0001-6886-1454; Hewitt, Alex W/0000-0002-5123-5999;
   Jaffe, Andrew/0000-0001-6886-1454; Craig, Jamie/0000-0001-9955-9696;
   Zack, Don/0000-0002-7966-1973; Saffery, Richard/0000-0002-9510-4181;
   Swaroop, Anand/0000-0002-1975-1141; Branham, Kari/0000-0002-2492-254X
FU Western Australian DNA Bank; Center for Inherited Disease Research
   (Johns Hopkins University); Ophthalmic Research Institute of Australia;
   American Health Assistance Foundation; Australian National Health;
   Medical Research Council Centres of Research Excellence grant [1023911];
   National Eye Institute (NEI) [EY016862, X01HG006605, R01EY020406];
   generosity of Agnes Nixon; NEI core grant [P30EY001765]; NATIONAL EYE
   INSTITUTE [R01EY016862, P30EY001765, ZIAEY000475, R01EY020406] Funding
   Source: NIH RePORTER
FX The authors gratefully acknowledge the technical advice provided by Dr.
   David Chandler and the assistance of the Western Australian DNA Bank and
   the Center for Inherited Disease Research (Johns Hopkins University).
   This work was supported by funding from the Ophthalmic Research
   Institute of Australia and the American Health Assistance Foundation to
   A. W. H. as well as from an Australian National Health and Medical
   Research Council Centres of Research Excellence grant 1023911
   (2012-2016) to J. E. C., D. A. M., and A. W. H. CERA receives
   operational infrastructure support from the Victorian government.
   Collection of the Michigan AMD-MMAP cohort was enabled by funding from
   the National Eye Institute (NEI; grant EY016862) to A. S. and J. R. H.
   Funding from the NEI (grant X01HG006605) to S. L. M. was used for the
   analysis of samples on the Illumina Human Methylation 450K platform at
   CIDR. Pyrosequencing validation was funded by NEI grant R01EY020406 (to
   S. L. M.) and the generosity of Agnes Nixon (to S. L. M.) and aided by
   NEI core grant P30EY001765.
CR Adwan L, 2013, PHARMACOL THERAPEUT, V139, P41, DOI 10.1016/j.pharmthera.2013.03.010
   Almen MS, 2012, GENOMICS, V99, P132, DOI 10.1016/j.ygeno.2011.12.007
   Baird PN, 2013, EPIGENOMICS-UK, V5, P239, DOI [10.2217/EPI.13.19, 10.2217/epi.13.19]
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Choy KW, 2002, INVEST OPHTH VIS SCI, V43, P1344
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hackler Laszlo Jr, 2012, Methods Mol Biol, V884, P289, DOI 10.1007/978-1-61779-848-1_21
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Haudenschild D, 2002, J BIOL CHEM, V277, P4309, DOI 10.1074/jbc.M109372200
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jiang YQ, 2013, BBA-REV CANCER, V1835, P155, DOI 10.1016/j.bbcan.2012.12.003
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Ladd-Acosta C., 2013, MOL PSYCHIAT
   Lee Ken W. K., 2013, Frontiers in Genetics, V4, P132, DOI 10.3389/fgene.2013.00132
   Maat W, 2007, INVEST OPHTH VIS SCI, V48, P486, DOI 10.1167/iovs.06-0781
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Merbs SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032602
   Miao CG, 2013, CELL SIGNAL, V25, P875, DOI 10.1016/j.cellsig.2012.12.017
   Nasonkin IO, 2013, DEVELOPMENT, V140, P1330, DOI 10.1242/dev.086603
   Oliver VF, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-17
   Roessler Jessica, 2012, BMC Res Notes, V5, P210, DOI 10.1186/1756-0500-5-210
   Rung L, 2013, CLIN OPHTHALMOL, V7, P395, DOI 10.2147/OPTH.S41585
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tost J, 2006, BIOTECHNIQUES, V40, P721, DOI 10.2144/000112190
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wan J, 2013, NUCLEIC ACIDS RES, V41, P8503, DOI 10.1093/nar/gkt652
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
NR 36
TC 38
Z9 41
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD DEC
PY 2013
VL 5
IS 6
BP 1527
EP 1535
DI 10.1016/j.celrep.2013.11.042
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AA5PW
UT WOS:000331153100006
PM 24373284
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Arakawa, S
   Takahashi, A
   Ashikawa, K
   Hosono, N
   Aoi, T
   Yasuda, M
   Oshima, Y
   Yoshida, S
   Enaida, H
   Tsuchihashi, T
   Mori, K
   Honda, S
   Negi, A
   Arakawa, A
   Kadonosono, K
   Kiyohara, Y
   Kamatani, N
   Nakamura, Y
   Ishibashi, T
   Kubo, M
AF Arakawa, Satoshi
   Takahashi, Atsushi
   Ashikawa, Kyota
   Hosono, Naoya
   Aoi, Tomomi
   Yasuda, Miho
   Oshima, Yuji
   Yoshida, Shigeo
   Enaida, Hiroshi
   Tsuchihashi, Takashi
   Mori, Keisuke
   Honda, Shigeru
   Negi, Akira
   Arakawa, Akira
   Kadonosono, Kazuaki
   Kiyohara, Yutaka
   Kamatani, Naoyuki
   Nakamura, Yusuke
   Ishibashi, Tatsuro
   Kubo, Michiaki
TI Genome-wide association study identifies two susceptibility loci for
   exudative age-related macular degeneration in the Japanese population
SO NATURE GENETICS
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   TOMOGRAPHIC FEATURES; GENETIC-VARIANTS; FACTOR-B; POLYMORPHISM;
   APOPTOSIS; RISK; PATHWAY; LINKAGE
AB Age-related macular degeneration (AMD), the leading cause of irreversible blindness in the world, is a complex disease caused by multiple environmental and genetic risk factors. To identify genetic factors that modify the risk of exudative AMD in the Japanese population, we conducted a genome-wide association study and a replication study using a total of 1,536 individuals with exudative AMD and 18,894 controls. In addition to CFH (rs800292, P = 4.23 x 10(-15)) and ARMS2 (rs3750847, P = 8.67 x 10(-29)) loci, we identified two new susceptibility loci for exudative AMD: TNFRSF10A-LOC389641 on chromosome 8p21 (rs13278062, combined P = 1.03 x 10(-12), odds ratio = 0.73) and REST-C4orf14-POLR2B-IGFBP7 on chromosome 4q12 (rs1713985, combined P = 2.34 x 10(-8), odds ratio = 1.30). Fine mapping revealed that rs13278062, which is known to alter TNFRSF10A transcriptional activity, had the most significant association in 8p21 region. Our results provide new insights into the pathophysiology of exudative AMD.
C1 [Arakawa, Satoshi; Ashikawa, Kyota; Hosono, Naoya; Aoi, Tomomi; Kubo, Michiaki] RIKEN Yokohama Inst, Ctr Genom Med, Lab Genotyping Dev, Yokohama, Kanagawa, Japan.
   [Arakawa, Satoshi; Yasuda, Miho; Oshima, Yuji; Yoshida, Shigeo; Enaida, Hiroshi; Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 812, Japan.
   [Takahashi, Atsushi; Kamatani, Naoyuki] RIKEN Yokohama Inst, Ctr Genom Med, Lab Stat Anal, Yokohama, Kanagawa, Japan.
   [Tsuchihashi, Takashi; Mori, Keisuke] Saitama Med Univ, Dept Ophthalmol, Saitama, Japan.
   [Honda, Shigeru; Negi, Akira] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 657, Japan.
   [Arakawa, Akira; Kadonosono, Kazuaki] Yokohama City Univ, Dept Ophthalmol, Med Ctr, Yokohama, Kanagawa 232, Japan.
   [Kiyohara, Yutaka] Kyushu Univ, Dept Environm Med, Grad Sch Med Sci, Fukuoka 812, Japan.
   [Nakamura, Yusuke] Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome, Tokyo, Japan.
C3 RIKEN; Kyushu University; RIKEN; Saitama Medical University; Kobe
   University; Yokohama City University; Kyushu University; University of
   Tokyo
RP Kubo, M (通讯作者)，RIKEN Yokohama Inst, Ctr Genom Med, Lab Genotyping Dev, Yokohama, Kanagawa, Japan.
EM mkubo@src.riken.jp
RI Kubo, Michiaki/N-7947-2015; Honda, Shigeru/W-4761-2019
OI Yoshida, Shigeo/0000-0003-1049-8909
FU Ministry of Education, Culture, Sports, Sciences and Technology of the
   Japanese government
FX We thank all of the subjects who participated in this study. We are
   grateful to A. Yoshida, K. Kano, S. Kawahara, R. Arita, K. Ishikawa, E.
   Hasegawa, R. Asato, S. Notomi, T. Asakuma and A. Kuni of the Kyushu
   University, K. Horie-Inoue, S. Inoue and T. Awata of the Saitama Medical
   University, H. Bessho, N. Kondo and W. Matsumiya of the Kobe university
   and M. Inoue of the Yokohama City University Medical Center for
   collecting samples. We thank the staff of the Laboratory for Genotyping
   Development, Center for Genomic Medicine, RIKEN, the staffs of the
   BioBank Japan project and the members of the Rotary Club of
   Osaka-Midosuji District 2660 Rotary International in Japan. We want to
   express special thanks to F. Miya for the support of gene expression
   data. This work was conducted as a part of the BioBank Japan Project and
   supported by the Ministry of Education, Culture, Sports, Sciences and
   Technology of the Japanese government.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Guan BX, 2002, ONCOGENE, V21, P3121, DOI 10.1038/sj.onc.1205430
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Li JH, 2003, J IMMUNOL, V171, P1526, DOI 10.4049/jimmunol.171.3.1526
   Matsumoto H, 2010, RETINA-J RET VIT DIS, V30, P425, DOI 10.1097/IAE.0b013e3181bd2d95
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Nakamura Yusuke, 2007, Clin Adv Hematol Oncol, V5, P696
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ohnishi Y, 2001, J HUM GENET, V46, P471, DOI 10.1007/s100380170047
   Parapuram SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013885
   Parihar A, 2008, LIFE SCI, V82, P1077, DOI 10.1016/j.lfs.2008.03.019
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Wang ML, 2009, MUTAT RES-FUND MOL M, V661, P85, DOI 10.1016/j.mrfmmm.2008.11.009
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 35
TC 106
Z9 111
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD OCT
PY 2011
VL 43
IS 10
BP 1001
EP U114
DI 10.1038/ng.938
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 825XT
UT WOS:000295316200016
PM 21909106
OA Green Published
DA 2022-11-30
ER

PT J
AU Kim, YJ
   Kim, KG
AF Kim, Young Jae
   Kim, Kwang Gi
TI Automated Segmentation Methods of Drusen to Diagnose Age-Related Macular
   Degeneration Screening in Retinal Images
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article
ID RENYIS ENTROPY; RISK
AB Existing drusen measurement is difficult to use in clinic because it requires a lot of time and effort for visual inspection. In order to resolve this problem, we propose an automatic drusen detection method to help clinical diagnosis of age-related macular degeneration. First, we changed the fundus image to a green channel and extracted the ROI of the macular area based on the optic disk. Next, we detected the candidate group using the difference image of the median filter within the ROI. We also segmented vessels and removed them from the image. Finally, we detected the drusen through Renyi's entropy threshold algorithm. We performed comparisons and statistical analysis between the manual detection results and automatic detection results for 30 cases in order to verify validity. As a result, the average sensitivity was 93.37% (80.95%similar to 100%) and the average DSC was 0.73 (0.3 similar to 0.98). In addition, the value of the ICC was 0.984 (CI: 0.967 similar to 0.993, p < 0.01), showing the high reliability of the proposed automatic method. We expect that the automatic drusen detection helps clinicians to improve the diagnostic performance in the detection of drusen on fundus image.
C1 [Kim, Young Jae; Kim, Kwang Gi] Gachon Univ, Coll Med, Dept Biomed Engn, Incheon, South Korea.
C3 Gachon University
RP Kim, KG (通讯作者)，Gachon Univ, Coll Med, Dept Biomed Engn, Incheon, South Korea.
EM kimkg@gachon.ac.kr
RI Khalid, Samina/AAV-3527-2021
OI Khalid, Samina/0000-0003-4771-6842; Kim, Young Jae/0000-0003-0443-0051;
   Kim, Kwang Gi/0000-0001-9714-6038
FU Gachon University, Republic of Korea [GCU 2017-0211, GCU 2017-5274]
FX This work was supported by a grant of the Gachon University, Republic of
   Korea (GCU 2017-0211, GCU 2017-5274).
CR Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Alhamami MA, 2017, OPTOMETRY VISION SCI, V94, P137, DOI 10.1097/OPX.0000000000001010
   Brandon L., 2003, LECT NOTES COMPUTER, V2878
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Das S, 2014, INT J ELECT COMMUN C, V5, P347
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Hadi G. M., 2016, ZANCO J PURE APPL SC, V28, P120
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Lin D, 2016, NEUROCOMPUTING, V216, P700, DOI 10.1016/j.neucom.2016.08.039
   Ng HF, 2006, PATTERN RECOGN LETT, V27, P1644, DOI 10.1016/j.patrec.2006.03.009
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Sahoo P, 1997, PATTERN RECOGN, V30, P71, DOI 10.1016/S0031-3203(96)00065-9
   Sahoo PK, 2004, PATTERN RECOGN, V37, P1149, DOI 10.1016/j.patcog.2003.10.008
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Tseng VL, 2012, JAMA-J AM MED ASSOC, V308, P493, DOI 10.1001/jama.2012.9014
   van Ginneken B, 2011, RADIOLOGY, V261, P719, DOI 10.1148/radiol.11091710
NR 16
TC 9
Z9 9
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748-670X
EI 1748-6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PY 2018
VL 2018
AR 6084798
DI 10.1155/2018/6084798
PG 8
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA GA6EW
UT WOS:000428426800001
PM 29721037
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Shuler, RK
   Schmidt, S
   Gallins, P
   Hauser, MA
   Scott, WK
   Caldwell, J
   Agarwal, A
   Haines, JL
   Pericak-Vance, MA
   Postel, EA
AF Shuler, R. Keith, Jr.
   Schmidt, Silke
   Gallins, Paul
   Hauser, Michael A.
   Scott, William K.
   Caldwell, Jennifer
   Agarwal, Anita
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
   Postel, Eric A.
TI Phenotype analysis of patients with the risk variant LOC387715 (A69S) in
   age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; GEOGRAPHIC ATROPHY; SUSCEPTIBILITY; GENE;
   ASSOCIATION; POLYMORPHISM; MACULOPATHY; SMOKING; Y402H; CFH
AB PURPOSE: To examine phenotypes of age-related macular degeneration (AMD) patients with the LOC387715 variant (T allele at rs10490924, A69S).
   DESIGN: Retrospective, observational. case series.
   METHODS: This clinic,based case series data set contained 775 unrelated cases of AMD. AMD phenotypes of three groups, determined by the number of LOC387715 risk alleles, were compared regarding the presence or absence of 16 phenotypic features.
   RESULTS: The number of AMD cases in each group was 164 cases (two risk alleles), 330 cases (one risk allele), and 281 cases (zero risk allele). The mean age at examination for homozygous carriers of the LOC387715 risk allele was significantly lower (73.9 years) than the age for carriers of one (76.4 years) or no (77.1 years) risk allele (P = .0003). Of the 16 features analyzed, only AMD grade (P = .00002) was significantly associated with the LOC387715 variant. As the number of LOC387715 risk alleles increased, the proportion of grade 5 AMD cases increased in a dose-response fashion.
   CONCLUSIONS: The LOC387715 variant appears to be an independent risk factor for grade 5 (neovascular) AMD. This variant may also be associated with an earlier onset of AMD. Phenotypes that suggest a high-risk genotype may prove valuable for diagnostic, therapeutic, and research purposes.
C1 [Shuler, R. Keith, Jr.; Caldwell, Jennifer; Postel, Eric A.] Duke Univ, Ctr Eye, Durham, NC 27710 USA.
   [Schmidt, Silke; Gallins, Paul; Hauser, Michael A.; Scott, William K.; Pericak-Vance, Margaret A.] Duke Univ, Ctr Human Genet, Durham, NC USA.
   [Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
C3 Duke University; Duke University; Vanderbilt University
RP Postel, EA (通讯作者)，Duke Univ, Ctr Eye, Box 3802, Durham, NC 27710 USA.
EM poste002@mc.duke.edu
RI Haines, Jonathan/C-3374-2012; Scott, William/A-7593-2009
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NATIONAL EYE INSTITUTE [U10EY012118] Funding Source: NIH RePORTER; NEI
   NIH HHS [U10 EY 12118-05] Funding Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shastry BS, 2006, OPHTHALMOLOGICA, V220, P291, DOI 10.1159/000094617
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   SHULER RK, 2007, IN PRESS OPHTHALMOLO
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 28
TC 31
Z9 32
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2008
VL 145
IS 2
BP 303
EP 307
DI 10.1016/j.ajo.2007.09.027
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 263GG
UT WOS:000253205000019
PM 18061132
DA 2022-11-30
ER

PT J
AU Metrangolo, C
   Donati, S
   Mazzola, M
   Fontanel, L
   Messina, W
   D'alterio, G
   Rubino, M
   Radice, P
   Premi, E
   Azzolini, C
AF Metrangolo, Cristian
   Donati, Simone
   Mazzola, Marco
   Fontanel, Liviana
   Messina, Walter
   D'alterio, Giulia
   Rubino, Marisa
   Radice, Paolo
   Premi, Elias
   Azzolini, Claudio
TI OCT Biomarkers in Neovascular Age-Related Macular Degeneration: A
   Narrative Review
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID OPTICAL-COHERENCE-TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; GROWTH-FACTOR
   THERAPY; SUBRETINAL HYPERREFLECTIVE MATERIAL; POSTERIOR VITREOMACULAR
   ADHESION; VISUAL-ACUITY; INTRAVITREAL BEVACIZUMAB; PHOTORECEPTOR
   INTEGRITY; RANIBIZUMAB TREATMENT; AFLIBERCEPT TREATMENT
AB Age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly people. Neovascular AMD (nAMD) is responsible for the majority of cases of severe visual loss in eyes with AMD. Optical coherence tomography (OCT) is the most widely used technology for the diagnosis and follow-up of nAMD patients, which is widely used to study and guide the clinical approach, as well as to predict and evaluate treatment response. The aim of this review is to describe and analyze various structural OCT-based biomarkers, which have practical value during both initial assessment and treatment follow-up of nAMD patients. While central retinal thickness has been the most common and one of the first OCT identified biomarkers, today, other qualitative and quantitative biomarkers provide novel insight into disease activity and offer superior prognostic value and better guidance for tailored therapeutic management. The key importance of retinal fluid compartmentalization (intraretinal fluid, subretinal fluid, and subretinal pigment epithelium (RPE) fluid) will be discussed firstly. In the second part, the structural alterations of different retinal layers in various stages of the disease (photoreceptors layer integrity, hyperreflective dots, outer retinal tubulations, subretinal hyperreflective material, and retinal pigment epithelial tears) will be analyzed in detail. The last part of the review will focus on how alterations of the vitreoretinal interface (vitreomacular adhesion and traction) and of the choroid (sub-RPE hyperreflective columns, prechoroidal clefts, choroidal caverns, choroidal thickness and choroidal volume, and choroidal vascular index) interact with nAMD progression. OCT technology is evolving very quickly, and new retinal biomarkers are continuously described. This up-to-date review article provides a comprehensive description on how structural OCT-based biomarkers provide a valuable tool to monitor the progression of the disease and the treatment response in nAMD patients. Thus, in this perspective, clinicians will be able to allocate hospital resources in the best possible way and tailor treatment to the individual patient's needs.
C1 [Metrangolo, Cristian; Donati, Simone; D'alterio, Giulia; Rubino, Marisa; Radice, Paolo; Premi, Elias] Osped Circolo & Fdn Macchi, Ophthalmol Unit, Varese, Italy.
   [Donati, Simone; Fontanel, Liviana; Messina, Walter; Premi, Elias; Azzolini, Claudio] Univ Insubria, Dept Med & Surg, Varese, Italy.
   [Mazzola, Marco] Multizonal Unit Ophthalmol Autonomous Prov Trento, Rovereto, Italy.
C3 Ospedale Circolo & Fondazione Macchi; University of Insubria
RP Donati, S (通讯作者)，Osped Circolo & Fdn Macchi, Ophthalmol Unit, Varese, Italy.; Donati, S (通讯作者)，Univ Insubria, Dept Med & Surg, Varese, Italy.
EM metrangolo.cristian@gmail.com; simone.donati@uninsubria.it;
   mazzola_89@yahoo.it; livifontanel@gmail.com; w.messina91@gmail.com;
   giuliad.alterio994@gmail.com; marisa.rubino@asst-settelaghi.it;
   p.radice@hotmail.it; elias.premi@gmail.com;
   claudio.azzolini@uninsubria.it
RI Donati, Simone/K-4382-2019
OI Donati, Simone/0000-0002-6920-7021; Azzolini,
   Claudio/0000-0002-1334-0974; Premi, Elias/0000-0003-0581-8488;
   D'ALTERIO, Giulia/0000-0003-0045-1728; mazzola,
   marco/0000-0001-5756-5254; Fontanel, Liviana/0000-0002-1032-8929
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Altay L, 2016, INVEST OPHTH VIS SCI, V57, P4315, DOI 10.1167/iovs.15-18855
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Ashraf M, 2017, RETINA-J RET VIT DIS, V37, P1738, DOI 10.1097/IAE.0000000000001423
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Branisteanu DC, 2020, EXP THER MED, V20, DOI 10.3892/etm.2020.9312
   Chakravarthy U, 2021, EYE, V35, P2983, DOI 10.1038/s41433-020-01354-4
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Cheong KX, 2020, EYE, V34, P2257, DOI 10.1038/s41433-020-0803-6
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chhablani JK, 2012, GRAEF ARCH CLIN EXP, V250, P1415, DOI 10.1007/s00417-012-1968-x
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2016, RETINA-J RET VIT DIS, V36, P1851, DOI 10.1097/IAE.0000000000001009
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Coscas G., 2009, OPTICAL COHERENCE TO, P195
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Daien V, 2021, BRIT J OPHTHALMOL, V105, P1475, DOI 10.1136/bjophthalmol-2020-317434
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Dirani A, 2015, RETINA-J RET VIT DIS, V35, P1166, DOI 10.1097/IAE.0000000000000439
   Dolz-Marco R, 2018, OPHTHALMOLOGY, V125, P1287, DOI 10.1016/j.ophtha.2018.02.036
   El-Hifnawy MA, 2017, INT J OPHTHALMOL-CHI, V10, P246, DOI 10.18240/ijo.2017.02.11
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   Fernandez-Avellaneda P, 2021, AM J OPHTHALMOL, V222, P112, DOI 10.1016/j.ajo.2020.09.003
   FRIEDMAN E, 1966, ARCH OPHTHALMOL-CHIC, V75, P334
   Gao M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009345
   Gattoussi S, 2019, ACTA OPHTHALMOL, V97, P364, DOI 10.1111/aos.13883
   Gattoussi S, 2017, INVEST OPHTH VIS SCI, V58, P2180, DOI 10.1167/iovs.16-20741
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Green-Simms AE, 2011, SEMIN OPHTHALMOL, V26, P137, DOI 10.3109/08820538.2011.559512
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Ho AC, 2018, OPHTHALMOL RETINA, V2, P676, DOI 10.1016/j.oret.2017.10.017
   Hosseini H, 2021, GRAEF ARCH CLIN EXP, V259, P1153, DOI 10.1007/s00417-020-05024-9
   Hwang HS, 2017, INVEST OPHTH VIS SCI, V58, P5958, DOI 10.1167/iovs.17-22725
   Invernizzi A, 2018, OPHTHALMOLOGY, V125, P237, DOI 10.1016/j.ophtha.2017.08.039
   Itoh Y, 2013, INVEST OPHTH VIS SCI, V54, P7302, DOI 10.1167/iovs.13-12702
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1099, DOI 10.1097/IAE.0b013e31828991d6
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kang EC, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/865083
   Karampelas M, 2020, OPHTHALMOL THER, V9, P739, DOI 10.1007/s40123-020-00291-5
   Kawashima Y, 2017, AM J OPHTHALMOL, V181, P61, DOI 10.1016/j.ajo.2017.06.015
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim JH, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/2578349
   Kim JM, 2017, RETINA-J RET VIT DIS, V37, P2047, DOI 10.1097/IAE.0000000000001435
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Kimura S, 2016, GRAEF ARCH CLIN EXP, V254, P1731, DOI 10.1007/s00417-016-3314-1
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kovacs A, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0960-6
   Krishnan R, 2015, RETINA-J RET VIT DIS, V35, P1750, DOI 10.1097/IAE.0000000000000714
   Kumar JB, 2020, RETINA-J RET VIT DIS, V40, P845, DOI 10.1097/IAE.0000000000002552
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Lee Kang Hoon, 2015, Korean J Ophthalmol, V29, P396, DOI 10.3341/kjo.2015.29.6.396
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Maggio E, 2017, OPHTHALMOLOGY, V124, P657, DOI 10.1016/j.ophtha.2017.01.018
   Maier M, 2012, KLIN MONATSBL AUGENH, V229, P1030, DOI 10.1055/s-0032-1315305
   Midena E, 2022, EYE, V36, P182, DOI 10.1038/s41433-021-01470-9
   Moraes G, 2021, OPHTHALMOLOGY, V128, P693, DOI 10.1016/j.ophtha.2020.09.025
   Kanadani TCM, 2018, OPHTHALMOLOGICA, V240, P200, DOI 10.1159/000488254
   Kanadani TCM, 2017, OPHTHALMIC RES, V58, P18, DOI 10.1159/000459626
   Moroz I, 2009, OPHTHAL SURG LAS IM, V40, P570, DOI 10.3928/15428877-20091030-06
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Musashi K, 2007, AM J OPHTHALMOL, V143, P883, DOI 10.1016/j.ajo.2006.12.024
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Novack RL, 2015, OPHTHALMOLOGY, V122, P796, DOI 10.1016/j.ophtha.2014.10.006
   Oishi A, 2018, RETINA-J RET VIT DIS, V38, P1331, DOI 10.1097/IAE.0000000000001688
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Otani T, 2010, RETINA-J RET VIT DIS, V30, P774, DOI 10.1097/IAE.0b013e3181c2e0d6
   Ou WC, 2017, AM J OPHTHALMOL, V180, P8, DOI 10.1016/j.ajo.2017.05.014
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Phadikar Prateep, 2017, Int J Retina Vitreous, V3, P1, DOI 10.1186/s40942-016-0054-7
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Preti RC, 2018, RETINA-J RET VIT DIS, V38, P1518, DOI 10.1097/IAE.0000000000001810
   Querques G, 2016, RETINA-J RET VIT DIS, V36, pS65, DOI 10.1097/IAE.0000000000001231
   Querques G, 2016, INVEST OPHTH VIS SCI, V57, P2578, DOI 10.1167/iovs.16-19083
   Rachitskaya Aleksandra V, 2015, Curr Ophthalmol Rep, V3, P26, DOI 10.1007/s40135-014-0057-1
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Riedl S, 2020, RETINA-J RET VIT DIS, V40, P2148, DOI 10.1097/IAE.0000000000002717
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Roh M, 2019, BRIT J OPHTHALMOL, V103, P1769, DOI 10.1136/bjophthalmol-2018-313316
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sastre-Ibanez M, 2019, J FR OPHTALMOL, V42, P63, DOI 10.1016/j.jfo.2018.04.017
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Shin HJ, 2012, GRAEF ARCH CLIN EXP, V250, P61, DOI 10.1007/s00417-011-1774-x
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Shiraki K, 2001, GRAEF ARCH CLIN EXP, V239, P430, DOI 10.1007/s004170100304
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singh SR, 2020, SURV OPHTHALMOL, V65, P451, DOI 10.1016/j.survophthal.2020.01.001
   Singh SR, 2019, SURV OPHTHALMOL, V64, P312, DOI 10.1016/j.survophthal.2018.11.002
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Vazquez-Alfageme C, 2019, RETINA-J RET VIT DIS, V39, P664, DOI 10.1097/IAE.0000000000002029
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wang J, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/9503795
   Wang XQ, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023200
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woronkowicz M, 2020, GRAEF ARCH CLIN EXP, V258, P2373, DOI 10.1007/s00417-020-04869-4
   Xie P, 2017, BRIT J OPHTHALMOL, V101, P1003, DOI 10.1136/bjophthalmol-2017-310155
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 125
TC 5
Z9 6
U1 1
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JUL 19
PY 2021
VL 2021
AR 9994098
DI 10.1155/2021/9994098
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TT2RV
UT WOS:000680198500001
PM 34336265
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Budiene, B
   Sakalauskaite, I
   Mikalauskaite, R
   Stanislovaitiene, D
   Trumpaitis, J
   Zaliuniene, D
AF Budiene, Brigita
   Sakalauskaite, Ieva
   Mikalauskaite, Rasa
   Stanislovaitiene, Daiva
   Trumpaitis, Jurgis
   Zaliuniene, Dalia
TI Ultrasound spectral analysis-based assessment of macular areas in
   patients with age related macular degeneration
SO JOURNAL OF VIBROENGINEERING
LA English
DT Article
DE ultrasound; age-related macular degeneration; spectral analysis;
   radiofrequency signals
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; DIAGNOSTIC-ACCURACY; FUTURE
AB Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in people aged 50 and older in the developed world. Early detection and treatment of AMD play the key role in helping patients at high risk for developing exudative to maintain their vision or slow down the progression of the disease. In this paper, the new technique for AMD evaluation using ultrasound spectral analysis is presented. Our aim was to compare B scan ultrasound signals backscattered from healthy tissues of macular area with signals from nonexudative and exudative AMD areas. In case-control study of 64 patients-144 tissues) we compared 82 cases of healthy tissue of macular area-I group) with 35 cases of nonexudative AMD-II group) and 30 cases of exudative AMD-III group) using B scan ultrasound. Estimated results showed that B scan amplitude and spectral intercept are informative to distinguish healthy tissues of macular area from AMD and spectral slope spectral, momentary bandwidth allow us to distinguish forms of AMD-nonexudative and exudative). We suggest that ultrasound spectral analysis is noninvasive, widely available, easy-to-use and less expensive method which can be used as an additional diagnostic tool in AMD detecting and differentiating when there are no possibilities to use more specific examination.
C1 [Budiene, Brigita; Stanislovaitiene, Daiva; Trumpaitis, Jurgis; Zaliuniene, Dalia] Hosp Lithuanian Univ Hlth Sci, Kaunas Clin, Eye Clin, Kaunas, Lithuania.
   [Sakalauskaite, Ieva; Mikalauskaite, Rasa] Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
C3 Hospital of Lithuanian University of Health Sciences Kauno Klinikos;
   Lithuanian University of Health Sciences
RP Budiene, B (通讯作者)，Hosp Lithuanian Univ Hlth Sci, Kaunas Clin, Eye Clin, Kaunas, Lithuania.
EM brigitabudiene@yahoo.com; iewaskl@gmail.com; rasa.mikalausk@gmail.com;
   daivastanislovaitiene@yahoo.com; j.trumpaitis@gmail.com;
   dalia.zaliuniene@lsmuni.lt
CR Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Boniface K. S., ACUTE SUBRETINAL HEM
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Coleman DJ, 2004, OPHTHALMOLOGY, V111, P1344, DOI 10.1016/j.ophtha.2003.10.029
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Framme C, 2005, CURR MED IMAGING, V1, P89, DOI 10.2174/1573405052952994
   Grid Amsler, AMSL GRID
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HODES BL, 1977, SURV OPHTHALMOL, V22, P29, DOI 10.1016/0039-6257(77)90026-1
   Jurkonis R, 2009, ELEKTRON ELEKTROTECH, P109
   Jurkonis R., 2012, BIOM ENG C
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Lovie-Kitchin Jan E, 2001, Clin Exp Optom, V84, P165
   Matthiessen ET, 2004, EYE, V18, P400, DOI 10.1038/sj.eye.6700651
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Paunksnis A., 2012, ULTRASOUND, P66
   Schwartz R., 2015, INT J RETINA VITREOU
   Shazlee MK, 2016, PAK J MED SCI, V32, P385, DOI 10.12669/pjms.322.9241
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Trumpaitis J, 2015, BALT J MOD COMPUT, V3, P55
   Trumpaitis J, 2014, J VIBROENG, V16, P3586
NR 27
TC 0
Z9 0
U1 0
U2 6
PU JVE INT LTD
PI KAUNAS
PA GELIU RATAS 15 A, KAUNAS, LT-50282, LITHUANIA
SN 1392-8716
J9 J VIBROENG
JI J. Vibroeng.
PD SEP
PY 2017
VL 19
IS 6
BP 4685
EP 4693
DI 10.21595/jve.2017.18160
PG 9
WC Engineering, Biomedical; Engineering, Mechanical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA FI8GR
UT WOS:000412241200049
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Choudhary, M
   Ismail, EN
   Yao, PL
   Tayyari, F
   Radu, RA
   Nusinowitz, S
   Boulton, ME
   Apte, RS
   Ruberti, JW
   Handa, JT
   Tontonoz, P
   Malek, G
AF Choudhary, Mayur
   Ismail, Ebraheim N.
   Yao, Pei-Li
   Tayyari, Faryan
   Radu, Roxana A.
   Nusinowitz, Steven
   Boulton, Michael E.
   Apte, Rajendra S.
   Ruberti, Jeffrey W.
   Handa, James T.
   Tontonoz, Peter
   Malek, Goldis
TI LXRs regulate features of age-related macular degeneration and may be a
   potential therapeutic target
SO JCI INSIGHT
LA English
DT Article
ID LIVER-X-RECEPTOR; MITOCHONDRIAL-DNA DAMAGE; GENOME-WIDE ASSOCIATION;
   NUCLEAR RECEPTORS; BRUCHS MEMBRANE; APOLIPOPROTEIN-E; CHOLESTEROL
   HOMEOSTASIS; LIPID-METABOLISM; BASAL DEPOSITS; HUMAN EYES
AB Effective treatments and animal models for the most prevalent neurodegenerative form of blindness in elderly people, called age-related macular degeneration (AMD), are lacking. Genomewide association studies have identified lipid metabolism and inflammation as AMD-associated pathogenic pathways. Given liver X receptors (LXRs), encoded by the nuclear receptor subfamily 1 group H members 2 and 3 (NR1H3 and NR1H2), are master regulators of these pathways, herein we investigated the role of LXR in human and mouse eyes as a function of age and disease and tested the therapeutic potential of targeting LXR. We identified immunopositive LXR fragments in human extracellular early dry AMD lesions and a decrease in LXR expression within the retinal pigment epithelium (RPE) as a function of age. Aged mice lacking LXR presented with isoformdependent ocular pathologies. Specifically, loss of the Nr1h3 isoform resulted in pathobiologies aligned with AMD, supported by compromised visual function, accumulation of native and oxidized lipids in the outer retina, and upregulation of ocular inflammatory cytokines, while absence of Nrlh2 was associated with ocular lipoidal degeneration. LXR activation not only ameliorated lipid accumulation and oxidant-induced injury in RPE cells but also decreased ocular inflammatory markers and lipid deposition in a mouse model, thereby providing translational support for pursuing LXR-active pharmaceuticals as potential therapies for dry AMD.
C1 [Choudhary, Mayur; Yao, Pei-Li; Tayyari, Faryan; Malek, Goldis] Duke Univ, Duke Eye Ctr, Dept Ophthalmol, Sch Med, Durham, NC 27710 USA.
   [Ismail, Ebraheim N.; Ruberti, Jeffrey W.] Northeastern Univ, Dept Bioengn, Boston, MA 02115 USA.
   [Radu, Roxana A.; Nusinowitz, Steven] UCLA, Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA USA.
   [Boulton, Michael E.] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Handa, James T.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
   [Tontonoz, Peter] UCLA, Dept Pathol & Lab Med, Los Angeles, CA USA.
   [Malek, Goldis] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA.
C3 Duke University; Northeastern University; University of California
   System; University of California Los Angeles; University of Alabama
   System; University of Alabama Birmingham; Washington University (WUSTL);
   Johns Hopkins University; Johns Hopkins Medicine; University of
   California System; University of California Los Angeles; Duke University
RP Malek, G (通讯作者)，Duke Univ, Dept Ophthalmol, Sch Med, 2351 Erwin Rd,POB 3802,Room 4006, Durham, NC 27710 USA.
EM gmalek@duke.edu
RI Tayyari, Faryan/AAS-9020-2020; Choudhary, Mayur/AAU-3497-2021
OI Choudhary, Mayur/0000-0001-8056-011X; Boulton,
   Michael/0000-0002-0796-1766; Malek, Goldis/0000-0003-0026-2388; Yao,
   Pei-Li/0000-0003-0832-3771; Radu, Roxana/0000-0002-5064-6403
FU National Eye Institute [R01 EY027802, R01 EY028160, P30 EY005722,
   EY000331, R01 EY019287-06, P30 EY02687, R01 EY027691]; Edward N. & Della
   L. Thome Memorial Foundation Award; Carl and Mildred Almen Reeves
   Foundation; Starr Foundation; Jeffrey Fort Innovation Fund; Glenn
   Foundation for Medical Research; Research to Prevent Blindness, Inc,;
   Thome Foundation; Bill and Emily Kuzma Family Gift for Retinal Research
FX This research was supported by the National Eye Institute grants R01
   EY027802 (GM), R01 EY028160 (GM), P30 EY005722 (to the Duke Eye Center),
   EY000331 (to the Stein Eye Institute, Core Grant for Vision Research),
   R01 EY019287-06 (RSA), P30 EY02687 (to Washington University, Core Grant
   for Vision Research), and R01 EY027691 (JTH, Robert Bond Welch
   Professor); the Edward N. & Della L. Thome Memorial Foundation Award
   (GM); the Carl and Mildred Almen Reeves Foundation (RSA); the Starr
   Foundation (RSA); the Bill and Emily Kuzma Family Gift for Retinal
   Research (RSA); the Jeffrey Fort Innovation Fund (RSA); the Glenn
   Foundation for Medical Research and the Thome Foundation (RSA); and the
   Research to Prevent Blindness, Inc, Core grant (to the Duke Eye Center).
   We are grateful to the donors and donor families for their generosity.
   We thank Neal Peachy for assistance with the c-wave recording protocols.
   Sincere thanks to Donald P. McDonnell and Ching-Yi Chang for plasmids
   used in transcriptional activity assays and valuable discussions. We
   thank Abdoulaye Sene, Xiaoping Qi, Eddie Meade, and Michael Lekwuwa for
   technical support.
CR Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   Ban N, 2018, J LIPID RES, V59, P1414, DOI 10.1194/jlr.M084442
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Calkin AC, 2010, ARTERIOSCL THROM VAS, V30, P1513, DOI 10.1161/ATVBAHA.109.191197
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chiu CJ, 2011, INVEST OPHTH VIS SCI, V52, P9099, DOI 10.1167/iovs.11-7782
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dai BL, 2017, INFLAMM RES, V66, P523, DOI 10.1007/s00011-017-1036-4
   Dhiman VK, 2018, NAT REV GENET, V19, P160, DOI 10.1038/nrg.2017.102
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edwards PA, 2002, VASC PHARMACOL, V38, P249, DOI 10.1016/S1537-1891(02)00175-1
   Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   FINE BS, 1981, AM J OPHTHALMOL, V91, P469, DOI 10.1016/0002-9394(81)90234-8
   FLIESLER SJ, 1993, FEBS LETT, V335, P234, DOI 10.1016/0014-5793(93)80736-E
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fu B, 2017, INT J OPHTHALMOL-CHI, V10, P535, DOI 10.18240/ijo.2017.04.06
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hazra S, 2012, DIABETES, V61, P3270, DOI 10.2337/db11-1596
   Heuser J, 1981, Methods Cell Biol, V22, P97
   Houck KA, 2004, MOL GENET METAB, V83, P184, DOI 10.1016/j.ymgme.2004.07.007
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Ismail EN, 2017, EXP EYE RES, V162, P62, DOI 10.1016/j.exer.2017.06.013
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853
   Komati R, 2017, MOLECULES, V22, DOI 10.3390/molecules22010088
   Lei CY, 2017, NEUROSCIENCE, V360, P48, DOI 10.1016/j.neuroscience.2017.07.053
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x
   Liao WL, 2011, J PROTEOME RES, V10, P241, DOI 10.1021/pr1008898
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Ma ZQ, 2017, CURR ISSUES MOL BIOL, V22, P41, DOI 10.21775/cimb.022.041
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Mitro N, 2007, FEBS LETT, V581, P1721, DOI 10.1016/j.febslet.2007.03.047
   Moutinho M, 2017, J LIPID RES, V58, P1937, DOI 10.1194/jlr.R075556
   Mukherjee S, 2009, INVEST OPHTH VIS SCI, V50, P5449, DOI 10.1167/iovs.09-3383
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Omari KM, 2009, AM J PATHOL, V174, P164, DOI 10.2353/ajpath.2009.080350
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Pardee K, 2004, SCI AGING KNOWLEDGE, V2004, P8
   Paterniti I, 2010, J NEUROCHEM, V112, P611, DOI 10.1111/j.1471-4159.2009.06471.x
   Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pinto LH, 2007, DOC OPHTHALMOL, V115, P127, DOI 10.1007/s10633-007-9064-y
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2019, INVEST OPHTH VIS SCI, V60, P461, DOI 10.1167/iovs.18-25786
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Saadane A, 2016, J BIOL CHEM, V291, P20427, DOI 10.1074/jbc.M116.744656
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Skerrett R, 2014, NEUROBIOL DIS, V72, P104, DOI 10.1016/j.nbd.2014.05.019
   Song XY, 2019, P NATL ACAD SCI USA, V116, P16507, DOI 10.1073/pnas.1904719116
   Sonoda J, 2008, FEBS LETT, V582, P2, DOI 10.1016/j.febslet.2007.11.016
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Whitfield M, 2016, BIOL REPROD, V94, DOI 10.1095/biolreprod.115.133538
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xing Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21309
   Xu P, 2013, MOL NEUROBIOL, V48, P715, DOI 10.1007/s12035-013-8461-3
   Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883
   Zhang MZ, 2012, J CLIN INVEST, V122, P4519, DOI 10.1172/JCI60363
   Zheng SJ, 2015, INVEST OPHTH VIS SCI, V56, P1168, DOI 10.1167/iovs.14-15612
NR 84
TC 20
Z9 20
U1 0
U2 1
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD JAN 16
PY 2020
VL 5
IS 1
AR e131928
DI 10.1172/jci.insight.131928
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA KD6HG
UT WOS:000507964700012
PM 31829999
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Schick, T
   Altay, L
   Viehweger, E
   Hoyng, CB
   den Hollander, AI
   Felsch, M
   Fauser, S
AF Schick, Tina
   Altay, Lebriz
   Viehweger, Eva
   Hoyng, Carel B.
   den Hollander, Anneke I.
   Felsch, Moritz
   Fauser, Sascha
TI Genetics of Unilateral and Bilateral Age-Related Macular Degeneration
   Severity Stages
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; POLYMORPHISMS; ASSOCIATION; PREVALENCE; PREDICTION;
   VARIANTS; DRUSEN; GENES; TWIN
AB Background
   Age-related macular degeneration (AMD) is a common disease causing visual impairment and blindness. Various gene variants are strongly associated with late stage AMD, but little is known about the genetics of early forms of the disease. This study evaluated associations of genetic factors and different AMD stages depending on unilateral and bilateral disease severity.
   Methods
   In this case-control study, participants were assigned to nine AMD severity stages based on the characteristics of each eye. 18 single nucleotide polymorphisms (SNPs) were geno-typed and attempted to correlate with AMD severity stages by uni- and multivariate logistic regression analyses and trend analyses. Area under the receiver operating characteristic curves (AUC) were calculated.
   Results
   Of 3444 individuals 1673 were controls, 379 had early AMD, 333 had intermediate AMD and 989 showed late AMD stages. With increasing severity of disease and bilateralism more SNPs with significant associations were found. Odds ratios, especially for the main risk polymorphisms in ARMS2 (rs10490924) and CFH (rs1061170), gained with increasing disease severity and bilateralism (exemplarily: rs1061170: unilateral early AMD: OR = 1.18; bilateral early AMD: OR = 1.20; unilateral intermediate AMD: OR = 1.28; bilateral intermediate AMD: OR = 1.39, unilateral geographic atrophy (GA): OR = 1.50; bilateral GA: OR = 1.71). Trend analyses showed p<0.0001 for ARMS2 (rs10490924) and for CFH (rs1061170), respectively. AUC of risk models for various AMD severity stages was lowest for unilateral early AMD (AUC = 0.629) and showed higher values in more severely and bilaterally affected individuals being highest for late AMD with GA in one eye and neovascular AMD in the other eye (AUC = 0.957).
   Conclusion
   The association of known genetic risk factors with AMD became stronger with increasing disease severity, which also led to an increasing discriminative ability of AMD cases and controls. Genetic predisposition was also associated with the disease severity of the fellow-eye, highlighting the importance of both eyes in AMD patients.
C1 [Schick, Tina; Altay, Lebriz; Viehweger, Eva; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Felsch, Moritz] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50931 Cologne, Germany.
   [Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
C3 University of Cologne; University of Cologne; Radboud University
   Nijmegen
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
EM sascha.fauser@gmail.com
RI Hollander, Anneke den/N-4911-2014
CR Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Dietzel M, 2014, GRAEF ARCH CLIN EXP, V252, P1273, DOI 10.1007/s00417-014-2690-7
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hawkins JR, 2002, HUM MUTAT, V19, P543, DOI 10.1002/humu.10060
   Hermann M, 2012, ACTA OPHTHALMOL, V90, pe500, DOI 10.1111/j.1755-3768.2011.02347.x
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 25
TC 7
Z9 7
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 3
PY 2016
VL 11
IS 6
AR e0156778
DI 10.1371/journal.pone.0156778
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DN8ZV
UT WOS:000377369700125
PM 27257685
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Fritsche, LG
   Igl, W
   Bailey, JNC
   Grassmann, F
   Sengupta, S
   Bragg-Gresham, JL
   Burdon, KP
   Hebbring, SJ
   Wen, C
   Gorski, M
   Kim, IK
   Cho, D
   Zack, D
   Souied, E
   Scholl, HPN
   Bala, E
   Lee, KE
   Hunter, DJ
   Sardell, RJ
   Mitchell, P
   Merriam, JE
   Cipriani, V
   Hoffman, JD
   Schick, T
   Lechanteur, YTE
   Guymer, RH
   Johnson, MP
   Jiang, YD
   Stanton, CM
   Buitendijk, GHS
   Zhan, XW
   Kwong, AM
   Boleda, A
   Brooks, M
   Gieser, L
   Ratnapriya, R
   Branham, KE
   Foerster, JR
   Heckenlively, JR
   Othman, MI
   Vote, BJ
   Liang, HH
   Souzeau, E
   McAllister, IL
   Isaacs, T
   Hall, J
   Lake, S
   Mackey, DA
   Constable, IJ
   Craig, JE
   Kitchner, TE
   Yang, ZL
   Su, ZG
   Luo, HR
   Chen, D
   Hong, OY
   Flagg, K
   Lin, D
   Mao, GP
   Ferreyra, H
   Starke, K
   von Strachwitz, CN
   Wolf, A
   Brandl, C
   Rudolph, G
   Olden, M
   Morrison, MA
   Morgan, DJ
   Schu, M
   Ahn, J
   Silvestri, G
   Tsironi, EE
   Park, KH
   Farrer, LA
   Orlin, A
   Brucker, A
   Li, MY
   Curcio, CA
   Mohand-Said, S
   Sahel, JM
   Audo, I
   Benchaboune, M
   Cree, AJ
   Rennie, CA
   Goverdhan, SV
   Grunin, M
   Hagbi-Levi, S
   Campochiaro, P
   Katsanis, N
   Holz, FG
   Blond, F
   Blanche, H
   Deleuze, JF
   Igo, RP
   Truitt, B
   Peachey, NS
   Meuer, SM
   Myers, CE
   Moore, EL
   Klein, R
   Hauser, MA
   Postel, EA
   Courtenay, MD
   Schwartz, SG
   Kovach, JL
   Scott, WK
   Liew, G
   Tan, AG
   Gopinath, B
   Merriam, JC
   Smith, RT
   Khan, JC
   Shahid, H
   Moore, AT
   McGrath, JA
   Laux, R
   Brantley, MA
   Agarwal, A
   Ersoy, L
   Caramoy, A
   Langmann, T
   Saksens, NTM
   de Jong, EK
   Hoyng, CB
   Cain, MS
   Richardson, AJ
   Martin, TM
   Blangero, J
   Weeks, DE
   Dhillon, B
   van Duijn, CM
   Doheny, KF
   Romm, J
   Klaver, CCW
   Hayward, C
   Gorin, MB
   Klein, ML
   Baird, PN
   den Hollander, AI
   Fauser, S
   Yates, JRW
   Allikmets, R
   Wang, JJ
   Schaumberg, DA
   Klein, BEK
   Hagstrom, SA
   Chowers, I
   Lotery, AJ
   Leveillard, T
   Zhang, K
   Brilliant, MH
   Hewitt, AW
   Swaroop, A
   Chew, EY
   Pericak-Vance, MA
   DeAngelis, M
   Stambolian, D
   Haines, JL
   Iyengar, SK
   Weber, BHF
   Abecasis, GR
   Heid, IM
AF Fritsche, Lars G.
   Igl, Wilmar
   Bailey, Jessica N. Cooke
   Grassmann, Felix
   Sengupta, Sebanti
   Bragg-Gresham, Jennifer L.
   Burdon, Kathryn P.
   Hebbring, Scott J.
   Wen, Cindy
   Gorski, Mathias
   Kim, Ivana K.
   Cho, David
   Zack, Donald
   Souied, Eric
   Scholl, Hendrik P. N.
   Bala, Elisa
   Lee, Kristine E.
   Hunter, David J.
   Sardell, Rebecca J.
   Mitchell, Paul
   Merriam, Joanna E.
   Cipriani, Valentina
   Hoffman, Joshua D.
   Schick, Tina
   Lechanteur, Yara T. E.
   Guymer, Robyn H.
   Johnson, Matthew P.
   Jiang, Yingda
   Stanton, Chloe M.
   Buitendijk, Gabrielle H. S.
   Zhan, Xiaowei
   Kwong, Alan M.
   Boleda, Alexis
   Brooks, Matthew
   Gieser, Linn
   Ratnapriya, Rinki
   Branham, Kari E.
   Foerster, Johanna R.
   Heckenlively, John R.
   Othman, Mohammad I.
   Vote, Brendan J.
   Liang, Helena Hai
   Souzeau, Emmanuelle
   McAllister, Ian L.
   Isaacs, Timothy
   Hall, Janette
   Lake, Stewart
   Mackey, David A.
   Constable, Ian J.
   Craig, Jamie E.
   Kitchner, Terrie E.
   Yang, Zhenglin
   Su, Zhiguang
   Luo, Hongrong
   Chen, Daniel
   Hong Ouyang
   Flagg, Ken
   Lin, Danni
   Mao, Guanping
   Ferreyra, Henry
   Starke, Klaus
   von Strachwitz, Claudia N.
   Wolf, Armin
   Brandl, Caroline
   Rudolph, Guenther
   Olden, Matthias
   Morrison, Margaux A.
   Morgan, Denise J.
   Schu, Matthew
   Ahn, Jeeyun
   Silvestri, Giuliana
   Tsironi, Evangelia E.
   Park, Kyu Hyung
   Farrer, Lindsay A.
   Orlin, Anton
   Brucker, Alexander
   Li, Mingyao
   Curcio, Christine A.
   Mohand-Said, Saddek
   Sahel, Jose-Main
   Audo, Isabelle
   Benchaboune, Mustapha
   Cree, Angela J.
   Rennie, Christina A.
   Goverdhan, Srinivas V.
   Grunin, Michelle
   Hagbi-Levi, Shira
   Campochiaro, Peter
   Katsanis, Nicholas
   Holz, Frank G.
   Blond, Frederic
   Blanche, Helene
   Deleuze, Jean-Francois
   Igo, Robert P., Jr.
   Truitt, Barbara
   Peachey, Neal S.
   Meuer, Stacy M.
   Myers, Chelsea E.
   Moore, Emily L.
   Klein, Ronald
   Hauser, Michael A.
   Postel, Eric A.
   Courtenay, Monique D.
   Schwartz, Stephen G.
   Kovach, Jaclyn L.
   Scott, William K.
   Liew, Gerald
   Tan, Ava G.
   Gopinath, Bamini
   Merriam, John C.
   Smith, R. Theodore
   Khan, Jane C.
   Shahid, Humma
   Moore, Anthony T.
   McGrath, J. Allie
   Laux, Renee
   Brantley, Milam A., Jr.
   Agarwal, Anita
   Ersoy, Lebriz
   Caramoy, Albert
   Langmann, Thomas
   Saksens, Nicole T. M.
   de Jong, Eiko K.
   Hoyng, Carel B.
   Cain, Melinda S.
   Richardson, Andrea J.
   Martin, Tammy M.
   Blangero, John
   Weeks, Daniel E.
   Dhillon, Bal
   van Duijn, Cornelia M.
   Doheny, Kimberly F.
   Romm, Jane
   Klaver, Caroline C. W.
   Hayward, Caroline
   Gorin, Michael B.
   Klein, Michael L.
   Baird, Paul N.
   den Hollander, Anneke I.
   Fauser, Sascha
   Yates, John R. W.
   Allikmets, Rando
   Wang, Jie Jin
   Schaumberg, Debra A.
   Klein, Barbara E. K.
   Hagstrom, Stephanie A.
   Chowers, Itay
   Lotery, Andrew J.
   Leveillard, Thierry
   Zhang, Kang
   Brilliant, Murray H.
   Hewitt, Alex W.
   Swaroop, Anand
   Chew, Emily Y.
   Pericak-Vance, Margaret A.
   DeAngelis, Margaret
   Stambolian, Dwight
   Haines, Jonathan L.
   Iyengar, Sudha K.
   Weber, Bernhard H. F.
   Abecasis, Goncalo R.
   Heid, Iris M.
TI A large genome-wide association study of age-related macular
   degeneration highlights contributions of rare and common variants
SO NATURE GENETICS
LA English
DT Article
ID SEQUENCING IDENTIFIES RARE; BODY-MASS INDEX; HIGH-RISK; SUSCEPTIBILITY
   LOCI; DISEASE; GENE; MUTATION; BIOLOGY; OSTEOARTHRITIS; METAANALYSIS
AB Advanced age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, with limited therapeutic options. Here we report on a study of >12 million variants, including 163,714 directly genotyped, mostly rare, protein-altering variants. Analyzing 16,144 patients and 17,832 controls, we identify 52 independently associated common and rare variants (P < 5 x 10(-8)) distributed across 34 loci. Although wet and dry AMD subtypes exhibit predominantly shared genetics, we identify the first genetic association signal specific to wet AMD, near MMP9 (difference P value = 4.1 x 10(-10)). Very rare coding variants (frequency <0.1 %) in CFH, CFI and TIMP3 suggest causal roles for these genes, as does a splice variant in SLC16A8. Our results support the hypothesis that rare coding variants can pinpoint causal genes within known genetic loci and illustrate that applying the approach systematically to detect new loci requires extremely large sample sizes.
C1 [Fritsche, Lars G.; Sengupta, Sebanti; Bragg-Gresham, Jennifer L.; Zhan, Xiaowei; Kwong, Alan M.; Foerster, Johanna R.; Abecasis, Goncalo R.] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Igl, Wilmar; Gorski, Mathias; Starke, Klaus; Brandl, Caroline; Olden, Matthias; Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, D-93053 Regensburg, Germany.
   [Bailey, Jessica N. Cooke; Igo, Robert P., Jr.; Truitt, Barbara; Laux, Renee; Haines, Jonathan L.; Iyengar, Sudha K.] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Grassmann, Felix; Brandl, Caroline; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Bragg-Gresham, Jennifer L.] Univ Michigan, Dept Internal Med Nephrol, Kidney Epidemiol & Cost Ctr, Ann Arbor, MI 48109 USA.
   [Burdon, Kathryn P.; Vote, Brendan J.; Mackey, David A.; Hewitt, Alex W.] Univ Tasmania, Menzies Res Inst Tasmania, Sch Med, Hobart, Tas, Australia.
   [Hebbring, Scott J.; Kitchner, Terrie E.; Brilliant, Murray H.] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA.
   [Wen, Cindy; Chen, Daniel; Lin, Danni; Mao, Guanping] Univ Calif San Diego, Dept Ophthalmol, San Diego, CA 92103 USA.
   [Wen, Cindy; Luo, Hongrong; Chen, Daniel; Hong Ouyang; Flagg, Ken; Lin, Danni; Mao, Guanping; Ferreyra, Henry; Zhang, Kang] Vet Affairs San Diego Hlth Syst, La Jolla, CA USA.
   [Kim, Ivana K.] Harvard Univ, Sch Med, Dept Ophthalmol, Retina Serv,Massachusetts Eye & Ear, Boston, MA USA.
   [Cho, David; Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Zack, Donald; Scholl, Hendrik P. N.; Campochiaro, Peter] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Zack, Donald] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.
   [Zack, Donald; Campochiaro, Peter] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
   [Zack, Donald] Johns Hopkins Univ, Sch Med, Inst Genet Med, Baltimore, MD USA.
   [Zack, Donald] Univ Paris 06, Inst Vis, Paris, France.
   [Souied, Eric] Univ Paris Est Creteil, Hop Henri Mondor, Hop Intercommunal Creteil, Creteil, France.
   [Scholl, Hendrik P. N.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Bala, Elisa; Peachey, Neal S.] Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH USA.
   [Lee, Kristine E.; Meuer, Stacy M.; Myers, Chelsea E.; Moore, Emily L.; Klein, Ronald; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Hunter, David J.; Schaumberg, Debra A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Hunter, David J.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Sardell, Rebecca J.; Courtenay, Monique D.; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Mitchell, Paul; Liew, Gerald; Tan, Ava G.; Gopinath, Bamini; Wang, Jie Jin] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Merriam, Joanna E.; Merriam, John C.; Smith, R. Theodore; Allikmets, Rando] CUNY, Dept Ophthalmol, New York, NY 10021 USA.
   [Cipriani, Valentina; Sahel, Jose-Main; Moore, Anthony T.; Yates, John R. W.] UCL, Inst Ophthalmol, London, England.
   [Cipriani, Valentina; Moore, Anthony T.; Yates, John R. W.] Moorfields Eye Hosp, London, England.
   [Hoffman, Joshua D.; McGrath, J. Allie] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
   [Schick, Tina; Ersoy, Lebriz; Caramoy, Albert; Langmann, Thomas; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Lechanteur, Yara T. E.; Saksens, Nicole T. M.; de Jong, Eiko K.; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Guymer, Robyn H.; Liang, Helena Hai; Mackey, David A.; Cain, Melinda S.; Richardson, Andrea J.; Baird, Paul N.; Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Johnson, Matthew P.; Blangero, John] Univ Texas Rio Grande Valley, Sch Med, South Texas Diabet & Obes Inst, Brownsville, TX USA.
   [Jiang, Yingda; Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Stanton, Chloe M.; Hayward, Caroline] Univ Edinburgh, Inst Genet & Mol Med, MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland.
   [Buitendijk, Gabrielle H. S.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; van Duijn, Cornelia M.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Zhan, Xiaowei] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Quantitat Biomed Res Ctr, Dallas, TX 75390 USA.
   [Zhan, Xiaowei] Univ Texas SW Med Ctr Dallas, Ctr Genet Host Def, Dallas, TX 75390 USA.
   [Boleda, Alexis; Brooks, Matthew; Gieser, Linn; Ratnapriya, Rinki; Swaroop, Anand] NEI, N NRL, US Natl Inst Hlth, Bethesda, MD USA.
   [Branham, Kari E.; Heckenlively, John R.; Othman, Mohammad I.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Souzeau, Emmanuelle; Hall, Janette; Lake, Stewart; Craig, Jamie E.] Flinders Univ S Australia, Flinders Med Ctr, Dept Ophthalmol, Adelaide, SA 5001, Australia.
   [McAllister, Ian L.; Isaacs, Timothy; Mackey, David A.; Constable, Ian J.; Khan, Jane C.; Hewitt, Alex W.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Visual Sci, Perth, WA 6009, Australia.
   [Yang, Zhenglin] Hosp Univ Elect Sci & Technol China, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Peoples R China.
   [Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China.
   [Yang, Zhenglin] Chinese Acad Sci, Sichuan Translat Med Hosp, Chengdu, Peoples R China.
   [Su, Zhiguang; Zhang, Kang] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Mol Med Res Ctr, Chengdu 610064, Peoples R China.
   [von Strachwitz, Claudia N.] EyeCte Southwest, Stuttgart, Germany.
   [Wolf, Armin; Rudolph, Guenther] Univ Munich, Univ Eye Clin, Munich, Germany.
   [Brandl, Caroline] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Morrison, Margaux A.; Morgan, Denise J.; DeAngelis, Margaret] Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Med Biomed Genet, Boston, MA USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02118 USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02118 USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA.
   [Schu, Matthew; Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
   [Ahn, Jeeyun] Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Dept Ophthalmol, Seoul, South Korea.
   [Silvestri, Giuliana] Queens Univ, Ctr Expt Med, Belfast, Antrim, North Ireland.
   [Tsironi, Evangelia E.] Univ Thessaly, Sch Med, Dept Ophthalmol, Larisa, Greece.
   [Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Songnam, South Korea.
   [Orlin, Anton] Weill Cornell Med Coll, Dept Ophthalmol, New York, NY USA.
   [Brucker, Alexander] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   [Li, Mingyao] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Mohand-Said, Saddek; Sahel, Jose-Main; Audo, Isabelle; Blond, Frederic; Leveillard, Thierry] INSERM, Paris, France.
   [Mohand-Said, Saddek; Sahel, Jose-Main; Audo, Isabelle; Blond, Frederic; Leveillard, Thierry] Inst Vis, Dept Genet, Paris, France.
   [Mohand-Said, Saddek; Sahel, Jose-Main; Audo, Isabelle; Blond, Frederic; Leveillard, Thierry] CNRS, Paris, France.
   [Mohand-Said, Saddek; Sahel, Jose-Main; Benchaboune, Mustapha] Ctr Hosp Natl Ophtalmol Quinze Vingts, Paris, France.
   [Sahel, Jose-Main] Fdn Ophtalmol Adolphe Rothschild, Paris, France.
   [Sahel, Jose-Main] Acad Sci, Inst France, Paris, France.
   [Audo, Isabelle] Inst Ophthalmol, Dept Mol Genet, London, England.
   [Cree, Angela J.; Goverdhan, Srinivas V.; Lotery, Andrew J.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton SO9 5NH, Hants, England.
   [Rennie, Christina A.] Univ Hosp Southampton, Southampton, Hants, England.
   [Grunin, Michelle; Hagbi-Levi, Shira; Chowers, Itay] Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   [Katsanis, Nicholas] Duke Univ, Ctr Human Dis Modeling, Durham, NC USA.
   [Katsanis, Nicholas] Duke Univ, Dept Cell Biol, Durham, NC USA.
   [Katsanis, Nicholas] Duke Univ, Dept Pediat, Durham, NC 27706 USA.
   [Blanche, Helene; Deleuze, Jean-Francois] Fdn Jean Dausset, CEPH, Paris, France.
   [Deleuze, Jean-Francois] Commissariat Energie Atom & Energies Alternat CEA, Ctr Natl Genotypage, Inst Genom, Evry, France.
   [Peachey, Neal S.; Hagstrom, Stephanie A.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Hauser, Michael A.; Postel, Eric A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Hauser, Michael A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   [Hauser, Michael A.] Duke Univ, Med Ctr, Duke Mol Physiol Inst, Durham, NC USA.
   [Schwartz, Stephen G.; Kovach, Jaclyn L.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Naples, FL USA.
   [Smith, R. Theodore] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Khan, Jane C.] Royal Perth Hosp, Dept Ophthalmol, Perth, WA 6001, Australia.
   [Khan, Jane C.; Shahid, Humma; Yates, John R. W.] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge, England.
   [Shahid, Humma] Cambridge Univ Hosp Natl Hlth Serv NHS Fdn Trust, Dept Ophthalmol, Cambridge, England.
   [Moore, Anthony T.] Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA USA.
   [Brantley, Milam A., Jr.; Agarwal, Anita] Vanderbilt Univ, Dept Ophthalmol & Visual Sci, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Martin, Tammy M.; Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Dhillon, Bal] Univ Edinburgh, Sch Clin Sci, Edinburgh, Midlothian, Scotland.
   [Doheny, Kimberly F.; Romm, Jane] Johns Hopkins Univ, Sch Med, Inst Med Genet, CIDR, Baltimore, MD USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90024 USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
   [Schaumberg, Debra A.] Univ Utah, Sch Med, Moran Eye Ctr, Ctr Translat Med, Salt Lake City, UT USA.
   [Schaumberg, Debra A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA.
   [Chew, Emily Y.] NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, US Natl Inst Hlth, Bethesda, MD 20892 USA.
   [Haines, Jonathan L.] Case Western Reserve Univ, Sch Med, Inst Computat Biol, Cleveland, OH 44106 USA.
C3 University of Michigan System; University of Michigan; University of
   Regensburg; Case Western Reserve University; University of Regensburg;
   University of Michigan System; University of Michigan; University of
   Tasmania; Menzies Institute for Medical Research; University of
   California System; University of California San Diego; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA San Diego
   Healthcare System; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; University of Pennsylvania;
   Pennsylvania Medicine; Johns Hopkins University; Johns Hopkins Medicine;
   Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; UDICE-French Research Universities; Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; CHI Creteil; University of Bonn; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Case Western
   Reserve University; Louis Stokes Cleveland Veterans Affairs Medical
   Center; University of Wisconsin System; University of Wisconsin Madison;
   Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; University of
   Miami; University of Sydney; City University of New York (CUNY) System;
   University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Vanderbilt University; University of Cologne; Radboud University
   Nijmegen; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital; University of Melbourne; University of Texas System;
   University of Texas Rio Grande Valley; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); University of Pittsburgh; University of
   Edinburgh; Erasmus University Rotterdam; Erasmus MC; Erasmus University
   Rotterdam; Erasmus MC; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   University of Michigan System; University of Michigan; Flinders Medical
   Centre; Flinders University South Australia; Lions Eye Institute;
   University of Western Australia; University of Electronic Science &
   Technology of China; Sichuan Provincial People's Hospital; Chinese
   Academy of Sciences; Sichuan University; University of Munich;
   University of Regensburg; Utah System of Higher Education; University of
   Utah; Boston University; Boston University; Boston University; Boston
   University; Boston University; Boston University; Boston University;
   Boston University; Boston University; Boston University; Seoul National
   University (SNU); Seoul National University Hospital; Queens University
   Belfast; University of Thessaly; Seoul National University (SNU);
   Cornell University; University of Pennsylvania; Pennsylvania Medicine;
   University of Pennsylvania; Pennsylvania Medicine; University of Alabama
   System; University of Alabama Birmingham; Institut National de la Sante
   et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Centre National de la Recherche
   Scientifique (CNRS); UDICE-French Research Universities; Universite
   Paris Cite; CHNO des Quinze-Vingts; UDICE-French Research Universities;
   Sorbonne Universite; Fondation Adolphe de Rothschild; University of
   London; University College London; University of Southampton; Hebrew
   University of Jerusalem; Hadassah University Medical Center; Duke
   University; Duke University; Duke University; Foundation Jean
   Dausset-CEPH; CEA; UDICE-French Research Universities; Universite Paris
   Saclay; Cleveland Clinic Foundation; Duke University; Duke University;
   Duke University; Bascom Palmer Eye Institute; New York University; Royal
   Perth Hospital; University of Western Australia; University of
   Cambridge; University of California System; University of California San
   Francisco; Vanderbilt University; Oregon Health & Science University;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; University of Edinburgh; Johns Hopkins University;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Radboud University
   Nijmegen; Columbia University; Utah System of Higher Education;
   University of Utah; Harvard University; Brigham & Women's Hospital;
   Harvard Medical School; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Case Western Reserve University
RP Abecasis, GR (通讯作者)，Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.; Heid, IM (通讯作者)，Univ Regensburg, Dept Genet Epidemiol, D-93053 Regensburg, Germany.; Iyengar, SK (通讯作者)，Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
EM ski@case.edu; goncalo@umich.edu; iris.heid@klinik.uni-regensburg.de
RI Grunin, Michelle/O-6044-2019; Allikmets, Rando/ABD-4533-2021; Stark,
   Klaus/L-7367-2013; Léveillard, Thierry/AAR-1804-2020; de Jong,
   Eiko/P-3407-2015; Zhang, Kang/Y-2740-2019; Su, Zhiguang/AFS-0022-2022;
   Burdon, Kathryn/A-5026-2009; Hewitt, Alex W/D-1936-2013; Haines,
   Jonathan/C-3374-2012; Burdon, Kathryn/AAD-2334-2022; Gopinath,
   Bamini/K-4286-2019; /S-1190-2019; Mackey, David A/H-5340-2014; Sahel,
   Jose-Alain/F-3172-2017; Hollander, Anneke den/N-4911-2014; Cipriani,
   Valentina/A-8549-2012; Lehtimäki, Terho/AAD-1094-2022; Mitchell,
   Paul/P-1498-2014; lake, stewart/AAH-6265-2021; Wang, Jie
   Jin/P-1499-2014; Weeks, Daniel E/B-2995-2012; wang, jie/GRS-0942-2022;
   Farrer, Lindsay/AAS-1035-2020; Peachey, Neal/G-5533-2010; Lechanteur,
   Yara/ABB-6875-2020; Liew, Gerald/AAB-6870-2022; Blangero,
   John/ABA-7175-2021; Souzeau, Emmanuelle/AAB-5608-2022; Klaver, Caroline
   C.W./A-2013-2016; Chen, Daniel Shin-Yu/AGD-8923-2022; Branham,
   Kari/AAA-8336-2022; Cooke Bailey, Jessica Nicole/AFQ-5925-2022; Bailey,
   Jessica Cooke/Q-5062-2019; Fritsche, Lars G/AAF-9387-2019; Igo,
   Rob/P-3438-2019
OI Grunin, Michelle/0000-0002-3155-2858; Stark, Klaus/0000-0002-7832-1942;
   Léveillard, Thierry/0000-0001-5692-8770; de Jong,
   Eiko/0000-0001-6520-0407; Zhang, Kang/0000-0002-4549-1697; Burdon,
   Kathryn/0000-0001-8217-1249; Hewitt, Alex W/0000-0002-5123-5999; Haines,
   Jonathan/0000-0002-4351-4728; Burdon, Kathryn/0000-0001-8217-1249;
   Gopinath, Bamini/0000-0003-3573-359X; /0000-0001-7488-250X; Mackey,
   David A/0000-0001-7914-4709; Sahel, Jose-Alain/0000-0002-4831-1153;
   Cipriani, Valentina/0000-0002-0839-9955; Lehtimäki,
   Terho/0000-0002-2555-4427; lake, stewart/0000-0003-0078-3319; Wang, Jie
   Jin/0000-0001-9491-4898; Weeks, Daniel E/0000-0001-9410-7228; Peachey,
   Neal/0000-0002-4419-7226; Lechanteur, Yara/0000-0003-0951-4625; Souzeau,
   Emmanuelle/0000-0002-2015-6577; Chen, Daniel
   Shin-Yu/0000-0001-5085-3579; Cooke Bailey, Jessica
   Nicole/0000-0002-4001-8702; Bailey, Jessica Cooke/0000-0002-4001-8702;
   Fritsche, Lars G/0000-0002-2110-1690; Igo, Rob/0000-0002-0024-1993;
   Blond, Frederic/0000-0002-2314-0570; Scott, William/0000-0001-9336-6404;
   smith, theodore/0000-0002-1693-943X; Audo, Isabelle/0000-0003-0698-5309;
   Cree, Angela/0000-0002-1987-8900; Su, Zhiguang/0000-0001-8635-9310;
   Blangero, John/0000-0001-6250-5723; Guymer, Robyn/0000-0002-9441-4356;
   constable, ian/0000-0002-2140-6478; Farrer, Lindsay/0000-0001-5533-4225;
   Brandl, Caroline/0000-0001-8223-6137; Baird, Paul/0000-0002-1305-3502;
   Schu, Matthew/0000-0003-0630-1026; Craig, Jamie/0000-0001-9955-9696;
   Hagbi-Levi, Shira/0000-0002-2891-0079; Weber, Bernhard
   H.F./0000-0002-8808-7723; Ahn, Jeeyun/0000-0001-9017-1652; Klaver,
   Caroline/0000-0002-2355-5258; Van Duijn, Cornelia/0000-0002-2374-9204;
   Tan, Ava Grace/0000-0003-3344-0339; Lotery, Andrew/0000-0001-5541-4305;
   Ratnapriya, Rinki/0000-0002-0469-4631; Grassmann,
   Felix/0000-0003-1390-7528; Branham, Kari/0000-0002-2492-254X; Dichgans,
   Martin/0000-0002-0654-387X; Kim, Ivana/0000-0003-0310-6129
FU Center for Inherited Diseases Research (CIDR) Program
   [HHSN268201200008I];  [1X01HG006934-01];  [R01 EY022310]; Medical
   Research Council [G0000067, MC_PC_U127561128] Funding Source:
   researchfish; National Institute for Health Research [NF-SI-0507-10204]
   Funding Source: researchfish; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY013435, R01EY022310, ZIAEY000546,
   P30EY001583, T32EY023194, ZIAEY000489, U10EY006594] Funding Source: NIH
   RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG006389] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASES [P30DK079626] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM080178] Funding Source: NIH
   RePORTER; NATIONAL LIBRARY OF MEDICINE [K22LM011938] Funding Source: NIH
   RePORTER; MRC [G0000067, MC_PC_U127561128] Funding Source: UKRI
FX We thank all participants of all the studies included for enabling this
   research by their participation in these studies. Computer resources for
   this project have been provided by the high-performance computing
   centers of the University of Michigan and the University of Regensburg.
   Group-specific acknowledgments can be found in the Supplementary Note.
   The Center for Inherited Diseases Research (CIDR) Program contract
   number is HHSN268201200008I. This and the main consortium work were
   predominantly funded by 1X01HG006934-01 to G.R.A. and R01 EY022310 to
   J.L.H.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cruchaga C, 2014, NATURE, V505, P550, DOI 10.1038/nature12825
   Daniele LL, 2008, AM J PHYSIOL-CELL PH, V295, pC451, DOI 10.1152/ajpcell.00124.2008
   Do R, 2015, NATURE, V518, P102, DOI 10.1038/nature13917
   Do R, 2012, HUM MOL GENET, V21, pR1, DOI 10.1093/hmg/dds387
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Flannick J, 2014, NAT GENET, V46, P357, DOI 10.1038/ng.2915
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Gibson G, 2012, NAT REV GENET, V13, P135, DOI 10.1038/nrg3118
   Halestrap AP, 2013, MOL ASPECTS MED, V34, P337, DOI 10.1016/j.mam.2012.05.003
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Johansen CT, 2010, NAT GENET, V42, P684, DOI 10.1038/ng.628
   Kottgen A, 2010, NAT GENET, V42, P376, DOI 10.1038/ng.568
   Lambert C, 2014, ARTHRITIS RHEUMATOL, V66, P960, DOI 10.1002/art.38315
   Lange LA, 2014, AM J HUM GENET, V94, P233, DOI 10.1016/j.ajhg.2014.01.010
   Lee SH, 2012, BIOINFORMATICS, V28, P2540, DOI 10.1093/bioinformatics/bts474
   Locke AE, 2015, NATURE, V518, P197, DOI 10.1038/nature14177
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Maller JB, 2012, NAT GENET, V44, P1294, DOI 10.1038/ng.2435
   Nejentsev S, 2009, SCIENCE, V324, P387, DOI 10.1126/science.1167728
   Nelson MR, 2012, SCIENCE, V337, P100, DOI 10.1126/science.1217876
   Price AL, 2010, AM J HUM GENET, V86, P832, DOI 10.1016/j.ajhg.2010.04.005
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivas MA, 2011, NAT GENET, V43, P1066, DOI 10.1038/ng.952
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   SHOSHAN V, 1981, P NATL ACAD SCI-BIOL, V78, P4828, DOI 10.1073/pnas.78.8.4828
   Shungin D, 2015, NATURE, V518, P187, DOI 10.1038/nature14132
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Speliotes EK, 2010, NAT GENET, V42, P937, DOI 10.1038/ng.686
   Stranger BE, 2012, PLOS GENET, V8, P272, DOI 10.1371/journal.pgen.1002639
   Styrkarsdottir U, 2014, NAT GENET, V46, P498, DOI 10.1038/ng.2957
   Styrkarsdottir U, 2013, NATURE, V497, P517, DOI 10.1038/nature12124
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Walters RG, 2010, NATURE, V463, P671, DOI 10.1038/nature08727
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   Wen XQ, 2014, BIOMETRICS, V70, P73, DOI 10.1111/biom.12112
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zuk O, 2014, P NATL ACAD SCI USA, V111, pE455, DOI 10.1073/pnas.1322563111
NR 52
TC 757
Z9 765
U1 5
U2 169
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD FEB
PY 2016
VL 48
IS 2
BP 134
EP 143
DI 10.1038/ng.3448
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DC2JV
UT WOS:000369043900010
PM 26691988
OA Green Submitted, Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Eng, VA
   Wood, EH
   Boddu, S
   Karth, PA
   Leng, T
AF Eng, Victor A.
   Wood, Edward H.
   Boddu, Sucharita
   Karth, Peter A.
   Leng, Theodore
TI Preventing Progression in Nonexudative Age-Related Macular Degeneration
   With Subthreshold Laser Therapy: A Systematic Review
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Review
ID BLOOD-RETINAL BARRIER; GRID PHOTOCOAGULATION; DIODE-LASER; PROPHYLACTIC
   TREATMENT; DRUSEN; MACULOPATHY; EDEMA; BREAKDOWN; BENEFITS; SAFETY
AB BACKGROUND AND OBJECTIVE: Age-related macular degeneration (AMD) is the leading cause of irreversible blindness among the elderly in developed countries. Subthreshold retinal laser therapy is a new technique that targets drusen - a marker of nonexudative AMD - without causing incidental retinal damage associated with conventional laser photocoagulation. This review summarizes published literature on subthreshold retinal laser therapy as prophylactic treatment of nonexudative AMD.
   PATIENTS AND METHODS: A literature search of the PubMed, Medline, and Embase databases was conducted from January 1997 to April 2018. Studies were analyzed based upon study design, laser parameters, drusen reduction, changes in visual acuity (VA), and the development of choroidal neovascularization (CNV) and/or geographic atrophy (GA).
   RESULTS: Twelve studies involving 2,481 eyes treated with subthreshold retinal laser therapy were included in this review. Treatment led to increased drusen reduction, and studies with significant VA improvement were associated with significant drusen reduction. There was no significant change in the risk of developing CNV or GA.
   CONCLUSIONS: Subthreshold retinal laser therapy is effective for reducing drusen and potentially improving vision in patients with nonexudative AMD. This therapy does not show benefits in reducing development of CNV or GA. Thus, its long-term efficacy to prevent progression to advanced AMD cannot yet be recommended.
C1 [Eng, Victor A.; Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, 2452 Watson Court, Palo Alto, CA 94303 USA.
   [Wood, Edward H.] Associated Retinal Consultants P C, Royal Oak, MI USA.
   [Boddu, Sucharita] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Karth, Peter A.] Oregon Eye Consultants, Eugene, OR USA.
C3 Stanford University; New York University
RP Leng, T (通讯作者)，Stanford Univ, Sch Med, Byers Eye Inst Stanford, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM tedleng@stanford.edu
RI Leng, Theodore/AAQ-7459-2020
OI Wood, Edward/0000-0001-8915-8346
CR Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   Figueira J, 2009, BRIT J OPHTHALMOL, V93, P1341, DOI 10.1136/bjo.2008.146712
   Fong DS, 2007, RETINA-J RET VIT DIS, V27, P816, DOI 10.1097/IAE.0b013e318042d32c
   FRANK RN, 1980, VISION RES, V20, P1073, DOI 10.1016/0042-6989(80)90044-9
   Frennesson CI, 2009, ACTA OPHTHALMOL, V87, P720, DOI 10.1111/j.1755-3768.2008.01396.x
   Friberg TR, 2009, OPHTHAL SURG LAS IM, V40, P530, DOI 10.3928/15428877-20091030-01
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Hageman GS, 2008, WEBVISION ORG RETINA, P1
   Hsu J, 2005, CAN J OPHTHALMOL, V40, P320, DOI 10.1016/S0008-4182(05)80075-4
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lavinsky D, 2016, INVEST OPHTH VIS SCI, V57, P2488, DOI 10.1167/iovs.15-18981
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Luttrull JK, 2016, INVEST OPHTH VIS SCI, V57, P265, DOI 10.1167/iovs.15-18163
   Luttrull JK, 2014, RETINA-J RET VIT DIS, V34, P2010, DOI 10.1097/IAE.0000000000000177
   Luttrull JK, 2012, RETINA-J RET VIT DIS, V32, P375, DOI 10.1097/IAE.0b013e3182206f6c
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Mojana F, 2011, RETINA-J RET VIT DIS, V31, P235, DOI 10.1097/IAE.0b013e3181ec80ad
   Nili-Ahmadabadi M, 2007, ARCH IRAN MED, V10, P14
   OCEBM Levels of Evidence Working Group, OXF LEV EV 2
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Parodi MB, 2015, GRAEF ARCH CLIN EXP, V253, P1647, DOI 10.1007/s00417-014-2845-6
   Pei-Pei W, 2015, EYE, V29, P313, DOI 10.1038/eye.2015.1
   Prahs P, 2010, GRAEF ARCH CLIN EXP, V248, P651, DOI 10.1007/s00417-009-1208-1
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   SATO Y, 1992, ARCH OPHTHALMOL-CHIC, V110, P277, DOI 10.1001/archopht.1992.01080140133040
   Schuele G, 2005, INVEST OPHTH VIS SCI, V46, P714, DOI 10.1167/iovs.04-0136
   Scorolli L, 2003, CAN J OPHTHALMOL, V38, P489, DOI 10.1016/S0008-4182(03)80028-5
   SEN HA, 1988, ARCH OPHTHALMOL-CHIC, V106, P1291
   Sramek C, 2011, INVEST OPHTH VIS SCI, V52, P1780, DOI 10.1167/iovs.10-5917
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Vujosevic S, 2010, RETINA-J RET VIT DIS, V30, P908, DOI 10.1097/IAE.0b013e3181c96986
   Wood EH, 2017, RETINA-J RET VIT DIS, V37, P1021, DOI 10.1097/IAE.0000000000001386
   Wood EH, 2016, OSLI RETINA, V47, P268, DOI 10.3928/23258160-20160229-10
NR 41
TC 2
Z9 2
U1 0
U2 5
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR
PY 2019
VL 50
IS 3
BP E61
EP E70
DI 10.3928/23258160-20190301-13
PG 10
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA HQ0BG
UT WOS:000462056800003
PM 30893458
DA 2022-11-30
ER

PT J
AU Sharma, NK
   Gupta, A
   Prabhakar, S
   Singh, R
   Sharma, S
   Anand, A
AF Sharma, Neel Kamal
   Gupta, Amod
   Prabhakar, Sudesh
   Singh, Ramandeep
   Sharma, Suresh
   Anand, Akshay
TI Single Nucleotide Polymorphism and Serum Levels of VEGFR2 are Associated
   With Age Related Macular Degeneration
SO CURRENT NEUROVASCULAR RESEARCH
LA English
DT Article
DE Angiogenesis; genotype; macular degeneration; single-neucleotide
   polymorphism; VEGFR2
ID ENDOTHELIAL GROWTH-FACTOR; KINASE DOMAIN; FACTOR GENE; ANGIOGENESIS
AB Age-related macular degeneration (AMD) is a leading cause of blindness and is the third leading cause of blindness. Genetic factors are known to influence an individual's risk for developing AMD. Linkage has earlier been shown to the vascular endothelial growth factor 2 (VEGF2) gene and AMD. To examine the role of VEGFR2 in north Indian population, we conducted a case control study. Total 176 subjects were enrolled in a case-control genetic study. Real-Time PCR was used to analyze the SNPs (rs1531289 and rs2305948) of VEGFR-2 gene. ELISA was conducted to determine the levels of VEGFR2. A non-parametric Mann-Whitney-U test was applied for comparison of the ELISA levels and pearson's Chi-square test was applied to study the association of polymorphism between various groups. The single SNP (rs1531289) AG genotype was significantly associated with AMD (OR= 2.13, 95%CI= 1.011-4.489, P=0.047). VEGFR2 levels were found to be increased significantly in AMD patients as compared to normal controls. We also found significant increase in the levels of wet AMD as compared to dry AMD. This study demonstrates higher levels of VEGFR2 and frequency of AG (rs1531289) genotype in AMD patient population, suggesting the role of VEGFR-2 in pathogenesis of AMD.
C1 [Sharma, Neel Kamal; Prabhakar, Sudesh; Anand, Akshay] Postgrad Inst Med Educ & Res, Dept Neurol, Chandigarh 160012, India.
   [Gupta, Amod; Singh, Ramandeep] Postgrad Inst Med Educ & Res, Dept Ophthalmol, Chandigarh 160012, India.
   [Sharma, Suresh] Panjab Univ, Dept Biostat, Chandigarh 160014, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh; Panjab University
RP Anand, A (通讯作者)，Postgrad Inst Med Educ & Res, Dept Neurol, Chandigarh 160012, India.
EM akshay2anand@gmail.com
RI Gupta, Amod/V-7633-2017
OI Gupta, Amod/0000-0001-8427-5738
FU Department of Science and Technology, India [SR/SO/HS-109/205]
FX The study was carried out at Department of Neurology, PGIMER,
   Chandigarh, India. We acknowledge Department of Science and Technology,
   India for providing funds (F.No. SR/SO/HS-109/205 dated 1-05-2007). We
   are grateful to the volunteers involved in the study, laboratory staff
   and all those who contributed in terms of time and effort.; The funders
   (F.No. SR/SO/HS-109/205 dated 1-05-2007) had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Carneiro AM, 2011, ACTA OPHTHALMOL, V29, P1755, DOI DOI 10.1111/J.1755-3768.2011.02240.X
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Pau ECD, 2009, CANCER-AM CANCER SOC, V115, P1701, DOI 10.1002/cncr.24193
   Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478
   Edwards AO, 2006, OPHTHALMOLOGY, V113, P509, DOI 10.1016/j.ophtha.2006.01.018
   Fang AM, 2009, MOL VIS, V15, P2710
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Pabst S, 2010, CHEST, V137, P156, DOI 10.1378/chest.09-1003
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Philipp W, 2000, INVEST OPHTH VIS SCI, V41, P2514
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   Sharma NK, 2009, ANN NEUROSCI, V16, P62, DOI 10.5214/ans.0972.7531.2009.160208
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Veikkola T, 2000, CANCER RES, V60, P203
NR 24
TC 39
Z9 40
U1 1
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2026
EI 1875-5739
J9 CURR NEUROVASC RES
JI Curr. Neurovasc. Res.
PD NOV
PY 2012
VL 9
IS 4
BP 256
EP 265
PG 10
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 022OG
UT WOS:000309968100005
PM 23030506
DA 2022-11-30
ER

PT J
AU Yamamoto, A
   Okada, AA
   Nakayama, M
   Yoshida, Y
   Kobayashi, H
AF Yamamoto, Akiko
   Okada, Annabelle A.
   Nakayama, Makiko
   Yoshida, Yumiko
   Kobayashi, Hiroaki
TI One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for
   Exudative Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Anti-vascular endothelial growth factor
ID INTRAVITREAL AFLIBERCEPT; VEGF TRAP; RANIBIZUMAB; BEVACIZUMAB
AB Purpose: The aim of this study was to investigate the 1-year outcomes of treat-and-extend aflibercept for exudative age-related macular degeneration (AMD) in Japan. Procedures: Clinical records of 67 patients (67 eyes) were reviewed. Monthly aflibercept was administered until resolution of exudation and maximal reduction of pigment epithelial detachment. Injection intervals were extended by 2-week units up to 12 weeks if no exudation was observed and shortened for recurrence. Results: Mean best-corrected visual acuity (logarithm of the minimum angle of resolution) improved from 0.29 to 0.14 at 12 months (p < 0.0001). Mean central retinal thickness decreased from 430 mu m to 236 mu m at 12 months (p < 0.0001). Fifty-nine eyes (88.0%) achieved a dry macula with a mean of 8.3 injections by study end. The injection interval was extended to 10 weeks in 44.8% and to 12 weeks in 17.9% of eyes. Conclusions: At 1 year, good outcomes were obtained using treat-and-extend aflibercept for exudative AMD in Japan. (C) 2017 S. Karger AG, Basel
C1 [Yamamoto, Akiko; Okada, Annabelle A.; Nakayama, Makiko; Yoshida, Yumiko; Kobayashi, Hiroaki] Kyorin Univ, Sch Med, Kyorin Univ Hosp, Dept Ophthalmol, Tokyo, Japan.
   [Yoshida, Yumiko] Kosei Hosp, Dept Ophthalmol, Tokyo, Japan.
   [Kobayashi, Hiroaki] Juntendo Univ Hosp, Dept Ophthalmol, Tokyo, Japan.
C3 Kyorin University; Juntendo University
RP Okada, AA (通讯作者)，Kyorin Univ, Sch Med, Dept Ophthalmol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.
EM aokada@eye-center.org
FU Bayer Healthcare AG; Bayer Yakuhin Ltd. (Japan); Novartis Pharma K.K.
   (Japan); Pfizer Japan, Inc.; Santen Pharmaceutical Co. Ltd. (Japan);
   Mitsubishi Tanabe Pharma Corporation (Japan); XOMA
FX Dr. Okada has received personal fees from Bayer Healthcare AG, grants
   and personal fees from Bayer Yakuhin Ltd. (Japan), grants and personal
   fees from Novartis Pharma K.K. (Japan), personal fees from Pfizer Japan,
   Inc., grants and personal fees from Santen Pharmaceutical Co. Ltd.
   (Japan), grants and personal fees from Mitsubishi Tanabe Pharma
   Corporation (Japan), and personal fees from XOMA. All other authors have
   no conflicts of interest to declare.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chin-Yee D, 2015, BR J OPHTHALMOL, DOI [10.1136/bjophthal-mol-2015-306987, DOI 10.1136/BJOPHTHAL-MOL-2015-306987]
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Ministry of Health, 2006, REP RES COMM CHOR DE, P263
   Ohnaka M, 2016, GRAEFES ARCH CLIN EX
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rezaei KA, 2015, GLOBAL TRENDS RETINA
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamamoto A, 2013, CLIN OPHTHALMOL, V7, P757, DOI 10.2147/OPTH.S42189
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 27
TC 18
Z9 18
U1 1
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 237
IS 3
BP 139
EP 144
DI 10.1159/000458538
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ES9UA
UT WOS:000399905700003
PM 28259869
DA 2022-11-30
ER

PT J
AU Lane, J
   Robbins, RA
   Rohan, EMF
   Crookes, K
   Essex, RW
   Maddess, T
   Sabeti, F
   Mazlin, JL
   Irons, J
   Gradden, T
   Dawel, A
   Barnes, N
   He, XM
   Smithson, M
   McKone, E
AF Lane, Jo
   Robbins, Rachel A.
   Rohan, Emilie M. F.
   Crookes, Kate
   Essex, Rohan W.
   Maddess, Ted
   Sabeti, Faran
   Mazlin, Jamie-Lee
   Irons, Jessica
   Gradden, Tamara
   Dawel, Amy
   Barnes, Nick
   He, Xuming
   Smithson, Michael
   McKone, Elinor
TI Caricaturing can improve facial expression recognition in low-resolution
   images and age-related macular degeneration
SO JOURNAL OF VISION
LA English
DT Article
DE age-related macular degeneration; facial expression; caricaturing;
   intensity
ID EMOTION RECOGNITION; LOW-VISION; REPRESENTATION; PERFORMANCE;
   PERCEPTION; ACCURACY; GENUINE; RATINGS
AB Previous studies of age-related macular degeneration (AMD) report impaired facial expression recognition even with enlarged face images. Here, we test potential benefits of caricaturing (exaggerating how the expression's shape differs from neutral) as an image enhancement procedure targeted at mid- to high-level cortical vision. Experiment 1 provides proof-of-concept using normal vision observers shown burred images as a partial simulation of AMD. Caricaturing significantly improved expression recognition (happy, sad, anger, disgust, fear, surprise) by similar to 4%-5% across young adults and older adults (mean age 73 years); two different severities of blur; high, medium, and low intensity of the original expression; and all intermediate accuracy levels (impaired but still above chance). Experiment 2 tested MAD patients, running 19 eyes monocularly (from 12 patients, 67-94 years) covering a wide range of vision loss (acuities 6/7.5 to poorer than 6/360). With faces pre-enlarged, recognition approached ceding and was only slightly worse than matched controls for high- and medium-intensity expressions. For low-intensity expressions, recognition of veridical expressions remained impaired and was significantly improved with caricaturing across all levels of vision loss by 5.8%. Overall, caricaturing benefits emerged when improvement was most needed, that is, when initial recognition of uncaricatured expressions was impaired.
C1 [Lane, Jo; Robbins, Rachel A.; Crookes, Kate; Mazlin, Jamie-Lee; Irons, Jessica; Gradden, Tamara; Dawel, Amy; Barnes, Nick; Smithson, Michael; McKone, Elinor] Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia.
   [Lane, Jo; Crookes, Kate; Dawel, Amy; McKone, Elinor] Australian Natl Univ, Arc Ctr Excellence Cognit & Its Disorders, Canberra, ACT, Australia.
   [Rohan, Emilie M. F.; Maddess, Ted; Sabeti, Faran] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Med Sch, Canberra, ACT, Australia.
   [Sabeti, Faran] Univ Canberra, Discipline Optometry & Vis Sci, Bruce, ACT, Australia.
   [Sabeti, Faran] Collaborat Res Bioactives & Biomarkers CRIBB Grp, Canberra, ACT, Australia.
   [Barnes, Nick] Commonwealth Sci & Ind Res Org, Data61, Canberra, ACT, Australia.
   [He, Xuming] Shanghai Tech Univ, Sch Informat Sci & Technol, Shanghai, Peoples R China.
C3 Australian National University; Australian National University;
   Australian National University; John Curtin School of Medical Research;
   Australian National University; University of Canberra; Commonwealth
   Scientific & Industrial Research Organisation (CSIRO); ShanghaiTech
   University
RP Lane, J (通讯作者)，Australian Natl Univ, Res Sch Populat Hlth, Canberra, ACT, Australia.
EM jo.lane@anu.edu.au
RI Crookes, Kate/H-8011-2013; Dawel, Amy/AAY-2083-2020; Barnes,
   Nick/Y-2744-2018; Sabeti, Faran/AAR-1767-2021; Maddess, Teddy
   L/A-3200-2008
OI Crookes, Kate/0000-0001-6887-6197; Dawel, Amy/0000-0001-6668-3121;
   Barnes, Nick/0000-0002-9343-9535; Maddess, Teddy L/0000-0003-4591-3658;
   SABETI, Faran/0000-0001-9187-7569; Essex, Rohan/0000-0001-5323-0334;
   Lane, Jo/0000-0002-2518-1050
FU John D. and Catherine T. MacArthur Foundation Research Network on Early
   Experience and Brain Development; Australian Research Council
   [CE110001021, DP150100684]; NHMRC [1082358, 1063458]; Rebecca Cooper
   Medical Foundation [PG2018040]
FX The Macular Disease Foundation Australia, specifically Mr. Rob Cummins,
   assisted with recruitment of people living with AMD. Concerning our use
   of some face stimuli from the NimStim database, we include this required
   acknowledgement: "Development of the MacBrain Face Stimulus Set was
   overseen by Nim Tottenham and supported by the John D. and Catherine T.
   MacArthur Foundation Research Network on Early Experience and Brain
   Development. Please contact Nim Tottenham at tott0006@tc.umn.edu for
   more information concerning the stimulus set.'' This research was
   supported by Australian Research Council grants CE110001021
   (www.ccd.edu.au; EM, KC, AD) and DP150100684 (EM), NHMRC Project Grant
   1063458 (TM, ER, TS), Rebecca Cooper Medical Foundation Grant PG2018040
   (FS), and NHMRC Project Grant 1082358 (NB). Designed experiment: JL, EM.
   Conducted the experiment: JL, RR, ER, FS, RE, TM, JM, JI.
   Analyzed/interpreted the data: JL, EM, KC, RR, MS, JI, ER, FS, RE, TM.
   Provided materials: AD, TG, JM, JI, EM, RE, TM, XH, NB. Wrote the
   article: JL, EM, KC. Proofed/revised the article: all authors.
CR Aviezer H, 2012, SCIENCE, V338, P1225, DOI 10.1126/science.1224313
   Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1111/1469-7610.00715
   Benson P. J., 1991, EUROPEAN J COGNITIVE, V3, P105, DOI DOI 10.1080/09541449108406222
   Benson PJ, 1999, PERCEPT PSYCHOPHYS, V61, P259, DOI 10.3758/BF03206887
   Boucart M, 2008, VISUAL NEUROSCI, V25, P603, DOI 10.1017/S0952523808080656
   Bunting R, 2012, AUST PRESCR, V35, P90, DOI 10.18773/austprescr.2012.038
   Calder AJ, 1997, P ROY SOC B-BIOL SCI, V264, P919, DOI 10.1098/rspb.1997.0127
   Calder AJ, 2000, COGNITION, V76, P105, DOI 10.1016/S0010-0277(00)00074-3
   Dalal N, 2005, PROC CVPR IEEE, P886, DOI 10.1109/cvpr.2005.177
   Dawel A, 2019, J EXP PSYCHOL-APPL, V25, P256, DOI 10.1037/xap0000180
   Dawel A, 2017, BEHAV RES METHODS, V49, P1539, DOI 10.3758/s13428-016-0813-2
   EKMAN P, 1986, MOTIV EMOTION, V10, P159, DOI 10.1007/BF00992253
   Elfenbein HA, 2003, J PERS SOC PSYCHOL, V85, P276, DOI 10.1037/0022-3514.85.2.276
   Farkas Leslie G., 1994, P241
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Gur RC, 2002, J NEUROSCI METH, V115, P137, DOI 10.1016/S0165-0270(02)00006-7
   Hager J.C., 2002, FACIAL ACTION CODING
   Irons J, 2014, J VISION, V14, DOI 10.1167/14.2.12
   Irons JL, 2017, VISION RES, V137, P61, DOI 10.1016/j.visres.2017.06.002
   Itz ML, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149796
   Johnson AP, 2017, INVEST OPHTH VIS SCI, V58, P2520, DOI 10.1167/iovs.16-21349
   Kanwisher N, 2014, NEW VISUAL NEUROSCIENCES, P733
   Kayaert G, 2005, EUR J NEUROSCI, V22, P212, DOI 10.1111/j.1460-9568.2005.04202.x
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kumfor F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067457
   Kumfor F, 2011, SOC NEUROSCI-UK, V6, P502, DOI 10.1080/17470919.2011.620779
   Lane J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209218
   Lane J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33543-3
   Leppanen JM, 2007, BRAIN RES, V1166, P103, DOI 10.1016/j.brainres.2007.06.060
   Li S., 2018, ARXIV180408348
   Makarainen M, 2014, COGN COMPUT, V6, P708, DOI 10.1007/s12559-014-9273-0
   Marmor DJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P117, DOI 10.1001/archophthalmol.2009.366
   McKone E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204361
   McKone E, 2009, VISION RES, V49, P268, DOI 10.1016/j.visres.2008.10.020
   McLellan T, 2010, COGNITION EMOTION, V24, P1277, DOI 10.1080/02699930903306181
   Ohman A., 1998, KAROLINSKA DIRECTED
   Palermo R, 2004, BEHAV RES METH INS C, V36, P634, DOI 10.3758/BF03206544
   Pasupathy A, 2001, J NEUROPHYSIOL, V86, P2505, DOI 10.1152/jn.2001.86.5.2505
   Peli E., 1989, NONINVASIVE ASSESSME, P64
   Ruffman T, 2008, NEUROSCI BIOBEHAV R, V32, P863, DOI 10.1016/j.neubiorev.2008.01.001
   Taylor DJ, 2018, OPHTHAL PHYSL OPT, V38, P98, DOI 10.1111/opo.12419
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Thorstenson CA, 2018, EMOTION, V18, P1032, DOI 10.1037/emo0000358
   Tottenham N, 2009, PSYCHIAT RES, V168, P242, DOI 10.1016/j.psychres.2008.05.006
   van Rheede JJ, 2015, INVEST OPHTH VIS SCI, V56, P4802, DOI 10.1167/iovs.14-16311
   Wegrzyn M, 2015, CORTEX, V69, P131, DOI 10.1016/j.cortex.2015.05.003
   World Health Organization, 2015, INT STAT CLASS DIS R
   Yang H, 2015, IEEE T IMAGE PROCESS, V24, P2393, DOI 10.1109/TIP.2015.2421438
NR 48
TC 6
Z9 6
U1 2
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 1534-7362
J9 J VISION
JI J. Vision
PD JUN
PY 2019
VL 19
IS 6
AR 18
DI 10.1167/19.6.18
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA IE9SO
UT WOS:000472717100018
PM 31215978
OA gold
DA 2022-11-30
ER

PT J
AU Ibrahim, AS
   Mander, S
   Hussein, KA
   Elsherbiny, NM
   Smith, SB
   Al-Shabrawey, M
   Tawfik, A
AF Ibrahim, Ahmed S.
   Mander, Suchreet
   Hussein, Khaled A.
   Elsherbiny, Nehal M.
   Smith, Sylvia B.
   Al-Shabrawey, Mohamed
   Tawfik, Amany
TI Hyperhomocysteinemia disrupts retinal pigment epithelial structure and
   function with features of age-related macular degeneration
SO ONCOTARGET
LA English
DT Article
DE age related macular degeneration; hyperhomocysteinemia; retinal pigment
   epithelium; cystathionine-beta-synthase and mouse; Gerotarget
ID CYSTATHIONINE-BETA-SYNTHASE; OUTER SEGMENT PHAGOCYTOSIS;
   HOMOCYSTEINE-THIOLACTONE; MICROVASCULAR DYSFUNCTION; PLASMA
   HOMOCYSTEINE; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; RPE CELLS; MICE;
   PHOTORECEPTORS
AB The disruption of retinal pigment epithelial (RPE) function and the degeneration of photoreceptors are cardinal features of age related macular degeneration (AMD); however there are still gaps in our understanding of underlying biological processes. Excess homocysteine (Hcy) has been reported to be elevated in plasma of patients with AMD. This study aimed to evaluate the direct effect of hyperhomocysteinemia (HHcy) on structure and function of RPE. Initial studies in a mouse model of HHcy, in which cystathionine-beta-synthase (cbs) was deficient, revealed abnormal RPE cell morphology with features similar to that of AMD upon optical coherence tomography (OCT), fluorescein angiography (FA), histological, and electron microscopic examinations. These features include atrophy, vacuolization, hypopigmentation, thickened basal laminar membrane, hyporeflective lucency, choroidal neovascularization (CNV), and disturbed RPE-photoreceptor relationship. Furthermore, intravitreal injection of Hcy per se in normal wild type (WT) mice resulted in diffuse hyper-fluorescence, albumin leakage, and CNV in the area of RPE. In vitro experiments on ARPE-19 showed that Hcy dose-dependently reduced tight junction protein expression, increased FITC dextran leakage, decreased transcellular electrical resistance, and impaired phagocytic activity. Collectively, our results demonstrated unreported effects of excess Hcy levels on RPE structure and function that lead to the development of AMD-like features.
C1 [Ibrahim, Ahmed S.; Mander, Suchreet; Hussein, Khaled A.; Elsherbiny, Nehal M.; Al-Shabrawey, Mohamed; Tawfik, Amany] Augusta Univ, Coll Dent Med, Dept Oral Biol & Anat, Augusta, GA USA.
   [Ibrahim, Ahmed S.; Mander, Suchreet; Hussein, Khaled A.; Smith, Sylvia B.; Al-Shabrawey, Mohamed; Tawfik, Amany] Augusta Univ, Med Coll Georgia, James & Jean Culver Vis Discovery Inst, Augusta, GA USA.
   [Ibrahim, Ahmed S.; Elsherbiny, Nehal M.] Mansoura Univ, Fac Pharm, Dept Biochem & Clin Biochem, Mansoura, Egypt.
   [Hussein, Khaled A.] Natl Res Ctr, Dept Surg & Med, Oral & Dent Res Div, Cairo, Egypt.
   [Smith, Sylvia B.; Al-Shabrawey, Mohamed; Tawfik, Amany] Augusta Univ, MCG, Dept Cellular Biol & Anat, Augusta, GA USA.
   [Smith, Sylvia B.; Al-Shabrawey, Mohamed] Augusta Univ, MCG, Dept Ophthalmol, Augusta, GA USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; Egyptian Knowledge Bank (EKB); Mansoura
   University; Egyptian Knowledge Bank (EKB); National Research Centre
   (NRC); University System of Georgia; Augusta University; University
   System of Georgia; Augusta University
RP Tawfik, A (通讯作者)，Augusta Univ, Coll Dent Med, Dept Oral Biol & Anat, Augusta, GA USA.; Tawfik, A (通讯作者)，Augusta Univ, Med Coll Georgia, James & Jean Culver Vis Discovery Inst, Augusta, GA USA.; Tawfik, A (通讯作者)，Augusta Univ, MCG, Dept Cellular Biol & Anat, Augusta, GA USA.
EM amtawfik@gru.edu
RI Tawfik, Amany/AAN-9902-2020; Elsherbiny, Nehal/AAF-9206-2019; Hussein,
   Khaled/GXN-2993-2022; ibrahim, ahmed/D-5241-2017
OI Tawfik, Amany/0000-0002-0245-8256; Elsherbiny,
   Nehal/0000-0001-5167-3377; ibrahim, ahmed/0000-0001-8480-6252; Hussein,
   Khaled/0000-0003-0824-511X
FU Dental College of Georgia, Augusta University; James and Jean Culver
   Vision Discovery Institute (VDI);  [5R01EY023315-02]; NATIONAL EYE
   INSTITUTE [R01EY023315, R01EY012830] Funding Source: NIH RePORTER
FX This work was supported by startup funds from the Dental College of
   Georgia, Augusta University, a pilot project grant from the James and
   Jean Culver Vision Discovery Institute (VDI) and 5R01EY023315-02 to M.
   Al-Shabrawey.
CR Arakawa Y, 2004, BIOCHEM BIOPH RES CO, V322, P297, DOI 10.1016/j.bbrc.2004.04.208
   Arnold Jennifer J, 2007, BMJ Clin Evid, V2007
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beard RS, 2011, AM J PHYSIOL-HEART C, V300, pH13, DOI 10.1152/ajpheart.00598.2010
   Beasley S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/417986
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Beltowski Jerzy, 2005, Postepy Hig Med Dosw (Online), V59, P392
   Bewley MC, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.23496
   BOK D, 1993, J CELL SCI, P189
   Bulloj A, 2013, EXP EYE RES, V113, P9, DOI 10.1016/j.exer.2013.05.002
   Chang HH, 2011, MOL VIS, V17, P1946
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ganapathy PS, 2009, INVEST OPHTH VIS SCI, V50, P4460, DOI 10.1167/iovs.09-3402
   German OL, 2008, J NEUROSCI RES, V86, P3503, DOI 10.1002/jnr.21813
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007
   Hornsby PJ, 2010, PFLUG ARCH EUR J PHY, V459, P291, DOI 10.1007/s00424-009-0723-6
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Ibrahim AS, 2015, J LIPID RES, V56, P599, DOI 10.1194/jlr.M056069
   Ibrahim AS, 2015, BBA-MOL CELL BIOL L, V1851, P290, DOI 10.1016/j.bbalip.2014.12.017
   Ibrahim AS, 2011, DIABETES, V60, P1122, DOI 10.2337/db10-1160
   Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45
   Jakubowski H, 1997, J BIOL CHEM, V272, P1935
   Jakubowski H, 2008, J PHYSIOL PHARMACOL, V59, P155
   Jakubowski H, 2006, J NUTR, V136, p1741S, DOI 10.1093/jn/136.6.1741S
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659
   LI L, 1991, EXP EYE RES, V52, P669, DOI 10.1016/0014-4835(91)90019-B
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Phillips BE, 2008, INVEST OPHTH VIS SCI, V49, P2568, DOI 10.1167/iovs.07-1204
   REMTULLA S, 1985, VISION RES, V25, P21, DOI 10.1016/0042-6989(85)90076-8
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   STREETEN BW, 1969, ARCH OPHTHALMOL-CHIC, V81, P383
   Tawfik A, 2014, AM J PATHOL, V184, P2573, DOI 10.1016/j.ajpath.2014.05.018
   Tawfik A, 2013, INVEST OPHTH VIS SCI, V54, P939, DOI 10.1167/iovs.12-10536
   Tyagi N, 2005, AM J PHYSIOL-HEART C, V289, pH2649, DOI 10.1152/ajpheart.00548.2005
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585
   Yu MZ, 2012, EXP EYE RES, V96, P124, DOI 10.1016/j.exer.2011.12.011
NR 44
TC 31
Z9 33
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 23
PY 2016
VL 7
IS 8
BP 8532
EP 8545
DI 10.18632/oncotarget.7384
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL4OW
UT WOS:000375618100008
PM 26885895
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Vujosevic, S
   Smolek, MK
   Lebow, KA
   Notaroberto, N
   Pallikaris, A
   Casciano, M
AF Vujosevic, Stela
   Smolek, Michael K.
   Lebow, Kenneth A.
   Notaroberto, Neil
   Pallikaris, Aristophanis
   Casciano, Margherita
TI Detection of Macular Function Changes in Early (AREDS 2) and
   Intermediate (AREDS 3) Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Visual function; Fundus perimeter;
   Retinal sensitivity; Retinal fixation; Functional screening
ID QUALITY-OF-LIFE; FUNDUS AUTOFLUORESCENCE; DRUSEN; MICROPERIMETRY;
   ABNORMALITIES; MACULOPATHY; PREVALENCE; VISION; EYES
AB Background/Aim:To evaluate if retinal sensitivity values obtained with a dedicated (screening) device can be used to functionally identify early and intermediate age-related macular degeneration (ARMD). Methods: A fully automatic fundus perimeter combined with an image-stabilized scanning laser ophthalmoscope was used in 200 ARMD patients (319 eyes) in 5 study sites. The age-matched control group consisted of 200 normals. Sensitivity point values (S values), mean retinal sensitivity, number of points below 24 dB (K value, cutoff for normal values) and fixation stability were recorded. Results: Of 319 eyes, 164 were classified as early (AREDS 2) and 155 as intermediate (AREDS 3) ARMD. Mean retinal sensitivity was significantly reduced in ARMD patients versus normals (p < 0.001). K values were different between normals and ARMD patients (p < 0.001). Fixation stability did not differ between early and intermediate ARMD patients. Conclusions: Macular sensitivity is reduced in pa-tients with early and intermediate ARMD when compared to age-matched normals. These changes may be detected with a screening device. Copyright (C) 2010 S. Karger AG, Basel
C1 [Vujosevic, Stela] Fdn GB Bietti, IRCCS, IT-00198 Rome, Italy.
   [Casciano, Margherita] Int Microperimetry Reading Ctr, Padua, Italy.
   [Smolek, Michael K.] LSU Eye Ctr, Dept Ophthalmol, New Orleans, LA USA.
   [Lebow, Kenneth A.] Penn Coll Optometry Private Practice, Adjunct Fac, Virginia Beach, VA USA.
   [Notaroberto, Neil] EyeCare 20 20, Slidell, LA USA.
   [Pallikaris, Aristophanis] Univ Crete, Inst Vis & Opt, Iraklion, Greece.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; Louisiana State University System; Louisiana State
   University; University of Crete
RP Vujosevic, S (通讯作者)，Fdn GB Bietti, IRCCS, Via Livenza 3, IT-00198 Rome, Italy.
EM stelavu@hotmail.com
RI Vujosevic, Stela/AAI-4874-2020
OI Vujosevic, Stela/0000-0001-6773-9967
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weingessel B, 2009, EYE, V23, P1052, DOI 10.1038/eye.2008.237
NR 28
TC 42
Z9 44
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 225
IS 3
BP 155
EP 160
DI 10.1159/000320340
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 739CU
UT WOS:000288691000005
PM 21150232
DA 2022-11-30
ER

PT J
AU Cornish, EE
   Nguyen, V
   Young, S
   Fraser-Bell, S
   Guymer, R
   Squirrell, D
   Barthelmes, D
   Gillies, MC
AF Cornish, Elisa E.
   Vuong Nguyen
   Young, Stephanie
   Fraser-Bell, Samantha
   Guymer, Robyn
   Squirrell, David
   Barthelmes, Daniel
   Gillies, Mark C.
TI Neovascular age-related macular degeneration at treatment intervals of
   14 weeks or greater
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE anti-vascular endothelial growth factor; neovascular age-related macular
   degeneration; treatment interval
ID EXTEND INTRAVITREAL THERAPY; 2-YEAR OUTCOMES; RANIBIZUMAB
AB Background We assessed the proportion of eyes with neovascular age-related macular degeneration (nAMD) in routine clinical practice that reach >= 14 week treatment intervals and their outcomes. Method We analysed data from the Fight Retinal Blindness! (FRB!) Project database, a prospectively designed registry of 'real-world' outcomes. Treatment-naive eyes starting vascular endothelial growth factor (VEGF) inhibitors for nAMD from 1st January 2006 were included. Eyes were defined to have reached the >= 14 week treatment interval if they received >= 2 consecutive injections at treatment intervals of >= 14 week but not exceeding 26 weeks. Outcomes were reported in a subgroup of eyes that had 12 months of follow-up from reaching this interval. Results Of the 3907 treatment-naive eyes that started treatment during the identified periods on a treat-and-extend regimen and received at least 8 injections over the first 2 years, 402 (10%) eyes received at least 2 consecutive injections at an interval of >= 14 week during their follow-up. Fifty-two percent of these eyes maintained vision to 12 months, however only 40% stayed at this interval and 25% of the lesions reactivated. Conclusion We found that only 10% of eyes with nAMD were extended beyond a 13-week injection interval and that over half had returned to a shorter interval by 12 months. Eyes that stayed at this extended treatment interval maintained stable vision. More data on the outcomes of eyes treated with intervals longer than 3 months are required to establish whether emerging VEGF inhibitors provide a more sustained effect than the currently available drugs.
C1 [Cornish, Elisa E.; Vuong Nguyen; Fraser-Bell, Samantha; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Save Sight Inst, Discipline Ophthalmol, Sydney Med Sch, Sydney, NSW, Australia.
   [Young, Stephanie] Gladesville Eye Specialists, Gladesville, NSW, Australia.
   [Guymer, Robyn] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Squirrell, David] Univ Auckland, Dept Ophthalmol, Auckland, New Zealand.
   [Squirrell, David] Auckland Dist Hlth Board, Auckland, New Zealand.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne; University of Auckland;
   Auckland District Health Board; University of Zurich; University Zurich
   Hospital
RP Cornish, EE (通讯作者)，Univ Sydney, Sydney Med Sch, Save Sight Inst, 8 Macquarie St, Sydney, NSW 2000, Australia.
EM elisa.cornish@sydney.edu.au
OI Nguyen, Vuong/0000-0001-9070-9803; Squirrell, David/0000-0002-8393-7100;
   Fraser-Bell, Samantha/0000-0001-5646-9359; Guymer,
   Robyn/0000-0002-9441-4356; Gillies, mark/0000-0001-8580-0274
FU Bayer; Macula Disease Foundation; National Health and Medical Research
   Council; Novartis Foundation; Royal Australian and New Zealand College
   of Ophthalmologists; Swiss National Foundation; Walter and Gertrud
   Siegenthaler
FX Bayer; Macula Disease Foundation; National Health and Medical Research
   Council; Novartis Foundation; Royal Australian and New Zealand College
   of Ophthalmologists; Swiss National Foundation; Walter and Gertrud
   Siegenthaler
CR [Anonymous], 2020, R LANGUAGE ENV STAT
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Daien V., 2019, BRIT J OPHTHALMOL
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Grunwald JE., 2016, INCIDENCE GROWTH GEO
   Guymer, 2021, INVEST OPHTHALMOL VI
   Iglicki M, 2021, EYE, V35, P1111, DOI 10.1038/s41433-020-01309-9
   Jackson CH, 2011, J STAT SOFTW, V38, P1
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2020, EYE, V34, P1825, DOI 10.1038/s41433-019-0747-x
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Teo KYC, 2020, RETINA-J RET VIT DIS, V40, P2285, DOI 10.1097/IAE.0000000000002779
NR 25
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2021
VL 49
IS 6
BP 570
EP 578
DI 10.1111/ceo.13962
EA JUL 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TU9ZD
UT WOS:000673304600001
PM 34129283
OA Green Published
DA 2022-11-30
ER

PT J
AU Bowers, AR
   Sheldon, SS
   DeCarlo, DK
   Peli, E
AF Bowers, Alex R.
   Sheldon, Sarah S.
   DeCarlo, Dawn K.
   Peli, Eli
TI Bioptic Telescope Use and Driving Patterns of Drivers with Age-Related
   Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE bioptic telescope; driving; macular degeneration; questionnaire; low
   vision; quality of life; vision rehabilitation
ID CENTRAL VISION LOSS; INCREASED DEPRESSIVE SYMPTOMS; QUALITY-OF-LIFE;
   OLDER DRIVERS; VISUAL IMPAIRMENT; UNITED-STATES; ADULTS; HABITS;
   RANIBIZUMAB; MACULOPATHY
AB Purpose: To investigate the telescope use and driving patterns of bioptic drivers with age-related macular degeneration (AMD).
   Methods: A questionnaire addressing telescope use and driving patterns was administered by telephone interview to three groups of bioptic drivers: AMD (n = 31; median 76 years); non-AMD first licensed with a bioptic (n = 38; 53 years); and nonAMD first licensed without a bioptic (n = 47; 37 years). Driving patterns of bioptic AMD drivers were also compared with those of normal vision (NV) drivers (n = 36; 74 years) and nonbioptic AMD drivers (n = 34; 79 years).
   Results: Bioptic usage patterns of AMD drivers did not differ from those of the younger bioptic drivers and greater visual difficulty without the bioptic was strongly correlated with greater bioptic helpfulness. Bioptic AMD drivers were more likely to report avoidance of night driving than the age-similar NV drivers (P = 0.06). However, they reported less difficulty than the nonbioptic AMD drivers in all driving situations (P <= 0.02). Weekly mileages of bioptic AMD drivers were lower than those of the younger bioptic drivers (P < 0.001), but not the NV group (P = 0.54), and were higher than those of the nonbioptic AMD group (P < 0.001).
   Conclusions: Our results suggest that bioptic telescopes met the visual demands of drivers with AMD and that those drivers had relatively unrestricted driving habits.
   Translational Relevance: Licensure with a bioptic telescope may prolong driving of older adults with AMD; however, objective measures of bioptic use, driving performance, and safety are needed.
C1 [Bowers, Alex R.; Sheldon, Sarah S.; Peli, Eli] Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear, Boston, MA USA.
   [DeCarlo, Dawn K.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Schepens Eye Research Institute; University of Alabama
   System; University of Alabama Birmingham
RP Bowers, AR (通讯作者)，Schepens Eye Res Inst, 20 Staniford St, Boston, MA 01208 USA.
EM alex_bowers@meei.harvard.edu
OI Bowers, Alex/0000-0002-6038-0178; Peli, Eli/0000-0002-1340-9257
FU National Institutes of Health [R01-AG041974, R01-EY12890, R00-EY018680,
   P50-AG11684, R21-EY14071]; Research to Prevent Blindness; Eyesight
   Foundation of Alabama; NATIONAL EYE INSTITUTE [R00EY018680, R21EY014071,
   R01EY012890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG041974] Funding Source: NIH RePORTER
FX Supported by grants from the National Institutes of Health R01-AG041974,
   R01-EY12890, R00-EY018680, P50-AG11684 (Royal Center for Research in
   Applied Gerontology) and R21-EY14071, Research to Prevent Blindness, and
   the Eyesight Foundation of Alabama.
CR Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4
   Bond T.G., 2015, APPLYING RASCH MODEL, V3rd ed., DOI DOI 10.4324/9781315814698
   Bowers A, 2005, OPTOMETRY VISION SCI, V82, P657, DOI 10.1097/01.opx.0000175558.33268.b5
   Bowers AR, 2005, INVEST OPHTH VIS SCI, V46, P66, DOI 10.1167/iovs.04-0271
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Coeckelbergh TRM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1509, DOI 10.1001/archopht.120.11.1509
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Corn A. L., 1990, REVIEW, VXXI, P221
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Dougherty BE, 2015, INVEST OPHTH VIS SCI, V56, P6326, DOI 10.1167/iovs.15-16882
   Dougherty BE, 2015, OPTOMETRY VISION SCI, V92, P395, DOI 10.1097/OPX.0000000000000547
   FEINBLOOM W, 1977, AM J OPTOM PHYS OPT, V54, P35
   Freeman EE, 2006, INVEST OPHTH VIS SCI, V47, P514, DOI 10.1167/iovs.05-0934
   Huss C, 2004, J VISUAL IMPAIR BLIN, V98, P641, DOI 10.1177/0145482X0409801008
   Huss C., 1988, J VIS REHABIL, V2, P31
   Jose R., 1984, REHABIL OPTOM, V2, P2
   Keeffe JE, 2002, BRIT J OPHTHALMOL, V86, P1118, DOI 10.1136/bjo.86.10.1118
   Kooijman Aart C, 2008, Vis Impair Res, V10, P1, DOI 10.1080/13882350802053582
   Linacre J., 2015, WINSTEPS RASCH MEASU
   Luo G, 2011, OPHTHAL PHYSL OPT, V31, P318, DOI 10.1111/j.1475-1313.2011.00829.x
   Lyman JM, 2001, ACCIDENT ANAL PREV, V33, P413, DOI 10.1016/S0001-4575(00)00055-5
   Marottoli RA, 2000, J GERONTOL B-PSYCHOL, V55, pS334, DOI 10.1093/geronb/55.6.S334
   Marottoli RA, 1997, J AM GERIATR SOC, V45, P202, DOI 10.1111/j.1532-5415.1997.tb04508.x
   Massof RW, 2007, INVEST OPHTH VIS SCI, V48, P4955, DOI 10.1167/iovs.06-0566
   McGwin G, 2004, INVEST OPHTH VIS SCI, V45, P3934, DOI 10.1167/iovs.04-0524
   Moore LW, 2005, APPL NURS RES, V18, P110, DOI 10.1016/j.apnr.2004.06.014
   Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P330, DOI 10.1167/iovs.13-13520
   Owsley C, 2012, OPTOMETRY VISION SCI, V89, P1249, DOI 10.1097/OPX.0b013e3182678dc8
   Park W L, 1995, J Am Optom Assoc, V66, P274
   Peli E., 2002, DRIVING CONFIDENCE P
   Ragland DR, 2005, J GERONTOL A-BIOL, V60, P399, DOI 10.1093/gerona/60.3.399
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scilley K, 2004, OPHTHAL EPIDEMIOL, V11, P131, DOI 10.1076/opep.11.2.131.28159
   Sengupta S, 2014, OPHTHALMOLOGY, V121, P727, DOI 10.1016/j.ophtha.2013.09.042
   Szlyk JP, 2000, J REHABIL RES DEV, V37, P101
   TAYLOR DG, 1990, J VIS REHABIL, V4, P29
   Vincent C, 2012, ASSIST TECHNOL, V24, P184, DOI 10.1080/10400435.2012.659955
   West CG, 2003, J AM GERIATR SOC, V51, P1348, DOI 10.1046/j.1532-5415.2003.51482.x
   Wood JM, 2013, INVEST OPHTH VIS SCI, V54, P3790, DOI 10.1167/iovs.12-11485
NR 44
TC 3
Z9 3
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD SEP
PY 2016
VL 5
IS 5
AR 5
DI 10.1167/tvst.5.5.5
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA ED2JY
UT WOS:000388671600005
PM 27642541
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Lesauskaite, V
   Zaliaduonyte-Peksiene, D
   Sinkunaite-Marsalkiene, G
   Zaliuniene, D
   Mizariene, V
   Gustiene, O
   Jasinskas, V
   Tamosiunas, A
AF Liutkeviciene, Rasa
   Lesauskaite, Vaiva
   Zaliaduonyte-Peksiene, Diana
   Sinkunaite-Marsalkiene, Giedre
   Zaliuniene, Dalia
   Mizariene, Vaida
   Gustiene, Olivija
   Jasinskas, Vytautas
   Tamosiunas, Abdonas
TI Role of MMP-2 (-1306 C/T) Polymorphism in Age-Related Macular
   Degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; gene polymorphism; matrix
   metalloproteinase-2
ID CHOROIDAL NEOVASCULAR MEMBRANES; MATRIX METALLOPROTEINASES; EXPRESSION;
   VARIANTS; THERAPY; DISEASE; GENE; MICE
AB Purpose: To determine if the frequency of the MMP-2 (-1306 C/T) genotype has an influence on the development of early age-related macular degeneration (AMD).
   Methodology: The study enrolled 387 patients with early AMD and a random sample of 682 healthy persons (control group). The genotyping of MMP-2 (-1306 C/T) was carried out using the real-time polymerase chain reaction method.
   Results: The analysis of the MMP-2 (-1306 C/T) gene polymorphism did not reveal any differences in the genotype distribution between the patients with AMD and the control subjects. When the study population was divided into age groups, the C/C genotype was more prevalent in the AMD patients aged <65 years than those aged >= 65 years (65.19% versus 53.88%, p = 0.0294), and the C/T genotype was more frequent in the AMD patients aged >= 65 years when compared with the AMD patients aged 565 years (40.78% versus 26.52%, p = 0.0037). Moreover, in the female group younger than 65 years, the frequency of the C/C genotype was greater in the AMD group than the control group (75% versus 58.91%, p = 0.0232).
   Conclusions: This study showed a significantly greater prevalence of the C/C and C/T genotypes in the patients with AMD younger than 65 years and those aged >= 65 years, respectively. Moreover, the AMD women aged 565 years were the carriers of the C/C genotype significantly more frequently than their control counterparts.
C1 [Liutkeviciene, Rasa; Zaliuniene, Dalia; Jasinskas, Vytautas] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, Kaunas, Lithuania.
   [Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
   [Lesauskaite, Vaiva; Sinkunaite-Marsalkiene, Giedre; Tamosiunas, Abdonas] Lithuanian Univ Hlth Sci, Med Acad, Inst Cardiol, Kaunas, Lithuania.
   [Zaliaduonyte-Peksiene, Diana; Mizariene, Vaida; Gustiene, Olivija] Lithuanian Univ Hlth Sci, Med Acad, Dept Cardiol, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences; Lithuanian
   University of Health Sciences
RP Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, Kaunas, Lithuania.
EM rliutkeviciene@gmail.com
RI Tamosiunas, Abdonas/AAD-4274-2021
OI Lesauskaite, Vaiva/0000-0003-2736-3111
FU Lithuanian Science Council [MIP-10330]; Wellcome Trust [064947/Z/01/Z];
   US National Institute on Aging [IR0I AG23522-01]; MacArthur Foundation
   (Health and Social Upheaval network); NATIONAL INSTITUTE ON AGING
   [R01AG023522] Funding Source: NIH RePORTER
FX Financial support was received from the Lithuanian Science Council
   [grant no. MIP-10330] and Wellcome Trust [grant no. 064947/Z/01/Z], the
   US National Institute on Aging [grant no. IR0I AG23522-01], and the
   MacArthur Foundation (Health and Social Upheaval network).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Bureau of the Census, 2006, INT PROJ POP AG 18 6
   Chaer RA, 2004, CARDIOLOGY, V101, P122, DOI 10.1159/000075993
   Chau KY, 2003, J HUM HYPERTENS, V17, P119
   Cousins SW, 2003, INVEST OPHTH VIS SCI, V44, P1221, DOI 10.1167/iovs.02-0285
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Grabauskas Vilius, 2003, Medicina (Kaunas), V39, P1215
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Lesauskaite V, 2006, GERONTOLOGY, V52, P40, DOI 10.1159/000089824
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Liutkeviciene R, 2010, MEDICINA-LITHUANIA, V46, P89, DOI 10.3390/medicina46020013
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   Ortak H, 2013, OPHTHALMIC GENET, V34, P217, DOI 10.3109/13816810.2013.781192
   Peasey A, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-255
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Price SJ, 2001, J BIOL CHEM, V276, P7549, DOI 10.1074/jbc.M010242200
   Seitzman RL, 2008, AM J EPIDEMIOL, V167, P1217, DOI 10.1093/aje/kwn024
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeng RP, 2013, MOL VIS, V19, P729
NR 25
TC 6
Z9 7
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2016
VL 37
IS 2
BP 170
EP 176
DI 10.3109/13816810.2015.1020556
PG 7
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA DK2HD
UT WOS:000374734400007
PM 26333112
DA 2022-11-30
ER

PT J
AU Jimenez-Gomez, Y
   Alba-Molina, D
   Blanco-Blanco, M
   Perez-Fajardo, L
   Reyes-Ortega, F
   Ortega-Llamas, L
   Villalba-Gonzalez, M
   De Isla, IFC
   Pugliese, F
   Stoikow, I
   Gonzalez-Andrades, M
AF Jimenez-Gomez, Yolanda
   Alba-Molina, David
   Blanco-Blanco, Mario
   Perez-Fajardo, Lorena
   Reyes-Ortega, Felisa
   Ortega-Llamas, Laura
   Villalba-Gonzalez, Marta
   Fernandez-Choquet de Isla, Ignacio
   Pugliese, Francisco
   Stoikow, Indira
   Gonzalez-Andrades, Miguel
TI Novel Treatments for Age-Related Macular Degeneration: A Review of
   Clinical Advances in Sustained Drug Delivery Systems
SO PHARMACEUTICS
LA English
DT Review
DE age-related macular degeneration; sustained drug delivery system;
   clinical trials
ID CILIARY NEUROTROPHIC FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   ENDOTHELIAL GROWTH-FACTOR; ANECORTAVE ACETATE; GEOGRAPHIC ATROPHY;
   BETA-CAROTENE; GENE-THERAPY; PIGMENT EPITHELIUM; EYE DISEASE; FOLLOW-UP
AB In recent years, the number of patients with ocular diseases is increasing as a consequence of population aging. Among them, one of the most common is the age-related macular degeneration (AMD), a condition that leads to vision loss if it is not treated. AMD is a multifactorial disorder with two advanced forms, dry and neovascular AMD. Currently, although there is no approved therapy that significantly impacts dry AMD progression, several pharmacologic therapies exist for neovascular AMD. Notwithstanding, evidence suggests a suboptimal result in a high number of patients receiving these therapeutic options. Consequently, finding effective strategies is not only a still unmet medical need in dry AMD but also in neovascular AMD. This underlines the need for new drug delivery technologies that can improve the pharmacological action and drug concentration at the target sites. In this regard, sustained drug delivery systems are presented as the most promising therapeutic options in AMD patients. This review summarized the pathogenesis and the current treatment options for AMD, focusing on the emerging ocular sustained drug delivery approaches undergoing clinical trials.
C1 [Jimenez-Gomez, Yolanda; Alba-Molina, David; Blanco-Blanco, Mario; Perez-Fajardo, Lorena; Reyes-Ortega, Felisa; Ortega-Llamas, Laura; Villalba-Gonzalez, Marta; Fernandez-Choquet de Isla, Ignacio; Pugliese, Francisco; Stoikow, Indira; Gonzalez-Andrades, Miguel] Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Dept Ophthalmol, Cordoba 14004, Spain.
C3 Universidad de Cordoba
RP Jimenez-Gomez, Y; Gonzalez-Andrades, M (通讯作者)，Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Dept Ophthalmol, Cordoba 14004, Spain.
EM yolanda.jimenez@imibic.org; david.alba@imibic.org;
   mario.blanco@imibic.org; lorena.perez@imibic.org;
   felisa.reyes@imibic.org; laura.ortega@imibic.org;
   marta.villalba7@gmail.com; jfchoquet@gmail.com;
   francisco-pugliese@hotmail.com; indirastoikow@gmail.com;
   miguel.gonzalez@imibic.org
FU Instituto de Salud Carlos III [ICI19/00006]; European Union (ERDF/ESF,
   "A way to make Europe"/"Investing in your future"); Consejeria de Salud
   y Familias, Junta de Andalucia; Fondo Social Europeo de Andalucia
   2014-2020; Plan Andaluz de Investigacion, Desarrollo e Innovacion
   (PAIDI2020) Fellowship - Consejeria de Economia, Conocimiento, Empresas
   y Universidad, Junta de Andalucia; Consejeria de Salud y Familias, Junta
   de Andalucia [PIGE_0194_2019]
FX D.A.-M. and L.P.-F. acknowledge funding from the research project
   ICI19/00006, funded by Instituto de Salud Carlos III and co-funded by
   European Union (ERDF/ESF, "A way to make Europe"/"Investing in your
   future"). Y.J.-G. acknowledges funding from Consejeria de Salud y
   Familias, Junta de Andalucia, co-funded by Fondo Social Europeo de
   Andalucia 2014-2020. F.R.-O. acknowledges funding from the Plan Andaluz
   de Investigacion, Desarrollo e Innovacion (PAIDI2020) Fellowship
   supported by Consejeria de Economia, Conocimiento, Empresas y
   Universidad, Junta de Andalucia co-funded by Fondo Social Europeo de
   Andalucia 2014-2020. M.B.-B. acknowledges funding from the research
   Project PIGE_0194_2019, funded by Consejeria de Salud y Familias, Junta
   de Andalucia.
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Augustin AJ, 2005, GRAEF ARCH CLIN EXP, V243, P9, DOI 10.1007/s00417-004-0961-4
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423
   Chaudhary V, 2016, CAN J OPHTHALMOL, V51, P302, DOI 10.1016/j.jcjo.2016.04.020
   Cheruvu NPS, 2006, INVEST OPHTH VIS SCI, V47, P4513, DOI 10.1167/iovs.06-0404
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cholkar K, 2012, WOODH PUB SER BIOMED, P1, DOI 10.1533/9781908818317.1
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clinical Trial, STUDY RO7250284 PART
   Clinical Trial, STUDY ASSESSING AR 1
   Clinical Trial, EXTENSION STUDY PORT
   Clinical Trial, SAFETY EFFICACY STUD
   Clinical Trial, STUDY RESPONSE TREAT
   Clinical Trial, STUDY EFFICACY SAFET
   Clinical Trial, TREATMENT ADV DRY AG
   Clinical Trial, STUDY EVALUATING TRE
   Clinical Trial, FOLLOW UP STUDY EVAL
   Clinical Trial, FOCUS 1 HUMAN STUDY
   Clinical Trial, STUDY EFFECTIVENESS
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Constable IJ, 2016, ASIA-PAC J OPHTHALMO, V5, P300, DOI 10.1097/APO.0000000000000222
   Crowell SR, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.1
   Damian Javier, 2006, Aten Primaria, V38, P51, DOI 10.1157/13090016
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Ghate D, 2007, INVEST OPHTH VIS SCI, V48, P2230, DOI 10.1167/iovs.06-0954
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Holan V, 2017, CELL TRANSPLANT, V26, P1538, DOI 10.1177/0963689717721227
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Kang-Mieler JJ, 2014, EXPERT OPIN DRUG DEL, V11, P1647, DOI 10.1517/17425247.2014.935338
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Kuppermann BD, 2021, RETINA-J RET VIT DIS, V41, P144, DOI 10.1097/IAE.0000000000002789
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lim JI, 2015, BRIT J OPHTHALMOL, V99, P618, DOI 10.1136/bjophthalmol-2014-306002
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Maloney MH, 2021, OPHTHALMOLOGY, V128, P417, DOI 10.1016/j.ophtha.2020.07.062
   MAURICE DM, 1977, EXP EYE RES, V25, P577, DOI 10.1016/0014-4835(77)90136-1
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Rezar-Dreindl S, 2017, RETINA-J RET VIT DIS, V37, P962, DOI 10.1097/IAE.0000000000001264
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rubio R.G., 2014, RETINA TODAY, P78
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   TORNQUIST P, 1990, EYE, V4, P303, DOI 10.1038/eye.1990.41
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Waite D, 2017, THER DELIV, V8, P685, DOI 10.4155/tde-2017-0097
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, WORD REP VIS
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 84
TC 0
Z9 0
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD JUL
PY 2022
VL 14
IS 7
AR 1473
DI 10.3390/pharmaceutics14071473
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 3J3CD
UT WOS:000833275500001
PM 35890368
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hong, T
   Tan, AG
   Mitchell, P
   Wang, JJ
AF Hong, Thomas
   Tan, Ava Grace
   Mitchell, Paul
   Wang, Jie Jin
TI A Review and Meta-analysis of the Association Between C-Reactive Protein
   and Age-related Macular Degeneration.
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE C-reactive protein; geographic atrophy; macular degeneration;
   meta-analysis; neo-vascular; systematic review
ID COMPLEMENT FACTOR-H; BLUE-MOUNTAINS-EYE; CARDIOVASCULAR-DISEASE;
   RISK-FACTORS; INFLAMMATORY MARKERS; VISUAL IMPAIRMENT; Y402H VARIANT;
   HEART-DISEASE; MACULOPATHY; HEALTH
AB Age-related macular degeneration (AMD) is the leading cause of blindness in people over 60 in western countries. Inflammatory markers have been implicated in the development and progression of AMD. C-reactive protein (CRP) is an inflammatory marker known to be associated with cardiovascular disease, and a link between AMD and CRP has been suggested. In this systematic review we summarize the currently available evidence from clinic-based and population-based studies investigating this association. A meta-analysis of evidence from eleven studies (41,690 study participants) shows that high serum levels (>3 mg/L) of CRP are associated with a two-fold likelihood of late onset AMD, compared to low levels ( <1mg/L). Sub-group meta-analyses show a higher association in studies using ophthalmoscopic examination, compared to those using photographic grading (pooled odds ratio 3.83 vs 1.36), to determine AMD status, or in clinic-based samples compared to population-based studies. (Surv Ophthalmol 56:184-194, 2011. (C) 2011 Elsevier Inc. All rights reserved.)
C1 [Hong, Thomas; Tan, Ava Grace; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Hong, Thomas; Tan, Ava Grace; Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; Centre for Eye Research Australia; University of
   Melbourne
RP Wang, JJ (通讯作者)，Univ Sydney, Ctr Vis Res, Westmead Millennium Inst, Dept Ophthalmol,Westmead Hosp, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; wang, jie/GRS-0942-2022; Wang, Jie
   Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898; Tan, Ava Grace/0000-0003-3344-0339
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Blumenfeld Z, 2007, SCAND J CLIN LAB INV, V67, P257, DOI 10.1080/00365510601113241
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bovill EG, 1996, AM J EPIDEMIOL, V143, P1107
   Daiger SP, 2005, SCIENCE, V308, P362, DOI 10.1126/science.1111655
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004
   Dixon JB, 2008, OBESITY, V16, P2010, DOI 10.1038/oby.2008.271
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Ishikawa S, 2007, J EPIDEMIOL, V17, P120, DOI 10.2188/jea.17.120
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lange LA, 2006, JAMA-J AM MED ASSOC, V296, P2703, DOI 10.1001/jama.296.22.2703
   Malik S, 2005, DIABETES CARE, V28, P690, DOI 10.2337/diacare.28.3.690
   Maseri A, 1996, BRIT MED J, V312, P1049
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morrow DA, 1998, J AM COLL CARDIOL, V31, P1460, DOI 10.1016/S0735-1097(98)00136-3
   Nordin G, 1996, SCAND J CLIN LAB INV, V56, P123, DOI 10.3109/00365519609088598
   PARNELL SJ, 1993, BRIT J GEN PRACT, V43, P65
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   Picklesimer AH, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.017
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Rifai N, 2001, CLIN CHEM, V47, P403
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Vanky E, 2008, SCAND J CLIN LAB INV, V68, P421, DOI 10.1080/00365510701810613
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 54
TC 59
Z9 60
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2011
VL 56
IS 3
BP 184
EP 194
DI 10.1016/j.survophthal.2010.08.007
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 758SU
UT WOS:000290187600002
PM 21420705
DA 2022-11-30
ER

EF